facial B-Claim
hirsutism I-Claim
is I-Claim
one I-Claim
of I-Claim
the I-Claim
characteristic I-Claim
features I-Claim
of I-Claim
polycystic I-Claim
ovary I-Claim
syndrome I-Claim
( I-Claim
pcos I-Claim
) I-Claim
, I-Claim
and I-Claim
this I-Claim
can I-Claim
lead I-Claim
to I-Claim
high I-Claim
levels I-Claim
of I-Claim
depression I-Claim
and I-Claim
anxiety I-Claim
. I-Claim
!LF! !LF!
to O
evaluate O
the O
impact O
of O
laser O
treatment O
on O
the O
severity O
of O
facial O
hirsutism O
and O
on O
psychological O
morbidity O
in O
women O
with O
pcos O
. O
!LF! !LF!
a O
randomized O
controlled O
trial O
of O
five O
high O
- O
fluence O
treatments O
( O
intervention O
) O
vs O
. O
five O
low O
- O
fluence O
treatments O
( O
control O
) O
was O
performed O
over O
6 O
months O
in O
a O
national O
health O
service O
teaching O
hospital O
. O
!LF! !LF!
subjects O
were O
88 O
women O
with O
facial O
hirsutism O
due O
to O
pcos O
recruited O
from O
hospital O
outpatient O
clinics O
and O
a O
patient O
support O
group O
in O
2001 O
- O
2002 O
. O
!LF! !LF!
the O
main O
outcomes O
were O
self O
- O
reported O
severity O
of O
facial O
hair O
( O
measured O
on O
a O
scale O
of O
1 O
- O
10 O
) O
, O
depression O
, O
anxiety O
( O
measured O
on O
the O
hospital O
anxiety O
and O
depression O
scale O
) O
and O
quality O
of O
life O
( O
measured O
on O
the O
whoqol O
- O
bref O
) O
. O
!LF! !LF!
self B-Premise
- B-Premise
reported B-Premise
severity I-Premise
of I-Premise
facial I-Premise
hair I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
51 I-Premise
) I-Premise
fell I-Premise
from I-Premise
7 I-Premise
. I-Premise
3 I-Premise
to I-Premise
3 I-Premise
. I-Premise
6 I-Premise
over I-Premise
the I-Premise
6 I-Premise
- I-Premise
month I-Premise
study I-Premise
period I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
37 I-Premise
) I-Premise
the I-Premise
corresponding I-Premise
scores I-Premise
were I-Premise
7 I-Premise
. I-Premise
1 I-Premise
and I-Premise
6 I-Premise
. I-Premise
1 I-Premise
. I-Premise
!LF! !LF!
the B-Premise
change I-Premise
was I-Premise
significantly I-Premise
greater I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
[ I-Premise
ancova I-Premise
f I-Premise
( I-Premise
( I-Premise
1 I-Premise
, I-Premise
83 I-Premise
) I-Premise
) I-Premise
= I-Premise
24 I-Premise
. I-Premise
5 I-Premise
, I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
] I-Premise
. I-Premise
!LF! !LF!
self B-Premise
- B-Premise
reported B-Premise
time I-Premise
spent I-Premise
on I-Premise
hair I-Premise
removal I-Premise
declined I-Premise
from I-Premise
112 I-Premise
to I-Premise
21 I-Premise
min I-Premise
per I-Premise
week I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
and I-Premise
from I-Premise
92 I-Premise
to I-Premise
56 I-Premise
min I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
[ I-Premise
f I-Premise
( I-Premise
( I-Premise
1 I-Premise
, I-Premise
80 I-Premise
) I-Premise
) I-Premise
= I-Premise
10 I-Premise
. I-Premise
2 I-Premise
, I-Premise
p I-Premise
< I-Premise
/ I-Premise
= I-Premise
0 I-Premise
. I-Premise
05 I-Premise
] I-Premise
. I-Premise
!LF! !LF!
mean B-Premise
depression I-Premise
scores I-Premise
fell I-Premise
from I-Premise
6 I-Premise
. I-Premise
7 I-Premise
to I-Premise
3 I-Premise
. I-Premise
6 I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
, I-Premise
compared I-Premise
with I-Premise
6 I-Premise
. I-Premise
1 I-Premise
to I-Premise
5 I-Premise
. I-Premise
4 I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
[ I-Premise
f I-Premise
( I-Premise
( I-Premise
1 I-Premise
, I-Premise
83 I-Premise
) I-Premise
) I-Premise
= I-Premise
14 I-Premise
. I-Premise
7 I-Premise
, I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
] I-Premise
. I-Premise
!LF! !LF!
a B-Premise
similar I-Premise
change I-Premise
was I-Premise
seen I-Premise
for I-Premise
mean I-Premise
anxiety I-Premise
scores I-Premise
: I-Premise
intervention I-Premise
11 I-Premise
. I-Premise
1 I-Premise
to I-Premise
8 I-Premise
. I-Premise
2 I-Premise
, I-Premise
control I-Premise
9 I-Premise
. I-Premise
6 I-Premise
to I-Premise
9 I-Premise
. I-Premise
3 I-Premise
[ I-Premise
f I-Premise
( I-Premise
( I-Premise
1 I-Premise
, I-Premise
84 I-Premise
) I-Premise
) I-Premise
= I-Premise
17 I-Premise
. I-Premise
8 I-Premise
, I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
] I-Premise
. I-Premise
!LF! !LF!
psychological B-Premise
quality I-Premise
of I-Premise
life I-Premise
also I-Premise
improved I-Premise
more I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
, I-Premise
from I-Premise
49 I-Premise
. I-Premise
6 I-Premise
to I-Premise
61 I-Premise
. I-Premise
2 I-Premise
vs I-Premise
. I-Premise
50 I-Premise
. I-Premise
1 I-Premise
to I-Premise
51 I-Premise
. I-Premise
5 I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
[ I-Premise
f I-Premise
( I-Premise
( I-Premise
1 I-Premise
, I-Premise
84 I-Premise
) I-Premise
) I-Premise
= I-Premise
10 I-Premise
. I-Premise
9 I-Premise
, I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
] I-Premise
. I-Premise
!LF! !LF!
laser B-Claim
treatment I-Claim
appeared I-Claim
to I-Claim
reduce I-Claim
the I-Claim
severity I-Claim
of I-Claim
facial I-Claim
hair I-Claim
and I-Claim
time I-Claim
spent I-Claim
on I-Claim
hair I-Claim
removal I-Claim
as I-Claim
well I-Claim
as I-Claim
alleviating I-Claim
depression I-Claim
and I-Claim
anxiety I-Claim
in I-Claim
women I-Claim
with I-Claim
pcos I-Claim
. I-Claim
!LF! !LF!
these B-Claim
findings I-Claim
suggest I-Claim
that I-Claim
ways I-Claim
of I-Claim
making I-Claim
this I-Claim
method I-Claim
of I-Claim
hair I-Claim
removal I-Claim
more I-Claim
widely I-Claim
available I-Claim
to I-Claim
women I-Claim
with I-Claim
facial I-Claim
hirsutism I-Claim
should I-Claim
be I-Claim
considered I-Claim
. I-Claim
!LF! !LF!
despite B-Claim
considerable I-Claim
improvement I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
ovarian I-Claim
cancer I-Claim
, I-Claim
the I-Claim
optimization I-Claim
of I-Claim
efficacy I-Claim
and I-Claim
tolerability I-Claim
remains I-Claim
an I-Claim
important I-Claim
issue I-Claim
. I-Claim
!LF! !LF!
therefore O
, O
we O
performed O
a O
randomized O
, O
phase O
iii O
non O
- O
inferiority O
trial O
comparing O
paclitaxel O
plus O
cisplatin O
( O
pt O
) O
with O
paclitaxel O
plus O
carboplatin O
( O
tc O
) O
in O
patients O
with O
advanced O
ovarian O
cancer O
. O
!LF! !LF!
a O
total O
of O
798 O
patients O
with O
international O
federation O
of O
gynecology O
and O
obstetrics O
stage O
iib O
- O
iv O
were O
randomly O
assigned O
to O
receive O
six O
courses O
of O
either O
pt O
or O
tc O
at O
3 O
- O
week O
intervals O
. O
!LF! !LF!
the O
primary O
endpoint O
was O
the O
proportion O
of O
patients O
without O
progression O
at O
2 O
years O
. O
!LF! !LF!
secondary O
endpoints O
included O
toxicity O
, O
response O
to O
treatment O
, O
quality O
of O
life O
, O
and O
overall O
and O
progression O
- O
free O
survival O
time O
. O
!LF! !LF!
quality O
of O
life O
was O
evaluated O
using O
the O
european O
organization O
for O
research O
and O
treatment O
of O
cancer O
quality O
- O
of O
- O
life O
questionnaire O
( O
qlq O
) O
- O
c30 O
, O
version O
2 O
. O
0 O
. O
!LF! !LF!
survival O
curves O
were O
calculated O
using O
the O
kaplan O
- O
meier O
method O
, O
and O
hazard O
ratios O
were O
estimated O
using O
the O
cox O
proportional O
hazards O
model O
. O
!LF! !LF!
the B-Premise
proportion I-Premise
of I-Premise
patients I-Premise
without I-Premise
progression I-Premise
at I-Premise
2 I-Premise
years I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significantly I-Premise
different I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
arms I-Premise
( I-Premise
40 I-Premise
. I-Premise
0 I-Premise
% I-Premise
for I-Premise
pt I-Premise
versus I-Premise
37 I-Premise
. I-Premise
5 I-Premise
% I-Premise
for I-Premise
tc I-Premise
, I-Premise
difference I-Premise
= I-Premise
2 I-Premise
. I-Premise
5 I-Premise
% I-Premise
, I-Premise
one I-Premise
- I-Premise
sided I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
ci I-Premise
] I-Premise
= I-Premise
- I-Premise
infinity I-Premise
to I-Premise
8 I-Premise
. I-Premise
2 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
median B-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
time I-Premise
in I-Premise
the I-Premise
tc I-Premise
arm I-Premise
( I-Premise
17 I-Premise
. I-Premise
2 I-Premise
months I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
15 I-Premise
. I-Premise
2 I-Premise
to I-Premise
19 I-Premise
. I-Premise
3 I-Premise
months I-Premise
) I-Premise
and I-Premise
the I-Premise
pt I-Premise
arm I-Premise
( I-Premise
19 I-Premise
. I-Premise
1 I-Premise
months I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
16 I-Premise
. I-Premise
7 I-Premise
to I-Premise
21 I-Premise
. I-Premise
5 I-Premise
months I-Premise
) I-Premise
were I-Premise
also I-Premise
not I-Premise
statistically I-Premise
significantly I-Premise
different I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
the B-Premise
same I-Premise
was I-Premise
true I-Premise
of I-Premise
median I-Premise
overall I-Premise
survival I-Premise
time I-Premise
( I-Premise
43 I-Premise
. I-Premise
3 I-Premise
months I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
37 I-Premise
. I-Premise
2 I-Premise
to I-Premise
47 I-Premise
. I-Premise
8 I-Premise
months I-Premise
versus I-Premise
44 I-Premise
. I-Premise
1 I-Premise
months I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
40 I-Premise
. I-Premise
2 I-Premise
to I-Premise
49 I-Premise
. I-Premise
4 I-Premise
months I-Premise
, I-Premise
for I-Premise
the I-Premise
tc I-Premise
and I-Premise
pt I-Premise
arms I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
tc I-Premise
regimen I-Premise
was I-Premise
associated I-Premise
with I-Premise
a I-Premise
higher I-Premise
frequency I-Premise
of I-Premise
hematologic I-Premise
toxicity I-Premise
, I-Premise
but B-Premise
a I-Premise
lower I-Premise
frequency I-Premise
of I-Premise
gastrointestinal I-Premise
and I-Premise
neurologic I-Premise
toxicity I-Premise
, I-Premise
than I-Premise
the I-Premise
pt I-Premise
regimen I-Premise
. I-Premise
!LF! !LF!
mean B-Premise
global I-Premise
quality I-Premise
- I-Premise
of I-Premise
- I-Premise
life I-Premise
scores I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
treatment I-Premise
were I-Premise
statistically I-Premise
significantly I-Premise
better I-Premise
in I-Premise
the I-Premise
tc I-Premise
arm I-Premise
than I-Premise
in I-Premise
the I-Premise
pt I-Premise
arm I-Premise
( I-Premise
65 I-Premise
. I-Premise
25 I-Premise
versus I-Premise
51 I-Premise
. I-Premise
97 I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
difference I-Premise
= I-Premise
- I-Premise
13 I-Premise
. I-Premise
28 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
- I-Premise
18 I-Premise
. I-Premise
88 I-Premise
to I-Premise
- I-Premise
7 I-Premise
. I-Premise
68 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Claim
tc I-Claim
regimen I-Claim
achieved I-Claim
comparable I-Claim
efficacy I-Claim
to I-Claim
the I-Claim
pt I-Claim
regimen I-Claim
but I-Claim
was I-Claim
associated I-Claim
with I-Claim
better I-Claim
tolerability I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
and I-Claim
should I-Claim
, I-Claim
therefore I-Claim
, I-Claim
be I-Claim
considered I-Claim
as I-Claim
an I-Claim
important I-Claim
alternative I-Claim
for I-Claim
standard I-Claim
first I-Claim
- I-Claim
line I-Claim
chemotherapy I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
the O
aim O
of O
this O
study O
was O
to O
compare O
the O
2 O
- O
year O
functional O
performance O
and O
quality O
of O
life O
in O
patients O
with O
operable O
squamous O
cell O
carcinoma O
of O
the O
esophagus O
, O
who O
have O
received O
either O
surgery O
or O
definitive O
chemoradiation O
( O
crt O
) O
. O
!LF! !LF!
the O
functional O
outcomes O
and O
quality O
of O
life O
in O
patients O
receiving O
esophagectomy O
or O
definitive O
crt O
is O
uncertain O
. O
!LF! !LF!
data O
were O
extracted O
from O
the O
database O
of O
a O
prospective O
randomized O
controlled O
trial O
that O
included O
patients O
with O
resectable O
mid O
or O
lower O
thoracic O
esophageal O
cancers O
. O
!LF! !LF!
the O
patients O
were O
randomized O
to O
either O
standard O
esophagectomy O
or O
definitive O
crt O
. O
!LF! !LF!
quality O
of O
life O
assessments O
were O
performed O
using O
the O
eortc O
qlq O
- O
c30 O
and O
qlq O
- O
oes24 O
modules O
. O
!LF! !LF!
other O
functional O
assessments O
included O
pulmonary O
and O
eating O
functions O
. O
!LF! !LF!
from O
july O
2000 O
to O
december O
2004 O
, O
a O
total O
of O
81 O
patients O
were O
enrolled O
into O
the O
study O
. O
!LF! !LF!
no B-Premise
significant I-Premise
longitudinal I-Premise
changes I-Premise
were I-Premise
detected I-Premise
in I-Premise
the I-Premise
global I-Premise
health I-Premise
status I-Premise
in I-Premise
both I-Premise
groups I-Premise
upon I-Premise
available I-Premise
follow I-Premise
- I-Premise
up I-Premise
. I-Premise
!LF! !LF!
surgery B-Premise
was I-Premise
associated I-Premise
with I-Premise
worsened I-Premise
physical I-Premise
functioning I-Premise
and I-Premise
fatigue I-Premise
symptoms I-Premise
up I-Premise
to I-Premise
6 I-Premise
months I-Premise
after I-Premise
treatment I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
and I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
021 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
and I-Premise
these I-Premise
scales I-Premise
improved I-Premise
at I-Premise
2 I-Premise
years I-Premise
. I-Premise
!LF! !LF!
in B-Premise
terms I-Premise
of I-Premise
pulmonary I-Premise
function I-Premise
, I-Premise
dyspnoic I-Premise
and I-Premise
coughing I-Premise
symptoms I-Premise
were I-Premise
significantly I-Premise
worsened I-Premise
3 I-Premise
months I-Premise
after I-Premise
surgery I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
024 I-Premise
and I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
036 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
whereas I-Premise
symptoms I-Premise
in I-Premise
the I-Premise
crt I-Premise
group I-Premise
progressively I-Premise
deteriorated I-Premise
over I-Premise
time I-Premise
. I-Premise
!LF! !LF!
concerning B-Premise
the I-Premise
eating I-Premise
function I-Premise
, I-Premise
both I-Premise
groups I-Premise
had I-Premise
improvements I-Premise
in I-Premise
dysphagia I-Premise
but I-Premise
there I-Premise
were I-Premise
frequent I-Premise
need I-Premise
for I-Premise
endoscopic I-Premise
intervention I-Premise
. I-Premise
!LF! !LF!
neither B-Premise
surgery I-Premise
nor I-Premise
definitive I-Premise
crt I-Premise
significantly I-Premise
impaired I-Premise
the I-Premise
global I-Premise
health I-Premise
status I-Premise
of I-Premise
patients I-Premise
. I-Premise
!LF! !LF!
surgery B-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
short I-Claim
- I-Claim
term I-Claim
negative I-Claim
impact I-Claim
in I-Claim
some I-Claim
aspects I-Claim
of I-Claim
health I-Claim
related I-Claim
quality I-Claim
of I-Claim
life I-Claim
assessments I-Claim
but B-Claim
these I-Claim
changes I-Claim
became I-Claim
insignificant I-Claim
2 I-Claim
years I-Claim
after I-Claim
treatment I-Claim
. I-Claim
!LF! !LF!
however O
, O
crt B-Claim
was I-Claim
associated I-Claim
with I-Claim
progressive I-Claim
deteriorations I-Claim
in I-Claim
pulmonary I-Claim
function I-Claim
in I-Claim
the I-Claim
longer I-Claim
term I-Claim
. I-Claim
!LF! !LF!
to O
observe O
the O
effect O
of O
tcm O
therapy O
for O
removing O
toxic O
substance O
and O
unblocking O
meridians O
on O
post O
- O
radiation O
quality O
of O
life O
( O
qof O
) O
in O
55 O
patients O
with O
lung O
cancer O
. O
!LF! !LF!
all O
patients O
were O
randomly O
assigned O
to O
two O
groups O
, O
the O
55 O
patients O
in O
the O
treated O
group O
were O
treated O
with O
radiotherapy O
combined O
with O
the O
tcm O
therapy O
, O
and O
the O
53 O
in O
the O
control O
group O
were O
given O
radiotherapy O
alone O
. O
!LF! !LF!
the O
clinical O
efficacy O
was O
evaluated O
by O
indexes O
including O
kps O
scores O
, O
qlq O
- O
c30 O
questionnaire O
, O
lc13 O
specific O
scale O
for O
lung O
cancer O
, O
evaluation O
criteria O
for O
tcm O
efficacy O
, O
the O
6 O
- O
min O
walking O
distance O
, O
and O
body O
weight O
, O
etc O
. O
!LF! !LF!
the B-Premise
kps I-Premise
score I-Premise
in I-Premise
the I-Premise
treated I-Premise
group I-Premise
after I-Premise
treatment I-Premise
was I-Premise
improved I-Premise
in I-Premise
13 I-Premise
patients I-Premise
( I-Premise
23 I-Premise
. I-Premise
6 I-Premise
% I-Premise
) I-Premise
, I-Premise
stabilized I-Premise
in I-Premise
27 I-Premise
( I-Premise
49 I-Premise
. I-Premise
6 I-Premise
% I-Premise
) I-Premise
and I-Premise
declined I-Premise
in I-Premise
15 I-Premise
( I-Premise
27 I-Premise
. I-Premise
3 I-Premise
% I-Premise
) I-Premise
, I-Premise
while I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
it I-Premise
was I-Premise
improved I-Premise
in I-Premise
7 I-Premise
( I-Premise
13 I-Premise
. I-Premise
2 I-Premise
% I-Premise
) I-Premise
, I-Premise
stabilized I-Premise
in I-Premise
21 I-Premise
( I-Premise
39 I-Premise
. I-Premise
6 I-Premise
% I-Premise
) I-Premise
and I-Premise
declined I-Premise
in I-Premise
25 I-Premise
( I-Premise
47 I-Premise
. I-Premise
2 I-Premise
% I-Premise
) I-Premise
, I-Premise
the I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
was I-Premise
significant I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
results I-Premise
from I-Premise
evaluation I-Premise
with I-Premise
qlq I-Premise
- I-Premise
c30 I-Premise
questionnaire I-Premise
and I-Premise
lc30 I-Premise
scale I-Premise
in I-Premise
the I-Premise
treated I-Premise
group I-Premise
was I-Premise
also I-Premise
superior I-Premise
to I-Premise
those I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
the B-Premise
scores I-Premise
of I-Premise
tcm I-Premise
efficacy I-Premise
( I-Premise
24 I-Premise
. I-Premise
52 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
8 I-Premise
. I-Premise
98 I-Premise
vs I-Premise
29 I-Premise
. I-Premise
76 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
7 I-Premise
. I-Premise
09 I-Premise
, I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
and I-Premise
the I-Premise
6 I-Premise
- I-Premise
min I-Premise
walking I-Premise
distance I-Premise
( I-Premise
233 I-Premise
. I-Premise
4 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
29 I-Premise
. I-Premise
2 I-Premise
m I-Premise
vs I-Premise
205 I-Premise
. I-Premise
8 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
31 I-Premise
. I-Premise
9 I-Premise
m I-Premise
, I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
were I-Premise
better I-Premise
in I-Premise
the I-Premise
treated I-Premise
group I-Premise
. I-Premise
!LF! !LF!
after B-Premise
treatment I-Premise
in I-Premise
the I-Premise
treated I-Premise
group I-Premise
, I-Premise
the I-Premise
body I-Premise
weight I-Premise
was I-Premise
increased I-Premise
in I-Premise
11 I-Premise
patients I-Premise
( I-Premise
20 I-Premise
. I-Premise
0 I-Premise
% I-Premise
) I-Premise
, I-Premise
stabilized I-Premise
in I-Premise
28 I-Premise
( I-Premise
50 I-Premise
. I-Premise
9 I-Premise
% I-Premise
) I-Premise
and I-Premise
decreased I-Premise
in I-Premise
16 I-Premise
( I-Premise
29 I-Premise
. I-Premise
1 I-Premise
% I-Premise
) I-Premise
, I-Premise
while I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
it I-Premise
was I-Premise
increased I-Premise
in I-Premise
5 I-Premise
( I-Premise
9 I-Premise
. I-Premise
4 I-Premise
% I-Premise
) I-Premise
, I-Premise
stabilized I-Premise
in I-Premise
26 I-Premise
( I-Premise
49 I-Premise
. I-Premise
1 I-Premise
% I-Premise
) I-Premise
and I-Premise
decreased I-Premise
in I-Premise
22 I-Premise
( I-Premise
41 I-Premise
. I-Premise
5 I-Premise
% I-Premise
) I-Premise
, I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
was I-Premise
significant I-Premise
, I-Premise
too I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
tcm B-Claim
therapy I-Claim
for I-Claim
removing I-Claim
toxic I-Claim
substance I-Claim
and I-Claim
unblocking I-Claim
meridians I-Claim
can I-Claim
improve I-Claim
the I-Claim
post I-Claim
- I-Claim
radiation I-Claim
qol I-Claim
of I-Claim
patients I-Claim
with I-Claim
lung I-Claim
cancer I-Claim
to I-Claim
some I-Claim
extent I-Claim
. I-Claim
!LF! !LF!
the O
averel O
trial O
[ O
a O
study O
of O
avastin O
( O
bevacizumab O
) O
in O
combination O
with O
herceptin O
( O
trastuzumab O
) O
/ O
docetaxel O
in O
patients O
with O
her2 O
- O
positive O
metastatic O
breast O
cancer O
] O
evaluated O
first O
- O
line O
bevacizumab O
- O
containing O
therapy O
for O
human O
epidermal O
growth O
factor O
receptor O
2 O
( O
her2 O
) O
- O
positive O
locally O
recurrent O
/ O
metastatic O
breast O
cancer O
( O
lr O
/ O
mbc O
) O
. O
!LF! !LF!
patients O
with O
measurable O
/ O
evaluable O
her2 O
- O
positive O
lr O
/ O
mbc O
who O
had O
not O
received O
trastuzumab O
or O
chemotherapy O
for O
lr O
/ O
mbc O
were O
stratified O
by O
prior O
adjuvant O
trastuzumab O
, O
prior O
( O
neo O
) O
adjuvant O
taxane O
, O
hormone O
receptor O
status O
, O
and O
measurable O
disease O
and O
were O
randomly O
assigned O
to O
receive O
docetaxel O
100 O
mg O
/ O
m O
( O
2 O
) O
plus O
trastuzumab O
8 O
mg O
/ O
kg O
loading O
dose O
followed O
by O
6 O
mg O
/ O
kg O
either O
with O
bevacizumab O
15 O
mg O
/ O
kg O
or O
without O
bevacizumab O
, O
all O
administered O
every O
3 O
weeks O
. O
!LF! !LF!
the O
primary O
end O
point O
was O
progression O
- O
free O
survival O
( O
pfs O
) O
. O
!LF! !LF!
additional O
end O
points O
included O
overall O
survival O
, O
response O
rate O
( O
rr O
) O
, O
safety O
, O
quality O
of O
life O
, O
and O
translational O
research O
. O
!LF! !LF!
results O
baseline O
characteristics O
of O
the O
424 O
patients O
were O
balanced O
between O
treatment O
arms O
. O
!LF! !LF!
most O
patients O
had O
visceral O
metastases O
, O
43 O
% O
had O
a O
disease O
- O
free O
interval O
less O
than O
12 O
months O
, O
and O
85 O
% O
had O
measurable O
disease O
. O
!LF! !LF!
median O
follow O
- O
up O
was O
26 O
months O
. O
!LF! !LF!
the B-Premise
hazard I-Premise
ratio I-Premise
for I-Premise
investigator I-Premise
- I-Premise
assessed I-Premise
pfs I-Premise
was I-Premise
0 I-Premise
. I-Premise
82 I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
65 I-Premise
to I-Premise
1 I-Premise
. I-Premise
02 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
0775 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
median I-Premise
pfs I-Premise
, I-Premise
13 I-Premise
. I-Premise
7 I-Premise
v I-Premise
16 I-Premise
. I-Premise
5 I-Premise
months I-Premise
in I-Premise
the I-Premise
non I-Premise
- I-Premise
bevacizumab I-Premise
and I-Premise
bevacizumab I-Premise
arms I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
pfs I-Premise
events I-Premise
in I-Premise
72 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
independent I-Premise
review I-Premise
committee I-Premise
- I-Premise
assessed I-Premise
pfs I-Premise
hazard I-Premise
ratio I-Premise
was I-Premise
0 I-Premise
. I-Premise
72 I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
54 I-Premise
to I-Premise
0 I-Premise
. I-Premise
94 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
0162 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
median I-Premise
pfs I-Premise
, I-Premise
13 I-Premise
. I-Premise
9 I-Premise
v I-Premise
16 I-Premise
. I-Premise
8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
pfs I-Premise
events I-Premise
in I-Premise
53 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
rr I-Premise
was I-Premise
70 I-Premise
% I-Premise
versus I-Premise
74 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
3492 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
grade B-Claim
≥ I-Claim
3 I-Claim
febrile I-Claim
neutropenia I-Claim
and I-Claim
hypertension I-Claim
were I-Claim
more I-Claim
common I-Claim
with I-Claim
bevacizumab I-Claim
- I-Claim
containing I-Claim
therapy I-Claim
. I-Claim
!LF! !LF!
high B-Premise
baseline I-Premise
plasma I-Premise
vascular I-Premise
endothelial I-Premise
growth I-Premise
factor I-Premise
a I-Premise
( I-Premise
vegf I-Premise
- I-Premise
a I-Premise
) I-Premise
concentrations I-Premise
were I-Premise
associated I-Premise
with I-Premise
greater I-Premise
bevacizumab I-Premise
benefit I-Premise
( I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
) I-Premise
. I-Premise
!LF! !LF!
combining B-Claim
bevacizumab I-Claim
with I-Claim
docetaxel I-Claim
and I-Claim
trastuzumab I-Claim
did I-Claim
not I-Claim
significantly I-Claim
improve I-Claim
investigator I-Claim
- I-Claim
assessed I-Claim
pfs I-Claim
. I-Claim
!LF! !LF!
the O
potential O
predictive O
value O
of O
plasma O
vegf O
- O
a O
is O
consistent O
with O
findings O
in O
her2 O
- O
negative O
lr O
/ O
mbc O
, O
warranting O
prospective O
evaluation O
. O
!LF! !LF!
vinorelbine B-Claim
prolongs I-Claim
survival I-Claim
and I-Claim
improves I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non I-Claim
- I-Claim
small I-Claim
- I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
nsclc I-Claim
) I-Claim
. I-Claim
!LF! !LF!
some B-Claim
studies I-Claim
have I-Claim
also I-Claim
suggested I-Claim
that I-Claim
gemcitabine I-Claim
is I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
effective I-Claim
in I-Claim
such I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
we O
compared O
the O
effectiveness O
and O
toxicity O
of O
the O
combination O
of O
vinorelbine O
plus O
gemcitabine O
with O
those O
of O
each O
drug O
given O
alone O
in O
an O
open O
- O
label O
, O
randomized O
phase O
iii O
trial O
in O
elderly O
patients O
with O
advanced O
nsclc O
. O
!LF! !LF!
patients O
aged O
70 O
years O
and O
older O
, O
enrolled O
between O
december O
1997 O
and O
november O
2000 O
, O
were O
randomly O
assigned O
to O
receive O
intravenous O
vinorelbine O
( O
30 O
mg O
/ O
m O
( O
2 O
) O
of O
body O
surface O
area O
) O
, O
gemcitabine O
( O
1200 O
mg O
/ O
m O
( O
2 O
) O
) O
, O
or O
vinorelbine O
( O
25 O
mg O
/ O
m O
( O
2 O
) O
) O
plus O
gemcitabine O
( O
1000 O
mg O
/ O
m O
( O
2 O
) O
) O
. O
!LF! !LF!
all O
treatments O
were O
delivered O
on O
days O
1 O
and O
8 O
every O
3 O
weeks O
for O
a O
maximum O
of O
six O
cycles O
. O
!LF! !LF!
the O
primary O
endpoint O
was O
survival O
. O
!LF! !LF!
survival O
curves O
were O
drawn O
using O
the O
kaplan O
- O
meier O
method O
and O
analyzed O
by O
the O
mantel O
- O
haenszel O
test O
. O
!LF! !LF!
secondary O
endpoints O
were O
quality O
of O
life O
and O
toxicity O
. O
!LF! !LF!
of O
698 O
patients O
available O
for O
intention O
- O
to O
- O
treat O
analysis O
, O
233 O
were O
assigned O
to O
receive O
vinorelbine O
, O
233 O
to O
gemcitabine O
, O
and O
232 O
to O
vinorelbine O
plus O
gemcitabine O
. O
!LF! !LF!
compared B-Premise
with I-Premise
each I-Premise
single I-Premise
drug I-Premise
, I-Premise
the I-Premise
combination I-Premise
treatment I-Premise
did I-Premise
not I-Premise
improve I-Premise
survival I-Premise
. I-Premise
!LF! !LF!
the B-Premise
hazard I-Premise
ratio I-Premise
of I-Premise
death I-Premise
for I-Premise
patients I-Premise
receiving I-Premise
the I-Premise
combination I-Premise
treatment I-Premise
was I-Premise
1 I-Premise
. I-Premise
17 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
ci I-Premise
] I-Premise
= I-Premise
0 I-Premise
. I-Premise
95 I-Premise
to I-Premise
1 I-Premise
. I-Premise
44 I-Premise
) I-Premise
that I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
vinorelbine I-Premise
and I-Premise
1 I-Premise
. I-Premise
06 I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
0 I-Premise
. I-Premise
86 I-Premise
to I-Premise
1 I-Premise
. I-Premise
29 I-Premise
) I-Premise
that I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
gemcitabine I-Premise
. I-Premise
!LF! !LF!
although B-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
similar I-Premise
across I-Premise
the I-Premise
three I-Premise
treatment I-Premise
arms I-Premise
, I-Premise
the B-Premise
combination I-Premise
treatment I-Premise
was I-Premise
more I-Premise
toxic I-Premise
than I-Premise
the I-Premise
two I-Premise
drugs I-Premise
given I-Premise
singly I-Premise
. I-Premise
!LF! !LF!
the B-Claim
combination I-Claim
of I-Claim
vinorelbine I-Claim
plus I-Claim
gemcitabine I-Claim
is I-Claim
not I-Claim
more I-Claim
effective I-Claim
than I-Claim
single I-Claim
- I-Claim
agent I-Claim
vinorelbine I-Claim
or I-Claim
gemcitabine I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
nsclc I-Claim
. I-Claim
!LF! !LF!
to O
evaluate O
the O
efficacy O
of O
a O
psychoeducational O
intervention O
in O
improving O
cancer O
- O
related O
fatigue O
. O
!LF! !LF!
this O
randomized O
controlled O
trial O
involved O
109 O
women O
commencing O
adjuvant O
chemotherapy O
for O
stage O
i O
or O
ii O
breast O
cancer O
in O
five O
chemotherapy O
treatment O
centers O
. O
!LF! !LF!
intervention O
group O
patients O
received O
an O
individualized O
fatigue O
education O
and O
support O
program O
delivered O
in O
the O
clinic O
and O
by O
phone O
over O
three O
- O
10 O
to O
20 O
- O
minute O
sessions O
1 O
week O
apart O
. O
!LF! !LF!
instruments O
included O
a O
numeric O
rating O
scale O
assessing O
confidence O
with O
managing O
fatigue O
"""" O
; O
"""" O
11 O
- O
point O
numeric O
rating O
scales O
measuring O
fatigue O
at O
worst O
, O
average O
, O
and O
best O
"""" O
; O
"""" O
the O
functional O
assessment O
of O
cancer O
therapy O
- O
fatigue O
and O
piper O
fatigue O
scales O
"""" O
; O
"""" O
the O
cancer O
self O
- O
efficacy O
scale O
"""" O
; O
"""" O
the O
european O
organisation O
for O
research O
and O
treatment O
of O
cancer O
quality O
of O
life O
questionnaire O
c30 O
"""" O
; O
"""" O
and O
the O
hospital O
anxiety O
and O
depression O
scale O
. O
!LF! !LF!
for O
each O
outcome O
, O
separate O
analyses O
of O
covariance O
of O
change O
scores O
between O
baseline O
( O
t1 O
) O
and O
the O
three O
follow O
- O
up O
time O
points O
( O
t2 O
, O
t3 O
, O
and O
t4 O
) O
were O
conducted O
, O
controlling O
for O
the O
variable O
' O
s O
corresponding O
baseline O
value O
. O
!LF! !LF!
compared B-Premise
with I-Premise
the I-Premise
intervention I-Premise
group I-Premise
, I-Premise
mean I-Premise
difference I-Premise
scores I-Premise
between I-Premise
the I-Premise
baseline I-Premise
( I-Premise
t1 I-Premise
) I-Premise
and I-Premise
immediate I-Premise
after I-Premise
the I-Premise
test I-Premise
( I-Premise
t2 I-Premise
) I-Premise
assessments I-Premise
increased I-Premise
significantly I-Premise
more I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
for I-Premise
worst I-Premise
and I-Premise
average I-Premise
fatigue I-Premise
, I-Premise
functional I-Premise
assessment I-Premise
of I-Premise
cancer I-Premise
therapy I-Premise
- I-Premise
fatigue I-Premise
, I-Premise
and I-Premise
piper I-Premise
fatigue I-Premise
severity I-Premise
and I-Premise
interference I-Premise
measures I-Premise
. I-Premise
!LF! !LF!
these B-Premise
differences I-Premise
were I-Premise
not I-Premise
observed I-Premise
between I-Premise
baseline I-Premise
and I-Premise
t3 I-Premise
and I-Premise
t4 I-Premise
assessments I-Premise
. I-Premise
!LF! !LF!
no B-Premise
significant I-Premise
differences I-Premise
were I-Premise
identified I-Premise
for I-Premise
any I-Premise
pre I-Premise
- I-Premise
or I-Premise
post I-Premise
- I-Premise
test I-Premise
change I-Premise
scores I-Premise
for I-Premise
confidence I-Premise
with I-Premise
managing I-Premise
fatigue I-Premise
, I-Premise
cancer I-Premise
self I-Premise
- I-Premise
efficacy I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
depression I-Premise
, I-Premise
or I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise
!LF! !LF!
preparatory B-Claim
education I-Claim
and I-Claim
support I-Claim
has I-Claim
the I-Claim
potential I-Claim
to I-Claim
assist I-Claim
women I-Claim
to I-Claim
cope I-Claim
with I-Claim
cancer I-Claim
- I-Claim
related I-Claim
fatigue I-Claim
in I-Claim
the I-Claim
short I-Claim
term I-Claim
. I-Claim
!LF! !LF!
however B-Claim
, I-Claim
further I-Claim
research I-Claim
is I-Claim
needed I-Claim
to I-Claim
identify I-Claim
ways I-Claim
to I-Claim
improve I-Claim
the I-Claim
potency I-Claim
and I-Claim
sustainability I-Claim
of I-Claim
psychoeducational I-Claim
interventions I-Claim
for I-Claim
managing I-Claim
cancer I-Claim
- I-Claim
related I-Claim
fatigue I-Claim
. I-Claim
!LF! !LF!
to O
evaluate O
the O
incidence O
and O
temporal O
resolution O
of O
dysuria O
after O
permanent O
prostate O
brachytherapy O
, O
and O
to O
identify O
predictors O
of O
brachytherapy O
- O
related O
dysuria O
. O
!LF! !LF!
the O
study O
included O
130 O
patients O
with O
no O
history O
of O
transurethral O
resection O
of O
the O
prostate O
before O
treatment O
, O
who O
had O
brachytherapy O
on O
one O
of O
two O
prospective O
randomized O
trials O
, O
with O
explicitly O
planned O
and O
executed O
urethral O
- O
sparing O
techniques O
( O
100 O
- O
150 O
% O
minimum O
peripheral O
dose O
) O
using O
either O
103pd O
or O
125i O
for O
clinical O
t1c O
- O
t2c O
prostate O
cancer O
. O
!LF! !LF!
the O
median O
follow O
- O
up O
was O
22 O
. O
6 O
months O
. O
!LF! !LF!
an O
alpha O
- O
blocker O
was O
initiated O
either O
prophylactically O
2 O
weeks O
before O
implantation O
and O
continued O
at O
least O
until O
the O
international O
prostate O
symptom O
score O
( O
ipss O
) O
returned O
to O
normal O
, O
or O
withheld O
until O
the O
onset O
of O
significant O
brachytherapy O
- O
related O
urinary O
morbidity O
. O
!LF! !LF!
dysuria O
was O
evaluated O
on O
a O
0 O
- O
10 O
scale O
, O
before O
brachytherapy O
and O
then O
at O
1 O
, O
3 O
, O
6 O
and O
12 O
months O
afterward O
, O
with O
a O
median O
of O
four O
dysuria O
questionnaires O
per O
patient O
. O
!LF! !LF!
clinical O
, O
treatment O
and O
dosimetric O
variables O
evaluated O
included O
alpha O
- O
blocker O
, O
age O
, O
ipss O
before O
and O
the O
maximum O
after O
treatment O
, O
prostate O
volume O
on O
ultrasonography O
, O
hormonal O
status O
, O
supplemental O
radiotherapy O
, O
isotope O
, O
urethral O
dose O
, O
v O
( O
100 O
/ O
200 O
) O
, O
d90 O
, O
and O
time O
to O
obtaining O
a O
normal O
ipss O
. O
!LF! !LF!
the O
maximum O
incidence O
of O
dysuria O
was O
85 O
% O
at O
1 O
month O
after O
brachytherapy O
, O
with O
subsequent O
resolution O
over O
time O
. O
!LF! !LF!
the B-Premise
use I-Premise
of I-Premise
prophylactic I-Premise
tamsulosin I-Premise
resulted I-Premise
in I-Premise
a I-Premise
statistically I-Premise
lower I-Premise
dysuria I-Premise
severity I-Premise
score I-Premise
( I-Premise
difference I-Premise
of I-Premise
2 I-Premise
. I-Premise
7 I-Premise
vs I-Premise
4 I-Premise
. I-Premise
2 I-Premise
, I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
005 I-Premise
) I-Premise
at I-Premise
1 I-Premise
month I-Premise
, I-Premise
with I-Premise
no I-Premise
discernible I-Premise
differences I-Premise
at I-Premise
3 I-Premise
, I-Premise
6 I-Premise
, I-Premise
12 I-Premise
and I-Premise
18 I-Premise
months I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
with I-Premise
dysuria I-Premise
had I-Premise
a I-Premise
statistically I-Premise
higher I-Premise
ipss I-Premise
. I-Premise
!LF! !LF!
the B-Premise
dysuria I-Premise
resolved I-Premise
faster I-Premise
in I-Premise
patients I-Premise
implanted I-Premise
with I-Premise
103pd I-Premise
but B-Premise
was I-Premise
unaffected I-Premise
by I-Premise
the I-Premise
use I-Premise
of I-Premise
supplemental I-Premise
radiotherapy I-Premise
and I-Premise
/ I-Premise
or I-Premise
androgen I-Premise
deprivation I-Premise
therapy I-Premise
. I-Premise
!LF! !LF!
in B-Premise
multivariate I-Premise
analysis I-Premise
, I-Premise
prophylactic I-Premise
alpha I-Premise
- I-Premise
blockers I-Premise
resulted I-Premise
in I-Premise
statistically I-Premise
lower I-Premise
maximum I-Premise
dysuria I-Premise
scores I-Premise
, I-Premise
while B-Premise
the I-Premise
maximum I-Premise
ipss I-Premise
after I-Premise
implantation I-Premise
and I-Premise
isotope I-Premise
type I-Premise
( I-Premise
but I-Premise
only I-Premise
at I-Premise
6 I-Premise
months I-Premise
) I-Premise
were I-Premise
the I-Premise
best I-Premise
predictors I-Premise
of I-Premise
the I-Premise
resolution I-Premise
of I-Premise
dysuria I-Premise
. I-Premise
!LF! !LF!
dysuria B-Claim
is I-Claim
common I-Claim
after I-Claim
brachytherapy I-Claim
but I-Claim
is I-Claim
typically I-Claim
mild I-Claim
. I-Claim
!LF! !LF!
prophylactic B-Claim
alpha I-Claim
- I-Claim
blockers I-Claim
gave I-Claim
significantly I-Claim
lower I-Claim
maximum I-Claim
dysuria I-Claim
scores I-Claim
but B-Claim
did I-Claim
not I-Claim
affect I-Claim
the I-Claim
time I-Claim
to I-Claim
the I-Claim
resolution I-Claim
of I-Claim
dysuria I-Claim
. I-Claim
!LF! !LF!
the B-Claim
maximum I-Claim
ipss I-Claim
after I-Claim
the I-Claim
implant I-Claim
was I-Claim
the I-Claim
best I-Claim
predictor I-Claim
of I-Claim
the I-Claim
resolution I-Claim
of I-Claim
dysuria I-Claim
. I-Claim
!LF! !LF!
the B-Claim
addition I-Claim
of I-Claim
bevacizumab I-Claim
to I-Claim
paclitaxel I-Claim
improved I-Claim
progression I-Claim
- I-Claim
free I-Claim
survival I-Claim
( I-Claim
pfs I-Claim
) I-Claim
of I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
breast I-Claim
cancer I-Claim
( I-Claim
mbc I-Claim
) I-Claim
. I-Claim
!LF! !LF!
we O
examined O
the O
efficacy O
and O
safety O
of O
adding O
gemcitabine O
to O
paclitaxel O
/ O
bevacizumab O
( O
pb O
) O
. O
!LF! !LF!
in O
this O
multicenter O
, O
open O
- O
label O
, O
randomized O
phase O
ii O
trial O
, O
women O
with O
locally O
advanced O
or O
mbc O
were O
randomly O
assigned O
to O
receive O
paclitaxel O
90 O
mg O
/ O
m O
( O
2 O
) O
( O
days O
1 O
, O
8 O
, O
15 O
) O
and O
bevacizumab O
10 O
mg O
/ O
kg O
( O
days O
1 O
, O
15 O
) O
with O
or O
without O
gemcitabine O
1500 O
mg O
/ O
m O
( O
2 O
) O
( O
days O
1 O
, O
15 O
) O
in O
28 O
- O
day O
cycles O
. O
!LF! !LF!
patients O
with O
prior O
cytotoxic O
therapy O
for O
mbc O
were O
ineligible O
. O
!LF! !LF!
the O
primary O
endpoint O
was O
investigator O
- O
assessed O
overall O
response O
rate O
( O
orr O
) O
"""" O
; O
"""" O
secondary O
endpoints O
were O
pfs O
, O
overall O
survival O
( O
os O
) O
, O
safety O
, O
and O
quality O
of O
life O
. O
!LF! !LF!
ninety O
- O
four O
patients O
received O
pb O
, O
and O
93 O
received O
paclitaxel O
/ O
bevacizumab O
/ O
gemcitabine O
( O
pb O
+ O
g O
) O
. O
!LF! !LF!
the B-Premise
orrs I-Premise
were I-Premise
48 I-Premise
. I-Premise
9 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
ci I-Premise
] I-Premise
, I-Premise
38 I-Premise
. I-Premise
5 I-Premise
% I-Premise
- I-Premise
59 I-Premise
. I-Premise
5 I-Premise
% I-Premise
) I-Premise
and I-Premise
58 I-Premise
. I-Premise
7 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
47 I-Premise
. I-Premise
9 I-Premise
% I-Premise
- I-Premise
68 I-Premise
. I-Premise
9 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
117 I-Premise
) I-Premise
with I-Premise
pb I-Premise
and I-Premise
pb I-Premise
+ I-Premise
g I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
the B-Premise
median I-Premise
pfs I-Premise
was I-Premise
8 I-Premise
. I-Premise
8 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
8 I-Premise
. I-Premise
1 I-Premise
- I-Premise
10 I-Premise
. I-Premise
4 I-Premise
months I-Premise
) I-Premise
and I-Premise
11 I-Premise
. I-Premise
3 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
9 I-Premise
. I-Premise
7 I-Premise
- I-Premise
12 I-Premise
. I-Premise
7 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
247 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0 I-Premise
. I-Premise
82 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
the I-Premise
median I-Premise
os I-Premise
was I-Premise
25 I-Premise
. I-Premise
0 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
18 I-Premise
. I-Premise
8 I-Premise
- I-Premise
not I-Premise
assessable I-Premise
[ I-Premise
n I-Premise
/ I-Premise
a I-Premise
] I-Premise
months I-Premise
) I-Premise
and I-Premise
24 I-Premise
. I-Premise
3 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
20 I-Premise
. I-Premise
3 I-Premise
- I-Premise
n I-Premise
/ I-Premise
a I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
475 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0 I-Premise
. I-Premise
84 I-Premise
) I-Premise
, I-Premise
with I-Premise
pb I-Premise
and I-Premise
pb I-Premise
+ I-Premise
g I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
there B-Premise
was I-Premise
significantly I-Premise
more I-Premise
grade I-Premise
3 I-Premise
- I-Premise
4 I-Premise
neutropenia I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
001 I-Premise
) I-Premise
and I-Premise
dyspnea I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
014 I-Premise
) I-Premise
with I-Premise
pb I-Premise
+ I-Premise
g I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
treated I-Premise
with I-Premise
pb I-Premise
experienced I-Premise
more I-Premise
improvement I-Premise
in I-Premise
total I-Premise
fact I-Premise
- I-Premise
b I-Premise
( I-Premise
functional I-Premise
assessment I-Premise
of I-Premise
cancer I-Premise
therapy I-Premise
- I-Premise
breast I-Premise
) I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
021 I-Premise
) I-Premise
, I-Premise
fact I-Premise
- I-Premise
b I-Premise
social I-Premise
/ I-Premise
family I-Premise
well I-Premise
- I-Premise
being I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
041 I-Premise
) I-Premise
, I-Premise
and I-Premise
breast I-Premise
cancer I-Premise
- I-Premise
additional I-Premise
concerns I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
008 I-Premise
) I-Premise
scores I-Premise
than I-Premise
patients I-Premise
treated I-Premise
with I-Premise
pb I-Premise
+ I-Premise
g I-Premise
. I-Premise
!LF! !LF!
the B-Claim
addition I-Claim
of I-Claim
gemcitabine I-Claim
to I-Claim
pb I-Claim
was I-Claim
not I-Claim
associated I-Claim
with I-Claim
a I-Claim
statistically I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
orr I-Claim
. I-Claim
!LF! !LF!
treatment B-Claim
with I-Claim
pb I-Claim
+ I-Claim
g I-Claim
increased I-Claim
the I-Claim
incidence I-Claim
of I-Claim
severe I-Claim
neutropenia I-Claim
and I-Claim
dyspnea I-Claim
, I-Claim
although B-Claim
the I-Claim
regimen I-Claim
generally I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
. I-Claim
!LF! !LF!
maintenance O
therapy O
, O
commenced O
immediately O
after O
the O
completion O
of O
first O
- O
line O
chemotherapy O
, O
is O
a O
promising O
strategy O
for O
improving O
treatment O
outcomes O
in O
patients O
with O
non O
- O
small O
- O
cell O
lung O
cancer O
( O
nsclc O
) O
. O
!LF! !LF!
the O
global O
phase O
iii O
sequential O
tarceva O
in O
unresectable O
nsclc O
( O
saturn O
) O
study O
evaluated O
the O
efficacy O
and O
safety O
of O
the O
epidermal O
growth O
factor O
receptor O
( O
egfr O
) O
tyrosine O
- O
kinase O
inhibitor O
erlotinib O
as O
maintenance O
treatment O
in O
nsclc O
patients O
without O
progression O
after O
first O
- O
line O
chemotherapy O
. O
!LF! !LF!
we O
report O
a O
retrospective O
subanalysis O
of O
asian O
patients O
enrolled O
in O
saturn O
. O
!LF! !LF!
patients O
with O
advanced O
nsclc O
with O
no O
evidence O
of O
progression O
after O
four O
cycles O
of O
chemotherapy O
were O
randomized O
to O
receive O
erlotinib O
150 O
mg O
/ O
day O
or O
placebo O
, O
until O
progressive O
disease O
or O
limiting O
toxicity O
. O
!LF! !LF!
the O
co O
- O
primary O
endpoints O
of O
saturn O
were O
progression O
- O
free O
survival O
( O
pfs O
) O
in O
all O
patients O
and O
in O
those O
with O
positive O
egfr O
immunohistochemistry O
( O
ihc O
) O
status O
. O
!LF! !LF!
secondary O
endpoints O
included O
overall O
survival O
( O
os O
) O
, O
disease O
control O
rate O
, O
safety O
, O
quality O
of O
life O
( O
qol O
) O
and O
biomarker O
analyses O
. O
!LF! !LF!
in O
total O
, O
126 O
patients O
from O
east O
and O
south O
- O
east O
asian O
centers O
were O
randomized O
( O
14 O
% O
of O
the O
intent O
- O
to O
- O
treat O
population O
) O
: O
88 O
from O
korea O
, O
28 O
from O
china O
and O
10 O
from O
malaysia O
"""" O
; O
"""" O
one O
patient O
was O
excluded O
from O
this O
analysis O
due O
to O
indian O
ethnicity O
. O
!LF! !LF!
pfs B-Premise
was I-Premise
significantly I-Premise
prolonged I-Premise
in I-Premise
the I-Premise
erlotinib I-Premise
treatment I-Premise
arm I-Premise
, I-Premise
both I-Premise
overall I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
hr I-Premise
] I-Premise
: I-Premise
0 I-Premise
. I-Premise
57 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0067 I-Premise
) I-Premise
and I-Premise
in I-Premise
patients I-Premise
with I-Premise
egfr I-Premise
ihc I-Premise
- I-Premise
positive I-Premise
disease I-Premise
( I-Premise
hr I-Premise
= I-Premise
0 I-Premise
. I-Premise
50 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0057 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
there B-Premise
was I-Premise
a I-Premise
trend I-Premise
towards I-Premise
an I-Premise
increase I-Premise
in I-Premise
os I-Premise
, I-Premise
which I-Premise
reached I-Premise
statistical I-Premise
significance I-Premise
in I-Premise
the I-Premise
egfr I-Premise
ihc I-Premise
- I-Premise
positive I-Premise
subgroup I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0233 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
overall I-Premise
response I-Premise
rate I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
with I-Premise
erlotinib I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
24 I-Premise
% I-Premise
versus I-Premise
5 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0025 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
erlotinib B-Claim
was I-Claim
generally I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
had I-Claim
no I-Claim
negative I-Claim
impact I-Claim
on I-Claim
qol I-Claim
in I-Claim
this I-Claim
subpopulation I-Claim
. I-Claim
!LF! !LF!
the B-Premise
most I-Premise
common I-Premise
treatment I-Premise
- I-Premise
related I-Premise
adverse I-Premise
events I-Premise
were I-Premise
rash I-Premise
, I-Premise
diarrhea I-Premise
and I-Premise
pruritus I-Premise
. I-Premise
!LF! !LF!
erlotinib B-Claim
was I-Claim
effective I-Claim
and I-Claim
well I-Claim
tolerated I-Claim
in I-Claim
asian I-Claim
patients I-Claim
, I-Claim
producing I-Claim
benefits I-Claim
consistent I-Claim
with I-Claim
those I-Claim
observed I-Claim
in I-Claim
the I-Claim
overall I-Claim
saturn I-Claim
population I-Claim
. I-Claim
!LF! !LF!
maintenance B-Claim
treatment I-Claim
with I-Claim
erlotinib I-Claim
appears I-Claim
to I-Claim
be I-Claim
a I-Claim
useful I-Claim
option I-Claim
for I-Claim
the I-Claim
management I-Claim
of I-Claim
asian I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
nsclc I-Claim
without I-Claim
progression I-Claim
after I-Claim
first I-Claim
- I-Claim
line I-Claim
chemotherapy I-Claim
. I-Claim
!LF! !LF!
to O
evaluate O
the O
safety O
and O
efficacy O
of O
abatacept O
during O
2 O
years O
of O
the O
attain O
( O
abatacept O
trial O
in O
treatment O
of O
anti O
- O
tnf O
inadequate O
responders O
) O
trial O
in O
patients O
with O
rheumatoid O
arthritis O
. O
!LF! !LF!
patients O
completing O
the O
6 O
- O
month O
, O
double O
- O
blind O
period O
were O
eligible O
to O
enter O
the O
long O
- O
term O
extension O
"""" O
; O
"""" O
patients O
received O
abatacept O
approximately O
10 O
mg O
/ O
kg O
, O
plus O
disease O
- O
modifying O
antirheumatic O
drugs O
. O
!LF! !LF!
safety O
and O
efficacy O
( O
american O
college O
of O
rheumatology O
( O
acr O
) O
criteria O
responses O
, O
das28 O
( O
c O
- O
reactive O
protein O
) O
, O
haq O
- O
di O
, O
sf O
- O
36 O
, O
medical O
outcomes O
study O
sleep O
problems O
index O
, O
fatigue O
vas O
) O
were O
assessed O
through O
2 O
years O
. O
!LF! !LF!
317 O
patients O
( O
218 O
from O
the O
abatacept O
and O
99 O
from O
the O
placebo O
group O
) O
entered O
and O
222 O
( O
70 O
% O
) O
completed O
18 O
months O
of O
long O
- O
term O
extension O
treatment O
. O
!LF! !LF!
the B-Premise
incidence I-Premise
and I-Premise
type I-Premise
of I-Premise
adverse I-Premise
events I-Premise
were I-Premise
consistent I-Premise
between I-Premise
the I-Premise
double I-Premise
- I-Premise
blind I-Premise
and I-Premise
cumulative I-Premise
( I-Premise
double I-Premise
- I-Premise
blind I-Premise
plus I-Premise
long I-Premise
- I-Premise
term I-Premise
extension I-Premise
) I-Premise
periods I-Premise
. I-Premise
!LF! !LF!
rates B-Premise
of I-Premise
serious I-Premise
adverse I-Premise
events I-Premise
were I-Premise
25 I-Premise
. I-Premise
6 I-Premise
and I-Premise
23 I-Premise
. I-Premise
4 I-Premise
per I-Premise
100 I-Premise
patient I-Premise
- I-Premise
years I-Premise
in I-Premise
the I-Premise
double I-Premise
- I-Premise
blind I-Premise
versus I-Premise
cumulative I-Premise
period I-Premise
. I-Premise
!LF! !LF!
at B-Premise
6 I-Premise
months I-Premise
and I-Premise
2 I-Premise
years I-Premise
, I-Premise
using I-Premise
non I-Premise
- I-Premise
responder I-Premise
analyses I-Premise
, I-Premise
acr I-Premise
responses I-Premise
in I-Premise
abatacept I-Premise
- I-Premise
treated I-Premise
patients I-Premise
were I-Premise
: I-Premise
acr I-Premise
20 I-Premise
, I-Premise
59 I-Premise
. I-Premise
4 I-Premise
% I-Premise
and I-Premise
56 I-Premise
. I-Premise
2 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
acr I-Premise
50 I-Premise
, I-Premise
23 I-Premise
. I-Premise
5 I-Premise
% I-Premise
and I-Premise
33 I-Premise
. I-Premise
2 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
acr I-Premise
70 I-Premise
, I-Premise
11 I-Premise
. I-Premise
5 I-Premise
% I-Premise
and I-Premise
16 I-Premise
. I-Premise
1 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
haq I-Premise
- I-Premise
di I-Premise
responses I-Premise
were I-Premise
54 I-Premise
. I-Premise
4 I-Premise
% I-Premise
and I-Premise
47 I-Premise
. I-Premise
9 I-Premise
% I-Premise
. I-Premise
!LF! !LF!
at B-Premise
6 I-Premise
months I-Premise
and I-Premise
2 I-Premise
years I-Premise
, I-Premise
using I-Premise
post I-Premise
- I-Premise
hoc I-Premise
as I-Premise
- I-Premise
observed I-Premise
analyses I-Premise
, I-Premise
the I-Premise
percentage I-Premise
of I-Premise
patients I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
) I-Premise
achieving I-Premise
das28 I-Premise
( I-Premise
c I-Premise
- I-Premise
reactive I-Premise
protein I-Premise
) I-Premise
low I-Premise
disease I-Premise
activity I-Premise
score I-Premise
( I-Premise
< I-Premise
or I-Premise
= I-Premise
3 I-Premise
. I-Premise
2 I-Premise
) I-Premise
and I-Premise
das28 I-Premise
( I-Premise
c I-Premise
- I-Premise
reactive I-Premise
protein I-Premise
) I-Premise
- I-Premise
defined I-Premise
remission I-Premise
( I-Premise
< I-Premise
2 I-Premise
. I-Premise
6 I-Premise
) I-Premise
increased I-Premise
from I-Premise
18 I-Premise
. I-Premise
3 I-Premise
% I-Premise
( I-Premise
13 I-Premise
. I-Premise
0 I-Premise
, I-Premise
23 I-Premise
. I-Premise
5 I-Premise
) I-Premise
to I-Premise
32 I-Premise
. I-Premise
0 I-Premise
% I-Premise
( I-Premise
24 I-Premise
. I-Premise
6 I-Premise
, I-Premise
39 I-Premise
. I-Premise
4 I-Premise
) I-Premise
and I-Premise
11 I-Premise
. I-Premise
1 I-Premise
% I-Premise
( I-Premise
6 I-Premise
. I-Premise
8 I-Premise
, I-Premise
15 I-Premise
. I-Premise
3 I-Premise
) I-Premise
to I-Premise
20 I-Premise
. I-Premise
3 I-Premise
% I-Premise
( I-Premise
13 I-Premise
. I-Premise
9 I-Premise
, I-Premise
26 I-Premise
. I-Premise
6 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
clinically B-Premise
meaningful I-Premise
improvements I-Premise
in I-Premise
sf I-Premise
- I-Premise
36 I-Premise
, I-Premise
pain I-Premise
, I-Premise
fatigue I-Premise
and I-Premise
sleep I-Premise
problems I-Premise
were I-Premise
also I-Premise
maintained I-Premise
throughout I-Premise
the I-Premise
2 I-Premise
years I-Premise
of I-Premise
abatacept I-Premise
treatment I-Premise
. I-Premise
!LF! !LF!
no B-Premise
unique I-Premise
safety I-Premise
observations I-Premise
were I-Premise
reported I-Premise
during I-Premise
open I-Premise
- I-Premise
label I-Premise
exposure I-Premise
. I-Premise
!LF! !LF!
improvements B-Premise
in I-Premise
the I-Premise
signs I-Premise
and I-Premise
symptoms I-Premise
of I-Premise
rheumatoid I-Premise
arthritis I-Premise
, I-Premise
physical I-Premise
function I-Premise
and I-Premise
health I-Premise
- I-Premise
related I-Premise
quality I-Premise
of I-Premise
life I-Premise
observed I-Premise
after I-Premise
6 I-Premise
months I-Premise
, I-Premise
were I-Premise
maintained I-Premise
throughout I-Premise
the I-Premise
2 I-Premise
years I-Premise
in I-Premise
this I-Premise
population I-Premise
with I-Premise
difficult I-Premise
- I-Premise
to I-Premise
- I-Premise
treat I-Premise
disease I-Premise
. I-Premise
!LF! !LF!
gemcitabine O
for O
advanced O
pancreatic O
cancer O
( O
apc O
) O
is O
palliative O
and O
the O
prognosis O
is O
poor O
, O
making O
health O
- O
related O
quality O
of O
life O
( O
hrqol O
) O
particularly O
important O
. O
!LF! !LF!
we O
evaluated O
hrqol O
with O
the O
euroqol O
( O
eq O
- O
5d™ O
) O
in O
patients O
with O
apc O
participating O
in O
cancer O
and O
leukemia O
group O
b O
80303 O
, O
a O
multicenter O
, O
double O
- O
blind O
, O
randomized O
trial O
comparing O
overall O
survival O
( O
os O
) O
between O
two O
treatment O
arms O
: O
gemcitabine O
with O
bevacizumab O
or O
gemcitabine O
with O
placebo O
. O
!LF! !LF!
a O
consecutive O
subsample O
of O
patients O
was O
invited O
to O
complete O
the O
eq O
- O
5d O
surveys O
. O
!LF! !LF!
because O
neither O
clinical O
nor O
hrqol O
outcomes O
differed O
based O
on O
the O
study O
arm O
, O
analyses O
were O
pooled O
. O
!LF! !LF!
changes O
in O
mean O
scores O
from O
baseline O
to O
eight O
weeks O
and O
the O
prognostic O
value O
of O
the O
eq O
- O
5d O
were O
evaluated O
. O
!LF! !LF!
mean B-Premise
index I-Premise
scores I-Premise
remained I-Premise
stable I-Premise
( I-Premise
0 I-Premise
. I-Premise
78 I-Premise
at I-Premise
baseline I-Premise
[ I-Premise
n I-Premise
= I-Premise
267 I-Premise
] I-Premise
, I-Premise
0 I-Premise
. I-Premise
79 I-Premise
at I-Premise
eight I-Premise
weeks I-Premise
[ I-Premise
n I-Premise
= I-Premise
186 I-Premise
] I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
34 I-Premise
, I-Premise
wilcoxon I-Premise
signed I-Premise
rank I-Premise
test I-Premise
) I-Premise
, I-Premise
attributable I-Premise
to I-Premise
a I-Premise
modest I-Premise
deterioration I-Premise
of I-Premise
physical I-Premise
function I-Premise
domain I-Premise
scores I-Premise
coincident I-Premise
with I-Premise
small I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
and I-Premise
anxiety I-Premise
/ I-Premise
depression I-Premise
scores I-Premise
. I-Premise
!LF! !LF!
a B-Premise
small I-Premise
decline I-Premise
in I-Premise
visual I-Premise
analogue I-Premise
scale I-Premise
scores I-Premise
was I-Premise
observed I-Premise
( I-Premise
70 I-Premise
. I-Premise
7 I-Premise
vs I-Premise
. I-Premise
68 I-Premise
. I-Premise
2 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
026 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
hrqol B-Premise
changes I-Premise
within I-Premise
chemotherapy I-Premise
response I-Premise
strata I-Premise
revealed I-Premise
stable I-Premise
index I-Premise
scores I-Premise
but B-Premise
a I-Premise
trend I-Premise
of I-Premise
worsened I-Premise
physical I-Premise
function I-Premise
among I-Premise
patients I-Premise
with I-Premise
disease I-Premise
progression I-Premise
compared I-Premise
with I-Premise
those I-Premise
with I-Premise
stable I-Premise
or I-Premise
improved I-Premise
disease I-Premise
. I-Premise
!LF! !LF!
visual B-Premise
analogue I-Premise
scale I-Premise
scores I-Premise
trended I-Premise
downward I-Premise
over I-Premise
time I-Premise
irrespective I-Premise
of I-Premise
chemotherapy I-Premise
response I-Premise
status I-Premise
, I-Premise
with I-Premise
a I-Premise
statistically I-Premise
meaningful I-Premise
deterioration I-Premise
in I-Premise
patients I-Premise
who I-Premise
progressed I-Premise
( I-Premise
68 I-Premise
. I-Premise
9 I-Premise
vs I-Premise
. I-Premise
64 I-Premise
. I-Premise
4 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
029 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
baseline O
scores O
from O
both O
eq O
- O
5d O
scales O
were O
significant O
predictors O
of O
os O
in O
cox O
proportional O
hazard O
models O
. O
!LF! !LF!
response B-Claim
to I-Claim
gemcitabine I-Claim
treatment I-Claim
in I-Claim
apc I-Claim
is I-Claim
not I-Claim
associated I-Claim
with I-Claim
appreciable I-Claim
improvement I-Claim
of I-Claim
global I-Claim
hrqol I-Claim
. I-Claim
!LF! !LF!
small O
improvements O
in O
pain O
and O
mood O
are O
observed O
despite O
progressive O
functional O
decline O
. O
!LF! !LF!
those B-Claim
who I-Claim
respond I-Claim
to I-Claim
gemcitabine I-Claim
may I-Claim
experience I-Claim
a I-Claim
slight I-Claim
slowing I-Claim
of I-Claim
functional I-Claim
deterioration I-Claim
. I-Claim
!LF! !LF!
bone O
- O
cancer O
pain O
is O
a O
common O
and O
refractory O
cancer O
pain O
. O
!LF! !LF!
opioids O
, O
on O
their O
own O
, O
do O
not O
control O
this O
type O
of O
pain O
well O
enough O
, O
and O
co O
- O
analgesics O
are O
necessary O
. O
!LF! !LF!
patients O
with O
bone O
metastasis O
- O
related O
pain O
at O
numeric O
rating O
scale O
≥4 O
were O
enrolled O
to O
this O
randomized O
placebo O
- O
controlled O
trial O
. O
!LF! !LF!
they O
had O
also O
received O
morphine O
or O
transdermal O
fentanyl O
patches O
for O
at O
least O
1 O
week O
. O
!LF! !LF!
during O
the O
3 O
- O
day O
efficacy O
phase O
, O
patients O
received O
placebo O
or O
1 O
- O
3 O
tablets O
of O
oxycodone O
/ O
paracetamol O
( O
5 O
/ O
325 O
mg O
) O
, O
four O
times O
daily O
for O
3 O
days O
. O
!LF! !LF!
all O
patients O
kept O
a O
daily O
pain O
diary O
. O
!LF! !LF!
the O
primary O
endpoint O
was O
the O
pain O
intensity O
difference O
( O
pid O
) O
. O
!LF! !LF!
secondary O
endpoints O
were O
cases O
of O
breakthrough O
pain O
and O
rescue O
morphine O
consumption O
. O
!LF! !LF!
additional O
analyses O
included O
the O
short O
form O
- O
6 O
dimensions O
( O
sf O
- O
6d O
) O
quality O
- O
of O
- O
life O
scale O
and O
a O
general O
impression O
( O
gi O
) O
of O
patient O
satisfaction O
with O
treatment O
at O
the O
end O
of O
the O
phase O
. O
!LF! !LF!
of O
the O
246 O
patients O
in O
the O
intent O
- O
to O
- O
treat O
set O
, O
89 O
· O
4 O
% O
completed O
the O
3 O
- O
day O
efficacy O
phase O
. O
!LF! !LF!
pids B-Premise
were I-Premise
0 I-Premise
· I-Premise
9 I-Premise
and I-Premise
0 I-Premise
· I-Premise
3 I-Premise
in I-Premise
the I-Premise
oxycodone I-Premise
/ I-Premise
paracetamol I-Premise
and I-Premise
placebo I-Premise
groups I-Premise
respectively I-Premise
, I-Premise
on I-Premise
day I-Premise
1 I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
· I-Premise
001 I-Premise
) I-Premise
, I-Premise
and I-Premise
1 I-Premise
· I-Premise
5 I-Premise
and I-Premise
0 I-Premise
· I-Premise
3 I-Premise
respectively I-Premise
on I-Premise
day I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
· I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
thirty B-Premise
- B-Premise
eight B-Premise
patients I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
and I-Premise
58 I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
, I-Premise
suffered I-Premise
breakthrough I-Premise
pain I-Premise
on I-Premise
day I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
· I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
sf I-Premise
- I-Premise
6d I-Premise
score I-Premise
decreased I-Premise
to I-Premise
21 I-Premise
· I-Premise
2 I-Premise
± I-Premise
2 I-Premise
· I-Premise
5 I-Premise
in I-Premise
the I-Premise
oxycodone I-Premise
/ I-Premise
paracetamol I-Premise
group I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
phase I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
· I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
in B-Premise
the I-Premise
oxycodone I-Premise
/ I-Premise
paracetamol I-Premise
group I-Premise
, I-Premise
67 I-Premise
% I-Premise
rated I-Premise
gi I-Premise
as I-Premise
good I-Premise
, I-Premise
very I-Premise
good I-Premise
, I-Premise
or I-Premise
excellent I-Premise
. I-Premise
!LF! !LF!
patients B-Claim
with I-Claim
bone I-Claim
- I-Claim
cancer I-Claim
pain I-Claim
, I-Claim
already I-Claim
on I-Claim
opioids I-Claim
, I-Claim
obtain I-Claim
clinically I-Claim
important I-Claim
, I-Claim
additional I-Claim
pain I-Claim
- I-Claim
control I-Claim
, I-Claim
with I-Claim
regular I-Claim
oxycodone I-Claim
/ I-Claim
paracetamol I-Claim
dosing I-Claim
. I-Claim
!LF! !LF!
to O
examine O
the O
effects O
of O
a O
seated O
exercise O
program O
on O
fatigue O
and O
quality O
of O
life O
( O
qol O
) O
in O
women O
with O
metastatic O
breast O
cancer O
. O
!LF! !LF!
randomized O
, O
controlled O
, O
longitudinal O
trial O
. O
!LF! !LF!
outpatient O
clinic O
of O
a O
comprehensive O
cancer O
center O
. O
!LF! !LF!
convenience O
sample O
of O
38 O
women O
who O
were O
beginning O
outpatient O
chemotherapy O
. O
!LF! !LF!
subjects O
were O
randomized O
to O
a O
control O
or O
intervention O
group O
"""" O
; O
"""" O
the O
intervention O
was O
performance O
of O
a O
seated O
exercise O
program O
using O
home O
videotape O
three O
times O
per O
week O
for O
four O
cycles O
of O
chemotherapy O
. O
!LF! !LF!
all O
subjects O
completed O
the O
functional O
assessment O
of O
chronic O
illness O
therapy O
fatigue O
version O
iv O
( O
facit O
f O
) O
at O
baseline O
and O
at O
the O
time O
of O
the O
next O
three O
cycles O
. O
!LF! !LF!
subjects O
were O
asked O
to O
document O
the O
frequency O
, O
duration O
, O
and O
intensity O
of O
all O
exercise O
participation O
on O
monthly O
calendars O
. O
!LF! !LF!
exercise O
, O
fatigue O
, O
and O
qol O
. O
!LF! !LF!
32 O
subjects O
, O
16 O
per O
group O
, O
completed O
the O
study O
follow O
- O
up O
. O
!LF! !LF!
with B-Premise
a I-Premise
mixed I-Premise
modeling I-Premise
approach I-Premise
, I-Premise
total I-Premise
facit I-Premise
f I-Premise
scores I-Premise
for I-Premise
the I-Premise
entire I-Premise
sample I-Premise
declined I-Premise
at I-Premise
a I-Premise
significant I-Premise
rate I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
003 I-Premise
) I-Premise
beginning I-Premise
with I-Premise
cycle I-Premise
3 I-Premise
but B-Premise
at I-Premise
a I-Premise
slower I-Premise
rate I-Premise
for I-Premise
the I-Premise
experimental I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
fatigue B-Premise
scores I-Premise
indicated I-Premise
less I-Premise
increase I-Premise
and I-Premise
physical I-Premise
well I-Premise
- I-Premise
being I-Premise
subscale I-Premise
scores I-Premise
showed I-Premise
less I-Premise
decline I-Premise
for I-Premise
the I-Premise
experimental I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
008 I-Premise
and I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise
!LF! !LF!
women B-Premise
with I-Premise
advanced I-Premise
breast I-Premise
cancer I-Premise
randomized I-Premise
to I-Premise
the I-Premise
seated I-Premise
exercise I-Premise
intervention I-Premise
had I-Premise
a I-Premise
slower I-Premise
decline I-Premise
in I-Premise
total I-Premise
and I-Premise
physical I-Premise
well I-Premise
- I-Premise
being I-Premise
and I-Premise
less I-Premise
increase I-Premise
in I-Premise
fatigue I-Premise
scores I-Premise
starting I-Premise
with I-Premise
the I-Premise
third I-Premise
cycle I-Premise
of I-Premise
chemotherapy I-Premise
. I-Premise
!LF! !LF!
seated B-Claim
exercise I-Claim
may I-Claim
be I-Claim
a I-Claim
feasible I-Claim
exercise I-Claim
program I-Claim
for I-Claim
women I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
for I-Claim
controlling I-Claim
fatigue I-Claim
and I-Claim
improving I-Claim
physical I-Claim
well I-Claim
- I-Claim
being I-Claim
. I-Claim
!LF! !LF!
few O
intervention O
programs O
assist O
patients O
and O
their O
family O
caregivers O
to O
manage O
advanced O
cancer O
and O
maintain O
their O
quality O
of O
life O
( O
qol O
) O
. O
!LF! !LF!
this O
study O
examined O
( O
i O
) O
whether O
patient O
- O
caregiver O
dyads O
( O
i O
. O
e O
. O
, O
pairs O
) O
randomly O
assigned O
to O
a O
brief O
or O
extensive O
dyadic O
intervention O
( O
the O
focus O
program O
) O
had O
better O
outcomes O
than O
dyads O
randomly O
assigned O
to O
usual O
care O
and O
( O
ii O
) O
whether O
patients O
' O
risk O
for O
distress O
and O
other O
factors O
moderated O
the O
effect O
of O
the O
brief O
or O
extensive O
program O
on O
outcomes O
. O
!LF! !LF!
advanced O
cancer O
patients O
and O
their O
caregivers O
( O
n O
= O
484 O
dyads O
) O
were O
stratified O
by O
patients O
' O
baseline O
risk O
for O
distress O
( O
high O
versus O
low O
) O
, O
cancer O
type O
( O
lung O
, O
colorectal O
, O
breast O
, O
or O
prostate O
) O
, O
and O
research O
site O
and O
then O
randomly O
assigned O
to O
a O
brief O
( O
three O
- O
session O
) O
or O
extensive O
( O
six O
- O
session O
) O
intervention O
or O
control O
. O
!LF! !LF!
the O
interventions O
offered O
dyads O
information O
and O
support O
. O
!LF! !LF!
intermediary O
outcomes O
were O
appraisals O
( O
i O
. O
e O
. O
, O
appraisal O
of O
illness O
/ O
caregiving O
, O
uncertainty O
, O
and O
hopelessness O
) O
and O
resources O
( O
i O
. O
e O
. O
, O
coping O
, O
interpersonal O
relationships O
, O
and O
self O
- O
efficacy O
) O
. O
!LF! !LF!
the O
primary O
outcome O
was O
qol O
. O
!LF! !LF!
data O
were O
collected O
prior O
to O
intervention O
and O
post O
- O
intervention O
( O
3 O
and O
6 O
months O
from O
baseline O
) O
. O
!LF! !LF!
the O
final O
sample O
was O
302 O
dyads O
. O
!LF! !LF!
repeated O
measures O
mancova O
was O
used O
to O
evaluate O
outcomes O
. O
!LF! !LF!
significant B-Premise
group I-Premise
by I-Premise
time I-Premise
interactions I-Premise
showed I-Premise
that I-Premise
there I-Premise
was I-Premise
an I-Premise
improvement I-Premise
in I-Premise
dyads I-Premise
' I-Premise
coping I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
, I-Premise
self I-Premise
- I-Premise
efficacy I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
, I-Premise
and I-Premise
social I-Premise
qol I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
and I-Premise
in I-Premise
caregivers I-Premise
' I-Premise
emotional I-Premise
qol I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
effects O
varied O
by O
intervention O
dose O
. O
!LF! !LF!
most O
effects O
were O
found O
at O
3 O
months O
only O
. O
!LF! !LF!
risk B-Premise
for I-Premise
distress I-Premise
accounted I-Premise
for I-Premise
very I-Premise
few I-Premise
moderation I-Premise
effects I-Premise
. I-Premise
!LF! !LF!
both B-Premise
brief I-Premise
and I-Premise
extensive I-Premise
programs I-Premise
had I-Premise
positive I-Premise
outcomes I-Premise
for I-Premise
patient I-Premise
- I-Premise
caregiver I-Premise
dyads I-Premise
, I-Premise
but B-Premise
few I-Premise
sustained I-Premise
effects I-Premise
. I-Premise
!LF! !LF!
patient B-Claim
- B-Claim
caregiver B-Claim
dyads I-Claim
benefit I-Claim
when I-Claim
viewed I-Claim
as I-Claim
the I-Claim
' I-Claim
unit I-Claim
of I-Claim
care I-Claim
' I-Claim
. I-Claim
!LF! !LF!
to O
observe O
the O
clinical O
efficacy O
of O
shenqi O
fuzheng O
injection O
( O
sfi O
) O
combined O
with O
chemotherapy O
in O
treating O
patients O
with O
advanced O
breast O
cancer O
. O
!LF! !LF!
sixty O
patients O
were O
randomly O
assigned O
to O
two O
groups O
by O
digital O
table O
, O
the O
control O
group O
and O
the O
treatment O
group O
, O
30 O
in O
each O
group O
. O
!LF! !LF!
all O
patients O
were O
treated O
with O
the O
same O
ctf O
regimen O
of O
chemotherapy O
for O
21 O
days O
as O
one O
therapeutic O
cycle O
, O
while O
those O
in O
the O
treatment O
group O
were O
given O
sfi O
additionally O
in O
the O
meanwhite O
. O
!LF! !LF!
the O
therapeutic O
efficacy O
was O
evaluated O
after O
2 O
cycles O
of O
treatment O
by O
observing O
the O
changes O
of O
short O
- O
term O
efficacy O
, O
tcm O
syndrome O
, O
quality O
of O
life O
and O
immune O
function O
, O
as O
well O
as O
the O
adverse O
reaction O
. O
!LF! !LF!
the B-Premise
total I-Premise
short I-Premise
- I-Premise
term I-Premise
remission I-Premise
rate I-Premise
, I-Premise
the I-Premise
improvement I-Premise
rate I-Premise
of I-Premise
clinical I-Premise
syndrome I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
50 I-Premise
. I-Premise
0 I-Premise
% I-Premise
, I-Premise
70 I-Premise
. I-Premise
0 I-Premise
% I-Premise
and I-Premise
76 I-Premise
. I-Premise
7 I-Premise
% I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
and I-Premise
43 I-Premise
. I-Premise
3 I-Premise
% I-Premise
, I-Premise
46 I-Premise
. I-Premise
7 I-Premise
% I-Premise
and I-Premise
50 I-Premise
. I-Premise
0 I-Premise
% I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
respectively I-Premise
, I-Premise
showing I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
( I-Premise
all I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
occurrence I-Premise
of I-Premise
adverse I-Premise
reaction I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
was I-Premise
lower I-Premise
than I-Premise
that I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
level I-Premise
of I-Premise
cd3 I-Premise
+ I-Premise
cd4 I-Premise
+ I-Premise
and I-Premise
cd4 I-Premise
+ I-Premise
/ I-Premise
cd8 I-Premise
+ I-Premise
ratio I-Premise
increased I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
and I-Premise
cd8 I-Premise
+ I-Premise
decreased I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
, I-Premise
while I-Premise
they I-Premise
showed I-Premise
insignificant I-Premise
change I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise
!LF! !LF!
for B-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
sfi I-Claim
can I-Claim
alleviate I-Claim
the I-Claim
bone I-Claim
marrow I-Claim
inhibition I-Claim
caused I-Claim
by I-Claim
chemotherapy I-Claim
, I-Claim
improve I-Claim
clinical I-Claim
symptoms I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
prolong I-Claim
the I-Claim
survival I-Claim
period I-Claim
by I-Claim
regulating I-Claim
cellular I-Claim
immune I-Claim
function I-Claim
of I-Claim
patients I-Claim
, I-Claim
so I-Claim
as I-Claim
to I-Claim
enhance I-Claim
the I-Claim
therapeutic I-Claim
effect I-Claim
of I-Claim
chemotherapy I-Claim
. I-Claim
!LF! !LF!
the O
american O
college O
of O
surgeons O
oncology O
group O
phase O
iii O
surgical O
prostatectomy O
versus O
interstitial O
radiation O
intervention O
trial O
comparing O
radical O
prostatectomy O
( O
rp O
) O
and O
brachytherapy O
( O
bt O
) O
closed O
after O
2 O
years O
due O
to O
poor O
accrual O
. O
!LF! !LF!
we O
report O
health O
- O
related O
quality O
of O
life O
( O
hrqol O
) O
at O
a O
mean O
of O
5 O
. O
3 O
years O
for O
168 O
trial O
- O
eligible O
men O
who O
either O
chose O
or O
were O
randomly O
assigned O
to O
rp O
or O
bt O
following O
a O
multidisciplinary O
educational O
session O
. O
!LF! !LF!
after O
initial O
lack O
of O
accrual O
, O
a O
multidisciplinary O
educational O
session O
was O
introduced O
for O
eligible O
patients O
. O
!LF! !LF!
in O
all O
, O
263 O
men O
attended O
47 O
sessions O
. O
!LF! !LF!
of O
those O
, O
34 O
consented O
to O
random O
assignment O
, O
62 O
chose O
rp O
, O
and O
94 O
chose O
bt O
. O
!LF! !LF!
five O
years O
later O
, O
these O
190 O
men O
underwent O
hrqol O
evaluation O
by O
using O
the O
cancer O
- O
specific O
50 O
- O
item O
expanded O
prostate O
cancer O
index O
composite O
, O
the O
short O
form O
12 O
physical O
component O
score O
, O
and O
short O
form O
12 O
mental O
component O
score O
. O
!LF! !LF!
response O
rate O
was O
88 O
. O
4 O
% O
. O
!LF! !LF!
the O
wilcoxon O
rank O
sum O
test O
was O
used O
to O
compare O
summary O
scores O
between O
the O
two O
interventions O
. O
!LF! !LF!
of O
168 O
survey O
responders O
, O
60 O
. O
7 O
% O
had O
bt O
( O
9 O
. O
5 O
% O
randomly O
assigned O
) O
and O
39 O
. O
3 O
% O
had O
rp O
( O
9 O
. O
5 O
% O
randomly O
assigned O
) O
. O
!LF! !LF!
median O
age O
was O
61 O
. O
4 O
years O
for O
bt O
and O
59 O
. O
4 O
for O
rp O
( O
p O
= O
. O
05 O
) O
. O
!LF! !LF!
median O
follow O
- O
up O
was O
5 O
. O
2 O
years O
( O
range O
, O
3 O
. O
2 O
to O
6 O
. O
5 O
years O
) O
. O
!LF! !LF!
for B-Premise
bt I-Premise
versus I-Premise
rp I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
bowel I-Premise
or I-Premise
hormonal I-Premise
domains I-Premise
, I-Premise
but O
men B-Premise
treated I-Premise
with I-Premise
bt I-Premise
scored I-Premise
better I-Premise
in I-Premise
urinary I-Premise
( I-Premise
91 I-Premise
. I-Premise
8 I-Premise
v I-Premise
88 I-Premise
. I-Premise
1 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
02 I-Premise
) I-Premise
and I-Premise
sexual I-Premise
( I-Premise
52 I-Premise
. I-Premise
5 I-Premise
v I-Premise
39 I-Premise
. I-Premise
2 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
001 I-Premise
) I-Premise
domains I-Premise
, I-Premise
and I-Premise
in I-Premise
patient I-Premise
satisfaction I-Premise
( I-Premise
93 I-Premise
. I-Premise
6 I-Premise
v I-Premise
76 I-Premise
. I-Premise
9 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
although O
treatment O
allocation O
was O
random O
in O
only O
19 O
% O
, O
all O
patients O
received O
identical O
information O
in O
a O
multidisciplinary O
setting O
before O
selecting O
rp O
, O
bt O
, O
or O
random O
assignment O
. O
!LF! !LF!
hrqol B-Claim
evaluated I-Claim
3 I-Claim
. I-Claim
2 I-Claim
to I-Claim
6 I-Claim
. I-Claim
5 I-Claim
years I-Claim
after I-Claim
treatment I-Claim
showed I-Claim
an I-Claim
advantage I-Claim
for I-Claim
bt I-Claim
in I-Claim
urinary I-Claim
and I-Claim
sexual I-Claim
domains I-Claim
and I-Claim
in I-Claim
patient I-Claim
satisfaction I-Claim
. I-Claim
!LF! !LF!
a O
multidimensional O
rehabilitation O
program O
for O
cancer O
survivors O
was O
developed O
to O
overcome O
cancer O
- O
related O
problems O
and O
to O
improve O
quality O
of O
life O
. O
!LF! !LF!
the O
two O
purposes O
of O
the O
study O
were O
to O
describe O
the O
effectiveness O
of O
the O
program O
and O
to O
obtain O
information O
about O
patient O
preferences O
for O
multi O
or O
mono O
dimensional O
rehabilitation O
programs O
. O
!LF! !LF!
cancer O
survivors O
with O
different O
diagnoses O
, O
and O
cancer O
- O
related O
physical O
and O
psychosocial O
problems O
. O
!LF! !LF!
a O
15 O
- O
week O
rehabilitation O
program O
including O
individual O
exercise O
, O
sports O
, O
psycho O
- O
education O
, O
and O
information O
. O
!LF! !LF!
group O
- O
wise O
randomization O
was O
implemented O
by O
assigning O
one O
half O
of O
the O
patients O
to O
the O
complete O
program O
while O
the O
other O
half O
were O
allowed O
to O
choose O
which O
program O
components O
they O
considered O
relevant O
. O
!LF! !LF!
health O
- O
related O
quality O
of O
life O
[ O
rand O
- O
36 O
and O
rotterdam O
symptom O
check O
list O
( O
rscl O
) O
] O
, O
exercise O
capacity O
( O
symptom O
limited O
bicycle O
ergometry O
) O
, O
muscle O
force O
( O
hand O
- O
held O
dynamometry O
) O
, O
and O
patient O
preferences O
. O
!LF! !LF!
measurements O
were O
performed O
before O
( O
t0 O
) O
and O
after O
the O
rehabilitation O
program O
( O
t1 O
) O
, O
and O
at O
a O
3 O
- O
month O
follow O
- O
up O
( O
t2 O
) O
. O
!LF! !LF!
after B-Premise
the I-Premise
rehabilitation I-Premise
program I-Premise
, I-Premise
cancer I-Premise
survivors I-Premise
( I-Premise
n I-Premise
= I-Premise
63 I-Premise
) I-Premise
displayed I-Premise
statistically I-Premise
significant I-Premise
improvements I-Premise
on I-Premise
health I-Premise
- I-Premise
related I-Premise
quality I-Premise
of I-Premise
life I-Premise
with I-Premise
effect I-Premise
sizes I-Premise
( I-Premise
es I-Premise
) I-Premise
varying I-Premise
from I-Premise
0 I-Premise
. I-Premise
38 I-Premise
to I-Premise
0 I-Premise
. I-Premise
99 I-Premise
( I-Premise
rand I-Premise
- I-Premise
36 I-Premise
) I-Premise
and I-Premise
from I-Premise
- I-Premise
0 I-Premise
. I-Premise
34 I-Premise
to I-Premise
- I-Premise
0 I-Premise
. I-Premise
57 I-Premise
( I-Premise
rscl I-Premise
) I-Premise
, I-Premise
most I-Premise
persistent I-Premise
at I-Premise
3 I-Premise
- I-Premise
month I-Premise
follow I-Premise
- I-Premise
up I-Premise
. I-Premise
!LF! !LF!
furthermore B-Premise
, I-Premise
statistically I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
exercise I-Premise
capacity I-Premise
and I-Premise
muscle I-Premise
force I-Premise
of I-Premise
upper I-Premise
and I-Premise
lower I-Premise
extremities I-Premise
were I-Premise
displayed I-Premise
after I-Premise
rehabilitation I-Premise
. I-Premise
!LF! !LF!
if B-Premise
offered I-Premise
a I-Premise
choice I-Premise
, I-Premise
80 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
prior I-Premise
to I-Premise
start I-Premise
and I-Premise
58 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
after I-Premise
completion I-Premise
of I-Premise
the I-Premise
program I-Premise
indicated I-Premise
that I-Premise
they I-Premise
preferred I-Premise
the I-Premise
entire I-Premise
multidimensional I-Premise
program I-Premise
. I-Premise
!LF! !LF!
a B-Claim
multidimensional I-Claim
rehabilitation I-Claim
program I-Claim
has I-Claim
statistically I-Claim
and I-Claim
clinically I-Claim
relevant I-Claim
beneficial I-Claim
effects I-Claim
on I-Claim
health I-Claim
- I-Claim
related I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
exercise I-Claim
capacity I-Claim
, I-Claim
and I-Claim
muscle I-Claim
force I-Claim
in I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
different I-Claim
diagnoses I-Claim
. I-Claim
!LF! !LF!
furthermore O
, O
if B-Claim
offered I-Claim
the I-Claim
choice I-Claim
, I-Claim
the I-Claim
majority I-Claim
of I-Claim
cancer I-Claim
survivors I-Claim
seem I-Claim
to I-Claim
prefer I-Claim
multidimensional I-Claim
programs I-Claim
to I-Claim
programs I-Claim
with I-Claim
only I-Claim
one I-Claim
component I-Claim
. I-Claim
!LF! !LF!
surgery O
and O
radiotherapy O
commonly O
cause O
adverse O
musculoskeletal O
problems O
, O
particularly O
loss O
of O
strength O
and O
range O
of O
motion O
, O
in O
the O
upper O
quadrant O
of O
breast O
cancer O
patients O
. O
!LF! !LF!
few O
well O
- O
designed O
studies O
have O
investigated O
whether O
these O
impairments O
can O
be O
prevented O
. O
!LF! !LF!
stretching B-Claim
is I-Claim
an I-Claim
effective I-Claim
technique I-Claim
for I-Claim
increasing I-Claim
range I-Claim
of I-Claim
motion I-Claim
, I-Claim
hence O
the O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
a O
stretching O
program O
reduced O
acute O
musculoskeletal O
impairments O
in O
patients O
undergoing O
radiotherapy O
for O
breast O
cancer O
. O
!LF! !LF!
sixty O
- O
four O
women O
were O
recruited O
prior O
to O
commencement O
of O
radiotherapy O
following O
breast O
cancer O
surgery O
. O
!LF! !LF!
participants O
were O
randomised O
to O
either O
a O
control O
or O
stretch O
group O
. O
!LF! !LF!
participants O
in O
both O
groups O
were O
reviewed O
by O
the O
physical O
therapist O
on O
a O
weekly O
basis O
for O
approximately O
6 O
weeks O
, O
and O
were O
given O
general O
information O
about O
skin O
care O
and O
lymphedema O
. O
!LF! !LF!
the O
control O
group O
received O
no O
advice O
about O
exercise O
. O
!LF! !LF!
the O
stretch O
group O
received O
instruction O
on O
low O
- O
load O
, O
prolonged O
pectoral O
stretches O
, O
which O
were O
to O
be O
performed O
daily O
and O
were O
checked O
at O
weekly O
visits O
. O
!LF! !LF!
shoulder O
range O
of O
motion O
, O
strength O
, O
arm O
circumference O
, O
and O
quality O
of O
life O
measurements O
were O
taken O
prior O
to O
, O
and O
at O
completion O
of O
radiotherapy O
, O
and O
at O
7 O
months O
after O
radiotherapy O
. O
!LF! !LF!
there B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
any I-Premise
outcome I-Premise
between I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
breast B-Premise
symptoms I-Premise
increased I-Premise
for I-Premise
both I-Premise
groups I-Premise
during I-Premise
radiotherapy I-Premise
, I-Premise
without I-Premise
loss I-Premise
of I-Premise
strength I-Premise
or I-Premise
range I-Premise
of I-Premise
movement I-Premise
. I-Premise
!LF! !LF!
the B-Premise
incidence I-Premise
of I-Premise
lymphedema I-Premise
during I-Premise
the I-Premise
study I-Premise
was I-Premise
low I-Premise
for I-Premise
both I-Premise
groups I-Premise
and I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
the B-Premise
pectoral I-Premise
stretching I-Premise
program I-Premise
did I-Premise
not I-Premise
influence I-Premise
the I-Premise
outcomes I-Premise
measured I-Premise
because I-Premise
the I-Premise
symptoms I-Premise
reported I-Premise
by I-Premise
patients I-Premise
were I-Premise
not I-Premise
a I-Premise
consequence I-Premise
of I-Premise
contracture I-Premise
. I-Premise
!LF! !LF!
postoperative B-Claim
outcomes I-Claim
of I-Claim
patients I-Claim
undergoing I-Claim
laparoscopic I-Claim
- I-Claim
assisted I-Claim
colectomy I-Claim
( I-Claim
lac I-Claim
) I-Claim
have I-Claim
shown I-Claim
modest I-Claim
improvements I-Claim
in I-Claim
recovery I-Claim
but I-Claim
only I-Claim
minimal I-Claim
differences I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
qol I-Claim
) I-Claim
compared I-Claim
with I-Claim
open I-Claim
colectomy I-Claim
. I-Claim
!LF! !LF!
we O
therefore O
sought O
to O
assess O
the O
effect O
of O
lac O
on O
qol O
in O
the O
short O
and O
long O
term O
, O
using O
individual O
item O
analysis O
of O
multi O
- O
item O
qol O
assessments O
. O
!LF! !LF!
qol O
variables O
were O
analyzed O
in O
449 O
randomized O
patients O
from O
the O
cost O
trial O
93 O
- O
46 O
- O
53 O
( O
int O
146 O
) O
. O
!LF! !LF!
both O
cross O
- O
sectional O
single O
- O
time O
and O
change O
from O
baseline O
assessments O
were O
run O
at O
day O
2 O
, O
week O
2 O
, O
month O
2 O
, O
and O
month O
18 O
postoperatively O
in O
an O
intention O
- O
to O
- O
treat O
analysis O
using O
wilcoxon O
rank O
- O
sum O
tests O
. O
!LF! !LF!
stepwise O
regression O
models O
were O
used O
to O
determine O
predictors O
of O
qol O
. O
!LF! !LF!
of O
449 O
colon O
cancer O
patients O
, O
230 O
underwent O
lac O
and O
219 O
underwent O
open O
colectomy O
. O
!LF! !LF!
subdomain B-Premise
analysis I-Premise
revealed I-Premise
a I-Premise
clinically I-Premise
moderate I-Premise
improvement I-Premise
from I-Premise
baseline I-Premise
for I-Premise
lac I-Premise
in I-Premise
total I-Premise
qol I-Premise
index I-Premise
at I-Premise
18 I-Premise
months I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
as I-Premise
well I-Premise
as I-Premise
other I-Premise
small I-Premise
symptomatic I-Premise
improvements I-Premise
. I-Premise
!LF! !LF!
poor O
preoperative O
qol O
as O
indicated O
by O
a O
rating O
scale O
of O
≤ O
50 O
was O
an O
independent O
predictor O
of O
poor O
qol O
at O
2 O
months O
postoperatively O
. O
!LF! !LF!
qol O
variables O
related O
to O
survival O
were O
baseline O
support O
( O
p O
= O
0 O
. O
001 O
) O
and O
baseline O
outlook O
( O
p O
= O
0 O
. O
01 O
) O
. O
!LF! !LF!
eighteen B-Premise
months I-Premise
after I-Premise
surgery I-Premise
, I-Premise
any I-Premise
differences I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
between I-Premise
patients I-Premise
randomized I-Premise
to I-Premise
lac I-Premise
or I-Premise
open I-Premise
colectomy I-Premise
favored I-Premise
lac I-Premise
. I-Premise
!LF! !LF!
however B-Premise
, I-Premise
the I-Premise
magnitude I-Premise
of I-Premise
the I-Premise
benefits I-Premise
was I-Premise
small I-Premise
. I-Premise
!LF! !LF!
patients B-Claim
with I-Claim
poor I-Claim
preoperative I-Claim
qol I-Claim
appear I-Claim
to I-Claim
be I-Claim
at I-Claim
higher I-Claim
risk I-Claim
for I-Claim
difficult I-Claim
postoperative I-Claim
courses I-Claim
, I-Claim
and I-Claim
may I-Claim
be I-Claim
candidates I-Claim
for I-Claim
enhanced I-Claim
ancillary I-Claim
services I-Claim
to I-Claim
address I-Claim
their I-Claim
particular I-Claim
needs I-Claim
. I-Claim
!LF! !LF!
the O
goal O
of O
this O
study O
was O
to O
assess O
the O
impact O
of O
neuronavigation O
on O
the O
cytoreductive O
treatment O
of O
solitary O
contrast O
- O
enhancing O
intracerebral O
tumors O
and O
outcomes O
of O
this O
treatment O
in O
cases O
in O
which O
neuronavigation O
was O
preoperatively O
judged O
to O
be O
redundant O
. O
!LF! !LF!
the O
authors O
conducted O
a O
prospective O
randomized O
study O
in O
which O
45 O
patients O
, O
each O
harboring O
a O
solitary O
contrast O
- O
enhancing O
intracerebral O
tumor O
, O
were O
randomized O
for O
surgery O
with O
or O
without O
neuronavigation O
. O
!LF! !LF!
peri O
- O
and O
postoperative O
parameters O
under O
investigation O
included O
the O
following O
: O
duration O
of O
the O
procedure O
"""" O
; O
"""" O
surgeon O
' O
s O
estimate O
of O
the O
usefulness O
of O
neuronavigation O
"""" O
; O
"""" O
quantification O
of O
the O
extent O
of O
resection O
, O
determined O
using O
magnetic O
resonance O
imaging O
"""" O
; O
"""" O
and O
the O
postoperative O
course O
, O
as O
evaluated O
by O
neurological O
examinations O
, O
the O
patient O
' O
s O
quality O
- O
of O
- O
life O
self O
- O
assessment O
, O
application O
of O
the O
barthel O
index O
and O
the O
karnofsky O
performance O
scale O
score O
, O
and O
the O
patient O
' O
s O
time O
of O
death O
. O
!LF! !LF!
the B-Premise
mean I-Premise
amount I-Premise
of I-Premise
residual I-Premise
tumor I-Premise
tissue I-Premise
was I-Premise
28 I-Premise
. I-Premise
9 I-Premise
% I-Premise
for I-Premise
standard I-Premise
surgery I-Premise
( I-Premise
ss I-Premise
) I-Premise
and I-Premise
13 I-Premise
. I-Premise
8 I-Premise
% I-Premise
for I-Premise
surgery I-Premise
involving I-Premise
neuronavigation I-Premise
( I-Premise
sn I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
corresponding I-Premise
mean I-Premise
amounts I-Premise
of I-Premise
residual I-Premise
contrast I-Premise
- I-Premise
enhancing I-Premise
tumor I-Premise
tissue I-Premise
were I-Premise
29 I-Premise
. I-Premise
2 I-Premise
and I-Premise
24 I-Premise
. I-Premise
4 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
these B-Premise
differences I-Premise
were I-Premise
not I-Premise
significant I-Premise
. I-Premise
!LF! !LF!
gross B-Premise
- B-Premise
total B-Premise
removal I-Premise
( I-Premise
gtr I-Premise
) I-Premise
was I-Premise
achieved I-Premise
in I-Premise
five I-Premise
patients I-Premise
who I-Premise
underwent I-Premise
ss I-Premise
and I-Premise
in I-Premise
three I-Premise
who I-Premise
underwent I-Premise
sn I-Premise
. I-Premise
!LF! !LF!
median B-Premise
survival I-Premise
was I-Premise
significantly I-Premise
shorter I-Premise
in I-Premise
the I-Premise
sn I-Premise
group I-Premise
( I-Premise
5 I-Premise
. I-Premise
6 I-Premise
months I-Premise
compared I-Premise
with I-Premise
9 I-Premise
months I-Premise
, I-Premise
unadjusted I-Premise
hazard I-Premise
ratio I-Premise
= I-Premise
1 I-Premise
. I-Premise
6 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
however B-Premise
, I-Premise
this I-Premise
difference I-Premise
may I-Premise
be I-Premise
attributable I-Premise
to I-Premise
the I-Premise
coincidental I-Premise
early I-Premise
death I-Premise
of I-Premise
three I-Premise
patients I-Premise
in I-Premise
the I-Premise
sn I-Premise
group I-Premise
. I-Premise
!LF! !LF!
no B-Premise
discernible I-Premise
important I-Premise
effect I-Premise
on I-Premise
the I-Premise
patients I-Premise
' I-Premise
3 I-Premise
- I-Premise
month I-Premise
postoperative I-Premise
course I-Premise
was I-Premise
identified I-Premise
. I-Premise
!LF! !LF!
there B-Claim
is I-Claim
no I-Claim
rationale I-Claim
for I-Claim
the I-Claim
routine I-Claim
use I-Claim
of I-Claim
neuronavigation I-Claim
to I-Claim
improve I-Claim
the I-Claim
extent I-Claim
of I-Claim
tumor I-Claim
resection I-Claim
and I-Claim
prognosis I-Claim
in I-Claim
patients I-Claim
harboring I-Claim
a I-Claim
solitary I-Claim
enhancing I-Claim
intracerebral I-Claim
lesion I-Claim
when I-Claim
neuronavigation I-Claim
is I-Claim
not I-Claim
already I-Claim
deemed I-Claim
advantageous I-Claim
because I-Claim
of I-Claim
the I-Claim
size I-Claim
or I-Claim
location I-Claim
of I-Claim
the I-Claim
lesion I-Claim
. I-Claim
!LF! !LF!
to O
test O
the O
ability O
of O
the O
cytoprotectant O
, O
amifostine O
, O
to O
reduce O
chemoradiotherapy O
- O
induced O
esophagitis O
and O
evaluate O
its O
influence O
on O
quality O
of O
life O
( O
qol O
) O
and O
swallowing O
symptoms O
. O
!LF! !LF!
a O
total O
of O
243 O
patients O
with O
stage O
ii O
to O
iiia O
/ O
b O
non O
- O
small O
- O
cell O
lung O
cancer O
received O
induction O
paclitaxel O
225 O
mg O
/ O
m O
( O
2 O
) O
intravenously O
( O
iv O
) O
days O
1 O
and O
22 O
and O
carboplatin O
area O
under O
the O
curve O
( O
auc O
) O
days O
1 O
and O
22 O
, O
followed O
by O
concurrent O
weekly O
paclitaxel O
( O
50 O
mg O
/ O
m O
( O
2 O
) O
iv O
) O
and O
carboplatin O
( O
auc O
2 O
) O
, O
and O
hyperfractionated O
radiation O
therapy O
( O
69 O
. O
6 O
gy O
at O
1 O
. O
2 O
gy O
bid O
) O
. O
!LF! !LF!
patients O
were O
randomly O
assigned O
at O
registration O
to O
amifostine O
( O
am O
) O
500 O
mg O
iv O
four O
times O
per O
week O
or O
no O
am O
during O
chemoradiotherapy O
. O
!LF! !LF!
beyond O
standard O
toxicity O
end O
points O
, O
physician O
dysphagia O
logs O
( O
pdls O
) O
, O
daily O
patient O
swallowing O
diaries O
, O
and O
qol O
( O
eortc O
qlq O
- O
c30 O
/ O
lc O
- O
13 O
) O
were O
also O
collected O
. O
!LF! !LF!
swallowing O
auc O
analyses O
were O
calculated O
from O
patient O
diaries O
and O
pdls O
. O
!LF! !LF!
a O
total O
of O
120 O
patients O
were O
randomly O
assigned O
to O
receive O
am O
, O
and O
122 O
, O
to O
receive O
no O
am O
( O
one O
patient O
was O
ineligible O
) O
"""" O
; O
"""" O
72 O
% O
received O
am O
per O
protocol O
or O
with O
a O
minor O
deviation O
. O
!LF! !LF!
am B-Premise
was I-Premise
associated I-Premise
with I-Premise
higher I-Premise
rates I-Premise
of I-Premise
acute I-Premise
nausea I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
, I-Premise
vomiting I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
007 I-Premise
) I-Premise
, I-Premise
cardiovascular I-Premise
toxicity I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
0001 I-Premise
) I-Premise
, I-Premise
and I-Premise
infection I-Premise
or I-Premise
febrile I-Premise
neutropenia I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
rate I-Premise
of I-Premise
> I-Premise
/ I-Premise
= I-Premise
grade I-Premise
3 I-Premise
esophagitis I-Premise
was I-Premise
30 I-Premise
% I-Premise
with I-Premise
am I-Premise
versus I-Premise
34 I-Premise
% I-Premise
without I-Premise
am I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
9 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
patient B-Premise
diaries I-Premise
demonstrated I-Premise
lower I-Premise
swallowing I-Premise
dysfunction I-Premise
auc I-Premise
with I-Premise
amifostine I-Premise
( I-Premise
z I-Premise
test I-Premise
p I-Premise
= I-Premise
. I-Premise
025 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
qol B-Premise
was I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
the I-Premise
two I-Premise
arms I-Premise
, I-Premise
except I-Premise
for I-Premise
pain I-Premise
, I-Premise
which I-Premise
showed I-Premise
more I-Premise
clinically I-Premise
meaningful I-Premise
improvement I-Premise
and I-Premise
less I-Premise
deterioration I-Premise
at I-Premise
6 I-Premise
weeks I-Premise
follow I-Premise
- I-Premise
up I-Premise
( I-Premise
v I-Premise
pretreatment I-Premise
) I-Premise
in I-Premise
the I-Premise
am I-Premise
arm I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
003 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
median I-Premise
survival I-Premise
rates I-Premise
for I-Premise
both I-Premise
arms I-Premise
were I-Premise
comparable I-Premise
( I-Premise
am I-Premise
, I-Premise
17 I-Premise
. I-Premise
3 I-Premise
v I-Premise
no I-Premise
am I-Premise
, I-Premise
17 I-Premise
. I-Premise
9 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
87 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
am B-Claim
did I-Claim
not I-Claim
significantly I-Claim
reduce I-Claim
esophagitis I-Claim
> I-Claim
/ I-Claim
= I-Claim
grade I-Claim
3 I-Claim
in I-Claim
patients I-Claim
receiving I-Claim
hyperfractionated I-Claim
radiation I-Claim
and I-Claim
chemotherapy I-Claim
. I-Claim
!LF! !LF!
however B-Claim
, I-Claim
patient I-Claim
self I-Claim
- I-Claim
assessments I-Claim
suggested I-Claim
a I-Claim
possible I-Claim
advantage I-Claim
to I-Claim
am I-Claim
that I-Claim
is I-Claim
being I-Claim
explored I-Claim
with I-Claim
modified I-Claim
dosing I-Claim
route I-Claim
strategies I-Claim
. I-Claim
!LF! !LF!
the O
impact O
of O
the O
side O
effects O
of O
megestrol O
acetate O
on O
the O
quality O
of O
life O
of O
noncachectic O
women O
with O
advanced O
breast O
cancer O
was O
studied O
in O
a O
dose O
- O
response O
clinical O
trial O
of O
the O
cancer O
and O
leukemia O
group O
b O
( O
calgb O
8741 O
) O
. O
!LF! !LF!
side O
effects O
of O
appetite O
increase O
and O
weight O
gain O
at O
higher O
doses O
were O
predicted O
to O
have O
a O
negative O
effect O
on O
quality O
of O
life O
. O
!LF! !LF!
stage O
iv O
breast O
cancer O
patients O
were O
randomized O
to O
receive O
either O
160 O
, O
800 O
, O
or O
1 O
, O
600 O
mg O
/ O
d O
of O
megestrol O
acetate O
. O
!LF! !LF!
quality O
of O
life O
was O
assessed O
in O
131 O
patients O
at O
trial O
entry O
and O
at O
1 O
and O
3 O
months O
while O
on O
treatment O
, O
by O
telephone O
interview O
, O
using O
the O
following O
measures O
: O
the O
functional O
living O
index O
- O
cancer O
( O
flic O
) O
, O
rand O
functional O
limitations O
scale O
, O
rand O
mental O
health O
inventory O
( O
mhi O
) O
, O
the O
body O
image O
subscale O
, O
and O
linear O
analog O
scales O
of O
drug O
side O
effects O
. O
!LF! !LF!
at B-Premise
3 I-Premise
months I-Premise
, I-Premise
women I-Premise
treated I-Premise
with I-Premise
160 I-Premise
mg I-Premise
/ I-Premise
d I-Premise
reported I-Premise
less I-Premise
severe I-Premise
side I-Premise
effects I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
0005 I-Premise
) I-Premise
, I-Premise
better I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
fls I-Premise
, I-Premise
p I-Premise
< I-Premise
. I-Premise
0005 I-Premise
) I-Premise
, I-Premise
less I-Premise
psychologic I-Premise
distress I-Premise
( I-Premise
mhi I-Premise
, I-Premise
p I-Premise
= I-Premise
. I-Premise
008 I-Premise
) I-Premise
, I-Premise
and I-Premise
an I-Premise
improvement I-Premise
in I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
flic I-Premise
, I-Premise
p I-Premise
= I-Premise
. I-Premise
003 I-Premise
) I-Premise
from I-Premise
the I-Premise
time I-Premise
of I-Premise
study I-Premise
entry I-Premise
as I-Premise
compared I-Premise
with I-Premise
those I-Premise
treated I-Premise
with I-Premise
1 I-Premise
, I-Premise
600 I-Premise
mg I-Premise
/ I-Premise
d I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
who I-Premise
received I-Premise
the I-Premise
800 I-Premise
- I-Premise
mg I-Premise
/ I-Premise
d I-Premise
dose I-Premise
fell I-Premise
between I-Premise
the I-Premise
low I-Premise
- I-Premise
and I-Premise
high I-Premise
- I-Premise
dose I-Premise
arms I-Premise
in I-Premise
reported I-Premise
intensity I-Premise
of I-Premise
drug I-Premise
side I-Premise
effects I-Premise
, I-Premise
but B-Premise
responded I-Premise
similarly I-Premise
to I-Premise
those I-Premise
in I-Premise
the I-Premise
160 I-Premise
- I-Premise
mg I-Premise
/ I-Premise
d I-Premise
group I-Premise
in I-Premise
terms I-Premise
of I-Premise
physical I-Premise
functioning I-Premise
, I-Premise
psychologic I-Premise
distress I-Premise
, I-Premise
and I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise
!LF! !LF!
unless B-Claim
additional I-Claim
follow I-Claim
- I-Claim
up I-Claim
data I-Claim
demonstrate I-Claim
a I-Claim
survival I-Claim
advantage I-Claim
at I-Claim
higher I-Claim
doses I-Claim
, I-Claim
the I-Claim
160 I-Claim
- I-Claim
mg I-Claim
/ I-Claim
d I-Claim
dose I-Claim
is I-Claim
optimal I-Claim
, I-Claim
achieving I-Claim
maximal I-Claim
treatment I-Claim
effect I-Claim
with I-Claim
the I-Claim
fewest I-Claim
side I-Claim
effects I-Claim
and I-Claim
better I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim
!LF! !LF!
study O
type O
- O
- O
therapy O
( O
rct O
) O
level O
of O
evidence O
1b O
. O
!LF! !LF!
what O
' O
s O
known O
on O
the O
subject O
? O
!LF! !LF!
and O
what O
does O
the O
study O
add O
? O
!LF! !LF!
androgen O
deprivation O
therapy O
( O
adt O
) O
is O
commonly O
used O
as O
a O
primary O
treatment O
for O
patients O
with O
prostate O
cancer O
( O
pca O
) O
who O
are O
not O
eligible O
for O
radical O
treatment O
options O
. O
!LF! !LF!
adt O
is O
also O
used O
in O
patients O
with O
pca O
as O
neo O
- O
adjuvant O
hormone O
therapy O
to O
reduce O
prostate O
volume O
and O
down O
- O
stage O
the O
disease O
before O
radiotherapy O
with O
curative O
intent O
. O
!LF! !LF!
the O
present O
study O
showed O
that O
adt O
with O
the O
gonadotropin O
hormone O
- O
releasing O
hormone O
( O
ghrh O
) O
antagonist O
degarelix O
is O
non O
- O
inferior O
to O
combined O
treatment O
with O
the O
lhrh O
agonist O
goserelin O
and O
bicalutamide O
in O
terms O
of O
reducing O
prostate O
volume O
during O
the O
treatment O
period O
of O
3 O
months O
. O
!LF! !LF!
degarelix O
treatment O
evokes O
, O
however O
, O
significantly O
better O
relief O
of O
lower O
urinary O
tract O
symptoms O
in O
patients O
having O
moderate O
and O
severe O
voiding O
problems O
. O
!LF! !LF!
to O
assess O
the O
efficacy O
of O
monthly O
degarelix O
treatment O
for O
reduction O
of O
total O
prostate O
volume O
( O
tpv O
) O
, O
relief O
of O
lower O
urinary O
tract O
symptoms O
( O
luts O
) O
and O
improvement O
of O
quality O
of O
life O
( O
qol O
) O
in O
patients O
with O
prostate O
cancer O
( O
pca O
) O
using O
monthly O
goserelin O
as O
active O
control O
. O
!LF! !LF!
this O
was O
a O
randomized O
, O
parallel O
- O
arm O
, O
active O
- O
controlled O
, O
open O
- O
label O
, O
multicentre O
trial O
on O
182 O
patients O
treated O
with O
either O
monthly O
degarelix O
( O
240 O
/ O
80 O
mg O
) O
or O
goserelin O
( O
3 O
. O
6 O
mg O
) O
for O
12 O
weeks O
. O
!LF! !LF!
for O
flare O
protection O
, O
goserelin O
- O
treated O
patients O
also O
received O
daily O
bicalutamide O
( O
50 O
mg O
) O
during O
the O
initial O
28 O
days O
. O
!LF! !LF!
key O
trial O
variables O
monitored O
monthly O
were O
tpv O
( O
primary O
endpoint O
) O
, O
serum O
testosterone O
, O
prostate O
- O
specific O
antigen O
( O
psa O
) O
, O
the O
international O
prostate O
symptom O
score O
( O
ipss O
) O
and O
the O
benign O
prostate O
hyperplasia O
impact O
index O
. O
!LF! !LF!
in O
all O
, O
175 O
patients O
completed O
the O
trial O
( O
96 O
. O
1 O
% O
) O
. O
!LF! !LF!
at B-Premise
week I-Premise
12 I-Premise
, I-Premise
changes I-Premise
in I-Premise
tpv I-Premise
for I-Premise
degarelix I-Premise
and I-Premise
goserelin I-Premise
were I-Premise
similar I-Premise
( I-Premise
- I-Premise
37 I-Premise
. I-Premise
2 I-Premise
% I-Premise
vs I-Premise
- I-Premise
39 I-Premise
. I-Premise
0 I-Premise
% I-Premise
) I-Premise
and I-Premise
met I-Premise
the I-Premise
predefined I-Premise
non I-Premise
- I-Premise
inferiority I-Premise
criterion I-Premise
. I-Premise
!LF! !LF!
decreases B-Premise
in I-Premise
ipss I-Premise
were I-Premise
greater I-Premise
in I-Premise
degarelix I-Premise
than I-Premise
in I-Premise
goserelin I-Premise
- I-Premise
treated I-Premise
patients I-Premise
, I-Premise
differences I-Premise
being I-Premise
statistically I-Premise
significant I-Premise
in I-Premise
patients I-Premise
with I-Premise
baseline I-Premise
ipss I-Premise
> I-Premise
13 I-Premise
( I-Premise
- I-Premise
6 I-Premise
. I-Premise
7 I-Premise
± I-Premise
1 I-Premise
. I-Premise
8 I-Premise
vs I-Premise
- I-Premise
4 I-Premise
. I-Premise
0 I-Premise
± I-Premise
1 I-Premise
. I-Premise
0 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
number I-Premise
of I-Premise
patients I-Premise
with I-Premise
an I-Premise
ipss I-Premise
change I-Premise
of I-Premise
≥ I-Premise
3 I-Premise
over I-Premise
baseline I-Premise
was I-Premise
also I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
patients I-Premise
treated I-Premise
with I-Premise
degarelix I-Premise
( I-Premise
61 I-Premise
. I-Premise
0 I-Premise
vs I-Premise
44 I-Premise
. I-Premise
3 I-Premise
% I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
both B-Claim
treatments I-Claim
were I-Claim
safe I-Claim
and I-Claim
well I-Claim
tolerated I-Claim
. I-Claim
!LF! !LF!
medical B-Claim
castration I-Claim
reduces I-Claim
tpv I-Claim
and I-Claim
could I-Claim
also I-Claim
improve I-Claim
luts I-Claim
in I-Claim
patients I-Claim
with I-Claim
pca I-Claim
. I-Claim
!LF! !LF!
while O
the B-Claim
short I-Claim
- I-Claim
term I-Claim
efficacy I-Claim
of I-Claim
degarelix I-Claim
and I-Claim
goserelin I-Claim
+ I-Claim
bicalutamide I-Claim
was I-Claim
the I-Claim
same I-Claim
in I-Claim
terms I-Claim
of I-Claim
tpv I-Claim
reduction I-Claim
, I-Claim
degarelix B-Claim
showed I-Claim
superiority I-Claim
in I-Claim
luts I-Claim
relief I-Claim
in I-Claim
symptomatic I-Claim
patients I-Claim
, I-Claim
which I-Claim
could I-Claim
highlight I-Claim
the I-Claim
different I-Claim
actions I-Claim
of I-Claim
these I-Claim
drugs I-Claim
on I-Claim
extrapituitary I-Claim
gonadotrophin I-Claim
- I-Claim
releasing I-Claim
hormone I-Claim
( I-Claim
gnrh I-Claim
) I-Claim
receptors I-Claim
in I-Claim
the I-Claim
bladder I-Claim
and I-Claim
/ I-Claim
or I-Claim
the I-Claim
prostate I-Claim
. I-Claim
!LF! !LF!
to O
assess O
whether O
omission O
of O
postoperative O
radiotherapy O
in O
women O
with O
' O
low O
- O
risk O
' O
axillary O
node O
negative O
breast O
cancer O
( O
t0 O
- O
2 O
) O
treated O
by O
breast O
- O
conserving O
surgery O
and O
endocrine O
therapy O
improves O
quality O
of O
life O
and O
is O
more O
cost O
- O
effective O
. O
!LF! !LF!
a O
randomised O
controlled O
clinical O
trial O
, O
using O
a O
method O
of O
minimisation O
balanced O
by O
centre O
, O
grade O
of O
cancer O
, O
age O
, O
lymphatic O
/ O
vascular O
invasion O
and O
preoperative O
endocrine O
therapy O
, O
was O
performed O
. O
!LF! !LF!
a O
non O
- O
randomised O
cohort O
was O
also O
recruited O
, O
in O
order O
to O
complete O
a O
comprehensive O
cohort O
study O
. O
!LF! !LF!
the O
setting O
was O
breast O
cancer O
clinics O
in O
cancer O
centres O
in O
the O
uk O
. O
!LF! !LF!
patients O
aged O
65 O
years O
or O
more O
were O
eligible O
provided O
that O
their O
cancers O
were O
considered O
to O
be O
at O
low O
risk O
of O
local O
recurrence O
, O
were O
suitable O
for O
breast O
- O
conservation O
surgery O
, O
were O
receiving O
endocrine O
therapy O
and O
were O
able O
and O
willing O
to O
give O
informed O
consent O
. O
!LF! !LF!
the O
standard O
treatment O
of O
postoperative O
breast O
irradiation O
or O
the O
omission O
of O
radiotherapy O
. O
!LF! !LF!
quality O
of O
life O
was O
the O
primary O
outcome O
measure O
, O
together O
with O
anxiety O
and O
depression O
and O
cost O
- O
effectiveness O
. O
!LF! !LF!
secondary O
outcome O
measures O
were O
recurrence O
rates O
, O
functional O
status O
, O
treatment O
- O
related O
morbidity O
and O
cosmesis O
. O
!LF! !LF!
the O
principal O
method O
of O
data O
collection O
was O
by O
questionnaire O
, O
completed O
at O
home O
with O
a O
research O
nurse O
at O
four O
times O
over O
15 O
months O
. O
!LF! !LF!
the B-Claim
hypothesised I-Claim
improvement I-Claim
in I-Claim
overall I-Claim
quality I-Claim
of I-Claim
life I-Claim
with I-Claim
the I-Claim
omission I-Claim
of I-Claim
radiotherapy I-Claim
was I-Claim
not I-Claim
seen I-Claim
in I-Claim
the I-Claim
euroqol I-Claim
assessment I-Claim
or I-Claim
in I-Claim
the I-Claim
functionality I-Claim
and I-Claim
symptoms I-Claim
summary I-Claim
domains I-Claim
of I-Claim
the I-Claim
european I-Claim
organisation I-Claim
for I-Claim
research I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
cancer I-Claim
( I-Claim
eortc I-Claim
) I-Claim
scales I-Claim
. I-Claim
!LF! !LF!
some O
differences O
were O
apparent O
within O
subscales O
of O
the O
eortc O
questionnaires O
, O
and O
insights O
into O
the O
impact O
of O
treatment O
were O
also O
provided O
by O
the O
qualitative O
data O
obtained O
by O
open O
- O
ended O
questions O
. O
!LF! !LF!
differences B-Premise
were I-Premise
most I-Premise
apparent I-Premise
shortly I-Premise
after I-Premise
the I-Premise
time I-Premise
of I-Premise
completion I-Premise
of I-Premise
radiotherapy I-Premise
. I-Premise
!LF! !LF!
radiotherapy B-Claim
was I-Claim
then I-Claim
associated I-Claim
with I-Claim
increased I-Claim
breast I-Claim
symptoms I-Claim
and I-Claim
with I-Claim
greater I-Claim
fatigue I-Claim
but I-Claim
with I-Claim
less I-Claim
insomnia I-Claim
and I-Claim
endocrine I-Claim
side I-Claim
- I-Claim
effects I-Claim
. I-Claim
!LF! !LF!
patients B-Premise
had I-Premise
significant I-Premise
concerns I-Premise
about I-Premise
the I-Premise
delivery I-Premise
of I-Premise
radiotherapy I-Premise
services I-Premise
, I-Premise
such I-Premise
as I-Premise
transport I-Premise
, I-Premise
accommodation I-Premise
and I-Premise
travel I-Premise
costs I-Premise
associated I-Premise
with I-Premise
receiving I-Premise
radiotherapy I-Premise
. I-Premise
!LF! !LF!
by B-Premise
the I-Premise
end I-Premise
of I-Premise
follow I-Premise
- I-Premise
up I-Premise
, I-Premise
patients I-Premise
receiving I-Premise
radiotherapy I-Premise
were I-Premise
expressing I-Premise
less I-Premise
anxiety I-Premise
about I-Premise
recurrence I-Premise
than I-Premise
those I-Premise
who I-Premise
had I-Premise
not I-Premise
received I-Premise
radiotherapy I-Premise
. I-Premise
!LF! !LF!
functionality B-Premise
was I-Premise
not I-Premise
greatly I-Premise
affected I-Premise
by I-Premise
treatment I-Premise
. I-Premise
!LF! !LF!
within B-Premise
the I-Premise
randomised I-Premise
controlled I-Premise
trial I-Premise
, I-Premise
the I-Premise
barthel I-Premise
index I-Premise
demonstrated I-Premise
a I-Premise
small I-Premise
but I-Premise
significant I-Premise
fall I-Premise
in I-Premise
functionality I-Premise
with I-Premise
radiotherapy I-Premise
compared I-Premise
with I-Premise
the I-Premise
no I-Premise
radiotherapy I-Premise
arm I-Premise
of I-Premise
the I-Premise
trial I-Premise
. I-Premise
!LF! !LF!
results B-Premise
from I-Premise
the I-Premise
non I-Premise
- I-Premise
randomised I-Premise
patients I-Premise
did I-Premise
not I-Premise
confirm I-Premise
this I-Premise
effect I-Premise
, I-Premise
however I-Premise
. I-Premise
!LF! !LF!
cosmetic B-Premise
results I-Premise
were I-Premise
better I-Premise
in I-Premise
those I-Premise
not I-Premise
receiving I-Premise
radiotherapy I-Premise
but B-Premise
this I-Premise
did I-Premise
not I-Premise
appear I-Premise
to I-Premise
be I-Premise
an I-Premise
important I-Premise
issue I-Premise
to I-Premise
the I-Premise
patients I-Premise
. I-Premise
!LF! !LF!
the B-Claim
use I-Claim
of I-Claim
home I-Claim
- I-Claim
based I-Claim
assessments I-Claim
by I-Claim
a I-Claim
research I-Claim
nurse I-Claim
proved I-Claim
to I-Claim
be I-Claim
an I-Claim
effective I-Claim
way I-Claim
of I-Claim
obtaining I-Claim
high I-Claim
- I-Claim
quality I-Claim
data I-Claim
. I-Claim
!LF! !LF!
costs O
to O
the O
nhs O
associated O
with O
postoperative O
radiotherapy O
were O
calculated O
to O
be O
of O
the O
order O
of O
2000 O
pounds O
per O
patient O
. O
!LF! !LF!
in B-Premise
the I-Premise
follow I-Premise
- I-Premise
up I-Premise
in I-Premise
this I-Premise
study I-Premise
, I-Premise
there I-Premise
were I-Premise
no I-Premise
recurrences I-Premise
, I-Premise
and I-Premise
the I-Premise
quality I-Premise
of I-Premise
life I-Premise
utilities I-Premise
from I-Premise
euroqol I-Premise
were I-Premise
almost I-Premise
identical I-Premise
. I-Premise
!LF! !LF!
although B-Premise
there I-Premise
are I-Premise
no I-Premise
differences I-Premise
in I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
scores I-Premise
between I-Premise
the I-Premise
patients I-Premise
treated I-Premise
with I-Premise
and I-Premise
without I-Premise
radiotherapy I-Premise
, I-Premise
there I-Premise
are I-Premise
several I-Premise
dimensions I-Premise
that I-Premise
exhibit I-Premise
significant I-Premise
advantage I-Premise
to I-Premise
the I-Premise
omission I-Premise
of I-Premise
irradiation I-Premise
. I-Premise
!LF! !LF!
over B-Premise
the I-Premise
first I-Premise
15 I-Premise
months I-Premise
, I-Premise
radiotherapy I-Premise
for I-Premise
this I-Premise
population I-Premise
is I-Premise
not I-Premise
a I-Premise
cost I-Premise
- I-Premise
effective I-Premise
treatment I-Premise
. I-Premise
!LF! !LF!
however O
, O
the O
early B-Claim
postoperative I-Claim
outcome I-Claim
does I-Claim
not I-Claim
give I-Claim
a I-Claim
complete I-Claim
answer I-Claim
and O
the B-Claim
eventual I-Claim
cost I-Claim
- I-Claim
effectiveness I-Claim
will I-Claim
only I-Claim
become I-Claim
clear I-Claim
after I-Claim
long I-Claim
- I-Claim
term I-Claim
follow I-Claim
- I-Claim
up I-Claim
. I-Claim
!LF! !LF!
extrapolations B-Claim
from I-Claim
these I-Claim
data I-Claim
suggest I-Claim
that I-Claim
radiotherapy I-Claim
may I-Claim
not I-Claim
be I-Claim
a I-Claim
cost I-Claim
- I-Claim
effective I-Claim
treatment I-Claim
unless I-Claim
it I-Claim
results I-Claim
in I-Claim
a I-Claim
recurrence I-Claim
rate I-Claim
that I-Claim
is I-Claim
at I-Claim
least I-Claim
5 I-Claim
% I-Claim
lower I-Claim
in I-Claim
absolute I-Claim
terms I-Claim
than I-Claim
those I-Claim
treated I-Claim
without I-Claim
radiotherapy I-Claim
. I-Claim
!LF! !LF!
further B-Claim
research I-Claim
is I-Claim
needed I-Claim
into I-Claim
a I-Claim
number I-Claim
of I-Claim
areas I-Claim
including I-Claim
the I-Claim
long I-Claim
- I-Claim
term I-Claim
aspects I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
clinical I-Claim
outcomes I-Claim
, I-Claim
costs I-Claim
and I-Claim
consequences I-Claim
of I-Claim
omitting I-Claim
radiotherapy I-Claim
. I-Claim
!LF! !LF!
a O
randomized O
controlled O
trial O
was O
performed O
to O
assess O
the O
outcome O
of O
early O
oral O
postoperative O
feeding O
( O
eof O
) O
compared O
with O
traditional O
oral O
feeding O
( O
tof O
) O
in O
gynecologic O
oncology O
patients O
undergoing O
a O
complex O
laparotomy O
, O
including O
upper O
abdominal O
surgery O
. O
!LF! !LF!
patients O
aged O
18 O
- O
75 O
years O
, O
undergoing O
an O
elective O
laparotomy O
and O
with O
a O
preoperative O
suspicion O
of O
gynecologic O
malignancy O
, O
were O
eligible O
. O
!LF! !LF!
exclusion O
criteria O
included O
infectious O
conditions O
, O
intestinal O
obstruction O
, O
severe O
malnutrition O
, O
american O
society O
of O
anesthesiologists O
score O
c4 O
, O
intestinal O
resection O
, O
and O
postoperative O
stay O
in O
the O
intensive O
care O
unit O
lasting O
24 O
h O
. O
patients O
allocated O
to O
eof O
received O
liquid O
diet O
in O
the O
first O
postoperative O
day O
and O
then O
regular O
diet O
. O
!LF! !LF!
patients O
received O
traditional O
feeding O
scheme O
until O
resolution O
of O
postoperative O
ileus O
to O
start O
liquid O
diet O
. O
!LF! !LF!
the O
primary O
end O
- O
point O
of O
the O
trial O
was O
length O
of O
hospital O
stay O
. O
!LF! !LF!
between O
january O
1 O
, O
2007 O
, O
and O
november O
17 O
, O
2007 O
, O
a O
total O
of O
143 O
patients O
were O
randomized O
to O
receive O
either O
eof O
or O
tof O
. O
!LF! !LF!
hospital B-Premise
stay I-Premise
for I-Premise
patients I-Premise
who I-Premise
received I-Premise
eof I-Premise
( I-Premise
n I-Premise
= I-Premise
71 I-Premise
) I-Premise
was I-Premise
4 I-Premise
. I-Premise
7 I-Premise
vs I-Premise
. I-Premise
5 I-Premise
. I-Premise
8 I-Premise
days I-Premise
for I-Premise
the I-Premise
tof I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
72 I-Premise
) I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
006 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
mean I-Premise
level I-Premise
of I-Premise
postoperative I-Premise
satisfaction I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
eof I-Premise
group I-Premise
( I-Premise
82 I-Premise
. I-Premise
8 I-Premise
vs I-Premise
. I-Premise
71 I-Premise
. I-Premise
7 I-Premise
mm I-Premise
, I-Premise
p I-Premise
b I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
who I-Premise
received I-Premise
the I-Premise
tof I-Premise
scheme I-Premise
had I-Premise
significantly I-Premise
higher I-Premise
overall I-Premise
postoperative I-Premise
complications I-Premise
( I-Premise
39 I-Premise
vs I-Premise
. I-Premise
17 I-Premise
% I-Premise
in I-Premise
eof I-Premise
group I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
003 I-Premise
) I-Premise
and I-Premise
infective I-Premise
complications I-Premise
( I-Premise
14 I-Premise
% I-Premise
in I-Premise
tof I-Premise
group I-Premise
vs I-Premise
. I-Premise
3 I-Premise
% I-Premise
in I-Premise
eof I-Premise
group I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
017 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
variables B-Premise
such I-Premise
as I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
, I-Premise
analgesic I-Premise
and I-Premise
antiemetic I-Premise
requirement I-Premise
as I-Premise
well I-Premise
as I-Premise
level I-Premise
of I-Premise
pain I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
were I-Premise
not I-Premise
different I-Premise
between I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
on B-Claim
the I-Claim
basis I-Claim
of I-Claim
these I-Claim
findings I-Claim
, I-Claim
the I-Claim
policy I-Claim
of I-Claim
eof I-Claim
should I-Claim
be I-Claim
used I-Claim
after I-Claim
a I-Claim
complex I-Claim
gynecologic I-Claim
oncologic I-Claim
laparotomy I-Claim
. I-Claim
!LF! !LF!
insomnia B-Claim
is I-Claim
a I-Claim
common I-Claim
complaint I-Claim
among I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim
!LF! !LF!
fortunately O
, O
cognitive O
- O
behavioral O
therapy O
for O
insomnia O
( O
cbt O
- O
i O
) O
has O
been O
shown O
to O
be O
an O
effective O
treatment O
in O
this O
population O
. O
!LF! !LF!
however O
, O
it O
is O
rarely O
implemented O
given O
its O
limited O
availability O
. O
!LF! !LF!
to O
address O
this O
barrier O
, O
we O
examined O
the O
ability O
of O
an O
easily O
accessible O
online O
cbt O
- O
i O
program O
to O
improve O
insomnia O
symptoms O
in O
cancer O
survivors O
. O
!LF! !LF!
twenty O
- O
eight O
cancer O
survivors O
with O
insomnia O
were O
randomly O
assigned O
to O
either O
an O
internet O
insomnia O
intervention O
( O
n O
= O
14 O
) O
or O
to O
a O
waitlist O
control O
group O
( O
n O
= O
14 O
) O
. O
!LF! !LF!
the O
online O
program O
, O
sleep O
healthy O
using O
the O
internet O
, O
delivers O
the O
primary O
components O
of O
cbt O
- O
i O
( O
sleep O
restriction O
, O
stimulus O
control O
, O
cognitive O
restructuring O
, O
sleep O
hygiene O
, O
and O
relapse O
prevention O
) O
. O
!LF! !LF!
pre O
- O
and O
post O
- O
assessment O
data O
were O
collected O
via O
online O
questionnaires O
and O
daily O
sleep O
diaries O
. O
!LF! !LF!
participants B-Premise
in I-Premise
the I-Premise
internet I-Premise
group I-Premise
showed I-Premise
significant I-Premise
improvements I-Premise
at I-Premise
post I-Premise
- I-Premise
assessment I-Premise
compared I-Premise
with I-Premise
those I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
in I-Premise
overall I-Premise
insomnia I-Premise
severity I-Premise
( I-Premise
f I-Premise
( I-Premise
1 I-Premise
, I-Premise
26 I-Premise
) I-Premise
= I-Premise
22 I-Premise
. I-Premise
8 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
sleep I-Premise
efficiency I-Premise
( I-Premise
f I-Premise
( I-Premise
1 I-Premise
, I-Premise
24 I-Premise
) I-Premise
= I-Premise
11 I-Premise
. I-Premise
45 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
002 I-Premise
) I-Premise
, I-Premise
sleep I-Premise
onset I-Premise
latency I-Premise
( I-Premise
f I-Premise
( I-Premise
1 I-Premise
, I-Premise
24 I-Premise
) I-Premise
= I-Premise
5 I-Premise
. I-Premise
18 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
03 I-Premise
) I-Premise
, I-Premise
soundness I-Premise
of I-Premise
sleep I-Premise
( I-Premise
f I-Premise
( I-Premise
1 I-Premise
, I-Premise
24 I-Premise
) I-Premise
= I-Premise
9 I-Premise
. I-Premise
34 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
005 I-Premise
) I-Premise
, I-Premise
restored I-Premise
feeling I-Premise
upon I-Premise
awakening I-Premise
( I-Premise
f I-Premise
( I-Premise
1 I-Premise
, I-Premise
24 I-Premise
) I-Premise
= I-Premise
11 I-Premise
. I-Premise
95 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
002 I-Premise
) I-Premise
, I-Premise
and I-Premise
general I-Premise
fatigue I-Premise
( I-Premise
f I-Premise
( I-Premise
1 I-Premise
, I-Premise
26 I-Premise
) I-Premise
= I-Premise
13 I-Premise
. I-Premise
88 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
although B-Premise
other I-Premise
group I-Premise
× I-Premise
time I-Premise
interactions I-Premise
were I-Premise
not I-Premise
significant I-Premise
, I-Premise
overall I-Premise
adjusted I-Premise
effect I-Premise
sizes I-Premise
for I-Premise
all I-Premise
sleep I-Premise
variables I-Premise
as I-Premise
well I-Premise
as I-Premise
for I-Premise
fatigue I-Premise
, I-Premise
depression I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
ranged I-Premise
from I-Premise
small I-Premise
to I-Premise
large I-Premise
. I-Premise
!LF! !LF!
cbt B-Claim
- B-Claim
i B-Claim
delivered I-Claim
through I-Claim
an I-Claim
interactive I-Claim
, I-Claim
individually I-Claim
tailored I-Claim
internet I-Claim
intervention I-Claim
may I-Claim
be I-Claim
a I-Claim
viable I-Claim
treatment I-Claim
option I-Claim
for I-Claim
cancer I-Claim
survivors I-Claim
experiencing I-Claim
insomnia I-Claim
. I-Claim
!LF! !LF!
to O
compare O
the O
effectiveness O
and O
tolerability O
of O
gemcitabine O
plus O
cisplatin O
with O
single O
- O
agent O
gemcitabine O
as O
first O
- O
line O
chemotherapy O
for O
locally O
advanced O
or O
metastatic O
pancreatic O
cancer O
. O
!LF! !LF!
patients O
with O
advanced O
adenocarcinoma O
of O
the O
pancreas O
were O
randomly O
assigned O
to O
receive O
either O
gemcitabine O
1 O
, O
000 O
mg O
/ O
m2 O
and O
cisplatin O
50 O
mg O
/ O
m2 O
given O
on O
days O
1 O
and O
15 O
of O
a O
4 O
- O
week O
cycle O
( O
gemcis O
arm O
) O
or O
gemcitabine O
alone O
at O
a O
dose O
of O
1 O
, O
000 O
mg O
/ O
m2 O
on O
days O
1 O
, O
8 O
, O
and O
15 O
of O
a O
4 O
- O
week O
regimen O
( O
gem O
arm O
) O
. O
!LF! !LF!
the O
primary O
end O
point O
was O
overall O
survival O
"""" O
; O
"""" O
secondary O
end O
points O
were O
progression O
- O
free O
survival O
, O
response O
rate O
, O
safety O
, O
and O
quality O
of O
life O
. O
!LF! !LF!
one O
hundred O
ninety O
- O
five O
patients O
were O
enrolled O
and O
showed O
baseline O
characteristics O
well O
balanced O
between O
treatment O
arms O
. O
!LF! !LF!
combination B-Premise
treatment I-Premise
in I-Premise
the I-Premise
gemcis I-Premise
arm I-Premise
was I-Premise
associated I-Premise
with I-Premise
a I-Premise
prolonged I-Premise
median I-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
( I-Premise
5 I-Premise
. I-Premise
3 I-Premise
months I-Premise
v I-Premise
3 I-Premise
. I-Premise
1 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
hr I-Premise
] I-Premise
= I-Premise
0 I-Premise
. I-Premise
75 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
053 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
also B-Premise
, I-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
superior I-Premise
for I-Premise
patients I-Premise
treated I-Premise
in I-Premise
the I-Premise
gemcis I-Premise
arm I-Premise
as I-Premise
compared I-Premise
with I-Premise
the I-Premise
gem I-Premise
arm I-Premise
( I-Premise
7 I-Premise
. I-Premise
5 I-Premise
v I-Premise
6 I-Premise
. I-Premise
0 I-Premise
months I-Premise
) I-Premise
, I-Premise
an B-Premise
advantage I-Premise
which I-Premise
did I-Premise
not I-Premise
, I-Premise
however I-Premise
, I-Premise
reach I-Premise
statistical I-Premise
significance I-Premise
( I-Premise
hr I-Premise
= I-Premise
0 I-Premise
. I-Premise
80 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
15 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
tumor B-Premise
response I-Premise
rates I-Premise
were I-Premise
comparable I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
( I-Premise
10 I-Premise
. I-Premise
2 I-Premise
% I-Premise
v I-Premise
8 I-Premise
. I-Premise
2 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
rate I-Premise
of I-Premise
stable I-Premise
disease I-Premise
was I-Premise
, I-Premise
however I-Premise
, I-Premise
greater I-Premise
in I-Premise
the I-Premise
combination I-Premise
arm I-Premise
( I-Premise
60 I-Premise
. I-Premise
2 I-Premise
% I-Premise
v I-Premise
40 I-Premise
. I-Premise
2 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. O
!LF! !LF!
grade B-Premise
3 I-Premise
to I-Premise
4 I-Premise
hematologic I-Premise
toxicity I-Premise
did I-Premise
not I-Premise
exceed I-Premise
15 I-Premise
% I-Premise
in I-Premise
both I-Premise
treatment I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
these B-Claim
results I-Claim
support I-Claim
the I-Claim
efficacy I-Claim
and I-Claim
safety I-Claim
of I-Claim
an I-Claim
every I-Claim
- I-Claim
2 I-Claim
- I-Claim
weeks I-Claim
treatment I-Claim
with I-Claim
gemcitabine I-Claim
plus I-Claim
cisplatin I-Claim
. I-Claim
!LF! !LF!
median B-Claim
overall I-Claim
survival I-Claim
and I-Claim
progression I-Claim
- I-Claim
free I-Claim
survival I-Claim
were I-Claim
more I-Claim
favorable I-Claim
in I-Claim
the I-Claim
combination I-Claim
arm I-Claim
as I-Claim
compared I-Claim
with I-Claim
gemcitabine I-Claim
alone I-Claim
, I-Claim
although B-Premise
the I-Premise
difference I-Premise
did I-Premise
not I-Premise
attain I-Premise
statistical I-Premise
significance I-Premise
. I-Premise
!LF! !LF!
extracellular O
adenosine O
5 O
' O
- O
triphosphate O
( O
atp O
) O
is O
involved O
in O
the O
regulation O
of O
a O
variety O
of O
biologic O
processes O
, O
including O
neurotransmission O
, O
muscle O
contraction O
, O
and O
liver O
glucose O
metabolism O
, O
via O
purinergic O
receptors O
. O
!LF! !LF!
in B-Claim
nonrandomized I-Claim
studies I-Claim
involving I-Claim
patients I-Claim
with I-Claim
different I-Claim
tumor I-Claim
types I-Claim
including I-Claim
non I-Claim
- I-Claim
small I-Claim
- I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
nsclc I-Claim
) I-Claim
, I-Claim
atp I-Claim
infusion I-Claim
appeared I-Claim
to I-Claim
inhibit I-Claim
loss I-Claim
of I-Claim
weight I-Claim
and I-Claim
deterioration I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
qol I-Claim
) I-Claim
and I-Claim
performance I-Claim
status I-Claim
. I-Claim
!LF! !LF!
we O
conducted O
a O
randomized O
clinical O
trial O
to O
evaluate O
the O
effects O
of O
atp O
in O
patients O
with O
advanced O
nsclc O
( O
stage O
iiib O
or O
iv O
) O
. O
!LF! !LF!
fifty O
- O
eight O
patients O
were O
randomly O
assigned O
to O
receive O
either O
10 O
intravenous O
30 O
- O
hour O
atp O
infusions O
, O
with O
the O
infusions O
given O
at O
- O
2 O
to O
4 O
- O
week O
intervals O
, O
or O
no O
atp O
. O
!LF! !LF!
outcome O
parameters O
were O
assessed O
every O
4 O
weeks O
until O
28 O
weeks O
. O
!LF! !LF!
between O
- O
group O
differences O
were O
tested O
for O
statistical O
significance O
by O
use O
of O
repeated O
- O
measures O
analysis O
, O
and O
reported O
p O
values O
are O
two O
- O
sided O
. O
!LF! !LF!
twenty O
- O
eight O
patients O
were O
allocated O
to O
receive O
atp O
treatment O
and O
30 O
received O
no O
atp O
. O
!LF! !LF!
mean B-Premise
weight I-Premise
changes I-Premise
per I-Premise
4 I-Premise
- I-Premise
week I-Premise
period I-Premise
were I-Premise
- I-Premise
1 I-Premise
. I-Premise
0 I-Premise
kg I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
ci I-Premise
] I-Premise
= I-Premise
- I-Premise
1 I-Premise
. I-Premise
5 I-Premise
to I-Premise
- I-Premise
0 I-Premise
. I-Premise
5 I-Premise
) I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
and I-Premise
0 I-Premise
. I-Premise
2 I-Premise
kg I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
- I-Premise
0 I-Premise
. I-Premise
2 I-Premise
to I-Premise
+ I-Premise
0 I-Premise
. I-Premise
6 I-Premise
) I-Premise
in I-Premise
the I-Premise
atp I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
002 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
serum B-Premise
albumin I-Premise
concentration I-Premise
declined I-Premise
by I-Premise
- I-Premise
1 I-Premise
. I-Premise
2 I-Premise
g I-Premise
/ I-Premise
l I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
- I-Premise
2 I-Premise
. I-Premise
0 I-Premise
to I-Premise
- I-Premise
0 I-Premise
. I-Premise
4 I-Premise
) I-Premise
per I-Premise
4 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
but I-Premise
remained I-Premise
stable I-Premise
( I-Premise
0 I-Premise
. I-Premise
0 I-Premise
g I-Premise
/ I-Premise
l I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
- I-Premise
0 I-Premise
. I-Premise
3 I-Premise
to I-Premise
+ I-Premise
0 I-Premise
. I-Premise
3 I-Premise
) I-Premise
in I-Premise
the I-Premise
atp I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
006 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
elbow B-Premise
flexor I-Premise
muscle I-Premise
strength I-Premise
declined I-Premise
by I-Premise
- I-Premise
5 I-Premise
. I-Premise
5 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
- I-Premise
9 I-Premise
. I-Premise
6 I-Premise
% I-Premise
to I-Premise
- I-Premise
1 I-Premise
. I-Premise
4 I-Premise
% I-Premise
) I-Premise
per I-Premise
4 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
but I-Premise
remained I-Premise
stable I-Premise
( I-Premise
0 I-Premise
. I-Premise
0 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
- I-Premise
1 I-Premise
. I-Premise
4 I-Premise
% I-Premise
to I-Premise
+ I-Premise
1 I-Premise
. I-Premise
4 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
atp I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
a B-Premise
similar I-Premise
pattern I-Premise
was I-Premise
observed I-Premise
for I-Premise
knee I-Premise
extensor I-Premise
muscles I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
effects I-Premise
of I-Premise
atp I-Premise
on I-Premise
body I-Premise
weight I-Premise
, I-Premise
muscle I-Premise
strength I-Premise
, I-Premise
and I-Premise
albumin I-Premise
concentration I-Premise
were I-Premise
especially I-Premise
marked I-Premise
in I-Premise
cachectic I-Premise
patients I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
0002 I-Premise
, I-Premise
p I-Premise
= I-Premise
. I-Premise
0001 I-Premise
, I-Premise
and I-Premise
p I-Premise
= I-Premise
. I-Premise
1 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
atp I-Premise
versus I-Premise
no I-Premise
atp I-Premise
) I-Premise
. I-Premise
!LF! !LF!
qol B-Premise
score I-Premise
changes I-Premise
per I-Premise
4 I-Premise
- I-Premise
week I-Premise
period I-Premise
in I-Premise
the I-Premise
atp I-Premise
group I-Premise
showed I-Premise
overall I-Premise
less I-Premise
deterioration I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
- I-Premise
physical I-Premise
scores I-Premise
( I-Premise
- I-Premise
0 I-Premise
. I-Premise
2 I-Premise
% I-Premise
versus I-Premise
- I-Premise
2 I-Premise
. I-Premise
4 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
2 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
functional I-Premise
scores I-Premise
( I-Premise
+ I-Premise
0 I-Premise
. I-Premise
4 I-Premise
% I-Premise
versus I-Premise
- I-Premise
5 I-Premise
. I-Premise
5 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
02 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
psychologic I-Premise
scores I-Premise
( I-Premise
- I-Premise
0 I-Premise
. I-Premise
7 I-Premise
% I-Premise
versus I-Premise
- I-Premise
2 I-Premise
. I-Premise
4 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
11 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
overall I-Premise
qol I-Premise
score I-Premise
( I-Premise
+ I-Premise
0 I-Premise
. I-Premise
1 I-Premise
% I-Premise
versus I-Premise
- I-Premise
3 I-Premise
. I-Premise
5 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
0001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
this O
randomized O
trial O
demonstrates O
that O
atp B-Claim
has I-Claim
beneficial I-Claim
effects I-Claim
on I-Claim
weight I-Claim
, I-Claim
muscle I-Claim
strength I-Claim
, I-Claim
and I-Claim
qol I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
nsclc I-Claim
. I-Claim
!LF! !LF!
abiraterone B-Claim
acetate I-Claim
plus I-Claim
prednisone I-Claim
significantly I-Claim
improves I-Claim
radiographic I-Claim
progression I-Claim
- I-Claim
free I-Claim
survival I-Claim
in I-Claim
asymptomatic I-Claim
or I-Claim
mildly I-Claim
symptomatic I-Claim
, I-Claim
chemotherapy I-Claim
- I-Claim
naive I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
castration I-Claim
- I-Claim
resistant I-Claim
prostate I-Claim
cancer I-Claim
compared I-Claim
with I-Claim
prednisone I-Claim
alone I-Claim
. I-Claim
!LF! !LF!
we O
describe O
analyses O
of O
data O
for O
patient O
- O
reported O
pain O
and O
functional O
status O
in O
a O
preplanned O
interim O
analysis O
of O
a O
phase O
3 O
trial O
. O
!LF! !LF!
between O
april O
28 O
, O
2009 O
, O
and O
june O
23 O
, O
2010 O
, O
patients O
with O
progressive O
, O
metastatic O
castration O
- O
resistant O
prostate O
cancer O
were O
enrolled O
into O
a O
multinational O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
trial O
. O
!LF! !LF!
patients O
were O
eligible O
if O
they O
were O
asymptomatic O
( O
score O
of O
0 O
or O
1 O
on O
item O
three O
of O
the O
brief O
pain O
inventory O
short O
form O
[ O
bpi O
- O
sf O
] O
questionnaire O
) O
or O
mildly O
symptomatic O
( O
score O
of O
2 O
or O
3 O
) O
and O
had O
not O
previously O
received O
chemotherapy O
. O
!LF! !LF!
patients O
were O
randomly O
assigned O
( O
1 O
: O
1 O
) O
to O
receive O
oral O
abiraterone O
( O
1 O
g O
daily O
) O
plus O
prednisone O
( O
5 O
mg O
twice O
daily O
) O
or O
placebo O
plus O
prednisone O
in O
continuous O
4 O
- O
week O
cycles O
. O
!LF! !LF!
pain O
was O
assessed O
with O
the O
bpi O
- O
sf O
questionnaire O
, O
and O
health O
- O
related O
quality O
of O
life O
( O
hrqol O
) O
with O
the O
functional O
assessment O
of O
cancer O
therapy O
- O
prostate O
( O
fact O
- O
p O
) O
questionnaire O
. O
!LF! !LF!
we O
analysed O
data O
with O
prespecified O
criteria O
for O
clinically O
meaningful O
pain O
progression O
and O
deterioration O
in O
hrqol O
. O
!LF! !LF!
all O
patients O
who O
underwent O
randomisation O
were O
included O
in O
analyses O
. O
!LF! !LF!
1088 O
patients O
underwent O
randomisation O
: O
546 O
were O
assigned O
to O
abiraterone O
plus O
prednisone O
and O
542 O
to O
placebo O
plus O
prednisone O
. O
!LF! !LF!
at O
the O
time O
of O
the O
second O
prespecified O
interim O
analysis O
, O
median O
follow O
- O
up O
was O
22 O
· O
2 O
months O
( O
iqr O
20 O
· O
2 O
- O
24 O
· O
8 O
) O
. O
!LF! !LF!
median B-Premise
time I-Premise
to I-Premise
progression I-Premise
of I-Premise
mean I-Premise
pain I-Premise
intensity I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
assigned I-Premise
to I-Premise
abiraterone I-Premise
plus I-Premise
prednisone I-Premise
( I-Premise
26 I-Premise
· I-Premise
7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
ci I-Premise
19 I-Premise
· I-Premise
3 I-Premise
- I-Premise
not I-Premise
estimable I-Premise
] I-Premise
) I-Premise
than I-Premise
in I-Premise
those I-Premise
assigned I-Premise
to I-Premise
placebo I-Premise
plus I-Premise
prednisone I-Premise
( I-Premise
18 I-Premise
· I-Premise
4 I-Premise
months I-Premise
[ I-Premise
14 I-Premise
· I-Premise
9 I-Premise
- I-Premise
not I-Premise
estimable I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
hr I-Premise
] I-Premise
0 I-Premise
· I-Premise
82 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
· I-Premise
67 I-Premise
- I-Premise
1 I-Premise
· I-Premise
00 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
· I-Premise
0490 I-Premise
) I-Premise
, I-Premise
as I-Premise
was I-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
of I-Premise
pain I-Premise
interference I-Premise
with I-Premise
daily I-Premise
activities I-Premise
( I-Premise
10 I-Premise
· I-Premise
3 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
ci I-Premise
9 I-Premise
· I-Premise
3 I-Premise
- I-Premise
13 I-Premise
· I-Premise
0 I-Premise
] I-Premise
vs I-Premise
7 I-Premise
· I-Premise
4 I-Premise
months I-Premise
[ I-Premise
6 I-Premise
· I-Premise
4 I-Premise
- I-Premise
8 I-Premise
· I-Premise
6 I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hr I-Premise
0 I-Premise
· I-Premise
79 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
· I-Premise
67 I-Premise
- I-Premise
0 I-Premise
· I-Premise
93 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
· I-Premise
005 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
median B-Premise
time I-Premise
to I-Premise
progression I-Premise
of I-Premise
worst I-Premise
pain I-Premise
was I-Premise
also I-Premise
longer I-Premise
with I-Premise
abiraterone I-Premise
plus I-Premise
prednisone I-Premise
( I-Premise
26 I-Premise
· I-Premise
7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
ci I-Premise
19 I-Premise
· I-Premise
4 I-Premise
- I-Premise
not I-Premise
estimable I-Premise
] I-Premise
) I-Premise
than I-Premise
with I-Premise
placebo I-Premise
plus I-Premise
prednisone I-Premise
( I-Premise
19 I-Premise
· I-Premise
4 I-Premise
months I-Premise
[ I-Premise
16 I-Premise
· I-Premise
6 I-Premise
- I-Premise
not I-Premise
estimable I-Premise
] I-Premise
) I-Premise
, I-Premise
but I-Premise
the I-Premise
difference I-Premise
was I-Premise
not I-Premise
significant I-Premise
( I-Premise
hr I-Premise
0 I-Premise
· I-Premise
85 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
· I-Premise
69 I-Premise
- I-Premise
1 I-Premise
· I-Premise
04 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
· I-Premise
109 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
median B-Premise
time I-Premise
to I-Premise
hrqol I-Premise
deterioration I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
assigned I-Premise
to I-Premise
abiraterone I-Premise
plus I-Premise
prednisone I-Premise
than I-Premise
in I-Premise
those I-Premise
assigned I-Premise
to I-Premise
placebo I-Premise
plus I-Premise
prednisone I-Premise
as I-Premise
assessed I-Premise
by I-Premise
the I-Premise
fact I-Premise
- I-Premise
p I-Premise
total I-Premise
score I-Premise
( I-Premise
12 I-Premise
· I-Premise
7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
ci I-Premise
11 I-Premise
· I-Premise
1 I-Premise
- I-Premise
14 I-Premise
· I-Premise
0 I-Premise
] I-Premise
vs I-Premise
8 I-Premise
· I-Premise
3 I-Premise
months I-Premise
[ I-Premise
7 I-Premise
· I-Premise
4 I-Premise
- I-Premise
10 I-Premise
· I-Premise
6 I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hr I-Premise
0 I-Premise
· I-Premise
78 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
· I-Premise
66 I-Premise
- I-Premise
0 I-Premise
· I-Premise
92 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
· I-Premise
003 I-Premise
) I-Premise
and I-Premise
by I-Premise
the I-Premise
score I-Premise
on I-Premise
its I-Premise
prostate I-Premise
- I-Premise
cancer I-Premise
- I-Premise
specific I-Premise
subscale I-Premise
( I-Premise
11 I-Premise
· I-Premise
1 I-Premise
months I-Premise
[ I-Premise
8 I-Premise
· I-Premise
6 I-Premise
- I-Premise
13 I-Premise
· I-Premise
8 I-Premise
] I-Premise
vs I-Premise
5 I-Premise
· I-Premise
8 I-Premise
months I-Premise
[ I-Premise
5 I-Premise
· I-Premise
5 I-Premise
- I-Premise
8 I-Premise
· I-Premise
3 I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hr I-Premise
0 I-Premise
· I-Premise
70 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
· I-Premise
60 I-Premise
- I-Premise
0 I-Premise
· I-Premise
83 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
0 I-Premise
· I-Premise
0001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
abiraterone B-Claim
plus I-Claim
prednisone I-Claim
delays I-Claim
patient I-Claim
- I-Claim
reported I-Claim
pain I-Claim
progression I-Claim
and I-Claim
hrqol I-Claim
deterioration I-Claim
in I-Claim
chemotherapy I-Claim
- I-Claim
naive I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
castration I-Claim
- I-Claim
resistant I-Claim
prostate I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
these B-Claim
results I-Claim
provide I-Claim
further I-Claim
support I-Claim
for I-Claim
the I-Claim
efficacy I-Claim
of I-Claim
abiraterone I-Claim
in I-Claim
this I-Claim
population I-Claim
. I-Claim
!LF! !LF!
postoperative B-Claim
adjuvant I-Claim
chemoradiation I-Claim
treatment I-Claim
after I-Claim
curative I-Claim
resection I-Claim
for I-Claim
rectal I-Claim
cancer I-Claim
was I-Claim
needed I-Claim
to I-Claim
reduce I-Claim
recurrence I-Claim
and I-Claim
improve I-Claim
a I-Claim
survival I-Claim
rate I-Claim
. I-Claim
!LF! !LF!
intravenous B-Claim
5 I-Claim
- I-Claim
fluorouracil I-Claim
( I-Claim
5 I-Claim
- I-Claim
fu I-Claim
) I-Claim
and I-Claim
leucovorin I-Claim
has I-Claim
been I-Claim
a I-Claim
mainstay I-Claim
of I-Claim
chemotherapy I-Claim
, I-Claim
but O
oral B-Claim
5 I-Claim
- I-Claim
fu I-Claim
derivatives I-Claim
have I-Claim
been I-Claim
shown I-Claim
a I-Claim
comparable I-Claim
antitumor I-Claim
activity I-Claim
. I-Claim
!LF! !LF!
intravenous O
5 O
- O
fu O
and O
oral O
doxifluridine O
were O
compared O
with O
respect O
to O
therapeutic O
efficacy O
, O
drug O
toxicity O
, O
and O
quality O
of O
life O
. O
!LF! !LF!
a O
total O
of O
166 O
patients O
were O
randomized O
to O
receive O
intravenous O
5 O
- O
fu O
( O
450 O
mg O
/ O
m2 O
/ O
day O
) O
or O
oral O
doxifluridine O
( O
900 O
mg O
/ O
m2 O
/ O
day O
) O
in O
combination O
with O
leucovorin O
( O
20 O
mg O
/ O
m2 O
/ O
day O
) O
for O
depth O
of O
invasion O
, O
nodal O
status O
, O
metastasis O
( O
tnm O
) O
stage O
ii O
and O
iii O
patients O
between O
october O
1997 O
and O
february O
1999 O
. O
!LF! !LF!
consecutive O
daily O
intravenous O
infusion O
for O
5 O
days O
per O
every O
month O
for O
a O
total O
of O
12 O
cycles O
( O
iv O
arm O
, O
n O
= O
74 O
) O
and O
oral O
doxifluridine O
daily O
for O
3 O
weeks O
and O
1 O
week O
rest O
for O
a O
total O
of O
12 O
cycles O
( O
oral O
arm O
, O
n O
= O
92 O
) O
. O
!LF! !LF!
drug O
toxicity O
and O
quality O
of O
life O
were O
observed O
. O
!LF! !LF!
quality O
of O
life O
was O
scored O
according O
to O
22 O
daily O
activity O
items O
( O
good O
, O
> O
or O
71 O
"""" O
; O
"""" O
fair O
, O
< O
70 O
"""" O
; O
"""" O
poor O
, O
< O
52 O
) O
. O
!LF! !LF!
there O
was O
no O
difference O
of O
sex O
between O
two O
groups O
( O
iv O
arm O
: O
male O
/ O
female O
= O
45 O
/ O
29 O
, O
oral O
arm O
: O
male O
/ O
female O
= O
59 O
/ O
33 O
) O
. O
!LF! !LF!
the O
mean O
age O
was O
52 O
. O
3 O
vs O
. O
59 O
. O
5 O
, O
respectively O
. O
!LF! !LF!
there O
was O
also O
no O
difference O
of O
tnm O
stage O
distribution O
and O
type O
of O
operation O
between O
groups O
( O
p O
> O
. O
05 O
) O
. O
!LF! !LF!
mean B-Premise
numbers I-Premise
of I-Premise
chemotherapy I-Premise
cycles I-Premise
were I-Premise
6 I-Premise
. I-Premise
5 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
3 I-Premise
. I-Premise
7 I-Premise
( I-Premise
iv I-Premise
arm I-Premise
) I-Premise
vs I-Premise
. I-Premise
7 I-Premise
. I-Premise
2 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
4 I-Premise
. I-Premise
3 I-Premise
( I-Premise
oral I-Premise
arm I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
the B-Premise
rate I-Premise
of I-Premise
recurrence I-Premise
was I-Premise
9 I-Premise
/ I-Premise
74 I-Premise
( I-Premise
12 I-Premise
. I-Premise
1 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
iv I-Premise
arm I-Premise
and I-Premise
6 I-Premise
/ I-Premise
92 I-Premise
( I-Premise
6 I-Premise
. I-Premise
5 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
937 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
local B-Premise
recurrence I-Premise
was I-Premise
2 I-Premise
/ I-Premise
74 I-Premise
( I-Premise
stage I-Premise
iii I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
2 I-Premise
. I-Premise
7 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
iv I-Premise
arm I-Premise
and I-Premise
1 I-Premise
/ I-Premise
92 I-Premise
( I-Premise
stage I-Premise
ii I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
1 I-Premise
. I-Premise
1 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
systemic B-Premise
recurrence I-Premise
was I-Premise
7 I-Premise
/ I-Premise
74 I-Premise
( I-Premise
stage I-Premise
iii I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
9 I-Premise
. I-Premise
4 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
iv I-Premise
arm I-Premise
and I-Premise
5 I-Premise
/ I-Premise
92 I-Premise
( I-Premise
stage I-Premise
iii I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
5 I-Premise
. I-Premise
4 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
the B-Premise
most I-Premise
common I-Premise
site I-Premise
of I-Premise
systemic I-Premise
recurrence I-Premise
was I-Premise
the I-Premise
liver I-Premise
. I-Premise
!LF! !LF!
toxicity B-Premise
profile I-Premise
was I-Premise
as I-Premise
follows I-Premise
: I-Premise
leukopenia I-Premise
( I-Premise
30 I-Premise
/ I-Premise
74 I-Premise
vs I-Premise
. I-Premise
17 I-Premise
/ I-Premise
92 I-Premise
) I-Premise
and I-Premise
alopecia I-Premise
( I-Premise
21 I-Premise
/ I-Premise
74 I-Premise
vs I-Premise
. I-Premise
13 I-Premise
/ I-Premise
92 I-Premise
) I-Premise
were I-Premise
statistically I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
iv I-Premise
arm I-Premise
. I-Premise
!LF! !LF!
diarrhea B-Premise
was I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
. I-Premise
!LF! !LF!
poor B-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
between I-Premise
two I-Premise
groups I-Premise
was I-Premise
observed I-Premise
at I-Premise
1 I-Premise
month I-Premise
( I-Premise
23 I-Premise
. I-Premise
9 I-Premise
% I-Premise
vs I-Premise
. I-Premise
13 I-Premise
% I-Premise
) I-Premise
and I-Premise
2 I-Premise
months I-Premise
( I-Premise
15 I-Premise
. I-Premise
8 I-Premise
% I-Premise
vs I-Premise
. I-Premise
3 I-Premise
. I-Premise
7 I-Premise
% I-Premise
) I-Premise
after I-Premise
chemotherapy I-Premise
. I-Premise
!LF! !LF!
good B-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
was I-Premise
observed I-Premise
at I-Premise
1 I-Premise
month I-Premise
( I-Premise
19 I-Premise
. I-Premise
5 I-Premise
% I-Premise
vs I-Premise
. I-Premise
49 I-Premise
% I-Premise
) I-Premise
and I-Premise
2 I-Premise
months I-Premise
( I-Premise
47 I-Premise
% I-Premise
vs I-Premise
. I-Premise
72 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
oral B-Claim
doxifluridine I-Claim
with I-Claim
leucovorin I-Claim
shows I-Claim
a I-Claim
comparable I-Claim
therapeutic I-Claim
efficacy I-Claim
to I-Claim
intravenous I-Claim
5 I-Claim
- I-Claim
fu I-Claim
regimen I-Claim
with I-Claim
high I-Claim
quality I-Claim
of I-Claim
life I-Claim
as I-Claim
postoperative I-Claim
adjuvant I-Claim
therapy I-Claim
. I-Claim
!LF! !LF!
the B-Claim
oral I-Claim
regimen I-Claim
also I-Claim
can I-Claim
be I-Claim
safely I-Claim
given I-Claim
with I-Claim
appropriate I-Claim
toxicity I-Claim
and I-Claim
tolerability I-Claim
. I-Claim
!LF! !LF!
this O
phase O
iii O
randomized O
trial O
compared O
two O
chemotherapy O
regimens O
, O
gemcitabine O
plus O
carboplatin O
and O
mitomycin O
, O
ifosfamide O
, O
and O
cisplatin O
, O
in O
chemotherapy O
- O
naive O
patients O
with O
advanced O
non O
- O
small O
- O
cell O
lung O
cancer O
( O
nsclc O
) O
. O
!LF! !LF!
the O
regimens O
were O
compared O
with O
regard O
to O
effects O
on O
survival O
, O
response O
rates O
, O
toxicity O
, O
and O
quality O
of O
life O
. O
!LF! !LF!
eligible O
patients O
had O
previously O
untreated O
stage O
iiib O
or O
iv O
nsclc O
suitable O
for O
cisplatin O
- O
based O
chemotherapy O
. O
!LF! !LF!
randomly O
assigned O
patients O
were O
to O
receive O
four O
cycles O
, O
each O
at O
3 O
- O
week O
intervals O
, O
of O
carboplatin O
area O
under O
the O
curve O
of O
5 O
on O
day O
1 O
plus O
gemcitabine O
1 O
, O
200 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
( O
gca O
) O
or O
mitomycin O
6 O
mg O
/ O
m O
( O
2 O
) O
, O
ifosfamide O
3g O
/ O
m O
( O
2 O
) O
, O
and O
cisplatin O
50 O
mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
( O
mic O
) O
. O
!LF! !LF!
between O
february O
1999 O
and O
august O
2001 O
, O
422 O
patients O
( O
gca O
, O
n O
= O
212 O
"""" O
; O
"""" O
mic O
, O
n O
= O
210 O
) O
were O
randomly O
assigned O
in O
the O
united O
kingdom O
. O
!LF! !LF!
the O
majority O
of O
patients O
received O
the O
intended O
four O
cycles O
( O
gca O
, O
64 O
% O
"""" O
; O
"""" O
mic O
, O
61 O
% O
) O
. O
!LF! !LF!
there B-Premise
was I-Premise
a I-Premise
significant I-Premise
survival I-Premise
advantage I-Premise
for I-Premise
gca I-Premise
compared I-Premise
with I-Premise
mic I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0 I-Premise
. I-Premise
76 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
61 I-Premise
to I-Premise
0 I-Premise
. I-Premise
93 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
008 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
median B-Premise
survival I-Premise
was I-Premise
10 I-Premise
months I-Premise
with I-Premise
gca I-Premise
and I-Premise
7 I-Premise
. I-Premise
6 I-Premise
months I-Premise
with I-Premise
mic I-Premise
( I-Premise
difference I-Premise
, I-Premise
2 I-Premise
. I-Premise
4 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
1 I-Premise
. I-Premise
0 I-Premise
to I-Premise
4 I-Premise
. I-Premise
0 I-Premise
) I-Premise
, I-Premise
and I-Premise
1 I-Premise
- I-Premise
year I-Premise
survival I-Premise
was I-Premise
40 I-Premise
% I-Premise
with I-Premise
gca I-Premise
and I-Premise
30 I-Premise
% I-Premise
with I-Premise
mic I-Premise
( I-Premise
difference I-Premise
, I-Premise
10 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
3 I-Premise
% I-Premise
to I-Premise
18 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
overall B-Premise
response I-Premise
rates I-Premise
were I-Premise
similar I-Premise
( I-Premise
42 I-Premise
% I-Premise
for I-Premise
gca I-Premise
v I-Premise
41 I-Premise
% I-Premise
for I-Premise
mic I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
84 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
more B-Premise
thrombocytopenia I-Premise
occurred I-Premise
with I-Premise
gca I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
, I-Premise
but B-Premise
this I-Premise
was I-Premise
not I-Premise
associated I-Premise
with I-Premise
increased I-Premise
hospital I-Premise
admission I-Premise
or I-Premise
fatality I-Premise
. I-Premise
!LF! !LF!
gca B-Premise
caused I-Premise
less I-Premise
nausea I-Premise
, I-Premise
vomiting I-Premise
, I-Premise
constipation I-Premise
, I-Premise
and I-Premise
alopecia I-Premise
and I-Premise
was I-Premise
associated I-Premise
with I-Premise
fewer I-Premise
admissions I-Premise
for I-Premise
administration I-Premise
and I-Premise
better I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise
!LF! !LF!
in B-Claim
patients I-Claim
with I-Claim
advanced I-Claim
nsclc I-Claim
, I-Claim
gca I-Claim
chemotherapy I-Claim
was I-Claim
shown I-Claim
to I-Claim
be I-Claim
a I-Claim
better I-Claim
- I-Claim
tolerated I-Claim
treatment I-Claim
that I-Claim
conferred I-Claim
a I-Claim
survival I-Claim
advantage I-Claim
over I-Claim
mic I-Claim
. I-Claim
!LF! !LF!
to O
perform O
a O
randomized O
trial O
comparing O
70 O
and O
80 O
gy O
radiotherapy O
for O
prostate O
cancer O
. O
!LF! !LF!
a O
total O
of O
306 O
patients O
with O
localized O
prostate O
cancer O
were O
randomized O
. O
!LF! !LF!
no O
androgen O
deprivation O
was O
allowed O
. O
!LF! !LF!
the O
primary O
endpoint O
was O
biochemical O
relapse O
according O
to O
the O
modified O
1997 O
- O
american O
society O
for O
therapeutic O
radiology O
and O
oncology O
and O
phoenix O
definitions O
. O
!LF! !LF!
toxicity O
was O
graded O
using O
the O
radiation O
therapy O
oncology O
group O
1991 O
criteria O
and O
the O
late O
effects O
on O
normal O
tissues O
- O
subjective O
, O
objective O
, O
management O
, O
analytic O
scales O
( O
lent O
- O
soma O
) O
scales O
. O
!LF! !LF!
the O
patients O
' O
quality O
of O
life O
was O
scored O
using O
the O
european O
organization O
for O
research O
and O
treatment O
of O
cancer O
quality O
of O
life O
questionnaire O
30 O
- O
item O
cancer O
- O
specific O
and O
25 O
- O
item O
prostate O
- O
specific O
modules O
. O
!LF! !LF!
the O
median O
follow O
- O
up O
was O
61 O
months O
. O
!LF! !LF!
according O
to O
the O
1997 O
- O
american O
society O
for O
therapeutic O
radiology O
and O
oncology O
definition O
, O
the O
5 O
- O
year O
biochemical O
relapse O
rate O
was O
39 O
% O
and O
28 O
% O
in O
the O
- O
70 O
and O
80 O
- O
gy O
arms O
, O
respectively O
( O
p O
= O
. O
036 O
) O
. O
!LF! !LF!
using O
the O
phoenix O
definition O
, O
the O
5 O
- O
year O
biochemical O
relapse O
rate O
was O
32 O
% O
and O
23 O
. O
5 O
% O
, O
respectively O
( O
p O
= O
. O
09 O
) O
. O
!LF! !LF!
the O
subgroup O
analysis O
showed O
a O
better O
biochemical O
outcome O
for O
the O
higher O
dose O
group O
with O
an O
initial O
prostate O
- O
specific O
antigen O
level O
> O
15 O
ng O
/ O
ml O
. O
!LF! !LF!
at O
the O
last O
follow O
- O
up O
date O
, O
26 O
patients O
had O
died O
, O
10 O
of O
their O
disease O
and O
none O
of O
toxicity O
, O
with O
no O
differences O
between O
the O
two O
arms O
. O
!LF! !LF!
according B-Premise
to I-Premise
the I-Premise
radiation I-Premise
therapy I-Premise
oncology I-Premise
group I-Premise
scale I-Premise
, I-Premise
the I-Premise
grade I-Premise
2 I-Premise
or I-Premise
greater I-Premise
rectal I-Premise
toxicity I-Premise
rate I-Premise
was I-Premise
14 I-Premise
% I-Premise
and I-Premise
19 I-Premise
. I-Premise
5 I-Premise
% I-Premise
for I-Premise
the I-Premise
- I-Premise
70 I-Premise
and I-Premise
80 I-Premise
- I-Premise
gy I-Premise
arms I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
22 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
the B-Premise
grade I-Premise
2 I-Premise
or I-Premise
greater I-Premise
urinary I-Premise
toxicity I-Premise
was I-Premise
10 I-Premise
% I-Premise
at I-Premise
70 I-Premise
gy I-Premise
and I-Premise
17 I-Premise
. I-Premise
5 I-Premise
% I-Premise
at I-Premise
80 I-Premise
gy I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
046 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
similar B-Premise
results I-Premise
were I-Premise
observed I-Premise
using I-Premise
the I-Premise
lent I-Premise
- I-Premise
soma I-Premise
scale I-Premise
. I-Premise
!LF! !LF!
bladder B-Premise
toxicity I-Premise
was I-Premise
more I-Premise
frequent I-Premise
at I-Premise
80 I-Premise
gy I-Premise
than I-Premise
at I-Premise
70 I-Premise
gy I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
039 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
quality I-Premise
- I-Premise
of I-Premise
- I-Premise
life I-Premise
questionnaire I-Premise
results I-Premise
before I-Premise
and I-Premise
5 I-Premise
years I-Premise
after I-Premise
treatment I-Premise
were I-Premise
available I-Premise
for I-Premise
103 I-Premise
patients I-Premise
with I-Premise
no I-Premise
differences I-Premise
found I-Premise
between I-Premise
the I-Premise
- I-Premise
70 I-Premise
and I-Premise
80 I-Premise
- I-Premise
gy I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
high B-Claim
- B-Claim
dose B-Claim
radiotherapy I-Claim
provided I-Claim
a I-Claim
better I-Claim
5 I-Claim
- I-Claim
year I-Claim
biochemical I-Claim
outcome I-Claim
with I-Claim
slightly I-Claim
greater I-Claim
toxicity I-Claim
. I-Claim
!LF! !LF!
several O
multicomponent O
regimens O
have O
been O
reported O
to O
be O
useful O
in O
advanced O
androgen O
- O
independent O
prostate O
cancer O
. O
!LF! !LF!
we O
used O
a O
randomized O
phase O
ii O
design O
to O
evaluate O
and O
compare O
two O
such O
regimens O
. O
!LF! !LF!
patients O
were O
accrued O
primarily O
in O
the O
community O
setting O
. O
!LF! !LF!
patients O
with O
progressive O
, O
androgen O
- O
independent O
prostate O
cancer O
were O
randomly O
assigned O
to O
one O
of O
two O
treatments O
: O
either O
ketoconazole O
/ O
doxorubicin O
alternating O
with O
vinblastine O
/ O
estramustine O
( O
ka O
/ O
ve O
) O
or O
paclitaxel O
, O
estramustine O
, O
and O
oral O
etoposide O
( O
tee O
) O
. O
!LF! !LF!
patients O
were O
prospectively O
stratified O
on O
the O
basis O
of O
disease O
volume O
. O
!LF! !LF!
the O
primary O
end O
points O
were O
response O
and O
overall O
survival O
time O
. O
!LF! !LF!
a O
total O
of O
75 O
patients O
were O
registered O
"""" O
; O
"""" O
71 O
are O
included O
in O
the O
analysis O
. O
!LF! !LF!
by O
the O
criterion O
of O
an O
80 O
% O
prostate O
- O
specific O
antigen O
reduction O
maintained O
for O
at O
least O
8 O
weeks O
, O
11 O
( O
30 O
% O
) O
of O
37 O
patients O
in O
the O
tee O
arm O
responded O
, O
whereas O
11 O
( O
32 O
% O
) O
of O
34 O
assigned O
to O
ka O
/ O
ve O
responded O
. O
!LF! !LF!
median B-Premise
survival I-Premise
was I-Premise
16 I-Premise
. I-Premise
9 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
ci I-Premise
] I-Premise
, I-Premise
10 I-Premise
. I-Premise
5 I-Premise
to I-Premise
21 I-Premise
. I-Premise
2 I-Premise
months I-Premise
) I-Premise
in I-Premise
the I-Premise
tee I-Premise
arm I-Premise
and I-Premise
23 I-Premise
. I-Premise
4 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
12 I-Premise
. I-Premise
9 I-Premise
to I-Premise
30 I-Premise
. I-Premise
6 I-Premise
months I-Premise
) I-Premise
for I-Premise
patients I-Premise
treated I-Premise
with I-Premise
ka I-Premise
/ I-Premise
ve I-Premise
. I-Premise
!LF! !LF!
many B-Premise
patients I-Premise
( I-Premise
24 I-Premise
% I-Premise
) I-Premise
failed I-Premise
to I-Premise
complete I-Premise
at I-Premise
least I-Premise
6 I-Premise
weeks I-Premise
of I-Premise
therapy I-Premise
, I-Premise
including I-Premise
five I-Premise
( I-Premise
8 I-Premise
% I-Premise
) I-Premise
treatment I-Premise
- I-Premise
related I-Premise
early I-Premise
deaths I-Premise
. I-Premise
!LF! !LF!
each B-Claim
of I-Claim
these I-Claim
regimens I-Claim
produced I-Claim
clinically I-Claim
significant I-Claim
responses I-Claim
, I-Claim
and O
the B-Claim
observed I-Claim
median I-Claim
survival I-Claim
( I-Claim
18 I-Claim
. I-Claim
9 I-Claim
months I-Claim
for I-Claim
all I-Claim
71 I-Claim
patients I-Claim
) I-Claim
compares I-Claim
favorably I-Claim
with I-Claim
previously I-Claim
published I-Claim
results I-Claim
, I-Claim
especially I-Claim
in I-Claim
the I-Claim
community I-Claim
setting I-Claim
. I-Claim
!LF! !LF!
nonetheless B-Claim
, I-Claim
it I-Claim
is I-Claim
apparent I-Claim
that I-Claim
these I-Claim
first I-Claim
- I-Claim
generation I-Claim
regimens I-Claim
must I-Claim
be I-Claim
applied I-Claim
judiciously I-Claim
, I-Claim
and O
thus B-Claim
we I-Claim
view I-Claim
efforts I-Claim
at I-Claim
better I-Claim
patient I-Claim
selection I-Claim
and I-Claim
the I-Claim
development I-Claim
of I-Claim
more I-Claim
tolerable I-Claim
therapies I-Claim
as I-Claim
higher I-Claim
priorities I-Claim
than I-Claim
carrying I-Claim
either I-Claim
of I-Claim
these I-Claim
regimens I-Claim
to I-Claim
phase I-Claim
iii I-Claim
evaluation I-Claim
in I-Claim
the I-Claim
cooperative I-Claim
group I-Claim
setting I-Claim
. I-Claim
!LF! !LF!
systematic B-Claim
assessment I-Claim
is I-Claim
vital I-Claim
to I-Claim
palliative I-Claim
care I-Claim
, O
but O
documentation O
confirming O
completion O
of O
systematic O
assessment O
in O
hospice O
settings O
is O
often O
inadequate O
or O
absent O
. O
!LF! !LF!
the O
objective O
of O
the O
study O
was O
to O
determine O
the O
efficacy O
of O
systematic O
feedback O
from O
standardized O
assessment O
tools O
for O
hospice O
patient O
- O
caregiver O
dyads O
in O
improving O
hospice O
outcomes O
compared O
with O
the O
usual O
clinical O
practice O
. O
!LF! !LF!
the O
sample O
of O
patients O
( O
n O
= O
709 O
) O
newly O
admitted O
to O
hospice O
home O
care O
in O
2 O
hospices O
had O
designated O
family O
caregivers O
. O
!LF! !LF!
the O
interdisciplinary O
teams O
( O
idts O
) O
caring O
for O
these O
dyads O
were O
randomly O
assigned O
to O
either O
experimental O
( O
n O
= O
338 O
) O
or O
control O
( O
n O
= O
371 O
) O
conditions O
. O
!LF! !LF!
data O
were O
collected O
from O
both O
groups O
of O
dyads O
using O
standardized O
assessments O
on O
admission O
and O
1 O
week O
after O
each O
of O
the O
first O
2 O
idt O
meetings O
in O
which O
these O
dyads O
were O
discussed O
. O
!LF! !LF!
the O
experimental O
intervention O
consisted O
of O
reporting O
data O
from O
the O
standardized O
assessments O
to O
the O
idts O
. O
!LF! !LF!
results B-Premise
showed I-Premise
improved I-Premise
patient I-Premise
depression I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
as I-Premise
a I-Premise
result I-Premise
of I-Premise
the I-Premise
intervention I-Premise
and I-Premise
improvement I-Premise
in I-Premise
both I-Premise
groups I-Premise
in I-Premise
patients I-Premise
' I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
no B-Premise
other I-Premise
patient I-Premise
outcomes I-Premise
( I-Premise
symptom I-Premise
distress I-Premise
, I-Premise
spiritual I-Premise
needs I-Premise
) I-Premise
or I-Premise
caregiver I-Premise
outcomes I-Premise
( I-Premise
depression I-Premise
, I-Premise
support I-Premise
, I-Premise
spiritual I-Premise
needs I-Premise
) I-Premise
were I-Premise
significantly I-Premise
different I-Premise
. I-Premise
!LF! !LF!
assessment O
of O
depression O
added O
to O
usual O
care O
probably O
had O
an O
effect O
because O
it O
is O
not O
normally O
a O
focus O
of O
hospice O
staff O
. O
!LF! !LF!
hospice B-Premise
care I-Premise
was I-Premise
so I-Premise
good I-Premise
during I-Premise
the I-Premise
study I-Premise
that I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
improved I-Premise
as I-Premise
a I-Premise
result I-Premise
of I-Premise
standard I-Premise
care I-Premise
and I-Premise
left I-Premise
little I-Premise
room I-Premise
for I-Premise
improvement I-Premise
in I-Premise
other I-Premise
variables I-Premise
. I-Premise
!LF! !LF!
systematic B-Claim
assessment I-Claim
of I-Claim
depression I-Claim
is I-Claim
needed I-Claim
in I-Claim
hospice I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
no O
caregiver O
variables O
changed O
, O
which O
may O
indicate O
a O
need O
for O
a O
focus O
on O
caregivers O
. O
!LF! !LF!
this O
study O
aims O
to O
examine O
the O
effectiveness O
of O
a O
self O
- O
management O
multimodal O
comprehensive O
coping O
strategy O
program O
( O
ccsp O
) O
on O
quality O
of O
life O
( O
qol O
) O
among O
breast O
cancer O
patients O
1 O
year O
after O
treatment O
. O
!LF! !LF!
patients O
( O
n O
= O
110 O
) O
with O
stage O
ii O
, O
iii O
, O
or O
iv O
breast O
cancer O
scheduled O
to O
receive O
high O
dose O
chemotherapy O
and O
autologous O
hematopoietic O
stem O
cell O
transplantation O
were O
randomized O
to O
either O
ccsp O
treatment O
or O
control O
group O
. O
!LF! !LF!
the O
ccsp O
intervention O
was O
taught O
2 O
week O
before O
hospital O
admission O
with O
reinforcement O
at O
specified O
times O
during O
treatment O
and O
3 O
months O
after O
discharge O
. O
!LF! !LF!
the O
ccsp O
components O
included O
educational O
information O
, O
cognitive O
restructuring O
, O
coping O
skills O
enhancement O
, O
and O
relaxation O
with O
guided O
imagery O
. O
!LF! !LF!
instruments O
administered O
at O
baseline O
included O
the O
following O
: O
quality O
of O
life O
index O
- O
cancer O
version O
( O
qoli O
- O
cv O
) O
, O
state O
- O
trait O
anxiety O
inventory O
, O
beck O
depression O
inventory O
, O
and O
coping O
strategies O
questionnaire O
. O
!LF! !LF!
at O
1 O
- O
year O
follow O
- O
up O
, O
patients O
( O
n O
= O
73 O
) O
completed O
and O
returned O
the O
follow O
- O
up O
qoli O
- O
cv O
. O
!LF! !LF!
patients O
were O
mainly O
≥ O
40 O
years O
of O
age O
, O
married O
, O
caucasian O
, O
and O
diagnosed O
with O
advanced O
breast O
cancer O
. O
!LF! !LF!
a B-Premise
model I-Premise
measuring I-Premise
effectiveness I-Premise
of I-Premise
ccsp I-Premise
on I-Premise
qol I-Premise
( I-Premise
total I-Premise
and I-Premise
subscale I-Premise
) I-Premise
at I-Premise
1 I-Premise
- I-Premise
year I-Premise
follow I-Premise
- I-Premise
up I-Premise
showed I-Premise
that I-Premise
the I-Premise
ccsp I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
38 I-Premise
) I-Premise
had I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
overall I-Premise
qol I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
, I-Premise
health I-Premise
and I-Premise
functioning I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
, I-Premise
and I-Premise
socioeconomic I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
and I-Premise
psychological I-Premise
/ I-Premise
spiritual I-Premise
well I-Premise
- I-Premise
being I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
35 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
ccsp I-Premise
patients I-Premise
frequently I-Premise
used I-Premise
the I-Premise
ccsp I-Premise
to I-Premise
manage I-Premise
psychological I-Premise
( I-Premise
51 I-Premise
% I-Premise
) I-Premise
and I-Premise
sleep I-Premise
problems I-Premise
( I-Premise
60 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
ccsp I-Premise
improved I-Premise
qol I-Premise
for I-Premise
patients I-Premise
at I-Premise
1 I-Premise
- I-Premise
year I-Premise
follow I-Premise
- I-Premise
up I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
overwhelmingly I-Premise
reported I-Premise
that I-Premise
ccsp I-Premise
was I-Premise
beneficial I-Premise
. I-Premise
!LF! !LF!
the B-Claim
ccsp I-Claim
as I-Claim
an I-Claim
effective I-Claim
coping I-Claim
intervention I-Claim
has I-Claim
potential I-Claim
as I-Claim
a I-Claim
self I-Claim
- I-Claim
management I-Claim
program I-Claim
for I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim
!LF! !LF!
the B-Claim
combination I-Claim
of I-Claim
etoposide I-Claim
plus I-Claim
cisplatin I-Claim
( I-Claim
ep I-Claim
) I-Claim
is I-Claim
considered I-Claim
to I-Claim
be I-Claim
standard I-Claim
therapy I-Claim
for I-Claim
small I-Claim
- I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
sclc I-Claim
) I-Claim
. I-Claim
!LF! !LF!
to O
determine O
whether O
drug O
intensification O
improves O
survival O
of O
patients O
with O
extensive O
sclc O
, O
we O
compared O
this O
treatment O
with O
a O
four O
- O
drug O
regimen O
containing O
ep O
plus O
cyclophosphamide O
and O
4 O
' O
- O
epidoxorubicin O
( O
pcde O
) O
. O
!LF! !LF!
in O
a O
phase O
iii O
clinical O
trial O
organized O
by O
the O
french O
federation O
of O
cancer O
institutes O
, O
patients O
were O
randomly O
assigned O
to O
receive O
either O
ep O
( O
n O
= O
109 O
"""" O
; O
"""" O
etoposide O
at O
a O
dose O
of O
100 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
- O
3 O
plus O
cisplatin O
at O
100 O
mg O
/ O
m O
( O
2 O
) O
on O
day O
2 O
) O
or O
pcde O
( O
n O
= O
117 O
"""" O
; O
"""" O
etoposide O
and O
cisplatin O
given O
as O
in O
ep O
plus O
cyclophosphamide O
at O
400 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
- O
3 O
and O
4 O
' O
- O
epidoxorubicin O
at O
40 O
mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
) O
every O
4 O
weeks O
. O
!LF! !LF!
both O
groups O
received O
a O
total O
of O
six O
cycles O
. O
!LF! !LF!
survival O
differences O
were O
analyzed O
by O
wilcoxon O
and O
log O
- O
rank O
tests O
. O
!LF! !LF!
associations O
of O
treatment O
group O
and O
putative O
prognostic O
variables O
with O
survival O
were O
tested O
in O
the O
cox O
proportional O
hazards O
model O
. O
!LF! !LF!
quality O
of O
life O
was O
assessed O
from O
the O
responses O
to O
the O
european O
organization O
for O
research O
and O
treatment O
of O
cancer O
quality O
- O
of O
- O
life O
questionnaire O
( O
c30 O
, O
health O
status O
and O
lung O
cancer O
module O
13 O
) O
. O
!LF! !LF!
all O
statistical O
tests O
were O
two O
- O
sided O
. O
!LF! !LF!
patients B-Premise
in I-Premise
the I-Premise
pcde I-Premise
arm I-Premise
had I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
higher I-Premise
frequency I-Premise
of I-Premise
combined I-Premise
complete I-Premise
plus I-Premise
partial I-Premise
responses I-Premise
compared I-Premise
with I-Premise
those I-Premise
in I-Premise
the I-Premise
ep I-Premise
arm I-Premise
( I-Premise
21 I-Premise
% I-Premise
plus I-Premise
55 I-Premise
% I-Premise
versus I-Premise
13 I-Premise
% I-Premise
plus I-Premise
48 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
02 I-Premise
for I-Premise
difference I-Premise
in I-Premise
combined I-Premise
objective I-Premise
responses I-Premise
) I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
in I-Premise
the I-Premise
pcde I-Premise
arm I-Premise
survived I-Premise
longer I-Premise
than I-Premise
those I-Premise
in I-Premise
the I-Premise
ep I-Premise
arm I-Premise
( I-Premise
1 I-Premise
- I-Premise
year I-Premise
survival I-Premise
rate I-Premise
: I-Premise
40 I-Premise
% I-Premise
and I-Premise
29 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
median I-Premise
survival I-Premise
: I-Premise
10 I-Premise
. I-Premise
5 I-Premise
and I-Premise
9 I-Premise
. I-Premise
3 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
log I-Premise
- I-Premise
rank I-Premise
p I-Premise
= I-Premise
. I-Premise
0067 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
in B-Premise
the I-Premise
cox I-Premise
model I-Premise
, I-Premise
the I-Premise
relative I-Premise
risk I-Premise
of I-Premise
death I-Premise
for I-Premise
patients I-Premise
in I-Premise
the I-Premise
pcde I-Premise
arm I-Premise
compared I-Premise
with I-Premise
those I-Premise
in I-Premise
the I-Premise
ep I-Premise
arm I-Premise
was I-Premise
0 I-Premise
. I-Premise
70 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
= I-Premise
0 I-Premise
. I-Premise
51 I-Premise
to I-Premise
0 I-Premise
. I-Premise
95 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
the B-Premise
disease I-Premise
also I-Premise
progressed I-Premise
more I-Premise
slowly I-Premise
in I-Premise
patients I-Premise
in I-Premise
the I-Premise
pcde I-Premise
arm I-Premise
. I-Premise
!LF! !LF!
hematologic B-Premise
toxicity I-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
pcde I-Premise
arm I-Premise
( I-Premise
22 I-Premise
% I-Premise
with I-Premise
documented I-Premise
infections I-Premise
compared I-Premise
with I-Premise
8 I-Premise
% I-Premise
in I-Premise
the I-Premise
ep I-Premise
arm I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
0038 I-Premise
) I-Premise
, I-Premise
and O
the B-Premise
toxicity I-Premise
- I-Premise
related I-Premise
death I-Premise
rate I-Premise
was I-Premise
9 I-Premise
% I-Premise
in I-Premise
the I-Premise
pcde I-Premise
arm I-Premise
versus I-Premise
5 I-Premise
. I-Premise
5 I-Premise
% I-Premise
in I-Premise
the I-Premise
ep I-Premise
arm I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
22 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Claim
global I-Claim
health I-Claim
status I-Claim
showed I-Claim
similar I-Claim
improvement I-Claim
in I-Claim
both I-Claim
arms I-Claim
during I-Claim
treatment I-Claim
. I-Claim
!LF! !LF!
compared B-Claim
with I-Claim
the I-Claim
ep I-Claim
regimen I-Claim
, I-Claim
the I-Claim
pcde I-Claim
regimen I-Claim
yielded I-Claim
higher I-Claim
response I-Claim
rates I-Claim
and I-Claim
better I-Claim
survival I-Claim
rates I-Claim
in I-Claim
patients I-Claim
with I-Claim
extensive I-Claim
sclc I-Claim
without I-Claim
affecting I-Claim
the I-Claim
quality I-Claim
of I-Claim
life I-Claim
of I-Claim
the I-Claim
patients I-Claim
during I-Claim
chemotherapy I-Claim
. I-Claim
!LF! !LF!
although O
many O
drug O
combination O
therapies O
have O
been O
proposed O
, O
there B-Claim
is I-Claim
no I-Claim
standard I-Claim
therapy I-Claim
for I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
gastric I-Claim
carcinoma I-Claim
. I-Claim
!LF! !LF!
the B-Claim
superiority I-Claim
of I-Claim
combination I-Claim
therapy I-Claim
over I-Claim
monochemotherapy I-Claim
has I-Claim
not I-Claim
been I-Claim
demonstrated I-Claim
convincingly I-Claim
. I-Claim
!LF! !LF!
to O
explore O
the O
role O
of O
monochemotherapy O
, O
the O
authors O
evaluated O
5 O
- O
fluorouracil O
( O
5 O
- O
fu O
) O
, O
modulated O
by O
6s O
- O
leucovorin O
( O
6s O
- O
lv O
) O
and O
a O
cisplatin O
- O
containing O
regimen O
, O
which O
was O
comprised O
of O
epirubicin O
, O
etoposide O
, O
and O
cisplatin O
with O
the O
addition O
of O
the O
reversal O
agent O
lonidamine O
( O
eep O
- O
l O
) O
. O
!LF! !LF!
after O
stratification O
according O
to O
performance O
status O
( O
ps O
) O
and O
resection O
of O
the O
primary O
tumor O
, O
72 O
patients O
with O
advanced O
gastric O
carcinoma O
were O
randomized O
to O
2 O
parallel O
phase O
ii O
trials O
with O
5 O
- O
fu O
/ O
6s O
- O
lv O
and O
eep O
- O
l O
, O
respectively O
. O
!LF! !LF!
thirty O
- O
six O
patients O
in O
study O
a O
received O
bolus O
6s O
- O
lv O
, O
100 O
mg O
/ O
m2 O
, O
followed O
by O
bolus O
5 O
- O
fu O
, O
370 O
mg O
/ O
m2 O
, O
on O
days O
1 O
- O
5 O
and O
36 O
others O
in O
study O
b O
received O
epirubicin O
, O
30 O
mg O
/ O
m2 O
, O
on O
days O
1 O
and O
5 O
"""" O
; O
"""" O
etoposide O
, O
100 O
mg O
/ O
m2 O
, O
on O
days O
1 O
, O
3 O
, O
and O
5 O
"""" O
; O
"""" O
cisplatin O
, O
30 O
mg O
/ O
m2 O
, O
on O
days O
2 O
and O
4 O
"""" O
; O
"""" O
and O
lonidamine O
, O
150 O
mg O
/ O
day O
. O
!LF! !LF!
there O
were O
6 O
partial O
responses O
( O
18 O
. O
2 O
% O
) O
( O
95 O
% O
confidence O
interval O
[ O
ci O
] O
+ O
/ O
- O
13 O
. O
2 O
) O
in O
study O
a O
and O
7 O
partial O
responses O
( O
21 O
. O
9 O
% O
) O
( O
95 O
% O
ci O
+ O
/ O
- O
14 O
. O
3 O
) O
in O
study O
b O
. O
!LF! !LF!
partial O
responses O
were O
more O
frequent O
in O
patients O
with O
resected O
tumors O
or O
with O
an O
eastern O
cooperative O
oncology O
group O
ps O
of O
0 O
- O
1 O
. O
!LF! !LF!
the B-Premise
median I-Premise
duration I-Premise
of I-Premise
response I-Premise
was I-Premise
8 I-Premise
. I-Premise
8 I-Premise
and I-Premise
8 I-Premise
. I-Premise
3 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
in I-Premise
study I-Premise
a I-Premise
and I-Premise
study I-Premise
b I-Premise
. I-Premise
!LF! !LF!
the B-Premise
median I-Premise
survival I-Premise
reached I-Premise
8 I-Premise
months I-Premise
in I-Premise
study I-Premise
a I-Premise
and I-Premise
9 I-Premise
months I-Premise
in I-Premise
study I-Premise
b I-Premise
. I-Premise
!LF! !LF!
in B-Premise
the I-Premise
whole I-Premise
population I-Premise
of I-Premise
patients I-Premise
survival I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
patients I-Premise
with I-Premise
a I-Premise
ps I-Premise
of I-Premise
0 I-Premise
- I-Premise
1 I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
with I-Premise
a I-Premise
ps I-Premise
of I-Premise
0 I-Premise
- I-Premise
1 I-Premise
and I-Premise
a I-Premise
resected I-Premise
tumor I-Premise
had I-Premise
the I-Premise
significantly I-Premise
longest I-Premise
survival I-Premise
both I-Premise
in I-Premise
eep I-Premise
- I-Premise
l I-Premise
treated I-Premise
patients I-Premise
and I-Premise
in I-Premise
all I-Premise
evaluable I-Premise
patients I-Premise
in I-Premise
the I-Premise
two I-Premise
studies I-Premise
. I-Premise
!LF! !LF!
the B-Premise
most I-Premise
frequent I-Premise
world I-Premise
health I-Premise
organization I-Premise
grade I-Premise
3 I-Premise
- I-Premise
4 I-Premise
toxic I-Premise
effects I-Premise
were I-Premise
gastrointestinal I-Premise
in I-Premise
study I-Premise
a I-Premise
and I-Premise
hematologic I-Premise
in I-Premise
study I-Premise
b I-Premise
. I-Premise
!LF! !LF!
no B-Premise
treatment I-Premise
- I-Premise
related I-Premise
death I-Premise
was I-Premise
observed I-Premise
. I-Premise
!LF! !LF!
the B-Claim
efficacy I-Claim
of I-Claim
5 I-Claim
- I-Claim
fu I-Claim
, I-Claim
modulated I-Claim
with I-Claim
6s I-Claim
- I-Claim
lv I-Claim
, I-Claim
is I-Claim
moderate I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
gastric I-Claim
carcinoma I-Claim
, I-Claim
similar I-Claim
to I-Claim
cisplatin I-Claim
- I-Claim
containing I-Claim
regimens I-Claim
. I-Claim
!LF! !LF!
ps B-Claim
and I-Claim
other I-Claim
prognostic I-Claim
factors I-Claim
could I-Claim
influence I-Claim
the I-Claim
response I-Claim
rate I-Claim
, I-Claim
which I-Claim
does I-Claim
not I-Claim
appear I-Claim
to I-Claim
be I-Claim
a I-Claim
reliable I-Claim
parameter I-Claim
for I-Claim
evaluating I-Claim
the I-Claim
outcome I-Claim
of I-Claim
chemotherapy I-Claim
trials I-Claim
. I-Claim
!LF! !LF!
to O
assess O
the O
effects O
of O
an O
expressive O
writing O
( O
ew O
) O
intervention O
on O
perceptions O
of O
emotional O
support O
in O
women O
completing O
treatment O
for O
early O
stage O
breast O
cancer O
. O
!LF! !LF!
women O
were O
recruited O
to O
the O
study O
during O
their O
final O
week O
of O
treatment O
. O
!LF! !LF!
of O
260 O
eligible O
patients O
, O
104 O
( O
40 O
% O
) O
agreed O
to O
participate O
, O
and O
93 O
were O
randomised O
. O
!LF! !LF!
women O
in O
the O
writing O
group O
wrote O
for O
20 O
min O
on O
four O
consecutive O
days O
. O
!LF! !LF!
the O
control O
group O
received O
normal O
care O
. O
!LF! !LF!
women O
' O
s O
perceptions O
of O
emotional O
support O
, O
quality O
of O
life O
( O
qol O
) O
, O
mood O
, O
and O
healthcare O
utilisation O
were O
assessed O
at O
baseline O
, O
1 O
month O
, O
3 O
months O
and O
6 O
months O
. O
!LF! !LF!
interviews O
were O
conducted O
to O
explore O
women O
' O
s O
experience O
of O
writing O
. O
!LF! !LF!
eighty O
participants O
completed O
all O
follow O
- O
ups O
. O
!LF! !LF!
there B-Premise
was I-Premise
a I-Premise
significant I-Premise
effect I-Premise
of I-Premise
group I-Premise
on I-Premise
women I-Premise
' I-Premise
s I-Premise
perceptions I-Premise
of I-Premise
social I-Premise
support I-Premise
with I-Premise
those I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
being I-Premise
more I-Premise
satisfied I-Premise
with I-Premise
the I-Premise
emotional I-Premise
support I-Premise
they I-Premise
received I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
satisfaction B-Premise
with I-Premise
emotional I-Premise
support I-Premise
was I-Premise
negatively I-Premise
correlated I-Premise
with I-Premise
depression I-Premise
/ I-Premise
dejection I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
and I-Premise
anger I-Premise
/ I-Premise
hostility I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
and I-Premise
positively I-Premise
correlated I-Premise
with I-Premise
social I-Premise
and I-Premise
family I-Premise
well I-Premise
- I-Premise
being I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
6 I-Premise
months I-Premise
post I-Premise
intervention I-Premise
. I-Premise
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
significant I-Premise
effects I-Premise
of I-Premise
the I-Premise
intervention I-Premise
on I-Premise
mood I-Premise
, I-Premise
qol I-Premise
or I-Premise
healthcare I-Premise
utilisation I-Premise
. I-Premise
!LF! !LF!
most B-Premise
participants I-Premise
found I-Premise
writing I-Premise
valuable I-Premise
and I-Premise
did I-Premise
not I-Premise
report I-Premise
any I-Premise
long I-Premise
- I-Premise
term I-Premise
negative I-Premise
effects I-Premise
. I-Premise
!LF! !LF!
ew B-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
higher I-Claim
level I-Claim
of I-Claim
satisfaction I-Claim
with I-Claim
emotional I-Claim
support I-Claim
compared I-Claim
with I-Claim
controls I-Claim
. I-Claim
!LF! !LF!
given O
the O
existing O
evidence O
supporting O
the O
importance O
of O
social O
support O
in O
adjustment O
to O
breast O
cancer O
, O
it B-Claim
seems I-Claim
feasible I-Claim
to I-Claim
suggest I-Claim
that I-Claim
ew I-Claim
may I-Claim
be I-Claim
a I-Claim
cost I-Claim
effective I-Claim
accessible I-Claim
treatment I-Claim
that I-Claim
could I-Claim
be I-Claim
incorporated I-Claim
into I-Claim
the I-Claim
ongoing I-Claim
care I-Claim
of I-Claim
women I-Claim
. I-Claim
!LF! !LF!
this O
study O
tested O
hyperbaric O
oxygen O
( O
hbo O
) O
as O
an O
adjunct O
to O
surgery O
and O
antibiotics O
in O
the O
treatment O
of O
bisphosphonate O
- O
related O
osteonecrosis O
of O
the O
jaw O
( O
onj O
) O
and O
evaluated O
its O
effects O
on O
gingival O
healing O
, O
pain O
, O
and O
quality O
of O
life O
. O
!LF! !LF!
the O
investigators O
implemented O
a O
randomized O
controlled O
trial O
and O
enrolled O
a O
sample O
composed O
of O
patients O
with O
onj O
, O
where O
the O
predictor O
variable O
was O
hbo O
administered O
at O
2 O
atm O
twice O
a O
day O
for O
40 O
treatments O
as O
an O
adjunct O
to O
conventional O
therapy O
of O
surgery O
and O
antibiotics O
versus O
conventional O
therapy O
alone O
. O
!LF! !LF!
over O
the O
next O
24 O
months O
, O
oral O
lesion O
size O
and O
number O
, O
pain O
, O
and O
quality O
of O
life O
were O
assessed O
. O
!LF! !LF!
forty O
- O
six O
patients O
( O
mean O
age O
, O
66 O
yrs O
"""" O
; O
"""" O
57 O
% O
women O
) O
contributed O
data O
to O
the O
trial O
. O
!LF! !LF!
there O
were O
no O
statistically O
significant O
differences O
in O
the O
distribution O
of O
variables O
used O
to O
assess O
randomization O
success O
between O
the O
hbo O
and O
standard O
treatment O
groups O
. O
!LF! !LF!
seventeen B-Premise
of I-Premise
25 I-Premise
hbo I-Premise
- I-Premise
treated I-Premise
patients I-Premise
( I-Premise
68 I-Premise
% I-Premise
) I-Premise
improved I-Premise
versus I-Premise
8 I-Premise
of I-Premise
21 I-Premise
controls I-Premise
( I-Premise
38 I-Premise
. I-Premise
1 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
043 I-Premise
, I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
test I-Premise
) I-Premise
. I-Premise
!LF! !LF!
mean B-Premise
time I-Premise
to I-Premise
improvement I-Premise
was I-Premise
39 I-Premise
. I-Premise
7 I-Premise
weeks I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
ci I-Premise
] I-Premise
, I-Premise
22 I-Premise
. I-Premise
4 I-Premise
to I-Premise
57 I-Premise
. I-Premise
0 I-Premise
weeks I-Premise
) I-Premise
for I-Premise
hbo I-Premise
- I-Premise
treated I-Premise
patients I-Premise
versus I-Premise
67 I-Premise
. I-Premise
9 I-Premise
weeks I-Premise
( I-Premise
95 I-Premise
ci I-Premise
, I-Premise
48 I-Premise
. I-Premise
4 I-Premise
to I-Premise
87 I-Premise
. I-Premise
5 I-Premise
weeks I-Premise
) I-Premise
for I-Premise
controls I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
03 I-Premise
, I-Premise
log I-Premise
- I-Premise
rank I-Premise
test I-Premise
) I-Premise
. I-Premise
!LF! !LF!
however B-Premise
, I-Premise
complete I-Premise
gingival I-Premise
healing I-Premise
occurred I-Premise
in I-Premise
only I-Premise
14 I-Premise
of I-Premise
25 I-Premise
hbo I-Premise
- I-Premise
treated I-Premise
patients I-Premise
( I-Premise
52 I-Premise
% I-Premise
) I-Premise
versus I-Premise
7 I-Premise
of I-Premise
21 I-Premise
controls I-Premise
( I-Premise
33 I-Premise
. I-Premise
3 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
203 I-Premise
, I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
test I-Premise
) I-Premise
, I-Premise
and I-Premise
time I-Premise
to I-Premise
healing I-Premise
was I-Premise
59 I-Premise
weeks I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
42 I-Premise
. I-Premise
8 I-Premise
% I-Premise
to I-Premise
75 I-Premise
. I-Premise
8 I-Premise
% I-Premise
) I-Premise
for I-Premise
hbo I-Premise
- I-Premise
treated I-Premise
patients I-Premise
versus I-Premise
70 I-Premise
weeks I-Premise
( I-Premise
95 I-Premise
ci I-Premise
, I-Premise
52 I-Premise
. I-Premise
2 I-Premise
% I-Premise
to I-Premise
88 I-Premise
. I-Premise
36 I-Premise
% I-Premise
) I-Premise
for I-Premise
controls I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
32 I-Premise
, I-Premise
log I-Premise
- I-Premise
rank I-Premise
test I-Premise
) I-Premise
. I-Premise
!LF! !LF!
pain B-Premise
decreased I-Premise
faster I-Premise
for I-Premise
hbo I-Premise
- I-Premise
treated I-Premise
subjects I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
01 I-Premise
, I-Premise
linear I-Premise
regression I-Premise
) I-Premise
. I-Premise
!LF! !LF!
quality B-Premise
- B-Premise
of B-Premise
- B-Premise
life B-Premise
scores I-Premise
for I-Premise
physical I-Premise
health I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
002 I-Premise
) I-Premise
and I-Premise
perceived I-Premise
health I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
043 I-Premise
) I-Premise
decreased I-Premise
at I-Premise
6 I-Premise
months I-Premise
for I-Premise
control I-Premise
group I-Premise
but I-Premise
for I-Premise
not I-Premise
the I-Premise
hbo I-Premise
group I-Premise
. I-Premise
!LF! !LF!
onj B-Claim
is I-Claim
multifactorial I-Claim
and I-Claim
no I-Claim
single I-Claim
treatment I-Claim
modality I-Claim
is I-Claim
likely I-Claim
to I-Claim
reverse I-Claim
it I-Claim
"""" I-Claim
; I-Claim
"""" I-Claim
however B-Claim
, I-Claim
it I-Claim
is I-Claim
treatable I-Claim
and I-Claim
even I-Claim
advanced I-Claim
presentations I-Claim
can I-Claim
improve I-Claim
with I-Claim
intensive I-Claim
multimodal I-Claim
therapy I-Claim
. I-Claim
!LF! !LF!
clinically B-Claim
, I-Claim
hbo I-Claim
appears I-Claim
to I-Claim
be I-Claim
a I-Claim
useful I-Claim
adjunct I-Claim
to I-Claim
onj I-Claim
treatment I-Claim
, I-Claim
particularly I-Claim
for I-Claim
more I-Claim
severe I-Claim
cases I-Claim
, I-Claim
although I-Claim
this I-Claim
study I-Claim
was I-Claim
underpowered I-Claim
to I-Claim
fully I-Claim
support I-Claim
this I-Claim
claim I-Claim
. I-Claim
!LF! !LF!
therapy O
for O
polycystic O
liver O
is O
invasive O
, O
expensive O
, O
and O
has O
disappointing O
long O
- O
term O
results O
. O
!LF! !LF!
treatment O
with O
somatostatin O
analogues O
slowed O
kidney O
growth O
in O
patients O
with O
polycystic O
kidney O
disease O
( O
pkd O
) O
and O
reduced O
liver O
and O
kidney O
volume O
in O
a O
pkd O
rodent O
model O
. O
!LF! !LF!
we O
evaluated O
the O
effects O
of O
lanreotide O
, O
a O
somatostatin O
analogue O
, O
in O
patients O
with O
polycystic O
liver O
because O
of O
autosomal O
- O
dominant O
( O
ad O
) O
pkd O
or O
autosomal O
- O
dominant O
polycystic O
liver O
disease O
( O
pcld O
) O
. O
!LF! !LF!
we O
performed O
a O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
trial O
in O
2 O
tertiary O
referral O
centers O
. O
!LF! !LF!
patients O
with O
polycystic O
liver O
( O
n O
= O
54 O
) O
were O
randomly O
assigned O
to O
groups O
given O
lanreotide O
( O
120 O
mg O
) O
or O
placebo O
, O
administered O
every O
28 O
days O
for O
24 O
weeks O
. O
!LF! !LF!
the O
primary O
end O
point O
was O
the O
difference O
in O
total O
liver O
volume O
, O
measured O
by O
computerized O
tomography O
at O
weeks O
0 O
and O
24 O
. O
!LF! !LF!
analyses O
were O
performed O
on O
an O
intention O
- O
to O
- O
treat O
basis O
. O
!LF! !LF!
baseline B-Premise
characteristics I-Premise
were I-Premise
comparable I-Premise
for I-Premise
both I-Premise
groups I-Premise
, I-Premise
except B-Premise
that I-Premise
more I-Premise
patients I-Premise
with I-Premise
adpkd I-Premise
were I-Premise
assigned I-Premise
to I-Premise
the I-Premise
placebo I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
mean I-Premise
liver I-Premise
volume I-Premise
decreased I-Premise
2 I-Premise
. I-Premise
9 I-Premise
% I-Premise
, I-Premise
from I-Premise
4606 I-Premise
ml I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
ci I-Premise
) I-Premise
: I-Premise
547 I-Premise
- I-Premise
8665 I-Premise
) I-Premise
to I-Premise
4471 I-Premise
ml I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
: I-Premise
542 I-Premise
- I-Premise
8401 I-Premise
ml I-Premise
) I-Premise
, I-Premise
in I-Premise
patients I-Premise
given I-Premise
lanreotide I-Premise
. I-Premise
!LF! !LF!
in B-Premise
the I-Premise
placebo I-Premise
group I-Premise
, I-Premise
the I-Premise
mean I-Premise
liver I-Premise
volume I-Premise
increased I-Premise
1 I-Premise
. I-Premise
6 I-Premise
% I-Premise
, I-Premise
from I-Premise
4689 I-Premise
ml I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
: I-Premise
613 I-Premise
- I-Premise
8765 I-Premise
ml I-Premise
) I-Premise
to I-Premise
4895 I-Premise
ml I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
: I-Premise
739 I-Premise
- I-Premise
9053 I-Premise
ml I-Premise
) I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
post B-Premise
hoc I-Premise
stratification I-Premise
for I-Premise
patients I-Premise
with I-Premise
adpkd I-Premise
or I-Premise
pcld I-Premise
revealed I-Premise
similar I-Premise
changes I-Premise
in I-Premise
liver I-Premise
volume I-Premise
, I-Premise
with I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
patients I-Premise
given I-Premise
lanreotide I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
01 I-Premise
for I-Premise
both I-Premise
diseases I-Premise
) I-Premise
. I-Premise
!LF! !LF!
in B-Claim
patients I-Claim
with I-Claim
polycystic I-Claim
liver I-Claim
, I-Claim
6 I-Claim
months I-Claim
of I-Claim
treatment I-Claim
with I-Claim
lanreotide I-Claim
reduces I-Claim
liver I-Claim
volume I-Claim
. I-Claim
!LF! !LF!
a B-Claim
combination I-Claim
of I-Claim
mitoxantrone I-Claim
plus I-Claim
prednisone I-Claim
is I-Claim
preferable I-Claim
to I-Claim
prednisone I-Claim
alone I-Claim
for I-Claim
reduction I-Claim
of I-Claim
pain I-Claim
in I-Claim
men I-Claim
with I-Claim
metastatic I-Claim
, I-Claim
hormone I-Claim
- I-Claim
resistant I-Claim
, I-Claim
prostate I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
the O
purpose O
of O
this O
study O
was O
to O
assess O
the O
effects O
of O
these O
treatments O
on O
health O
- O
related O
quality O
of O
life O
( O
hql O
) O
. O
!LF! !LF!
men O
with O
metastatic O
prostate O
cancer O
( O
n O
= O
161 O
) O
were O
randomized O
to O
receive O
either O
daily O
prednisone O
alone O
or O
mitoxantrone O
( O
every O
3 O
weeks O
) O
plus O
prednisone O
. O
!LF! !LF!
those O
who O
received O
prednisone O
alone O
could O
have O
mitoxantrone O
added O
after O
6 O
weeks O
if O
there O
was O
no O
improvement O
in O
pain O
. O
!LF! !LF!
hql O
was O
assessed O
before O
treatment O
initiation O
and O
then O
every O
3 O
weeks O
using O
the O
european O
organization O
for O
research O
and O
treatment O
of O
cancer O
quality O
- O
of O
- O
life O
questionnaire O
c30 O
( O
eortc O
qlq O
- O
c30 O
) O
and O
the O
quality O
of O
life O
module O
- O
prostate O
14 O
( O
qolm O
- O
p14 O
) O
, O
a O
trial O
- O
specific O
module O
developed O
for O
this O
study O
. O
!LF! !LF!
an O
intent O
- O
to O
- O
treat O
analysis O
was O
used O
to O
determine O
the O
mean O
duration O
of O
hql O
improvement O
and O
differences O
in O
improvement O
duration O
between O
groups O
of O
patients O
. O
!LF! !LF!
at B-Premise
6 I-Premise
weeks I-Premise
, I-Premise
both I-Premise
groups I-Premise
showed I-Premise
improvement I-Premise
in I-Premise
several I-Premise
hql I-Premise
domains I-Premise
, I-Premise
and O
only B-Premise
physical I-Premise
functioning I-Premise
and I-Premise
pain I-Premise
were I-Premise
better I-Premise
in I-Premise
the I-Premise
mitoxantrone I-Premise
- I-Premise
plus I-Premise
- I-Premise
prednisone I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
prednisone I-Premise
- I-Premise
alone I-Premise
group I-Premise
. I-Premise
!LF! !LF!
after B-Premise
6 I-Premise
weeks I-Premise
, I-Premise
patients I-Premise
taking I-Premise
prednisone I-Premise
showed I-Premise
no I-Premise
improvement I-Premise
in I-Premise
hql I-Premise
scores I-Premise
, I-Premise
whereas I-Premise
those I-Premise
taking I-Premise
mitoxantrone I-Premise
plus I-Premise
prednisone I-Premise
showed I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
009 I-Premise
) I-Premise
, I-Premise
four I-Premise
functioning I-Premise
domains I-Premise
, I-Premise
and I-Premise
nine I-Premise
symptoms I-Premise
( I-Premise
. I-Premise
001 I-Premise
< I-Premise
p I-Premise
< I-Premise
. I-Premise
1 I-Premise
) I-Premise
, I-Premise
and O
the B-Premise
improvement I-Premise
( I-Premise
> I-Premise
10 I-Premise
units I-Premise
on I-Premise
a I-Premise
scale I-Premise
of I-Premise
0 I-Premise
to100 I-Premise
) I-Premise
lasted I-Premise
longer I-Premise
than I-Premise
in I-Premise
the I-Premise
prednisone I-Premise
- I-Premise
alone I-Premise
group I-Premise
( I-Premise
. I-Premise
004 I-Premise
< I-Premise
p I-Premise
< I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
addition I-Premise
of I-Premise
mitoxantrone I-Premise
to I-Premise
prednisone I-Premise
after I-Premise
failure I-Premise
of I-Premise
prednisone I-Premise
alone I-Premise
was I-Premise
associated I-Premise
with I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
, I-Premise
pain I-Premise
impact I-Premise
, I-Premise
pain I-Premise
relief I-Premise
, I-Premise
insomnia I-Premise
, I-Premise
and I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
. I-Premise
001 I-Premise
< I-Premise
p I-Premise
< I-Premise
. I-Premise
003 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
treatment B-Claim
with I-Claim
mitoxantrone I-Claim
plus I-Claim
prednisone I-Claim
was I-Claim
associated I-Claim
with I-Claim
greater I-Claim
and I-Claim
longer I-Claim
- I-Claim
lasting I-Claim
improvement I-Claim
in I-Claim
several I-Claim
hql I-Claim
domains I-Claim
and I-Claim
symptoms I-Claim
than I-Claim
treatment I-Claim
with I-Claim
prednisone I-Claim
alone I-Claim
. I-Claim
!LF! !LF!
studies O
on O
quality O
of O
life O
( O
qol O
) O
among O
women O
with O
endometrial O
cancer O
have O
shown O
that O
patients O
who O
undergo O
pelvic O
radiotherapy O
report O
lower O
role O
functioning O
and O
more O
diarrhea O
and O
fatigue O
. O
!LF! !LF!
in O
the O
post O
operative O
radiation O
therapy O
in O
endometrial O
cancer O
( O
portec O
) O
trial O
, O
patients O
with O
endometrial O
carcinoma O
were O
randomly O
assigned O
to O
receive O
external O
- O
beam O
radiotherapy O
( O
ebrt O
) O
or O
vaginal O
brachytherapy O
( O
vbt O
) O
. O
!LF! !LF!
qol O
was O
evaluated O
by O
using O
the O
european O
organisation O
for O
research O
and O
treatment O
of O
cancer O
quality O
of O
life O
questionnaire O
c30 O
and O
subscales O
from O
the O
prostate O
cancer O
module O
, O
pr O
- O
25 O
, O
and O
the O
ovarian O
cancer O
module O
, O
ov O
- O
28 O
. O
!LF! !LF!
portec O
- O
2 O
accrued O
427 O
patients O
between O
2002 O
and O
2006 O
, O
of O
whom O
214 O
were O
randomly O
assigned O
to O
ebrt O
, O
and O
213 O
were O
randomly O
assigned O
to O
vbt O
. O
!LF! !LF!
three O
- O
hundred O
forty O
- O
eight O
patients O
( O
81 O
% O
) O
were O
evaluable O
for O
qol O
. O
!LF! !LF!
qol O
outcomes O
were O
analyzed O
at O
a O
median O
follow O
- O
up O
of O
2 O
years O
. O
!LF! !LF!
at O
baseline O
after O
surgery O
, O
patient O
functioning O
was O
at O
the O
lowest O
level O
, O
and O
it O
increased O
during O
and O
after O
radiotherapy O
to O
reach O
a O
plateau O
after O
12 O
months O
. O
!LF! !LF!
patients B-Premise
in I-Premise
the I-Premise
vbt I-Premise
group I-Premise
reported I-Premise
better I-Premise
social I-Premise
functioning I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
002 I-Premise
) I-Premise
and I-Premise
lower I-Premise
symptom I-Premise
scores I-Premise
for I-Premise
diarrhea I-Premise
, I-Premise
fecal I-Premise
leakage I-Premise
, I-Premise
the I-Premise
need I-Premise
to I-Premise
stay I-Premise
close I-Premise
to I-Premise
the I-Premise
toilet I-Premise
, I-Premise
and I-Premise
limitation I-Premise
in I-Premise
daily I-Premise
activities I-Premise
because I-Premise
of I-Premise
bowel I-Premise
symptoms I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
at O
baseline O
, O
15 O
% O
of O
patients O
were O
sexually O
active O
"""" O
; O
"""" O
this O
increased O
significantly O
to O
39 O
% O
during O
the O
first O
year O
( O
p O
< O
. O
001 O
) O
. O
!LF! !LF!
sexual B-Premise
functioning I-Premise
and I-Premise
symptoms I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
who I-Premise
received I-Premise
ebrt I-Premise
reported I-Premise
significantly I-Premise
higher I-Premise
levels I-Premise
of I-Premise
diarrhea I-Premise
and I-Premise
bowel I-Premise
symptoms I-Premise
. I-Premise
!LF! !LF!
this O
resulted O
in O
a O
higher O
need O
to O
remain O
close O
to O
a O
toilet O
and O
, O
as O
a O
consequence O
, O
more O
limitation O
of O
daily O
activities O
because O
of O
bowel O
symptoms O
and O
decreased O
social O
functioning O
. O
!LF! !LF!
vaginal B-Claim
brachytherapy I-Claim
provides I-Claim
a I-Claim
better I-Claim
qol I-Claim
, I-Claim
and I-Claim
should I-Claim
be I-Claim
the I-Claim
preferred I-Claim
treatment I-Claim
from I-Claim
a I-Claim
qol I-Claim
perspective I-Claim
. I-Claim
!LF! !LF!
to O
assess O
the O
safety O
and O
health O
- O
related O
quality O
of O
life O
( O
hrqol O
) O
of O
continuous O
combined O
hormone O
replacement O
therapy O
( O
cchrt O
) O
with O
estradiol O
valerate O
/ O
medroxyprogesterone O
acetate O
( O
e O
( O
2 O
) O
v O
/ O
mpa O
) O
over O
nine O
years O
and O
at O
follow O
- O
up O
one O
year O
after O
discontinuation O
. O
!LF! !LF!
a O
total O
of O
419 O
women O
were O
randomized O
to O
one O
of O
four O
treatments O
: O
once O
- O
daily O
1 O
mg O
e2v O
/ O
2 O
. O
5 O
mg O
mpa O
( O
1 O
+ O
2 O
. O
5 O
group O
) O
"""" O
; O
"""" O
1 O
mg O
e2v O
/ O
5 O
mg O
mpa O
daily O
( O
1 O
+ O
5 O
group O
) O
"""" O
; O
"""" O
2 O
mg O
e2v O
/ O
2 O
. O
5 O
mg O
mpa O
daily O
( O
2 O
+ O
2 O
. O
5 O
group O
) O
"""" O
; O
"""" O
2 O
mg O
e2v O
/ O
5 O
mg O
mpa O
daily O
( O
2 O
+ O
5 O
group O
) O
( O
indivina O
, O
orion O
pharma O
) O
. O
!LF! !LF!
for O
the O
last O
six O
months O
, O
all O
received O
the O
1 O
+ O
2 O
. O
5 O
dosage O
. O
!LF! !LF!
the O
2 O
+ O
2 O
. O
5 O
dosage O
was O
discontinued O
at O
the O
end O
of O
year O
7 O
. O
!LF! !LF!
a O
total O
of O
198 O
women O
continued O
after O
year O
7 O
. O
!LF! !LF!
annualized O
percentage O
rates O
for O
cardiovascular O
events O
[ O
corrected O
] O
and O
endometrial O
cancers O
[ O
corrected O
] O
were O
below O
national O
rates O
for O
finland O
and O
those O
reported O
for O
the O
women O
' O
s O
health O
initiative O
. O
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
serious I-Premise
events I-Premise
with I-Premise
the I-Premise
1 I-Premise
+ I-Premise
2 I-Premise
. I-Premise
5 I-Premise
dosage I-Premise
or I-Premise
after I-Premise
cchrt I-Premise
discontinuation I-Premise
. I-Premise
!LF! !LF!
climacteric B-Premise
symptoms I-Premise
remained I-Premise
significantly I-Premise
below I-Premise
baseline I-Premise
values I-Premise
after I-Premise
dosage I-Premise
reduction I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
some B-Premise
symptoms I-Premise
recurred I-Premise
after I-Premise
discontinuation I-Premise
of I-Premise
cchrt I-Premise
. I-Premise
!LF! !LF!
hrqol B-Premise
ratings I-Premise
improved I-Premise
with I-Premise
cchrt I-Premise
, I-Premise
irrespective I-Premise
of I-Premise
dosage I-Premise
, I-Premise
including I-Premise
depressed I-Premise
mood I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
health I-Premise
perception I-Premise
and I-Premise
sexual I-Premise
interest I-Premise
. I-Premise
!LF! !LF!
scores B-Premise
on I-Premise
a I-Premise
scale I-Premise
assessing I-Premise
daily I-Premise
functioning I-Premise
and I-Premise
enjoyment I-Premise
( I-Premise
q I-Premise
- I-Premise
les I-Premise
- I-Premise
q I-Premise
) I-Premise
improved I-Premise
from I-Premise
year I-Premise
7 I-Premise
to I-Premise
year I-Premise
9 I-Premise
. I-Premise
!LF! !LF!
they B-Premise
deteriorated I-Premise
during I-Premise
follow I-Premise
- I-Premise
up I-Premise
in I-Premise
women I-Premise
not I-Premise
continuing I-Premise
cchrt I-Premise
. I-Premise
!LF! !LF!
lower B-Claim
dosages I-Claim
of I-Claim
hrt I-Claim
were I-Claim
as I-Claim
effective I-Claim
as I-Claim
higher I-Claim
doses I-Claim
in I-Claim
improving I-Claim
climacteric I-Claim
symptoms I-Claim
and I-Claim
hrqol I-Claim
ratings I-Claim
and I-Claim
had I-Claim
fewer I-Claim
safety I-Claim
concerns I-Claim
. I-Claim
!LF! !LF!
following B-Premise
discontinuation I-Premise
of I-Premise
cchrt I-Premise
, I-Premise
patient I-Premise
satisfaction I-Premise
was I-Premise
variable I-Premise
, I-Premise
with I-Premise
15 I-Premise
% I-Premise
electing I-Premise
to I-Premise
continue I-Premise
or I-Premise
restart I-Premise
hrt I-Premise
and I-Premise
7 I-Premise
% I-Premise
resuming I-Premise
at I-Premise
follow I-Premise
- I-Premise
up I-Premise
. I-Premise
!LF! !LF!
this B-Claim
supports I-Claim
the I-Claim
need I-Claim
for I-Claim
an I-Claim
individualized I-Claim
approach I-Claim
to I-Claim
therapy I-Claim
recommendations I-Claim
. I-Claim
!LF! !LF!
few O
randomized O
trials O
have O
compared O
the O
survival O
benefit O
of O
interferon O
- O
alfa O
over O
controls O
in O
metastatic O
renal O
cell O
carcinoma O
, O
and O
none O
has O
been O
performed O
using O
interleukin O
- O
2 O
. O
!LF! !LF!
the O
programme O
etude O
rein O
cytokines O
( O
percy O
) O
quattro O
trial O
was O
designed O
to O
evaluate O
both O
cytokines O
for O
their O
survival O
benefit O
to O
intermediate O
prognosis O
patients O
, O
who O
represent O
the O
majority O
of O
candidates O
for O
these O
treatments O
. O
!LF! !LF!
patients O
were O
randomized O
in O
a O
2 O
- O
by O
- O
2 O
factorial O
design O
to O
medroxyprogesterone O
acetate O
200 O
mg O
daily O
, O
interferon O
- O
alfa O
9 O
million O
iu O
3 O
times O
a O
week O
, O
subcutaneous O
interleukin O
- O
2 O
9 O
million O
iu O
daily O
, O
or O
a O
combination O
of O
both O
cytokines O
. O
!LF! !LF!
tumor O
response O
was O
evaluated O
at O
week O
12 O
and O
month O
6 O
"""" O
; O
"""" O
progression O
- O
free O
patients O
received O
further O
identical O
treatment O
for O
a O
maximum O
of O
3 O
additional O
months O
. O
!LF! !LF!
primary O
endpoint O
was O
overall O
survival O
"""" O
; O
"""" O
secondary O
endpoints O
were O
disease O
- O
free O
survival O
, O
response O
rate O
, O
toxicity O
, O
and O
quality O
of O
life O
. O
!LF! !LF!
survival O
was O
analyzed O
on O
an O
intent O
- O
to O
- O
treat O
basis O
. O
!LF! !LF!
from O
january O
2000 O
to O
july O
2004 O
, O
492 O
patients O
were O
enrolled O
. O
!LF! !LF!
analysis O
was O
performed O
after O
a O
29 O
. O
2 O
- O
month O
median O
follow O
- O
up O
( O
range O
, O
0 O
months O
to O
54 O
. O
6 O
months O
) O
. O
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
significant I-Premise
survival I-Premise
differences I-Premise
between I-Premise
the I-Premise
244 I-Premise
interferon I-Premise
- I-Premise
alfa I-Premise
- I-Premise
treated I-Premise
patients I-Premise
and I-Premise
248 I-Premise
noninterferon I-Premise
- I-Premise
alfa I-Premise
patients I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1 I-Premise
. I-Premise
00 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
81 I-Premise
- I-Premise
1 I-Premise
. I-Premise
24 I-Premise
) I-Premise
or I-Premise
between I-Premise
the I-Premise
247 I-Premise
interleukin I-Premise
- I-Premise
2 I-Premise
and I-Premise
245 I-Premise
noninterleukin I-Premise
- I-Premise
2 I-Premise
- I-Premise
treated I-Premise
patients I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1 I-Premise
. I-Premise
07 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
87 I-Premise
- I-Premise
1 I-Premise
. I-Premise
33 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
log I-Premise
rank I-Premise
, I-Premise
0 I-Premise
. I-Premise
99 I-Premise
and I-Premise
0 I-Premise
. I-Premise
52 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise
!LF! !LF!
grade B-Premise
3 I-Premise
- I-Premise
4 I-Premise
toxicities I-Premise
were I-Premise
significantly I-Premise
more I-Premise
frequent I-Premise
in I-Premise
cytokine I-Premise
- I-Premise
treated I-Premise
patients I-Premise
than I-Premise
in I-Premise
medroxyprogesterone I-Premise
- I-Premise
treated I-Premise
patients I-Premise
. I-Premise
!LF! !LF!
subcutaneous B-Claim
interleukin I-Claim
- I-Claim
2 I-Claim
and I-Claim
/ I-Claim
or I-Claim
interferon I-Claim
- I-Claim
alfa I-Claim
provide I-Claim
no I-Claim
survival I-Claim
benefit I-Claim
in I-Claim
metastatic I-Claim
renal I-Claim
cancers I-Claim
of I-Claim
intermediate I-Claim
prognosis I-Claim
, I-Claim
and I-Claim
they I-Claim
induce I-Claim
a I-Claim
significant I-Claim
risk I-Claim
of I-Claim
toxicity I-Claim
. I-Claim
!LF! !LF!
newly B-Claim
available I-Claim
angiogenesis I-Claim
inhibitors I-Claim
should I-Claim
be I-Claim
preferred I-Claim
for I-Claim
these I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
to O
investigate O
whether O
the O
effect O
of O
hypofractionated O
thoracic O
radiotherapy O
( O
trt O
) O
is O
comparable O
to O
more O
standard O
fractionated O
radiotherapy O
( O
rt O
) O
in O
advanced O
non O
- O
small O
- O
cell O
lung O
cancer O
( O
nsclc O
) O
. O
!LF! !LF!
a O
total O
of O
421 O
patients O
with O
locally O
advanced O
stage O
iii O
or O
stage O
iv O
nsclc O
tumors O
were O
included O
. O
!LF! !LF!
inclusion O
criteria O
were O
inoperable O
, O
disease O
too O
advanced O
for O
curative O
radiotherapy O
, O
and O
chest O
symptoms O
or O
central O
tumor O
threatening O
the O
airways O
. O
!LF! !LF!
patients O
were O
randomly O
assigned O
to O
three O
arms O
: O
a O
, O
17 O
gy O
per O
two O
fractions O
( O
n O
= O
146 O
) O
"""" O
; O
"""" O
b O
, O
42 O
gy O
per O
15 O
fractions O
( O
n O
= O
145 O
) O
"""" O
; O
"""" O
and O
c O
, O
50 O
gy O
per O
25 O
fractions O
( O
n O
= O
130 O
) O
. O
!LF! !LF!
four O
hundred O
seven O
patients O
were O
eligible O
for O
the O
study O
"""" O
; O
"""" O
395 O
patients O
( O
97 O
% O
) O
participated O
in O
the O
health O
- O
related O
quality O
- O
of O
- O
life O
( O
hrqol O
) O
study O
. O
!LF! !LF!
the O
european O
organization O
for O
research O
and O
treatment O
of O
cancer O
( O
eortc O
) O
quality O
of O
life O
questionnaire O
( O
qlq O
) O
- O
c30 O
and O
eortc O
qlq O
- O
lung O
cancer O
- O
specific O
module O
( O
lc13 O
) O
were O
used O
to O
investigate O
airway O
symptom O
relief O
and O
changes O
in O
hrqol O
. O
!LF! !LF!
assessments O
were O
performed O
before O
trt O
and O
until O
week O
54 O
. O
!LF! !LF!
clinicians O
' O
assessments O
of O
symptom O
improvement O
were O
at O
2 O
, O
6 O
, O
and O
14 O
weeks O
after O
completion O
of O
trt O
. O
!LF! !LF!
the O
patients O
were O
observed O
for O
a O
minimum O
of O
3 O
years O
. O
!LF! !LF!
results O
baseline O
prognostic O
data O
were O
equally O
distributed O
in O
the O
treatment O
groups O
. O
!LF! !LF!
patient O
compliance O
with O
respect O
to O
the O
hrqol O
investigation O
was O
minimum O
74 O
% O
. O
!LF! !LF!
hrqol B-Premise
and I-Premise
symptom I-Premise
relief I-Premise
were I-Premise
equivalent I-Premise
in I-Premise
the I-Premise
treatment I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
no B-Premise
significant I-Premise
difference I-Premise
in I-Premise
survival I-Premise
among I-Premise
arms I-Premise
a I-Premise
, I-Premise
b I-Premise
, I-Premise
and I-Premise
c I-Premise
was I-Premise
found I-Premise
, I-Premise
with I-Premise
median I-Premise
survival I-Premise
8 I-Premise
. I-Premise
2 I-Premise
, I-Premise
7 I-Premise
. I-Premise
0 I-Premise
, I-Premise
and I-Premise
6 I-Premise
. I-Premise
8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
our B-Claim
data I-Claim
indicate I-Claim
that I-Claim
protracted I-Claim
palliative I-Claim
trt I-Claim
renders I-Claim
no I-Claim
improvement I-Claim
in I-Claim
symptom I-Claim
relief I-Claim
, I-Claim
hrqol I-Claim
, I-Claim
or I-Claim
survival I-Claim
when I-Claim
compared I-Claim
with I-Claim
short I-Claim
- I-Claim
term I-Claim
hypofractionated I-Claim
treatment I-Claim
in I-Claim
advanced I-Claim
nsclc I-Claim
. I-Claim
!LF! !LF!
cisplatin B-Claim
reduces I-Claim
plasma I-Claim
ghrelin I-Claim
levels I-Claim
through I-Claim
the I-Claim
5 I-Claim
- I-Claim
hydroxytryptamine I-Claim
( I-Claim
5 I-Claim
- I-Claim
ht I-Claim
) I-Claim
receptor I-Claim
. I-Claim
!LF! !LF!
this O
may O
cause O
cisplatin O
- O
induced O
gastrointestinal O
disorders O
and O
hinders O
the O
continuation O
of O
chemotherapy O
. O
!LF! !LF!
the O
authors O
of O
this O
report O
conducted O
a O
prospective O
, O
randomized O
phase O
2 O
trial O
to O
evaluate O
the O
effects O
of O
exogenous O
ghrelin O
during O
cisplatin O
- O
based O
chemotherapy O
. O
!LF! !LF!
forty O
- O
two O
patients O
with O
esophageal O
cancer O
who O
were O
receiving O
cisplatin O
- O
based O
neoadjuvant O
chemotherapy O
were O
assigned O
to O
either O
a O
ghrelin O
group O
( O
n O
= O
21 O
) O
or O
a O
placebo O
group O
( O
n O
= O
21 O
) O
. O
!LF! !LF!
they O
received O
either O
intravenous O
infusions O
of O
synthetic O
human O
ghrelin O
( O
3 O
μg O
/ O
kg O
) O
or O
saline O
twice O
daily O
for O
1 O
week O
with O
cisplatin O
administration O
. O
!LF! !LF!
the O
primary O
endpoint O
was O
changes O
in O
oral O
calorie O
intake O
, O
and O
the O
secondary O
endpoints O
were O
chemotherapy O
- O
related O
adverse O
events O
"""" O
; O
"""" O
appetite O
visual O
analog O
scale O
( O
vas O
) O
scores O
"""" O
; O
"""" O
changes O
in O
gastrointestinal O
hormones O
and O
nutritional O
status O
, O
including O
rapid O
turnover O
proteins O
, O
and O
quality O
of O
life O
( O
qol O
) O
estimated O
with O
the O
european O
organization O
for O
research O
and O
treatment O
of O
cancer O
qol O
core O
questionnaire O
( O
qlq O
- O
c30 O
) O
. O
!LF! !LF!
two O
patients O
were O
excluded O
from O
the O
final O
analysis O
: O
one O
patient O
suspended O
ghrelin O
administration O
because O
of O
excessive O
diaphoresis O
, O
and O
another O
patient O
in O
the O
placebo O
group O
failed O
to O
monitor O
the O
self O
- O
questionnaire O
. O
!LF! !LF!
food B-Premise
intake I-Premise
and I-Premise
appetite I-Premise
vas I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
ghrelin I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
( I-Premise
18 I-Premise
. I-Premise
2 I-Premise
± I-Premise
5 I-Premise
. I-Premise
2 I-Premise
kcal I-Premise
/ I-Premise
kg I-Premise
/ I-Premise
day I-Premise
vs I-Premise
12 I-Premise
. I-Premise
7 I-Premise
± I-Premise
3 I-Premise
. I-Premise
4 I-Premise
kcal I-Premise
/ I-Premise
kg I-Premise
/ I-Premise
day I-Premise
[ I-Premise
p I-Premise
= I-Premise
. I-Premise
001 I-Premise
] I-Premise
and I-Premise
6 I-Premise
. I-Premise
2 I-Premise
± I-Premise
0 I-Premise
. I-Premise
9 I-Premise
vs I-Premise
4 I-Premise
. I-Premise
1 I-Premise
± I-Premise
0 I-Premise
. I-Premise
9 I-Premise
[ I-Premise
p I-Premise
< I-Premise
. I-Premise
0001 I-Premise
] I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
in I-Premise
the I-Premise
ghrelin I-Premise
group I-Premise
had I-Premise
fewer I-Premise
adverse I-Premise
events I-Premise
during I-Premise
chemotherapy I-Premise
related I-Premise
to I-Premise
anorexia I-Premise
and I-Premise
nausea I-Premise
than I-Premise
patients I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise
!LF! !LF!
significant B-Premise
deterioration I-Premise
was I-Premise
noted I-Premise
after I-Premise
chemotherapy I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
in I-Premise
qol I-Premise
scores I-Premise
, I-Premise
appetite I-Premise
, I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
, I-Premise
and I-Premise
global I-Premise
health I-Premise
status I-Premise
. I-Premise
!LF! !LF!
short B-Claim
- B-Claim
term B-Claim
administration I-Claim
of I-Claim
exogenous I-Claim
ghrelin I-Claim
at I-Claim
the I-Claim
start I-Claim
of I-Claim
cisplatin I-Claim
- I-Claim
based I-Claim
chemotherapy I-Claim
stimulated I-Claim
food I-Claim
intake I-Claim
and I-Claim
minimized I-Claim
adverse I-Claim
events I-Claim
. I-Claim
!LF! !LF!
chemoradiotherapy O
( O
crt O
) O
- O
induced O
oral O
mucositis O
( O
om O
) O
adversely O
affects O
a O
patient O
' O
s O
oral O
functions O
and O
quality O
of O
life O
( O
qol O
) O
. O
!LF! !LF!
low O
- O
level O
laser O
therapy O
( O
lllt O
) O
showed O
some O
preventive O
and O
curative O
effects O
against O
clinically O
reported O
objective O
measures O
of O
om O
in O
few O
trials O
including O
our O
recently O
published O
study O
. O
!LF! !LF!
there O
is O
dearth O
of O
evidence O
regarding O
the O
effects O
of O
lllt O
on O
patient O
' O
s O
subjective O
experience O
of O
om O
and O
qol O
. O
!LF! !LF!
hence O
, O
we O
did O
this O
study O
to O
evaluate O
the O
effects O
of O
lllt O
on O
a O
patient O
' O
s O
reported O
measures O
of O
om O
and O
qol O
in O
head O
and O
neck O
cancer O
( O
hnc O
) O
patients O
receiving O
crt O
. O
!LF! !LF!
this O
triple O
blinded O
study O
randomized O
220 O
hnc O
patients O
scheduled O
for O
crt O
( O
three O
weekly O
cisplatin O
+ O
rt O
= O
66 O
gray O
( O
2 O
gy O
/ O
session O
) O
, O
five O
fractions O
/ O
week O
for O
6 O
. O
5 O
weeks O
, O
total O
33 O
fractions O
) O
into O
laser O
( O
110 O
) O
and O
placebo O
( O
110 O
) O
groups O
. O
!LF! !LF!
the O
laser O
group O
received O
lllt O
( O
technomed O
electronics O
advanced O
laser O
therapy O
1000 O
, O
he O
- O
ne O
, O
λ O
= O
632 O
. O
8 O
nm O
, O
power O
density O
= O
24 O
mw O
/ O
cm O
( O
2 O
) O
, O
dosage O
= O
3 O
. O
0 O
j O
at O
each O
point O
, O
total O
dose O
/ O
session O
= O
36 O
- O
40 O
j O
, O
spot O
size O
1 O
cm O
( O
2 O
) O
, O
irradiation O
time O
/ O
point O
125 O
s O
) O
before O
each O
radiation O
session O
, O
while O
the O
placebo O
group O
did O
not O
receive O
laser O
therapy O
. O
!LF! !LF!
methodology O
was O
similar O
to O
our O
recently O
published O
study O
( O
gautam O
et O
al O
. O
!LF! !LF!
radiother O
oncol O
104 O
: O
349 O
- O
354 O
, O
2012 O
) O
. O
!LF! !LF!
in O
this O
part O
of O
our O
study O
, O
a O
blinded O
assessor O
collected O
subjective O
outcomes O
of O
the O
patient O
' O
s O
reported O
measures O
of O
om O
using O
oral O
mucositis O
weekly O
questionnaire O
- O
head O
and O
neck O
( O
omwq O
- O
hn O
) O
and O
qol O
using O
functional O
assessment O
of O
cancer O
treatment O
- O
head O
and O
neck O
( O
fact O
- O
hn O
) O
questionnaire O
. O
!LF! !LF!
data O
were O
analyzed O
using O
repeated O
measure O
anova O
through O
general O
linear O
model O
. O
!LF! !LF!
statistical O
significance O
was O
kept O
at O
p O
< O
0 O
. O
05 O
. O
!LF! !LF!
results B-Premise
analysis I-Premise
revealed I-Premise
that I-Premise
omwq I-Premise
- I-Premise
hn I-Premise
( I-Premise
f I-Premise
= I-Premise
12 I-Premise
. I-Premise
199 I-Premise
, I-Premise
df I-Premise
= I-Premise
6 I-Premise
, I-Premise
1314 I-Premise
, I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
and I-Premise
fact I-Premise
- I-Premise
hn I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
lllt I-Premise
than I-Premise
placebo I-Premise
group I-Premise
patients I-Premise
. I-Premise
!LF! !LF!
also O
, O
a B-Premise
significant I-Premise
reduction I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
in I-Premise
incidence I-Premise
of I-Premise
severe I-Premise
om I-Premise
, I-Premise
need I-Premise
for I-Premise
opioid I-Premise
analgesics I-Premise
, I-Premise
and I-Premise
total I-Premise
parenteral I-Premise
nutrition I-Premise
was I-Premise
observed I-Premise
. I-Premise
!LF! !LF!
lllt B-Claim
was I-Claim
effective I-Claim
in I-Claim
improving I-Claim
the I-Claim
patient I-Claim
' I-Claim
s I-Claim
subjective I-Claim
experience I-Claim
of I-Claim
om I-Claim
and I-Claim
qol I-Claim
in I-Claim
hnc I-Claim
patients I-Claim
receiving I-Claim
crt I-Claim
. I-Claim
!LF! !LF!
due O
to O
concerns O
of O
fragility O
fracture O
, O
exercise O
is O
a O
perceived O
contraindication O
for O
prostate O
cancer O
patients O
with O
bone O
metastases O
. O
!LF! !LF!
these O
patients O
experience O
significant O
functional O
impairment O
and O
muscle O
atrophy O
, O
which O
may O
lead O
to O
an O
increased O
likelihood O
of O
skeletal O
complications O
( O
i O
. O
e O
. O
, O
pathological O
fracture O
, O
bone O
pain O
) O
and O
/ O
or O
falls O
. O
!LF! !LF!
safe O
resistance O
exercise O
prescription O
may O
counteract O
this O
effect O
. O
!LF! !LF!
the O
aim O
of O
this O
feasibility O
trial O
was O
to O
determine O
the O
safety O
and O
efficacy O
of O
resistance O
exercise O
by O
prostate O
cancer O
survivors O
with O
bone O
metastatic O
disease O
. O
!LF! !LF!
twenty O
men O
with O
established O
bone O
metastases O
secondary O
to O
prostate O
cancer O
were O
randomly O
assigned O
to O
a O
12 O
- O
week O
resistance O
exercise O
program O
in O
which O
exercise O
prescription O
was O
based O
on O
the O
location O
of O
bone O
lesions O
( O
n O
= O
10 O
) O
or O
usual O
care O
( O
n O
= O
10 O
) O
. O
!LF! !LF!
outcomes O
included O
safety O
and O
tolerance O
of O
the O
exercise O
program O
, O
physical O
function O
, O
physical O
activity O
level O
, O
body O
composition O
, O
fatigue O
, O
quality O
of O
life O
and O
psychological O
distress O
. O
!LF! !LF!
outcomes O
were O
compared O
between O
groups O
using O
analysis O
of O
covariance O
adjusted O
for O
baseline O
values O
. O
!LF! !LF!
participants O
had O
significant O
disease O
load O
with O
65 O
% O
of O
participants O
presenting O
with O
two O
or O
more O
regions O
affected O
by O
bone O
metastases O
and O
an O
average O
gleason O
score O
of O
8 O
. O
2±0 O
. O
9 O
. O
!LF! !LF!
five O
participants O
( O
exercise O
= O
2 O
"""" O
; O
"""" O
usual O
care O
= O
3 O
) O
did O
not O
complete O
the O
intervention O
, O
three O
of O
which O
were O
due O
to O
advancing O
disease O
( O
exercise O
= O
2 O
"""" O
; O
"""" O
usual O
care O
= O
1 O
) O
. O
!LF! !LF!
no B-Premise
adverse I-Premise
events I-Premise
or I-Premise
skeletal I-Premise
complications I-Premise
occurred I-Premise
during I-Premise
the I-Premise
supervised I-Premise
exercise I-Premise
sessions I-Premise
. I-Premise
!LF! !LF!
the B-Premise
exercise I-Premise
program I-Premise
was I-Premise
well I-Premise
tolerated I-Premise
as I-Premise
evidenced I-Premise
by I-Premise
high I-Premise
attendance I-Premise
( I-Premise
83 I-Premise
% I-Premise
) I-Premise
and I-Premise
compliance I-Premise
rates I-Premise
( I-Premise
93 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
ability I-Premise
of I-Premise
the I-Premise
participants I-Premise
to I-Premise
exercise I-Premise
at I-Premise
an I-Premise
intensity I-Premise
within I-Premise
the I-Premise
target I-Premise
range I-Premise
for I-Premise
cancer I-Premise
survivors I-Premise
( I-Premise
rating I-Premise
of I-Premise
perceived I-Premise
exertion I-Premise
= I-Premise
13 I-Premise
. I-Premise
8±1 I-Premise
. I-Premise
5 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
change I-Premise
in I-Premise
physical I-Premise
function I-Premise
( I-Premise
muscle I-Premise
strength I-Premise
∼11 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
submaximal I-Premise
aerobic I-Premise
exercise I-Premise
capacity I-Premise
∼5 I-Premise
% I-Premise
and I-Premise
ambulation I-Premise
∼12 I-Premise
% I-Premise
) I-Premise
, I-Premise
physical I-Premise
activity I-Premise
level I-Premise
( I-Premise
∼24 I-Premise
% I-Premise
) I-Premise
and I-Premise
lean I-Premise
mass I-Premise
( I-Premise
∼3 I-Premise
% I-Premise
) I-Premise
differed I-Premise
significantly I-Premise
between I-Premise
groups I-Premise
following I-Premise
the I-Premise
intervention I-Premise
, I-Premise
with I-Premise
favorable I-Premise
changes I-Premise
in I-Premise
the I-Premise
exercise I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
usual I-Premise
care I-Premise
group I-Premise
. I-Premise
!LF! !LF!
no B-Premise
significant I-Premise
between I-Premise
- I-Premise
group I-Premise
differences I-Premise
were I-Premise
observed I-Premise
for I-Premise
fatigue I-Premise
, I-Premise
quality I-Premise
of I-Premise
life I-Premise
or I-Premise
psychological I-Premise
distress I-Premise
. I-Premise
!LF! !LF!
this B-Claim
initial I-Claim
evidence I-Claim
involving I-Claim
a I-Claim
small I-Claim
sample I-Claim
size I-Claim
suggests I-Claim
that I-Claim
appropriately I-Claim
designed I-Claim
and I-Claim
supervised I-Claim
resistance I-Claim
exercise I-Claim
may I-Claim
be I-Claim
safe I-Claim
and I-Claim
well I-Claim
tolerated I-Claim
by I-Claim
prostate I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
bone I-Claim
metastatic I-Claim
disease I-Claim
and I-Claim
can I-Claim
lead I-Claim
to I-Claim
improvements I-Claim
in I-Claim
physical I-Claim
function I-Claim
, I-Claim
physical I-Claim
activity I-Claim
levels I-Claim
and I-Claim
lean I-Claim
mass I-Claim
. I-Claim
!LF! !LF!
future B-Claim
trials I-Claim
involving I-Claim
larger I-Claim
sample I-Claim
sizes I-Claim
are I-Claim
required I-Claim
to I-Claim
expand I-Claim
these I-Claim
preliminary I-Claim
findings I-Claim
. I-Claim
!LF! !LF!
a O
recent O
randomized O
trial O
to O
compare O
external O
beam O
radiation O
therapy O
( O
ebrt O
) O
to O
cryoablation O
for O
localized O
disease O
showed O
cryoablation O
to O
be O
noninferior O
to O
external O
beam O
ebrt O
in O
disease O
progression O
and O
overall O
and O
disease O
- O
specific O
survival O
. O
!LF! !LF!
we O
report O
on O
the O
quality O
of O
life O
( O
qol O
) O
outcomes O
for O
this O
trial O
. O
!LF! !LF!
from O
december O
1997 O
through O
february O
2003 O
, O
244 O
men O
with O
newly O
diagnosed O
localized O
prostate O
cancer O
were O
randomly O
assigned O
to O
cryoablation O
or O
ebrt O
( O
median O
dose O
68 O
gy O
) O
. O
!LF! !LF!
all O
patients O
received O
neoadjuvant O
antiandrogen O
therapy O
. O
!LF! !LF!
patients O
completed O
the O
eortc O
qlq O
c30 O
and O
the O
prostate O
cancer O
index O
( O
pci O
) O
before O
treatment O
and O
at O
1 O
. O
5 O
, O
3 O
, O
6 O
, O
12 O
, O
18 O
, O
24 O
, O
and O
36 O
months O
post O
- O
treatment O
. O
!LF! !LF!
regardless B-Premise
of I-Premise
treatment I-Premise
arm I-Premise
, I-Premise
participants I-Premise
reported I-Premise
high I-Premise
levels I-Premise
of I-Premise
qol I-Premise
with I-Premise
few I-Premise
exceptions I-Premise
. I-Premise
!LF! !LF!
cryoablation B-Premise
was I-Premise
associated I-Premise
with I-Premise
more I-Premise
acute I-Premise
urinary I-Premise
dysfunction I-Premise
( I-Premise
mean I-Premise
pci I-Premise
urinary I-Premise
function I-Premise
cryoablation I-Premise
= I-Premise
69 I-Premise
. I-Premise
4 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
mean I-Premise
ebrt I-Premise
= I-Premise
90 I-Premise
. I-Premise
7 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
which I-Premise
resolved I-Premise
over I-Premise
time I-Premise
. I-Premise
!LF! !LF!
no B-Premise
late I-Premise
arising I-Premise
qol I-Premise
issues I-Premise
were I-Premise
observed I-Premise
. I-Premise
!LF! !LF!
both B-Premise
ebrt I-Premise
and I-Premise
cryoablation I-Premise
participants I-Premise
reported I-Premise
decreases I-Premise
in I-Premise
sexual I-Premise
function I-Premise
at I-Premise
3 I-Premise
months I-Premise
with I-Premise
the I-Premise
cryoablation I-Premise
patients I-Premise
reporting I-Premise
poorer I-Premise
functioning I-Premise
( I-Premise
mean I-Premise
cryoablation I-Premise
= I-Premise
7 I-Premise
. I-Premise
2 I-Premise
: I-Premise
mean I-Premise
ebrt I-Premise
= I-Premise
32 I-Premise
. I-Premise
9 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
mean B-Premise
sexual I-Premise
function I-Premise
score I-Premise
was I-Premise
15 I-Premise
points I-Premise
lower I-Premise
at I-Premise
3 I-Premise
years I-Premise
for I-Premise
the I-Premise
cryoablation I-Premise
group I-Premise
and I-Premise
13 I-Premise
% I-Premise
more I-Premise
of I-Premise
the I-Premise
cryoablation I-Premise
men I-Premise
said I-Premise
that I-Premise
sexuality I-Premise
was I-Premise
a I-Premise
moderate I-Premise
or I-Premise
big I-Premise
problem I-Premise
. I-Premise
!LF! !LF!
in B-Claim
this I-Claim
randomized I-Claim
trial I-Claim
, I-Claim
no I-Claim
long I-Claim
- I-Claim
term I-Claim
qol I-Claim
advantage I-Claim
for I-Claim
either I-Claim
treatment I-Claim
was I-Claim
apparent I-Claim
with B-Claim
the I-Claim
exception I-Claim
of I-Claim
poorer I-Claim
sexual I-Claim
function I-Claim
reported I-Claim
by I-Claim
those I-Claim
treated I-Claim
with I-Claim
cryoablation I-Claim
. I-Claim
!LF! !LF!
men O
who O
wish O
to O
increase O
their O
odds O
of O
retaining O
sexual O
function O
might O
be O
counseled O
to O
choose O
ebrt O
over O
cryoablation O
. O
!LF! !LF!
it B-Claim
has I-Claim
been I-Claim
shown I-Claim
that I-Claim
nonpharmacologic I-Claim
interventions I-Claim
are I-Claim
effective I-Claim
management I-Claim
techniques I-Claim
for I-Claim
cancer I-Claim
- I-Claim
related I-Claim
fatigue I-Claim
( I-Claim
crf I-Claim
) I-Claim
in I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim
!LF! !LF!
however O
, O
few O
studies O
have O
investigated O
their O
effectiveness O
in O
patients O
who O
are O
receiving O
chemotherapy O
. O
!LF! !LF!
in O
this O
study O
, O
the O
authors O
tested O
the O
effectiveness O
of O
a O
brief O
behaviorally O
oriented O
intervention O
in O
reducing O
crf O
and O
improving O
physical O
function O
and O
associated O
distress O
in O
individuals O
who O
were O
receiving O
chemotherapy O
. O
!LF! !LF!
for O
this O
randomized O
controlled O
trial O
, O
60 O
patients O
with O
cancer O
were O
recruited O
and O
received O
either O
usual O
care O
or O
the O
intervention O
. O
!LF! !LF!
the O
intervention O
was O
delivered O
on O
an O
individual O
basis O
on O
3 O
occasions O
over O
a O
period O
from O
9 O
weeks O
to O
12 O
weeks O
, O
and O
the O
objective O
of O
the O
intervention O
was O
to O
alter O
fatigue O
- O
related O
thoughts O
and O
behavior O
. O
!LF! !LF!
primary O
outcomes O
were O
assessed O
as O
follows O
: O
crf O
using O
the O
visual O
analogue O
scale O
- O
global O
fatigue O
"""" O
; O
"""" O
physical O
functioning O
using O
the O
european O
organization O
for O
research O
and O
treatment O
of O
cancer O
quality O
- O
of O
- O
life O
core O
30 O
questionnaire O
, O
and O
crf O
- O
associated O
distress O
using O
the O
fatigue O
outcome O
measure O
. O
!LF! !LF!
assessments O
were O
made O
on O
4 O
occasions O
: O
at O
baseline O
( O
t0 O
) O
, O
at O
the O
end O
of O
chemotherapy O
( O
t1 O
) O
, O
1 O
month O
after O
chemotherapy O
( O
t2 O
) O
, O
and O
9 O
months O
after O
recruitment O
( O
t3 O
) O
. O
!LF! !LF!
normally O
distributed O
data O
were O
analyzed O
using O
t O
tests O
and O
random O
- O
slope O
/ O
random O
- O
intercept O
mixed O
models O
. O
!LF! !LF!
the B-Premise
intervention I-Premise
demonstrated I-Premise
a I-Premise
trend I-Premise
toward I-Premise
improved I-Premise
crf I-Premise
, I-Premise
although B-Premise
this I-Premise
effect I-Premise
was I-Premise
reduced I-Premise
once I-Premise
confounders I-Premise
had I-Premise
been I-Premise
controlled I-Premise
statistically I-Premise
. I-Premise
!LF! !LF!
there B-Premise
was I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
coefficient I-Premise
, I-Premise
10 I-Premise
. I-Premise
0 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
, I-Premise
2 I-Premise
. I-Premise
5 I-Premise
- I-Premise
17 I-Premise
. I-Premise
5 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
009 I-Premise
) I-Premise
, I-Premise
and I-Premise
this I-Premise
effect I-Premise
remained I-Premise
once I-Premise
the I-Premise
confounding I-Premise
effects I-Premise
of I-Premise
mood I-Premise
disturbance I-Premise
and I-Premise
comorbid I-Premise
disorders I-Premise
were I-Premise
controlled I-Premise
statistically I-Premise
. I-Premise
!LF! !LF!
no B-Premise
decrease I-Premise
in I-Premise
fatigue I-Premise
- I-Premise
related I-Premise
distress I-Premise
was I-Premise
detected I-Premise
. I-Premise
!LF! !LF!
the B-Claim
behaviorally I-Claim
oriented I-Claim
intervention I-Claim
brought I-Claim
about I-Claim
significant I-Claim
improvements I-Claim
in I-Claim
physical I-Claim
functioning I-Claim
, I-Claim
indicated I-Claim
a I-Claim
trend I-Claim
toward I-Claim
improved I-Claim
crf I-Claim
, I-Claim
but I-Claim
detected I-Claim
no I-Claim
effect I-Claim
for I-Claim
fatigue I-Claim
- I-Claim
related I-Claim
distress I-Claim
. I-Claim
!LF! !LF!
radiotherapy B-Claim
is I-Claim
an I-Claim
effective I-Claim
palliative I-Claim
treatment I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
painful I-Claim
bone I-Claim
metastases I-Claim
. I-Claim
!LF! !LF!
although O
single O
- O
and O
multiple O
- O
fraction O
radiotherapy O
are O
thought O
to O
provide O
equal O
palliation O
, O
which O
treatment O
schedule O
provides O
better O
value O
for O
the O
money O
is O
unknown O
. O
!LF! !LF!
we O
compared O
quality O
- O
adjusted O
life O
expectancy O
( O
the O
overall O
valuation O
of O
the O
health O
of O
the O
patients O
) O
and O
societal O
costs O
for O
patients O
receiving O
either O
single O
- O
or O
multiple O
- O
fraction O
radiotherapy O
. O
!LF! !LF!
a O
societal O
cost O
- O
utility O
analysis O
was O
performed O
on O
a O
dutch O
randomized O
, O
controlled O
trial O
of O
1157 O
patients O
with O
painful O
bone O
metastases O
that O
compared O
pain O
responses O
and O
quality O
of O
life O
from O
a O
single O
- O
fraction O
treatment O
schedule O
of O
8 O
gy O
with O
a O
treatment O
schedule O
of O
six O
fractions O
of O
4 O
gy O
each O
. O
!LF! !LF!
the O
societal O
values O
of O
life O
expectancies O
were O
assessed O
with O
the O
euroqol O
classification O
system O
( O
eq O
- O
5d O
) O
questionnaire O
. O
!LF! !LF!
a O
subset O
of O
166 O
patients O
also O
answered O
additional O
questionnaires O
to O
estimate O
nonradiotherapy O
and O
nonmedical O
costs O
. O
!LF! !LF!
statistical O
tests O
were O
two O
- O
sided O
. O
!LF! !LF!
comparing B-Premise
the I-Premise
single I-Premise
- I-Premise
and I-Premise
multiple I-Premise
- I-Premise
fraction I-Premise
radiotherapy I-Premise
schedules I-Premise
, I-Premise
no I-Premise
differences I-Premise
were I-Premise
found I-Premise
in I-Premise
life I-Premise
expectancy I-Premise
( I-Premise
43 I-Premise
. I-Premise
0 I-Premise
versus I-Premise
40 I-Premise
. I-Premise
4 I-Premise
weeks I-Premise
, I-Premise
p I-Premise
= I-Premise
. I-Premise
20 I-Premise
) I-Premise
or I-Premise
quality I-Premise
- I-Premise
adjusted I-Premise
life I-Premise
expectancy I-Premise
( I-Premise
17 I-Premise
. I-Premise
7 I-Premise
versus I-Premise
16 I-Premise
. I-Premise
0 I-Premise
weeks I-Premise
, I-Premise
p I-Premise
= I-Premise
. I-Premise
21 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
estimated I-Premise
cost I-Premise
of I-Premise
radiotherapy I-Premise
, I-Premise
including I-Premise
retreatments I-Premise
and I-Premise
nonmedical I-Premise
costs I-Premise
, I-Premise
was I-Premise
statistically I-Premise
significantly I-Premise
lower I-Premise
for I-Premise
the I-Premise
single I-Premise
- I-Premise
fraction I-Premise
schedule I-Premise
than I-Premise
for I-Premise
the I-Premise
multiple I-Premise
- I-Premise
fraction I-Premise
schedule I-Premise
( I-Premise
$ I-Premise
2438 I-Premise
versus I-Premise
$ I-Premise
3311 I-Premise
, I-Premise
difference I-Premise
= I-Premise
$ I-Premise
873 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
ci I-Premise
] I-Premise
on I-Premise
the I-Premise
difference I-Premise
= I-Premise
$ I-Premise
449 I-Premise
to I-Premise
$ I-Premise
1297 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
estimated I-Premise
difference I-Premise
in I-Premise
total I-Premise
societal I-Premise
costs I-Premise
was I-Premise
larger I-Premise
, I-Premise
also I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
single I-Premise
- I-Premise
fraction I-Premise
schedule I-Premise
, I-Premise
but B-Premise
it I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
$ I-Premise
4700 I-Premise
versus I-Premise
$ I-Premise
6453 I-Premise
, I-Premise
difference I-Premise
= I-Premise
$ I-Premise
1753 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
on I-Premise
the I-Premise
difference I-Premise
= I-Premise
- I-Premise
$ I-Premise
99 I-Premise
to I-Premise
$ I-Premise
3604 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
06 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
for B-Premise
willingness I-Premise
- I-Premise
to I-Premise
- I-Premise
pay I-Premise
between I-Premise
$ I-Premise
5000 I-Premise
and I-Premise
$ I-Premise
40 I-Premise
0 I-Premise
per I-Premise
quality I-Premise
- I-Premise
adjusted I-Premise
life I-Premise
year I-Premise
, I-Premise
the I-Premise
single I-Premise
- I-Premise
fraction I-Premise
schedule I-Premise
was I-Premise
statistically I-Premise
significantly I-Premise
more I-Premise
cost I-Premise
- I-Premise
effective I-Premise
than I-Premise
the I-Premise
multiple I-Premise
- I-Premise
fraction I-Premise
schedule I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
compared B-Claim
with I-Claim
multiple I-Claim
- I-Claim
fraction I-Claim
radiotherapy I-Claim
, I-Claim
single I-Claim
- I-Claim
fraction I-Claim
radiotherapy I-Claim
provides I-Claim
equal I-Claim
palliation I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
has I-Claim
lower I-Claim
medical I-Claim
and I-Claim
societal I-Claim
costs I-Claim
, I-Claim
at I-Claim
least I-Claim
in I-Claim
the I-Claim
netherlands I-Claim
. I-Claim
!LF! !LF!
therefore B-Claim
, I-Claim
single I-Claim
- I-Claim
fraction I-Claim
radiotherapy I-Claim
should I-Claim
be I-Claim
considered I-Claim
as I-Claim
the I-Claim
palliative I-Claim
treatment I-Claim
of I-Claim
choice I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
painful I-Claim
bone I-Claim
metastases I-Claim
. I-Claim
!LF! !LF!
for B-Claim
malignant I-Claim
pleural I-Claim
mesothelioma I-Claim
( I-Claim
mpm I-Claim
) I-Claim
patients I-Claim
with I-Claim
a I-Claim
poor I-Claim
prognosis I-Claim
, I-Claim
maintaining I-Claim
health I-Claim
- I-Claim
related I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
hrqol I-Claim
) I-Claim
is I-Claim
important I-Claim
. I-Claim
!LF! !LF!
this O
article O
compares O
the O
impact O
on O
hrqol O
of O
first O
- O
line O
treatment O
with O
cisplatin O
versus O
raltitrexed O
and O
cisplatin O
. O
!LF! !LF!
patients O
with O
histologically O
- O
proven O
unresectable O
mpm O
, O
not O
pretreated O
with O
chemotherapy O
were O
randomly O
assigned O
to O
receive O
cisplatin O
80 O
mg O
/ O
m2 O
intravenously O
on O
day O
1 O
, O
with O
or O
without O
preceding O
infusion O
of O
raltitrexed O
3 O
mg O
/ O
m2 O
. O
!LF! !LF!
hrqol O
was O
assessed O
with O
the O
european O
organisation O
for O
research O
and O
treatment O
of O
cancer O
core O
quality O
of O
life O
questionnaire O
c30 O
( O
eortc O
qlq O
- O
c30 O
) O
and O
eortc O
lung O
cancer O
module O
( O
qlq O
- O
lc13 O
) O
tools O
. O
!LF! !LF!
assessments O
were O
conducted O
at O
baseline O
, O
immediately O
before O
every O
treatment O
cycle O
, O
at O
the O
end O
of O
treatment O
, O
and O
every O
six O
weeks O
for O
12 O
months O
. O
!LF! !LF!
two O
hundred O
fifty O
patients O
were O
randomly O
assigned O
, O
80 O
% O
were O
male O
with O
a O
median O
age O
of O
58 O
years O
, O
who O
performance O
status O
0 O
, O
1 O
, O
and O
2 O
, O
in O
25 O
% O
, O
62 O
% O
, O
and O
13 O
% O
of O
cases O
. O
!LF! !LF!
the B-Premise
clinical I-Premise
results I-Premise
found I-Premise
raltitrexed I-Premise
and I-Premise
cisplatin I-Premise
to I-Premise
be I-Premise
superior I-Premise
to I-Premise
cisplatin I-Premise
with I-Premise
regard I-Premise
to I-Premise
overall I-Premise
survival I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
048 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
global I-Premise
hrqol I-Premise
scale I-Premise
was I-Premise
comparable I-Premise
at I-Premise
baseline I-Premise
on I-Premise
both I-Premise
treatment I-Premise
arms I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
848 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
at B-Premise
no I-Premise
point I-Premise
was I-Premise
any I-Premise
significant I-Premise
difference I-Premise
apparent I-Premise
on I-Premise
this I-Premise
end I-Premise
point I-Premise
. I-Premise
!LF! !LF!
both B-Premise
treatments I-Premise
led I-Premise
to I-Premise
an I-Premise
improvement I-Premise
, I-Premise
over I-Premise
time I-Premise
, I-Premise
in I-Premise
dyspnoea I-Premise
. I-Premise
!LF! !LF!
this B-Claim
effect I-Claim
is I-Claim
an I-Claim
important I-Claim
clinically I-Claim
meaningful I-Claim
reduction I-Claim
from I-Claim
baseline I-Claim
in I-Claim
the I-Claim
cisplatin I-Claim
/ I-Claim
raltitrexed I-Claim
arm I-Claim
. I-Claim
!LF! !LF!
however B-Premise
, I-Premise
the I-Premise
majority I-Premise
of I-Premise
scales I-Premise
of I-Premise
the I-Premise
eortc I-Premise
qlq I-Premise
- I-Premise
c30 I-Premise
or I-Premise
lc13 I-Premise
showed I-Premise
stabilization I-Premise
of I-Premise
hrqol I-Premise
with I-Premise
few I-Premise
clinically I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
treatment I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
this B-Claim
study I-Claim
provides I-Claim
important I-Claim
information I-Claim
about I-Claim
the I-Claim
hrqol I-Claim
of I-Claim
chemotherapy I-Claim
- I-Claim
treated I-Claim
mpm I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
the O
physiological O
and O
psychological O
stress O
that O
brain O
tumor O
patients O
undergo O
during O
the O
entire O
surgical O
experience O
can O
considerably O
affect O
several O
aspects O
of O
their O
hospitalization O
. O
!LF! !LF!
the O
purpose O
of O
this O
study O
was O
to O
examine O
the O
effects O
of O
live O
music O
therapy O
on O
quality O
of O
life O
indicators O
, O
amount O
of O
medications O
administered O
and O
length O
of O
stay O
for O
persons O
receiving O
elective O
surgical O
procedures O
of O
the O
brain O
. O
!LF! !LF!
subjects O
( O
n O
= O
27 O
) O
were O
patients O
admitted O
for O
some O
type O
of O
surgical O
procedure O
of O
the O
brain O
. O
!LF! !LF!
subjects O
were O
randomly O
assigned O
to O
either O
the O
control O
group O
receiving O
no O
music O
intervention O
( O
n O
= O
13 O
) O
or O
the O
experimental O
group O
receiving O
pre O
and O
postoperative O
live O
music O
therapy O
sessions O
( O
n O
= O
14 O
) O
. O
!LF! !LF!
anxiety O
, O
mood O
, O
pain O
, O
perception O
of O
hospitalization O
or O
procedure O
, O
relaxation O
, O
and O
stress O
were O
measured O
using O
a O
self O
- O
report O
visual O
analog O
scale O
( O
vas O
) O
for O
each O
of O
the O
variables O
. O
!LF! !LF!
the O
documented O
administration O
of O
postoperative O
pain O
medications O
"""" O
; O
"""" O
the O
frequency O
, O
dosage O
, O
type O
, O
and O
how O
it O
was O
given O
was O
also O
compared O
between O
groups O
. O
!LF! !LF!
experimental O
subjects O
live O
and O
interactive O
music O
therapy O
sessions O
, O
including O
a O
pre O
- O
operative O
session O
and O
continuing O
with O
daily O
sessions O
until O
the O
patient O
was O
discharged O
home O
. O
!LF! !LF!
control O
subjects O
received O
routine O
hospital O
care O
without O
any O
music O
therapy O
intervention O
. O
!LF! !LF!
differences O
in O
experimental O
pretest O
and O
posttest O
scores O
were O
analyzed O
using O
a O
wilcoxon O
matched O
- O
pairs O
signed O
- O
rank O
test O
. O
!LF! !LF!
results B-Premise
indicated I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
for I-Premise
4 I-Premise
of I-Premise
the I-Premise
6 I-Premise
quality I-Premise
of I-Premise
life I-Premise
measures I-Premise
: I-Premise
anxiety I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
, I-Premise
perception I-Premise
of I-Premise
hospitalization I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
, I-Premise
relaxation I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
and I-Premise
stress I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
no B-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
were I-Premise
found I-Premise
for I-Premise
mood I-Premise
( I-Premise
p I-Premise
> I-Premise
. I-Premise
05 I-Premise
) I-Premise
or I-Premise
pain I-Premise
( I-Premise
p I-Premise
> I-Premise
. I-Premise
05 I-Premise
) I-Premise
levels I-Premise
. I-Premise
!LF! !LF!
administration O
amounts O
of O
nausea O
and O
pain O
medications O
were O
compared O
with O
a O
two O
- O
way O
anova O
with O
one O
repeated O
measure O
resulting O
in O
no O
significant O
differences O
between O
groups O
and O
medications O
, O
f O
( O
1 O
, O
51 O
) O
= O
0 O
. O
03 O
"""" O
; O
"""" O
p O
> O
. O
05 O
. O
!LF! !LF!
results O
indicate O
no O
significant O
differences O
between O
groups O
for O
length O
of O
stay O
( O
t O
= O
. O
97 O
, O
df O
= O
25 O
, O
p O
> O
. O
05 O
) O
. O
!LF! !LF!
this B-Claim
research I-Claim
study I-Claim
indicates I-Claim
that I-Claim
live I-Claim
music I-Claim
therapy I-Claim
using I-Claim
patient I-Claim
- I-Claim
preferred I-Claim
music I-Claim
can I-Claim
be I-Claim
beneficial I-Claim
in I-Claim
improving I-Claim
quality I-Claim
of I-Claim
life I-Claim
indicators I-Claim
such I-Claim
as I-Claim
anxiety I-Claim
, I-Claim
perception I-Claim
of I-Claim
the I-Claim
hospitalization I-Claim
or I-Claim
procedure I-Claim
, I-Claim
relaxation I-Claim
, I-Claim
and I-Claim
stress I-Claim
in I-Claim
patients I-Claim
undergoing I-Claim
surgical I-Claim
procedures I-Claim
of I-Claim
the I-Claim
brain I-Claim
. I-Claim
!LF! !LF!
spiritual O
well O
- O
being O
and O
sense O
of O
meaning O
are O
important O
concerns O
for O
clinicians O
who O
care O
for O
patients O
with O
cancer O
. O
!LF! !LF!
we O
developed O
individual O
meaning O
- O
centered O
psychotherapy O
( O
imcp O
) O
to O
address O
the O
need O
for O
brief O
interventions O
targeting O
spiritual O
well O
- O
being O
and O
meaning O
for O
patients O
with O
advanced O
cancer O
. O
!LF! !LF!
patients O
with O
stage O
iii O
or O
iv O
cancer O
( O
n O
= O
120 O
) O
were O
randomly O
assigned O
to O
seven O
sessions O
of O
either O
imcp O
or O
therapeutic O
massage O
( O
tm O
) O
. O
!LF! !LF!
patients O
were O
assessed O
before O
and O
after O
completing O
the O
intervention O
and O
2 O
months O
postintervention O
. O
!LF! !LF!
primary O
outcome O
measures O
assessed O
spiritual O
well O
- O
being O
and O
quality O
of O
life O
"""" O
; O
"""" O
secondary O
outcomes O
included O
anxiety O
, O
depression O
, O
hopelessness O
, O
symptom O
burden O
, O
and O
symptom O
- O
related O
distress O
. O
!LF! !LF!
of O
the O
120 O
participants O
randomly O
assigned O
, O
78 O
( O
65 O
% O
) O
completed O
the O
post O
- O
treatment O
assessment O
and O
67 O
( O
56 O
% O
) O
completed O
the O
2 O
- O
month O
follow O
- O
up O
. O
!LF! !LF!
at B-Premise
the I-Premise
post I-Premise
- I-Premise
treatment I-Premise
assessment I-Premise
, I-Premise
imcp I-Premise
participants I-Premise
demonstrated I-Premise
significantly I-Premise
greater I-Premise
improvement I-Premise
than I-Premise
the I-Premise
control I-Premise
condition I-Premise
for I-Premise
the I-Premise
primary I-Premise
outcomes I-Premise
of I-Premise
spiritual I-Premise
well I-Premise
- I-Premise
being I-Premise
( I-Premise
b I-Premise
= I-Premise
0 I-Premise
. I-Premise
39 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
, I-Premise
including I-Premise
both I-Premise
components I-Premise
of I-Premise
spiritual I-Premise
well I-Premise
- I-Premise
being I-Premise
( I-Premise
sense I-Premise
of I-Premise
meaning I-Premise
: I-Premise
b I-Premise
= I-Premise
0 I-Premise
. I-Premise
34 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
003 I-Premise
and I-Premise
faith I-Premise
: I-Premise
b I-Premise
= I-Premise
0 I-Premise
. I-Premise
42 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
b I-Premise
= I-Premise
0 I-Premise
. I-Premise
76 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
013 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
significantly B-Premise
greater I-Premise
improvements I-Premise
for I-Premise
imcp I-Premise
patients I-Premise
were I-Premise
also I-Premise
observed I-Premise
for I-Premise
the I-Premise
secondary I-Premise
outcomes I-Premise
of I-Premise
symptom I-Premise
burden I-Premise
( I-Premise
b I-Premise
= I-Premise
- I-Premise
6 I-Premise
. I-Premise
56 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
and I-Premise
symptom I-Premise
- I-Premise
related I-Premise
distress I-Premise
( I-Premise
b I-Premise
= I-Premise
- I-Premise
0 I-Premise
. I-Premise
47 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
but I-Premise
not I-Premise
for I-Premise
anxiety I-Premise
, I-Premise
depression I-Premise
, I-Premise
or I-Premise
hopelessness I-Premise
. I-Premise
!LF! !LF!
at B-Premise
the I-Premise
2 I-Premise
- I-Premise
month I-Premise
follow I-Premise
- I-Premise
up I-Premise
assessment I-Premise
, I-Premise
the I-Premise
improvements I-Premise
observed I-Premise
for I-Premise
the I-Premise
imcp I-Premise
group I-Premise
were I-Premise
no I-Premise
longer I-Premise
significantly I-Premise
greater I-Premise
than I-Premise
those I-Premise
observed I-Premise
for I-Premise
the I-Premise
tm I-Premise
group I-Premise
. I-Premise
!LF! !LF!
imcp B-Claim
has I-Claim
clear I-Claim
short I-Claim
- I-Claim
term I-Claim
benefits I-Claim
for I-Claim
spiritual I-Claim
suffering I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
clinicians O
working O
with O
patients O
who O
have O
advanced O
cancer O
should O
consider O
imcp O
as O
an O
approach O
to O
enhance O
quality O
of O
life O
and O
spiritual O
well O
- O
being O
. O
!LF! !LF!
recently B-Claim
, I-Claim
the I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
gastric I-Claim
cancer I-Claim
by I-Claim
continuous I-Claim
infusion I-Claim
of I-Claim
5 I-Claim
- I-Claim
fluorouracil I-Claim
( I-Claim
5 I-Claim
- I-Claim
fu I-Claim
) I-Claim
with I-Claim
low I-Claim
- I-Claim
dose I-Claim
cisplatin I-Claim
( I-Claim
cddp I-Claim
) I-Claim
has I-Claim
improved I-Claim
efficacy I-Claim
without I-Claim
severe I-Claim
toxicities I-Claim
. I-Claim
!LF! !LF!
the B-Claim
possible I-Claim
effectiveness I-Claim
of I-Claim
5 I-Claim
- I-Claim
fu I-Claim
+ I-Claim
low I-Claim
- I-Claim
dose I-Claim
cddp I-Claim
for I-Claim
colorectal I-Claim
cancer I-Claim
( I-Claim
crc I-Claim
) I-Claim
is I-Claim
intriguing I-Claim
. I-Claim
!LF! !LF!
one O
hundred O
fifty O
- O
five O
patients O
with O
far O
- O
advanced O
crc O
including O
at O
least O
one O
measurable O
lesion O
were O
enrolled O
in O
a O
prospective O
randomized O
clinical O
trial O
funded O
by O
the O
japanese O
foundation O
for O
multidisciplinary O
treatment O
of O
cancer O
. O
!LF! !LF!
these O
patients O
were O
assigned O
to O
the O
two O
arms O
to O
assess O
the O
value O
of O
low O
- O
dose O
cddp O
when O
added O
to O
a O
continuous O
intravenous O
infusion O
of O
5 O
- O
fu O
at O
a O
dose O
of O
300 O
mg O
/ O
m O
( O
2 O
) O
/ O
24 O
hrs O
in O
a O
one O
- O
week O
cycle O
consisting O
of O
5 O
days O
of O
treatment O
and O
2 O
days O
of O
rest O
for O
at O
least O
12 O
weeks O
. O
!LF! !LF!
cd O
- O
dp O
was O
given O
intravenously O
at O
a O
dose O
of O
3 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
- O
5 O
and O
days O
8 O
- O
12 O
, O
and O
then O
at O
a O
dose O
of O
7 O
mg O
/ O
m O
( O
2 O
) O
twice O
a O
week O
. O
!LF! !LF!
three O
patients O
were O
excluded O
from O
the O
trial O
. O
!LF! !LF!
the B-Premise
response I-Premise
rate I-Premise
in I-Premise
the I-Premise
5 I-Premise
- I-Premise
fu I-Premise
+ I-Premise
low I-Premise
- I-Premise
dose I-Premise
cddp I-Premise
arm I-Premise
( I-Premise
n I-Premise
= I-Premise
75 I-Premise
) I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
that I-Premise
in I-Premise
the I-Premise
5 I-Premise
- I-Premise
fu I-Premise
arm I-Premise
( I-Premise
n I-Premise
= I-Premise
77 I-Premise
) I-Premise
( I-Premise
25 I-Premise
. I-Premise
3 I-Premise
% I-Premise
vs I-Premise
. I-Premise
11 I-Premise
. I-Premise
7 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
037 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
there B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
median I-Premise
overall I-Premise
survival I-Premise
time I-Premise
between I-Premise
the I-Premise
5 I-Premise
- I-Premise
fu I-Premise
+ I-Premise
low I-Premise
- I-Premise
dose I-Premise
cddp I-Premise
arm I-Premise
and I-Premise
the I-Premise
5 I-Premise
- I-Premise
fu I-Premise
arm I-Premise
( I-Premise
479 I-Premise
and I-Premise
491 I-Premise
days I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise
!LF! !LF!
grades B-Premise
3 I-Premise
/ I-Premise
4 I-Premise
toxicities I-Premise
occurred I-Premise
infrequently I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
the B-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
almost I-Premise
the I-Premise
same I-Premise
between I-Premise
the I-Premise
arms I-Premise
. O
!LF! !LF!
low B-Claim
- B-Claim
dose B-Claim
cddp I-Claim
improved I-Claim
the I-Claim
response I-Claim
rate I-Claim
while I-Claim
keeping I-Claim
toxicities I-Claim
within I-Claim
clinically I-Claim
acceptable I-Claim
limits I-Claim
. I-Claim
!LF! !LF!
however B-Claim
, I-Claim
this I-Claim
combined I-Claim
treatment I-Claim
did I-Claim
not I-Claim
confer I-Claim
a I-Claim
survival I-Claim
advantage I-Claim
over I-Claim
treatment I-Claim
with I-Claim
continuous I-Claim
infusion I-Claim
of I-Claim
5 I-Claim
- I-Claim
fu I-Claim
alone I-Claim
for I-Claim
patients I-Claim
with I-Claim
far I-Claim
- I-Claim
advanced I-Claim
crc I-Claim
"""" I-Claim
; I-Claim
"""" I-Claim
that I-Claim
might I-Claim
be I-Claim
attributable I-Claim
to I-Claim
the I-Claim
short I-Claim
cddp I-Claim
administration I-Claim
setting I-Claim
of I-Claim
12 I-Claim
weeks I-Claim
. I-Claim
!LF! !LF!
recent B-Claim
studies I-Claim
have I-Claim
shown I-Claim
that I-Claim
administering I-Claim
the I-Claim
aromatase I-Claim
inhibitor I-Claim
exemestane I-Claim
after I-Claim
2 I-Claim
- I-Claim
3 I-Claim
years I-Claim
of I-Claim
tamoxifen I-Claim
therapy I-Claim
significantly I-Claim
improves I-Claim
disease I-Claim
- I-Claim
free I-Claim
survival I-Claim
in I-Claim
postmenopausal I-Claim
women I-Claim
with I-Claim
primary I-Claim
breast I-Claim
cancer I-Claim
in I-Claim
comparison I-Claim
with I-Claim
standard I-Claim
5 I-Claim
- I-Claim
year I-Claim
tamoxifen I-Claim
treatment I-Claim
. I-Claim
!LF! !LF!
although O
many O
of O
the O
adverse O
effects O
associated O
with O
exemestane O
and O
tamoxifen O
have O
been O
analysed O
, O
there O
are O
no O
comparative O
data O
concerning O
body O
weight O
and O
body O
composition O
. O
!LF! !LF!
the O
aim O
of O
this O
randomised O
study O
was O
to O
evaluate O
the O
longitudinal O
changes O
in O
body O
composition O
and O
lipid O
profiles O
in O
postmenopausal O
women O
switched O
from O
tamoxifen O
to O
exemestane O
. O
!LF! !LF!
in O
total O
, O
60 O
overweight O
or O
obese O
postmenopausal O
patients O
were O
enrolled O
. O
!LF! !LF!
their O
anthropometric O
data O
, O
body O
composition O
, O
including O
fat O
mass O
( O
fm O
) O
and O
fat O
- O
free O
mass O
( O
ffm O
) O
, O
and O
lipid O
profiles O
, O
caloric O
intake O
and O
physical O
activity O
were O
assessed O
1 O
week O
before O
randomisation O
, O
and O
6 O
and O
12 O
months O
later O
. O
!LF! !LF!
in O
all O
, O
55 O
patients O
( O
27 O
on O
tamoxifen O
and O
28 O
on O
exemestane O
) O
completed O
the O
1 O
- O
year O
study O
period O
. O
!LF! !LF!
fat B-Premise
mass I-Premise
had I-Premise
significantly I-Premise
decreased I-Premise
by I-Premise
month I-Premise
12 I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
, I-Premise
but I-Premise
not I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
the B-Premise
between I-Premise
- I-Premise
group I-Premise
difference I-Premise
was I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
ffm I-Premise
/ I-Premise
fm I-Premise
ratio I-Premise
had I-Premise
significantly I-Premise
increased I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
group I-Premise
, I-Premise
but I-Premise
not I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
the B-Premise
between I-Premise
- I-Premise
group I-Premise
difference I-Premise
was I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
triglycerides B-Premise
and I-Premise
high I-Premise
- I-Premise
density I-Premise
lipoprotein I-Premise
cholesterol I-Premise
significantly I-Premise
decreased I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
, I-Premise
and O
low B-Premise
- B-Premise
density B-Premise
lipoprotein I-Premise
cholesterol I-Premise
significantly I-Premise
increased I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
group I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
1 I-Premise
- I-Premise
year I-Premise
study I-Premise
period I-Premise
. I-Premise
!LF! !LF!
our B-Claim
findings I-Claim
suggest I-Claim
that I-Claim
switching I-Claim
patients I-Claim
to I-Claim
adjuvant I-Claim
exemestane I-Claim
treatment I-Claim
after I-Claim
at I-Claim
least I-Claim
2 I-Claim
years I-Claim
of I-Claim
tamoxifen I-Claim
therapy I-Claim
may I-Claim
be I-Claim
associated I-Claim
with I-Claim
an I-Claim
advantage I-Claim
over I-Claim
continuing I-Claim
adjuvant I-Claim
tamoxifen I-Claim
treatment I-Claim
in I-Claim
terms I-Claim
of I-Claim
body I-Claim
composition I-Claim
. I-Claim
!LF! !LF!
anti B-Claim
- B-Claim
aromatase B-Claim
therapy I-Claim
is I-Claim
important I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
in I-Claim
postmenopausal I-Claim
women I-Claim
but O
they O
have O
effects O
on O
the O
bone O
mineral O
density O
( O
bmd O
) O
and O
osteoporosis O
. O
!LF! !LF!
cyclooxygenase B-Claim
- B-Claim
2 B-Claim
( I-Claim
cox I-Claim
- I-Claim
2 I-Claim
) I-Claim
inhibitors I-Claim
have I-Claim
been I-Claim
shown I-Claim
to I-Claim
be I-Claim
effective I-Claim
in I-Claim
chemoprevention I-Claim
in I-Claim
animal I-Claim
and I-Claim
clinical I-Claim
studies I-Claim
. I-Claim
!LF! !LF!
a O
proof O
of O
principle O
study O
was O
performed O
to O
investigate O
the O
efficacy O
of O
combing O
anti O
- O
aromatase O
therapy O
( O
exemestane O
) O
and O
cox O
- O
2 O
inhibitors O
neoadjuvantly O
. O
!LF! !LF!
the O
changes O
in O
the O
bmd O
, O
bone O
turnover O
proteins O
and O
quality O
- O
of O
- O
life O
( O
qol O
) O
were O
analyzed O
and O
presented O
here O
. O
!LF! !LF!
82 O
postmenopausal O
patients O
with O
histologically O
confirmed O
invasive O
hormone O
- O
sensitive O
breast O
cancers O
were O
included O
for O
the O
neoadjuvant O
therapy O
( O
nht O
) O
. O
!LF! !LF!
30 O
patients O
received O
exemestane O
( O
exe O
) O
25 O
mg O
daily O
and O
celecoxib O
( O
cxb O
) O
400 O
mg O
twice O
daily O
( O
group O
a O
) O
, O
24 O
patients O
received O
exe O
25 O
mg O
daily O
( O
group O
b O
) O
and O
28 O
patients O
received O
letrozole O
( O
let O
) O
2 O
. O
5 O
mg O
daily O
( O
group O
c O
) O
. O
!LF! !LF!
the O
same O
assigned O
treatment O
was O
intended O
to O
continue O
for O
2 O
years O
to O
study O
the O
changes O
in O
the O
bone O
metabolism O
. O
!LF! !LF!
bmd O
of O
48 O
patients O
were O
analyzed O
"""" O
; O
"""" O
23 O
belongs O
to O
group O
a O
, O
10 O
to O
group O
b O
and O
15 O
to O
group O
c O
. O
the O
serum O
bone O
turnover O
proteins O
bone O
- O
specific O
alkaline O
phosphatase O
( O
bap O
) O
and O
carboxyterminal O
crosslinked O
telopeptide O
of O
type O
i O
collagen O
( O
ictp O
) O
, O
were O
measured O
with O
commercially O
available O
test O
kits O
before O
treatment O
, O
3 O
months O
and O
15 O
months O
after O
treatment O
. O
!LF! !LF!
functional O
assessment O
of O
cancer O
therapy O
core O
questionnaire O
( O
fact O
- O
g O
) O
with O
its O
additional O
breast O
cancer O
subscale O
were O
performed O
at O
baseline O
, O
4 O
, O
8 O
, O
and O
12 O
weeks O
after O
nht O
. O
!LF! !LF!
difference B-Premise
between I-Premise
groups I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
007 I-Premise
) I-Premise
for I-Premise
bmd I-Premise
at I-Premise
femur I-Premise
was I-Premise
significant I-Premise
. I-Premise
!LF! !LF!
the B-Premise
changes I-Premise
of I-Premise
bmd I-Premise
in I-Premise
group I-Premise
b I-Premise
patients I-Premise
were I-Premise
significantly I-Premise
greater I-Premise
than I-Premise
patients I-Premise
in I-Premise
group I-Premise
a I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
011 I-Premise
, I-Premise
ci I-Premise
= I-Premise
0 I-Premise
. I-Premise
063 I-Premise
- I-Premise
0 I-Premise
. I-Premise
437 I-Premise
) I-Premise
, I-Premise
and I-Premise
group I-Premise
c I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
003 I-Premise
, I-Premise
ci I-Premise
= I-Premise
0 I-Premise
. I-Premise
146 I-Premise
- I-Premise
0 I-Premise
. I-Premise
620 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
mean I-Premise
bap I-Premise
increased I-Premise
from I-Premise
baseline I-Premise
in I-Premise
group I-Premise
b I-Premise
patients I-Premise
but I-Premise
decreased I-Premise
from I-Premise
baseline I-Premise
in I-Premise
group I-Premise
c I-Premise
patients I-Premise
at I-Premise
3 I-Premise
months I-Premise
and I-Premise
15 I-Premise
months I-Premise
. I-Premise
!LF! !LF!
no B-Premise
statistical I-Premise
significance I-Premise
was I-Premise
found I-Premise
in I-Premise
the I-Premise
fact I-Premise
- I-Premise
g I-Premise
scores I-Premise
and I-Premise
fact I-Premise
- I-Premise
b I-Premise
scores I-Premise
among I-Premise
different I-Premise
groups I-Premise
at I-Premise
baseline I-Premise
, I-Premise
week I-Premise
4 I-Premise
, I-Premise
week I-Premise
8 I-Premise
and I-Premise
week I-Premise
12 I-Premise
after I-Premise
nht I-Premise
. I-Premise
!LF! !LF!
the B-Premise
breast I-Premise
cancer I-Premise
subscale I-Premise
scores I-Premise
in I-Premise
group I-Premise
a I-Premise
patients I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
that I-Premise
of I-Premise
group I-Premise
c I-Premise
patients I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
021 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
after B-Premise
4 I-Premise
weeks I-Premise
of I-Premise
nht I-Premise
, I-Premise
negative I-Premise
changes I-Premise
of I-Premise
fact I-Premise
- I-Premise
b I-Premise
and I-Premise
fact I-Premise
- I-Premise
g I-Premise
scores I-Premise
were I-Premise
found I-Premise
in I-Premise
group I-Premise
b I-Premise
and I-Premise
c I-Premise
patients I-Premise
, I-Premise
but B-Premise
there I-Premise
were I-Premise
positive I-Premise
changes I-Premise
in I-Premise
group I-Premise
a I-Premise
patients I-Premise
. I-Premise
!LF! !LF!
significant B-Premise
differences I-Premise
of I-Premise
fact I-Premise
- I-Premise
b I-Premise
score I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
008 I-Premise
) I-Premise
and I-Premise
fact I-Premise
- I-Premise
g I-Premise
score I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
019 I-Premise
) I-Premise
were I-Premise
observed I-Premise
at I-Premise
that I-Premise
time I-Premise
point I-Premise
. I-Premise
!LF! !LF!
article O
from O
the O
special O
issue O
on O
targeted O
inhibitors O
. O
!LF! !LF!
hot O
flushes O
and O
night O
sweats O
( O
hfns O
) O
affect O
65 O
- O
85 O
% O
of O
women O
after O
breast O
cancer O
treatment O
"""" O
; O
"""" O
they O
are O
distressing O
, O
causing O
sleep O
problems O
and O
decreased O
quality O
of O
life O
. O
!LF! !LF!
hormone B-Claim
replacement I-Claim
therapy I-Claim
is I-Claim
often I-Claim
either I-Claim
undesirable I-Claim
or I-Claim
contraindicated I-Claim
. I-Claim
!LF! !LF!
safe B-Claim
, I-Claim
effective I-Claim
non I-Claim
- I-Claim
hormonal I-Claim
treatments I-Claim
are I-Claim
needed I-Claim
. I-Claim
!LF! !LF!
we O
investigated O
whether O
cognitive O
behavioural O
therapy O
( O
cbt O
) O
can O
help O
breast O
cancer O
survivors O
to O
effectively O
manage O
hfns O
. O
!LF! !LF!
in O
this O
randomised O
controlled O
trial O
, O
we O
recruited O
women O
from O
breast O
clinics O
in O
london O
, O
uk O
, O
who O
had O
problematic O
hfns O
( O
minimum O
ten O
problematic O
episodes O
a O
week O
) O
after O
breast O
- O
cancer O
treatment O
. O
!LF! !LF!
participants O
were O
randomly O
allocated O
to O
receive O
either O
usual O
care O
or O
usual O
care O
plus O
group O
cbt O
( O
1 O
: O
1 O
) O
. O
!LF! !LF!
randomisation O
was O
done O
in O
blocks O
of O
12 O
- O
20 O
participants O
, O
stratifying O
by O
age O
( O
younger O
than O
50 O
years O
, O
50 O
years O
or O
older O
) O
, O
and O
was O
done O
with O
a O
computer O
- O
generated O
sequence O
. O
!LF! !LF!
the O
trial O
statistician O
and O
researchers O
collecting O
outcome O
measures O
were O
masked O
to O
group O
allocation O
. O
!LF! !LF!
group O
cbt O
comprised O
one O
90 O
min O
session O
a O
week O
for O
6 O
weeks O
, O
and O
included O
psycho O
- O
education O
, O
paced O
breathing O
, O
and O
cognitive O
and O
behavioural O
strategies O
to O
manage O
hfns O
. O
!LF! !LF!
assessments O
were O
done O
at O
baseline O
, O
9 O
weeks O
, O
and O
26 O
weeks O
after O
randomisation O
. O
!LF! !LF!
the O
primary O
outcome O
was O
the O
adjusted O
mean O
difference O
in O
hfns O
problem O
rating O
( O
1 O
- O
10 O
) O
between O
cbt O
and O
usual O
care O
groups O
at O
9 O
weeks O
after O
randomisation O
. O
!LF! !LF!
analysis O
of O
the O
primary O
endpoint O
was O
done O
by O
modified O
intention O
to O
treat O
. O
!LF! !LF!
the O
trial O
is O
registered O
, O
isrctn13771934 O
, O
and O
was O
closed O
march O
15 O
, O
2011 O
. O
!LF! !LF!
between O
may O
5 O
, O
2009 O
, O
and O
aug O
27 O
, O
2010 O
, O
96 O
women O
were O
randomly O
allocated O
to O
group O
cbt O
( O
n O
= O
47 O
) O
or O
usual O
care O
( O
n O
= O
49 O
) O
. O
!LF! !LF!
group B-Premise
cbt I-Premise
significantly I-Premise
reduced I-Premise
hfns I-Premise
problem I-Premise
rating I-Premise
at I-Premise
9 I-Premise
weeks I-Premise
after I-Premise
randomisation I-Premise
compared I-Premise
with I-Premise
usual I-Premise
care I-Premise
( I-Premise
mean I-Premise
difference I-Premise
- I-Premise
1 I-Premise
· I-Premise
67 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
- I-Premise
2 I-Premise
· I-Premise
43 I-Premise
to I-Premise
- I-Premise
0 I-Premise
· I-Premise
91 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
0 I-Premise
· I-Premise
0001 I-Premise
) I-Premise
and I-Premise
improvements I-Premise
were I-Premise
maintained I-Premise
at I-Premise
26 I-Premise
weeks I-Premise
( I-Premise
mean I-Premise
difference I-Premise
- I-Premise
1 I-Premise
· I-Premise
76 I-Premise
, I-Premise
- I-Premise
2 I-Premise
· I-Premise
54 I-Premise
to I-Premise
- I-Premise
0 I-Premise
· I-Premise
99 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
0 I-Premise
· I-Premise
0001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
we B-Premise
recorded I-Premise
no I-Premise
cbt I-Premise
- I-Premise
related I-Premise
adverse I-Premise
events I-Premise
. I-Premise
!LF! !LF!
group B-Claim
cbt I-Claim
seems I-Claim
to I-Claim
be I-Claim
a I-Claim
safe I-Claim
and I-Claim
effective I-Claim
treatment I-Claim
for I-Claim
women I-Claim
who I-Claim
have I-Claim
problematic I-Claim
hfns I-Claim
after I-Claim
breast I-Claim
cancer I-Claim
treatment I-Claim
with I-Claim
additional I-Claim
benefits I-Claim
to I-Claim
mood I-Claim
, I-Claim
sleep I-Claim
, I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim
!LF! !LF!
the O
treatment O
could O
be O
incorporated O
into O
breast O
cancer O
survivorship O
programmes O
and O
delivered O
by O
trained O
breast O
cancer O
nurses O
. O
!LF! !LF!
most B-Claim
patients I-Claim
with I-Claim
advanced I-Claim
ovarian I-Claim
cancer I-Claim
develop I-Claim
recurrent I-Claim
disease I-Claim
. I-Claim
!LF! !LF!
for B-Claim
those I-Claim
patients I-Claim
who I-Claim
recur I-Claim
at I-Claim
least I-Claim
6 I-Claim
months I-Claim
after I-Claim
initial I-Claim
therapy I-Claim
, I-Claim
paclitaxel I-Claim
platinum I-Claim
has I-Claim
shown I-Claim
a I-Claim
modest I-Claim
survival I-Claim
advantage I-Claim
over I-Claim
platinum I-Claim
without I-Claim
paclitaxel I-Claim
"""" I-Claim
; I-Claim
"""" I-Claim
however B-Premise
, I-Premise
many I-Premise
patients I-Premise
develop I-Premise
clinically I-Premise
relevant I-Premise
neurotoxicity I-Premise
, I-Premise
frequently I-Premise
resulting I-Premise
in I-Premise
treatment I-Premise
discontinuation I-Premise
. O
!LF! !LF!
thus O
, O
an O
alternative O
regimen O
without O
significant O
neurotoxicity O
was O
evaluated O
by O
comparing O
gemcitabine O
plus O
carboplatin O
with O
single O
- O
agent O
carboplatin O
in O
platinum O
- O
sensitive O
recurrent O
ovarian O
cancer O
patients O
. O
!LF! !LF!
patients O
with O
platinum O
- O
sensitive O
recurrent O
ovarian O
cancer O
were O
randomly O
assigned O
to O
receive O
either O
gemcitabine O
plus O
carboplatin O
or O
carboplatin O
alone O
, O
every O
21 O
days O
. O
!LF! !LF!
the O
primary O
objective O
was O
to O
compare O
progression O
- O
free O
survival O
( O
pfs O
) O
. O
!LF! !LF!
three O
hundred O
fifty O
- O
six O
patients O
( O
178 O
gemcitabine O
plus O
carboplatin O
"""" O
; O
"""" O
178 O
carboplatin O
) O
were O
randomly O
assigned O
. O
!LF! !LF!
patients O
received O
a O
median O
of O
six O
cycles O
in O
both O
arms O
. O
!LF! !LF!
with B-Premise
a I-Premise
median I-Premise
follow I-Premise
- I-Premise
up I-Premise
of I-Premise
17 I-Premise
months I-Premise
, I-Premise
median I-Premise
pfs I-Premise
was I-Premise
8 I-Premise
. I-Premise
6 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
7 I-Premise
. I-Premise
9 I-Premise
to I-Premise
9 I-Premise
. I-Premise
7 I-Premise
months I-Premise
) I-Premise
for I-Premise
gemcitabine I-Premise
plus I-Premise
carboplatin I-Premise
and I-Premise
5 I-Premise
. I-Premise
8 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
5 I-Premise
. I-Premise
2 I-Premise
to I-Premise
7 I-Premise
. I-Premise
1 I-Premise
months I-Premise
) I-Premise
for I-Premise
carboplatin I-Premise
. I-Premise
!LF! !LF!
the B-Premise
hazard I-Premise
ration I-Premise
( I-Premise
hr I-Premise
) I-Premise
for I-Premise
pfs I-Premise
was I-Premise
0 I-Premise
. I-Premise
72 I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
58 I-Premise
to I-Premise
0 I-Premise
. I-Premise
90 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
0031 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
response B-Premise
rate I-Premise
was I-Premise
47 I-Premise
. I-Premise
2 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
39 I-Premise
. I-Premise
9 I-Premise
% I-Premise
to I-Premise
54 I-Premise
. I-Premise
5 I-Premise
% I-Premise
) I-Premise
for I-Premise
gemcitabine I-Premise
plus I-Premise
carboplatin I-Premise
and I-Premise
30 I-Premise
. I-Premise
9 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
24 I-Premise
. I-Premise
1 I-Premise
% I-Premise
to I-Premise
37 I-Premise
. I-Premise
7 I-Premise
% I-Premise
) I-Premise
for I-Premise
carboplatin I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
0016 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
hr I-Premise
for I-Premise
overall I-Premise
survival I-Premise
was I-Premise
0 I-Premise
. I-Premise
96 I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
75 I-Premise
to1 I-Premise
. I-Premise
23 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
7349 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
while B-Premise
myelosuppression I-Premise
was I-Premise
significantly I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
combination I-Premise
, I-Premise
sequelae I-Premise
such I-Premise
as I-Premise
febrile I-Premise
neutropenia I-Premise
or I-Premise
infections I-Premise
were I-Premise
uncommon I-Premise
. I-Premise
!LF! !LF!
no B-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
scores I-Premise
between I-Premise
arms I-Premise
were I-Premise
noted I-Premise
. I-Premise
!LF! !LF!
gemcitabine B-Claim
plus I-Claim
carboplatin I-Claim
significantly I-Claim
improves I-Claim
pfs I-Claim
and I-Claim
response I-Claim
rate I-Claim
without I-Claim
worsening I-Claim
quality I-Claim
of I-Claim
life I-Claim
for I-Claim
patients I-Claim
with I-Claim
platinum I-Claim
- I-Claim
sensitive I-Claim
recurrent I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
there O
are O
very O
few O
randomized O
controlled O
studies O
on O
exercise O
in O
cancer O
patients O
. O
!LF! !LF!
consequently O
, O
there O
are O
no O
guidelines O
available O
with O
regard O
to O
the O
exercises O
that O
can O
be O
recommended O
and O
difficulties O
are O
encountered O
in O
the O
clinical O
practice O
as O
to O
which O
exercise O
is O
more O
suitable O
to O
the O
patients O
. O
!LF! !LF!
the O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
impact O
of O
pilates O
exercises O
on O
physical O
performance O
, O
flexibility O
, O
fatigue O
, O
depression O
and O
quality O
of O
life O
in O
women O
who O
had O
been O
treated O
for O
breast O
cancer O
. O
!LF! !LF!
randomized O
controlled O
trial O
. O
!LF! !LF!
out O
patient O
group O
, O
department O
of O
physical O
medicine O
and O
rehabilitation O
and O
medical O
oncology O
department O
, O
university O
hospital O
. O
!LF! !LF!
fifty O
- O
two O
patients O
with O
breast O
cancer O
were O
divided O
into O
either O
pilates O
exercise O
( O
group O
1 O
) O
and O
control O
group O
( O
group O
2 O
) O
. O
!LF! !LF!
patients O
in O
group O
1 O
performed O
pilates O
and O
home O
exercises O
and O
patients O
in O
group O
2 O
performed O
only O
home O
exercises O
. O
!LF! !LF!
pilates O
exercise O
sessions O
were O
performed O
three O
times O
a O
week O
for O
a O
period O
of O
eight O
weeks O
in O
the O
rehabilitation O
unit O
. O
!LF! !LF!
subjects O
were O
assessed O
before O
and O
after O
rehabilitation O
program O
, O
with O
respect O
to O
, O
6 O
- O
min O
walk O
test O
( O
6mwt O
) O
, O
modified O
sit O
and O
reach O
test O
, O
brief O
fatigue O
inventory O
( O
bfi O
) O
, O
beck O
depression O
index O
( O
bdi O
) O
and O
the O
european O
organisation O
for O
research O
and O
treatment O
of O
cancer O
quality O
of O
life O
c30 O
( O
eortc O
qlq O
- O
c30 O
) O
and O
eortc O
qlq O
br23 O
. O
!LF! !LF!
after B-Premise
the I-Premise
exercise I-Premise
program I-Premise
, I-Premise
improvements I-Premise
were I-Premise
observed I-Premise
in I-Premise
group I-Premise
1 I-Premise
in I-Premise
6 I-Premise
- I-Premise
minute I-Premise
walk I-Premise
test I-Premise
, I-Premise
bdi I-Premise
, I-Premise
eortc I-Premise
qlq I-Premise
- I-Premise
c30 I-Premise
functional I-Premise
, I-Premise
and I-Premise
eortc I-Premise
qlq I-Premise
- I-Premise
c30 I-Premise
br23 I-Premise
functional I-Premise
scores I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
in O
contrast O
, O
no B-Premise
significant I-Premise
improvement I-Premise
was I-Premise
observed I-Premise
in I-Premise
group I-Premise
2 I-Premise
after I-Premise
the I-Premise
exercise I-Premise
program I-Premise
in I-Premise
any I-Premise
of I-Premise
parameters I-Premise
in I-Premise
comparison I-Premise
to I-Premise
the I-Premise
pre I-Premise
- I-Premise
exercise I-Premise
period I-Premise
( I-Premise
p I-Premise
> I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
when B-Premise
the I-Premise
two I-Premise
exercise I-Premise
groups I-Premise
were I-Premise
compared I-Premise
, I-Premise
there I-Premise
were I-Premise
significant I-Premise
differences I-Premise
in I-Premise
6mwt I-Premise
in I-Premise
pilates I-Premise
- I-Premise
exercise I-Premise
group I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
pilates B-Claim
exercises I-Claim
are I-Claim
effective I-Claim
and I-Claim
safe I-Claim
in I-Claim
female I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
there B-Claim
is I-Claim
a I-Claim
need I-Claim
for I-Claim
further I-Claim
studies I-Claim
so I-Claim
that I-Claim
its I-Claim
effect I-Claim
can I-Claim
be I-Claim
confirmed I-Claim
. I-Claim
!LF! !LF!
this O
study O
addressed O
the O
effects O
of O
pilates O
exercise O
, O
as O
a O
new O
approach O
, O
on O
functional O
capacity O
, O
fatigue O
, O
depression O
and O
quality O
of O
life O
in O
breast O
cancer O
patients O
in O
whom O
there O
are O
doubts O
regarding O
the O
efficacy O
and O
usefulness O
of O
the O
exercise O
. O
!LF! !LF!
treatment O
- O
induced O
arm O
lymphoedema O
is O
a O
common O
and O
distressing O
complication O
of O
curative O
surgery O
and O
radiotherapy O
for O
early O
breast O
cancer O
. O
!LF! !LF!
a O
number O
of O
studies O
testing O
alpha O
- O
tocopherol O
( O
vitamin O
e O
) O
and O
pentoxifylline O
suggest O
evidence O
of O
clinical O
regression O
of O
superficial O
radiation O
- O
induced O
fibrosis O
but O
there O
is O
only O
very O
limited O
evidence O
from O
randomised O
trials O
. O
!LF! !LF!
arm O
lymphoedema O
after O
lymphatic O
radiotherapy O
and O
surgery O
has O
been O
used O
in O
the O
present O
study O
as O
a O
clinical O
system O
for O
testing O
these O
drugs O
in O
a O
double O
- O
blind O
placebo O
- O
controlled O
randomised O
phase O
ii O
trial O
. O
!LF! !LF!
sixty O
- O
eight O
eligible O
research O
volunteers O
with O
a O
minimum O
20 O
% O
increase O
in O
arm O
volume O
at O
a O
median O
15 O
. O
5 O
years O
( O
range O
2 O
- O
41 O
) O
after O
axillary O
/ O
supraclavicular O
radiotherapy O
( O
plus O
axillary O
surgery O
in O
51 O
/ O
68 O
( O
75 O
% O
) O
cases O
) O
were O
randomised O
to O
active O
drugs O
or O
placebo O
. O
!LF! !LF!
all O
volunteers O
were O
given O
dl O
- O
alpha O
tocopheryl O
acetate O
500 O
mg O
twice O
a O
day O
orally O
plus O
pentoxifylline O
400 O
mg O
twice O
a O
day O
orally O
, O
or O
corresponding O
placebos O
, O
for O
6 O
months O
. O
!LF! !LF!
the O
primary O
endpoint O
was O
volume O
of O
the O
ipsilateral O
limb O
measured O
opto O
- O
electronically O
using O
a O
perometer O
and O
expressed O
as O
a O
percentage O
of O
the O
contralateral O
limb O
volume O
. O
!LF! !LF!
at B-Premise
12 I-Premise
months I-Premise
post I-Premise
- I-Premise
randomisation I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
treatment I-Premise
and I-Premise
control I-Premise
groups I-Premise
in I-Premise
terms I-Premise
of I-Premise
arm I-Premise
volume I-Premise
. I-Premise
!LF! !LF!
absolute B-Premise
change I-Premise
in I-Premise
arm I-Premise
volume I-Premise
at I-Premise
12 I-Premise
months I-Premise
was I-Premise
2 I-Premise
. I-Premise
5 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
- I-Premise
0 I-Premise
. I-Premise
40 I-Premise
to I-Premise
5 I-Premise
. I-Premise
3 I-Premise
) I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
compared I-Premise
to I-Premise
1 I-Premise
. I-Premise
2 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
- I-Premise
2 I-Premise
. I-Premise
8 I-Premise
to I-Premise
5 I-Premise
. I-Premise
1 I-Premise
) I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise
!LF! !LF!
the B-Premise
difference I-Premise
in I-Premise
mean I-Premise
volume I-Premise
change I-Premise
between I-Premise
randomisation I-Premise
groups I-Premise
at I-Premise
12 I-Premise
months I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
6 I-Premise
) I-Premise
, I-Premise
- I-Premise
1 I-Premise
. I-Premise
3 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
- I-Premise
6 I-Premise
. I-Premise
1 I-Premise
to I-Premise
3 I-Premise
. I-Premise
5 I-Premise
) I-Premise
, I-Premise
nor I-Premise
was I-Premise
there I-Premise
a I-Premise
significant I-Premise
difference I-Premise
in I-Premise
response I-Premise
at I-Premise
6 I-Premise
months I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
7 I-Premise
) I-Premise
, I-Premise
where I-Premise
mean I-Premise
change I-Premise
in I-Premise
arm I-Premise
volume I-Premise
from I-Premise
baseline I-Premise
in I-Premise
the I-Premise
treatment I-Premise
and I-Premise
placebo I-Premise
groups I-Premise
was I-Premise
- I-Premise
2 I-Premise
. I-Premise
3 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
- I-Premise
7 I-Premise
. I-Premise
9 I-Premise
to I-Premise
3 I-Premise
. I-Premise
4 I-Premise
) I-Premise
and I-Premise
- I-Premise
1 I-Premise
. I-Premise
1 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
- I-Premise
3 I-Premise
. I-Premise
9 I-Premise
to I-Premise
1 I-Premise
. I-Premise
7 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
randomised I-Premise
groups I-Premise
in I-Premise
terms I-Premise
of I-Premise
secondary I-Premise
endpoints I-Premise
, I-Premise
including I-Premise
tissue I-Premise
induration I-Premise
( I-Premise
fibrosis I-Premise
) I-Premise
in I-Premise
the I-Premise
irradiated I-Premise
breast I-Premise
or I-Premise
chest I-Premise
wall I-Premise
, I-Premise
pectoral I-Premise
fold I-Premise
or I-Premise
supraclavicular I-Premise
fossa I-Premise
, I-Premise
change I-Premise
in I-Premise
photographic I-Premise
breast I-Premise
/ I-Premise
chest I-Premise
wall I-Premise
appearance I-Premise
or I-Premise
patient I-Premise
self I-Premise
- I-Premise
assessment I-Premise
of I-Premise
function I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
at I-Premise
either I-Premise
6 I-Premise
or I-Premise
12 I-Premise
months I-Premise
. I-Premise
!LF! !LF!
the B-Claim
study I-Claim
fails I-Claim
to I-Claim
demonstrate I-Claim
efficacy I-Claim
of I-Claim
dl I-Claim
- I-Claim
alpha I-Claim
tocopheryl I-Claim
acetate I-Claim
plus I-Claim
pentoxifylline I-Claim
in I-Claim
patients I-Claim
with I-Claim
arm I-Claim
lymphoedema I-Claim
following I-Claim
axillary I-Claim
surgery I-Claim
and I-Claim
lymphatic I-Claim
radiotherapy I-Claim
, I-Claim
nor I-Claim
does I-Claim
it I-Claim
suggest I-Claim
any I-Claim
benefits I-Claim
of I-Claim
these I-Claim
drugs I-Claim
in I-Claim
radiation I-Claim
- I-Claim
induced I-Claim
induration I-Claim
( I-Claim
fibrosis I-Claim
) I-Claim
in I-Claim
the I-Claim
breast I-Claim
, I-Claim
chest I-Claim
wall I-Claim
, I-Claim
pectoral I-Claim
fold I-Claim
, I-Claim
axilla I-Claim
or I-Claim
supraclavicular I-Claim
fossa I-Claim
. I-Claim
!LF! !LF!
many O
patients O
with O
advanced O
ovarian O
cancer O
will O
develop O
recurrent O
disease O
. O
!LF! !LF!
for B-Premise
those I-Premise
patients I-Premise
who I-Premise
have I-Premise
recurrence I-Premise
of I-Premise
disease I-Premise
at I-Premise
least I-Premise
6 I-Premise
months I-Premise
after I-Premise
initial I-Premise
therapy I-Premise
, I-Premise
the I-Premise
paclitaxel I-Premise
- I-Premise
platinum I-Premise
combination I-Premise
has I-Premise
been I-Premise
shown I-Premise
to I-Premise
be I-Premise
a I-Premise
superior I-Premise
treatment I-Premise
to I-Premise
platinum I-Premise
monotherapy I-Premise
. I-Premise
!LF! !LF!
however B-Claim
, I-Claim
many I-Claim
patients I-Claim
develop I-Claim
clinically I-Claim
relevant I-Claim
neurotoxicity I-Claim
, I-Claim
frequently I-Claim
resulting I-Claim
in I-Claim
treatment I-Claim
discontinuation I-Claim
. I-Claim
!LF! !LF!
the O
efficacy O
and O
safety O
of O
an O
alternative O
regimen O
that O
does O
not O
show O
significant O
neurotoxicity O
were O
evaluated O
by O
comparing O
gemcitabine O
- O
carboplatin O
with O
carboplatin O
in O
platinum O
- O
sensitive O
recurrent O
ovarian O
cancer O
patients O
in O
a O
gynecologic O
cancer O
intergroup O
trial O
of O
the O
arbeitsgemeinschaft O
gynakologische O
onkologie O
ovarian O
cancer O
study O
group O
, O
the O
national O
cancer O
institute O
of O
canada O
clinical O
trials O
group O
, O
and O
the O
european O
organisation O
for O
research O
and O
treatment O
of O
cancer O
gynaecological O
cancer O
group O
. O
!LF! !LF!
participants O
with O
recurrent O
platinum O
- O
sensitive O
ovarian O
cancer O
were O
randomly O
assigned O
to O
receive O
either O
gemcitabine O
- O
carboplatin O
or O
carboplatin O
every O
21 O
days O
. O
!LF! !LF!
the O
primary O
objective O
was O
to O
compare O
progression O
- O
free O
survival O
( O
pfs O
) O
between O
the O
groups O
. O
!LF! !LF!
from O
september O
1999 O
to O
april O
2002 O
, O
356 O
patients O
( O
178 O
participants O
received O
gemcitabine O
- O
carboplatin O
, O
178 O
received O
carboplatin O
only O
) O
were O
randomized O
to O
treatment O
. O
!LF! !LF!
patients O
received O
six O
cycles O
of O
either O
gemcitabine O
- O
carboplatin O
or O
carboplatin O
. O
!LF! !LF!
with B-Premise
a I-Premise
median I-Premise
follow I-Premise
- I-Premise
up I-Premise
of I-Premise
17 I-Premise
months I-Premise
, I-Premise
median I-Premise
pfs I-Premise
was I-Premise
8 I-Premise
. I-Premise
6 I-Premise
months I-Premise
for I-Premise
gemcitabine I-Premise
- I-Premise
carboplatin I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
ci I-Premise
] I-Premise
7 I-Premise
. I-Premise
9 I-Premise
- I-Premise
9 I-Premise
. I-Premise
7 I-Premise
months I-Premise
) I-Premise
and I-Premise
5 I-Premise
. I-Premise
8 I-Premise
months I-Premise
for I-Premise
carboplatin I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
5 I-Premise
. I-Premise
2 I-Premise
- I-Premise
7 I-Premise
. I-Premise
1 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
hr I-Premise
] I-Premise
0 I-Premise
. I-Premise
72 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
. I-Premise
58 I-Premise
- I-Premise
0 I-Premise
. I-Premise
90 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0032 I-Premise
] I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
response I-Premise
rate I-Premise
for I-Premise
the I-Premise
gemcitabine I-Premise
- I-Premise
carboplatin I-Premise
group I-Premise
was I-Premise
47 I-Premise
. I-Premise
2 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
39 I-Premise
. I-Premise
9 I-Premise
- I-Premise
54 I-Premise
. I-Premise
5 I-Premise
% I-Premise
) I-Premise
and I-Premise
30 I-Premise
. I-Premise
9 I-Premise
% I-Premise
for I-Premise
carboplatin I-Premise
group I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
24 I-Premise
. I-Premise
1 I-Premise
- I-Premise
37 I-Premise
. I-Premise
7 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0016 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
hr I-Premise
for I-Premise
overall I-Premise
survival I-Premise
was I-Premise
0 I-Premise
. I-Premise
96 I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
. I-Premise
75 I-Premise
- I-Premise
1 I-Premise
. I-Premise
23 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
7349 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
treated I-Premise
with I-Premise
gemcitabine I-Premise
- I-Premise
carboplatin I-Premise
reported I-Premise
significantly I-Premise
faster I-Premise
palliation I-Premise
of I-Premise
abdominal I-Premise
symptoms I-Premise
and I-Premise
a I-Premise
significantly I-Premise
improved I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise
!LF! !LF!
gemcitabine B-Claim
- B-Claim
carboplatin B-Claim
treatment I-Claim
significantly I-Claim
improves I-Claim
the I-Claim
pfs I-Claim
of I-Claim
patients I-Claim
with I-Claim
platinum I-Claim
- I-Claim
sensitive I-Claim
recurrent I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
the O
combination O
of O
cisplatin O
and O
etoposide O
( O
pe O
) O
has O
been O
a O
standard O
treatment O
for O
patients O
with O
poor O
- O
prognosis O
small O
cell O
lung O
cancer O
( O
sclc O
) O
. O
!LF! !LF!
this O
non O
- O
inferiority O
design O
trial O
aimed O
to O
determine O
whether O
the O
combination O
of O
gemcitabine O
and O
carboplatin O
( O
gc O
) O
results O
in O
similar O
survival O
but O
is O
less O
toxic O
with O
better O
quality O
of O
life O
. O
!LF! !LF!
previously O
untreated O
patients O
with O
sclc O
with O
extensive O
disease O
or O
limited O
stage O
with O
poor O
prognostic O
factors O
were O
randomly O
assigned O
to O
six O
3 O
- O
weekly O
cycles O
of O
gc O
or O
pe O
. O
!LF! !LF!
241 O
patients O
( O
121 O
gc O
, O
120 O
pe O
) O
were O
recruited O
, O
of O
which O
216 O
( O
90 O
% O
) O
had O
died O
. O
!LF! !LF!
there B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
overall I-Premise
survival I-Premise
( I-Premise
hr I-Premise
1 I-Premise
. I-Premise
01 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
. I-Premise
77 I-Premise
to I-Premise
1 I-Premise
. I-Premise
32 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
median B-Premise
survival I-Premise
with I-Premise
gc I-Premise
and I-Premise
pe I-Premise
was I-Premise
8 I-Premise
. I-Premise
0 I-Premise
and I-Premise
8 I-Premise
. I-Premise
1 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
median B-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
was I-Premise
5 I-Premise
. I-Premise
9 I-Premise
months I-Premise
with I-Premise
gc I-Premise
and I-Premise
6 I-Premise
. I-Premise
3 I-Premise
months I-Premise
with I-Premise
pe I-Premise
. I-Premise
!LF! !LF!
grade B-Premise
3 I-Premise
or I-Premise
4 I-Premise
myelosuppressions I-Premise
were I-Premise
more I-Premise
frequent I-Premise
with I-Premise
gc I-Premise
( I-Premise
anaemia I-Premise
: I-Premise
14 I-Premise
% I-Premise
gc I-Premise
vs I-Premise
2 I-Premise
% I-Premise
pe I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
leucopenia I-Premise
: I-Premise
32 I-Premise
% I-Premise
gc I-Premise
vs I-Premise
13 I-Premise
% I-Premise
pe I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
thrombocytopenia I-Premise
: I-Premise
22 I-Premise
% I-Premise
gc I-Premise
vs I-Premise
4 I-Premise
% I-Premise
pe I-Premise
) I-Premise
, I-Premise
but B-Premise
these I-Premise
were I-Premise
not I-Premise
associated I-Premise
with I-Premise
increased I-Premise
hospital I-Premise
admissions I-Premise
, I-Premise
infections I-Premise
or I-Premise
fatalities I-Premise
. I-Premise
!LF! !LF!
grade B-Premise
2 I-Premise
- I-Premise
3 I-Premise
alopecia I-Premise
( I-Premise
68 I-Premise
% I-Premise
pe I-Premise
vs I-Premise
17 I-Premise
% I-Premise
gc I-Premise
) I-Premise
and I-Premise
nausea I-Premise
( I-Premise
43 I-Premise
% I-Premise
pe I-Premise
vs I-Premise
26 I-Premise
% I-Premise
gc I-Premise
) I-Premise
were I-Premise
more I-Premise
frequent I-Premise
with I-Premise
pe I-Premise
. I-Premise
!LF! !LF!
patients O
given O
gc O
received O
more O
chemotherapy O
as O
outpatients O
( O
89 O
% O
gc O
vs O
66 O
% O
pe O
of O
treatment O
cycles O
) O
. O
!LF! !LF!
in B-Premise
qol I-Premise
questionnaires I-Premise
, I-Premise
more I-Premise
patients I-Premise
receiving I-Premise
pe I-Premise
reported I-Premise
being I-Premise
upset I-Premise
by I-Premise
hair I-Premise
loss I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
004 I-Premise
) I-Premise
and I-Premise
impaired I-Premise
cognitive I-Premise
functioning I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
04 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
gc B-Claim
is I-Claim
as I-Claim
effective I-Claim
as I-Claim
pe I-Claim
in I-Claim
terms I-Claim
of I-Claim
overall I-Claim
survival I-Claim
and I-Claim
progression I-Claim
- I-Claim
free I-Claim
survival I-Claim
and I-Claim
has I-Claim
a I-Claim
toxicity I-Claim
profile I-Claim
more I-Claim
acceptable I-Claim
to I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
to O
assess O
the O
efficacy O
of O
a O
novel O
coloplasty O
colonic O
pouch O
design O
in O
optimizing O
bowel O
function O
after O
ultralow O
anterior O
resection O
. O
!LF! !LF!
a B-Claim
colonic I-Claim
j I-Claim
- I-Claim
pouch I-Claim
may I-Claim
reduce I-Claim
excessive I-Claim
stool I-Claim
frequency I-Claim
and I-Claim
incontinence I-Claim
after I-Claim
anterior I-Claim
resection I-Claim
, I-Claim
but I-Claim
at I-Claim
the I-Claim
risk I-Claim
of I-Claim
evacuation I-Claim
problems I-Claim
. I-Claim
!LF! !LF!
experimental B-Claim
surgery I-Claim
on I-Claim
pigs I-Claim
has I-Claim
suggested I-Claim
that I-Claim
a I-Claim
coloplasty I-Claim
pouch I-Claim
( I-Claim
cp I-Claim
) I-Claim
may I-Claim
be I-Claim
a I-Claim
useful I-Claim
alternative I-Claim
. O
!LF! !LF!
although O
cp O
has O
recently O
been O
shown O
to O
be O
feasible O
in O
patients O
, O
there O
is O
no O
randomized O
controlled O
trial O
comparing O
bowel O
function O
with O
the O
j O
- O
pouch O
. O
!LF! !LF!
after O
anterior O
resection O
for O
cancer O
, O
patients O
were O
allocated O
to O
either O
j O
- O
pouch O
or O
cp O
- O
anal O
anastomoses O
. O
!LF! !LF!
continence O
scoring O
, O
anorectal O
manometry O
, O
and O
endoanal O
ultrasound O
assessments O
were O
made O
before O
surgery O
. O
!LF! !LF!
all O
complications O
were O
recorded O
, O
and O
these O
preoperative O
assessments O
were O
repeated O
at O
4 O
months O
. O
!LF! !LF!
the O
assessments O
were O
repeated O
again O
at O
1 O
year O
, O
and O
a O
quality O
of O
life O
questionnaire O
was O
added O
. O
!LF! !LF!
eighty O
- O
eight O
patients O
were O
recruited O
from O
october O
1998 O
to O
april O
2000 O
. O
!LF! !LF!
both O
groups O
were O
well O
matched O
for O
age O
, O
gender O
, O
staging O
, O
adjuvant O
therapy O
, O
and O
mean O
follow O
- O
up O
. O
!LF! !LF!
there O
were O
no O
differences O
in O
the O
intraoperative O
time O
and O
hospital O
stay O
. O
!LF! !LF!
cp B-Premise
resulted I-Premise
in I-Premise
more I-Premise
anastomotic I-Premise
leaks I-Premise
. I-Premise
!LF! !LF!
at B-Premise
4 I-Premise
months I-Premise
, I-Premise
j I-Premise
- I-Premise
pouch I-Premise
patients I-Premise
had I-Premise
10 I-Premise
. I-Premise
3 I-Premise
% I-Premise
less I-Premise
stool I-Premise
fragmentation I-Premise
but I-Premise
poorer I-Premise
stool I-Premise
deferment I-Premise
and I-Premise
more I-Premise
nocturnal I-Premise
leakage I-Premise
. I-Premise
!LF! !LF!
however O
, O
there B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
bowel I-Premise
function I-Premise
, I-Premise
continence I-Premise
score I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
anorectal I-Premise
manometry I-Premise
and I-Premise
endoanal I-Premise
ultrasound I-Premise
findings I-Premise
. I-Premise
!LF! !LF!
coloplasty B-Claim
pouches I-Claim
resulted I-Claim
in I-Claim
more I-Claim
anastomotic I-Claim
leaks I-Claim
and I-Claim
minimal I-Claim
differences I-Claim
in I-Claim
bowel I-Claim
function I-Claim
. I-Claim
!LF! !LF!
at O
present O
, O
the B-Claim
j I-Claim
- I-Claim
pouch I-Claim
remains I-Claim
the I-Claim
benchmark I-Claim
for I-Claim
routine I-Claim
clinical I-Claim
practice I-Claim
, I-Claim
and O
due B-Claim
care I-Claim
( I-Claim
including I-Claim
defunctioning I-Claim
stoma I-Claim
) I-Claim
should I-Claim
be I-Claim
exercised I-Claim
in I-Claim
situations I-Claim
requiring I-Claim
cp I-Claim
. I-Claim
!LF! !LF!
from O
1984 O
to O
1989 O
, O
the O
swiss O
group O
for O
clinical O
cancer O
research O
( O
sakk O
) O
performed O
a O
randomized O
phase O
iii O
trial O
comparing O
early O
versus O
late O
alternating O
chemotherapy O
in O
patients O
with O
small O
- O
cell O
lung O
cancer O
. O
!LF! !LF!
406 O
eligible O
patients O
were O
entered O
into O
the O
trial O
. O
!LF! !LF!
regimen O
a O
consisted O
of O
pav O
( O
cisplatin O
, O
adriamycin O
, O
vp O
16 O
- O
213 O
, O
and O
regimen O
b O
of O
cymoc O
( O
cyclophosphamide O
, O
methotrexate O
, O
oncovin O
, O
ccnu O
) O
. O
!LF! !LF!
cycles O
were O
repeated O
as O
rapidly O
as O
possible O
. O
!LF! !LF!
patients O
were O
randomized O
to O
receive O
either O
ababab O
( O
early O
alternating O
chemotherapy O
) O
or O
aaabbb O
( O
late O
alternating O
chemotherapy O
) O
. O
!LF! !LF!
after O
six O
cycles O
patients O
with O
limited O
disease O
in O
complete O
or O
partial O
remission O
and O
those O
with O
extensive O
disease O
in O
complete O
remission O
received O
irradiation O
to O
the O
primary O
( O
45 O
gy O
) O
and O
the O
cns O
( O
36 O
gy O
) O
. O
!LF! !LF!
the B-Premise
overall I-Premise
remission I-Premise
rate I-Premise
was I-Premise
87 I-Premise
% I-Premise
with I-Premise
31 I-Premise
% I-Premise
complete I-Premise
remissions I-Premise
. I-Premise
!LF! !LF!
the B-Premise
median I-Premise
survival I-Premise
of I-Premise
all I-Premise
406 I-Premise
eligible I-Premise
patients I-Premise
was I-Premise
346 I-Premise
days I-Premise
with I-Premise
15 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
alive I-Premise
at I-Premise
two I-Premise
years I-Premise
. I-Premise
!LF! !LF!
the B-Premise
overall I-Premise
remission I-Premise
rate I-Premise
, I-Premise
the I-Premise
rate I-Premise
of I-Premise
complete I-Premise
remission I-Premise
, I-Premise
the I-Premise
median I-Premise
survival I-Premise
and I-Premise
the I-Premise
rate I-Premise
of I-Premise
long I-Premise
- I-Premise
term I-Premise
survival I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
in I-Premise
the I-Premise
two I-Premise
treatment I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
in B-Premise
limited I-Premise
disease I-Premise
the I-Premise
estimated I-Premise
percentages I-Premise
of I-Premise
survival I-Premise
at I-Premise
2 I-Premise
years I-Premise
were I-Premise
33 I-Premise
% I-Premise
in I-Premise
the I-Premise
early I-Premise
and I-Premise
24 I-Premise
% I-Premise
in I-Premise
the I-Premise
late I-Premise
alternating I-Premise
chemotherapy I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
with I-Premise
extensive I-Premise
disease I-Premise
survived I-Premise
significantly I-Premise
longer I-Premise
with I-Premise
late I-Premise
alternating I-Premise
chemotherapy I-Premise
than I-Premise
on I-Premise
the I-Premise
early I-Premise
alternation I-Premise
regimen I-Premise
( I-Premise
median I-Premise
survival I-Premise
336 I-Premise
days I-Premise
versus I-Premise
301 I-Premise
days I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
in B-Premise
the I-Premise
latter I-Premise
patients I-Premise
the I-Premise
received I-Premise
dose I-Premise
intensities I-Premise
( I-Premise
rdi I-Premise
) I-Premise
of I-Premise
cisplatin I-Premise
, I-Premise
adriamycin I-Premise
and I-Premise
etoposide I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
late I-Premise
- I-Premise
alternation I-Premise
arm I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
treated I-Premise
with I-Premise
early I-Premise
alternating I-Premise
chemotherapy I-Premise
rated I-Premise
their I-Premise
tumor I-Premise
symptoms I-Premise
, I-Premise
functional I-Premise
states I-Premise
, I-Premise
fatigue I-Premise
/ I-Premise
malaise I-Premise
and I-Premise
restriction I-Premise
of I-Premise
social I-Premise
activity I-Premise
significantly I-Premise
better I-Premise
, I-Premise
reflecting I-Premise
an I-Premise
improved I-Premise
subjective I-Premise
adjustment I-Premise
. I-Premise
!LF! !LF!
alternating B-Claim
chemotherapy I-Claim
with I-Claim
pav I-Claim
- I-Claim
cymoc I-Claim
plus I-Claim
consolidating I-Claim
radiotherapy I-Claim
is I-Claim
a I-Claim
feasible I-Claim
and I-Claim
effective I-Claim
treatment I-Claim
for I-Claim
small I-Claim
- I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
, I-Claim
with I-Claim
acceptable I-Claim
toxicity I-Claim
. I-Claim
!LF! !LF!
whereas O
patients B-Claim
with I-Claim
early I-Claim
alternating I-Claim
chemotherapy I-Claim
achieve I-Claim
a I-Claim
better I-Claim
subjective I-Claim
adjustment I-Claim
, I-Claim
late B-Claim
alternating I-Claim
chemotherapy I-Claim
allows I-Claim
for I-Claim
a I-Claim
higher I-Claim
rdi I-Claim
of I-Claim
cisplatin I-Claim
, I-Claim
adriamycin I-Claim
and I-Claim
etoposide I-Claim
, I-Claim
which I-Claim
results I-Claim
in I-Claim
a I-Claim
significantly I-Claim
longer I-Claim
median I-Claim
survival I-Claim
of I-Claim
patients I-Claim
with I-Claim
extensive I-Claim
disease I-Claim
. I-Claim
!LF! !LF!
assess O
toxicity O
and O
efficacy O
of O
cisplatin O
( O
cis O
) O
doublet O
combinations O
in O
advanced O
and O
recurrent O
cervical O
carcinoma O
. O
!LF! !LF!
patients O
were O
randomly O
assigned O
to O
paclitaxel O
135 O
mg O
/ O
m O
( O
2 O
) O
over O
24 O
hours O
plus O
cis O
50 O
mg O
/ O
m O
( O
2 O
) O
day O
2 O
every O
3 O
weeks O
( O
pc O
, O
reference O
arm O
) O
"""" O
; O
"""" O
vinorelbine O
30 O
mg O
/ O
m O
( O
2 O
) O
days O
1 O
and O
8 O
plus O
cis O
50 O
mg O
/ O
m O
( O
2 O
) O
day O
1 O
every O
3 O
weeks O
( O
vc O
) O
"""" O
; O
"""" O
gemcitabine O
1 O
, O
000 O
mg O
/ O
m O
( O
2 O
) O
day O
1 O
and O
8 O
plus O
cis O
50 O
mg O
/ O
m O
( O
2 O
) O
day O
1 O
every O
3 O
weeks O
( O
gc O
) O
"""" O
; O
"""" O
or O
topotecan O
0 O
. O
75 O
mg O
/ O
m O
( O
2 O
) O
days O
1 O
, O
2 O
, O
and O
3 O
plus O
cis O
50 O
mg O
/ O
m O
( O
2 O
) O
day O
1 O
every O
3 O
weeks O
( O
tc O
) O
. O
!LF! !LF!
survival O
was O
the O
primary O
end O
point O
with O
a O
33 O
% O
improvement O
relative O
to O
pc O
considered O
important O
( O
85 O
% O
power O
, O
alpha O
= O
5 O
% O
) O
. O
!LF! !LF!
quality O
- O
of O
- O
life O
data O
were O
prospectively O
collected O
. O
!LF! !LF!
a O
total O
of O
513 O
patients O
were O
enrolled O
when O
a O
planned O
interim O
analysis O
recommended O
early O
closure O
for O
futility O
. O
!LF! !LF!
the B-Premise
experimental I-Premise
- I-Premise
to I-Premise
- I-Premise
pc I-Premise
hazard I-Premise
ratios I-Premise
of I-Premise
death I-Premise
were I-Premise
1 I-Premise
. I-Premise
15 I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
79 I-Premise
to I-Premise
1 I-Premise
. I-Premise
67 I-Premise
) I-Premise
for I-Premise
vc I-Premise
, I-Premise
1 I-Premise
. I-Premise
32 I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
91 I-Premise
to I-Premise
1 I-Premise
. I-Premise
92 I-Premise
) I-Premise
for I-Premise
gc I-Premise
, I-Premise
and I-Premise
1 I-Premise
. I-Premise
26 I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
86 I-Premise
to I-Premise
1 I-Premise
. I-Premise
82 I-Premise
) I-Premise
for I-Premise
tc I-Premise
. I-Premise
!LF! !LF!
the B-Premise
hazard I-Premise
ratios I-Premise
for I-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
( I-Premise
pfs I-Premise
) I-Premise
were I-Premise
1 I-Premise
. I-Premise
36 I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
97 I-Premise
to I-Premise
1 I-Premise
. I-Premise
90 I-Premise
) I-Premise
for I-Premise
vc I-Premise
, I-Premise
1 I-Premise
. I-Premise
39 I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
99 I-Premise
to I-Premise
1 I-Premise
. I-Premise
96 I-Premise
) I-Premise
for I-Premise
gc I-Premise
, I-Premise
and I-Premise
1 I-Premise
. I-Premise
27 I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
90 I-Premise
to I-Premise
1 I-Premise
. I-Premise
78 I-Premise
) I-Premise
for I-Premise
tc I-Premise
. I-Premise
!LF! !LF!
response B-Premise
rates I-Premise
( I-Premise
rrs I-Premise
) I-Premise
for I-Premise
pc I-Premise
, I-Premise
vc I-Premise
, I-Premise
gc I-Premise
, I-Premise
and I-Premise
tc I-Premise
were I-Premise
29 I-Premise
. I-Premise
1 I-Premise
% I-Premise
, I-Premise
25 I-Premise
. I-Premise
9 I-Premise
% I-Premise
, I-Premise
22 I-Premise
. I-Premise
3 I-Premise
% I-Premise
, I-Premise
and I-Premise
23 I-Premise
. I-Premise
4 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
the B-Premise
arms I-Premise
were I-Premise
comparable I-Premise
with I-Premise
respect I-Premise
to I-Premise
toxicity I-Premise
except I-Premise
for I-Premise
leucopenia I-Premise
, I-Premise
neutropenia I-Premise
, I-Premise
infection I-Premise
, I-Premise
and I-Premise
alopecia I-Premise
. I-Premise
!LF! !LF!
vc B-Claim
, I-Claim
gc I-Claim
, I-Claim
and I-Claim
tc I-Claim
are I-Claim
not I-Claim
superior I-Claim
to I-Claim
pc I-Claim
in I-Claim
terms I-Claim
of I-Claim
overall I-Claim
survival I-Claim
( I-Claim
os I-Claim
) I-Claim
. I-Claim
!LF! !LF!
however B-Claim
, I-Claim
the I-Claim
trend I-Claim
in I-Claim
rr I-Claim
, I-Claim
pfs I-Claim
, I-Claim
and I-Claim
os I-Claim
favors I-Claim
pc I-Claim
. I-Claim
!LF! !LF!
differences B-Claim
in I-Claim
chemotherapy I-Claim
scheduling I-Claim
, I-Claim
pre I-Claim
- I-Claim
existing I-Claim
morbidity I-Claim
, I-Claim
and I-Claim
toxicity I-Claim
are I-Claim
important I-Claim
in I-Claim
individualizing I-Claim
therapy I-Claim
. I-Claim
!LF! !LF!
to O
report O
5 O
- O
year O
contrast O
- O
enhanced O
magnetic O
resonance O
imaging O
findings O
of O
the O
rest O
trial O
recruits O
who O
underwent O
either O
uterine O
artery O
embolization O
( O
uae O
) O
or O
myomectomy O
. O
!LF! !LF!
a O
total O
of O
157 O
patients O
were O
randomized O
to O
uae O
or O
surgery O
( O
hysterectomy O
or O
myomectomy O
) O
. O
!LF! !LF!
ninety O
- O
nine O
patients O
who O
had O
uae O
and O
eight O
patients O
who O
had O
myomectomy O
were O
analyzed O
. O
!LF! !LF!
mri O
scans O
at O
baseline O
, O
6 O
months O
, O
and O
5 O
years O
were O
independently O
interpreted O
by O
two O
radiologists O
. O
!LF! !LF!
dominant O
fibroid O
diameter O
, O
uterine O
volume O
, O
total O
fibroid O
infarction O
( O
complete O
100 O
% O
, O
almost O
complete O
90 O
- O
99 O
% O
, O
partial O
< O
90 O
% O
) O
, O
and O
new O
fibroid O
formation O
were O
the O
main O
parameters O
assessed O
and O
related O
to O
the O
need O
for O
reintervention O
. O
!LF! !LF!
in B-Premise
the I-Premise
uae I-Premise
group I-Premise
, I-Premise
mean I-Premise
± I-Premise
standard I-Premise
deviation I-Premise
uterine I-Premise
volume I-Premise
was I-Premise
670 I-Premise
± I-Premise
503 I-Premise
, I-Premise
422 I-Premise
± I-Premise
353 I-Premise
, I-Premise
and I-Premise
292 I-Premise
± I-Premise
287 I-Premise
ml I-Premise
at I-Premise
baseline I-Premise
, I-Premise
6 I-Premise
months I-Premise
, I-Premise
and I-Premise
5 I-Premise
years I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
mean B-Premise
dominant I-Premise
fibroid I-Premise
diameter I-Premise
was I-Premise
7 I-Premise
. I-Premise
6 I-Premise
± I-Premise
3 I-Premise
. I-Premise
0 I-Premise
, I-Premise
5 I-Premise
. I-Premise
8 I-Premise
± I-Premise
2 I-Premise
. I-Premise
9 I-Premise
, I-Premise
and I-Premise
5 I-Premise
± I-Premise
2 I-Premise
. I-Premise
9 I-Premise
cm I-Premise
at I-Premise
baseline I-Premise
, I-Premise
6 I-Premise
months I-Premise
, I-Premise
and I-Premise
5 I-Premise
years I-Premise
. I-Premise
!LF! !LF!
fibroid B-Premise
infarction I-Premise
at I-Premise
6 I-Premise
months I-Premise
was I-Premise
complete I-Premise
in I-Premise
35 I-Premise
% I-Premise
of I-Premise
women I-Premise
, I-Premise
almost I-Premise
complete I-Premise
in I-Premise
29 I-Premise
% I-Premise
, I-Premise
and I-Premise
partial I-Premise
in I-Premise
36 I-Premise
% I-Premise
. I-Premise
!LF! !LF!
need B-Premise
for I-Premise
reintervention I-Premise
was I-Premise
19 I-Premise
, I-Premise
10 I-Premise
, I-Premise
and I-Premise
33 I-Premise
% I-Premise
in I-Premise
these I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
123 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
no B-Premise
myomectomy I-Premise
cases I-Premise
had I-Premise
further I-Premise
intervention I-Premise
. I-Premise
!LF! !LF!
at B-Premise
5 I-Premise
years I-Premise
, I-Premise
the I-Premise
prevalence I-Premise
of I-Premise
new I-Premise
fibroid I-Premise
was I-Premise
60 I-Premise
% I-Premise
in I-Premise
the I-Premise
myomectomy I-Premise
group I-Premise
and I-Premise
7 I-Premise
% I-Premise
in I-Premise
the I-Premise
uae I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
008 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
there B-Premise
is I-Premise
a I-Premise
further I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
both I-Premise
uterine I-Premise
volume I-Premise
and I-Premise
dominant I-Premise
fibroid I-Premise
diameter I-Premise
between I-Premise
6 I-Premise
months I-Premise
and I-Premise
5 I-Premise
years I-Premise
after I-Premise
uae I-Premise
. I-Premise
!LF! !LF!
complete B-Claim
fibroid I-Claim
infarction I-Claim
does I-Claim
not I-Claim
translate I-Claim
into I-Claim
total I-Claim
freedom I-Claim
from I-Claim
a I-Claim
subsequent I-Claim
reintervention I-Claim
. I-Claim
!LF! !LF!
new B-Claim
fibroid I-Claim
formation I-Claim
is I-Claim
significantly I-Claim
higher I-Claim
after I-Claim
myomectomy I-Claim
. I-Claim
!LF! !LF!
the O
current O
study O
examined O
the O
effect O
of O
recombinant O
human O
deoxyribonuclease O
( O
rhdnase O
) O
on O
quality O
of O
life O
( O
qol O
) O
measures O
, O
clinical O
improvement O
, O
and O
dna O
content O
of O
thick O
oropharyngeal O
secretions O
( O
ops O
) O
in O
patients O
with O
head O
- O
and O
- O
neck O
( O
h O
& O
n O
) O
cancers O
. O
!LF! !LF!
thirty O
- O
six O
patients O
with O
local O
- O
regional O
advanced O
h O
& O
amp O
"""" O
; O
"""" O
n O
cancer O
receiving O
chemoradiationtherapy O
( O
crt O
) O
were O
randomized O
to O
receive O
either O
placebo O
or O
rhdnase O
. O
!LF! !LF!
endpoints O
included O
md O
anderson O
symptom O
inventory O
- O
head O
and O
neck O
( O
mdasi O
- O
hn O
) O
and O
functional O
assessment O
of O
cancer O
therapy O
- O
head O
and O
neck O
( O
fact O
- O
nh O
) O
scores O
, O
along O
with O
clinical O
assessment O
and O
dna O
concentration O
of O
ops O
. O
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
patients I-Premise
' I-Premise
qol I-Premise
outcomes I-Premise
over I-Premise
the I-Premise
study I-Premise
period I-Premise
. I-Premise
!LF! !LF!
both B-Premise
groups I-Premise
showed I-Premise
an I-Premise
increase I-Premise
in I-Premise
symptom I-Premise
and I-Premise
interference I-Premise
scores I-Premise
, I-Premise
although O
patients B-Premise
in I-Premise
the I-Premise
rhdnase I-Premise
group I-Premise
showed I-Premise
a I-Premise
greater I-Premise
decline I-Premise
in I-Premise
both I-Premise
scores I-Premise
during I-Premise
the I-Premise
3 I-Premise
months I-Premise
posttreatment I-Premise
. I-Premise
!LF! !LF!
similarly B-Premise
, I-Premise
both I-Premise
groups I-Premise
showed I-Premise
a I-Premise
decline I-Premise
in I-Premise
physical I-Premise
and I-Premise
functional I-Premise
well I-Premise
being I-Premise
but I-Premise
recovered I-Premise
in I-Premise
the I-Premise
3 I-Premise
months I-Premise
posttreatment I-Premise
follow I-Premise
- I-Premise
up I-Premise
, I-Premise
with I-Premise
the I-Premise
rhdnase I-Premise
group I-Premise
exhibiting I-Premise
speedier I-Premise
recovery I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
in I-Premise
the I-Premise
rhdnase I-Premise
group I-Premise
exhibited I-Premise
significant I-Premise
clinical I-Premise
improvement I-Premise
in I-Premise
ops I-Premise
, I-Premise
blindly I-Premise
assessed I-Premise
by I-Premise
a I-Premise
physician I-Premise
, I-Premise
compared I-Premise
with I-Premise
the I-Premise
placebo I-Premise
group I-Premise
( I-Premise
67 I-Premise
% I-Premise
vs I-Premise
27 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
046 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
rhdnase I-Premise
group I-Premise
showed I-Premise
no I-Premise
change I-Premise
in I-Premise
ops I-Premise
- I-Premise
dna I-Premise
concentration I-Premise
, I-Premise
although O
the B-Premise
placebo I-Premise
group I-Premise
showed I-Premise
a I-Premise
significant I-Premise
increase I-Premise
in I-Premise
dna I-Premise
concentration I-Premise
during I-Premise
the I-Premise
drug I-Premise
trial I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
045 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
there B-Claim
was I-Claim
no I-Claim
differences I-Claim
in I-Claim
acute I-Claim
toxicities I-Claim
between I-Claim
the I-Claim
2 I-Claim
groups I-Claim
. I-Claim
!LF! !LF!
our B-Claim
preliminary I-Claim
data I-Claim
suggest I-Claim
that I-Claim
rhdnase I-Claim
did I-Claim
not I-Claim
significantly I-Claim
improve I-Claim
study I-Claim
primary I-Claim
endpoints I-Claim
of I-Claim
qol I-Claim
measures I-Claim
compared I-Claim
with I-Claim
the I-Claim
placebo I-Claim
group I-Claim
. I-Claim
!LF! !LF!
however O
, O
there B-Claim
was I-Claim
a I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
secondary I-Claim
endpoints I-Claim
of I-Claim
clinically I-Claim
assessed I-Claim
ops I-Claim
and I-Claim
dna I-Claim
concentration I-Claim
compared I-Claim
with I-Claim
placebo I-Claim
in I-Claim
h I-Claim
& I-Claim
n I-Claim
cancer I-Claim
patients I-Claim
treated I-Claim
with I-Claim
crt I-Claim
. I-Claim
!LF! !LF!
further O
investigation O
in O
larger O
numbers O
of O
patients O
is O
warranted O
. O
!LF! !LF!
thalidomide O
with O
melphalan O
/ O
prednisone O
( O
mpt O
) O
was O
defined O
as O
standard O
treatment O
in O
elderly O
patients O
with O
multiple O
myeloma O
( O
mm O
) O
based O
on O
five O
randomized O
trials O
. O
!LF! !LF!
in O
one O
of O
these O
trials O
, O
hovon49 O
, O
a O
prospective O
health O
- O
related O
quality O
- O
of O
- O
life O
( O
hrqol O
) O
study O
was O
initiated O
in O
order O
to O
assess O
the O
impact O
of O
thalidomide O
on O
qol O
. O
!LF! !LF!
patients O
aged O
> O
65 O
years O
with O
newly O
diagnosed O
mm O
were O
randomized O
to O
receive O
melphalan O
plus O
prednisone O
( O
mp O
) O
or O
mpt O
, O
followed O
by O
thalidomide O
maintenance O
in O
the O
mpt O
arm O
. O
!LF! !LF!
two O
hundred O
eighty O
- O
four O
patients O
were O
included O
in O
this O
side O
study O
( O
mp O
, O
n O
= O
149 O
"""" O
; O
"""" O
mpt O
n O
= O
135 O
) O
. O
!LF! !LF!
hrqol O
was O
assessed O
with O
the O
eortc O
core O
qol O
questionnaire O
( O
qlq O
- O
c30 O
) O
and O
the O
myeloma O
- O
specific O
module O
( O
qlq O
- O
my24 O
) O
at O
baseline O
and O
at O
predetermined O
intervals O
during O
treatment O
. O
!LF! !LF!
the B-Premise
qlq I-Premise
- I-Premise
c30 I-Premise
subscales I-Premise
physical I-Premise
function I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
044 I-Premise
) I-Premise
and I-Premise
constipation I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
showed I-Premise
an I-Premise
improvement I-Premise
during I-Premise
induction I-Premise
in I-Premise
favour I-Premise
of I-Premise
the I-Premise
mp I-Premise
arm I-Premise
. I-Premise
!LF! !LF!
during B-Premise
thalidomide I-Premise
maintenance I-Premise
, I-Premise
the I-Premise
scores I-Premise
for I-Premise
the I-Premise
qlq I-Premise
- I-Premise
my24 I-Premise
paraesthesia I-Premise
became I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
mpt I-Premise
arm I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
qlq I-Premise
- I-Premise
c30 I-Premise
subscales I-Premise
pain I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
12 I-Premise
) I-Premise
, I-Premise
insomnia I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
068 I-Premise
) I-Premise
, I-Premise
appetite I-Premise
loss I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
074 I-Premise
) I-Premise
and I-Premise
the I-Premise
qlq I-Premise
- I-Premise
my24 I-Premise
item I-Premise
sick I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
086 I-Premise
) I-Premise
scored I-Premise
marginally I-Premise
better I-Premise
during I-Premise
thalidomide I-Premise
maintenance I-Premise
. I-Premise
!LF! !LF!
the B-Premise
overall I-Premise
qol I-Premise
- I-Premise
scale I-Premise
qlq I-Premise
- I-Premise
c30 I-Premise
- I-Premise
hrqol I-Premise
showed I-Premise
a I-Premise
significant I-Premise
time I-Premise
trend I-Premise
towards I-Premise
more I-Premise
favourable I-Premise
mean I-Premise
values I-Premise
during I-Premise
protocol I-Premise
treatment I-Premise
without I-Premise
differences I-Premise
between I-Premise
mp I-Premise
and I-Premise
mpt I-Premise
. I-Premise
!LF! !LF!
for B-Premise
the I-Premise
qlq I-Premise
- I-Premise
c30 I-Premise
subscales I-Premise
emotional I-Premise
function I-Premise
and I-Premise
future I-Premise
perspectives I-Premise
, I-Premise
difference I-Premise
in I-Premise
favour I-Premise
of I-Premise
the I-Premise
mpt I-Premise
arm I-Premise
from I-Premise
the I-Premise
start I-Premise
of I-Premise
treatment I-Premise
was I-Premise
observed I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
018 I-Premise
and I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
045 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
with I-Premise
no I-Premise
significant I-Premise
' I-Premise
time I-Premise
× I-Premise
arm I-Premise
' I-Premise
interaction I-Premise
, I-Premise
indicating I-Premise
a I-Premise
persistent I-Premise
better I-Premise
patient I-Premise
perspective I-Premise
with I-Premise
mpt I-Premise
treatment I-Premise
. I-Premise
!LF! !LF!
this B-Claim
study I-Claim
shows I-Claim
that I-Claim
the I-Claim
higher I-Claim
frequency I-Claim
of I-Claim
toxicity I-Claim
associated I-Claim
with I-Claim
mpt I-Claim
does I-Claim
not I-Claim
translate I-Claim
into I-Claim
a I-Claim
negative I-Claim
effect I-Claim
on I-Claim
hrqol I-Claim
and I-Claim
that I-Claim
mpt I-Claim
holds I-Claim
a I-Claim
better I-Claim
patient I-Claim
perspective I-Claim
. I-Claim
!LF! !LF!
paclitaxel O
and O
pegylated O
liposomal O
doxorubicin O
( O
pld O
) O
are O
active O
cytotoxic O
agents O
for O
the O
treatment O
of O
human O
immunodeficiency O
virus O
( O
hiv O
) O
- O
associated O
kaposi O
sarcoma O
( O
ks O
) O
. O
!LF! !LF!
a O
randomized O
trial O
comparing O
the O
efficacy O
and O
toxicity O
of O
paclitaxel O
and O
pld O
was O
performed O
, O
and O
the O
effects O
of O
therapy O
on O
symptom O
palliation O
and O
quality O
of O
life O
were O
determined O
. O
!LF! !LF!
patients O
with O
advanced O
hiv O
- O
associated O
ks O
were O
randomly O
assigned O
to O
receive O
paclitaxel O
at O
a O
dose O
of O
100 O
mg O
/ O
m2 O
intravenously O
( O
iv O
) O
every O
2 O
weeks O
or O
pld O
at O
a O
dose O
of O
20 O
mg O
/ O
m2 O
iv O
every O
3 O
weeks O
. O
!LF! !LF!
the O
ks O
functional O
assessment O
of O
hiv O
( O
fahi O
) O
quality O
of O
life O
instrument O
was O
used O
before O
and O
after O
every O
other O
treatment O
cycle O
. O
!LF! !LF!
the O
study O
included O
73 O
analyzable O
patients O
enrolled O
between O
1998 O
and O
2002 O
, O
including O
36 O
in O
the O
paclitaxel O
arm O
and O
37 O
in O
the O
pld O
arm O
"""" O
; O
"""" O
73 O
% O
of O
patients O
received O
highly O
active O
antiretroviral O
therapy O
( O
haart O
) O
and O
32 O
% O
had O
an O
undetectable O
viral O
load O
( O
< O
400 O
copies O
/ O
ml O
) O
. O
!LF! !LF!
treatment B-Premise
was I-Premise
associated I-Premise
with I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
024 I-Premise
) I-Premise
and I-Premise
swelling I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
of B-Premise
the I-Premise
36 I-Premise
patients I-Premise
who I-Premise
reported I-Premise
that I-Premise
pain I-Premise
interfered I-Premise
with I-Premise
their I-Premise
normal I-Premise
work I-Premise
or I-Premise
activities I-Premise
at I-Premise
baseline I-Premise
, I-Premise
25 I-Premise
( I-Premise
69 I-Premise
% I-Premise
) I-Premise
improved I-Premise
. I-Premise
!LF! !LF!
of B-Premise
the I-Premise
41 I-Premise
patients I-Premise
who I-Premise
reported I-Premise
swelling I-Premise
at I-Premise
baseline I-Premise
, I-Premise
38 I-Premise
( I-Premise
93 I-Premise
% I-Premise
) I-Premise
improved I-Premise
. I-Premise
!LF! !LF!
comparing B-Premise
the I-Premise
paclitaxel I-Premise
and I-Premise
pld I-Premise
arms I-Premise
revealed I-Premise
comparable I-Premise
response I-Premise
rates I-Premise
( I-Premise
56 I-Premise
% I-Premise
vs I-Premise
46 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
49 I-Premise
) I-Premise
, I-Premise
median I-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
( I-Premise
17 I-Premise
. I-Premise
5 I-Premise
months I-Premise
vs I-Premise
12 I-Premise
. I-Premise
2 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
66 I-Premise
) I-Premise
, I-Premise
and I-Premise
2 I-Premise
- I-Premise
year I-Premise
survival I-Premise
rates I-Premise
( I-Premise
79 I-Premise
% I-Premise
vs I-Premise
78 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
75 I-Premise
) I-Premise
, I-Premise
but B-Premise
somewhat I-Premise
more I-Premise
grade I-Premise
3 I-Premise
to I-Premise
5 I-Premise
toxicity I-Premise
for I-Premise
paclitaxel I-Premise
( I-Premise
84 I-Premise
% I-Premise
vs I-Premise
66 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
077 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
treatment B-Claim
with I-Claim
either I-Claim
paclitaxel I-Claim
or I-Claim
pld I-Claim
appears I-Claim
to I-Claim
produce I-Claim
significant I-Claim
improvements I-Claim
in I-Claim
pain I-Claim
and I-Claim
swelling I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
, I-Claim
symptomatic I-Claim
, I-Claim
hiv I-Claim
- I-Claim
associated I-Claim
ks I-Claim
treated I-Claim
in I-Claim
the I-Claim
haart I-Claim
era I-Claim
. I-Claim
!LF! !LF!
the O
phase O
3 O
vista O
study O
in O
transplant O
- O
ineligible O
myeloma O
patients O
demonstrated O
superior O
efficacy O
with O
bortezomib O
- O
melphalan O
- O
prednisone O
( O
vmp O
"""" O
; O
"""" O
nine O
6 O
- O
wk O
cycles O
) O
vs O
. O
melphalan O
- O
prednisone O
( O
mp O
) O
but O
also O
increased O
toxicity O
. O
!LF! !LF!
health O
- O
related O
quality O
of O
life O
( O
hrqol O
"""" O
; O
"""" O
exploratory O
endpoint O
) O
was O
evaluated O
using O
the O
european O
organization O
for O
research O
and O
treatment O
of O
cancer O
( O
eortc O
) O
quality O
of O
life O
questionnaire O
( O
qlq O
- O
c30 O
) O
. O
!LF! !LF!
the O
phase O
3 O
vista O
study O
in O
transplant O
- O
ineligible O
myeloma O
patients O
demonstrated O
superior O
efficacy O
with O
bortezomib O
- O
melphalan O
- O
prednisone O
( O
vmp O
"""" O
; O
"""" O
nine O
6 O
- O
wk O
cycles O
) O
vs O
. O
melphalan O
- O
prednisone O
( O
mp O
) O
but O
also O
increased O
toxicity O
. O
!LF! !LF!
health O
- O
related O
quality O
of O
life O
( O
hrqol O
"""" O
; O
"""" O
exploratory O
endpoint O
) O
was O
evaluated O
using O
the O
european O
organization O
for O
research O
and O
treatment O
of O
cancer O
( O
eortc O
) O
quality O
of O
life O
questionnaire O
( O
qlq O
- O
c30 O
) O
. O
!LF! !LF!
eortc O
qlq O
- O
c30 O
was O
administered O
at O
screening O
, O
on O
day O
1 O
of O
each O
cycle O
, O
at O
the O
end O
- O
of O
- O
treatment O
visit O
, O
and O
every O
8 O
wk O
until O
progression O
. O
!LF! !LF!
eortc O
qlq O
- O
c30 O
scores O
were O
evaluated O
among O
patients O
with O
a O
valid O
baseline O
and O
at O
least O
one O
post O
- O
baseline O
hrqol O
assessment O
. O
!LF! !LF!
at O
baseline O
, O
domain O
scores O
were O
similar O
between O
arms O
. O
!LF! !LF!
by B-Premise
cycle I-Premise
4 I-Premise
, I-Premise
mean I-Premise
differences I-Premise
were I-Premise
clinically I-Premise
meaningful I-Premise
for I-Premise
most I-Premise
domains I-Premise
, I-Premise
indicating I-Premise
poorer I-Premise
health I-Premise
status I-Premise
with I-Premise
vmp I-Premise
. I-Premise
!LF! !LF!
from B-Premise
cycle I-Premise
5 I-Premise
onwards I-Premise
, I-Premise
improvements I-Premise
relative I-Premise
to I-Premise
baseline I-Premise
/ I-Premise
mp I-Premise
were I-Premise
observed I-Premise
for I-Premise
all I-Premise
domains I-Premise
with I-Premise
vmp I-Premise
. I-Premise
!LF! !LF!
mean B-Premise
scores I-Premise
were I-Premise
generally I-Premise
improved I-Premise
by I-Premise
the I-Premise
end I-Premise
- I-Premise
of I-Premise
- I-Premise
treatment I-Premise
assessment I-Premise
vs I-Premise
. I-Premise
baseline I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
among B-Premise
responding I-Premise
patients I-Premise
, I-Premise
mean I-Premise
scores I-Premise
generally I-Premise
improved I-Premise
from I-Premise
time I-Premise
of I-Premise
response I-Premise
to I-Premise
end I-Premise
- I-Premise
of I-Premise
- I-Premise
treatment I-Premise
assessment I-Premise
, I-Premise
substantially I-Premise
driven I-Premise
by I-Premise
patients I-Premise
achieving I-Premise
complete I-Premise
response I-Premise
( I-Premise
cr I-Premise
) I-Premise
. I-Premise
!LF! !LF!
multivariate B-Premise
analysis I-Premise
showed I-Premise
a I-Premise
significant I-Premise
impact I-Premise
of I-Premise
duration I-Premise
of I-Premise
response I-Premise
/ I-Premise
cr I-Premise
on I-Premise
improving I-Premise
global I-Premise
health I-Premise
status I-Premise
, I-Premise
pain I-Premise
, I-Premise
and I-Premise
appetite I-Premise
loss I-Premise
scores I-Premise
. I-Premise
!LF! !LF!
analyses B-Claim
by I-Claim
bortezomib I-Claim
dose I-Claim
intensity I-Claim
indicated I-Claim
better I-Claim
hrqol I-Claim
in I-Claim
patients I-Claim
receiving I-Claim
lower I-Claim
dose I-Claim
intensity I-Claim
. I-Claim
!LF! !LF!
these B-Claim
findings I-Claim
demonstrate I-Claim
clinically I-Claim
meaningful I-Claim
, I-Claim
transitory I-Claim
hrqol I-Claim
decrements I-Claim
with I-Claim
vmp I-Claim
and I-Claim
relatively I-Claim
lower I-Claim
hrqol I-Claim
vs I-Claim
. I-Claim
mp I-Claim
during I-Claim
early I-Claim
treatment I-Claim
cycles I-Claim
, I-Claim
associated I-Claim
with I-Claim
the I-Claim
expected I-Claim
additional I-Claim
toxicities I-Claim
. I-Claim
!LF! !LF!
however B-Claim
, I-Claim
hrqol I-Claim
is I-Claim
not I-Claim
compromised I-Claim
in I-Claim
the I-Claim
long I-Claim
term I-Claim
, I-Claim
recovering I-Claim
by I-Claim
the I-Claim
end I-Claim
- I-Claim
of I-Claim
- I-Claim
treatment I-Claim
visit I-Claim
to I-Claim
be I-Claim
comparable I-Claim
vs I-Claim
. I-Claim
mp I-Claim
. I-Claim
!LF! !LF!
chemotherapy B-Claim
prolongs I-Claim
survival I-Claim
and I-Claim
improves I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
qol I-Claim
) I-Claim
for I-Claim
good I-Claim
performance I-Claim
status I-Claim
( I-Claim
ps I-Claim
) I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non I-Claim
- I-Claim
small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
nsclc I-Claim
) I-Claim
. I-Claim
!LF! !LF!
targeted B-Claim
therapies I-Claim
may I-Claim
improve I-Claim
chemotherapy I-Claim
effectiveness I-Claim
without I-Claim
worsening I-Claim
toxicity I-Claim
. I-Claim
!LF! !LF!
sgn O
- O
15 O
is O
an O
antibody O
- O
drug O
conjugate O
( O
adc O
) O
, O
consisting O
of O
a O
chimeric O
murine O
monoclonal O
antibody O
recognizing O
the O
lewis O
y O
( O
le O
( O
y O
) O
) O
antigen O
, O
conjugated O
to O
doxorubicin O
. O
!LF! !LF!
le B-Claim
( I-Claim
y I-Claim
) I-Claim
is I-Claim
an I-Claim
attractive I-Claim
target I-Claim
since I-Claim
it I-Claim
is I-Claim
expressed I-Claim
by I-Claim
most I-Claim
nsclc I-Claim
. I-Claim
!LF! !LF!
sgn B-Premise
- B-Premise
15 B-Premise
was I-Premise
active I-Premise
against I-Premise
le I-Premise
( I-Premise
y I-Premise
) I-Premise
- I-Premise
positive I-Premise
tumors I-Premise
in I-Premise
early I-Premise
phase I-Premise
clinical I-Premise
trials I-Premise
and I-Premise
was I-Premise
synergistic I-Premise
with I-Premise
docetaxel I-Premise
in I-Premise
preclinical I-Premise
experiments I-Premise
. I-Premise
!LF! !LF!
this O
phase O
ii O
, O
open O
- O
label O
study O
was O
conducted O
to O
confirm O
the O
activity O
of O
sgn O
- O
15 O
plus O
docetaxel O
in O
previously O
treated O
nsclc O
patients O
. O
!LF! !LF!
sixty O
- O
two O
patients O
with O
recurrent O
or O
metastatic O
nsclc O
expressing O
le O
( O
y O
) O
, O
one O
or O
two O
prior O
chemotherapy O
regimens O
, O
and O
ps O
< O
or O
2 O
were O
randomized O
2 O
: O
1 O
to O
receive O
sgn O
- O
15 O
200 O
mg O
/ O
m2 O
/ O
week O
with O
docetaxel O
35 O
mg O
/ O
m2 O
/ O
week O
( O
arm O
a O
) O
or O
docetaxel O
35 O
mg O
/ O
m2 O
/ O
week O
alone O
( O
arm O
b O
) O
for O
6 O
of O
8 O
weeks O
. O
!LF! !LF!
intrapatient O
dose O
- O
escalation O
of O
sgn O
- O
15 O
to O
350 O
mg O
/ O
m2 O
was O
permitted O
in O
the O
second O
half O
of O
the O
study O
. O
!LF! !LF!
endpoints O
were O
survival O
, O
safety O
, O
efficacy O
, O
and O
quality O
of O
life O
. O
!LF! !LF!
forty O
patients O
on O
arm O
a O
and O
19 O
on O
arm O
b O
received O
at O
least O
one O
treatment O
. O
!LF! !LF!
patients B-Premise
on I-Premise
arms I-Premise
a I-Premise
and I-Premise
b I-Premise
had I-Premise
median I-Premise
survivals I-Premise
of I-Premise
31 I-Premise
. I-Premise
4 I-Premise
and I-Premise
25 I-Premise
. I-Premise
3 I-Premise
weeks I-Premise
, I-Premise
12 I-Premise
- I-Premise
month I-Premise
survivals I-Premise
of I-Premise
29 I-Premise
% I-Premise
and I-Premise
24 I-Premise
% I-Premise
, I-Premise
and I-Premise
18 I-Premise
- I-Premise
month I-Premise
survivals I-Premise
of I-Premise
18 I-Premise
% I-Premise
and I-Premise
8 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. O
!LF! !LF!
toxicity B-Premise
was I-Premise
mild I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
qol B-Premise
analyses I-Premise
favored I-Premise
arm I-Premise
a I-Premise
. I-Premise
sgn B-Claim
- B-Claim
15 B-Claim
plus I-Claim
docetaxel I-Claim
is I-Claim
a I-Claim
well I-Claim
- I-Claim
tolerated I-Claim
and I-Claim
active I-Claim
second I-Claim
and I-Claim
third I-Claim
line I-Claim
treatment I-Claim
for I-Claim
nsclc I-Claim
patients I-Claim
. O
!LF! !LF!
ongoing O
studies O
are O
exploring O
alternate O
schedules O
to O
maximize O
synergy O
between O
these O
agents O
. O
!LF! !LF!
the O
combination O
of O
radiotherapy O
plus O
long O
- O
term O
medical O
suppression O
of O
androgens O
( O
> O
or O
= O
2 O
years O
) O
improves O
overall O
survival O
in O
patients O
with O
locally O
advanced O
prostate O
cancer O
. O
!LF! !LF!
we O
compared O
the O
use O
of O
radiotherapy O
plus O
short O
- O
term O
androgen O
suppression O
with O
the O
use O
of O
radiotherapy O
plus O
long O
- O
term O
androgen O
suppression O
in O
the O
treatment O
of O
locally O
advanced O
prostate O
cancer O
. O
!LF! !LF!
we O
randomly O
assigned O
patients O
with O
locally O
advanced O
prostate O
cancer O
who O
had O
received O
external O
- O
beam O
radiotherapy O
plus O
6 O
months O
of O
androgen O
suppression O
to O
two O
groups O
, O
one O
to O
receive O
no O
further O
treatment O
( O
short O
- O
term O
suppression O
) O
and O
the O
other O
to O
receive O
2 O
. O
5 O
years O
of O
further O
treatment O
with O
a O
luteinizing O
hormone O
- O
releasing O
hormone O
agonist O
( O
long O
- O
term O
suppression O
) O
. O
!LF! !LF!
an O
outcome O
of O
noninferiority O
of O
short O
- O
term O
androgen O
suppression O
as O
compared O
with O
long O
- O
term O
suppression O
required O
a O
hazard O
ratio O
of O
more O
than O
1 O
. O
35 O
for O
overall O
survival O
, O
with O
a O
one O
- O
sided O
alpha O
level O
of O
0 O
. O
05 O
. O
!LF! !LF!
an O
interim O
analysis O
showed O
futility O
, O
and O
the O
results O
are O
presented O
with O
an O
adjusted O
one O
- O
sided O
alpha O
level O
of O
0 O
. O
0429 O
. O
!LF! !LF!
a O
total O
of O
1113 O
men O
were O
registered O
, O
of O
whom O
970 O
were O
randomly O
assigned O
, O
483 O
to O
short O
- O
term O
suppression O
and O
487 O
to O
long O
- O
term O
suppression O
. O
!LF! !LF!
after B-Premise
a I-Premise
median I-Premise
follow I-Premise
- I-Premise
up I-Premise
of I-Premise
6 I-Premise
. I-Premise
4 I-Premise
years I-Premise
, I-Premise
132 I-Premise
patients I-Premise
in I-Premise
the I-Premise
short I-Premise
- I-Premise
term I-Premise
group I-Premise
and I-Premise
98 I-Premise
in I-Premise
the I-Premise
long I-Premise
- I-Premise
term I-Premise
group I-Premise
had I-Premise
died I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
the B-Premise
number I-Premise
of I-Premise
deaths I-Premise
due I-Premise
to I-Premise
prostate I-Premise
cancer I-Premise
was I-Premise
47 I-Premise
in I-Premise
the I-Premise
short I-Premise
- I-Premise
term I-Premise
group I-Premise
and I-Premise
29 I-Premise
in I-Premise
the I-Premise
long I-Premise
- I-Premise
term I-Premise
group I-Premise
. I-Premise
!LF! !LF!
the B-Premise
5 I-Premise
- I-Premise
year I-Premise
overall I-Premise
mortality I-Premise
for I-Premise
short I-Premise
- I-Premise
term I-Premise
and I-Premise
long I-Premise
- I-Premise
term I-Premise
suppression I-Premise
was I-Premise
19 I-Premise
. I-Premise
0 I-Premise
% I-Premise
and I-Premise
15 I-Premise
. I-Premise
2 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
the O
observed O
hazard O
ratio O
was O
1 O
. O
42 O
( O
upper O
95 O
. O
71 O
% O
confidence O
limit O
, O
1 O
. O
79 O
"""" O
; O
"""" O
p O
= O
0 O
. O
65 O
for O
noninferiority O
) O
. O
!LF! !LF!
adverse B-Premise
events I-Premise
in I-Premise
both I-Premise
groups I-Premise
included I-Premise
fatigue I-Premise
, I-Premise
diminished I-Premise
sexual I-Premise
function I-Premise
, I-Premise
and I-Premise
hot I-Premise
flushes I-Premise
. I-Premise
!LF! !LF!
the B-Claim
combination I-Claim
of I-Claim
radiotherapy I-Claim
plus I-Claim
6 I-Claim
months I-Claim
of I-Claim
androgen I-Claim
suppression I-Claim
provides I-Claim
inferior I-Claim
survival I-Claim
as I-Claim
compared I-Claim
with I-Claim
radiotherapy I-Claim
plus I-Claim
3 I-Claim
years I-Claim
of I-Claim
androgen I-Claim
suppression I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
locally I-Claim
advanced I-Claim
prostate I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
cancer O
cachexia O
is O
a O
common O
problem O
among O
advanced O
cancer O
patients O
. O
!LF! !LF!
a O
mixture O
of O
beta O
- O
hydroxyl O
beta O
- O
methyl O
butyrate O
, O
glutamine O
, O
and O
arginine O
( O
hmb O
/ O
arg O
/ O
gln O
) O
previously O
showed O
activity O
for O
increasing O
lean O
body O
mass O
( O
lbm O
) O
among O
patients O
with O
cancer O
cachexia O
. O
!LF! !LF!
therefore O
a O
phase O
iii O
trial O
was O
implemented O
to O
confirm O
this O
activity O
. O
!LF! !LF!
four O
hundred O
seventy O
- O
two O
advanced O
cancer O
patients O
with O
between O
2 O
% O
and O
10 O
% O
weight O
loss O
were O
randomized O
to O
a O
mixture O
of O
beta O
- O
hydroxyl O
beta O
- O
methyl O
butyrate O
, O
glutamine O
, O
and O
arginine O
or O
an O
isonitrogenous O
, O
isocaloric O
control O
mixture O
taken O
twice O
a O
day O
for O
8 O
weeks O
. O
!LF! !LF!
lean O
body O
mass O
was O
estimated O
by O
bioimpedance O
and O
skin O
- O
fold O
measurements O
. O
!LF! !LF!
body O
plethysmography O
was O
used O
when O
available O
. O
!LF! !LF!
weight O
, O
the O
schwartz O
fatigue O
scale O
, O
and O
the O
spitzer O
quality O
of O
life O
scale O
were O
also O
measured O
. O
!LF! !LF!
only O
37 O
% O
of O
the O
patients O
completed O
protocol O
treatment O
. O
!LF! !LF!
the O
majority O
of O
the O
patient O
loss O
was O
because O
of O
patient O
preference O
( O
45 O
% O
of O
enrolled O
patients O
) O
. O
!LF! !LF!
however O
, O
loss O
of O
power O
was O
not O
an O
issue O
because O
of O
the O
planned O
large O
target O
sample O
size O
. O
!LF! !LF!
based O
on O
an O
intention O
to O
treat O
analysis O
, O
there O
was O
no O
statistically O
significant O
difference O
in O
the O
8 O
- O
week O
lean O
body O
mass O
between O
the O
two O
arms O
. O
!LF! !LF!
the O
secondary O
endpoints O
were O
also O
not O
significantly O
different O
between O
the O
arms O
. O
!LF! !LF!
based B-Premise
on I-Premise
the I-Premise
results I-Premise
of I-Premise
the I-Premise
area I-Premise
under I-Premise
the I-Premise
curve I-Premise
( I-Premise
auc I-Premise
) I-Premise
analysis I-Premise
, I-Premise
patients I-Premise
receiving I-Premise
hmb I-Premise
/ I-Premise
arg I-Premise
/ I-Premise
gln I-Premise
had I-Premise
a I-Premise
strong I-Premise
trend I-Premise
higher I-Premise
lbm I-Premise
throughout I-Premise
the I-Premise
study I-Premise
as I-Premise
measured I-Premise
by I-Premise
both I-Premise
bioimpedance I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
08 I-Premise
) I-Premise
and I-Premise
skin I-Premise
- I-Premise
fold I-Premise
measurements I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
08 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
among B-Premise
the I-Premise
subset I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
concurrent I-Premise
chemotherapy I-Premise
, I-Premise
there I-Premise
were I-Premise
again I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
the I-Premise
endpoints I-Premise
. I-Premise
!LF! !LF!
the O
secondary O
endpoints O
were O
also O
not O
significantly O
different O
between O
the O
arms O
. O
!LF! !LF!
this B-Claim
trial I-Claim
was I-Claim
unable I-Claim
to I-Claim
adequately I-Claim
test I-Claim
the I-Claim
ability I-Claim
of I-Claim
beta I-Claim
- I-Claim
hydroxy I-Claim
beta I-Claim
- I-Claim
methylbutyrate I-Claim
, I-Claim
glutamine I-Claim
, I-Claim
and I-Claim
arginine I-Claim
to I-Claim
reverse I-Claim
or I-Claim
prevent I-Claim
lean I-Claim
body I-Claim
mass I-Claim
wasting I-Claim
among I-Claim
cancer I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
possible O
contributing O
factors O
beyond O
the O
efficacy O
of O
the O
intervention O
were O
the O
inability O
of O
patients O
to O
complete O
an O
8 O
- O
week O
course O
of O
treatment O
and O
return O
in O
a O
timely O
fashion O
for O
follow O
- O
up O
assessment O
, O
and O
because O
the O
patients O
may O
have O
only O
had O
weight O
loss O
possible O
not O
related O
to O
cachexia O
, O
but O
other O
causes O
of O
weight O
loss O
, O
such O
as O
decreased O
appetite O
. O
!LF! !LF!
however O
, O
there O
was O
a O
strong O
trend O
towards O
an O
increased O
body O
mass O
among O
patients O
taking O
the O
juven O
compound O
using O
the O
secondary O
endpoint O
of O
auc O
. O
!LF! !LF!
to O
assess O
the O
safety O
, O
tolerability O
and O
efficacy O
of O
abatacept O
in O
patients O
with O
rheumatoid O
arthritis O
( O
ra O
) O
who O
had O
failed O
anti O
- O
tumour O
necrosis O
factor O
( O
tnf O
) O
therapy O
and O
were O
switched O
to O
abatacept O
directly O
or O
after O
completing O
washout O
. O
!LF! !LF!
in O
this O
international O
, O
6 O
- O
month O
, O
open O
- O
label O
trial O
, O
patients O
had O
active O
ra O
, O
an O
inadequate O
response O
to O
anti O
- O
tnf O
therapy O
for O
3 O
months O
or O
longer O
and O
a O
disease O
activity O
score O
in O
28 O
joints O
( O
das28 O
( O
c O
- O
reactive O
protein O
"""" O
; O
"""" O
crp O
) O
of O
5 O
. O
1 O
or O
greater O
. O
!LF! !LF!
"""" O
washout O
"""" O
patients O
discontinued O
anti O
- O
tnf O
therapy O
2 O
months O
or O
longer O
pre O
- O
screening O
"""" O
; O
"""" O
"""" O
direct O
- O
switch O
100 O
"""" O
patients O
began O
abatacept O
( O
approximately O
10 O
mg O
/ O
kg O
) O
at O
their O
next O
scheduled O
anti O
- O
tnf O
therapy O
dose O
. O
!LF! !LF!
1046 O
patients O
were O
treated O
( O
449 O
washout O
, O
597 O
direct O
- O
switch O
"""" O
; O
"""" O
baseline O
characteristics O
were O
similar O
between O
groups O
) O
. O
!LF! !LF!
at B-Premise
6 I-Premise
months I-Premise
, I-Premise
adverse I-Premise
events I-Premise
( I-Premise
ae I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
78 I-Premise
. I-Premise
0 I-Premise
% I-Premise
vs I-Premise
79 I-Premise
. I-Premise
2 I-Premise
% I-Premise
) I-Premise
, I-Premise
serious I-Premise
ae I-Premise
( I-Premise
11 I-Premise
. I-Premise
1 I-Premise
% I-Premise
vs I-Premise
9 I-Premise
. I-Premise
9 I-Premise
% I-Premise
) I-Premise
and I-Premise
discontinuations I-Premise
due I-Premise
to I-Premise
ae I-Premise
( I-Premise
3 I-Premise
. I-Premise
8 I-Premise
% I-Premise
vs I-Premise
4 I-Premise
. I-Premise
0 I-Premise
% I-Premise
) I-Premise
and I-Premise
serious I-Premise
ae I-Premise
( I-Premise
2 I-Premise
. I-Premise
0 I-Premise
% I-Premise
vs I-Premise
1 I-Premise
. I-Premise
3 I-Premise
% I-Premise
) I-Premise
were I-Premise
comparable I-Premise
in I-Premise
washout I-Premise
versus I-Premise
direct I-Premise
- I-Premise
switch I-Premise
patients I-Premise
. I-Premise
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
opportunistic I-Premise
infections I-Premise
. I-Premise
!LF! !LF!
at B-Premise
6 I-Premise
months I-Premise
, I-Premise
in I-Premise
washout I-Premise
versus I-Premise
direct I-Premise
- I-Premise
switch I-Premise
patients I-Premise
, I-Premise
similar I-Premise
clinically I-Premise
meaningful I-Premise
improvements I-Premise
were I-Premise
seen I-Premise
in I-Premise
das28 I-Premise
( I-Premise
crp I-Premise
) I-Premise
( I-Premise
> I-Premise
or I-Premise
= I-Premise
1 I-Premise
. I-Premise
2 I-Premise
unit I-Premise
improvement I-Premise
, I-Premise
59 I-Premise
. I-Premise
5 I-Premise
% I-Premise
vs I-Premise
53 I-Premise
. I-Premise
6 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
low I-Premise
disease I-Premise
activity I-Premise
state I-Premise
, I-Premise
22 I-Premise
. I-Premise
5 I-Premise
% I-Premise
vs I-Premise
22 I-Premise
. I-Premise
3 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
das28 I-Premise
- I-Premise
defined I-Premise
remission I-Premise
, I-Premise
12 I-Premise
. I-Premise
0 I-Premise
% I-Premise
vs I-Premise
13 I-Premise
. I-Premise
7 I-Premise
% I-Premise
) I-Premise
, I-Premise
physical I-Premise
function I-Premise
( I-Premise
health I-Premise
assessment I-Premise
questionnaire I-Premise
disability I-Premise
index I-Premise
> I-Premise
or I-Premise
= I-Premise
0 I-Premise
. I-Premise
22 I-Premise
improvement I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
46 I-Premise
. I-Premise
3 I-Premise
% I-Premise
vs I-Premise
47 I-Premise
. I-Premise
1 I-Premise
% I-Premise
) I-Premise
and I-Premise
health I-Premise
- I-Premise
related I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
mean I-Premise
change I-Premise
in I-Premise
short I-Premise
- I-Premise
form I-Premise
36 I-Premise
scores I-Premise
: I-Premise
physical I-Premise
component I-Premise
summary I-Premise
, I-Premise
5 I-Premise
. I-Premise
5 I-Premise
vs I-Premise
6 I-Premise
. I-Premise
1 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
mental I-Premise
component I-Premise
summary I-Premise
, I-Premise
4 I-Premise
. I-Premise
8 I-Premise
vs I-Premise
5 I-Premise
. I-Premise
4 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
abatacept B-Claim
demonstrated I-Claim
acceptable I-Claim
safety I-Claim
and I-Claim
tolerability I-Claim
and I-Claim
clinically I-Claim
meaningful I-Claim
efficacy I-Claim
over I-Claim
6 I-Claim
months I-Claim
in I-Claim
patients I-Claim
with I-Claim
inadequate I-Claim
response I-Claim
to I-Claim
anti I-Claim
- I-Claim
tnf I-Claim
therapy I-Claim
. I-Claim
!LF! !LF!
results B-Claim
were I-Claim
comparable I-Claim
with I-Claim
or I-Claim
without I-Claim
a I-Claim
washout I-Claim
, I-Claim
supporting I-Claim
direct I-Claim
switching I-Claim
from I-Claim
anti I-Claim
- I-Claim
tnf I-Claim
therapy I-Claim
to I-Claim
abatacept I-Claim
as I-Claim
an I-Claim
option I-Claim
in I-Claim
clinical I-Claim
practice I-Claim
. I-Claim
!LF! !LF!
to O
assess O
patient O
- O
reported O
prostate O
cancer O
- O
specific O
quality O
of O
life O
2 O
and O
3 O
years O
after O
radiotherapy O
to O
the O
prostate O
in O
a O
randomized O
dose O
- O
escalation O
trial O
of O
70 O
versus O
78 O
gy O
conducted O
from O
1993 O
to O
1998 O
. O
!LF! !LF!
two O
years O
after O
completing O
radiotherapy O
, O
a O
questionnaire O
that O
assessed O
bladder O
, O
rectal O
, O
and O
sexual O
function O
was O
sent O
to O
301 O
patients O
in O
the O
study O
. O
!LF! !LF!
three O
years O
after O
treatment O
, O
a O
second O
questionnaire O
was O
sent O
to O
the O
175 O
patients O
with O
adequate O
follow O
- O
up O
. O
!LF! !LF!
three B-Premise
years I-Premise
after I-Premise
radiotherapy I-Premise
, I-Premise
urinary I-Premise
incontinence I-Premise
was I-Premise
reported I-Premise
by I-Premise
35 I-Premise
% I-Premise
of I-Premise
patients I-Premise
, I-Premise
but I-Premise
only I-Premise
6 I-Premise
% I-Premise
required I-Premise
the I-Premise
use I-Premise
of I-Premise
a I-Premise
pad I-Premise
or I-Premise
other I-Premise
protective I-Premise
device I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
reported I-Premise
increased I-Premise
leakage I-Premise
with I-Premise
a I-Premise
full I-Premise
bladder I-Premise
( I-Premise
urge I-Premise
incontinence I-Premise
) I-Premise
between I-Premise
the I-Premise
2 I-Premise
and I-Premise
3 I-Premise
- I-Premise
year I-Premise
questionnaires I-Premise
( I-Premise
42 I-Premise
% I-Premise
versus I-Premise
50 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
03 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
at B-Premise
3 I-Premise
years I-Premise
, I-Premise
33 I-Premise
% I-Premise
of I-Premise
patients I-Premise
reported I-Premise
rectal I-Premise
bleeding I-Premise
compared I-Premise
with I-Premise
47 I-Premise
% I-Premise
at I-Premise
2 I-Premise
years I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
006 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
in I-Premise
the I-Premise
78 I-Premise
- I-Premise
gy I-Premise
arm I-Premise
reported I-Premise
more I-Premise
frequent I-Premise
bowel I-Premise
movements I-Premise
at I-Premise
3 I-Premise
years I-Premise
and I-Premise
less I-Premise
change I-Premise
in I-Premise
bowel I-Premise
function I-Premise
at I-Premise
2 I-Premise
years I-Premise
than I-Premise
patients I-Premise
in I-Premise
the I-Premise
70 I-Premise
- I-Premise
gy I-Premise
arm I-Premise
. I-Premise
!LF! !LF!
before B-Premise
radiotherapy I-Premise
, I-Premise
84 I-Premise
% I-Premise
of I-Premise
patients I-Premise
reported I-Premise
erections I-Premise
adequate I-Premise
for I-Premise
intercourse I-Premise
at I-Premise
least I-Premise
a I-Premise
few I-Premise
times I-Premise
during I-Premise
the I-Premise
previous I-Premise
year I-Premise
. I-Premise
!LF! !LF!
after B-Premise
2 I-Premise
and I-Premise
3 I-Premise
years I-Premise
, I-Premise
this I-Premise
had I-Premise
decreased I-Premise
to I-Premise
49 I-Premise
% I-Premise
and I-Premise
41 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
by B-Claim
patient I-Claim
- I-Claim
reported I-Claim
questionnaire I-Claim
, I-Claim
78 I-Claim
gy I-Claim
produced I-Claim
an I-Claim
increase I-Claim
in I-Claim
bowel I-Claim
movement I-Claim
frequency I-Claim
and I-Claim
no I-Claim
increase I-Claim
in I-Claim
bladder I-Claim
or I-Claim
sexual I-Claim
side I-Claim
effects I-Claim
at I-Claim
3 I-Claim
years I-Claim
compared I-Claim
with I-Claim
70 I-Claim
gy I-Claim
. I-Claim
!LF! !LF!
comparing B-Claim
the I-Claim
results I-Claim
2 I-Claim
and I-Claim
3 I-Claim
years I-Claim
after I-Claim
radiotherapy I-Claim
, I-Claim
the I-Claim
symptoms I-Claim
of I-Claim
rectal I-Claim
bleeding I-Claim
had I-Claim
improved I-Claim
, I-Claim
erectile I-Claim
function I-Claim
had I-Claim
decreased I-Claim
, I-Claim
and I-Claim
urinary I-Claim
urge I-Claim
incontinence I-Claim
had I-Claim
increased I-Claim
. I-Claim
!LF! !LF!
due O
to O
the O
various O
inter O
- O
individual O
differences O
in O
the O
biological O
characteristics O
of O
tumor O
cells O
, O
as O
well O
as O
issues O
on O
the O
efficacy O
, O
adverse O
reactions O
, O
and O
defects O
of O
existing O
drugs O
, O
we O
compared O
the O
clinical O
efficacy O
and O
toxicity O
of O
pemetrexed O
and O
gemcitabine O
combined O
with O
cisplatin O
for O
the O
treatment O
of O
previously O
untreated O
advanced O
non O
- O
small O
cell O
lung O
cancer O
( O
nsclc O
) O
. O
!LF! !LF!
251 O
patients O
were O
randomly O
divided O
into O
pemetrexed O
combined O
with O
cisplatin O
group O
( O
pp O
group O
) O
with O
127 O
cases O
and O
gemcitabine O
combined O
with O
cisplatin O
group O
( O
gp O
group O
) O
with O
124 O
cases O
. O
!LF! !LF!
pp O
group O
received O
pemetrexed O
500 O
mg O
/ O
m² O
iv O
infusion O
d1 O
and O
cisplatin O
75 O
mg O
/ O
m² O
iv O
infusion O
d1 O
, O
whereas O
gp O
group O
received O
gemcitabine O
1 O
, O
000 O
mg O
/ O
m² O
iv O
infusion O
d1 O
, O
8 O
and O
cisplatin O
75 O
mg O
/ O
m² O
iv O
infusion O
d1 O
. O
!LF! !LF!
the O
treatment O
cycle O
was O
once O
every O
three O
weeks O
. O
!LF! !LF!
in O
addition O
, O
folic O
acid O
, O
vitamin O
b12 O
, O
and O
dexamethasone O
were O
administered O
in O
both O
groups O
. O
!LF! !LF!
the B-Premise
total I-Premise
clinical I-Premise
effective I-Premise
rates I-Premise
in I-Premise
pp I-Premise
group I-Premise
and I-Premise
gp I-Premise
group I-Premise
were I-Premise
25 I-Premise
. I-Premise
20 I-Premise
% I-Premise
and I-Premise
17 I-Premise
. I-Premise
74 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
the B-Premise
total I-Premise
efficiencies I-Premise
of I-Premise
non I-Premise
- I-Premise
squamous I-Premise
cell I-Premise
carcinoma I-Premise
were I-Premise
27 I-Premise
. I-Premise
62 I-Premise
% I-Premise
and I-Premise
16 I-Premise
. I-Premise
00 I-Premise
% I-Premise
. I-Premise
!LF! !LF!
the B-Premise
tumor I-Premise
progression I-Premise
duration I-Premise
in I-Premise
these I-Premise
two I-Premise
groups I-Premise
was I-Premise
6 I-Premise
. I-Premise
5 I-Premise
and I-Premise
5 I-Premise
. I-Premise
6 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
the B-Premise
median I-Premise
survival I-Premise
time I-Premise
in I-Premise
the I-Premise
two I-Premise
groups I-Premise
was I-Premise
16 I-Premise
. I-Premise
9 I-Premise
and I-Premise
17 I-Premise
. I-Premise
0 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
with I-Premise
59 I-Premise
. I-Premise
62 I-Premise
% I-Premise
and I-Premise
65 I-Premise
. I-Premise
87 I-Premise
% I-Premise
survival I-Premise
rates I-Premise
of I-Premise
1 I-Premise
year I-Premise
and I-Premise
27 I-Premise
. I-Premise
28 I-Premise
% I-Premise
and I-Premise
27 I-Premise
. I-Premise
93 I-Premise
% I-Premise
survival I-Premise
rates I-Premise
of I-Premise
2 I-Premise
years I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
the B-Premise
total I-Premise
efficacy I-Premise
of I-Premise
non I-Premise
- I-Premise
squamous I-Premise
cell I-Premise
carcinoma I-Premise
in I-Premise
the I-Premise
pp I-Premise
group I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
that I-Premise
in I-Premise
gp I-Premise
group I-Premise
. I-Premise
!LF! !LF!
the B-Premise
results I-Premise
were I-Premise
statistically I-Premise
significant I-Premise
. I-Premise
!LF! !LF!
however O
, O
there O
were O
no O
significant O
differences O
in O
total O
response O
rates O
, O
tumor O
progression O
duration O
, O
and O
median O
survival O
rates O
of O
1 O
and O
2 O
years O
. O
!LF! !LF!
the B-Premise
rate I-Premise
of I-Premise
adverse I-Premise
reactions I-Premise
, I-Premise
including I-Premise
white I-Premise
blood I-Premise
cell I-Premise
reduction I-Premise
, I-Premise
lower I-Premise
platelet I-Premise
count I-Premise
, I-Premise
lower I-Premise
hemoglobin I-Premise
, I-Premise
and I-Premise
hair I-Premise
loss I-Premise
in I-Premise
the I-Premise
pp I-Premise
group I-Premise
was I-Premise
significantly I-Premise
lower I-Premise
than I-Premise
that I-Premise
in I-Premise
the I-Premise
gp I-Premise
group I-Premise
. I-Premise
!LF! !LF!
the O
results O
were O
statistically O
significant O
. O
!LF! !LF!
the B-Claim
clinical I-Claim
efficacy I-Claim
of I-Claim
pemetrexed I-Claim
and I-Claim
gemcitabine I-Claim
combined I-Claim
with I-Claim
cisplatin I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
previously I-Claim
untreated I-Claim
advanced I-Claim
nsclc I-Claim
was I-Claim
roughly I-Claim
the I-Claim
same I-Claim
, I-Claim
but B-Claim
the I-Claim
adverse I-Claim
reactions I-Claim
decreased I-Claim
significantly I-Claim
in I-Claim
the I-Claim
pp I-Claim
group I-Claim
compared I-Claim
with I-Claim
those I-Claim
in I-Claim
the I-Claim
gp I-Claim
group I-Claim
. I-Claim
!LF! !LF!
therefore B-Claim
, I-Claim
pemetrexed I-Claim
combined I-Claim
with I-Claim
cisplatin I-Claim
can I-Claim
be I-Claim
used I-Claim
as I-Claim
a I-Claim
safe I-Claim
and I-Claim
effective I-Claim
drug I-Claim
for I-Claim
clinical I-Claim
first I-Claim
- I-Claim
line I-Claim
treatment I-Claim
for I-Claim
previously I-Claim
untreated I-Claim
nsclc I-Claim
. I-Claim
!LF! !LF!
this O
randomised O
multicentre O
trial O
was O
conducted O
to O
establish O
the O
optimal O
duration O
of O
palliative O
chemotherapy O
in O
advanced O
non O
- O
small O
- O
cell O
lung O
cancer O
( O
nsclc O
) O
. O
!LF! !LF!
we O
compared O
a O
policy O
of O
three O
vs O
six O
courses O
of O
new O
- O
generation O
platinum O
- O
based O
combination O
chemotherapy O
with O
regard O
to O
effects O
on O
quality O
of O
life O
( O
qol O
) O
and O
survival O
. O
!LF! !LF!
patients O
with O
stage O
iiib O
or O
iv O
nsclc O
and O
who O
performance O
status O
( O
ps O
) O
0 O
- O
2 O
were O
randomised O
to O
receive O
three O
( O
c3 O
) O
or O
six O
( O
c6 O
) O
courses O
of O
carboplatin O
( O
area O
under O
the O
curve O
( O
auc O
) O
4 O
, O
chatelut O
' O
s O
formula O
, O
equivalent O
to O
calvert O
' O
s O
auc O
5 O
) O
on O
day O
1 O
and O
vinorelbine O
25 O
mg O
m O
( O
- O
2 O
) O
on O
days O
1 O
and O
8 O
of O
a O
3 O
- O
week O
cycle O
. O
!LF! !LF!
key O
end O
points O
were O
qol O
at O
18 O
weeks O
, O
measured O
with O
eortc O
quality O
of O
life O
questionnaire O
( O
qlq O
) O
- O
c30 O
and O
qlq O
- O
lc13 O
, O
and O
overall O
survival O
. O
!LF! !LF!
secondary O
end O
points O
were O
progression O
- O
free O
survival O
and O
need O
of O
palliative O
radiotherapy O
. O
!LF! !LF!
two O
hundred O
and O
ninety O
- O
seven O
patients O
were O
randomised O
( O
c3 O
150 O
, O
c6 O
147 O
) O
. O
!LF! !LF!
their O
median O
age O
was O
65 O
years O
, O
30 O
% O
had O
ps O
2 O
and O
76 O
% O
stage O
iv O
disease O
. O
!LF! !LF!
seventy O
- O
eight O
and O
54 O
% O
of O
c3 O
and O
c6 O
patients O
, O
respectively O
, O
completed O
all O
scheduled O
chemotherapy O
courses O
. O
!LF! !LF!
compliance O
with O
qol O
questionnaires O
was O
88 O
% O
. O
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
significant I-Premise
group I-Premise
differences I-Premise
in I-Premise
global I-Premise
qol I-Premise
, I-Premise
pain I-Premise
or I-Premise
fatigue I-Premise
up I-Premise
to I-Premise
26 I-Premise
weeks I-Premise
. I-Premise
!LF! !LF!
the B-Premise
dyspnoea I-Premise
palliation I-Premise
rate I-Premise
was I-Premise
lower I-Premise
in I-Premise
the I-Premise
c3 I-Premise
arm I-Premise
at I-Premise
18 I-Premise
and I-Premise
26 I-Premise
weeks I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
, I-Premise
but B-Premise
this I-Premise
finding I-Premise
was I-Premise
inconsistent I-Premise
across I-Premise
different I-Premise
methods I-Premise
of I-Premise
analysis I-Premise
. I-Premise
!LF! !LF!
median B-Premise
survival I-Premise
in I-Premise
the I-Premise
c3 I-Premise
group I-Premise
was I-Premise
28 I-Premise
vs I-Premise
32 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
c6 I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
75 I-Premise
, I-Premise
hr I-Premise
1 I-Premise
. I-Premise
04 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
. I-Premise
82 I-Premise
- I-Premise
1 I-Premise
. I-Premise
31 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
one B-Premise
- B-Premise
and I-Premise
2 I-Premise
- I-Premise
year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
25 I-Premise
and I-Premise
9 I-Premise
% I-Premise
vs I-Premise
25 I-Premise
and I-Premise
5 I-Premise
% I-Premise
in I-Premise
the I-Premise
c3 I-Premise
and I-Premise
c6 I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
median B-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
was I-Premise
16 I-Premise
and I-Premise
21 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
c3 I-Premise
and I-Premise
c6 I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
21 I-Premise
, I-Premise
hr I-Premise
0 I-Premise
. I-Premise
86 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
. I-Premise
68 I-Premise
- I-Premise
1 I-Premise
. I-Premise
08 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
in B-Claim
conclusion I-Claim
, I-Claim
palliative I-Claim
chemotherapy I-Claim
with I-Claim
carboplatin I-Claim
and I-Claim
vinorelbine I-Claim
beyond I-Claim
three I-Claim
courses I-Claim
conveys I-Claim
no I-Claim
survival I-Claim
or I-Claim
consistent I-Claim
qol I-Claim
benefits I-Claim
in I-Claim
advanced I-Claim
nsclc I-Claim
. I-Claim
!LF! !LF!
to O
determine O
the O
efficacy O
, O
impact O
on O
quality O
- O
of O
- O
life O
( O
qol O
) O
and O
tolerability O
of O
two O
different O
irinotecan O
administration O
schedules O
in O
combination O
with O
capecitabine O
as O
first O
- O
line O
treatment O
of O
metastatic O
colorectal O
cancer O
. O
!LF! !LF!
we O
carried O
out O
a O
randomized O
phase O
ii O
trial O
to O
select O
one O
of O
the O
following O
treatment O
regimens O
for O
further O
investigation O
: O
weekly O
irinotecan O
at O
a O
dose O
of O
70 O
mg O
/ O
m O
( O
2 O
) O
days O
1 O
, O
8 O
, O
15 O
, O
22 O
, O
29 O
( O
arm O
a O
) O
or O
3 O
- O
weekly O
irinotecan O
at O
a O
dose O
of O
300 O
/ O
240 O
mg O
/ O
m O
( O
2 O
) O
day O
1 O
and O
days O
22 O
( O
arm O
b O
) O
in O
combination O
with O
capecitabine O
1000 O
mg O
/ O
m O
( O
2 O
) O
twice O
daily O
days O
1 O
- O
14 O
and O
days O
22 O
- O
35 O
every O
6 O
weeks O
. O
!LF! !LF!
seventy O
- O
five O
patients O
with O
good O
performance O
status O
entered O
the O
trial O
. O
!LF! !LF!
the O
two O
arms O
were O
well O
balanced O
for O
relevant O
patient O
and O
disease O
characteristics O
. O
!LF! !LF!
the B-Premise
most I-Premise
frequent I-Premise
toxic I-Premise
effects I-Premise
were I-Premise
grade I-Premise
3 I-Premise
/ I-Premise
4 I-Premise
diarrhea I-Premise
( I-Premise
arm I-Premise
a I-Premise
: I-Premise
34 I-Premise
% I-Premise
, I-Premise
b I-Premise
: I-Premise
19 I-Premise
% I-Premise
) I-Premise
, I-Premise
grade I-Premise
3 I-Premise
/ I-Premise
4 I-Premise
neutropenia I-Premise
( I-Premise
a I-Premise
: I-Premise
5 I-Premise
% I-Premise
, I-Premise
b I-Premise
: I-Premise
19 I-Premise
% I-Premise
) I-Premise
and I-Premise
grade I-Premise
2 I-Premise
/ I-Premise
3 I-Premise
alopecia I-Premise
( I-Premise
a I-Premise
: I-Premise
26 I-Premise
% I-Premise
, I-Premise
b I-Premise
: I-Premise
65 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
other B-Premise
grade I-Premise
3 I-Premise
/ I-Premise
4 I-Premise
toxic I-Premise
effects I-Premise
were I-Premise
rare I-Premise
( I-Premise
< I-Premise
5 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
response B-Premise
rates I-Premise
were I-Premise
34 I-Premise
% I-Premise
[ I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
ci I-Premise
) I-Premise
20 I-Premise
% I-Premise
to I-Premise
51 I-Premise
% I-Premise
] I-Premise
in I-Premise
arm I-Premise
a I-Premise
and I-Premise
35 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
: I-Premise
20 I-Premise
% I-Premise
to I-Premise
53 I-Premise
% I-Premise
) I-Premise
in I-Premise
arm I-Premise
b I-Premise
. I-Premise
!LF! !LF!
median B-Premise
time I-Premise
to I-Premise
progression I-Premise
was I-Premise
6 I-Premise
. I-Premise
9 I-Premise
( I-Premise
4 I-Premise
. I-Premise
6 I-Premise
- I-Premise
10 I-Premise
. I-Premise
1 I-Premise
) I-Premise
and I-Premise
9 I-Premise
. I-Premise
2 I-Premise
( I-Premise
7 I-Premise
. I-Premise
9 I-Premise
- I-Premise
11 I-Premise
. I-Premise
5 I-Premise
) I-Premise
months I-Premise
and I-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
17 I-Premise
. I-Premise
4 I-Premise
( I-Premise
12 I-Premise
. I-Premise
6 I-Premise
- I-Premise
23 I-Premise
. I-Premise
0 I-Premise
+ I-Premise
) I-Premise
and I-Premise
24 I-Premise
. I-Premise
7 I-Premise
( I-Premise
16 I-Premise
. I-Premise
3 I-Premise
- I-Premise
26 I-Premise
. I-Premise
4 I-Premise
+ I-Premise
) I-Premise
months I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
with I-Premise
an I-Premise
objective I-Premise
tumor I-Premise
response I-Premise
reported I-Premise
better I-Premise
physical I-Premise
well I-Premise
- I-Premise
being I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
, I-Premise
mood I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
, I-Premise
functional I-Premise
performance I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
and I-Premise
less I-Premise
effort I-Premise
to I-Premise
cope I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
non I-Premise
- I-Premise
responders I-Premise
and I-Premise
stable I-Premise
disease I-Premise
patients I-Premise
. I-Premise
!LF! !LF!
the O
primary O
end O
point O
of O
this O
study O
was O
the O
objective O
response O
rate O
and O
based O
on O
the O
statistical O
design O
of O
the O
trial O
, O
the O
3 O
- O
weekly O
irinotecan O
schedule O
was O
selected O
over O
weekly O
irinotecan O
administration O
. O
!LF! !LF!
the B-Claim
3 I-Claim
- I-Claim
weekly I-Claim
irinotecan I-Claim
schedule I-Claim
also I-Claim
seemed I-Claim
advantageous I-Claim
in I-Claim
terms I-Claim
of I-Claim
grade I-Claim
3 I-Claim
/ I-Claim
4 I-Claim
diarrhea I-Claim
, I-Claim
time I-Claim
to I-Claim
progression I-Claim
, I-Claim
overall I-Claim
survival I-Claim
and I-Claim
patient I-Claim
convenience I-Claim
, I-Claim
but B-Claim
the I-Claim
study I-Claim
was I-Claim
not I-Claim
designed I-Claim
to I-Claim
detect I-Claim
differences I-Claim
in I-Claim
these I-Claim
parameters I-Claim
. I-Claim
!LF! !LF!
in O
addition O
, O
tumor B-Claim
response I-Claim
was I-Claim
shown I-Claim
to I-Claim
have I-Claim
a I-Claim
beneficial I-Claim
effect I-Claim
on I-Claim
qol I-Claim
indicators I-Claim
. I-Claim
!LF! !LF!
to O
compare O
protracted O
venous O
infusion O
( O
pvi O
) O
5 O
- O
fluorouracil O
( O
5 O
- O
fu O
) O
with O
and O
without O
mitomycin O
c O
( O
mmc O
) O
in O
a O
prospectively O
randomised O
study O
and O
analyse O
for O
tumour O
response O
, O
survival O
, O
toxicity O
and O
quality O
of O
life O
( O
ql O
) O
. O
!LF! !LF!
two O
hundred O
patients O
with O
advanced O
colorectal O
cancer O
received O
pvi O
5 O
- O
fu O
300 O
mg O
/ O
m2 O
/ O
day O
for O
a O
maximum O
of O
24 O
weeks O
and O
were O
randomised O
to O
pvi O
5 O
- O
fu O
alone O
or O
pvi O
5 O
- O
fu O
+ O
mmc O
10 O
mg O
/ O
m2 O
( O
7 O
mg O
/ O
m2 O
from O
june O
1995 O
) O
6 O
weekly O
for O
4 O
courses O
. O
!LF! !LF!
overall B-Premise
response I-Premise
was I-Premise
54 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
ci I-Premise
] I-Premise
44 I-Premise
. I-Premise
1 I-Premise
% I-Premise
- I-Premise
63 I-Premise
. I-Premise
9 I-Premise
% I-Premise
) I-Premise
with I-Premise
pvi I-Premise
5 I-Premise
- I-Premise
fu I-Premise
+ I-Premise
mmc I-Premise
compared I-Premise
to I-Premise
38 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
: I-Premise
28 I-Premise
. I-Premise
3 I-Premise
% I-Premise
- I-Premise
47 I-Premise
. I-Premise
7 I-Premise
% I-Premise
) I-Premise
for I-Premise
pvi I-Premise
5 I-Premise
- I-Premise
fu I-Premise
alone I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
024 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
median I-Premise
failure I-Premise
free I-Premise
survival I-Premise
was I-Premise
7 I-Premise
. I-Premise
9 I-Premise
months I-Premise
in I-Premise
pvi I-Premise
5 I-Premise
- I-Premise
fu I-Premise
plus I-Premise
mmc I-Premise
and I-Premise
5 I-Premise
. I-Premise
4 I-Premise
months I-Premise
with I-Premise
pvi I-Premise
5 I-Premise
- I-Premise
fu I-Premise
alone I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
033 I-Premise
) I-Premise
and I-Premise
at I-Premise
one I-Premise
year I-Premise
31 I-Premise
. I-Premise
9 I-Premise
% I-Premise
for I-Premise
the I-Premise
combination I-Premise
compared I-Premise
to I-Premise
17 I-Premise
. I-Premise
7 I-Premise
% I-Premise
for I-Premise
pvi I-Premise
5 I-Premise
- I-Premise
fu I-Premise
alone I-Premise
. I-Premise
!LF! !LF!
median B-Premise
survival I-Premise
was I-Premise
14 I-Premise
months I-Premise
with I-Premise
mmc I-Premise
and I-Premise
15 I-Premise
months I-Premise
in I-Premise
5 I-Premise
- I-Premise
fu I-Premise
alone I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
one I-Premise
- I-Premise
year I-Premise
survival I-Premise
51 I-Premise
. I-Premise
7 I-Premise
% I-Premise
vs I-Premise
. I-Premise
57 I-Premise
. I-Premise
2 I-Premise
% I-Premise
. I-Premise
!LF! !LF!
pvi B-Premise
5 I-Premise
- I-Premise
fu I-Premise
+ I-Premise
mmc I-Premise
caused I-Premise
more I-Premise
overall I-Premise
haematological I-Premise
toxicity I-Premise
but I-Premise
ctc I-Premise
grades I-Premise
3 I-Premise
/ I-Premise
4 I-Premise
was I-Premise
increased I-Premise
only I-Premise
for I-Premise
thrombocytopaenia I-Premise
. I-Premise
!LF! !LF!
two B-Premise
patients I-Premise
treated I-Premise
with I-Premise
a I-Premise
cumulative I-Premise
dose I-Premise
of I-Premise
mmc I-Premise
of I-Premise
40 I-Premise
mg I-Premise
/ I-Premise
m2 I-Premise
developed I-Premise
haemolytic I-Premise
uraemic I-Premise
syndrome I-Premise
warranting I-Premise
the I-Premise
reduction I-Premise
in I-Premise
cumulative I-Premise
mmc I-Premise
dose I-Premise
to I-Premise
28 I-Premise
mg I-Premise
/ I-Premise
m2 I-Premise
. I-Premise
!LF! !LF!
the B-Premise
global I-Premise
ql I-Premise
scores I-Premise
were I-Premise
better I-Premise
for I-Premise
pvi I-Premise
5 I-Premise
- I-Premise
fu I-Premise
+ I-Premise
mmc I-Premise
arm I-Premise
at I-Premise
24 I-Premise
weeks I-Premise
, I-Premise
but B-Premise
the I-Premise
remaining I-Premise
ql I-Premise
data I-Premise
showed I-Premise
no I-Premise
differences I-Premise
. I-Premise
!LF! !LF!
pvi B-Claim
5 I-Claim
- I-Claim
fu I-Claim
+ I-Claim
mmc I-Claim
results I-Claim
in I-Claim
failure I-Claim
- I-Claim
free I-Claim
survival I-Claim
and I-Claim
response I-Claim
advantage I-Claim
, I-Claim
tolerable I-Claim
toxicity I-Claim
and I-Claim
better I-Claim
ql I-Claim
when I-Claim
compared I-Claim
to I-Claim
pvi I-Claim
5 I-Claim
- I-Claim
fu I-Claim
alone I-Claim
but I-Claim
no I-Claim
overall I-Claim
survival I-Claim
advantage I-Claim
. I-Claim
!LF! !LF!
there B-Premise
is I-Premise
no I-Premise
irreversible I-Premise
toxicity I-Premise
with I-Premise
mmc I-Premise
at I-Premise
a I-Premise
cumulative I-Premise
dose I-Premise
of I-Premise
28 I-Premise
mg I-Premise
/ I-Premise
m2 I-Premise
. I-Premise
!LF! !LF!
to O
compare O
in O
a O
phase O
iii O
study O
the O
safety O
and O
efficacy O
of O
fludarabine O
to O
that O
of O
cyclophosphamide O
, O
vincristine O
, O
and O
prednisone O
( O
cvp O
) O
in O
recurrent O
, O
low O
- O
grade O
, O
non O
- O
hodgkin O
' O
s O
lymphoma O
after O
previous O
response O
to O
systemic O
treatment O
. O
!LF! !LF!
patients O
were O
randomized O
to O
fludarabine O
( O
25 O
mg O
/ O
m O
( O
2 O
) O
intravenously O
on O
days O
1 O
to O
5 O
, O
every O
28 O
days O
) O
or O
cvp O
( O
cyclophosphamide O
750 O
mg O
/ O
m O
( O
2 O
) O
and O
vincristine O
1 O
. O
2 O
mg O
/ O
m O
( O
2 O
) O
both O
intravenously O
on O
day O
1 O
and O
prednisone O
40 O
mg O
/ O
m O
( O
2 O
) O
orally O
on O
days O
1 O
to O
5 O
, O
every O
21 O
days O
) O
. O
!LF! !LF!
the O
primary O
outcome O
assessed O
was O
progression O
- O
free O
survival O
( O
pfs O
) O
"""" O
; O
"""" O
secondary O
outcomes O
included O
treatment O
- O
free O
survival O
( O
tfs O
) O
, O
overall O
survival O
( O
os O
) O
, O
treatment O
- O
related O
toxicity O
, O
and O
quality O
of O
life O
( O
qol O
) O
according O
to O
the O
european O
organization O
for O
research O
and O
treatment O
of O
cancer O
' O
s O
quality O
of O
life O
questionnaire O
c O
- O
30 O
version O
1 O
. O
0 O
instrument O
. O
!LF! !LF!
ninety O
- O
one O
patients O
were O
randomized O
, O
47 O
to O
fludarabine O
and O
44 O
to O
cvp O
. O
!LF! !LF!
there B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
response I-Premise
rates I-Premise
, I-Premise
with I-Premise
64 I-Premise
% I-Premise
( I-Premise
complete I-Premise
response I-Premise
[ I-Premise
cr I-Premise
] I-Premise
, I-Premise
9 I-Premise
% I-Premise
) I-Premise
for I-Premise
fludarabine I-Premise
versus I-Premise
52 I-Premise
% I-Premise
( I-Premise
cr I-Premise
, I-Premise
7 I-Premise
% I-Premise
) I-Premise
for I-Premise
cvp I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
72 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
with B-Premise
a I-Premise
median I-Premise
follow I-Premise
- I-Premise
up I-Premise
of I-Premise
42 I-Premise
months I-Premise
, I-Premise
median I-Premise
pfs I-Premise
( I-Premise
11 I-Premise
months I-Premise
v I-Premise
9 I-Premise
. I-Premise
1 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
and I-Premise
tfs I-Premise
( I-Premise
15 I-Premise
months I-Premise
v I-Premise
11 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
02 I-Premise
) I-Premise
were I-Premise
superior I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
fludarabine I-Premise
. I-Premise
!LF! !LF!
no B-Premise
difference I-Premise
in I-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
detected I-Premise
( I-Premise
57 I-Premise
months I-Premise
for I-Premise
fludarabine I-Premise
v I-Premise
44 I-Premise
months I-Premise
for I-Premise
cvp I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
95 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
three B-Premise
patients I-Premise
receiving I-Premise
fludarabine I-Premise
died I-Premise
of I-Premise
treatment I-Premise
- I-Premise
related I-Premise
toxicity I-Premise
compared I-Premise
with I-Premise
none I-Premise
of I-Premise
the I-Premise
patients I-Premise
receiving I-Premise
cvp I-Premise
. I-Premise
!LF! !LF!
peripheral B-Premise
neuropathy I-Premise
and I-Premise
alopecia I-Premise
were I-Premise
more I-Premise
common I-Premise
with I-Premise
cvp I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
receiving I-Premise
fludarabine I-Premise
had I-Premise
higher I-Premise
scores I-Premise
for I-Premise
social I-Premise
function I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
008 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
no B-Premise
other I-Premise
differences I-Premise
in I-Premise
qol I-Premise
were I-Premise
detected I-Premise
. I-Premise
!LF! !LF!
in B-Claim
recurrent I-Claim
low I-Claim
- I-Claim
grade I-Claim
lymphoma I-Claim
, I-Claim
fludarabine I-Claim
improves I-Claim
pfs I-Claim
, I-Claim
tfs I-Claim
, I-Claim
and I-Claim
social I-Claim
function I-Claim
scores I-Claim
in I-Claim
comparison I-Claim
with I-Claim
cvp I-Claim
but I-Claim
does I-Claim
not I-Claim
improve I-Claim
os I-Claim
. I-Claim
!LF! !LF!
for B-Claim
patients I-Claim
with I-Claim
anthracycline I-Claim
- I-Claim
pretreated I-Claim
metastatic I-Claim
breast I-Claim
carcinoma I-Claim
, I-Claim
capecitabine I-Claim
plus I-Claim
docetaxel I-Claim
significantly I-Claim
increased I-Claim
overall I-Claim
survival I-Claim
compared I-Claim
with I-Claim
docetaxel I-Claim
alone I-Claim
. I-Claim
!LF! !LF!
the O
current O
study O
evaluated O
the O
cost O
- O
effectiveness O
of O
the O
capecitabine O
/ O
docetaxel O
combination O
versus O
docetaxel O
monotherapy O
, O
comparing O
the O
gain O
in O
quality O
- O
adjusted O
survival O
with O
associated O
health O
care O
costs O
. O
!LF! !LF!
patients O
were O
randomized O
to O
receive O
21 O
- O
day O
cycles O
of O
oral O
capecitabine O
1250 O
mg O
/ O
m2 O
twice O
daily O
, O
on O
days O
1 O
- O
14 O
, O
plus O
docetaxel O
75 O
mg O
/ O
m2 O
day O
1 O
( O
n O
= O
255 O
) O
, O
or O
docetaxel O
100 O
mg O
/ O
m2 O
on O
day O
1 O
( O
n O
= O
256 O
) O
. O
!LF! !LF!
health O
and O
cost O
outcomes O
in O
the O
two O
arms O
were O
compared O
, O
and O
cost O
- O
effectiveness O
was O
estimated O
. O
!LF! !LF!
data O
on O
survival O
time O
and O
medical O
care O
resource O
use O
were O
prospectively O
collected O
in O
the O
trial O
. O
!LF! !LF!
costs O
associated O
with O
medical O
care O
resource O
use O
and O
quality O
- O
of O
- O
life O
adjustments O
were O
obtained O
from O
the O
published O
literature O
. O
!LF! !LF!
the O
incremental O
cost O
- O
effectiveness O
ratio O
was O
calculated O
as O
the O
cost O
per O
quality O
- O
adjusted O
life O
year O
( O
qaly O
) O
gained O
. O
!LF! !LF!
capecitabine B-Premise
/ B-Premise
docetaxel B-Premise
increased I-Premise
the I-Premise
median I-Premise
overall I-Premise
survival I-Premise
by I-Premise
3 I-Premise
months I-Premise
compared I-Premise
with I-Premise
docetaxel I-Premise
alone I-Premise
( I-Premise
14 I-Premise
. I-Premise
5 I-Premise
vs I-Premise
. I-Premise
11 I-Premise
. I-Premise
5 I-Premise
months I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
mean I-Premise
quality I-Premise
- I-Premise
adjusted I-Premise
survival I-Premise
was I-Premise
increased I-Premise
by I-Premise
1 I-Premise
. I-Premise
8 I-Premise
months I-Premise
in I-Premise
the I-Premise
capecitabine I-Premise
/ I-Premise
docetaxel I-Premise
group I-Premise
. I-Premise
!LF! !LF!
the B-Premise
total I-Premise
medical I-Premise
- I-Premise
resource I-Premise
utilization I-Premise
cost I-Premise
per I-Premise
patient I-Premise
was I-Premise
8 I-Premise
. I-Premise
9 I-Premise
% I-Premise
higher I-Premise
with I-Premise
the I-Premise
combination I-Premise
: I-Premise
24 I-Premise
, I-Premise
475 I-Premise
dollars I-Premise
for I-Premise
combination I-Premise
therapy I-Premise
versus I-Premise
22 I-Premise
, I-Premise
477 I-Premise
dollars I-Premise
for I-Premise
single I-Premise
- I-Premise
agent I-Premise
docetaxel I-Premise
. I-Premise
!LF! !LF!
the B-Premise
mean I-Premise
cost I-Premise
per I-Premise
qaly I-Premise
gained I-Premise
with I-Premise
combination I-Premise
therapy I-Premise
was I-Premise
13 I-Premise
, I-Premise
558 I-Premise
dollars I-Premise
( I-Premise
standard I-Premise
deviation I-Premise
, I-Premise
6742 I-Premise
dollars I-Premise
) I-Premise
. I-Premise
!LF! !LF!
cost B-Premise
savings I-Premise
due I-Premise
to I-Premise
reduced I-Premise
docetaxel I-Premise
dose I-Premise
and I-Premise
hospital I-Premise
use I-Premise
were I-Premise
the I-Premise
major I-Premise
cost I-Premise
offsets I-Premise
with I-Premise
the I-Premise
combination I-Premise
. I-Premise
!LF! !LF!
sensitivity B-Premise
analyses I-Premise
showed I-Premise
that I-Premise
varying I-Premise
the I-Premise
mean I-Premise
hospital I-Premise
cost I-Premise
per I-Premise
day I-Premise
from I-Premise
the I-Premise
5th I-Premise
to I-Premise
the I-Premise
95th I-Premise
percentile I-Premise
resulted I-Premise
in I-Premise
cost I-Premise
- I-Premise
utility I-Premise
ratios I-Premise
ranging I-Premise
from I-Premise
20 I-Premise
, I-Premise
326 I-Premise
dollars I-Premise
to I-Premise
as I-Premise
low I-Premise
as I-Premise
6360 I-Premise
dollars I-Premise
. I-Premise
!LF! !LF!
capecitabine B-Claim
/ B-Claim
docetaxel B-Claim
was I-Claim
a I-Claim
cost I-Claim
- I-Claim
effective I-Claim
treatment I-Claim
in I-Claim
patients I-Claim
with I-Claim
anthracycline I-Claim
- I-Claim
pretreated I-Claim
advanced I-Claim
breast I-Claim
carcinoma I-Claim
, I-Claim
and I-Claim
had I-Claim
an I-Claim
incremental I-Claim
cost I-Claim
- I-Claim
effectiveness I-Claim
ratio I-Claim
that I-Claim
compares I-Claim
very I-Claim
favorably I-Claim
with I-Claim
that I-Claim
of I-Claim
many I-Claim
other I-Claim
oncology I-Claim
therapies I-Claim
. I-Claim
!LF! !LF!
epoetin B-Claim
alfa I-Claim
administered I-Claim
at I-Claim
40 I-Claim
, I-Claim
000 I-Claim
u I-Claim
once I-Claim
weekly I-Claim
( I-Claim
qw I-Claim
) I-Claim
to I-Claim
anemic I-Claim
cancer I-Claim
patients I-Claim
receiving I-Claim
chemotherapy I-Claim
increases I-Claim
hemoglobin I-Claim
levels I-Claim
, I-Claim
improves I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
qol I-Claim
) I-Claim
, I-Claim
and I-Claim
reduces I-Claim
transfusions I-Claim
. I-Claim
!LF! !LF!
the O
benefit O
of O
epoetin O
alfa O
in O
maintaining O
hemoglobin O
levels O
in O
cancer O
patients O
with O
hemoglobin O
less O
than O
12 O
g O
/ O
dl O
has O
not O
been O
evaluated O
. O
!LF! !LF!
breast O
cancer O
patients O
( O
n O
= O
354 O
) O
receiving O
chemotherapy O
were O
randomly O
assigned O
in O
1 O
: O
1 O
ratio O
to O
epoetin O
alfa O
( O
40 O
, O
000 O
u O
qw O
) O
or O
standard O
of O
care O
( O
soc O
) O
. O
!LF! !LF!
qol O
was O
assessed O
at O
baseline O
and O
week O
12 O
. O
!LF! !LF!
hemoglobin O
responses O
, O
transfusion O
requirements O
, O
and O
prognostic O
factors O
for O
responses O
were O
measured O
. O
!LF! !LF!
at B-Premise
week I-Premise
12 I-Premise
, I-Premise
functional I-Premise
assessment I-Premise
of I-Premise
cancer I-Premise
therapy I-Premise
- I-Premise
anemia I-Premise
( I-Premise
fact I-Premise
- I-Premise
an I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
mean I-Premise
, I-Premise
2 I-Premise
. I-Premise
16 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
12 I-Premise
. I-Premise
84 I-Premise
for I-Premise
epoetin I-Premise
alfa I-Premise
v I-Premise
- I-Premise
4 I-Premise
. I-Premise
43 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
13 I-Premise
. I-Premise
42 I-Premise
for I-Premise
soc I-Premise
) I-Premise
and I-Premise
fact I-Premise
- I-Premise
an I-Premise
fatigue I-Premise
( I-Premise
mean I-Premise
, I-Premise
1 I-Premise
. I-Premise
85 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
10 I-Premise
. I-Premise
52 I-Premise
for I-Premise
epoetin I-Premise
alfa I-Premise
v I-Premise
- I-Premise
3 I-Premise
. I-Premise
55 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
11 I-Premise
. I-Premise
14 I-Premise
for I-Premise
soc I-Premise
) I-Premise
change I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
alfa I-Premise
group I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
0001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
hemoglobin B-Premise
responses I-Premise
defined I-Premise
as I-Premise
mean I-Premise
hemoglobin I-Premise
> I-Premise
or I-Premise
= I-Premise
12 I-Premise
g I-Premise
/ I-Premise
dl I-Premise
or I-Premise
a I-Premise
> I-Premise
or I-Premise
= I-Premise
2 I-Premise
g I-Premise
/ I-Premise
dl I-Premise
increase I-Premise
compared I-Premise
with I-Premise
baseline I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
alfa I-Premise
group I-Premise
versus I-Premise
soc I-Premise
: I-Premise
52 I-Premise
. I-Premise
0 I-Premise
% I-Premise
v I-Premise
5 I-Premise
. I-Premise
1 I-Premise
% I-Premise
and I-Premise
65 I-Premise
. I-Premise
7 I-Premise
% I-Premise
v I-Premise
6 I-Premise
. I-Premise
3 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
0001 I-Premise
for I-Premise
both I-Premise
comparisons I-Premise
) I-Premise
. I-Premise
!LF! !LF!
percentage B-Premise
transfused I-Premise
was I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
alfa I-Premise
group I-Premise
compared I-Premise
with I-Premise
soc I-Premise
( I-Premise
8 I-Premise
. I-Premise
6 I-Premise
% I-Premise
v I-Premise
22 I-Premise
. I-Premise
9 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
more B-Premise
than I-Premise
90 I-Premise
% I-Premise
of I-Premise
patients I-Premise
did I-Premise
not I-Premise
require I-Premise
a I-Premise
dose I-Premise
increase I-Premise
and I-Premise
28 I-Premise
. I-Premise
7 I-Premise
% I-Premise
had I-Premise
a I-Premise
dose I-Premise
reduction I-Premise
. I-Premise
!LF! !LF!
epoetin B-Claim
alfa I-Claim
administered I-Claim
at I-Claim
40 I-Claim
, I-Claim
000 I-Claim
u I-Claim
qw I-Claim
is I-Claim
effective I-Claim
in I-Claim
improving I-Claim
qol I-Claim
, I-Claim
maintaining I-Claim
hemoglobin I-Claim
level I-Claim
, I-Claim
and I-Claim
reducing I-Claim
transfusion I-Claim
requirements I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
the B-Claim
high I-Claim
effectiveness I-Claim
observed I-Claim
could I-Claim
be I-Claim
attributed I-Claim
in I-Claim
part I-Claim
to I-Claim
early I-Claim
treatment I-Claim
with I-Claim
epoetin I-Claim
alfa I-Claim
. I-Claim
!LF! !LF!
during B-Premise
the I-Premise
last I-Premise
decade I-Premise
, I-Premise
survival I-Premise
rates I-Premise
for I-Premise
breast I-Premise
cancer I-Premise
have I-Premise
increased I-Premise
as I-Premise
a I-Premise
result I-Premise
of I-Premise
earlier I-Premise
detection I-Premise
and I-Premise
increased I-Premise
use I-Premise
of I-Premise
adjuvant I-Premise
therapy I-Premise
. I-Premise
!LF! !LF!
limited O
data O
exist O
on O
the O
psychosocial O
aspects O
of O
the O
transitional O
period O
between O
the O
end O
of O
primary O
treatment O
and O
survivorship O
. O
!LF! !LF!
we O
investigated O
the O
baseline O
psychosocial O
status O
of O
women O
enrolled O
in O
a O
randomized O
trial O
testing O
two O
psychosocial O
interventions O
for O
women O
at O
the O
end O
of O
primary O
treatment O
. O
!LF! !LF!
participants O
, O
identified O
within O
1 O
month O
after O
surgery O
( O
registration O
) O
, O
provided O
demographic O
information O
and O
limited O
measures O
of O
quality O
of O
life O
. O
!LF! !LF!
they O
were O
followed O
until O
they O
finished O
primary O
treatment O
( O
enrollment O
) O
, O
at O
which O
time O
they O
completed O
a O
mailed O
baseline O
survey O
that O
included O
standardized O
measures O
of O
quality O
of O
life O
( O
including O
standardized O
scales O
of O
physical O
and O
emotional O
functioning O
) O
, O
mood O
, O
symptoms O
, O
and O
sexual O
functioning O
. O
!LF! !LF!
a O
total O
of O
558 O
patients O
( O
mean O
age O
= O
56 O
. O
9 O
years O
) O
were O
enrolled O
in O
the O
study O
between O
july O
1 O
, O
1999 O
, O
and O
june O
30 O
, O
2002 O
. O
!LF! !LF!
health O
outcomes O
were O
examined O
according O
to O
treatment O
received O
: O
mastectomy O
with O
and O
without O
chemotherapy O
, O
and O
lumpectomy O
with O
and O
without O
chemotherapy O
. O
!LF! !LF!
all O
statistical O
tests O
were O
two O
- O
sided O
. O
!LF! !LF!
among B-Premise
all I-Premise
treatment I-Premise
groups I-Premise
, I-Premise
patients I-Premise
who I-Premise
had I-Premise
a I-Premise
mastectomy I-Premise
had I-Premise
the I-Premise
poorest I-Premise
physical I-Premise
functioning I-Premise
at I-Premise
registration I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
and I-Premise
at I-Premise
enrollment I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
at B-Premise
enrollment I-Premise
, I-Premise
mood I-Premise
and I-Premise
emotional I-Premise
functioning I-Premise
were I-Premise
similar I-Premise
among I-Premise
all I-Premise
patients I-Premise
, I-Premise
with I-Premise
no I-Premise
differences I-Premise
by I-Premise
type I-Premise
of I-Premise
treatment I-Premise
received I-Premise
. I-Premise
!LF! !LF!
at B-Premise
enrollment I-Premise
, I-Premise
symptoms I-Premise
, I-Premise
including I-Premise
muscle I-Premise
stiffness I-Premise
, I-Premise
breast I-Premise
sensitivity I-Premise
, I-Premise
aches I-Premise
and I-Premise
pains I-Premise
, I-Premise
tendency I-Premise
to I-Premise
take I-Premise
naps I-Premise
, I-Premise
and I-Premise
difficulty I-Premise
concentrating I-Premise
, I-Premise
were I-Premise
common I-Premise
among I-Premise
patients I-Premise
in I-Premise
all I-Premise
groups I-Premise
and I-Premise
were I-Premise
statistically I-Premise
significantly I-Premise
associated I-Premise
with I-Premise
poor I-Premise
physical I-Premise
functioning I-Premise
and I-Premise
emotional I-Premise
well I-Premise
- I-Premise
being I-Premise
. I-Premise
!LF! !LF!
sexual B-Premise
functioning I-Premise
was I-Premise
worse I-Premise
for I-Premise
women I-Premise
who I-Premise
received I-Premise
chemotherapy I-Premise
than I-Premise
for I-Premise
those I-Premise
who I-Premise
did I-Premise
not I-Premise
, I-Premise
regardless I-Premise
of I-Premise
type I-Premise
of I-Premise
surgery I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
at B-Claim
the I-Claim
end I-Claim
of I-Claim
primary I-Claim
treatment I-Claim
for I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
women I-Claim
in I-Claim
all I-Claim
treatment I-Claim
groups I-Claim
report I-Claim
good I-Claim
emotional I-Claim
functioning I-Claim
but I-Claim
report I-Claim
decreased I-Claim
physical I-Claim
functioning I-Claim
, I-Claim
particularly I-Claim
among I-Claim
women I-Claim
who I-Claim
have I-Claim
a I-Claim
mastectomy I-Claim
or I-Claim
receive I-Claim
chemotherapy I-Claim
. I-Claim
!LF! !LF!
clinical B-Claim
interventions I-Claim
to I-Claim
address I-Claim
common I-Claim
symptoms I-Claim
associated I-Claim
with I-Claim
treatment I-Claim
should I-Claim
be I-Claim
considered I-Claim
to I-Claim
improve I-Claim
physical I-Claim
and I-Claim
emotional I-Claim
functioning I-Claim
at I-Claim
the I-Claim
end I-Claim
of I-Claim
primary I-Claim
treatment I-Claim
for I-Claim
breast I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
in B-Premise
a I-Premise
multinational I-Premise
trial I-Premise
of I-Premise
anaemic I-Premise
patients I-Premise
with I-Premise
cancer I-Premise
receiving I-Premise
nonplatinum I-Premise
- I-Premise
containing I-Premise
chemotherapy I-Premise
, I-Premise
epoetin I-Premise
- I-Premise
alfa I-Premise
effectively I-Premise
increased I-Premise
haemoglobin I-Premise
levels I-Premise
, I-Premise
reduced I-Premise
red I-Premise
blood I-Premise
cell I-Premise
transfusion I-Premise
requirements I-Premise
, I-Premise
and I-Premise
improved I-Premise
qol I-Premise
. I-Premise
!LF! !LF!
although O
the O
study O
was O
not O
designed O
or O
powered O
to O
evaluate O
survival O
, O
a B-Premise
survival I-Premise
trend I-Premise
was I-Premise
noted I-Premise
favouring I-Premise
epoetin I-Premise
- I-Premise
alfa I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
median I-Premise
survival I-Premise
17 I-Premise
vs I-Premise
11 I-Premise
months I-Premise
[ I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
126 I-Premise
] I-Premise
) I-Premise
. I-Premise
!LF! !LF!
to O
determine O
the O
incremental O
cost O
utility O
of O
epoetin O
- O
alfa O
versus O
placebo O
in O
anaemic O
patients O
with O
stage O
iv O
breast O
cancer O
from O
a O
uk O
national O
health O
service O
perspective O
. O
!LF! !LF!
patient O
data O
regarding O
transfusions O
, O
epoetin O
- O
alfa O
usage O
, O
chemotherapy O
treatment O
cycles O
, O
and O
adverse O
events O
were O
recorded O
, O
with O
survival O
follow O
- O
up O
for O
12 O
- O
36 O
months O
post O
- O
study O
. O
!LF! !LF!
stage O
iv O
breast O
cancer O
therapy O
costs O
were O
collected O
by O
surveying O
uk O
oncologists O
, O
and O
utilities O
for O
associated O
health O
states O
were O
from O
published O
sources O
. O
!LF! !LF!
costs O
were O
in O
british O
pounds O
and O
year O
2000 O
values O
. O
!LF! !LF!
costs O
and O
benefits O
were O
jointly O
determined O
for O
the O
stage O
iv O
breast O
cancer O
subgroup O
( O
n O
= O
55 O
) O
. O
!LF! !LF!
incremental O
cost O
- O
utility O
ratios O
( O
icurs O
) O
were O
calculated O
assuming O
a O
6 O
% O
annual O
discount O
rate O
for O
costs O
and O
a O
1 O
. O
5 O
% O
annual O
discount O
rate O
for O
benefits O
. O
!LF! !LF!
bootstrap O
simulations O
( O
10 O
, O
000 O
iterations O
) O
were O
conducted O
to O
account O
for O
uncertainty O
, O
and O
sensitivity O
analyses O
were O
conducted O
to O
establish O
robustness O
. O
!LF! !LF!
the B-Premise
icur I-Premise
for I-Premise
epoetin I-Premise
- I-Premise
alfa I-Premise
treatment I-Premise
was I-Premise
pounds I-Premise
8 I-Premise
, I-Premise
851 I-Premise
per I-Premise
qaly I-Premise
, I-Premise
with I-Premise
a I-Premise
99 I-Premise
% I-Premise
probability I-Premise
of I-Premise
a I-Premise
positive I-Premise
net I-Premise
benefit I-Premise
in I-Premise
qalys I-Premise
( I-Premise
net I-Premise
benefit I-Premise
= I-Premise
0 I-Premise
. I-Premise
4805 I-Premise
years I-Premise
of I-Premise
perfect I-Premise
life I-Premise
) I-Premise
and I-Premise
a I-Premise
94 I-Premise
% I-Premise
probability I-Premise
of I-Premise
being I-Premise
acceptable I-Premise
using I-Premise
a I-Premise
threshold I-Premise
icur I-Premise
of I-Premise
pounds I-Premise
30 I-Premise
, I-Premise
000 I-Premise
/ I-Premise
qaly I-Premise
. I-Premise
!LF! !LF!
the B-Premise
main I-Premise
cost I-Premise
drivers I-Premise
distinguishing I-Premise
epoetin I-Premise
- I-Premise
alfa I-Premise
from I-Premise
placebo I-Premise
were I-Premise
the I-Premise
costs I-Premise
of I-Premise
drug I-Premise
and I-Premise
patient I-Premise
care I-Premise
due I-Premise
to I-Premise
increased I-Premise
survival I-Premise
. I-Premise
!LF! !LF!
the B-Claim
available I-Claim
data I-Claim
suggest I-Claim
a I-Claim
high I-Claim
probability I-Claim
of I-Claim
favourable I-Claim
cost I-Claim
- I-Claim
utility I-Claim
outcomes I-Claim
with I-Claim
epoetin I-Claim
- I-Claim
alfa I-Claim
treatment I-Claim
for I-Claim
anaemia I-Claim
in I-Claim
patients I-Claim
with I-Claim
stage I-Claim
iv I-Claim
breast I-Claim
cancer I-Claim
receiving I-Claim
nonplatinum I-Claim
- I-Claim
containing I-Claim
chemotherapy I-Claim
. I-Claim
!LF! !LF!
additional B-Claim
studies I-Claim
are I-Claim
warranted I-Claim
. I-Claim
!LF! !LF!
the O
eortc O
24971 O
/ O
tax O
323 O
, O
a O
phase O
iii O
study O
of O
358 O
patients O
with O
unresectable O
locoregionally O
advanced O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
, O
showed O
an O
improved O
progression O
- O
free O
and O
overall O
survival O
( O
os O
) O
with O
less O
toxicity O
when O
docetaxel O
( O
t O
) O
was O
added O
to O
cisplatin O
and O
5 O
- O
fluorouracil O
( O
pf O
) O
for O
induction O
and O
given O
before O
radiotherapy O
( O
rt O
) O
. O
!LF! !LF!
the O
impact O
of O
the O
addition O
of O
docetaxel O
on O
patients O
' O
health O
- O
related O
quality O
of O
life O
( O
hrqol O
) O
and O
symptoms O
was O
investigated O
. O
!LF! !LF!
hrqol O
was O
assessed O
at O
baseline O
, O
at O
end O
of O
cycle O
2 O
, O
and O
4 O
, O
6 O
, O
and O
9 O
months O
after O
completion O
of O
rt O
using O
the O
european O
organisation O
for O
research O
and O
treatment O
of O
cancer O
( O
eortc O
) O
quality O
of O
life O
questionnaire O
c30 O
( O
qlq O
- O
c30 O
) O
and O
the O
eortc O
qlq O
head O
and O
neck O
cancer O
- O
specific O
module O
( O
eortc O
qlq O
- O
h O
& O
amp O
"""" O
; O
"""" O
n35 O
) O
. O
!LF! !LF!
the O
primary O
hrqol O
scale O
was O
global O
hrqol O
per O
protocol O
. O
!LF! !LF!
compliance O
to O
hrqol O
assessments O
was O
97 O
% O
at O
baseline O
, O
but O
dropped O
to O
54 O
% O
by O
6 O
months O
. O
!LF! !LF!
data O
were O
analysed O
up O
to O
6 O
months O
. O
!LF! !LF!
there B-Premise
was I-Premise
a I-Premise
trend I-Premise
towards I-Premise
improved I-Premise
global I-Premise
hrqol I-Premise
during I-Premise
the I-Premise
treatment I-Premise
period I-Premise
. I-Premise
!LF! !LF!
at B-Premise
6 I-Premise
months I-Premise
after I-Premise
the I-Premise
end I-Premise
of I-Premise
rt I-Premise
, I-Premise
global I-Premise
hrqol I-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
tpf I-Premise
arm I-Premise
than I-Premise
in I-Premise
the I-Premise
pf I-Premise
arm I-Premise
, I-Premise
but B-Premise
the I-Premise
low I-Premise
compliance I-Premise
does I-Premise
not I-Premise
allow I-Premise
to I-Premise
draw I-Premise
definitive I-Premise
conclusions I-Premise
. I-Premise
!LF! !LF!
swallowing B-Premise
and I-Premise
coughing I-Premise
problems I-Premise
decreased I-Premise
more I-Premise
in I-Premise
the I-Premise
tpf I-Premise
arm I-Premise
than I-Premise
in I-Premise
the I-Premise
pf I-Premise
arm I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
cycle I-Premise
2 I-Premise
, I-Premise
but B-Premise
to I-Premise
a I-Premise
limited I-Premise
extent I-Premise
. I-Premise
!LF! !LF!
induction B-Claim
chemotherapy I-Claim
with I-Claim
tpf I-Claim
before I-Claim
rt I-Claim
not I-Claim
only I-Claim
improves I-Claim
survival I-Claim
and I-Claim
reduces I-Claim
toxicity I-Claim
compared I-Claim
with I-Claim
pf I-Claim
but I-Claim
also I-Claim
seems I-Claim
to I-Claim
improve I-Claim
global I-Claim
hrqol I-Claim
in I-Claim
a I-Claim
more I-Claim
sustainable I-Claim
manner I-Claim
. I-Claim
!LF! !LF!
a O
randomised O
controlled O
trial O
( O
rct O
) O
demonstrated O
that O
cognitive O
behaviour O
therapy O
( O
cbt O
) O
for O
fatigue O
during O
curative O
cancer O
treatment O
was O
effective O
shortly O
after O
cancer O
treatment O
. O
!LF! !LF!
this O
study O
aimed O
to O
identify O
which O
patient O
characteristics O
predict O
fatigue O
improvement O
after O
cbt O
. O
!LF! !LF!
in O
addition O
, O
the O
long O
- O
term O
effectiveness O
was O
investigated O
. O
!LF! !LF!
patients O
with O
various O
malignancies O
participated O
in O
the O
rct O
( O
n O
= O
210 O
) O
. O
!LF! !LF!
participants O
were O
assessed O
before O
cancer O
treatment O
( O
t1 O
) O
, O
postintervention O
( O
t2 O
) O
, O
which O
was O
at O
least O
2 O
months O
after O
cancer O
treatment O
, O
and O
after O
1 O
- O
year O
follow O
- O
up O
( O
t3 O
) O
. O
!LF! !LF!
monthly O
fatigue O
assessments O
were O
completed O
between O
t2 O
and O
t3 O
. O
!LF! !LF!
a O
regression O
analysis O
with O
interactions O
was O
performed O
to O
determine O
if O
domains O
of O
quality O
of O
life O
( O
eortc O
- O
qlq O
- O
c30 O
) O
functioning O
( O
health O
survey O
short O
form O
- O
36 O
) O
or O
psychological O
distress O
( O
symptom O
checklist O
- O
90 O
) O
moderated O
the O
effect O
of O
cbt O
on O
fatigue O
. O
!LF! !LF!
analyses O
of O
covariance O
were O
used O
to O
study O
the O
long O
- O
term O
effectiveness O
of O
cbt O
. O
!LF! !LF!
fatigue B-Premise
at I-Premise
t2 I-Premise
was I-Premise
predicted I-Premise
by I-Premise
a I-Premise
significant I-Premise
interaction I-Premise
between I-Premise
self I-Premise
- I-Premise
reported I-Premise
cognitive I-Premise
functioning I-Premise
and I-Premise
cbt I-Premise
. I-Premise
!LF! !LF!
no B-Premise
interactions I-Premise
were I-Premise
found I-Premise
between I-Premise
other I-Premise
domains I-Premise
of I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
functioning I-Premise
, I-Premise
psychological I-Premise
distress I-Premise
and I-Premise
cbt I-Premise
. I-Premise
!LF! !LF!
at B-Premise
t3 I-Premise
, I-Premise
no I-Premise
significant I-Premise
difference I-Premise
on I-Premise
fatigue I-Premise
was I-Premise
found I-Premise
between I-Premise
cbt I-Premise
and I-Premise
usual I-Premise
care I-Premise
. I-Premise
!LF! !LF!
exploratory B-Premise
analyses I-Premise
showed I-Premise
that I-Premise
the I-Premise
difference I-Premise
nearly I-Premise
reached I-Premise
significance I-Premise
until I-Premise
7 I-Premise
months I-Premise
postintervention I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
who I-Premise
experienced I-Premise
more I-Premise
concentration I-Premise
and I-Premise
memory I-Premise
problems I-Premise
at I-Premise
t1 I-Premise
benefited I-Premise
more I-Premise
from I-Premise
cbt I-Premise
for I-Premise
fatigue I-Premise
and I-Premise
are I-Premise
indicators I-Premise
. I-Premise
!LF! !LF!
after B-Premise
a I-Premise
year I-Premise
of I-Premise
follow I-Premise
- I-Premise
up I-Premise
, I-Premise
the I-Premise
effect I-Premise
of I-Premise
cbt I-Premise
for I-Premise
fatigue I-Premise
was I-Premise
no I-Premise
longer I-Premise
observed I-Premise
, I-Premise
and I-Premise
the I-Premise
effect I-Premise
on I-Premise
fatigue I-Premise
seemed I-Premise
to I-Premise
be I-Premise
diminished I-Premise
7 I-Premise
months I-Premise
postintervention I-Premise
. I-Premise
!LF! !LF!
the B-Claim
implication I-Claim
is I-Claim
that I-Claim
cbt I-Claim
for I-Claim
fatigue I-Claim
should I-Claim
be I-Claim
offered I-Claim
to I-Claim
patients I-Claim
with I-Claim
cancer I-Claim
with I-Claim
the I-Claim
highest I-Claim
chance I-Claim
to I-Claim
benefit I-Claim
. I-Claim
!LF! !LF!
a O
phase O
iii O
randomized O
trial O
was O
carried O
out O
to O
compare O
two O
schedules O
of O
the O
vinorelbine O
( O
vnr O
) O
- O
cisplatin O
( O
cddp O
) O
regimen O
in O
patients O
with O
locally O
advanced O
unresectable O
poor O
prognosis O
stage O
iiib O
or O
metastatic O
stage O
iv O
non O
- O
small O
cell O
lung O
cancer O
. O
!LF! !LF!
the O
primary O
endpoints O
were O
overall O
survival O
( O
os O
) O
and O
analysis O
of O
toxicity O
, O
while O
secondary O
endpoints O
included O
response O
rates O
, O
time O
- O
to O
- O
progression O
( O
ttp O
) O
and O
quality O
of O
life O
( O
qol O
) O
. O
!LF! !LF!
eligible O
patients O
were O
randomized O
to O
receive O
: O
( O
a O
) O
vnr O
25mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
, O
8 O
and O
15 O
plus O
cddp O
100mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
every O
4 O
weeks O
or O
( O
b O
) O
vnr O
30 O
mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
and O
8 O
plus O
cddp O
80 O
mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
every O
3 O
weeks O
. O
!LF! !LF!
all O
patients O
were O
chemotherapy O
- O
naive O
and O
had O
an O
ecog O
performance O
status O
( O
ps O
) O
of O
0 O
- O
1 O
. O
!LF! !LF!
overall O
278 O
patients O
were O
enrolled O
into O
the O
trial O
. O
!LF! !LF!
overall O
response O
rate O
was O
34 O
% O
( O
95 O
% O
cl O
26 O
- O
42 O
% O
) O
in O
the O
weekly O
vnr O
/ O
cddp O
arm O
, O
and O
32 O
% O
( O
95 O
% O
cl O
24 O
- O
40 O
% O
) O
in O
patients O
treated O
with O
day O
1 O
- O
8 O
vnr O
/ O
cddp O
without O
any O
statistically O
significant O
difference O
. O
!LF! !LF!
median B-Premise
ttp I-Premise
was I-Premise
4 I-Premise
. I-Premise
5 I-Premise
and I-Premise
4 I-Premise
. I-Premise
6 I-Premise
months I-Premise
respectively I-Premise
for I-Premise
weekly I-Premise
vnr I-Premise
/ I-Premise
cddp I-Premise
arm I-Premise
and I-Premise
the I-Premise
day I-Premise
1 I-Premise
- I-Premise
8 I-Premise
vnr I-Premise
/ I-Premise
cddp I-Premise
one I-Premise
. I-Premise
!LF! !LF!
this B-Premise
difference I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
log I-Premise
- I-Premise
rank I-Premise
test I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
818 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
median B-Premise
os I-Premise
was I-Premise
9 I-Premise
. I-Premise
45 I-Premise
and I-Premise
10 I-Premise
months I-Premise
respectively I-Premise
for I-Premise
weekly I-Premise
vnr I-Premise
/ I-Premise
cddp I-Premise
arm I-Premise
and I-Premise
the I-Premise
day I-Premise
1 I-Premise
- I-Premise
8 I-Premise
vnr I-Premise
/ I-Premise
cddp I-Premise
one I-Premise
without I-Premise
statistically I-Premise
a I-Premise
significant I-Premise
difference I-Premise
( I-Premise
log I-Premise
- I-Premise
rank I-Premise
test I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
259 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
- I-Premise
1 I-Premise
and I-Premise
2 I-Premise
- I-Premise
year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
31 I-Premise
and I-Premise
36 I-Premise
% I-Premise
, I-Premise
and I-Premise
10 I-Premise
and I-Premise
11 I-Premise
% I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
the B-Premise
incidence I-Premise
of I-Premise
severe I-Premise
neutropenia I-Premise
( I-Premise
34 I-Premise
% I-Premise
versus I-Premise
68 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0001 I-Premise
) I-Premise
and I-Premise
of I-Premise
febrile I-Premise
neutropenia I-Premise
( I-Premise
5 I-Premise
% I-Premise
versus I-Premise
12 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
026 I-Premise
) I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
the I-Premise
rate I-Premise
of I-Premise
therapy I-Premise
omissions I-Premise
( I-Premise
10 I-Premise
% I-Premise
versus I-Premise
24 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0037 I-Premise
) I-Premise
were I-Premise
higher I-Premise
in I-Premise
the I-Premise
weekly I-Premise
vnr I-Premise
/ I-Premise
cddp I-Premise
arm I-Premise
than I-Premise
in I-Premise
the I-Premise
day I-Premise
1 I-Premise
- I-Premise
8 I-Premise
vnr I-Premise
/ I-Premise
cddp I-Premise
one I-Premise
. I-Premise
!LF! !LF!
the B-Premise
weekly I-Premise
vnr I-Premise
/ I-Premise
cddp I-Premise
regimen I-Premise
was I-Premise
associated I-Premise
with I-Premise
a I-Premise
lower I-Premise
received I-Premise
dose I-Premise
intensity I-Premise
in I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
fashion I-Premise
( I-Premise
9 I-Premise
% I-Premise
versus I-Premise
22 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0001 I-Premise
) I-Premise
and I-Premise
with I-Premise
a I-Premise
lower I-Premise
non I-Premise
- I-Premise
statistically I-Premise
significant I-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
as I-Premise
compared I-Premise
to I-Premise
the I-Premise
day I-Premise
1 I-Premise
- I-Premise
8 I-Premise
vnr I-Premise
/ I-Premise
cddp I-Premise
schedule I-Premise
. I-Premise
!LF! !LF!
the B-Claim
combination I-Claim
of I-Claim
day I-Claim
1 I-Claim
- I-Claim
8 I-Claim
vnr I-Claim
plus I-Claim
cddp I-Claim
every I-Claim
3 I-Claim
weeks I-Claim
is I-Claim
less I-Claim
toxic I-Claim
and I-Claim
better I-Claim
tolerated I-Claim
than I-Claim
the I-Claim
regimen I-Claim
of I-Claim
weekly I-Claim
vnr I-Claim
plus I-Claim
cddp I-Claim
every I-Claim
4 I-Claim
weeks I-Claim
. I-Claim
!LF! !LF!
the B-Claim
two I-Claim
schedules I-Claim
are I-Claim
equivalent I-Claim
in I-Claim
terms I-Claim
of I-Claim
overall I-Claim
response I-Claim
rate I-Claim
, I-Claim
median I-Claim
time I-Claim
- I-Claim
to I-Claim
- I-Claim
progression I-Claim
and I-Claim
overall I-Claim
survival I-Claim
. I-Claim
!LF! !LF!
the B-Claim
combination I-Claim
of I-Claim
vnr I-Claim
on I-Claim
day I-Claim
1 I-Claim
- I-Claim
8 I-Claim
plus I-Claim
cddp I-Claim
every I-Claim
3 I-Claim
weeks I-Claim
may I-Claim
be I-Claim
considered I-Claim
as I-Claim
a I-Claim
reference I-Claim
regimen I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
disease I-Claim
and I-Claim
those I-Claim
who I-Claim
deserve I-Claim
a I-Claim
postoperative I-Claim
therapy I-Claim
, I-Claim
and I-Claim
for I-Claim
future I-Claim
studies I-Claim
. I-Claim
!LF! !LF!
cancer O
related O
fatigue O
( O
crf O
) O
is O
a O
common O
problem O
for O
cancer O
patients O
across O
diagnoses O
during O
chemotherapy O
and O
is O
associated O
with O
physical O
inactivity O
, O
lower O
functional O
level O
and O
lack O
of O
energy O
. O
!LF! !LF!
few O
rct O
exercise O
intervention O
studies O
have O
included O
cancer O
patients O
undergoing O
chemotherapy O
. O
!LF! !LF!
the O
objective O
of O
this O
study O
is O
to O
evaluate O
whether O
a O
six O
- O
week O
supervised O
multimodal O
exercise O
intervention O
, O
adjunct O
to O
chemotherapy O
and O
standard O
care O
, O
can O
reduce O
the O
patient O
' O
s O
crf O
level O
. O
!LF! !LF!
data O
is O
based O
on O
analyses O
of O
a O
prospective O
randomised O
controlled O
trial O
' O
the O
body O
cancer O
trial O
' O
. O
!LF! !LF!
213 O
cancer O
patients O
with O
different O
diagnoses O
were O
randomised O
into O
an O
intervention O
group O
or O
wait O
- O
list O
control O
group O
. O
!LF! !LF!
the O
primary O
outcome O
, O
fatigue O
score O
( O
crf O
) O
, O
was O
evaluated O
by O
the O
functional O
assessment O
of O
cancer O
therapy O
- O
anaemia O
questionnaire O
( O
fact O
- O
an O
- O
) O
( O
fact O
- O
g O
score O
& O
fact O
- O
an O
anemia O
subscale O
) O
. O
!LF! !LF!
supervised O
exercise O
, O
comprising O
high O
- O
intensity O
cardiovascular O
and O
heavy O
resistance O
training O
, O
relaxation O
- O
and O
body O
awareness O
training O
and O
massage O
, O
9 O
h O
weekly O
for O
6 O
weeks O
. O
!LF! !LF!
crf B-Premise
was I-Premise
significantly I-Premise
reduced I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
, I-Premise
corresponding I-Premise
to I-Premise
a I-Premise
fatigue I-Premise
score I-Premise
reduction I-Premise
of I-Premise
3 I-Premise
. I-Premise
04 I-Premise
( I-Premise
effect I-Premise
size I-Premise
of I-Premise
0 I-Premise
. I-Premise
44 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
. I-Premise
17 I-Premise
- I-Premise
0 I-Premise
. I-Premise
72 I-Premise
) I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
002 I-Premise
) I-Premise
, I-Premise
the I-Premise
fact I-Premise
- I-Premise
an I-Premise
score I-Premise
by I-Premise
5 I-Premise
. I-Premise
40 I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
015 I-Premise
) I-Premise
, I-Premise
the I-Premise
fact I-Premise
- I-Premise
an I-Premise
toi I-Premise
score I-Premise
by I-Premise
5 I-Premise
. I-Premise
22 I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
009 I-Premise
) I-Premise
and I-Premise
the I-Premise
anaemia I-Premise
- I-Premise
ans I-Premise
by I-Premise
3 I-Premise
. I-Premise
76 I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
002 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
there B-Premise
was I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
effect I-Premise
on I-Premise
the I-Premise
general I-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
( I-Premise
fact I-Premise
- I-Premise
g I-Premise
) I-Premise
or I-Premise
on I-Premise
any I-Premise
of I-Premise
the I-Premise
individual I-Premise
wellbeing I-Premise
scores I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
physical I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
13 I-Premise
) I-Premise
, I-Premise
emotional I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
87 I-Premise
) I-Premise
, I-Premise
social I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
83 I-Premise
) I-Premise
and I-Premise
functional I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
26 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
in B-Claim
summary I-Claim
, I-Claim
this I-Claim
six I-Claim
- I-Claim
week I-Claim
supervised I-Claim
multimodal I-Claim
exercise I-Claim
intervention I-Claim
can I-Claim
lead I-Claim
to I-Claim
significant I-Claim
reduction I-Claim
in I-Claim
self I-Claim
- I-Claim
reported I-Claim
crf I-Claim
in I-Claim
cancer I-Claim
patients I-Claim
undergoing I-Claim
chemotherapy I-Claim
. I-Claim
!LF! !LF!
chemotherapy O
with O
a O
platinum O
agent O
and O
a O
taxane O
( O
paclitaxel O
) O
is O
considered O
the O
standard O
of O
care O
for O
treatment O
of O
ovarian O
carcinoma O
. O
!LF! !LF!
we O
compared O
the O
combination O
of O
docetaxel O
- O
carboplatin O
with O
the O
combination O
of O
paclitaxel O
- O
carboplatin O
as O
first O
- O
line O
chemotherapy O
for O
stage O
ic O
- O
iv O
epithelial O
ovarian O
or O
primary O
peritoneal O
cancer O
. O
!LF! !LF!
we O
randomly O
assigned O
1077 O
patients O
to O
receive O
docetaxel O
at O
75 O
mg O
/ O
m2 O
of O
body O
surface O
area O
( O
1 O
- O
hour O
intravenous O
infusion O
) O
or O
paclitaxel O
at O
175 O
mg O
/ O
m2 O
( O
3 O
- O
hour O
intravenous O
infusion O
) O
. O
!LF! !LF!
both O
treatments O
then O
were O
followed O
by O
carboplatin O
to O
an O
area O
under O
the O
plasma O
concentration O
- O
time O
curve O
of O
5 O
. O
!LF! !LF!
the O
treatments O
were O
repeated O
every O
3 O
weeks O
for O
six O
cycles O
"""" O
; O
"""" O
in O
responding O
patients O
, O
an O
additional O
three O
cycles O
of O
single O
- O
agent O
carboplatin O
was O
permitted O
. O
!LF! !LF!
survival O
curves O
were O
calculated O
by O
the O
kaplan O
- O
meier O
method O
, O
and O
hazard O
ratios O
were O
estimated O
with O
the O
cox O
proportional O
hazards O
model O
. O
!LF! !LF!
all O
statistical O
tests O
were O
two O
- O
sided O
. O
!LF! !LF!
after B-Premise
a I-Premise
median I-Premise
follow I-Premise
- I-Premise
up I-Premise
of I-Premise
23 I-Premise
months I-Premise
, I-Premise
both I-Premise
groups I-Premise
had I-Premise
similar I-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
( I-Premise
medians I-Premise
of I-Premise
15 I-Premise
. I-Premise
0 I-Premise
months I-Premise
for I-Premise
docetaxel I-Premise
- I-Premise
carboplatin I-Premise
and I-Premise
14 I-Premise
. I-Premise
8 I-Premise
months I-Premise
for I-Premise
paclitaxel I-Premise
- I-Premise
carboplatin I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
hr I-Premise
] I-Premise
docetaxel I-Premise
- I-Premise
paclitaxel I-Premise
= I-Premise
0 I-Premise
. I-Premise
97 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
ci I-Premise
] I-Premise
= I-Premise
0 I-Premise
. I-Premise
83 I-Premise
to I-Premise
1 I-Premise
. I-Premise
13 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
707 I-Premise
) I-Premise
, I-Premise
overall I-Premise
survival I-Premise
rates I-Premise
at I-Premise
2 I-Premise
years I-Premise
( I-Premise
64 I-Premise
. I-Premise
2 I-Premise
% I-Premise
and I-Premise
68 I-Premise
. I-Premise
9 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hr I-Premise
= I-Premise
1 I-Premise
. I-Premise
13 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
0 I-Premise
. I-Premise
92 I-Premise
to I-Premise
1 I-Premise
. I-Premise
39 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
238 I-Premise
) I-Premise
, I-Premise
and I-Premise
objective I-Premise
tumor I-Premise
( I-Premise
58 I-Premise
. I-Premise
7 I-Premise
% I-Premise
and I-Premise
59 I-Premise
. I-Premise
5 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
difference I-Premise
between I-Premise
docetaxel I-Premise
and I-Premise
paclitaxel I-Premise
= I-Premise
- I-Premise
0 I-Premise
. I-Premise
8 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
- I-Premise
8 I-Premise
. I-Premise
6 I-Premise
% I-Premise
to I-Premise
7 I-Premise
. I-Premise
1 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
868 I-Premise
) I-Premise
and I-Premise
ca I-Premise
- I-Premise
125 I-Premise
( I-Premise
75 I-Premise
. I-Premise
8 I-Premise
% I-Premise
and I-Premise
76 I-Premise
. I-Premise
8 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
difference I-Premise
docetaxel I-Premise
- I-Premise
paclitaxel I-Premise
= I-Premise
- I-Premise
1 I-Premise
. I-Premise
0 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
- I-Premise
7 I-Premise
. I-Premise
2 I-Premise
% I-Premise
to I-Premise
5 I-Premise
. I-Premise
1 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
794 I-Premise
) I-Premise
response I-Premise
rates I-Premise
. I-Premise
!LF! !LF!
however B-Premise
, I-Premise
docetaxel I-Premise
- I-Premise
carboplatin I-Premise
was I-Premise
associated I-Premise
with I-Premise
substantially I-Premise
less I-Premise
overall I-Premise
and I-Premise
grade I-Premise
2 I-Premise
or I-Premise
higher I-Premise
neurotoxicity I-Premise
than I-Premise
paclitaxel I-Premise
- I-Premise
carboplatin I-Premise
( I-Premise
grade I-Premise
> I-Premise
or I-Premise
2 I-Premise
neurosensory I-Premise
toxicity I-Premise
in I-Premise
11 I-Premise
% I-Premise
versus I-Premise
30 I-Premise
% I-Premise
, I-Premise
difference I-Premise
= I-Premise
19 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
15 I-Premise
% I-Premise
to I-Premise
24 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
grade I-Premise
> I-Premise
or I-Premise
2 I-Premise
neuromotor I-Premise
toxicity I-Premise
in I-Premise
3 I-Premise
% I-Premise
versus I-Premise
7 I-Premise
% I-Premise
, I-Premise
difference I-Premise
= I-Premise
4 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
1 I-Premise
% I-Premise
to I-Premise
7 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
treatment B-Premise
with I-Premise
docetaxel I-Premise
- I-Premise
carboplatin I-Premise
was I-Premise
associated I-Premise
with I-Premise
statistically I-Premise
significantly I-Premise
more I-Premise
grade I-Premise
3 I-Premise
- I-Premise
4 I-Premise
neutropenia I-Premise
( I-Premise
94 I-Premise
% I-Premise
versus I-Premise
84 I-Premise
% I-Premise
, I-Premise
difference I-Premise
= I-Premise
11 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
7 I-Premise
% I-Premise
to I-Premise
14 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
and I-Premise
neutropenic I-Premise
complications I-Premise
than I-Premise
treatment I-Premise
with I-Premise
paclitaxel I-Premise
- I-Premise
carboplatin I-Premise
, I-Premise
although B-Premise
myelosuppression I-Premise
did I-Premise
not I-Premise
influence I-Premise
dose I-Premise
delivery I-Premise
or I-Premise
patient I-Premise
safety I-Premise
. I-Premise
!LF! !LF!
global B-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
similar I-Premise
in I-Premise
both I-Premise
arms I-Premise
, I-Premise
but B-Premise
substantive I-Premise
differences I-Premise
in I-Premise
many I-Premise
symptom I-Premise
scores I-Premise
favored I-Premise
docetaxel I-Premise
. I-Premise
!LF! !LF!
docetaxel B-Claim
- B-Claim
carboplatin B-Claim
appears I-Claim
to I-Claim
be I-Claim
similar I-Claim
to I-Claim
paclitaxel I-Claim
- I-Claim
carboplatin I-Claim
in I-Claim
terms I-Claim
of I-Claim
progression I-Claim
- I-Claim
free I-Claim
survival I-Claim
and I-Claim
response I-Claim
, I-Claim
although B-Claim
longer I-Claim
follow I-Claim
- I-Claim
up I-Claim
is I-Claim
required I-Claim
for I-Claim
a I-Claim
definitive I-Claim
statement I-Claim
on I-Claim
survival I-Claim
. I-Claim
!LF! !LF!
thus B-Claim
, I-Claim
docetaxel I-Claim
- I-Claim
carboplatin I-Claim
represents I-Claim
an I-Claim
alternative I-Claim
first I-Claim
- I-Claim
line I-Claim
chemotherapy I-Claim
regimen I-Claim
for I-Claim
patients I-Claim
with I-Claim
newly I-Claim
diagnosed I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
exercise O
for O
health O
was O
a O
randomized O
, O
controlled O
trial O
designed O
to O
evaluate O
two O
modes O
of O
delivering O
( O
face O
- O
to O
- O
face O
[ O
ftf O
] O
and O
over O
- O
the O
- O
telephone O
[ O
tel O
] O
) O
an O
8 O
- O
month O
translational O
exercise O
intervention O
, O
commencing O
6 O
- O
weeks O
post O
- O
breast O
cancer O
surgery O
( O
ps O
) O
. O
!LF! !LF!
outcomes O
included O
quality O
of O
life O
( O
qol O
) O
, O
function O
( O
fitness O
and O
upper O
body O
) O
and O
treatment O
- O
related O
side O
effects O
( O
fatigue O
, O
lymphoedema O
, O
body O
mass O
index O
, O
menopausal O
symptoms O
, O
anxiety O
, O
depression O
and O
pain O
) O
. O
!LF! !LF!
generalised O
estimating O
equation O
modelling O
determined O
time O
( O
baseline O
[ O
5 O
weeks O
ps O
] O
, O
mid O
- O
intervention O
[ O
6 O
months O
ps O
] O
, O
post O
- O
intervention O
[ O
12 O
months O
ps O
] O
) O
, O
group O
( O
ftf O
, O
tel O
, O
usual O
care O
[ O
uc O
] O
) O
and O
time O
- O
by O
- O
group O
effects O
. O
!LF! !LF!
194 O
women O
representative O
of O
the O
breast O
cancer O
population O
were O
randomised O
to O
the O
ftf O
( O
n O
= O
67 O
) O
, O
tel O
( O
n O
= O
67 O
) O
and O
uc O
( O
n O
= O
60 O
) O
groups O
. O
!LF! !LF!
there B-Premise
were I-Premise
significant I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
interaction I-Premise
effects I-Premise
on I-Premise
qol I-Premise
, I-Premise
fitness I-Premise
and I-Premise
fatigue I-Premise
with I-Premise
differences I-Premise
being I-Premise
observed I-Premise
between I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
and I-Premise
the I-Premise
uc I-Premise
group I-Premise
. I-Premise
!LF! !LF!
trends B-Premise
observed I-Premise
for I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
were I-Premise
similar I-Premise
. I-Premise
!LF! !LF!
the B-Premise
treatment I-Premise
groups I-Premise
reported I-Premise
improved I-Premise
qol I-Premise
, I-Premise
fitness I-Premise
and I-Premise
fatigue I-Premise
over I-Premise
time I-Premise
and I-Premise
changes I-Premise
observed I-Premise
between I-Premise
baseline I-Premise
and I-Premise
post I-Premise
- I-Premise
intervention I-Premise
were I-Premise
clinically I-Premise
relevant I-Premise
. I-Premise
!LF! !LF!
in B-Premise
contrast I-Premise
, I-Premise
the I-Premise
uc I-Premise
group I-Premise
experienced I-Premise
no I-Premise
change I-Premise
, I-Premise
or I-Premise
worsening I-Premise
qol I-Premise
, I-Premise
fitness I-Premise
and I-Premise
fatigue I-Premise
, I-Premise
mid I-Premise
- I-Premise
intervention I-Premise
. I-Premise
!LF! !LF!
although B-Premise
improvements I-Premise
in I-Premise
the I-Premise
uc I-Premise
group I-Premise
occurred I-Premise
by I-Premise
12 I-Premise
- I-Premise
months I-Premise
post I-Premise
- I-Premise
surgery I-Premise
, I-Premise
the B-Premise
change I-Premise
did I-Premise
not I-Premise
meet I-Premise
the I-Premise
clinically I-Premise
relevant I-Premise
threshold I-Premise
. I-Premise
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
other I-Premise
treatment I-Premise
- I-Premise
related I-Premise
side I-Premise
effects I-Premise
between I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
this B-Claim
translational I-Claim
intervention I-Claim
trial I-Claim
, I-Claim
delivered I-Claim
either I-Claim
ftf I-Claim
or I-Claim
tel I-Claim
, I-Claim
supports I-Claim
exercise I-Claim
as I-Claim
a I-Claim
form I-Claim
of I-Claim
adjuvant I-Claim
breast I-Claim
cancer I-Claim
therapy I-Claim
that I-Claim
can I-Claim
prevent I-Claim
declines I-Claim
in I-Claim
fitness I-Claim
and I-Claim
function I-Claim
during I-Claim
treatment I-Claim
and I-Claim
optimise I-Claim
recovery I-Claim
post I-Claim
- I-Claim
treatment I-Claim
. I-Claim
!LF! !LF!
malignant B-Claim
pleural I-Claim
effusion I-Claim
( I-Claim
mpe I-Claim
) I-Claim
is I-Claim
a I-Claim
common I-Claim
complication I-Claim
of I-Claim
advanced I-Claim
non I-Claim
- I-Claim
small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
nsclc I-Claim
) I-Claim
. I-Claim
!LF! !LF!
bevacizumab B-Claim
, I-Claim
a I-Claim
humanized I-Claim
monoclonal I-Claim
antibody I-Claim
against I-Claim
vascular I-Claim
endothelial I-Claim
growth I-Claim
factor I-Claim
( I-Claim
vegf I-Claim
) I-Claim
, I-Claim
has I-Claim
been I-Claim
shown I-Claim
to I-Claim
be I-Claim
efficient I-Claim
in I-Claim
suppressing I-Claim
the I-Claim
accumulation I-Claim
of I-Claim
pleural I-Claim
fluid I-Claim
. I-Claim
!LF! !LF!
however O
, O
whether O
intrapleural O
delivery O
of O
bevacizumab O
can O
be O
used O
to O
treat O
mpe O
remains O
unknown O
. O
!LF! !LF!
the O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
efficacy O
and O
safety O
of O
combined O
intrapleural O
therapy O
with O
bevacizumab O
and O
cisplatin O
, O
an O
antineoplastic O
agent O
, O
in O
controlling O
mpe O
. O
!LF! !LF!
a O
total O
of O
72 O
nsclc O
study O
subjects O
with O
mpe O
were O
randomly O
assigned O
to O
one O
of O
two O
groups O
. O
!LF! !LF!
the O
first O
group O
received O
intrapleural O
bevacizumab O
( O
300 O
mg O
) O
with O
cisplatin O
( O
30 O
mg O
) O
therapy O
and O
the O
second O
group O
received O
intrapleural O
cisplatin O
( O
30 O
mg O
) O
therapy O
alone O
. O
!LF! !LF!
pleural O
fluid O
was O
collected O
from O
both O
groups O
prior O
to O
and O
following O
treatment O
. O
!LF! !LF!
the O
levels O
of O
vegf O
and O
carcinoembryonic O
antigen O
( O
cea O
) O
in O
the O
pleural O
fluid O
were O
determined O
by O
elisa O
. O
!LF! !LF!
in B-Premise
70 I-Premise
evaluable I-Premise
study I-Premise
subjects I-Premise
, I-Premise
the I-Premise
curative I-Premise
efficacy I-Premise
in I-Premise
the I-Premise
bevacizumab I-Premise
group I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
that I-Premise
found I-Premise
in I-Premise
the I-Premise
cisplatin I-Premise
group I-Premise
( I-Premise
83 I-Premise
. I-Premise
33 I-Premise
vs I-Premise
. I-Premise
50 I-Premise
. I-Premise
00 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
therapy B-Premise
with I-Premise
combined I-Premise
bevacizumab I-Premise
plus I-Premise
cisplatin I-Premise
significantly I-Premise
reduced I-Premise
vegf I-Premise
levels I-Premise
in I-Premise
the I-Premise
pleural I-Premise
fluid I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
in B-Premise
the I-Premise
bevacizumab I-Premise
group I-Premise
, I-Premise
the I-Premise
levels I-Premise
of I-Premise
vegf I-Premise
in I-Premise
the I-Premise
pleural I-Premise
fluid I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
compared I-Premise
to I-Premise
those I-Premise
of I-Premise
the I-Premise
cisplatin I-Premise
group I-Premise
after I-Premise
treatment I-Premise
, I-Premise
which I-Premise
showed I-Premise
greater I-Premise
efficacy I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
in B-Premise
addition I-Premise
, I-Premise
combination I-Premise
therapy I-Premise
showed I-Premise
greater I-Premise
efficacy I-Premise
in I-Premise
the I-Premise
patients I-Premise
with I-Premise
high I-Premise
levels I-Premise
of I-Premise
vegf I-Premise
expression I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
there B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
grade I-Premise
iii I-Premise
/ I-Premise
iv I-Premise
adverse I-Premise
events I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
all B-Premise
procedures I-Premise
were I-Premise
well I-Premise
tolerated I-Premise
by I-Premise
the I-Premise
patients I-Premise
. I-Premise
!LF! !LF!
combined B-Claim
intrapleural I-Claim
therapy I-Claim
with I-Claim
bevacizumab I-Claim
and I-Claim
cisplatin I-Claim
was I-Claim
effective I-Claim
and I-Claim
safe I-Claim
in I-Claim
managing I-Claim
nsclc I-Claim
- I-Claim
mediated I-Claim
mpe I-Claim
. I-Claim
!LF! !LF!
we B-Claim
propose I-Claim
that I-Claim
vegf I-Claim
expression I-Claim
levels I-Claim
in I-Claim
mpe I-Claim
could I-Claim
serve I-Claim
as I-Claim
a I-Claim
prognostic I-Claim
marker I-Claim
for I-Claim
bevacizumab I-Claim
therapy I-Claim
. I-Claim
!LF! !LF!
in B-Claim
endocrine I-Claim
therapy I-Claim
trials I-Claim
in I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
patients I-Claim
with I-Claim
response I-Claim
( I-Claim
complete I-Claim
response I-Claim
/ I-Claim
partial I-Claim
response I-Claim
[ I-Claim
cr I-Claim
/ I-Claim
pr I-Claim
] I-Claim
) I-Claim
and I-Claim
patients I-Claim
with I-Claim
stable I-Claim
disease I-Claim
for I-Claim
at I-Claim
least I-Claim
6 I-Claim
months I-Claim
( I-Claim
sd I-Claim
( I-Claim
6m I-Claim
) I-Claim
) I-Claim
have I-Claim
shown I-Claim
similar I-Claim
survival I-Claim
and I-Claim
therefore I-Claim
are I-Claim
often I-Claim
defined I-Claim
as I-Claim
a I-Claim
population I-Claim
with I-Claim
clinical I-Claim
benefit I-Claim
( I-Claim
patients I-Claim
with I-Claim
cr I-Claim
/ I-Claim
pr I-Claim
or I-Claim
sd I-Claim
( I-Claim
6m I-Claim
) I-Claim
) I-Claim
. I-Claim
!LF! !LF!
we O
evaluated O
the O
impact O
of O
response O
and O
/ O
or O
clinical O
benefit O
on O
quality O
of O
life O
( O
ql O
) O
in O
postmenopausal O
patients O
under O
second O
- O
line O
endocrine O
treatment O
after O
failure O
of O
tamoxifen O
. O
!LF! !LF!
one O
hundred O
twenty O
- O
eight O
of O
177 O
eligible O
patients O
of O
a O
randomized O
trial O
( O
swiss O
group O
for O
clinical O
cancer O
research O
20 O
/ O
90 O
) O
receiving O
either O
formestane O
( O
250 O
mg O
intramuscularly O
biweekly O
) O
or O
megestrol O
acetate O
( O
160 O
mg O
orally O
daily O
) O
were O
analyzed O
. O
!LF! !LF!
the O
baseline O
characteristics O
( O
with O
the O
exception O
of O
site O
of O
metastases O
) O
were O
balanced O
among O
patients O
with O
cr O
/ O
pr O
, O
sd O
( O
6m O
) O
, O
and O
progressive O
disease O
( O
pd O
) O
. O
!LF! !LF!
patients O
completed O
ql O
indicators O
at O
baseline O
and O
at O
1 O
, O
3 O
, O
5 O
, O
7 O
, O
9 O
, O
and O
11 O
months O
. O
!LF! !LF!
responders O
were O
separately O
compared O
with O
nonresponders O
( O
patients O
with O
sd O
( O
6m O
) O
or O
pd O
) O
and O
with O
patients O
with O
sd O
( O
6m O
) O
, O
and O
patients O
with O
clinical O
benefit O
were O
compared O
with O
patients O
with O
pd O
by O
analysis O
of O
covariance O
with O
adjustment O
for O
baseline O
scores O
. O
!LF! !LF!
overall O
, O
88 O
% O
( O
557 O
of O
634 O
) O
of O
expected O
ql O
forms O
were O
received O
. O
!LF! !LF!
in O
the O
comparison O
of O
responders O
versus O
patients O
with O
both O
sd O
( O
6m O
) O
and O
pd O
, O
responders B-Premise
indicated I-Premise
better I-Premise
physical I-Premise
well I-Premise
- I-Premise
being I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
4 I-Premise
) I-Premise
and I-Premise
mood I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
02 I-Premise
) I-Premise
at I-Premise
month I-Premise
3 I-Premise
. I-Premise
!LF! !LF!
compared B-Premise
only I-Premise
with I-Premise
patients I-Premise
with I-Premise
sd I-Premise
( I-Premise
6m I-Premise
) I-Premise
, I-Premise
responders I-Premise
showed I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
baseline I-Premise
ql I-Premise
and I-Premise
time I-Premise
to I-Premise
treatment I-Premise
failure I-Premise
( I-Premise
328 I-Premise
. I-Premise
5 I-Premise
v I-Premise
340 I-Premise
days I-Premise
) I-Premise
. I-Premise
!LF! !LF!
while B-Premise
under I-Premise
treatment I-Premise
, I-Premise
responders I-Premise
reported I-Premise
significantly I-Premise
better I-Premise
physical I-Premise
well I-Premise
- I-Premise
being I-Premise
( I-Premise
months I-Premise
3 I-Premise
to I-Premise
11 I-Premise
) I-Premise
, I-Premise
mood I-Premise
( I-Premise
months I-Premise
5 I-Premise
to I-Premise
11 I-Premise
) I-Premise
, I-Premise
coping I-Premise
( I-Premise
months I-Premise
5 I-Premise
to I-Premise
9 I-Premise
) I-Premise
, I-Premise
and I-Premise
appetite I-Premise
( I-Premise
months I-Premise
7 I-Premise
to I-Premise
11 I-Premise
) I-Premise
and I-Premise
less I-Premise
dizziness I-Premise
( I-Premise
month I-Premise
9 I-Premise
) I-Premise
than I-Premise
patients I-Premise
with I-Premise
sd I-Premise
( I-Premise
6m I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
changes I-Premise
between I-Premise
baseline I-Premise
and I-Premise
months I-Premise
5 I-Premise
and I-Premise
7 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
indicated I-Premise
improvement I-Premise
in I-Premise
responders I-Premise
but I-Premise
heterogeneous I-Premise
patterns I-Premise
in I-Premise
patients I-Premise
with I-Premise
sd I-Premise
( I-Premise
6m I-Premise
) I-Premise
. I-Premise
!LF! !LF!
although B-Premise
the I-Premise
cr I-Premise
/ I-Premise
pr I-Premise
and I-Premise
sd I-Premise
( I-Premise
6m I-Premise
) I-Premise
groups I-Premise
had I-Premise
similar I-Premise
times I-Premise
to I-Premise
treatment I-Premise
failure I-Premise
, I-Premise
patients B-Claim
with I-Claim
cr I-Claim
/ I-Claim
pr I-Claim
reported I-Claim
better I-Claim
ql I-Claim
, I-Claim
suggesting I-Claim
more I-Claim
beneficial I-Claim
response I-Claim
to I-Claim
second I-Claim
- I-Claim
line I-Claim
endocrine I-Claim
treatment I-Claim
. I-Claim
!LF! !LF!
patients O
' O
subjective O
perspective O
should O
be O
taken O
into O
account O
in O
this O
mainly O
palliative O
setting O
. O
!LF! !LF!
future O
trials O
should O
be O
designed O
so O
that O
the O
cr O
/ O
pr O
and O
sd O
( O
6m O
) O
groups O
are O
investigated O
separately O
. O
!LF! !LF!
to O
describe O
the O
food O
and O
drug O
administration O
( O
fda O
) O
review O
and O
approval O
of O
erlotinib O
( O
tarceva O
, O
osi O
pharmaceuticals O
, O
melville O
, O
ny O
) O
for O
treatment O
of O
patients O
with O
locally O
advanced O
or O
metastatic O
non O
- O
small O
cell O
lung O
cancer O
( O
nsclc O
) O
after O
failure O
of O
at O
least O
one O
prior O
chemotherapy O
regimen O
. O
!LF! !LF!
the O
fda O
reviewed O
raw O
data O
in O
electronic O
format O
from O
a O
randomized O
controlled O
clinical O
trial O
comparing O
erlotinib O
with O
placebo O
in O
patients O
with O
locally O
advanced O
or O
metastatic O
nsclc O
after O
failure O
of O
at O
least O
one O
prior O
chemotherapy O
regimen O
. O
!LF! !LF!
patients O
were O
randomized O
in O
a O
2 O
: O
1 O
ratio O
( O
erlotinib O
, O
n O
= O
488 O
and O
placebo O
, O
n O
= O
243 O
) O
. O
!LF! !LF!
erlotinib B-Claim
was I-Claim
superior I-Claim
to I-Claim
placebo I-Claim
for I-Claim
survival I-Claim
, I-Claim
progression I-Claim
- I-Claim
free I-Claim
survival I-Claim
, I-Claim
and I-Claim
tumor I-Claim
response I-Claim
rate I-Claim
. I-Claim
!LF! !LF!
exploratory B-Claim
analyses I-Claim
indicate I-Claim
that I-Claim
epidermal I-Claim
growth I-Claim
factor I-Claim
receptor I-Claim
status I-Claim
may I-Claim
be I-Claim
an I-Claim
important I-Claim
predictor I-Claim
of I-Claim
the I-Claim
erlotinib I-Claim
survival I-Claim
effect I-Claim
. I-Claim
!LF! !LF!
rash B-Premise
( I-Premise
75 I-Premise
% I-Premise
versus I-Premise
17 I-Premise
% I-Premise
) I-Premise
and I-Premise
diarrhea I-Premise
( I-Premise
54 I-Premise
% I-Premise
versus I-Premise
18 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
erlotnib I-Premise
and I-Premise
placebo I-Premise
group I-Premise
respectively I-Premise
were I-Premise
the I-Premise
most I-Premise
common I-Premise
adverse I-Premise
events I-Premise
. I-Premise
!LF! !LF!
severe B-Premise
rash I-Premise
occurred I-Premise
in I-Premise
9 I-Premise
% I-Premise
and I-Premise
severe I-Premise
diarrhea I-Premise
in I-Premise
6 I-Premise
% I-Premise
of I-Premise
erlotinib I-Premise
- I-Premise
treated I-Premise
patients I-Premise
and I-Premise
each I-Premise
resulted I-Premise
in I-Premise
study I-Premise
discontinuation I-Premise
in I-Premise
1 I-Premise
% I-Premise
of I-Premise
patients I-Premise
. I-Premise
!LF! !LF!
dose B-Premise
reductions I-Premise
were I-Premise
required I-Premise
for I-Premise
10 I-Premise
% I-Premise
of I-Premise
patients I-Premise
with I-Premise
rash I-Premise
and I-Premise
4 I-Premise
% I-Premise
of I-Premise
patients I-Premise
with I-Premise
diarrhea I-Premise
. I-Premise
!LF! !LF!
on O
november O
18 O
, O
2004 O
, O
the O
fda O
granted O
erlotinib O
regular O
approval O
for O
treatment O
of O
patients O
with O
locally O
advanced O
or O
metastatic O
nsclc O
after O
failure O
of O
at O
least O
one O
prior O
chemotherapy O
regimen O
. O
!LF! !LF!
the O
applicant O
has O
committed O
to O
conduct O
post O
- O
marketing O
clinical O
trials O
to O
assess O
further O
the O
effect O
of O
epidermal O
growth O
factor O
receptor O
expression O
, O
measured O
with O
immunohistochemical O
staining O
, O
on O
erlotinib O
treatment O
effect O
. O
!LF! !LF!
gastrojejunostomy O
( O
gjj O
) O
and O
stent O
placement O
are O
the O
most O
commonly O
used O
palliative O
treatments O
for O
malignant O
gastric O
outlet O
obstruction O
( O
goo O
) O
. O
!LF! !LF!
in O
a O
recent O
randomized O
trial O
, O
stent O
placement O
was O
preferred O
in O
patients O
with O
a O
relatively O
short O
survival O
and O
gjj O
in O
patients O
with O
a O
longer O
survival O
. O
!LF! !LF!
as O
health O
economic O
aspects O
have O
only O
been O
studied O
in O
general O
terms O
, O
we O
estimated O
the O
cost O
of O
gjj O
and O
that O
of O
stent O
placement O
in O
such O
patients O
. O
!LF! !LF!
in O
the O
sustent O
study O
, O
patients O
were O
randomized O
to O
gjj O
( O
n O
= O
18 O
) O
or O
stent O
placement O
( O
n O
= O
21 O
) O
. O
!LF! !LF!
pancreatic O
cancer O
was O
the O
most O
common O
cause O
of O
goo O
. O
!LF! !LF!
we O
compared O
initial O
costs O
and O
costs O
during O
follow O
- O
up O
. O
!LF! !LF!
for O
cost O
- O
effectiveness O
, O
the O
incremental O
cost O
- O
effectiveness O
ratio O
was O
calculated O
. O
!LF! !LF!
food B-Premise
intake I-Premise
improved I-Premise
more I-Premise
rapidly I-Premise
after I-Premise
stent I-Premise
placement I-Premise
than I-Premise
after I-Premise
gjj I-Premise
, I-Premise
but B-Premise
long I-Premise
- I-Premise
term I-Premise
relief I-Premise
of I-Premise
obstructive I-Premise
symptoms I-Premise
was I-Premise
better I-Premise
after I-Premise
gjj I-Premise
. I-Premise
!LF! !LF!
more B-Premise
major I-Premise
complications I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
occurred I-Premise
and I-Premise
more I-Premise
reinterventions I-Premise
were I-Premise
performed I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
after I-Premise
stent I-Premise
placement I-Premise
than I-Premise
after I-Premise
gjj I-Premise
. I-Premise
!LF! !LF!
initial B-Premise
costs I-Premise
were I-Premise
higher I-Premise
for I-Premise
gjj I-Premise
compared I-Premise
to I-Premise
stent I-Premise
placement I-Premise
( I-Premise
euro8315 I-Premise
vs I-Premise
. I-Premise
euro4820 I-Premise
, I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
we B-Premise
found I-Premise
no I-Premise
difference I-Premise
in I-Premise
follow I-Premise
- I-Premise
up I-Premise
costs I-Premise
. I-Premise
!LF! !LF!
total B-Premise
costs I-Premise
per I-Premise
patient I-Premise
were I-Premise
higher I-Premise
for I-Premise
gjj I-Premise
compared I-Premise
to I-Premise
stent I-Premise
placement I-Premise
( I-Premise
euro12433 I-Premise
vs I-Premise
. I-Premise
euro8819 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
049 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
incremental I-Premise
cost I-Premise
- I-Premise
effectiveness I-Premise
ratio I-Premise
of I-Premise
gjj I-Premise
compared I-Premise
to I-Premise
stent I-Premise
placement I-Premise
was I-Premise
euro164 I-Premise
per I-Premise
extra I-Premise
day I-Premise
with I-Premise
a I-Premise
gastric I-Premise
outlet I-Premise
obstruction I-Premise
scoring I-Premise
system I-Premise
( I-Premise
gooss I-Premise
) I-Premise
> I-Premise
or I-Premise
= I-Premise
2 I-Premise
adjusted I-Premise
for I-Premise
survival I-Premise
. I-Premise
!LF! !LF!
medical B-Claim
effects I-Claim
were I-Claim
better I-Claim
after I-Claim
gjj I-Claim
, O
although B-Claim
gjj I-Claim
had I-Claim
higher I-Claim
total I-Claim
costs I-Claim
. I-Claim
!LF! !LF!
since B-Claim
the I-Claim
cost I-Claim
difference I-Claim
between I-Claim
the I-Claim
two I-Claim
treatments I-Claim
was I-Claim
only I-Claim
small I-Claim
, I-Claim
cost B-Claim
should I-Claim
not I-Claim
play I-Claim
a I-Claim
predominant I-Claim
role I-Claim
when I-Claim
deciding I-Claim
on I-Claim
the I-Claim
type I-Claim
of I-Claim
treatment I-Claim
assigned I-Claim
to I-Claim
patients I-Claim
with I-Claim
malignant I-Claim
goo I-Claim
. I-Claim
!LF! !LF!
we O
conducted O
a O
prospective O
, O
randomized O
, O
multicentre O
clinical O
trial O
comparing O
the O
effects O
and O
costs O
of O
gm O
- O
csf O
as O
an O
adjunct O
to O
intensive O
chemotherapy O
in O
elderly O
patients O
with O
acute O
myeloid O
leukaemia O
( O
aml O
) O
. O
!LF! !LF!
the O
patients O
were O
randomized O
to O
either O
daunomycin O
- O
cytosine O
arabinoside O
( O
control O
arm O
: O
n O
= O
161 O
) O
or O
daunomycin O
- O
cytosine O
arabinoside O
with O
gm O
- O
csf O
( O
gm O
- O
csf O
arm O
: O
n O
= O
157 O
) O
. O
!LF! !LF!
the O
primary O
end O
- O
point O
was O
the O
effect O
of O
gm O
- O
csf O
on O
the O
percentage O
of O
complete O
remissions O
( O
cr O
) O
. O
!LF! !LF!
survival O
duration O
, O
disease O
- O
free O
survival O
, O
quality O
of O
life O
and O
costs O
were O
evaluated O
separately O
. O
!LF! !LF!
cr B-Premise
after I-Premise
remission I-Premise
induction I-Premise
treatment I-Premise
was I-Premise
achieved I-Premise
in I-Premise
55 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
and I-Premise
in I-Premise
56 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
gm I-Premise
- I-Premise
csf I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
ns I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
duration I-Premise
of I-Premise
survival I-Premise
and I-Premise
disease I-Premise
- I-Premise
free I-Premise
survival I-Premise
at I-Premise
2 I-Premise
years I-Premise
after I-Premise
randomization I-Premise
were I-Premise
estimated I-Premise
at I-Premise
22 I-Premise
% I-Premise
and I-Premise
19 I-Premise
% I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
and I-Premise
22 I-Premise
% I-Premise
and I-Premise
14 I-Premise
% I-Premise
for I-Premise
the I-Premise
gm I-Premise
- I-Premise
csf I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
ns I-Premise
) I-Premise
. I-Premise
!LF! !LF!
considering B-Premise
the I-Premise
short I-Premise
- I-Premise
term I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
the I-Premise
administration I-Premise
of I-Premise
gm I-Premise
- I-Premise
csf I-Premise
resulted I-Premise
in I-Premise
more I-Premise
problems I-Premise
with I-Premise
regard I-Premise
to I-Premise
depressed I-Premise
mood I-Premise
, I-Premise
diarrhoea I-Premise
and I-Premise
rash I-Premise
/ I-Premise
eczema I-Premise
. I-Premise
!LF! !LF!
with B-Premise
regard I-Premise
to I-Premise
the I-Premise
long I-Premise
- I-Premise
term I-Premise
quality I-Premise
of I-Premise
life I-Premise
there I-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
the B-Premise
average I-Premise
costs I-Premise
of I-Premise
the I-Premise
primary I-Premise
treatment I-Premise
were I-Premise
higher I-Premise
in I-Premise
gm I-Premise
- I-Premise
csf I-Premise
- I-Premise
treated I-Premise
patients I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
i I-Premise
. I-Premise
e I-Premise
. I-Premise
us I-Premise
$ I-Premise
40782 I-Premise
and I-Premise
us I-Premise
$ I-Premise
34465 I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
costs I-Premise
during I-Premise
the I-Premise
follow I-Premise
- I-Premise
up I-Premise
period I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
the B-Claim
results I-Claim
of I-Claim
this I-Claim
randomized I-Claim
clinical I-Claim
trial I-Claim
indicate I-Claim
that I-Claim
daunomycin I-Claim
- I-Claim
cytosine I-Claim
arabinoside I-Claim
plus I-Claim
gm I-Claim
- I-Claim
csf I-Claim
is I-Claim
not I-Claim
a I-Claim
cost I-Claim
- I-Claim
effective I-Claim
treatment I-Claim
strategy I-Claim
when I-Claim
compared I-Claim
with I-Claim
daunomycin I-Claim
- I-Claim
cytosine I-Claim
arabinoside I-Claim
alone I-Claim
. I-Claim
!LF! !LF!
androgen O
treatment O
for O
prostate O
cancer O
can O
adversely O
affect O
functional O
domains O
of O
quality O
of O
life O
. O
!LF! !LF!
we O
aimed O
to O
assess O
quality O
of O
life O
in O
men O
with O
locally O
advanced O
prostate O
cancer O
in O
an O
open O
- O
label O
phase O
iii O
randomised O
comparison O
between O
lifelong O
endocrine O
treatment O
with O
and O
without O
radiotherapy O
. O
!LF! !LF!
we O
obtained O
quality O
- O
of O
- O
life O
information O
from O
872 O
( O
99 O
% O
) O
of O
875 O
eligible O
men O
with O
locally O
advanced O
prostate O
cancer O
( O
t3 O
"""" O
; O
"""" O
78 O
% O
) O
who O
were O
randomly O
assigned O
, O
between O
1996 O
and O
2002 O
, O
to O
3 O
months O
of O
total O
androgen O
blockade O
followed O
by O
continuous O
endocrine O
treatment O
( O
439 O
patients O
) O
or O
the O
same O
hormonal O
treatment O
with O
radiotherapy O
3 O
months O
after O
randomisation O
( O
436 O
patients O
) O
. O
!LF! !LF!
prospective O
outcomes O
included O
patient O
- O
reported O
symptoms O
and O
quality O
of O
life O
assessed O
with O
questionnaires O
from O
baseline O
to O
4 O
years O
after O
randomisation O
. O
!LF! !LF!
analysis O
was O
by O
intention O
to O
treat O
. O
!LF! !LF!
this O
study O
is O
registered O
as O
an O
international O
standard O
randomised O
controlled O
trial O
, O
number O
isrctn01534787 O
. O
!LF! !LF!
438 O
of O
439 O
men O
assigned O
endocrine O
treatment O
and O
434 O
of O
436 O
assigned O
endocrine O
plus O
radiotherapy O
completed O
at O
least O
one O
questionnaire O
. O
!LF! !LF!
missing O
data O
at O
baseline O
and O
during O
follow O
- O
up O
was O
equally O
distributed O
between O
groups O
. O
!LF! !LF!
at B-Premise
4 I-Premise
years I-Premise
, I-Premise
64 I-Premise
( I-Premise
18 I-Premise
% I-Premise
) I-Premise
of I-Premise
353 I-Premise
patients I-Premise
on I-Premise
combined I-Premise
therapy I-Premise
and I-Premise
39 I-Premise
( I-Premise
12 I-Premise
% I-Premise
) I-Premise
of I-Premise
337 I-Premise
on I-Premise
endocrine I-Premise
- I-Premise
alone I-Premise
therapy I-Premise
had I-Premise
moderate I-Premise
to I-Premise
severe I-Premise
urinary I-Premise
bother I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
005 I-Premise
) I-Premise
, I-Premise
and I-Premise
16 I-Premise
( I-Premise
4 I-Premise
% I-Premise
) I-Premise
of I-Premise
355 I-Premise
on I-Premise
combined I-Premise
therapy I-Premise
and I-Premise
five I-Premise
( I-Premise
2 I-Premise
% I-Premise
) I-Premise
of I-Premise
338 I-Premise
on I-Premise
endocrine I-Premise
treatment I-Premise
alone I-Premise
had I-Premise
pain I-Premise
while I-Premise
urinating I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
024 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
37 B-Premise
( I-Premise
11 I-Premise
% I-Premise
) I-Premise
of I-Premise
350 I-Premise
in I-Premise
the I-Premise
combined I-Premise
group I-Premise
and I-Premise
23 I-Premise
( I-Premise
7 I-Premise
% I-Premise
) I-Premise
of I-Premise
35 I-Premise
in I-Premise
the I-Premise
endocrine I-Premise
- I-Premise
only I-Premise
group I-Premise
had I-Premise
overall I-Premise
bother I-Premise
from I-Premise
all I-Premise
bowel I-Premise
symptoms I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
022 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
281 B-Premise
( I-Premise
85 I-Premise
% I-Premise
) I-Premise
of I-Premise
332 I-Premise
in I-Premise
the I-Premise
combined I-Premise
- I-Premise
treatment I-Premise
group I-Premise
and I-Premise
227 I-Premise
( I-Premise
72 I-Premise
% I-Premise
) I-Premise
of I-Premise
313 I-Premise
in I-Premise
the I-Premise
endocrine I-Premise
- I-Premise
only I-Premise
group I-Premise
had I-Premise
erectile I-Premise
dysfunction I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0002 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
quality B-Premise
of I-Premise
life I-Premise
at I-Premise
4 I-Premise
years I-Premise
was I-Premise
similar I-Premise
, I-Premise
with I-Premise
the I-Premise
exception I-Premise
of I-Premise
decreased I-Premise
social I-Premise
function I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
endocrine I-Premise
treatment I-Premise
plus I-Premise
radiotherapy I-Premise
. I-Premise
!LF! !LF!
although B-Claim
addition I-Claim
of I-Claim
radiotherapy I-Claim
to I-Claim
endocrine I-Claim
treatment I-Claim
significantly I-Claim
increased I-Claim
some I-Claim
treatment I-Claim
- I-Claim
related I-Claim
symptoms I-Claim
, I-Claim
none I-Claim
were I-Claim
serious I-Claim
. I-Claim
!LF! !LF!
given O
the O
substantial O
survival O
benefit O
of O
combined O
treatment O
, O
the B-Claim
increase I-Claim
of I-Claim
symptoms I-Claim
seems I-Claim
acceptable I-Claim
and I-Claim
has I-Claim
little I-Claim
extra I-Claim
effect I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
after I-Claim
4 I-Claim
years I-Claim
compared I-Claim
with I-Claim
endocrine I-Claim
treatment I-Claim
alone I-Claim
. I-Claim
!LF! !LF!
the O
aim O
of O
this O
randomised O
trial O
was O
to O
evaluate O
the O
activity O
and O
toxicity O
of O
a O
biweekly O
regimen O
including O
6s O
- O
leucovorin O
- O
modulated O
5 O
- O
fluorouracil O
( O
lfa O
- O
5 O
- O
fu O
) O
, O
combined O
with O
either O
irinotecan O
( O
cpt O
- O
11 O
+ O
lfa O
5 O
- O
fu O
) O
or O
raltitrexed O
( O
tomudex O
) O
( O
tom O
+ O
lfa O
- O
5 O
- O
fu O
) O
, O
in O
advanced O
colorectal O
cancer O
patients O
, O
and O
to O
make O
a O
preliminary O
comparison O
of O
both O
these O
experimental O
regimens O
with O
a O
biweekly O
administration O
of O
lfa O
- O
5 O
- O
fu O
modulated O
by O
methotrexate O
( O
mtx O
+ O
lfa O
- O
5 O
- O
fu O
) O
. O
!LF! !LF!
one O
hundred O
fifty O
- O
nine O
patients O
with O
advanced O
colorectal O
carcinoma O
previously O
untreated O
for O
the O
metastatic O
disease O
( O
34 O
of O
them O
previously O
exposed O
to O
adjuvant O
5 O
- O
fu O
) O
were O
randomly O
allocated O
to O
receive O
: O
cpt O
- O
11 O
, O
200 O
mg O
/ O
m2 O
i O
. O
v O
. O
!LF! !LF!
on O
day O
1 O
, O
followed O
on O
day O
2 O
by O
lfa O
, O
250 O
mg O
/ O
m2 O
i O
. O
v O
. O
!LF! !LF!
infusion O
and O
5 O
- O
fu O
, O
850 O
mg O
/ O
m2 O
s O
i O
. O
v O
. O
!LF! !LF!
bolus O
( O
arm O
a O
) O
"""" O
; O
"""" O
tom O
, O
3 O
mg O
/ O
m2 O
i O
. O
v O
. O
!LF! !LF!
on O
day O
1 O
, O
followed O
on O
day O
2 O
by O
lfa O
, O
250 O
mg O
/ O
m2 O
i O
. O
v O
. O
!LF! !LF!
infusion O
and O
5 O
- O
fu O
, O
1050 O
mg O
/ O
m2 O
i O
. O
v O
. O
!LF! !LF!
bolus O
( O
arm O
b O
) O
"""" O
; O
"""" O
or O
mtx O
, O
750 O
mg O
/ O
m2 O
i O
. O
v O
. O
!LF! !LF!
on O
day O
1 O
, O
followed O
on O
day O
2 O
by O
lfa O
, O
250 O
mg O
/ O
m2 O
i O
. O
v O
. O
!LF! !LF!
infusion O
and O
5 O
- O
fu O
, O
800 O
mg O
/ O
m2 O
i O
. O
v O
. O
!LF! !LF!
bolus O
( O
arm O
c O
) O
. O
!LF! !LF!
courses O
were O
repeated O
every O
two O
weeks O
in O
all O
arms O
of O
the O
trial O
. O
!LF! !LF!
response O
rate O
( O
rr O
) O
was O
evaluated O
after O
every O
four O
courses O
. O
!LF! !LF!
the O
sample O
size O
was O
defined O
to O
have O
an O
80 O
% O
power O
to O
detect O
a O
35 O
% O
rr O
for O
each O
experimental O
treatment O
, O
and O
to O
show O
a O
difference O
of O
at O
least O
4 O
% O
in O
rr O
with O
the O
standard O
treatment O
if O
the O
true O
difference O
is O
15 O
% O
or O
more O
. O
!LF! !LF!
the O
rrs O
were O
: O
34 O
% O
( O
95 O
% O
confidence O
interval O
( O
95 O
% O
, O
ci O
) O
: O
21 O
% O
- O
48 O
% O
) O
in O
arm O
a O
, O
including O
3 O
complete O
responses O
( O
crs O
) O
and O
15 O
partial O
responses O
( O
prs O
) O
, O
24 O
% O
( O
95 O
% O
ci O
: O
14 O
% O
- O
38 O
% O
) O
in O
arm O
b O
, O
including O
2 O
crs O
and O
11 O
prs O
, O
and O
24 O
% O
( O
95 O
% O
ci O
: O
14 O
% O
- O
38 O
% O
) O
, O
with O
2 O
crs O
and O
11 O
prs O
, O
in O
arm O
c O
. O
after B-Premise
a I-Premise
median I-Premise
follow I-Premise
- I-Premise
up I-Premise
time I-Premise
of I-Premise
62 I-Premise
( I-Premise
range I-Premise
18 I-Premise
- I-Premise
108 I-Premise
) I-Premise
weeks I-Premise
, I-Premise
the I-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
was I-Premise
38 I-Premise
, I-Premise
25 I-Premise
, I-Premise
and I-Premise
27 I-Premise
weeks I-Premise
for I-Premise
arm I-Premise
a I-Premise
, I-Premise
b I-Premise
, I-Premise
and I-Premise
c I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
with B-Premise
94 I-Premise
patients I-Premise
still I-Premise
alive I-Premise
, I-Premise
the I-Premise
one I-Premise
- I-Premise
year I-Premise
probability I-Premise
of I-Premise
survival I-Premise
was I-Premise
61 I-Premise
% I-Premise
, I-Premise
54 I-Premise
% I-Premise
, I-Premise
and I-Premise
59 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
who B-Premise
grade I-Premise
3 I-Premise
or I-Premise
4 I-Premise
neutropenia I-Premise
and I-Premise
diarrhoea I-Premise
affected I-Premise
46 I-Premise
% I-Premise
and I-Premise
16 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
cpt I-Premise
- I-Premise
11 I-Premise
+ I-Premise
lfa I-Premise
5 I-Premise
- I-Premise
fu I-Premise
. I-Premise
!LF! !LF!
median B-Premise
relative I-Premise
dose I-Premise
intensity I-Premise
over I-Premise
eight I-Premise
cycles I-Premise
( I-Premise
di8 I-Premise
) I-Premise
was I-Premise
78 I-Premise
% I-Premise
for I-Premise
cpt I-Premise
- I-Premise
11 I-Premise
and I-Premise
82 I-Premise
% I-Premise
for I-Premise
5 I-Premise
- I-Premise
fu I-Premise
. I-Premise
!LF! !LF!
severe B-Premise
toxicities I-Premise
of I-Premise
tom I-Premise
+ I-Premise
lfa I-Premise
- I-Premise
5 I-Premise
- I-Premise
fu I-Premise
were I-Premise
neutropenia I-Premise
( I-Premise
16 I-Premise
% I-Premise
) I-Premise
and I-Premise
diarrhoea I-Premise
( I-Premise
16 I-Premise
% I-Premise
) I-Premise
, I-Premise
but I-Premise
median I-Premise
relative I-Premise
di8 I-Premise
was I-Premise
93 I-Premise
% I-Premise
for I-Premise
tom I-Premise
, I-Premise
and I-Premise
82 I-Premise
% I-Premise
for I-Premise
5 I-Premise
- I-Premise
fu I-Premise
. I-Premise
!LF! !LF!
cpt B-Premise
- B-Premise
11 B-Premise
+ I-Premise
lfa I-Premise
- I-Premise
5 I-Premise
- I-Premise
fu I-Premise
compares I-Premise
favorably I-Premise
in I-Premise
term I-Premise
of I-Premise
activity I-Premise
and I-Premise
toxicity I-Premise
with I-Premise
other I-Premise
combination I-Premise
regimens I-Premise
including I-Premise
cpt I-Premise
- I-Premise
11 I-Premise
and I-Premise
continuous I-Premise
infusional I-Premise
5 I-Premise
- I-Premise
fu I-Premise
. I-Premise
!LF! !LF!
the B-Claim
hypothesis I-Claim
of I-Claim
a I-Claim
rr I-Claim
15 I-Claim
% I-Claim
higher I-Claim
than I-Claim
the I-Claim
mtx I-Claim
+ I-Claim
lfa I-Claim
- I-Claim
5 I-Claim
- I-Claim
fu I-Claim
treatment I-Claim
can I-Claim
not I-Claim
be I-Claim
ruled I-Claim
out I-Claim
after I-Claim
this I-Claim
interim I-Claim
analysis I-Claim
. I-Claim
!LF! !LF!
the B-Claim
tom I-Claim
+ I-Claim
lfa I-Claim
5 I-Claim
- I-Claim
fu I-Claim
regimen I-Claim
showed I-Claim
a I-Claim
rr I-Claim
and I-Claim
a I-Claim
toxicity I-Claim
profile I-Claim
very I-Claim
close I-Claim
to I-Claim
the I-Claim
mtx I-Claim
+ I-Claim
lfa I-Claim
5 I-Claim
- I-Claim
fu I-Claim
combination I-Claim
, I-Claim
and I-Claim
does I-Claim
not I-Claim
deserve I-Claim
further I-Claim
evaluation I-Claim
in I-Claim
advanced I-Claim
colorectal I-Claim
cancer I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
adjuvant O
chemotherapy O
for O
early O
stage O
non O
- O
small O
- O
cell O
lung O
cancer O
( O
nsclc O
) O
is O
now O
the O
standard O
of O
care O
, O
but O
there O
is O
little O
information O
regarding O
its O
impact O
on O
quality O
of O
life O
( O
qol O
) O
. O
!LF! !LF!
we O
report O
the O
qol O
results O
of O
jbr O
. O
10 O
, O
a O
north O
american O
, O
intergroup O
, O
randomized O
trial O
of O
adjuvant O
cisplatin O
and O
vinorelbine O
compared O
with O
observation O
in O
patients O
who O
have O
completely O
resected O
, O
stages O
ib O
to O
ii O
nsclc O
. O
!LF! !LF!
qol O
was O
assessed O
with O
the O
european O
organisation O
for O
research O
and O
treatment O
of O
cancer O
quality O
of O
life O
questionnaire O
c30 O
and O
a O
trial O
- O
specific O
checklist O
at O
baseline O
and O
at O
weeks O
5 O
and O
9 O
for O
those O
who O
received O
chemotherapy O
and O
at O
follow O
- O
up O
months O
3 O
, O
6 O
, O
9 O
, O
12 O
, O
18 O
, O
24 O
, O
30 O
and O
36 O
. O
!LF! !LF!
a O
10 O
- O
point O
change O
in O
qol O
scores O
from O
baseline O
was O
considered O
clinically O
significant O
. O
!LF! !LF!
four O
hundred O
eighty O
- O
two O
patients O
were O
randomly O
assigned O
on O
jbr O
. O
10 O
. O
!LF! !LF!
a O
total O
of O
173 O
patients O
( O
82 O
% O
of O
the O
expected O
) O
in O
the O
observation O
arm O
and O
186 O
( O
85 O
% O
of O
expected O
) O
in O
the O
chemotherapy O
arm O
completed O
baseline O
qol O
assessments O
. O
!LF! !LF!
the B-Premise
two I-Premise
groups I-Premise
were I-Premise
comparable I-Premise
, I-Premise
with I-Premise
low I-Premise
global I-Premise
qol I-Premise
scores I-Premise
and I-Premise
significant I-Premise
symptom I-Premise
burden I-Premise
, I-Premise
especially I-Premise
pain I-Premise
and I-Premise
fatigue I-Premise
, I-Premise
after I-Premise
thoracotomy I-Premise
. I-Premise
!LF! !LF!
changes O
in O
qol O
during O
chemotherapy O
were O
relatively O
modest O
"""" O
; O
"""" O
fatigue B-Premise
, I-Premise
nausea I-Premise
, I-Premise
and I-Premise
vomiting I-Premise
worsened I-Premise
, I-Premise
but B-Premise
there I-Premise
was I-Premise
a I-Premise
reduction I-Premise
in I-Premise
pain I-Premise
and I-Premise
no I-Premise
change I-Premise
in I-Premise
global I-Premise
qol I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
in I-Premise
the I-Premise
observation I-Premise
arm I-Premise
showed I-Premise
considerable I-Premise
improvements I-Premise
in I-Premise
qol I-Premise
by I-Premise
3 I-Premise
months I-Premise
. I-Premise
!LF! !LF!
qol B-Premise
, I-Premise
except I-Premise
for I-Premise
symptoms I-Premise
of I-Premise
sensory I-Premise
neuropathy I-Premise
and I-Premise
hearing I-Premise
loss I-Premise
, I-Premise
in I-Premise
those I-Premise
treated I-Premise
with I-Premise
chemotherapy I-Premise
returned I-Premise
to I-Premise
baseline I-Premise
by I-Premise
9 I-Premise
months I-Premise
. I-Premise
!LF! !LF!
the B-Claim
findings I-Claim
of I-Claim
this I-Claim
trial I-Claim
indicate I-Claim
that I-Claim
the I-Claim
negative I-Claim
effects I-Claim
of I-Claim
adjuvant I-Claim
chemotherapy I-Claim
on I-Claim
qol I-Claim
appear I-Claim
to I-Claim
be I-Claim
temporary I-Claim
, I-Claim
and I-Claim
that I-Claim
improvements I-Claim
( I-Claim
with I-Claim
a I-Claim
return I-Claim
to I-Claim
baseline I-Claim
function I-Claim
) I-Claim
are I-Claim
likely I-Claim
in I-Claim
most I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
promising O
results O
in O
a O
randomized O
phase O
ii O
trial O
with O
the O
hypoxic O
cytotoxin O
tirapazamine O
( O
tpz O
) O
combined O
with O
cisplatin O
( O
cis O
) O
and O
radiation O
led O
to O
this O
phase O
iii O
trial O
. O
!LF! !LF!
patients O
with O
previously O
untreated O
stage O
iii O
or O
iv O
( O
excluding O
t1 O
- O
2n1 O
and O
m1 O
) O
squamous O
cell O
carcinoma O
of O
the O
oral O
cavity O
, O
oropharynx O
, O
hypopharynx O
, O
or O
larynx O
were O
randomly O
assigned O
to O
receive O
definitive O
radiotherapy O
( O
70 O
gy O
in O
7 O
weeks O
) O
concurrently O
with O
either O
cis O
( O
100 O
mg O
/ O
m O
( O
2 O
) O
) O
on O
day O
1 O
of O
weeks O
1 O
, O
4 O
, O
and O
7 O
or O
cis O
( O
75 O
mg O
/ O
m O
( O
2 O
) O
) O
plus O
tpz O
( O
290 O
mg O
/ O
m O
( O
2 O
) O
/ O
d O
) O
on O
day O
1 O
of O
weeks O
1 O
, O
4 O
, O
and O
7 O
and O
tpz O
alone O
( O
160 O
mg O
/ O
m O
( O
2 O
) O
/ O
d O
) O
on O
days O
1 O
, O
3 O
, O
and O
5 O
of O
weeks O
2 O
and O
3 O
( O
tpz O
/ O
cis O
) O
. O
!LF! !LF!
the O
primary O
end O
point O
was O
overall O
survival O
( O
os O
) O
. O
!LF! !LF!
the O
planned O
sample O
size O
was O
850 O
, O
estimated O
to O
result O
in O
334 O
deaths O
, O
which O
would O
provide O
90 O
% O
power O
to O
detect O
a O
difference O
in O
2 O
- O
year O
survival O
rates O
of O
60 O
% O
v O
70 O
% O
for O
cis O
versus O
tpz O
/ O
cis O
, O
respectively O
( O
hazard O
ratio O
= O
0 O
. O
69 O
) O
. O
!LF! !LF!
eight O
hundred O
sixty O
- O
one O
patients O
were O
accrued O
from O
89 O
sites O
in O
16 O
countries O
. O
!LF! !LF!
in B-Premise
an I-Premise
intent I-Premise
- I-Premise
to I-Premise
- I-Premise
treat I-Premise
analysis I-Premise
, I-Premise
the I-Premise
2 I-Premise
- I-Premise
year I-Premise
os I-Premise
rates I-Premise
were I-Premise
65 I-Premise
. I-Premise
7 I-Premise
% I-Premise
for I-Premise
cis I-Premise
and I-Premise
66 I-Premise
. I-Premise
2 I-Premise
% I-Premise
for I-Premise
tpz I-Premise
/ I-Premise
cis I-Premise
( I-Premise
tpz I-Premise
/ I-Premise
cis I-Premise
- I-Premise
- I-Premise
cis I-Premise
: I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
- I-Premise
5 I-Premise
. I-Premise
9 I-Premise
% I-Premise
to I-Premise
6 I-Premise
. I-Premise
9 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
failure I-Premise
- I-Premise
free I-Premise
survival I-Premise
, I-Premise
time I-Premise
to I-Premise
locoregional I-Premise
failure I-Premise
, I-Premise
or I-Premise
quality I-Premise
of I-Premise
life I-Premise
as I-Premise
measured I-Premise
by I-Premise
functional I-Premise
assessment I-Premise
of I-Premise
cancer I-Premise
therapy I-Premise
- I-Premise
head I-Premise
and I-Premise
neck I-Premise
. I-Premise
!LF! !LF!
we B-Claim
found I-Claim
no I-Claim
evidence I-Claim
that I-Claim
the I-Claim
addition I-Claim
of I-Claim
tpz I-Claim
to I-Claim
chemoradiotherapy I-Claim
, I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
head I-Claim
and I-Claim
neck I-Claim
cancer I-Claim
not I-Claim
selected I-Claim
for I-Claim
the I-Claim
presence I-Claim
of I-Claim
hypoxia I-Claim
, I-Claim
improves I-Claim
os I-Claim
. I-Claim
!LF! !LF!
the O
combination O
of O
carboplatin O
and O
paclitaxel O
is O
the O
standard O
of O
care O
for O
the O
treatment O
of O
ovarian O
cancer O
, O
yet O
rates O
of O
recurrence O
and O
death O
remain O
high O
. O
!LF! !LF!
we O
performed O
a O
prospective O
randomized O
phase O
iii O
study O
to O
examine O
whether O
sequential O
administration O
of O
topotecan O
can O
improve O
the O
efficacy O
of O
carboplatin O
and O
paclitaxel O
in O
first O
- O
line O
treatment O
of O
advanced O
epithelial O
ovarian O
cancer O
. O
!LF! !LF!
a O
total O
of O
1308 O
patients O
with O
previously O
untreated O
ovarian O
cancer O
( O
international O
federation O
of O
gynecology O
and O
obstetrics O
stages O
iib O
- O
iv O
) O
were O
randomly O
assigned O
to O
receive O
six O
cycles O
of O
paclitaxel O
and O
carboplatin O
followed O
by O
either O
four O
cycles O
of O
topotecan O
( O
tc O
- O
top O
"""" O
; O
"""" O
658 O
patients O
) O
or O
surveillance O
( O
tc O
"""" O
; O
"""" O
650 O
patients O
) O
on O
a O
3 O
- O
week O
per O
cycle O
schedule O
. O
!LF! !LF!
the O
primary O
endpoint O
was O
overall O
survival O
, O
and O
secondary O
endpoints O
were O
progression O
- O
free O
survival O
, O
response O
rate O
, O
toxicity O
, O
and O
quality O
of O
life O
. O
!LF! !LF!
time O
- O
to O
- O
event O
data O
were O
analyzed O
using O
the O
kaplan O
- O
meier O
method O
, O
and O
a O
stratified O
log O
- O
rank O
test O
was O
used O
to O
compare O
distributions O
between O
treatment O
groups O
. O
!LF! !LF!
hazard O
ratios O
( O
hrs O
) O
with O
95 O
% O
confidence O
intervals O
( O
cis O
) O
were O
estimated O
using O
a O
cox O
proportional O
hazards O
model O
. O
!LF! !LF!
categorical O
data O
were O
compared O
using O
a O
stratified O
cochran O
- O
mantel O
- O
haenszel O
test O
. O
!LF! !LF!
all O
statistical O
tests O
were O
two O
- O
sided O
. O
!LF! !LF!
median B-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
was I-Premise
18 I-Premise
. I-Premise
2 I-Premise
months I-Premise
in I-Premise
the I-Premise
tc I-Premise
- I-Premise
top I-Premise
arm I-Premise
versus I-Premise
18 I-Premise
. I-Premise
5 I-Premise
months I-Premise
in I-Premise
the I-Premise
tc I-Premise
arm I-Premise
( I-Premise
stratum I-Premise
- I-Premise
adjusted I-Premise
hr I-Premise
= I-Premise
0 I-Premise
. I-Premise
97 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
0 I-Premise
. I-Premise
85 I-Premise
to I-Premise
1 I-Premise
. I-Premise
10 I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
688 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
median B-Premise
overall I-Premise
survival I-Premise
was I-Premise
43 I-Premise
. I-Premise
1 I-Premise
months I-Premise
for I-Premise
the I-Premise
tc I-Premise
- I-Premise
top I-Premise
arm I-Premise
versus I-Premise
44 I-Premise
. I-Premise
5 I-Premise
months I-Premise
for I-Premise
the I-Premise
tc I-Premise
arm I-Premise
( I-Premise
stratum I-Premise
- I-Premise
adjusted I-Premise
hr I-Premise
= I-Premise
1 I-Premise
. I-Premise
01 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
0 I-Premise
. I-Premise
86 I-Premise
to I-Premise
1 I-Premise
. I-Premise
18 I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
885 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
at B-Premise
3 I-Premise
years I-Premise
, I-Premise
overall I-Premise
survival I-Premise
in I-Premise
both I-Premise
arms I-Premise
was I-Premise
57 I-Premise
% I-Premise
( I-Premise
58 I-Premise
. I-Premise
5 I-Premise
% I-Premise
in I-Premise
the I-Premise
tc I-Premise
arm I-Premise
and I-Premise
55 I-Premise
. I-Premise
7 I-Premise
% I-Premise
in I-Premise
the I-Premise
tc I-Premise
- I-Premise
top I-Premise
arm I-Premise
) I-Premise
. I-Premise
!LF! !LF!
compared B-Premise
with I-Premise
patients I-Premise
in I-Premise
the I-Premise
tc I-Premise
arm I-Premise
, I-Premise
patients I-Premise
in I-Premise
the I-Premise
tc I-Premise
- I-Premise
top I-Premise
arm I-Premise
had I-Premise
more I-Premise
grade I-Premise
3 I-Premise
- I-Premise
4 I-Premise
hematologic I-Premise
toxic I-Premise
effects I-Premise
( I-Premise
requiring I-Premise
more I-Premise
supportive I-Premise
care I-Premise
) I-Premise
and I-Premise
more I-Premise
grade I-Premise
3 I-Premise
- I-Premise
4 I-Premise
infections I-Premise
( I-Premise
5 I-Premise
. I-Premise
1 I-Premise
% I-Premise
versus I-Premise
2 I-Premise
. I-Premise
7 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
034 I-Premise
) I-Premise
but I-Premise
did I-Premise
not I-Premise
have I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
increase I-Premise
in I-Premise
febrile I-Premise
neutropenia I-Premise
( I-Premise
3 I-Premise
. I-Premise
3 I-Premise
% I-Premise
versus I-Premise
3 I-Premise
. I-Premise
1 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
80 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
among B-Premise
patients I-Premise
who I-Premise
had I-Premise
measurable I-Premise
disease I-Premise
( I-Premise
tc I-Premise
, I-Premise
n I-Premise
= I-Premise
147 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
tc I-Premise
- I-Premise
top I-Premise
, I-Premise
n I-Premise
= I-Premise
145 I-Premise
) I-Premise
, I-Premise
overall I-Premise
( I-Premise
i I-Premise
. I-Premise
e I-Premise
. I-Premise
, I-Premise
complete I-Premise
or I-Premise
partial I-Premise
) I-Premise
response I-Premise
was I-Premise
69 I-Premise
. I-Premise
0 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
61 I-Premise
. I-Premise
4 I-Premise
% I-Premise
to I-Premise
76 I-Premise
. I-Premise
5 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
tc I-Premise
- I-Premise
top I-Premise
arm I-Premise
and I-Premise
76 I-Premise
. I-Premise
2 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
69 I-Premise
. I-Premise
3 I-Premise
% I-Premise
to I-Premise
83 I-Premise
. I-Premise
1 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
tc I-Premise
arm I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
166 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Claim
sequential I-Claim
addition I-Claim
of I-Claim
topotecan I-Claim
to I-Claim
carboplatin I-Claim
- I-Claim
paclitaxel I-Claim
did I-Claim
not I-Claim
result I-Claim
in I-Claim
superior I-Claim
overall I-Claim
response I-Claim
or I-Claim
progression I-Claim
- I-Claim
free I-Claim
or I-Claim
overall I-Claim
survival I-Claim
. I-Claim
!LF! !LF!
therefore B-Claim
, I-Claim
this I-Claim
regimen I-Claim
is I-Claim
not I-Claim
recommended I-Claim
as I-Claim
standard I-Claim
of I-Claim
care I-Claim
treatment I-Claim
for I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
to O
examine O
health O
- O
related O
quality O
of O
life O
, O
we O
investigated O
the O
effect O
of O
adjuvant O
chemotherapy O
regimens O
on O
utility O
scores O
assessed O
by O
the O
euroqol O
- O
5d O
( O
eq O
- O
5d O
) O
instrument O
in O
a O
randomized O
, O
controlled O
trial O
for O
breast O
cancer O
patients O
after O
surgery O
. O
!LF! !LF!
we O
also O
investigated O
the O
relationship O
between O
functional O
assessment O
of O
cancer O
therapy O
( O
fact O
) O
scale O
scores O
and O
eq O
- O
5d O
utilities O
. O
!LF! !LF!
patients O
were O
randomly O
assigned O
to O
the O
following O
four O
chemotherapy O
regimens O
: O
four O
cycles O
of O
anthracycline O
followed O
by O
paclitaxel O
( O
acp O
) O
, O
four O
cycles O
of O
anthracycline O
- O
containing O
regimens O
followed O
by O
docetaxel O
( O
acd O
) O
, O
eight O
cycles O
of O
paclitaxel O
( O
ptx O
) O
, O
and O
eight O
cycles O
of O
docetaxel O
( O
dtx O
) O
. O
!LF! !LF!
of O
1060 O
registered O
, O
the O
first O
300 O
consecutive O
patients O
were O
included O
in O
the O
current O
utility O
study O
. O
!LF! !LF!
utility O
scores O
were O
assessed O
using O
the O
eq O
- O
5d O
instrument O
at O
baseline O
"""" O
; O
"""" O
cycles O
3 O
, O
5 O
, O
and O
7 O
"""" O
; O
"""" O
7 O
months O
"""" O
; O
"""" O
and O
1 O
year O
. O
!LF! !LF!
we O
also O
evaluated O
the O
correlation O
between O
these O
scores O
and O
fact O
- O
g O
, O
- O
b O
, O
and O
- O
taxane O
scores O
at O
each O
time O
point O
. O
!LF! !LF!
utility B-Premise
scores I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
the I-Premise
dtx I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
acp I-Premise
and I-Premise
acd I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
mean B-Premise
utility I-Premise
scores I-Premise
in I-Premise
the I-Premise
dtx I-Premise
group I-Premise
were I-Premise
lowest I-Premise
at I-Premise
7 I-Premise
months I-Premise
and I-Premise
tended I-Premise
to I-Premise
remain I-Premise
low I-Premise
for I-Premise
a I-Premise
long I-Premise
time I-Premise
. I-Premise
!LF! !LF!
the B-Premise
combined I-Premise
anthracycline I-Premise
followed I-Premise
by I-Premise
taxane I-Premise
group I-Premise
had I-Premise
significantly I-Premise
higher I-Premise
utility I-Premise
scores I-Premise
that I-Premise
the I-Premise
taxane I-Premise
- I-Premise
alone I-Premise
group I-Premise
, I-Premise
with I-Premise
no I-Premise
significant I-Premise
difference I-Premise
depending I-Premise
on I-Premise
the I-Premise
type I-Premise
of I-Premise
taxane I-Premise
. I-Premise
!LF! !LF!
only B-Premise
the I-Premise
fact I-Premise
- I-Premise
g I-Premise
social I-Premise
/ I-Premise
family I-Premise
well I-Premise
- I-Premise
being I-Premise
subscale I-Premise
had I-Premise
no I-Premise
relationship I-Premise
with I-Premise
eq I-Premise
- I-Premise
5d I-Premise
responses I-Premise
and I-Premise
utility I-Premise
scores I-Premise
. I-Premise
!LF! !LF!
although B-Claim
the I-Claim
regimens I-Claim
in I-Claim
this I-Claim
study I-Claim
were I-Claim
similar I-Claim
in I-Claim
that I-Claim
they I-Claim
included I-Claim
taxane I-Claim
, I-Claim
the I-Claim
mean I-Claim
utility I-Claim
scores I-Claim
and I-Claim
longitudinal I-Claim
patterns I-Claim
of I-Claim
utility I-Claim
scores I-Claim
were I-Claim
different I-Claim
among I-Claim
regimens I-Claim
. I-Claim
!LF! !LF!
topical O
photodynamic O
therapy O
( O
pdt O
) O
with O
aminolevulinic O
acid O
( O
ala O
) O
and O
5 O
% O
imiquimod O
cream O
are O
effective O
therapies O
for O
the O
treatment O
of O
actinic O
keratoses O
( O
aks O
) O
, O
but O
no O
split O
- O
face O
studies O
directly O
comparing O
these O
treatment O
options O
are O
available O
in O
the O
literature O
. O
!LF! !LF!
to O
compare O
the O
efficacy O
and O
tolerability O
of O
ala O
- O
pdt O
and O
imiquimod O
5 O
% O
cream O
for O
the O
treatment O
of O
aks O
. O
!LF! !LF!
sixty O
- O
one O
patients O
were O
enrolled O
from O
the O
salt O
lake O
city O
veterans O
affairs O
hospital O
"""" O
; O
"""" O
51 O
completed O
the O
study O
and O
were O
included O
in O
the O
analysis O
. O
!LF! !LF!
all O
patients O
were O
randomized O
to O
receive O
half O
of O
a O
sachet O
of O
imiquimod O
5 O
% O
cream O
twice O
weekly O
on O
half O
of O
their O
face O
and O
two O
sessions O
of O
pdt O
with O
20 O
% O
solution O
of O
ala O
applied O
for O
1 O
hour O
to O
the O
other O
side O
of O
the O
face O
. O
!LF! !LF!
the B-Premise
75 I-Premise
% I-Premise
ak I-Premise
clearance I-Premise
rate I-Premise
was I-Premise
34 I-Premise
. I-Premise
6 I-Premise
% I-Premise
for I-Premise
ala I-Premise
- I-Premise
pdt I-Premise
and I-Premise
25 I-Premise
% I-Premise
for I-Premise
imiquimod I-Premise
5 I-Premise
% I-Premise
cream I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
30 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
mean I-Premise
reduction I-Premise
in I-Premise
ak I-Premise
count I-Premise
was I-Premise
59 I-Premise
. I-Premise
2 I-Premise
% I-Premise
for I-Premise
ala I-Premise
- I-Premise
pdt I-Premise
and I-Premise
41 I-Premise
. I-Premise
4 I-Premise
% I-Premise
for I-Premise
imiquimod I-Premise
5 I-Premise
% I-Premise
cream I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
002 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
dermatology B-Premise
life I-Premise
quality I-Premise
index I-Premise
( I-Premise
dlqi I-Premise
) I-Premise
scores I-Premise
were I-Premise
assessed I-Premise
for I-Premise
each I-Premise
treatment I-Premise
modality I-Premise
at I-Premise
week I-Premise
4 I-Premise
and I-Premise
were I-Premise
1 I-Premise
. I-Premise
95 I-Premise
and I-Premise
1 I-Premise
. I-Premise
38 I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
20 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
sample I-Premise
size I-Premise
was I-Premise
small I-Premise
, I-Premise
and I-Premise
patients I-Premise
applied I-Premise
a I-Premise
small I-Premise
amount I-Premise
of I-Premise
imiquimod I-Premise
5 I-Premise
% I-Premise
cream I-Premise
( I-Premise
half I-Premise
a I-Premise
sachet I-Premise
) I-Premise
to I-Premise
a I-Premise
large I-Premise
surface I-Premise
area I-Premise
. I-Premise
!LF! !LF!
there B-Claim
was I-Claim
no I-Claim
statistically I-Claim
significant I-Claim
difference I-Claim
in I-Claim
treatment I-Claim
response I-Claim
when I-Claim
the I-Claim
100 I-Claim
% I-Claim
or I-Claim
75 I-Claim
% I-Claim
clearance I-Claim
rate I-Claim
cutoff I-Claim
was I-Claim
used I-Claim
, I-Claim
but B-Claim
our I-Claim
secondary I-Claim
outcome I-Claim
suggests I-Claim
that I-Claim
two I-Claim
sessions I-Claim
of I-Claim
ala I-Claim
- I-Claim
pdt I-Claim
is I-Claim
superior I-Claim
to I-Claim
imiquimod I-Claim
5 I-Claim
% I-Claim
cream I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
aks I-Claim
. I-Claim
!LF! !LF!
there B-Claim
was I-Claim
no I-Claim
statistically I-Claim
significant I-Claim
difference I-Claim
in I-Claim
effect I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
as I-Claim
assessed I-Claim
using I-Claim
the I-Claim
dlqi I-Claim
. I-Claim
!LF! !LF!
we O
aimed O
at O
investigating O
the O
efficacy O
, O
tolerability O
, O
and O
quality O
of O
life O
( O
qol O
) O
of O
gemcitabine O
( O
gem O
) O
compared O
with O
pegylated O
liposomal O
doxorubicin O
( O
pld O
) O
in O
the O
salvage O
treatment O
of O
recurrent O
ovarian O
cancer O
. O
!LF! !LF!
a O
phase O
iii O
randomized O
multicenter O
trial O
was O
planned O
to O
compare O
gem O
( O
1 O
, O
000 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
, O
8 O
, O
and O
15 O
every O
28 O
days O
) O
with O
pld O
( O
40 O
mg O
/ O
m O
( O
2 O
) O
every O
28 O
days O
) O
in O
ovarian O
cancer O
patients O
who O
experienced O
treatment O
failure O
with O
only O
one O
platinum O
/ O
paclitaxel O
regimen O
and O
who O
experienced O
recurrence O
or O
progression O
within O
12 O
months O
after O
completion O
of O
primary O
treatment O
. O
!LF! !LF!
one O
hundred O
fifty O
- O
three O
patients O
were O
randomly O
assigned O
to O
pld O
( O
n O
= O
76 O
) O
or O
gem O
( O
n O
= O
77 O
) O
. O
!LF! !LF!
treatment O
arms O
were O
well O
balanced O
for O
clinicopathologic O
characteristics O
. O
!LF! !LF!
grade O
3 O
or O
4 O
neutropenia O
was O
more O
frequent O
in O
gem O
- O
treated O
patients O
versus O
pld O
- O
treated O
patients O
( O
p O
= O
. O
007 O
) O
. O
!LF! !LF!
grade O
3 O
or O
4 O
palmar O
- O
plantar O
erythrodysesthesia O
was O
documented O
in O
a O
higher O
proportion O
of O
pld O
patients O
( O
6 O
% O
) O
versus O
gem O
patients O
( O
0 O
% O
"""" O
; O
"""" O
p O
= O
. O
061 O
) O
. O
!LF! !LF!
the B-Premise
overall I-Premise
response I-Premise
rate I-Premise
was I-Premise
16 I-Premise
% I-Premise
in I-Premise
the I-Premise
pld I-Premise
arm I-Premise
compared I-Premise
with I-Premise
29 I-Premise
% I-Premise
in I-Premise
the I-Premise
gem I-Premise
arm I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
056 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
no B-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
in I-Premise
time I-Premise
to I-Premise
progression I-Premise
( I-Premise
ttp I-Premise
) I-Premise
curves I-Premise
according I-Premise
to I-Premise
treatment I-Premise
allocation I-Premise
was I-Premise
documented I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
411 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
however B-Premise
, I-Premise
a I-Premise
trend I-Premise
for I-Premise
more I-Premise
favorable I-Premise
overall I-Premise
survival I-Premise
was I-Premise
documented I-Premise
in I-Premise
the I-Premise
pld I-Premise
arm I-Premise
compared I-Premise
with I-Premise
the I-Premise
gem I-Premise
arm I-Premise
, I-Premise
although B-Premise
the I-Premise
p I-Premise
value I-Premise
was I-Premise
of I-Premise
borderline I-Premise
statistical I-Premise
significance I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
048 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
statistically B-Premise
significantly I-Premise
higher I-Premise
global I-Premise
qol I-Premise
scores I-Premise
were I-Premise
found I-Premise
in I-Premise
pld I-Premise
- I-Premise
treated I-Premise
patients I-Premise
at I-Premise
the I-Premise
first I-Premise
and I-Premise
second I-Premise
postbaseline I-Premise
qol I-Premise
assessments I-Premise
. I-Premise
!LF! !LF!
gem B-Claim
does I-Claim
not I-Claim
provide I-Claim
an I-Claim
advantage I-Claim
compared I-Claim
with I-Claim
pld I-Claim
in I-Claim
terms I-Claim
of I-Claim
ttp I-Claim
in I-Claim
ovarian I-Claim
cancer I-Claim
patients I-Claim
who I-Claim
experience I-Claim
recurrence I-Claim
within I-Claim
12 I-Claim
months I-Claim
after I-Claim
primary I-Claim
treatment I-Claim
but I-Claim
should I-Claim
be I-Claim
considered I-Claim
in I-Claim
the I-Claim
spectrum I-Claim
of I-Claim
drugs I-Claim
to I-Claim
be I-Claim
possibly I-Claim
used I-Claim
in I-Claim
the I-Claim
salvage I-Claim
setting I-Claim
. I-Claim
!LF! !LF!
the O
aim O
of O
this O
multicenter O
randomized O
trial O
was O
to O
assess O
the O
efficacy O
and O
safety O
of O
sentinel O
lymph O
node O
( O
sln O
) O
biopsy O
compared O
with O
axillary O
lymph O
node O
dissection O
( O
alnd O
) O
. O
!LF! !LF!
all O
studies O
on O
sln O
biopsy O
in O
breast O
cancer O
report O
a O
variable O
false O
negative O
rate O
, O
whose O
prognostic O
consequences O
are O
still O
unclear O
. O
!LF! !LF!
from O
may O
1999 O
to O
december O
2004 O
, O
patients O
with O
breast O
cancer O
< O
or O
3 O
cm O
were O
randomly O
assigned O
to O
receive O
sln O
biopsy O
associated O
with O
alnd O
( O
alnd O
arm O
) O
or O
sln O
biopsy O
followed O
by O
alnd O
only O
if O
the O
sln O
was O
metastatic O
( O
sln O
arm O
) O
. O
!LF! !LF!
the O
main O
aim O
was O
the O
comparison O
of O
disease O
- O
free O
survival O
in O
the O
2 O
arms O
. O
!LF! !LF!
a O
total O
of O
749 O
patients O
were O
randomized O
and O
697 O
were O
available O
for O
analysis O
. O
!LF! !LF!
slns O
were O
identified O
in O
662 O
of O
697 O
patients O
( O
95 O
% O
) O
and O
positive O
slns O
were O
found O
in O
189 O
of O
662 O
patients O
( O
28 O
. O
5 O
% O
) O
. O
!LF! !LF!
in O
the O
alnd O
group O
, O
positive O
non O
- O
slns O
were O
found O
in O
18 O
patients O
with O
negative O
sln O
, O
giving O
a O
false O
negative O
rate O
of O
16 O
. O
7 O
% O
( O
18 O
of O
108 O
) O
. O
!LF! !LF!
postoperative B-Premise
side I-Premise
effects I-Premise
were I-Premise
significantly I-Premise
less I-Premise
in I-Premise
the I-Premise
sln I-Premise
group I-Premise
and I-Premise
there I-Premise
was I-Premise
no I-Premise
negative I-Premise
impact I-Premise
of I-Premise
the I-Premise
sln I-Premise
procedure I-Premise
on I-Premise
psychologic I-Premise
well I-Premise
being I-Premise
. I-Premise
!LF! !LF!
at O
a O
median O
follow O
- O
up O
of O
56 O
months O
, O
there O
were O
more O
locoregional O
recurrences O
in O
the O
sln O
arm O
, O
and O
the O
5 O
- O
year O
disease O
- O
free O
survival O
was O
89 O
. O
9 O
% O
in O
the O
alnd O
arm O
and O
87 O
. O
6 O
% O
in O
the O
sln O
arm O
, O
with O
a O
difference O
of O
2 O
. O
3 O
% O
( O
95 O
% O
confidence O
interval O
: O
- O
3 O
. O
1 O
% O
to O
7 O
. O
6 O
% O
) O
. O
!LF! !LF!
however B-Premise
, I-Premise
the I-Premise
number I-Premise
of I-Premise
enrolled I-Premise
patients I-Premise
was I-Premise
not I-Premise
sufficient I-Premise
to I-Premise
draw I-Premise
definitive I-Premise
conclusions I-Premise
. I-Premise
!LF! !LF!
sln B-Claim
biopsy I-Claim
is I-Claim
an I-Claim
effective I-Claim
and I-Claim
well I-Claim
- I-Claim
tolerated I-Claim
procedure I-Claim
. I-Claim
!LF! !LF!
however B-Claim
, I-Claim
its I-Claim
safety I-Claim
should I-Claim
be I-Claim
confirmed I-Claim
by I-Claim
the I-Claim
results I-Claim
of I-Claim
larger I-Claim
randomized I-Claim
trials I-Claim
and I-Claim
meta I-Claim
- I-Claim
analyses I-Claim
. I-Claim
!LF! !LF!
nocturnal O
administration O
of O
branched O
- O
chain O
amino O
acid O
( O
bcaa O
) O
granules O
improves O
serum O
albumin O
levels O
in O
patients O
with O
cirrhosis O
. O
!LF! !LF!
however O
, O
it O
is O
unclear O
whether O
or O
not O
this O
administration O
method O
can O
improve O
the O
patients O
' O
quality O
of O
life O
( O
qol O
) O
. O
!LF! !LF!
in O
this O
study O
, O
we O
aimed O
to O
investigate O
the O
efficacy O
of O
bcaa O
granules O
, O
given O
nocturnally O
, O
in O
improving O
qol O
in O
these O
patients O
. O
!LF! !LF!
we O
performed O
a O
multicenter O
, O
randomized O
controlled O
trial O
examining O
the O
comparative O
effects O
of O
bcaa O
granules O
given O
orally O
for O
3 O
months O
with O
daytime O
or O
nocturnal O
administration O
in O
patients O
with O
compensated O
cirrhosis O
. O
!LF! !LF!
health O
- O
related O
qol O
was O
measured O
by O
a O
japanese O
version O
of O
the O
questionnaire O
on O
subjective O
and O
objective O
symptoms O
, O
and O
the O
short O
form O
- O
8 O
( O
sf O
- O
8 O
) O
questionnaire O
. O
!LF! !LF!
twenty O
- O
one O
patients O
received O
bcaa O
granules O
three O
times O
a O
day O
( O
one O
sachet O
after O
each O
meal O
: O
the O
daytime O
group O
) O
, O
and O
16 O
patients O
received O
the O
granules O
twice O
a O
day O
( O
one O
sachet O
after O
breakfast O
, O
and O
two O
sachets O
before O
bedtime O
: O
the O
nocturnal O
group O
) O
. O
!LF! !LF!
baseline O
characteristics O
did O
not O
differ O
between O
the O
groups O
( O
whole O
cohort O
: O
child O
- O
pugh O
grade O
a O
/ O
b O
, O
21 O
/ O
16 O
"""" O
; O
"""" O
mean O
age O
, O
68 O
. O
2 O
years O
) O
. O
!LF! !LF!
there B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
any I-Premise
of I-Premise
the I-Premise
subjects I-Premise
revealed I-Premise
by I-Premise
the I-Premise
questionnaire I-Premise
regarding I-Premise
subjective I-Premise
or I-Premise
objective I-Premise
symptoms I-Premise
, I-Premise
or I-Premise
by I-Premise
the I-Premise
sf I-Premise
- I-Premise
8 I-Premise
between I-Premise
the I-Premise
daytime I-Premise
group I-Premise
and I-Premise
the I-Premise
nocturnal I-Premise
group I-Premise
after I-Premise
3 I-Premise
months I-Premise
of I-Premise
treatment I-Premise
. I-Premise
!LF! !LF!
the B-Premise
daytime I-Premise
group I-Premise
showed I-Premise
a I-Premise
significant I-Premise
effect I-Premise
on I-Premise
general I-Premise
health I-Premise
, I-Premise
vitality I-Premise
, I-Premise
social I-Premise
functioning I-Premise
, I-Premise
mental I-Premise
health I-Premise
, I-Premise
and I-Premise
role I-Premise
emotional I-Premise
as I-Premise
revealed I-Premise
on I-Premise
the I-Premise
sf I-Premise
- I-Premise
8 I-Premise
. I-Premise
!LF! !LF!
conversely B-Premise
, I-Premise
the I-Premise
nocturnal I-Premise
group I-Premise
exhibited I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
the I-Premise
occurrence I-Premise
of I-Premise
muscle I-Premise
cramps I-Premise
in I-Premise
the I-Premise
legs I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
014 I-Premise
) I-Premise
and I-Premise
significantly I-Premise
improved I-Premise
fisher I-Premise
' I-Premise
s I-Premise
ratio I-Premise
after I-Premise
3 I-Premise
months I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
04 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
nocturnal B-Claim
administration I-Claim
of I-Claim
bcaa I-Claim
granules I-Claim
in I-Claim
patients I-Claim
with I-Claim
cirrhosis I-Claim
reduced I-Claim
the I-Claim
occurrence I-Claim
of I-Claim
muscle I-Claim
cramps I-Claim
in I-Claim
the I-Claim
leg I-Claim
but I-Claim
did I-Claim
not I-Claim
improve I-Claim
the I-Claim
patients I-Claim
' I-Claim
qol I-Claim
. I-Claim
!LF! !LF!
treatment O
of O
patients O
with O
advanced O
or O
metastatic O
esophagogastric O
adenocarcinoma O
should O
not O
only O
prolong O
life O
but O
also O
provide O
relief O
of O
symptoms O
and O
improve O
quality O
of O
life O
( O
qol O
) O
. O
!LF! !LF!
esophagogastric O
adenocarcinoma O
mainly O
occurs O
in O
elderly O
patients O
, O
but O
they O
are O
underrepresented O
in O
most O
clinical O
trials O
and O
often O
do O
not O
receive O
effective O
combination O
chemotherapy O
, O
most O
probably O
for O
fear O
of O
intolerance O
. O
!LF! !LF!
using O
validated O
instruments O
, O
we O
prospectively O
assessed O
qol O
within O
the O
randomized O
flot65 O
+ O
phase O
ii O
trial O
. O
!LF! !LF!
within O
the O
flot65 O
+ O
trial O
, O
a O
total O
of O
143 O
patients O
aged O
≥65 O
years O
were O
randomly O
allocated O
to O
receive O
biweekly O
oxaliplatin O
plus O
5 O
- O
fluorouracil O
( O
5 O
- O
fu O
) O
continuous O
infusion O
and O
folinic O
acid O
( O
flo O
) O
or O
the O
same O
regimen O
in O
combination O
with O
docetaxel O
50 O
mg O
/ O
m O
( O
2 O
) O
( O
flot O
) O
. O
!LF! !LF!
the O
european O
organisation O
for O
research O
and O
treatment O
of O
cancer O
quality O
of O
life O
questionnaire O
c30 O
( O
eortc O
qlq O
- O
c30 O
) O
and O
the O
gastric O
module O
sto22 O
were O
administered O
every O
8 O
weeks O
until O
progression O
. O
!LF! !LF!
time O
to O
definitive O
deterioration O
of O
qol O
parameters O
was O
analyzed O
and O
compared O
within O
the O
treatment O
arms O
. O
!LF! !LF!
the O
median O
age O
of O
patients O
was O
70 O
years O
. O
!LF! !LF!
patients B-Premise
receiving I-Premise
flot I-Premise
exhibited I-Premise
higher I-Premise
response I-Premise
rates I-Premise
and I-Premise
had I-Premise
improved I-Premise
disease I-Premise
- I-Premise
free I-Premise
and I-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
( I-Premise
pfs I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the O
proportions O
of O
patients O
with O
evaluable O
baseline O
eortc O
qlq O
- O
c30 O
and O
sto22 O
questionnaires O
were O
balanced O
( O
83 O
% O
in O
flot O
and O
89 O
% O
in O
flo O
) O
. O
!LF! !LF!
considering O
evaluable O
patients O
with O
assessable O
questionnaires O
( O
n O
= O
123 O
) O
, O
neither O
functioning O
nor O
symptom O
parameters O
differed O
significantly O
in O
favor O
of O
one O
of O
the O
two O
treatment O
groups O
. O
!LF! !LF!
particularly O
, O
there B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
regarding I-Premise
time I-Premise
to I-Premise
definitive I-Premise
deterioration I-Premise
of I-Premise
global I-Premise
health I-Premise
status I-Premise
/ I-Premise
quality I-Premise
of I-Premise
life I-Premise
from I-Premise
baseline I-Premise
( I-Premise
primary I-Premise
endpoint I-Premise
) I-Premise
. I-Premise
!LF! !LF!
notably O
, O
patients B-Premise
receiving I-Premise
flo I-Premise
or I-Premise
flot I-Premise
as I-Premise
palliative I-Premise
treatment I-Premise
( I-Premise
n I-Premise
= I-Premise
98 I-Premise
) I-Premise
achieved I-Premise
comparable I-Premise
qol I-Premise
results I-Premise
. I-Premise
!LF! !LF!
although B-Premise
toxicity I-Premise
was I-Premise
higher I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
flot I-Premise
, I-Premise
no B-Premise
negative I-Premise
impact I-Premise
of I-Premise
the I-Premise
addition I-Premise
of I-Premise
docetaxel I-Premise
on I-Premise
qol I-Premise
parameters I-Premise
could I-Premise
be I-Premise
demonstrated I-Premise
. I-Premise
!LF! !LF!
thus O
, O
elderly B-Claim
patients I-Claim
in I-Claim
need I-Claim
of I-Claim
intensified I-Claim
chemotherapy I-Claim
may I-Claim
receive I-Claim
flot I-Claim
without I-Claim
compromising I-Claim
patient I-Claim
- I-Claim
reported I-Claim
outcome I-Claim
parameters I-Claim
. I-Claim
!LF! !LF!
to O
compare O
the O
toxicities O
, O
tumor O
control O
, O
survival O
, O
and O
quality O
of O
life O
of O
nasopharyngeal O
cancer O
( O
npc O
) O
patients O
treated O
with O
sequential O
neoadjuvant O
chemotherapy O
followed O
by O
concurrent O
cisplatin O
- O
radiotherapy O
( O
crt O
) O
or O
crt O
alone O
. O
!LF! !LF!
previously O
untreated O
stage O
iii O
to O
ivb O
npc O
were O
randomly O
assigned O
to O
( O
1 O
) O
neoadjuvant O
docetaxel O
75 O
mg O
/ O
m O
( O
2 O
) O
and O
cisplatin O
75 O
mg O
/ O
m O
( O
2 O
) O
every O
3 O
weeks O
for O
two O
cycles O
, O
followed O
by O
cisplatin O
40 O
mg O
/ O
m O
( O
2 O
) O
/ O
wk O
concurrent O
with O
radiotherapy O
, O
or O
( O
2 O
) O
crt O
alone O
. O
!LF! !LF!
planned O
accrual O
was O
30 O
patients O
per O
arm O
to O
detect O
20 O
% O
difference O
of O
toxicities O
based O
on O
95 O
% O
cis O
. O
!LF! !LF!
from O
november O
2002 O
to O
november O
2004 O
, O
65 O
eligible O
patients O
were O
randomly O
assigned O
to O
neoadjuvant O
chemotherapy O
followed O
by O
crt O
( O
n O
= O
34 O
) O
or O
crt O
alone O
( O
n O
= O
31 O
) O
. O
!LF! !LF!
there B-Premise
was I-Premise
a I-Premise
high I-Premise
rate I-Premise
of I-Premise
grade I-Premise
3 I-Premise
/ I-Premise
4 I-Premise
neutropenia I-Premise
( I-Premise
97 I-Premise
% I-Premise
) I-Premise
but I-Premise
not I-Premise
neutropenic I-Premise
fever I-Premise
( I-Premise
12 I-Premise
% I-Premise
) I-Premise
during I-Premise
neoadjuvant I-Premise
chemotherapy I-Premise
. I-Premise
!LF! !LF!
no B-Premise
significant I-Premise
differences I-Premise
in I-Premise
rates I-Premise
of I-Premise
acute I-Premise
toxicities I-Premise
were I-Premise
observed I-Premise
between I-Premise
the I-Premise
two I-Premise
arms I-Premise
during I-Premise
crt I-Premise
. I-Premise
!LF! !LF!
dose B-Premise
intensities I-Premise
of I-Premise
concurrent I-Premise
cisplatin I-Premise
, I-Premise
late I-Premise
rt I-Premise
toxicities I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
scores I-Premise
were I-Premise
comparable I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
the B-Premise
3 I-Premise
- I-Premise
year I-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
for I-Premise
neoadjuvant I-Premise
versus I-Premise
control I-Premise
arm I-Premise
was I-Premise
88 I-Premise
. I-Premise
2 I-Premise
% I-Premise
and I-Premise
59 I-Premise
. I-Premise
5 I-Premise
% I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
= I-Premise
0 I-Premise
. I-Premise
49 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
20 I-Premise
to I-Premise
1 I-Premise
. I-Premise
19 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
12 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
3 I-Premise
- I-Premise
year I-Premise
overall I-Premise
survival I-Premise
for I-Premise
neoadjuvant I-Premise
versus I-Premise
control I-Premise
arm I-Premise
was I-Premise
94 I-Premise
. I-Premise
1 I-Premise
% I-Premise
and I-Premise
67 I-Premise
. I-Premise
7 I-Premise
% I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
= I-Premise
0 I-Premise
. I-Premise
24 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
078 I-Premise
to I-Premise
0 I-Premise
. I-Premise
73 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
012 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
neoadjuvant B-Claim
docetaxel I-Claim
- I-Claim
cisplatin I-Claim
followed I-Claim
by I-Claim
crt I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
with I-Claim
a I-Claim
manageable I-Claim
toxicity I-Claim
profile I-Claim
that I-Claim
allowed I-Claim
subsequent I-Claim
delivery I-Claim
of I-Claim
full I-Claim
- I-Claim
dose I-Claim
crt I-Claim
. I-Claim
!LF! !LF!
preliminary B-Claim
results I-Claim
suggested I-Claim
a I-Claim
positive I-Claim
impact I-Claim
on I-Claim
survival I-Claim
. I-Claim
!LF! !LF!
a O
phase O
iii O
study O
to O
definitively O
test O
this O
neoadjuvant O
- O
concurrent O
strategy O
is O
warranted O
. O
!LF! !LF!
fatigue O
is O
a O
frequent O
problem O
after O
surgical O
treatment O
of O
solid O
tumours O
. O
!LF! !LF!
aerobic B-Claim
exercise I-Claim
and I-Claim
psychosocial I-Claim
interventions I-Claim
have I-Claim
been I-Claim
shown I-Claim
to I-Claim
reduce I-Claim
the I-Claim
severity I-Claim
of I-Claim
this I-Claim
symptom I-Claim
in I-Claim
cancer I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
therefore O
, O
we O
compared O
the O
effect O
of O
the O
two O
therapies O
on O
fatigue O
in O
a O
randomised O
controlled O
study O
. O
!LF! !LF!
seventy O
- O
two O
patients O
who O
underwent O
surgery O
for O
lung O
( O
n O
= O
27 O
) O
or O
gastrointestinal O
tumours O
( O
n O
= O
42 O
) O
were O
assigned O
to O
an O
aerobic O
exercise O
group O
( O
stationary O
biking O
30 O
min O
five O
times O
weekly O
) O
or O
a O
progressive O
relaxation O
training O
group O
( O
45 O
min O
three O
times O
per O
week O
) O
. O
!LF! !LF!
both O
interventions O
were O
carried O
out O
for O
3 O
weeks O
. O
!LF! !LF!
at O
the O
beginning O
and O
the O
end O
of O
the O
study O
, O
we O
evaluated O
physical O
, O
cognitive O
and O
emotional O
status O
and O
somatic O
complaints O
with O
the O
european O
organization O
for O
research O
and O
treatment O
of O
cancer O
quality O
of O
life O
questionnaire O
core O
module O
( O
eortc O
- O
qlq O
- O
30 O
) O
questionnaire O
, O
and O
maximal O
physical O
performance O
with O
an O
ergometric O
stress O
test O
. O
!LF! !LF!
physical B-Premise
performance I-Premise
of I-Premise
the I-Premise
training I-Premise
group I-Premise
improved I-Premise
significantly I-Premise
during I-Premise
the I-Premise
programme I-Premise
( I-Premise
9 I-Premise
. I-Premise
4 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
20 I-Premise
watts I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
but I-Premise
remained I-Premise
unchanged I-Premise
in I-Premise
the I-Premise
relaxation I-Premise
group I-Premise
( I-Premise
1 I-Premise
. I-Premise
5 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
14 I-Premise
. I-Premise
8 I-Premise
watts I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
37 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
fatigue B-Premise
and I-Premise
global I-Premise
health I-Premise
scores I-Premise
improved I-Premise
in I-Premise
both I-Premise
groups I-Premise
during I-Premise
the I-Premise
intervention I-Premise
( I-Premise
fatigue I-Premise
: I-Premise
training I-Premise
group I-Premise
21 I-Premise
% I-Premise
, I-Premise
relaxation I-Premise
group I-Premise
19 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
global I-Premise
health I-Premise
of I-Premise
both I-Premise
groups I-Premise
19 I-Premise
% I-Premise
, I-Premise
p I-Premise
for I-Premise
all I-Premise
< I-Premise
or I-Premise
= I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
however B-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
changes I-Premise
in I-Premise
the I-Premise
scores I-Premise
of I-Premise
both I-Premise
groups I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
67 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
we B-Claim
conclude I-Claim
that I-Claim
a I-Claim
structured I-Claim
aerobic I-Claim
training I-Claim
programme I-Claim
improves I-Claim
the I-Claim
physical I-Claim
performance I-Claim
of I-Claim
patients I-Claim
recovering I-Claim
from I-Claim
surgery I-Claim
for I-Claim
solid I-Claim
tumours I-Claim
. I-Claim
!LF! !LF!
however B-Claim
, I-Claim
exercise I-Claim
is I-Claim
not I-Claim
better I-Claim
than I-Claim
progressive I-Claim
relaxation I-Claim
training I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
fatigue I-Claim
in I-Claim
this I-Claim
setting I-Claim
. I-Claim
!LF! !LF!
the O
randomized O
, O
controlled O
bolero O
- O
2 O
( O
breast O
cancer O
trials O
of O
oral O
everolimus O
) O
trial O
demonstrated O
significantly O
improved O
progression O
- O
free O
survival O
with O
the O
use O
of O
everolimus O
plus O
exemestane O
( O
eve O
+ O
exe O
) O
versus O
placebo O
plus O
exemestane O
( O
pbo O
+ O
exe O
) O
in O
patients O
with O
advanced O
breast O
cancer O
who O
developed O
disease O
progression O
after O
treatment O
with O
nonsteroidal O
aromatase O
inhibitors O
. O
!LF! !LF!
this O
analysis O
investigated O
the O
treatment O
effects O
on O
health O
- O
related O
quality O
of O
life O
( O
hrqol O
) O
. O
!LF! !LF!
using O
the O
european O
organisation O
for O
research O
and O
treatment O
of O
cancer O
quality O
of O
life O
questionnaire O
- O
core O
30 O
( O
eortc O
qlq O
- O
c30 O
) O
questionnaire O
, O
hrqol O
was O
assessed O
at O
baseline O
and O
every O
6 O
weeks O
thereafter O
until O
disease O
progression O
and O
/ O
or O
treatment O
discontinuation O
. O
!LF! !LF!
the O
30 O
items O
in O
15 O
subscales O
of O
the O
qlq O
- O
c30 O
include O
global O
health O
status O
wherein O
higher O
scores O
( O
range O
, O
0 O
- O
100 O
) O
indicate O
better O
hrqol O
. O
!LF! !LF!
this O
analysis O
included O
a O
protocol O
- O
specified O
time O
to O
definitive O
deterioration O
( O
tdd O
) O
analysis O
at O
a O
5 O
% O
decrease O
in O
hrqol O
versus O
baseline O
, O
with O
no O
subsequent O
increase O
above O
this O
threshold O
. O
!LF! !LF!
the O
authors O
report O
additional O
sensitivity O
analyses O
using O
10 O
- O
point O
minimal O
important O
difference O
decreases O
in O
the O
global O
health O
status O
score O
versus O
baseline O
. O
!LF! !LF!
treatment O
arms O
were O
compared O
using O
the O
stratified O
log O
- O
rank O
test O
and O
cox O
proportional O
hazards O
model O
adjusted O
for O
trial O
stratum O
( O
visceral O
metastases O
, O
previous O
hormone O
sensitivity O
) O
, O
age O
, O
sex O
, O
race O
, O
baseline O
global O
health O
status O
score O
and O
eastern O
cooperative O
oncology O
group O
performance O
status O
, O
prognostic O
risk O
factors O
, O
and O
treatment O
history O
. O
!LF! !LF!
baseline O
global O
health O
status O
scores O
were O
found O
to O
be O
similar O
between O
treatment O
groups O
( O
64 O
. O
7 O
vs O
65 O
. O
3 O
) O
. O
!LF! !LF!
the B-Premise
median I-Premise
tdd I-Premise
in I-Premise
hrqol I-Premise
was I-Premise
8 I-Premise
. I-Premise
3 I-Premise
months I-Premise
with I-Premise
eve I-Premise
+ I-Premise
exe I-Premise
versus I-Premise
5 I-Premise
. I-Premise
8 I-Premise
months I-Premise
with I-Premise
pbo I-Premise
+ I-Premise
exe I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0 I-Premise
. I-Premise
74 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
0084 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
at B-Premise
the I-Premise
10 I-Premise
- I-Premise
point I-Premise
minimal I-Premise
important I-Premise
difference I-Premise
, I-Premise
the I-Premise
median I-Premise
tdd I-Premise
with I-Premise
eve I-Premise
+ I-Premise
exe I-Premise
was I-Premise
11 I-Premise
. I-Premise
7 I-Premise
months I-Premise
versus I-Premise
8 I-Premise
. I-Premise
4 I-Premise
months I-Premise
with I-Premise
pbo I-Premise
+ I-Premise
exe I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0 I-Premise
. I-Premise
80 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
1017 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
in B-Claim
patients I-Claim
with I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
who I-Claim
develop I-Claim
disease I-Claim
progression I-Claim
after I-Claim
treatment I-Claim
with I-Claim
nonsteroidal I-Claim
aromatase I-Claim
inhibitors I-Claim
, I-Claim
eve I-Claim
+ I-Claim
exe I-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
longer I-Claim
tdd I-Claim
in I-Claim
global I-Claim
hrqol I-Claim
versus I-Claim
pbo I-Claim
+ I-Claim
exe I-Claim
. I-Claim
!LF! !LF!
mucositis B-Premise
occurs I-Premise
in I-Premise
almost I-Premise
all I-Premise
patients I-Premise
treated I-Premise
with I-Premise
radiotherapy I-Premise
for I-Premise
head I-Premise
and I-Premise
neck I-Premise
cancer I-Premise
. I-Premise
!LF! !LF!
the O
aim O
of O
this O
multicenter O
, O
double O
- O
blind O
, O
prospective O
, O
randomized O
trial O
was O
to O
evaluate O
the O
clinical O
efficacy O
of O
an O
economically O
viable O
antimicrobial O
lozenge O
( O
bacitracin O
, O
clotrimazole O
, O
and O
gentamicin O
[ O
bcog O
] O
) O
in O
the O
alleviation O
of O
radiation O
- O
induced O
mucositis O
in O
patients O
with O
head O
and O
neck O
cancer O
. O
!LF! !LF!
one O
hundred O
thirty O
- O
seven O
eligible O
patients O
were O
randomized O
to O
treatment O
with O
either O
antimicrobial O
lozenge O
( O
69 O
patients O
) O
or O
placebo O
lozenge O
( O
68 O
patients O
) O
. O
!LF! !LF!
the O
primary O
end O
point O
of O
the O
study O
was O
the O
time O
to O
development O
of O
severe O
mucositis O
from O
the O
start O
of O
radiotherapy O
. O
!LF! !LF!
secondary O
end O
points O
included O
severity O
and O
duration O
of O
mucositis O
, O
pain O
measurement O
, O
radiation O
therapy O
interruption O
, O
and O
quality O
of O
life O
. O
!LF! !LF!
mucositis O
was O
scored O
using O
a O
validated O
mucositis O
scoring O
system O
. O
!LF! !LF!
toxicity B-Premise
profiles I-Premise
were I-Premise
similar I-Premise
between I-Premise
the I-Premise
two I-Premise
arms I-Premise
of I-Premise
the I-Premise
study I-Premise
. I-Premise
!LF! !LF!
the B-Premise
median I-Premise
time I-Premise
to I-Premise
development I-Premise
of I-Premise
severe I-Premise
mucositis I-Premise
from I-Premise
the I-Premise
start I-Premise
of I-Premise
radiotherapy I-Premise
was I-Premise
3 I-Premise
. I-Premise
61 I-Premise
weeks I-Premise
on I-Premise
bcog I-Premise
and I-Premise
3 I-Premise
. I-Premise
96 I-Premise
weeks I-Premise
on I-Premise
placebo I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
61 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
arms I-Premise
in I-Premise
the I-Premise
extent I-Premise
of I-Premise
severe I-Premise
mucositis I-Premise
as I-Premise
measured I-Premise
by I-Premise
physician I-Premise
, I-Premise
in I-Premise
oral I-Premise
toxicities I-Premise
as I-Premise
recorded I-Premise
by I-Premise
patients I-Premise
, I-Premise
or I-Premise
in I-Premise
radiotherapy I-Premise
delays I-Premise
. I-Premise
!LF! !LF!
this O
study O
was O
conducted O
on O
the O
basis O
of O
a O
pilot O
study O
that O
demonstrated O
the O
bcog O
lozenge O
to O
be O
tolerable O
and O
microbiologically O
efficacious O
. O
!LF! !LF!
a O
validated O
mucositis O
scoring O
system O
was O
used O
. O
!LF! !LF!
however O
, O
in B-Claim
this I-Claim
group I-Claim
of I-Claim
patients I-Claim
treated I-Claim
with I-Claim
conventional I-Claim
radiotherapy I-Claim
, I-Claim
the I-Claim
lozenge I-Claim
did I-Claim
not I-Claim
impact I-Claim
significantly I-Claim
on I-Claim
the I-Claim
severity I-Claim
of I-Claim
mucositis I-Claim
. I-Claim
!LF! !LF!
whether B-Claim
such I-Claim
a I-Claim
lozenge I-Claim
would I-Claim
be I-Claim
beneficial I-Claim
in I-Claim
treatment I-Claim
situations I-Claim
where I-Claim
rate I-Claim
of I-Claim
severe I-Claim
mucositis I-Claim
is I-Claim
higher I-Claim
( I-Claim
ie I-Claim
, I-Claim
in I-Claim
patients I-Claim
treated I-Claim
with I-Claim
unconventional I-Claim
fractionation I-Claim
or I-Claim
with I-Claim
concomitant I-Claim
chemotherapy I-Claim
) I-Claim
is I-Claim
unknown I-Claim
. I-Claim
!LF! !LF!
for B-Claim
men I-Claim
with I-Claim
localised I-Claim
prostate I-Claim
cancer I-Claim
, I-Claim
surgery I-Claim
provides I-Claim
a I-Claim
survival I-Claim
benefit I-Claim
compared I-Claim
with I-Claim
watchful I-Claim
waiting I-Claim
. I-Claim
!LF! !LF!
treatments O
are O
associated O
with O
morbidity O
. O
!LF! !LF!
results O
for O
functional O
outcome O
and O
quality O
of O
life O
are O
rarely O
reported O
beyond O
10 O
years O
and O
are O
lacking O
from O
randomised O
settings O
. O
!LF! !LF!
we O
report O
results O
for O
quality O
of O
life O
for O
men O
in O
the O
scandinavian O
prostate O
cancer O
group O
study O
number O
4 O
( O
spcg O
- O
4 O
) O
after O
a O
median O
follow O
- O
up O
of O
more O
than O
12 O
years O
. O
!LF! !LF!
all O
living O
swedish O
and O
finnish O
men O
( O
400 O
of O
695 O
) O
randomly O
assigned O
to O
radical O
prostatectomy O
or O
watchful O
waiting O
in O
spcg O
- O
4 O
from O
1989 O
to O
1999 O
were O
included O
in O
our O
analysis O
. O
!LF! !LF!
an O
additional O
281 O
men O
were O
included O
in O
a O
population O
- O
based O
control O
group O
matched O
for O
region O
and O
age O
. O
!LF! !LF!
physical O
symptoms O
, O
symptom O
- O
induced O
stress O
, O
and O
self O
- O
assessed O
quality O
of O
life O
were O
evaluated O
with O
a O
study O
- O
specific O
questionnaire O
. O
!LF! !LF!
longitudinal O
data O
were O
available O
for O
166 O
swedish O
men O
who O
had O
answered O
quality O
- O
of O
- O
life O
questionnaires O
at O
an O
earlier O
timepoint O
. O
!LF! !LF!
182 O
( O
88 O
% O
) O
of O
208 O
men O
in O
the O
radical O
prostatectomy O
group O
, O
167 O
( O
87 O
% O
) O
of O
192 O
men O
in O
the O
watchful O
- O
waiting O
group O
, O
and O
214 O
( O
76 O
% O
) O
of O
281 O
men O
in O
the O
population O
- O
based O
control O
group O
answered O
the O
questionnaire O
. O
!LF! !LF!
men O
in O
spcg O
- O
4 O
had O
a O
median O
follow O
- O
up O
of O
12 O
· O
2 O
years O
( O
range O
7 O
- O
17 O
) O
and O
a O
median O
age O
of O
77 O
· O
0 O
years O
( O
range O
61 O
- O
88 O
) O
. O
!LF! !LF!
high B-Premise
self I-Premise
- I-Premise
assessed I-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
reported I-Premise
by I-Premise
62 I-Premise
( I-Premise
35 I-Premise
% I-Premise
) I-Premise
of I-Premise
179 I-Premise
men I-Premise
allocated I-Premise
radical I-Premise
prostatectomy I-Premise
, I-Premise
55 I-Premise
( I-Premise
34 I-Premise
% I-Premise
) I-Premise
of I-Premise
160 I-Premise
men I-Premise
assigned I-Premise
to I-Premise
watchful I-Premise
waiting I-Premise
, I-Premise
and I-Premise
93 I-Premise
( I-Premise
45 I-Premise
% I-Premise
) I-Premise
of I-Premise
208 I-Premise
men I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise
!LF! !LF!
anxiety B-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
spcg I-Premise
- I-Premise
4 I-Premise
groups I-Premise
( I-Premise
77 I-Premise
[ I-Premise
43 I-Premise
% I-Premise
] I-Premise
of I-Premise
178 I-Premise
and I-Premise
69 I-Premise
[ I-Premise
43 I-Premise
% I-Premise
] I-Premise
of I-Premise
161 I-Premise
men I-Premise
) I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
68 I-Premise
[ I-Premise
33 I-Premise
% I-Premise
] I-Premise
of I-Premise
208 I-Premise
men I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
relative I-Premise
risk I-Premise
1 I-Premise
· I-Premise
42 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
1 I-Premise
· I-Premise
07 I-Premise
- I-Premise
1 I-Premise
· I-Premise
88 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
prevalence B-Premise
of I-Premise
erectile I-Premise
dysfunction I-Premise
was I-Premise
84 I-Premise
% I-Premise
( I-Premise
146 I-Premise
of I-Premise
173 I-Premise
men I-Premise
) I-Premise
in I-Premise
the I-Premise
radical I-Premise
prostatectomy I-Premise
group I-Premise
, I-Premise
80 I-Premise
% I-Premise
( I-Premise
122 I-Premise
of I-Premise
153 I-Premise
) I-Premise
in I-Premise
the I-Premise
watchful I-Premise
- I-Premise
waiting I-Premise
group I-Premise
, I-Premise
and I-Premise
46 I-Premise
% I-Premise
( I-Premise
95 I-Premise
of I-Premise
208 I-Premise
) I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
and I-Premise
prevalence I-Premise
of I-Premise
urinary I-Premise
leakage I-Premise
was I-Premise
41 I-Premise
% I-Premise
( I-Premise
71 I-Premise
of I-Premise
173 I-Premise
) I-Premise
, I-Premise
11 I-Premise
% I-Premise
( I-Premise
18 I-Premise
of I-Premise
164 I-Premise
) I-Premise
, I-Premise
and I-Premise
3 I-Premise
% I-Premise
( I-Premise
six I-Premise
of I-Premise
209 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
distress B-Premise
caused I-Premise
by I-Premise
these I-Premise
symptoms I-Premise
was I-Premise
reported I-Premise
significantly I-Premise
more I-Premise
often I-Premise
by I-Premise
men I-Premise
allocated I-Premise
radical I-Premise
prostatectomy I-Premise
than I-Premise
by I-Premise
men I-Premise
assigned I-Premise
to I-Premise
watchful I-Premise
waiting I-Premise
. I-Premise
!LF! !LF!
in B-Premise
a I-Premise
longitudinal I-Premise
analysis I-Premise
of I-Premise
men I-Premise
in I-Premise
spcg I-Premise
- I-Premise
4 I-Premise
who I-Premise
provided I-Premise
information I-Premise
at I-Premise
two I-Premise
follow I-Premise
- I-Premise
up I-Premise
points I-Premise
9 I-Premise
years I-Premise
apart I-Premise
, I-Premise
38 I-Premise
( I-Premise
45 I-Premise
% I-Premise
) I-Premise
of I-Premise
85 I-Premise
men I-Premise
allocated I-Premise
radical I-Premise
prostatectomy I-Premise
and I-Premise
48 I-Premise
( I-Premise
60 I-Premise
% I-Premise
) I-Premise
of I-Premise
80 I-Premise
men I-Premise
allocated I-Premise
watchful I-Premise
waiting I-Premise
reported I-Premise
an I-Premise
increase I-Premise
in I-Premise
number I-Premise
of I-Premise
physical I-Premise
symptoms I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
50 I-Premise
( I-Premise
61 I-Premise
% I-Premise
) I-Premise
of I-Premise
82 I-Premise
and I-Premise
47 I-Premise
( I-Premise
64 I-Premise
% I-Premise
) I-Premise
of I-Premise
74 I-Premise
men I-Premise
, I-Premise
respectively I-Premise
, I-Premise
reported I-Premise
a I-Premise
reduction I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise
!LF! !LF!
for B-Premise
men I-Premise
in I-Premise
spcg I-Premise
- I-Premise
4 I-Premise
, I-Premise
negative I-Premise
side I-Premise
- I-Premise
effects I-Premise
were I-Premise
common I-Premise
and I-Premise
added I-Premise
more I-Premise
stress I-Premise
than I-Premise
was I-Premise
reported I-Premise
in I-Premise
the I-Premise
control I-Premise
population I-Premise
. I-Premise
!LF! !LF!
in B-Claim
the I-Claim
radical I-Claim
prostatectomy I-Claim
group I-Claim
, I-Claim
erectile I-Claim
dysfunction I-Claim
and I-Claim
urinary I-Claim
leakage I-Claim
were I-Claim
often I-Claim
consequences I-Claim
of I-Claim
surgery I-Claim
. I-Claim
!LF! !LF!
in B-Claim
the I-Claim
watchful I-Claim
- I-Claim
waiting I-Claim
group I-Claim
, I-Claim
side I-Claim
- I-Claim
effects I-Claim
can I-Claim
be I-Claim
caused I-Claim
by I-Claim
tumour I-Claim
progression I-Claim
. I-Claim
!LF! !LF!
the B-Claim
number I-Claim
and I-Claim
severity I-Claim
of I-Claim
side I-Claim
- I-Claim
effects I-Claim
changes I-Claim
over I-Claim
time I-Claim
at I-Claim
a I-Claim
higher I-Claim
rate I-Claim
than I-Claim
is I-Claim
caused I-Claim
by I-Claim
normal I-Claim
ageing I-Claim
and I-Claim
a I-Claim
loss I-Claim
of I-Claim
sexual I-Claim
ability I-Claim
is I-Claim
a I-Claim
persistent I-Claim
psychological I-Claim
problem I-Claim
for I-Claim
both I-Claim
interventions I-Claim
. I-Claim
!LF! !LF!
an O
understanding O
of O
the O
patterns O
of O
side O
- O
effects O
and O
time O
dimension O
of O
their O
occurrence O
for O
each O
treatment O
is O
important O
for O
full O
patient O
information O
. O
!LF! !LF!
for B-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
prostate I-Claim
cancer I-Claim
, I-Claim
treatment I-Claim
is I-Claim
primarily I-Claim
palliative I-Claim
, I-Claim
relying I-Claim
mainly I-Claim
on I-Claim
the I-Claim
suppression I-Claim
of I-Claim
systemic I-Claim
androgen I-Claim
hormone I-Claim
levels I-Claim
. I-Claim
!LF! !LF!
to O
help O
document O
the O
achievement O
of O
palliation O
and O
to O
characterize O
positive O
and O
negative O
effects O
of O
treatment O
, O
we O
evaluated O
quality O
- O
of O
- O
life O
( O
qol O
) O
parameters O
in O
patients O
with O
metastatic O
prostate O
cancer O
who O
were O
randomly O
assigned O
to O
two O
methods O
of O
androgen O
deprivation O
. O
!LF! !LF!
patients O
( O
n O
= O
739 O
) O
with O
stage O
m1 O
( O
bone O
or O
soft O
tissue O
metastasis O
) O
prostate O
cancer O
were O
enrolled O
in O
a O
qol O
protocol O
that O
was O
a O
companion O
to O
southwest O
oncology O
group O
int O
- O
0105 O
, O
a O
randomized O
double O
- O
blind O
trial O
comparing O
treatment O
with O
bilateral O
orchiectomy O
( O
surgical O
castration O
) O
plus O
either O
flutamide O
or O
placebo O
. O
!LF! !LF!
patients O
completed O
a O
comprehensive O
battery O
of O
qol O
questionnaires O
at O
random O
assignment O
to O
treatment O
and O
at O
1 O
, O
3 O
, O
and O
6 O
months O
later O
. O
!LF! !LF!
data O
were O
collected O
on O
three O
treatment O
- O
specific O
symptoms O
( O
diarrhea O
, O
gas O
pain O
, O
and O
body O
image O
) O
, O
on O
physical O
functioning O
, O
and O
on O
emotional O
functioning O
. O
!LF! !LF!
all O
p O
values O
are O
two O
- O
sided O
. O
!LF! !LF!
questionnaire O
return O
rates O
for O
this O
study O
never O
dropped O
below O
80 O
% O
"""" O
; O
"""" O
only O
2 O
% O
of O
the O
patients O
did O
not O
submit O
baseline O
qol O
assessments O
. O
!LF! !LF!
cross B-Premise
- B-Premise
sectional B-Premise
analyses I-Premise
( I-Premise
corrected I-Premise
for I-Premise
multiple I-Premise
testing I-Premise
) I-Premise
identified I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
that I-Premise
favored I-Premise
orchiectomy I-Premise
plus I-Premise
placebo I-Premise
for I-Premise
two I-Premise
of I-Premise
the I-Premise
five I-Premise
primary I-Premise
qol I-Premise
parameters I-Premise
as I-Premise
follows I-Premise
: I-Premise
patients I-Premise
receiving I-Premise
flutamide I-Premise
reported I-Premise
more I-Premise
diarrhea I-Premise
at I-Premise
3 I-Premise
months I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
001 I-Premise
) I-Premise
and I-Premise
worse I-Premise
emotional I-Premise
functioning I-Premise
at I-Premise
3 I-Premise
and I-Premise
6 I-Premise
months I-Premise
( I-Premise
both I-Premise
p I-Premise
< I-Premise
. I-Premise
003 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
longitudinal B-Premise
analyses I-Premise
replicated I-Premise
these I-Premise
findings I-Premise
. I-Premise
!LF! !LF!
other B-Premise
analyzed I-Premise
qol I-Premise
parameters I-Premise
favored I-Premise
the I-Premise
group I-Premise
receiving I-Premise
placebo I-Premise
but B-Premise
were I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
after I-Premise
adjustment I-Premise
for I-Premise
multiple I-Premise
testing I-Premise
. I-Premise
!LF! !LF!
we B-Claim
found I-Claim
a I-Claim
consistent I-Claim
pattern I-Claim
of I-Claim
better I-Claim
qol I-Claim
outcomes I-Claim
at I-Claim
each I-Claim
follow I-Claim
- I-Claim
up I-Claim
assessment I-Claim
during I-Claim
the I-Claim
first I-Claim
6 I-Claim
months I-Claim
of I-Claim
treatment I-Claim
for I-Claim
orchiectomized I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
prostate I-Claim
cancer I-Claim
who I-Claim
received I-Claim
placebo I-Claim
versus I-Claim
flutamide I-Claim
. I-Claim
!LF! !LF!
improvement B-Claim
over I-Claim
time I-Claim
was I-Claim
evident I-Claim
in I-Claim
both I-Claim
treatment I-Claim
groups I-Claim
but I-Claim
more I-Claim
so I-Claim
for I-Claim
patients I-Claim
receiving I-Claim
placebo I-Claim
. I-Claim
!LF! !LF!
regularly O
collecting O
patient O
- O
reported O
outcomes O
( O
pros O
) O
of O
health O
- O
related O
quality O
of O
life O
with O
feedback O
to O
oncologists O
may O
assist O
in O
eliciting O
and O
monitoring O
patients O
' O
problems O
during O
cancer O
treatment O
. O
!LF! !LF!
this O
study O
examined O
how O
pro O
feedback O
had O
an O
impact O
on O
patient O
- O
physician O
communication O
over O
time O
to O
gain O
a O
better O
understanding O
of O
how O
it O
may O
influence O
patient O
care O
. O
!LF! !LF!
exploratory O
analyses O
were O
performed O
on O
a O
data O
set O
from O
a O
previous O
study O
. O
!LF! !LF!
patients O
were O
randomly O
assigned O
to O
intervention O
( O
regular O
completion O
of O
european O
organisation O
for O
research O
and O
treatment O
of O
cancer O
quality O
of O
life O
questionnaire O
- O
core O
30 O
and O
hospital O
anxiety O
and O
depression O
scale O
with O
feedback O
to O
oncologists O
) O
, O
attention O
- O
control O
( O
completion O
of O
same O
questionnaires O
without O
feedback O
) O
, O
and O
control O
( O
standard O
care O
) O
arms O
. O
!LF! !LF!
the O
content O
of O
consultation O
audio O
recordings O
between O
28 O
oncologists O
and O
198 O
patients O
over O
four O
consecutive O
visits O
( O
792 O
consultations O
) O
was O
analyzed O
. O
!LF! !LF!
mixed O
- O
effects O
models O
and O
multivariate O
regressions O
were O
used O
to O
examine O
the O
longitudinal O
impact O
of O
the O
intervention O
on O
patient O
- O
physician O
communication O
, O
dynamics O
of O
patient O
- O
physician O
interaction O
, O
and O
the O
association O
between O
pros O
and O
the O
content O
of O
clinic O
discussion O
. O
!LF! !LF!
patients B-Premise
in I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
discussed I-Premise
more I-Premise
symptoms I-Premise
over I-Premise
time I-Premise
compared I-Premise
with I-Premise
patients I-Premise
in I-Premise
the I-Premise
attention I-Premise
- I-Premise
control I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
008 I-Premise
) I-Premise
and I-Premise
control I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
04 I-Premise
) I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
no B-Premise
study I-Premise
arm I-Premise
effect I-Premise
was I-Premise
observed I-Premise
for I-Premise
function I-Premise
discussions I-Premise
. I-Premise
!LF! !LF!
discussion O
topics O
were O
predominantly O
raised O
by O
patients O
/ O
relatives O
, O
regardless O
of O
arm O
allocation O
. O
!LF! !LF!
clinic B-Premise
discussions I-Premise
were I-Premise
associated I-Premise
with I-Premise
severity I-Premise
of I-Premise
patient I-Premise
- I-Premise
reported I-Premise
symptoms I-Premise
but I-Premise
not I-Premise
with I-Premise
patient I-Premise
- I-Premise
reported I-Premise
functional I-Premise
concerns I-Premise
. I-Premise
!LF! !LF!
a B-Premise
positive I-Premise
longitudinal I-Premise
impact I-Premise
of I-Premise
the I-Premise
intervention I-Premise
on I-Premise
symptom I-Premise
discussion I-Premise
was I-Premise
observed I-Premise
, I-Premise
but B-Premise
not I-Premise
for I-Premise
function I-Premise
discussion I-Premise
, I-Premise
suggesting I-Premise
that I-Premise
potentially I-Premise
serious I-Premise
problems I-Premise
may I-Premise
remain I-Premise
unaddressed I-Premise
. I-Premise
!LF! !LF!
training B-Claim
oncologists I-Claim
in I-Claim
responding I-Claim
to I-Claim
patient I-Claim
- I-Claim
reported I-Claim
functional I-Claim
concerns I-Claim
may I-Claim
increase I-Claim
the I-Claim
impact I-Claim
of I-Claim
this I-Claim
intervention I-Claim
. I-Claim
!LF! !LF!
anemia B-Claim
is I-Claim
an I-Claim
expected I-Claim
consequence I-Claim
of I-Claim
intensive I-Claim
chemotherapy I-Claim
regimens I-Claim
administered I-Claim
to I-Claim
patients I-Claim
with I-Claim
acute I-Claim
leukemia I-Claim
. I-Claim
!LF! !LF!
this O
study O
was O
designed O
to O
determine O
whether O
epoetin O
alpha O
would O
decrease O
the O
number O
of O
transfusion O
events O
and O
units O
of O
packed O
erythrocytes O
( O
prbcs O
) O
transfused O
, O
and O
the O
secondary O
objective O
was O
to O
study O
the O
effects O
of O
epoetin O
alpha O
on O
quality O
of O
life O
( O
qol O
) O
and O
complete O
remission O
( O
cr O
) O
rates O
. O
!LF! !LF!
patients O
with O
acute O
lymphoblastic O
leukemia O
( O
all O
) O
, O
lymphoblastic O
lymphoma O
( O
ll O
) O
, O
or O
burkitt O
lymphoma O
( O
bl O
) O
who O
were O
receiving O
frontline O
myelosuppressive O
chemotherapy O
were O
randomized O
to O
receive O
epoetin O
alpha O
or O
no O
epoetin O
during O
the O
first O
6 O
cycles O
of O
their O
planned O
chemotherapy O
. O
!LF! !LF!
qol O
was O
assessed O
by O
using O
the O
edmonton O
symptom O
assessment O
scale O
( O
esas O
) O
and O
the O
functional O
assessment O
of O
cancer O
therapy O
( O
fact O
) O
- O
anemia O
questionnaires O
. O
!LF! !LF!
fifty O
- O
five O
patients O
were O
randomized O
to O
receive O
epoetin O
alpha O
, O
and O
54 O
patients O
received O
no O
epoetin O
. O
!LF! !LF!
transfusion O
data O
were O
available O
for O
79 O
of O
81 O
evaluable O
patients O
( O
98 O
% O
) O
who O
completed O
the O
treatment O
/ O
observation O
period O
. O
!LF! !LF!
the B-Premise
trial I-Premise
was I-Premise
stopped I-Premise
early I-Premise
because I-Premise
of I-Premise
poor I-Premise
accrual I-Premise
before I-Premise
the I-Premise
target I-Premise
of I-Premise
123 I-Premise
evaluable I-Premise
patients I-Premise
was I-Premise
met I-Premise
. I-Premise
!LF! !LF!
a B-Premise
mean I-Premise
of I-Premise
10 I-Premise
. I-Premise
6 I-Premise
units I-Premise
of I-Premise
prbcs I-Premise
over I-Premise
5 I-Premise
months I-Premise
were I-Premise
administered I-Premise
to I-Premise
those I-Premise
who I-Premise
received I-Premise
epoetin I-Premise
alpha I-Premise
compared I-Premise
with I-Premise
13 I-Premise
units I-Premise
for I-Premise
those I-Premise
who I-Premise
did I-Premise
not I-Premise
receive I-Premise
epoetin I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
04 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
there B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
qol I-Premise
as I-Premise
assessed I-Premise
by I-Premise
the I-Premise
fact I-Premise
- I-Premise
anemia I-Premise
or I-Premise
esas I-Premise
instruments I-Premise
. I-Premise
!LF! !LF!
the B-Premise
cr I-Premise
rate I-Premise
and I-Premise
the I-Premise
3 I-Premise
- I-Premise
year I-Premise
cr I-Premise
duration I-Premise
were I-Premise
not I-Premise
affected I-Premise
adversely I-Premise
by I-Premise
use I-Premise
of I-Premise
epoetin I-Premise
alpha I-Premise
. I-Premise
!LF! !LF!
epoetin B-Claim
alpha I-Claim
decreased I-Claim
the I-Claim
number I-Claim
of I-Claim
prbc I-Claim
transfusions I-Claim
and I-Claim
did I-Claim
not I-Claim
appear I-Claim
to I-Claim
have I-Claim
a I-Claim
negative I-Claim
impact I-Claim
on I-Claim
remission I-Claim
duration I-Claim
. I-Claim
!LF! !LF!
no B-Claim
difference I-Claim
in I-Claim
qol I-Claim
was I-Claim
observed I-Claim
. I-Claim
!LF! !LF!
a O
single O
- O
item O
linear O
analogue O
self O
- O
assessment O
scale O
for O
mood O
was O
compared O
with O
a O
28 O
- O
item O
adjective O
checklist O
for O
emotional O
well O
- O
being O
. O
!LF! !LF!
to O
confirm O
its O
concurrent O
validity O
and O
responsiveness O
to O
treatment O
and O
recurrence O
in O
patients O
with O
breast O
cancer O
, O
emotional O
well O
- O
being O
was O
assessed O
every O
3 O
months O
for O
2 O
years O
and O
at O
1 O
and O
6 O
months O
after O
recurrence O
in O
1 O
, O
169 O
patients O
who O
were O
premenopausal O
and O
960 O
patients O
who O
were O
postmenopausal O
. O
!LF! !LF!
these O
patients O
were O
enrolled O
in O
two O
international O
breast O
cancer O
study O
group O
randomized O
clinical O
trials O
in O
operable O
breast O
cancer O
conducted O
from O
1986 O
to O
1993 O
. O
!LF! !LF!
to O
assess O
concurrent O
validity O
, O
pearson O
' O
s O
correlation O
between O
the O
linear O
analogue O
self O
- O
assessment O
scale O
and O
the O
adjective O
checklist O
were O
calculated O
for O
each O
time O
- O
point O
within O
each O
treatment O
group O
and O
for O
the O
two O
assessments O
after O
recurrence O
. O
!LF! !LF!
responsiveness O
to O
treatment O
and O
recurrence O
were O
analyzed O
using O
paired O
t O
tests O
and O
the O
squared O
ratio O
of O
these O
t O
tests O
, O
an O
estimate O
of O
relative O
efficiency O
. O
!LF! !LF!
concurrent O
validity O
of O
the O
mood O
linear O
analogue O
self O
- O
assessment O
was O
consistently O
confirmed O
across O
four O
language O
groups O
. O
!LF! !LF!
both B-Claim
measures I-Claim
were I-Claim
responsive I-Claim
"""" I-Claim
; I-Claim
"""" I-Claim
out B-Premise
of I-Premise
24 I-Premise
changes I-Premise
over I-Premise
time I-Premise
, I-Premise
19 I-Premise
were I-Premise
in I-Premise
the I-Premise
expected I-Premise
direction I-Premise
for I-Premise
the I-Premise
linear I-Premise
analogue I-Premise
self I-Premise
- I-Premise
assessment I-Premise
scale I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
0 I-Premise
. I-Premise
05 I-Premise
for I-Premise
9 I-Premise
of I-Premise
19 I-Premise
) I-Premise
and I-Premise
17 I-Premise
for I-Premise
the I-Premise
adjective I-Premise
checklist I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
0 I-Premise
. I-Premise
05 I-Premise
for I-Premise
10 I-Premise
of I-Premise
17 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
linear I-Premise
analogue I-Premise
self I-Premise
- I-Premise
assessment I-Premise
scale I-Premise
was I-Premise
less I-Premise
but I-Premise
significantly I-Premise
efficient I-Premise
for I-Premise
detection I-Premise
of I-Premise
treatment I-Premise
effects I-Premise
, I-Premise
with I-Premise
relative I-Premise
efficiency I-Premise
estimates I-Premise
ranging I-Premise
from I-Premise
0 I-Premise
. I-Premise
16 I-Premise
to I-Premise
2 I-Premise
. I-Premise
45 I-Premise
and I-Premise
a I-Premise
median I-Premise
of I-Premise
0 I-Premise
. I-Premise
66 I-Premise
among I-Premise
the I-Premise
comparisons I-Premise
with I-Premise
relatively I-Premise
stable I-Premise
estimates I-Premise
( I-Premise
/ I-Premise
t I-Premise
/ I-Premise
> I-Premise
or I-Premise
= I-Premise
1 I-Premise
. I-Premise
0 I-Premise
) I-Premise
and I-Premise
more I-Premise
efficient I-Premise
for I-Premise
recurrence I-Premise
than I-Premise
the I-Premise
adjective I-Premise
checklist I-Premise
. I-Premise
!LF! !LF!
the B-Claim
mood I-Claim
linear I-Claim
analogue I-Claim
self I-Claim
- I-Claim
assessment I-Claim
scale I-Claim
is I-Claim
a I-Claim
valid I-Claim
indicator I-Claim
of I-Claim
emotional I-Claim
well I-Claim
- I-Claim
being I-Claim
in I-Claim
patients I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
in I-Claim
large I-Claim
multicenter I-Claim
, I-Claim
multicultural I-Claim
trials I-Claim
in I-Claim
which I-Claim
comprehensive I-Claim
scales I-Claim
are I-Claim
less I-Claim
feasible I-Claim
. I-Claim
!LF! !LF!
this B-Claim
investigation I-Claim
supports I-Claim
the I-Claim
clinical I-Claim
relevance I-Claim
of I-Claim
linear I-Claim
analogue I-Claim
self I-Claim
- I-Claim
assessment I-Claim
scales I-Claim
as I-Claim
indicators I-Claim
of I-Claim
components I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
cancer I-Claim
clinical I-Claim
trials I-Claim
. I-Claim
!LF! !LF!
to O
analyze O
the O
predictive O
value O
of O
psa O
for O
progression O
and O
the O
role O
of O
testosterone O
for O
quality O
of O
life O
( O
qol O
) O
in O
patients O
with O
androgen O
deprivation O
therapy O
( O
adt O
) O
for O
metastatic O
prostate O
cancer O
. O
!LF! !LF!
psa O
and O
testosterone O
data O
were O
used O
from O
a O
phase O
iii O
trial O
randomizing O
patients O
without O
progression O
and O
psa O
< O
4 O
ng O
/ O
ml O
( O
n O
= O
193 O
) O
, O
after O
6 O
months O
induction O
course O
, O
between O
continuous O
( O
cad O
) O
( O
n O
= O
96 O
) O
and O
intermittent O
( O
iad O
) O
( O
n O
= O
97 O
) O
adt O
. O
!LF! !LF!
the O
2 O
- O
year O
risk O
of O
progression O
was O
calculated O
for O
baseline O
psa O
, O
' O
fast O
' O
and O
' O
slow O
' O
psa O
decline O
to O
< O
4 O
ng O
/ O
ml O
( O
60 O
days O
cut O
- O
off O
) O
, O
psa O
nadir O
, O
performance O
status O
and O
pain O
. O
!LF! !LF!
testosterone O
kinetics O
and O
qol O
were O
also O
evaluated O
. O
!LF! !LF!
univariate O
kaplan O
meier O
survival O
analysis O
and O
log O
rank O
tests O
were O
used O
to O
compare O
the O
risk O
of O
progression O
. O
!LF! !LF!
for O
progression O
analysis O
, O
173 O
patients O
' O
data O
were O
available O
. O
!LF! !LF!
the O
2 O
- O
year O
risk O
of O
progression O
for O
baseline O
psa O
< O
50 O
ng O
/ O
ml O
, O
50 O
to O
< O
500 O
ng O
/ O
ml O
, O
and O
≥ O
500 O
ng O
/ O
ml O
was O
25 O
% O
, O
55 O
% O
, O
and O
76 O
% O
( O
p O
= O
0 O
. O
03 O
) O
in O
cad O
, O
and O
38 O
% O
, O
64 O
% O
, O
and O
85 O
% O
( O
p O
= O
0 O
. O
006 O
) O
in O
iad O
, O
respectively O
. O
!LF! !LF!
the B-Premise
2 I-Premise
- I-Premise
year I-Premise
risk I-Premise
of I-Premise
progression I-Premise
for I-Premise
psa I-Premise
nadir I-Premise
≤ I-Premise
0 I-Premise
. I-Premise
2 I-Premise
ng I-Premise
/ I-Premise
ml I-Premise
, I-Premise
and I-Premise
> I-Premise
0 I-Premise
. I-Premise
2 I-Premise
to I-Premise
4 I-Premise
ng I-Premise
/ I-Premise
ml I-Premise
in I-Premise
cad I-Premise
was I-Premise
31 I-Premise
% I-Premise
and I-Premise
70 I-Premise
% I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
in B-Premise
the I-Premise
iad I-Premise
group I-Premise
, I-Premise
a I-Premise
similar I-Premise
trend I-Premise
was I-Premise
seen I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
with I-Premise
psa I-Premise
nadir I-Premise
≤ I-Premise
0 I-Premise
. I-Premise
2 I-Premise
ng I-Premise
/ I-Premise
ml I-Premise
, I-Premise
though I-Premise
had I-Premise
significantly I-Premise
higher I-Premise
2 I-Premise
- I-Premise
year I-Premise
risk I-Premise
of I-Premise
progression I-Premise
compared I-Premise
to I-Premise
cad I-Premise
( I-Premise
53 I-Premise
% I-Premise
vs I-Premise
. I-Premise
31 I-Premise
% I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
03 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
psa O
decline O
showed O
no O
predictive O
value O
. O
!LF! !LF!
patients B-Premise
without I-Premise
pain I-Premise
had I-Premise
a I-Premise
significantly I-Premise
lower I-Premise
2 I-Premise
- I-Premise
year I-Premise
risk I-Premise
of I-Premise
progression I-Premise
in I-Premise
both I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
without B-Premise
adt I-Premise
testosterone I-Premise
remained I-Premise
at I-Premise
castrate I-Premise
level I-Premise
for I-Premise
4 I-Premise
months I-Premise
. I-Premise
!LF! !LF!
after O
the O
first O
and O
second O
iad O
cycle O
92 O
% O
and O
46 O
% O
, O
respectively O
, O
had O
a O
normalized O
testosterone O
. O
!LF! !LF!
no B-Premise
qol I-Premise
difference I-Premise
was I-Premise
found I-Premise
, I-Premise
although I-Premise
more I-Premise
side I-Premise
effects I-Premise
occurred I-Premise
in I-Premise
cad I-Premise
. I-Premise
!LF! !LF!
metastatic B-Claim
prostate I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
high I-Claim
baseline I-Claim
psa I-Claim
, I-Claim
pain I-Claim
, I-Claim
and I-Claim
high I-Claim
psa I-Claim
nadir I-Claim
have I-Claim
a I-Claim
poor I-Claim
prognosis I-Claim
with I-Claim
adt I-Claim
. I-Claim
!LF! !LF!
patients B-Claim
with I-Claim
low I-Claim
psa I-Claim
nadir I-Claim
do I-Claim
significantly I-Claim
worse I-Claim
with I-Claim
iad I-Claim
compared I-Claim
with I-Claim
cad I-Claim
. I-Claim
!LF! !LF!
low O
testosterone O
after O
adt O
and O
incomplete O
testosterone O
recovery O
may O
explain O
similar O
qol O
. O
!LF! !LF!
therefore O
, O
iad B-Claim
is I-Claim
not I-Claim
a I-Claim
good I-Claim
treatment I-Claim
option I-Claim
for I-Claim
many I-Claim
metastatic I-Claim
prostate I-Claim
cancer I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
to O
compare O
the O
efficacy O
of O
low O
- O
frequency O
low O
- O
intensity O
electrotherapy O
and O
manual O
lymphatic O
drainage O
in O
the O
treatment O
of O
chronic O
upper O
limb O
breast O
cancer O
- O
related O
lymphoedema O
. O
!LF! !LF!
cross O
- O
over O
single O
- O
blind O
random O
clinical O
trial O
. O
!LF! !LF!
rehabilitation O
service O
. O
!LF! !LF!
thirty O
- O
six O
women O
with O
chronic O
upper O
limb O
breast O
cancer O
- O
related O
lymphoedema O
. O
!LF! !LF!
patients O
were O
randomized O
to O
undergo O
10 O
sessions O
of O
manual O
lymphatic O
drainage O
followed O
by O
10 O
sessions O
of O
low O
- O
frequency O
low O
- O
intensity O
electrotherapy O
or O
to O
undergo O
first O
low O
- O
frequency O
low O
- O
intensity O
electrotherapy O
followed O
by O
manual O
lymphatic O
drainage O
. O
!LF! !LF!
there O
was O
a O
month O
of O
washout O
time O
between O
treatments O
. O
!LF! !LF!
each O
patient O
was O
examined O
just O
before O
and O
after O
each O
treatment O
. O
!LF! !LF!
researchers O
and O
outcome O
assessors O
were O
blinded O
for O
assigned O
treatment O
. O
!LF! !LF!
outcomes O
were O
lymphoedema O
volume O
, O
pain O
, O
heaviness O
and O
tightness O
, O
and O
health O
- O
related O
quality O
of O
life O
measured O
with O
the O
functional O
assessment O
of O
cancer O
therapy O
questionnaire O
for O
breast O
cancer O
version O
4 O
( O
fact O
- O
b O
+ O
4 O
) O
. O
!LF! !LF!
carry O
- O
over O
, O
period O
and O
treatment O
effects O
were O
analysed O
. O
!LF! !LF!
treatment O
effect O
was O
assessed O
using O
paired O
t O
- O
test O
. O
!LF! !LF!
thirty O
patients O
finalized O
treatment O
. O
!LF! !LF!
comparing B-Premise
the I-Premise
changes I-Premise
in I-Premise
low I-Premise
- I-Premise
frequency I-Premise
low I-Premise
- I-Premise
intensity I-Premise
electrotherapy I-Premise
with I-Premise
manual I-Premise
lymphatic I-Premise
drainage I-Premise
changes I-Premise
, I-Premise
there I-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
. I-Premise
!LF! !LF!
low B-Premise
- B-Premise
frequency B-Premise
low I-Premise
- I-Premise
intensity I-Premise
electrotherapy I-Premise
did I-Premise
not I-Premise
reduce I-Premise
lymphoedema I-Premise
volume I-Premise
( I-Premise
mean I-Premise
of I-Premise
change I-Premise
= I-Premise
19 I-Premise
. I-Premise
77 I-Premise
ml I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
36 I-Premise
) I-Premise
, I-Premise
but O
significant B-Premise
reductions I-Premise
were I-Premise
observed I-Premise
in I-Premise
pain I-Premise
, I-Premise
heaviness I-Premise
and I-Premise
tightness I-Premise
( I-Premise
mean I-Premise
of I-Premise
change I-Premise
= I-Premise
13 I-Premise
. I-Premise
1 I-Premise
, I-Premise
16 I-Premise
. I-Premise
2 I-Premise
and I-Premise
6 I-Premise
. I-Premise
4 I-Premise
mm I-Premise
, I-Premise
respectively I-Premise
) I-Premise
, I-Premise
and I-Premise
fact I-Premise
- I-Premise
b I-Premise
+ I-Premise
4 I-Premise
summaries I-Premise
improved I-Premise
significantly I-Premise
( I-Premise
trial I-Premise
outcome I-Premise
index I-Premise
mean I-Premise
of I-Premise
change I-Premise
= I-Premise
5 I-Premise
. I-Premise
4 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
015 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
manual B-Premise
lymphatic I-Premise
drainage I-Premise
showed I-Premise
no I-Premise
significant I-Premise
changes I-Premise
in I-Premise
any I-Premise
of I-Premise
the I-Premise
outcomes I-Premise
. I-Premise
!LF! !LF!
although B-Claim
there I-Claim
are I-Claim
no I-Claim
significant I-Claim
differences I-Claim
between I-Claim
treatment I-Claim
changes I-Claim
, I-Claim
the B-Claim
observed I-Claim
trend I-Claim
towards I-Claim
a I-Claim
better I-Claim
health I-Claim
- I-Claim
related I-Claim
quality I-Claim
of I-Claim
life I-Claim
is I-Claim
remarkable I-Claim
in I-Claim
low I-Claim
- I-Claim
frequency I-Claim
low I-Claim
- I-Claim
intensity I-Claim
electrotherapy I-Claim
. I-Claim
!LF! !LF!
molecular O
markers O
to O
predict O
response O
to O
5 O
- O
fluorouracil O
( O
fu O
) O
- O
based O
treatment O
of O
recurrent O
or O
metastasised O
colorectal O
cancer O
( O
mcrc O
) O
are O
not O
established O
. O
!LF! !LF!
the O
aim O
of O
this O
trial O
was O
to O
determine O
the O
value O
of O
thymidylate O
synthase O
( O
ts O
) O
, O
a O
key O
enzyme O
of O
dna O
synthesis O
and O
target O
of O
5 O
- O
fu O
, O
to O
predict O
response O
to O
chemotherapy O
of O
mcrc O
. O
!LF! !LF!
tumour O
tissue O
was O
obtained O
from O
168 O
patients O
with O
mcrc O
for O
relative O
thymidylate O
synthase O
( O
ts O
) O
mrna O
quantitation O
. O
!LF! !LF!
patients O
were O
randomised O
to O
receive O
either O
5 O
- O
fu O
/ O
folinic O
acid O
( O
fa O
, O
fufa O
) O
alone O
or O
in O
combination O
with O
irinotecan O
5 O
- O
fluorouracil O
/ O
folinic O
acid O
and O
irinotecan O
( O
folfiri O
) O
stratified O
by O
ts O
( O
low O
versus O
high O
) O
. O
!LF! !LF!
primary O
end O
- O
point O
was O
overall O
response O
to O
first O
- O
line O
treatment O
among O
ts O
high O
patients O
. O
!LF! !LF!
all O
parties O
, O
except O
for O
the O
randomisation O
centre O
, O
were O
blinded O
for O
ts O
status O
. O
!LF! !LF!
biopsies O
( O
n O
= O
168 O
) O
were O
taken O
without O
complications O
. O
!LF! !LF!
ts O
levels O
were O
available O
for O
147 O
patients O
( O
87 O
. O
5 O
% O
) O
. O
!LF! !LF!
analysing B-Premise
response I-Premise
to I-Premise
fufa I-Premise
and I-Premise
folfiri I-Premise
in I-Premise
the I-Premise
per I-Premise
protocol I-Premise
set I-Premise
( I-Premise
n I-Premise
= I-Premise
119 I-Premise
) I-Premise
after I-Premise
un I-Premise
- I-Premise
blinding I-Premise
ts I-Premise
in I-Premise
the I-Premise
data I-Premise
base I-Premise
revealed I-Premise
a I-Premise
trend I-Premise
to I-Premise
better I-Premise
overall I-Premise
response I-Premise
to I-Premise
folfiri I-Premise
( I-Premise
9 I-Premise
/ I-Premise
19 I-Premise
, I-Premise
47 I-Premise
% I-Premise
) I-Premise
in I-Premise
ts I-Premise
high I-Premise
compared I-Premise
to I-Premise
fufa I-Premise
( I-Premise
5 I-Premise
/ I-Premise
23 I-Premise
, I-Premise
22 I-Premise
% I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
077 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
in B-Premise
patients I-Premise
with I-Premise
biopsies I-Premise
taken I-Premise
from I-Premise
liver I-Premise
lesions I-Premise
( I-Premise
n I-Premise
= I-Premise
91 I-Premise
) I-Premise
overall I-Premise
response I-Premise
to I-Premise
folfiri I-Premise
and I-Premise
fufa I-Premise
in I-Premise
ts I-Premise
high I-Premise
was I-Premise
53 I-Premise
% I-Premise
( I-Premise
9 I-Premise
/ I-Premise
17 I-Premise
) I-Premise
and I-Premise
18 I-Premise
% I-Premise
( I-Premise
3 I-Premise
/ I-Premise
17 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
035 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
in B-Premise
patients I-Premise
with I-Premise
low I-Premise
ts I-Premise
, I-Premise
no I-Premise
remarkable I-Premise
difference I-Premise
in I-Premise
overall I-Premise
response I-Premise
to I-Premise
folfiri I-Premise
and I-Premise
fufa I-Premise
was I-Premise
observed I-Premise
. I-Premise
!LF! !LF!
taking B-Claim
a I-Claim
pre I-Claim
- I-Claim
treatment I-Claim
biopsy I-Claim
is I-Claim
a I-Claim
safe I-Claim
and I-Claim
feasible I-Claim
procedure I-Claim
in I-Claim
mcrc I-Claim
. I-Claim
!LF! !LF!
after B-Claim
validation I-Claim
of I-Claim
our I-Claim
data I-Claim
in I-Claim
a I-Claim
larger I-Claim
group I-Claim
ts I-Claim
determination I-Claim
may I-Claim
have I-Claim
the I-Claim
potential I-Claim
to I-Claim
better I-Claim
help I-Claim
direct I-Claim
systemic I-Claim
treatment I-Claim
in I-Claim
patients I-Claim
with I-Claim
primarily I-Claim
non I-Claim
- I-Claim
resectable I-Claim
mcrc I-Claim
. I-Claim
!LF! !LF!
it O
is O
not O
known O
whether O
low O
- O
dose O
radioiodine O
( O
1 O
. O
1 O
gbq O
[ O
30 O
mci O
] O
) O
is O
as O
effective O
as O
high O
- O
dose O
radioiodine O
( O
3 O
. O
7 O
gbq O
[ O
100 O
mci O
] O
) O
for O
treating O
patients O
with O
differentiated O
thyroid O
cancer O
or O
whether O
the O
effects O
of O
radioiodine O
( O
especially O
at O
a O
low O
dose O
) O
are O
influenced O
by O
using O
either O
recombinant O
human O
thyrotropin O
( O
thyrotropin O
alfa O
) O
or O
thyroid O
hormone O
withdrawal O
. O
!LF! !LF!
at O
29 O
centers O
in O
the O
united O
kingdom O
, O
we O
conducted O
a O
randomized O
noninferiority O
trial O
comparing O
low O
- O
dose O
and O
high O
- O
dose O
radioiodine O
, O
each O
in O
combination O
with O
either O
thyrotropin O
alfa O
or O
thyroid O
hormone O
withdrawal O
before O
ablation O
. O
!LF! !LF!
patients O
( O
age O
range O
, O
16 O
to O
80 O
years O
) O
had O
tumor O
stage O
t1 O
to O
t3 O
, O
with O
possible O
spread O
to O
nearby O
lymph O
nodes O
but O
without O
metastasis O
. O
!LF! !LF!
end O
points O
were O
the O
rate O
of O
success O
of O
ablation O
at O
6 O
to O
9 O
months O
, O
adverse O
events O
, O
quality O
of O
life O
, O
and O
length O
of O
hospital O
stay O
. O
!LF! !LF!
a O
total O
of O
438 O
patients O
underwent O
randomization O
"""" O
; O
"""" O
data O
could O
be O
analyzed O
for O
421 O
. O
!LF! !LF!
ablation B-Premise
success I-Premise
rates I-Premise
were I-Premise
85 I-Premise
. I-Premise
0 I-Premise
% I-Premise
in I-Premise
the I-Premise
group I-Premise
receiving I-Premise
low I-Premise
- I-Premise
dose I-Premise
radioiodine I-Premise
versus I-Premise
88 I-Premise
. I-Premise
9 I-Premise
% I-Premise
in I-Premise
the I-Premise
group I-Premise
receiving I-Premise
the I-Premise
high I-Premise
dose I-Premise
and I-Premise
87 I-Premise
. I-Premise
1 I-Premise
% I-Premise
in I-Premise
the I-Premise
thyrotropin I-Premise
alfa I-Premise
group I-Premise
versus I-Premise
86 I-Premise
. I-Premise
7 I-Premise
% I-Premise
in I-Premise
the I-Premise
group I-Premise
undergoing I-Premise
thyroid I-Premise
hormone I-Premise
withdrawal I-Premise
. I-Premise
!LF! !LF!
all B-Premise
95 I-Premise
% I-Premise
confidence I-Premise
intervals I-Premise
for I-Premise
the I-Premise
differences I-Premise
were I-Premise
within I-Premise
±10 I-Premise
percentage I-Premise
points I-Premise
, I-Premise
indicating I-Premise
noninferiority I-Premise
. I-Premise
!LF! !LF!
similar B-Premise
results I-Premise
were I-Premise
found I-Premise
for I-Premise
low I-Premise
- I-Premise
dose I-Premise
radioiodine I-Premise
plus I-Premise
thyrotropin I-Premise
alfa I-Premise
( I-Premise
84 I-Premise
. I-Premise
3 I-Premise
% I-Premise
) I-Premise
versus I-Premise
high I-Premise
- I-Premise
dose I-Premise
radioiodine I-Premise
plus I-Premise
thyroid I-Premise
hormone I-Premise
withdrawal I-Premise
( I-Premise
87 I-Premise
. I-Premise
6 I-Premise
% I-Premise
) I-Premise
or I-Premise
high I-Premise
- I-Premise
dose I-Premise
radioiodine I-Premise
plus I-Premise
thyrotropin I-Premise
alfa I-Premise
( I-Premise
90 I-Premise
. I-Premise
2 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
more B-Premise
patients I-Premise
in I-Premise
the I-Premise
high I-Premise
- I-Premise
dose I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
low I-Premise
- I-Premise
dose I-Premise
group I-Premise
were I-Premise
hospitalized I-Premise
for I-Premise
at I-Premise
least I-Premise
3 I-Premise
days I-Premise
( I-Premise
36 I-Premise
. I-Premise
3 I-Premise
% I-Premise
vs I-Premise
. I-Premise
13 I-Premise
. I-Premise
0 I-Premise
% I-Premise
, I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
proportions I-Premise
of I-Premise
patients I-Premise
with I-Premise
adverse I-Premise
events I-Premise
were I-Premise
21 I-Premise
% I-Premise
in I-Premise
the I-Premise
low I-Premise
- I-Premise
dose I-Premise
group I-Premise
versus I-Premise
33 I-Premise
% I-Premise
in I-Premise
the I-Premise
high I-Premise
- I-Premise
dose I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
007 I-Premise
) I-Premise
and I-Premise
23 I-Premise
% I-Premise
in I-Premise
the I-Premise
thyrotropin I-Premise
alfa I-Premise
group I-Premise
versus I-Premise
30 I-Premise
% I-Premise
in I-Premise
the I-Premise
group I-Premise
undergoing I-Premise
thyroid I-Premise
hormone I-Premise
withdrawal I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
11 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
low B-Claim
- B-Claim
dose B-Claim
radioiodine I-Claim
plus I-Claim
thyrotropin I-Claim
alfa I-Claim
was I-Claim
as I-Claim
effective I-Claim
as I-Claim
high I-Claim
- I-Claim
dose I-Claim
radioiodine I-Claim
, I-Claim
with I-Claim
a I-Claim
lower I-Claim
rate I-Claim
of I-Claim
adverse I-Claim
events I-Claim
. I-Claim
!LF! !LF!
although O
numerous O
treatment O
modalities O
have O
been O
explored O
in O
patients O
with O
advanced O
hcc O
, O
the O
therapeutic O
options O
are O
still O
limited O
. O
!LF! !LF!
somatostatin B-Claim
has I-Claim
been I-Claim
shown I-Claim
to I-Claim
have I-Claim
antimitotic I-Claim
activity I-Claim
in I-Claim
endocrine I-Claim
as I-Claim
well I-Claim
as I-Claim
in I-Claim
a I-Claim
variety I-Claim
of I-Claim
nonendocrine I-Claim
tumors I-Claim
. I-Claim
!LF! !LF!
expression B-Premise
of I-Premise
somatostatin I-Premise
receptors I-Premise
is I-Premise
found I-Premise
in I-Premise
hccs I-Premise
, I-Premise
but O
the B-Claim
efficacy I-Claim
of I-Claim
the I-Claim
somatostatin I-Claim
analogue I-Claim
octreotide I-Claim
remains I-Claim
controversial I-Claim
. I-Claim
!LF! !LF!
therefore O
, O
a O
randomized O
double O
- O
blind O
placebo O
- O
controlled O
multicenter O
trial O
was O
performed O
to O
assess O
the O
efficacy O
of O
long O
- O
acting O
octreotide O
for O
the O
treatment O
of O
advanced O
hcc O
. O
!LF! !LF!
one O
hundred O
twenty O
untreated O
patients O
with O
histologically O
confirmed O
hcc O
were O
randomized O
to O
receive O
either O
long O
- O
acting O
octreotide O
( O
sandostation O
lar O
30 O
mg O
) O
intramuscularly O
every O
4 O
weeks O
or O
placebo O
. O
!LF! !LF!
the O
study O
groups O
were O
comparable O
with O
respect O
to O
clinical O
characteristics O
. O
!LF! !LF!
there B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
the I-Premise
cumulative I-Premise
survival I-Premise
. I-Premise
!LF! !LF!
the B-Premise
median I-Premise
survival I-Premise
time I-Premise
was I-Premise
4 I-Premise
. I-Premise
7 I-Premise
months I-Premise
in I-Premise
the I-Premise
octreotide I-Premise
group I-Premise
compared I-Premise
with I-Premise
5 I-Premise
. I-Premise
3 I-Premise
months I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise
!LF! !LF!
six B-Premise
- B-Premise
month B-Premise
survival I-Premise
rates I-Premise
were I-Premise
41 I-Premise
% I-Premise
for I-Premise
octreotide I-Premise
patients I-Premise
and I-Premise
42 I-Premise
% I-Premise
for I-Premise
control I-Premise
patients I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
the B-Premise
unadjusted I-Premise
relative I-Premise
risk I-Premise
for I-Premise
mortality I-Premise
in I-Premise
the I-Premise
octreotide I-Premise
group I-Premise
compared I-Premise
with I-Premise
patients I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
was I-Premise
1 I-Premise
. I-Premise
11 I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
. I-Premise
76 I-Premise
- I-Premise
1 I-Premise
. I-Premise
63 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
59 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
when B-Premise
adjusted I-Premise
for I-Premise
okuda I-Premise
, I-Premise
ctp I-Premise
, I-Premise
and I-Premise
cancer I-Premise
of I-Premise
the I-Premise
liver I-Premise
italian I-Premise
program I-Premise
( I-Premise
clip I-Premise
) I-Premise
scores I-Premise
, I-Premise
the I-Premise
relative I-Premise
risk I-Premise
for I-Premise
octreotide I-Premise
did I-Premise
not I-Premise
change I-Premise
markedly I-Premise
and I-Premise
was I-Premise
1 I-Premise
. I-Premise
05 I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
. I-Premise
71 I-Premise
- I-Premise
1 I-Premise
. I-Premise
55 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
83 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Claim
clip I-Claim
score I-Claim
seems I-Claim
to I-Claim
predict I-Claim
survival I-Claim
better I-Claim
than I-Claim
both I-Claim
okuda I-Claim
and I-Claim
ctp I-Claim
score I-Claim
. I-Claim
!LF! !LF!
the B-Claim
randomized I-Claim
controlled I-Claim
double I-Claim
- I-Claim
blind I-Claim
hector I-Claim
trial I-Claim
showed I-Claim
no I-Claim
survival I-Claim
benefit I-Claim
for I-Claim
hcc I-Claim
patients I-Claim
treated I-Claim
with I-Claim
long I-Claim
- I-Claim
acting I-Claim
octreotide I-Claim
compared I-Claim
with I-Claim
placebo I-Claim
. I-Claim
!LF! !LF!
we O
investigated O
the O
role O
of O
tamoxifen O
and O
radiotherapy O
( O
rt O
) O
for O
the O
prevention O
and O
treatment O
of O
gynecomastia O
and O
breast O
pain O
during O
adjuvant O
bicalutamide O
monotherapy O
after O
radical O
prostatectomy O
( O
rp O
) O
in O
patients O
with O
prostate O
cancer O
. O
!LF! !LF!
also O
, O
we O
evaluated O
their O
effects O
on O
patient O
hormonal O
status O
, O
quality O
of O
life O
( O
qol O
) O
, O
sexual O
function O
and O
prostate O
specific O
antigen O
relapse O
- O
free O
survival O
. O
!LF! !LF!
this O
was O
a O
multicenter O
prospective O
trial O
. O
!LF! !LF!
from O
january O
2002 O
to O
february O
2004 O
, O
102 O
patients O
who O
had O
undergone O
rp O
for O
localized O
or O
locally O
advanced O
prostate O
cancer O
were O
recruited O
and O
randomized O
into O
3 O
groups O
, O
namely O
group O
1 O
- O
those O
receiving O
only O
150 O
mg O
bicalutamide O
as O
adjuvant O
hormonal O
therapy O
, O
group O
2 O
- O
those O
receiving O
bicalutamide O
and O
10 O
mg O
tamoxifen O
, O
and O
group O
3 O
- O
those O
receiving O
bicalutamide O
and O
rt O
. O
!LF! !LF!
patients O
in O
group O
1 O
in O
whom O
gynecomastia O
or O
breast O
pain O
developed O
were O
subsequently O
randomized O
to O
receive O
tamoxifen O
or O
rt O
soon O
after O
symptoms O
started O
. O
!LF! !LF!
gynecomastia O
, O
breast O
pain O
, O
prostate O
specific O
antigen O
, O
qol O
, O
sexual O
function O
and O
hormonal O
levels O
were O
assessed O
. O
!LF! !LF!
minimum O
followup O
was O
12 O
months O
. O
!LF! !LF!
of B-Premise
group I-Premise
1 I-Premise
patients I-Premise
67 I-Premise
% I-Premise
had I-Premise
gynecomastia I-Premise
compared I-Premise
with I-Premise
8 I-Premise
% I-Premise
in I-Premise
group I-Premise
2 I-Premise
and I-Premise
34 I-Premise
% I-Premise
in I-Premise
group I-Premise
3 I-Premise
. I-Premise
!LF! !LF!
breast B-Premise
pain I-Premise
was I-Premise
more I-Premise
frequent I-Premise
in I-Premise
group I-Premise
1 I-Premise
than I-Premise
in I-Premise
groups I-Premise
2 I-Premise
and I-Premise
3 I-Premise
( I-Premise
58 I-Premise
% I-Premise
vs I-Premise
7 I-Premise
% I-Premise
and I-Premise
30 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise
!LF! !LF!
differences B-Premise
were I-Premise
significant I-Premise
between I-Premise
groups I-Premise
1 I-Premise
and I-Premise
2 I-Premise
( I-Premise
or I-Premise
0 I-Premise
. I-Premise
12 I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
and I-Premise
groups I-Premise
1 I-Premise
and I-Premise
3 I-Premise
( I-Premise
or I-Premise
0 I-Premise
. I-Premise
52 I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
in B-Premise
patients I-Premise
in I-Premise
group I-Premise
1 I-Premise
who I-Premise
had I-Premise
gynecomastia I-Premise
or I-Premise
breast I-Premise
pain I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
symptoms I-Premise
was I-Premise
achieved I-Premise
in I-Premise
those I-Premise
receiving I-Premise
tamoxifen I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
treatments B-Premise
were I-Premise
well I-Premise
tolerated I-Premise
in I-Premise
the I-Premise
3 I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
no B-Premise
differences I-Premise
in I-Premise
qol I-Premise
between I-Premise
groups I-Premise
2 I-Premise
and I-Premise
3 I-Premise
were I-Premise
found I-Premise
. I-Premise
!LF! !LF!
at B-Premise
a I-Premise
median I-Premise
followup I-Premise
of I-Premise
26 I-Premise
months I-Premise
we I-Premise
observed I-Premise
12 I-Premise
biochemical I-Premise
relapses I-Premise
. I-Premise
!LF! !LF!
gynecomastia B-Claim
and I-Claim
breast I-Claim
pain I-Claim
induced I-Claim
by I-Claim
bicalutamide I-Claim
monotherapy I-Claim
after I-Claim
rp I-Claim
can I-Claim
be I-Claim
prevented I-Claim
and I-Claim
treated I-Claim
. I-Claim
!LF! !LF!
tamoxifen B-Claim
has I-Claim
been I-Claim
shown I-Claim
to I-Claim
be I-Claim
more I-Claim
effective I-Claim
and I-Claim
safe I-Claim
than I-Claim
rt I-Claim
in I-Claim
this I-Claim
setting I-Claim
. I-Claim
!LF! !LF!
qol B-Claim
and I-Claim
sexual I-Claim
function I-Claim
are I-Claim
not I-Claim
negatively I-Claim
influenced I-Claim
by I-Claim
these I-Claim
2 I-Claim
treatment I-Claim
options I-Claim
. O
!LF! !LF!
to O
test O
the O
hypothesis O
that O
modulation O
of O
bcl O
- O
2 O
with O
13 O
- O
cis O
retinoic O
acid O
( O
cra O
) O
/ O
interferon O
- O
alpha2b O
( O
ifn O
) O
with O
paclitaxel O
( O
tax O
) O
, O
or O
mitoxantrone O
, O
estramustine O
and O
vinorelbine O
( O
mev O
) O
will O
have O
clinical O
activity O
in O
men O
with O
metastatic O
castrate O
- O
resistant O
prostate O
cancer O
( O
crpc O
) O
. O
!LF! !LF!
70 O
patients O
were O
treated O
with O
either O
mev O
( O
arm O
a O
) O
in O
a O
3 O
- O
week O
cycle O
or O
cra O
/ O
ifn O
/ O
tax O
with O
an O
8 O
- O
week O
cycle O
( O
arm O
b O
) O
. O
!LF! !LF!
patients O
were O
assessed O
for O
response O
, O
toxicity O
, O
quality O
of O
life O
( O
qol O
) O
, O
and O
the O
effect O
of O
treatment O
on O
bcl O
- O
2 O
levels O
in O
peripheral O
blood O
mononuclear O
cells O
( O
pbmc O
) O
. O
!LF! !LF!
the B-Premise
psa I-Premise
response I-Premise
rates I-Premise
were I-Premise
50 I-Premise
% I-Premise
and I-Premise
23 I-Premise
% I-Premise
, I-Premise
measurable I-Premise
disease I-Premise
response I-Premise
rates I-Premise
( I-Premise
cr I-Premise
+ I-Premise
pr I-Premise
) I-Premise
14 I-Premise
% I-Premise
and I-Premise
15 I-Premise
% I-Premise
, I-Premise
and I-Premise
median I-Premise
overall I-Premise
survival I-Premise
19 I-Premise
. I-Premise
4 I-Premise
months I-Premise
and I-Premise
13 I-Premise
. I-Premise
9 I-Premise
months I-Premise
on I-Premise
arm I-Premise
a I-Premise
and I-Premise
arm I-Premise
b I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
transient B-Premise
grade I-Premise
4 I-Premise
neutropenia I-Premise
occurred I-Premise
in I-Premise
18 I-Premise
and I-Premise
2 I-Premise
patients I-Premise
, I-Premise
and I-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
thrombosis I-Premise
in I-Premise
7 I-Premise
patients I-Premise
and I-Premise
1 I-Premise
patient I-Premise
in I-Premise
arm I-Premise
a I-Premise
and I-Premise
arm I-Premise
b I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
on I-Premise
arm I-Premise
b I-Premise
reported I-Premise
a I-Premise
clinically I-Premise
significant I-Premise
decline I-Premise
in I-Premise
qol I-Premise
between I-Premise
baseline I-Premise
and I-Premise
week I-Premise
9 I-Premise
/ I-Premise
10 I-Premise
( I-Premise
. I-Premise
71 I-Premise
s I-Premise
. I-Premise
d I-Premise
. I-Premise
) O
, I-Premise
and I-Premise
a I-Premise
significantly I-Premise
lower I-Premise
level I-Premise
of I-Premise
qol I-Premise
than I-Premise
arm I-Premise
a I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
as B-Premise
hypothesized I-Premise
, I-Premise
bcl I-Premise
- I-Premise
2 I-Premise
levels I-Premise
decreased I-Premise
with I-Premise
cra I-Premise
/ I-Premise
ifn I-Premise
therapy I-Premise
only I-Premise
in I-Premise
arm I-Premise
b I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
03 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
treatment B-Claim
with I-Claim
mev I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
demonstrated I-Claim
clinical I-Claim
activity I-Claim
in I-Claim
patients I-Claim
with I-Claim
crpc I-Claim
. I-Claim
!LF! !LF!
given B-Claim
the I-Claim
adverse I-Claim
effect I-Claim
of I-Claim
cra I-Claim
/ I-Claim
ifn I-Claim
/ I-Claim
tax I-Claim
on I-Claim
qol I-Claim
, I-Claim
the I-Claim
study I-Claim
of I-Claim
other I-Claim
novel I-Claim
agents I-Claim
that I-Claim
target I-Claim
bcl I-Claim
- I-Claim
2 I-Claim
family I-Claim
proteins I-Claim
is I-Claim
warranted I-Claim
. I-Claim
!LF! !LF!
the O
feasibility O
of O
measuring O
bcl O
- O
2 O
protein O
in O
a O
cooperative O
group O
setting O
is O
hypothesis O
generating O
and O
supports O
further O
study O
as O
a O
marker O
for O
bcl O
- O
2 O
targeted O
therapy O
. O
!LF! !LF!
taxol B-Premise
( I-Premise
paclitaxel I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
bristol I-Premise
- I-Premise
myers I-Premise
squibb I-Premise
, I-Premise
wallingford I-Premise
, I-Premise
ct I-Premise
) I-Premise
is I-Premise
a I-Premise
new I-Premise
anticancer I-Premise
agent I-Premise
with I-Premise
activity I-Premise
in I-Premise
a I-Premise
number I-Premise
of I-Premise
human I-Premise
tumors I-Premise
, I-Premise
including I-Premise
epithelial I-Premise
ovarian I-Premise
cancer I-Premise
. I-Premise
!LF! !LF!
in O
nonrandomized O
trials O
, O
doses O
studied O
have O
ranged O
from O
135 O
mg O
/ O
m2 O
to O
250 O
mg O
/ O
m2 O
administered O
over O
24 O
hours O
with O
premedication O
to O
avoid O
hypersensitivity O
reactions O
( O
hsrs O
) O
. O
!LF! !LF!
this O
study O
addressed O
two O
questions O
: O
the O
dose O
- O
response O
relationship O
of O
taxol O
in O
relapsed O
ovarian O
cancer O
and O
the O
safety O
of O
a O
short O
infusion O
given O
with O
premedication O
. O
!LF! !LF!
women O
with O
platinum O
- O
pretreated O
epithelial O
ovarian O
cancer O
and O
measurable O
recurrent O
disease O
were O
randomized O
in O
a O
bifactorial O
design O
to O
receive O
either O
175 O
or O
135 O
mg O
/ O
m2 O
of O
taxol O
over O
either O
24 O
or O
3 O
hours O
. O
!LF! !LF!
major O
end O
points O
were O
the O
frequency O
of O
significant O
hsrs O
and O
objective O
response O
rate O
. O
!LF! !LF!
secondary O
end O
points O
were O
progression O
- O
free O
and O
overall O
survival O
. O
!LF! !LF!
of O
407 O
patients O
randomized O
, O
391 O
were O
eligible O
and O
382 O
assessable O
for O
response O
. O
!LF! !LF!
analysis O
was O
performed O
according O
to O
the O
bifactorial O
design O
. O
!LF! !LF!
severe B-Premise
hsrs I-Premise
were I-Premise
rare I-Premise
( I-Premise
1 I-Premise
. I-Premise
5 I-Premise
% I-Premise
patients I-Premise
) I-Premise
and I-Premise
were I-Premise
not I-Premise
affected I-Premise
by I-Premise
either I-Premise
dose I-Premise
or I-Premise
schedule I-Premise
. I-Premise
!LF! !LF!
response B-Premise
was I-Premise
slightly I-Premise
higher I-Premise
at I-Premise
the I-Premise
175 I-Premise
- I-Premise
mg I-Premise
/ I-Premise
m2 I-Premise
dose I-Premise
( I-Premise
20 I-Premise
% I-Premise
) I-Premise
than I-Premise
at I-Premise
135 I-Premise
mg I-Premise
/ I-Premise
m2 I-Premise
( I-Premise
15 I-Premise
% I-Premise
) I-Premise
, I-Premise
but B-Premise
this I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
2 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
however B-Premise
, I-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
in I-Premise
the I-Premise
high I-Premise
- I-Premise
dose I-Premise
group I-Premise
( I-Premise
19 I-Premise
v I-Premise
14 I-Premise
weeks I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
significantly B-Premise
more I-Premise
neutropenia I-Premise
was I-Premise
seen I-Premise
when I-Premise
taxol I-Premise
was I-Premise
administered I-Premise
as I-Premise
a I-Premise
24 I-Premise
- I-Premise
hour I-Premise
infusion I-Premise
. I-Premise
!LF! !LF!
response B-Premise
rates I-Premise
were I-Premise
similar I-Premise
in I-Premise
the I-Premise
- I-Premise
24 I-Premise
and I-Premise
3 I-Premise
- I-Premise
hour I-Premise
groups I-Premise
( I-Premise
19 I-Premise
% I-Premise
and I-Premise
16 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
6 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
no B-Premise
survival I-Premise
differences I-Premise
were I-Premise
noted I-Premise
. I-Premise
!LF! !LF!
the B-Claim
3 I-Claim
- I-Claim
hour I-Claim
infusion I-Claim
of I-Claim
taxol I-Claim
is I-Claim
safe I-Claim
when I-Claim
given I-Claim
with I-Claim
premedication I-Claim
and I-Claim
is I-Claim
associated I-Claim
with I-Claim
less I-Claim
neutropenia I-Claim
. I-Claim
!LF! !LF!
there O
is O
a O
modest O
dose O
effect O
with O
longer O
time O
to O
progression O
at O
175 O
mg O
/ O
m2 O
. O
!LF! !LF!
the B-Claim
observation I-Claim
that I-Claim
longer I-Claim
infusion I-Claim
produces I-Claim
more I-Claim
myelosuppression I-Claim
but I-Claim
does I-Claim
not I-Claim
yield I-Claim
higher I-Claim
response I-Claim
rates I-Claim
should I-Claim
lead I-Claim
to I-Claim
further I-Claim
studies I-Claim
to I-Claim
determine I-Claim
the I-Claim
optimal I-Claim
dose I-Claim
and I-Claim
schedule I-Claim
of I-Claim
this I-Claim
interesting I-Claim
new I-Claim
agent I-Claim
. I-Claim
!LF! !LF!
anaemia O
is O
common O
in O
patients O
receiving O
chemotherapy O
, O
causing O
symptoms O
that O
have O
a O
major O
impact O
on O
quality O
of O
life O
( O
qol O
) O
. O
!LF! !LF!
epoetin O
beta O
rapidly O
increases O
haemoglobin O
( O
hb O
) O
levels O
and O
improves O
qol O
in O
anaemic O
patients O
with O
a O
variety O
of O
tumours O
. O
!LF! !LF!
this O
was O
a O
randomized O
, O
double O
- O
blind O
, O
parallel O
- O
group O
, O
dose O
- O
finding O
study O
assessing O
the O
efficacy O
and O
safety O
of O
once O
- O
weekly O
epoetin O
beta O
in O
patients O
with O
solid O
tumours O
receiving O
chemotherapy O
. O
!LF! !LF!
adult O
patients O
with O
anaemia O
( O
hb O
< O
11 O
g O
/ O
dl O
) O
were O
randomized O
to O
receive O
epoetin O
beta O
30 O
, O
000 O
iu O
or O
20 O
, O
000 O
iu O
once O
weekly O
for O
12 O
weeks O
. O
!LF! !LF!
all O
patients O
received O
oral O
iron O
supplementation O
. O
!LF! !LF!
haemoglobin O
levels O
, O
transfusion O
need O
and O
qol O
[ O
functional O
assessment O
of O
cancer O
therapy O
- O
fatigue O
( O
fact O
- O
f O
) O
subscale O
score O
] O
were O
assessed O
at O
regular O
intervals O
. O
!LF! !LF!
fifty O
patients O
were O
randomized O
"""" O
; O
"""" O
30 O
patients O
received O
epoetin O
beta O
30 O
, O
000 O
iu O
once O
weekly O
and O
20 O
received O
20 O
, O
000 O
iu O
once O
weekly O
. O
!LF! !LF!
mean B-Premise
( I-Premise
+ I-Premise
/ I-Premise
- I-Premise
sd I-Premise
) I-Premise
increase I-Premise
in I-Premise
hb I-Premise
from I-Premise
baseline I-Premise
to I-Premise
week I-Premise
12 I-Premise
was I-Premise
1 I-Premise
. I-Premise
75 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
2 I-Premise
. I-Premise
15 I-Premise
g I-Premise
/ I-Premise
dl I-Premise
in I-Premise
the I-Premise
30 I-Premise
, I-Premise
000 I-Premise
iu I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
008 I-Premise
vs I-Premise
. I-Premise
baseline I-Premise
) I-Premise
and I-Premise
1 I-Premise
. I-Premise
04 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
1 I-Premise
. I-Premise
75 I-Premise
g I-Premise
/ I-Premise
dl I-Premise
in I-Premise
the I-Premise
20 I-Premise
, I-Premise
000 I-Premise
iu I-Premise
group I-Premise
( I-Premise
non I-Premise
- I-Premise
significant I-Premise
) I-Premise
. I-Premise
!LF! !LF!
haemoglobin B-Premise
response I-Premise
( I-Premise
increase I-Premise
in I-Premise
hb I-Premise
> I-Premise
or I-Premise
= I-Premise
2 I-Premise
g I-Premise
/ I-Premise
dl I-Premise
from I-Premise
baseline I-Premise
) I-Premise
was I-Premise
observed I-Premise
in I-Premise
78 I-Premise
. I-Premise
3 I-Premise
% I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
epoetin I-Premise
beta I-Premise
30 I-Premise
, I-Premise
000 I-Premise
iu I-Premise
and I-Premise
66 I-Premise
. I-Premise
7 I-Premise
% I-Premise
receiving I-Premise
epoetin I-Premise
beta I-Premise
20 I-Premise
, I-Premise
000 I-Premise
iu I-Premise
. I-Premise
!LF! !LF!
improvements O
in O
fact O
- O
f O
subscale O
score O
were O
significantly O
( O
p O
< O
0 O
. O
001 O
) O
correlated O
with O
increases O
in O
hb O
level O
. O
!LF! !LF!
transfusion O
use O
was O
low O
during O
the O
study O
in O
both O
groups O
. O
!LF! !LF!
both B-Premise
epoetin I-Premise
beta I-Premise
regiments I-Premise
were I-Premise
well I-Premise
tolerated I-Premise
and I-Premise
there I-Premise
were I-Premise
no I-Premise
dose I-Premise
- I-Premise
dependent I-Premise
adverse I-Premise
events I-Premise
. I-Premise
!LF! !LF!
epoetin B-Claim
beta I-Claim
30 I-Claim
, I-Claim
000 I-Claim
iu I-Claim
once I-Claim
weekly I-Claim
is I-Claim
an I-Claim
effective I-Claim
and I-Claim
well I-Claim
- I-Claim
tolerated I-Claim
treatment I-Claim
of I-Claim
anaemia I-Claim
in I-Claim
patients I-Claim
with I-Claim
solid I-Claim
tumours I-Claim
. I-Claim
!LF! !LF!
before O
the O
knowledge O
that O
5 O
years O
of O
adjuvant O
tamoxifen O
is O
less O
efficacious O
than O
2 O
to O
3 O
years O
of O
tamoxifen O
followed O
by O
2 O
to O
3 O
years O
of O
anastrozole O
/ O
exemestane O
, O
we O
designed O
a O
multicenter O
double O
- O
blind O
randomized O
controlled O
trial O
in O
women O
taking O
tamoxifen O
with O
a O
thickened O
endometrium O
to O
compare O
uterine O
and O
quality O
- O
of O
- O
life O
parameters O
between O
those O
switching O
to O
anastrozole O
and O
those O
continuing O
tamoxifen O
. O
!LF! !LF!
asymptomatic O
postmenopausal O
women O
who O
took O
adjuvant O
tamoxifen O
for O
2 O
to O
3 O
years O
for O
operable O
breast O
cancer O
with O
a O
double O
endometrial O
thickness O
greater O
than O
7 O
mm O
were O
randomized O
to O
20 O
mg O
tamoxifen O
or O
1 O
mg O
anastrozole O
for O
the O
remaining O
duration O
, O
totaling O
5 O
years O
. O
!LF! !LF!
tablets O
were O
unrecognizable O
for O
drug O
assignment O
. O
!LF! !LF!
the O
primary O
endpoints O
were O
the O
differences O
in O
double O
endometrial O
thickness O
and O
uterine O
volume O
after O
1 O
year O
. O
!LF! !LF!
uterine O
and O
quality O
- O
of O
- O
life O
data O
were O
analyzed O
using O
regression O
methods O
, O
and O
missing O
values O
were O
handled O
using O
multiple O
imputation O
. O
!LF! !LF!
seventy O
- O
two O
women O
( O
median O
age O
, O
60 O
y O
) O
were O
randomized O
in O
five O
hospitals O
. O
!LF! !LF!
relative B-Premise
to I-Premise
women I-Premise
continuing I-Premise
tamoxifen I-Premise
, I-Premise
women I-Premise
switching I-Premise
to I-Premise
anastrozole I-Premise
experienced I-Premise
a I-Premise
decrease I-Premise
of I-Premise
53 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
41 I-Premise
% I-Premise
- I-Premise
63 I-Premise
% I-Premise
) I-Premise
in I-Premise
double I-Premise
endometrial I-Premise
thickness I-Premise
and I-Premise
a I-Premise
decrease I-Premise
of I-Premise
51 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
39 I-Premise
% I-Premise
- I-Premise
60 I-Premise
% I-Premise
) I-Premise
in I-Premise
uterine I-Premise
volume I-Premise
. I-Premise
!LF! !LF!
vaginal B-Premise
dryness I-Premise
( I-Premise
b I-Premise
= I-Premise
0 I-Premise
. I-Premise
064 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
016 I-Premise
- I-Premise
0 I-Premise
. I-Premise
112 I-Premise
) I-Premise
and I-Premise
sexual I-Premise
problems I-Premise
( I-Premise
b I-Premise
= I-Premise
0 I-Premise
. I-Premise
054 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
007 I-Premise
- I-Premise
0 I-Premise
. I-Premise
102 I-Premise
) I-Premise
increased I-Premise
in I-Premise
women I-Premise
taking I-Premise
anastrozole I-Premise
compared I-Premise
with I-Premise
women I-Premise
taking I-Premise
tamoxifen I-Premise
. I-Premise
!LF! !LF!
treatment B-Premise
arms I-Premise
did I-Premise
not I-Premise
differ I-Premise
regarding I-Premise
withdrawal I-Premise
rate I-Premise
and I-Premise
the I-Premise
experience I-Premise
of I-Premise
( I-Premise
serious I-Premise
) I-Premise
adverse I-Premise
events I-Premise
. I-Premise
!LF! !LF!
despite O
premature O
trial O
closure O
, O
our O
data O
provided O
valuable O
insights O
. O
!LF! !LF!
switching B-Claim
to I-Claim
anastrozole I-Claim
strongly I-Claim
decreased I-Claim
the I-Claim
endometrial I-Claim
thickness I-Claim
and I-Claim
uterine I-Claim
volume I-Claim
but I-Claim
increased I-Claim
sexual I-Claim
disturbances I-Claim
. I-Claim
!LF! !LF!
safe B-Claim
and I-Claim
effective I-Claim
interventions I-Claim
are I-Claim
needed I-Claim
to I-Claim
alleviate I-Claim
sexual I-Claim
dysfunction I-Claim
. I-Claim
!LF! !LF!
depression B-Claim
, I-Claim
anxiety I-Claim
, I-Claim
fatigue I-Claim
, I-Claim
and I-Claim
impaired I-Claim
wellbeing I-Claim
are I-Claim
common I-Claim
, I-Claim
important I-Claim
, I-Claim
and I-Claim
closely I-Claim
related I-Claim
in I-Claim
advanced I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
we O
aimed O
to O
identify O
the O
effects O
of O
an O
established O
antidepressant O
on O
these O
symptoms O
and O
survival O
in O
patients O
with O
advanced O
cancer O
who O
did O
not O
have O
major O
depression O
as O
assessed O
by O
clinicians O
. O
!LF! !LF!
between O
july O
, O
2001 O
, O
and O
february O
, O
2006 O
, O
189 O
patients O
with O
advanced O
cancer O
were O
randomly O
assigned O
sertraline O
50 O
mg O
( O
n O
= O
95 O
) O
, O
or O
placebo O
( O
n O
= O
94 O
) O
, O
once O
per O
day O
. O
!LF! !LF!
the O
primary O
outcome O
was O
depression O
as O
assessed O
by O
the O
centre O
for O
epidemiologic O
studies O
depression O
scale O
( O
ces O
- O
d O
) O
"""" O
; O
"""" O
the O
main O
secondary O
outcomes O
were O
: O
anxiety O
as O
assessed O
by O
hospital O
anxiety O
and O
depression O
scales O
( O
hads O
- O
a O
) O
"""" O
; O
"""" O
overall O
quality O
of O
life O
and O
fatigue O
as O
assessed O
by O
functional O
assessment O
of O
cancer O
therapy O
general O
and O
fatigue O
scales O
( O
fact O
- O
g O
and O
fact O
- O
f O
, O
respectively O
) O
"""" O
; O
"""" O
and O
clinicians O
' O
ratings O
of O
quality O
of O
life O
by O
use O
of O
spizter O
' O
s O
quality O
of O
life O
index O
( O
sqli O
) O
. O
!LF! !LF!
multiple O
measures O
were O
used O
for O
corroboration O
of O
the O
most O
important O
outcomes O
. O
!LF! !LF!
primary O
analyses O
were O
done O
by O
intention O
to O
treat O
and O
were O
based O
on O
scale O
scores O
at O
4 O
weeks O
and O
8 O
weeks O
. O
!LF! !LF!
the O
benefits O
of O
sertraline O
compared O
with O
placebo O
are O
expressed O
on O
a O
range O
from O
100 O
( O
ie O
, O
maximum O
benefit O
) O
to O
- O
100 O
( O
ie O
, O
maximum O
harm O
) O
"""" O
; O
"""" O
a O
difference O
of O
10 O
was O
deemed O
clinically O
significant O
. O
!LF! !LF!
this O
clinical O
trial O
is O
registered O
at O
current O
controlled O
trials O
website O
http O
: O
/ O
/ O
www O
. O
controlled O
- O
trials O
. O
com O
/ O
isrctn72466475 O
. O
!LF! !LF!
sertraline B-Premise
had I-Premise
no I-Premise
significant I-Premise
effect I-Premise
( I-Premise
scale I-Premise
, I-Premise
benefit I-Premise
over I-Premise
placebo I-Premise
[ I-Premise
95 I-Premise
% I-Premise
ci I-Premise
] I-Premise
) I-Premise
on I-Premise
depression I-Premise
( I-Premise
ces I-Premise
- I-Premise
d I-Premise
0 I-Premise
. I-Premise
4 I-Premise
[ I-Premise
- I-Premise
2 I-Premise
. I-Premise
6 I-Premise
to I-Premise
3 I-Premise
. I-Premise
4 I-Premise
] I-Premise
) I-Premise
, I-Premise
anxiety I-Premise
( I-Premise
hads I-Premise
- I-Premise
a I-Premise
2 I-Premise
. I-Premise
0 I-Premise
[ I-Premise
- I-Premise
1 I-Premise
. I-Premise
5 I-Premise
to I-Premise
5 I-Premise
. I-Premise
5 I-Premise
] I-Premise
) I-Premise
, I-Premise
fatigue I-Premise
( I-Premise
fact I-Premise
- I-Premise
f I-Premise
0 I-Premise
. I-Premise
3 I-Premise
[ I-Premise
- I-Premise
4 I-Premise
. I-Premise
3 I-Premise
to I-Premise
4 I-Premise
. I-Premise
9 I-Premise
] I-Premise
) I-Premise
, I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
fact I-Premise
- I-Premise
g I-Premise
1 I-Premise
. I-Premise
7 I-Premise
[ I-Premise
- I-Premise
1 I-Premise
. I-Premise
3 I-Premise
to I-Premise
4 I-Premise
. I-Premise
7 I-Premise
] I-Premise
) I-Premise
, I-Premise
or I-Premise
clinicians I-Premise
' I-Premise
ratings I-Premise
( I-Premise
sqli I-Premise
2 I-Premise
. I-Premise
0 I-Premise
[ I-Premise
- I-Premise
2 I-Premise
. I-Premise
5 I-Premise
to I-Premise
6 I-Premise
. I-Premise
5 I-Premise
] I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
95 I-Premise
% I-Premise
ci I-Premise
ruled I-Premise
out I-Premise
a I-Premise
clinically I-Premise
significant I-Premise
benefit I-Premise
for I-Premise
all I-Premise
main I-Premise
outcomes I-Premise
. I-Premise
!LF! !LF!
sertraline B-Premise
was I-Premise
discontinued I-Premise
more I-Premise
often I-Premise
and I-Premise
earlier I-Premise
than I-Premise
was I-Premise
placebo I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
1 I-Premise
. I-Premise
46 I-Premise
[ I-Premise
1 I-Premise
. I-Premise
03 I-Premise
- I-Premise
2 I-Premise
. I-Premise
06 I-Premise
] I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
03 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
recruitment O
was O
stopped O
after O
the B-Premise
first I-Premise
planned I-Premise
interim I-Premise
analysis I-Premise
in I-Premise
february I-Premise
2006 I-Premise
( I-Premise
n I-Premise
= I-Premise
150 I-Premise
) I-Premise
showed I-Premise
that I-Premise
survival I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
assigned I-Premise
placebo I-Premise
than I-Premise
in I-Premise
patients I-Premise
assigned I-Premise
sertraline I-Premise
( I-Premise
unadjusted I-Premise
hazard I-Premise
ratio I-Premise
1 I-Premise
. I-Premise
60 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
ci I-Premise
1 I-Premise
. I-Premise
04 I-Premise
- I-Premise
2 I-Premise
. I-Premise
45 I-Premise
] I-Premise
, I-Premise
log I-Premise
- I-Premise
rank I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
04 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
adjusted I-Premise
hazard I-Premise
ratio I-Premise
1 I-Premise
. I-Premise
62 I-Premise
[ I-Premise
1 I-Premise
. I-Premise
06 I-Premise
- I-Premise
2 I-Premise
. I-Premise
41 I-Premise
] I-Premise
, I-Premise
cox I-Premise
model I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
however B-Premise
, I-Premise
at I-Premise
the I-Premise
final I-Premise
analysis I-Premise
in I-Premise
july I-Premise
2006 I-Premise
of I-Premise
all I-Premise
patients I-Premise
( I-Premise
n I-Premise
= I-Premise
189 I-Premise
) I-Premise
and I-Premise
with I-Premise
longer I-Premise
follow I-Premise
- I-Premise
up I-Premise
, I-Premise
survival I-Premise
did I-Premise
not I-Premise
differ I-Premise
significantly I-Premise
between I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
( I-Premise
unadjusted I-Premise
hazard I-Premise
ratio I-Premise
1 I-Premise
. I-Premise
35 I-Premise
[ I-Premise
0 I-Premise
. I-Premise
95 I-Premise
- I-Premise
1 I-Premise
. I-Premise
91 I-Premise
] I-Premise
, I-Premise
log I-Premise
- I-Premise
rank I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
09 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
adjusted I-Premise
hazard I-Premise
ratio I-Premise
1 I-Premise
. I-Premise
27 I-Premise
[ I-Premise
0 I-Premise
. I-Premise
87 I-Premise
- I-Premise
1 I-Premise
. I-Premise
84 I-Premise
] I-Premise
, I-Premise
cox I-Premise
model I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
20 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the O
trial O
was O
closed O
because O
it O
had O
ruled O
out O
a O
significant O
benefit O
of O
sertraline O
. O
!LF! !LF!
sertraline B-Claim
did I-Claim
not I-Claim
improve I-Claim
symptoms I-Claim
, I-Claim
wellbeing I-Claim
, I-Claim
or I-Claim
survival I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
who I-Claim
do I-Claim
not I-Claim
have I-Claim
major I-Claim
depression I-Claim
, I-Claim
and I-Claim
should I-Claim
be I-Claim
reserved I-Claim
for I-Claim
those I-Claim
with I-Claim
a I-Claim
proven I-Claim
indication I-Claim
. I-Claim
!LF! !LF!
this O
double O
- O
blind O
randomized O
phase O
ii O
trial O
examined O
whether O
vandetanib O
, O
an O
inhibitor O
of O
vascular O
endothelial O
and O
epidermal O
growth O
factor O
receptors O
, O
could O
prolong O
progression O
- O
free O
survival O
in O
responding O
patients O
with O
small O
- O
cell O
lung O
cancer O
. O
!LF! !LF!
eligible O
patients O
with O
complete O
response O
( O
cr O
) O
or O
partial O
response O
( O
pr O
) O
to O
combination O
chemotherapy O
( O
+ O
/ O
- O
thoracic O
or O
prophylactic O
cranial O
radiation O
) O
received O
oral O
vandetanib O
300 O
mg O
/ O
d O
or O
matched O
placebo O
. O
!LF! !LF!
with O
100 O
patients O
and O
77 O
events O
, O
the O
study O
had O
80 O
% O
power O
to O
detect O
an O
improvement O
in O
median O
progression O
- O
free O
survival O
from O
4 O
to O
6 O
. O
5 O
months O
( O
one O
- O
sided O
, O
10 O
% O
- O
level O
test O
) O
. O
!LF! !LF!
between O
may O
2003 O
and O
march O
2006 O
, O
107 O
patients O
were O
accrued O
"""" O
; O
"""" O
46 O
had O
limited O
disease O
and O
61 O
extensive O
disease O
. O
!LF! !LF!
there O
were O
fewer O
patients O
with O
a O
performance O
status O
of O
0 O
( O
n O
= O
11 O
v O
20 O
) O
, O
and O
fewer O
had O
cr O
to O
initial O
therapy O
( O
n O
= O
4 O
v O
8 O
) O
in O
the O
vandetanib O
arm O
. O
!LF! !LF!
vandetanib B-Premise
patients I-Premise
had I-Premise
more I-Premise
toxicity I-Premise
and I-Premise
required I-Premise
more I-Premise
dose I-Premise
modifications I-Premise
for I-Premise
gastrointestinal I-Premise
toxicity I-Premise
and I-Premise
rash I-Premise
. I-Premise
!LF! !LF!
asymptomatic B-Premise
corrected I-Premise
qt I-Premise
interval I-Premise
( I-Premise
qtc I-Premise
) I-Premise
prolongation I-Premise
was I-Premise
observed I-Premise
in I-Premise
eight I-Premise
vandetanib I-Premise
patients I-Premise
. I-Premise
!LF! !LF!
median B-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
for I-Premise
vandetanib I-Premise
and I-Premise
placebo I-Premise
was I-Premise
2 I-Premise
. I-Premise
7 I-Premise
and I-Premise
2 I-Premise
. I-Premise
8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
hr I-Premise
] I-Premise
, I-Premise
1 I-Premise
. I-Premise
01 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
80 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
75 I-Premise
to I-Premise
1 I-Premise
. I-Premise
36 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
one I-Premise
- I-Premise
sided I-Premise
p I-Premise
= I-Premise
. I-Premise
51 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
overall B-Premise
survival I-Premise
for I-Premise
vandetanib I-Premise
was I-Premise
10 I-Premise
. I-Premise
6 I-Premise
versus I-Premise
11 I-Premise
. I-Premise
9 I-Premise
months I-Premise
for I-Premise
placebo I-Premise
( I-Premise
hr I-Premise
, I-Premise
1 I-Premise
. I-Premise
43 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
80 I-Premise
% I-Premise
ci I-Premise
, I-Premise
1 I-Premise
. I-Premise
00 I-Premise
to I-Premise
2 I-Premise
. I-Premise
05 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
one I-Premise
- I-Premise
sided I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
9 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
in B-Premise
planned I-Premise
subgroup I-Premise
analyses I-Premise
, I-Premise
a I-Premise
significant I-Premise
interaction I-Premise
was I-Premise
noted I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
01 I-Premise
) I-Premise
: I-Premise
limited I-Premise
- I-Premise
stage I-Premise
vandetanib I-Premise
patients I-Premise
had I-Premise
longer I-Premise
overall I-Premise
survival I-Premise
( I-Premise
hr I-Premise
, I-Premise
0 I-Premise
. I-Premise
45 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
one I-Premise
- I-Premise
sided I-Premise
p I-Premise
= I-Premise
. I-Premise
07 I-Premise
) I-Premise
and I-Premise
extensive I-Premise
- I-Premise
stage I-Premise
vandetanib I-Premise
patients I-Premise
shorter I-Premise
survival I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
hr I-Premise
, I-Premise
2 I-Premise
. I-Premise
27 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
one I-Premise
- I-Premise
sided I-Premise
p I-Premise
= I-Premise
. I-Premise
996 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
vandetanib B-Claim
failed I-Claim
to I-Claim
demonstrate I-Claim
efficacy I-Claim
as I-Claim
maintenance I-Claim
therapy I-Claim
for I-Claim
small I-Claim
- I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
cancer O
cells O
rely O
on O
angiogenesis O
for O
growth O
and O
dissemination O
, O
and O
small O
cell O
lung O
cancer O
( O
sclc O
) O
is O
a O
highly O
angiogenic O
tumor O
. O
!LF! !LF!
we O
evaluated O
thalidomide O
, O
an O
anti O
- O
angiogenic O
agent O
, O
when O
combined O
with O
chemotherapy O
and O
as O
maintenance O
treatment O
. O
!LF! !LF!
a O
total O
of O
724 O
patients O
( O
51 O
% O
with O
limited O
and O
49 O
% O
with O
extensive O
disease O
) O
were O
randomly O
assigned O
to O
receive O
placebo O
or O
thalidomide O
capsules O
, O
100 O
- O
200 O
mg O
daily O
for O
up O
to O
2 O
years O
. O
!LF! !LF!
all O
patients O
received O
etoposide O
and O
carboplatin O
every O
3 O
weeks O
for O
up O
to O
six O
cycles O
. O
!LF! !LF!
endpoints O
were O
overall O
survival O
, O
progression O
- O
free O
survival O
, O
tumor O
response O
rate O
, O
toxicity O
, O
and O
quality O
of O
life O
( O
qol O
) O
. O
!LF! !LF!
hazard O
ratios O
( O
hrs O
) O
for O
comparing O
thalidomide O
against O
placebo O
were O
estimated O
using O
cox O
regression O
modeling O
. O
!LF! !LF!
statistical O
tests O
were O
two O
- O
sided O
. O
!LF! !LF!
the B-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
10 I-Premise
. I-Premise
5 I-Premise
months I-Premise
( I-Premise
placebo I-Premise
) I-Premise
and I-Premise
10 I-Premise
. I-Premise
1 I-Premise
months I-Premise
( I-Premise
thalidomide I-Premise
) I-Premise
( I-Premise
hr I-Premise
for I-Premise
death I-Premise
= I-Premise
1 I-Premise
. I-Premise
09 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
ci I-Premise
] I-Premise
= I-Premise
0 I-Premise
. I-Premise
93 I-Premise
to I-Premise
1 I-Premise
. I-Premise
27 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
28 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
among B-Premise
patients I-Premise
with I-Premise
limited I-Premise
- I-Premise
stage I-Premise
disease I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
evidence I-Premise
of I-Premise
a I-Premise
survival I-Premise
difference I-Premise
( I-Premise
hr I-Premise
for I-Premise
death I-Premise
= I-Premise
0 I-Premise
. I-Premise
91 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
0 I-Premise
. I-Premise
73 I-Premise
to I-Premise
1 I-Premise
. I-Premise
15 I-Premise
) I-Premise
, I-Premise
but B-Premise
among I-Premise
patients I-Premise
with I-Premise
extensive I-Premise
disease I-Premise
, I-Premise
survival I-Premise
was I-Premise
worse I-Premise
in I-Premise
the I-Premise
thalidomide I-Premise
group I-Premise
( I-Premise
hr I-Premise
for I-Premise
death I-Premise
= I-Premise
1 I-Premise
. I-Premise
36 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
1 I-Premise
. I-Premise
10 I-Premise
to I-Premise
1 I-Premise
. I-Premise
68 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
progression B-Premise
- B-Premise
free B-Premise
survival I-Premise
rates I-Premise
were I-Premise
also I-Premise
similar I-Premise
in I-Premise
the I-Premise
two I-Premise
groups I-Premise
( I-Premise
hr I-Premise
= I-Premise
1 I-Premise
. I-Premise
07 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
0 I-Premise
. I-Premise
92 I-Premise
to I-Premise
1 I-Premise
. I-Premise
24 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
thalidomide B-Premise
was I-Premise
associated I-Premise
with I-Premise
an I-Premise
increased I-Premise
risk I-Premise
of I-Premise
having I-Premise
a I-Premise
thrombotic I-Premise
event I-Premise
, I-Premise
mainly I-Premise
pulmonary I-Premise
embolus I-Premise
and I-Premise
deep I-Premise
vein I-Premise
thrombosis I-Premise
( I-Premise
19 I-Premise
% I-Premise
thalidomide I-Premise
vs I-Premise
10 I-Premise
% I-Premise
placebo I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hr I-Premise
= I-Premise
2 I-Premise
. I-Premise
13 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
1 I-Premise
. I-Premise
41 I-Premise
to I-Premise
3 I-Premise
. I-Premise
20 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
between I-Premise
treatments I-Premise
in I-Premise
hematological I-Premise
and I-Premise
nonhematological I-Premise
toxic I-Premise
effects I-Premise
, I-Premise
except B-Premise
more I-Premise
patients I-Premise
in I-Premise
the I-Premise
thalidomide I-Premise
group I-Premise
had I-Premise
rash I-Premise
, I-Premise
constipation I-Premise
, I-Premise
or I-Premise
neuropathy I-Premise
. I-Premise
!LF! !LF!
overall O
, O
qol B-Claim
scores I-Claim
were I-Claim
similar I-Claim
in I-Claim
the I-Claim
two I-Claim
treatment I-Claim
groups I-Claim
, I-Claim
but B-Claim
thalidomide I-Claim
was I-Claim
associated I-Claim
with I-Claim
less I-Claim
insomnia I-Claim
and I-Claim
diarrhea I-Claim
and I-Claim
more I-Claim
constipation I-Claim
and I-Claim
peripheral I-Claim
neuropathy I-Claim
. I-Claim
!LF! !LF!
in O
this O
large O
randomized O
trial O
, O
thalidomide B-Claim
in I-Claim
combination I-Claim
with I-Claim
chemotherapy I-Claim
did I-Claim
not I-Claim
improve I-Claim
survival I-Claim
of I-Claim
patients I-Claim
with I-Claim
sclc I-Claim
but I-Claim
was I-Claim
associated I-Claim
with I-Claim
an I-Claim
increased I-Claim
risk I-Claim
of I-Claim
thrombotic I-Claim
events I-Claim
. I-Claim
!LF! !LF!
vinorelbine B-Claim
, I-Claim
a I-Claim
semisynthetic I-Claim
vinca I-Claim
alkaloid I-Claim
, I-Claim
represents I-Claim
a I-Claim
well I-Claim
- I-Claim
tolerated I-Claim
treatment I-Claim
for I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non I-Claim
- I-Claim
small I-Claim
- I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
nsclc I-Claim
) I-Claim
. I-Claim
!LF! !LF!
we O
explored O
the O
quality O
of O
life O
( O
qol O
) O
of O
such O
patients O
in O
a O
multicenter O
randomized O
trial O
that O
compared O
vinorelbine O
treatment O
with O
supportive O
care O
alone O
. O
!LF! !LF!
eligible O
patients O
were O
70 O
years O
of O
age O
or O
older O
, O
had O
stage O
iv O
or O
iiib O
nsclc O
that O
was O
ineligible O
for O
radiotherapy O
, O
and O
had O
a O
performance O
status O
of O
0 O
- O
2 O
( O
a O
status O
of O
fully O
active O
to O
a O
status O
of O
capable O
of O
all O
self O
- O
care O
but O
unable O
to O
work O
) O
. O
!LF! !LF!
vinorelbine O
was O
given O
intravenously O
on O
days O
1 O
and O
8 O
of O
a O
21 O
- O
day O
treatment O
cycle O
, O
for O
a O
total O
of O
six O
cycles O
. O
!LF! !LF!
qol O
was O
evaluated O
with O
european O
organization O
for O
research O
and O
treatment O
of O
cancer O
questionnaires O
qlq O
- O
c30 O
and O
qlq O
- O
lc13 O
, O
and O
the O
qol O
data O
were O
analyzed O
by O
fitting O
a O
linear O
mixed O
model O
for O
each O
qol O
scale O
. O
!LF! !LF!
survival O
curves O
were O
plotted O
and O
were O
compared O
with O
the O
mantel O
- O
haenszel O
test O
. O
!LF! !LF!
relative O
hazards O
of O
death O
and O
95 O
% O
confidence O
intervals O
( O
cis O
) O
were O
estimated O
by O
the O
cox O
model O
. O
!LF! !LF!
investigators O
, O
blinded O
to O
the O
results O
, O
stopped O
the O
trial O
early O
because O
of O
a O
low O
enrollment O
rate O
. O
!LF! !LF!
( O
from O
april O
1996 O
to O
november O
1997 O
, O
191 O
of O
the O
350 O
targeted O
patients O
were O
randomly O
assigned O
. O
) O
!LF! !LF!
data O
from O
161 O
patients O
have O
been O
analyzed O
. O
!LF! !LF!
vinorelbine B-Premise
- B-Premise
treated B-Premise
patients I-Premise
scored I-Premise
better I-Premise
than I-Premise
control I-Premise
patients I-Premise
on I-Premise
qol I-Premise
functioning I-Premise
scales I-Premise
, I-Premise
and I-Premise
they I-Premise
reported I-Premise
fewer I-Premise
lung I-Premise
cancer I-Premise
- I-Premise
related I-Premise
symptoms I-Premise
but I-Premise
reported I-Premise
worse I-Premise
toxicity I-Premise
- I-Premise
related I-Premise
symptoms I-Premise
. I-Premise
!LF! !LF!
there B-Premise
was I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
two I-Premise
- I-Premise
sided I-Premise
p I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
survival I-Premise
advantage I-Premise
for I-Premise
patients I-Premise
receiving I-Premise
vinorelbine I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
median B-Premise
survival I-Premise
increased I-Premise
from I-Premise
21 I-Premise
to I-Premise
28 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
vinorelbine I-Premise
- I-Premise
treated I-Premise
group I-Premise
. I-Premise
!LF! !LF!
the B-Premise
relative I-Premise
hazard I-Premise
of I-Premise
death I-Premise
for I-Premise
vinorelbine I-Premise
- I-Premise
treated I-Premise
patients I-Premise
was I-Premise
0 I-Premise
. I-Premise
65 I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
0 I-Premise
. I-Premise
45 I-Premise
- I-Premise
0 I-Premise
. I-Premise
93 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
vinorelbine B-Claim
improves I-Claim
survival I-Claim
of I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
nsclc I-Claim
and I-Claim
possibly I-Claim
improves I-Claim
overall I-Claim
qol I-Claim
. I-Claim
!LF! !LF!
the O
management O
of O
cancer O
- O
related O
anorexia O
/ O
cachexia O
syndrome O
( O
cacs O
) O
is O
a O
great O
challenge O
in O
clinical O
practice O
. O
!LF! !LF!
to O
date O
, O
practice O
guidelines O
for O
the O
prevention O
and O
treatment O
of O
cacs O
are O
lacking O
. O
!LF! !LF!
the O
authors O
conducted O
a O
randomized O
study O
to O
confirm O
the O
effectiveness O
and O
safety O
of O
treatment O
of O
cacs O
utilizing O
megestrol O
acetate O
( O
ma O
) O
plus O
thalidomide O
. O
!LF! !LF!
one O
hundred O
and O
two O
candidates O
with O
cacs O
were O
randomly O
assigned O
to O
two O
treatment O
groups O
( O
trial O
group O
and O
control O
group O
) O
: O
the O
trial O
group O
received O
ma O
( O
160 O
mg O
po O
, O
bid O
) O
plus O
thalidomide O
( O
50 O
mg O
po O
, O
bid O
) O
, O
while O
the O
control O
group O
received O
ma O
( O
160 O
mg O
po O
, O
bid O
) O
alone O
. O
!LF! !LF!
treatment O
duration O
was O
8 O
weeks O
. O
!LF! !LF!
analysis B-Premise
of I-Premise
the I-Premise
trial I-Premise
group I-Premise
demonstrated I-Premise
a I-Premise
significant I-Premise
increase I-Premise
from I-Premise
baseline I-Premise
in I-Premise
body I-Premise
weight I-Premise
( I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
, I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
, I-Premise
appetite I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
, I-Premise
and I-Premise
grip I-Premise
strength I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
, I-Premise
and I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
fatigue I-Premise
, I-Premise
glasgow I-Premise
prognostic I-Premise
score I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
, I-Premise
eastern I-Premise
cooperative I-Premise
oncology I-Premise
group I-Premise
performance I-Premise
status I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
03 I-Premise
) I-Premise
, I-Premise
il I-Premise
- I-Premise
6 I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
, I-Premise
and I-Premise
tumor I-Premise
necrosis I-Premise
factor I-Premise
- I-Premise
α I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
in B-Premise
contrast I-Premise
, I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
endpoints I-Premise
with I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
from I-Premise
baseline I-Premise
included I-Premise
body I-Premise
weight I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
and I-Premise
appetite I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
mean I-Premise
changes I-Premise
in I-Premise
the I-Premise
endpoints I-Premise
from I-Premise
baseline I-Premise
in I-Premise
the I-Premise
trial I-Premise
group I-Premise
were I-Premise
significantly I-Premise
greater I-Premise
compared I-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
: I-Premise
in I-Premise
the I-Premise
primary I-Premise
endpoints I-Premise
, I-Premise
body I-Premise
weight I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
, I-Premise
fatigue I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
, I-Premise
and I-Premise
in I-Premise
the I-Premise
secondary I-Premise
endpoints I-Premise
, I-Premise
grip I-Premise
strength I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
, I-Premise
glasgow I-Premise
prognostic I-Premise
score I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
, I-Premise
eastern I-Premise
cooperative I-Premise
oncology I-Premise
group I-Premise
performance I-Premise
status I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
, I-Premise
il I-Premise
- I-Premise
6 I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
and I-Premise
tumor I-Premise
necrosis I-Premise
factor I-Premise
- I-Premise
α I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
toxicity B-Premise
was I-Premise
found I-Premise
to I-Premise
be I-Premise
relatively I-Premise
negligible I-Premise
in I-Premise
both I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
a B-Claim
combination I-Claim
regimen I-Claim
of I-Claim
ma I-Claim
and I-Claim
thalidomide I-Claim
is I-Claim
more I-Claim
effective I-Claim
than I-Claim
ma I-Claim
alone I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
cacs I-Claim
. I-Claim
!LF! !LF!
this O
randomised O
non O
- O
inferiority O
trial O
was O
designed O
to O
assess O
whether O
radiosurgery O
plus O
adjuvant O
whole O
brain O
radiotherapy O
( O
rs O
+ O
wbrt O
) O
is O
as O
effective O
as O
surgery O
plus O
whole O
brain O
radiotherapy O
( O
s O
+ O
wbrt O
) O
for O
cancer O
patients O
with O
a O
solitary O
brain O
metastasis O
, O
with O
respect O
to O
overall O
survival O
and O
quality O
of O
life O
. O
!LF! !LF!
major O
inclusion O
criteria O
were O
a O
history O
of O
systemic O
cancer O
within O
5 O
years O
and O
enhanced O
magnetic O
resonance O
imaging O
- O
confirmed O
solitary O
brain O
metastasis O
suitable O
for O
both O
radiosurgery O
and O
surgery O
. O
!LF! !LF!
all O
patients O
were O
to O
receive O
wbrt O
( O
30 O
gy O
in O
10 O
fractions O
) O
. O
!LF! !LF!
between O
february O
2003 O
and O
april O
2009 O
, O
40 O
patients O
were O
considered O
eligible O
, O
22 O
consented O
to O
randomisation O
and O
21 O
were O
analysed O
( O
11 O
rs O
+ O
wbrt O
, O
10 O
s O
+ O
wbrt O
) O
. O
!LF! !LF!
the O
trial O
was O
closed O
early O
due O
to O
slow O
accrual O
. O
!LF! !LF!
the B-Premise
estimated I-Premise
median I-Premise
overall I-Premise
survival I-Premise
times I-Premise
for I-Premise
rs I-Premise
+ I-Premise
wbrt I-Premise
and I-Premise
s I-Premise
+ I-Premise
wbrt I-Premise
patients I-Premise
were I-Premise
6 I-Premise
. I-Premise
2 I-Premise
and I-Premise
2 I-Premise
. I-Premise
8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
0 I-Premise
. I-Premise
53 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
0 I-Premise
. I-Premise
20 I-Premise
- I-Premise
1 I-Premise
. I-Premise
43 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
20 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
corresponding B-Premise
median I-Premise
failure I-Premise
- I-Premise
free I-Premise
survival I-Premise
times I-Premise
were I-Premise
3 I-Premise
. I-Premise
1 I-Premise
and I-Premise
1 I-Premise
. I-Premise
7 I-Premise
months I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
20 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
for B-Premise
19 I-Premise
' I-Premise
per I-Premise
protocol I-Premise
' I-Premise
patients I-Premise
, I-Premise
2 I-Premise
/ I-Premise
10 I-Premise
in I-Premise
the I-Premise
rs I-Premise
+ I-Premise
wbrt I-Premise
arm I-Premise
had I-Premise
distant I-Premise
intracranial I-Premise
failure I-Premise
( I-Premise
one I-Premise
also I-Premise
had I-Premise
local I-Premise
failure I-Premise
) I-Premise
and I-Premise
3 I-Premise
/ I-Premise
9 I-Premise
s I-Premise
+ I-Premise
wbrt I-Premise
patients I-Premise
had I-Premise
distant I-Premise
intracranial I-Premise
failure I-Premise
( I-Premise
no I-Premise
local I-Premise
failures I-Premise
) I-Premise
. I-Premise
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
grade I-Premise
3 I-Premise
- I-Premise
4 I-Premise
late I-Premise
radiation I-Premise
toxicities I-Premise
. I-Premise
!LF! !LF!
two B-Claim
months I-Claim
after I-Claim
starting I-Claim
treatment I-Claim
there I-Claim
were I-Claim
no I-Claim
significant I-Claim
differences I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
between I-Claim
the I-Claim
arms I-Claim
. I-Claim
!LF! !LF!
this B-Claim
randomised I-Claim
trial I-Claim
encountered I-Claim
the I-Claim
accrual I-Claim
difficulties I-Claim
and I-Claim
consequent I-Claim
low I-Claim
statistical I-Claim
power I-Claim
commonly I-Claim
associated I-Claim
with I-Claim
interdisciplinary I-Claim
studies I-Claim
drawing I-Claim
from I-Claim
a I-Claim
small I-Claim
eligible I-Claim
population I-Claim
, I-Claim
but O
can O
contribute O
to O
future O
overviews O
on O
the O
management O
of O
solitary O
brain O
metastases O
. O
!LF! !LF!
the B-Claim
impact I-Claim
of I-Claim
treatment I-Claim
on I-Claim
health I-Claim
- I-Claim
related I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
hrqol I-Claim
) I-Claim
is I-Claim
an I-Claim
important I-Claim
consideration I-Claim
in I-Claim
the I-Claim
adjuvant I-Claim
treatment I-Claim
of I-Claim
operable I-Claim
breast I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
here O
we O
report O
mature O
hrqol O
outcomes O
from O
the O
atac O
trial O
, O
comparing O
anastrozole O
with O
tamoxifen O
as O
primary O
adjuvant O
therapy O
for O
postmenopausal O
women O
with O
localized O
breast O
cancer O
. O
!LF! !LF!
patients O
completed O
the O
functional O
assessment O
of O
cancer O
therapy O
- O
breast O
( O
fact O
- O
b O
) O
questionnaire O
plus O
endocrine O
subscale O
( O
es O
) O
at O
baseline O
, O
3 O
and O
6 O
months O
, O
and O
every O
6 O
months O
thereafter O
. O
!LF! !LF!
baseline O
characteristics O
in O
the O
hrqol O
sub O
- O
protocol O
were O
well O
balanced O
between O
the O
anastrozole O
( O
n O
= O
335 O
) O
and O
tamoxifen O
( O
n O
= O
347 O
) O
groups O
in O
the O
primary O
analysis O
population O
. O
!LF! !LF!
as B-Premise
with I-Premise
previously I-Premise
published I-Premise
results I-Premise
at I-Premise
2 I-Premise
years I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
trial I-Premise
outcome I-Premise
index I-Premise
of I-Premise
the I-Premise
fact I-Premise
- I-Premise
b I-Premise
, I-Premise
the I-Premise
primary I-Premise
endpoint I-Premise
of I-Premise
the I-Premise
study I-Premise
, I-Premise
between I-Premise
treatments I-Premise
at I-Premise
5 I-Premise
years I-Premise
. I-Premise
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
in I-Premise
es I-Premise
total I-Premise
scores I-Premise
. I-Premise
!LF! !LF!
consistent O
with O
the O
2 O
- O
year O
analysis O
, O
there B-Claim
were I-Claim
differences I-Claim
between I-Claim
treatment I-Claim
groups I-Claim
in I-Claim
patient I-Claim
- I-Claim
reported I-Claim
side I-Claim
effects I-Claim
: I-Claim
diarrhea B-Premise
( I-Premise
anastrozole I-Premise
3 I-Premise
. I-Premise
1 I-Premise
% I-Premise
vs I-Premise
. I-Premise
tamoxifen I-Premise
1 I-Premise
. I-Premise
3 I-Premise
% I-Premise
) I-Premise
, I-Premise
vaginal I-Premise
dryness I-Premise
( I-Premise
18 I-Premise
. I-Premise
5 I-Premise
% I-Premise
vs I-Premise
. I-Premise
9 I-Premise
. I-Premise
1 I-Premise
% I-Premise
) I-Premise
, I-Premise
diminished I-Premise
libido I-Premise
( I-Premise
34 I-Premise
. I-Premise
0 I-Premise
% I-Premise
vs I-Premise
. I-Premise
26 I-Premise
. I-Premise
1 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
dyspareunia I-Premise
( I-Premise
17 I-Premise
. I-Premise
3 I-Premise
% I-Premise
vs I-Premise
. I-Premise
8 I-Premise
. I-Premise
1 I-Premise
% I-Premise
) I-Premise
were I-Premise
significantly I-Premise
more I-Premise
frequent I-Premise
with I-Premise
anastrozole I-Premise
compared I-Premise
to I-Premise
tamoxifen I-Premise
. I-Premise
!LF! !LF!
dizziness B-Premise
( I-Premise
3 I-Premise
. I-Premise
1 I-Premise
% I-Premise
vs I-Premise
. I-Premise
5 I-Premise
. I-Premise
4 I-Premise
% I-Premise
) I-Premise
and I-Premise
vaginal I-Premise
discharge I-Premise
( I-Premise
1 I-Premise
. I-Premise
2 I-Premise
% I-Premise
vs I-Premise
. I-Premise
5 I-Premise
. I-Premise
2 I-Premise
% I-Premise
) I-Premise
were I-Premise
significantly I-Premise
less I-Premise
frequent I-Premise
with I-Premise
anastrozole I-Premise
compared I-Premise
to I-Premise
tamoxifen I-Premise
. I-Premise
!LF! !LF!
in B-Claim
this I-Claim
, I-Claim
the I-Claim
first I-Claim
report I-Claim
of I-Claim
hrqol I-Claim
over I-Claim
5 I-Claim
years I-Claim
of I-Claim
initial I-Claim
adjuvant I-Claim
therapy I-Claim
with I-Claim
an I-Claim
aromatase I-Claim
inhibitor I-Claim
, I-Claim
we I-Claim
conclude I-Claim
that I-Claim
anastrozole I-Claim
and I-Claim
tamoxifen I-Claim
had I-Claim
similar I-Claim
impacts I-Claim
on I-Claim
hrqol I-Claim
, I-Claim
which I-Claim
was I-Claim
maintained I-Claim
or I-Claim
slightly I-Claim
improved I-Claim
during I-Claim
the I-Claim
treatment I-Claim
period I-Claim
for I-Claim
both I-Claim
groups I-Claim
. I-Claim
!LF! !LF!
axillary B-Claim
clearance I-Claim
in I-Claim
early I-Claim
breast I-Claim
cancer I-Claim
aims I-Claim
to I-Claim
improve I-Claim
locoregional I-Claim
control I-Claim
and I-Claim
provide I-Claim
staging I-Claim
information I-Claim
but O
is O
associated O
with O
undesirable O
morbidity O
. O
!LF! !LF!
we O
therefore O
investigated O
whether O
avoiding O
axillary O
surgery O
in O
older O
women O
would O
result O
in O
improved O
quality O
of O
life O
( O
ql O
) O
with O
similar O
disease O
- O
free O
survival O
( O
dfs O
) O
and O
overall O
survival O
( O
os O
) O
. O
!LF! !LF!
between O
1993 O
and O
2002 O
, O
women O
> O
or O
= O
60 O
years O
old O
with O
clinically O
node O
- O
negative O
operable O
breast O
cancer O
in O
whom O
adjuvant O
tamoxifen O
was O
considered O
indicated O
regardless O
of O
pathologic O
nodal O
status O
were O
randomly O
assigned O
to O
primary O
surgery O
plus O
axillary O
clearance O
( O
sx O
+ O
ax O
) O
followed O
by O
tamoxifen O
( O
tam O
) O
versus O
sx O
without O
ax O
followed O
by O
tam O
for O
5 O
consecutive O
years O
. O
!LF! !LF!
the O
primary O
end O
point O
was O
ql O
reported O
by O
the O
patient O
and O
by O
physician O
assessment O
. O
!LF! !LF!
a O
total O
of O
473 O
patients O
( O
234 O
to O
sx O
+ O
ax O
, O
239 O
to O
sx O
) O
were O
randomly O
assigned O
. O
!LF! !LF!
the O
median O
age O
was O
74 O
years O
"""" O
; O
"""" O
80 O
% O
had O
estrogen O
receptor O
- O
positive O
disease O
. O
!LF! !LF!
in B-Premise
both I-Premise
the I-Premise
patients I-Premise
' I-Premise
subjective I-Premise
assessment I-Premise
of I-Premise
their I-Premise
ql I-Premise
and I-Premise
the I-Premise
physicians I-Premise
' I-Premise
perception I-Premise
of I-Premise
the I-Premise
patients I-Premise
' I-Premise
ql I-Premise
, I-Premise
the I-Premise
largest I-Premise
adverse I-Premise
ql I-Premise
effects I-Premise
of I-Premise
ax I-Premise
were I-Premise
observed I-Premise
from I-Premise
baseline I-Premise
to I-Premise
the I-Premise
first I-Premise
postoperative I-Premise
assessment I-Premise
, I-Premise
but B-Premise
the I-Premise
differences I-Premise
tended I-Premise
to I-Premise
disappear I-Premise
in I-Premise
6 I-Premise
to I-Premise
12 I-Premise
months I-Premise
. I-Premise
!LF! !LF!
at B-Premise
a I-Premise
median I-Premise
follow I-Premise
- I-Premise
up I-Premise
of I-Premise
6 I-Premise
. I-Premise
6 I-Premise
years I-Premise
, I-Premise
results I-Premise
for I-Premise
sx I-Premise
+ I-Premise
ax I-Premise
and I-Premise
sx I-Premise
yielded I-Premise
similar I-Premise
dfs I-Premise
( I-Premise
6 I-Premise
- I-Premise
year I-Premise
dfs I-Premise
, I-Premise
67 I-Premise
% I-Premise
v I-Premise
66 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
hr I-Premise
] I-Premise
sx I-Premise
+ I-Premise
ax I-Premise
/ I-Premise
sx I-Premise
, I-Premise
1 I-Premise
. I-Premise
06 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
79 I-Premise
to I-Premise
1 I-Premise
. I-Premise
42 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
69 I-Premise
) I-Premise
and I-Premise
os I-Premise
( I-Premise
6 I-Premise
- I-Premise
year I-Premise
os I-Premise
, I-Premise
75 I-Premise
% I-Premise
v I-Premise
73 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hr I-Premise
sx I-Premise
+ I-Premise
ax I-Premise
/ I-Premise
sx I-Premise
, I-Premise
1 I-Premise
. I-Premise
05 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
76 I-Premise
to I-Premise
1 I-Premise
. I-Premise
46 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
77 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
avoiding B-Claim
axillary I-Claim
clearance I-Claim
for I-Claim
women I-Claim
> I-Claim
or I-Claim
= I-Claim
60 I-Claim
years I-Claim
old I-Claim
who I-Claim
have I-Claim
clinically I-Claim
node I-Claim
- I-Claim
negative I-Claim
disease I-Claim
and I-Claim
receive I-Claim
tam I-Claim
for I-Claim
endocrine I-Claim
- I-Claim
responsive I-Claim
disease I-Claim
yields I-Claim
similar I-Claim
efficacy I-Claim
with I-Claim
better I-Claim
early I-Claim
ql I-Claim
. I-Claim
!LF! !LF!
chemotherapy B-Claim
is I-Claim
moderately I-Claim
efficient I-Claim
as I-Claim
a I-Claim
treatment I-Claim
for I-Claim
pancreatic I-Claim
adenocarcinoma I-Claim
, I-Claim
but B-Claim
patient I-Claim
survival I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
has I-Claim
improved I-Claim
with I-Claim
this I-Claim
modality I-Claim
in I-Claim
some I-Claim
trials I-Claim
. I-Claim
!LF! !LF!
in O
a O
previous O
phase O
ii O
trial O
, O
5 O
- O
fluorouracil O
( O
5 O
- O
fu O
) O
plus O
cisplatin O
( O
fup O
) O
yielded O
a O
26 O
. O
5 O
% O
response O
rate O
and O
a O
29 O
% O
survival O
rate O
at O
1 O
year O
. O
!LF! !LF!
the O
present O
study O
aimed O
to O
compare O
fup O
with O
5 O
- O
fu O
alone O
, O
which O
was O
the O
control O
arm O
in O
former O
mayo O
clinic O
trials O
. O
!LF! !LF!
patients O
with O
untreated O
cytologically O
or O
histologically O
proven O
metastatic O
or O
locally O
advanced O
adenocarcinoma O
of O
the O
pancreas O
were O
deemed O
measurable O
or O
evaluable O
. O
!LF! !LF!
chemotherapy O
regimens O
consisted O
of O
a O
control O
fu O
arm O
( O
5 O
- O
fu O
500 O
mg O
/ O
m O
( O
2 O
) O
/ O
day O
for O
5 O
days O
) O
and O
the O
investigational O
fup O
arm O
( O
continuous O
5 O
- O
fu O
1000 O
mg O
/ O
m O
( O
2 O
) O
/ O
day O
for O
5 O
days O
plus O
cisplatin O
100 O
mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
or O
day O
2 O
) O
. O
!LF! !LF!
in O
both O
arms O
, O
chemotherapy O
was O
repeated O
at O
day O
29 O
. O
!LF! !LF!
two O
- O
hundred O
and O
seven O
patients O
from O
18 O
centres O
were O
randomised O
: O
103 O
in O
the O
fu O
arm O
and O
104 O
in O
fup O
arm O
. O
!LF! !LF!
treatment O
arms O
were O
balanced O
with O
respect O
to O
performance O
status O
grade O
0 O
- O
1 O
( O
83 O
% O
versus O
86 O
% O
, O
respectively O
) O
and O
the O
presence O
of O
metastases O
( O
92 O
% O
versus O
89 O
% O
, O
respectively O
) O
. O
!LF! !LF!
the O
median O
number O
of O
cycles O
administered O
was O
two O
in O
both O
arms O
( O
range O
0 O
- O
14 O
) O
. O
!LF! !LF!
five O
patients O
did O
not O
receive O
any O
chemotherapy O
and O
45 O
received O
only O
one O
cycle O
. O
!LF! !LF!
toxicity B-Premise
( I-Premise
who I-Premise
grade I-Premise
3 I-Premise
- I-Premise
4 I-Premise
) I-Premise
was I-Premise
lower I-Premise
with I-Premise
fu I-Premise
than I-Premise
with I-Premise
fup I-Premise
( I-Premise
20 I-Premise
% I-Premise
versus I-Premise
48 I-Premise
% I-Premise
, I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
as I-Premise
was I-Premise
neutropenia I-Premise
( I-Premise
6 I-Premise
% I-Premise
versus I-Premise
23 I-Premise
% I-Premise
) I-Premise
, I-Premise
vomiting I-Premise
( I-Premise
4 I-Premise
% I-Premise
versus I-Premise
17 I-Premise
% I-Premise
) I-Premise
and I-Premise
toxicity I-Premise
- I-Premise
related I-Premise
deaths I-Premise
( I-Premise
one I-Premise
versus I-Premise
four I-Premise
early I-Premise
in I-Premise
the I-Premise
trial I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
response I-Premise
rate I-Premise
was I-Premise
low I-Premise
in I-Premise
both I-Premise
arms I-Premise
, I-Premise
but I-Premise
superior I-Premise
in I-Premise
the I-Premise
fup I-Premise
arm I-Premise
: I-Premise
12 I-Premise
% I-Premise
versus I-Premise
0 I-Premise
% I-Premise
( I-Premise
intention I-Premise
- I-Premise
to I-Premise
- I-Premise
treat I-Premise
analysis I-Premise
, I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
survival I-Premise
rates I-Premise
at I-Premise
6 I-Premise
months I-Premise
were I-Premise
28 I-Premise
% I-Premise
and I-Premise
38 I-Premise
% I-Premise
for I-Premise
the I-Premise
fu I-Premise
and I-Premise
fup I-Premise
arms I-Premise
, I-Premise
respectively I-Premise
, I-Premise
and I-Premise
1 I-Premise
- I-Premise
year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
9 I-Premise
% I-Premise
and I-Premise
17 I-Premise
% I-Premise
( I-Premise
log I-Premise
- I-Premise
rank I-Premise
test I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
10 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
one B-Premise
- B-Premise
year B-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
was I-Premise
0 I-Premise
% I-Premise
with I-Premise
fu I-Premise
versus I-Premise
10 I-Premise
% I-Premise
with I-Premise
fup I-Premise
( I-Premise
log I-Premise
- I-Premise
rank I-Premise
test I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
in B-Claim
advanced I-Claim
pancreatic I-Claim
carcinomas I-Claim
with I-Claim
a I-Claim
poor I-Claim
prognosis I-Claim
, I-Claim
fup I-Claim
was I-Claim
superior I-Claim
to I-Claim
fu I-Claim
in I-Claim
terms I-Claim
of I-Claim
response I-Claim
and I-Claim
progression I-Claim
- I-Claim
free I-Claim
survival I-Claim
, I-Claim
but I-Claim
not I-Claim
in I-Claim
terms I-Claim
of I-Claim
overall I-Claim
survival I-Claim
. I-Claim
!LF! !LF!
the O
low O
response O
rate O
is O
partly O
related O
to O
the O
number O
of O
patients O
who O
received O
only O
one O
cycle O
of O
chemotherapy O
. O
!LF! !LF!
a B-Claim
more I-Claim
effective I-Claim
, I-Claim
better I-Claim
tolerated I-Claim
version I-Claim
of I-Claim
this I-Claim
fup I-Claim
combination I-Claim
is I-Claim
needed I-Claim
. I-Claim
!LF! !LF!
after O
surgery O
for O
differentiated O
thyroid O
carcinoma O
, O
many O
patients O
are O
treated O
with O
radioiodine O
to O
ablate O
remnant O
thyroid O
tissue O
. O
!LF! !LF!
this B-Claim
procedure I-Claim
has I-Claim
been I-Claim
performed I-Claim
with I-Claim
the I-Claim
patient I-Claim
in I-Claim
the I-Claim
hypothyroid I-Claim
state I-Claim
to I-Claim
promote I-Claim
endogenous I-Claim
tsh I-Claim
stimulation I-Claim
and I-Claim
is I-Claim
often I-Claim
associated I-Claim
with I-Claim
hypothyroid I-Claim
symptoms I-Claim
and I-Claim
impaired I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim
!LF! !LF!
this O
international O
, O
randomized O
, O
controlled O
, O
multicenter O
trial O
aimed O
to O
compare O
the O
efficacy O
and O
safety O
of O
recombinant O
human O
tsh O
( O
rhtsh O
) O
to O
prepare O
euthyroid O
patients O
on O
l O
- O
thyroxine O
therapy O
( O
euthyroid O
group O
) O
to O
ablate O
remnant O
thyroid O
tissue O
with O
3 O
. O
7 O
gbq O
( O
100 O
mci O
) O
131i O
, O
compared O
with O
that O
with O
conventional O
remnant O
ablation O
performed O
in O
the O
hypothyroid O
state O
( O
hypothyroid O
group O
) O
. O
!LF! !LF!
quality O
of O
life O
was O
determined O
at O
the O
time O
of O
randomization O
and O
ablation O
. O
!LF! !LF!
after O
the O
administration O
of O
the O
131 O
- O
i O
dose O
, O
the O
rate O
of O
radiation O
clearance O
from O
blood O
, O
thyroid O
remnant O
, O
and O
whole O
body O
was O
measured O
. O
!LF! !LF!
the O
predefined O
primary O
criterion O
for O
successful O
ablation O
was O
"""" O
no O
visible O
uptake O
in O
the O
thyroid O
bed O
, O
or O
if O
visible O
, O
fractional O
uptake O
less O
than O
0 O
. O
1 O
% O
"""" O
on O
neck O
scans O
performed O
8 O
months O
after O
therapy O
and O
was O
satisfied O
in O
100 O
% O
of O
patients O
in O
both O
groups O
. O
!LF! !LF!
a O
secondary O
criterion O
for O
ablation O
, O
an O
rhtsh O
- O
stimulated O
serum O
thyroglobulin O
concentration O
less O
than O
2 O
ng O
/ O
ml O
, O
was O
fulfilled O
by O
23 O
of O
24 O
( O
96 O
% O
) O
euthyroid O
patients O
and O
18 O
of O
21 O
( O
86 O
% O
) O
hypothyroid O
patients O
( O
p O
= O
0 O
. O
2341 O
) O
. O
!LF! !LF!
quality B-Premise
of I-Premise
life I-Premise
was I-Premise
well I-Premise
preserved I-Premise
in I-Premise
the I-Premise
euthyroid I-Premise
group I-Premise
, I-Premise
compared I-Premise
with I-Premise
the I-Premise
hypothyroid I-Premise
group I-Premise
, I-Premise
as I-Premise
demonstrated I-Premise
by I-Premise
their I-Premise
lower I-Premise
pretreatment I-Premise
scores I-Premise
on I-Premise
the I-Premise
billewicz I-Premise
scale I-Premise
for I-Premise
hypothyroid I-Premise
signs I-Premise
and I-Premise
symptoms I-Premise
, I-Premise
27 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
7 I-Premise
vs I-Premise
. I-Premise
18 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
4 I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
0001 I-Premise
) I-Premise
and I-Premise
their I-Premise
significantly I-Premise
higher I-Premise
short I-Premise
form I-Premise
- I-Premise
36 I-Premise
health I-Premise
assessment I-Premise
scale I-Premise
scores I-Premise
in I-Premise
five I-Premise
of I-Premise
eight I-Premise
categories I-Premise
. I-Premise
!LF! !LF!
euthyroid B-Premise
patients I-Premise
had I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
one I-Premise
third I-Premise
lower I-Premise
radiation I-Premise
dose I-Premise
to I-Premise
the I-Premise
blood I-Premise
, I-Premise
compared I-Premise
with I-Premise
patients I-Premise
in I-Premise
the I-Premise
hypothyroid I-Premise
group I-Premise
. I-Premise
!LF! !LF!
this B-Claim
study I-Claim
demonstrates I-Claim
comparable I-Claim
remnant I-Claim
ablation I-Claim
rates I-Claim
in I-Claim
patients I-Claim
prepared I-Claim
for I-Claim
131i I-Claim
remnant I-Claim
ablation I-Claim
with I-Claim
3 I-Claim
. I-Claim
7 I-Claim
gbq I-Claim
by I-Claim
either I-Claim
administering I-Claim
rhtsh I-Claim
or I-Claim
withholding I-Claim
thyroid I-Claim
hormone I-Claim
. I-Claim
!LF! !LF!
rhtsh B-Claim
- B-Claim
prepared B-Claim
patients I-Claim
maintained I-Claim
a I-Claim
higher I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
received I-Claim
less I-Claim
radiation I-Claim
exposure I-Claim
to I-Claim
the I-Claim
blood I-Claim
. I-Claim
!LF! !LF!
as O
patients O
with O
pancreas O
and O
periampullary O
cancer O
( O
ppc O
) O
experience O
improved O
survival O
rates O
and O
longevity O
, O
the O
focus O
shifts O
toward O
living O
life O
while O
surviving O
cancer O
. O
!LF! !LF!
fatigue O
is O
the O
most O
commonly O
reported O
symptom O
in O
all O
cancer O
patients O
. O
!LF! !LF!
exercise O
has O
been O
found O
to O
effectively O
decrease O
fatigue O
levels O
and O
improve O
physical O
functioning O
in O
cancer O
patients O
. O
!LF! !LF!
one O
hundred O
two O
patients O
with O
resected O
ppc O
consented O
to O
participate O
in O
this O
study O
and O
were O
randomized O
to O
either O
an O
intervention O
group O
( O
ig O
) O
or O
a O
usual O
care O
group O
( O
ucg O
) O
. O
!LF! !LF!
subjects O
completed O
visual O
analog O
scales O
, O
the O
facit O
- O
fatigue O
scale O
and O
the O
short O
form O
- O
36v2 O
after O
surgery O
and O
again O
3 O
to O
6 O
months O
after O
hospital O
discharge O
. O
!LF! !LF!
patients O
in O
the O
ig O
and O
ucg O
were O
comparable O
with O
regard O
to O
demographics O
, O
comorbidities O
, O
cancer O
type O
and O
staging O
, O
type O
of O
resection O
, O
preoperative O
fatigue O
and O
pain O
levels O
, O
adjuvant O
therapy O
, O
and O
baseline O
walking O
distance O
. O
!LF! !LF!
patients B-Premise
in I-Premise
the I-Premise
ig I-Premise
had I-Premise
significantly I-Premise
improved I-Premise
scores I-Premise
on I-Premise
the I-Premise
facit I-Premise
- I-Premise
fatigue I-Premise
scale I-Premise
at I-Premise
study I-Premise
completion I-Premise
, I-Premise
improved I-Premise
fatigue I-Premise
and I-Premise
pain I-Premise
scores I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
overall I-Premise
physical I-Premise
functioning I-Premise
and I-Premise
mental I-Premise
health I-Premise
composite I-Premise
scores I-Premise
. I-Premise
!LF! !LF!
at B-Premise
study I-Premise
completion I-Premise
, I-Premise
participants I-Premise
in I-Premise
the I-Premise
ig I-Premise
were I-Premise
walking I-Premise
twice I-Premise
as I-Premise
far I-Premise
and I-Premise
were I-Premise
significantly I-Premise
more I-Premise
likely I-Premise
to I-Premise
have I-Premise
continued I-Premise
walking I-Premise
or I-Premise
another I-Premise
form I-Premise
of I-Premise
exercise I-Premise
as I-Premise
compared I-Premise
with I-Premise
the I-Premise
ucg I-Premise
. I-Premise
!LF! !LF!
using O
hierarchical O
cluster O
analysis O
, O
3 O
mutually O
exclusive O
symptom O
groupings O
were O
identified O
in O
the O
cohort O
. O
!LF! !LF!
kaplan B-Premise
- B-Premise
meier B-Premise
survival I-Premise
analysis I-Premise
did I-Premise
not I-Premise
indicate I-Premise
an I-Premise
overall I-Premise
survival I-Premise
benefit I-Premise
for I-Premise
the I-Premise
ig I-Premise
. I-Premise
!LF! !LF!
this B-Claim
is I-Claim
the I-Claim
first I-Claim
prospective I-Claim
, I-Claim
randomized I-Claim
controlled I-Claim
trial I-Claim
to I-Claim
report I-Claim
that I-Claim
participation I-Claim
in I-Claim
a I-Claim
home I-Claim
walking I-Claim
program I-Claim
confers I-Claim
a I-Claim
significant I-Claim
benefit I-Claim
in I-Claim
resected I-Claim
ppc I-Claim
patients I-Claim
with I-Claim
regard I-Claim
to I-Claim
fatigue I-Claim
levels I-Claim
, I-Claim
physical I-Claim
functioning I-Claim
, I-Claim
and I-Claim
health I-Claim
- I-Claim
related I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim
!LF! !LF!
treatment B-Claim
with I-Claim
cisplatin I-Claim
- I-Claim
based I-Claim
chemotherapy I-Claim
provides I-Claim
a I-Claim
modest I-Claim
survival I-Claim
advantage I-Claim
over I-Claim
supportive I-Claim
care I-Claim
alone I-Claim
in I-Claim
advanced I-Claim
non I-Claim
- I-Claim
small I-Claim
- I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
nsclc I-Claim
) I-Claim
. I-Claim
!LF! !LF!
to O
determine O
whether O
a O
new O
agent O
, O
paclitaxel O
, O
would O
further O
improve O
survival O
in O
nsclc O
, O
the O
eastern O
cooperative O
oncology O
group O
conducted O
a O
randomized O
trial O
comparing O
paclitaxel O
plus O
cisplatin O
to O
a O
standard O
chemotherapy O
regimen O
consisting O
of O
cisplatin O
and O
etoposide O
. O
!LF! !LF!
the O
study O
was O
carried O
out O
by O
a O
multi O
- O
institutional O
cooperative O
group O
in O
chemotherapy O
- O
naive O
stage O
iiib O
to O
iv O
nsclc O
patients O
randomized O
to O
receive O
paclitaxel O
plus O
cisplatin O
or O
etoposide O
plus O
cisplatin O
. O
!LF! !LF!
paclitaxel O
was O
administered O
at O
two O
different O
dose O
levels O
( O
135 O
mg O
/ O
m O
( O
2 O
) O
and O
250 O
mg O
/ O
m O
( O
2 O
) O
) O
, O
and O
etoposide O
was O
given O
at O
a O
dose O
of O
100 O
mg O
/ O
m O
( O
2 O
) O
daily O
on O
days O
1 O
to O
3 O
. O
!LF! !LF!
each O
regimen O
was O
repeated O
every O
21 O
days O
and O
each O
included O
cisplatin O
( O
75 O
mg O
/ O
m O
( O
2 O
) O
) O
. O
!LF! !LF!
the O
characteristics O
of O
the O
599 O
patients O
were O
well O
- O
balanced O
across O
the O
three O
treatment O
groups O
. O
!LF! !LF!
superior B-Premise
survival I-Premise
was I-Premise
observed I-Premise
with I-Premise
the I-Premise
combined I-Premise
paclitaxel I-Premise
regimens I-Premise
( I-Premise
median I-Premise
survival I-Premise
time I-Premise
, I-Premise
9 I-Premise
. I-Premise
9 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
1 I-Premise
- I-Premise
year I-Premise
survival I-Premise
rate I-Premise
, I-Premise
38 I-Premise
. I-Premise
9 I-Premise
% I-Premise
) I-Premise
compared I-Premise
with I-Premise
etoposide I-Premise
plus I-Premise
cisplatin I-Premise
( I-Premise
median I-Premise
survival I-Premise
time I-Premise
, I-Premise
7 I-Premise
. I-Premise
6 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
1 I-Premise
- I-Premise
year I-Premise
survival I-Premise
rate I-Premise
, I-Premise
31 I-Premise
. I-Premise
8 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
48 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
comparing B-Premise
survival I-Premise
for I-Premise
the I-Premise
two I-Premise
dose I-Premise
levels I-Premise
of I-Premise
paclitaxel I-Premise
revealed I-Premise
no I-Premise
significant I-Premise
difference I-Premise
. I-Premise
!LF! !LF!
the B-Premise
median I-Premise
survival I-Premise
duration I-Premise
for I-Premise
the I-Premise
stage I-Premise
iiib I-Premise
subgroup I-Premise
was I-Premise
7 I-Premise
. I-Premise
9 I-Premise
months I-Premise
for I-Premise
etoposide I-Premise
plus I-Premise
cisplatin I-Premise
patients I-Premise
versus I-Premise
13 I-Premise
. I-Premise
1 I-Premise
months I-Premise
for I-Premise
all I-Premise
paclitaxel I-Premise
patients I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
152 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
for B-Premise
the I-Premise
stage I-Premise
iv I-Premise
subgroup I-Premise
, I-Premise
the I-Premise
median I-Premise
survival I-Premise
time I-Premise
for I-Premise
etoposide I-Premise
plus I-Premise
cisplatin I-Premise
was I-Premise
7 I-Premise
. I-Premise
6 I-Premise
months I-Premise
compared I-Premise
with I-Premise
8 I-Premise
. I-Premise
9 I-Premise
months I-Premise
for I-Premise
paclitaxel I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
246 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
with B-Premise
the I-Premise
exceptions I-Premise
of I-Premise
increased I-Premise
granulocytopenia I-Premise
on I-Premise
the I-Premise
low I-Premise
- I-Premise
dose I-Premise
paclitaxel I-Premise
regimen I-Premise
and I-Premise
increased I-Premise
myalgias I-Premise
, I-Premise
neurotoxicity I-Premise
, I-Premise
and I-Premise
, I-Premise
possibly I-Premise
, I-Premise
increased I-Premise
treatment I-Premise
- I-Premise
related I-Premise
cardiac I-Premise
events I-Premise
with I-Premise
high I-Premise
- I-Premise
dose I-Premise
paclitaxel I-Premise
, I-Premise
toxicity I-Premise
was I-Premise
similar I-Premise
across I-Premise
all I-Premise
three I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
quality B-Premise
of I-Premise
life I-Premise
( I-Premise
qol I-Premise
) I-Premise
declined I-Premise
significantly I-Premise
over I-Premise
the I-Premise
6 I-Premise
months I-Premise
. I-Premise
!LF! !LF!
however O
, O
qol B-Claim
scores I-Claim
were I-Claim
not I-Claim
significantly I-Claim
different I-Claim
among I-Claim
the I-Claim
regimens I-Claim
. I-Claim
!LF! !LF!
as O
a O
result O
of O
these O
observations O
, O
paclitaxel B-Claim
( I-Claim
135 I-Claim
mg I-Claim
/ I-Claim
m I-Claim
( I-Claim
2 I-Claim
) I-Claim
) I-Claim
combined I-Claim
with I-Claim
cisplatin I-Claim
has I-Claim
replaced I-Claim
etoposide I-Claim
plus I-Claim
cisplatin I-Claim
as I-Claim
the I-Claim
reference I-Claim
regimen I-Claim
in I-Claim
our I-Claim
recently I-Claim
completed I-Claim
phase I-Claim
iii I-Claim
trial I-Claim
. I-Claim
!LF! !LF!
to O
assess O
the O
long O
term O
risks O
and O
benefits O
of O
hormone O
replacement O
therapy O
( O
combined O
hormone O
therapy O
versus O
placebo O
, O
and O
oestrogen O
alone O
versus O
combined O
hormone O
therapy O
) O
. O
!LF! !LF!
multicentre O
, O
randomised O
, O
placebo O
controlled O
, O
double O
blind O
trial O
. O
!LF! !LF!
general O
practices O
in O
uk O
( O
384 O
) O
, O
australia O
( O
91 O
) O
, O
and O
new O
zealand O
( O
24 O
) O
. O
!LF! !LF!
postmenopausal O
women O
aged O
50 O
- O
69 O
years O
at O
randomisation O
. O
!LF! !LF!
at O
early O
closure O
of O
the O
trial O
, O
56 O
, O
583 O
had O
been O
screened O
, O
8980 O
entered O
run O
- O
in O
, O
and O
5692 O
( O
26 O
% O
of O
target O
of O
22 O
, O
300 O
) O
started O
treatment O
. O
!LF! !LF!
oestrogen O
only O
therapy O
( O
conjugated O
equine O
oestrogens O
0 O
. O
625 O
mg O
orally O
daily O
) O
or O
combined O
hormone O
therapy O
( O
conjugated O
equine O
oestrogens O
plus O
medroxyprogesterone O
acetate O
2 O
. O
5 O
/ O
5 O
. O
0 O
mg O
orally O
daily O
) O
. O
!LF! !LF!
ten O
years O
of O
treatment O
planned O
. O
!LF! !LF!
major O
cardiovascular O
disease O
, O
osteoporotic O
fractures O
, O
and O
breast O
cancer O
. O
!LF! !LF!
other O
cancers O
, O
death O
from O
all O
causes O
, O
venous O
thromboembolism O
, O
cerebrovascular O
disease O
, O
dementia O
, O
and O
quality O
of O
life O
. O
!LF! !LF!
the O
trial O
was O
prematurely O
closed O
during O
recruitment O
, O
after O
a O
median O
follow O
- O
up O
of O
11 O
. O
9 O
months O
( O
interquartile O
range O
7 O
. O
1 O
- O
19 O
. O
6 O
, O
total O
6498 O
women O
years O
) O
in O
those O
enrolled O
, O
after O
the O
publication O
of O
early O
results O
from O
the O
women O
' O
s O
health O
initiative O
study O
. O
!LF! !LF!
the O
mean O
age O
of O
randomised O
women O
was O
62 O
. O
8 O
( O
sd O
4 O
. O
8 O
) O
years O
. O
!LF! !LF!
when B-Premise
combined I-Premise
hormone I-Premise
therapy I-Premise
( I-Premise
n I-Premise
= I-Premise
2196 I-Premise
) I-Premise
was I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
n I-Premise
= I-Premise
2189 I-Premise
) I-Premise
, I-Premise
there I-Premise
was I-Premise
a I-Premise
significant I-Premise
increase I-Premise
in I-Premise
the I-Premise
number I-Premise
of I-Premise
major I-Premise
cardiovascular I-Premise
events I-Premise
( I-Premise
7 I-Premise
v I-Premise
0 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
016 I-Premise
) I-Premise
and I-Premise
venous I-Premise
thromboembolisms I-Premise
( I-Premise
22 I-Premise
v I-Premise
3 I-Premise
, I-Premise
hazard I-Premise
ratio I-Premise
7 I-Premise
. I-Premise
36 I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
2 I-Premise
. I-Premise
20 I-Premise
to I-Premise
24 I-Premise
. I-Premise
60 I-Premise
) I-Premise
) I-Premise
. I-Premise
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
numbers I-Premise
of I-Premise
breast I-Premise
or I-Premise
other I-Premise
cancers I-Premise
( I-Premise
22 I-Premise
v I-Premise
25 I-Premise
, I-Premise
hazard I-Premise
ratio I-Premise
0 I-Premise
. I-Premise
88 I-Premise
( I-Premise
0 I-Premise
. I-Premise
49 I-Premise
to I-Premise
1 I-Premise
. I-Premise
56 I-Premise
) I-Premise
) I-Premise
, I-Premise
cerebrovascular I-Premise
events I-Premise
( I-Premise
14 I-Premise
v I-Premise
19 I-Premise
, I-Premise
0 I-Premise
. I-Premise
73 I-Premise
( I-Premise
0 I-Premise
. I-Premise
37 I-Premise
to I-Premise
1 I-Premise
. I-Premise
46 I-Premise
) I-Premise
) I-Premise
, I-Premise
fractures I-Premise
( I-Premise
40 I-Premise
v I-Premise
58 I-Premise
, I-Premise
0 I-Premise
. I-Premise
69 I-Premise
( I-Premise
0 I-Premise
. I-Premise
46 I-Premise
to I-Premise
1 I-Premise
. I-Premise
03 I-Premise
) I-Premise
) I-Premise
, I-Premise
and I-Premise
overall I-Premise
deaths I-Premise
( I-Premise
8 I-Premise
v I-Premise
5 I-Premise
, I-Premise
1 I-Premise
. I-Premise
60 I-Premise
( I-Premise
0 I-Premise
. I-Premise
52 I-Premise
to I-Premise
4 I-Premise
. I-Premise
89 I-Premise
) I-Premise
) I-Premise
. I-Premise
!LF! !LF!
comparison B-Premise
of I-Premise
combined I-Premise
hormone I-Premise
therapy I-Premise
( I-Premise
n I-Premise
= I-Premise
815 I-Premise
) I-Premise
versus I-Premise
oestrogen I-Premise
therapy I-Premise
( I-Premise
n I-Premise
= I-Premise
826 I-Premise
) I-Premise
outcomes I-Premise
revealed I-Premise
no I-Premise
significant I-Premise
differences I-Premise
. I-Premise
!LF! !LF!
hormone B-Claim
replacement I-Claim
therapy I-Claim
increases I-Claim
cardiovascular I-Claim
and I-Claim
thromboembolic I-Claim
risk I-Claim
when I-Claim
started I-Claim
many I-Claim
years I-Claim
after I-Claim
the I-Claim
menopause I-Claim
. I-Claim
!LF! !LF!
the B-Claim
results I-Claim
are I-Claim
consistent I-Claim
with I-Claim
the I-Claim
findings I-Claim
of I-Claim
the I-Claim
women I-Claim
' I-Claim
s I-Claim
health I-Claim
initiative I-Claim
study I-Claim
and I-Claim
secondary I-Claim
prevention I-Claim
studies I-Claim
. I-Claim
!LF! !LF!
research B-Claim
is I-Claim
needed I-Claim
to I-Claim
assess I-Claim
the I-Claim
long I-Claim
term I-Claim
risks I-Claim
and I-Claim
benefits I-Claim
of I-Claim
starting I-Claim
hormone I-Claim
replacement I-Claim
therapy I-Claim
near I-Claim
the I-Claim
menopause I-Claim
, I-Claim
when I-Claim
the I-Claim
effect I-Claim
may I-Claim
be I-Claim
different I-Claim
. I-Claim
!LF! !LF!
imatinib O
is O
the O
standard O
treatment O
of O
advanced O
gi O
stromal O
tumors O
( O
gists O
) O
. O
!LF! !LF!
it B-Claim
is I-Claim
not I-Claim
known I-Claim
whether I-Claim
imatinib I-Claim
may I-Claim
be I-Claim
stopped I-Claim
in I-Claim
patients I-Claim
in I-Claim
whom I-Claim
disease I-Claim
is I-Claim
controlled I-Claim
. I-Claim
!LF! !LF!
this O
prospective O
, O
randomized O
, O
multicentric O
phase O
iii O
study O
was O
designed O
to O
compare O
continuous O
( O
cont O
) O
compared O
with O
interrupted O
( O
int O
) O
imatinib O
beyond O
1 O
year O
of O
treatment O
in O
patients O
with O
advanced O
gist O
. O
!LF! !LF!
the O
primary O
end O
point O
was O
progression O
- O
free O
survival O
. O
!LF! !LF!
secondary O
end O
points O
included O
overall O
survival O
, O
response O
rate O
after O
reinitiation O
of O
imatinib O
, O
and O
quality O
of O
life O
. O
!LF! !LF!
early O
stopping O
rules O
in O
cases O
of O
rapid O
progression O
of O
disease O
were O
defined O
, O
with O
preplanned O
interim O
analyses O
. O
!LF! !LF!
between O
may O
2002 O
and O
april O
2004 O
, O
182 O
patients O
with O
advanced O
gist O
were O
enrolled O
. O
!LF! !LF!
between O
may O
2003 O
and O
april O
2004 O
, O
98 O
patients O
in O
response O
or O
stable O
disease O
under O
imatinib O
reached O
more O
than O
1 O
year O
of O
follow O
- O
up O
. O
!LF! !LF!
forty O
were O
not O
eligible O
for O
randomization O
, O
and O
58 O
patients O
were O
randomly O
assigned O
, O
32 O
and O
26 O
patients O
in O
the O
int O
and O
cont O
arms O
, O
respectively O
. O
!LF! !LF!
as B-Premise
of I-Premise
october I-Premise
15 I-Premise
, I-Premise
2005 I-Premise
, I-Premise
eight I-Premise
of I-Premise
26 I-Premise
patients I-Premise
in I-Premise
the I-Premise
cont I-Premise
group I-Premise
and I-Premise
26 I-Premise
of I-Premise
32 I-Premise
patients I-Premise
in I-Premise
the I-Premise
int I-Premise
group I-Premise
had I-Premise
documented I-Premise
disease I-Premise
progression I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
0001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
twenty B-Premise
- B-Premise
four B-Premise
of I-Premise
26 I-Premise
patients I-Premise
with I-Premise
documented I-Premise
progression I-Premise
in I-Premise
the I-Premise
int I-Premise
arm I-Premise
responded I-Premise
to I-Premise
imatinib I-Premise
reintroduction I-Premise
. I-Premise
!LF! !LF!
no B-Premise
differences I-Premise
in I-Premise
overall I-Premise
survival I-Premise
or I-Premise
imatinib I-Premise
resistance I-Premise
were I-Premise
observed I-Premise
between I-Premise
the I-Premise
two I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
quality B-Premise
of I-Premise
life I-Premise
evaluated I-Premise
6 I-Premise
months I-Premise
after I-Premise
random I-Premise
assignment I-Premise
using I-Premise
the I-Premise
30 I-Premise
- I-Premise
item I-Premise
quality I-Premise
of I-Premise
life I-Premise
questionnaire I-Premise
was I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
of I-Premise
randomly I-Premise
assigned I-Premise
patients I-Premise
. I-Premise
!LF! !LF!
imatinib B-Claim
interruption I-Claim
results I-Claim
in I-Claim
rapid I-Claim
progression I-Claim
in I-Claim
most I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
gist I-Claim
, I-Claim
and I-Claim
can I-Claim
not I-Claim
be I-Claim
recommended I-Claim
in I-Claim
routine I-Claim
practice I-Claim
unless I-Claim
patient I-Claim
experience I-Claim
significant I-Claim
toxicity I-Claim
. I-Claim
!LF! !LF!
this O
report O
describes O
the O
quality O
of O
life O
( O
qol O
) O
findings O
of O
a O
randomized O
placebo O
controlled O
study O
of O
erlotinib O
, O
an O
epidermal O
growth O
factor O
receptor O
inhibitor O
, O
in O
patients O
with O
non O
- O
small O
- O
cell O
lung O
cancer O
( O
nsclc O
) O
. O
!LF! !LF!
this O
double O
- O
blind O
phase O
iii O
trial O
randomly O
assigned O
731 O
patients O
with O
nsclc O
who O
had O
progressed O
after O
prior O
chemotherapy O
to O
erlotinib O
150 O
mg O
daily O
or O
placebo O
, O
with O
survival O
as O
the O
primary O
study O
outcome O
. O
!LF! !LF!
qol O
was O
assessed O
by O
european O
organisation O
for O
research O
and O
treatment O
of O
cancer O
qlq O
- O
c30 O
and O
the O
lung O
cancer O
module O
qlq O
- O
lc13 O
. O
!LF! !LF!
the O
primary O
end O
points O
for O
qol O
analysis O
were O
time O
to O
deterioration O
of O
three O
common O
lung O
cancer O
symptoms O
: O
cough O
, O
dyspnea O
, O
and O
pain O
. O
!LF! !LF!
survival B-Premise
was I-Premise
significantly I-Premise
longer I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0 I-Premise
. I-Premise
70 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
. I-Premise
0001 I-Premise
) I-Premise
in I-Premise
the I-Premise
erlotinib I-Premise
arm I-Premise
. I-Premise
!LF! !LF!
compliance B-Premise
with I-Premise
qol I-Premise
was I-Premise
87 I-Premise
% I-Premise
at I-Premise
baseline I-Premise
and I-Premise
more I-Premise
than I-Premise
70 I-Premise
% I-Premise
during I-Premise
treatment I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
receiving I-Premise
erlotinib I-Premise
had I-Premise
significantly I-Premise
longer I-Premise
median I-Premise
time I-Premise
to I-Premise
deterioration I-Premise
for I-Premise
all I-Premise
three I-Premise
symptoms I-Premise
( I-Premise
4 I-Premise
. I-Premise
9 I-Premise
v I-Premise
3 I-Premise
. I-Premise
7 I-Premise
months I-Premise
for I-Premise
cough I-Premise
[ I-Premise
p I-Premise
= I-Premise
. I-Premise
04 I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
4 I-Premise
. I-Premise
7 I-Premise
v I-Premise
2 I-Premise
. I-Premise
9 I-Premise
months I-Premise
for I-Premise
dyspnea I-Premise
[ I-Premise
p I-Premise
= I-Premise
. I-Premise
04 I-Premise
] I-Premise
, I-Premise
and I-Premise
2 I-Premise
. I-Premise
8 I-Premise
v I-Premise
1 I-Premise
. I-Premise
9 I-Premise
months I-Premise
for I-Premise
pain I-Premise
[ I-Premise
p I-Premise
= I-Premise
. I-Premise
03 I-Premise
] I-Premise
) I-Premise
. I-Premise
!LF! !LF!
qol B-Premise
response I-Premise
analyses I-Premise
showed I-Premise
that I-Premise
44 I-Premise
% I-Premise
, I-Premise
34 I-Premise
% I-Premise
, I-Premise
and I-Premise
42 I-Premise
% I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
erlotinib I-Premise
had I-Premise
improvement I-Premise
in I-Premise
these I-Premise
three I-Premise
symptoms I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
this B-Premise
was I-Premise
accompanied I-Premise
by I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
the I-Premise
physical I-Premise
function I-Premise
( I-Premise
31 I-Premise
% I-Premise
erlotinib I-Premise
v I-Premise
19 I-Premise
% I-Premise
placebo I-Premise
, I-Premise
p I-Premise
= I-Premise
. I-Premise
01 I-Premise
) I-Premise
, I-Premise
and I-Premise
global I-Premise
qol I-Premise
( I-Premise
35 I-Premise
% I-Premise
v I-Premise
26 I-Premise
% I-Premise
, I-Premise
p I-Premise
< I-Premise
. I-Premise
0001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
with I-Premise
complete I-Premise
or I-Premise
partial I-Premise
response I-Premise
were I-Premise
more I-Premise
likely I-Premise
to I-Premise
have I-Premise
improvement I-Premise
in I-Premise
the I-Premise
qol I-Premise
response I-Premise
than I-Premise
patients I-Premise
with I-Premise
stable I-Premise
or I-Premise
progressive I-Premise
disease I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
erlotinib B-Claim
not I-Claim
only I-Claim
improves I-Claim
survival I-Claim
in I-Claim
previously I-Claim
treated I-Claim
patients I-Claim
with I-Claim
nsclc I-Claim
, I-Claim
but I-Claim
also I-Claim
improves I-Claim
tumor I-Claim
- I-Claim
related I-Claim
symptoms I-Claim
and I-Claim
important I-Claim
aspects I-Claim
of I-Claim
qol I-Claim
. I-Claim
!LF! !LF!
menopausal B-Claim
symptoms I-Claim
( I-Claim
e I-Claim
. I-Claim
g I-Claim
. I-Claim
, I-Claim
hot I-Claim
flashes I-Claim
, I-Claim
vaginal I-Claim
dryness I-Claim
, I-Claim
and I-Claim
stress I-Claim
urinary I-Claim
incontinence I-Claim
) I-Claim
are I-Claim
very I-Claim
common I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
and I-Claim
can I-Claim
not I-Claim
be I-Claim
managed I-Claim
with I-Claim
standard I-Claim
estrogen I-Claim
replacement I-Claim
therapy I-Claim
( I-Claim
ert I-Claim
) I-Claim
in I-Claim
these I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
the O
purpose O
of O
this O
study O
was O
to O
test O
the O
efficacy O
of O
a O
comprehensive O
menopausal O
assessment O
( O
cma O
) O
intervention O
program O
in O
achieving O
relief O
of O
symptoms O
, O
the O
improvement O
in O
quality O
of O
life O
( O
qol O
) O
, O
and O
sexual O
functioning O
in O
breast O
cancer O
survivors O
. O
!LF! !LF!
using O
a O
two O
- O
group O
, O
randomized O
controlled O
design O
, O
we O
assigned O
76 O
postmenopausal O
breast O
cancer O
survivors O
with O
at O
least O
one O
severe O
target O
symptom O
either O
to O
the O
intervention O
group O
or O
to O
a O
usual O
- O
care O
group O
. O
!LF! !LF!
seventy O
- O
two O
women O
were O
evaluable O
at O
the O
end O
of O
the O
study O
period O
. O
!LF! !LF!
the O
cma O
intervention O
, O
delivered O
by O
a O
nurse O
practitioner O
, O
focused O
on O
symptom O
assessment O
, O
education O
, O
counseling O
and O
, O
as O
appropriate O
, O
specific O
pharmacologic O
and O
behavioral O
interventions O
for O
each O
of O
the O
three O
target O
symptoms O
. O
!LF! !LF!
psychosocial O
symptoms O
were O
assessed O
with O
the O
use O
of O
a O
self O
- O
report O
screening O
instrument O
, O
and O
distressed O
women O
were O
referred O
for O
counseling O
if O
needed O
. O
!LF! !LF!
the O
intervention O
took O
place O
over O
a O
4 O
- O
month O
period O
. O
!LF! !LF!
outcomes O
measured O
were O
scores O
on O
a O
composite O
menopausal O
symptom O
scale O
, O
the O
rand O
short O
form O
health O
survey O
vitality O
scale O
, O
and O
the O
cancer O
rehabilitation O
evaluation O
system O
( O
cares O
) O
sexual O
functioning O
scale O
at O
baseline O
and O
at O
4 O
- O
month O
follow O
- O
up O
. O
!LF! !LF!
all O
statistical O
tests O
were O
two O
- O
sided O
and O
were O
performed O
at O
the O
alpha O
= O
. O
!LF! !LF!
5 O
significance O
level O
. O
!LF! !LF!
patients B-Premise
receiving I-Premise
the I-Premise
intervention I-Premise
demonstrated I-Premise
statistically I-Premise
significant I-Premise
improvement I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
0004 I-Premise
) I-Premise
in I-Premise
menopausal I-Premise
symptoms I-Premise
but I-Premise
no I-Premise
significant I-Premise
change I-Premise
in I-Premise
vitality I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
77 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
sexual B-Premise
functioning I-Premise
was I-Premise
statistically I-Premise
significantly I-Premise
improved I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
04 I-Premise
) I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
usual I-Premise
- I-Premise
care I-Premise
group I-Premise
. I-Premise
!LF! !LF!
a B-Claim
clinical I-Claim
assessment I-Claim
and I-Claim
intervention I-Claim
program I-Claim
for I-Claim
menopausal I-Claim
symptom I-Claim
management I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
is I-Claim
feasible I-Claim
and I-Claim
acceptable I-Claim
to I-Claim
patients I-Claim
, I-Claim
leading I-Claim
to I-Claim
reduction I-Claim
in I-Claim
symptoms I-Claim
and I-Claim
improvement I-Claim
in I-Claim
sexual I-Claim
functioning I-Claim
. I-Claim
!LF! !LF!
measurable B-Claim
improvement I-Claim
in I-Claim
a I-Claim
general I-Claim
qol I-Claim
measure I-Claim
was I-Claim
not I-Claim
demonstrated I-Claim
. I-Claim
!LF! !LF!
this O
study O
is O
the O
first O
large O
prospective O
rct O
of O
sentinel O
node O
biopsy O
( O
snb O
) O
compared O
with O
standard O
axillary O
treatment O
( O
level O
i O
- O
iii O
axillary O
lymph O
node O
dissection O
or O
four O
node O
sampling O
) O
, O
which O
includes O
comprehensive O
and O
repeated O
quality O
of O
life O
( O
qol O
) O
assessments O
over O
18 O
months O
. O
!LF! !LF!
patients O
( O
n O
= O
829 O
) O
completed O
the O
functional O
assessment O
of O
cancer O
therapy O
- O
breast O
( O
fact O
- O
b O
+ O
4 O
) O
and O
the O
spielberger O
state O
/ O
trait O
anxiety O
inventory O
( O
stai O
) O
at O
baseline O
( O
pre O
- O
surgery O
) O
and O
at O
1 O
, O
3 O
, O
6 O
, O
12 O
, O
and O
18 O
months O
post O
- O
surgery O
. O
!LF! !LF!
there B-Claim
were I-Claim
significant I-Claim
differences I-Claim
between I-Claim
treatment I-Claim
groups I-Claim
favouring I-Claim
the I-Claim
snb I-Claim
group I-Claim
throughout I-Claim
the I-Claim
18 I-Claim
months I-Claim
assessment I-Claim
. I-Claim
!LF! !LF!
patients B-Premise
in I-Premise
the I-Premise
standard I-Premise
treatment I-Premise
group I-Premise
showed I-Premise
a I-Premise
greater I-Premise
decline I-Premise
in I-Premise
trial I-Premise
outcome I-Premise
index I-Premise
( I-Premise
toi I-Premise
) I-Premise
scores I-Premise
( I-Premise
physical I-Premise
well I-Premise
- I-Premise
being I-Premise
, I-Premise
functional I-Premise
well I-Premise
- I-Premise
being I-Premise
and I-Premise
breast I-Premise
cancer I-Premise
concerns I-Premise
subscales I-Premise
in I-Premise
fact I-Premise
- I-Premise
b I-Premise
+ I-Premise
4 I-Premise
) I-Premise
and I-Premise
recovered I-Premise
more I-Premise
slowly I-Premise
than I-Premise
patients I-Premise
in I-Premise
the I-Premise
snb I-Premise
group I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
change I-Premise
in I-Premise
total I-Premise
fact I-Premise
- I-Premise
b I-Premise
+ I-Premise
4 I-Premise
scores I-Premise
( I-Premise
measuring I-Premise
global I-Premise
qol I-Premise
) I-Premise
closely I-Premise
resembled I-Premise
the I-Premise
toi I-Premise
results I-Premise
. I-Premise
!LF! !LF!
18 B-Premise
months I-Premise
post I-Premise
- I-Premise
surgery I-Premise
approximately I-Premise
twice I-Premise
as I-Premise
many I-Premise
patients I-Premise
in I-Premise
the I-Premise
standard I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
snb I-Premise
group I-Premise
reported I-Premise
substantial I-Premise
arm I-Premise
swelling I-Premise
( I-Premise
14 I-Premise
% I-Premise
versus I-Premise
7 I-Premise
% I-Premise
) I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
002 I-Premise
) I-Premise
or I-Premise
numbness I-Premise
( I-Premise
19 I-Premise
% I-Premise
versus I-Premise
8 I-Premise
. I-Premise
7 I-Premise
% I-Premise
) I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
despite O
the O
uncertainty O
about O
undergoing O
a O
relatively O
new O
procedure O
and O
the O
possible O
need O
for O
further O
surgery O
, O
there B-Premise
was I-Premise
no I-Premise
evidence I-Premise
of I-Premise
increased I-Premise
anxiety I-Premise
amongst I-Premise
patients I-Premise
randomised I-Premise
to I-Premise
snb I-Premise
( I-Premise
p I-Premise
> I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
for B-Premise
6 I-Premise
months I-Premise
post I-Premise
- I-Premise
surgery I-Premise
younger I-Premise
patients I-Premise
reported I-Premise
less I-Premise
favourable I-Premise
qol I-Premise
scores I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
and I-Premise
greater I-Premise
levels I-Premise
of I-Premise
anxiety I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
in B-Claim
view I-Claim
of I-Claim
the I-Claim
benefits I-Claim
regarding I-Claim
arm I-Claim
functioning I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
the I-Claim
data I-Claim
from I-Claim
this I-Claim
randomised I-Claim
study I-Claim
support I-Claim
the I-Claim
use I-Claim
of I-Claim
snb I-Claim
in I-Claim
patients I-Claim
with I-Claim
clinically I-Claim
node I-Claim
negative I-Claim
breast I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
treosulfan O
, O
an O
alkylating O
agent O
, O
has O
demonstrated O
activity O
in O
recurrent O
ovarian O
carcinoma O
. O
!LF! !LF!
it O
is O
equieffective O
as O
oral O
( O
p O
. O
o O
. O
) O
!LF! !LF!
and O
intravenous O
( O
i O
. O
v O
. O
) O
!LF! !LF!
formulation O
. O
!LF! !LF!
to O
explore O
the O
preference O
and O
compliance O
of O
elderly O
patients O
regarding O
p O
. O
o O
. O
!LF! !LF!
or O
i O
. O
v O
. O
!LF! !LF!
treosulfan O
for O
the O
treatment O
of O
relapsed O
ovarian O
carcinoma O
, O
women O
aged O
65 O
years O
or O
older O
were O
included O
in O
this O
prospective O
multicenter O
study O
. O
!LF! !LF!
since O
elderly O
patients O
usually O
have O
several O
concomitant O
diseases O
and O
experience O
more O
treatment O
toxicity O
, O
an O
interim O
safety O
analysis O
was O
planned O
and O
performed O
after O
25 O
patients O
finished O
therapy O
to O
assess O
the O
tolerability O
of O
the O
treatment O
regimens O
. O
!LF! !LF!
patients O
had O
a O
free O
choice O
of O
treosulfan O
i O
. O
v O
. O
!LF! !LF!
( O
7 O
, O
000 O
mg O
/ O
m O
( O
2 O
) O
day O
1 O
of O
a O
28 O
- O
day O
cycle O
) O
or O
p O
. O
o O
. O
!LF! !LF!
( O
600 O
mg O
/ O
m O
( O
2 O
) O
day O
1 O
- O
28 O
of O
a O
56 O
- O
day O
cycle O
) O
for O
a O
maximum O
of O
12 O
cycles O
( O
i O
. O
v O
. O
) O
!LF! !LF!
or O
12 O
months O
( O
p O
. O
o O
. O
) O
. O
!LF! !LF!
indecisive O
patients O
were O
randomized O
. O
!LF! !LF!
toxicity O
was O
evaluated O
according O
to O
the O
nci O
- O
ctc O
version O
2 O
. O
0 O
. O
!LF! !LF!
twenty O
- O
five O
of O
51 O
recruited O
patients O
completed O
therapy O
at O
the O
time O
of O
the O
planned O
interim O
analysis O
( O
median O
age O
, O
75 O
years O
"""" O
; O
"""" O
range O
, O
70 O
- O
82 O
) O
. O
!LF! !LF!
median O
ecog O
was O
1 O
, O
and O
median O
number O
of O
prior O
chemotherapy O
regimens O
was O
2 O
. O
!LF! !LF!
a O
median O
number O
of O
4 O
cycles O
( O
range O
, O
1 O
- O
12 O
) O
were O
administered O
per O
patient O
. O
!LF! !LF!
anemia B-Premise
was I-Premise
the I-Premise
most I-Premise
common I-Premise
hematological I-Premise
toxicity I-Premise
( I-Premise
88 I-Premise
% I-Premise
of I-Premise
patients I-Premise
) I-Premise
. I-Premise
!LF! !LF!
most B-Premise
frequent I-Premise
non I-Premise
- I-Premise
hematological I-Premise
toxicities I-Premise
were I-Premise
nausea I-Premise
( I-Premise
76 I-Premise
% I-Premise
) I-Premise
, I-Premise
constipation I-Premise
( I-Premise
68 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
fatigue I-Premise
( I-Premise
64 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
treatment B-Claim
was I-Claim
generally I-Claim
well I-Claim
tolerated I-Claim
despite I-Claim
the I-Claim
fact I-Claim
that I-Claim
most I-Claim
patients I-Claim
suffered I-Claim
from I-Claim
multiple I-Claim
comorbidities I-Claim
and I-Claim
were I-Claim
heavily I-Claim
pretreated I-Claim
. I-Claim
!LF! !LF!
there B-Claim
were I-Claim
no I-Claim
unexpected I-Claim
hematological I-Claim
or I-Claim
non I-Claim
- I-Claim
hematological I-Claim
toxicities I-Claim
. I-Claim
!LF! !LF!
based O
on O
this O
safety O
analysis O
, O
the O
next O
step O
of O
study O
recruitment O
was O
continued O
. O
!LF! !LF!
the O
purpose O
of O
this O
article O
is O
to O
compare O
quality O
of O
life O
( O
qol O
) O
and O
menopausal O
symptoms O
among O
premenopausal O
patients O
with O
lymph O
node O
- O
negative O
breast O
cancer O
receiving O
chemotherapy O
, O
goserelin O
, O
or O
their O
sequential O
combination O
, O
and O
to O
investigate O
differential O
effects O
by O
age O
. O
!LF! !LF!
we O
evaluated O
qol O
data O
from O
874 O
pre O
- O
and O
perimenopausal O
women O
with O
lymph O
node O
- O
negative O
breast O
cancer O
who O
were O
randomly O
assigned O
to O
receive O
six O
courses O
of O
classical O
cyclophosphamide O
, O
methotrexate O
, O
and O
fluorouracil O
( O
cmf O
) O
chemotherapy O
, O
ovarian O
suppression O
with O
goserelin O
for O
24 O
months O
, O
or O
six O
courses O
of O
classical O
cmf O
followed O
by O
18 O
months O
of O
goserelin O
. O
!LF! !LF!
we O
report O
qol O
data O
collected O
during O
3 O
years O
after O
random O
assignment O
in O
patients O
without O
disease O
recurrence O
. O
!LF! !LF!
overall B-Premise
, I-Premise
patients I-Premise
receiving I-Premise
goserelin I-Premise
alone I-Premise
showed I-Premise
a I-Premise
marked I-Premise
improvement I-Premise
or I-Premise
less I-Premise
deterioration I-Premise
in I-Premise
qol I-Premise
measures I-Premise
over I-Premise
the I-Premise
first I-Premise
6 I-Premise
months I-Premise
than I-Premise
those I-Premise
patients I-Premise
treated I-Premise
with I-Premise
cmf I-Premise
. I-Premise
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
differences I-Premise
at I-Premise
3 I-Premise
years I-Premise
after I-Premise
random I-Premise
assignment I-Premise
according I-Premise
to I-Premise
treatment I-Premise
except I-Premise
for I-Premise
hot I-Premise
flashes I-Premise
. I-Premise
!LF! !LF!
as B-Premise
reflected I-Premise
in I-Premise
the I-Premise
hot I-Premise
flashes I-Premise
scores I-Premise
, I-Premise
patients I-Premise
in I-Premise
all I-Premise
three I-Premise
treatment I-Premise
groups I-Premise
experienced I-Premise
induced I-Premise
amenorrhea I-Premise
, I-Premise
but B-Premise
the I-Premise
onset I-Premise
of I-Premise
ovarian I-Premise
function I-Premise
suppression I-Premise
was I-Premise
slightly I-Premise
delayed I-Premise
for I-Premise
patients I-Premise
receiving I-Premise
chemotherapy I-Premise
. I-Premise
!LF! !LF!
younger B-Premise
patients I-Premise
( I-Premise
< I-Premise
40 I-Premise
years I-Premise
) I-Premise
who I-Premise
received I-Premise
goserelin I-Premise
alone I-Premise
returned I-Premise
to I-Premise
their I-Premise
premenopausal I-Premise
status I-Premise
at I-Premise
6 I-Premise
months I-Premise
after I-Premise
the I-Premise
cessation I-Premise
of I-Premise
therapy I-Premise
, I-Premise
while I-Premise
those I-Premise
who I-Premise
received I-Premise
cmf I-Premise
showed I-Premise
marginal I-Premise
changes I-Premise
from I-Premise
their I-Premise
baseline I-Premise
hot I-Premise
flashes I-Premise
scores I-Premise
. I-Premise
!LF! !LF!
age B-Claim
- B-Claim
adjusted B-Claim
risk I-Claim
profiles I-Claim
that I-Claim
consider I-Claim
patient I-Claim
- I-Claim
reported I-Claim
outcomes I-Claim
enable I-Claim
patients I-Claim
to I-Claim
adapt I-Claim
to I-Claim
their I-Claim
disease I-Claim
and I-Claim
treatment I-Claim
, I-Claim
such I-Claim
as I-Claim
considering I-Claim
the I-Claim
trade I-Claim
- I-Claim
offs I-Claim
between I-Claim
delayed I-Claim
endocrine I-Claim
symptoms I-Claim
, I-Claim
but I-Claim
higher I-Claim
risk I-Claim
of I-Claim
permanent I-Claim
menopause I-Claim
with I-Claim
chemotherapy I-Claim
, I-Claim
and I-Claim
immediate I-Claim
but I-Claim
reversible I-Claim
endocrine I-Claim
symptoms I-Claim
with I-Claim
goserelin I-Claim
, I-Claim
in I-Claim
younger I-Claim
premenopausal I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
with O
the O
adoption O
of O
enhanced O
recovery O
and O
emerging O
new O
modalities O
of O
analgesia O
after O
laparoscopic O
colorectal O
resection O
( O
lcr O
) O
, O
the O
role O
of O
epidural O
analgesia O
has O
been O
questioned O
. O
!LF! !LF!
this O
pilot O
trial O
assessed O
the O
feasibility O
of O
a O
randomized O
controlled O
trial O
( O
rct O
) O
comparing O
epidural O
analgesia O
and O
use O
of O
a O
local O
anaesthetic O
wound O
infusion O
catheter O
( O
wic O
) O
following O
lcr O
. O
!LF! !LF!
between O
april O
2010 O
and O
may O
2011 O
, O
patients O
undergoing O
elective O
lcr O
in O
two O
centres O
were O
randomized O
to O
analgesia O
via O
epidural O
or O
wic O
. O
!LF! !LF!
sham O
procedures O
were O
used O
to O
blind O
surgeons O
, O
patients O
and O
outcome O
assessors O
. O
!LF! !LF!
the O
primary O
outcome O
was O
the O
feasibility O
of O
a O
large O
rct O
, O
and O
all O
outcomes O
for O
a O
definitive O
trial O
were O
tested O
. O
!LF! !LF!
the O
success O
of O
blinding O
was O
assessed O
using O
a O
mixed O
- O
methods O
approach O
. O
!LF! !LF!
forty O
- O
five O
patients O
were O
eligible O
, O
of O
whom O
34 O
were O
randomized O
( O
mean O
( O
s O
. O
d O
. O
) O
age O
70 O
( O
11 O
· O
8 O
) O
years O
) O
. O
!LF! !LF!
patients O
were O
followed O
up O
per O
- O
protocol O
"""" O
; O
"""" O
there O
were O
no O
deaths O
, O
and O
five O
patients O
had O
a O
total O
of O
six O
complications O
. O
!LF! !LF!
challenges O
with O
capturing O
pain O
data O
were O
identified O
and O
resolved O
. O
!LF! !LF!
mean B-Premise
( I-Premise
s I-Premise
. I-Premise
d I-Premise
. I-Premise
) I-Premise
pain I-Premise
scores I-Premise
on I-Premise
the I-Premise
day I-Premise
of I-Premise
discharge I-Premise
were I-Premise
1 I-Premise
· I-Premise
9 I-Premise
( I-Premise
3 I-Premise
· I-Premise
1 I-Premise
) I-Premise
in I-Premise
the I-Premise
epidural I-Premise
group I-Premise
and I-Premise
0 I-Premise
· I-Premise
7 I-Premise
( I-Premise
0 I-Premise
· I-Premise
7 I-Premise
) I-Premise
in I-Premise
the I-Premise
wic I-Premise
group I-Premise
. I-Premise
!LF! !LF!
median B-Premise
length I-Premise
of I-Premise
stay I-Premise
was I-Premise
4 I-Premise
( I-Premise
range I-Premise
2 I-Premise
- I-Premise
35 I-Premise
, I-Premise
interquartile I-Premise
range I-Premise
3 I-Premise
- I-Premise
5 I-Premise
) I-Premise
days I-Premise
. I-Premise
!LF! !LF!
mean B-Premise
use I-Premise
of I-Premise
additional I-Premise
analgesia I-Premise
( I-Premise
intravenous I-Premise
morphine I-Premise
equivalents I-Premise
) I-Premise
was I-Premise
12 I-Premise
mg I-Premise
in I-Premise
the I-Premise
wic I-Premise
arm I-Premise
and I-Premise
9 I-Premise
mg I-Premise
in I-Premise
the I-Premise
epidural I-Premise
arm I-Premise
. I-Premise
!LF! !LF!
patient O
blinding O
was O
successful O
in O
both O
arms O
. O
!LF! !LF!
qualitative B-Claim
interviews I-Claim
suggested I-Claim
that I-Claim
patients I-Claim
found I-Claim
participation I-Claim
in I-Claim
the I-Claim
trial I-Claim
acceptable I-Claim
and I-Claim
that I-Claim
they I-Claim
would I-Claim
consider I-Claim
participating I-Claim
in I-Claim
a I-Claim
future I-Claim
trial I-Claim
. I-Claim
!LF! !LF!
a B-Claim
blinded I-Claim
rct I-Claim
investigating I-Claim
the I-Claim
role I-Claim
of I-Claim
epidural I-Claim
and I-Claim
wic I-Claim
administration I-Claim
for I-Claim
postoperative I-Claim
analgesia I-Claim
following I-Claim
lcr I-Claim
is I-Claim
feasible I-Claim
. I-Claim
!LF! !LF!
rigorous B-Claim
standard I-Claim
operating I-Claim
procedures I-Claim
for I-Claim
data I-Claim
collection I-Claim
are I-Claim
required I-Claim
. I-Claim
!LF! !LF!
in O
a O
previous O
study O
of O
treatment O
for O
advanced O
colorectal O
cancer O
, O
the O
lv5fu2 O
regimen O
, O
comprising O
leucovorin O
( O
lv O
) O
plus O
bolus O
and O
infusional O
fluorouracil O
( O
5fu O
) O
every O
2 O
weeks O
, O
was O
superior O
to O
the O
standard O
north O
central O
cancer O
treatment O
group O
/ O
mayo O
clinic O
5 O
- O
day O
bolus O
5fu O
/ O
lv O
regimen O
. O
!LF! !LF!
this O
phase O
iii O
study O
investigated O
the O
effect O
of O
combining O
oxaliplatin O
with O
lv5fu2 O
, O
with O
progression O
- O
free O
survival O
as O
the O
primary O
end O
point O
. O
!LF! !LF!
four O
hundred O
twenty O
previously O
untreated O
patients O
with O
measurable O
disease O
were O
randomized O
to O
receive O
a O
2 O
- O
hour O
infusion O
of O
lv O
( O
200 O
mg O
/ O
m O
( O
2 O
) O
/ O
d O
) O
followed O
by O
a O
5fu O
bolus O
( O
400 O
mg O
/ O
m O
( O
2 O
) O
/ O
d O
) O
and O
22 O
- O
hour O
infusion O
( O
600 O
mg O
/ O
m O
( O
2 O
) O
/ O
d O
) O
for O
2 O
consecutive O
days O
every O
2 O
weeks O
, O
either O
alone O
or O
together O
with O
oxaliplatin O
85 O
mg O
/ O
m O
( O
2 O
) O
as O
a O
2 O
- O
hour O
infusion O
on O
day O
1 O
. O
!LF! !LF!
patients B-Premise
allocated I-Premise
to I-Premise
oxaliplatin I-Premise
plus I-Premise
lv5fu2 I-Premise
had I-Premise
significantly I-Premise
longer I-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
( I-Premise
median I-Premise
, I-Premise
9 I-Premise
. I-Premise
0 I-Premise
v I-Premise
6 I-Premise
. I-Premise
2 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
0003 I-Premise
) I-Premise
and I-Premise
better I-Premise
response I-Premise
rate I-Premise
( I-Premise
50 I-Premise
. I-Premise
7 I-Premise
% I-Premise
v I-Premise
22 I-Premise
. I-Premise
3 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
0001 I-Premise
) I-Premise
when I-Premise
compared I-Premise
with I-Premise
the I-Premise
control I-Premise
arm I-Premise
. I-Premise
!LF! !LF!
the B-Premise
improvement I-Premise
in I-Premise
overall I-Premise
survival I-Premise
did I-Premise
not I-Premise
reach I-Premise
significance I-Premise
( I-Premise
median I-Premise
, I-Premise
16 I-Premise
. I-Premise
2 I-Premise
v I-Premise
14 I-Premise
. I-Premise
7 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
12 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
lv5fu2 B-Premise
plus I-Premise
oxaliplatin I-Premise
gave I-Premise
higher I-Premise
frequencies I-Premise
of I-Premise
national I-Premise
cancer I-Premise
institute I-Premise
common I-Premise
toxicity I-Premise
criteria I-Premise
grade I-Premise
3 I-Premise
/ I-Premise
4 I-Premise
neutropenia I-Premise
( I-Premise
41 I-Premise
. I-Premise
7 I-Premise
% I-Premise
v I-Premise
5 I-Premise
. I-Premise
3 I-Premise
% I-Premise
of I-Premise
patients I-Premise
) I-Premise
, I-Premise
grade I-Premise
3 I-Premise
/ I-Premise
4 I-Premise
diarrhea I-Premise
( I-Premise
11 I-Premise
. I-Premise
9 I-Premise
% I-Premise
v I-Premise
5 I-Premise
. I-Premise
3 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
grade I-Premise
3 I-Premise
neurosensory I-Premise
toxicity I-Premise
( I-Premise
18 I-Premise
. I-Premise
2 I-Premise
% I-Premise
v I-Premise
0 I-Premise
% I-Premise
) I-Premise
, I-Premise
but I-Premise
this I-Premise
did I-Premise
not I-Premise
result I-Premise
in I-Premise
impairment I-Premise
of I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
qol I-Premise
) I-Premise
. I-Premise
!LF! !LF!
survival B-Premise
without I-Premise
disease I-Premise
progression I-Premise
or I-Premise
deterioration I-Premise
in I-Premise
global I-Premise
health I-Premise
status I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
allocated I-Premise
to I-Premise
oxaliplatin I-Premise
treatment I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
004 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Claim
lv5fu2 I-Claim
- I-Claim
oxaliplatin I-Claim
combination I-Claim
seems I-Claim
beneficial I-Claim
as I-Claim
first I-Claim
- I-Claim
line I-Claim
therapy I-Claim
in I-Claim
advanced I-Claim
colorectal I-Claim
cancer I-Claim
, I-Claim
demonstrating I-Claim
a I-Claim
prolonged I-Claim
progression I-Claim
- I-Claim
free I-Claim
survival I-Claim
with I-Claim
acceptable I-Claim
tolerability I-Claim
and I-Claim
maintenance I-Claim
of I-Claim
qol I-Claim
. I-Claim
!LF! !LF!
few O
reports O
have O
examined O
the O
use O
of O
recombinant O
human O
thyroid O
- O
stimulating O
hormone O
( O
rhtsh O
) O
for O
ablation O
of O
postsurgical O
thyroid O
remnants O
after O
low O
- O
dose O
radioactive O
iodine O
( O
ri O
) O
therapy O
, O
compared O
with O
conventional O
thyroid O
hormone O
withdrawal O
. O
!LF! !LF!
we O
investigated O
whether O
patient O
preparation O
using O
rhtsh O
was O
comparable O
to O
conventional O
thyroid O
hormone O
withdrawal O
with O
respect O
to O
efficacy O
of O
postsurgical O
remnant O
ablation O
in O
low O
- O
risk O
patients O
receiving O
a O
30 O
mci O
ri O
. O
!LF! !LF!
in O
addition O
, O
we O
also O
evaluated O
the O
impact O
of O
rhtsh O
( O
rhtsh O
vs O
. O
conventional O
thyroid O
hormone O
withdrawal O
) O
on O
quality O
of O
life O
( O
qol O
) O
of O
thyroid O
cancer O
patients O
undergoing O
ri O
ablation O
. O
!LF! !LF!
this O
study O
included O
three O
groups O
of O
patients O
, O
enrolled O
consecutively O
. O
!LF! !LF!
from O
february O
2006 O
to O
march O
2007 O
, O
291 O
patients O
were O
enrolled O
and O
randomized O
, O
after O
total O
thyroidectomy O
: O
( O
1 O
) O
withdrawal O
of O
levothyroxine O
( O
lt4 O
) O
for O
4 O
weeks O
( O
t4 O
- O
wd O
group O
, O
n O
= O
89 O
) O
, O
( O
2 O
) O
withdrawal O
of O
lt4 O
for O
4 O
weeks O
plus O
2 O
weeks O
on O
and O
then O
2 O
weeks O
off O
liothyronine O
( O
lt3 O
) O
( O
t3 O
- O
wd O
group O
, O
n O
= O
133 O
) O
, O
and O
( O
3 O
) O
rhtsh O
administration O
( O
rhtsh O
group O
, O
n O
= O
69 O
) O
. O
!LF! !LF!
qol O
was O
determined O
at O
the O
time O
of O
ablation O
. O
!LF! !LF!
patients O
in O
the O
three O
groups O
did O
not O
differ O
significantly O
in O
baseline O
characteristics O
or O
tumor O
, O
node O
and O
metastasis O
( O
tnm O
) O
staging O
. O
!LF! !LF!
in B-Premise
all I-Premise
study I-Premise
groups I-Premise
, I-Premise
serum I-Premise
tsh I-Premise
levels I-Premise
showed I-Premise
very I-Premise
good I-Premise
stimulation I-Premise
( I-Premise
mean I-Premise
, I-Premise
82 I-Premise
. I-Premise
24 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
18 I-Premise
. I-Premise
21 I-Premise
mu I-Premise
/ I-Premise
l I-Premise
) I-Premise
, I-Premise
without I-Premise
significant I-Premise
between I-Premise
- I-Premise
group I-Premise
differences I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
5213 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
follow O
- O
up O
examinations O
were O
performed O
12 O
months O
after O
ablation O
to O
assess O
ablation O
outcome O
in O
each O
group O
by O
131 O
whole O
body O
scans O
( O
wbss O
) O
, O
serum O
thyroglobulin O
measurement O
after O
tsh O
stimulation O
, O
and O
neck O
ultrasonography O
. O
!LF! !LF!
the B-Premise
successful I-Premise
ablation I-Premise
rate I-Premise
was I-Premise
91 I-Premise
. I-Premise
0 I-Premise
% I-Premise
in I-Premise
t4 I-Premise
- I-Premise
wd I-Premise
group I-Premise
, I-Premise
91 I-Premise
. I-Premise
7 I-Premise
% I-Premise
in I-Premise
t3 I-Premise
- I-Premise
wd I-Premise
group I-Premise
, I-Premise
and I-Premise
91 I-Premise
. I-Premise
3 I-Premise
% I-Premise
in I-Premise
rhtsh I-Premise
group I-Premise
, I-Premise
without I-Premise
significant I-Premise
between I-Premise
- I-Premise
preparation I-Premise
differences I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
2061 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
qol B-Premise
was I-Premise
better I-Premise
preserved I-Premise
in I-Premise
rhtsh I-Premise
group I-Premise
than I-Premise
in I-Premise
t4 I-Premise
- I-Premise
wd I-Premise
and I-Premise
t3 I-Premise
- I-Premise
wd I-Premise
groups I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
0001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
however B-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
qol I-Premise
difference I-Premise
at I-Premise
the I-Premise
time I-Premise
of I-Premise
ablation I-Premise
between I-Premise
t4 I-Premise
- I-Premise
wd I-Premise
and I-Premise
t3 I-Premise
- I-Premise
wd I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
our B-Claim
study I-Claim
indicates I-Claim
that I-Claim
use I-Claim
of I-Claim
rhtsh I-Claim
preserves I-Claim
qol I-Claim
in I-Claim
patients I-Claim
undergoing I-Claim
ri I-Claim
ablation I-Claim
and I-Claim
affords I-Claim
an I-Claim
ablation I-Claim
success I-Claim
rate I-Claim
comparable I-Claim
to I-Claim
that I-Claim
seen I-Claim
after I-Claim
thyroid I-Claim
hormone I-Claim
withdrawal I-Claim
. I-Claim
!LF! !LF!
notably O
, O
ablation O
preparation O
using O
withdrawal O
of O
lt3 O
for O
2 O
weeks O
did O
not O
prevent O
development O
of O
profound O
hypothyroidism O
, O
as O
also O
occurred O
when O
lt4 O
alone O
was O
withdrawn O
for O
4 O
weeks O
. O
!LF! !LF!
to O
determine O
whether O
an O
internet B-Claim
- B-Claim
based B-Claim
tailored I-Claim
education I-Claim
program I-Claim
is I-Claim
effective I-Claim
for I-Claim
disease I-Claim
- I-Claim
free I-Claim
cancer I-Claim
survivors I-Claim
with I-Claim
cancer I-Claim
- I-Claim
related I-Claim
fatigue I-Claim
( I-Claim
crf I-Claim
) I-Claim
. I-Claim
!LF! !LF!
we O
randomly O
assigned O
patients O
who O
had O
completed O
primary O
cancer O
treatment O
within O
the O
past O
24 O
months O
in O
any O
of O
four O
korean O
hospitals O
and O
had O
reported O
moderate O
to O
severe O
fatigue O
for O
at O
least O
1 O
week O
to O
participate O
in O
a O
12 O
- O
week O
, O
internet O
- O
based O
, O
individually O
tailored O
crf O
education O
program O
or O
to O
receive O
routine O
care O
. O
!LF! !LF!
we O
based O
the O
program O
on O
the O
crf O
guidelines O
of O
the O
national O
comprehensive O
cancer O
network O
( O
nccn O
) O
and O
incorporated O
the O
transtheoretic O
model O
( O
ttm O
) O
. O
!LF! !LF!
at O
baseline O
and O
12 O
weeks O
, O
we O
used O
the O
brief O
fatigue O
inventory O
( O
bfi O
) O
and O
fatigue O
severity O
scale O
( O
fss O
) O
as O
primary O
outcomes O
and O
the O
hospital O
anxiety O
and O
depression O
scale O
( O
hads O
) O
and O
european O
organisation O
for O
research O
and O
treatment O
of O
cancer O
quality O
of O
life O
questionnaire O
c30 O
( O
eortc O
qlq O
- O
c30 O
) O
for O
secondary O
outcomes O
. O
!LF! !LF!
we O
recruited O
273 O
participants O
and O
randomly O
assigned O
136 O
to O
the O
intervention O
group O
. O
!LF! !LF!
compared B-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
the I-Premise
intervention I-Premise
group I-Premise
had I-Premise
an I-Premise
improvement I-Premise
in I-Premise
fatigue I-Premise
as I-Premise
shown I-Premise
by I-Premise
a I-Premise
significantly I-Premise
greater I-Premise
decrease I-Premise
in I-Premise
bfi I-Premise
global I-Premise
score I-Premise
( I-Premise
- I-Premise
0 I-Premise
. I-Premise
66 I-Premise
points I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
- I-Premise
1 I-Premise
. I-Premise
04 I-Premise
to I-Premise
- I-Premise
0 I-Premise
. I-Premise
27 I-Premise
) I-Premise
and I-Premise
fss I-Premise
total I-Premise
score I-Premise
( I-Premise
- I-Premise
0 I-Premise
. I-Premise
49 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
- I-Premise
0 I-Premise
. I-Premise
78 I-Premise
to I-Premise
- I-Premise
0 I-Premise
. I-Premise
21 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
in B-Premise
secondary I-Premise
outcomes I-Premise
, I-Premise
the I-Premise
intervention I-Premise
group I-Premise
experienced I-Premise
a I-Premise
significantly I-Premise
greater I-Premise
decrease I-Premise
in I-Premise
hads I-Premise
anxiety I-Premise
score I-Premise
( I-Premise
- I-Premise
0 I-Premise
. I-Premise
90 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
- I-Premise
1 I-Premise
. I-Premise
51 I-Premise
to I-Premise
- I-Premise
0 I-Premise
. I-Premise
29 I-Premise
) I-Premise
as I-Premise
well I-Premise
as I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
5 I-Premise
. I-Premise
22 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
93 I-Premise
to I-Premise
9 I-Premise
. I-Premise
50 I-Premise
) I-Premise
and I-Premise
several I-Premise
functioning I-Premise
scores I-Premise
of I-Premise
the I-Premise
eortc I-Premise
qlq I-Premise
- I-Premise
c30 I-Premise
. I-Premise
!LF! !LF!
an B-Claim
internet I-Claim
- I-Claim
based I-Claim
education I-Claim
program I-Claim
based I-Claim
on I-Claim
nccn I-Claim
guidelines I-Claim
and I-Claim
ttm I-Claim
may I-Claim
help I-Claim
patients I-Claim
manage I-Claim
crf I-Claim
. I-Claim
!LF! !LF!
the O
aim O
of O
this O
study O
was O
to O
compare O
the O
quality O
of O
life O
( O
qol O
) O
of O
high O
- O
risk O
breast O
cancer O
patients O
included O
in O
a O
randomized O
clinical O
trial O
( O
pegase O
1 O
) O
comparing O
conventional O
chemotherapy O
versus O
adding O
an O
additional O
high O
- O
dose O
chemotherapy O
( O
hdc O
) O
cycle O
with O
blood O
stem O
cell O
support O
. O
!LF! !LF!
a O
total O
of O
314 O
patients O
were O
included O
in O
the O
clinical O
trial O
. O
!LF! !LF!
qol O
evaluations O
were O
available O
for O
199 O
patients O
. O
!LF! !LF!
qol O
was O
assessed O
over O
a O
1 O
- O
year O
follow O
- O
up O
period O
, O
using O
the O
european O
organization O
for O
research O
and O
treatment O
of O
cancer O
quality O
of O
life O
questionnaire O
c O
- O
30 O
. O
!LF! !LF!
the O
results O
were O
analyzed O
using O
a O
linear O
mixed O
- O
effects O
model O
. O
!LF! !LF!
toxicity B-Premise
of I-Premise
hdc I-Premise
has I-Premise
a I-Premise
strong I-Premise
negative I-Premise
impact I-Premise
on I-Premise
patients I-Premise
' I-Premise
qol I-Premise
during I-Premise
the I-Premise
treatment I-Premise
phase I-Premise
. I-Premise
!LF! !LF!
this B-Premise
negative I-Premise
impact I-Premise
tended I-Premise
to I-Premise
last I-Premise
longer I-Premise
in I-Premise
the I-Premise
hdc I-Premise
group I-Premise
, I-Premise
as I-Premise
for I-Premise
most I-Premise
of I-Premise
the I-Premise
qlq I-Premise
- I-Premise
c30 I-Premise
scales I-Premise
, I-Premise
the I-Premise
qol I-Premise
scores I-Premise
of I-Premise
hdc I-Premise
patients I-Premise
tend I-Premise
to I-Premise
improve I-Premise
at I-Premise
a I-Premise
slower I-Premise
rate I-Premise
than I-Premise
that I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
standard I-Premise
chemotherapy I-Premise
. I-Premise
!LF! !LF!
in O
particular O
, O
physical B-Premise
functioning I-Premise
remains I-Premise
deteriorated I-Premise
1 I-Premise
year I-Premise
after I-Premise
inclusion I-Premise
for I-Premise
hdc I-Premise
patients I-Premise
comparatively I-Premise
to I-Premise
conventional I-Premise
chemotherapy I-Premise
patients I-Premise
( I-Premise
85 I-Premise
. I-Premise
99 I-Premise
vs I-Premise
. I-Premise
76 I-Premise
. I-Premise
65 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
021 I-Premise
) I-Premise
, O
and B-Premise
the I-Premise
pain I-Premise
score I-Premise
was I-Premise
still I-Premise
higher I-Premise
in I-Premise
the I-Premise
hdc I-Premise
group I-Premise
at I-Premise
that I-Premise
time I-Premise
( I-Premise
28 I-Premise
. I-Premise
32 I-Premise
vs I-Premise
. I-Premise
15 I-Premise
. I-Premise
97 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
004 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
hdc B-Claim
has I-Claim
a I-Claim
negative I-Claim
impact I-Claim
on I-Claim
qol I-Claim
even I-Claim
after I-Claim
treatment I-Claim
phase I-Claim
. I-Claim
!LF! !LF!
in O
the O
absence O
of O
an O
overall O
survival O
benefit O
of O
using O
hdc O
for O
high O
- O
risk O
breast O
cancer O
patients O
, O
qol O
studies O
with O
a O
longer O
follow O
- O
up O
play O
an O
important O
role O
in O
informing O
the O
complex O
trade O
- O
off O
implied O
by O
hdc O
between O
higher O
toxicity O
, O
reduced O
risk O
of O
relapse O
, O
and O
qol O
decrease O
after O
the O
active O
phase O
of O
treatment O
. O
!LF! !LF!
the O
aim O
of O
this O
study O
was O
to O
compare O
the O
analgesic O
and O
adverse O
effects O
, O
doses O
, O
as O
well O
as O
cost O
of O
opioid O
drugs O
, O
supportive O
drug O
therapy O
and O
other O
analgesic O
drugs O
in O
patients O
treated O
with O
oral O
sustained O
- O
release O
morphine O
, O
transdermal O
fentanyl O
, O
and O
oral O
methadone O
. O
!LF! !LF!
one O
hundred O
and O
eight O
cancer O
patients O
, O
no O
longer O
responsive O
to O
opioids O
for O
moderate O
pain O
, O
were O
selected O
to O
randomly O
receive O
initial O
daily O
doses O
of O
60 O
mg O
of O
oral O
sustained O
- O
release O
morphine O
, O
15 O
mg O
of O
oral O
methadone O
, O
or O
0 O
. O
6 O
mg O
( O
25 O
microg O
/ O
h O
) O
of O
transdermal O
fentanyl O
. O
!LF! !LF!
oral O
morphine O
was O
used O
as O
breakthrough O
pain O
medication O
during O
opioid O
titration O
. O
!LF! !LF!
opioid O
doses O
, O
pain O
intensity O
, O
adverse O
effects O
, O
symptomatic O
drugs O
, O
were O
recorded O
at O
week O
intervals O
for O
4 O
weeks O
. O
!LF! !LF!
costs O
of O
opioid O
therapy O
, O
supportive O
drugs O
, O
and O
other O
analgesic O
drugs O
were O
also O
evaluated O
. O
!LF! !LF!
seventy O
patients O
completed O
the O
4 O
weeks O
period O
of O
study O
. O
!LF! !LF!
five O
, O
five O
, O
and O
four O
patients O
, O
treated O
with O
oral O
morphine O
, O
transdermal O
fentanyl O
, O
and O
oral O
methadone O
, O
respectively O
, O
required O
opioid O
switching O
. O
!LF! !LF!
no B-Premise
differences I-Premise
in I-Premise
pain I-Premise
and I-Premise
symptom I-Premise
intensity I-Premise
were I-Premise
observed I-Premise
. I-Premise
!LF! !LF!
opioid B-Premise
escalation I-Premise
index I-Premise
was I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
methadone I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
0001 I-Premise
) I-Premise
, I-Premise
although I-Premise
requiring I-Premise
up I-Premise
and I-Premise
down I-Premise
changes I-Premise
in I-Premise
doses I-Premise
. I-Premise
!LF! !LF!
at B-Premise
the I-Premise
doses I-Premise
used I-Premise
, I-Premise
methadone I-Premise
was I-Premise
significantly I-Premise
less I-Premise
expensive I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
0001 I-Premise
) I-Premise
, I-Premise
while I-Premise
the I-Premise
use I-Premise
and I-Premise
costs I-Premise
of I-Premise
supportive I-Premise
drugs I-Premise
and I-Premise
other I-Premise
analgesics I-Premise
were I-Premise
similar I-Premise
in I-Premise
the I-Premise
three I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
no B-Premise
relevant I-Premise
differences I-Premise
in I-Premise
adverse I-Premise
effects I-Premise
were I-Premise
observed I-Premise
among I-Premise
the I-Premise
groups I-Premise
during I-Premise
either I-Premise
the I-Premise
titration I-Premise
phase I-Premise
and I-Premise
chronic I-Premise
treatment I-Premise
. I-Premise
!LF! !LF!
all B-Claim
the I-Claim
three I-Claim
opioids I-Claim
used I-Claim
as I-Claim
first I-Claim
- I-Claim
line I-Claim
therapy I-Claim
were I-Claim
effective I-Claim
, I-Claim
well I-Claim
tolerated I-Claim
, I-Claim
and I-Claim
required I-Claim
similar I-Claim
amounts I-Claim
of I-Claim
symptomatic I-Claim
drugs I-Claim
or I-Claim
co I-Claim
- I-Claim
analgesics I-Claim
. I-Claim
!LF! !LF!
methadone B-Claim
was I-Claim
significantly I-Claim
less I-Claim
expensive I-Claim
, I-Claim
but I-Claim
required I-Claim
more I-Claim
changes I-Claim
, I-Claim
up I-Claim
and I-Claim
down I-Claim
, I-Claim
of I-Claim
the I-Claim
doses I-Claim
, I-Claim
suggesting I-Claim
that I-Claim
dose I-Claim
titration I-Claim
of I-Claim
this I-Claim
drug I-Claim
requires I-Claim
major I-Claim
clinical I-Claim
expertise I-Claim
. I-Claim
!LF! !LF!
we O
sought O
the O
extent O
to O
which O
arm O
morbidity O
could O
be O
reduced O
by O
using O
sentinel O
- O
lymph O
- O
node O
- O
based O
management O
in O
women O
with O
clinically O
node O
- O
negative O
early O
breast O
cancer O
. O
!LF! !LF!
one O
thousand O
eighty O
- O
eight O
women O
were O
randomly O
allocated O
to O
sentinel O
- O
lymph O
- O
node O
biopsy O
followed O
by O
axillary O
clearance O
if O
the O
sentinel O
node O
was O
positive O
or O
not O
detected O
( O
snbm O
) O
or O
routine O
axillary O
clearance O
( O
rac O
, O
sentinel O
- O
lymph O
- O
node O
biopsy O
followed O
immediately O
by O
axillary O
clearance O
) O
. O
!LF! !LF!
sentinel O
nodes O
were O
located O
using O
blue O
dye O
, O
alone O
or O
with O
technetium O
- O
labeled O
antimony O
sulfide O
colloid O
. O
!LF! !LF!
the O
primary O
endpoint O
was O
increase O
in O
arm O
volume O
from O
baseline O
to O
the O
average O
of O
measurements O
at O
6 O
and O
12 O
months O
. O
!LF! !LF!
secondary O
endpoints O
were O
the O
proportions O
of O
women O
with O
at O
least O
15 O
% O
increase O
in O
arm O
volume O
or O
early O
axillary O
morbidity O
, O
and O
average O
scores O
for O
arm O
symptoms O
, O
dysfunctions O
, O
and O
disabilities O
assessed O
at O
6 O
and O
12 O
months O
by O
patients O
with O
the O
snac O
study O
- O
specific O
scales O
and O
other O
quality O
- O
of O
- O
life O
instruments O
. O
!LF! !LF!
sensitivity O
, O
false O
- O
negative O
rates O
, O
and O
negative O
predictive O
values O
for O
sentinel O
- O
lymph O
- O
node O
biopsy O
were O
estimated O
in O
the O
rac O
group O
. O
!LF! !LF!
the B-Premise
average I-Premise
increase I-Premise
in I-Premise
arm I-Premise
volume I-Premise
was I-Premise
2 I-Premise
. I-Premise
8 I-Premise
% I-Premise
in I-Premise
the I-Premise
snbm I-Premise
group I-Premise
and I-Premise
4 I-Premise
. I-Premise
2 I-Premise
% I-Premise
in I-Premise
the I-Premise
rac I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
002 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
in I-Premise
the I-Premise
snbm I-Premise
group I-Premise
gave I-Premise
lower I-Premise
ratings I-Premise
for I-Premise
arm I-Premise
swelling I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
symptoms I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
and I-Premise
dysfunctions I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
, I-Premise
but I-Premise
not I-Premise
disabilities I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
5 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
sentinel B-Premise
nodes I-Premise
were I-Premise
found I-Premise
in I-Premise
95 I-Premise
% I-Premise
of I-Premise
the I-Premise
snbm I-Premise
group I-Premise
( I-Premise
29 I-Premise
% I-Premise
positive I-Premise
) I-Premise
and I-Premise
93 I-Premise
% I-Premise
of I-Premise
the I-Premise
rac I-Premise
group I-Premise
( I-Premise
25 I-Premise
% I-Premise
positive I-Premise
) I-Premise
. I-Premise
!LF! !LF!
snb O
had O
sensitivity O
94 O
. O
5 O
% O
, O
false O
- O
negative O
rate O
5 O
. O
5 O
% O
, O
and O
negative O
predictive O
value O
98 O
% O
. O
!LF! !LF!
snbm B-Claim
was I-Claim
successfully I-Claim
undertaken I-Claim
in I-Claim
a I-Claim
wide I-Claim
range I-Claim
of I-Claim
surgical I-Claim
centers I-Claim
and I-Claim
caused I-Claim
significantly I-Claim
less I-Claim
morbidity I-Claim
than I-Claim
rac I-Claim
. I-Claim
!LF! !LF!
this O
phase O
iii O
, O
double O
- O
blind O
, O
randomized O
, O
multicenter O
study O
evaluated O
the O
efficacy O
, O
pharmacodynamics O
, O
and O
safety O
of O
the O
oral O
aromatase O
inactivator O
exemestane O
( O
exe O
) O
versus O
megestrol O
acetate O
( O
ma O
) O
in O
postmenopausal O
women O
with O
progressive O
advanced O
breast O
cancer O
who O
experienced O
failure O
of O
tamoxifen O
. O
!LF! !LF!
a O
total O
of O
769 O
patients O
were O
randomized O
to O
exe O
25 O
mg O
/ O
d O
( O
n O
= O
366 O
) O
or O
ma O
( O
n O
= O
403 O
) O
40 O
mg O
four O
times O
daily O
. O
!LF! !LF!
tumor O
response O
, O
duration O
of O
tumor O
control O
, O
tumor O
- O
related O
signs O
and O
symptoms O
( O
trss O
) O
, O
quality O
of O
life O
( O
qol O
) O
, O
survival O
, O
and O
tolerability O
were O
evaluated O
. O
!LF! !LF!
overall B-Premise
objective I-Premise
response I-Premise
( I-Premise
or I-Premise
) I-Premise
rates I-Premise
were I-Premise
higher I-Premise
in I-Premise
patients I-Premise
treated I-Premise
with I-Premise
exe I-Premise
than I-Premise
in I-Premise
those I-Premise
treated I-Premise
with I-Premise
ma I-Premise
( I-Premise
15 I-Premise
. I-Premise
0 I-Premise
% I-Premise
v I-Premise
12 I-Premise
. I-Premise
4 I-Premise
% I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
a B-Premise
similar I-Premise
trend I-Premise
was I-Premise
noted I-Premise
in I-Premise
patients I-Premise
with I-Premise
visceral I-Premise
metastases I-Premise
( I-Premise
13 I-Premise
. I-Premise
5 I-Premise
% I-Premise
v I-Premise
10 I-Premise
. I-Premise
5 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
median B-Premise
survival I-Premise
time I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
with I-Premise
exe I-Premise
( I-Premise
median I-Premise
not I-Premise
reached I-Premise
) I-Premise
than I-Premise
with I-Premise
ma I-Premise
( I-Premise
123 I-Premise
. I-Premise
4 I-Premise
weeks I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
039 I-Premise
) I-Premise
, I-Premise
as I-Premise
were I-Premise
the I-Premise
median I-Premise
duration I-Premise
of I-Premise
overall I-Premise
success I-Premise
( I-Premise
or I-Premise
or I-Premise
stable I-Premise
disease I-Premise
> I-Premise
or I-Premise
= I-Premise
24 I-Premise
weeks I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
60 I-Premise
. I-Premise
1 I-Premise
v I-Premise
49 I-Premise
. I-Premise
1 I-Premise
weeks I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
025 I-Premise
) I-Premise
, I-Premise
time I-Premise
to I-Premise
tumor I-Premise
progression I-Premise
( I-Premise
20 I-Premise
. I-Premise
3 I-Premise
v I-Premise
16 I-Premise
. I-Premise
6 I-Premise
weeks I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
037 I-Premise
) I-Premise
, I-Premise
and I-Premise
time I-Premise
to I-Premise
treatment I-Premise
failure I-Premise
( I-Premise
16 I-Premise
. I-Premise
3 I-Premise
v I-Premise
15 I-Premise
. I-Premise
7 I-Premise
weeks I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
042 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
compared B-Premise
with I-Premise
ma I-Premise
, I-Premise
there I-Premise
were I-Premise
similar I-Premise
or I-Premise
greater I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
, I-Premise
trss I-Premise
, I-Premise
and I-Premise
qol I-Premise
with I-Premise
exe I-Premise
. I-Premise
!LF! !LF!
both B-Claim
drugs I-Claim
were I-Claim
well I-Claim
tolerated I-Claim
. I-Claim
!LF! !LF!
grade B-Premise
3 I-Premise
or I-Premise
4 I-Premise
weight I-Premise
changes I-Premise
were I-Premise
more I-Premise
common I-Premise
with I-Premise
ma I-Premise
( I-Premise
17 I-Premise
. I-Premise
1 I-Premise
% I-Premise
v I-Premise
7 I-Premise
. I-Premise
6 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
exe B-Claim
prolongs I-Claim
survival I-Claim
time I-Claim
, I-Claim
time I-Claim
to I-Claim
tumor I-Claim
progression I-Claim
, I-Claim
and I-Claim
time I-Claim
to I-Claim
treatment I-Claim
failure I-Claim
compared I-Claim
with I-Claim
ma I-Claim
and I-Claim
offers I-Claim
a I-Claim
well I-Claim
- I-Claim
tolerated I-Claim
treatment I-Claim
option I-Claim
for I-Claim
postmenopausal I-Claim
women I-Claim
with I-Claim
progressive I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
who I-Claim
experienced I-Claim
failure I-Claim
of I-Claim
tamoxifen I-Claim
. I-Claim
!LF! !LF!
a O
randomized O
phase O
iii O
trial O
was O
conducted O
to O
determine O
whether O
combination O
therapy O
with O
13 O
- O
cis O
- O
retinoic O
acid O
( O
13 O
- O
cra O
) O
plus O
interferon O
alfa O
- O
2a O
( O
ifnalpha2a O
) O
is O
superior O
to O
ifnalpha2a O
alone O
in O
patients O
with O
advanced O
renal O
cell O
carcinoma O
( O
rcc O
) O
. O
!LF! !LF!
two O
hundred O
eighty O
- O
four O
patients O
were O
randomized O
to O
treatment O
with O
ifnalpha2a O
plus O
13 O
- O
cra O
or O
treatment O
with O
ifnalpha2a O
alone O
. O
!LF! !LF!
ifnalpha2a O
was O
given O
daily O
subcutaneously O
, O
starting O
at O
a O
dose O
of O
3 O
million O
units O
( O
mu O
) O
. O
!LF! !LF!
the O
dose O
was O
escalated O
every O
7 O
days O
from O
3 O
to O
9 O
mu O
( O
by O
increments O
of O
3 O
mu O
) O
, O
unless O
> O
/ O
= O
grade O
2 O
toxicity O
occurred O
, O
in O
which O
case O
dose O
escalation O
was O
stopped O
. O
!LF! !LF!
patients O
randomized O
to O
combination O
therapy O
were O
given O
oral O
13 O
- O
cra O
1 O
mg O
/ O
kg O
/ O
d O
plus O
ifnalpha2a O
. O
!LF! !LF!
quality O
of O
life O
( O
qol O
) O
was O
assessed O
. O
!LF! !LF!
complete B-Premise
or I-Premise
partial I-Premise
responses I-Premise
were I-Premise
achieved I-Premise
by I-Premise
12 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
ifnalpha2a I-Premise
plus I-Premise
13 I-Premise
- I-Premise
cra I-Premise
and I-Premise
6 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
ifnalpha2a I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
14 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
median B-Premise
duration I-Premise
of I-Premise
response I-Premise
( I-Premise
complete I-Premise
and I-Premise
partial I-Premise
combined I-Premise
) I-Premise
in I-Premise
the I-Premise
group I-Premise
treated I-Premise
with I-Premise
the I-Premise
combination I-Premise
was I-Premise
33 I-Premise
months I-Premise
( I-Premise
range I-Premise
, I-Premise
9 I-Premise
to I-Premise
50 I-Premise
months I-Premise
) I-Premise
, I-Premise
versus I-Premise
22 I-Premise
months I-Premise
( I-Premise
range I-Premise
, I-Premise
5 I-Premise
to I-Premise
38 I-Premise
months I-Premise
) I-Premise
for I-Premise
the I-Premise
second I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
nineteen B-Premise
percent I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
ifnalpha2a I-Premise
plus I-Premise
13 I-Premise
- I-Premise
cra I-Premise
were I-Premise
progression I-Premise
- I-Premise
free I-Premise
at I-Premise
24 I-Premise
months I-Premise
, I-Premise
compared I-Premise
with I-Premise
10 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
ifnalpha2a I-Premise
alone I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
median B-Premise
survival I-Premise
time I-Premise
for I-Premise
all I-Premise
patients I-Premise
was I-Premise
15 I-Premise
months I-Premise
, I-Premise
with I-Premise
no I-Premise
difference I-Premise
in I-Premise
survival I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
arms I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
26 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
qol B-Premise
decreased I-Premise
during I-Premise
the I-Premise
first I-Premise
8 I-Premise
weeks I-Premise
of I-Premise
treatment I-Premise
, I-Premise
and I-Premise
a I-Premise
partial I-Premise
recovery I-Premise
followed I-Premise
. I-Premise
!LF! !LF!
lower B-Premise
scores I-Premise
were I-Premise
associated I-Premise
with I-Premise
the I-Premise
combination I-Premise
therapy I-Premise
. I-Premise
!LF! !LF!
response B-Claim
proportion I-Claim
and I-Claim
survival I-Claim
did I-Claim
not I-Claim
improve I-Claim
significantly I-Claim
with I-Claim
the I-Claim
addition I-Claim
of I-Claim
13 I-Claim
- I-Claim
cra I-Claim
to I-Claim
ifnalpha2a I-Claim
therapy I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
rcc I-Claim
. I-Claim
!LF! !LF!
13 B-Claim
- B-Claim
cra B-Claim
may I-Claim
lengthen I-Claim
response I-Claim
to I-Claim
ifnalpha2a I-Claim
therapy I-Claim
in I-Claim
patients I-Claim
with I-Claim
ifnalpha2a I-Claim
- I-Claim
sensitive I-Claim
tumors I-Claim
. I-Claim
!LF! !LF!
treatment B-Claim
, I-Claim
particularly I-Claim
the I-Claim
combination I-Claim
therapy I-Claim
, I-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
decrease I-Claim
in I-Claim
qol I-Claim
. I-Claim
!LF! !LF!
transthoracic O
and O
transhiatal O
esophagectomy O
are O
two O
common O
procedures O
for O
esophageal O
cancer O
resection O
. O
!LF! !LF!
prospective O
studies O
comparing O
the O
two O
methods O
in O
asian O
people O
are O
few O
. O
!LF! !LF!
in O
addition O
, O
the O
data O
comparing O
their O
effects O
on O
the O
quality O
of O
life O
are O
lacking O
. O
!LF! !LF!
a O
prospective O
randomized O
study O
was O
conducted O
from O
january O
2003 O
. O
!LF! !LF!
patients O
of O
resectable O
esophageal O
cancer O
of O
comparable O
stage O
were O
allocated O
to O
undergo O
the O
transthoracic O
or O
transhiatal O
procedure O
in O
turn O
. O
!LF! !LF!
they O
were O
all O
reconstructed O
with O
stomach O
interposition O
through O
the O
retrosternal O
route O
. O
!LF! !LF!
discharged O
patients O
were O
followed O
- O
up O
in O
the O
outpatient O
clinic O
. O
!LF! !LF!
they O
were O
questioned O
on O
the O
topics O
of O
( O
i O
) O
severity O
of O
pain O
, O
( O
ii O
) O
ease O
of O
swallowing O
, O
( O
iii O
) O
satisfaction O
of O
daily O
activities O
, O
( O
iv O
) O
dependence O
on O
medications O
, O
( O
v O
) O
working O
ability O
, O
( O
vi O
) O
fatigue O
, O
( O
vii O
) O
appetite O
, O
( O
viii O
) O
sociality O
, O
( O
ix O
) O
happiness O
and O
( O
x O
) O
self O
respect O
, O
in O
the O
third O
, O
sixth O
and O
twelfth O
month O
. O
!LF! !LF!
also O
the O
demographic O
data O
, O
operative O
results O
and O
survival O
were O
recorded O
. O
!LF! !LF!
up O
to O
december O
2006 O
, O
eighty O
- O
seven O
patients O
of O
stage O
ii O
and O
iii O
, O
including O
71 O
patients O
of O
middle O
third O
lesions O
and O
16 O
lower O
third O
lesions O
were O
enrolled O
. O
!LF! !LF!
the B-Premise
operation I-Premise
time I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
, I-Premise
and I-Premise
the I-Premise
leakage I-Premise
rate I-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
transthoracic I-Premise
group I-Premise
( I-Premise
student I-Premise
' I-Premise
s I-Premise
t I-Premise
- I-Premise
test I-Premise
and I-Premise
fischer I-Premise
' I-Premise
s I-Premise
exact I-Premise
test I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise
!LF! !LF!
however O
, O
intraoperative B-Premise
blood I-Premise
loss I-Premise
and I-Premise
postoperative I-Premise
hospital I-Premise
stay I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
( I-Premise
student I-Premise
t I-Premise
- I-Premise
test I-Premise
) I-Premise
. I-Premise
!LF! !LF!
also O
, O
the B-Premise
kaplan I-Premise
- I-Premise
meier I-Premise
survival I-Premise
curves I-Premise
of I-Premise
these I-Premise
two I-Premise
groups I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
by I-Premise
log I-Premise
- I-Premise
rank I-Premise
test I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
286 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
score I-Premise
on I-Premise
the I-Premise
quality I-Premise
of I-Premise
life I-Premise
of I-Premise
transhiatal I-Premise
patients I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
that I-Premise
of I-Premise
transthoracic I-Premise
patients I-Premise
in I-Premise
the I-Premise
third I-Premise
, I-Premise
sixth I-Premise
and I-Premise
twelfth I-Premise
month I-Premise
. I-Premise
!LF! !LF!
transhiatal B-Claim
esophagectomy I-Claim
is I-Claim
a I-Claim
safe I-Claim
and I-Claim
fast I-Claim
procedure I-Claim
. I-Claim
!LF! !LF!
the B-Claim
survival I-Claim
was I-Claim
similar I-Claim
to I-Claim
that I-Claim
of I-Claim
transthoracic I-Claim
approach I-Claim
. I-Claim
!LF! !LF!
its B-Claim
leakage I-Claim
rate I-Claim
was I-Claim
lower I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
was I-Claim
better I-Claim
. I-Claim
!LF! !LF!
hot B-Claim
flashes I-Claim
are I-Claim
a I-Claim
significant I-Claim
problem I-Claim
for I-Claim
many I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim
!LF! !LF!
hot B-Claim
flashes I-Claim
can I-Claim
cause I-Claim
discomfort I-Claim
, I-Claim
disrupted I-Claim
sleep I-Claim
, I-Claim
anxiety I-Claim
, I-Claim
and I-Claim
decreased I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim
!LF! !LF!
a O
well O
- O
tolerated O
and O
effective O
mind O
- O
body O
treatment O
for O
hot O
flashes O
would O
be O
of O
great O
value O
. O
!LF! !LF!
on O
the O
basis O
of O
previous O
case O
studies O
, O
this O
study O
was O
developed O
to O
evaluate O
the O
effect O
of O
a O
hypnosis O
intervention O
for O
hot O
flashes O
. O
!LF! !LF!
sixty O
female O
breast O
cancer O
survivors O
with O
hot O
flashes O
were O
randomly O
assigned O
to O
receive O
hypnosis O
intervention O
( O
five O
weekly O
sessions O
) O
or O
no O
treatment O
. O
!LF! !LF!
eligible O
patients O
had O
to O
have O
a O
history O
of O
primary O
breast O
cancer O
without O
evidence O
of O
detectable O
disease O
and O
14 O
or O
more O
weekly O
hot O
flashes O
for O
at O
least O
1 O
month O
. O
!LF! !LF!
the O
major O
outcome O
measure O
was O
a O
bivariate O
construct O
that O
represented O
hot O
flash O
frequency O
and O
hot O
flash O
score O
, O
which O
was O
analyzed O
by O
a O
classic O
sums O
and O
differences O
comparison O
. O
!LF! !LF!
secondary O
outcome O
measures O
were O
self O
- O
reports O
of O
interference O
of O
hot O
flashes O
on O
daily O
activities O
. O
!LF! !LF!
fifty O
- O
one O
randomly O
assigned O
women O
completed O
the O
study O
. O
!LF! !LF!
by B-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
treatment I-Premise
period I-Premise
, I-Premise
hot I-Premise
flash I-Premise
scores I-Premise
( I-Premise
frequency I-Premise
x I-Premise
average I-Premise
severity I-Premise
) I-Premise
decreased I-Premise
68 I-Premise
% I-Premise
from I-Premise
baseline I-Premise
to I-Premise
end I-Premise
point I-Premise
in I-Premise
the I-Premise
hypnosis I-Premise
arm I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
significant B-Premise
improvements I-Premise
in I-Premise
self I-Premise
- I-Premise
reported I-Premise
anxiety I-Premise
, I-Premise
depression I-Premise
, I-Premise
interference I-Premise
of I-Premise
hot I-Premise
flashes I-Premise
on I-Premise
daily I-Premise
activities I-Premise
, I-Premise
and I-Premise
sleep I-Premise
were I-Premise
observed I-Premise
for I-Premise
patients I-Premise
who I-Premise
received I-Premise
the I-Premise
hypnosis I-Premise
intervention I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
005 I-Premise
) I-Premise
in I-Premise
comparison I-Premise
to I-Premise
the I-Premise
no I-Premise
treatment I-Premise
control I-Premise
group I-Premise
. I-Premise
!LF! !LF!
hypnosis B-Claim
appears I-Claim
to I-Claim
reduce I-Claim
perceived I-Claim
hot I-Claim
flashes I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
and I-Claim
may I-Claim
have I-Claim
additional I-Claim
benefits I-Claim
such I-Claim
as I-Claim
reduced I-Claim
anxiety I-Claim
and I-Claim
depression I-Claim
, I-Claim
and I-Claim
improved I-Claim
sleep I-Claim
. I-Claim
!LF! !LF!
the O
tax O
327 O
study O
compared O
docetaxel O
administered O
every O
3 O
weeks O
( O
d3 O
) O
, O
weekly O
docetaxel O
( O
d1 O
) O
, O
and O
mitoxantrone O
( O
m O
) O
, O
each O
with O
prednisone O
( O
p O
) O
, O
in O
1 O
, O
006 O
men O
with O
metastatic O
hormone O
- O
resistant O
prostate O
cancer O
( O
hrpc O
) O
. O
!LF! !LF!
the O
original O
analysis O
, O
undertaken O
in O
august O
2003 O
when O
557 O
deaths O
had O
occurred O
, O
showed O
significantly O
better O
survival O
and O
response O
rates O
for O
pain O
, O
prostate O
- O
specific O
antigen O
( O
psa O
) O
, O
and O
quality O
of O
life O
for O
d3p O
when O
compared O
with O
mp O
. O
!LF! !LF!
here O
, O
we O
report O
an O
updated O
analysis O
of O
survival O
. O
!LF! !LF!
investigators O
were O
asked O
to O
provide O
the O
date O
of O
death O
or O
last O
follow O
- O
up O
for O
all O
participants O
who O
were O
alive O
in O
august O
2003 O
. O
!LF! !LF!
by O
march O
2007 O
, O
data O
on O
310 O
additional O
deaths O
were O
obtained O
( O
total O
= O
867 O
deaths O
) O
. O
!LF! !LF!
the B-Premise
survival I-Premise
benefit I-Premise
of I-Premise
d3p I-Premise
compared I-Premise
with I-Premise
mp I-Premise
has I-Premise
persisted I-Premise
with I-Premise
extended I-Premise
follow I-Premise
- I-Premise
up I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
004 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
median O
survival O
time O
was O
19 O
. O
2 O
months O
( O
95 O
% O
ci O
, O
17 O
. O
5 O
to O
21 O
. O
3 O
months O
) O
in O
the O
d3p O
arm O
, O
17 O
. O
8 O
months O
( O
95 O
% O
ci O
, O
16 O
. O
2 O
to O
19 O
. O
2 O
months O
) O
in O
the O
d1p O
arm O
, O
and O
16 O
. O
3 O
months O
( O
95 O
% O
ci O
, O
14 O
. O
3 O
to O
17 O
. O
9 O
months O
) O
in O
the O
mp O
arm O
. O
!LF! !LF!
more B-Premise
patients I-Premise
survived I-Premise
> I-Premise
/ I-Premise
= I-Premise
3 I-Premise
years I-Premise
in I-Premise
the I-Premise
d3p I-Premise
and I-Premise
d1p I-Premise
arms I-Premise
( I-Premise
18 I-Premise
. I-Premise
6 I-Premise
% I-Premise
and I-Premise
16 I-Premise
. I-Premise
6 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
mp I-Premise
arm I-Premise
( I-Premise
13 I-Premise
. I-Premise
5 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
similar B-Premise
trends I-Premise
in I-Premise
survival I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
were I-Premise
seen I-Premise
for I-Premise
men I-Premise
greater I-Premise
than I-Premise
and I-Premise
less I-Premise
than I-Premise
65 I-Premise
years I-Premise
of I-Premise
age I-Premise
, I-Premise
for I-Premise
those I-Premise
with I-Premise
and I-Premise
without I-Premise
pain I-Premise
at I-Premise
baseline I-Premise
, I-Premise
and I-Premise
for I-Premise
those I-Premise
with I-Premise
baseline I-Premise
psa I-Premise
greater I-Premise
than I-Premise
and I-Premise
less I-Premise
than I-Premise
the I-Premise
median I-Premise
value I-Premise
of I-Premise
115 I-Premise
ng I-Premise
/ I-Premise
ml I-Premise
. I-Premise
!LF! !LF!
the B-Claim
present I-Claim
analysis I-Claim
confirms I-Claim
that I-Claim
survival I-Claim
of I-Claim
men I-Claim
with I-Claim
metastatic I-Claim
hrpc I-Claim
is I-Claim
significantly I-Claim
longer I-Claim
after I-Claim
treatment I-Claim
with I-Claim
d3p I-Claim
than I-Claim
with I-Claim
mp I-Claim
. I-Claim
!LF! !LF!
consistent O
results O
are O
observed O
across O
subgroups O
of O
patients O
. O
!LF! !LF!
both O
gastrojejunostomy O
( O
gjj O
) O
and O
stent O
placement O
are O
commonly O
used O
palliative O
treatments O
of O
obstructive O
symptoms O
caused O
by O
malignant O
gastric O
outlet O
obstruction O
( O
goo O
) O
. O
!LF! !LF!
compare O
gjj O
and O
stent O
placement O
. O
!LF! !LF!
multicenter O
, O
randomized O
trial O
. O
!LF! !LF!
twenty O
- O
one O
centers O
in O
the O
netherlands O
. O
!LF! !LF!
patients O
with O
goo O
. O
!LF! !LF!
gjj O
and O
stent O
placement O
. O
!LF! !LF!
outcomes O
were O
medical O
effects O
, O
quality O
of O
life O
, O
and O
costs O
. O
!LF! !LF!
analysis O
was O
by O
intent O
to O
treat O
. O
!LF! !LF!
eighteen O
patients O
were O
randomized O
to O
gjj O
and O
21 O
to O
stent O
placement O
. O
!LF! !LF!
food B-Premise
intake I-Premise
improved I-Premise
more I-Premise
rapidly I-Premise
after I-Premise
stent I-Premise
placement I-Premise
than I-Premise
after I-Premise
gjj I-Premise
( I-Premise
goo I-Premise
scoring I-Premise
system I-Premise
score I-Premise
> I-Premise
or I-Premise
= I-Premise
2 I-Premise
: I-Premise
median I-Premise
5 I-Premise
vs I-Premise
8 I-Premise
days I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
. I-Premise
01 I-Premise
) I-Premise
but B-Premise
long I-Premise
- I-Premise
term I-Premise
relief I-Premise
was I-Premise
better I-Premise
after I-Premise
gjj I-Premise
, I-Premise
with I-Premise
more I-Premise
patients I-Premise
living I-Premise
more I-Premise
days I-Premise
with I-Premise
a I-Premise
goo I-Premise
scoring I-Premise
system I-Premise
score I-Premise
of I-Premise
2 I-Premise
or I-Premise
more I-Premise
than I-Premise
after I-Premise
stent I-Premise
placement I-Premise
( I-Premise
72 I-Premise
vs I-Premise
50 I-Premise
days I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
more B-Premise
major I-Premise
complications I-Premise
( I-Premise
stent I-Premise
: I-Premise
6 I-Premise
in I-Premise
4 I-Premise
patients I-Premise
vs I-Premise
gjj I-Premise
: I-Premise
0 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
02 I-Premise
) I-Premise
, I-Premise
recurrent I-Premise
obstructive I-Premise
symptoms I-Premise
( I-Premise
stent I-Premise
: I-Premise
8 I-Premise
in I-Premise
5 I-Premise
patients I-Premise
vs I-Premise
gjj I-Premise
: I-Premise
1 I-Premise
in I-Premise
1 I-Premise
patient I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
02 I-Premise
) I-Premise
, I-Premise
and I-Premise
reinterventions I-Premise
( I-Premise
stent I-Premise
: I-Premise
10 I-Premise
in I-Premise
7 I-Premise
patients I-Premise
vs I-Premise
gjj I-Premise
: I-Premise
2 I-Premise
in I-Premise
2 I-Premise
patients I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
. I-Premise
01 I-Premise
) I-Premise
were I-Premise
observed I-Premise
after I-Premise
stent I-Premise
placement I-Premise
compared I-Premise
with I-Premise
gjj I-Premise
. I-Premise
!LF! !LF!
when B-Premise
stent I-Premise
obstruction I-Premise
was I-Premise
not I-Premise
regarded I-Premise
as I-Premise
a I-Premise
major I-Premise
complication I-Premise
, I-Premise
no I-Premise
differences I-Premise
in I-Premise
complications I-Premise
were I-Premise
found I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
4 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
there B-Premise
were I-Premise
also I-Premise
no I-Premise
differences I-Premise
in I-Premise
median I-Premise
survival I-Premise
( I-Premise
stent I-Premise
: I-Premise
56 I-Premise
days I-Premise
vs I-Premise
gjj I-Premise
: I-Premise
78 I-Premise
days I-Premise
) I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise
!LF! !LF!
mean B-Premise
total I-Premise
costs I-Premise
of I-Premise
gjj I-Premise
were I-Premise
higher I-Premise
compared I-Premise
with I-Premise
stent I-Premise
placement I-Premise
( I-Premise
$ I-Premise
16 I-Premise
, I-Premise
535 I-Premise
vs I-Premise
$ I-Premise
11 I-Premise
, I-Premise
720 I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
049 I-Premise
[ I-Premise
comparing I-Premise
medians I-Premise
] I-Premise
) I-Premise
. I-Premise
!LF! !LF!
because O
of O
the O
small O
study O
population O
, O
only O
initial O
hospital O
costs O
would O
have O
been O
statistically O
significant O
if O
the O
bonferroni O
correction O
for O
multiple O
testing O
had O
been O
applied O
. O
!LF! !LF!
relatively O
small O
patient O
population O
. O
!LF! !LF!
despite B-Premise
slow I-Premise
initial I-Premise
symptom I-Premise
improvement I-Premise
, I-Premise
gjj B-Claim
was I-Claim
associated I-Claim
with I-Claim
better I-Claim
long I-Claim
- I-Claim
term I-Claim
results I-Claim
and I-Claim
is I-Claim
therefore I-Claim
the I-Claim
treatment I-Claim
of I-Claim
choice I-Claim
in I-Claim
patients I-Claim
with I-Claim
a I-Claim
life I-Claim
expectancy I-Claim
of I-Claim
2 I-Claim
months I-Claim
or I-Claim
longer I-Claim
. I-Claim
!LF! !LF!
because B-Claim
stent I-Claim
placement I-Claim
was I-Claim
associated I-Claim
with I-Claim
better I-Claim
short I-Claim
- I-Claim
term I-Claim
outcomes I-Claim
, I-Claim
this B-Claim
treatment I-Claim
is I-Claim
preferable I-Claim
for I-Claim
patients I-Claim
expected I-Claim
to I-Claim
live I-Claim
less I-Claim
than I-Claim
2 I-Claim
months I-Claim
. I-Claim
!LF! !LF!
vasomotor O
symptoms O
are O
common O
adverse O
effects O
of O
antiestrogen O
hormone O
treatment O
in O
conventional O
breast O
cancer O
care O
. O
!LF! !LF!
hormone O
replacement O
therapy O
is O
contraindicated O
in O
patients O
with O
breast O
cancer O
. O
!LF! !LF!
venlafaxine O
( O
effexor O
) O
, O
the O
therapy O
of O
choice O
for O
these O
symptoms O
, O
has O
numerous O
adverse O
effects O
. O
!LF! !LF!
recent O
studies O
suggest O
acupuncture O
may O
be O
effective O
in O
reducing O
vasomotor O
symptoms O
in O
menopausal O
women O
. O
!LF! !LF!
this O
randomized O
controlled O
trial O
tested O
whether O
acupuncture O
reduces O
vasomotor O
symptoms O
and O
produces O
fewer O
adverse O
effects O
than O
venlafaxine O
. O
!LF! !LF!
fifty O
patients O
were O
randomly O
assigned O
to O
receive O
12 O
weeks O
of O
acupuncture O
( O
n O
= O
25 O
) O
or O
venlafaxine O
( O
n O
= O
25 O
) O
treatment O
. O
!LF! !LF!
health O
outcomes O
were O
measured O
for O
up O
to O
1 O
year O
post O
- O
treatment O
. O
!LF! !LF!
both B-Premise
groups I-Premise
exhibited I-Premise
significant I-Premise
decreases I-Premise
in I-Premise
hot I-Premise
flashes I-Premise
, I-Premise
depressive I-Premise
symptoms I-Premise
, I-Premise
and I-Premise
other I-Premise
quality I-Premise
- I-Premise
of I-Premise
- I-Premise
life I-Premise
symptoms I-Premise
, I-Premise
including I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
mental I-Premise
health I-Premise
from I-Premise
pre I-Premise
- I-Premise
to I-Premise
post I-Premise
- I-Premise
treatment I-Premise
. I-Premise
!LF! !LF!
these B-Premise
changes I-Premise
were I-Premise
similar I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
indicating I-Premise
that I-Premise
acupuncture I-Premise
was I-Premise
as I-Premise
effective I-Premise
as I-Premise
venlafaxine I-Premise
. I-Premise
!LF! !LF!
by B-Premise
2 I-Premise
weeks I-Premise
post I-Premise
- I-Premise
treatment I-Premise
, I-Premise
the I-Premise
venlafaxine I-Premise
group I-Premise
experienced I-Premise
significant I-Premise
increases I-Premise
in I-Premise
hot I-Premise
flashes I-Premise
, I-Premise
whereas I-Premise
hot I-Premise
flashes I-Premise
in I-Premise
the I-Premise
acupuncture I-Premise
group I-Premise
remained I-Premise
at I-Premise
low I-Premise
levels I-Premise
. I-Premise
!LF! !LF!
the B-Premise
venlafaxine I-Premise
group I-Premise
experienced I-Premise
18 I-Premise
incidences I-Premise
of I-Premise
adverse I-Premise
effects I-Premise
( I-Premise
eg I-Premise
, I-Premise
nausea I-Premise
, I-Premise
dry I-Premise
mouth I-Premise
, I-Premise
dizziness I-Premise
, I-Premise
anxiety I-Premise
) I-Premise
, I-Premise
whereas I-Premise
the I-Premise
acupuncture I-Premise
group I-Premise
experienced I-Premise
no I-Premise
negative I-Premise
adverse I-Premise
effects I-Premise
. I-Premise
!LF! !LF!
acupuncture B-Premise
had I-Premise
the I-Premise
additional I-Premise
benefit I-Premise
of I-Premise
increased I-Premise
sex I-Premise
drive I-Premise
in I-Premise
some I-Premise
women I-Premise
, I-Premise
and I-Premise
most I-Premise
reported I-Premise
an I-Premise
improvement I-Premise
in I-Premise
their I-Premise
energy I-Premise
, I-Premise
clarity I-Premise
of I-Premise
thought I-Premise
, I-Premise
and I-Premise
sense I-Premise
of I-Premise
well I-Premise
- I-Premise
being I-Premise
. I-Premise
!LF! !LF!
acupuncture B-Claim
appears I-Claim
to I-Claim
be I-Claim
equivalent I-Claim
to I-Claim
drug I-Claim
therapy I-Claim
in I-Claim
these I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
it B-Claim
is I-Claim
a I-Claim
safe I-Claim
, I-Claim
effective I-Claim
and I-Claim
durable I-Claim
treatment I-Claim
for I-Claim
vasomotor I-Claim
symptoms I-Claim
secondary I-Claim
to I-Claim
long I-Claim
- I-Claim
term I-Claim
antiestrogen I-Claim
hormone I-Claim
use I-Claim
in I-Claim
patients I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
surgical O
resection O
is O
regarded O
as O
the O
only O
curative O
option O
for O
resectable O
oesophageal O
cancer O
, O
but O
pulmonary O
complications O
occurring O
in O
more O
than O
half O
of O
patients O
after O
open O
oesophagectomy O
are O
a O
great O
concern O
. O
!LF! !LF!
we O
assessed O
whether O
minimally O
invasive O
oesophagectomy O
reduces O
morbidity O
compared O
with O
open O
oesophagectomy O
. O
!LF! !LF!
we O
did O
a O
multicentre O
, O
open O
- O
label O
, O
randomised O
controlled O
trial O
at O
five O
study O
centres O
in O
three O
countries O
between O
june O
1 O
, O
2009 O
, O
and O
march O
31 O
, O
2011 O
. O
!LF! !LF!
patients O
aged O
18 O
- O
75 O
years O
with O
resectable O
cancer O
of O
the O
oesophagus O
or O
gastro O
- O
oesophageal O
junction O
were O
randomly O
assigned O
via O
a O
computer O
- O
generated O
randomisation O
sequence O
to O
receive O
either O
open O
transthoracic O
or O
minimally O
invasive O
transthoracic O
oesophagectomy O
. O
!LF! !LF!
randomisation O
was O
stratified O
by O
centre O
. O
!LF! !LF!
patients O
, O
and O
investigators O
undertaking O
interventions O
, O
assessing O
outcomes O
, O
and O
analysing O
data O
, O
were O
not O
masked O
to O
group O
assignment O
. O
!LF! !LF!
the O
primary O
outcome O
was O
pulmonary O
infection O
within O
the O
first O
2 O
weeks O
after O
surgery O
and O
during O
the O
whole O
stay O
in O
hospital O
. O
!LF! !LF!
analysis O
was O
by O
intention O
to O
treat O
. O
!LF! !LF!
this O
trial O
is O
registered O
with O
the O
netherlands O
trial O
register O
, O
ntr O
tc O
2452 O
. O
!LF! !LF!
we O
randomly O
assigned O
56 O
patients O
to O
the O
open O
oesophagectomy O
group O
and O
59 O
to O
the O
minimally O
invasive O
oesophagectomy O
group O
. O
!LF! !LF!
16 B-Premise
( I-Premise
29 I-Premise
% I-Premise
) I-Premise
patients I-Premise
in I-Premise
the I-Premise
open I-Premise
oesophagectomy I-Premise
group I-Premise
had I-Premise
pulmonary I-Premise
infection I-Premise
in I-Premise
the I-Premise
first I-Premise
2 I-Premise
weeks I-Premise
compared I-Premise
with I-Premise
five I-Premise
( I-Premise
9 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
minimally I-Premise
invasive I-Premise
group I-Premise
( I-Premise
relative I-Premise
risk I-Premise
[ I-Premise
rr I-Premise
] I-Premise
0 I-Premise
· I-Premise
30 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
· I-Premise
12 I-Premise
- I-Premise
0 I-Premise
· I-Premise
76 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
· I-Premise
005 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
19 B-Premise
( I-Premise
34 I-Premise
% I-Premise
) I-Premise
patients I-Premise
in I-Premise
the I-Premise
open I-Premise
oesophagectomy I-Premise
group I-Premise
had I-Premise
pulmonary I-Premise
infection I-Premise
in I-Premise
- I-Premise
hospital I-Premise
compared I-Premise
with I-Premise
seven I-Premise
( I-Premise
12 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
minimally I-Premise
invasive I-Premise
group I-Premise
( I-Premise
0 I-Premise
· I-Premise
35 I-Premise
, I-Premise
0 I-Premise
· I-Premise
16 I-Premise
- I-Premise
0 I-Premise
· I-Premise
78 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
· I-Premise
005 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
for B-Premise
in I-Premise
- I-Premise
hospital I-Premise
mortality I-Premise
, I-Premise
one I-Premise
patient I-Premise
in I-Premise
the I-Premise
open I-Premise
oesophagectomy I-Premise
group I-Premise
died I-Premise
from I-Premise
anastomotic I-Premise
leakage I-Premise
and I-Premise
two I-Premise
in I-Premise
the I-Premise
minimally I-Premise
invasive I-Premise
group I-Premise
from I-Premise
aspiration I-Premise
and I-Premise
mediastinitis I-Premise
after I-Premise
anastomotic I-Premise
leakage I-Premise
. I-Premise
!LF! !LF!
these B-Claim
findings I-Claim
provide I-Claim
evidence I-Claim
for I-Claim
the I-Claim
short I-Claim
- I-Claim
term I-Claim
benefits I-Claim
of I-Claim
minimally I-Claim
invasive I-Claim
oesophagectomy I-Claim
for I-Claim
patients I-Claim
with I-Claim
resectable I-Claim
oesophageal I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
we O
aimed O
to O
assess O
the O
effectiveness O
of O
acupuncture O
for O
cancer O
- O
related O
fatigue O
( O
crf O
) O
in O
patients O
with O
breast O
cancer O
. O
!LF! !LF!
we O
conducted O
a O
pragmatic O
, O
randomized O
controlled O
trial O
comparing O
acupuncture O
with O
enhanced O
usual O
care O
. O
!LF! !LF!
three O
hundred O
two O
outpatients O
with O
breast O
cancer O
participated O
. O
!LF! !LF!
we O
randomly O
assigned O
75 O
patients O
to O
usual O
care O
and O
227 O
patients O
to O
acupuncture O
plus O
usual O
care O
( O
random O
assignment O
of O
1 O
: O
3 O
respectively O
) O
with O
minimization O
controlling O
for O
baseline O
general O
fatigue O
and O
maintenance O
treatment O
. O
!LF! !LF!
treatment O
was O
delivered O
by O
acupuncturists O
once O
a O
week O
for O
6 O
weeks O
through O
needling O
three O
pairs O
of O
acupoints O
. O
!LF! !LF!
the O
usual O
care O
group O
received O
a O
booklet O
with O
information O
about O
fatigue O
and O
its O
management O
. O
!LF! !LF!
primary O
outcome O
was O
general O
fatigue O
at O
6 O
weeks O
, O
measured O
with O
the O
multidimensional O
fatigue O
inventory O
( O
mfi O
) O
. O
!LF! !LF!
other O
measurements O
included O
the O
hospital O
anxiety O
and O
depression O
scale O
, O
functional O
assessment O
of O
cancer O
therapy O
- O
general O
quality O
- O
of O
- O
life O
scale O
, O
and O
expectation O
of O
acupuncture O
effect O
. O
!LF! !LF!
analyses O
were O
by O
intention O
to O
treat O
. O
!LF! !LF!
two O
hundred O
forty O
- O
six O
of O
302 O
patients O
randomly O
assigned O
provided O
complete O
data O
at O
6 O
weeks O
. O
!LF! !LF!
the B-Premise
difference I-Premise
in I-Premise
the I-Premise
mean I-Premise
general I-Premise
fatigue I-Premise
score I-Premise
, I-Premise
between I-Premise
those I-Premise
who I-Premise
received I-Premise
the I-Premise
intervention I-Premise
and I-Premise
those I-Premise
who I-Premise
did I-Premise
not I-Premise
, I-Premise
was I-Premise
- I-Premise
3 I-Premise
. I-Premise
11 I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
- I-Premise
3 I-Premise
. I-Premise
97 I-Premise
to I-Premise
- I-Premise
2 I-Premise
. I-Premise
25 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
intervention I-Premise
also I-Premise
improved I-Premise
all I-Premise
other I-Premise
fatigue I-Premise
aspects I-Premise
measured I-Premise
by I-Premise
mfi I-Premise
, I-Premise
including I-Premise
physical I-Premise
fatigue I-Premise
and I-Premise
mental I-Premise
fatigue I-Premise
( I-Premise
acupuncture I-Premise
effect I-Premise
, I-Premise
- I-Premise
2 I-Premise
. I-Premise
36 I-Premise
and I-Premise
- I-Premise
1 I-Premise
. I-Premise
94 I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
both I-Premise
at I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
anxiety I-Premise
and I-Premise
depression I-Premise
( I-Premise
acupuncture I-Premise
effect I-Premise
, I-Premise
- I-Premise
1 I-Premise
. I-Premise
83 I-Premise
and I-Premise
- I-Premise
2 I-Premise
. I-Premise
13 I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
both I-Premise
at I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
physical I-Premise
well I-Premise
- I-Premise
being I-Premise
effect I-Premise
, I-Premise
3 I-Premise
. I-Premise
30 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
functional I-Premise
well I-Premise
- I-Premise
being I-Premise
effect I-Premise
, I-Premise
3 I-Premise
. I-Premise
57 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
both I-Premise
at I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
emotional I-Premise
well I-Premise
- I-Premise
being I-Premise
effect I-Premise
, I-Premise
1 I-Premise
. I-Premise
93 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
001 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
and I-Premise
social I-Premise
functioning I-Premise
well I-Premise
- I-Premise
being I-Premise
effect I-Premise
, I-Premise
1 I-Premise
. I-Premise
05 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
acupuncture B-Claim
is I-Claim
an I-Claim
effective I-Claim
intervention I-Claim
for I-Claim
managing I-Claim
the I-Claim
symptom I-Claim
of I-Claim
crf I-Claim
and I-Claim
improving I-Claim
patients I-Claim
' I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim
!LF! !LF!
the O
intergroup O
conducted O
this O
breast O
cancer O
adjuvant O
trial O
to O
compare O
an O
investigational O
16 O
- O
week O
regimen O
with O
cyclophosphamide O
, O
doxorubicin O
, O
and O
fluorouracil O
( O
5 O
- O
fu O
"""" O
; O
"""" O
caf O
) O
. O
!LF! !LF!
the O
16 O
- O
week O
regimen O
features O
greater O
doxorubicin O
and O
5 O
- O
fu O
dose O
- O
intensity O
than O
caf O
and O
improved O
scheduling O
of O
antimetabolites O
with O
sequential O
methotrexate O
and O
5 O
- O
fu O
, O
as O
well O
as O
infusion O
5 O
- O
fu O
. O
!LF! !LF!
a O
total O
of O
646 O
node O
- O
positive O
, O
receptor O
- O
negative O
patients O
were O
randomly O
assigned O
to O
receive O
either O
the O
1 O
6 O
- O
week O
regimen O
or O
six O
cycles O
of O
caf O
. O
!LF! !LF!
breast O
cancer O
outcomes O
included O
recurrence O
as O
well O
as O
disease O
- O
free O
and O
overall O
survival O
. O
!LF! !LF!
toxicity O
was O
evaluated O
by O
the O
common O
toxicity O
criteria O
( O
ctc O
) O
. O
!LF! !LF!
treatment O
- O
related O
quality O
of O
life O
was O
assessed O
by O
the O
breast O
chemotherapy O
questionnaire O
( O
bcq O
) O
before O
, O
during O
, O
and O
4 O
months O
after O
treatment O
in O
163 O
patients O
. O
!LF! !LF!
the O
trial O
was O
designed O
to O
use O
one O
- O
sided O
tests O
of O
significance O
for O
power O
calculations O
, O
but O
is O
now O
reported O
with O
both O
one O
- O
sided O
and O
the O
traditional O
two O
- O
sided O
tests O
of O
significance O
. O
!LF! !LF!
at B-Premise
a I-Premise
median I-Premise
follow I-Premise
- I-Premise
up I-Premise
of I-Premise
3 I-Premise
. I-Premise
9 I-Premise
years I-Premise
, I-Premise
the I-Premise
estimated I-Premise
4 I-Premise
- I-Premise
year I-Premise
recurrence I-Premise
- I-Premise
free I-Premise
survival I-Premise
rate I-Premise
was I-Premise
67 I-Premise
. I-Premise
5 I-Premise
% I-Premise
with I-Premise
the I-Premise
16 I-Premise
- I-Premise
week I-Premise
regimen I-Premise
versus I-Premise
62 I-Premise
. I-Premise
7 I-Premise
% I-Premise
with I-Premise
caf I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
19 I-Premise
, I-Premise
two I-Premise
- I-Premise
sided I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
095 I-Premise
, I-Premise
one I-Premise
- I-Premise
sided I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
estimated I-Premise
4 I-Premise
- I-Premise
year I-Premise
survival I-Premise
rate I-Premise
was I-Premise
78 I-Premise
. I-Premise
1 I-Premise
% I-Premise
with I-Premise
the I-Premise
16 I-Premise
- I-Premise
week I-Premise
regimen I-Premise
versus I-Premise
71 I-Premise
. I-Premise
4 I-Premise
% I-Premise
with I-Premise
caf I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
10 I-Premise
, I-Premise
two I-Premise
- I-Premise
sided I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
05 I-Premise
, I-Premise
one I-Premise
- I-Premise
sided I-Premise
) I-Premise
. I-Premise
!LF! !LF!
caf B-Premise
produced I-Premise
significantly I-Premise
higher I-Premise
grades I-Premise
of I-Premise
leukopenia I-Premise
, I-Premise
granulocytopenia I-Premise
, I-Premise
and I-Premise
thrombocytopenia I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
liver I-Premise
and I-Premise
cardiac I-Premise
toxicity I-Premise
, I-Premise
whereas O
the B-Premise
16 I-Premise
- I-Premise
week I-Premise
regimen I-Premise
produced I-Premise
significantly I-Premise
higher I-Premise
grades I-Premise
of I-Premise
anemia I-Premise
, I-Premise
nausea I-Premise
, I-Premise
stomatitis I-Premise
, I-Premise
and I-Premise
weight I-Premise
loss I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
skin I-Premise
and I-Premise
neurotoxicity I-Premise
. I-Premise
!LF! !LF!
there B-Premise
were I-Premise
three I-Premise
treatment I-Premise
- I-Premise
related I-Premise
deaths I-Premise
with I-Premise
caf I-Premise
but B-Premise
none I-Premise
with I-Premise
the I-Premise
16 I-Premise
- I-Premise
week I-Premise
regimen I-Premise
. I-Premise
!LF! !LF!
during B-Premise
treatment I-Premise
, I-Premise
quality I-Premise
of I-Premise
life I-Premise
declined I-Premise
significantly I-Premise
more I-Premise
with I-Premise
the I-Premise
16 I-Premise
- I-Premise
week I-Premise
regimen I-Premise
than I-Premise
caf I-Premise
, I-Premise
but B-Premise
by I-Premise
4 I-Premise
months I-Premise
posttreatment I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
difference I-Premise
. I-Premise
!LF! !LF!
the B-Premise
16 I-Premise
- I-Premise
week I-Premise
regimen I-Premise
produced I-Premise
marginally I-Premise
better I-Premise
breast I-Premise
cancer I-Premise
outcomes I-Premise
than I-Premise
caf I-Premise
with I-Premise
similar I-Premise
toxicity I-Premise
but I-Premise
a I-Premise
greater I-Premise
reduction I-Premise
in I-Premise
during I-Premise
- I-Premise
treatment I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise
!LF! !LF!
the B-Claim
16 I-Claim
- I-Claim
week I-Claim
regimen I-Claim
should I-Claim
not I-Claim
be I-Claim
used I-Claim
instead I-Claim
of I-Claim
a I-Claim
standard I-Claim
- I-Claim
dose I-Claim
regimen I-Claim
without I-Claim
careful I-Claim
consideration I-Claim
of I-Claim
the I-Claim
16 I-Claim
- I-Claim
week I-Claim
regimen I-Claim
' I-Claim
s I-Claim
pros I-Claim
and I-Claim
cons I-Claim
, I-Claim
which I-Claim
include I-Claim
its I-Claim
complicated I-Claim
schedule I-Claim
. I-Claim
!LF! !LF!
it B-Claim
should I-Claim
probably I-Claim
not I-Claim
be I-Claim
tested I-Claim
further I-Claim
, I-Claim
but B-Claim
its I-Claim
antimetabolite I-Claim
schedules I-Claim
and I-Claim
frequent I-Claim
drug I-Claim
administration I-Claim
( I-Claim
ie I-Claim
, I-Claim
dose I-Claim
density I-Claim
) I-Claim
should I-Claim
be I-Claim
considered I-Claim
in I-Claim
the I-Claim
development I-Claim
of I-Claim
new I-Claim
regimens I-Claim
. I-Claim
!LF! !LF!
the O
aim O
of O
the O
study O
is O
to O
demonstrate O
that O
intrapatient O
dose O
escalation O
of O
carboplatin O
would O
improve O
the O
outcome O
in O
ovarian O
cancer O
compared O
with O
flat O
dosing O
. O
!LF! !LF!
patients O
with O
untreated O
stage O
ic O
- O
iv O
ovarian O
cancer O
received O
six O
cycles O
of O
carboplatin O
area O
under O
the O
curve O
6 O
( O
auc O
6 O
) O
3 O
weekly O
either O
with O
no O
dose O
modification O
except O
for O
toxicity O
( O
arm O
a O
) O
or O
with O
dose O
escalations O
in O
cycles O
2 O
- O
6 O
based O
on O
nadir O
neutrophil O
and O
platelet O
counts O
( O
arm O
b O
) O
. O
!LF! !LF!
the O
primary O
end O
- O
point O
was O
progression O
- O
free O
survival O
( O
pfs O
) O
. O
!LF! !LF!
nine O
hundred O
and O
sixty O
- O
four O
patients O
were O
recruited O
from O
71 O
centers O
. O
!LF! !LF!
dose O
escalation O
was O
achieved O
in O
77 O
% O
of O
patients O
who O
had O
≥1 O
cycle O
. O
!LF! !LF!
the B-Premise
median I-Premise
aucs I-Premise
( I-Premise
cycle I-Premise
2 I-Premise
- I-Premise
6 I-Premise
) I-Premise
received I-Premise
were I-Premise
6 I-Premise
. I-Premise
0 I-Premise
( I-Premise
arm I-Premise
a I-Premise
) I-Premise
and I-Premise
7 I-Premise
. I-Premise
2 I-Premise
( I-Premise
arm I-Premise
b I-Premise
) I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
grade B-Premise
3 I-Premise
/ I-Premise
4 I-Premise
non I-Premise
- I-Premise
hematological I-Premise
toxicity I-Premise
was I-Premise
higher I-Premise
in I-Premise
arm I-Premise
b I-Premise
( I-Premise
31 I-Premise
% I-Premise
versus I-Premise
22 I-Premise
% I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
median I-Premise
pfs I-Premise
was I-Premise
12 I-Premise
. I-Premise
1 I-Premise
months I-Premise
in I-Premise
arm I-Premise
a I-Premise
and I-Premise
b I-Premise
[ I-Premise
hazard I-Premise
ratio I-Premise
( I-Premise
hr I-Premise
) I-Premise
0 I-Premise
. I-Premise
99 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
ci I-Premise
) I-Premise
0 I-Premise
. I-Premise
85 I-Premise
- I-Premise
1 I-Premise
. I-Premise
15 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
93 I-Premise
] I-Premise
. I-Premise
!LF! !LF!
the B-Premise
median I-Premise
overall I-Premise
survival I-Premise
( I-Premise
os I-Premise
) I-Premise
was I-Premise
34 I-Premise
. I-Premise
1 I-Premise
and I-Premise
30 I-Premise
. I-Premise
7 I-Premise
months I-Premise
in I-Premise
arms I-Premise
a I-Premise
and I-Premise
b I-Premise
, I-Premise
respectively I-Premise
( I-Premise
hr I-Premise
0 I-Premise
. I-Premise
98 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
. I-Premise
81 I-Premise
- I-Premise
1 I-Premise
. I-Premise
18 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
82 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
in B-Premise
multivariate I-Premise
analysis I-Premise
, I-Premise
baseline I-Premise
neutrophil I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
baseline I-Premise
platelet I-Premise
counts I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
and I-Premise
the I-Premise
difference I-Premise
between I-Premise
white I-Premise
blood I-Premise
cell I-Premise
( I-Premise
wbc I-Premise
) I-Premise
and I-Premise
neutrophil I-Premise
count I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
009 I-Premise
) I-Premise
had I-Premise
a I-Premise
significant I-Premise
adverse I-Premise
prognostic I-Premise
value I-Premise
. I-Premise
!LF! !LF!
intrapatient B-Claim
dose I-Claim
escalation I-Claim
of I-Claim
carboplatin I-Claim
based I-Claim
on I-Claim
nadir I-Claim
blood I-Claim
counts I-Claim
is I-Claim
feasible I-Claim
and I-Claim
safe I-Claim
. I-Claim
!LF! !LF!
however B-Claim
, I-Claim
it I-Claim
provided I-Claim
no I-Claim
improvement I-Claim
in I-Claim
pfs I-Claim
or I-Claim
os I-Claim
compared I-Claim
with I-Claim
flat I-Claim
dosing I-Claim
. I-Claim
!LF! !LF!
baseline O
neutrophils O
over O
- O
ride O
nadir O
counts O
in O
prognostic O
significance O
. O
!LF! !LF!
these O
data O
may O
have O
wider O
implications O
particularly O
in O
respect O
of O
the O
management O
of O
chemotherapy O
- O
induced O
neutropenia O
. O
!LF! !LF!
lymphoma O
patients O
commonly O
experience O
declines O
in O
physical O
functioning O
and O
quality O
of O
life O
( O
qol O
) O
that O
may O
be O
reversed O
with O
exercise O
training O
. O
!LF! !LF!
we O
conducted O
a O
randomized O
controlled O
trial O
in O
edmonton O
, O
alberta O
, O
canada O
, O
between O
2005 O
and O
2008 O
that O
stratified O
122 O
lymphoma O
patients O
by O
major O
disease O
type O
and O
current O
treatment O
status O
and O
randomly O
assigned O
them O
to O
usual O
care O
( O
uc O
"""" O
; O
"""" O
n O
= O
62 O
) O
or O
12 O
weeks O
of O
supervised O
aerobic O
exercise O
training O
( O
aet O
"""" O
; O
"""" O
n O
= O
60 O
) O
. O
!LF! !LF!
our O
primary O
end O
point O
was O
patient O
- O
rated O
physical O
functioning O
assessed O
by O
the O
trial O
outcome O
index O
- O
anemia O
. O
!LF! !LF!
secondary O
end O
points O
were O
overall O
qol O
, O
psychosocial O
functioning O
, O
cardiovascular O
fitness O
, O
and O
body O
composition O
. O
!LF! !LF!
follow O
- O
up O
assessment O
for O
our O
primary O
end O
point O
was O
96 O
% O
( O
117 O
of O
122 O
) O
at O
postintervention O
and O
90 O
% O
( O
110 O
of O
122 O
) O
at O
6 O
- O
month O
follow O
- O
up O
. O
!LF! !LF!
median O
adherence O
to O
the O
supervised O
exercise O
program O
was O
92 O
% O
. O
!LF! !LF!
at B-Premise
postintervention I-Premise
, I-Premise
aet I-Premise
was I-Premise
superior I-Premise
to I-Premise
uc I-Premise
for I-Premise
patient I-Premise
- I-Premise
rated I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
mean I-Premise
group I-Premise
difference I-Premise
, I-Premise
+ I-Premise
9 I-Premise
. I-Premise
0 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
2 I-Premise
. I-Premise
0 I-Premise
to I-Premise
16 I-Premise
. I-Premise
0 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
012 I-Premise
) I-Premise
, I-Premise
overall I-Premise
qol I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
021 I-Premise
) I-Premise
, I-Premise
fatigue I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
013 I-Premise
) I-Premise
, I-Premise
happiness I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
004 I-Premise
) I-Premise
, I-Premise
depression I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
005 I-Premise
) I-Premise
, I-Premise
general I-Premise
health I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
cardiovascular I-Premise
fitness I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
and I-Premise
lean I-Premise
body I-Premise
mass I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
008 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
change O
in O
peak O
cardiovascular O
fitness O
mediated O
the O
change O
in O
patient O
- O
rated O
physical O
functioning O
. O
!LF! !LF!
aet B-Premise
did I-Premise
not I-Premise
interfere I-Premise
with I-Premise
chemotherapy I-Premise
completion I-Premise
rate I-Premise
or I-Premise
treatment I-Premise
response I-Premise
. I-Premise
!LF! !LF!
at B-Premise
6 I-Premise
- I-Premise
month I-Premise
follow I-Premise
- I-Premise
up I-Premise
, I-Premise
aet I-Premise
was I-Premise
still I-Premise
borderline I-Premise
or I-Premise
significantly I-Premise
superior I-Premise
to I-Premise
uc I-Premise
for I-Premise
overall I-Premise
qol I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
054 I-Premise
) I-Premise
, I-Premise
happiness I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
034 I-Premise
) I-Premise
, I-Premise
and I-Premise
depression I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
009 I-Premise
) I-Premise
without I-Premise
an I-Premise
increased I-Premise
risk I-Premise
of I-Premise
disease I-Premise
recurrence I-Premise
/ I-Premise
progression I-Premise
. I-Premise
!LF! !LF!
aet B-Claim
significantly I-Claim
improved I-Claim
important I-Claim
patient I-Claim
- I-Claim
rated I-Claim
outcomes I-Claim
and I-Claim
objective I-Claim
physical I-Claim
functioning I-Claim
in I-Claim
lymphoma I-Claim
patients I-Claim
without I-Claim
interfering I-Claim
with I-Claim
medical I-Claim
treatments I-Claim
or I-Claim
response I-Claim
. I-Claim
!LF! !LF!
exercise B-Claim
training I-Claim
to I-Claim
improve I-Claim
cardiovascular I-Claim
fitness I-Claim
should I-Claim
be I-Claim
considered I-Claim
in I-Claim
the I-Claim
management I-Claim
of I-Claim
lymphoma I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
the O
purpose O
of O
this O
blinded O
, O
randomized O
clinical O
trial O
was O
to O
compare O
two O
topical O
agents O
( O
calendula O
weleda O
cream O
vs O
. O
essex O
cream O
) O
in O
reducing O
the O
risk O
of O
severe O
acute O
radiation O
skin O
reactions O
( O
arsr O
) O
in O
relation O
to O
adjuvant O
radiotherapy O
( O
rt O
) O
for O
breast O
cancer O
. O
!LF! !LF!
the O
primary O
endpoint O
was O
the O
difference O
in O
proportion O
of O
patients O
with O
arsr O
, O
assessed O
with O
the O
radiation O
therapy O
oncology O
group O
/ O
the O
organization O
for O
research O
and O
treatment O
of O
cancer O
acute O
radiation O
morbidity O
scoring O
criteria O
( O
rtog O
/ O
eortc O
scale O
) O
at O
follow O
- O
up O
. O
!LF! !LF!
the O
secondary O
endpoints O
included O
patient O
reported O
outcome O
measures O
"""" O
; O
"""" O
quality O
of O
life O
questionnaire O
( O
qlq O
- O
c30 O
) O
, O
sleep O
disturbances O
( O
mos O
- O
sleep O
questionnaire O
) O
and O
symptoms O
from O
the O
irradiated O
area O
( O
visual O
analogue O
scale O
) O
. O
!LF! !LF!
patients O
' O
experiences O
and O
adherence O
to O
the O
topical O
agents O
were O
also O
evaluated O
. O
!LF! !LF!
a O
total O
of O
420 O
patients O
were O
randomised O
and O
411 O
were O
analysed O
. O
!LF! !LF!
with O
the O
exception O
of O
previous O
chemotherapy O
, O
the O
treatment O
groups O
were O
well O
balanced O
, O
both O
regarding O
treatment O
- O
and O
patient O
- O
related O
factors O
. O
!LF! !LF!
the B-Premise
incidence I-Premise
of I-Premise
severe I-Premise
arsr I-Premise
( I-Premise
rtog I-Premise
/ I-Premise
eortc I-Premise
grade I-Premise
≤2 I-Premise
) I-Premise
at I-Premise
the I-Premise
follow I-Premise
- I-Premise
up I-Premise
visit I-Premise
was I-Premise
23 I-Premise
% I-Premise
( I-Premise
n I-Premise
= I-Premise
45 I-Premise
) I-Premise
in I-Premise
the I-Premise
calendula I-Premise
group I-Premise
and I-Premise
19 I-Premise
% I-Premise
( I-Premise
n I-Premise
= I-Premise
38 I-Premise
) I-Premise
in I-Premise
the I-Premise
essex I-Premise
group I-Premise
. I-Premise
!LF! !LF!
we B-Premise
found I-Premise
no I-Premise
difference I-Premise
in I-Premise
severe I-Premise
arsr I-Premise
between I-Premise
the I-Premise
groups I-Premise
at I-Premise
any I-Premise
point I-Premise
of I-Premise
assessment I-Premise
. I-Premise
!LF! !LF!
the B-Premise
patients I-Premise
reported I-Premise
low I-Premise
levels I-Premise
of I-Premise
skin I-Premise
related I-Premise
symptoms I-Premise
and I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
groups I-Premise
were I-Premise
found I-Premise
. I-Premise
!LF! !LF!
no B-Claim
differences I-Claim
in I-Claim
arsr I-Claim
between I-Claim
patients I-Claim
randomised I-Claim
to I-Claim
calendula I-Claim
or I-Claim
essex I-Claim
cream I-Claim
was I-Claim
found I-Claim
. I-Claim
!LF! !LF!
arsr B-Claim
seem I-Claim
to I-Claim
be I-Claim
a I-Claim
relatively I-Claim
limited I-Claim
problem I-Claim
, I-Claim
probably I-Claim
more I-Claim
influenced I-Claim
by I-Claim
treatment I-Claim
related I-Claim
factors I-Claim
than I-Claim
by I-Claim
choice I-Claim
of I-Claim
skin I-Claim
care I-Claim
products I-Claim
in I-Claim
this I-Claim
patient I-Claim
group I-Claim
. I-Claim
!LF! !LF!
an O
open O
, O
randomized O
study O
was O
performed O
to O
assess O
the O
effects O
of O
supportive O
pamidronate O
treatment O
on O
morbidity O
from O
bone O
metastases O
in O
breast O
cancer O
patients O
. O
!LF! !LF!
eighty O
- O
one O
pamidronate O
patients O
and O
80 O
control O
patients O
were O
monitored O
for O
a O
median O
of O
18 O
and O
21 O
months O
, O
respectively O
, O
for O
events O
of O
skeletal O
morbidity O
and O
the O
radiologic O
course O
of O
metastatic O
bone O
disease O
. O
!LF! !LF!
the O
oral O
pamidronate O
dose O
was O
600 O
mg O
/ O
d O
( O
high O
dose O
[ O
hd O
] O
) O
during O
the O
earliest O
study O
years O
, O
then O
changed O
to O
300 O
mg O
/ O
d O
( O
low O
dose O
[ O
ld O
] O
) O
because O
of O
gastrointestinal O
toxicity O
. O
!LF! !LF!
twenty O
- O
nine O
of O
81 O
pamidronate O
( O
hd O
/ O
ld O
) O
patients O
first O
received O
600 O
mg O
/ O
d O
and O
were O
then O
changed O
to O
300 O
mg O
/ O
d O
"""" O
; O
"""" O
52 O
of O
81 O
pamidronate O
ld O
patients O
received O
300 O
mg O
/ O
d O
throughout O
the O
study O
. O
!LF! !LF!
tumor O
treatment O
was O
unrestricted O
. O
!LF! !LF!
an O
overall O
intent O
- O
to O
- O
treat O
analysis O
was O
performed O
. O
!LF! !LF!
in B-Premise
the I-Premise
pamidronate I-Premise
group I-Premise
, I-Premise
the I-Premise
occurrence I-Premise
of I-Premise
hypercalcemia I-Premise
, I-Premise
severe I-Premise
bone I-Premise
pain I-Premise
, I-Premise
and I-Premise
symptomatic I-Premise
impending I-Premise
fractures I-Premise
decreased I-Premise
by I-Premise
65 I-Premise
% I-Premise
, I-Premise
30 I-Premise
% I-Premise
, I-Premise
and I-Premise
50 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
event I-Premise
- I-Premise
rates I-Premise
of I-Premise
systemic I-Premise
treatment I-Premise
and I-Premise
radiotherapy I-Premise
decreased I-Premise
by I-Premise
35 I-Premise
% I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
event I-Premise
- I-Premise
free I-Premise
period I-Premise
( I-Premise
efp I-Premise
) I-Premise
, I-Premise
radiologic I-Premise
course I-Premise
of I-Premise
disease I-Premise
, I-Premise
and I-Premise
survival I-Premise
did I-Premise
not I-Premise
improve I-Premise
. I-Premise
!LF! !LF!
subgroup B-Claim
analyses I-Claim
suggested I-Claim
a I-Claim
dose I-Claim
- I-Claim
dependent I-Claim
treatment I-Claim
effect I-Claim
. I-Claim
!LF! !LF!
compared B-Premise
with I-Premise
their I-Premise
controls I-Premise
, I-Premise
in I-Premise
pamidronate I-Premise
hd I-Premise
/ I-Premise
ld I-Premise
patients I-Premise
, I-Premise
events I-Premise
occurred I-Premise
60 I-Premise
% I-Premise
to I-Premise
90 I-Premise
% I-Premise
less I-Premise
frequently I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
and I-Premise
the I-Premise
efp I-Premise
was I-Premise
prolonged I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
002 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
in B-Premise
pamidronate I-Premise
ld I-Premise
patients I-Premise
, I-Premise
event I-Premise
- I-Premise
rates I-Premise
decreased I-Premise
by I-Premise
15 I-Premise
% I-Premise
to I-Premise
45 I-Premise
% I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
. I-Premise
04 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
gastrointestinal B-Premise
toxicity I-Premise
of I-Premise
pamidronate I-Premise
caused I-Premise
a I-Premise
23 I-Premise
% I-Premise
drop I-Premise
- I-Premise
out I-Premise
rate I-Premise
, I-Premise
but B-Claim
other I-Claim
cancer I-Claim
- I-Claim
associated I-Claim
factors I-Claim
seemed I-Claim
to I-Claim
contribute I-Claim
to I-Claim
this I-Claim
toxicity I-Claim
. I-Claim
!LF! !LF!
pamidronate B-Claim
treatment I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
efficaciously I-Claim
reduced I-Claim
skeletal I-Claim
morbidity I-Claim
. I-Claim
!LF! !LF!
the B-Claim
effect I-Claim
appeared I-Claim
to I-Claim
be I-Claim
dose I-Claim
- I-Claim
dependent I-Claim
. I-Claim
!LF! !LF!
further B-Claim
research I-Claim
on I-Claim
dose I-Claim
and I-Claim
mode I-Claim
of I-Claim
treatment I-Claim
is I-Claim
mandatory I-Claim
. I-Claim
!LF! !LF!
dermatitis B-Claim
is I-Claim
a I-Claim
frequent I-Claim
adverse I-Claim
effect I-Claim
of I-Claim
adjuvant I-Claim
breast I-Claim
radiotherapy I-Claim
. I-Claim
!LF! !LF!
it B-Claim
is I-Claim
more I-Claim
likely I-Claim
in I-Claim
full I-Claim
- I-Claim
breasted I-Claim
women I-Claim
and I-Claim
when I-Claim
the I-Claim
radiation I-Claim
is I-Claim
distributed I-Claim
nonhomogeneously I-Claim
in I-Claim
the I-Claim
breast I-Claim
. I-Claim
!LF! !LF!
breast O
intensity O
- O
modulated O
radiation O
therapy O
( O
imrt O
) O
is O
a O
technique O
that O
ensures O
a O
more O
homogeneous O
dose O
distribution O
. O
!LF! !LF!
a O
multicenter O
, O
double O
- O
blind O
, O
randomized O
clinical O
trial O
was O
performed O
to O
test O
if O
breast O
imrt O
would O
reduce O
the O
rate O
of O
acute O
skin O
reaction O
( O
notably O
moist O
desquamation O
) O
, O
decrease O
pain O
, O
and O
improve O
quality O
of O
life O
compared O
with O
standard O
radiotherapy O
using O
wedges O
. O
!LF! !LF!
patients O
were O
assessed O
each O
week O
during O
and O
up O
to O
6 O
weeks O
after O
radiotherapy O
. O
!LF! !LF!
a O
total O
of O
358 O
patients O
were O
randomly O
assigned O
between O
july O
2003 O
and O
march O
2005 O
in O
two O
canadian O
centers O
, O
and O
331 O
were O
included O
in O
the O
analysis O
. O
!LF! !LF!
breast B-Premise
imrt I-Premise
significantly I-Premise
improved I-Premise
the I-Premise
dose I-Premise
distribution I-Premise
compared I-Premise
with I-Premise
standard I-Premise
radiation I-Premise
. I-Premise
!LF! !LF!
this B-Premise
translated I-Premise
into I-Premise
a I-Premise
lower I-Premise
proportion I-Premise
of I-Premise
patients I-Premise
experiencing I-Premise
moist I-Premise
desquamation I-Premise
during I-Premise
or I-Premise
up I-Premise
to I-Premise
6 I-Premise
weeks I-Premise
after I-Premise
their I-Premise
radiation I-Premise
treatment I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
31 I-Premise
. I-Premise
2 I-Premise
% I-Premise
with I-Premise
imrt I-Premise
compared I-Premise
with I-Premise
47 I-Premise
. I-Premise
8 I-Premise
% I-Premise
with I-Premise
standard I-Premise
treatment I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
002 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
a B-Premise
multivariate I-Premise
analysis I-Premise
found I-Premise
the I-Premise
use I-Premise
of I-Premise
breast I-Premise
imrt I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
003 I-Premise
) I-Premise
and I-Premise
smaller I-Premise
breast I-Premise
size I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
were I-Premise
significantly I-Premise
associated I-Premise
with I-Premise
a I-Premise
decreased I-Premise
risk I-Premise
of I-Premise
moist I-Premise
desquamation I-Premise
. I-Premise
!LF! !LF!
the B-Premise
use I-Premise
of I-Premise
imrt I-Premise
did I-Premise
not I-Premise
correlate I-Premise
with I-Premise
pain I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
, O
but O
the B-Premise
presence I-Premise
of I-Premise
moist I-Premise
desquamation I-Premise
did I-Premise
significantly I-Premise
correlate I-Premise
with I-Premise
pain I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
002 I-Premise
) I-Premise
and I-Premise
a I-Premise
reduced I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
003 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
breast B-Claim
imrt I-Claim
significantly I-Claim
reduced I-Claim
the I-Claim
occurrence I-Claim
of I-Claim
moist I-Claim
desquamation I-Claim
compared I-Claim
with I-Claim
a I-Claim
standard I-Claim
wedged I-Claim
technique I-Claim
. I-Claim
!LF! !LF!
moist B-Claim
desquamation I-Claim
was I-Claim
correlated I-Claim
with I-Claim
increased I-Claim
pain I-Claim
and I-Claim
reduction I-Claim
in I-Claim
the I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim
!LF! !LF!
this O
study O
aimed O
to O
compare O
quality O
of O
life O
( O
qol O
) O
, O
functional O
outcome O
, O
body O
image O
, O
and O
cosmesis O
after O
hand O
- O
assisted O
laparoscopic O
( O
lrp O
) O
versus O
open O
restorative O
proctocolectomy O
( O
orp O
) O
. O
!LF! !LF!
the O
potential O
long O
- O
term O
advantages O
of O
lrp O
over O
orp O
remain O
to O
be O
determined O
. O
!LF! !LF!
the O
most O
likely O
advantage O
of O
lrp O
is O
the O
superior O
cosmetic O
result O
. O
!LF! !LF!
it O
is O
, O
however O
, O
unclear O
whether O
the O
size O
and O
location O
of O
incisions O
affect O
body O
image O
and O
qol O
. O
!LF! !LF!
in O
a O
previously O
conducted O
randomized O
trial O
comparing O
lrp O
with O
orp O
, O
60 O
patients O
were O
prospectively O
evaluated O
. O
!LF! !LF!
the O
primary O
end O
points O
were O
body O
image O
and O
cosmesis O
. O
!LF! !LF!
the O
secondary O
end O
points O
were O
morbidity O
, O
qol O
, O
and O
functional O
outcome O
. O
!LF! !LF!
a O
body O
image O
questionnaire O
was O
used O
to O
evaluate O
body O
image O
and O
cosmesis O
. O
!LF! !LF!
the O
short O
form O
- O
36 O
health O
survey O
and O
the O
gastrointestinal O
quality O
of O
life O
inventory O
were O
used O
to O
assess O
qol O
. O
!LF! !LF!
body O
image O
and O
qol O
also O
were O
assessed O
preoperatively O
. O
!LF! !LF!
a O
total O
of O
53 O
patients O
completed O
the O
qol O
and O
functional O
outcome O
questionnaires O
. O
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
functional I-Premise
outcome I-Premise
, I-Premise
morbidity I-Premise
, I-Premise
or I-Premise
qol I-Premise
between I-Premise
lrp I-Premise
and I-Premise
orp I-Premise
. I-Premise
!LF! !LF!
at O
a O
median O
of O
2 O
. O
7 O
years O
after O
surgery O
, O
46 O
patients O
returned O
the O
questionnaires O
regarding O
body O
image O
, O
cosmesis O
, O
and O
morbidity O
. O
!LF! !LF!
the B-Premise
body I-Premise
image I-Premise
and I-Premise
cosmesis I-Premise
scores I-Premise
of I-Premise
female I-Premise
patients I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
lrp I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
orp I-Premise
group I-Premise
( I-Premise
body I-Premise
image I-Premise
, I-Premise
17 I-Premise
. I-Premise
4 I-Premise
vs I-Premise
14 I-Premise
. I-Premise
9 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
cosmesis I-Premise
, I-Premise
19 I-Premise
. I-Premise
1 I-Premise
vs I-Premise
13 I-Premise
. I-Premise
0 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
female I-Premise
patients I-Premise
in I-Premise
the I-Premise
orp I-Premise
group I-Premise
had I-Premise
significantly I-Premise
lower I-Premise
body I-Premise
image I-Premise
scores I-Premise
than I-Premise
the I-Premise
male I-Premise
patients I-Premise
( I-Premise
14 I-Premise
. I-Premise
9 I-Premise
vs I-Premise
18 I-Premise
. I-Premise
3 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
this B-Claim
study I-Claim
is I-Claim
the I-Claim
first I-Claim
to I-Claim
show I-Claim
that I-Claim
orp I-Claim
has I-Claim
a I-Claim
negative I-Claim
impact I-Claim
on I-Claim
body I-Claim
image I-Claim
and I-Claim
cosmesis I-Claim
as I-Claim
compared I-Claim
with I-Claim
lrp I-Claim
. I-Claim
!LF! !LF!
functional B-Claim
outcome I-Claim
, I-Claim
qol I-Claim
, I-Claim
and I-Claim
morbidity I-Claim
are I-Claim
similar I-Claim
for I-Claim
the I-Claim
two I-Claim
approaches I-Claim
. I-Claim
!LF! !LF!
the B-Claim
advantages I-Claim
of I-Claim
a I-Claim
long I-Claim
- I-Claim
lasting I-Claim
improved I-Claim
body I-Claim
image I-Claim
and I-Claim
cosmesis I-Claim
for I-Claim
this I-Claim
relatively I-Claim
young I-Claim
patient I-Claim
population I-Claim
may I-Claim
compensate I-Claim
for I-Claim
the I-Claim
longer I-Claim
operating I-Claim
times I-Claim
and I-Claim
higher I-Claim
costs I-Claim
, I-Claim
particularly I-Claim
for I-Claim
women I-Claim
. I-Claim
!LF! !LF!
there O
are O
few O
randomized O
controlled O
trials O
on O
the O
effectiveness O
of O
palliative O
care O
interventions O
to O
improve O
the O
care O
of O
patients O
with O
advanced O
cancer O
. O
!LF! !LF!
to O
determine O
the O
effect O
of O
a O
nursing O
- O
led O
intervention O
on O
quality O
of O
life O
, O
symptom O
intensity O
, O
mood O
, O
and O
resource O
use O
in O
patients O
with O
advanced O
cancer O
. O
!LF! !LF!
randomized O
controlled O
trial O
conducted O
from O
november O
2003 O
through O
may O
2008 O
of O
322 O
patients O
with O
advanced O
cancer O
in O
a O
rural O
, O
national O
cancer O
institute O
- O
designated O
comprehensive O
cancer O
center O
in O
new O
hampshire O
and O
affiliated O
outreach O
clinics O
and O
a O
va O
medical O
center O
in O
vermont O
. O
!LF! !LF!
a O
multicomponent O
, O
psychoeducational O
intervention O
( O
project O
enable O
[ O
educate O
, O
nurture O
, O
advise O
, O
before O
life O
ends O
] O
) O
conducted O
by O
advanced O
practice O
nurses O
consisting O
of O
4 O
weekly O
educational O
sessions O
and O
monthly O
follow O
- O
up O
sessions O
until O
death O
or O
study O
completion O
( O
n O
= O
161 O
) O
vs O
usual O
care O
( O
n O
= O
161 O
) O
. O
!LF! !LF!
quality O
of O
life O
was O
measured O
by O
the O
functional O
assessment O
of O
chronic O
illness O
therapy O
for O
palliative O
care O
( O
score O
range O
, O
0 O
- O
184 O
) O
. O
!LF! !LF!
symptom O
intensity O
was O
measured O
by O
the O
edmonton O
symptom O
assessment O
scale O
( O
score O
range O
, O
0 O
- O
900 O
) O
. O
!LF! !LF!
mood O
was O
measured O
by O
the O
center O
for O
epidemiological O
studies O
depression O
scale O
( O
range O
, O
0 O
- O
60 O
) O
. O
!LF! !LF!
these O
measures O
were O
assessed O
at O
baseline O
, O
1 O
month O
, O
and O
every O
3 O
months O
until O
death O
or O
study O
completion O
. O
!LF! !LF!
intensity O
of O
service O
was O
measured O
as O
the O
number O
of O
days O
in O
the O
hospital O
and O
in O
the O
intensive O
care O
unit O
( O
icu O
) O
and O
the O
number O
of O
emergency O
department O
visits O
recorded O
in O
the O
electronic O
medical O
record O
. O
!LF! !LF!
a O
total O
of O
322 O
participants O
with O
cancer O
of O
the O
gastrointestinal O
tract O
( O
41 O
% O
"""" O
; O
"""" O
67 O
in O
the O
usual O
care O
group O
vs O
66 O
in O
the O
intervention O
group O
) O
, O
lung O
( O
36 O
% O
"""" O
; O
"""" O
58 O
vs O
59 O
) O
, O
genitourinary O
tract O
( O
12 O
% O
"""" O
; O
"""" O
20 O
vs O
19 O
) O
, O
and O
breast O
( O
10 O
% O
"""" O
; O
"""" O
16 O
vs O
17 O
) O
were O
randomized O
. O
!LF! !LF!
the B-Premise
estimated I-Premise
treatment I-Premise
effects I-Premise
( I-Premise
intervention I-Premise
minus I-Premise
usual I-Premise
care I-Premise
) I-Premise
for I-Premise
all I-Premise
participants I-Premise
were I-Premise
a I-Premise
mean I-Premise
( I-Premise
se I-Premise
) I-Premise
of I-Premise
4 I-Premise
. I-Premise
6 I-Premise
( I-Premise
2 I-Premise
) I-Premise
for I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
02 I-Premise
) I-Premise
, I-Premise
- I-Premise
27 I-Premise
. I-Premise
8 I-Premise
( I-Premise
15 I-Premise
) I-Premise
for I-Premise
symptom I-Premise
intensity I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
06 I-Premise
) I-Premise
, I-Premise
and I-Premise
- I-Premise
1 I-Premise
. I-Premise
8 I-Premise
( I-Premise
0 I-Premise
. I-Premise
81 I-Premise
) I-Premise
for I-Premise
depressed I-Premise
mood I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
estimated I-Premise
treatment I-Premise
effects I-Premise
in I-Premise
participants I-Premise
who I-Premise
died I-Premise
during I-Premise
the I-Premise
study I-Premise
were I-Premise
a I-Premise
mean I-Premise
( I-Premise
se I-Premise
) I-Premise
of I-Premise
8 I-Premise
. I-Premise
6 I-Premise
( I-Premise
3 I-Premise
. I-Premise
6 I-Premise
) I-Premise
for I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
02 I-Premise
) I-Premise
, I-Premise
- I-Premise
24 I-Premise
. I-Premise
2 I-Premise
( I-Premise
20 I-Premise
. I-Premise
5 I-Premise
) I-Premise
for I-Premise
symptom I-Premise
intensity I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
24 I-Premise
) I-Premise
, I-Premise
and I-Premise
- I-Premise
2 I-Premise
. I-Premise
7 I-Premise
( I-Premise
1 I-Premise
. I-Premise
2 I-Premise
) I-Premise
for I-Premise
depressed I-Premise
mood I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
intensity O
of O
service O
did O
not O
differ O
between O
the O
2 O
groups O
. O
!LF! !LF!
compared B-Claim
with I-Claim
participants I-Claim
receiving I-Claim
usual I-Claim
oncology I-Claim
care I-Claim
, I-Claim
those I-Claim
receiving I-Claim
a I-Claim
nurse I-Claim
- I-Claim
led I-Claim
, I-Claim
palliative I-Claim
care I-Claim
- I-Claim
focused I-Claim
intervention I-Claim
addressing I-Claim
physical I-Claim
, I-Claim
psychosocial I-Claim
, I-Claim
and I-Claim
care I-Claim
coordination I-Claim
provided I-Claim
concurrently I-Claim
with I-Claim
oncology I-Claim
care I-Claim
had I-Claim
higher I-Claim
scores I-Claim
for I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
mood I-Claim
, I-Claim
but B-Claim
did I-Claim
not I-Claim
have I-Claim
improvements I-Claim
in I-Claim
symptom I-Claim
intensity I-Claim
scores I-Claim
or I-Claim
reduced I-Claim
days I-Claim
in I-Claim
the I-Claim
hospital I-Claim
or I-Claim
icu I-Claim
or I-Claim
emergency I-Claim
department I-Claim
visits I-Claim
. I-Claim
!LF! !LF!
to O
determine O
the O
efficacy O
of O
topotecan O
in O
combination O
with O
standard O
chemotherapy O
in O
previously O
untreated O
patients O
with O
extensive O
- O
stage O
small O
- O
cell O
lung O
cancer O
( O
sclc O
) O
, O
the O
eastern O
cooperative O
oncology O
group O
( O
ecog O
) O
conducted O
a O
phase O
iii O
trial O
. O
!LF! !LF!
eligible O
patients O
had O
measurable O
or O
assessable O
disease O
and O
an O
ecog O
performance O
status O
of O
0 O
to O
2 O
"""" O
; O
"""" O
stable O
brain O
metastases O
were O
allowed O
. O
!LF! !LF!
all O
patients O
received O
four O
cycles O
of O
cisplatin O
and O
etoposide O
every O
3 O
weeks O
( O
step O
1 O
"""" O
; O
"""" O
pe O
) O
. O
!LF! !LF!
patients O
with O
stable O
or O
responding O
disease O
were O
then O
randomized O
to O
observation O
or O
four O
cycles O
of O
topotecan O
( O
1 O
. O
5 O
mg O
/ O
m O
( O
2 O
) O
/ O
d O
for O
5 O
days O
, O
every O
3 O
weeks O
"""" O
; O
"""" O
step O
2 O
) O
. O
!LF! !LF!
a O
total O
of O
402 O
eligible O
patients O
were O
registered O
to O
step O
1 O
, O
and O
223 O
eligible O
patients O
were O
registered O
to O
step O
2 O
( O
observation O
, O
n O
= O
111 O
"""" O
; O
"""" O
topotecan O
, O
n O
= O
112 O
) O
. O
!LF! !LF!
complete B-Premise
and I-Premise
partial I-Premise
response I-Premise
rates I-Premise
to I-Premise
induction I-Premise
pe I-Premise
were I-Premise
3 I-Premise
% I-Premise
and I-Premise
32 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
a B-Premise
7 I-Premise
% I-Premise
response I-Premise
rate I-Premise
was I-Premise
observed I-Premise
with I-Premise
topotecan I-Premise
( I-Premise
complete I-Premise
response I-Premise
, I-Premise
2 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
partial I-Premise
response I-Premise
, I-Premise
5 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
median I-Premise
survival I-Premise
time I-Premise
for I-Premise
all I-Premise
402 I-Premise
eligible I-Premise
patients I-Premise
was I-Premise
9 I-Premise
. I-Premise
6 I-Premise
months I-Premise
. I-Premise
!LF! !LF!
progression B-Premise
- B-Premise
free B-Premise
survival I-Premise
( I-Premise
pfs I-Premise
) I-Premise
from I-Premise
date I-Premise
of I-Premise
randomization I-Premise
on I-Premise
step I-Premise
2 I-Premise
was I-Premise
significantly I-Premise
better I-Premise
with I-Premise
topotecan I-Premise
compared I-Premise
with I-Premise
observation I-Premise
( I-Premise
3 I-Premise
. I-Premise
6 I-Premise
months I-Premise
v I-Premise
2 I-Premise
. I-Premise
3 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
however O
, O
overall B-Premise
survival I-Premise
from I-Premise
date I-Premise
of I-Premise
randomization I-Premise
on I-Premise
step I-Premise
2 I-Premise
was I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
the I-Premise
observation I-Premise
and I-Premise
topotecan I-Premise
arms I-Premise
( I-Premise
8 I-Premise
. I-Premise
9 I-Premise
months I-Premise
v I-Premise
9 I-Premise
. I-Premise
3 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
43 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
grade B-Premise
4 I-Premise
neutropenia I-Premise
and I-Premise
thrombocytopenia I-Premise
occurred I-Premise
in I-Premise
50 I-Premise
% I-Premise
and I-Premise
3 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
of I-Premise
pe I-Premise
patients I-Premise
in I-Premise
step I-Premise
1 I-Premise
and I-Premise
60 I-Premise
% I-Premise
and I-Premise
13 I-Premise
% I-Premise
of I-Premise
topotecan I-Premise
patients I-Premise
in I-Premise
step I-Premise
2 I-Premise
. I-Premise
!LF! !LF!
grade B-Premise
4 I-Premise
/ I-Premise
5 I-Premise
infection I-Premise
was I-Premise
observed I-Premise
in I-Premise
4 I-Premise
. I-Premise
6 I-Premise
% I-Premise
of I-Premise
pe I-Premise
patients I-Premise
and I-Premise
1 I-Premise
. I-Premise
8 I-Premise
% I-Premise
of I-Premise
topotecan I-Premise
patients I-Premise
. I-Premise
!LF! !LF!
grade B-Premise
3 I-Premise
/ I-Premise
4 I-Premise
anemia I-Premise
developed I-Premise
in I-Premise
22 I-Premise
% I-Premise
of I-Premise
patients I-Premise
who I-Premise
received I-Premise
topotecan I-Premise
. I-Premise
!LF! !LF!
no B-Premise
difference I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
between I-Premise
topotecan I-Premise
and I-Premise
observation I-Premise
was I-Premise
observed I-Premise
at I-Premise
any I-Premise
assessment I-Premise
time I-Premise
or I-Premise
for I-Premise
any I-Premise
of I-Premise
the I-Premise
subscale I-Premise
scores I-Premise
. I-Premise
!LF! !LF!
four B-Claim
cycles I-Claim
of I-Claim
pe I-Claim
induction I-Claim
therapy I-Claim
followed I-Claim
by I-Claim
four I-Claim
cycles I-Claim
of I-Claim
topotecan I-Claim
improved I-Claim
pfs I-Claim
but I-Claim
failed I-Claim
to I-Claim
improve I-Claim
overall I-Claim
survival I-Claim
or I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
extensive I-Claim
- I-Claim
stage I-Claim
sclc I-Claim
. I-Claim
!LF! !LF!
four B-Claim
cycles I-Claim
of I-Claim
standard I-Claim
pe I-Claim
remains I-Claim
an I-Claim
appropriate I-Claim
first I-Claim
- I-Claim
line I-Claim
treatment I-Claim
for I-Claim
extensive I-Claim
- I-Claim
stage I-Claim
sclc I-Claim
patients I-Claim
with I-Claim
good I-Claim
performance I-Claim
status I-Claim
. I-Claim
!LF! !LF!
patients O
with O
lymphoma O
experience O
sleep O
problems O
that O
may O
be O
managed O
with O
aerobic O
exercise O
but O
no O
previous O
study O
has O
examined O
this O
issue O
. O
!LF! !LF!
we O
randomized O
122 O
patients O
with O
lymphoma O
to O
usual O
care O
( O
n O
= O
62 O
) O
or O
12 O
weeks O
of O
supervised O
aerobic O
exercise O
training O
( O
aet O
"""" O
; O
"""" O
n O
= O
60 O
) O
. O
!LF! !LF!
our O
primary O
sleep O
endpoint O
was O
global O
sleep O
quality O
assessed O
by O
the O
pittsburgh O
sleep O
quality O
index O
( O
psqi O
) O
. O
!LF! !LF!
secondary O
endpoints O
were O
the O
psqi O
component O
scores O
. O
!LF! !LF!
planned O
subgroup O
analyses O
were O
also O
conducted O
. O
!LF! !LF!
intention B-Premise
- B-Premise
to B-Premise
- B-Premise
treat B-Premise
analyses I-Premise
indicated I-Premise
that I-Premise
aet I-Premise
resulted I-Premise
in I-Premise
a I-Premise
nonsignificant I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
16 I-Premise
) I-Premise
improvement I-Premise
in I-Premise
global I-Premise
sleep I-Premise
quality I-Premise
compared I-Premise
with I-Premise
usual I-Premise
care I-Premise
[ I-Premise
mean I-Premise
group I-Premise
difference I-Premise
= I-Premise
- I-Premise
0 I-Premise
. I-Premise
64 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
ci I-Premise
) I-Premise
, I-Premise
- I-Premise
1 I-Premise
. I-Premise
56 I-Premise
to I-Premise
+ I-Premise
0 I-Premise
. I-Premise
27 I-Premise
] I-Premise
. I-Premise
!LF! !LF!
in B-Premise
planned I-Premise
subgroup I-Premise
analyses I-Premise
, I-Premise
statistically I-Premise
significant I-Premise
or I-Premise
borderline I-Premise
significant I-Premise
interactions I-Premise
were I-Premise
identified I-Premise
for I-Premise
type I-Premise
of I-Premise
lymphoma I-Premise
( I-Premise
p I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0 I-Premise
. I-Premise
006 I-Premise
) I-Premise
, I-Premise
current I-Premise
treatment I-Premise
status I-Premise
( I-Premise
p I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0 I-Premise
. I-Premise
036 I-Premise
) I-Premise
, I-Premise
time I-Premise
since I-Premise
diagnosis I-Premise
( I-Premise
p I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0 I-Premise
. I-Premise
010 I-Premise
) I-Premise
, I-Premise
body I-Premise
mass I-Premise
index I-Premise
( I-Premise
p I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0 I-Premise
. I-Premise
075 I-Premise
) I-Premise
, I-Premise
and I-Premise
baseline I-Premise
sleep I-Premise
quality I-Premise
( I-Premise
p I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0 I-Premise
. I-Premise
041 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
specifically O
, O
aet B-Premise
improved I-Premise
global I-Premise
sleep I-Premise
quality I-Premise
in I-Premise
patients I-Premise
with I-Premise
lymphoma I-Premise
who I-Premise
had I-Premise
indolent I-Premise
non I-Premise
- I-Premise
hodgkin I-Premise
lymphoma I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
were I-Premise
receiving I-Premise
chemotherapy I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
013 I-Premise
) I-Premise
, I-Premise
were I-Premise
< I-Premise
2 I-Premise
years I-Premise
post I-Premise
- I-Premise
diagnosis I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
005 I-Premise
) I-Premise
, I-Premise
were I-Premise
obese I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
025 I-Premise
) I-Premise
, I-Premise
and I-Premise
were I-Premise
poor I-Premise
sleepers I-Premise
at I-Premise
baseline I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
007 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
aet B-Claim
did I-Claim
not I-Claim
significantly I-Claim
improve I-Claim
sleep I-Claim
quality I-Claim
in I-Claim
this I-Claim
heterogeneous I-Claim
sample I-Claim
of I-Claim
patients I-Claim
with I-Claim
lymphoma I-Claim
"""" I-Claim
; I-Claim
"""" I-Claim
however B-Claim
, I-Claim
clinically I-Claim
identifiable I-Claim
subgroups I-Claim
appeared I-Claim
to I-Claim
benefit I-Claim
. I-Claim
!LF! !LF!
future O
exercise O
trials O
targeting O
these O
responsive O
subgroups O
are O
needed O
to O
confirm O
these O
findings O
. O
!LF! !LF!
if O
replicated O
in O
larger O
and O
more O
focused O
trials O
, O
aerobic O
exercise O
may O
be O
an O
attractive O
option O
to O
manage O
sleep O
dysfunction O
in O
patients O
with O
cancer O
because O
of O
its O
favorable O
safety O
profile O
and O
other O
documented O
health O
benefits O
. O
!LF! !LF!
in B-Claim
vivo I-Claim
data I-Claim
have I-Claim
shown I-Claim
a I-Claim
more I-Claim
potent I-Claim
antiangiogenic I-Claim
effect I-Claim
and I-Claim
a I-Claim
higher I-Claim
antitumor I-Claim
activity I-Claim
of I-Claim
low I-Claim
- I-Claim
dose I-Claim
interferon I-Claim
( I-Claim
ifn I-Claim
) I-Claim
given I-Claim
twice I-Claim
daily I-Claim
. I-Claim
!LF! !LF!
in O
a O
randomized O
phase O
ii O
trial O
, O
the O
authors O
tested O
the O
hypothesis O
that O
twice O
- O
daily O
low O
- O
dose O
ifn O
is O
more O
effective O
than O
daily O
intermediate O
- O
dose O
ifn O
in O
patients O
with O
metastatic O
renal O
cell O
cancer O
( O
mrcc O
) O
. O
!LF! !LF!
a O
total O
of O
118 O
patients O
( O
59 O
per O
arm O
) O
were O
randomly O
assigned O
to O
receive O
ifn O
at O
a O
dose O
of O
0 O
. O
5 O
million O
units O
( O
mu O
) O
given O
subcutaneously O
twice O
daily O
( O
ifn1 O
) O
or O
ifn O
at O
a O
dose O
of O
5 O
mu O
given O
subcutaneously O
daily O
( O
ifn5 O
) O
. O
!LF! !LF!
the O
primary O
endpoint O
was O
progression O
- O
free O
survival O
( O
pfs O
) O
. O
!LF! !LF!
secondary O
endpoints O
included O
response O
rate O
( O
rr O
) O
, O
overall O
survival O
( O
os O
) O
, O
toxicity O
, O
and O
quality O
of O
life O
( O
qol O
) O
. O
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
either I-Premise
pfs I-Premise
or I-Premise
os I-Premise
between I-Premise
ifn1 I-Premise
and I-Premise
ifn5 I-Premise
( I-Premise
median I-Premise
of I-Premise
3 I-Premise
. I-Premise
7 I-Premise
months I-Premise
and I-Premise
median I-Premise
of I-Premise
3 I-Premise
. I-Premise
4 I-Premise
months I-Premise
pfs I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
median I-Premise
of I-Premise
25 I-Premise
. I-Premise
5 I-Premise
months I-Premise
and I-Premise
median I-Premise
of I-Premise
17 I-Premise
. I-Premise
5 I-Premise
months I-Premise
os I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
rrs I-Premise
were I-Premise
identical I-Premise
in I-Premise
the I-Premise
2 I-Premise
arms I-Premise
( I-Premise
6 I-Premise
. I-Premise
7 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
95 I-Premise
% I-Premise
ci I-Premise
] I-Premise
, I-Premise
1 I-Premise
. I-Premise
8 I-Premise
- I-Premise
16 I-Premise
. I-Premise
5 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
two B-Premise
patients I-Premise
, I-Premise
1 I-Premise
in I-Premise
each I-Premise
arm I-Premise
, I-Premise
remained I-Premise
in I-Premise
complete I-Premise
remission I-Premise
at I-Premise
the I-Premise
time I-Premise
of I-Premise
last I-Premise
follow I-Premise
- I-Premise
up I-Premise
, I-Premise
at I-Premise
45 I-Premise
and I-Premise
38 I-Premise
months I-Premise
from I-Premise
treatment I-Premise
. I-Premise
!LF! !LF!
thirty B-Premise
- B-Premise
two B-Premise
patients I-Premise
receiving I-Premise
ifn5 I-Premise
and I-Premise
19 I-Premise
patients I-Premise
receiving I-Premise
ifn1 I-Premise
experienced I-Premise
grade I-Premise
3 I-Premise
or I-Premise
higher I-Premise
adverse I-Premise
events I-Premise
( I-Premise
graded I-Premise
using I-Premise
the I-Premise
national I-Premise
cancer I-Premise
institute I-Premise
common I-Premise
toxicity I-Premise
criteria I-Premise
[ I-Premise
version I-Premise
2 I-Premise
. I-Premise
0 I-Premise
] I-Premise
) I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
025 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
eighteen B-Premise
patients I-Premise
receiving I-Premise
ifn5 I-Premise
and I-Premise
4 I-Premise
patients I-Premise
receiving I-Premise
ifn1 I-Premise
had I-Premise
dose I-Premise
reductions I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
002 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
there B-Premise
was I-Premise
a I-Premise
significant I-Premise
deterioration I-Premise
in I-Premise
qol I-Premise
and I-Premise
an I-Premise
increase I-Premise
in I-Premise
depression I-Premise
associated I-Premise
with I-Premise
ifn5 I-Premise
but I-Premise
no I-Premise
change I-Premise
was I-Premise
noted I-Premise
with I-Premise
ifn1 I-Premise
. I-Premise
!LF! !LF!
compared B-Claim
with I-Claim
ifn5 I-Claim
, I-Claim
ifn1 I-Claim
is I-Claim
neither I-Claim
more I-Claim
nor I-Claim
less I-Claim
effective I-Claim
but I-Claim
is I-Claim
less I-Claim
toxic I-Claim
, I-Claim
with I-Claim
a I-Claim
better I-Claim
reported I-Claim
qol I-Claim
. I-Claim
!LF! !LF!
these B-Claim
results I-Claim
may I-Claim
have I-Claim
implications I-Claim
for I-Claim
the I-Claim
design I-Claim
of I-Claim
combination I-Claim
regimens I-Claim
incorporating I-Claim
ifn I-Claim
with I-Claim
targeted I-Claim
agents I-Claim
. I-Claim
!LF! !LF!
to O
determine O
whether O
patients O
with O
locally O
advanced O
non O
- O
small O
cell O
lung O
cancer O
unsuitable O
for O
resection O
or O
radical O
radiotherapy O
, O
and O
with O
minimal O
thoracic O
symptoms O
, O
should O
be O
given O
palliative O
thoracic O
radiotherapy O
immediately O
or O
as O
needed O
to O
treat O
symptoms O
. O
!LF! !LF!
multicentre O
randomised O
controlled O
trial O
. O
!LF! !LF!
23 O
centres O
in O
the O
united O
kingdom O
, O
ireland O
, O
and O
south O
africa O
. O
!LF! !LF!
230 O
patients O
with O
previously O
untreated O
, O
non O
- O
small O
cell O
lung O
cancer O
that O
is O
locally O
too O
advanced O
for O
resection O
or O
radical O
radiotherapy O
with O
curative O
intent O
, O
with O
minimal O
thoracic O
symptoms O
, O
and O
with O
no O
indication O
for O
immediate O
thoracic O
radiotherapy O
. O
!LF! !LF!
all O
patients O
were O
given O
supportive O
treatment O
and O
were O
randomised O
to O
receive O
palliative O
thoracic O
radiotherapy O
either O
immediately O
or O
delayed O
until O
needed O
to O
treat O
symptoms O
. O
!LF! !LF!
the O
recommended O
regimens O
were O
17 O
gy O
in O
two O
fractions O
one O
week O
apart O
or O
10 O
gy O
as O
a O
single O
dose O
. O
!LF! !LF!
primary O
- O
- O
patients O
alive O
and O
without O
moderate O
or O
severe O
cough O
, O
chest O
pain O
, O
haemoptysis O
, O
or O
dyspnoea O
six O
months O
from O
randomisation O
, O
as O
recorded O
by O
clinicians O
. O
!LF! !LF!
secondary O
- O
- O
quality O
of O
life O
, O
adverse O
events O
, O
survival O
. O
!LF! !LF!
from O
december O
1992 O
to O
may O
1999 O
, O
230 O
patients O
were O
randomised O
. O
!LF! !LF!
104 O
/ O
115 O
of O
the O
patients O
in O
the O
immediate O
treatment O
group O
received O
thoracic O
radiotherapy O
( O
90 O
received O
one O
of O
the O
recommended O
regimens O
) O
. O
!LF! !LF!
in O
the O
delayed O
treatment O
group O
, O
48 O
/ O
115 O
( O
42 O
% O
) O
patients O
received O
thoracic O
radiotherapy O
( O
29 O
received O
one O
of O
the O
recommended O
regimens O
) O
"""" O
; O
"""" O
64 O
( O
56 O
% O
) O
died O
without O
receiving O
thoracic O
radiotherapy O
"""" O
; O
"""" O
the O
remaining O
three O
( O
3 O
% O
) O
were O
alive O
at O
the O
end O
of O
the O
study O
without O
having O
received O
the O
treatment O
. O
!LF! !LF!
for O
patients O
who O
received O
thoracic O
radiotherapy O
, O
the O
median O
time O
to O
start O
was O
15 O
days O
in O
the O
immediate O
treatment O
group O
and O
125 O
days O
in O
the O
delayed O
treatment O
group O
. O
!LF! !LF!
the B-Premise
primary I-Premise
outcome I-Premise
measure I-Premise
was I-Premise
achieved I-Premise
in I-Premise
28 I-Premise
% I-Premise
of I-Premise
the I-Premise
immediate I-Premise
treatment I-Premise
group I-Premise
and I-Premise
26 I-Premise
% I-Premise
of I-Premise
patients I-Premise
from I-Premise
the I-Premise
delayed I-Premise
treatment I-Premise
group I-Premise
( I-Premise
27 I-Premise
/ I-Premise
97 I-Premise
and I-Premise
27 I-Premise
/ I-Premise
103 I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
absolute I-Premise
difference I-Premise
1 I-Premise
. I-Premise
6 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
- I-Premise
10 I-Premise
. I-Premise
7 I-Premise
% I-Premise
to I-Premise
13 I-Premise
. I-Premise
9 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
no B-Premise
evidence I-Premise
of I-Premise
a I-Premise
difference I-Premise
was I-Premise
observed I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
groups I-Premise
in I-Premise
terms I-Premise
of I-Premise
activity I-Premise
level I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
depression I-Premise
, I-Premise
and I-Premise
psychological I-Premise
distress I-Premise
, I-Premise
as I-Premise
recorded I-Premise
by I-Premise
the I-Premise
patients I-Premise
. I-Premise
!LF! !LF!
adverse B-Premise
events I-Premise
were I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
immediate I-Premise
treatment I-Premise
group I-Premise
. I-Premise
!LF! !LF!
neither B-Premise
group I-Premise
had I-Premise
a I-Premise
survival I-Premise
advantage I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
0 I-Premise
. I-Premise
95 I-Premise
, I-Premise
0 I-Premise
. I-Premise
73 I-Premise
to I-Premise
1 I-Premise
. I-Premise
24 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
71 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
median B-Premise
survival I-Premise
was I-Premise
8 I-Premise
. I-Premise
3 I-Premise
months I-Premise
and I-Premise
7 I-Premise
. I-Premise
9 I-Premise
months I-Premise
, I-Premise
and O
the B-Premise
survival I-Premise
rates I-Premise
were I-Premise
31 I-Premise
% I-Premise
and I-Premise
29 I-Premise
% I-Premise
at I-Premise
12 I-Premise
months I-Premise
, I-Premise
for I-Premise
the I-Premise
immediate I-Premise
and I-Premise
delayed I-Premise
treatment I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
in B-Claim
minimally I-Claim
symptomatic I-Claim
patients I-Claim
with I-Claim
locally I-Claim
advanced I-Claim
non I-Claim
- I-Claim
small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
, I-Claim
no I-Claim
persuasive I-Claim
evidence I-Claim
was I-Claim
found I-Claim
to I-Claim
indicate I-Claim
that I-Claim
giving I-Claim
immediate I-Claim
palliative I-Claim
thoracic I-Claim
radiotherapy I-Claim
improves I-Claim
symptom I-Claim
control I-Claim
, I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
or I-Claim
survival I-Claim
when I-Claim
compared I-Claim
with I-Claim
delaying I-Claim
until I-Claim
symptoms I-Claim
require I-Claim
treatment I-Claim
. I-Claim
!LF! !LF!
to O
determine O
whether O
palliation O
of O
chest O
symptoms O
from O
a O
10 O
gy O
single O
fraction O
( O
regimen O
1 O
) O
was O
equivalent O
to O
that O
from O
30 O
gy O
in O
10 O
fractions O
( O
regimen O
2 O
) O
. O
!LF! !LF!
patients O
with O
cytologically O
proven O
, O
symptomatic O
lung O
cancer O
not O
amenable O
to O
curative O
therapy O
, O
with O
performance O
status O
0 O
- O
3 O
, O
were O
randomised O
to O
receive O
either O
30 O
gy O
in O
10 O
fractions O
or O
a O
10 O
gy O
single O
fraction O
. O
!LF! !LF!
local O
symptoms O
were O
scored O
on O
a O
physician O
- O
assessed O
, O
five O
- O
point O
categorical O
scale O
and O
summed O
to O
produce O
a O
total O
symptom O
score O
( O
tss O
) O
. O
!LF! !LF!
this O
, O
performance O
status O
, O
hospital O
anxiety O
and O
depression O
( O
had O
) O
score O
and O
spitzer O
' O
s O
quality O
- O
of O
- O
life O
index O
were O
noted O
before O
treatment O
, O
at O
1 O
month O
after O
treatment O
and O
every O
2 O
months O
thereafter O
. O
!LF! !LF!
palliation O
was O
defined O
as O
an O
improvement O
of O
one O
point O
or O
more O
in O
the O
categorical O
scale O
. O
!LF! !LF!
equivalence O
was O
defined O
as O
less O
than O
20 O
% O
difference O
in O
the O
number O
achieving O
an O
improvement O
in O
the O
tss O
. O
!LF! !LF!
we O
randomised O
149 O
patients O
and O
analysed O
74 O
in O
each O
arm O
. O
!LF! !LF!
according O
to O
the O
design O
criteria O
, O
palliation O
was O
equivalent O
between O
the O
two O
arms O
. O
!LF! !LF!
tss B-Premise
improved I-Premise
in I-Premise
49 I-Premise
patients I-Premise
( I-Premise
77 I-Premise
% I-Premise
) I-Premise
on I-Premise
regimen I-Premise
1 I-Premise
, I-Premise
and I-Premise
in I-Premise
57 I-Premise
( I-Premise
92 I-Premise
% I-Premise
) I-Premise
patients I-Premise
on I-Premise
regimen I-Premise
2 I-Premise
, I-Premise
a I-Premise
difference I-Premise
of I-Premise
15 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
ci I-Premise
] I-Premise
3 I-Premise
- I-Premise
28 I-Premise
) I-Premise
in I-Premise
the I-Premise
proportion I-Premise
improving I-Premise
between I-Premise
the I-Premise
two I-Premise
regimens I-Premise
. I-Premise
!LF! !LF!
a B-Premise
complete I-Premise
resolution I-Premise
of I-Premise
all I-Premise
symptoms I-Premise
was I-Premise
achieved I-Premise
in I-Premise
three I-Premise
( I-Premise
5 I-Premise
% I-Premise
) I-Premise
on I-Premise
regimen I-Premise
1 I-Premise
, I-Premise
and I-Premise
in I-Premise
14 I-Premise
( I-Premise
23 I-Premise
% I-Premise
) I-Premise
patients I-Premise
on I-Premise
regimen I-Premise
2 I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
a I-Premise
difference I-Premise
in I-Premise
the I-Premise
proportion I-Premise
between I-Premise
the I-Premise
two I-Premise
regimens I-Premise
of I-Premise
21 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
10 I-Premise
- I-Premise
33 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
a B-Premise
significantly I-Premise
higher I-Premise
proportion I-Premise
of I-Premise
patients I-Premise
experienced I-Premise
palliation I-Premise
and I-Premise
complete I-Premise
resolution I-Premise
of I-Premise
chest I-Premise
pain I-Premise
and I-Premise
dyspnoea I-Premise
with I-Premise
regimen I-Premise
2 I-Premise
. I-Premise
!LF! !LF!
no B-Premise
differences I-Premise
were I-Premise
observed I-Premise
in I-Premise
toxicity I-Premise
. I-Premise
!LF! !LF!
the B-Premise
median I-Premise
survival I-Premise
was I-Premise
22 I-Premise
. I-Premise
7 I-Premise
weeks I-Premise
for I-Premise
regimen I-Premise
1 I-Premise
and I-Premise
28 I-Premise
. I-Premise
3 I-Premise
weeks I-Premise
for I-Premise
regimen I-Premise
2 I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
197 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
although B-Claim
this I-Claim
trial I-Claim
met I-Claim
the I-Claim
pre I-Claim
- I-Claim
determined I-Claim
criteria I-Claim
for I-Claim
equivalence I-Claim
between I-Claim
the I-Claim
two I-Claim
palliative I-Claim
regimens I-Claim
, I-Claim
significantly B-Claim
more I-Claim
patients I-Claim
achieved I-Claim
complete I-Claim
resolution I-Claim
of I-Claim
symptoms I-Claim
and I-Claim
palliation I-Claim
of I-Claim
chest I-Claim
pain I-Claim
and I-Claim
dyspnoea I-Claim
with I-Claim
the I-Claim
fractionated I-Claim
regimen I-Claim
. I-Claim
!LF! !LF!
few O
exercise O
trials O
in O
cancer O
patients O
have O
reported O
longer O
- O
term O
follow O
- O
up O
. O
!LF! !LF!
here O
, O
we O
report O
a O
6 O
- O
month O
follow O
- O
up O
of O
exercise O
behavior O
and O
patient O
- O
rated O
outcomes O
from O
an O
exercise O
trial O
in O
breast O
cancer O
patients O
. O
!LF! !LF!
breast O
cancer O
patients O
initiating O
adjuvant O
chemotherapy O
( O
n O
= O
242 O
) O
were O
randomly O
assigned O
to O
usual O
care O
( O
n O
= O
82 O
) O
, O
resistance O
exercise O
training O
( O
ret O
"""" O
; O
"""" O
n O
= O
82 O
) O
, O
or O
aerobic O
exercise O
training O
( O
aet O
"""" O
; O
"""" O
n O
= O
78 O
) O
for O
the O
duration O
of O
their O
chemotherapy O
. O
!LF! !LF!
at O
6 O
- O
month O
follow O
- O
up O
, O
participants O
were O
mailed O
a O
questionnaire O
that O
assessed O
quality O
of O
life O
, O
self O
- O
esteem O
, O
fatigue O
, O
anxiety O
, O
depression O
, O
and O
exercise O
behavior O
. O
!LF! !LF!
two O
hundred O
one O
( O
83 O
. O
1 O
% O
) O
participants O
provided O
6 O
- O
month O
follow O
- O
up O
data O
. O
!LF! !LF!
adjusted B-Premise
linear I-Premise
mixed I-Premise
- I-Premise
model I-Premise
analyses I-Premise
showed I-Premise
that I-Premise
, I-Premise
at I-Premise
6 I-Premise
- I-Premise
month I-Premise
follow I-Premise
- I-Premise
up I-Premise
, I-Premise
the I-Premise
ret I-Premise
group I-Premise
reported I-Premise
higher I-Premise
self I-Premise
- I-Premise
esteem I-Premise
[ I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
1 I-Premise
. I-Premise
6 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
) I-Premise
, I-Premise
0 I-Premise
. I-Premise
1 I-Premise
- I-Premise
3 I-Premise
. I-Premise
2 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
032 I-Premise
] I-Premise
and I-Premise
the I-Premise
aet I-Premise
group I-Premise
reported I-Premise
lower I-Premise
anxiety I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
- I-Premise
4 I-Premise
. I-Premise
7 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
- I-Premise
0 I-Premise
. I-Premise
0 I-Premise
to I-Premise
- I-Premise
9 I-Premise
. I-Premise
3 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
049 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
usual I-Premise
care I-Premise
group I-Premise
. I-Premise
!LF! !LF!
moreover O
, O
compared B-Premise
with I-Premise
participants I-Premise
reporting I-Premise
no I-Premise
regular I-Premise
exercise I-Premise
during I-Premise
the I-Premise
follow I-Premise
- I-Premise
up I-Premise
period I-Premise
, I-Premise
those I-Premise
reporting I-Premise
regular I-Premise
aerobic I-Premise
and I-Premise
resistance I-Premise
exercise I-Premise
also I-Premise
reported I-Premise
better I-Premise
patient I-Premise
- I-Premise
rated I-Premise
outcomes I-Premise
, I-Premise
including I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
9 I-Premise
. I-Premise
5 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
1 I-Premise
. I-Premise
2 I-Premise
- I-Premise
17 I-Premise
. I-Premise
8 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
025 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
improvements B-Premise
in I-Premise
self I-Premise
- I-Premise
esteem I-Premise
observed I-Premise
with I-Premise
ret I-Premise
during I-Premise
breast I-Premise
cancer I-Premise
chemotherapy I-Premise
were I-Premise
maintained I-Premise
at I-Premise
6 I-Premise
- I-Premise
month I-Premise
follow I-Premise
- I-Premise
up I-Premise
whereas O
reductions B-Premise
in I-Premise
anxiety I-Premise
not I-Premise
observed I-Premise
with I-Premise
aet I-Premise
during I-Premise
breast I-Premise
cancer I-Premise
chemotherapy I-Premise
emerged I-Premise
at I-Premise
6 I-Premise
- I-Premise
month I-Premise
follow I-Premise
- I-Premise
up I-Premise
. I-Premise
!LF! !LF!
moreover O
, O
adopting B-Premise
a I-Premise
combined I-Premise
aerobic I-Premise
and I-Premise
resistance I-Premise
exercise I-Premise
program I-Premise
after I-Premise
breast I-Premise
cancer I-Premise
chemotherapy I-Premise
was I-Premise
associated I-Premise
with I-Premise
further I-Premise
improvements I-Premise
in I-Premise
patient I-Premise
- I-Premise
rated I-Premise
outcomes I-Premise
. I-Premise
!LF! !LF!
exercise B-Claim
training I-Claim
during I-Claim
breast I-Claim
cancer I-Claim
chemotherapy I-Claim
may I-Claim
result I-Claim
in I-Claim
some I-Claim
longer I-Claim
- I-Claim
term I-Claim
and I-Claim
late I-Claim
effects I-Claim
for I-Claim
selected I-Claim
patient I-Claim
- I-Claim
rated I-Claim
outcomes I-Claim
. I-Claim
!LF! !LF!
two O
million O
people O
across O
the O
u O
. O
k O
. O
are O
living O
with O
cancer O
, O
often O
experienced O
as O
a O
long O
- O
term O
condition O
. O
!LF! !LF!
they O
may O
have O
unmet O
needs O
after O
active O
treatment O
. O
!LF! !LF!
rehabilitation O
aims O
to O
address O
these O
needs O
, O
maximize O
psychological O
and O
physical O
function O
, O
and O
enable O
minimum O
dependency O
regardless O
of O
life O
expectancy O
. O
!LF! !LF!
we O
aimed O
to O
test O
, O
in O
a O
randomized O
controlled O
trial O
, O
the O
clinical O
and O
cost O
effectiveness O
of O
a O
rehabilitation O
intervention O
for O
patients O
with O
advanced O
, O
recurrent O
cancer O
. O
!LF! !LF!
we O
conducted O
a O
two O
- O
arm O
, O
wait O
- O
list O
control O
, O
randomized O
trial O
of O
a O
complex O
rehabilitation O
intervention O
delivered O
by O
a O
hospice O
- O
based O
multidisciplinary O
team O
vs O
. O
usual O
care O
for O
active O
, O
progressive O
, O
recurrent O
hematological O
and O
breast O
malignancies O
, O
with O
a O
follow O
- O
up O
at O
three O
months O
. O
!LF! !LF!
the O
primary O
outcome O
was O
the O
psychological O
subscale O
of O
the O
supportive O
care O
needs O
survey O
( O
scns O
) O
. O
!LF! !LF!
secondary O
outcomes O
were O
other O
domains O
of O
the O
scns O
, O
psychological O
status O
, O
continuity O
of O
care O
, O
quality O
of O
life O
, O
and O
resource O
use O
. O
!LF! !LF!
forty O
- O
one O
participants O
were O
enrolled O
and O
36 O
completed O
the O
trial O
. O
!LF! !LF!
the B-Premise
primary I-Premise
outcome I-Premise
was I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
( I-Premise
adjusted I-Premise
difference I-Premise
- I-Premise
16 I-Premise
. I-Premise
8 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
- I-Premise
28 I-Premise
. I-Premise
34 I-Premise
to I-Premise
- I-Premise
5 I-Premise
. I-Premise
3 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
006 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
scns I-Premise
physical I-Premise
and I-Premise
patient I-Premise
care I-Premise
subscales I-Premise
( I-Premise
- I-Premise
14 I-Premise
. I-Premise
2 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
- I-Premise
26 I-Premise
. I-Premise
2 I-Premise
to I-Premise
- I-Premise
2 I-Premise
. I-Premise
2 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
and I-Premise
- I-Premise
7 I-Premise
. I-Premise
4 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
- I-Premise
13 I-Premise
. I-Premise
7 I-Premise
to I-Premise
- I-Premise
1 I-Premise
. I-Premise
1 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
and I-Premise
self I-Premise
- I-Premise
reported I-Premise
health I-Premise
state I-Premise
( I-Premise
12 I-Premise
. I-Premise
8 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
3 I-Premise
. I-Premise
2 I-Premise
to I-Premise
22 I-Premise
. I-Premise
4 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
also I-Premise
differed I-Premise
significantly I-Premise
. I-Premise
!LF! !LF!
the B-Premise
incremental I-Premise
cost I-Premise
- I-Premise
effectiveness I-Premise
ratio I-Premise
was I-Premise
19 I-Premise
, I-Premise
39£ I-Premise
per I-Premise
quality I-Premise
- I-Premise
adjusted I-Premise
life I-Premise
year I-Premise
. I-Premise
!LF! !LF!
this B-Claim
intervention I-Claim
significantly I-Claim
reduced I-Claim
the I-Claim
unmet I-Claim
needs I-Claim
of I-Claim
cancer I-Claim
survivors I-Claim
and I-Claim
it I-Claim
is I-Claim
likely I-Claim
that I-Claim
it I-Claim
is I-Claim
cost I-Claim
- I-Claim
effective I-Claim
. I-Claim
!LF! !LF!
despite B-Claim
small I-Claim
numbers I-Claim
, I-Claim
the I-Claim
main I-Claim
effect I-Claim
size I-Claim
was I-Claim
robust I-Claim
. I-Claim
!LF! !LF!
we B-Claim
recommend I-Claim
implementation I-Claim
alongside I-Claim
evaluation I-Claim
in I-Claim
wider I-Claim
clinical I-Claim
settings I-Claim
and I-Claim
patient I-Claim
populations I-Claim
. I-Claim
!LF! !LF!
the O
aim O
of O
this O
study O
was O
to O
assess O
efficacy O
and O
safety O
of O
association O
of O
duloxetine O
and O
rehabilitation O
compared O
with O
rehabilitation O
alone O
in O
men O
with O
sui O
after O
radical O
retropubic O
prostatectomy O
( O
rrp O
) O
, O
and O
to O
compare O
continence O
rate O
even O
after O
planned O
duloxetine O
suspension O
. O
!LF! !LF!
after O
catheter O
removal O
, O
112 O
patients O
were O
randomized O
to O
receive O
rehabilitation O
and O
duloxetine O
( O
group O
a O
) O
or O
rehabilitation O
alone O
( O
group O
b O
) O
, O
for O
16 O
wk O
. O
!LF! !LF!
postprostatectomy O
sui O
with O
daily O
incontinent O
episodes O
frequency O
( O
ief O
) O
of O
four O
or O
greater O
. O
!LF! !LF!
after O
16 O
wk O
both O
groups O
suspended O
duloxetine O
/ O
placebo O
and O
continued O
rehabilitation O
. O
!LF! !LF!
all O
patients O
completed O
incontinence O
quality O
of O
life O
( O
i O
- O
qol O
) O
questionnaire O
and O
bladder O
diary O
. O
!LF! !LF!
wilcoxon O
test O
was O
used O
to O
analyse O
changes O
in O
ief O
and O
in O
i O
- O
qol O
score O
"""" O
; O
"""" O
fisher O
exact O
test O
was O
used O
to O
compare O
continent O
patients O
between O
the O
groups O
. O
!LF! !LF!
adverse O
events O
for O
duloxetine O
was O
15 O
. O
2 O
% O
. O
!LF! !LF!
102 O
men O
completed O
the O
study O
. O
!LF! !LF!
there B-Premise
was I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
pad I-Premise
use I-Premise
in I-Premise
group I-Premise
a I-Premise
. I-Premise
!LF! !LF!
after B-Premise
16 I-Premise
wk I-Premise
, I-Premise
39 I-Premise
patients I-Premise
versus I-Premise
27 I-Premise
were I-Premise
dry I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
007 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
at B-Premise
20 I-Premise
wk I-Premise
, I-Premise
4 I-Premise
wk I-Premise
after I-Premise
planned I-Premise
interruption I-Premise
of I-Premise
duloxetine I-Premise
, I-Premise
we I-Premise
observed I-Premise
a I-Premise
u I-Premise
- I-Premise
turn I-Premise
, I-Premise
23 I-Premise
patients I-Premise
were I-Premise
completely I-Premise
dry I-Premise
in I-Premise
group I-Premise
a I-Premise
versus I-Premise
38 I-Premise
in I-Premise
group I-Premise
b I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
008 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
whereas B-Premise
, I-Premise
after I-Premise
24 I-Premise
wk I-Premise
, I-Premise
31 I-Premise
in I-Premise
group I-Premise
a I-Premise
versus I-Premise
41 I-Premise
in I-Premise
group I-Premise
b I-Premise
were I-Premise
dry I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
08 I-Premise
) I-Premise
. O
!LF! !LF!
the B-Claim
decrease I-Claim
in I-Claim
ief I-Claim
and I-Claim
improvements I-Claim
in I-Claim
i I-Claim
- I-Claim
qol I-Claim
scores I-Claim
were I-Claim
significantly I-Claim
greater I-Claim
in I-Claim
group I-Claim
a I-Claim
for I-Claim
the I-Claim
first I-Claim
16 I-Claim
wk I-Claim
. I-Claim
!LF! !LF!
the B-Claim
data I-Claim
suggest I-Claim
that I-Claim
combination I-Claim
therapy I-Claim
might I-Claim
provide I-Claim
another I-Claim
treatment I-Claim
option I-Claim
for I-Claim
sui I-Claim
in I-Claim
men I-Claim
that I-Claim
might I-Claim
increase I-Claim
the I-Claim
percentage I-Claim
of I-Claim
early I-Claim
postsurgery I-Claim
continence I-Claim
. I-Claim
!LF! !LF!
to O
pilot O
an O
investigation O
of O
individualized O
homeopathy O
for O
symptoms O
of O
estrogen O
withdrawal O
in O
breast O
cancer O
survivors O
. O
!LF! !LF!
randomized O
, O
double O
- O
blinded O
, O
placebo O
- O
controlled O
trial O
. O
!LF! !LF!
outpatient O
department O
of O
a O
national O
health O
service O
( O
nhs O
) O
homeopathic O
hospital O
. O
!LF! !LF!
fifty O
- O
seven O
( O
57 O
) O
women O
met O
inclusion O
criteria O
and O
53 O
were O
randomized O
to O
the O
study O
. O
!LF! !LF!
after O
2 O
weeks O
of O
baseline O
assessment O
, O
all O
participants O
received O
a O
consultation O
plus O
either O
oral O
homeopathic O
medicine O
or O
placebo O
, O
assessed O
every O
4 O
weeks O
for O
16 O
weeks O
. O
!LF! !LF!
the O
primary O
outcome O
measures O
were O
the O
activity O
score O
and O
profile O
score O
of O
the O
measure O
yourself O
medical O
outcome O
profile O
( O
mymop O
) O
. O
!LF! !LF!
eighty O
- O
five O
percent O
( O
85 O
% O
) O
( O
45 O
/ O
53 O
) O
of O
women O
completed O
the O
study O
. O
!LF! !LF!
there B-Premise
was I-Premise
no I-Premise
evidence I-Premise
of I-Premise
a I-Premise
difference I-Premise
seen I-Premise
between I-Premise
groups I-Premise
for I-Premise
either I-Premise
activity I-Premise
( I-Premise
adjusted I-Premise
difference I-Premise
= I-Premise
- I-Premise
0 I-Premise
. I-Premise
4 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
ci I-Premise
- I-Premise
1 I-Premise
. I-Premise
0 I-Premise
to I-Premise
0 I-Premise
. I-Premise
2 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
17 I-Premise
) I-Premise
or I-Premise
profile I-Premise
scores I-Premise
( I-Premise
adjusted I-Premise
difference I-Premise
= I-Premise
- I-Premise
0 I-Premise
. I-Premise
4 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
- I-Premise
0 I-Premise
. I-Premise
9 I-Premise
to I-Premise
0 I-Premise
. I-Premise
1 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
13 I-Premise
) I-Premise
using I-Premise
this I-Premise
trial I-Premise
design I-Premise
, I-Premise
although B-Claim
post I-Claim
hoc I-Claim
power I-Claim
calculations I-Claim
suggests I-Claim
that I-Claim
65 I-Claim
- I-Claim
175 I-Claim
would I-Claim
be I-Claim
needed I-Claim
per I-Claim
group I-Claim
to I-Claim
detect I-Claim
differences I-Claim
of I-Claim
this I-Claim
magnitude I-Claim
with I-Claim
sufficient I-Claim
precision I-Claim
. I-Claim
!LF! !LF!
clinically B-Premise
relevant I-Premise
improvements I-Premise
in I-Premise
symptoms I-Premise
and I-Premise
mood I-Premise
disturbance I-Premise
were I-Premise
seen I-Premise
for I-Premise
both I-Premise
groups I-Premise
over I-Premise
the I-Premise
study I-Premise
period I-Premise
. I-Premise
!LF! !LF!
improvements B-Claim
were I-Claim
seen I-Claim
for I-Claim
symptom I-Claim
scores I-Claim
over I-Claim
the I-Claim
study I-Claim
period I-Claim
. I-Claim
!LF! !LF!
however B-Claim
, I-Claim
presuming I-Claim
these I-Claim
improvements I-Claim
were I-Claim
caused I-Claim
by I-Claim
the I-Claim
individualized I-Claim
homeopathic I-Claim
approach I-Claim
, I-Claim
the I-Claim
study I-Claim
failed I-Claim
to I-Claim
show I-Claim
clearly I-Claim
that I-Claim
the I-Claim
specific I-Claim
effect I-Claim
of I-Claim
the I-Claim
remedy I-Claim
added I-Claim
further I-Claim
to I-Claim
the I-Claim
nonspecific I-Claim
effects I-Claim
of I-Claim
the I-Claim
consultation I-Claim
. I-Claim
!LF! !LF!
future B-Claim
trial I-Claim
design I-Claim
must I-Claim
ensure I-Claim
adequate I-Claim
power I-Claim
to I-Claim
account I-Claim
for I-Claim
the I-Claim
nonspecific I-Claim
impact I-Claim
of I-Claim
such I-Claim
complex I-Claim
individualized I-Claim
interventions I-Claim
while I-Claim
pragmatic I-Claim
designs I-Claim
may I-Claim
more I-Claim
readily I-Claim
answer I-Claim
questions I-Claim
of I-Claim
clinical I-Claim
and I-Claim
cost I-Claim
effectiveness I-Claim
. O
!LF! !LF!
a O
phase O
iii O
trial O
( O
cancer O
and O
leukemia O
group O
b O
calgb O
- O
49907 O
) O
was O
conducted O
to O
test O
whether O
older O
patients O
with O
early O
- O
stage O
breast O
cancer O
would O
have O
equivalent O
relapse O
- O
free O
and O
overall O
survival O
with O
capecitabine O
compared O
with O
standard O
chemotherapy O
. O
!LF! !LF!
the O
quality O
of O
life O
( O
qol O
) O
substudy O
tested O
whether O
capecitabine O
treatment O
would O
be O
associated O
with O
a O
better O
qol O
than O
standard O
chemotherapy O
. O
!LF! !LF!
qol O
was O
assessed O
in O
350 O
patients O
randomly O
assigned O
to O
either O
standard O
chemotherapy O
( O
cyclophosphamide O
, O
methotrexate O
, O
and O
fluorouracil O
[ O
cmf O
] O
or O
doxorubicin O
and O
cyclophosphamide O
[ O
ac O
] O
"""" O
; O
"""" O
n O
= O
182 O
) O
or O
capecitabine O
( O
n O
= O
168 O
) O
. O
!LF! !LF!
patients O
were O
interviewed O
by O
telephone O
before O
treatment O
( O
baseline O
) O
, O
midtreatment O
, O
within O
1 O
month O
post O
- O
treatment O
, O
and O
at O
12 O
, O
18 O
, O
and O
24 O
months O
postbaseline O
by O
using O
questionnaires O
from O
the O
european O
organisation O
for O
research O
and O
treatment O
of O
cancer O
quality O
of O
life O
questionnaire O
c30 O
( O
eortc O
qlq O
- O
c30 O
) O
, O
a O
breast O
systemic O
adverse O
effects O
scale O
( O
eortc O
br23 O
) O
, O
and O
the O
hospital O
anxiety O
and O
depression O
scale O
( O
hads O
) O
. O
!LF! !LF!
compared B-Premise
with I-Premise
patients I-Premise
who I-Premise
were I-Premise
treated I-Premise
with I-Premise
standard I-Premise
chemotherapy I-Premise
, I-Premise
patients I-Premise
who I-Premise
were I-Premise
treated I-Premise
with I-Premise
capecitabine I-Premise
had I-Premise
significantly I-Premise
better I-Premise
qol I-Premise
, I-Premise
role I-Premise
function I-Premise
, I-Premise
and I-Premise
social I-Premise
function I-Premise
, I-Premise
fewer I-Premise
systemic I-Premise
adverse I-Premise
effects I-Premise
, I-Premise
less I-Premise
psychological I-Premise
distress I-Premise
, I-Premise
and I-Premise
less I-Premise
fatigue I-Premise
during I-Premise
and I-Premise
at I-Premise
the I-Premise
completion I-Premise
of I-Premise
treatment I-Premise
( I-Premise
p I-Premise
≤ I-Premise
. I-Premise
005 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
capecitabine B-Premise
treatment I-Premise
was I-Premise
associated I-Premise
with I-Premise
less I-Premise
nausea I-Premise
, I-Premise
vomiting I-Premise
, I-Premise
and I-Premise
constipation I-Premise
and I-Premise
with I-Premise
better I-Premise
appetite I-Premise
than I-Premise
standard I-Premise
treatment I-Premise
( I-Premise
p I-Premise
≤ I-Premise
. I-Premise
004 I-Premise
) I-Premise
, I-Premise
but I-Premise
worse I-Premise
hand I-Premise
- I-Premise
foot I-Premise
syndrome I-Premise
and I-Premise
diarrhea I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
005 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
these O
differences O
all O
resolved O
by O
12 O
months O
. O
!LF! !LF!
standard B-Claim
chemotherapy I-Claim
was I-Claim
superior I-Claim
to I-Claim
capecitabine I-Claim
in I-Claim
improving I-Claim
relapse I-Claim
- I-Claim
free I-Claim
and I-Claim
overall I-Claim
survival I-Claim
for I-Claim
older I-Claim
women I-Claim
with I-Claim
early I-Claim
- I-Claim
stage I-Claim
breast I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
although O
capecitabine B-Claim
was I-Claim
associated I-Claim
with I-Claim
better I-Claim
qol I-Claim
during I-Claim
treatment I-Claim
, O
qol B-Premise
was I-Premise
similar I-Premise
for I-Premise
both I-Premise
groups I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise
!LF! !LF!
the O
brief O
period O
of O
poorer O
qol O
with O
standard O
treatment O
is O
a O
modest O
price O
to O
pay O
for O
a O
chance O
at O
improved O
survival O
. O
!LF! !LF!
to O
assess O
whether O
the O
administration O
of O
recombinant O
human O
erythropoietin O
( O
r O
- O
huepo O
) O
would O
increase O
the O
hematocrit O
, O
reduce O
the O
requirement O
for O
transfusion O
, O
and O
improve O
the O
quality O
of O
life O
in O
anemic O
cancer O
patients O
receiving O
myelosuppressive O
, O
cisplatin O
- O
based O
chemotherapy O
. O
!LF! !LF!
one O
hundred O
thirty O
- O
two O
anemic O
cancer O
patients O
receiving O
cyclic O
, O
cisplatin O
- O
containing O
, O
myelosuppressive O
chemotherapy O
were O
evaluated O
. O
!LF! !LF!
patients O
received O
either O
r O
- O
huepo O
( O
150 O
u O
/ O
kg O
) O
or O
placebo O
, O
subcutaneously O
, O
three O
times O
a O
week O
for O
3 O
months O
. O
!LF! !LF!
responses O
were O
assessed O
by O
measuring O
changes O
in O
hemoglobin O
/ O
hematocrit O
, O
transfusion O
requirement O
, O
and O
quality O
of O
life O
. O
!LF! !LF!
the B-Premise
mean I-Premise
hematocrit I-Premise
increased I-Premise
by I-Premise
6 I-Premise
. I-Premise
0 I-Premise
percentage I-Premise
points I-Premise
in I-Premise
the I-Premise
r I-Premise
- I-Premise
huepo I-Premise
group I-Premise
versus I-Premise
1 I-Premise
. I-Premise
3 I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise
!LF! !LF!
a B-Premise
decrease I-Premise
in I-Premise
transfusion I-Premise
requirement I-Premise
did I-Premise
not I-Premise
reach I-Premise
significance I-Premise
over I-Premise
all I-Premise
3 I-Premise
months I-Premise
, I-Premise
but I-Premise
there I-Premise
was I-Premise
a I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
the I-Premise
percentage I-Premise
of I-Premise
patients I-Premise
transfused I-Premise
in I-Premise
the I-Premise
second I-Premise
and I-Premise
third I-Premise
months I-Premise
( I-Premise
27 I-Premise
% I-Premise
r I-Premise
- I-Premise
huepo I-Premise
vs I-Premise
. I-Premise
56 I-Premise
% I-Premise
placebo I-Premise
) I-Premise
and I-Premise
a I-Premise
trend I-Premise
toward I-Premise
reduction I-Premise
in I-Premise
the I-Premise
mean I-Premise
total I-Premise
number I-Premise
of I-Premise
units I-Premise
transfused I-Premise
( I-Premise
1 I-Premise
. I-Premise
20 I-Premise
units I-Premise
r I-Premise
- I-Premise
huepo I-Premise
vs I-Premise
. I-Premise
2 I-Premise
. I-Premise
02 I-Premise
units I-Premise
placebo I-Premise
) I-Premise
, I-Premise
suggesting I-Premise
a I-Premise
lag I-Premise
of I-Premise
1 I-Premise
month I-Premise
before I-Premise
r I-Premise
- I-Premise
huepo I-Premise
can I-Premise
affect I-Premise
the I-Premise
transfusion I-Premise
requirement I-Premise
. I-Premise
!LF! !LF!
pretreatment B-Premise
serum I-Premise
erythropoietin I-Premise
levels I-Premise
were I-Premise
lower I-Premise
in I-Premise
responders I-Premise
than I-Premise
in I-Premise
nonresponders I-Premise
( I-Premise
73 I-Premise
. I-Premise
5 I-Premise
iu I-Premise
/ I-Premise
l I-Premise
and I-Premise
86 I-Premise
. I-Premise
3 I-Premise
iu I-Premise
/ I-Premise
l I-Premise
means I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise
!LF! !LF!
however B-Premise
, I-Premise
the I-Premise
magnitude I-Premise
of I-Premise
this I-Premise
difference I-Premise
was I-Premise
not I-Premise
helpful I-Premise
in I-Premise
defining I-Premise
which I-Premise
patients I-Premise
were I-Premise
likely I-Premise
to I-Premise
respond I-Premise
. I-Premise
!LF! !LF!
there B-Premise
was I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
arms I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
r I-Premise
- I-Premise
huepo I-Premise
- I-Premise
treated I-Premise
group I-Premise
. I-Premise
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
significant I-Premise
adverse I-Premise
effects I-Premise
associated I-Premise
with I-Premise
r I-Premise
- I-Premise
huepo I-Premise
. I-Premise
!LF! !LF!
r B-Claim
- B-Claim
huepo B-Claim
is I-Claim
safe I-Claim
and I-Claim
can I-Claim
cause I-Claim
a I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
the I-Claim
hematocrit I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
of I-Claim
anemic I-Claim
cancer I-Claim
patients I-Claim
receiving I-Claim
myelosuppressive I-Claim
, I-Claim
cisplatin I-Claim
- I-Claim
based I-Claim
chemotherapy I-Claim
. I-Claim
!LF! !LF!
after B-Claim
1 I-Claim
month I-Claim
of I-Claim
r I-Claim
- I-Claim
huepo I-Claim
, I-Claim
there I-Claim
is I-Claim
also I-Claim
a I-Claim
reduction I-Claim
in I-Claim
transfusion I-Claim
requirement I-Claim
. I-Claim
!LF! !LF!
older O
breast O
cancer O
survivors O
( O
bcss O
) O
are O
at O
risk O
for O
late O
and O
long O
- O
term O
treatment O
effects O
on O
quality O
of O
life O
( O
qol O
) O
, O
including O
lower O
physical O
functioning O
and O
fear O
of O
recurrence O
. O
!LF! !LF!
two O
promising O
approaches O
to O
address O
this O
include O
dance O
/ O
movement O
therapy O
and O
mindfulness O
. O
!LF! !LF!
the O
purpose O
of O
this O
2 O
- O
group O
randomized O
controlled O
pilot O
feasibility O
study O
was O
to O
test O
short O
- O
term O
effects O
of O
a O
12 O
- O
week O
mindful O
movement O
program O
( O
mmp O
) O
intervention O
combining O
mindfulness O
with O
self O
- O
directed O
movement O
on O
qol O
and O
mindfulness O
in O
female O
bcss O
50 O
years O
or O
older O
and O
at O
12 O
months O
or O
more O
following O
treatment O
. O
!LF! !LF!
consented O
participants O
were O
randomized O
to O
an O
experimental O
group O
( O
eg O
) O
( O
12 O
weekly O
mmp O
sessions O
) O
or O
a O
control O
group O
( O
no O
sessions O
) O
. O
!LF! !LF!
all O
completed O
questionnaires O
3 O
times O
. O
!LF! !LF!
the O
eg O
participants O
kept O
home O
practice O
diaries O
. O
!LF! !LF!
analysis O
was O
conducted O
after O
intervention O
for O
immediate O
effects O
on O
outcome O
variables O
and O
6 O
weeks O
later O
for O
maintenance O
of O
effects O
. O
!LF! !LF!
participants O
( O
n O
= O
49 O
) O
ranged O
in O
age O
from O
50 O
to O
90 O
years O
( O
average O
, O
65 O
. O
6 O
years O
) O
and O
were O
at O
9 O
. O
8 O
years O
since O
diagnosis O
( O
range O
, O
1 O
- O
32 O
years O
) O
, O
and O
the O
majority O
were O
white O
, O
unpartnered O
, O
and O
retired O
. O
!LF! !LF!
after B-Premise
intervention I-Premise
, I-Premise
eg I-Premise
participants I-Premise
showed I-Premise
improved I-Premise
qol I-Premise
via I-Premise
decreased I-Premise
fear I-Premise
of I-Premise
recurrence I-Premise
and I-Premise
increased I-Premise
mindfulness I-Premise
attitude I-Premise
. I-Premise
!LF! !LF!
at B-Premise
6 I-Premise
weeks I-Premise
, I-Premise
initial I-Premise
effects I-Premise
were I-Premise
retained I-Premise
. I-Premise
!LF! !LF!
the B-Premise
mmp I-Premise
appears I-Premise
to I-Premise
benefit I-Premise
older I-Premise
bcss I-Premise
by I-Premise
reducing I-Premise
fear I-Premise
of I-Premise
recurrence I-Premise
and I-Premise
improving I-Premise
mindfulness I-Premise
attitude I-Premise
. I-Premise
!LF! !LF!
although B-Claim
these I-Claim
findings I-Claim
are I-Claim
promising I-Claim
, I-Claim
a I-Claim
larger I-Claim
study I-Claim
is I-Claim
needed I-Claim
to I-Claim
determine I-Claim
more I-Claim
specifically I-Claim
what I-Claim
short I-Claim
- I-Claim
and I-Claim
long I-Claim
- I-Claim
term I-Claim
effects I-Claim
are I-Claim
possible I-Claim
. I-Claim
!LF! !LF!
the B-Claim
combination I-Claim
of I-Claim
self I-Claim
- I-Claim
directed I-Claim
movement I-Claim
and I-Claim
mindfulness I-Claim
, I-Claim
as I-Claim
tested I-Claim
here I-Claim
, I-Claim
may I-Claim
be I-Claim
a I-Claim
valuable I-Claim
tool I-Claim
for I-Claim
promoting I-Claim
health I-Claim
and I-Claim
well I-Claim
- I-Claim
being I-Claim
in I-Claim
older I-Claim
long I-Claim
- I-Claim
term I-Claim
survivors I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
n O
, O
n O
- O
diethyl O
- O
2 O
- O
[ O
- O
4 O
( O
phenylmethyl O
) O
phenoxy O
] O
ethanamine O
( O
dppe O
"""" O
; O
"""" O
tesmilifene O
) O
is O
a O
novel O
agent O
that O
augments O
chemotherapy O
cytotoxicity O
in O
vitro O
and O
in O
vivo O
. O
!LF! !LF!
a O
phase O
ii O
trial O
combining O
dppe O
and O
doxorubicin O
( O
dox O
) O
in O
metastatic O
breast O
carcinoma O
showed O
increased O
response O
over O
that O
expected O
with O
dox O
. O
!LF! !LF!
we O
report O
a O
phase O
iii O
trial O
comparing O
dox O
with O
dppe O
plus O
dox O
in O
metastatic O
or O
recurrent O
breast O
cancer O
. O
!LF! !LF!
anthracycline O
- O
naive O
women O
with O
measurable O
metastatic O
disease O
were O
randomly O
assigned O
to O
receive O
, O
every O
21 O
days O
, O
either O
dox O
60 O
mg O
/ O
m O
( O
2 O
) O
intravenously O
or O
dox O
during O
the O
last O
20 O
minutes O
of O
an O
80 O
- O
minute O
infusion O
of O
dppe O
( O
5 O
. O
3 O
mg O
/ O
kg O
) O
, O
in O
both O
cases O
to O
cumulative O
dox O
doses O
of O
450 O
mg O
/ O
m O
( O
2 O
) O
. O
!LF! !LF!
patients O
receiving O
dppe O
were O
aggressively O
premedicated O
to O
ameliorate O
toxicity O
. O
!LF! !LF!
end O
points O
included O
progression O
- O
free O
survival O
( O
pfs O
) O
, O
response O
rate O
( O
rr O
) O
, O
and O
response O
duration O
( O
rd O
) O
, O
quality O
of O
life O
( O
qol O
) O
, O
toxicity O
, O
and O
overall O
survival O
( O
os O
) O
. O
!LF! !LF!
a O
planned O
interim O
analysis O
failed O
to O
detect O
an O
rr O
difference O
more O
than O
5 O
% O
. O
!LF! !LF!
the O
study O
was O
closed O
to O
additional O
accrual O
and O
all O
dppe O
was O
discontinued O
. O
!LF! !LF!
the O
final O
analysis O
was O
conducted O
as O
planned O
after O
256 O
progression O
events O
( O
median O
follow O
- O
up O
, O
20 O
. O
5 O
months O
) O
. O
!LF! !LF!
there B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
rr I-Premise
, I-Premise
rd I-Premise
, I-Premise
or I-Premise
pfs I-Premise
between I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
dppe B-Premise
plus I-Premise
dox I-Premise
was I-Premise
statistically I-Premise
superior I-Premise
to I-Premise
dox I-Premise
in I-Premise
os I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0 I-Premise
. I-Premise
66 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
48 I-Premise
to I-Premise
0 I-Premise
. I-Premise
91 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
021 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
dppe B-Premise
plus I-Premise
dox I-Premise
was I-Premise
associated I-Premise
with I-Premise
more I-Premise
gastrointestinal I-Premise
and I-Premise
cns I-Premise
toxicity I-Premise
. I-Premise
!LF! !LF!
no B-Premise
consistent I-Premise
influence I-Premise
on I-Premise
qol I-Premise
was I-Premise
detected I-Premise
. I-Premise
!LF! !LF!
this B-Claim
study I-Claim
demonstrated I-Claim
no I-Claim
advantage I-Claim
in I-Claim
rr I-Claim
, I-Claim
rd I-Claim
, I-Claim
or I-Claim
pfs I-Claim
but I-Claim
significantly I-Claim
superior I-Claim
os I-Claim
for I-Claim
dppe I-Claim
plus I-Claim
dox I-Claim
. I-Claim
!LF! !LF!
additional B-Claim
studies I-Claim
of I-Claim
dppe I-Claim
are I-Claim
warranted I-Claim
. I-Claim
!LF! !LF!
experimental B-Claim
and I-Claim
early I-Claim
clinical I-Claim
investigations I-Claim
have I-Claim
demonstrated I-Claim
encouraging I-Claim
results I-Claim
for I-Claim
estramustine I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
malignant I-Claim
glioma I-Claim
. O
!LF! !LF!
the O
present O
study O
is O
an O
open O
randomized O
clinical O
trial O
comparing O
estramustine O
phosphate O
( O
estracyt O
) O
in O
addition O
to O
radiotherapy O
with O
radiotherapy O
alone O
as O
first O
line O
treatment O
of O
astrocytoma O
grade O
iii O
and O
iv O
. O
!LF! !LF!
the O
140 O
patients O
included O
were O
in O
a O
good O
clinical O
condition O
with O
a O
median O
age O
of O
55 O
years O
( O
range O
22 O
- O
87 O
) O
. O
!LF! !LF!
estramustine O
was O
given O
orally O
, O
280 O
mg O
twice O
daily O
, O
as O
soon O
as O
the O
diagnosis O
was O
established O
, O
during O
and O
after O
the O
radiotherapy O
for O
a O
period O
of O
in O
total O
3 O
months O
. O
!LF! !LF!
radiotherapy O
was O
delivered O
on O
weekdays O
2 O
gy O
daily O
up O
to O
56 O
gy O
. O
!LF! !LF!
eighteen O
patients O
were O
excluded O
due O
to O
misclassification O
, O
leaving O
122 O
patients O
eligible O
for O
evaluation O
. O
!LF! !LF!
overall B-Premise
the I-Premise
treatment I-Premise
was I-Premise
well I-Premise
tolerated I-Premise
. O
!LF! !LF!
mild B-Premise
or I-Premise
moderate I-Premise
nausea I-Premise
was I-Premise
the I-Premise
most I-Premise
common I-Premise
side I-Premise
effect I-Premise
of I-Premise
estramustine I-Premise
. I-Premise
!LF! !LF!
the O
minimum O
follow O
- O
up O
time O
was O
5 O
. O
2 O
years O
for O
the O
surviving O
patients O
. O
!LF! !LF!
for B-Premise
astrocytoma I-Premise
grade I-Premise
iii I-Premise
the I-Premise
median I-Premise
survival I-Premise
time I-Premise
was I-Premise
10 I-Premise
. I-Premise
6 I-Premise
( I-Premise
1 I-Premise
. I-Premise
3 I-Premise
- I-Premise
92 I-Premise
. I-Premise
7 I-Premise
) I-Premise
months I-Premise
for I-Premise
the I-Premise
radiotherapy I-Premise
only I-Premise
group I-Premise
and I-Premise
17 I-Premise
. I-Premise
3 I-Premise
( I-Premise
0 I-Premise
. I-Premise
4 I-Premise
- I-Premise
96 I-Premise
. I-Premise
9 I-Premise
+ I-Premise
) I-Premise
months I-Premise
for I-Premise
the I-Premise
estramustine I-Premise
+ I-Premise
radiotherapy I-Premise
group I-Premise
. I-Premise
!LF! !LF!
in B-Premise
grade I-Premise
iv I-Premise
the I-Premise
corresponding I-Premise
median I-Premise
survival I-Premise
time I-Premise
was I-Premise
12 I-Premise
. I-Premise
3 I-Premise
( I-Premise
2 I-Premise
. I-Premise
1 I-Premise
- I-Premise
89 I-Premise
. I-Premise
2 I-Premise
) I-Premise
and I-Premise
10 I-Premise
. I-Premise
3 I-Premise
( I-Premise
0 I-Premise
. I-Premise
3 I-Premise
- I-Premise
91 I-Premise
. I-Premise
7 I-Premise
+ I-Premise
) I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
median B-Premise
time I-Premise
to I-Premise
progress I-Premise
for I-Premise
radiotherapy I-Premise
only I-Premise
and I-Premise
radiotherapy I-Premise
and I-Premise
estramustin I-Premise
group I-Premise
in I-Premise
grade I-Premise
iii I-Premise
tumours I-Premise
was I-Premise
6 I-Premise
. I-Premise
5 I-Premise
and I-Premise
10 I-Premise
. I-Premise
1 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
in B-Premise
grade I-Premise
iv I-Premise
tumours I-Premise
the I-Premise
corresponding I-Premise
figures I-Premise
were I-Premise
5 I-Premise
. I-Premise
1 I-Premise
and I-Premise
3 I-Premise
. I-Premise
3 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
although B-Premise
there I-Premise
was I-Premise
a I-Premise
tendency I-Premise
for I-Premise
improved I-Premise
survival I-Premise
in I-Premise
grade I-Premise
iii I-Premise
, I-Premise
no I-Premise
statistical I-Premise
significant I-Premise
differences I-Premise
were I-Premise
found I-Premise
between I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
no B-Premise
differences I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
groups I-Premise
were I-Premise
evident I-Premise
with I-Premise
respect I-Premise
to I-Premise
quality I-Premise
of I-Premise
life I-Premise
according I-Premise
to I-Premise
the I-Premise
eortc I-Premise
qlq I-Premise
- I-Premise
protocol I-Premise
. I-Premise
!LF! !LF!
in B-Claim
conclusion I-Claim
, I-Claim
this I-Claim
first I-Claim
randomized I-Claim
study I-Claim
did I-Claim
not I-Claim
demonstrate I-Claim
any I-Claim
significant I-Claim
improvement I-Claim
of I-Claim
using I-Claim
estramustine I-Claim
in I-Claim
addition I-Claim
to I-Claim
conventional I-Claim
radiotherapy I-Claim
, I-Claim
however B-Claim
, I-Claim
a I-Claim
trend I-Claim
for I-Claim
a I-Claim
positive I-Claim
response I-Claim
for I-Claim
the I-Claim
estramustine I-Claim
group I-Claim
was I-Claim
found I-Claim
in I-Claim
patients I-Claim
with I-Claim
grade I-Claim
iii I-Claim
glioma I-Claim
. I-Claim
!LF! !LF!
in B-Claim
advanced I-Claim
not I-Claim
selected I-Claim
nsclc I-Claim
chemotherapy I-Claim
achieved I-Claim
an I-Claim
advantage I-Claim
of I-Claim
approximately I-Claim
1 I-Claim
- I-Claim
2 I-Claim
months I-Claim
on I-Claim
median I-Claim
survival I-Claim
versus I-Claim
best I-Claim
supportive I-Claim
care I-Claim
. I-Claim
!LF! !LF!
chemotherapy B-Claim
seems I-Claim
to I-Claim
improve I-Claim
symptoms I-Claim
control I-Claim
, I-Claim
even O
if O
randomised O
studies O
with O
quality O
of O
life O
as O
first O
endpoint O
are O
lacking O
and O
often O
chemotherapy O
toxicity O
compromises O
the O
frail O
cost O
/ O
benefit O
ratio O
. O
!LF! !LF!
the O
aim O
of O
the O
present O
study O
is O
to O
evaluate O
the O
impact O
on O
qol O
, O
substituting O
cisplatin O
, O
a O
pivot O
drug O
in O
nsclc O
therapy O
, O
with O
carboplatin O
, O
an O
analogue O
with O
an O
improved O
toxicity O
profile O
. O
!LF! !LF!
the O
combination O
of O
cisplatin O
with O
mitomycin O
and O
vinblastine O
was O
one O
of O
the O
most O
frequently O
used O
in O
the O
palliative O
setting O
at O
the O
time O
of O
design O
of O
our O
study O
. O
!LF! !LF!
patients O
were O
randomized O
to O
receive O
mvp O
regimen O
( O
mitomycin O
- O
c O
8 O
mg O
/ O
m2 O
d1 O
, O
vinblastine O
4 O
mg O
/ O
m2 O
d O
1 O
- O
8 O
, O
cisplatin O
100 O
mg O
/ O
m2 O
d1 O
) O
or O
mvc O
regimen O
( O
mitomycin O
- O
c O
8 O
mg O
/ O
m2 O
d1 O
, O
vinblastine O
4 O
mg O
/ O
m2 O
d O
1 O
- O
8 O
, O
carboplatin O
300 O
mg O
/ O
m2 O
d1 O
) O
every O
3 O
weeks O
. O
!LF! !LF!
the O
qol O
was O
evaluated O
by O
the O
spitzer O
ql O
- O
index O
and O
by O
the O
eortc O
qlq O
- O
c30 O
+ O
lc O
13 O
questionnaires O
before O
chemotherapy O
, O
after O
one O
cycle O
, O
after O
three O
cycles O
, O
and O
then O
every O
6 O
weeks O
in O
the O
first O
6 O
months O
and O
every O
3 O
months O
thenafter O
. O
!LF! !LF!
from O
september O
1994 O
to O
july O
1997 O
, O
153 O
consecutive O
patients O
were O
randomized O
to O
mvp O
( O
75 O
patients O
) O
or O
mvc O
arm O
( O
78 O
patients O
) O
. O
!LF! !LF!
despite B-Premise
difficulties I-Premise
in I-Premise
carrying I-Premise
out I-Premise
and I-Premise
analysing I-Premise
qol I-Premise
items I-Premise
in I-Premise
such I-Premise
patients I-Premise
, I-Premise
the I-Premise
global I-Premise
qol I-Premise
evaluated I-Premise
by I-Premise
the I-Premise
spitzer I-Premise
' I-Premise
s I-Premise
questionnaire I-Premise
suggested I-Premise
an I-Premise
advantage I-Premise
for I-Premise
mvc I-Premise
regimen I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
and I-Premise
a I-Premise
significant I-Premise
difference I-Premise
was I-Premise
observed I-Premise
in I-Premise
global I-Premise
health I-Premise
subdomain I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
04 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
disease I-Premise
- I-Premise
related I-Premise
symptoms I-Premise
improved I-Premise
with I-Premise
time I-Premise
, I-Premise
and O
the B-Premise
benefits I-Premise
lasted I-Premise
for I-Premise
the I-Premise
entire I-Premise
treatment I-Premise
period I-Premise
. I-Premise
!LF! !LF!
when B-Premise
evaluated I-Premise
with I-Premise
the I-Premise
eortc I-Premise
questionnaire I-Premise
there I-Premise
was I-Premise
significantly I-Premise
less I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0001 I-Premise
) I-Premise
, I-Premise
appetite I-Premise
loss I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
, I-Premise
insomnia I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
03 I-Premise
) I-Premise
, I-Premise
constipation I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
and I-Premise
peripheral I-Premise
neuropathy I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
in I-Premise
favour I-Premise
of I-Premise
mvc I-Premise
, I-Premise
and I-Premise
a I-Premise
trend I-Premise
for I-Premise
less I-Premise
hair I-Premise
loss I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
advantage I-Premise
lasted I-Premise
for I-Premise
all I-Premise
the I-Premise
duration I-Premise
of I-Premise
chemotherapy I-Premise
. I-Premise
!LF! !LF!
no B-Premise
differences I-Premise
were I-Premise
observed I-Premise
in I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
subdomain I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
40 I-Premise
) I-Premise
between I-Premise
the I-Premise
two I-Premise
regimen I-Premise
. I-Premise
!LF! !LF!
qol O
was O
the O
first O
endpoint O
and O
the O
statistical O
power O
was O
inadequate O
to O
assess O
other O
parameters O
. O
!LF! !LF!
however O
, O
we B-Premise
reported I-Premise
a I-Premise
response I-Premise
rate I-Premise
of I-Premise
43 I-Premise
. I-Premise
1 I-Premise
and I-Premise
38 I-Premise
. I-Premise
6 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
in I-Premise
mvp I-Premise
and I-Premise
mvc I-Premise
arm I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
59 I-Premise
) I-Premise
and I-Premise
a I-Premise
median I-Premise
survival I-Premise
of I-Premise
10 I-Premise
. I-Premise
2 I-Premise
and I-Premise
7 I-Premise
. I-Premise
2 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
cisplatin I-Premise
and I-Premise
carboplatin I-Premise
arm I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
39 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
carboplatin I-Premise
containing I-Premise
regimen I-Premise
( I-Premise
mvc I-Premise
) I-Premise
has I-Premise
a I-Premise
significant I-Premise
better I-Premise
toxicity I-Premise
profile I-Premise
than I-Premise
the I-Premise
cisplatin I-Premise
containing I-Premise
( I-Premise
mvp I-Premise
) I-Premise
regimen I-Premise
as I-Premise
proven I-Premise
both I-Premise
by I-Premise
the I-Premise
eortc I-Premise
questionnaires I-Premise
and I-Premise
by I-Premise
the I-Premise
who I-Premise
toxicity I-Premise
data I-Premise
reported I-Premise
by I-Premise
physicians I-Premise
. I-Premise
!LF! !LF!
no B-Claim
significant I-Claim
differences I-Claim
in I-Claim
terms I-Claim
of I-Claim
response I-Claim
rate I-Claim
, I-Claim
time I-Claim
to I-Claim
progression I-Claim
and I-Claim
overall I-Claim
survival I-Claim
were I-Claim
observed I-Claim
between I-Claim
the I-Claim
two I-Claim
regimen I-Claim
. I-Claim
!LF! !LF!
the B-Claim
two I-Claim
chemotherapy I-Claim
regimen I-Claim
showed I-Claim
a I-Claim
similar I-Claim
effectiveness I-Claim
in I-Claim
symptom I-Claim
palliation I-Claim
when I-Claim
evaluated I-Claim
with I-Claim
c30 I-Claim
addendum I-Claim
of I-Claim
eortc I-Claim
qol I-Claim
questionnaire I-Claim
. I-Claim
!LF! !LF!
with B-Premise
the I-Premise
spitzer I-Premise
' I-Premise
s I-Premise
questionnaires I-Premise
a I-Premise
trend I-Premise
towards I-Premise
an I-Premise
improved I-Premise
quality I-Premise
of I-Premise
life I-Premise
index I-Premise
was I-Premise
observed I-Premise
during I-Premise
treatment I-Premise
with I-Premise
the I-Premise
carboplatin I-Premise
combination I-Premise
in I-Premise
comparison I-Premise
to I-Premise
the I-Premise
cisplatin I-Premise
combination I-Premise
. I-Premise
!LF! !LF!
this B-Premise
difference I-Premise
, I-Premise
however I-Premise
, I-Premise
was I-Premise
not I-Premise
observed I-Premise
when I-Premise
the I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
evaluated I-Premise
with I-Premise
the I-Premise
eortc I-Premise
patients I-Premise
compiled I-Premise
questionnaires I-Premise
. I-Premise
!LF! !LF!
a B-Claim
carboplatin I-Claim
containing I-Claim
regimen I-Claim
with I-Claim
better I-Claim
toxicity I-Claim
profile I-Claim
and I-Claim
a I-Claim
similar I-Claim
potentiality I-Claim
for I-Claim
symptoms I-Claim
control I-Claim
offers I-Claim
an I-Claim
option I-Claim
in I-Claim
comparison I-Claim
to I-Claim
similar I-Claim
cisplatin I-Claim
containing I-Claim
combinations I-Claim
in I-Claim
the I-Claim
palliative I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
nsclc I-Claim
. I-Claim
!LF! !LF!
to O
determine O
1 O
- O
year O
outcomes O
of O
a O
four O
- O
component O
behavioral O
therapy O
( O
bt O
) O
sleep O
intervention O
( O
individualized O
sleep O
promotion O
plan O
[ O
ispp O
] O
) O
versus O
a O
healthy O
eating O
control O
( O
hec O
) O
on O
cancer O
- O
related O
fatigue O
in O
women O
receiving O
breast O
cancer O
adjuvant O
chemotherapy O
treatment O
( O
ctx O
) O
. O
!LF! !LF!
a O
total O
of O
219 O
participants O
from O
12 O
oncology O
clinics O
were O
randomly O
assigned O
in O
a O
clinical O
trial O
. O
!LF! !LF!
before O
ctx O
, O
research O
nurses O
coached O
intervention O
participants O
to O
develop O
a O
bt O
plan O
including O
stimulus O
control O
, O
modified O
sleep O
restriction O
, O
relaxation O
therapy O
, O
and O
sleep O
hygiene O
. O
!LF! !LF!
bt O
plans O
were O
revised O
before O
each O
ctx O
and O
30 O
, O
60 O
, O
and O
90 O
days O
after O
the O
last O
ctx O
and O
reinforced O
7 O
to O
9 O
days O
later O
. O
!LF! !LF!
hec O
participants O
received O
nutritional O
information O
and O
equal O
attention O
. O
!LF! !LF!
pittsburgh O
sleep O
quality O
index O
( O
psqi O
) O
, O
daily O
diary O
, O
wrist O
actigraph O
, O
and O
piper O
fatigue O
scale O
measures O
and O
repeated O
linear O
mixed O
model O
analysis O
following O
the O
intent O
to O
treat O
paradigm O
were O
used O
. O
!LF! !LF!
sleep B-Premise
quality I-Premise
differed I-Premise
over I-Premise
1 I-Premise
years I-Premise
time I-Premise
( I-Premise
f I-Premise
[ I-Premise
4 I-Premise
, I-Premise
162 I-Premise
] I-Premise
= I-Premise
7 I-Premise
. I-Premise
7 I-Premise
, I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
by I-Premise
group I-Premise
, I-Premise
f I-Premise
[ I-Premise
1 I-Premise
, I-Premise
173 I-Premise
] I-Premise
= I-Premise
4 I-Premise
. I-Premise
8 I-Premise
, I-Premise
p I-Premise
= I-Premise
. I-Premise
029 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
and I-Premise
over I-Premise
time I-Premise
by I-Premise
group I-Premise
, I-Premise
f I-Premise
[ I-Premise
4 I-Premise
, I-Premise
162 I-Premise
] I-Premise
= I-Premise
3 I-Premise
. I-Premise
3 I-Premise
, I-Premise
p I-Premise
= I-Premise
. I-Premise
013 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
pairwise B-Premise
comparisons I-Premise
revealed I-Premise
significant I-Premise
differences I-Premise
between I-Premise
groups I-Premise
at I-Premise
90 I-Premise
days I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
002 I-Premise
) I-Premise
but B-Premise
not I-Premise
at I-Premise
1 I-Premise
year I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
052 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
seven O
days O
of O
diary O
and O
actigraphy O
data O
did O
not O
corroborate O
with O
monthly O
reflections O
( O
psqi O
) O
. O
!LF! !LF!
the B-Premise
night I-Premise
awakenings I-Premise
( I-Premise
actigraph I-Premise
) I-Premise
pattern I-Premise
was I-Premise
significantly I-Premise
different I-Premise
by I-Premise
group I-Premise
over I-Premise
time I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
046 I-Premise
) I-Premise
, I-Premise
with I-Premise
no I-Premise
differences I-Premise
between I-Premise
groups I-Premise
at I-Premise
90 I-Premise
days I-Premise
or I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise
!LF! !LF!
fatigue B-Premise
was I-Premise
lower I-Premise
at I-Premise
1 I-Premise
year I-Premise
than I-Premise
before I-Premise
ctx I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
no B-Premise
group I-Premise
effects I-Premise
were I-Premise
found I-Premise
. I-Premise
!LF! !LF!
the B-Claim
bt I-Claim
group I-Claim
, I-Claim
on I-Claim
average I-Claim
, I-Claim
experienced I-Claim
significant I-Claim
improvement I-Claim
on I-Claim
global I-Claim
sleep I-Claim
quality I-Claim
compared I-Claim
with I-Claim
the I-Claim
hec I-Claim
group I-Claim
, I-Claim
but B-Claim
not I-Claim
on I-Claim
objective I-Claim
sleep I-Claim
or I-Claim
fatigue I-Claim
outcomes I-Claim
. I-Claim
!LF! !LF!
to O
compare O
the O
outcomes O
of O
uterine O
artery O
embolization O
( O
uae O
) O
for O
leiomyomas O
with O
use O
of O
tris O
- O
acryl O
gelatin O
microspheres O
( O
tagm O
) O
versus O
spherical O
polyvinyl O
alcohol O
( O
pva O
) O
particles O
. O
!LF! !LF!
patients O
undergoing O
uae O
were O
randomly O
assigned O
to O
receive O
tagms O
or O
pva O
. O
!LF! !LF!
embolization O
was O
performed O
in O
a O
standardized O
manner O
. O
!LF! !LF!
outcome O
data O
were O
collected O
at O
3 O
months O
after O
embolization O
, O
including O
assessment O
of O
clinical O
symptoms O
, O
scores O
from O
a O
fibroid O
tumor O
- O
specific O
symptom O
and O
quality O
of O
life O
( O
qol O
) O
questionnaire O
, O
and O
findings O
on O
contrast O
material O
- O
enhanced O
magnetic O
resonance O
( O
mr O
) O
imaging O
, O
including O
the O
degree O
of O
tumor O
infarction O
and O
volume O
reduction O
. O
!LF! !LF!
data O
were O
analyzed O
with O
use O
of O
t O
tests O
, O
the O
mann O
- O
whitney O
u O
test O
, O
and O
chi2 O
tests O
as O
appropriate O
. O
!LF! !LF!
thirty O
- O
six O
patients O
were O
treated O
. O
!LF! !LF!
there O
were O
no O
differences O
in O
the O
two O
treatment O
groups O
at O
baseline O
. O
!LF! !LF!
clinical O
follow O
- O
up O
was O
obtained O
in O
35 O
patients O
. O
!LF! !LF!
among B-Premise
the I-Premise
clinical I-Premise
outcome I-Premise
measures I-Premise
, I-Premise
qol I-Premise
score I-Premise
improvement I-Premise
was I-Premise
greater I-Premise
for I-Premise
uae I-Premise
with I-Premise
tagms I-Premise
compared I-Premise
with I-Premise
pva I-Premise
( I-Premise
49 I-Premise
. I-Premise
0 I-Premise
vs I-Premise
27 I-Premise
. I-Premise
9 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
02 I-Premise
) I-Premise
, I-Premise
but B-Premise
no I-Premise
other I-Premise
differences I-Premise
were I-Premise
noted I-Premise
. I-Premise
!LF! !LF!
of B-Premise
the I-Premise
25 I-Premise
patients I-Premise
in I-Premise
whom I-Premise
3 I-Premise
- I-Premise
month I-Premise
mr I-Premise
imaging I-Premise
follow I-Premise
- I-Premise
up I-Premise
was I-Premise
completed I-Premise
, I-Premise
those I-Premise
treated I-Premise
with I-Premise
tagm I-Premise
were I-Premise
significantly I-Premise
more I-Premise
likely I-Premise
to I-Premise
have I-Premise
complete I-Premise
infarction I-Premise
of I-Premise
all I-Premise
leiomyomas I-Premise
( I-Premise
six I-Premise
patients I-Premise
vs I-Premise
one I-Premise
patient I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
02 I-Premise
) I-Premise
, I-Premise
were I-Premise
more I-Premise
likely I-Premise
to I-Premise
have I-Premise
at I-Premise
least I-Premise
90 I-Premise
% I-Premise
tumor I-Premise
infarction I-Premise
( I-Premise
eight I-Premise
patients I-Premise
vs I-Premise
four I-Premise
patients I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
, I-Premise
and I-Premise
had I-Premise
a I-Premise
lower I-Premise
mean I-Premise
percent I-Premise
of I-Premise
residual I-Premise
perfused I-Premise
fibroid I-Premise
tumor I-Premise
tissue I-Premise
( I-Premise
9 I-Premise
. I-Premise
6 I-Premise
% I-Premise
vs I-Premise
44 I-Premise
. I-Premise
3 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
004 I-Premise
) I-Premise
compared I-Premise
with I-Premise
patients I-Premise
treated I-Premise
with I-Premise
pva I-Premise
. I-Premise
!LF! !LF!
based O
on O
these O
differences O
between O
the O
embolic O
agents O
, O
enrollment O
in O
this O
study O
was O
terminated O
. O
!LF! !LF!
the B-Claim
use I-Claim
of I-Claim
spherical I-Claim
pva I-Claim
particles I-Claim
in I-Claim
the I-Claim
manner I-Claim
described I-Claim
herein I-Claim
results I-Claim
in I-Claim
an I-Claim
unacceptably I-Claim
high I-Claim
rate I-Claim
of I-Claim
failed I-Claim
tumor I-Claim
infarction I-Claim
in I-Claim
uae I-Claim
. I-Claim
!LF! !LF!
to O
determine O
the O
efficacy O
and O
safety O
of O
a O
biweekly O
regimen O
of O
leucovorin O
( O
lv O
) O
plus O
fluorouracil O
( O
fu O
) O
alone O
or O
in O
combination O
with O
cisplatin O
or O
irinotecan O
in O
patients O
with O
previously O
untreated O
metastatic O
gastric O
adenocarcinoma O
and O
to O
select O
the O
best O
arm O
for O
a O
phase O
iii O
study O
. O
!LF! !LF!
one O
hundred O
thirty O
- O
six O
patients O
( O
two O
were O
ineligible O
) O
were O
enrolled O
onto O
the O
randomized O
multicenter O
phase O
ii O
trial O
. O
!LF! !LF!
patients O
received O
lv O
200 O
mg O
/ O
m O
( O
2 O
) O
( O
2 O
- O
hour O
infusion O
) O
followed O
by O
fu O
400 O
mg O
/ O
m O
( O
2 O
) O
( O
bolus O
) O
and O
fu O
600 O
mg O
/ O
m O
( O
2 O
) O
( O
22 O
- O
hour O
continuous O
infusion O
) O
on O
days O
1 O
and O
2 O
every O
14 O
days O
( O
lv5fu2 O
"""" O
; O
"""" O
arm O
a O
) O
, O
lv5fu2 O
plus O
cisplatin O
50 O
mg O
/ O
m O
( O
2 O
) O
( O
1 O
- O
hour O
infusion O
) O
on O
day O
1 O
or O
2 O
( O
arm O
b O
) O
, O
or O
lv5fu2 O
plus O
irinotecan O
180 O
mg O
/ O
m O
( O
2 O
) O
( O
2 O
- O
hour O
infusion O
) O
on O
day O
1 O
( O
arm O
c O
) O
. O
!LF! !LF!
the B-Premise
overall I-Premise
response I-Premise
rates I-Premise
, I-Premise
which I-Premise
were I-Premise
confirmed I-Premise
by I-Premise
an I-Premise
independent I-Premise
expert I-Premise
panel I-Premise
, I-Premise
were I-Premise
13 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
3 I-Premise
. I-Premise
4 I-Premise
% I-Premise
to I-Premise
23 I-Premise
. I-Premise
3 I-Premise
% I-Premise
) I-Premise
, I-Premise
27 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
14 I-Premise
. I-Premise
1 I-Premise
% I-Premise
to I-Premise
40 I-Premise
. I-Premise
4 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
40 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
25 I-Premise
. I-Premise
7 I-Premise
% I-Premise
to I-Premise
54 I-Premise
. I-Premise
3 I-Premise
% I-Premise
) I-Premise
for I-Premise
arms I-Premise
a I-Premise
, I-Premise
b I-Premise
, I-Premise
and I-Premise
c I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
median B-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
and I-Premise
overall I-Premise
survival I-Premise
times I-Premise
were I-Premise
3 I-Premise
. I-Premise
2 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
1 I-Premise
. I-Premise
8 I-Premise
to I-Premise
4 I-Premise
. I-Premise
6 I-Premise
months I-Premise
) I-Premise
and I-Premise
6 I-Premise
. I-Premise
8 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
2 I-Premise
. I-Premise
6 I-Premise
to I-Premise
11 I-Premise
. I-Premise
1 I-Premise
months I-Premise
) I-Premise
with I-Premise
lv5fu2 I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
4 I-Premise
. I-Premise
9 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
3 I-Premise
. I-Premise
5 I-Premise
to I-Premise
6 I-Premise
. I-Premise
3 I-Premise
months I-Premise
) I-Premise
and I-Premise
9 I-Premise
. I-Premise
5 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
6 I-Premise
. I-Premise
9 I-Premise
to I-Premise
12 I-Premise
. I-Premise
2 I-Premise
months I-Premise
) I-Premise
with I-Premise
lv5fu2 I-Premise
- I-Premise
cisplatin I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
and I-Premise
6 I-Premise
. I-Premise
9 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
5 I-Premise
. I-Premise
5 I-Premise
to I-Premise
8 I-Premise
. I-Premise
3 I-Premise
months I-Premise
) I-Premise
and I-Premise
11 I-Premise
. I-Premise
3 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
9 I-Premise
. I-Premise
3 I-Premise
to I-Premise
13 I-Premise
. I-Premise
3 I-Premise
months I-Premise
) I-Premise
with I-Premise
lv5fu2 I-Premise
- I-Premise
irinotecan I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
of B-Claim
the I-Claim
three I-Claim
regimens I-Claim
tested I-Claim
, I-Claim
the I-Claim
combination I-Claim
of I-Claim
lv5fu2 I-Claim
- I-Claim
irinotecan I-Claim
is I-Claim
the I-Claim
most I-Claim
promising I-Claim
and I-Claim
will I-Claim
be I-Claim
assessed I-Claim
in I-Claim
a I-Claim
phase I-Claim
iii I-Claim
trial I-Claim
. I-Claim
!LF! !LF!
lv5fu2 O
with O
high O
- O
dose O
leucovorin O
( O
lv O
) O
, O
weekly O
infusional O
5 O
- O
fluorouracil O
( O
5fu O
) O
( O
aio O
schedule O
) O
and O
raltitrexed O
have O
been O
demonstrated O
to O
be O
active O
agents O
in O
first O
- O
line O
treatment O
of O
colorectal O
cancer O
. O
!LF! !LF!
we O
performed O
a O
4 O
- O
arm O
randomised O
trial O
to O
compare O
( O
1 O
) O
a O
low O
- O
dose O
intravenous O
bolus O
of O
lv O
( O
20 O
mg O
/ O
m2 O
) O
, O
followed O
by O
an O
intravenous O
bolus O
of O
5fu O
( O
400 O
mg O
/ O
m2 O
) O
, O
followed O
by O
a O
22 O
- O
hour O
continuous O
infusion O
of O
5fu O
( O
600 O
mg O
/ O
m2 O
) O
on O
day O
1 O
and O
day O
2 O
/ O
2 O
weeks O
( O
ldlv5fu2 O
arm O
) O
, O
( O
2 O
) O
a O
weekly O
continuous O
infusion O
of O
high O
- O
dose O
5fu O
( O
2 O
. O
6 O
g O
/ O
m2 O
/ O
week O
) O
for O
6 O
weeks O
followed O
by O
a O
rest O
week O
( O
hd O
- O
fu O
arm O
) O
and O
( O
3 O
) O
raltitrexed O
( O
tomudex O
arm O
"""" O
; O
"""" O
3 O
mg O
/ O
m2 O
/ O
3 O
weeks O
) O
to O
standard O
lv5fu2 O
. O
!LF! !LF!
from O
1997 O
to O
2001 O
, O
294 O
patients O
were O
included O
. O
!LF! !LF!
the O
4 O
arms O
were O
well O
balanced O
for O
sex O
ratio O
, O
age O
, O
who O
performance O
status O
, O
the O
primary O
tumour O
site O
and O
prior O
adjuvant O
chemotherapy O
. O
!LF! !LF!
treatment O
was O
stopped O
due O
to O
low O
accrual O
. O
!LF! !LF!
two B-Premise
toxicity I-Premise
- I-Premise
related I-Premise
deaths I-Premise
were I-Premise
observed I-Premise
in I-Premise
the I-Premise
tomudex I-Premise
arm I-Premise
. I-Premise
!LF! !LF!
the B-Premise
treatments I-Premise
gave I-Premise
rise I-Premise
to I-Premise
different I-Premise
rates I-Premise
of I-Premise
grade I-Premise
3 I-Premise
- I-Premise
4 I-Premise
neutropenia I-Premise
( I-Premise
3 I-Premise
, I-Premise
4 I-Premise
, I-Premise
11 I-Premise
and I-Premise
14 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
lv5fu2 I-Premise
, I-Premise
ldlv5fu2 I-Premise
, I-Premise
hd I-Premise
- I-Premise
fu I-Premise
and I-Premise
tomudex I-Premise
arms I-Premise
, I-Premise
respectively I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
028 I-Premise
) I-Premise
, I-Premise
leucopenia I-Premise
and I-Premise
vomiting I-Premise
. I-Premise
!LF! !LF!
at B-Premise
least I-Premise
one I-Premise
episode I-Premise
of I-Premise
grade I-Premise
3 I-Premise
- I-Premise
4 I-Premise
toxicity I-Premise
was I-Premise
observed I-Premise
in I-Premise
27 I-Premise
, I-Premise
25 I-Premise
, I-Premise
38 I-Premise
and I-Premise
47 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
lv5fu2 I-Premise
, I-Premise
ldlv5fu2 I-Premise
, I-Premise
hd I-Premise
- I-Premise
fu I-Premise
and I-Premise
tomudex I-Premise
arms I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
016 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
an B-Premise
objective I-Premise
response I-Premise
was I-Premise
observed I-Premise
in I-Premise
28 I-Premise
, I-Premise
21 I-Premise
, I-Premise
22 I-Premise
and I-Premise
10 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
lv5fu2 I-Premise
, I-Premise
ldlv5fu2 I-Premise
, I-Premise
hd I-Premise
- I-Premise
fu I-Premise
and I-Premise
tomudex I-Premise
arms I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
04 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
progression B-Premise
- B-Premise
free B-Premise
survival I-Premise
( I-Premise
pfs I-Premise
) I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
tomudex I-Premise
arm I-Premise
was I-Premise
statistically I-Premise
lower I-Premise
compared I-Premise
to I-Premise
that I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
lv5fu2 I-Premise
or I-Premise
ldlv5fu2 I-Premise
( I-Premise
combined I-Premise
group I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
013 I-Premise
, I-Premise
log I-Premise
rank I-Premise
test I-Premise
) I-Premise
. I-Premise
!LF! !LF!
in B-Claim
conclusion I-Claim
, I-Claim
tomudex I-Claim
is I-Claim
more I-Claim
toxic I-Claim
and I-Claim
yields I-Claim
shorter I-Claim
pfs I-Claim
than I-Claim
infusional I-Claim
5fu I-Claim
. I-Claim
!LF! !LF!
despite B-Claim
the I-Claim
early I-Claim
closure I-Claim
of I-Claim
the I-Claim
study I-Claim
and I-Claim
the I-Claim
lack I-Claim
of I-Claim
power I-Claim
of I-Claim
the I-Claim
comparison I-Claim
, I-Claim
it I-Claim
seems I-Claim
that I-Claim
ldlv5fu2 I-Claim
could I-Claim
be I-Claim
considered I-Claim
as I-Claim
an I-Claim
active I-Claim
, I-Claim
easier I-Claim
and I-Claim
less I-Claim
expensive I-Claim
option I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
metastatic I-Claim
colorectal I-Claim
cancer I-Claim
compared I-Claim
to I-Claim
classic I-Claim
lv5fu2 I-Claim
or I-Claim
weekly I-Claim
hd I-Claim
- I-Claim
fu I-Claim
. I-Claim
!LF! !LF!
to O
compare O
the O
outcome O
of O
treatment O
of O
mediastinoscopy O
- O
verified O
n2 O
non O
- O
small O
- O
cell O
lung O
cancer O
treated O
with O
induction O
chemotherapy O
followed O
by O
either O
surgery O
or O
radiotherapy O
( O
rt O
) O
, O
with O
both O
options O
followed O
by O
consolidation O
chemotherapy O
. O
!LF! !LF!
a O
randomized O
phase O
iii O
trial O
for O
stage O
iiia O
( O
t1 O
- O
t3n2m0 O
) O
non O
- O
small O
cell O
lung O
cancer O
was O
conducted O
by O
the O
radiation O
therapy O
oncology O
group O
( O
rtog O
) O
and O
eastern O
cooperative O
oncology O
group O
between O
april O
1990 O
and O
april O
1994 O
. O
!LF! !LF!
after O
documentation O
of O
n2 O
disease O
by O
mediastinoscopy O
or O
anterior O
mediastinotomy O
, O
patients O
received O
induction O
chemotherapy O
with O
cisplatin O
, O
vinblastine O
, O
and O
mitomycin O
- O
c O
. O
mitomycin O
- O
c O
was O
later O
dropped O
from O
the O
induction O
regimen O
. O
!LF! !LF!
patients O
were O
then O
randomized O
to O
surgery O
or O
rt O
( O
64 O
gy O
in O
7 O
weeks O
) O
followed O
by O
cisplatin O
and O
vinblastine O
. O
!LF! !LF!
rtog O
89 O
- O
01 O
accrued O
75 O
patients O
, O
of O
whom O
73 O
were O
eligible O
and O
analyzable O
. O
!LF! !LF!
twelve O
patients O
received O
induction O
chemotherapy O
but O
were O
not O
randomized O
to O
rt O
or O
surgery O
thereafter O
. O
!LF! !LF!
forty O
- O
five O
patients O
were O
randomized O
to O
postinduction O
rt O
or O
surgery O
. O
!LF! !LF!
of O
the O
analyzable O
patients O
, O
90 O
% O
had O
a O
karnofsky O
performance O
score O
of O
90 O
- O
100 O
, O
18 O
% O
had O
weight O
loss O
> O
5 O
% O
, O
37 O
% O
had O
squamous O
cell O
histologic O
features O
, O
and O
54 O
% O
had O
bulky O
n2 O
disease O
. O
!LF! !LF!
the O
distribution O
of O
bulky O
n2 O
disease O
was O
uniform O
among O
the O
treatment O
arms O
. O
!LF! !LF!
the B-Premise
incidence I-Premise
of I-Premise
grade I-Premise
4 I-Premise
toxicity I-Premise
was I-Premise
56 I-Premise
% I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
mitomycin I-Premise
- I-Premise
c I-Premise
and I-Premise
29 I-Premise
% I-Premise
in I-Premise
those I-Premise
who I-Premise
did I-Premise
not I-Premise
. I-Premise
!LF! !LF!
only B-Premise
1 I-Premise
patient I-Premise
in I-Premise
each I-Premise
group I-Premise
had I-Premise
acute I-Premise
nonhematologic I-Premise
toxicity I-Premise
greater I-Premise
than I-Premise
grade I-Premise
3 I-Premise
( I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
) I-Premise
. I-Premise
!LF! !LF!
no B-Premise
acute I-Premise
grade I-Premise
4 I-Premise
radiation I-Premise
toxicity I-Premise
developed I-Premise
. I-Premise
!LF! !LF!
the B-Premise
incidences I-Premise
of I-Premise
long I-Premise
- I-Premise
term I-Premise
toxicity I-Premise
were I-Premise
equivalent I-Premise
across I-Premise
the I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
three B-Premise
treatment I-Premise
- I-Premise
related I-Premise
deaths I-Premise
occurred I-Premise
: I-Premise
2 I-Premise
patients I-Premise
in I-Premise
the I-Premise
surgical I-Premise
arms I-Premise
( I-Premise
one I-Premise
late I-Premise
pulmonary I-Premise
toxicity I-Premise
and I-Premise
one I-Premise
pulmonary I-Premise
embolus I-Premise
) I-Premise
, I-Premise
and I-Premise
1 I-Premise
patient I-Premise
in I-Premise
the I-Premise
radiation I-Premise
arm I-Premise
( I-Premise
radiation I-Premise
pneumonitis I-Premise
) I-Premise
. I-Premise
!LF! !LF!
induction B-Premise
chemotherapy I-Premise
was I-Premise
completed I-Premise
in I-Premise
78 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
. I-Premise
!LF! !LF!
complete B-Premise
resection I-Premise
was I-Premise
performed I-Premise
in I-Premise
73 I-Premise
% I-Premise
of I-Premise
26 I-Premise
patients I-Premise
undergoing I-Premise
thoracotomy I-Premise
. I-Premise
!LF! !LF!
consolidation B-Premise
chemotherapy I-Premise
was I-Premise
completed I-Premise
in I-Premise
75 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
. I-Premise
!LF! !LF!
no B-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
was I-Premise
found I-Premise
among I-Premise
the I-Premise
treatment I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
the B-Premise
overall I-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
rate I-Premise
was I-Premise
53 I-Premise
% I-Premise
at I-Premise
1 I-Premise
year I-Premise
and I-Premise
17 I-Premise
% I-Premise
at I-Premise
3 I-Premise
years I-Premise
. I-Premise
!LF! !LF!
the B-Premise
median I-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
was I-Premise
14 I-Premise
months I-Premise
. I-Premise
!LF! !LF!
no B-Premise
difference I-Premise
in I-Premise
the I-Premise
1 I-Premise
- I-Premise
year I-Premise
survival I-Premise
rate I-Premise
( I-Premise
70 I-Premise
% I-Premise
vs I-Premise
. I-Premise
66 I-Premise
% I-Premise
) I-Premise
or I-Premise
median I-Premise
survival I-Premise
time I-Premise
( I-Premise
19 I-Premise
. I-Premise
4 I-Premise
vs I-Premise
. I-Premise
17 I-Premise
. I-Premise
4 I-Premise
months I-Premise
) I-Premise
between I-Premise
the I-Premise
surgery I-Premise
and I-Premise
rt I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
the B-Premise
median I-Premise
survival I-Premise
in I-Premise
the I-Premise
patients I-Premise
receiving I-Premise
induction I-Premise
chemotherapy I-Premise
only I-Premise
was I-Premise
8 I-Premise
. I-Premise
9 I-Premise
months I-Premise
. I-Premise
!LF! !LF!
mitomycin B-Premise
- B-Premise
c B-Premise
had I-Premise
no I-Premise
impact I-Premise
on I-Premise
survival I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
75 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
no B-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
was I-Premise
noted I-Premise
in I-Premise
the I-Premise
time I-Premise
to I-Premise
local I-Premise
failure I-Premise
between I-Premise
the I-Premise
surgical I-Premise
and I-Premise
rt I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
the B-Claim
patient I-Claim
accrual I-Claim
to I-Claim
this I-Claim
trial I-Claim
made I-Claim
its I-Claim
results I-Claim
inconclusive I-Claim
, I-Claim
but O
several O
observations O
are O
notable O
. O
!LF! !LF!
in O
this O
trial O
, O
histologic B-Claim
confirmation I-Claim
of I-Claim
n2 I-Claim
disease I-Claim
in I-Claim
the I-Claim
surgical I-Claim
and I-Claim
nonsurgical I-Claim
arms I-Claim
eliminated I-Claim
the I-Claim
usual I-Claim
biases I-Claim
from I-Claim
clinical I-Claim
staging I-Claim
. I-Claim
!LF! !LF!
in O
this O
setting O
, O
local B-Claim
control I-Claim
and I-Claim
survival I-Claim
were I-Claim
essentially I-Claim
equal I-Claim
between I-Claim
the I-Claim
surgical I-Claim
and I-Claim
rt I-Claim
arms I-Claim
. I-Claim
!LF! !LF!
the B-Claim
- I-Claim
3 I-Claim
and I-Claim
5 I-Claim
- I-Claim
year I-Claim
survival I-Claim
rates I-Claim
of I-Claim
nonsurgical I-Claim
therapy I-Claim
were I-Claim
comparable I-Claim
to I-Claim
published I-Claim
surgical I-Claim
trials I-Claim
of I-Claim
n2 I-Claim
disease I-Claim
. I-Claim
!LF! !LF!
amitriptyline B-Claim
is I-Claim
the I-Claim
most I-Claim
common I-Claim
analgesic I-Claim
adjuvant I-Claim
used I-Claim
in I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
neuropathic I-Claim
pain I-Claim
, I-Claim
even O
though O
no B-Claim
specific I-Claim
studies I-Claim
have I-Claim
demonstrated I-Claim
a I-Claim
benefit I-Claim
. I-Claim
!LF! !LF!
a O
randomized O
placebo O
- O
controlled O
, O
double O
- O
blind O
crossover O
study O
was O
designed O
to O
evidence O
the O
effects O
of O
amitriptyline O
in O
patients O
with O
neuropathic O
cancer O
pain O
. O
!LF! !LF!
sixteen O
advanced O
cancer O
patients O
with O
neuropathic O
pain O
on O
systemic O
morphine O
therapy O
, O
no O
longer O
receiving O
oncologic O
treatment O
, O
presenting O
moderate O
pain O
( O
about O
4 O
or O
more O
, O
but O
less O
than O
7 O
, O
on O
a O
numerical O
scale O
of O
0 O
- O
10 O
) O
in O
the O
last O
week O
, O
and O
given O
a O
stable O
morphine O
dose O
in O
the O
last O
2 O
days O
were O
admitted O
to O
the O
study O
. O
!LF! !LF!
during O
the O
first O
week O
of O
study O
, O
patients O
were O
administered O
25 O
mg O
of O
amitriptyline O
or O
equivalent O
drops O
of O
placebo O
at O
night O
for O
3 O
days O
and O
50 O
mg O
for O
the O
following O
4 O
days O
. O
!LF! !LF!
doses O
for O
patients O
aged O
more O
than O
65 O
years O
were O
15 O
mg O
( O
first O
3 O
days O
) O
and O
30 O
mg O
( O
3 O
days O
after O
) O
. O
!LF! !LF!
after O
a O
week O
, O
a O
crossover O
took O
place O
for O
the O
second O
week O
, O
with O
the O
other O
treatment O
at O
an O
inverse O
sequence O
. O
!LF! !LF!
opioid O
consumption O
, O
pain O
intensity O
, O
symptoms O
and O
adverse O
effects O
, O
mood O
, O
sleep O
, O
patient O
' O
s O
preference O
, O
quality O
of O
life O
before O
starting O
the O
study O
, O
the O
first O
week O
after O
and O
the O
second O
week O
after O
were O
recorded O
. O
!LF! !LF!
no B-Premise
significant I-Premise
benefits I-Premise
in I-Premise
analgesia I-Premise
were I-Premise
found I-Premise
in I-Premise
the I-Premise
global I-Premise
pain I-Premise
intensity I-Premise
of I-Premise
the I-Premise
previous I-Premise
week I-Premise
of I-Premise
treatment I-Premise
, I-Premise
the I-Premise
least I-Premise
pain I-Premise
intensity I-Premise
or I-Premise
the I-Premise
pain I-Premise
evaluated I-Premise
just I-Premise
after I-Premise
a I-Premise
week I-Premise
of I-Premise
treatment I-Premise
, I-Premise
at I-Premise
the I-Premise
moment I-Premise
of I-Premise
the I-Premise
visit I-Premise
, I-Premise
when I-Premise
amitriptyline I-Premise
was I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
. I-Premise
!LF! !LF!
a B-Premise
significant I-Premise
difference I-Premise
was I-Premise
evidenced I-Premise
for I-Premise
the I-Premise
worst I-Premise
pain I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
035 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
no B-Premise
differences I-Premise
in I-Premise
opioid I-Premise
doses I-Premise
during I-Premise
the I-Premise
period I-Premise
of I-Premise
study I-Premise
were I-Premise
found I-Premise
. I-Premise
!LF! !LF!
drowsiness B-Premise
, I-Premise
confusion I-Premise
and I-Premise
dry I-Premise
mouth I-Premise
were I-Premise
significantly I-Premise
more I-Premise
intense I-Premise
with I-Premise
amitriptyline I-Premise
than I-Premise
with I-Premise
placebo I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
036 I-Premise
, I-Premise
0 I-Premise
. I-Premise
003 I-Premise
, I-Premise
and I-Premise
0 I-Premise
. I-Premise
034 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
substantial I-Premise
differences I-Premise
between I-Premise
the I-Premise
two I-Premise
treatments I-Premise
in I-Premise
spitzer I-Premise
' I-Premise
s I-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
and I-Premise
for I-Premise
each I-Premise
item I-Premise
. I-Premise
!LF! !LF!
no B-Premise
differences I-Premise
in I-Premise
patients I-Premise
' I-Premise
preference I-Premise
for I-Premise
the I-Premise
two I-Premise
treatment I-Premise
periods I-Premise
were I-Premise
found I-Premise
. I-Premise
!LF! !LF!
the B-Claim
analgesic I-Claim
effects I-Claim
of I-Claim
amitriptyline I-Claim
were I-Claim
slight I-Claim
and I-Claim
associated I-Claim
with I-Claim
adverse I-Claim
effects I-Claim
. I-Claim
!LF! !LF!
in O
light O
of O
the O
results O
obtained O
in O
the O
study O
, O
the B-Claim
extensive I-Claim
use I-Claim
of I-Claim
the I-Claim
drug I-Claim
for I-Claim
cancer I-Claim
pain I-Claim
should I-Claim
be I-Claim
questioned I-Claim
. I-Claim
!LF! !LF!
anemia B-Claim
, I-Claim
highly I-Claim
common I-Claim
among I-Claim
cancer I-Claim
patients I-Claim
, I-Claim
is I-Claim
often I-Claim
an I-Claim
underlying I-Claim
cause I-Claim
of I-Claim
cancer I-Claim
- I-Claim
related I-Claim
fatigue I-Claim
and I-Claim
other I-Claim
quality I-Claim
- I-Claim
of I-Claim
- I-Claim
life I-Claim
( I-Claim
qol I-Claim
) I-Claim
deficits I-Claim
. I-Claim
!LF! !LF!
although O
randomized O
clinical O
trials O
have O
shown O
that O
treatment O
with O
epoetin O
alfa O
increases O
hemoglobin O
levels O
, O
reduces O
fatigue O
, O
lessens O
transfusion O
requirements O
, O
and O
improves O
overall O
qol O
, O
cancer O
- O
related O
anemia O
and O
fatigue O
remain O
undertreated O
. O
!LF! !LF!
this O
is O
, O
in O
part O
, O
because O
scales O
and O
measures O
of O
qol O
are O
still O
relatively O
unfamiliar O
to O
most O
clinicians O
and O
because O
population O
- O
based O
reference O
ranges O
are O
lacking O
, O
thus O
making O
clinical O
trial O
results O
difficult O
to O
interpret O
. O
!LF! !LF!
to O
aid O
in O
the O
interpretation O
of O
qol O
results O
from O
clinical O
trials O
, O
we O
administered O
the O
functional O
assessment O
of O
cancer O
therapy O
- O
anemia O
( O
fact O
- O
an O
) O
qol O
instrument O
to O
a O
nationally O
representative O
sample O
of O
1 O
, O
400 O
people O
using O
an O
internet O
survey O
panel O
in O
the O
united O
states O
. O
!LF! !LF!
we O
then O
compared O
the O
fact O
- O
an O
data O
from O
the O
internet O
survey O
with O
the O
qol O
data O
of O
a O
375 O
- O
patient O
randomized O
, O
double O
- O
blind O
clinical O
trial O
evaluating O
epoetin O
alfa O
versus O
placebo O
in O
anemic O
cancer O
patients O
. O
!LF! !LF!
fact O
- O
an O
, O
as O
administered O
to O
the O
survey O
population O
, O
displayed O
good O
psychometric O
properties O
and O
was O
able O
to O
discriminate O
between O
respondents O
with O
histories O
of O
specified O
illnesses O
, O
including O
anemia O
and O
cancer O
, O
and O
those O
without O
. O
!LF! !LF!
comparison B-Premise
of I-Premise
the I-Premise
population I-Premise
norm I-Premise
and I-Premise
clinical I-Premise
trial I-Premise
data I-Premise
showed I-Premise
that I-Premise
treatment I-Premise
with I-Premise
epoetin I-Premise
alfa I-Premise
resulted I-Premise
in I-Premise
clinically I-Premise
meaningful I-Premise
as I-Premise
well I-Premise
as I-Premise
statistically I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
qol I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
reliable O
population O
norm O
data O
are O
now O
available O
to O
aid O
in O
the O
interpretation O
of O
clinical O
trial O
results O
where O
the O
fact O
- O
an O
questionnaire O
is O
administered O
. O
!LF! !LF!
in B-Claim
the I-Claim
clinical I-Claim
trial I-Claim
, I-Claim
treatment I-Claim
with I-Claim
epoetin I-Claim
alfa I-Claim
overcame I-Claim
much I-Claim
of I-Claim
the I-Claim
qol I-Claim
deficit I-Claim
seen I-Claim
in I-Claim
anemic I-Claim
cancer I-Claim
patients I-Claim
compared I-Claim
with I-Claim
the I-Claim
norm I-Claim
population I-Claim
sample I-Claim
. I-Claim
!LF! !LF!
a O
multicenter O
trial O
was O
conducted O
to O
determine O
the O
efficacy O
and O
toxicity O
of O
escalating O
dosages O
of O
liposomal O
tretinoin O
( O
all O
- O
trans O
- O
retinoic O
acid O
) O
administered O
once O
or O
three O
times O
weekly O
in O
patients O
with O
acquired O
immunodeficiency O
syndrome O
( O
aids O
) O
- O
associated O
kaposi O
sarcoma O
. O
!LF! !LF!
seventy O
- O
six O
patients O
with O
acquired O
immunodeficiency O
syndrome O
( O
aids O
) O
- O
associated O
kaposi O
sarcoma O
were O
randomized O
to O
receive O
the O
study O
drug O
either O
once O
( O
n O
= O
30 O
) O
or O
3 O
times O
weekly O
( O
n O
= O
46 O
) O
. O
!LF! !LF!
the O
starting O
dosage O
was O
60 O
mg O
/ O
m O
( O
2 O
) O
, O
which O
was O
escalated O
to O
90 O
mg O
/ O
m O
( O
2 O
) O
and O
then O
120 O
mg O
/ O
m O
( O
2 O
) O
if O
the O
drug O
was O
well O
tolerated O
( O
< O
or O
= O
grade O
2 O
toxicities O
[ O
according O
to O
the O
southwest O
oncology O
group O
toxicity O
scale O
] O
) O
. O
!LF! !LF!
four O
weeks O
of O
therapy O
constituted O
1 O
cycle O
"""" O
; O
"""" O
patients O
could O
receive O
up O
to O
8 O
cycles O
and O
those O
who O
completed O
8 O
cycles O
were O
given O
the O
option O
of O
receiving O
extended O
therapy O
. O
!LF! !LF!
clinical O
response O
was O
defined O
as O
complete O
response O
( O
cr O
) O
, O
partial O
response O
( O
pr O
) O
, O
or O
stable O
disease O
( O
sd O
) O
. O
!LF! !LF!
efficacy O
was O
assessed O
after O
the O
completion O
of O
3 O
treatment O
cycles O
"""" O
; O
"""" O
28 O
. O
9 O
% O
of O
patients O
( O
22 O
of O
76 O
patients O
) O
responded O
( O
no O
crs O
, O
1 O
pr O
, O
and O
21 O
sds O
) O
. O
!LF! !LF!
among B-Premise
the I-Premise
patients I-Premise
receiving I-Premise
treatment I-Premise
3 I-Premise
times I-Premise
weekly I-Premise
, I-Premise
16 I-Premise
of I-Premise
49 I-Premise
patients I-Premise
( I-Premise
32 I-Premise
. I-Premise
7 I-Premise
% I-Premise
) I-Premise
achieved I-Premise
a I-Premise
clinical I-Premise
response I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
third I-Premise
treatment I-Premise
cycle I-Premise
( I-Premise
no I-Premise
crs I-Premise
, I-Premise
1 I-Premise
pr I-Premise
, I-Premise
and I-Premise
15 I-Premise
sds I-Premise
) I-Premise
. I-Premise
!LF! !LF!
concomitant B-Premise
or I-Premise
prior I-Premise
use I-Premise
of I-Premise
protease I-Premise
inhibitors I-Premise
did I-Premise
not I-Premise
appear I-Premise
to I-Premise
affect I-Premise
the I-Premise
patient I-Premise
' I-Premise
s I-Premise
response I-Premise
to I-Premise
treatment I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
183 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
liposomal B-Premise
tretinoin I-Premise
is I-Premise
a I-Premise
new I-Premise
therapeutic I-Premise
agent I-Premise
that I-Premise
has I-Premise
been I-Premise
reported I-Premise
to I-Premise
have I-Premise
some I-Premise
clinical I-Premise
activity I-Premise
in I-Premise
patients I-Premise
with I-Premise
aids I-Premise
- I-Premise
associated I-Premise
kaposi I-Premise
sarcoma I-Premise
. I-Premise
!LF! !LF!
a B-Claim
three I-Claim
- I-Claim
times I-Claim
- I-Claim
per I-Claim
- I-Claim
week I-Claim
dosing I-Claim
schedule I-Claim
was I-Claim
noted I-Claim
to I-Claim
be I-Claim
more I-Claim
effective I-Claim
compared I-Claim
with I-Claim
a I-Claim
once I-Claim
- I-Claim
a I-Claim
- I-Claim
week I-Claim
schedule I-Claim
without I-Claim
any I-Claim
significant I-Claim
difference I-Claim
in I-Claim
toxicity I-Claim
reported I-Claim
. I-Claim
!LF! !LF!
chronic O
gastrointestinal O
symptoms O
after O
pelvic O
radiotherapy O
are O
common O
, O
multifactorial O
in O
cause O
, O
and O
affect O
patients O
' O
quality O
of O
life O
. O
!LF! !LF!
we O
assessed O
whether O
such O
patients O
could O
be O
helped O
if O
a O
practitioner O
followed O
an O
investigative O
and O
management O
algorithm O
, O
and O
whether O
outcomes O
differed O
by O
whether O
a O
nurse O
or O
a O
gastroenterologist O
led O
this O
algorithm O
- O
based O
care O
. O
!LF! !LF!
for O
this O
three O
- O
arm O
randomised O
controlled O
trial O
we O
recruited O
patients O
( O
aged O
≥18 O
years O
) O
from O
clinics O
in O
london O
, O
uk O
, O
with O
new O
- O
onset O
gastrointestinal O
symptoms O
persisting O
6 O
months O
after O
pelvic O
radiotherapy O
. O
!LF! !LF!
using O
a O
computer O
- O
generated O
randomisation O
sequence O
, O
we O
randomly O
allocated O
patients O
to O
one O
of O
three O
groups O
( O
1 O
: O
1 O
: O
1 O
"""" O
; O
"""" O
stratified O
by O
tumour O
site O
[ O
urological O
, O
gynaecological O
, O
or O
gastrointestinal O
] O
, O
and O
degree O
of O
bowel O
dysfunction O
[ O
ibdq O
- O
b O
score O
< O
60 O
vs O
60 O
- O
70 O
] O
) O
: O
usual O
care O
( O
a O
detailed O
self O
- O
help O
booklet O
) O
, O
gastroenterologist O
- O
led O
algorithm O
- O
based O
treatment O
, O
or O
nurse O
- O
led O
algorithm O
- O
based O
treatment O
. O
!LF! !LF!
the O
primary O
endpoint O
was O
change O
in O
inflammatory O
bowel O
disease O
questionnaire O
- O
bowel O
subset O
score O
( O
ibdq O
- O
b O
) O
at O
6 O
months O
, O
analysed O
by O
intention O
to O
treat O
. O
!LF! !LF!
between O
nov O
26 O
, O
2007 O
, O
and O
dec O
12 O
, O
2011 O
, O
we O
enrolled O
and O
randomly O
allocated O
218 O
patients O
to O
treatment O
: O
80 O
to O
the O
nurse O
group O
, O
70 O
to O
the O
gastroenterologist O
group O
, O
and O
68 O
to O
the O
booklet O
group O
( O
figure O
) O
. O
!LF! !LF!
most O
had O
a O
baseline O
ibdq O
- O
b O
score O
indicating O
moderate O
- O
to O
- O
severe O
symptoms O
. O
!LF! !LF!
we B-Premise
recorded I-Premise
the I-Premise
following I-Premise
pair I-Premise
- I-Premise
wise I-Premise
mean I-Premise
difference I-Premise
in I-Premise
change I-Premise
in I-Premise
ibdq I-Premise
- I-Premise
b I-Premise
score I-Premise
between I-Premise
groups I-Premise
: I-Premise
nurse I-Premise
versus I-Premise
booklet I-Premise
4 I-Premise
· I-Premise
12 I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
· I-Premise
04 I-Premise
- I-Premise
8 I-Premise
· I-Premise
19 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
· I-Premise
04 I-Premise
) I-Premise
, I-Premise
gastroenterologist I-Premise
versus I-Premise
booklet I-Premise
5 I-Premise
· I-Premise
47 I-Premise
( I-Premise
1 I-Premise
· I-Premise
14 I-Premise
- I-Premise
9 I-Premise
· I-Premise
81 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
· I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
outcomes B-Premise
in I-Premise
the I-Premise
nurse I-Premise
group I-Premise
were I-Premise
not I-Premise
inferior I-Premise
to I-Premise
outcomes I-Premise
in I-Premise
the I-Premise
gastroenterologist I-Premise
group I-Premise
( I-Premise
mean I-Premise
difference I-Premise
1 I-Premise
· I-Premise
36 I-Premise
, I-Premise
one I-Premise
sided I-Premise
95 I-Premise
% I-Premise
ci I-Premise
- I-Premise
1 I-Premise
· I-Premise
48 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
patients B-Claim
given I-Claim
targeted I-Claim
intervention I-Claim
following I-Claim
a I-Claim
detailed I-Claim
clinical I-Claim
algorithm I-Claim
had I-Claim
better I-Claim
improvements I-Claim
in I-Claim
radiotherapy I-Claim
- I-Claim
induced I-Claim
gastrointestinal I-Claim
symptoms I-Claim
than I-Claim
did I-Claim
patients I-Claim
given I-Claim
usual I-Claim
care I-Claim
. I-Claim
!LF! !LF!
our B-Claim
findings I-Claim
suggest I-Claim
that I-Claim
, I-Claim
for I-Claim
most I-Claim
patients I-Claim
, I-Claim
this I-Claim
algorithm I-Claim
- I-Claim
based I-Claim
care I-Claim
can I-Claim
be I-Claim
given I-Claim
by I-Claim
a I-Claim
trained I-Claim
nurse I-Claim
. I-Claim
!LF! !LF!
the O
purpose O
of O
this O
analysis O
was O
to O
assess O
the O
impact O
of O
pretreatment O
factors O
on O
quality O
of O
life O
( O
qol O
) O
in O
patients O
with O
locally O
advanced O
nonsmall O
cell O
lung O
cancer O
( O
nsclc O
) O
. O
!LF! !LF!
in O
particular O
, O
this O
study O
focused O
on O
the O
possible O
interaction O
between O
gender O
- O
specific O
baseline O
health O
- O
related O
qol O
and O
karnofsky O
performance O
score O
( O
kps O
) O
in O
a O
prospective O
randomized O
lung O
cancer O
trial O
. O
!LF! !LF!
qol O
information O
, O
using O
validated O
instruments O
( O
functional O
assessment O
of O
cancer O
therapy O
- O
lung O
[ O
fact O
- O
l O
] O
, O
version O
2 O
, O
and O
functional O
living O
index O
- O
cancer O
[ O
flic O
] O
) O
, O
was O
prospectively O
collected O
in O
patients O
with O
locally O
advanced O
nsclc O
treated O
on O
radiation O
therapy O
oncology O
group O
( O
rtog O
) O
trial O
89 O
- O
01 O
. O
!LF! !LF!
between O
april O
1990 O
and O
april O
1994 O
, O
70 O
eligible O
patients O
participated O
in O
a O
phase O
iii O
trial O
comparing O
a O
regimen O
containing O
sequential O
chemotherapy O
and O
radiation O
therapy O
versus O
sequential O
chemotherapy O
plus O
surgery O
. O
!LF! !LF!
of O
these O
70 O
patients O
, O
46 O
underwent O
pretreatment O
flic O
and O
49 O
underwent O
pretreatment O
fact O
- O
l O
. O
!LF! !LF!
there B-Premise
was I-Premise
a I-Premise
significant I-Premise
interaction I-Premise
between I-Premise
gender I-Premise
and I-Premise
kps I-Premise
using I-Premise
flic I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
009 I-Premise
) I-Premise
, I-Premise
which I-Premise
also I-Premise
showed I-Premise
a I-Premise
trend I-Premise
toward I-Premise
significance I-Premise
with I-Premise
fact I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
09 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
significant B-Premise
kps I-Premise
- I-Premise
by I-Premise
- I-Premise
gender I-Premise
interactions I-Premise
were I-Premise
noted I-Premise
for I-Premise
fact I-Premise
- I-Premise
l I-Premise
in I-Premise
the I-Premise
physical I-Premise
well I-Premise
- I-Premise
being I-Premise
and I-Premise
additional I-Premise
concerns I-Premise
- I-Premise
lung I-Premise
subscales I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
012 I-Premise
and I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0003 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
results I-Premise
of I-Premise
both I-Premise
the I-Premise
flic I-Premise
and I-Premise
fact I-Premise
- I-Premise
l I-Premise
demonstrated I-Premise
significantly I-Premise
lower I-Premise
scores I-Premise
corresponding I-Premise
to I-Premise
lower I-Premise
kps I-Premise
values I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
009 I-Premise
and I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
016 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise
!LF! !LF!
results B-Claim
of I-Claim
this I-Claim
randomized I-Claim
study I-Claim
incorporating I-Claim
prospective I-Claim
qol I-Claim
measurements I-Claim
suggested I-Claim
that I-Claim
in I-Claim
patients I-Claim
with I-Claim
locally I-Claim
advanced I-Claim
nsclc I-Claim
, I-Claim
analyzing I-Claim
qol I-Claim
data I-Claim
by I-Claim
either I-Claim
gender I-Claim
or I-Claim
performance I-Claim
status I-Claim
alone I-Claim
may I-Claim
not I-Claim
accurately I-Claim
reflect I-Claim
how I-Claim
these I-Claim
factors I-Claim
depend I-Claim
upon I-Claim
each I-Claim
another I-Claim
. I-Claim
!LF! !LF!
understanding O
the O
interaction O
between O
gender O
and O
performance O
status O
could O
lead O
to O
better O
prognosticators O
and O
potentially O
could O
tailor O
interventions O
for O
specific O
groups O
of O
patients O
with O
lung O
cancer O
. O
!LF! !LF!
this O
study O
sought O
to O
evaluate O
effectiveness O
of O
autologous O
dendritic O
cell O
vaccine O
( O
immunotherapy O
) O
for O
glioblastoma O
multiforme O
( O
gbm O
) O
. O
!LF! !LF!
patients O
14 O
to O
70 O
years O
of O
age O
with O
newly O
diagnosed O
gbm O
and O
karnofsky O
performance O
scale O
( O
kps O
) O
score O
> O
70 O
who O
were O
receiving O
initial O
treatment O
were O
enrolled O
and O
were O
randomized O
into O
2 O
groups O
during O
the O
5 O
- O
year O
study O
period O
. O
!LF! !LF!
eighteen O
patients O
underwent O
conventional O
treatment O
( O
surgery O
, O
radiotherapy O
, O
and O
chemotherapy O
) O
and O
received O
adjuvant O
autologous O
dendritic O
cell O
vaccine O
, O
and O
16 O
patients O
( O
control O
group O
) O
underwent O
conventional O
treatment O
only O
. O
!LF! !LF!
administration O
of O
the O
vaccine O
was O
begun O
within O
1 O
to O
2 O
months O
postoperatively O
, O
with O
10 O
inoculations O
given O
over O
6 O
months O
. O
!LF! !LF!
outcome O
measures O
were O
overall O
survival O
( O
os O
) O
"""" O
; O
"""" O
progression O
- O
free O
survival O
( O
pfs O
) O
"""" O
; O
"""" O
- O
1 O
, O
- O
2 O
, O
and O
3 O
- O
year O
survival O
rates O
, O
and O
quality O
of O
life O
( O
qol O
) O
. O
!LF! !LF!
follow O
- O
up O
time O
ranged O
from O
14 O
to O
56 O
months O
( O
median O
, O
33 O
months O
) O
. O
!LF! !LF!
the B-Premise
- I-Premise
1 I-Premise
, I-Premise
- I-Premise
2 I-Premise
, I-Premise
and I-Premise
3 I-Premise
- I-Premise
year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
88 I-Premise
. I-Premise
9 I-Premise
% I-Premise
, I-Premise
44 I-Premise
. I-Premise
4 I-Premise
% I-Premise
, I-Premise
and I-Premise
16 I-Premise
. I-Premise
7 I-Premise
% I-Premise
for I-Premise
the I-Premise
vaccine I-Premise
group I-Premise
, I-Premise
respectively I-Premise
, I-Premise
and I-Premise
75 I-Premise
. I-Premise
0 I-Premise
% I-Premise
, I-Premise
18 I-Premise
. I-Premise
8 I-Premise
% I-Premise
, I-Premise
and I-Premise
0 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
299 I-Premise
, I-Premise
0 I-Premise
. I-Premise
0035 I-Premise
, I-Premise
0 I-Premise
. I-Premise
0014 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
median I-Premise
os I-Premise
for I-Premise
the I-Premise
vaccine I-Premise
group I-Premise
was I-Premise
31 I-Premise
. I-Premise
9 I-Premise
months I-Premise
and I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
was I-Premise
15 I-Premise
. I-Premise
0 I-Premise
months I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
002 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
median I-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
( I-Premise
pfs I-Premise
) I-Premise
for I-Premise
the I-Premise
vaccine I-Premise
group I-Premise
was I-Premise
8 I-Premise
. I-Premise
5 I-Premise
months I-Premise
, I-Premise
and I-Premise
8 I-Premise
. I-Premise
0 I-Premise
months I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
075 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
surviving I-Premise
fraction I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
vaccine I-Premise
group I-Premise
based I-Premise
on I-Premise
kaplan I-Premise
- I-Premise
meier I-Premise
analysis I-Premise
. I-Premise
!LF! !LF!
adjuvant B-Claim
immunotherapy I-Claim
with I-Claim
whole I-Claim
- I-Claim
cell I-Claim
lysate I-Claim
dendritic I-Claim
cell I-Claim
vaccine I-Claim
may I-Claim
improve I-Claim
short I-Claim
- I-Claim
term I-Claim
survival I-Claim
. I-Claim
!LF! !LF!
it B-Claim
seems I-Claim
to I-Claim
be I-Claim
safe I-Claim
, I-Claim
and I-Claim
its I-Claim
long I-Claim
- I-Claim
term I-Claim
effectiveness I-Claim
is I-Claim
worthy I-Claim
of I-Claim
further I-Claim
investigation I-Claim
. I-Claim
!LF! !LF!
patients O
with O
cancer O
are O
characterized O
by O
a O
profound O
impairment O
of O
glucose O
utilization O
, O
with O
lipids O
being O
the O
preferred O
metabolic O
fuel O
. O
!LF! !LF!
in O
contrast O
, O
the O
energy O
needs O
of O
malignant O
tumors O
are O
almost O
entirely O
met O
by O
glucose O
. O
!LF! !LF!
we O
therefore O
studied O
the O
effects O
of O
a O
high O
- O
fat O
diet O
, O
particularly O
on O
body O
composition O
. O
!LF! !LF!
twenty O
- O
three O
moderately O
malnourished O
patients O
with O
gastrointestinal O
carcinomas O
were O
randomized O
to O
receive O
either O
a O
conventional O
diet O
supplying O
35 O
nonprotein O
kcal O
and O
1 O
. O
1 O
g O
of O
protein O
/ O
kg O
per O
day O
( O
group O
a O
, O
n O
= O
11 O
) O
or O
a O
fat O
- O
enriched O
artificial O
liquid O
diet O
( O
20 O
nonprotein O
kcal O
/ O
kg O
per O
day O
) O
plus O
normal O
meals O
( O
group O
b O
, O
n O
= O
12 O
) O
for O
a O
period O
of O
eight O
weeks O
, O
i O
. O
e O
. O
, O
from O
the O
first O
to O
the O
third O
chemotherapy O
cycle O
. O
!LF! !LF!
the O
fat O
content O
of O
the O
artificial O
diet O
was O
66 O
% O
of O
the O
nonprotein O
calories O
. O
!LF! !LF!
the O
day O
before O
the O
nutritional O
interventions O
, O
and O
again O
after O
four O
and O
eight O
weeks O
, O
body O
compartments O
were O
determined O
using O
bioelectrical O
impedance O
analysis O
, O
lymphocyte O
subpopulations O
were O
quantified O
using O
flow O
cytometry O
, O
and O
some O
aspects O
of O
the O
quality O
of O
life O
were O
rated O
using O
four O
linear O
analog O
self O
- O
assessment O
( O
lasa O
) O
scales O
. O
!LF! !LF!
the O
statistical O
calculations O
were O
done O
as O
an O
exploratory O
data O
analysis O
. O
!LF! !LF!
the O
consumption O
of O
non O
- O
protein O
calories O
did O
not O
differ O
significantly O
between O
the O
two O
patient O
groups O
. O
!LF! !LF!
an B-Premise
average I-Premise
weight I-Premise
gain I-Premise
in I-Premise
group I-Premise
b I-Premise
contrasted I-Premise
with I-Premise
an I-Premise
average I-Premise
weight I-Premise
loss I-Premise
in I-Premise
group I-Premise
a I-Premise
after I-Premise
four I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
and I-Premise
eight I-Premise
weeks I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
fat B-Premise
- B-Premise
free B-Premise
mass I-Premise
showed I-Premise
an I-Premise
intergroup I-Premise
difference I-Premise
in I-Premise
favor I-Premise
of I-Premise
group I-Premise
b I-Premise
after I-Premise
eight I-Premise
weeks I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
body B-Premise
cell I-Premise
mass I-Premise
was I-Premise
maintained I-Premise
throughout I-Premise
the I-Premise
study I-Premise
in I-Premise
group I-Premise
b I-Premise
, I-Premise
but I-Premise
declined I-Premise
significantly I-Premise
up I-Premise
to I-Premise
weeks I-Premise
4 I-Premise
and I-Premise
8 I-Premise
in I-Premise
group I-Premise
a I-Premise
( I-Premise
intergroup I-Premise
difference I-Premise
: I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
and I-Premise
0 I-Premise
. I-Premise
01 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise
!LF! !LF!
a B-Premise
decrease I-Premise
in I-Premise
the I-Premise
total I-Premise
lymphocyte I-Premise
count I-Premise
by I-Premise
559 I-Premise
cells I-Premise
/ I-Premise
mul I-Premise
occurred I-Premise
with I-Premise
the I-Premise
fat I-Premise
- I-Premise
enriched I-Premise
diet I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
several B-Premise
aspects I-Premise
of I-Premise
the I-Premise
quality I-Premise
of I-Premise
life I-Premise
were I-Premise
rated I-Premise
to I-Premise
be I-Premise
better I-Premise
in I-Premise
group I-Premise
b I-Premise
than I-Premise
in I-Premise
group I-Premise
a I-Premise
, I-Premise
although B-Premise
not I-Premise
all I-Premise
differences I-Premise
reached I-Premise
statistical I-Premise
significance I-Premise
. I-Premise
!LF! !LF!
in B-Claim
patients I-Claim
with I-Claim
cancer I-Claim
, I-Claim
a I-Claim
high I-Claim
- I-Claim
fat I-Claim
diet I-Claim
may I-Claim
possibly I-Claim
support I-Claim
the I-Claim
maintenance I-Claim
of I-Claim
both I-Claim
body I-Claim
weight I-Claim
and I-Claim
body I-Claim
cell I-Claim
mass I-Claim
. I-Claim
!LF! !LF!
however B-Claim
, I-Claim
monitoring I-Claim
the I-Claim
lymphocyte I-Claim
count I-Claim
is I-Claim
advisable I-Claim
. I-Claim
!LF! !LF!
prior O
studies O
have O
suggested O
that O
melatonin O
, O
a O
frequently O
used O
integrative O
medicine O
, O
can O
attenuate O
weight O
loss O
, O
anorexia O
, O
and O
fatigue O
in O
patients O
with O
cancer O
. O
!LF! !LF!
these O
studies O
were O
limited O
by O
a O
lack O
of O
blinding O
and O
absence O
of O
placebo O
controls O
. O
!LF! !LF!
the O
primary O
purpose O
of O
this O
study O
was O
to O
compare O
melatonin O
with O
placebo O
for O
appetite O
improvement O
in O
patients O
with O
cancer O
cachexia O
. O
!LF! !LF!
we O
performed O
a O
randomized O
, O
double O
- O
blind O
, O
28 O
- O
day O
trial O
of O
melatonin O
20 O
mg O
versus O
placebo O
in O
patients O
with O
advanced O
lung O
or O
gi O
cancer O
, O
appetite O
scores O
≥ O
4 O
on O
a O
0 O
to O
10 O
scale O
( O
10 O
= O
worst O
appetite O
) O
, O
and O
history O
of O
weight O
loss O
≥ O
5 O
% O
. O
!LF! !LF!
assessments O
included O
weight O
, O
symptoms O
by O
the O
edmonton O
symptom O
assessment O
scale O
, O
and O
quality O
of O
life O
by O
the O
functional O
assessment O
of O
anorexia O
/ O
cachexia O
therapy O
( O
faact O
) O
questionnaire O
. O
!LF! !LF!
differences O
between O
groups O
from O
baseline O
to O
day O
28 O
were O
analyzed O
using O
one O
- O
sided O
, O
two O
- O
sample O
t O
tests O
or O
wilcoxon O
two O
- O
sample O
tests O
. O
!LF! !LF!
interim O
analysis O
halfway O
through O
the O
trial O
had O
a O
lan O
- O
demets O
monitoring O
boundary O
with O
an O
o O
' O
brien O
- O
fleming O
stopping O
rule O
. O
!LF! !LF!
decision O
boundaries O
were O
to O
accept O
the O
null O
hypothesis O
of O
futility O
if O
the O
test O
statistic O
z O
< O
0 O
. O
39 O
( O
p O
≥ O
. O
348 O
) O
and O
reject O
the O
null O
hypothesis O
if O
z O
> O
2 O
. O
54 O
( O
p O
≤ O
. O
0056 O
) O
. O
!LF! !LF!
after O
interim O
analysis O
of O
48 O
patients O
, O
the O
study O
was O
closed O
for O
futility O
. O
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
groups I-Premise
for I-Premise
appetite I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
78 I-Premise
) I-Premise
or I-Premise
other I-Premise
symptoms I-Premise
, I-Premise
weight I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
17 I-Premise
) I-Premise
, I-Premise
faact I-Premise
score I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
95 I-Premise
) I-Premise
, I-Premise
toxicity I-Premise
, I-Premise
or I-Premise
survival I-Premise
from I-Premise
baseline I-Premise
to I-Premise
day I-Premise
28 I-Premise
. I-Premise
!LF! !LF!
in B-Claim
cachectic I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
, I-Claim
oral I-Claim
melatonin I-Claim
20 I-Claim
mg I-Claim
at I-Claim
night I-Claim
did I-Claim
not I-Claim
improve I-Claim
appetite I-Claim
, I-Claim
weight I-Claim
, I-Claim
or I-Claim
quality I-Claim
of I-Claim
life I-Claim
compared I-Claim
with I-Claim
placebo I-Claim
. I-Claim
!LF! !LF!
gynecological O
neoplastic O
disease O
progression O
is O
characterized O
by O
specific O
energy O
metabolism O
alterations O
and O
by O
symptoms O
including O
fatigue O
, O
anorexia O
, O
nausea O
, O
anemia O
, O
and O
immunodepression O
, O
which O
result O
in O
a O
cachexia O
syndrome O
and O
a O
marked O
decrease O
in O
patient O
quality O
of O
life O
( O
qol O
) O
. O
!LF! !LF!
therapeutic O
protocols O
associated O
with O
appropriate O
and O
effective O
psychological O
and O
social O
support O
systems O
are O
essential O
to O
counteract O
the O
symptoms O
of O
neoplastic O
disease O
in O
incurable O
patients O
. O
!LF! !LF!
a O
phase O
iii O
randomized O
study O
was O
performed O
to O
establish O
the O
most O
effective O
and O
safest O
treatment O
to O
improve O
the O
key O
symptoms O
in O
advanced O
gynecological O
cancer O
patients O
, O
i O
. O
e O
. O
, O
lean O
body O
mass O
( O
lbm O
) O
, O
resting O
energy O
expenditure O
( O
ree O
) O
, O
fatigue O
, O
and O
qol O
. O
!LF! !LF!
in O
addition O
, O
the O
impact O
of O
the O
treatment O
arms O
on O
the O
main O
metabolic O
and O
inflammatory O
parameters O
, O
including O
c O
- O
reactive O
protein O
( O
crp O
) O
, O
interleukin O
( O
il O
) O
- O
6 O
, O
tumor O
necrosis O
factor O
( O
tnf O
) O
- O
α O
, O
leptin O
, O
reactive O
oxygen O
species O
( O
ros O
) O
, O
and O
glutathione O
peroxidase O
, O
was O
evaluated O
. O
!LF! !LF!
the O
change O
in O
the O
glasgow O
prognostic O
score O
( O
gps O
) O
during O
treatment O
was O
also O
assessed O
. O
!LF! !LF!
a O
total O
of O
104 O
advanced O
- O
stage O
gynecological O
cancer O
patients O
were O
enrolled O
and O
randomly O
assigned O
to O
receive O
either O
megestrol O
acetate O
( O
ma O
) O
plus O
l O
- O
carnitine O
, O
celecoxib O
, O
and O
antioxidants O
( O
arm O
1 O
) O
or O
ma O
alone O
( O
arm O
2 O
) O
. O
!LF! !LF!
the O
treatment O
duration O
was O
4 O
months O
. O
!LF! !LF!
the B-Premise
combination I-Premise
arm I-Premise
was I-Premise
more I-Premise
effective I-Premise
than I-Premise
arm I-Premise
2 I-Premise
with I-Premise
respect I-Premise
to I-Premise
lbm I-Premise
, I-Premise
ree I-Premise
, I-Premise
fatigue I-Premise
, I-Premise
and I-Premise
global I-Premise
qol I-Premise
. I-Premise
!LF! !LF!
as B-Premise
for I-Premise
the I-Premise
secondary I-Premise
efficacy I-Premise
endpoints I-Premise
, I-Premise
patient I-Premise
appetite I-Premise
increased I-Premise
, I-Premise
and I-Premise
ecog I-Premise
ps I-Premise
decreased I-Premise
significantly I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
the B-Premise
inflammation I-Premise
and I-Premise
oxidative I-Premise
stress I-Premise
parameters I-Premise
il I-Premise
- I-Premise
6 I-Premise
, I-Premise
tnf I-Premise
- I-Premise
α I-Premise
, I-Premise
crp I-Premise
, I-Premise
and I-Premise
ros I-Premise
decreased I-Premise
significantly I-Premise
in I-Premise
arm I-Premise
1 I-Premise
, I-Premise
while I-Premise
no I-Premise
significant I-Premise
change I-Premise
was I-Premise
observed I-Premise
in I-Premise
arm I-Premise
2 I-Premise
. I-Premise
!LF! !LF!
the B-Claim
combined I-Claim
treatment I-Claim
improved I-Claim
both I-Claim
immunometabolic I-Claim
alterations I-Claim
and I-Claim
patient I-Claim
qol I-Claim
. I-Claim
!LF! !LF!
multimodality B-Claim
therapies I-Claim
for I-Claim
cachexia I-Claim
ideally I-Claim
should I-Claim
be I-Claim
introduced I-Claim
within I-Claim
a I-Claim
context I-Claim
of I-Claim
"""" I-Claim
best I-Claim
supportive I-Claim
care I-Claim
"""" I-Claim
that I-Claim
includes I-Claim
optimal I-Claim
symptom I-Claim
management I-Claim
and I-Claim
careful I-Claim
psychosocial I-Claim
counseling I-Claim
. I-Claim
!LF! !LF!
the O
aim O
of O
this O
study O
was O
to O
evaluate O
pamidronate O
for O
bone O
pain O
in O
a O
randomised O
double O
- O
blind O
trial O
and O
to O
evaluate O
the O
contribution O
of O
new O
markers O
of O
bone O
resorption O
in O
patients O
with O
bone O
metastases O
. O
!LF! !LF!
fifty O
- O
two O
patients O
with O
painful O
bone O
metastases O
were O
randomised O
to O
receive O
a O
two O
- O
hour O
infusion O
of O
pamidronate O
120 O
mg O
or O
an O
identical O
infusion O
of O
saline O
. O
!LF! !LF!
four O
weeks O
later O
, O
all O
patients O
received O
pamidronate O
120 O
mg O
. O
!LF! !LF!
bone O
resorption O
markers O
measured O
included O
urinary O
calcium O
( O
uca O
) O
, O
hydroxyproline O
( O
hyp O
) O
, O
and O
the O
collagen O
breakdown O
products O
: O
ntx O
, O
crosslaps O
and O
free O
dpd O
. O
!LF! !LF!
symptomatic B-Premise
response I-Premise
during I-Premise
the I-Premise
first I-Premise
four I-Premise
weeks I-Premise
was I-Premise
seen I-Premise
after I-Premise
pamidronate I-Premise
, I-Premise
but I-Premise
not I-Premise
with I-Premise
placebo I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
quality B-Premise
of I-Premise
life I-Premise
was I-Premise
maintained I-Premise
with I-Premise
pamidronate I-Premise
and I-Premise
deteriorated I-Premise
after I-Premise
placebo I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
resorption B-Premise
markers I-Premise
did I-Premise
not I-Premise
decrease I-Premise
after I-Premise
placebo I-Premise
, I-Premise
but B-Premise
ntx I-Premise
and I-Premise
crosslaps I-Premise
both I-Premise
decreased I-Premise
by I-Premise
70 I-Premise
% I-Premise
after I-Premise
pamidronate I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
a B-Premise
second I-Premise
infusion I-Premise
of I-Premise
pamidronate I-Premise
did I-Premise
not I-Premise
decrease I-Premise
resorption I-Premise
further I-Premise
, I-Premise
but B-Premise
maintained I-Premise
the I-Premise
suppression I-Premise
of I-Premise
resorption I-Premise
at I-Premise
similar I-Premise
levels I-Premise
for I-Premise
a I-Premise
further I-Premise
four I-Premise
weeks I-Premise
. I-Premise
!LF! !LF!
symptomatic B-Premise
response I-Premise
to I-Premise
pamidronate I-Premise
correlated I-Premise
closely I-Premise
with I-Premise
the I-Premise
rate I-Premise
of I-Premise
bone I-Premise
resorption I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
it B-Premise
was I-Premise
more I-Premise
frequent I-Premise
in I-Premise
those I-Premise
patients I-Premise
with I-Premise
an I-Premise
initial I-Premise
ntx I-Premise
value I-Premise
of I-Premise
< I-Premise
2 I-Premise
times I-Premise
the I-Premise
upper I-Premise
limit I-Premise
of I-Premise
normal I-Premise
( I-Premise
17 I-Premise
of I-Premise
27 I-Premise
, I-Premise
62 I-Premise
% I-Premise
) I-Premise
and I-Premise
in I-Premise
those I-Premise
where I-Premise
the I-Premise
level I-Premise
of I-Premise
ntx I-Premise
returned I-Premise
to I-Premise
normal I-Premise
( I-Premise
19 I-Premise
of I-Premise
32 I-Premise
, I-Premise
59 I-Premise
% I-Premise
) I-Premise
, I-Premise
than I-Premise
in I-Premise
the I-Premise
patients I-Premise
with I-Premise
either I-Premise
high I-Premise
baseline I-Premise
values I-Premise
of I-Premise
ntx I-Premise
( I-Premise
> I-Premise
2 I-Premise
times I-Premise
the I-Premise
upper I-Premise
limit I-Premise
of I-Premise
normal I-Premise
) I-Premise
or I-Premise
ntx I-Premise
levels I-Premise
which I-Premise
failed I-Premise
to I-Premise
normalise I-Premise
for I-Premise
whom I-Premise
the I-Premise
response I-Premise
frequencies I-Premise
were I-Premise
2 I-Premise
of I-Premise
16 I-Premise
( I-Premise
13 I-Premise
% I-Premise
) I-Premise
and I-Premise
0 I-Premise
of I-Premise
11 I-Premise
( I-Premise
0 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
subjective B-Claim
benefit I-Claim
after I-Claim
intravenous I-Claim
pamidronate I-Claim
is I-Claim
confirmed I-Claim
in I-Claim
this I-Claim
placebo I-Claim
- I-Claim
controlled I-Claim
study I-Claim
. I-Claim
!LF! !LF!
the B-Claim
new I-Claim
bone I-Claim
resorption I-Claim
markers I-Claim
of I-Claim
collagen I-Claim
breakdown I-Claim
were I-Claim
able I-Claim
to I-Claim
predict I-Claim
clinical I-Claim
response I-Claim
to I-Claim
pamidronate I-Claim
. I-Claim
!LF! !LF!
over O
30 O
% O
of O
patients O
with O
non O
- O
small O
cell O
lung O
cancer O
( O
nsclc O
) O
develop O
brain O
metastases O
. O
!LF! !LF!
if O
inoperable O
, O
optimal O
supportive O
care O
( O
osc O
) O
, O
including O
steroids O
, O
and O
whole O
brain O
radiotherapy O
( O
wbrt O
) O
are O
generally O
considered O
to O
be O
standard O
care O
, O
although O
there O
is O
no O
randomised O
evidence O
demonstrating O
that O
the O
addition O
of O
wbrt O
to O
osc O
improves O
survival O
or O
quality O
of O
life O
. O
!LF! !LF!
quartz O
is O
a O
randomised O
, O
non O
- O
inferiority O
, O
phase O
iii O
trial O
comparing O
osc O
+ O
wbrt O
versus O
osc O
in O
patients O
with O
inoperable O
brain O
metastases O
from O
nsclc O
. O
!LF! !LF!
the O
primary O
outcome O
measure O
is O
quality O
- O
adjusted O
life O
years O
( O
qalys O
) O
. O
!LF! !LF!
quartz O
was O
threatened O
with O
both O
loss O
of O
funding O
and O
early O
closure O
due O
to O
poor O
accrual O
. O
!LF! !LF!
a O
lack O
of O
preliminary O
randomised O
data O
supporting O
the O
trial O
' O
s O
hypotheses O
was O
thought O
to O
underlie O
the O
poor O
accrual O
, O
so O
, O
with O
no O
knowledge O
of O
the O
data O
, O
the O
independent O
trial O
steering O
committee O
agreed O
to O
the O
unusual O
step O
of O
releasing O
interim O
data O
. O
!LF! !LF!
between O
march O
2007 O
and O
april O
2010 O
, O
151 O
( O
of O
the O
planned O
534 O
) O
patients O
were O
randomised O
( O
75 O
osc O
+ O
wbrt O
, O
76 O
osc O
) O
. O
!LF! !LF!
participants O
' O
baseline O
demographics O
included O
median O
age O
67 O
years O
( O
interquartile O
range O
62 O
- O
73 O
) O
, O
60 O
% O
male O
, O
50 O
% O
with O
a O
karnofsky O
performance O
status O
< O
70 O
"""" O
; O
"""" O
steroid O
usage O
was O
similar O
in O
the O
two O
groups O
"""" O
; O
"""" O
64 O
/ O
75 O
( O
85 O
% O
) O
received O
wbrt O
( O
20 O
gy O
in O
five O
fractions O
) O
. O
!LF! !LF!
median B-Premise
survival I-Premise
was I-Premise
: I-Premise
osc I-Premise
+ I-Premise
wbrt I-Premise
49 I-Premise
days I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
39 I-Premise
- I-Premise
61 I-Premise
) I-Premise
, I-Premise
osc I-Premise
51 I-Premise
days I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
27 I-Premise
- I-Premise
57 I-Premise
) I-Premise
- I-Premise
hazard I-Premise
ratio I-Premise
1 I-Premise
. I-Premise
11 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
0 I-Premise
. I-Premise
80 I-Premise
- I-Premise
1 I-Premise
. I-Premise
53 I-Premise
) I-Premise
in I-Premise
favour I-Premise
of I-Premise
wbrt I-Premise
. I-Premise
!LF! !LF!
quality B-Premise
of I-Premise
life I-Premise
assessed I-Premise
using I-Premise
eq I-Premise
- I-Premise
5d I-Premise
showed I-Premise
no I-Premise
evidence I-Premise
of I-Premise
a I-Premise
difference I-Premise
. I-Premise
!LF! !LF!
the B-Premise
estimated I-Premise
mean I-Premise
qalys I-Premise
was I-Premise
: I-Premise
osc I-Premise
+ I-Premise
wbrt I-Premise
31 I-Premise
days I-Premise
and I-Premise
osc I-Premise
30 I-Premise
days I-Premise
, I-Premise
difference I-Premise
- I-Premise
1 I-Premise
day I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
- I-Premise
12 I-Premise
. I-Premise
0 I-Premise
to I-Premise
+ I-Premise
13 I-Premise
. I-Premise
2 I-Premise
days I-Premise
) I-Premise
. I-Premise
!LF! !LF!
these B-Claim
interim I-Claim
data I-Claim
indicate I-Claim
no I-Claim
early I-Claim
evidence I-Claim
of I-Claim
detriment I-Claim
to I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
overall I-Claim
survival I-Claim
or I-Claim
qalys I-Claim
for I-Claim
patients I-Claim
allocated I-Claim
to I-Claim
osc I-Claim
alone I-Claim
. I-Claim
!LF! !LF!
they O
provide O
key O
information O
for O
discussing O
the O
trial O
with O
patients O
and O
strengthen O
the O
argument O
for O
continuing O
quartz O
to O
definitively O
answer O
this O
important O
clinical O
question O
. O
!LF! !LF!
the O
aim O
of O
the O
study O
was O
to O
compare O
clinical O
outcomes O
and O
quality O
of O
life O
in O
patients O
undergoing O
surgery O
for O
pilonidal O
disease O
with O
unroofing O
and O
marsupialization O
( O
um O
) O
or O
rhomboid O
excision O
and O
limberg O
flap O
( O
relp O
) O
procedures O
. O
!LF! !LF!
one O
hundred O
forty O
consecutive O
patients O
with O
pilonidal O
sinus O
were O
randomly O
assigned O
to O
receive O
either O
um O
or O
relp O
procedures O
. O
!LF! !LF!
a O
specifically O
designed O
questionnaire O
was O
administered O
at O
three O
months O
to O
assess O
time O
from O
the O
operation O
until O
the O
patient O
was O
able O
to O
walk O
, O
return O
to O
daily O
activities O
, O
or O
sit O
without O
pain O
, O
time O
to O
return O
to O
work O
or O
school O
, O
and O
time O
to O
healing O
. O
!LF! !LF!
postoperative O
pain O
was O
assessed O
with O
a O
visual O
analog O
scale O
and O
the O
mcgill O
pain O
questionnaire O
. O
!LF! !LF!
patients O
' O
quality O
of O
life O
was O
evaluated O
with O
the O
cardiff O
wound O
impact O
schedule O
( O
cwis O
) O
. O
!LF! !LF!
questionnaires O
were O
administered O
by O
a O
clinician O
blinded O
to O
treatment O
. O
!LF! !LF!
compared B-Premise
with I-Premise
relp I-Premise
, I-Premise
patients I-Premise
receiving I-Premise
um I-Premise
had I-Premise
significantly I-Premise
shorter I-Premise
duration I-Premise
of I-Premise
operation I-Premise
and I-Premise
hospital I-Premise
stay I-Premise
, I-Premise
shorter I-Premise
time I-Premise
periods I-Premise
to I-Premise
walk I-Premise
, I-Premise
return I-Premise
to I-Premise
daily I-Premise
activities I-Premise
, I-Premise
or I-Premise
sit I-Premise
without I-Premise
pain I-Premise
and I-Premise
to I-Premise
return I-Premise
to I-Premise
work I-Premise
or I-Premise
school I-Premise
, I-Premise
and I-Premise
fewer I-Premise
complications I-Premise
. I-Premise
!LF! !LF!
time B-Premise
to I-Premise
final I-Premise
healing I-Premise
was I-Premise
significantly I-Premise
shorter I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
scores I-Premise
on I-Premise
the I-Premise
cwis I-Premise
were I-Premise
higher I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
relp I-Premise
than I-Premise
in I-Premise
those I-Premise
receiving I-Premise
um I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
with I-Premise
um I-Premise
had I-Premise
lower I-Premise
levels I-Premise
of I-Premise
pain I-Premise
one I-Premise
week I-Premise
after I-Premise
surgery I-Premise
. I-Premise
!LF! !LF!
the B-Claim
unroofing I-Claim
and I-Claim
marsupialization I-Claim
procedure I-Claim
provides I-Claim
more I-Claim
clinical I-Claim
benefits I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
pilonidal I-Claim
disease I-Claim
than I-Claim
rhomboid I-Claim
excision I-Claim
and I-Claim
limberg I-Claim
flap I-Claim
and I-Claim
should I-Claim
be I-Claim
considered I-Claim
the I-Claim
procedure I-Claim
of I-Claim
choice I-Claim
. I-Claim
!LF! !LF!
however B-Claim
, I-Claim
it I-Claim
may I-Claim
be I-Claim
associated I-Claim
with I-Claim
more I-Claim
inconvenience I-Claim
in I-Claim
wound I-Claim
care I-Claim
and I-Claim
longer I-Claim
healing I-Claim
time I-Claim
than I-Claim
rhomboid I-Claim
excision I-Claim
and I-Claim
lindberg I-Claim
flap I-Claim
. I-Claim
!LF! !LF!
maintenance O
therapy O
can O
delay O
progression O
and O
prolong O
survival O
in O
metastatic O
non O
- O
small O
- O
cell O
lung O
cancer O
( O
mnsclc O
) O
. O
!LF! !LF!
as O
treatment O
for O
mnsclc O
is O
non O
- O
curative O
, O
its O
impact O
on O
patient O
health O
- O
related O
quality O
of O
life O
( O
hrqol O
) O
is O
an O
important O
consideration O
. O
!LF! !LF!
saturn O
( O
sequential O
tarceva O
in O
unresectable O
nsclc O
) O
was O
a O
randomised O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
, O
multicentre O
study O
investigating O
the O
impact O
of O
erlotinib O
maintenance O
therapy O
on O
hrqol O
in O
patients O
with O
locally O
advanced O
or O
recurrent O
nsclc O
. O
!LF! !LF!
eligible O
patients O
who O
had O
previously O
completed O
four O
cycles O
of O
platinum O
- O
based O
chemotherapy O
were O
randomised O
1 O
: O
1 O
to O
receive O
erlotinib O
150 O
mg O
/ O
day O
or O
placebo O
until O
disease O
progression O
, O
unacceptable O
toxicity O
or O
death O
. O
!LF! !LF!
patient O
hrqol O
was O
assessed O
using O
the O
functional O
assessment O
of O
cancer O
therapy O
- O
lung O
questionnaire O
, O
in O
terms O
of O
time O
to O
symptom O
progression O
( O
tsp O
) O
, O
time O
to O
deterioration O
( O
ttd O
) O
in O
trial O
outcome O
index O
( O
toi O
) O
and O
ttd O
. O
!LF! !LF!
exploratory O
analysis O
was O
based O
on O
time O
to O
analgesia O
and O
appearance O
of O
key O
symptoms O
( O
pain O
, O
cough O
and O
dyspnoea O
) O
. O
!LF! !LF!
compared B-Premise
with I-Premise
placebo I-Premise
, I-Premise
erlotinib I-Premise
maintenance I-Premise
therapy I-Premise
prolonged I-Premise
progression I-Premise
- I-Premise
free I-Premise
and I-Premise
overall I-Premise
survival I-Premise
by I-Premise
41 I-Premise
% I-Premise
and I-Premise
23 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
at O
baseline O
, O
hrqol O
measures O
were O
comparable O
between O
the O
two O
treatment O
groups O
. O
!LF! !LF!
maintenance B-Premise
therapy I-Premise
with I-Premise
erlotinib I-Premise
did I-Premise
not I-Premise
impact I-Premise
on I-Premise
deterioration I-Premise
in I-Premise
hrqol I-Premise
: I-Premise
tsp I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
hr I-Premise
] I-Premise
= I-Premise
0 I-Premise
. I-Premise
91 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
ci I-Premise
) I-Premise
0 I-Premise
. I-Premise
74 I-Premise
- I-Premise
1 I-Premise
. I-Premise
12 I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
n I-Premise
= I-Premise
785 I-Premise
) I-Premise
, I-Premise
ttd I-Premise
in I-Premise
toi I-Premise
( I-Premise
hr I-Premise
= I-Premise
1 I-Premise
. I-Premise
06 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
. I-Premise
87 I-Premise
- I-Premise
1 I-Premise
. I-Premise
31 I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
n I-Premise
= I-Premise
781 I-Premise
) I-Premise
and I-Premise
ttd I-Premise
in I-Premise
hrqol I-Premise
( I-Premise
hr I-Premise
= I-Premise
0 I-Premise
. I-Premise
96 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
. I-Premise
79 I-Premise
- I-Premise
1 I-Premise
. I-Premise
16 I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
n I-Premise
= I-Premise
776 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
time B-Premise
to I-Premise
pain I-Premise
and I-Premise
time I-Premise
to I-Premise
analgesic I-Premise
use I-Premise
were I-Premise
significantly I-Premise
delayed I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
erlotinib I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
hr I-Premise
= I-Premise
0 I-Premise
. I-Premise
61 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
. I-Premise
42 I-Premise
- I-Premise
0 I-Premise
. I-Premise
88 I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0080 I-Premise
and I-Premise
hr I-Premise
= I-Premise
0 I-Premise
. I-Premise
66 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
. I-Premise
46 I-Premise
- I-Premise
0 I-Premise
. I-Premise
94 I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0199 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise
!LF! !LF!
a B-Premise
non I-Premise
- I-Premise
significant I-Premise
trend I-Premise
towards I-Premise
delayed I-Premise
time I-Premise
to I-Premise
cough I-Premise
and I-Premise
time I-Premise
to I-Premise
dyspnoea I-Premise
( I-Premise
hr I-Premise
= I-Premise
0 I-Premise
. I-Premise
77 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
. I-Premise
49 I-Premise
- I-Premise
1 I-Premise
. I-Premise
21 I-Premise
] I-Premise
and I-Premise
hr I-Premise
= I-Premise
0 I-Premise
. I-Premise
75 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
. I-Premise
48 I-Premise
- I-Premise
1 I-Premise
. I-Premise
17 I-Premise
] I-Premise
, I-Premise
respectively I-Premise
) I-Premise
was I-Premise
also I-Premise
observed I-Premise
. I-Premise
!LF! !LF!
erlotinib B-Claim
maintenance I-Claim
therapy I-Claim
significantly I-Claim
extends I-Claim
progression I-Claim
- I-Claim
free I-Claim
survival I-Claim
without I-Claim
compromising I-Claim
patient I-Claim
hrqol I-Claim
in I-Claim
comparison I-Claim
with I-Claim
placebo I-Claim
, I-Claim
with I-Claim
some I-Claim
improvement I-Claim
in I-Claim
symptoms I-Claim
. I-Claim
!LF! !LF!
in O
the O
randomized O
, O
multinational O
phase O
ii O
/ O
iii O
trial O
( O
v325 O
) O
of O
untreated O
advanced O
gastric O
cancer O
patients O
, O
the O
phase O
ii O
part O
selected O
docetaxel O
, O
cisplatin O
, O
and O
fluorouracil O
( O
dcf O
) O
over O
docetaxel O
and O
cisplatin O
for O
comparison O
against O
cisplatin O
and O
fluorouracil O
( O
cf O
"""" O
; O
"""" O
reference O
regimen O
) O
in O
the O
phase O
iii O
part O
. O
!LF! !LF!
advanced O
gastric O
cancer O
patients O
were O
randomly O
assigned O
to O
docetaxel O
75 O
mg O
/ O
m2 O
and O
cisplatin O
75 O
mg O
/ O
m2 O
( O
day O
1 O
) O
plus O
fluorouracil O
750 O
mg O
/ O
m2 O
/ O
d O
( O
days O
1 O
to O
5 O
) O
every O
3 O
weeks O
or O
cisplatin O
100 O
mg O
/ O
m2 O
( O
day O
1 O
) O
plus O
fluorouracil O
1 O
, O
000 O
mg O
/ O
m2 O
/ O
d O
( O
days O
1 O
to O
5 O
) O
every O
4 O
weeks O
. O
!LF! !LF!
the O
primary O
end O
point O
was O
time O
- O
to O
- O
progression O
( O
ttp O
) O
. O
!LF! !LF!
in O
445 O
randomly O
assigned O
and O
treated O
patients O
( O
dcf O
= O
221 O
"""" O
; O
"""" O
cf O
= O
224 O
) O
, O
ttp O
was O
longer O
with O
dcf O
versus O
cf O
( O
32 O
% O
risk O
reduction O
"""" O
; O
"""" O
log O
- O
rank O
p O
< O
. O
001 O
) O
. O
!LF! !LF!
overall B-Premise
survival I-Premise
was I-Premise
longer I-Premise
with I-Premise
dcf I-Premise
versus I-Premise
cf I-Premise
( I-Premise
23 I-Premise
% I-Premise
risk I-Premise
reduction I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
log I-Premise
- I-Premise
rank I-Premise
p I-Premise
= I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
two B-Premise
- B-Premise
year B-Premise
survival I-Premise
rate I-Premise
was I-Premise
18 I-Premise
% I-Premise
with I-Premise
dcf I-Premise
and I-Premise
9 I-Premise
% I-Premise
with I-Premise
cf I-Premise
. I-Premise
!LF! !LF!
overall B-Premise
response I-Premise
rate I-Premise
was I-Premise
higher I-Premise
with I-Premise
dcf I-Premise
( I-Premise
chi2 I-Premise
p I-Premise
= I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
grade B-Premise
3 I-Premise
to I-Premise
4 I-Premise
treatment I-Premise
- I-Premise
related I-Premise
adverse I-Premise
events I-Premise
occurred I-Premise
in I-Premise
69 I-Premise
% I-Premise
( I-Premise
dcf I-Premise
) I-Premise
v I-Premise
59 I-Premise
% I-Premise
( I-Premise
cf I-Premise
) I-Premise
of I-Premise
patients I-Premise
. I-Premise
!LF! !LF!
frequent B-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
toxicities I-Premise
for I-Premise
dcf I-Premise
v I-Premise
cf I-Premise
were I-Premise
: I-Premise
neutropenia I-Premise
( I-Premise
82 I-Premise
% I-Premise
v I-Premise
57 I-Premise
% I-Premise
) I-Premise
, I-Premise
stomatitis I-Premise
( I-Premise
21 I-Premise
% I-Premise
v I-Premise
27 I-Premise
% I-Premise
) I-Premise
, I-Premise
diarrhea I-Premise
( I-Premise
19 I-Premise
% I-Premise
v I-Premise
8 I-Premise
% I-Premise
) I-Premise
, I-Premise
lethargy I-Premise
( I-Premise
19 I-Premise
% I-Premise
v I-Premise
14 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
complicated B-Premise
neutropenia I-Premise
was I-Premise
more I-Premise
frequent I-Premise
with I-Premise
dcf I-Premise
than I-Premise
cf I-Premise
( I-Premise
29 I-Premise
% I-Premise
v I-Premise
12 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
adding B-Claim
docetaxel I-Claim
to I-Claim
cf I-Claim
significantly I-Claim
improved I-Claim
ttp I-Claim
, I-Claim
survival I-Claim
, I-Claim
and I-Claim
response I-Claim
rate I-Claim
in I-Claim
gastric I-Claim
cancer I-Claim
patients I-Claim
, I-Claim
but I-Claim
resulted I-Claim
in I-Claim
some I-Claim
increase I-Claim
in I-Claim
toxicity I-Claim
. I-Claim
!LF! !LF!
incorporation B-Claim
of I-Claim
docetaxel I-Claim
, I-Claim
as I-Claim
in I-Claim
dcf I-Claim
or I-Claim
with I-Claim
other I-Claim
active I-Claim
drug I-Claim
( I-Claim
s I-Claim
) I-Claim
, I-Claim
is I-Claim
a I-Claim
new I-Claim
therapy I-Claim
option I-Claim
for I-Claim
patients I-Claim
with I-Claim
untreated I-Claim
advanced I-Claim
gastric I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
hormonal B-Claim
breast I-Claim
cancer I-Claim
treatment I-Claim
increases I-Claim
menopausal I-Claim
symptoms I-Claim
in I-Claim
women I-Claim
. I-Claim
!LF! !LF!
this O
study O
investigated O
differences O
between O
the O
symptoms O
associated O
with O
either O
adjuvant O
tamoxifen O
or O
exemestane O
. O
!LF! !LF!
ten O
common O
symptoms O
were O
assessed O
by O
self O
- O
report O
questionnaire O
administered O
to O
1 O
, O
614 O
consecutive O
patients O
at O
baseline O
and O
every O
3 O
months O
during O
the O
first O
year O
of O
a O
double O
- O
blind O
, O
randomized O
trial O
of O
postmenopausal O
women O
with O
early O
hormone O
receptor O
- O
positive O
breast O
cancer O
. O
!LF! !LF!
symptoms O
were O
categorized O
as O
none O
, O
mild O
, O
moderate O
, O
or O
severe O
. O
!LF! !LF!
a O
hot O
flash O
score O
was O
calculated O
at O
each O
time O
point O
. O
!LF! !LF!
symptoms O
were O
analyzed O
by O
repeated O
- O
measures O
analysis O
of O
variance O
. O
!LF! !LF!
each O
time O
period O
was O
tested O
repeatedly O
against O
the O
baseline O
"""" O
; O
"""" O
an O
overall O
p O
value O
was O
assigned O
for O
each O
reported O
symptom O
. O
!LF! !LF!
compliance O
was O
excellent O
, O
with O
7 O
, O
286 O
questionnaires O
analyzed O
. O
!LF! !LF!
baseline O
symptom O
prevalence O
ranged O
from O
2 O
% O
( O
vaginal O
bleeding O
) O
to O
60 O
% O
to O
70 O
% O
( O
bone O
/ O
muscle O
aches O
and O
low O
energy O
) O
. O
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
vaginal I-Premise
bleeding I-Premise
, I-Premise
mood I-Premise
alteration I-Premise
, I-Premise
or I-Premise
low I-Premise
energy I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
receiving I-Premise
tamoxifen I-Premise
had I-Premise
significantly I-Premise
more I-Premise
vaginal I-Premise
discharge I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
0001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
exemestane B-Premise
patients I-Premise
reported I-Premise
more I-Premise
bone I-Premise
/ I-Premise
muscle I-Premise
aches I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
0001 I-Premise
) I-Premise
, I-Premise
vaginal I-Premise
dryness I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
0004 I-Premise
) I-Premise
, I-Premise
and I-Premise
difficulty I-Premise
sleeping I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
in B-Premise
both I-Premise
groups I-Premise
, I-Premise
the I-Premise
hot I-Premise
flash I-Premise
score I-Premise
peaked I-Premise
at I-Premise
3 I-Premise
months I-Premise
and I-Premise
decreased I-Premise
thereafter I-Premise
. I-Premise
!LF! !LF!
at B-Premise
12 I-Premise
months I-Premise
, I-Premise
patients I-Premise
receiving I-Premise
tamoxifen I-Premise
had I-Premise
a I-Premise
significantly I-Premise
higher I-Premise
mean I-Premise
hot I-Premise
flash I-Premise
score I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
, I-Premise
with I-Premise
daily I-Premise
hot I-Premise
flashes I-Premise
increasing I-Premise
from I-Premise
baseline I-Premise
by I-Premise
33 I-Premise
% I-Premise
compared I-Premise
with I-Premise
a I-Premise
7 I-Premise
% I-Premise
increase I-Premise
from I-Premise
baseline I-Premise
with I-Premise
exemestane I-Premise
. I-Premise
!LF! !LF!
at B-Premise
12 I-Premise
months I-Premise
, I-Premise
exemestane I-Premise
was I-Premise
associated I-Premise
with I-Premise
fewer I-Premise
hot I-Premise
flashes I-Premise
and I-Premise
less I-Premise
vaginal I-Premise
discharge I-Premise
than I-Premise
tamoxifen I-Premise
, I-Premise
but I-Premise
with I-Premise
more I-Premise
vaginal I-Premise
dryness I-Premise
, I-Premise
bone I-Premise
/ I-Premise
muscle I-Premise
aches I-Premise
, I-Premise
and I-Premise
difficulty I-Premise
sleeping I-Premise
. I-Premise
!LF! !LF!
symptoms B-Claim
were I-Claim
common I-Claim
in I-Claim
both I-Claim
groups I-Claim
. I-Claim
!LF! !LF!
we O
aimed O
to O
determine O
the O
effectiveness O
of O
a O
lay O
- O
administered O
tailored O
education O
and O
coaching O
( O
tec O
) O
intervention O
( O
aimed O
at O
reducing O
pain O
misconceptions O
and O
enhancing O
self O
- O
efficacy O
for O
communicating O
with O
physicians O
) O
on O
cancer O
pain O
severity O
, O
pain O
- O
related O
impairment O
, O
and O
quality O
of O
life O
. O
!LF! !LF!
cancer O
patients O
with O
baseline O
"""" O
worst O
pain O
"""" O
of O
≥4 O
on O
a O
0 O
- O
10 O
scale O
or O
at O
least O
moderate O
functional O
impairment O
due O
to O
pain O
were O
randomly O
assigned O
to O
tec O
or O
enhanced O
usual O
care O
( O
euc O
) O
during O
a O
telephone O
interview O
conducted O
in O
advance O
of O
a O
planned O
oncology O
office O
visit O
( O
265 O
patients O
randomized O
to O
tec O
or O
euc O
"""" O
; O
"""" O
258 O
completed O
at O
least O
one O
follow O
- O
up O
) O
. O
!LF! !LF!
patients O
completed O
questionnaires O
before O
and O
after O
the O
visit O
and O
were O
interviewed O
by O
telephone O
at O
2 O
, O
6 O
, O
and O
12 O
weeks O
. O
!LF! !LF!
mixed O
effects O
regressions O
were O
used O
to O
evaluate O
the O
intervention O
adjusting O
for O
patient O
, O
practice O
, O
and O
site O
characteristics O
. O
!LF! !LF!
compared B-Premise
to I-Premise
euc I-Premise
, I-Premise
tec I-Premise
was I-Premise
associated I-Premise
with I-Premise
increased I-Premise
pain I-Premise
communication I-Premise
self I-Premise
- I-Premise
efficacy I-Premise
after I-Premise
the I-Premise
intervention I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
both B-Premise
groups I-Premise
showed I-Premise
significant I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
0001 I-Premise
) I-Premise
, I-Premise
similar I-Premise
, I-Premise
reductions I-Premise
in I-Premise
pain I-Premise
misconceptions I-Premise
. I-Premise
!LF! !LF!
at B-Premise
2 I-Premise
weeks I-Premise
, I-Premise
assignment I-Premise
to I-Premise
tec I-Premise
was I-Premise
associated I-Premise
with I-Premise
improvement I-Premise
in I-Premise
pain I-Premise
- I-Premise
related I-Premise
impairment I-Premise
( I-Premise
- I-Premise
0 I-Premise
. I-Premise
25 I-Premise
points I-Premise
on I-Premise
a I-Premise
5 I-Premise
- I-Premise
point I-Premise
scale I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
- I-Premise
0 I-Premise
. I-Premise
43 I-Premise
to I-Premise
- I-Premise
0 I-Premise
. I-Premise
06 I-Premise
, I-Premise
p I-Premise
= I-Premise
. I-Premise
01 I-Premise
) I-Premise
but B-Premise
not I-Premise
in I-Premise
pain I-Premise
severity I-Premise
( I-Premise
- I-Premise
0 I-Premise
. I-Premise
21 I-Premise
points I-Premise
on I-Premise
an I-Premise
11 I-Premise
- I-Premise
point I-Premise
scale I-Premise
, I-Premise
- I-Premise
0 I-Premise
. I-Premise
60 I-Premise
to I-Premise
0 I-Premise
. I-Premise
17 I-Premise
, I-Premise
p I-Premise
= I-Premise
. I-Premise
27 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
improvement I-Premise
in I-Premise
pain I-Premise
- I-Premise
related I-Premise
impairment I-Premise
was I-Premise
not I-Premise
sustained I-Premise
at I-Premise
6 I-Premise
and I-Premise
12 I-Premise
weeks I-Premise
. I-Premise
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
significant I-Premise
intervention I-Premise
by I-Premise
subgroup I-Premise
interactions I-Premise
( I-Premise
p I-Premise
> I-Premise
. I-Premise
10 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
we B-Claim
conclude I-Claim
that I-Claim
tec I-Claim
, I-Claim
compared I-Claim
with I-Claim
euc I-Claim
, I-Claim
resulted I-Claim
in I-Claim
improved I-Claim
pain I-Claim
communication I-Claim
self I-Claim
- I-Claim
efficacy I-Claim
and I-Claim
temporary I-Claim
improvement I-Claim
in I-Claim
pain I-Claim
- I-Claim
related I-Claim
impairment I-Claim
, I-Claim
but I-Claim
no I-Claim
improvement I-Claim
in I-Claim
pain I-Claim
severity I-Claim
. I-Claim
!LF! !LF!
in B-Claim
phase I-Claim
ii I-Claim
trials I-Claim
, I-Claim
paclitaxel I-Claim
has I-Claim
been I-Claim
shown I-Claim
to I-Claim
have I-Claim
antitumor I-Claim
activity I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non I-Claim
- I-Claim
small I-Claim
- I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
nsclc I-Claim
) I-Claim
. I-Claim
!LF! !LF!
however O
, O
the O
survival O
and O
quality O
- O
of O
- O
life O
( O
qol O
) O
benefits O
of O
paclitaxel O
used O
as O
a O
single O
agent O
compared O
with O
supportive O
care O
alone O
have O
not O
been O
assessed O
in O
a O
randomized O
clinical O
trial O
. O
!LF! !LF!
a O
total O
of O
157 O
patients O
with O
stage O
iiib O
or O
iv O
nsclc O
who O
had O
received O
no O
prior O
chemotherapy O
were O
randomly O
assigned O
to O
receive O
either O
best O
supportive O
care O
alone O
( O
78 O
patients O
) O
or O
paclitaxel O
plus O
supportive O
care O
( O
79 O
patients O
) O
. O
!LF! !LF!
paclitaxel O
was O
administered O
as O
a O
3 O
- O
hour O
intravenous O
infusion O
every O
3 O
weeks O
. O
!LF! !LF!
supportive O
care O
included O
palliative O
radiotherapy O
and O
supportive O
therapy O
with O
corticosteroids O
, O
antibiotics O
, O
analgesics O
, O
antiemetics O
, O
transfusions O
, O
and O
other O
symptomatic O
therapy O
as O
required O
. O
!LF! !LF!
the O
primary O
end O
point O
of O
the O
study O
was O
survival O
. O
!LF! !LF!
time O
to O
disease O
progression O
, O
response O
rate O
, O
adverse O
events O
, O
and O
qol O
were O
secondary O
end O
points O
. O
!LF! !LF!
pretreatment O
characteristics O
were O
evenly O
distributed O
between O
the O
two O
arms O
. O
!LF! !LF!
survival B-Premise
was I-Premise
statistically I-Premise
significantly I-Premise
better I-Premise
in I-Premise
the I-Premise
paclitaxel I-Premise
plus I-Premise
supportive I-Premise
care I-Premise
arm I-Premise
than I-Premise
in I-Premise
the I-Premise
supportive I-Premise
care I-Premise
alone I-Premise
arm I-Premise
( I-Premise
two I-Premise
- I-Premise
sided I-Premise
p I-Premise
= I-Premise
. I-Premise
037 I-Premise
) I-Premise
( I-Premise
median I-Premise
survival I-Premise
= I-Premise
6 I-Premise
. I-Premise
8 I-Premise
months I-Premise
versus I-Premise
4 I-Premise
. I-Premise
8 I-Premise
months I-Premise
) I-Premise
. I-Premise
!LF! !LF!
cox B-Premise
multivariate I-Premise
analysis I-Premise
showed I-Premise
paclitaxel I-Premise
plus I-Premise
supportive I-Premise
care I-Premise
to I-Premise
be I-Premise
statistically I-Premise
significantly I-Premise
associated I-Premise
with I-Premise
improved I-Premise
survival I-Premise
( I-Premise
two I-Premise
- I-Premise
sided I-Premise
p I-Premise
= I-Premise
. I-Premise
048 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
qol B-Premise
was I-Premise
similar I-Premise
for I-Premise
both I-Premise
treatment I-Premise
arms I-Premise
, I-Premise
except B-Premise
for I-Premise
the I-Premise
functional I-Premise
activity I-Premise
score I-Premise
of I-Premise
the I-Premise
rotterdam I-Premise
symptom I-Premise
checklist I-Premise
, I-Premise
where I-Premise
qol I-Premise
data I-Premise
statistically I-Premise
significantly I-Premise
favored I-Premise
the I-Premise
paclitaxel I-Premise
plus I-Premise
supportive I-Premise
care I-Premise
arm I-Premise
( I-Premise
two I-Premise
- I-Premise
sided I-Premise
p I-Premise
= I-Premise
. I-Premise
043 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Claim
addition I-Claim
of I-Claim
paclitaxel I-Claim
to I-Claim
best I-Claim
supportive I-Claim
care I-Claim
significantly I-Claim
improved I-Claim
survival I-Claim
and I-Claim
time I-Claim
to I-Claim
disease I-Claim
progression I-Claim
compared I-Claim
with I-Claim
best I-Claim
supportive I-Claim
care I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
nsclc I-Claim
and I-Claim
may I-Claim
improve I-Claim
some I-Claim
aspects I-Claim
of I-Claim
qol I-Claim
. I-Claim
!LF! !LF!
national O
cancer O
institute O
of O
canada O
clinical O
trials O
group O
co O
. O
17 O
demonstrated O
the O
antiepidermal O
growth O
factor O
receptor O
( O
anti O
- O
egfr O
) O
monoclonal O
antibody O
cetuximab O
improves O
overall O
and O
progression O
- O
free O
survival O
in O
patients O
with O
advanced O
, O
chemotherapy O
- O
refractory O
colorectal O
cancer O
( O
crc O
) O
, O
particularly O
in O
patients O
with O
wild O
- O
type O
kras O
tumors O
. O
!LF! !LF!
this O
article O
reports O
the O
health O
- O
related O
quality O
- O
of O
- O
life O
( O
hrql O
) O
outcomes O
from O
co O
. O
17 O
. O
!LF! !LF!
patients O
( O
n O
= O
572 O
) O
with O
pretreated O
egfr O
- O
detectable O
advanced O
crc O
were O
randomly O
assigned O
to O
cetuximab O
and O
best O
supportive O
care O
( O
bsc O
) O
or O
to O
bsc O
alone O
. O
!LF! !LF!
hrql O
primary O
end O
points O
assessed O
by O
the O
eortc O
qlq O
- O
c30 O
were O
physical O
function O
( O
pf O
) O
and O
global O
health O
status O
( O
ghs O
) O
"""" O
; O
"""" O
mean O
changes O
from O
baseline O
to O
8 O
and O
16 O
weeks O
were O
assessed O
. O
!LF! !LF!
post O
hoc O
analysis O
by O
kras O
mutation O
status O
was O
performed O
. O
!LF! !LF!
questionnaire O
compliance O
was O
94 O
% O
at O
baseline O
, O
but O
it O
declined O
differentially O
( O
67 O
% O
v O
47 O
% O
for O
cetuximab O
v O
bsc O
at O
16 O
weeks O
) O
. O
!LF! !LF!
pf B-Premise
change I-Premise
scores I-Premise
were I-Premise
- I-Premise
3 I-Premise
. I-Premise
9 I-Premise
for I-Premise
cetuximab I-Premise
and I-Premise
- I-Premise
8 I-Premise
. I-Premise
6 I-Premise
for I-Premise
bsc I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
046 I-Premise
) I-Premise
at I-Premise
8 I-Premise
weeks I-Premise
and I-Premise
were I-Premise
- I-Premise
5 I-Premise
. I-Premise
9 I-Premise
and I-Premise
- I-Premise
12 I-Premise
. I-Premise
5 I-Premise
for I-Premise
cetuximab I-Premise
and I-Premise
bsc I-Premise
, I-Premise
respectively I-Premise
, I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
027 I-Premise
) I-Premise
at I-Premise
16 I-Premise
weeks I-Premise
. I-Premise
!LF! !LF!
ghs B-Premise
change I-Premise
scores I-Premise
were I-Premise
- I-Premise
0 I-Premise
. I-Premise
5 I-Premise
and I-Premise
- I-Premise
7 I-Premise
. I-Premise
1 I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
008 I-Premise
) I-Premise
at I-Premise
8 I-Premise
weeks I-Premise
and I-Premise
were I-Premise
- I-Premise
3 I-Premise
. I-Premise
6 I-Premise
and I-Premise
- I-Premise
15 I-Premise
. I-Premise
2 I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
008 I-Premise
) I-Premise
at I-Premise
16 I-Premise
weeks I-Premise
for I-Premise
cetuximab I-Premise
and I-Premise
bsc I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
in B-Premise
patients I-Premise
who I-Premise
had I-Premise
tumors I-Premise
with I-Premise
wild I-Premise
- I-Premise
type I-Premise
kras I-Premise
status I-Premise
, I-Premise
cetuximab I-Premise
resulted I-Premise
in I-Premise
less I-Premise
pf I-Premise
deterioration I-Premise
at I-Premise
8 I-Premise
weeks I-Premise
( I-Premise
- I-Premise
0 I-Premise
. I-Premise
7 I-Premise
v I-Premise
- I-Premise
7 I-Premise
. I-Premise
2 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
11 I-Premise
) I-Premise
and I-Premise
16 I-Premise
weeks I-Premise
( I-Premise
- I-Premise
3 I-Premise
. I-Premise
4 I-Premise
v I-Premise
- I-Premise
13 I-Premise
. I-Premise
8 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
008 I-Premise
) I-Premise
compared I-Premise
with I-Premise
bsc I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
with I-Premise
wild I-Premise
- I-Premise
type I-Premise
status I-Premise
who I-Premise
received I-Premise
cetuximab I-Premise
experienced I-Premise
improved I-Premise
ghs I-Premise
at I-Premise
8 I-Premise
weeks I-Premise
, I-Premise
whereas I-Premise
patients I-Premise
who I-Premise
received I-Premise
bsc I-Premise
alone I-Premise
deteriorated I-Premise
( I-Premise
3 I-Premise
. I-Premise
2 I-Premise
v I-Premise
- I-Premise
7 I-Premise
. I-Premise
7 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
002 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
cetuximab B-Premise
preserved I-Premise
ghs I-Premise
at I-Premise
16 I-Premise
weeks I-Premise
( I-Premise
- I-Premise
0 I-Premise
. I-Premise
2 I-Premise
v I-Premise
- I-Premise
18 I-Premise
. I-Premise
1 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
no B-Premise
significant I-Premise
differences I-Premise
were I-Premise
noted I-Premise
between I-Premise
study I-Premise
arms I-Premise
for I-Premise
patients I-Premise
with I-Premise
mutated I-Premise
kras I-Premise
tumors I-Premise
. I-Premise
!LF! !LF!
cetuximab B-Claim
offers I-Claim
important I-Claim
hrql I-Claim
and I-Claim
survival I-Claim
benefits I-Claim
for I-Claim
pretreated I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
, I-Claim
wild I-Claim
- I-Claim
type I-Claim
kras I-Claim
crc I-Claim
. I-Claim
!LF! !LF!
to O
evaluate O
the O
impact O
of O
letrozole O
compared O
with O
placebo O
after O
adjuvant O
tamoxifen O
on O
quality O
of O
life O
( O
qol O
) O
in O
the O
ma O
. O
17 O
trial O
. O
!LF! !LF!
patients O
completed O
the O
short O
form O
36 O
- O
item O
health O
survey O
( O
sf O
- O
36 O
) O
and O
the O
menopause O
specific O
quality O
of O
life O
questionnaire O
( O
menqol O
) O
at O
baseline O
, O
6 O
months O
, O
and O
annually O
. O
!LF! !LF!
mean O
change O
scores O
from O
baseline O
were O
compared O
between O
groups O
for O
summary O
measures O
and O
domains O
. O
!LF! !LF!
a O
response O
analysis O
compared O
the O
proportion O
of O
patients O
who O
demonstrated O
an O
important O
change O
in O
qol O
. O
!LF! !LF!
of O
5 O
, O
187 O
randomly O
assigned O
women O
in O
the O
trial O
, O
3 O
, O
612 O
( O
69 O
. O
9 O
% O
) O
participated O
in O
the O
qol O
substudy O
: O
1 O
, O
799 O
were O
allocated O
to O
placebo O
and O
1 O
, O
813 O
were O
allocated O
to O
letrozole O
. O
!LF! !LF!
no B-Premise
differences I-Premise
were I-Premise
seen I-Premise
between I-Premise
groups I-Premise
in I-Premise
mean I-Premise
change I-Premise
scores I-Premise
from I-Premise
baseline I-Premise
for I-Premise
the I-Premise
sf I-Premise
- I-Premise
36 I-Premise
physical I-Premise
and I-Premise
mental I-Premise
component I-Premise
summary I-Premise
scores I-Premise
at I-Premise
6 I-Premise
, I-Premise
12 I-Premise
, I-Premise
24 I-Premise
, I-Premise
and I-Premise
36 I-Premise
months I-Premise
. I-Premise
!LF! !LF!
small B-Premise
( I-Premise
< I-Premise
0 I-Premise
. I-Premise
2 I-Premise
standard I-Premise
deviations I-Premise
) I-Premise
but I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
mean I-Premise
change I-Premise
scores I-Premise
from I-Premise
baseline I-Premise
were I-Premise
seen I-Premise
for I-Premise
the I-Premise
sf I-Premise
- I-Premise
36 I-Premise
domains I-Premise
of I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
12 I-Premise
months I-Premise
) I-Premise
, I-Premise
bodily I-Premise
pain I-Premise
( I-Premise
6 I-Premise
months I-Premise
) I-Premise
and I-Premise
vitality I-Premise
( I-Premise
6 I-Premise
and I-Premise
12 I-Premise
months I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
menqol I-Premise
vasomotor I-Premise
( I-Premise
6 I-Premise
, I-Premise
12 I-Premise
, I-Premise
and I-Premise
24 I-Premise
months I-Premise
) I-Premise
and I-Premise
sexual I-Premise
domains I-Premise
( I-Premise
12 I-Premise
and I-Premise
24 I-Premise
months I-Premise
) I-Premise
. I-Premise
!LF! !LF!
on B-Premise
the I-Premise
response I-Premise
analysis I-Premise
, I-Premise
a I-Premise
significant I-Premise
difference I-Premise
was I-Premise
seen I-Premise
between I-Premise
groups I-Premise
for I-Premise
the I-Premise
bodily I-Premise
pain I-Premise
domain I-Premise
( I-Premise
percentage I-Premise
of I-Premise
patients I-Premise
reporting I-Premise
a I-Premise
worsening I-Premise
of I-Premise
qol I-Premise
, I-Premise
47 I-Premise
% I-Premise
placebo I-Premise
v I-Premise
51 I-Premise
% I-Premise
letrozole I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
009 I-Premise
) I-Premise
and I-Premise
the I-Premise
vasomotor I-Premise
domain I-Premise
( I-Premise
22 I-Premise
% I-Premise
placebo I-Premise
v I-Premise
29 I-Premise
% I-Premise
letrozole I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
letrozole B-Claim
did I-Claim
not I-Claim
have I-Claim
an I-Claim
adverse I-Claim
impact I-Claim
on I-Claim
overall I-Claim
qol I-Claim
. I-Claim
!LF! !LF!
small B-Claim
effects I-Claim
were I-Claim
seen I-Claim
in I-Claim
some I-Claim
domains I-Claim
consistent I-Claim
with I-Claim
a I-Claim
minority I-Claim
of I-Claim
patients I-Claim
experiencing I-Claim
changes I-Claim
in I-Claim
qol I-Claim
compatible I-Claim
with I-Claim
a I-Claim
reduction I-Claim
in I-Claim
estrogen I-Claim
synthesis I-Claim
. I-Claim
!LF! !LF!
the B-Claim
combination I-Claim
of I-Claim
interferon I-Claim
alfa I-Claim
( I-Claim
ifnalpha I-Claim
) I-Claim
and I-Claim
isotretinoin I-Claim
has I-Claim
shown I-Claim
a I-Claim
direct I-Claim
antiproliferative I-Claim
effect I-Claim
on I-Claim
human I-Claim
melanoma I-Claim
cell I-Claim
lines I-Claim
, I-Claim
but B-Claim
it I-Claim
remained I-Claim
unclear I-Claim
whether I-Claim
this I-Claim
combination I-Claim
is I-Claim
more I-Claim
effective I-Claim
than I-Claim
ifnalpha I-Claim
alone I-Claim
in I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
melanoma I-Claim
. I-Claim
!LF! !LF!
we O
evaluated O
safety O
and O
efficacy O
of O
ifnalpha O
and O
isotretinoin O
compared O
with O
ifnalpha O
alone O
as O
adjuvant O
treatment O
in O
patients O
with O
primary O
malignant O
melanoma O
stage O
iia O
and O
iib O
. O
!LF! !LF!
in O
a O
prospective O
, O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
trial O
, O
407 O
melanoma O
patients O
in O
stage O
iia O
( O
301 O
patients O
) O
and O
iib O
( O
106 O
patients O
) O
were O
randomly O
assigned O
to O
either O
ifnalpha O
and O
isotretinoin O
( O
isotretinoin O
group O
"""" O
; O
"""" O
206 O
patients O
) O
or O
ifnalpha O
and O
placebo O
( O
placebo O
group O
"""" O
; O
"""" O
201 O
patients O
) O
after O
excision O
of O
the O
primary O
tumor O
. O
!LF! !LF!
ifnalpha O
was O
administered O
three O
times O
a O
week O
at O
a O
dose O
of O
3 O
million O
units O
subcutaneously O
for O
24 O
months O
. O
!LF! !LF!
isotretinoin O
at O
a O
dose O
of O
20 O
mg O
for O
patients O
< O
or O
= O
73 O
kg O
, O
30 O
mg O
for O
patients O
greater O
than O
73 O
kg O
, O
or O
placebo O
daily O
for O
24 O
months O
. O
!LF! !LF!
a B-Premise
scheduled I-Premise
interim I-Premise
analysis I-Premise
revealed I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
survival I-Premise
rates I-Premise
, I-Premise
with I-Premise
the I-Premise
isotretinoin I-Premise
group I-Premise
and I-Premise
the I-Premise
placebo I-Premise
group I-Premise
showing I-Premise
5 I-Premise
- I-Premise
year I-Premise
disease I-Premise
- I-Premise
free I-Premise
survival I-Premise
rates I-Premise
of I-Premise
55 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
46 I-Premise
% I-Premise
to I-Premise
65 I-Premise
% I-Premise
) I-Premise
and I-Premise
67 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
59 I-Premise
% I-Premise
to I-Premise
75 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
, I-Premise
and I-Premise
overall I-Premise
5 I-Premise
- I-Premise
year I-Premise
survival I-Premise
rates I-Premise
of I-Premise
76 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
67 I-Premise
% I-Premise
to I-Premise
84 I-Premise
% I-Premise
) I-Premise
and I-Premise
81 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
74 I-Premise
% I-Premise
to I-Premise
88 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
the O
trial O
was O
stopped O
for O
futility O
. O
!LF! !LF!
the B-Claim
addition I-Claim
of I-Claim
isotretinoin I-Claim
to I-Claim
an I-Claim
adjuvant I-Claim
treatment I-Claim
of I-Claim
low I-Claim
- I-Claim
dose I-Claim
ifnalpha I-Claim
in I-Claim
patients I-Claim
with I-Claim
stage I-Claim
iia I-Claim
and I-Claim
iib I-Claim
melanoma I-Claim
had I-Claim
no I-Claim
significant I-Claim
effect I-Claim
on I-Claim
disease I-Claim
- I-Claim
free I-Claim
or I-Claim
overall I-Claim
survival I-Claim
and I-Claim
is I-Claim
therefore I-Claim
not I-Claim
recommended I-Claim
. I-Claim
!LF! !LF!
a O
randomised O
controlled O
trial O
of O
radiotherapy O
alone O
versus O
radiotherapy O
with O
concomitant O
and O
adjuvant O
temozolomide O
for O
patients O
with O
glioblastoma O
showed O
that O
survival O
was O
higher O
for O
patients O
assigned O
combination O
treatment O
compared O
with O
those O
assigned O
standard O
radiotherapy O
alone O
. O
!LF! !LF!
this O
paper O
reports O
the O
health O
- O
related O
quality O
of O
life O
( O
hrqol O
) O
of O
the O
patients O
in O
this O
trial O
. O
!LF! !LF!
573 O
patients O
with O
newly O
diagnosed O
glioblastoma O
were O
randomly O
allocated O
either O
radiotherapy O
alone O
or O
radiotherapy O
and O
temozolomide O
. O
!LF! !LF!
the O
primary O
endpoint O
was O
survival O
, O
and O
hrqol O
was O
a O
secondary O
endpoint O
. O
!LF! !LF!
we O
assessed O
hrqol O
at O
baseline O
and O
at O
every O
3 O
months O
during O
treatment O
until O
progression O
using O
the O
european O
organisation O
for O
research O
and O
treatment O
of O
cancer O
( O
eortc O
) O
quality O
of O
life O
questionnaire O
core O
- O
30 O
( O
qlq O
- O
c30 O
) O
and O
the O
eortc O
brain O
cancer O
module O
( O
eortc O
bn O
- O
20 O
) O
. O
!LF! !LF!
we O
calculated O
changes O
from O
baseline O
score O
for O
seven O
predefined O
hrqol O
measures O
( O
fatigue O
, O
overall O
health O
, O
social O
function O
, O
emotional O
function O
, O
future O
uncertainty O
, O
insomnia O
, O
and O
communication O
deficit O
) O
and O
differences O
between O
groups O
for O
these O
measures O
at O
every O
time O
point O
. O
!LF! !LF!
the O
significance O
of O
, O
and O
proportions O
of O
patients O
with O
, O
improved O
hrqol O
scores O
- O
- O
defined O
as O
a O
change O
of O
10 O
points O
or O
more O
- O
- O
were O
recorded O
. O
!LF! !LF!
baseline O
questionnaires O
were O
available O
for O
490 O
( O
86 O
% O
) O
patients O
. O
!LF! !LF!
baseline O
hrqol O
scores O
did O
not O
differ O
between O
groups O
. O
!LF! !LF!
at B-Premise
first I-Premise
follow I-Premise
- I-Premise
up I-Premise
, I-Premise
groups I-Premise
differed I-Premise
only I-Premise
in I-Premise
social I-Premise
functioning I-Premise
, I-Premise
favouring I-Premise
the I-Premise
radiotherapy I-Premise
- I-Premise
only I-Premise
group I-Premise
( I-Premise
mean I-Premise
score I-Premise
79 I-Premise
. I-Premise
0 I-Premise
[ I-Premise
sd I-Premise
3 I-Premise
. I-Premise
2 I-Premise
] I-Premise
for I-Premise
patients I-Premise
assigned I-Premise
radiotherapy I-Premise
vs I-Premise
67 I-Premise
. I-Premise
4 I-Premise
[ I-Premise
2 I-Premise
. I-Premise
7 I-Premise
] I-Premise
for I-Premise
those I-Premise
assigned I-Premise
radiotherapy I-Premise
and I-Premise
temozolomide I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
difference I-Premise
between I-Premise
groups I-Premise
11 I-Premise
. I-Premise
6 I-Premise
points I-Premise
[ I-Premise
95 I-Premise
% I-Premise
ci I-Premise
3 I-Premise
. I-Premise
5 I-Premise
- I-Premise
19 I-Premise
. I-Premise
7 I-Premise
] I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0052 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
over B-Premise
subsequent I-Premise
assessments I-Premise
, I-Premise
hrqol I-Premise
was I-Premise
much I-Premise
the I-Premise
same I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
addition B-Claim
of I-Claim
temozolomide I-Claim
during I-Claim
and I-Claim
after I-Claim
radiotherapy I-Claim
for I-Claim
patients I-Claim
with I-Claim
newly I-Claim
diagnosed I-Claim
glioblastoma I-Claim
significantly I-Claim
improved I-Claim
survival I-Claim
without I-Claim
a I-Claim
negative I-Claim
effect I-Claim
on I-Claim
hrqol I-Claim
. I-Claim
!LF! !LF!
to O
determine O
the O
feasibility O
of O
administering O
a O
flavonoid O
- O
rich O
adjunctive O
treatment O
( O
concord O
grape O
juice O
) O
for O
the O
management O
of O
chemotherapy O
- O
induced O
nausea O
and O
vomiting O
( O
cinv O
) O
"""" O
; O
"""" O
to O
evaluate O
the O
usefulness O
of O
existing O
measures O
for O
assessing O
cinv O
frequency O
and O
severity O
, O
quality O
of O
life O
, O
control O
over O
life O
events O
, O
and O
psychological O
state O
"""" O
; O
"""" O
to O
identify O
any O
actual O
or O
potential O
adverse O
events O
associated O
with O
frequent O
grape O
juice O
intake O
"""" O
; O
"""" O
and O
to O
provide O
preliminary O
data O
concerning O
the O
effect O
of O
concord O
grape O
juice O
on O
cinv O
, O
quality O
of O
life O
, O
perceived O
control O
over O
life O
events O
, O
and O
psychological O
state O
. O
!LF! !LF!
double O
- O
blind O
, O
randomized O
clinical O
trial O
. O
!LF! !LF!
a O
cancer O
center O
in O
an O
academic O
health O
science O
center O
in O
the O
northeastern O
united O
states O
. O
!LF! !LF!
77 O
adult O
patients O
with O
cancer O
receiving O
moderately O
or O
highly O
emetogenic O
chemotherapy O
agents O
. O
!LF! !LF!
participants O
drank O
4 O
oz O
. O
!LF! !LF!
of O
grape O
juice O
or O
placebo O
prior O
to O
meals O
for O
one O
week O
following O
each O
of O
four O
chemotherapy O
treatment O
cycles O
. O
!LF! !LF!
they O
recorded O
frequency O
, O
duration O
, O
and O
distress O
of O
nausea O
, O
vomiting O
, O
and O
retching O
daily O
, O
beginning O
the O
evening O
of O
chemotherapy O
administration O
and O
continuing O
for O
seven O
days O
. O
!LF! !LF!
data O
were O
analyzed O
with O
generalized O
estimating O
equations O
methodology O
to O
model O
differences O
between O
groups O
over O
time O
. O
!LF! !LF!
nausea B-Premise
and I-Premise
vomiting I-Premise
frequency I-Premise
, I-Premise
duration I-Premise
, I-Premise
and I-Premise
distress I-Premise
were I-Premise
lower I-Premise
for I-Premise
experimental I-Premise
group I-Premise
members I-Premise
, I-Premise
although B-Premise
a I-Premise
high I-Premise
attrition I-Premise
rate I-Premise
( I-Premise
50 I-Premise
% I-Premise
) I-Premise
resulted I-Premise
in I-Premise
insufficient I-Premise
power I-Premise
to I-Premise
detect I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
over I-Premise
time I-Premise
. I-Premise
!LF! !LF!
greater O
levels O
of O
anxiety O
, O
depression O
, O
and O
hostility O
at O
baseline O
were O
related O
to O
nausea O
and O
vomiting O
, O
quality O
of O
life O
, O
and O
perceived O
control O
over O
decision O
making O
. O
!LF! !LF!
the B-Claim
effect I-Claim
of I-Claim
grape I-Claim
juice I-Claim
flavonoids I-Claim
on I-Claim
cinv I-Claim
should I-Claim
be I-Claim
investigated I-Claim
further I-Claim
with I-Claim
a I-Claim
larger I-Claim
sample I-Claim
to I-Claim
determine I-Claim
whether I-Claim
preliminary I-Claim
findings I-Claim
are I-Claim
supported I-Claim
. I-Claim
!LF! !LF!
alterations O
to O
the O
study O
protocol O
will O
be O
necessary O
to O
decrease O
attrition O
. O
!LF! !LF!
flavonoid B-Claim
- B-Claim
rich B-Claim
fruits I-Claim
and I-Claim
vegetables I-Claim
may I-Claim
provide I-Claim
additional I-Claim
protection I-Claim
against I-Claim
cinv I-Claim
. I-Claim
!LF! !LF!
if O
the O
compounds O
work O
, O
they O
would O
offer O
a O
low O
- O
cost O
, O
readily O
available O
adjunctive O
treatment O
for O
the O
management O
of O
cinv O
. O
!LF! !LF!
the B-Claim
role I-Claim
of I-Claim
adjuvant I-Claim
chemotherapy I-Claim
in I-Claim
postmenopausal I-Claim
patients I-Claim
with I-Claim
lymph I-Claim
node I-Claim
- I-Claim
negative I-Claim
breast I-Claim
cancer I-Claim
is I-Claim
controversial I-Claim
. I-Claim
!LF! !LF!
after O
demonstrating O
the O
efficacy O
of O
chemotherapy O
combined O
with O
tamoxifen O
for O
postmenopausal O
patients O
with O
lymph O
node O
- O
positive O
disease O
, O
the O
international O
breast O
cancer O
study O
group O
launched O
a O
randomized O
trial O
( O
trial O
ix O
) O
to O
evaluate O
the O
role O
of O
adjuvant O
chemotherapy O
preceding O
treatment O
with O
tamoxifen O
for O
patients O
with O
lymph O
node O
- O
negative O
disease O
. O
!LF! !LF!
after O
stratification O
by O
estrogen O
receptor O
( O
er O
) O
status O
, O
patients O
were O
randomly O
assigned O
to O
receive O
three O
28 O
- O
day O
courses O
of O
"""" O
classical O
"""" O
adjuvant O
cmf O
chemotherapy O
( O
cyclophosphamide O
at O
100 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
- O
14 O
, O
orally O
"""" O
; O
"""" O
methotrexate O
at O
40 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
, O
intravenously O
"""" O
; O
"""" O
and O
5 O
- O
fluorouracil O
at O
600 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
, O
intravenously O
) O
followed O
by O
tamoxifen O
( O
20 O
mg O
/ O
day O
, O
orally O
for O
57 O
months O
) O
( O
cmf O
- O
- O
> O
tamoxifen O
) O
or O
to O
receive O
tamoxifen O
alone O
( O
20 O
mg O
/ O
day O
, O
orally O
for O
60 O
months O
) O
. O
!LF! !LF!
we O
enrolled O
1669 O
eligible O
patients O
, O
382 O
( O
23 O
% O
) O
with O
er O
- O
negative O
tumors O
, O
1217 O
( O
73 O
% O
) O
with O
er O
- O
positive O
tumors O
, O
and O
70 O
( O
4 O
% O
) O
with O
unknown O
er O
status O
. O
!LF! !LF!
the O
median O
follow O
- O
up O
was O
71 O
months O
. O
!LF! !LF!
all O
statistical O
tests O
were O
two O
- O
sided O
. O
!LF! !LF!
the B-Premise
added I-Premise
benefit I-Premise
of I-Premise
cmf I-Premise
followed I-Premise
by I-Premise
tamoxifen I-Premise
over I-Premise
tamoxifen I-Premise
alone I-Premise
was I-Premise
statistically I-Premise
significantly I-Premise
dependent I-Premise
on I-Premise
er I-Premise
status I-Premise
( I-Premise
tests I-Premise
for I-Premise
interaction I-Premise
: I-Premise
p I-Premise
= I-Premise
. I-Premise
01 I-Premise
for I-Premise
disease I-Premise
- I-Premise
free I-Premise
survival I-Premise
[ I-Premise
dfs I-Premise
] I-Premise
and I-Premise
p I-Premise
= I-Premise
. I-Premise
07 I-Premise
for I-Premise
overall I-Premise
survival I-Premise
[ I-Premise
os I-Premise
] I-Premise
) I-Premise
. I-Premise
!LF! !LF!
for B-Premise
patients I-Premise
with I-Premise
er I-Premise
- I-Premise
negative I-Premise
tumors I-Premise
, I-Premise
the I-Premise
addition I-Premise
of I-Premise
cmf I-Premise
statistically I-Premise
significantly I-Premise
improved I-Premise
dfs I-Premise
( I-Premise
5 I-Premise
- I-Premise
year I-Premise
dfs I-Premise
= I-Premise
84 I-Premise
% I-Premise
for I-Premise
cmf I-Premise
- I-Premise
- I-Premise
> I-Premise
tamoxifen I-Premise
versus I-Premise
69 I-Premise
% I-Premise
for I-Premise
tamoxifen I-Premise
alone I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
difference I-Premise
= I-Premise
15 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
ci I-Premise
] I-Premise
= I-Premise
6 I-Premise
% I-Premise
to I-Premise
24 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
risk I-Premise
ratio I-Premise
[ I-Premise
rr I-Premise
] I-Premise
= I-Premise
0 I-Premise
. I-Premise
52 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
0 I-Premise
. I-Premise
34 I-Premise
to I-Premise
0 I-Premise
. I-Premise
79 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
003 I-Premise
) I-Premise
and I-Premise
os I-Premise
( I-Premise
5 I-Premise
- I-Premise
year I-Premise
os I-Premise
= I-Premise
89 I-Premise
% I-Premise
for I-Premise
cmf I-Premise
- I-Premise
- I-Premise
> I-Premise
tamoxifen I-Premise
versus I-Premise
81 I-Premise
% I-Premise
for I-Premise
tamoxifen I-Premise
alone I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
difference I-Premise
= I-Premise
8 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
0 I-Premise
% I-Premise
to I-Premise
16 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
rr I-Premise
= I-Premise
0 I-Premise
. I-Premise
51 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
0 I-Premise
. I-Premise
30 I-Premise
to I-Premise
0 I-Premise
. I-Premise
87 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
by B-Premise
contrast I-Premise
, I-Premise
for I-Premise
patients I-Premise
with I-Premise
er I-Premise
- I-Premise
positive I-Premise
tumors I-Premise
, I-Premise
addition I-Premise
of I-Premise
cmf I-Premise
provided I-Premise
no I-Premise
benefit I-Premise
in I-Premise
terms I-Premise
of I-Premise
dfs I-Premise
( I-Premise
5 I-Premise
- I-Premise
year I-Premise
dfs I-Premise
= I-Premise
84 I-Premise
% I-Premise
for I-Premise
cmf I-Premise
- I-Premise
- I-Premise
> I-Premise
tamoxifen I-Premise
versus I-Premise
85 I-Premise
% I-Premise
for I-Premise
tamoxifen I-Premise
alone I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
difference I-Premise
= I-Premise
- I-Premise
1 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
- I-Premise
6 I-Premise
% I-Premise
to I-Premise
4 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
rr I-Premise
= I-Premise
0 I-Premise
. I-Premise
99 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
0 I-Premise
. I-Premise
75 I-Premise
to I-Premise
1 I-Premise
. I-Premise
30 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
92 I-Premise
) I-Premise
or I-Premise
os I-Premise
( I-Premise
5 I-Premise
- I-Premise
year I-Premise
os I-Premise
= I-Premise
95 I-Premise
% I-Premise
for I-Premise
cmf I-Premise
- I-Premise
- I-Premise
> I-Premise
tamoxifen I-Premise
versus I-Premise
93 I-Premise
% I-Premise
for I-Premise
tamoxifen I-Premise
alone I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
difference I-Premise
= I-Premise
2 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
- I-Premise
1 I-Premise
% I-Premise
to I-Premise
5 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
rr I-Premise
= I-Premise
0 I-Premise
. I-Premise
95 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
0 I-Premise
. I-Premise
64 I-Premise
to I-Premise
1 I-Premise
. I-Premise
40 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
80 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
postmenopausal B-Claim
patients I-Claim
with I-Claim
lymph I-Claim
node I-Claim
- I-Claim
negative I-Claim
breast I-Claim
cancer I-Claim
benefited I-Claim
substantially I-Claim
from I-Claim
adjuvant I-Claim
chemotherapy I-Claim
if I-Claim
their I-Claim
cancer I-Claim
was I-Claim
er I-Claim
- I-Claim
negative I-Claim
( I-Claim
i I-Claim
. I-Claim
e I-Claim
. I-Claim
, I-Claim
endocrine I-Claim
- I-Claim
nonresponsive I-Claim
) I-Claim
. I-Claim
!LF! !LF!
in B-Claim
contrast I-Claim
, I-Claim
if I-Claim
their I-Claim
cancer I-Claim
was I-Claim
er I-Claim
- I-Claim
positive I-Claim
( I-Claim
i I-Claim
. I-Claim
e I-Claim
. I-Claim
, I-Claim
endocrine I-Claim
- I-Claim
responsive I-Claim
) I-Claim
, I-Claim
they I-Claim
obtained I-Claim
no I-Claim
benefit I-Claim
from I-Claim
the I-Claim
combination I-Claim
treatment I-Claim
compared I-Claim
with I-Claim
tamoxifen I-Claim
alone I-Claim
. I-Claim
!LF! !LF!
in O
phase O
ii O
studies O
, O
irinotecan O
is O
active O
in O
metastatic O
colorectal O
cancer O
, O
but O
the O
overall O
benefit O
has O
not O
been O
assessed O
in O
a O
randomised O
clinical O
trial O
. O
!LF! !LF!
patients O
with O
proven O
metastatic O
colorectal O
cancer O
, O
which O
had O
progressed O
within O
6 O
months O
of O
treatment O
with O
fluorouracil O
, O
were O
randomly O
assigned O
either O
300 O
- O
350 O
mg O
/ O
m2 O
irinotecan O
every O
3 O
weeks O
with O
supportive O
care O
or O
supportive O
care O
alone O
, O
in O
a O
2 O
: O
1 O
ratio O
. O
!LF! !LF!
189 O
patients O
were O
allocated O
irinotecan O
and O
supportive O
care O
and O
90 O
supportive O
care O
alone O
. O
!LF! !LF!
the O
mean O
age O
of O
the O
participants O
was O
58 O
. O
8 O
years O
"""" O
; O
"""" O
181 O
( O
65 O
% O
) O
were O
men O
and O
98 O
( O
35 O
% O
) O
were O
women O
. O
!LF! !LF!
who O
performance O
status O
was O
0 O
in O
79 O
( O
42 O
% O
) O
patients O
, O
1 O
in O
77 O
( O
41 O
% O
) O
patients O
, O
and O
2 O
in O
32 O
( O
17 O
% O
) O
patients O
. O
!LF! !LF!
tumour O
- O
related O
symptoms O
were O
present O
in O
134 O
( O
71 O
% O
) O
patients O
and O
weight O
loss O
of O
more O
than O
5 O
% O
was O
seen O
in O
15 O
( O
8 O
% O
) O
patients O
. O
!LF! !LF!
with B-Premise
a I-Premise
median I-Premise
follow I-Premise
- I-Premise
up I-Premise
of I-Premise
13 I-Premise
months I-Premise
, I-Premise
the I-Premise
overall I-Premise
survival I-Premise
was I-Premise
significantly I-Premise
better I-Premise
in I-Premise
the I-Premise
irinotecan I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0001 I-Premise
) I-Premise
, I-Premise
with I-Premise
36 I-Premise
. I-Premise
2 I-Premise
% I-Premise
1 I-Premise
- I-Premise
year I-Premise
survival I-Premise
in I-Premise
the I-Premise
irinotecan I-Premise
group I-Premise
versus I-Premise
13 I-Premise
. I-Premise
8 I-Premise
% I-Premise
in I-Premise
the I-Premise
supportive I-Premise
- I-Premise
care I-Premise
group I-Premise
. I-Premise
!LF! !LF!
the B-Premise
survival I-Premise
benefit I-Premise
, I-Premise
adjusted I-Premise
for I-Premise
prognostic I-Premise
factors I-Premise
in I-Premise
a I-Premise
multivariate I-Premise
analysis I-Premise
, I-Premise
remained I-Premise
significant I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
survival B-Premise
without I-Premise
performance I-Premise
- I-Premise
status I-Premise
deterioration I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0001 I-Premise
) I-Premise
, I-Premise
without I-Premise
weight I-Premise
loss I-Premise
of I-Premise
more I-Premise
than I-Premise
5 I-Premise
% I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
018 I-Premise
) I-Premise
, I-Premise
and I-Premise
pain I-Premise
- I-Premise
free I-Premise
survival I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
003 I-Premise
) I-Premise
were I-Premise
significantly I-Premise
better I-Premise
in I-Premise
the I-Premise
patients I-Premise
given I-Premise
irinotecan I-Premise
. I-Premise
!LF! !LF!
in B-Premise
a I-Premise
quality I-Premise
- I-Premise
of I-Premise
- I-Premise
life I-Premise
analysis I-Premise
, I-Premise
all I-Premise
significant I-Premise
differences I-Premise
, I-Premise
except I-Premise
on I-Premise
diarrhoea I-Premise
score I-Premise
, I-Premise
were I-Premise
in I-Premise
favour I-Premise
of I-Premise
the I-Premise
irinotecan I-Premise
group I-Premise
. I-Premise
!LF! !LF!
our B-Claim
study I-Claim
shows I-Claim
that I-Claim
despite I-Claim
the I-Claim
side I-Claim
- I-Claim
effects I-Claim
of I-Claim
treatment I-Claim
, I-Claim
patients I-Claim
who I-Claim
have I-Claim
metastatic I-Claim
colorectal I-Claim
cancer I-Claim
, I-Claim
and I-Claim
for I-Claim
whom I-Claim
fluorouracil I-Claim
has I-Claim
failed I-Claim
, I-Claim
have I-Claim
a I-Claim
longer I-Claim
survival I-Claim
, I-Claim
fewer I-Claim
tumour I-Claim
- I-Claim
related I-Claim
symptoms I-Claim
, I-Claim
and I-Claim
a I-Claim
better I-Claim
quality I-Claim
of I-Claim
life I-Claim
when I-Claim
treated I-Claim
with I-Claim
irinotecan I-Claim
than I-Claim
with I-Claim
supportive I-Claim
care I-Claim
alone I-Claim
. I-Claim
!LF! !LF!
the O
standard O
doublet O
, O
vinorelbine O
- O
cisplatin O
, O
was O
compared O
with O
a O
triplet O
of O
vinorelbine O
- O
ifosfamide O
- O
cisplatin O
, O
in O
terms O
of O
survival O
, O
in O
patients O
with O
advanced O
non O
- O
small O
- O
cell O
lung O
cancer O
( O
nsclc O
) O
. O
!LF! !LF!
from O
february O
1998 O
to O
june O
1999 O
, O
259 O
chemonaive O
patients O
entered O
the O
study O
and O
were O
randomised O
to O
receive O
either O
vinorelbine O
- O
cisplatin O
( O
np O
"""" O
; O
"""" O
vinorelbine O
30 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
, O
8 O
and O
15 O
with O
cisplatin O
80 O
mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
) O
or O
vinorelbine O
- O
ifosfamide O
- O
cisplatin O
( O
nip O
"""" O
; O
"""" O
vinorelbine O
25 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
, O
ifosfamide O
3 O
g O
/ O
m O
( O
2 O
) O
on O
day O
1 O
and O
cisplatin O
75 O
mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
) O
, O
with O
both O
regimens O
being O
repeated O
every O
3 O
weeks O
. O
!LF! !LF!
all O
patients O
had O
stage O
iv O
or O
relapsed O
disease O
and O
a O
performance O
score O
of O
0 O
or O
1 O
. O
!LF! !LF!
the B-Premise
overall I-Premise
response I-Premise
rate I-Premise
was I-Premise
34 I-Premise
. I-Premise
6 I-Premise
% I-Premise
for I-Premise
np I-Premise
and I-Premise
35 I-Premise
. I-Premise
7 I-Premise
% I-Premise
for I-Premise
nip I-Premise
. I-Premise
!LF! !LF!
median B-Premise
and I-Premise
1 I-Premise
- I-Premise
year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
10 I-Premise
. I-Premise
0 I-Premise
months I-Premise
and I-Premise
38 I-Premise
. I-Premise
4 I-Premise
% I-Premise
for I-Premise
np I-Premise
, I-Premise
and I-Premise
8 I-Premise
. I-Premise
2 I-Premise
months I-Premise
and I-Premise
33 I-Premise
. I-Premise
7 I-Premise
% I-Premise
for I-Premise
nip I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
a O
median O
of O
four O
cycles O
was O
administered O
in O
each O
arm O
. O
!LF! !LF!
the B-Premise
major I-Premise
world I-Premise
health I-Premise
organization I-Premise
grade I-Premise
3 I-Premise
- I-Premise
4 I-Premise
toxicities I-Premise
for I-Premise
np I-Premise
and I-Premise
nip I-Premise
, I-Premise
respectively I-Premise
, I-Premise
were I-Premise
: I-Premise
neutropenia I-Premise
( I-Premise
20 I-Premise
. I-Premise
3 I-Premise
% I-Premise
compared I-Premise
with I-Premise
9 I-Premise
% I-Premise
of I-Premise
cycles I-Premise
) I-Premise
, I-Premise
anaemia I-Premise
( I-Premise
4 I-Premise
. I-Premise
1 I-Premise
% I-Premise
compared I-Premise
with I-Premise
5 I-Premise
% I-Premise
of I-Premise
cycles I-Premise
) I-Premise
, I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
( I-Premise
22 I-Premise
. I-Premise
2 I-Premise
% I-Premise
compared I-Premise
with I-Premise
19 I-Premise
. I-Premise
4 I-Premise
% I-Premise
of I-Premise
patients I-Premise
) I-Premise
and I-Premise
alopecia I-Premise
( I-Premise
5 I-Premise
. I-Premise
6 I-Premise
% I-Premise
compared I-Premise
with I-Premise
29 I-Premise
. I-Premise
8 I-Premise
% I-Premise
of I-Premise
patients I-Premise
) I-Premise
. I-Premise
!LF! !LF!
four B-Premise
toxic I-Premise
deaths I-Premise
occurred I-Premise
in I-Premise
the I-Premise
np I-Premise
arm I-Premise
and I-Premise
eight I-Premise
in I-Premise
the I-Premise
nip I-Premise
arm I-Premise
. I-Premise
!LF! !LF!
the B-Premise
different I-Premise
schedules I-Premise
of I-Premise
vinorelbine I-Premise
in I-Premise
the I-Premise
two I-Premise
arms I-Premise
led I-Premise
to I-Premise
a I-Premise
greater I-Premise
survival I-Premise
in I-Premise
the I-Premise
np I-Premise
arm I-Premise
without I-Premise
impairing I-Premise
the I-Premise
tolerance I-Premise
profile I-Premise
, I-Premise
although B-Premise
this I-Premise
is I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
. I-Premise
!LF! !LF!
this B-Claim
confirms I-Claim
that I-Claim
the I-Claim
two I-Claim
- I-Claim
drug I-Claim
combination I-Claim
np I-Claim
is I-Claim
a I-Claim
reference I-Claim
treatment I-Claim
for I-Claim
metastatic I-Claim
nsclc I-Claim
. I-Claim
!LF! !LF!
the B-Claim
role I-Claim
of I-Claim
three I-Claim
- I-Claim
drug I-Claim
combinations I-Claim
remains I-Claim
questionable I-Claim
in I-Claim
this I-Claim
subset I-Claim
of I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
chemotherapy B-Claim
can I-Claim
profoundly I-Claim
affect I-Claim
patients I-Claim
' I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
qol I-Claim
) I-Claim
, I-Claim
yet O
few O
clinical O
trials O
in O
advanced O
cervical O
cancer O
have O
included O
qol O
outcomes O
. O
!LF! !LF!
our O
purpose O
was O
to O
assess O
the O
impact O
of O
cisplatin O
( O
c O
) O
versus O
cisplatin O
plus O
paclitaxel O
( O
cp O
) O
on O
overall O
qol O
and O
pain O
in O
cervical O
cancer O
patients O
. O
!LF! !LF!
qol O
was O
assessed O
using O
fact O
- O
cx O
, O
consisting O
of O
the O
functional O
assessment O
of O
cancer O
therapy O
( O
fact O
- O
g O
) O
plus O
a O
cervix O
cancer O
- O
specific O
subscale O
, O
the O
brief O
pain O
inventory O
- O
short O
form O
( O
bpi O
- O
sf O
) O
, O
and O
a O
neurotoxicity O
subscale O
. O
!LF! !LF!
time O
points O
were O
: O
baseline O
( O
prior O
to O
randomization O
) O
and O
prior O
to O
chemotherapy O
cycles O
2 O
, O
3 O
, O
and O
4 O
. O
!LF! !LF!
overall B-Premise
( I-Premise
fact I-Premise
- I-Premise
g I-Premise
) I-Premise
scores I-Premise
did I-Premise
not I-Premise
differ I-Premise
significantly I-Premise
between I-Premise
arms I-Premise
at I-Premise
the I-Premise
fourth I-Premise
assessment I-Premise
( I-Premise
c I-Premise
= I-Premise
70 I-Premise
. I-Premise
3 I-Premise
( I-Premise
19 I-Premise
. I-Premise
6 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
cp I-Premise
= I-Premise
72 I-Premise
. I-Premise
8 I-Premise
( I-Premise
17 I-Premise
. I-Premise
4 I-Premise
) I-Premise
) I-Premise
. I-Premise
!LF! !LF!
scores B-Premise
were I-Premise
stable I-Premise
over I-Premise
time I-Premise
and I-Premise
considerably I-Premise
lower I-Premise
than I-Premise
the I-Premise
general I-Premise
population I-Premise
norms I-Premise
. I-Premise
!LF! !LF!
the B-Premise
bpi I-Premise
- I-Premise
sf I-Premise
revealed I-Premise
a I-Premise
decline I-Premise
in I-Premise
pain I-Premise
scores I-Premise
in I-Premise
both I-Premise
arms I-Premise
from I-Premise
the I-Premise
first I-Premise
to I-Premise
fourth I-Premise
assessments I-Premise
. I-Premise
!LF! !LF!
the B-Premise
cp I-Premise
arm I-Premise
produced I-Premise
a I-Premise
significantly I-Premise
higher I-Premise
response I-Premise
rate I-Premise
and I-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
( I-Premise
pfs I-Premise
) I-Premise
but B-Premise
not I-Premise
overall I-Premise
survival I-Premise
( I-Premise
os I-Premise
) I-Premise
. I-Premise
!LF! !LF!
greater B-Premise
myelosuppression I-Premise
was I-Premise
reported I-Premise
in I-Premise
the I-Premise
combination I-Premise
arm I-Premise
. I-Premise
!LF! !LF!
the B-Premise
rate I-Premise
of I-Premise
qol I-Premise
drop I-Premise
- I-Premise
out I-Premise
for I-Premise
any I-Premise
reason I-Premise
was I-Premise
higher I-Premise
for I-Premise
c I-Premise
( I-Premise
53 I-Premise
% I-Premise
) I-Premise
compared I-Premise
to I-Premise
cp I-Premise
( I-Premise
38 I-Premise
% I-Premise
) I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
at O
the O
fourth O
time O
point O
, O
60 O
% O
of O
living O
patients O
in O
both O
arms O
completed O
a O
qol O
assessment O
. O
!LF! !LF!
there B-Claim
was I-Claim
no I-Claim
significant I-Claim
difference I-Claim
in I-Claim
overall I-Claim
qol I-Claim
scores I-Claim
between I-Claim
treatment I-Claim
arms I-Claim
or I-Claim
serially I-Claim
. I-Claim
!LF! !LF!
combined B-Claim
with I-Claim
qol I-Claim
results I-Claim
, I-Claim
the I-Claim
significant I-Claim
increase I-Claim
in I-Claim
response I-Claim
and I-Claim
pfs I-Claim
in I-Claim
the I-Claim
cp I-Claim
arm I-Claim
and I-Claim
the I-Claim
higher I-Claim
drop I-Claim
- I-Claim
out I-Claim
rate I-Claim
in I-Claim
the I-Claim
c I-Claim
arm I-Claim
suggest I-Claim
a I-Claim
better I-Claim
outcome I-Claim
for I-Claim
the I-Claim
combination I-Claim
regimen I-Claim
despite I-Claim
its I-Claim
increased I-Claim
myelosuppression I-Claim
. I-Claim
!LF! !LF!
to O
compare O
the O
effects O
of O
cannabis O
extract O
( O
ce O
) O
, O
delta O
- O
9 O
- O
tetrahydrocannabinol O
( O
thc O
) O
, O
and O
placebo O
( O
pl O
) O
on O
appetite O
and O
quality O
of O
life O
( O
qol O
) O
in O
patients O
with O
cancer O
- O
related O
anorexia O
- O
cachexia O
syndrome O
( O
cacs O
) O
. O
!LF! !LF!
adult O
patients O
with O
advanced O
cancer O
, O
cacs O
, O
weight O
loss O
( O
> O
or O
= O
5 O
% O
over O
6 O
months O
) O
, O
and O
eastern O
cooperative O
oncology O
group O
( O
ecog O
) O
performance O
status O
( O
ps O
) O
< O
or O
= O
2 O
were O
randomly O
assigned O
( O
2 O
: O
2 O
: O
1 O
) O
to O
receive O
ce O
( O
standardized O
for O
2 O
. O
5 O
mg O
thc O
and O
1 O
mg O
cannabidiol O
) O
or O
thc O
( O
2 O
. O
5 O
mg O
) O
or O
pl O
orally O
, O
twice O
daily O
for O
6 O
weeks O
. O
!LF! !LF!
appetite O
, O
mood O
, O
and O
nausea O
were O
monitored O
daily O
with O
a O
visual O
analog O
scale O
( O
vas O
) O
"""" O
; O
"""" O
qol O
was O
assessed O
with O
the O
european O
organisation O
for O
research O
and O
treatment O
of O
cancer O
quality O
of O
life O
questionnaire O
c30 O
( O
composite O
score O
: O
questions O
29 O
and O
30 O
) O
. O
!LF! !LF!
cannabinoid O
- O
related O
toxicity O
was O
assessed O
every O
2 O
weeks O
. O
!LF! !LF!
of O
289 O
patients O
screened O
, O
243 O
were O
randomly O
assigned O
and O
164 O
( O
ce O
, O
66 O
of O
95 O
patients O
"""" O
; O
"""" O
thc O
, O
65 O
of O
100 O
patients O
"""" O
; O
"""" O
and O
pl O
, O
33 O
of O
48 O
patients O
) O
completed O
treatment O
. O
!LF! !LF!
at O
baseline O
, O
groups O
were O
comparable O
for O
age O
( O
mean O
, O
61 O
years O
) O
, O
sex O
( O
54 O
% O
men O
) O
, O
weight O
loss O
( O
32 O
% O
> O
or O
= O
10 O
% O
) O
, O
ps O
( O
13 O
% O
ecog O
= O
2 O
) O
, O
antineoplastic O
treatment O
( O
50 O
% O
) O
, O
appetite O
( O
mean O
vas O
score O
, O
31 O
/ O
100 O
mm O
) O
, O
and O
qol O
( O
mean O
score O
, O
30 O
/ O
100 O
) O
. O
!LF! !LF!
intent B-Premise
- B-Premise
to B-Premise
- B-Premise
treat B-Premise
analysis I-Premise
showed I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
three I-Premise
arms I-Premise
for I-Premise
appetite I-Premise
, I-Premise
qol I-Premise
, I-Premise
or I-Premise
cannabinoid I-Premise
- I-Premise
related I-Premise
toxicity I-Premise
. I-Premise
!LF! !LF!
increased B-Premise
appetite I-Premise
was I-Premise
reported I-Premise
by I-Premise
73 I-Premise
% I-Premise
, I-Premise
58 I-Premise
% I-Premise
, I-Premise
and I-Premise
69 I-Premise
% I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
ce I-Premise
, I-Premise
thc I-Premise
, I-Premise
or I-Premise
pl I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
an O
independent O
data O
review O
board O
recommended O
termination O
of O
recruitment O
because O
of O
insufficient O
differences O
between O
study O
arms O
. O
!LF! !LF!
ce B-Premise
at I-Premise
the I-Premise
oral I-Premise
dose I-Premise
administered I-Premise
was I-Premise
well I-Premise
tolerated I-Premise
by I-Premise
these I-Premise
patients I-Premise
with I-Premise
cacs I-Premise
. I-Premise
!LF! !LF!
no B-Claim
differences I-Claim
in I-Claim
patients I-Claim
' I-Claim
appetite I-Claim
or I-Claim
qol I-Claim
were I-Claim
found I-Claim
either I-Claim
between I-Claim
ce I-Claim
, I-Claim
thc I-Claim
, I-Claim
and I-Claim
pl I-Claim
or I-Claim
between I-Claim
ce I-Claim
and I-Claim
thc I-Claim
at I-Claim
the I-Claim
dosages I-Claim
investigated I-Claim
. I-Claim
!LF! !LF!
it O
is O
well O
documented O
that O
stress O
is O
associated O
with O
negative O
health O
outcomes O
in O
cancer O
patients O
. O
!LF! !LF!
the O
purpose O
of O
this O
study O
was O
to O
assess O
the O
effects O
of O
a O
novel O
mindfulness O
intervention O
called O
mindfulness O
- O
based O
art O
therapy O
( O
mbat O
) O
versus O
standard O
educational O
support O
, O
on O
indices O
of O
stress O
and O
quality O
of O
life O
in O
breast O
cancer O
patients O
with O
high O
stress O
levels O
. O
!LF! !LF!
a O
total O
of O
191 O
women O
were O
enrolled O
, O
stratified O
by O
age O
and O
stress O
level O
, O
and O
randomized O
to O
receive O
either O
an O
8 O
- O
week O
mbat O
intervention O
or O
a O
breast O
cancer O
educational O
support O
program O
of O
equal O
time O
and O
duration O
. O
!LF! !LF!
psychosocial O
stress O
was O
measured O
using O
the O
symptoms O
checklist O
- O
90 O
- O
revised O
, O
and O
quality O
of O
life O
was O
measured O
using O
the O
medical O
outcomes O
study O
short O
- O
form O
health O
survey O
at O
baseline O
, O
immediately O
post O
- O
intervention O
, O
and O
at O
6 O
months O
. O
!LF! !LF!
results B-Premise
showed I-Premise
overall I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
psychosocial I-Premise
stress I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
in I-Premise
both I-Premise
the I-Premise
mbat I-Premise
and I-Premise
educational I-Premise
support I-Premise
groups I-Premise
immediately I-Premise
post I-Premise
- I-Premise
intervention I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
however B-Premise
, I-Premise
participants I-Premise
with I-Premise
high I-Premise
stress I-Premise
levels I-Premise
at I-Premise
baseline I-Premise
had I-Premise
significantly I-Premise
improved I-Premise
overall I-Premise
outcomes I-Premise
only I-Premise
in I-Premise
the I-Premise
mbat I-Premise
group I-Premise
, I-Premise
both I-Premise
immediately I-Premise
post I-Premise
- I-Premise
intervention I-Premise
and I-Premise
at I-Premise
6 I-Premise
months I-Premise
. I-Premise
!LF! !LF!
in O
addition O
, O
at B-Premise
6 I-Premise
months I-Premise
follow I-Premise
- I-Premise
up I-Premise
, I-Premise
participants I-Premise
attending I-Premise
five I-Premise
or I-Premise
more I-Premise
sessions I-Premise
trended I-Premise
toward I-Premise
retaining I-Premise
treatment I-Premise
effects I-Premise
better I-Premise
in I-Premise
the I-Premise
mbat I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise
!LF! !LF!
finally O
, O
black B-Premise
women I-Premise
and I-Premise
white I-Premise
women I-Premise
were I-Premise
similar I-Premise
in I-Premise
terms I-Premise
of I-Premise
how I-Premise
they I-Premise
benefited I-Premise
from I-Premise
the I-Premise
mbat I-Premise
intervention I-Premise
, I-Premise
even I-Premise
though I-Premise
white I-Premise
participants I-Premise
tended I-Premise
to I-Premise
have I-Premise
higher I-Premise
educational I-Premise
level I-Premise
and I-Premise
marital I-Premise
status I-Premise
. I-Premise
!LF! !LF!
in B-Claim
conclusion I-Claim
, I-Claim
mbat I-Claim
is I-Claim
associated I-Claim
with I-Claim
significant I-Claim
, I-Claim
sustained I-Claim
benefits I-Claim
across I-Claim
a I-Claim
diverse I-Claim
range I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
, I-Claim
particularly I-Claim
those I-Claim
with I-Claim
high I-Claim
stress I-Claim
levels I-Claim
. I-Claim
!LF! !LF!
this O
study O
was O
designed O
to O
evaluate O
efficacy O
, O
toxicity O
, O
and O
adverse O
effects O
of O
combination O
of O
chemotherapy O
drugs O
and O
intraperitoneal O
perfusion O
of O
verapamil O
in O
the O
treatment O
of O
malignant O
ascites O
. O
!LF! !LF!
seventy O
- O
two O
patients O
with O
malignant O
ascites O
were O
divided O
into O
two O
study O
groups O
. O
!LF! !LF!
patients O
in O
control O
group O
( O
31 O
cases O
) O
received O
conventional O
chemotherapy O
, O
whereas O
patients O
in O
the O
combined O
treatment O
group O
( O
41 O
cases O
) O
were O
given O
verapamil O
intraperitoneally O
in O
addition O
to O
chemotherapy O
drugs O
. O
!LF! !LF!
thirty O
days O
after O
the O
treatment O
, O
efficacy O
, O
toxicity O
, O
and O
adverse O
effects O
were O
assessed O
in O
both O
study O
groups O
. O
!LF! !LF!
the B-Premise
treatment I-Premise
of I-Premise
control I-Premise
group I-Premise
led I-Premise
to I-Premise
1 I-Premise
case I-Premise
of I-Premise
complete I-Premise
remission I-Premise
and I-Premise
2 I-Premise
cases I-Premise
of I-Premise
partial I-Premise
remission I-Premise
, I-Premise
making I-Premise
the I-Premise
rate I-Premise
of I-Premise
efficacy I-Premise
( I-Premise
complete I-Premise
+ I-Premise
partial I-Premise
remission I-Premise
) I-Premise
of I-Premise
9 I-Premise
. I-Premise
7 I-Premise
% I-Premise
. I-Premise
!LF! !LF!
the B-Premise
combined I-Premise
treatment I-Premise
group I-Premise
demonstrated I-Premise
13 I-Premise
cases I-Premise
of I-Premise
complete I-Premise
remission I-Premise
and I-Premise
22 I-Premise
cases I-Premise
of I-Premise
partial I-Premise
remission I-Premise
. I-Premise
!LF! !LF!
thus O
, O
the B-Premise
rate I-Premise
of I-Premise
efficacy I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
combined I-Premise
treatment I-Premise
group I-Premise
( I-Premise
85 I-Premise
. I-Premise
36 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
vs I-Premise
. I-Premise
control I-Premise
group I-Premise
) I-Premise
. I-Premise
!LF! !LF!
using O
kps O
scores O
, O
changes O
in O
quality O
of O
life O
were O
compared O
before O
and O
after O
the O
treatment O
. O
!LF! !LF!
the B-Premise
quality I-Premise
of I-Premise
life I-Premise
improved I-Premise
in I-Premise
control I-Premise
group I-Premise
by I-Premise
13 I-Premise
. I-Premise
7 I-Premise
% I-Premise
, I-Premise
while I-Premise
combined I-Premise
treatment I-Premise
group I-Premise
showed I-Premise
improvement I-Premise
of I-Premise
83 I-Premise
. I-Premise
5 I-Premise
% I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
vs I-Premise
. I-Premise
control I-Premise
group I-Premise
) I-Premise
. I-Premise
!LF! !LF!
further O
, O
cumulative B-Premise
survival I-Premise
rate I-Premise
was I-Premise
also I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
combined I-Premise
treatment I-Premise
group I-Premise
. I-Premise
!LF! !LF!
treatment B-Premise
toxicity I-Premise
and I-Premise
the I-Premise
rate I-Premise
of I-Premise
adverse I-Premise
effects I-Premise
and I-Premise
intestinal I-Premise
adhesion I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
study I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
intraperitoneal B-Claim
perfusion I-Claim
of I-Claim
verapamil I-Claim
enhances I-Claim
the I-Claim
efficacy I-Claim
of I-Claim
chemotherapy I-Claim
drugs I-Claim
, I-Claim
prolongs I-Claim
survival I-Claim
, I-Claim
and I-Claim
improves I-Claim
the I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim
!LF! !LF!
intraperitoneal B-Claim
administration I-Claim
limits I-Claim
cardiotoxicity I-Claim
of I-Claim
verapamil I-Claim
. I-Claim
!LF! !LF!
impaired B-Claim
cognition I-Claim
, I-Claim
fatigue I-Claim
, I-Claim
and I-Claim
diminished I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
qol I-Claim
) I-Claim
are I-Claim
commonly I-Claim
associated I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
chemotherapy I-Claim
. I-Claim
!LF! !LF!
this O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
pilot O
trial O
assessed O
the O
feasibility O
of O
quantifying O
the O
effects O
of O
epoetin O
alfa O
on O
cognitive O
function O
and O
mood O
, O
and O
evaluated O
its O
effects O
on O
fatigue O
and O
qol O
in O
patients O
with O
breast O
cancer O
treated O
with O
anthracycline O
- O
based O
adjuvant O
or O
neoadjuvant O
chemotherapy O
. O
!LF! !LF!
patients O
were O
randomized O
to O
receive O
epoetin O
alfa O
40 O
, O
000 O
u O
subcutaneously O
once O
weekly O
or O
placebo O
at O
the O
beginning O
of O
4 O
cycles O
of O
chemotherapy O
administered O
over O
12 O
weeks O
. O
!LF! !LF!
cognitive O
function O
was O
assessed O
by O
executive O
interview O
( O
exit25 O
) O
and O
clock O
drawing O
tasks O
"""" O
; O
"""" O
mood O
by O
profile O
of O
mood O
states O
"""" O
; O
"""" O
anemia O
- O
related O
symptoms O
, O
including O
fatigue O
, O
by O
the O
functional O
assessment O
of O
cancer O
therapy O
- O
anemia O
( O
fact O
- O
an O
) O
subscale O
"""" O
; O
"""" O
and O
qol O
by O
linear O
analog O
scale O
assessment O
. O
!LF! !LF!
ninety O
- O
four O
patients O
were O
evaluable O
for O
efficacy O
and O
safety O
. O
!LF! !LF!
mean B-Premise
change I-Premise
in I-Premise
exit25 I-Premise
scores I-Premise
from I-Premise
baseline I-Premise
to I-Premise
cycle I-Premise
4 I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
alfa I-Premise
group I-Premise
was I-Premise
1 I-Premise
. I-Premise
3 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
3 I-Premise
. I-Premise
3 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
the B-Premise
mean I-Premise
change I-Premise
was I-Premise
0 I-Premise
. I-Premise
3 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
2 I-Premise
. I-Premise
4 I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
( I-Premise
a I-Premise
negative I-Premise
change I-Premise
indicates I-Premise
improved I-Premise
executive I-Premise
function I-Premise
) I-Premise
. I-Premise
!LF! !LF!
there B-Premise
was I-Premise
no I-Premise
difference I-Premise
between I-Premise
groups I-Premise
in I-Premise
mean I-Premise
change I-Premise
in I-Premise
exit25 I-Premise
score I-Premise
from I-Premise
baseline I-Premise
to I-Premise
6 I-Premise
- I-Premise
month I-Premise
follow I-Premise
- I-Premise
up I-Premise
assessment I-Premise
. I-Premise
!LF! !LF!
mean B-Premise
hemoglobin I-Premise
levels I-Premise
were I-Premise
higher I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
alfa I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
placebo I-Premise
group I-Premise
after I-Premise
4 I-Premise
cycles I-Premise
of I-Premise
chemotherapy I-Premise
. I-Premise
!LF! !LF!
epoetin B-Premise
alfa I-Premise
recipients I-Premise
had I-Premise
less I-Premise
of I-Premise
a I-Premise
decrease I-Premise
in I-Premise
fact I-Premise
- I-Premise
an I-Premise
subscale I-Premise
scores I-Premise
from I-Premise
baseline I-Premise
to I-Premise
cycle I-Premise
4 I-Premise
and I-Premise
improvement I-Premise
in I-Premise
fact I-Premise
- I-Premise
an I-Premise
subscale I-Premise
scores I-Premise
at I-Premise
6 I-Premise
- I-Premise
month I-Premise
follow I-Premise
- I-Premise
up I-Premise
assessment I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
. I-Premise
!LF! !LF!
epoetin B-Claim
alfa I-Claim
therapy I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
. I-Claim
!LF! !LF!
these B-Claim
data I-Claim
suggest I-Claim
that I-Claim
epoetin I-Claim
alfa I-Claim
may I-Claim
have I-Claim
attenuated I-Claim
the I-Claim
cognitive I-Claim
impairment I-Claim
and I-Claim
fatigue I-Claim
that I-Claim
occurred I-Claim
during I-Claim
adjuvant I-Claim
breast I-Claim
cancer I-Claim
chemotherapy I-Claim
. I-Claim
!LF! !LF!
in O
the O
asia O
- O
pacific O
region O
and O
elsewhere O
, O
almost O
85 O
% O
of O
patients O
with O
hepatocellular O
carcinoma O
( O
hcc O
) O
are O
inoperable O
at O
diagnosis O
and O
have O
a O
dismal O
prognosis O
. O
!LF! !LF!
tamoxifen B-Claim
( I-Claim
tmx I-Claim
) I-Claim
is I-Claim
believed I-Claim
to I-Claim
inhibit I-Claim
hcc I-Claim
positive I-Claim
for I-Claim
estrogen I-Claim
receptor I-Claim
( I-Claim
er I-Claim
) I-Claim
, I-Claim
but I-Claim
most I-Claim
hccs I-Claim
are I-Claim
er I-Claim
negative I-Claim
. I-Claim
!LF! !LF!
results B-Claim
of I-Claim
previous I-Claim
phase I-Claim
3 I-Claim
trials I-Claim
in I-Claim
inoperable I-Claim
hcc I-Claim
have I-Claim
been I-Claim
conflicting I-Claim
and I-Claim
inconclusive I-Claim
. I-Claim
!LF! !LF!
at B-Claim
higher I-Claim
doses I-Claim
, I-Claim
however I-Claim
, I-Claim
tmx I-Claim
inhibits I-Claim
hcc I-Claim
through I-Claim
er I-Claim
- I-Claim
independent I-Claim
mechanisms I-Claim
. I-Claim
!LF! !LF!
a O
multicenter O
randomized O
controlled O
trial O
was O
performed O
to O
assess O
the O
role O
of O
high O
- O
dose O
tmx O
versus O
placebo O
( O
p O
) O
in O
the O
treatment O
of O
patients O
with O
inoperable O
hcc O
with O
respect O
to O
survival O
and O
quality O
of O
life O
( O
qol O
) O
. O
!LF! !LF!
a O
total O
of O
329 O
patients O
from O
10 O
centers O
in O
9 O
countries O
in O
the O
asia O
- O
pacific O
region O
enrolled O
in O
a O
double O
- O
blind O
randomized O
controlled O
trial O
of O
tmx O
120 O
mg O
/ O
d O
( O
tmx120 O
) O
against O
p O
as O
a O
control O
arm O
with O
an O
intermediate O
dosage O
of O
tmx O
60 O
mg O
/ O
d O
( O
tmx60 O
) O
to O
assess O
possible O
dose O
response O
. O
!LF! !LF!
an O
independent O
data O
monitoring O
committee O
reviewed O
all O
aspects O
of O
the O
trial O
. O
!LF! !LF!
qol O
was O
assessed O
using O
the O
european O
organization O
for O
research O
and O
treatment O
of O
cancer O
qlq O
- O
c30 O
questionnaire O
. O
!LF! !LF!
three B-Premise
- B-Premise
month B-Premise
survival I-Premise
rates I-Premise
for I-Premise
the I-Premise
p I-Premise
, I-Premise
tmx60 I-Premise
, I-Premise
and I-Premise
tmx120 I-Premise
groups I-Premise
were I-Premise
44 I-Premise
% I-Premise
, I-Premise
41 I-Premise
% I-Premise
, I-Premise
and I-Premise
35 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
with I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
trend I-Premise
difference I-Premise
in I-Premise
survival I-Premise
across I-Premise
the I-Premise
3 I-Premise
treatment I-Premise
regimens I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
011 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
there B-Premise
was I-Premise
a I-Premise
significantly I-Premise
higher I-Premise
risk I-Premise
of I-Premise
death I-Premise
in I-Premise
the I-Premise
tmx120 I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
p I-Premise
group I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1 I-Premise
. I-Premise
39 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
, I-Premise
1 I-Premise
. I-Premise
07 I-Premise
- I-Premise
1 I-Premise
. I-Premise
81 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
adverse B-Premise
drug I-Premise
reactions I-Premise
were I-Premise
reported I-Premise
in I-Premise
3 I-Premise
% I-Premise
( I-Premise
9 I-Premise
patients I-Premise
) I-Premise
, I-Premise
and O
8 B-Premise
patients I-Premise
were I-Premise
lost I-Premise
to I-Premise
follow I-Premise
- I-Premise
up I-Premise
. I-Premise
!LF! !LF!
in O
conclusion O
, O
tmx B-Claim
does I-Claim
not I-Claim
prolong I-Claim
survival I-Claim
in I-Claim
patients I-Claim
with I-Claim
inoperable I-Claim
hcc I-Claim
and I-Claim
has I-Claim
an I-Claim
increasingly I-Claim
negative I-Claim
impact I-Claim
with I-Claim
increasing I-Claim
dose I-Claim
. I-Claim
!LF! !LF!
no B-Claim
appreciable I-Claim
advantage I-Claim
to I-Claim
qol I-Claim
with I-Claim
tmx I-Claim
was I-Claim
observed I-Claim
. I-Claim
!LF! !LF!
this O
is O
a O
randomized O
phase O
ii O
study O
designed O
to O
compare O
the O
toxicity O
profile O
of O
a O
non O
- O
platinum O
- O
based O
with O
a O
platinum O
- O
based O
regimen O
in O
the O
treatment O
of O
advanced O
non O
- O
small O
cell O
lung O
cancer O
. O
!LF! !LF!
eighty O
- O
nine O
chemotherapy O
- O
naive O
patients O
were O
randomized O
either O
to O
gemcitabine O
( O
1 O
, O
000 O
mg O
/ O
m2 O
, O
30 O
- O
min O
infusion O
on O
days O
1 O
, O
8 O
and O
15 O
) O
and O
oral O
etoposide O
( O
50 O
mg O
, O
days O
1 O
- O
14 O
"""" O
; O
"""" O
ge O
group O
) O
or O
gemcitabine O
at O
the O
same O
schedule O
and O
cisplatin O
( O
75 O
mg O
/ O
m2 O
on O
day O
15 O
"""" O
; O
"""" O
gp O
group O
) O
. O
!LF! !LF!
the O
primary O
endpoint O
is O
toxicity O
, O
and O
secondary O
endpoints O
include O
response O
rate O
, O
survival O
outcome O
and O
quality O
of O
life O
( O
qol O
) O
. O
!LF! !LF!
the B-Premise
incidence I-Premise
of I-Premise
who I-Premise
grade I-Premise
3 I-Premise
or I-Premise
4 I-Premise
anemia I-Premise
, I-Premise
neutropenia I-Premise
and I-Premise
thrombocytopenia I-Premise
was I-Premise
29 I-Premise
, I-Premise
44 I-Premise
and I-Premise
22 I-Premise
% I-Premise
( I-Premise
ge I-Premise
group I-Premise
) I-Premise
, I-Premise
and I-Premise
28 I-Premise
, I-Premise
49 I-Premise
and I-Premise
23 I-Premise
% I-Premise
( I-Premise
gp I-Premise
group I-Premise
) I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
75 I-Premise
, I-Premise
0 I-Premise
. I-Premise
95 I-Premise
and I-Premise
0 I-Premise
. I-Premise
87 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
rate I-Premise
of I-Premise
grade I-Premise
2 I-Premise
or I-Premise
above I-Premise
nausea I-Premise
was I-Premise
numerically I-Premise
higher I-Premise
in I-Premise
the I-Premise
gp I-Premise
arm I-Premise
, I-Premise
but B-Premise
the I-Premise
difference I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
ge I-Premise
15 I-Premise
. I-Premise
5 I-Premise
% I-Premise
, I-Premise
gp I-Premise
27 I-Premise
. I-Premise
7 I-Premise
% I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
20 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
rate I-Premise
of I-Premise
vomiting I-Premise
in I-Premise
the I-Premise
ge I-Premise
and I-Premise
gp I-Premise
arms I-Premise
was I-Premise
20 I-Premise
. I-Premise
0 I-Premise
and I-Premise
20 I-Premise
. I-Premise
5 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
96 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
however B-Premise
, I-Premise
subjective I-Premise
changes I-Premise
in I-Premise
qol I-Premise
scores I-Premise
on I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
gp I-Premise
arm I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
other B-Premise
symptoms I-Premise
including I-Premise
sore I-Premise
mouth I-Premise
and I-Premise
hair I-Premise
loss I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
ge I-Premise
arm I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
003 I-Premise
and I-Premise
0 I-Premise
. I-Premise
007 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise
!LF! !LF!
there B-Premise
were I-Premise
also I-Premise
significant I-Premise
differences I-Premise
observed I-Premise
in I-Premise
emotional I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
014 I-Premise
) I-Premise
, I-Premise
cognitive I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
028 I-Premise
) I-Premise
and I-Premise
social I-Premise
functioning I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
034 I-Premise
) I-Premise
in I-Premise
favor I-Premise
of I-Premise
gp I-Premise
. I-Premise
!LF! !LF!
the B-Premise
differences I-Premise
in I-Premise
tumor I-Premise
response I-Premise
( I-Premise
35 I-Premise
. I-Premise
5 I-Premise
and I-Premise
46 I-Premise
. I-Premise
5 I-Premise
% I-Premise
for I-Premise
ge I-Premise
and I-Premise
gp I-Premise
, I-Premise
respectively I-Premise
) I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
. I-Premise
!LF! !LF!
median B-Premise
time I-Premise
to I-Premise
disease I-Premise
progression I-Premise
( I-Premise
33 I-Premise
. I-Premise
8 I-Premise
and I-Premise
40 I-Premise
. I-Premise
7 I-Premise
weeks I-Premise
, I-Premise
respectively I-Premise
) I-Premise
and I-Premise
overall I-Premise
survival I-Premise
( I-Premise
41 I-Premise
. I-Premise
4 I-Premise
and I-Premise
57 I-Premise
. I-Premise
3 I-Premise
weeks I-Premise
, I-Premise
respectively I-Premise
) I-Premise
were I-Premise
of I-Premise
borderline I-Premise
significance I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
gp I-Premise
arm I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
055 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
this B-Claim
toxicity I-Claim
profile I-Claim
of I-Claim
ge I-Claim
is I-Claim
similar I-Claim
to I-Claim
gp I-Claim
, I-Claim
but B-Claim
the I-Claim
apparent I-Claim
inferior I-Claim
efficacy I-Claim
may I-Claim
discourage I-Claim
further I-Claim
investigation I-Claim
. O
!LF! !LF!
to O
evaluate O
the O
analgesic O
effect O
, O
safety O
, O
and O
cost O
- O
effectiveness O
of O
controlled O
- O
release O
oxycodone O
( O
cro O
) O
to O
control O
postoperative O
pain O
in O
patients O
with O
liver O
cancer O
who O
are O
undergoing O
transarterial O
chemoembolization O
. O
!LF! !LF!
this O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
, O
prospective O
clinical O
study O
received O
institutional O
review O
board O
approval O
. O
!LF! !LF!
after O
written O
informed O
consent O
was O
obtained O
, O
210 O
patients O
with O
liver O
cancer O
were O
randomized O
into O
three O
groups O
of O
70 O
patients O
. O
!LF! !LF!
group O
1 O
received O
20 O
mg O
of O
cro O
, O
group O
2 O
received O
10 O
mg O
of O
cro O
, O
and O
group O
3 O
received O
a O
placebo O
at O
1 O
hour O
before O
transarterial O
chemoembolization O
( O
t O
( O
0 O
) O
) O
and O
12 O
( O
t O
( O
12 O
) O
) O
and O
24 O
( O
t O
( O
24 O
) O
) O
hours O
after O
t O
( O
0 O
) O
. O
!LF! !LF!
pain O
intensity O
on O
a O
numeric O
rating O
scale O
, O
percentage O
of O
patients O
with O
each O
degree O
of O
pain O
, O
quality O
of O
life O
, O
adverse O
reactions O
, O
analgesic O
costs O
, O
and O
hospital O
stays O
were O
evaluated O
and O
compared O
among O
the O
three O
groups O
. O
!LF! !LF!
numeric B-Premise
rating I-Premise
scale I-Premise
scores I-Premise
for I-Premise
pain I-Premise
intensity I-Premise
in I-Premise
group I-Premise
1 I-Premise
and I-Premise
group I-Premise
2 I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
than I-Premise
those I-Premise
in I-Premise
group I-Premise
3 I-Premise
at I-Premise
t I-Premise
( I-Premise
0 I-Premise
- I-Premise
12 I-Premise
) I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
t I-Premise
( I-Premise
12 I-Premise
- I-Premise
24 I-Premise
) I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
and I-Premise
t I-Premise
( I-Premise
24 I-Premise
- I-Premise
48 I-Premise
) I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
when B-Premise
group I-Premise
1 I-Premise
with I-Premise
group I-Premise
2 I-Premise
were I-Premise
compared I-Premise
, I-Premise
numeric I-Premise
rating I-Premise
scale I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
group I-Premise
1 I-Premise
than I-Premise
in I-Premise
group I-Premise
2 I-Premise
during I-Premise
the I-Premise
period I-Premise
of I-Premise
t I-Premise
( I-Premise
0 I-Premise
- I-Premise
12 I-Premise
) I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
but B-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
at I-Premise
t I-Premise
( I-Premise
12 I-Premise
- I-Premise
24 I-Premise
) I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
68 I-Premise
) I-Premise
and I-Premise
t I-Premise
( I-Premise
24 I-Premise
- I-Premise
48 I-Premise
) I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
10 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
analgesic B-Premise
cost I-Premise
and I-Premise
hospital I-Premise
stay I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
treated I-Premise
groups I-Premise
than I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise
!LF! !LF!
no B-Premise
significant I-Premise
difference I-Premise
was I-Premise
observed I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
and I-Premise
adverse I-Premise
events I-Premise
between I-Premise
the I-Premise
treated I-Premise
groups I-Premise
and I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise
!LF! !LF!
cro B-Claim
is I-Claim
effective I-Claim
, I-Claim
safe I-Claim
, I-Claim
and I-Claim
cost I-Claim
- I-Claim
effective I-Claim
in I-Claim
the I-Claim
control I-Claim
of I-Claim
postoperative I-Claim
pain I-Claim
after I-Claim
transarterial I-Claim
chemoembolization I-Claim
for I-Claim
patients I-Claim
with I-Claim
inoperable I-Claim
liver I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
health O
- O
related O
quality O
of O
life O
( O
hrqol O
) O
, O
symptoms O
of O
depression O
, O
and O
adverse O
events O
( O
aes O
) O
were O
compared O
between O
japanese O
postmenopausal O
patients O
with O
hormone O
- O
sensitive O
breast O
cancer O
( O
bc O
) O
who O
received O
adjuvant O
tamoxifen O
, O
exemestane O
, O
or O
anastrozole O
in O
an O
open O
- O
labeled O
, O
randomized O
, O
multicenter O
trial O
designated O
as O
the O
national O
surgical O
adjuvant O
study O
of O
breast O
cancer O
( O
n O
- O
sas O
bc O
) O
4 O
substudy O
of O
the O
tamoxifen O
exemestane O
adjuvant O
multinational O
( O
team O
) O
trial O
. O
!LF! !LF!
during O
the O
first O
year O
of O
treatment O
, O
hrqol O
and O
symptoms O
of O
depression O
were O
analyzed O
using O
the O
functional O
assessment O
of O
cancer O
therapy O
- O
breast O
( O
fact O
- O
b O
) O
and O
its O
endocrine O
symptom O
subscale O
( O
es O
) O
, O
and O
the O
center O
for O
epidemiologic O
studies O
depression O
scale O
( O
ces O
- O
d O
) O
, O
respectively O
. O
!LF! !LF!
in O
addition O
, O
predefined O
aes O
were O
analyzed O
. O
!LF! !LF!
a O
total O
of O
166 O
eligible O
patients O
were O
randomly O
assigned O
to O
receive O
adjuvant O
tamoxifen O
, O
exemestane O
, O
or O
anastrozole O
. O
!LF! !LF!
fact B-Premise
- B-Premise
b B-Premise
scores I-Premise
increased I-Premise
after I-Premise
treatment I-Premise
began I-Premise
and I-Premise
remained I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
group I-Premise
or I-Premise
anastrozole I-Premise
group I-Premise
during I-Premise
the I-Premise
first I-Premise
year I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
045 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
fact B-Premise
- B-Premise
b B-Premise
scores I-Premise
were I-Premise
similar I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
group I-Premise
and I-Premise
anastrozole I-Premise
group I-Premise
. I-Premise
!LF! !LF!
es B-Premise
scores I-Premise
and I-Premise
ces I-Premise
- I-Premise
d I-Premise
scores I-Premise
were I-Premise
similar I-Premise
in I-Premise
all I-Premise
treatment I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
arthralgia B-Premise
and I-Premise
fatigue I-Premise
were I-Premise
less I-Premise
frequent I-Premise
, I-Premise
but I-Premise
vaginal I-Premise
discharge I-Premise
was I-Premise
more I-Premise
frequent I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
group I-Premise
or I-Premise
anastrozole I-Premise
group I-Premise
. I-Premise
!LF! !LF!
hrqol B-Claim
was I-Claim
better I-Claim
in I-Claim
japanese I-Claim
postmenopausal I-Claim
women I-Claim
treated I-Claim
with I-Claim
tamoxifen I-Claim
than I-Claim
those I-Claim
treated I-Claim
with I-Claim
exemestane I-Claim
or I-Claim
anastrozole I-Claim
. I-Claim
!LF! !LF!
hrqol B-Claim
and I-Claim
aes I-Claim
were I-Claim
similar I-Claim
with I-Claim
exemestane I-Claim
and I-Claim
anastrozole I-Claim
. I-Claim
!LF! !LF!
given B-Claim
the I-Claim
results I-Claim
of I-Claim
the I-Claim
team I-Claim
trial I-Claim
, I-Claim
upfront I-Claim
use I-Claim
of I-Claim
tamoxifen I-Claim
followed I-Claim
by I-Claim
an I-Claim
aromatase I-Claim
inhibitor I-Claim
( I-Claim
ai I-Claim
) I-Claim
may I-Claim
be I-Claim
an I-Claim
important I-Claim
option I-Claim
for I-Claim
adjuvant I-Claim
endocrine I-Claim
therapy I-Claim
in I-Claim
japanese I-Claim
postmenopausal I-Claim
women I-Claim
. I-Claim
!LF! !LF!
we O
compared O
fulvestrant O
500 O
mg O
regimen O
with O
the O
approved O
dose O
of O
fulvestrant O
250 O
mg O
per O
month O
for O
treatment O
of O
postmenopausal O
women O
with O
estrogen O
receptor O
- O
positive O
advanced O
breast O
cancer O
who O
experienced O
progression O
after O
prior O
endocrine O
therapy O
. O
!LF! !LF!
comparison O
of O
faslodex O
in O
recurrent O
or O
metastatic O
breast O
cancer O
( O
confirm O
) O
is O
a O
double O
- O
blind O
, O
parallel O
- O
group O
, O
multicenter O
, O
phase O
iii O
study O
. O
!LF! !LF!
patients O
were O
randomly O
assigned O
to O
fulvestrant O
500 O
mg O
( O
500 O
mg O
intramuscularly O
[ O
im O
] O
on O
day O
0 O
, O
then O
500 O
mg O
im O
on O
days O
14 O
and O
28 O
and O
every O
28 O
days O
thereafter O
) O
or O
250 O
mg O
every O
28 O
days O
. O
!LF! !LF!
primary O
end O
point O
was O
progression O
- O
free O
survival O
( O
pfs O
) O
. O
!LF! !LF!
secondary O
end O
points O
included O
objective O
response O
rate O
, O
clinical O
benefit O
rate O
( O
cbr O
) O
, O
duration O
of O
clinical O
benefit O
( O
docb O
) O
, O
overall O
survival O
( O
os O
) O
, O
and O
quality O
of O
life O
( O
qol O
) O
. O
!LF! !LF!
pfs B-Premise
was I-Premise
significantly I-Premise
longer I-Premise
for I-Premise
fulvestrant I-Premise
500 I-Premise
mg I-Premise
( I-Premise
n I-Premise
= I-Premise
362 I-Premise
) I-Premise
than I-Premise
250 I-Premise
mg I-Premise
( I-Premise
n I-Premise
= I-Premise
374 I-Premise
) I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
hr I-Premise
] I-Premise
= I-Premise
0 I-Premise
. I-Premise
80 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
68 I-Premise
to I-Premise
0 I-Premise
. I-Premise
94 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
006 I-Premise
) I-Premise
, I-Premise
corresponding I-Premise
to I-Premise
a I-Premise
20 I-Premise
% I-Premise
reduction I-Premise
in I-Premise
risk I-Premise
of I-Premise
progression I-Premise
. I-Premise
!LF! !LF!
objective B-Premise
response I-Premise
rate I-Premise
was I-Premise
similar I-Premise
for I-Premise
fulvestrant I-Premise
500 I-Premise
mg I-Premise
and I-Premise
250 I-Premise
mg I-Premise
( I-Premise
9 I-Premise
. I-Premise
1 I-Premise
% I-Premise
v I-Premise
10 I-Premise
. I-Premise
2 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise
!LF! !LF!
cbr B-Premise
was I-Premise
45 I-Premise
. I-Premise
6 I-Premise
% I-Premise
for I-Premise
fulvestrant I-Premise
500 I-Premise
mg I-Premise
and I-Premise
39 I-Premise
. I-Premise
6 I-Premise
% I-Premise
for I-Premise
fulvestrant I-Premise
250 I-Premise
mg I-Premise
. I-Premise
docb B-Premise
and I-Premise
os I-Premise
were I-Premise
16 I-Premise
. I-Premise
6 I-Premise
and I-Premise
25 I-Premise
. I-Premise
1 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
the I-Premise
500 I-Premise
- I-Premise
mg I-Premise
group I-Premise
, I-Premise
whereas I-Premise
docb I-Premise
and I-Premise
os I-Premise
were I-Premise
13 I-Premise
. I-Premise
9 I-Premise
and I-Premise
22 I-Premise
. I-Premise
8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
in I-Premise
the I-Premise
250 I-Premise
- I-Premise
mg I-Premise
group I-Premise
. I-Premise
!LF! !LF!
fulvestrant B-Claim
500 I-Claim
mg I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
with I-Claim
no I-Claim
dose I-Claim
- I-Claim
dependent I-Claim
adverse I-Claim
events I-Claim
. I-Claim
!LF! !LF!
qol B-Claim
was I-Claim
similar I-Claim
for I-Claim
both I-Claim
arms I-Claim
. I-Claim
!LF! !LF!
fulvestrant B-Claim
500 I-Claim
mg I-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
statistically I-Claim
significant I-Claim
increase I-Claim
in I-Claim
pfs I-Claim
and I-Claim
not I-Claim
associated I-Claim
with I-Claim
increased I-Claim
toxicity I-Claim
, I-Claim
corresponding O
to O
a O
clinically O
meaningful O
improvement O
in O
benefit O
versus O
risk O
compared O
with O
fulvestrant O
250 O
mg O
. O
!LF! !LF!
a O
randomized O
controlled O
trial O
previously O
conducted O
in O
radiation O
oncology O
patients O
demonstrated O
that O
nutrition O
intervention O
had O
a O
beneficial O
impact O
on O
body O
weight O
, O
nutritional O
status O
, O
and O
quality O
of O
life O
compared O
with O
standard O
practice O
, O
but O
it O
did O
not O
report O
on O
dietary O
intake O
data O
. O
!LF! !LF!
to O
determine O
the O
impact O
of O
nutrition O
intervention O
compared O
with O
standard O
practice O
on O
dietary O
intake O
in O
outpatients O
receiving O
radiotherapy O
. O
!LF! !LF!
prospective O
, O
randomized O
, O
controlled O
trial O
. O
!LF! !LF!
sixty O
consecutive O
radiation O
oncology O
outpatients O
( O
51 O
men O
and O
nine O
women O
"""" O
; O
"""" O
age O
61 O
. O
9 O
+ O
/ O
- O
14 O
years O
[ O
mean O
+ O
/ O
- O
standard O
deviation O
] O
) O
. O
!LF! !LF!
australian O
private O
radiotherapy O
facility O
. O
!LF! !LF!
patients O
were O
randomly O
assigned O
to O
receive O
either O
nutrition O
intervention O
( O
n O
= O
29 O
) O
( O
nutrition O
counseling O
following O
the O
american O
dietetic O
association O
[ O
ada O
] O
medical O
nutrition O
therapy O
[ O
mnt O
] O
protocol O
for O
radiation O
oncology O
) O
or O
standard O
practice O
( O
n O
= O
31 O
) O
( O
general O
nutrition O
talk O
and O
booklet O
) O
. O
!LF! !LF!
dietary O
intake O
( O
protein O
, O
energy O
, O
fiber O
) O
assessed O
at O
baseline O
and O
at O
4 O
, O
8 O
, O
and O
12 O
weeks O
after O
starting O
radiotherapy O
. O
!LF! !LF!
repeated O
- O
measures O
analysis O
of O
variance O
done O
on O
an O
intention O
to O
treat O
basis O
. O
!LF! !LF!
the B-Premise
nutrition I-Premise
intervention I-Premise
group I-Premise
had I-Premise
a I-Premise
higher I-Premise
mean I-Premise
total I-Premise
energy I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
029 I-Premise
) I-Premise
and I-Premise
protein I-Premise
intake I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
standard I-Premise
practice I-Premise
group I-Premise
. I-Premise
!LF! !LF!
mean B-Premise
intake I-Premise
per I-Premise
kilogram I-Premise
of I-Premise
body I-Premise
weight I-Premise
for I-Premise
the I-Premise
nutrition I-Premise
intervention I-Premise
group I-Premise
ranged I-Premise
from I-Premise
28 I-Premise
to I-Premise
31 I-Premise
kcal I-Premise
/ I-Premise
kg I-Premise
/ I-Premise
day I-Premise
compared I-Premise
with I-Premise
25 I-Premise
to I-Premise
29 I-Premise
kcal I-Premise
/ I-Premise
kg I-Premise
/ I-Premise
day I-Premise
for I-Premise
the I-Premise
standard I-Premise
practice I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
022 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
nutrition I-Premise
intervention I-Premise
group I-Premise
had I-Premise
a I-Premise
higher I-Premise
mean I-Premise
protein I-Premise
intake I-Premise
( I-Premise
1 I-Premise
. I-Premise
1 I-Premise
to I-Premise
1 I-Premise
. I-Premise
3 I-Premise
g I-Premise
/ I-Premise
kg I-Premise
/ I-Premise
day I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
standard I-Premise
practice I-Premise
group I-Premise
( I-Premise
1 I-Premise
. I-Premise
0 I-Premise
to I-Premise
1 I-Premise
. I-Premise
1 I-Premise
g I-Premise
/ I-Premise
kg I-Premise
/ I-Premise
day I-Premise
) I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
although B-Premise
the I-Premise
change I-Premise
in I-Premise
fiber I-Premise
intake I-Premise
between I-Premise
the I-Premise
groups I-Premise
was I-Premise
not I-Premise
significant I-Premise
, I-Premise
there B-Premise
was I-Premise
a I-Premise
trend I-Premise
in I-Premise
the I-Premise
anticipated I-Premise
direction I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
083 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
intensive B-Claim
nutrition I-Claim
intervention I-Claim
following I-Claim
the I-Claim
ada I-Claim
mnt I-Claim
protocol I-Claim
results I-Claim
in I-Claim
improved I-Claim
dietary I-Claim
intake I-Claim
compared I-Claim
with I-Claim
standard I-Claim
practice I-Claim
and I-Claim
seems I-Claim
to I-Claim
beneficially I-Claim
impact I-Claim
nutrition I-Claim
- I-Claim
related I-Claim
outcomes I-Claim
previously I-Claim
observed I-Claim
in I-Claim
oncology I-Claim
outpatients I-Claim
receiving I-Claim
radiotherapy I-Claim
. I-Claim
!LF! !LF!
the B-Claim
ada I-Claim
mnt I-Claim
protocol I-Claim
for I-Claim
radiation I-Claim
oncology I-Claim
is I-Claim
a I-Claim
useful I-Claim
guide I-Claim
to I-Claim
the I-Claim
level I-Claim
of I-Claim
nutrition I-Claim
support I-Claim
required I-Claim
. I-Claim
!LF! !LF!
to O
determine O
if O
the O
type O
of O
embolic O
material O
used O
for O
uterine O
artery O
embolization O
( O
uae O
) O
for O
leiomyomas O
has O
an O
impact O
on O
short O
- O
term O
recovery O
or O
the O
effectiveness O
of O
embolization O
. O
!LF! !LF!
one O
hundred O
patients O
were O
randomly O
assigned O
to O
undergo O
uae O
with O
polyvinyl O
alcohol O
( O
pva O
) O
particles O
or O
tris O
- O
acryl O
gelatin O
microspheres O
. O
!LF! !LF!
short O
- O
term O
, O
in O
- O
hospital O
medication O
use O
and O
pain O
levels O
were O
recorded O
. O
!LF! !LF!
after O
discharge O
, O
symptom O
severity O
, O
temperature O
, O
and O
medications O
used O
were O
recorded O
daily O
for O
1 O
week O
and O
symptom O
levels O
were O
measured O
for O
weeks O
2 O
- O
4 O
. O
!LF! !LF!
three O
months O
after O
embolization O
, O
contrast O
material O
- O
enhanced O
magnetic O
resonance O
imaging O
examinations O
were O
evaluated O
blindly O
to O
determine O
the O
extent O
of O
leiomyoma O
infarction O
. O
!LF! !LF!
symptom O
and O
quality O
of O
life O
( O
qol O
) O
status O
was O
determined O
with O
use O
of O
questionnaires O
. O
!LF! !LF!
analysis O
was O
completed O
with O
use O
of O
chi O
( O
2 O
) O
analysis O
, O
fisher O
exact O
tests O
, O
student O
t O
tests O
, O
and O
analysis O
of O
variance O
as O
appropriate O
. O
!LF! !LF!
regression O
analysis O
was O
used O
to O
analyze O
the O
impact O
on O
outcome O
of O
baseline O
factors O
( O
other O
than O
type O
of O
embolic O
agent O
) O
. O
!LF! !LF!
no O
significant O
differences O
were O
noted O
at O
baseline O
between O
the O
two O
treatment O
groups O
. O
!LF! !LF!
on B-Premise
average I-Premise
, I-Premise
there I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
volumes I-Premise
of I-Premise
tris I-Premise
- I-Premise
acryl I-Premise
microspheres I-Premise
used I-Premise
( I-Premise
9 I-Premise
. I-Premise
0 I-Premise
ml I-Premise
vs I-Premise
3 I-Premise
. I-Premise
0 I-Premise
ml I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
0001 I-Premise
) I-Premise
, I-Premise
whereas O
microcatheter B-Premise
occlusion I-Premise
was I-Premise
more I-Premise
common I-Premise
with I-Premise
pva I-Premise
( I-Premise
28 I-Premise
% I-Premise
vs I-Premise
4 I-Premise
% I-Premise
, I-Premise
p I-Premise
= I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
pain I-Premise
severity I-Premise
, I-Premise
other I-Premise
postprocedural I-Premise
symptoms I-Premise
, I-Premise
or I-Premise
medication I-Premise
use I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
there B-Premise
were I-Premise
also I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
frequency I-Premise
of I-Premise
incompletely I-Premise
infarcted I-Premise
leiomyomas I-Premise
, I-Premise
degree I-Premise
of I-Premise
improvement I-Premise
in I-Premise
symptom I-Premise
score I-Premise
, I-Premise
patient I-Premise
satisfaction I-Premise
, I-Premise
or I-Premise
qol I-Premise
. I-Premise
!LF! !LF!
no B-Claim
substantive I-Claim
differences I-Claim
were I-Claim
detected I-Claim
between I-Claim
outcomes I-Claim
of I-Claim
embolization I-Claim
with I-Claim
pva I-Claim
particles I-Claim
or I-Claim
tris I-Claim
- I-Claim
acryl I-Claim
gelatin I-Claim
microspheres I-Claim
. I-Claim
!LF! !LF!
previous B-Claim
trials I-Claim
have I-Claim
suggested I-Claim
a I-Claim
quality I-Claim
- I-Claim
of I-Claim
- I-Claim
life I-Claim
( I-Claim
qol I-Claim
) I-Claim
improvement I-Claim
for I-Claim
anemic I-Claim
cancer I-Claim
patients I-Claim
treated I-Claim
with I-Claim
erythropoietin I-Claim
, I-Claim
but I-Claim
few I-Claim
used I-Claim
qol I-Claim
as I-Claim
the I-Claim
primary I-Claim
outcome I-Claim
. I-Claim
!LF! !LF!
we O
designed O
a O
trial O
to O
investigate O
the O
effects O
of O
epoetin O
alfa O
therapy O
on O
the O
qol O
of O
anemic O
patients O
with O
advanced O
non O
- O
small O
- O
cell O
carcinoma O
of O
the O
lung O
( O
nsclc O
) O
. O
!LF! !LF!
a O
multicenter O
, O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
trial O
was O
conducted O
. O
!LF! !LF!
the O
proposed O
sample O
size O
was O
300 O
patients O
. O
!LF! !LF!
eligible O
patients O
were O
required O
to O
have O
nsclc O
unsuitable O
for O
curative O
therapy O
and O
baseline O
hemoglobin O
( O
hgb O
) O
levels O
less O
than O
121 O
g O
/ O
l O
. O
!LF! !LF!
patients O
were O
assigned O
to O
12 O
weekly O
injections O
of O
subcutaneous O
epoetin O
alpha O
or O
placebo O
, O
targeting O
hgb O
levels O
between O
120 O
and O
140 O
g O
/ O
l O
. O
!LF! !LF!
the O
primary O
outcome O
was O
the O
difference O
in O
the O
change O
in O
functional O
assessment O
of O
cancer O
therapy O
- O
anemia O
scores O
between O
baseline O
and O
12 O
weeks O
. O
!LF! !LF!
reports O
of O
thrombotic O
events O
in O
other O
epoetin O
trials O
prompted O
an O
unplanned O
safety O
analysis O
after O
70 O
patients O
had O
been O
randomly O
assigned O
( O
33 O
to O
the O
active O
arm O
and O
37 O
to O
the O
placebo O
arm O
) O
. O
!LF! !LF!
this B-Premise
revealed I-Premise
a I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
median I-Premise
survival I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
patients I-Premise
on I-Premise
the I-Premise
placebo I-Premise
arm I-Premise
of I-Premise
the I-Premise
trial I-Premise
( I-Premise
63 I-Premise
v I-Premise
129 I-Premise
days I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1 I-Premise
. I-Premise
84 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
04 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the O
steering O
committee O
closed O
the O
trial O
. O
!LF! !LF!
patient B-Premise
numbers I-Premise
compromised I-Premise
the I-Premise
interpretation I-Premise
of I-Premise
the I-Premise
qol I-Premise
analysis I-Premise
, I-Premise
but O
a B-Premise
positive I-Premise
hgb I-Premise
response I-Premise
was I-Premise
noted I-Premise
with I-Premise
epoetin I-Premise
alfa I-Premise
treatment I-Premise
. I-Premise
!LF! !LF!
an B-Claim
unplanned I-Claim
safety I-Claim
analysis I-Claim
suggested I-Claim
decreased I-Claim
overall I-Claim
survival I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
nsclc I-Claim
treated I-Claim
with I-Claim
epoetin I-Claim
alfa I-Claim
. I-Claim
!LF! !LF!
although O
infrequent O
, O
other O
similar O
reports O
highlight O
the O
need O
for O
ongoing O
trials O
evaluating O
erythropoietin O
receptor O
agonists O
to O
ensure O
that O
overall O
survival O
is O
monitored O
closely O
. O
!LF! !LF!
we O
report O
results O
of O
a O
randomized O
prospective O
study O
that O
compared O
single O
agents O
of O
low O
toxicity O
given O
both O
as O
the O
first O
- O
line O
and O
second O
- O
line O
chemotherapy O
with O
combination O
chemotherapy O
in O
advanced O
breast O
cancer O
with O
distant O
metastases O
. O
!LF! !LF!
patients O
in O
the O
single O
- O
agent O
arm O
( O
n O
= O
153 O
) O
received O
weekly O
epirubicin O
( O
e O
) O
20 O
mg O
/ O
m2 O
until O
progression O
or O
until O
the O
cumulative O
dose O
of O
1 O
, O
000 O
mg O
/ O
m2 O
, O
followed O
by O
mitomycin O
( O
m O
) O
8 O
mg O
/ O
m2 O
every O
4 O
weeks O
, O
and O
those O
in O
the O
combination O
chemotherapy O
arm O
( O
n O
= O
150 O
) O
were O
first O
given O
cyclophosphamide O
500 O
mg O
/ O
m2 O
, O
e O
60 O
mg O
/ O
m2 O
, O
and O
fluorouracil O
500 O
mg O
/ O
m2 O
three O
times O
per O
week O
( O
cef O
) O
followed O
by O
m O
8 O
mg O
/ O
m2 O
plus O
vinblastine O
( O
v O
) O
6 O
mg O
/ O
m2 O
every O
4 O
weeks O
. O
!LF! !LF!
exclusion O
criteria O
included O
age O
greater O
than O
70 O
years O
, O
world O
health O
organization O
( O
who O
) O
performance O
status O
greater O
than O
2 O
, O
prior O
chemotherapy O
for O
metastatic O
disease O
, O
and O
presence O
of O
liver O
metastases O
in O
patients O
younger O
than O
50 O
. O
!LF! !LF!
an B-Premise
objective I-Premise
response I-Premise
( I-Premise
complete I-Premise
[ I-Premise
cr I-Premise
] I-Premise
or I-Premise
partial I-Premise
[ I-Premise
pr I-Premise
] I-Premise
) I-Premise
was I-Premise
obtained I-Premise
in I-Premise
55 I-Premise
% I-Premise
, I-Premise
48 I-Premise
% I-Premise
, I-Premise
16 I-Premise
% I-Premise
, I-Premise
and I-Premise
7 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
cef I-Premise
, I-Premise
e I-Premise
, I-Premise
m I-Premise
, I-Premise
and I-Premise
mv I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
a B-Premise
response I-Premise
to I-Premise
cef I-Premise
tended I-Premise
to I-Premise
last I-Premise
longer I-Premise
than I-Premise
a I-Premise
response I-Premise
to I-Premise
e I-Premise
( I-Premise
median I-Premise
, I-Premise
12 I-Premise
v I-Premise
10 I-Premise
. I-Premise
5 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
07 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
treatment B-Premise
- B-Premise
related B-Premise
toxicity I-Premise
was I-Premise
less I-Premise
in I-Premise
the I-Premise
single I-Premise
- I-Premise
agent I-Premise
arm I-Premise
and I-Premise
quality I-Premise
- I-Premise
of I-Premise
- I-Premise
life I-Premise
( I-Premise
qol I-Premise
) I-Premise
analysis I-Premise
favored I-Premise
the I-Premise
single I-Premise
- I-Premise
agent I-Premise
arm I-Premise
. I-Premise
!LF! !LF!
no B-Premise
significant I-Premise
difference I-Premise
in I-Premise
time I-Premise
to I-Premise
progression I-Premise
or I-Premise
survival I-Premise
was I-Premise
found I-Premise
between I-Premise
the I-Premise
two I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
similarly B-Premise
, I-Premise
no I-Premise
difference I-Premise
in I-Premise
survival I-Premise
was I-Premise
found I-Premise
when I-Premise
the I-Premise
patients I-Premise
who I-Premise
received I-Premise
both I-Premise
the I-Premise
planned I-Premise
first I-Premise
- I-Premise
and I-Premise
second I-Premise
- I-Premise
line I-Premise
treatments I-Premise
were I-Premise
compared I-Premise
or I-Premise
when I-Premise
survival I-Premise
was I-Premise
calculated I-Premise
from I-Premise
the I-Premise
beginning I-Premise
of I-Premise
the I-Premise
second I-Premise
- I-Premise
line I-Premise
therapy I-Premise
. I-Premise
!LF! !LF!
patients B-Claim
treated I-Claim
with I-Claim
single I-Claim
- I-Claim
agent I-Claim
e I-Claim
followed I-Claim
by I-Claim
single I-Claim
- I-Claim
agent I-Claim
m I-Claim
had I-Claim
similar I-Claim
survival I-Claim
, I-Claim
but I-Claim
less I-Claim
treatment I-Claim
- I-Claim
related I-Claim
toxicity I-Claim
and I-Claim
better I-Claim
qol I-Claim
as I-Claim
compared I-Claim
with I-Claim
those I-Claim
treated I-Claim
with I-Claim
cef I-Claim
followed I-Claim
by I-Claim
mv I-Claim
. I-Claim
!LF! !LF!
premenopausal O
women O
with O
breast O
cancer O
receiving O
adjuvant O
chemotherapy O
are O
at O
risk O
for O
amenorrhea O
. O
!LF! !LF!
the O
national O
surgical O
adjuvant O
breast O
and O
bowel O
project O
b O
- O
30 O
trial O
included O
menstrual O
history O
( O
mh O
) O
and O
quality O
- O
of O
- O
life O
( O
qol O
) O
studies O
to O
compare O
treatments O
on O
these O
outcomes O
. O
!LF! !LF!
patients O
were O
randomly O
assigned O
to O
sequential O
doxorubicin O
( O
a O
) O
and O
cyclophosphamide O
( O
c O
) O
followed O
by O
docetaxel O
( O
t O
"""" O
; O
"""" O
ac→t O
) O
, O
concurrent O
tac O
, O
or O
at O
, O
which O
varied O
in O
duration O
( O
24 O
, O
12 O
, O
12 O
weeks O
, O
respectively O
) O
, O
and O
use O
of O
c O
. O
endocrine O
therapy O
was O
prescribed O
for O
women O
with O
hormone O
receptor O
- O
positive O
tumors O
. O
!LF! !LF!
mh O
and O
qol O
were O
assessed O
with O
standardized O
questionnaires O
at O
baseline O
"""" O
; O
"""" O
cycle O
4 O
, O
day O
1 O
"""" O
; O
"""" O
and O
every O
6 O
months O
through O
24 O
months O
. O
!LF! !LF!
prespecified O
analyses O
examined O
rates O
of O
amenorrhea O
by O
treatment O
arm O
, O
the O
relationship O
between O
amenorrhea O
and O
qol O
, O
and O
qol O
by O
treatment O
arm O
. O
!LF! !LF!
amenorrhea B-Premise
12 I-Premise
months I-Premise
after I-Premise
random I-Premise
assignment I-Premise
was I-Premise
significantly I-Premise
different I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
: I-Premise
69 I-Premise
. I-Premise
8 I-Premise
% I-Premise
for I-Premise
ac→t I-Premise
, I-Premise
57 I-Premise
. I-Premise
7 I-Premise
% I-Premise
for I-Premise
tac I-Premise
, I-Premise
and I-Premise
37 I-Premise
. I-Premise
9 I-Premise
% I-Premise
for I-Premise
at I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
at I-Premise
group I-Premise
without I-Premise
tamoxifen I-Premise
had I-Premise
the I-Premise
lowest I-Premise
rate I-Premise
of I-Premise
amenorrhea I-Premise
. I-Premise
!LF! !LF!
qol B-Premise
was I-Premise
poorer I-Premise
for I-Premise
patients I-Premise
receiving I-Premise
ac→t I-Premise
at I-Premise
6 I-Premise
months I-Premise
but I-Premise
similar I-Premise
to I-Premise
others I-Premise
by I-Premise
12 I-Premise
months I-Premise
. I-Premise
!LF! !LF!
post B-Premise
- B-Premise
treatment B-Premise
symptoms I-Premise
were I-Premise
increased I-Premise
above I-Premise
baseline I-Premise
for I-Premise
all I-Premise
treatments I-Premise
. I-Premise
!LF! !LF!
multivariable B-Premise
repeated I-Premise
measures I-Premise
modeling I-Premise
demonstrated I-Premise
that I-Premise
treatment I-Premise
arm I-Premise
, I-Premise
time I-Premise
point I-Premise
, I-Premise
age I-Premise
, I-Premise
and I-Premise
tamoxifen I-Premise
use I-Premise
were I-Premise
significantly I-Premise
associated I-Premise
with I-Premise
symptom I-Premise
severity I-Premise
( I-Premise
all I-Premise
p I-Premise
values I-Premise
< I-Premise
. I-Premise
002 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
amenorrhea B-Claim
rates I-Claim
differed I-Claim
significantly I-Claim
by I-Claim
treatment I-Claim
arm I-Claim
, I-Claim
with I-Claim
the I-Claim
at I-Claim
arm I-Claim
having I-Claim
the I-Claim
lowest I-Claim
rate I-Claim
. I-Claim
!LF! !LF!
patients B-Claim
treated I-Claim
with I-Claim
longer I-Claim
duration I-Claim
therapy I-Claim
( I-Claim
ac→t I-Claim
) I-Claim
had I-Claim
greater I-Claim
symptom I-Claim
severity I-Claim
and I-Claim
poorer I-Claim
qol I-Claim
at I-Claim
6 I-Claim
months I-Claim
, I-Claim
but I-Claim
did I-Claim
not I-Claim
differ I-Claim
from I-Claim
shorter I-Claim
duration I-Claim
treatments I-Claim
at I-Claim
12 I-Claim
months I-Claim
. I-Claim
!LF! !LF!
to O
investigate O
whether O
frequent O
hospital O
follow O
- O
up O
in O
the O
first O
year O
after O
breast O
cancer O
treatment O
might O
partly O
be O
replaced O
by O
nurse O
- O
led O
telephone O
follow O
- O
up O
without O
deteriorating O
health O
- O
related O
quality O
of O
life O
( O
hrqol O
) O
, O
and O
whether O
a O
short O
educational O
group O
programme O
( O
egp O
) O
would O
enhance O
hrqol O
. O
!LF! !LF!
a O
multicentre O
pragmatic O
randomised O
controlled O
trial O
( O
rct O
) O
with O
a O
2×2 O
factorial O
design O
was O
performed O
among O
320 O
breast O
cancer O
patients O
who O
were O
treated O
with O
curative O
intent O
. O
!LF! !LF!
participants O
were O
randomised O
to O
follow O
- O
up O
care O
as O
usual O
( O
3 O
- O
monthly O
outpatient O
clinic O
visits O
) O
, O
nurse O
- O
led O
telephone O
follow O
- O
up O
, O
or O
the O
former O
strategies O
combined O
with O
an O
educational O
group O
programme O
. O
!LF! !LF!
the O
primary O
outcome O
for O
both O
interventions O
was O
hrqol O
, O
measured O
by O
eortc O
qlq O
- O
c30 O
. O
!LF! !LF!
secondary O
outcomes O
were O
role O
and O
emotional O
functioning O
and O
feelings O
of O
control O
and O
anxiety O
. O
!LF! !LF!
data O
of O
299 O
patients O
were O
available O
for O
evaluation O
. O
!LF! !LF!
there B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
hrqol I-Premise
between I-Premise
nurse I-Premise
- I-Premise
led I-Premise
telephone I-Premise
and I-Premise
hospital I-Premise
follow I-Premise
- I-Premise
up I-Premise
at I-Premise
12 I-Premise
months I-Premise
after I-Premise
treatment I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
42 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
ci I-Premise
) I-Premise
for I-Premise
difference I-Premise
: I-Premise
- I-Premise
1 I-Premise
. I-Premise
93 I-Premise
- I-Premise
4 I-Premise
. I-Premise
64 I-Premise
) I-Premise
and I-Premise
neither I-Premise
between I-Premise
follow I-Premise
- I-Premise
up I-Premise
with I-Premise
or I-Premise
without I-Premise
egp I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
86 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
for I-Premise
difference I-Premise
: I-Premise
- I-Premise
3 I-Premise
. I-Premise
59 I-Premise
- I-Premise
3 I-Premise
. I-Premise
00 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
furthermore O
, O
no B-Premise
differences I-Premise
between I-Premise
the I-Premise
intervention I-Premise
groups I-Premise
and I-Premise
their I-Premise
corresponding I-Premise
control I-Premise
groups I-Premise
were I-Premise
found I-Premise
in I-Premise
role I-Premise
and I-Premise
emotional I-Premise
functioning I-Premise
, I-Premise
and I-Premise
feelings I-Premise
of I-Premise
control I-Premise
and I-Premise
anxiety I-Premise
( I-Premise
all I-Premise
p I-Premise
- I-Premise
values I-Premise
> I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
replacement B-Claim
of I-Claim
most I-Claim
hospital I-Claim
follow I-Claim
- I-Claim
up I-Claim
visits I-Claim
in I-Claim
the I-Claim
first I-Claim
year I-Claim
after I-Claim
breast I-Claim
cancer I-Claim
treatment I-Claim
by I-Claim
nurse I-Claim
- I-Claim
led I-Claim
telephone I-Claim
follow I-Claim
- I-Claim
up I-Claim
does I-Claim
not I-Claim
impede I-Claim
patient I-Claim
outcomes I-Claim
. I-Claim
!LF! !LF!
hence O
, O
nurse B-Claim
- B-Claim
led B-Claim
telephone I-Claim
follow I-Claim
- I-Claim
up I-Claim
seems I-Claim
an I-Claim
appropriate I-Claim
way I-Claim
to I-Claim
reduce I-Claim
clinic I-Claim
visits I-Claim
and I-Claim
represents I-Claim
an I-Claim
accepted I-Claim
alternative I-Claim
strategy I-Claim
. I-Claim
!LF! !LF!
an O
egp O
does O
not O
unequivocally O
affect O
positive O
hrqol O
outcomes O
. O
!LF! !LF!
to O
investigate O
the O
impact O
of O
dietary O
counseling O
or O
nutritional O
supplements O
on O
outcomes O
in O
cancer O
patients O
: O
nutritional O
, O
morbidity O
, O
and O
quality O
of O
life O
( O
qol O
) O
during O
and O
3 O
months O
after O
radiotherapy O
. O
!LF! !LF!
a O
total O
of O
111 O
colorectal O
cancer O
outpatients O
referred O
for O
radiotherapy O
, O
stratified O
by O
staging O
, O
were O
randomly O
assigned O
: O
group O
1 O
( O
g1 O
"""" O
; O
"""" O
n O
= O
37 O
) O
, O
dietary O
counseling O
( O
regular O
foods O
) O
"""" O
; O
"""" O
group O
2 O
( O
g2 O
"""" O
; O
"""" O
n O
= O
37 O
) O
, O
protein O
supplements O
"""" O
; O
"""" O
and O
group O
3 O
( O
g3 O
"""" O
; O
"""" O
n O
= O
37 O
) O
, O
ad O
libitum O
intake O
. O
!LF! !LF!
nutritional O
intake O
( O
diet O
history O
) O
, O
status O
( O
ottery O
' O
s O
subjective O
global O
assessment O
) O
, O
and O
qol O
( O
european O
organisation O
for O
research O
and O
treatment O
of O
cancer O
quality O
of O
life O
questionnaire O
version O
3 O
. O
0 O
) O
were O
evaluated O
at O
baseline O
, O
at O
the O
end O
, O
and O
3 O
months O
after O
radiotherapy O
. O
!LF! !LF!
at B-Premise
radiotherapy I-Premise
completion I-Premise
, I-Premise
energy I-Premise
intake I-Premise
increased I-Premise
in I-Premise
g1 I-Premise
/ I-Premise
g2 I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
. I-Premise
04 I-Premise
) I-Premise
, I-Premise
g1 I-Premise
more I-Premise
than I-Premise
g2 I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
and I-Premise
decreased I-Premise
in I-Premise
g3 I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
protein B-Premise
intake I-Premise
increased I-Premise
in I-Premise
g1 I-Premise
/ I-Premise
g2 I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
. I-Premise
007 I-Premise
) I-Premise
, I-Premise
g1 I-Premise
less I-Premise
than I-Premise
g2 I-Premise
( I-Premise
not I-Premise
significant I-Premise
) I-Premise
, I-Premise
and I-Premise
decreased I-Premise
in I-Premise
g3 I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
at B-Premise
3 I-Premise
months I-Premise
, I-Premise
g1 I-Premise
maintained I-Premise
nutritional I-Premise
intake I-Premise
and I-Premise
g2 I-Premise
/ I-Premise
g3 I-Premise
returned I-Premise
to I-Premise
baseline I-Premise
. I-Premise
!LF! !LF!
after B-Premise
radiotherapy I-Premise
and I-Premise
at I-Premise
3 I-Premise
months I-Premise
, I-Premise
rates I-Premise
of I-Premise
anorexia I-Premise
, I-Premise
nausea I-Premise
, I-Premise
vomiting I-Premise
, I-Premise
and I-Premise
diarrhea I-Premise
were I-Premise
higher I-Premise
in I-Premise
g3 I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
at B-Premise
radiotherapy I-Premise
completion I-Premise
, I-Premise
in I-Premise
g1 I-Premise
all I-Premise
qol I-Premise
function I-Premise
scores I-Premise
improved I-Premise
proportionally I-Premise
to I-Premise
adequate I-Premise
intake I-Premise
or I-Premise
nutritional I-Premise
status I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
05 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
whereas I-Premise
in I-Premise
g2 I-Premise
only I-Premise
three I-Premise
of I-Premise
six I-Premise
function I-Premise
scores I-Premise
improved I-Premise
proportionally I-Premise
to I-Premise
protein I-Premise
intake I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
04 I-Premise
) I-Premise
, I-Premise
and I-Premise
in I-Premise
g3 I-Premise
all I-Premise
scores I-Premise
worsened I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
at B-Premise
3 I-Premise
months I-Premise
, I-Premise
g1 I-Premise
patients I-Premise
maintained I-Premise
/ I-Premise
improved I-Premise
function I-Premise
, I-Premise
symptoms I-Premise
, I-Premise
and I-Premise
single I-Premise
- I-Premise
item I-Premise
scores I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
02 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
in I-Premise
g2 I-Premise
, I-Premise
only I-Premise
few I-Premise
function I-Premise
and I-Premise
symptom I-Premise
scales I-Premise
improved I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
05 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
in I-Premise
g3 I-Premise
, I-Premise
qol I-Premise
remained I-Premise
as I-Premise
poor I-Premise
as I-Premise
after I-Premise
radiotherapy I-Premise
. I-Premise
!LF! !LF!
in B-Premise
g1 I-Premise
/ I-Premise
g2 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
improvement I-Premise
/ I-Premise
deterioration I-Premise
of I-Premise
qol I-Premise
correlated I-Premise
with I-Premise
better I-Premise
or I-Premise
poorer I-Premise
intake I-Premise
or I-Premise
nutritional I-Premise
status I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
003 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
during B-Claim
radiotherapy I-Claim
, I-Claim
both I-Claim
interventions I-Claim
positively I-Claim
influenced I-Claim
outcomes I-Claim
"""" I-Claim
; I-Claim
"""" I-Claim
dietary B-Claim
counseling I-Claim
was I-Claim
of I-Claim
similar I-Claim
or I-Claim
higher I-Claim
benefit I-Claim
, I-Claim
whereas I-Claim
even I-Claim
3 I-Claim
months I-Claim
after I-Claim
rt I-Claim
, I-Claim
it I-Claim
was I-Claim
the I-Claim
only I-Claim
method I-Claim
to I-Claim
sustain I-Claim
a I-Claim
significant I-Claim
impact I-Claim
on I-Claim
patient I-Claim
outcomes I-Claim
. I-Claim
!LF! !LF!
this O
phase O
iii O
study O
was O
performed O
to O
determine O
the O
superiority O
of O
doxorubicin O
( O
dox O
) O
and O
vinorelbine O
( O
vnb O
) O
( O
arm O
1 O
) O
versus O
dox O
alone O
( O
arm O
2 O
) O
in O
metastatic O
breast O
cancer O
( O
mbc O
) O
for O
overall O
survival O
( O
os O
) O
, O
time O
to O
treatment O
failure O
( O
ttf O
) O
, O
toxicity O
, O
and O
quality O
of O
life O
( O
qol O
) O
. O
!LF! !LF!
three O
hundred O
three O
patients O
were O
randomized O
to O
dox O
50 O
mg O
/ O
m O
( O
2 O
) O
intravenously O
( O
iv O
) O
on O
day O
1 O
and O
vnb O
25 O
mg O
/ O
m O
( O
2 O
) O
iv O
on O
days O
1 O
and O
8 O
( O
arm O
1 O
) O
or O
dox O
70 O
mg O
/ O
m O
( O
2 O
) O
iv O
on O
day O
1 O
( O
arm O
2 O
) O
. O
!LF! !LF!
both O
regimens O
were O
given O
every O
3 O
weeks O
until O
a O
cumulative O
dox O
dose O
of O
450 O
mg O
/ O
m O
( O
2 O
) O
. O
!LF! !LF!
after O
16 O
of O
the O
first O
65 O
randomized O
patients O
experienced O
febrile O
neutropenia O
( O
fn O
) O
, O
the O
doses O
were O
reduced O
to O
dox O
40 O
mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
and O
vnb O
20 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
versus O
dox O
60 O
mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
. O
!LF! !LF!
eligible O
patients O
were O
vinca O
alkaloid O
and O
anthracycline O
naive O
. O
!LF! !LF!
chemotherapy O
was O
first O
- O
line O
or O
second O
- O
line O
for O
mbc O
. O
!LF! !LF!
three O
patients O
were O
ineligible O
. O
!LF! !LF!
thus O
, O
300 O
patients O
were O
assessable O
for O
toxicity O
and O
to O
determine O
time O
to O
disease O
progression O
( O
ttp O
) O
, O
ttf O
, O
and O
os O
. O
!LF! !LF!
two O
hundred O
eighty O
- O
nine O
patients O
were O
assessable O
for O
response O
, O
and O
99 O
responders O
were O
assessable O
for O
response O
duration O
( O
rd O
) O
. O
!LF! !LF!
the B-Premise
response I-Premise
rates I-Premise
, I-Premise
qol I-Premise
, I-Premise
and I-Premise
median I-Premise
rd I-Premise
, I-Premise
ttp I-Premise
, I-Premise
and I-Premise
ttf I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
the I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
median B-Premise
os I-Premise
was I-Premise
13 I-Premise
. I-Premise
8 I-Premise
months I-Premise
for I-Premise
arm I-Premise
1 I-Premise
versus I-Premise
14 I-Premise
. I-Premise
4 I-Premise
months I-Premise
for I-Premise
arm I-Premise
2 I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
4 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
grade B-Premise
3 I-Premise
or I-Premise
4 I-Premise
granulocytopenia I-Premise
was I-Premise
equivalent I-Premise
in I-Premise
both I-Premise
arms I-Premise
but I-Premise
more I-Premise
grade I-Premise
3 I-Premise
/ I-Premise
4 I-Premise
neurotoxicity I-Premise
, I-Premise
mild I-Premise
venous I-Premise
toxicity I-Premise
, I-Premise
and I-Premise
fn I-Premise
were I-Premise
seen I-Premise
on I-Premise
arm I-Premise
1 I-Premise
. I-Premise
!LF! !LF!
the B-Claim
survival I-Claim
with I-Claim
dox I-Claim
and I-Claim
vnb I-Claim
is I-Claim
not I-Claim
superior I-Claim
to I-Claim
dox I-Claim
alone I-Claim
in I-Claim
mbc I-Claim
. I-Claim
!LF! !LF!
to O
analyze O
the O
prospectively O
collected O
health O
- O
related O
quality O
- O
of O
- O
life O
( O
hrqol O
) O
data O
from O
patients O
enrolled O
in O
two O
radiation O
therapy O
oncology O
group O
randomized O
phase O
iii O
head O
and O
neck O
cancer O
trials O
( O
90 O
- O
03 O
and O
91 O
- O
11 O
) O
to O
assess O
their O
value O
as O
an O
independent O
prognostic O
factor O
for O
locoregional O
control O
( O
lrc O
) O
and O
/ O
or O
overall O
survival O
( O
os O
) O
. O
!LF! !LF!
hrqol O
questionnaires O
, O
using O
a O
validated O
instrument O
, O
the O
functional O
assessment O
of O
cancer O
therapy O
- O
head O
and O
neck O
( O
fact O
- O
h O
& O
amp O
"""" O
; O
"""" O
n O
) O
, O
version O
2 O
, O
were O
completed O
by O
patients O
before O
the O
start O
of O
treatment O
. O
!LF! !LF!
os O
and O
lrc O
were O
the O
outcome O
measures O
analyzed O
using O
a O
multivariate O
cox O
proportional O
hazard O
model O
. O
!LF! !LF!
baseline O
fact O
- O
h O
& O
amp O
"""" O
; O
"""" O
n O
data O
were O
available O
for O
1 O
, O
093 O
patients O
and O
missing O
for O
417 O
patients O
. O
!LF! !LF!
no O
significant O
difference O
in O
outcome O
was O
found O
between O
the O
patients O
with O
and O
without O
baseline O
fact O
- O
h O
& O
amp O
"""" O
; O
"""" O
n O
data O
( O
p O
= O
0 O
. O
58 O
) O
. O
!LF! !LF!
the O
median O
follow O
- O
up O
time O
was O
27 O
. O
2 O
months O
for O
all O
patients O
and O
49 O
months O
for O
surviving O
patients O
. O
!LF! !LF!
multivariate O
analyses O
were O
performed O
for O
both O
os O
and O
lrc O
. O
!LF! !LF!
beyond B-Premise
tumor I-Premise
and I-Premise
nodal I-Premise
stage I-Premise
, I-Premise
karnofsky I-Premise
performance I-Premise
status I-Premise
, I-Premise
primary I-Premise
site I-Premise
, I-Premise
cigarette I-Premise
use I-Premise
, I-Premise
use I-Premise
of I-Premise
concurrent I-Premise
chemotherapy I-Premise
, I-Premise
and I-Premise
altered I-Premise
fractionation I-Premise
schedules I-Premise
, I-Premise
the I-Premise
fact I-Premise
- I-Premise
h I-Premise
& I-Premise
amp I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
n I-Premise
score I-Premise
was I-Premise
independently I-Premise
predictive I-Premise
of I-Premise
lrc I-Premise
( I-Premise
but I-Premise
not I-Premise
os I-Premise
) I-Premise
, I-Premise
with I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0038 I-Premise
. I-Premise
!LF! !LF!
the B-Premise
functional I-Premise
well I-Premise
- I-Premise
being I-Premise
component I-Premise
of I-Premise
the I-Premise
fact I-Premise
- I-Premise
h I-Premise
& I-Premise
amp I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
n I-Premise
predicted I-Premise
most I-Premise
significantly I-Premise
for I-Premise
lrc I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0004 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
this B-Claim
study I-Claim
represents I-Claim
, I-Claim
to I-Claim
our I-Claim
knowledge I-Claim
, I-Claim
the I-Claim
largest I-Claim
analysis I-Claim
of I-Claim
hrqol I-Claim
as I-Claim
a I-Claim
prognostic I-Claim
factor I-Claim
in I-Claim
locally I-Claim
advanced I-Claim
head I-Claim
and I-Claim
neck I-Claim
cancer I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
the B-Claim
results I-Claim
of I-Claim
this I-Claim
study I-Claim
have I-Claim
demonstrated I-Claim
the I-Claim
importance I-Claim
of I-Claim
baseline I-Claim
hrqol I-Claim
as I-Claim
a I-Claim
significant I-Claim
and I-Claim
independent I-Claim
predictor I-Claim
of I-Claim
lrc I-Claim
in I-Claim
patients I-Claim
with I-Claim
locally I-Claim
advanced I-Claim
head I-Claim
and I-Claim
neck I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
lymphedema O
is O
an O
adverse O
effect O
of O
breast O
cancer O
surgery O
. O
!LF! !LF!
aqua O
lymphatic O
therapy O
( O
alt O
) O
is O
a O
novel O
treatment O
for O
limb O
volume O
reduction O
. O
!LF! !LF!
the O
aim O
of O
this O
study O
was O
to O
examine O
whether O
alt O
is O
a O
safe O
method O
and O
whether O
there O
are O
differences O
in O
adherence O
, O
limb O
volume O
, O
and O
quality O
of O
life O
between O
women O
who O
perform O
only O
self O
- O
management O
treatment O
and O
women O
who O
participate O
as O
well O
in O
alt O
. O
!LF! !LF!
design O
of O
the O
study O
was O
single O
- O
blind O
randomized O
clinical O
trial O
. O
!LF! !LF!
the O
setting O
was O
in O
a O
hydrotherapy O
pool O
, O
1 O
. O
2 O
m O
depth O
, O
and O
a O
temperature O
of O
32 O
- O
33 O
degrees O
capital O
es O
, O
cyrillic O
. O
!LF! !LF!
forty O
- O
eight O
women O
( O
56 O
+ O
/ O
- O
10 O
years O
) O
, O
with O
a O
12 O
. O
8 O
% O
lymphedema O
relative O
volume O
, O
participated O
in O
the O
study O
. O
!LF! !LF!
the O
control O
group O
was O
instructed O
to O
perform O
the O
self O
- O
management O
treatment O
. O
!LF! !LF!
the O
study O
group O
joined O
a O
weekly O
session O
of O
alt O
for O
3 O
months O
in O
addition O
to O
the O
self O
- O
management O
therapy O
. O
!LF! !LF!
adherence O
was O
assessed O
by O
a O
self O
- O
reported O
diary O
, O
limb O
volume O
by O
a O
water O
displacement O
device O
, O
quality O
of O
life O
by O
the O
upper O
limb O
lymphedema O
questionnaire O
( O
ull27 O
) O
, O
prior O
to O
, O
and O
after O
the O
intervention O
period O
. O
!LF! !LF!
there B-Premise
was I-Premise
no I-Premise
episode I-Premise
of I-Premise
arm I-Premise
infection I-Premise
or I-Premise
aggravation I-Premise
in I-Premise
limb I-Premise
volume I-Premise
during I-Premise
the I-Premise
study I-Premise
period I-Premise
. I-Premise
!LF! !LF!
alt B-Premise
had I-Premise
a I-Premise
positive I-Premise
, I-Premise
statistically I-Premise
and I-Premise
clinically I-Premise
significant I-Premise
immediate I-Premise
effect I-Premise
on I-Premise
limb I-Premise
volume I-Premise
but B-Premise
no I-Premise
long I-Premise
- I-Premise
term I-Premise
effect I-Premise
was I-Premise
noted I-Premise
. I-Premise
!LF! !LF!
the B-Premise
adherence I-Premise
rate I-Premise
to I-Premise
alt I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
the I-Premise
adherence I-Premise
to I-Premise
self I-Premise
- I-Premise
management I-Premise
therapy I-Premise
. I-Premise
!LF! !LF!
qol B-Premise
improved I-Premise
in I-Premise
the I-Premise
study I-Premise
group I-Premise
. I-Premise
!LF! !LF!
alt B-Claim
was I-Claim
found I-Claim
to I-Claim
be I-Claim
a I-Claim
safe I-Claim
method I-Claim
, I-Claim
with I-Claim
high I-Claim
adherence I-Claim
, I-Claim
in I-Claim
treating I-Claim
women I-Claim
who I-Claim
suffer I-Claim
from I-Claim
mild I-Claim
to I-Claim
moderate I-Claim
lymphedema I-Claim
. I-Claim
!LF! !LF!
a B-Claim
significant I-Claim
immediate I-Claim
and I-Claim
insignificant I-Claim
long I-Claim
- I-Claim
term I-Claim
effect I-Claim
on I-Claim
limb I-Claim
volume I-Claim
was I-Claim
noted I-Claim
. I-Claim
!LF! !LF!
recombinant O
human O
tsh O
( O
rhtsh O
) O
has O
become O
the O
modality O
of O
choice O
for O
radioiodine O
remnant O
ablation O
( O
rra O
) O
in O
low O
- O
risk O
thyroid O
cancer O
patients O
. O
!LF! !LF!
the O
aims O
of O
the O
present O
prospective O
randomized O
study O
were O
to O
evaluate O
the O
impact O
of O
tsh O
stimulation O
procedure O
( O
hypothyroidism O
vs O
. O
rhtsh O
) O
on O
quality O
of O
life O
( O
qol O
) O
of O
thyroid O
cancer O
patients O
undergoing O
rra O
and O
to O
evaluate O
efficacy O
of O
both O
procedures O
. O
!LF! !LF!
l O
- O
t4 O
was O
initiated O
in O
both O
groups O
after O
thyroidectomy O
. O
!LF! !LF!
after O
randomization O
, O
l O
- O
t4 O
was O
discontinued O
in O
hypothyroid O
( O
hypo O
) O
group O
and O
continued O
in O
rhtsh O
group O
. O
!LF! !LF!
a O
measure O
of O
3 O
. O
7 O
gbq O
of O
radioiodine O
was O
given O
to O
both O
groups O
. O
!LF! !LF!
the O
functional O
assessment O
of O
chronic O
illness O
therapy O
- O
fatigue O
( O
facit O
- O
f O
) O
was O
administered O
from O
the O
early O
postoperative O
period O
to O
9 O
months O
. O
!LF! !LF!
socio O
- O
demographic O
parameters O
, O
anxiety O
and O
depression O
scales O
were O
also O
evaluated O
( O
ces O
- O
d O
, O
bdi O
and O
spielberger O
state O
- O
trait O
questionnaires O
) O
. O
!LF! !LF!
at O
9 O
months O
, O
patients O
underwent O
an O
rhtsh O
stimulation O
test O
, O
diagnostic O
( O
131 O
) O
i O
whole O
body O
scan O
( O
dxwbs O
) O
and O
neck O
ultrasonography O
. O
!LF! !LF!
a O
total O
of O
74 O
patients O
were O
enrolled O
for O
the O
study O
. O
!LF! !LF!
there B-Premise
was I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
qol I-Premise
from I-Premise
baseline I-Premise
( I-Premise
t0 I-Premise
) I-Premise
to I-Premise
t1 I-Premise
( I-Premise
rra I-Premise
period I-Premise
) I-Premise
in I-Premise
the I-Premise
hypothyroid I-Premise
group I-Premise
with I-Premise
significant I-Premise
differences I-Premise
in I-Premise
facit I-Premise
- I-Premise
f I-Premise
toi I-Premise
( I-Premise
p I-Premise
< I-Premise
10 I-Premise
( I-Premise
- I-Premise
3 I-Premise
) I-Premise
) I-Premise
, I-Premise
fact I-Premise
- I-Premise
g I-Premise
total I-Premise
score I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
005 I-Premise
) I-Premise
and I-Premise
facit I-Premise
- I-Premise
f I-Premise
total I-Premise
score I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
003 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
by B-Premise
contrast I-Premise
, I-Premise
qol I-Premise
was I-Premise
preserved I-Premise
in I-Premise
the I-Premise
rhtsh I-Premise
group I-Premise
. I-Premise
!LF! !LF!
in O
the O
multivariate O
analysis O
, O
facit O
- O
toi O
changes O
were O
only O
affected O
by O
the O
modality O
of O
tsh O
stimulation O
performed O
for O
rra O
. O
!LF! !LF!
from B-Premise
3 I-Premise
to I-Premise
9 I-Premise
months I-Premise
, I-Premise
changes I-Premise
of I-Premise
qol I-Premise
scales I-Premise
and I-Premise
subscales I-Premise
were I-Premise
no I-Premise
longer I-Premise
statistically I-Premise
different I-Premise
in I-Premise
both I-Premise
groups I-Premise
of I-Premise
patients I-Premise
. I-Premise
!LF! !LF!
based B-Premise
on I-Premise
serum I-Premise
rhtsh I-Premise
- I-Premise
stimulated I-Premise
tg I-Premise
alone I-Premise
( I-Premise
tg I-Premise
< I-Premise
0 I-Premise
. I-Premise
8 I-Premise
microg I-Premise
/ I-Premise
l I-Premise
, I-Premise
brahms I-Premise
tg I-Premise
kryptor I-Premise
) I-Premise
, I-Premise
no I-Premise
difference I-Premise
in I-Premise
ablation I-Premise
success I-Premise
was I-Premise
observed I-Premise
between I-Premise
rhtsh I-Premise
and I-Premise
hypothyroidism I-Premise
groups I-Premise
, I-Premise
91 I-Premise
. I-Premise
7 I-Premise
% I-Premise
and I-Premise
97 I-Premise
. I-Premise
1 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
a B-Premise
higher I-Premise
rate I-Premise
of I-Premise
persistent I-Premise
thyroid I-Premise
remnants I-Premise
was I-Premise
observed I-Premise
in I-Premise
the I-Premise
rhtsh I-Premise
arm I-Premise
, I-Premise
although B-Premise
in I-Premise
most I-Premise
cases I-Premise
uptake I-Premise
was I-Premise
< I-Premise
0 I-Premise
. I-Premise
1 I-Premise
% I-Premise
and I-Premise
of I-Premise
no I-Premise
clinical I-Premise
significance I-Premise
. I-Premise
!LF! !LF!
rhtsh B-Claim
preserves I-Claim
qol I-Claim
of I-Claim
patients I-Claim
undergoing I-Claim
rra I-Claim
with I-Claim
similar I-Claim
rates I-Claim
of I-Claim
ablation I-Claim
success I-Claim
compared I-Claim
to I-Claim
hypothyrodism I-Claim
. I-Claim
!LF! !LF!
however O
, O
there O
is O
a O
wide O
heterogeneity O
in O
the O
clinical O
impact O
of O
hypothyroidism O
. O
!LF! !LF!
chemotherapy O
- O
induced O
anemia O
( O
cia O
) O
is O
responsive O
to O
treatment O
with O
erythropoiesis O
- O
stimulating O
agents O
( O
esas O
) O
such O
as O
darbepoetin O
alfa O
. O
!LF! !LF!
administration O
of O
esas O
on O
a O
synchronous O
schedule O
with O
chemotherapy O
administration O
could O
benefit O
patients O
by O
reducing O
clinic O
visits O
and O
potentially O
enhancing O
on O
- O
time O
chemotherapy O
delivery O
. O
!LF! !LF!
this O
phase O
2 O
, O
25 O
- O
week O
, O
open O
- O
label O
study O
evaluated O
the O
noninferiority O
of O
darbepoetin O
alfa O
administered O
weekly O
vs O
. O
as O
an O
extended O
dosing O
schedule O
( O
every O
2 O
or O
3 O
weeks O
) O
in O
patients O
with O
cia O
. O
!LF! !LF!
patients O
were O
randomized O
1 O
: O
1 O
to O
an O
extended O
dosing O
schedule O
( O
eds O
: O
darbepoetin O
alfa O
300 O
μg O
q2w O
if O
chemotherapy O
was O
qw O
, O
q2w O
, O
or O
q4w O
or O
darbepoetin O
alfa O
500 O
μg O
q3w O
if O
chemotherapy O
was O
q3w O
) O
or O
weekly O
( O
150 O
μg O
qw O
regardless O
of O
chemotherapy O
schedule O
) O
. O
!LF! !LF!
stratification O
factors O
included O
chemotherapy O
cycle O
length O
, O
screening O
hemoglobin O
( O
< O
10 O
g O
/ O
dl O
vs O
. O
≥10 O
g O
/ O
dl O
) O
, O
and O
tumor O
type O
( O
lung O
/ O
gynecological O
vs O
. O
other O
nonmyeloid O
malignancies O
) O
. O
!LF! !LF!
the O
primary O
endpoint O
was O
change O
in O
hemoglobin O
from O
baseline O
to O
week O
13 O
. O
!LF! !LF!
seven O
hundred O
fifty O
- O
two O
patients O
( O
374 O
qw O
patients O
"""" O
; O
"""" O
378 O
eds O
patients O
) O
received O
≥1 O
dose O
of O
darbepoetin O
alfa O
and O
were O
included O
in O
the O
analysis O
. O
!LF! !LF!
demographics O
and O
disease O
state O
were O
similar O
between O
groups O
. O
!LF! !LF!
seventy B-Premise
- B-Premise
one B-Premise
percent I-Premise
of I-Premise
patients I-Premise
in I-Premise
the I-Premise
eds I-Premise
group I-Premise
and I-Premise
76 I-Premise
% I-Premise
in I-Premise
the I-Premise
qw I-Premise
group I-Premise
achieved I-Premise
the I-Premise
target I-Premise
hemoglobin I-Premise
of I-Premise
≥11 I-Premise
. I-Premise
0 I-Premise
g I-Premise
/ I-Premise
dl I-Premise
. I-Premise
!LF! !LF!
there O
was O
a O
minimal O
difference O
in O
the O
primary O
endpoint O
of O
mean O
change O
in O
hemoglobin O
( O
baseline O
to O
week O
13 O
) O
between O
the O
qw O
and O
the O
eds O
groups O
( O
- O
0 O
. O
04 O
g O
/ O
dl O
"""" O
; O
"""" O
95 O
% O
confidence O
interval O
: O
- O
0 O
. O
26 O
, O
0 O
. O
17 O
g O
/ O
dl O
) O
. O
!LF! !LF!
the O
upper O
limit O
of O
the O
95 O
% O
confidence O
interval O
was O
less O
than O
the O
prespecified O
limit O
of O
< O
0 O
. O
75 O
g O
/ O
dl O
, O
supporting O
noninferiority O
of O
the O
eds O
dosing O
schedule O
. O
!LF! !LF!
reported B-Premise
adverse I-Premise
events I-Premise
were I-Premise
similar I-Premise
between I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
a B-Premise
slight I-Premise
increase I-Premise
in I-Premise
transfusions I-Premise
was I-Premise
reported I-Premise
in I-Premise
the I-Premise
qw I-Premise
group I-Premise
. I-Premise
!LF! !LF!
darbepoetin B-Claim
alfa I-Claim
, I-Claim
when I-Claim
administered I-Claim
synchronously I-Claim
with I-Claim
chemotherapy I-Claim
, I-Claim
on I-Claim
an I-Claim
eds I-Claim
appears I-Claim
to I-Claim
be I-Claim
similarly I-Claim
efficacious I-Claim
to I-Claim
darbepoetin I-Claim
alfa I-Claim
weekly I-Claim
dosing I-Claim
with I-Claim
no I-Claim
unexpected I-Claim
adverse I-Claim
events I-Claim
. I-Claim
!LF! !LF!
this O
study O
provides O
prospective O
data O
on O
how O
multiple O
dosing O
regimens O
available O
with O
darbepoetin O
alfa O
can O
be O
synchronized O
with O
chemotherapy O
administered O
across O
a O
range O
of O
dosing O
schedules O
. O
!LF! !LF!
this O
randomized O
phase O
ii O
trial O
evaluated O
two O
docetaxel O
- O
based O
regimens O
to O
see O
which O
would O
be O
most O
promising O
according O
to O
overall O
response O
rate O
( O
orr O
) O
for O
comparison O
in O
a O
phase O
iii O
trial O
with O
epirubicin O
- O
cisplatin O
- O
fluorouracil O
( O
ecf O
) O
as O
first O
- O
line O
advanced O
gastric O
cancer O
therapy O
. O
!LF! !LF!
chemotherapy O
- O
naive O
patients O
with O
measurable O
unresectable O
and O
/ O
or O
metastatic O
gastric O
carcinoma O
, O
a O
performance O
status O
< O
or O
= O
1 O
, O
and O
adequate O
hematologic O
, O
hepatic O
, O
and O
renal O
function O
randomly O
received O
< O
or O
= O
eight O
3 O
- O
weekly O
cycles O
of O
ecf O
( O
epirubicin O
50 O
mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
, O
cisplatin O
60 O
mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
, O
and O
fluorouracil O
[ O
fu O
] O
200 O
mg O
/ O
m O
( O
2 O
) O
/ O
d O
on O
days O
1 O
to O
21 O
) O
, O
tc O
( O
docetaxel O
initially O
85 O
mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
[ O
later O
reduced O
to O
75 O
mg O
/ O
m O
( O
2 O
) O
as O
a O
result O
of O
toxicity O
] O
and O
cisplatin O
75 O
mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
) O
, O
or O
tcf O
( O
tc O
plus O
fu O
300 O
mg O
/ O
m O
( O
2 O
) O
/ O
d O
on O
days O
1 O
to O
14 O
) O
. O
!LF! !LF!
study O
objectives O
included O
response O
( O
primary O
) O
, O
survival O
, O
toxicity O
, O
and O
quality O
of O
life O
( O
qol O
) O
. O
!LF! !LF!
orr B-Premise
was I-Premise
25 I-Premise
. I-Premise
0 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
13 I-Premise
% I-Premise
to I-Premise
41 I-Premise
% I-Premise
) I-Premise
for I-Premise
ecf I-Premise
, I-Premise
18 I-Premise
. I-Premise
5 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
9 I-Premise
% I-Premise
to I-Premise
34 I-Premise
% I-Premise
) I-Premise
for I-Premise
tc I-Premise
, I-Premise
and I-Premise
36 I-Premise
. I-Premise
6 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
23 I-Premise
% I-Premise
to I-Premise
53 I-Premise
% I-Premise
) I-Premise
for I-Premise
tcf I-Premise
( I-Premise
n I-Premise
= I-Premise
119 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
median B-Premise
overall I-Premise
survival I-Premise
times I-Premise
were I-Premise
8 I-Premise
. I-Premise
3 I-Premise
, I-Premise
11 I-Premise
. I-Premise
0 I-Premise
, I-Premise
and I-Premise
10 I-Premise
. I-Premise
4 I-Premise
months I-Premise
for I-Premise
ecf I-Premise
, I-Premise
tc I-Premise
, I-Premise
and I-Premise
tcf I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
toxicity B-Premise
was I-Premise
acceptable I-Premise
, I-Premise
with I-Premise
one I-Premise
toxic I-Premise
death I-Premise
( I-Premise
tc I-Premise
arm I-Premise
) I-Premise
. I-Premise
!LF! !LF!
grade B-Premise
3 I-Premise
or I-Premise
4 I-Premise
neutropenia I-Premise
occurred I-Premise
in I-Premise
more I-Premise
treatment I-Premise
cycles I-Premise
with I-Premise
docetaxel I-Premise
( I-Premise
tc I-Premise
, I-Premise
49 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
tcf I-Premise
, I-Premise
57 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
ecf I-Premise
, I-Premise
34 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
global B-Claim
health I-Claim
status I-Claim
/ I-Claim
qol I-Claim
substantially I-Claim
improved I-Claim
with I-Claim
ecf I-Claim
and I-Claim
remained I-Claim
similar I-Claim
to I-Claim
baseline I-Claim
with I-Claim
both I-Claim
docetaxel I-Claim
regimens I-Claim
. I-Claim
!LF! !LF!
time B-Premise
to I-Premise
response I-Premise
and I-Premise
orr I-Premise
favor I-Premise
tcf I-Premise
over I-Premise
tc I-Premise
for I-Premise
further I-Premise
evaluation I-Premise
, I-Premise
particularly I-Premise
in I-Premise
the I-Premise
neoadjuvant I-Premise
setting I-Premise
. I-Premise
!LF! !LF!
a B-Premise
trend I-Premise
towards I-Premise
increased I-Premise
myelosuppression I-Premise
and I-Premise
infectious I-Premise
complications I-Premise
with I-Premise
tcf I-Premise
versus I-Premise
tc I-Premise
or I-Premise
ecf I-Premise
was I-Premise
observed I-Premise
. I-Premise
!LF! !LF!
increased O
attention O
has O
focused O
on O
exercise O
as O
a O
quality O
of O
life O
intervention O
for O
breast O
cancer O
survivors O
during O
and O
after O
adjuvant O
therapy O
. O
!LF! !LF!
our O
objective O
was O
to O
examine O
the O
effects O
of O
an O
oncologist O
' O
s O
recommendation O
to O
exercise O
on O
self O
- O
reported O
exercise O
behavior O
in O
newly O
diagnosed O
breast O
cancer O
survivors O
attending O
their O
first O
adjuvant O
therapy O
consultation O
. O
!LF! !LF!
using O
a O
single O
- O
blinded O
, O
3 O
- O
armed O
, O
randomized O
controlled O
trial O
, O
450 O
breast O
cancer O
survivors O
were O
randomly O
assigned O
to O
receive O
an O
oncologist O
exercise O
recommendation O
only O
, O
an O
oncologist O
exercise O
recommendation O
plus O
referral O
to O
an O
exercise O
specialist O
, O
or O
usual O
care O
. O
!LF! !LF!
the O
primary O
outcome O
was O
self O
- O
reported O
total O
exercise O
( O
in O
metabolic O
equivalent O
[ O
met O
] O
hours O
per O
week O
) O
at O
5 O
weeks O
postconsultation O
. O
!LF! !LF!
the O
follow O
- O
up O
assessment O
rate O
was O
73 O
% O
( O
329 O
of O
450 O
) O
. O
!LF! !LF!
intention B-Premise
- B-Premise
to B-Premise
- B-Premise
treat B-Premise
analysis I-Premise
based I-Premise
on I-Premise
participants I-Premise
with I-Premise
follow I-Premise
- I-Premise
up I-Premise
data I-Premise
indicated I-Premise
a I-Premise
significant I-Premise
difference I-Premise
in I-Premise
total I-Premise
exercise I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
recommendation I-Premise
- I-Premise
only I-Premise
group I-Premise
over I-Premise
the I-Premise
usual I-Premise
care I-Premise
group I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
3 I-Premise
. I-Premise
4 I-Premise
met I-Premise
hr I-Premise
per I-Premise
week I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
ci I-Premise
] I-Premise
, I-Premise
0 I-Premise
. I-Premise
7 I-Premise
- I-Premise
6 I-Premise
. I-Premise
1 I-Premise
met I-Premise
hr I-Premise
per I-Premise
week I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
011 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
there B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
recommendation I-Premise
- I-Premise
plus I-Premise
- I-Premise
referral I-Premise
group I-Premise
and I-Premise
the I-Premise
usual I-Premise
care I-Premise
group I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
1 I-Premise
. I-Premise
5 I-Premise
met I-Premise
hr I-Premise
per I-Premise
week I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
- I-Premise
1 I-Premise
. I-Premise
0 I-Premise
to I-Premise
4 I-Premise
. I-Premise
0 I-Premise
met I-Premise
hr I-Premise
per I-Premise
week I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
244 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
ancillary B-Premise
"""" I-Premise
on I-Premise
- I-Premise
treatment I-Premise
"""" I-Premise
analyzes I-Premise
showed I-Premise
that I-Premise
participants I-Premise
who I-Premise
recalled I-Premise
an I-Premise
exercise I-Premise
recommendation I-Premise
reported I-Premise
significantly I-Premise
more I-Premise
total I-Premise
exercise I-Premise
than I-Premise
participants I-Premise
who I-Premise
did I-Premise
not I-Premise
recall I-Premise
an I-Premise
exercise I-Premise
recommendation I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
4 I-Premise
. I-Premise
1 I-Premise
met I-Premise
hr I-Premise
per I-Premise
week I-Premise
: I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
1 I-Premise
. I-Premise
9 I-Premise
- I-Premise
6 I-Premise
. I-Premise
4 I-Premise
met I-Premise
hr I-Premise
per I-Premise
week I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
our B-Claim
findings I-Claim
suggest I-Claim
that I-Claim
an I-Claim
oncologist I-Claim
recommendation I-Claim
may I-Claim
increase I-Claim
exercise I-Claim
behavior I-Claim
in I-Claim
newly I-Claim
diagnosed I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
, I-Claim
particularly I-Claim
if I-Claim
it I-Claim
is I-Claim
recalled I-Claim
1 I-Claim
week I-Claim
after I-Claim
the I-Claim
recommendation I-Claim
. I-Claim
!LF! !LF!
research O
has O
shown O
that O
self O
- O
directed O
stress O
management O
training O
improves O
mental O
well O
- O
being O
in O
patients O
undergoing O
chemotherapy O
. O
!LF! !LF!
the O
present O
study O
extends O
this O
work O
by O
evaluating O
separate O
and O
combined O
effects O
of O
stress O
management O
training O
and O
home O
- O
based O
exercise O
. O
!LF! !LF!
following O
assessment O
of O
mental O
and O
physical O
well O
- O
being O
, O
depression O
, O
anxiety O
, O
exercise O
, O
and O
stress O
reduction O
activity O
before O
chemotherapy O
started O
, O
patients O
were O
randomized O
to O
stress O
management O
training O
( O
sm O
) O
, O
exercise O
( O
ex O
) O
, O
combined O
stress O
management O
and O
exercise O
( O
smex O
) O
, O
or O
usual O
care O
only O
( O
uco O
) O
. O
!LF! !LF!
outcomes O
were O
reassessed O
6 O
and O
12 O
weeks O
after O
chemotherapy O
started O
. O
!LF! !LF!
significance O
testing O
of O
group O
- O
by O
- O
time O
interactions O
in O
286 O
patients O
who O
completed O
all O
assessments O
was O
used O
to O
evaluate O
intervention O
efficacy O
. O
!LF! !LF!
interaction B-Premise
effects I-Premise
for I-Premise
mental I-Premise
and I-Premise
physical I-Premise
well I-Premise
- I-Premise
being I-Premise
scores I-Premise
were I-Premise
not I-Premise
significant I-Premise
. I-Premise
!LF! !LF!
depression B-Premise
scores I-Premise
yielded I-Premise
a I-Premise
linear I-Premise
interaction I-Premise
comparing I-Premise
uco I-Premise
and I-Premise
smex I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
019 I-Premise
) I-Premise
, I-Premise
with I-Premise
decreases I-Premise
in I-Premise
smex I-Premise
but I-Premise
not I-Premise
uco I-Premise
. I-Premise
!LF! !LF!
anxiety B-Premise
scores I-Premise
yielded I-Premise
a I-Premise
quadratic I-Premise
interaction I-Premise
comparing I-Premise
uco I-Premise
and I-Premise
smex I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
049 I-Premise
) I-Premise
, I-Premise
with I-Premise
trends I-Premise
for I-Premise
changes I-Premise
in I-Premise
smex I-Premise
but I-Premise
not I-Premise
uco I-Premise
. I-Premise
!LF! !LF!
additional B-Premise
analyses I-Premise
yielded I-Premise
quadratic I-Premise
interactions I-Premise
for I-Premise
exercise I-Premise
activity I-Premise
comparing I-Premise
uco I-Premise
and I-Premise
smex I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
022 I-Premise
) I-Premise
, I-Premise
with I-Premise
positive I-Premise
changes I-Premise
in I-Premise
smex I-Premise
but I-Premise
not I-Premise
uco I-Premise
, I-Premise
and I-Premise
for I-Premise
stress I-Premise
management I-Premise
activity I-Premise
comparing I-Premise
uco I-Premise
and I-Premise
sm I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
and I-Premise
uco I-Premise
and I-Premise
smex I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
013 I-Premise
) I-Premise
, I-Premise
with I-Premise
positive I-Premise
changes I-Premise
in I-Premise
sm I-Premise
and I-Premise
smex I-Premise
but I-Premise
not I-Premise
uco I-Premise
. I-Premise
!LF! !LF!
only B-Claim
the I-Claim
combined I-Claim
intervention I-Claim
yielded I-Claim
effects I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
outcomes I-Claim
, I-Claim
and I-Claim
these I-Claim
were I-Claim
limited I-Claim
to I-Claim
anxiety I-Claim
and I-Claim
depression I-Claim
. I-Claim
!LF! !LF!
these B-Premise
findings I-Premise
are I-Premise
consistent I-Premise
with I-Premise
evidence I-Premise
that I-Premise
only I-Premise
the I-Premise
combined I-Premise
intervention I-Premise
yielded I-Premise
increases I-Premise
in I-Premise
both I-Premise
exercise I-Premise
and I-Premise
stress I-Premise
management I-Premise
activity I-Premise
. I-Premise
!LF! !LF!
future O
research O
should O
investigate O
ways O
to O
augment O
this O
intervention O
to O
enhance O
its O
benefits O
. O
!LF! !LF!
to O
determine O
the O
long O
- O
term O
outcome O
and O
health O
- O
related O
quality O
of O
life O
( O
hrql O
) O
of O
patients O
with O
endometrial O
carcinoma O
( O
ec O
) O
treated O
with O
or O
without O
pelvic O
radiotherapy O
in O
the O
post O
operative O
radiation O
therapy O
in O
endometrial O
carcinoma O
1 O
( O
portec O
- O
1 O
) O
trial O
. O
!LF! !LF!
between O
1990 O
and O
1997 O
, O
714 O
patients O
with O
stage O
ic O
grade O
1 O
to O
2 O
or O
ib O
grade O
2 O
to O
3 O
ec O
were O
randomly O
allocated O
to O
pelvic O
external O
- O
beam O
radiotherapy O
( O
ebrt O
) O
or O
no O
additional O
treatment O
( O
nat O
) O
. O
!LF! !LF!
hrql O
was O
evaluated O
with O
the O
short O
form O
36 O
- O
item O
( O
sf O
- O
36 O
) O
questionnaire O
"""" O
; O
"""" O
subscales O
from O
the O
european O
organisation O
for O
research O
and O
treatment O
of O
cancer O
( O
eortc O
) O
pr25 O
module O
for O
bowel O
and O
bladder O
symptoms O
and O
the O
ov28 O
and O
cx24 O
modules O
for O
sexual O
symptoms O
"""" O
; O
"""" O
and O
demographic O
questions O
. O
!LF! !LF!
analysis O
was O
by O
intention O
- O
to O
- O
treat O
. O
!LF! !LF!
median O
follow O
- O
up O
was O
13 O
. O
3 O
years O
. O
!LF! !LF!
the B-Premise
15 I-Premise
- I-Premise
year I-Premise
actuarial I-Premise
locoregional I-Premise
recurrence I-Premise
rates I-Premise
were I-Premise
5 I-Premise
. I-Premise
8 I-Premise
% I-Premise
for I-Premise
ebrt I-Premise
versus I-Premise
15 I-Premise
. I-Premise
5 I-Premise
% I-Premise
for I-Premise
nat I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
and I-Premise
15 I-Premise
- I-Premise
year I-Premise
overall I-Premise
survival I-Premise
was I-Premise
52 I-Premise
% I-Premise
versus I-Premise
60 I-Premise
% I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
14 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
of O
the O
351 O
patients O
confirmed O
to O
be O
alive O
with O
correct O
address O
, O
246 O
( O
70 O
% O
) O
returned O
the O
questionnaire O
. O
!LF! !LF!
patients B-Premise
treated I-Premise
with I-Premise
ebrt I-Premise
reported I-Premise
significant I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
01 I-Premise
) I-Premise
and I-Premise
clinically I-Premise
relevant I-Premise
higher I-Premise
rates I-Premise
of I-Premise
urinary I-Premise
incontinence I-Premise
, I-Premise
diarrhea I-Premise
, I-Premise
and I-Premise
fecal I-Premise
leakage I-Premise
leading I-Premise
to I-Premise
more I-Premise
limitations I-Premise
in I-Premise
daily I-Premise
activities I-Premise
. I-Premise
!LF! !LF!
increased B-Premise
symptoms I-Premise
were I-Premise
reflected I-Premise
by I-Premise
the I-Premise
frequent I-Premise
use I-Premise
of I-Premise
incontinence I-Premise
materials I-Premise
after I-Premise
ebrt I-Premise
( I-Premise
day I-Premise
and I-Premise
night I-Premise
use I-Premise
, I-Premise
42 I-Premise
. I-Premise
9 I-Premise
% I-Premise
v I-Premise
15 I-Premise
. I-Premise
2 I-Premise
% I-Premise
for I-Premise
nat I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
treated I-Premise
with I-Premise
ebrt I-Premise
reported I-Premise
lower I-Premise
scores I-Premise
on I-Premise
the I-Premise
sf I-Premise
- I-Premise
36 I-Premise
scales I-Premise
"""" I-Premise
physical I-Premise
functioning I-Premise
"""" I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
004 I-Premise
) I-Premise
and I-Premise
"""" I-Premise
role I-Premise
- I-Premise
physical I-Premise
"""" I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
003 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
ebrt B-Claim
for I-Claim
endometrial I-Claim
cancer I-Claim
is I-Claim
associated I-Claim
with I-Claim
long I-Claim
- I-Claim
term I-Claim
urinary I-Claim
and I-Claim
bowel I-Claim
symptoms I-Claim
and I-Claim
lower I-Claim
physical I-Claim
and I-Claim
role I-Claim
- I-Claim
physical I-Claim
functioning I-Claim
, I-Claim
even I-Claim
15 I-Claim
years I-Claim
after I-Claim
treatment I-Claim
. I-Claim
!LF! !LF!
despite B-Claim
its I-Claim
efficacy I-Claim
in I-Claim
reducing I-Claim
locoregional I-Claim
recurrence I-Claim
, I-Claim
ebrt I-Claim
should I-Claim
be I-Claim
avoided I-Claim
in I-Claim
patients I-Claim
with I-Claim
low I-Claim
- I-Claim
and I-Claim
intermediate I-Claim
- I-Claim
risk I-Claim
ec I-Claim
. I-Claim
!LF! !LF!
the O
impact O
of O
psychotherapeutic O
support O
on O
survival O
for O
patients O
with O
gastrointestinal O
cancer O
undergoing O
surgery O
was O
studied O
. O
!LF! !LF!
a O
randomized O
controlled O
trial O
was O
conducted O
in O
cooperation O
with O
the O
departments O
of O
general O
surgery O
and O
medical O
psychology O
, O
university O
hospital O
of O
hamburg O
, O
germany O
, O
from O
january O
1991 O
to O
january O
1993 O
. O
!LF! !LF!
consenting O
patients O
( O
n O
= O
271 O
) O
with O
a O
preliminary O
diagnosis O
of O
cancer O
of O
the O
esophagus O
, O
stomach O
, O
liver O
/ O
gallbladder O
, O
pancreas O
, O
or O
colon O
/ O
rectum O
were O
stratified O
by O
sex O
and O
randomly O
assigned O
to O
a O
control O
group O
that O
received O
standard O
care O
as O
provided O
on O
the O
surgical O
wards O
, O
or O
to O
an O
experimental O
group O
that O
received O
formal O
psychotherapeutic O
support O
in O
addition O
to O
routine O
care O
during O
the O
hospital O
stay O
. O
!LF! !LF!
from O
june O
2003 O
to O
december O
2003 O
, O
the O
10 O
- O
year O
follow O
- O
up O
was O
conducted O
. O
!LF! !LF!
survival O
status O
for O
all O
patients O
was O
determined O
from O
our O
own O
records O
and O
from O
three O
external O
sources O
: O
the O
hamburg O
cancer O
registry O
, O
family O
doctors O
, O
and O
the O
general O
citizen O
registration O
offices O
. O
!LF! !LF!
kaplan B-Premise
- B-Premise
meier B-Premise
survival I-Premise
curves I-Premise
demonstrated I-Premise
better I-Premise
survival I-Premise
for I-Premise
the I-Premise
experimental I-Premise
group I-Premise
than I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise
!LF! !LF!
the B-Premise
unadjusted I-Premise
significance I-Premise
level I-Premise
for I-Premise
group I-Premise
differences I-Premise
was I-Premise
p I-Premise
= I-Premise
. I-Premise
0006 I-Premise
for I-Premise
survival I-Premise
to I-Premise
10 I-Premise
years I-Premise
. I-Premise
!LF! !LF!
cox B-Premise
regression I-Premise
models I-Premise
that I-Premise
took I-Premise
tnm I-Premise
staging I-Premise
or I-Premise
the I-Premise
residual I-Premise
tumor I-Premise
classification I-Premise
and I-Premise
tumor I-Premise
site I-Premise
into I-Premise
account I-Premise
also I-Premise
found I-Premise
significant I-Premise
differences I-Premise
at I-Premise
10 I-Premise
years I-Premise
. I-Premise
!LF! !LF!
secondary B-Premise
analyses I-Premise
found I-Premise
that I-Premise
differences I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
experimental I-Premise
group I-Premise
occurred I-Premise
in I-Premise
patients I-Premise
with I-Premise
stomach I-Premise
, I-Premise
pancreatic I-Premise
, I-Premise
primary I-Premise
liver I-Premise
, I-Premise
or I-Premise
colorectal I-Premise
cancer I-Premise
. I-Premise
!LF! !LF!
the B-Claim
results I-Claim
of I-Claim
this I-Claim
study I-Claim
indicate I-Claim
that I-Claim
patients I-Claim
with I-Claim
gastrointestinal I-Claim
cancer I-Claim
, I-Claim
who I-Claim
undergo I-Claim
surgery I-Claim
for I-Claim
stomach I-Claim
, I-Claim
pancreatic I-Claim
, I-Claim
primary I-Claim
liver I-Claim
, I-Claim
or I-Claim
colorectal I-Claim
cancer I-Claim
, I-Claim
benefit I-Claim
from I-Claim
a I-Claim
formal I-Claim
program I-Claim
of I-Claim
psychotherapeutic I-Claim
support I-Claim
during I-Claim
the I-Claim
inpatient I-Claim
hospital I-Claim
stay I-Claim
in I-Claim
terms I-Claim
of I-Claim
long I-Claim
- I-Claim
term I-Claim
survival I-Claim
. I-Claim
!LF! !LF!
compared O
with O
placebo O
, O
prophylactic O
treatment O
with O
bisphosphonates O
reduces O
risk O
of O
skeletal O
events O
in O
patients O
with O
multiple O
myeloma O
. O
!LF! !LF!
however O
, O
because O
of O
toxicity O
associated O
with O
long O
- O
term O
bisphosphonate O
treatment O
, O
establishing O
the O
lowest O
effective O
dose O
is O
important O
. O
!LF! !LF!
this O
study O
compared O
the O
effect O
of O
two O
doses O
of O
pamidronate O
on O
health O
- O
related O
quality O
of O
life O
and O
skeletal O
morbidity O
in O
patients O
with O
newly O
diagnosed O
multiple O
myeloma O
. O
!LF! !LF!
this O
double O
- O
blind O
, O
randomised O
, O
phase O
3 O
trial O
was O
undertaken O
at O
37 O
clinics O
in O
denmark O
, O
norway O
, O
and O
sweden O
. O
!LF! !LF!
patients O
with O
multiple O
myeloma O
who O
were O
starting O
antimyeloma O
treatment O
were O
randomly O
assigned O
in O
a O
1 O
: O
1 O
ratio O
to O
receive O
one O
of O
two O
doses O
of O
pamidronate O
( O
30 O
mg O
or O
90 O
mg O
) O
given O
by O
intravenous O
infusion O
once O
a O
month O
for O
at O
least O
3 O
years O
. O
!LF! !LF!
randomisation O
was O
done O
by O
use O
of O
a O
central O
, O
computerised O
minimisation O
system O
. O
!LF! !LF!
primary O
outcome O
was O
physical O
function O
after O
12 O
months O
estimated O
by O
the O
european O
organisation O
for O
research O
and O
treatment O
of O
cancer O
( O
eortc O
) O
qlq O
- O
c30 O
questionnaire O
( O
scale O
0 O
- O
100 O
) O
. O
!LF! !LF!
all O
patients O
who O
returned O
questionnaires O
at O
12 O
months O
and O
were O
still O
on O
study O
treatment O
were O
included O
in O
the O
analysis O
of O
the O
primary O
endpoint O
. O
!LF! !LF!
from O
january O
, O
2001 O
, O
until O
august O
, O
2005 O
, O
504 O
patients O
were O
randomly O
assigned O
to O
pamidronate O
30 O
mg O
or O
90 O
mg O
( O
252 O
in O
each O
group O
) O
. O
!LF! !LF!
157 O
patients O
in O
the O
90 O
mg O
group O
and O
156 O
in O
the O
30 O
mg O
group O
were O
included O
in O
the O
primary O
analysis O
. O
!LF! !LF!
mean B-Premise
physical I-Premise
function I-Premise
at I-Premise
12 I-Premise
months I-Premise
was I-Premise
66 I-Premise
points I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
62 I-Premise
· I-Premise
9 I-Premise
- I-Premise
70 I-Premise
· I-Premise
0 I-Premise
) I-Premise
in I-Premise
the I-Premise
90 I-Premise
mg I-Premise
group I-Premise
and I-Premise
68 I-Premise
points I-Premise
( I-Premise
64 I-Premise
· I-Premise
6 I-Premise
- I-Premise
71 I-Premise
· I-Premise
4 I-Premise
) I-Premise
in I-Premise
the I-Premise
30 I-Premise
mg I-Premise
group I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
of I-Premise
difference I-Premise
- I-Premise
6 I-Premise
· I-Premise
6 I-Premise
to I-Premise
3 I-Premise
· I-Premise
3 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
· I-Premise
52 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
median B-Premise
time I-Premise
to I-Premise
first I-Premise
skeletal I-Premise
- I-Premise
related I-Premise
event I-Premise
in I-Premise
patients I-Premise
who I-Premise
had I-Premise
such I-Premise
an I-Premise
event I-Premise
was I-Premise
9 I-Premise
· I-Premise
2 I-Premise
months I-Premise
( I-Premise
8 I-Premise
· I-Premise
1 I-Premise
- I-Premise
10 I-Premise
· I-Premise
7 I-Premise
) I-Premise
in I-Premise
the I-Premise
90 I-Premise
mg I-Premise
group I-Premise
and I-Premise
10 I-Premise
· I-Premise
2 I-Premise
months I-Premise
( I-Premise
7 I-Premise
· I-Premise
3 I-Premise
- I-Premise
14 I-Premise
· I-Premise
0 I-Premise
) I-Premise
in I-Premise
the I-Premise
30 I-Premise
mg I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
· I-Premise
63 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
in O
a O
retrospective O
analysis O
, O
eight B-Premise
patients I-Premise
in I-Premise
the I-Premise
pamidronate I-Premise
90 I-Premise
mg I-Premise
group I-Premise
developed I-Premise
osteonecrosis I-Premise
of I-Premise
the I-Premise
jaw I-Premise
compared I-Premise
with I-Premise
two I-Premise
patients I-Premise
in I-Premise
the I-Premise
30 I-Premise
mg I-Premise
group I-Premise
. I-Premise
!LF! !LF!
monthly B-Claim
infusion I-Claim
of I-Claim
pamidronate I-Claim
30 I-Claim
mg I-Claim
should I-Claim
be I-Claim
the I-Claim
recommended I-Claim
dose I-Claim
for I-Claim
prevention I-Claim
of I-Claim
bone I-Claim
disease I-Claim
in I-Claim
patients I-Claim
with I-Claim
multiple I-Claim
myeloma I-Claim
. I-Claim
!LF! !LF!
bone B-Claim
metastases I-Claim
are I-Claim
a I-Claim
common I-Claim
cause I-Claim
of I-Claim
morbidity I-Claim
in I-Claim
patients I-Claim
with I-Claim
prostate I-Claim
carcinoma I-Claim
. I-Claim
!LF! !LF!
we O
studied O
the O
effect O
of O
a O
new O
bisphosphonate O
, O
zoledronic O
acid O
, O
which O
blocks O
bone O
destruction O
, O
on O
skeletal O
complications O
in O
prostate O
cancer O
patients O
with O
bone O
metastases O
. O
!LF! !LF!
patients O
with O
hormone O
- O
refractory O
prostate O
cancer O
and O
a O
history O
of O
bone O
metastases O
were O
randomly O
assigned O
to O
a O
double O
- O
blind O
treatment O
regimen O
of O
intravenous O
zoledronic O
acid O
at O
4 O
mg O
( O
n O
= O
214 O
) O
, O
zoledronic O
acid O
at O
8 O
mg O
( O
subsequently O
reduced O
to O
4 O
mg O
"""" O
; O
"""" O
8 O
/ O
4 O
) O
( O
n O
= O
221 O
) O
, O
or O
placebo O
( O
n O
= O
208 O
) O
every O
3 O
weeks O
for O
15 O
months O
. O
!LF! !LF!
proportions O
of O
patients O
with O
skeletal O
- O
related O
events O
, O
time O
to O
the O
first O
skeletal O
- O
related O
event O
, O
skeletal O
morbidity O
rate O
, O
pain O
and O
analgesic O
scores O
, O
disease O
progression O
, O
and O
safety O
were O
assessed O
. O
!LF! !LF!
all O
statistical O
tests O
were O
two O
- O
sided O
. O
!LF! !LF!
approximately O
38 O
% O
of O
patients O
who O
received O
zoledronic O
acid O
at O
4 O
mg O
, O
28 O
% O
who O
received O
zoledronic O
acid O
at O
8 O
/ O
4 O
mg O
, O
and O
31 O
% O
who O
received O
placebo O
completed O
the O
study O
. O
!LF! !LF!
a B-Premise
greater I-Premise
proportion I-Premise
of I-Premise
patients I-Premise
who I-Premise
received I-Premise
placebo I-Premise
had I-Premise
skeletal I-Premise
- I-Premise
related I-Premise
events I-Premise
than I-Premise
those I-Premise
who I-Premise
received I-Premise
zoledronic I-Premise
acid I-Premise
at I-Premise
4 I-Premise
mg I-Premise
( I-Premise
44 I-Premise
. I-Premise
2 I-Premise
% I-Premise
versus I-Premise
33 I-Premise
. I-Premise
2 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
difference I-Premise
= I-Premise
- I-Premise
11 I-Premise
. I-Premise
0 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
ci I-Premise
] I-Premise
= I-Premise
- I-Premise
20 I-Premise
. I-Premise
3 I-Premise
% I-Premise
to I-Premise
- I-Premise
1 I-Premise
. I-Premise
8 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
021 I-Premise
) I-Premise
or I-Premise
those I-Premise
who I-Premise
received I-Premise
zoledronic I-Premise
acid I-Premise
at I-Premise
8 I-Premise
/ I-Premise
4 I-Premise
mg I-Premise
( I-Premise
38 I-Premise
. I-Premise
5 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
difference I-Premise
versus I-Premise
placebo I-Premise
= I-Premise
- I-Premise
5 I-Premise
. I-Premise
8 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
- I-Premise
15 I-Premise
. I-Premise
1 I-Premise
% I-Premise
to I-Premise
3 I-Premise
. I-Premise
6 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
222 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
median B-Premise
time I-Premise
to I-Premise
first I-Premise
skeletal I-Premise
- I-Premise
related I-Premise
event I-Premise
was I-Premise
321 I-Premise
days I-Premise
for I-Premise
patients I-Premise
who I-Premise
received I-Premise
placebo I-Premise
, I-Premise
was I-Premise
not I-Premise
reached I-Premise
for I-Premise
patients I-Premise
who I-Premise
received I-Premise
zoledronic I-Premise
acid I-Premise
at I-Premise
4 I-Premise
mg I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
011 I-Premise
versus I-Premise
placebo I-Premise
) I-Premise
, I-Premise
and I-Premise
was I-Premise
363 I-Premise
days I-Premise
for I-Premise
those I-Premise
who I-Premise
received I-Premise
zoledronic I-Premise
acid I-Premise
at I-Premise
8 I-Premise
/ I-Premise
4 I-Premise
mg I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
491 I-Premise
versus I-Premise
placebo I-Premise
) I-Premise
. I-Premise
!LF! !LF!
compared B-Premise
with I-Premise
urinary I-Premise
markers I-Premise
in I-Premise
patients I-Premise
who I-Premise
received I-Premise
placebo I-Premise
, I-Premise
urinary I-Premise
markers I-Premise
of I-Premise
bone I-Premise
resorption I-Premise
were I-Premise
statistically I-Premise
significantly I-Premise
decreased I-Premise
in I-Premise
patients I-Premise
who I-Premise
received I-Premise
zoledronic I-Premise
acid I-Premise
at I-Premise
either I-Premise
dose I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
pain B-Premise
and I-Premise
analgesic I-Premise
scores I-Premise
increased I-Premise
more I-Premise
in I-Premise
patients I-Premise
who I-Premise
received I-Premise
placebo I-Premise
than I-Premise
in I-Premise
patients I-Premise
who I-Premise
received I-Premise
zoledronic I-Premise
acid I-Premise
, I-Premise
but O
there B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
disease I-Premise
progression I-Premise
, I-Premise
performance I-Premise
status I-Premise
, I-Premise
or I-Premise
quality I-Premise
- I-Premise
of I-Premise
- I-Premise
life I-Premise
scores I-Premise
among I-Premise
the I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
zoledronic B-Claim
acid I-Claim
at I-Claim
4 I-Claim
mg I-Claim
given I-Claim
as I-Claim
a I-Claim
15 I-Claim
- I-Claim
minute I-Claim
infusion I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
, I-Claim
but O
the B-Claim
8 I-Claim
- I-Claim
mg I-Claim
dose I-Claim
was I-Claim
associated I-Claim
with I-Claim
renal I-Claim
function I-Claim
deterioration I-Claim
. I-Claim
!LF! !LF!
zoledronic B-Claim
acid I-Claim
at I-Claim
4 I-Claim
mg I-Claim
reduced I-Claim
skeletal I-Claim
- I-Claim
related I-Claim
events I-Claim
in I-Claim
prostate I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
bone I-Claim
metastases I-Claim
. I-Claim
!LF! !LF!
for O
patients O
undergoing O
oncologic O
surgery O
, O
the O
quality O
of O
life O
( O
qol O
) O
is O
generally O
accepted O
as O
an O
important O
outcome O
parameter O
in O
addition O
to O
long O
- O
term O
survival O
, O
mortality O
and O
complication O
rates O
. O
!LF! !LF!
this O
study O
focussed O
on O
the O
qol O
in O
patients O
after O
oesophagectomy O
for O
cancer O
, O
comparing O
the O
method O
of O
reconstruction O
( O
narrow O
gastric O
tube O
vs O
whole O
stomach O
) O
. O
!LF! !LF!
in O
a O
prospective O
randomised O
single O
- O
centre O
study O
from O
2007 O
to O
2008 O
, O
104 O
patients O
underwent O
oesophagectomy O
for O
cancer O
. O
!LF! !LF!
to O
assess O
the O
qol O
, O
a O
questionnaire O
in O
reference O
to O
the O
eortc O
- O
qlq O
- O
c30 O
and O
the O
qlq O
- O
oes24 O
was O
administered O
at O
3 O
weeks O
, O
6 O
months O
and O
1 O
year O
after O
surgery O
. O
!LF! !LF!
clinical O
data O
were O
collected O
prospectively O
, O
and O
follow O
- O
up O
was O
performed O
regularly O
. O
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
narrow I-Premise
gastric I-Premise
tube I-Premise
group I-Premise
( I-Premise
ngt I-Premise
group I-Premise
, I-Premise
n I-Premise
= I-Premise
52 I-Premise
) I-Premise
and I-Premise
the I-Premise
whole I-Premise
- I-Premise
stomach I-Premise
group I-Premise
( I-Premise
ws I-Premise
group I-Premise
, I-Premise
n I-Premise
= I-Premise
52 I-Premise
) I-Premise
with I-Premise
regard I-Premise
to I-Premise
patient I-Premise
and I-Premise
cancer I-Premise
characteristics I-Premise
, I-Premise
operative I-Premise
procedure I-Premise
, I-Premise
postoperative I-Premise
intensive I-Premise
care I-Premise
unit I-Premise
( I-Premise
icu I-Premise
) I-Premise
hospitalisation I-Premise
, I-Premise
and I-Premise
overall I-Premise
survival I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise
!LF! !LF!
regarding B-Premise
the I-Premise
postoperative I-Premise
complication I-Premise
, I-Premise
there I-Premise
were I-Premise
more I-Premise
cases I-Premise
of I-Premise
postoperative I-Premise
reflux I-Premise
oesophagitis I-Premise
and I-Premise
impairment I-Premise
of I-Premise
pulmonary I-Premise
function I-Premise
in I-Premise
the I-Premise
ws I-Premise
group I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
regarding B-Premise
the I-Premise
qol I-Premise
investigation I-Premise
, I-Premise
the I-Premise
scores I-Premise
of I-Premise
qol I-Premise
dropped I-Premise
for I-Premise
all I-Premise
patients I-Premise
at I-Premise
3 I-Premise
weeks I-Premise
after I-Premise
surgery I-Premise
. I-Premise
!LF! !LF!
slowly O
, O
recovery B-Premise
was I-Premise
found I-Premise
at I-Premise
both I-Premise
6 I-Premise
months I-Premise
and I-Premise
1 I-Premise
year I-Premise
in I-Premise
both I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
in I-Premise
the I-Premise
ngt I-Premise
group I-Premise
reported I-Premise
significantly I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
better I-Premise
scores I-Premise
of I-Premise
qol I-Premise
at I-Premise
both I-Premise
6 I-Premise
months I-Premise
and I-Premise
1 I-Premise
year I-Premise
. I-Premise
!LF! !LF!
patients B-Claim
who I-Claim
underwent I-Claim
gastric I-Claim
tube I-Claim
reconstruction I-Claim
develop I-Claim
less I-Claim
postoperative I-Claim
digestive I-Claim
tract I-Claim
complications I-Claim
, I-Claim
and I-Claim
have I-Claim
a I-Claim
quicker I-Claim
recovery I-Claim
and I-Claim
a I-Claim
better I-Claim
qol I-Claim
during I-Claim
the I-Claim
follow I-Claim
- I-Claim
up I-Claim
period I-Claim
. I-Claim
!LF! !LF!
further O
investigation O
and O
data O
collection O
will O
allow O
the O
assessment O
of O
this O
procedure O
beyond O
1 O
year O
after O
operation O
. O
!LF! !LF!
to O
carry O
out O
a O
preliminary O
trial O
evaluating O
the O
effectiveness O
of O
two O
types O
of O
homeopathy O
for O
the O
treatment O
of O
menopausal O
symptoms O
in O
breast O
cancer O
survivors O
. O
!LF! !LF!
randomized O
, O
double O
- O
blinded O
, O
placebo O
- O
controlled O
. O
!LF! !LF!
private O
medical O
clinic O
, O
seattle O
, O
wa O
. O
!LF! !LF!
women O
with O
a O
history O
of O
breast O
cancer O
who O
had O
completed O
all O
surgery O
, O
chemotherapy O
, O
and O
radiation O
treatment O
and O
who O
had O
an O
average O
of O
at O
least O
three O
hot O
flashes O
per O
day O
for O
the O
previous O
month O
. O
!LF! !LF!
subjects O
were O
randomized O
to O
receive O
either O
an O
individualized O
homeopathic O
single O
remedy O
, O
a O
homeopathic O
combination O
medicine O
, O
or O
placebo O
. O
!LF! !LF!
patients O
were O
seen O
by O
homeopathic O
providers O
every O
2 O
months O
for O
1 O
year O
. O
!LF! !LF!
hot O
flash O
frequency O
and O
severity O
, O
kupperman O
menopausal O
index O
( O
kmi O
) O
, O
short O
form O
36 O
( O
sf O
- O
36 O
) O
. O
!LF! !LF!
there B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
found I-Premise
in I-Premise
the I-Premise
primary I-Premise
outcome I-Premise
measure I-Premise
, I-Premise
the I-Premise
hot I-Premise
flash I-Premise
severity I-Premise
score I-Premise
, I-Premise
although B-Premise
there I-Premise
was I-Premise
a I-Premise
positive I-Premise
trend I-Premise
in I-Premise
the I-Premise
single I-Premise
remedy I-Premise
group I-Premise
during I-Premise
the I-Premise
first I-Premise
3 I-Premise
months I-Premise
of I-Premise
the I-Premise
study I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
1 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
a B-Premise
statistically I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
general I-Premise
health I-Premise
score I-Premise
in I-Premise
both I-Premise
homeopathy I-Premise
groups I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
on I-Premise
the I-Premise
sf I-Premise
- I-Premise
36 I-Premise
after I-Premise
1 I-Premise
year I-Premise
was I-Premise
found I-Premise
. I-Premise
!LF! !LF!
evidence B-Premise
of I-Premise
a I-Premise
homeopathic I-Premise
"""" I-Premise
drug I-Premise
proving I-Premise
"""" I-Premise
in I-Premise
the I-Premise
subjects I-Premise
receiving I-Premise
the I-Premise
homeopathic I-Premise
combination I-Premise
medicine I-Premise
who I-Premise
were I-Premise
not I-Premise
taking I-Premise
tamoxifen I-Premise
also I-Premise
was I-Premise
found I-Premise
. I-Premise
!LF! !LF!
small B-Claim
sample I-Claim
size I-Claim
precludes I-Claim
definitive I-Claim
answers I-Claim
, I-Claim
but B-Claim
results I-Claim
from I-Claim
this I-Claim
preliminary I-Claim
trial I-Claim
suggest I-Claim
that I-Claim
homeopathy I-Claim
may I-Claim
be I-Claim
of I-Claim
value I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
menopausal I-Claim
symptoms I-Claim
and I-Claim
improving I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
especially I-Claim
in I-Claim
those I-Claim
women I-Claim
not I-Claim
on I-Claim
tamoxifen I-Claim
. I-Claim
!LF! !LF!
larger B-Claim
studies I-Claim
should I-Claim
be I-Claim
carried I-Claim
out I-Claim
that I-Claim
also I-Claim
include I-Claim
healthy I-Claim
women I-Claim
who I-Claim
want I-Claim
to I-Claim
avoid I-Claim
hormone I-Claim
replacement I-Claim
therapy I-Claim
. I-Claim
!LF! !LF!
increased B-Claim
expression I-Claim
of I-Claim
metalloproteinases I-Claim
is I-Claim
associated I-Claim
with I-Claim
poor I-Claim
prognosis I-Claim
in I-Claim
small I-Claim
- I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
sclc I-Claim
) I-Claim
. I-Claim
!LF! !LF!
this O
trial O
was O
undertaken O
to O
determine O
whether O
adjuvant O
treatment O
with O
the O
metalloproteinase O
inhibitor O
marimastat O
could O
prolong O
survival O
in O
responding O
patients O
with O
sclc O
after O
chemotherapy O
. O
!LF! !LF!
sclc O
patients O
in O
complete O
or O
partial O
remission O
were O
eligible O
. O
!LF! !LF!
they O
were O
stratified O
by O
radiotherapy O
( O
early O
, O
late O
, O
or O
none O
) O
, O
stage O
( O
extensive O
or O
limited O
) O
, O
response O
( O
complete O
or O
partial O
) O
, O
and O
cooperative O
group O
( O
national O
cancer O
institute O
of O
canada O
- O
clinical O
trials O
group O
or O
european O
organization O
for O
research O
and O
treatment O
of O
cancer O
) O
. O
!LF! !LF!
they O
were O
randomized O
to O
receive O
marimastat O
10 O
mg O
or O
placebo O
orally O
bid O
for O
up O
to O
2 O
years O
. O
!LF! !LF!
there O
were O
532 O
eligible O
patients O
( O
266 O
marimastat O
and O
266 O
placebo O
) O
. O
!LF! !LF!
stage O
was O
limited O
for O
279 O
patients O
( O
52 O
% O
) O
and O
extensive O
for O
253 O
( O
48 O
% O
) O
. O
!LF! !LF!
best B-Premise
response I-Premise
to I-Premise
induction I-Premise
therapy I-Premise
was I-Premise
complete I-Premise
remission I-Premise
for I-Premise
176 I-Premise
patients I-Premise
( I-Premise
33 I-Premise
% I-Premise
) I-Premise
, I-Premise
partial I-Premise
remission I-Premise
for I-Premise
341 I-Premise
( I-Premise
64 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
15 I-Premise
patients I-Premise
( I-Premise
3 I-Premise
% I-Premise
) I-Premise
had I-Premise
undergone I-Premise
surgical I-Premise
resection I-Premise
. I-Premise
!LF! !LF!
the B-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
for I-Premise
marimastat I-Premise
patients I-Premise
was I-Premise
4 I-Premise
. I-Premise
3 I-Premise
months I-Premise
compared I-Premise
with I-Premise
4 I-Premise
. I-Premise
4 I-Premise
months I-Premise
for I-Premise
placebo I-Premise
patients I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
81 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
median B-Premise
survivals I-Premise
for I-Premise
marimastat I-Premise
and I-Premise
placebo I-Premise
patients I-Premise
were I-Premise
9 I-Premise
. I-Premise
3 I-Premise
months I-Premise
and I-Premise
9 I-Premise
. I-Premise
7 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
90 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
toxicity B-Premise
was I-Premise
generally I-Premise
limited I-Premise
to I-Premise
musculoskeletal I-Premise
symptoms I-Premise
( I-Premise
18 I-Premise
% I-Premise
grade I-Premise
3 I-Premise
/ I-Premise
4 I-Premise
for I-Premise
marimastat I-Premise
) I-Premise
. I-Premise
!LF! !LF!
dose B-Premise
modifications I-Premise
for I-Premise
musculoskeletal I-Premise
toxicity I-Premise
were I-Premise
required I-Premise
in I-Premise
90 I-Premise
patients I-Premise
( I-Premise
33 I-Premise
% I-Premise
) I-Premise
on I-Premise
the I-Premise
marimastat I-Premise
arm I-Premise
, I-Premise
and I-Premise
87 I-Premise
( I-Premise
32 I-Premise
% I-Premise
) I-Premise
permanently I-Premise
stopped I-Premise
marimastat I-Premise
because I-Premise
of I-Premise
toxicity I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
on I-Premise
marimastat I-Premise
had I-Premise
significantly I-Premise
poorer I-Premise
quality I-Premise
of I-Premise
life I-Premise
at I-Premise
3 I-Premise
and I-Premise
6 I-Premise
months I-Premise
. I-Premise
!LF! !LF!
treatment B-Claim
with I-Claim
marimastat I-Claim
after I-Claim
induction I-Claim
therapy I-Claim
for I-Claim
sclc I-Claim
did I-Claim
not I-Claim
result I-Claim
in I-Claim
improved I-Claim
survival I-Claim
and I-Claim
had I-Claim
a I-Claim
negative I-Claim
impact I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim
!LF! !LF!
morbidity B-Claim
associated I-Claim
with I-Claim
wound I-Claim
complications I-Claim
may I-Claim
translate I-Claim
into I-Claim
disability I-Claim
and I-Claim
quality I-Claim
- I-Claim
of I-Claim
- I-Claim
life I-Claim
disadvantages I-Claim
for I-Claim
patients I-Claim
treated I-Claim
with I-Claim
radiotherapy I-Claim
( I-Claim
rt I-Claim
) I-Claim
for I-Claim
soft I-Claim
tissue I-Claim
sarcoma I-Claim
( I-Claim
sts I-Claim
) I-Claim
of I-Claim
the I-Claim
extremities I-Claim
. I-Claim
!LF! !LF!
functional O
outcome O
and O
health O
status O
of O
extremity O
sts O
patients O
randomized O
in O
a O
phase O
iii O
trial O
comparing O
preoperative O
versus O
postoperative O
rt O
is O
described O
. O
!LF! !LF!
one O
hundred O
ninety O
patients O
with O
extremity O
sts O
were O
randomized O
after O
stratification O
by O
tumor O
size O
dichotomized O
at O
10 O
cm O
. O
!LF! !LF!
function O
and O
quality O
of O
life O
were O
measured O
by O
the O
musculoskeletal O
tumor O
society O
rating O
scale O
( O
msts O
) O
, O
the O
toronto O
extremity O
salvage O
score O
( O
tess O
) O
, O
and O
the O
short O
form O
- O
36 O
( O
sf O
- O
36 O
) O
at O
randomization O
, O
6 O
weeks O
, O
and O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
months O
after O
surgery O
. O
!LF! !LF!
one O
hundred O
eighty O
- O
five O
patients O
had O
function O
data O
. O
!LF! !LF!
patients B-Premise
treated I-Premise
with I-Premise
postoperative I-Premise
rt I-Premise
had I-Premise
better I-Premise
function I-Premise
with I-Premise
higher I-Premise
msts I-Premise
( I-Premise
25 I-Premise
. I-Premise
8 I-Premise
v I-Premise
21 I-Premise
. I-Premise
3 I-Premise
, I-Premise
p I-Premise
< I-Premise
. I-Premise
01 I-Premise
) I-Premise
, I-Premise
tess I-Premise
( I-Premise
69 I-Premise
. I-Premise
8 I-Premise
v I-Premise
60 I-Premise
. I-Premise
6 I-Premise
, I-Premise
p I-Premise
= I-Premise
. I-Premise
01 I-Premise
) I-Premise
, I-Premise
and I-Premise
sf I-Premise
- I-Premise
36 I-Premise
bodily I-Premise
pain I-Premise
( I-Premise
67 I-Premise
. I-Premise
7 I-Premise
v I-Premise
58 I-Premise
. I-Premise
5 I-Premise
, I-Premise
p I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
scores I-Premise
at I-Premise
6 I-Premise
weeks I-Premise
after I-Premise
surgery I-Premise
. I-Premise
!LF! !LF!
there O
were O
no O
differences O
at O
later O
time O
points O
. O
!LF! !LF!
scores B-Premise
on I-Premise
the I-Premise
physical I-Premise
function I-Premise
, I-Premise
role I-Premise
- I-Premise
physical I-Premise
, I-Premise
and I-Premise
general I-Premise
health I-Premise
subscales I-Premise
of I-Premise
the I-Premise
sf I-Premise
- I-Premise
36 I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
than I-Premise
canadian I-Premise
normative I-Premise
data I-Premise
at I-Premise
all I-Premise
time I-Premise
points I-Premise
. I-Premise
!LF! !LF!
after O
treatment O
arm O
was O
controlled O
for O
, O
msts O
change O
scores O
were O
predicted O
by O
a O
lower O
- O
extremity O
tumor O
, O
a O
large O
resection O
specimen O
, O
and O
motor O
nerve O
sacrifice O
"""" O
; O
"""" O
tess O
change O
scores O
were O
predicted O
by O
lower O
- O
extremity O
tumor O
and O
prior O
incomplete O
excision O
. O
!LF! !LF!
when B-Premise
wound I-Premise
complication I-Premise
was I-Premise
included I-Premise
in I-Premise
the I-Premise
model I-Premise
, I-Premise
patients I-Premise
with I-Premise
complications I-Premise
had I-Premise
lower I-Premise
msts I-Premise
and I-Premise
tess I-Premise
scores I-Premise
in I-Premise
the I-Premise
first I-Premise
2 I-Premise
years I-Premise
after I-Premise
treatment I-Premise
. I-Premise
!LF! !LF!
the B-Claim
timing I-Claim
of I-Claim
rt I-Claim
has I-Claim
minimal I-Claim
impact I-Claim
on I-Claim
the I-Claim
function I-Claim
of I-Claim
sts I-Claim
patients I-Claim
in I-Claim
the I-Claim
first I-Claim
year I-Claim
after I-Claim
surgery I-Claim
. O
!LF! !LF!
tumor B-Claim
characteristics I-Claim
and I-Claim
wound I-Claim
complications I-Claim
have I-Claim
a I-Claim
detrimental I-Claim
effect I-Claim
on I-Claim
patient I-Claim
function I-Claim
. I-Claim
!LF! !LF!
this O
randomized O
controlled O
trial O
assessed O
the O
effect O
of O
a O
smart O
( O
stress O
management O
and O
resiliency O
training O
) O
program O
among O
25 O
women O
diagnosed O
with O
breast O
cancer O
. O
!LF! !LF!
resilience O
, O
perceived O
stress O
, O
anxiety O
, O
and O
quality O
of O
life O
improved O
at O
12 O
weeks O
in O
the O
active O
but O
not O
the O
control O
arm O
. O
!LF! !LF!
a O
brief O
training O
in O
the O
smart O
program O
can O
enhance O
resilience O
and O
quality O
of O
life O
and O
decrease O
stress O
and O
anxiety O
. O
!LF! !LF!
patients O
with O
breast O
cancer O
experience O
stress O
and O
anxiety O
related O
to O
their O
diagnosis O
, O
with O
resulting O
lower O
quality O
of O
life O
. O
!LF! !LF!
the O
purpose O
of O
this O
study O
was O
to O
assess O
the O
effect O
of O
a O
smart O
( O
stress O
management O
and O
resiliency O
training O
) O
program O
for O
increasing O
resiliency O
and O
for O
decreasing O
stress O
and O
anxiety O
among O
mentors O
who O
themselves O
were O
previously O
diagnosed O
with O
breast O
cancer O
. O
!LF! !LF!
the O
program O
consisted O
of O
two O
90 O
- O
minute O
group O
training O
sessions O
, O
a O
brief O
individual O
session O
, O
and O
3 O
follow O
- O
up O
telephone O
calls O
. O
!LF! !LF!
twenty O
- O
four O
mentors O
at O
mayo O
clinic O
in O
rochester O
, O
minnesota O
, O
were O
randomized O
in O
a O
single O
- O
blind O
, O
wait O
- O
list O
controlled O
clinical O
trial O
to O
either O
the O
smart O
intervention O
or O
a O
control O
group O
for O
12 O
weeks O
. O
!LF! !LF!
primary O
outcome O
measures O
assessed O
at O
baseline O
and O
at O
week O
12 O
included O
the O
connor O
davidson O
resilience O
scale O
, O
perceived O
stress O
scale O
, O
smith O
anxiety O
scale O
, O
and O
linear O
analog O
self O
assessment O
scale O
. O
!LF! !LF!
twenty O
patients O
completed O
the O
study O
. O
!LF! !LF!
a B-Premise
statistically I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
resilience I-Premise
, I-Premise
perceived I-Premise
stress I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
and I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
at I-Premise
12 I-Premise
weeks I-Premise
, I-Premise
compared I-Premise
with I-Premise
baseline I-Premise
was I-Premise
observed I-Premise
in I-Premise
the I-Premise
study I-Premise
arm I-Premise
. I-Premise
!LF! !LF!
no B-Premise
significant I-Premise
difference I-Premise
in I-Premise
any I-Premise
of I-Premise
these I-Premise
measures I-Premise
was I-Premise
noted I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise
!LF! !LF!
this B-Claim
study I-Claim
demonstrates I-Claim
that I-Claim
a I-Claim
brief I-Claim
, I-Claim
predominantly I-Claim
group I-Claim
- I-Claim
based I-Claim
resilience I-Claim
training I-Claim
intervention I-Claim
is I-Claim
feasible I-Claim
in I-Claim
patients I-Claim
with I-Claim
previous I-Claim
breast I-Claim
cancer I-Claim
"""" I-Claim
; I-Claim
"""" I-Claim
also I-Claim
, I-Claim
it I-Claim
may I-Claim
be I-Claim
efficacious I-Claim
. I-Claim
!LF! !LF!
both O
gemcitabine O
( O
gem O
) O
and O
fluoropyrimidines O
are O
valuable O
treatment O
for O
advanced O
pancreatic O
cancer O
. O
!LF! !LF!
this O
open O
- O
label O
study O
was O
designed O
to O
compare O
the O
overall O
survival O
( O
os O
) O
of O
patients O
randomly O
assigned O
to O
gem O
alone O
or O
gem O
plus O
capecitabine O
( O
gem O
- O
cap O
) O
. O
!LF! !LF!
patients O
with O
previously O
untreated O
histologically O
or O
cytologically O
proven O
locally O
advanced O
or O
metastatic O
carcinoma O
of O
the O
pancreas O
with O
a O
performance O
status O
< O
or O
= O
2 O
were O
recruited O
. O
!LF! !LF!
patients O
were O
randomly O
assigned O
to O
gem O
or O
gem O
- O
cap O
. O
!LF! !LF!
the O
primary O
outcome O
measure O
was O
survival O
. O
!LF! !LF!
meta O
- O
analysis O
of O
published O
studies O
was O
also O
conducted O
. O
!LF! !LF!
between O
may O
2002 O
and O
january O
2005 O
, O
533 O
patients O
were O
randomly O
assigned O
to O
gem O
( O
n O
= O
266 O
) O
and O
gem O
- O
cap O
( O
n O
= O
267 O
) O
arms O
. O
!LF! !LF!
gem B-Premise
- B-Premise
cap B-Premise
significantly I-Premise
improved I-Premise
objective I-Premise
response I-Premise
rate I-Premise
( I-Premise
19 I-Premise
. I-Premise
1 I-Premise
% I-Premise
v I-Premise
12 I-Premise
. I-Premise
4 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
034 I-Premise
) I-Premise
and I-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
hr I-Premise
] I-Premise
, I-Premise
0 I-Premise
. I-Premise
78 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
66 I-Premise
to I-Premise
0 I-Premise
. I-Premise
93 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
004 I-Premise
) I-Premise
and I-Premise
was I-Premise
associated I-Premise
with I-Premise
a I-Premise
trend I-Premise
toward I-Premise
improved I-Premise
os I-Premise
( I-Premise
hr I-Premise
, I-Premise
0 I-Premise
. I-Premise
86 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
72 I-Premise
to I-Premise
1 I-Premise
. I-Premise
02 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
08 I-Premise
) I-Premise
compared I-Premise
with I-Premise
gem I-Premise
alone I-Premise
. I-Premise
!LF! !LF!
this B-Premise
trend I-Premise
for I-Premise
os I-Premise
benefit I-Premise
for I-Premise
gem I-Premise
- I-Premise
cap I-Premise
was I-Premise
consistent I-Premise
across I-Premise
different I-Premise
prognostic I-Premise
subgroups I-Premise
according I-Premise
to I-Premise
baseline I-Premise
stratification I-Premise
factors I-Premise
( I-Premise
stage I-Premise
and I-Premise
performance I-Premise
status I-Premise
) I-Premise
and I-Premise
remained I-Premise
after I-Premise
adjusting I-Premise
for I-Premise
these I-Premise
stratification I-Premise
factors I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
077 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
moreover O
, O
the B-Premise
meta I-Premise
- I-Premise
analysis I-Premise
of I-Premise
two I-Premise
additional I-Premise
studies I-Premise
involving I-Premise
935 I-Premise
patients I-Premise
showed I-Premise
a I-Premise
significant I-Premise
survival I-Premise
benefit I-Premise
in I-Premise
favor I-Premise
of I-Premise
gem I-Premise
- I-Premise
cap I-Premise
( I-Premise
hr I-Premise
, I-Premise
0 I-Premise
. I-Premise
86 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
75 I-Premise
to I-Premise
0 I-Premise
. I-Premise
98 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
02 I-Premise
) I-Premise
with I-Premise
no I-Premise
intertrial I-Premise
heterogeneity I-Premise
. I-Premise
!LF! !LF!
on B-Claim
the I-Claim
basis I-Claim
of I-Claim
our I-Claim
trial I-Claim
and I-Claim
the I-Claim
meta I-Claim
- I-Claim
analysis I-Claim
, I-Claim
gem I-Claim
- I-Claim
cap I-Claim
should I-Claim
be I-Claim
considered I-Claim
as I-Claim
one I-Claim
of I-Claim
the I-Claim
standard I-Claim
first I-Claim
- I-Claim
line I-Claim
options I-Claim
in I-Claim
locally I-Claim
advanced I-Claim
and I-Claim
metastatic I-Claim
pancreatic I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
the O
world O
health O
organization O
( O
who O
) O
guidelines O
for O
the O
treatment O
of O
cancer O
pain O
recommend O
nonopioid O
analgesics O
as O
first O
- O
line O
therapy O
, O
so O
- O
called O
"""" O
weak O
"""" O
analgesics O
combined O
with O
nonopioid O
analgesics O
as O
second O
- O
line O
therapy O
, O
and O
so O
- O
called O
"""" O
strong O
"""" O
opioids O
( O
with O
nonopioid O
analgesics O
) O
only O
as O
third O
- O
line O
therapy O
. O
!LF! !LF!
however O
, O
these O
guidelines O
can O
be O
questioned O
with O
regard O
to O
the O
extent O
of O
efficacy O
as O
well O
as O
the O
rationale O
for O
not O
using O
strong O
opioids O
as O
first O
- O
line O
treatment O
, O
especially O
in O
terminal O
cancer O
patients O
. O
!LF! !LF!
the O
purpose O
of O
this O
randomized O
study O
was O
to O
prospectively O
compare O
the O
efficacy O
and O
tolerability O
of O
strong O
opioids O
as O
first O
- O
line O
agents O
with O
the O
recommendations O
of O
the O
who O
in O
terminal O
cancer O
patients O
. O
!LF! !LF!
one O
hundred O
patients O
with O
mild O
- O
moderate O
pain O
were O
randomized O
to O
treatment O
according O
to O
who O
guidelines O
or O
to O
treatment O
with O
strong O
opioids O
. O
!LF! !LF!
evaluated O
outcomes O
included O
pain O
intensity O
, O
need O
for O
change O
in O
therapy O
, O
quality O
of O
life O
, O
karnofsky O
performance O
status O
, O
general O
condition O
of O
the O
patient O
, O
and O
adverse O
events O
. O
!LF! !LF!
no B-Premise
between I-Premise
- I-Premise
treatment I-Premise
differences I-Premise
were I-Premise
observed I-Premise
for I-Premise
changes I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
or I-Premise
performance I-Premise
status I-Premise
, I-Premise
but O
patients B-Premise
started I-Premise
on I-Premise
strong I-Premise
opioids I-Premise
had I-Premise
significantly I-Premise
better I-Premise
pain I-Premise
relief I-Premise
than I-Premise
patients I-Premise
treated I-Premise
according I-Premise
to I-Premise
who I-Premise
guidelines I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
041 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
additionally B-Premise
, I-Premise
patients I-Premise
started I-Premise
on I-Premise
strong I-Premise
opioids I-Premise
required I-Premise
significantly I-Premise
fewer I-Premise
changes I-Premise
in I-Premise
therapy I-Premise
, I-Premise
had I-Premise
greater I-Premise
reduction I-Premise
in I-Premise
pain I-Premise
when I-Premise
a I-Premise
change I-Premise
was I-Premise
initiated I-Premise
, I-Premise
and I-Premise
reported I-Premise
greater I-Premise
satisfaction I-Premise
with I-Premise
treatment I-Premise
than I-Premise
the I-Premise
comparator I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
041 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
strong B-Claim
opioids I-Claim
were I-Claim
safe I-Claim
and I-Claim
well I-Claim
- I-Claim
tolerated I-Claim
, I-Claim
with I-Claim
no I-Claim
development I-Claim
of I-Claim
tolerance I-Claim
or I-Claim
serious I-Claim
adverse I-Claim
events I-Claim
. I-Claim
!LF! !LF!
these B-Claim
data I-Claim
suggest I-Claim
the I-Claim
utility I-Claim
of I-Claim
strong I-Claim
opioids I-Claim
for I-Claim
first I-Claim
- I-Claim
line I-Claim
treatment I-Claim
of I-Claim
pain I-Claim
in I-Claim
patients I-Claim
with I-Claim
terminal I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
it O
is O
not O
clear O
whether O
the O
administration O
of O
radioiodine O
provides O
any O
benefit O
to O
patients O
with O
low O
- O
risk O
thyroid O
cancer O
after O
a O
complete O
surgical O
resection O
. O
!LF! !LF!
the O
administration O
of O
the O
smallest O
possible O
amount O
of O
radioiodine O
would O
improve O
care O
. O
!LF! !LF!
in O
our O
randomized O
, O
phase O
3 O
trial O
, O
we O
compared O
two O
thyrotropin O
- O
stimulation O
methods O
( O
thyroid O
hormone O
withdrawal O
and O
use O
of O
recombinant O
human O
thyrotropin O
) O
and O
two O
radioiodine O
( O
( O
131 O
) O
i O
) O
doses O
( O
i O
. O
e O
. O
, O
administered O
activities O
) O
( O
1 O
. O
1 O
gbq O
and O
3 O
. O
7 O
gbq O
) O
in O
a O
2 O
- O
by O
- O
2 O
design O
. O
!LF! !LF!
inclusion O
criteria O
were O
an O
age O
of O
18 O
years O
or O
older O
"""" O
; O
"""" O
total O
thyroidectomy O
for O
differentiated O
thyroid O
carcinoma O
"""" O
; O
"""" O
tumor O
- O
node O
- O
metastasis O
( O
tnm O
) O
stage O
, O
ascertained O
on O
pathological O
examination O
( O
p O
) O
of O
a O
surgical O
specimen O
, O
of O
pt1 O
( O
with O
tumor O
diameter O
≤1 O
cm O
) O
and O
n1 O
or O
nx O
, O
pt1 O
( O
with O
tumor O
diameter O
> O
1 O
to O
2 O
cm O
) O
and O
any O
n O
stage O
, O
or O
pt2n0 O
"""" O
; O
"""" O
absence O
of O
distant O
metastasis O
"""" O
; O
"""" O
and O
no O
iodine O
contamination O
. O
!LF! !LF!
thyroid O
ablation O
was O
assessed O
8 O
months O
after O
radioiodine O
administration O
by O
neck O
ultrasonography O
and O
measurement O
of O
recombinant O
human O
thyrotropin O
- O
stimulated O
thyroglobulin O
. O
!LF! !LF!
comparisons O
were O
based O
on O
an O
equivalence O
framework O
. O
!LF! !LF!
there O
were O
752 O
patients O
enrolled O
between O
2007 O
and O
2010 O
"""" O
; O
"""" O
92 O
% O
had O
papillary O
cancer O
. O
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
unexpected I-Premise
serious I-Premise
adverse I-Premise
events I-Premise
. I-Premise
!LF! !LF!
in B-Premise
the I-Premise
684 I-Premise
patients I-Premise
with I-Premise
data I-Premise
that I-Premise
could I-Premise
be I-Premise
evaluated I-Premise
, I-Premise
ultrasonography I-Premise
of I-Premise
the I-Premise
neck I-Premise
was I-Premise
normal I-Premise
in I-Premise
652 I-Premise
( I-Premise
95 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
stimulated I-Premise
thyroglobulin I-Premise
level I-Premise
was I-Premise
1 I-Premise
. I-Premise
0 I-Premise
ng I-Premise
per I-Premise
milliliter I-Premise
or I-Premise
less I-Premise
in I-Premise
621 I-Premise
of I-Premise
the I-Premise
652 I-Premise
patients I-Premise
( I-Premise
95 I-Premise
% I-Premise
) I-Premise
without I-Premise
detectable I-Premise
thyroglobulin I-Premise
antibodies I-Premise
. I-Premise
!LF! !LF!
thyroid B-Premise
ablation I-Premise
was I-Premise
complete I-Premise
in I-Premise
631 I-Premise
of I-Premise
the I-Premise
684 I-Premise
patients I-Premise
( I-Premise
92 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
ablation I-Premise
rate I-Premise
was I-Premise
equivalent I-Premise
between I-Premise
the I-Premise
( I-Premise
131 I-Premise
) I-Premise
i I-Premise
doses I-Premise
and I-Premise
between I-Premise
the I-Premise
thyrotropin I-Premise
- I-Premise
stimulation I-Premise
methods I-Premise
. I-Premise
!LF! !LF!
the B-Claim
use I-Claim
of I-Claim
recombinant I-Claim
human I-Claim
thyrotropin I-Claim
and I-Claim
low I-Claim
- I-Claim
dose I-Claim
( I-Claim
1 I-Claim
. I-Claim
1 I-Claim
gbq I-Claim
) I-Claim
postoperative I-Claim
radioiodine I-Claim
ablation I-Claim
may I-Claim
be I-Claim
sufficient I-Claim
for I-Claim
the I-Claim
management I-Claim
of I-Claim
low I-Claim
- I-Claim
risk I-Claim
thyroid I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
the O
aim O
of O
this O
study O
was O
to O
compare O
the O
toxicity O
and O
efficacy O
of O
radiation O
therapy O
( O
rt O
) O
for O
localized O
carcinoma O
of O
the O
prostate O
, O
using O
a O
hypofractionated O
( O
55 O
gy O
/ O
20 O
fractions O
/ O
4 O
weeks O
) O
vs O
. O
a O
conventionally O
fractionated O
( O
64 O
gy O
/ O
32 O
fractions O
/ O
6 O
. O
5 O
weeks O
) O
dose O
schedule O
. O
!LF! !LF!
a O
total O
of O
217 O
patients O
were O
randomized O
to O
either O
the O
hypofractionated O
( O
108 O
patients O
) O
or O
the O
conventional O
( O
109 O
patients O
) O
dose O
schedule O
, O
with O
planning O
with O
two O
- O
dimensional O
( O
2d O
) O
ct O
scan O
planning O
methodology O
in O
the O
majority O
of O
cases O
. O
!LF! !LF!
all O
patients O
were O
followed O
for O
a O
median O
of O
48 O
( O
6 O
- O
108 O
) O
months O
. O
!LF! !LF!
gastrointestinal O
( O
gi O
) O
and O
genitourinary O
( O
gu O
) O
toxicity O
was O
evaluated O
before O
rt O
and O
after O
its O
completion O
using O
modified O
late O
effects O
of O
normal O
tissue O
- O
subjective O
, O
objective O
, O
management O
, O
analytic O
( O
lent O
- O
soma O
) O
scales O
and O
the O
european O
organization O
for O
research O
and O
treatment O
of O
cancer O
sexual O
function O
questionnaire O
. O
!LF! !LF!
efficacy O
of O
rt O
based O
on O
clinical O
, O
radiologic O
, O
and O
prostate O
- O
specific O
antigen O
data O
were O
also O
evaluated O
at O
baseline O
and O
after O
rt O
. O
!LF! !LF!
gastrointestinal B-Premise
and I-Premise
gu I-Premise
toxicity I-Premise
persisted I-Premise
5 I-Premise
years I-Premise
after I-Premise
rt I-Premise
and I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
the I-Premise
two I-Premise
dose I-Premise
schedules I-Premise
other I-Premise
than I-Premise
in I-Premise
regard I-Premise
to I-Premise
urgency I-Premise
of I-Premise
defecation I-Premise
. I-Premise
!LF! !LF!
however B-Premise
, I-Premise
1 I-Premise
- I-Premise
month I-Premise
gi I-Premise
toxicity I-Premise
was I-Premise
not I-Premise
only I-Premise
worse I-Premise
in I-Premise
patients I-Premise
with I-Premise
the I-Premise
hypofractionated I-Premise
rt I-Premise
schedule I-Premise
but I-Premise
also I-Premise
adversely I-Premise
affected I-Premise
daily I-Premise
activities I-Premise
. I-Premise
!LF! !LF!
nadir B-Premise
prostate I-Premise
- I-Premise
specific I-Premise
antigen I-Premise
values I-Premise
occurred I-Premise
at I-Premise
a I-Premise
median I-Premise
of I-Premise
18 I-Premise
. I-Premise
0 I-Premise
( I-Premise
3 I-Premise
. I-Premise
0 I-Premise
- I-Premise
54 I-Premise
. I-Premise
0 I-Premise
) I-Premise
months I-Premise
after I-Premise
rt I-Premise
. I-Premise
!LF! !LF!
a B-Premise
total I-Premise
of I-Premise
76 I-Premise
biochemical I-Premise
relapses I-Premise
, I-Premise
with I-Premise
or I-Premise
without I-Premise
clinical I-Premise
relapses I-Premise
, I-Premise
have I-Premise
occurred I-Premise
since I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
of I-Premise
these I-Premise
, I-Premise
37 I-Premise
were I-Premise
in I-Premise
the I-Premise
hypofractionated I-Premise
and I-Premise
39 I-Premise
in I-Premise
the I-Premise
conventional I-Premise
schedule I-Premise
. I-Premise
!LF! !LF!
the B-Premise
5 I-Premise
- I-Premise
year I-Premise
biochemical I-Premise
+ I-Premise
/ I-Premise
- I-Premise
clinical I-Premise
relapse I-Premise
- I-Premise
free I-Premise
and I-Premise
overall I-Premise
survival I-Premise
was I-Premise
55 I-Premise
. I-Premise
9 I-Premise
% I-Premise
and I-Premise
85 I-Premise
. I-Premise
3 I-Premise
% I-Premise
respectively I-Premise
for I-Premise
all I-Premise
patients I-Premise
, I-Premise
and I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
the I-Premise
two I-Premise
schedules I-Premise
. I-Premise
!LF! !LF!
radiation B-Claim
therapy I-Claim
for I-Claim
prostate I-Claim
carcinoma I-Claim
causes I-Claim
persistent I-Claim
gi I-Claim
toxicity I-Claim
that I-Claim
is I-Claim
largely I-Claim
independent I-Claim
of I-Claim
the I-Claim
two I-Claim
dose I-Claim
schedules I-Claim
. I-Claim
!LF! !LF!
the B-Claim
hypofractionated I-Claim
schedule I-Claim
is I-Claim
equivalent I-Claim
in I-Claim
efficacy I-Claim
to I-Claim
the I-Claim
conventional I-Claim
schedule I-Claim
. I-Claim
!LF! !LF!
to O
assess O
the O
effectiveness O
of O
mindfulness O
- O
based O
stress O
reduction O
( O
mbsr O
) O
for O
mood O
, O
breast O
- O
and O
endocrine O
- O
specific O
quality O
of O
life O
, O
and O
well O
- O
being O
after O
hospital O
treatment O
in O
women O
with O
stage O
0 O
to O
iii O
breast O
cancer O
. O
!LF! !LF!
a O
randomized O
, O
wait O
- O
listed O
, O
controlled O
trial O
was O
carried O
out O
in O
229 O
women O
after O
surgery O
, O
chemotherapy O
, O
and O
radiotherapy O
for O
breast O
cancer O
. O
!LF! !LF!
patients O
were O
randomly O
assigned O
to O
the O
8 O
- O
week O
mbsr O
program O
or O
standard O
care O
. O
!LF! !LF!
profile O
of O
mood O
states O
( O
poms O
"""" O
; O
"""" O
primary O
outcome O
) O
, O
functional O
assessment O
of O
cancer O
therapy O
- O
breast O
( O
fact O
- O
b O
) O
, O
functional O
assessment O
of O
cancer O
therapy O
- O
endocrine O
symptoms O
( O
fact O
- O
es O
) O
scales O
and O
the O
who O
five O
- O
item O
well O
- O
being O
questionnaire O
( O
who O
- O
5 O
) O
evaluated O
mood O
, O
quality O
of O
life O
, O
and O
well O
- O
being O
at O
weeks O
0 O
, O
8 O
, O
and O
12 O
. O
!LF! !LF!
for O
each O
outcome O
measure O
, O
a O
repeated O
- O
measures O
analysis O
of O
variance O
model O
, O
which O
incorporated O
week O
0 O
measurements O
as O
a O
covariate O
, O
was O
used O
to O
compare O
treatment O
groups O
at O
8 O
and O
12 O
weeks O
. O
!LF! !LF!
there B-Premise
were I-Premise
statistically I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
outcome I-Premise
in I-Premise
the I-Premise
experimental I-Premise
group I-Premise
compared I-Premise
with I-Premise
control I-Premise
group I-Premise
at I-Premise
both I-Premise
8 I-Premise
and I-Premise
12 I-Premise
weeks I-Premise
( I-Premise
except I-Premise
as I-Premise
indicated I-Premise
) I-Premise
for I-Premise
poms I-Premise
total I-Premise
mood I-Premise
disturbance I-Premise
( I-Premise
and I-Premise
its I-Premise
subscales I-Premise
of I-Premise
anxiety I-Premise
, I-Premise
depression I-Premise
[ I-Premise
8 I-Premise
weeks I-Premise
only I-Premise
] I-Premise
, I-Premise
anger I-Premise
[ I-Premise
12 I-Premise
weeks I-Premise
only I-Premise
] I-Premise
, I-Premise
vigor I-Premise
, I-Premise
fatigue I-Premise
, I-Premise
and I-Premise
confusion I-Premise
[ I-Premise
8 I-Premise
weeks I-Premise
only I-Premise
] I-Premise
) I-Premise
, I-Premise
fact I-Premise
- I-Premise
b I-Premise
, I-Premise
fact I-Premise
- I-Premise
es I-Premise
, I-Premise
( I-Premise
and I-Premise
functional I-Premise
assessment I-Premise
of I-Premise
cancer I-Premise
therapy I-Premise
subscales I-Premise
of I-Premise
physical I-Premise
, I-Premise
social I-Premise
[ I-Premise
8 I-Premise
weeks I-Premise
only I-Premise
] I-Premise
, I-Premise
emotional I-Premise
, I-Premise
and I-Premise
functional I-Premise
well I-Premise
- I-Premise
being I-Premise
) I-Premise
, I-Premise
and I-Premise
who I-Premise
- I-Premise
5 I-Premise
. I-Premise
!LF! !LF!
msbr B-Premise
improved I-Premise
mood I-Premise
, I-Premise
breast I-Premise
- I-Premise
and I-Premise
endocrine I-Premise
- I-Premise
related I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
and I-Premise
well I-Premise
- I-Premise
being I-Premise
more I-Premise
effectively I-Premise
than I-Premise
standard I-Premise
care I-Premise
in I-Premise
women I-Premise
with I-Premise
stage I-Premise
0 I-Premise
to I-Premise
iii I-Premise
breast I-Premise
cancer I-Premise
, I-Premise
and I-Premise
these I-Premise
results I-Premise
persisted I-Premise
at I-Premise
three I-Premise
months I-Premise
. I-Premise
!LF! !LF!
to B-Claim
our I-Claim
knowledge I-Claim
, I-Claim
this I-Claim
study I-Claim
provided I-Claim
novel I-Claim
evidence I-Claim
that I-Claim
mbsr I-Claim
can I-Claim
help I-Claim
alleviate I-Claim
long I-Claim
- I-Claim
term I-Claim
emotional I-Claim
and I-Claim
physical I-Claim
adverse I-Claim
effects I-Claim
of I-Claim
medical I-Claim
treatments I-Claim
, I-Claim
including I-Claim
endocrine I-Claim
treatments I-Claim
. I-Claim
!LF! !LF!
mbsr B-Claim
is I-Claim
recommended I-Claim
to I-Claim
support I-Claim
survivors I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
this O
trial O
was O
conducted O
to O
determine O
whether O
high O
- O
dose O
fluorouracil O
( O
fu O
) O
given O
as O
a O
weekly O
24 O
- O
hour O
infusion O
is O
more O
active O
than O
bolus O
fu O
+ O
leucovorin O
( O
lv O
) O
, O
and O
whether O
high O
- O
dose O
infusional O
fu O
can O
be O
modulated O
by O
lv O
. O
!LF! !LF!
a O
total O
of O
497 O
patients O
with O
previously O
untreated O
metastatic O
colorectal O
cancer O
were O
randomly O
assigned O
to O
receive O
bolus O
fu O
425 O
mg O
/ O
m2 O
intravenously O
+ O
lv O
20 O
mg O
/ O
m2 O
on O
days O
1 O
to O
5 O
and O
repeated O
on O
day O
28 O
( O
fu O
+ O
lv O
) O
, O
or O
fu O
2600 O
mg O
/ O
m2 O
as O
a O
24 O
- O
hour O
infusion O
alone O
( O
fu24h O
) O
or O
in O
combination O
with O
500 O
mg O
/ O
m2 O
lv O
( O
fu24h O
+ O
lv O
) O
- O
all O
given O
weekly O
x6 O
followed O
by O
a O
2 O
- O
week O
rest O
period O
. O
!LF! !LF!
survival O
was O
the O
major O
study O
end O
point O
. O
!LF! !LF!
with B-Premise
a I-Premise
median I-Premise
follow I-Premise
- I-Premise
up I-Premise
of I-Premise
more I-Premise
than I-Premise
3 I-Premise
years I-Premise
, I-Premise
survival I-Premise
did I-Premise
not I-Premise
differ I-Premise
among I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
( I-Premise
median I-Premise
fu I-Premise
+ I-Premise
lv I-Premise
, I-Premise
11 I-Premise
. I-Premise
1 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
10 I-Premise
. I-Premise
2 I-Premise
to I-Premise
15 I-Premise
. I-Premise
0 I-Premise
months I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
fu24h I-Premise
, I-Premise
13 I-Premise
. I-Premise
0 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
10 I-Premise
. I-Premise
4 I-Premise
to I-Premise
15 I-Premise
. I-Premise
4 I-Premise
months I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
fu24h I-Premise
+ I-Premise
lv I-Premise
, I-Premise
13 I-Premise
. I-Premise
7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
12 I-Premise
. I-Premise
0 I-Premise
to I-Premise
16 I-Premise
. I-Premise
4 I-Premise
months I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
724 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
progression B-Premise
- B-Premise
free B-Premise
survival I-Premise
( I-Premise
pfs I-Premise
) I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
for I-Premise
fu24h I-Premise
+ I-Premise
lv I-Premise
( I-Premise
median I-Premise
fu I-Premise
+ I-Premise
lv I-Premise
, I-Premise
4 I-Premise
. I-Premise
0 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
3 I-Premise
. I-Premise
4 I-Premise
to I-Premise
4 I-Premise
. I-Premise
9 I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
fu24h I-Premise
, I-Premise
4 I-Premise
. I-Premise
1 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
3 I-Premise
. I-Premise
4 I-Premise
to I-Premise
5 I-Premise
. I-Premise
0 I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
fu24h I-Premise
+ I-Premise
lv I-Premise
5 I-Premise
. I-Premise
6 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
4 I-Premise
. I-Premise
4 I-Premise
to I-Premise
6 I-Premise
. I-Premise
7 I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
029 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
response I-Premise
rates I-Premise
in I-Premise
the I-Premise
subgroup I-Premise
of I-Premise
patients I-Premise
with I-Premise
measurable I-Premise
disease I-Premise
were I-Premise
12 I-Premise
% I-Premise
, I-Premise
10 I-Premise
% I-Premise
, I-Premise
and I-Premise
17 I-Premise
% I-Premise
for I-Premise
fu I-Premise
+ I-Premise
lv I-Premise
, I-Premise
fu24h I-Premise
, I-Premise
and I-Premise
fu24h I-Premise
+ I-Premise
lv I-Premise
, I-Premise
respectively I-Premise
( I-Premise
not I-Premise
significant I-Premise
) I-Premise
. I-Premise
!LF! !LF!
occurrence B-Premise
of I-Premise
grade I-Premise
3 I-Premise
and I-Premise
4 I-Premise
diarrhea I-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
fu24h I-Premise
+ I-Premise
lv I-Premise
arm I-Premise
( I-Premise
22 I-Premise
% I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
fu24h I-Premise
( I-Premise
6 I-Premise
% I-Premise
) I-Premise
or I-Premise
fu I-Premise
+ I-Premise
lv I-Premise
( I-Premise
9 I-Premise
% I-Premise
) I-Premise
arms I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
however B-Premise
, I-Premise
stomatitis I-Premise
( I-Premise
11 I-Premise
% I-Premise
in I-Premise
fu I-Premise
+ I-Premise
lv I-Premise
v I-Premise
3 I-Premise
% I-Premise
in I-Premise
fu24h I-Premise
v I-Premise
5 I-Premise
% I-Premise
in I-Premise
fu24h I-Premise
+ I-Premise
lv I-Premise
arms I-Premise
) I-Premise
and I-Premise
hematologic I-Premise
toxicity I-Premise
were I-Premise
higher I-Premise
in I-Premise
the I-Premise
bolus I-Premise
fu I-Premise
+ I-Premise
lv I-Premise
arm I-Premise
. I-Premise
!LF! !LF!
global B-Claim
quality I-Claim
of I-Claim
life I-Claim
did I-Claim
not I-Claim
differ I-Claim
within I-Claim
the I-Claim
three I-Claim
arms I-Claim
. I-Claim
!LF! !LF!
neither B-Claim
fu24h I-Claim
+ I-Claim
lv I-Claim
nor I-Claim
fu24h I-Claim
prolong I-Claim
survival I-Claim
, I-Claim
relative I-Claim
to I-Claim
bolus I-Claim
fu I-Claim
+ I-Claim
lv I-Claim
. I-Claim
!LF! !LF!
leucovorin B-Claim
increases I-Claim
pfs I-Claim
if I-Claim
added I-Claim
to I-Claim
fu24h I-Claim
, I-Claim
but I-Claim
increases I-Claim
toxicity I-Claim
. I-Claim
!LF! !LF!
the O
european O
study O
group O
for O
pancreatic O
cancer O
( O
espac O
- O
1 O
) O
study O
is O
the O
largest O
study O
of O
adjuvant O
treatment O
for O
pancreatic O
ductal O
adenocarcinoma O
to O
date O
and O
confirmed O
a O
survival O
advantage O
for O
adjuvant O
chemotherapy O
but O
not O
for O
chemoradiation O
. O
!LF! !LF!
the O
importance O
of O
parallel O
evaluation O
of O
survival O
and O
quality O
of O
life O
( O
qol O
) O
has O
been O
recognized O
as O
fundamental O
and O
the O
aim O
was O
to O
assess O
qol O
and O
quality O
adjusted O
survival O
. O
!LF! !LF!
a O
longitudinal O
qol O
study O
on O
a O
subset O
of O
espac O
- O
1 O
patients O
who O
prospectively O
completed O
the O
eortc O
qlq O
c O
- O
30 O
questionnaire O
during O
treatment O
and O
follow O
- O
up O
. O
!LF! !LF!
an O
integrated O
quality O
- O
survival O
product O
method O
was O
used O
to O
adjust O
any O
treatment O
effect O
on O
survival O
by O
a O
function O
of O
measured O
qol O
, O
calculated O
over O
a O
restricted O
24 O
- O
month O
- O
period O
( O
qalm O
- O
24 O
) O
. O
!LF! !LF!
three O
hundred O
and O
sixteen O
patients O
completed O
1 O
, O
201 O
questionnaires O
. O
!LF! !LF!
there O
were O
no O
differences O
between O
treatment O
groups O
in O
dimension O
scores O
at O
baseline O
( O
randomization O
) O
. O
!LF! !LF!
for B-Premise
the I-Premise
chemotherapy I-Premise
group I-Premise
, I-Premise
the I-Premise
mean I-Premise
quality I-Premise
adjusted I-Premise
life I-Premise
months I-Premise
over I-Premise
24 I-Premise
months I-Premise
( I-Premise
qalm I-Premise
- I-Premise
24 I-Premise
) I-Premise
was I-Premise
9 I-Premise
. I-Premise
6 I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
: I-Premise
8 I-Premise
. I-Premise
7 I-Premise
, I-Premise
11 I-Premise
. I-Premise
2 I-Premise
) I-Premise
months I-Premise
compared I-Premise
with I-Premise
the I-Premise
mean I-Premise
qalm I-Premise
- I-Premise
24 I-Premise
of I-Premise
8 I-Premise
. I-Premise
6 I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
: I-Premise
7 I-Premise
. I-Premise
6 I-Premise
, I-Premise
10 I-Premise
. I-Premise
5 I-Premise
) I-Premise
months I-Premise
for I-Premise
the I-Premise
no I-Premise
chemotherapy I-Premise
group I-Premise
. I-Premise
!LF! !LF!
for B-Premise
the I-Premise
chemoradiation I-Premise
group I-Premise
, I-Premise
the I-Premise
mean I-Premise
qalm I-Premise
- I-Premise
24 I-Premise
was I-Premise
7 I-Premise
. I-Premise
1 I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
: I-Premise
6 I-Premise
. I-Premise
0 I-Premise
, I-Premise
9 I-Premise
. I-Premise
0 I-Premise
) I-Premise
months I-Premise
compared I-Premise
with I-Premise
the I-Premise
mean I-Premise
qalm I-Premise
- I-Premise
24 I-Premise
of I-Premise
8 I-Premise
. I-Premise
1 I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
: I-Premise
7 I-Premise
. I-Premise
0 I-Premise
, I-Premise
10 I-Premise
. I-Premise
0 I-Premise
) I-Premise
months I-Premise
for I-Premise
the I-Premise
no I-Premise
chemoradiation I-Premise
group I-Premise
. I-Premise
!LF! !LF!
the B-Claim
previously I-Claim
reported I-Claim
survival I-Claim
advantage I-Claim
supporting I-Claim
the I-Claim
use I-Claim
of I-Claim
adjuvant I-Claim
chemotherapy I-Claim
is I-Claim
maintained I-Claim
when I-Claim
adjusted I-Claim
using I-Claim
quality I-Claim
adjusted I-Claim
survival I-Claim
methodology I-Claim
. I-Claim
!LF! !LF!
chemotherapy B-Claim
provided I-Claim
on I-Claim
average I-Claim
an I-Claim
additional I-Claim
1 I-Claim
. I-Claim
0 I-Claim
quality I-Claim
- I-Claim
adjusted I-Claim
life I-Claim
months I-Claim
within I-Claim
a I-Claim
restricted I-Claim
2 I-Claim
- I-Claim
year I-Claim
time I-Claim
period I-Claim
from I-Claim
the I-Claim
time I-Claim
of I-Claim
resection I-Claim
. I-Claim
!LF! !LF!
improvements O
can O
be O
made O
in O
the O
quality O
of O
cancer O
care O
if O
supportive O
care O
needs O
are O
addressed O
"""" O
; O
"""" O
however O
, O
there O
are O
few O
trials O
of O
supportive O
care O
interventions O
to O
guide O
policy O
and O
practice O
. O
!LF! !LF!
this O
study O
aimed O
to O
determine O
the O
effectiveness O
of O
a O
nurse O
- O
delivered O
telephone O
supportive O
intervention O
( O
the O
"""" O
connect O
"""" O
intervention O
) O
. O
!LF! !LF!
this O
study O
was O
a O
pilot O
randomized O
controlled O
trial O
. O
!LF! !LF!
intervention O
group O
patients O
received O
5 O
calls O
from O
a O
specialist O
colorectal O
nurse O
in O
the O
6 O
months O
after O
hospital O
discharge O
. O
!LF! !LF!
each O
call O
was O
standardized O
, O
comprising O
the O
assessment O
of O
unmet O
need O
and O
the O
provision O
of O
information O
and O
emotional O
support O
. O
!LF! !LF!
connect O
was O
in O
addition O
to O
standard O
clinical O
follow O
- O
up O
. O
!LF! !LF!
patients O
allocated O
to O
the O
control O
group O
received O
standard O
follow O
- O
up O
only O
. O
!LF! !LF!
this O
study O
took O
place O
at O
the O
royal O
prince O
alfred O
hospital O
, O
sydney O
, O
australia O
. O
!LF! !LF!
patients O
( O
n O
= O
75 O
) O
were O
included O
who O
had O
been O
surgically O
treated O
for O
colorectal O
cancer O
( O
any O
stage O
) O
. O
!LF! !LF!
the O
main O
outcome O
measures O
were O
the O
unmet O
supportive O
care O
needs O
, O
health O
service O
utilization O
, O
and O
quality O
of O
life O
at O
1 O
, O
3 O
, O
and O
6 O
months O
postdischarge O
. O
!LF! !LF!
of O
87 O
eligible O
patients O
, O
75 O
consented O
( O
86 O
% O
consent O
rate O
) O
. O
!LF! !LF!
thirty O
- O
nine O
patients O
were O
randomly O
assigned O
to O
connect O
and O
36 O
to O
usual O
care O
. O
!LF! !LF!
at B-Premise
6 I-Premise
months I-Premise
, I-Premise
there I-Premise
was I-Premise
a I-Premise
clinically I-Premise
relevant I-Premise
, I-Premise
but I-Premise
nonsignificant I-Premise
reduction I-Premise
in I-Premise
presentations I-Premise
to I-Premise
emergency I-Premise
departments I-Premise
( I-Premise
21 I-Premise
% I-Premise
vs I-Premise
33 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
χ1 I-Premise
= I-Premise
1 I-Premise
. I-Premise
41 I-Premise
, I-Premise
p I-Premise
= I-Premise
. I-Premise
23 I-Premise
) I-Premise
and I-Premise
readmission I-Premise
to I-Premise
the I-Premise
hospital I-Premise
( I-Premise
37 I-Premise
% I-Premise
vs I-Premise
47 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
χ1 I-Premise
= I-Premise
0 I-Premise
. I-Premise
82 I-Premise
, I-Premise
p I-Premise
= I-Premise
. I-Premise
37 I-Premise
) I-Premise
among I-Premise
intervention I-Premise
compared I-Premise
with I-Premise
control I-Premise
group I-Premise
participants I-Premise
. I-Premise
!LF! !LF!
nonsignificant B-Premise
differences I-Premise
between I-Premise
groups I-Premise
were I-Premise
found I-Premise
for I-Premise
all I-Premise
unmet I-Premise
supportive I-Premise
care I-Premise
need I-Premise
and I-Premise
quality I-Premise
- I-Premise
of I-Premise
- I-Premise
life I-Premise
scores I-Premise
, I-Premise
change I-Premise
scores I-Premise
, I-Premise
and I-Premise
trends I-Premise
. I-Premise
!LF! !LF!
however B-Premise
, I-Premise
at I-Premise
6 I-Premise
months I-Premise
, I-Premise
total I-Premise
quality I-Premise
- I-Premise
of I-Premise
- I-Premise
life I-Premise
scores I-Premise
were I-Premise
higher I-Premise
for I-Premise
intervention I-Premise
group I-Premise
patients I-Premise
than I-Premise
controls I-Premise
( I-Premise
106 I-Premise
. I-Premise
0 I-Premise
vs I-Premise
98 I-Premise
. I-Premise
6 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
this O
difference O
( O
7 O
. O
4 O
) O
was O
clinically O
relevant O
. O
!LF! !LF!
improvements B-Claim
in I-Claim
total I-Claim
quality I-Claim
- I-Claim
of I-Claim
- I-Claim
life I-Claim
change I-Claim
scores I-Claim
demonstrated I-Claim
that I-Claim
at I-Claim
6 I-Claim
months I-Claim
, I-Claim
improvements I-Claim
were I-Claim
more I-Claim
than I-Claim
twice I-Claim
as I-Claim
large I-Claim
and I-Claim
clinically I-Claim
significant I-Claim
in I-Claim
the I-Claim
intervention I-Claim
compared I-Claim
with I-Claim
the I-Claim
control I-Claim
group I-Claim
. I-Claim
!LF! !LF!
connect B-Claim
has I-Claim
shown I-Claim
promising I-Claim
indications I-Claim
on I-Claim
health I-Claim
system I-Claim
and I-Claim
patient I-Claim
outcomes I-Claim
that I-Claim
warrant I-Claim
a I-Claim
larger I-Claim
study I-Claim
to I-Claim
further I-Claim
investigate I-Claim
the I-Claim
potential I-Claim
of I-Claim
this I-Claim
intervention I-Claim
. I-Claim
!LF! !LF!
we O
conducted O
a O
multicenter O
, O
randomized O
trial O
to O
compare O
progression O
- O
free O
survival O
( O
pfs O
) O
, O
overall O
survival O
( O
os O
) O
, O
and O
quality O
of O
life O
in O
women O
with O
metastatic O
breast O
cancer O
( O
mbc O
) O
receiving O
high O
- O
dose O
chemotherapy O
plus O
autologous O
stem O
- O
cell O
transplantation O
( O
asct O
"""" O
; O
"""" O
hdct O
) O
compared O
with O
standard O
- O
dose O
therapy O
. O
!LF! !LF!
between O
april O
1997 O
and O
december O
2000 O
, O
386 O
women O
with O
mbc O
and O
no O
prior O
chemotherapy O
for O
metastatic O
disease O
were O
registered O
. O
!LF! !LF!
after O
initial O
response O
to O
anthracycline O
- O
or O
taxane O
- O
based O
induction O
chemotherapy O
, O
224 O
patients O
were O
randomly O
assigned O
: O
112 O
to O
high O
- O
dose O
cyclophosphamide O
, O
mitoxantrone O
, O
and O
carboplatin O
chemotherapy O
and O
asct O
( O
hdct O
) O
, O
and O
112 O
to O
standard O
therapy O
( O
st O
) O
. O
!LF! !LF!
median O
age O
was O
47 O
years O
( O
range O
, O
25 O
to O
67 O
years O
) O
. O
!LF! !LF!
thirty O
two O
percent O
of O
women O
randomly O
assigned O
had O
estrogen O
and O
progesterone O
receptor O
- O
negative O
breast O
cancer O
, O
42 O
% O
had O
visceral O
metastases O
, O
and O
58 O
% O
had O
bone O
metastases O
. O
!LF! !LF!
complete O
remission O
rates O
before O
random O
assignment O
were O
11 O
% O
for O
those O
receiving O
hdct O
and O
12 O
% O
for O
those O
receiving O
st O
. O
after B-Premise
a I-Premise
median I-Premise
follow I-Premise
- I-Premise
up I-Premise
of I-Premise
48 I-Premise
months I-Premise
, I-Premise
79 I-Premise
deaths I-Premise
were I-Premise
observed I-Premise
in I-Premise
the I-Premise
hdct I-Premise
arm I-Premise
and I-Premise
77 I-Premise
deaths I-Premise
were I-Premise
observed I-Premise
in I-Premise
the I-Premise
st I-Premise
arm I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
seven B-Premise
patients I-Premise
( I-Premise
6 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
hdct I-Premise
arm I-Premise
died I-Premise
as I-Premise
a I-Premise
result I-Premise
of I-Premise
toxicity I-Premise
. I-Premise
!LF! !LF!
the B-Premise
median I-Premise
os I-Premise
was I-Premise
24 I-Premise
months I-Premise
for I-Premise
the I-Premise
hdct I-Premise
arm I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
21 I-Premise
to I-Premise
35 I-Premise
months I-Premise
) I-Premise
and I-Premise
28 I-Premise
months I-Premise
for I-Premise
st I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
22 I-Premise
to I-Premise
33 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
hr I-Premise
] I-Premise
, I-Premise
0 I-Premise
. I-Premise
9 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
6 I-Premise
to I-Premise
1 I-Premise
. I-Premise
2 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
43 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
pfs B-Premise
was I-Premise
11 I-Premise
months I-Premise
for I-Premise
hdct I-Premise
and I-Premise
9 I-Premise
months I-Premise
for I-Premise
st I-Premise
( I-Premise
hr I-Premise
, I-Premise
0 I-Premise
. I-Premise
6 I-Premise
in I-Premise
favor I-Premise
of I-Premise
hdct I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
5 I-Premise
to I-Premise
0 I-Premise
. I-Premise
9 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
006 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
hdct B-Claim
did I-Claim
not I-Claim
improve I-Claim
os I-Claim
in I-Claim
women I-Claim
with I-Claim
mbc I-Claim
when I-Claim
used I-Claim
as I-Claim
consolidation I-Claim
after I-Claim
response I-Claim
to I-Claim
induction I-Claim
chemotherapy I-Claim
. I-Claim
!LF! !LF!
care O
closer O
to O
home O
is O
being O
explored O
as O
a O
means O
of O
improving O
patient O
experience O
as O
well O
as O
efficiency O
in O
terms O
of O
cost O
savings O
. O
!LF! !LF!
evidence O
that O
community O
cancer O
services O
improve O
care O
quality O
and O
/ O
or O
generate O
cost O
savings O
is O
currently O
limited O
. O
!LF! !LF!
a O
randomised O
study O
was O
undertaken O
to O
compare O
delivery O
of O
cancer O
treatment O
in O
the O
hospital O
with O
two O
different O
community O
settings O
. O
!LF! !LF!
ninety O
- O
seven O
patients O
being O
offered O
outpatient O
- O
based O
cancer O
treatment O
were O
randomised O
to O
treatment O
delivered O
in O
a O
hospital O
day O
unit O
, O
at O
the O
patient O
' O
s O
home O
or O
in O
local O
general O
practice O
( O
gp O
) O
surgeries O
. O
!LF! !LF!
the O
primary O
outcome O
was O
patient O
- O
perceived O
benefits O
, O
using O
the O
emotional O
function O
domain O
of O
the O
eortc O
quality O
of O
life O
( O
qol O
) O
qlqc30 O
questionnaire O
evaluated O
after O
12 O
weeks O
. O
!LF! !LF!
secondary O
outcomes O
included O
additional O
qol O
measures O
, O
patient O
satisfaction O
, O
safety O
and O
health O
economics O
. O
!LF! !LF!
there B-Premise
was I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
qol I-Premise
difference I-Premise
between I-Premise
treatment I-Premise
in I-Premise
the I-Premise
combined I-Premise
community I-Premise
locations I-Premise
relative I-Premise
to I-Premise
hospital I-Premise
( I-Premise
difference I-Premise
of I-Premise
- I-Premise
7 I-Premise
. I-Premise
2 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
: I-Premise
- I-Premise
19 I-Premise
· I-Premise
5 I-Premise
to I-Premise
+ I-Premise
5 I-Premise
· I-Premise
2 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
25 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
there B-Premise
was I-Premise
a I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
community I-Premise
locations I-Premise
in I-Premise
favour I-Premise
of I-Premise
home I-Premise
( I-Premise
+ I-Premise
15 I-Premise
· I-Premise
2 I-Premise
, I-Premise
1 I-Premise
· I-Premise
3 I-Premise
to I-Premise
29 I-Premise
· I-Premise
1 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
033 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
hospital O
anxiety O
and O
depression O
scale O
scores O
were O
consistent O
with O
the O
primary O
outcome O
measure O
. O
!LF! !LF!
there B-Premise
was I-Premise
no I-Premise
evidence I-Premise
that I-Premise
community I-Premise
treatment I-Premise
compromised I-Premise
patient I-Premise
safety I-Premise
and O
no B-Premise
significant I-Premise
difference I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
in I-Premise
terms I-Premise
of I-Premise
overall I-Premise
costs I-Premise
or I-Premise
quality I-Premise
adjusted I-Premise
life I-Premise
year I-Premise
. I-Premise
!LF! !LF!
seventy B-Premise
- B-Premise
eight B-Premise
percent I-Premise
of I-Premise
patients I-Premise
expressed I-Premise
satisfaction I-Premise
with I-Premise
their I-Premise
treatment I-Premise
whatever I-Premise
their I-Premise
location I-Premise
, I-Premise
whereas I-Premise
57 I-Premise
% I-Premise
of I-Premise
patients I-Premise
preferred I-Premise
future I-Premise
treatment I-Premise
to I-Premise
continue I-Premise
at I-Premise
the I-Premise
hospital I-Premise
, I-Premise
81 I-Premise
% I-Premise
at I-Premise
gp I-Premise
surgeries I-Premise
and I-Premise
90 I-Premise
% I-Premise
at I-Premise
home I-Premise
. I-Premise
!LF! !LF!
although O
initial O
pre O
- O
trial O
interviews O
revealed O
concerns O
among O
health O
- O
care O
professionals O
and O
some O
patients O
regarding O
community O
treatment O
, O
opinions O
were O
largely O
more O
favourable O
in O
post O
- O
trial O
interviews O
. O
!LF! !LF!
patient B-Claim
qol I-Claim
favours I-Claim
delivering I-Claim
cancer I-Claim
treatment I-Claim
in I-Claim
the I-Claim
home I-Claim
rather I-Claim
than I-Claim
gp I-Claim
surgeries I-Claim
. I-Claim
!LF! !LF!
nevertheless B-Claim
, I-Claim
both I-Claim
community I-Claim
settings I-Claim
were I-Claim
acceptable I-Claim
to I-Claim
and I-Claim
preferred I-Claim
by I-Claim
patients I-Claim
compared I-Claim
with I-Claim
hospital I-Claim
, I-Claim
were I-Claim
safe I-Claim
, I-Claim
with I-Claim
no I-Claim
detrimental I-Claim
impact I-Claim
on I-Claim
overall I-Claim
health I-Claim
- I-Claim
care I-Claim
costs I-Claim
. I-Claim
!LF! !LF!
docetaxel B-Claim
has I-Claim
shown I-Claim
activity I-Claim
in I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non I-Claim
- I-Claim
small I-Claim
- I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
nsclc I-Claim
) I-Claim
. I-Claim
!LF! !LF!
this O
randomized O
phase O
iii O
trial O
evaluated O
the O
efficacy O
and O
safety O
of O
docetaxel O
versus O
vinorelbine O
( O
the O
current O
standard O
treatment O
) O
in O
elderly O
patients O
. O
!LF! !LF!
chemotherapy O
- O
naive O
patients O
age O
70 O
years O
or O
older O
with O
stage O
iiib O
/ O
iv O
nsclc O
and O
performance O
status O
2 O
or O
lower O
were O
eligible O
. O
!LF! !LF!
patients O
randomly O
received O
docetaxel O
60 O
mg O
/ O
m2 O
( O
day O
1 O
) O
or O
vinorelbine O
25 O
mg O
/ O
m2 O
( O
days O
1 O
and O
8 O
) O
every O
21 O
days O
for O
four O
cycles O
. O
!LF! !LF!
the O
primary O
end O
point O
was O
overall O
survival O
. O
!LF! !LF!
overall O
disease O
- O
related O
symptom O
improvement O
was O
assessed O
using O
an O
eight O
- O
item O
questionnaire O
. O
!LF! !LF!
in O
total O
, O
182 O
patients O
were O
enrolled O
. O
!LF! !LF!
median O
age O
was O
76 O
years O
( O
range O
, O
70 O
years O
to O
86 O
years O
) O
. O
!LF! !LF!
there B-Premise
was I-Premise
no I-Premise
statistical I-Premise
difference I-Premise
in I-Premise
median I-Premise
overall I-Premise
survival I-Premise
with I-Premise
docetaxel I-Premise
versus I-Premise
vinorelbine I-Premise
( I-Premise
14 I-Premise
. I-Premise
3 I-Premise
months I-Premise
v I-Premise
9 I-Premise
. I-Premise
9 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0 I-Premise
. I-Premise
780 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
561 I-Premise
to I-Premise
1 I-Premise
. I-Premise
085 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
138 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
there B-Premise
was I-Premise
a I-Premise
significant I-Premise
difference I-Premise
in I-Premise
median I-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
( I-Premise
5 I-Premise
. I-Premise
5 I-Premise
months I-Premise
v I-Premise
3 I-Premise
. I-Premise
1 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
response B-Premise
rates I-Premise
were I-Premise
also I-Premise
significantly I-Premise
improved I-Premise
with I-Premise
docetaxel I-Premise
versus I-Premise
vinorelbine I-Premise
( I-Premise
22 I-Premise
. I-Premise
7 I-Premise
% I-Premise
v I-Premise
9 I-Premise
. I-Premise
9 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
019 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
most I-Premise
common I-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
toxicities I-Premise
were I-Premise
neutropenia I-Premise
( I-Premise
82 I-Premise
. I-Premise
9 I-Premise
% I-Premise
for I-Premise
docetaxel I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
69 I-Premise
. I-Premise
2 I-Premise
% I-Premise
for I-Premise
vinorelbine I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
031 I-Premise
) I-Premise
and I-Premise
leukopenia I-Premise
( I-Premise
58 I-Premise
. I-Premise
0 I-Premise
% I-Premise
for I-Premise
docetaxel I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
51 I-Premise
. I-Premise
7 I-Premise
% I-Premise
for I-Premise
vinorelbine I-Premise
) I-Premise
. I-Premise
!LF! !LF!
other B-Premise
toxicities I-Premise
were I-Premise
mild I-Premise
and I-Premise
generally I-Premise
well I-Premise
tolerated I-Premise
. I-Premise
!LF! !LF!
docetaxel B-Premise
improved I-Premise
overall I-Premise
disease I-Premise
- I-Premise
related I-Premise
symptoms I-Premise
over I-Premise
vinorelbine I-Premise
( I-Premise
odds I-Premise
ratio I-Premise
, I-Premise
1 I-Premise
. I-Premise
86 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
1 I-Premise
. I-Premise
09 I-Premise
to I-Premise
3 I-Premise
. I-Premise
20 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
docetaxel B-Premise
improved I-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
, I-Premise
response I-Premise
rate I-Premise
, I-Premise
and I-Premise
disease I-Premise
- I-Premise
related I-Premise
symptoms I-Premise
versus I-Premise
vinorelbine I-Premise
. I-Premise
!LF! !LF!
overall B-Claim
survival I-Claim
was I-Claim
not I-Claim
statistically I-Claim
significantly I-Claim
improved I-Claim
at I-Claim
this I-Claim
time I-Claim
. I-Claim
!LF! !LF!
docetaxel B-Claim
monotherapy I-Claim
may I-Claim
be I-Claim
considered I-Claim
as I-Claim
an I-Claim
option I-Claim
in I-Claim
the I-Claim
standard I-Claim
treatment I-Claim
of I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
nsclc I-Claim
. I-Claim
!LF! !LF!
to O
determine O
the O
effectiveness O
of O
the O
alleviating O
depression O
among O
patients O
with O
cancer O
( O
adapt O
- O
c O
) O
collaborative O
care O
management O
for O
major O
depression O
or O
dysthymia O
. O
!LF! !LF!
study O
patients O
included O
472 O
low O
- O
income O
, O
predominantly O
female O
hispanic O
patients O
with O
cancer O
age O
> O
or O
= O
18 O
years O
with O
major O
depression O
( O
49 O
% O
) O
, O
dysthymia O
( O
5 O
% O
) O
, O
or O
both O
( O
46 O
% O
) O
. O
!LF! !LF!
patients O
were O
randomly O
assigned O
to O
intervention O
( O
n O
= O
242 O
) O
or O
enhanced O
usual O
care O
( O
euc O
"""" O
; O
"""" O
n O
= O
230 O
) O
. O
!LF! !LF!
intervention O
patients O
had O
access O
for O
up O
to O
12 O
months O
to O
a O
depression O
clinical O
specialist O
( O
supervised O
by O
a O
psychiatrist O
) O
who O
offered O
education O
, O
structured O
psychotherapy O
, O
and O
maintenance O
/ O
relapse O
prevention O
support O
. O
!LF! !LF!
the O
psychiatrist O
prescribed O
antidepressant O
medications O
for O
patients O
preferring O
or O
assessed O
to O
require O
medication O
. O
!LF! !LF!
at B-Premise
12 I-Premise
months I-Premise
, I-Premise
63 I-Premise
% I-Premise
of I-Premise
intervention I-Premise
patients I-Premise
had I-Premise
a I-Premise
50 I-Premise
% I-Premise
or I-Premise
greater I-Premise
reduction I-Premise
in I-Premise
depressive I-Premise
symptoms I-Premise
from I-Premise
baseline I-Premise
as I-Premise
assessed I-Premise
by I-Premise
the I-Premise
patient I-Premise
health I-Premise
questionnaire I-Premise
- I-Premise
9 I-Premise
( I-Premise
phq I-Premise
- I-Premise
9 I-Premise
) I-Premise
depression I-Premise
scale I-Premise
compared I-Premise
with I-Premise
50 I-Premise
% I-Premise
of I-Premise
euc I-Premise
patients I-Premise
( I-Premise
odds I-Premise
ratio I-Premise
[ I-Premise
or I-Premise
] I-Premise
= I-Premise
1 I-Premise
. I-Premise
98 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
1 I-Premise
. I-Premise
16 I-Premise
to I-Premise
3 I-Premise
. I-Premise
38 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
improvement B-Premise
was I-Premise
also I-Premise
found I-Premise
for I-Premise
5 I-Premise
- I-Premise
point I-Premise
decrease I-Premise
in I-Premise
phq I-Premise
- I-Premise
9 I-Premise
score I-Premise
among I-Premise
72 I-Premise
. I-Premise
2 I-Premise
% I-Premise
of I-Premise
intervention I-Premise
patients I-Premise
compared I-Premise
with I-Premise
59 I-Premise
. I-Premise
7 I-Premise
% I-Premise
of I-Premise
euc I-Premise
patients I-Premise
( I-Premise
or I-Premise
= I-Premise
1 I-Premise
. I-Premise
99 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
1 I-Premise
. I-Premise
14 I-Premise
to I-Premise
3 I-Premise
. I-Premise
50 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
intervention B-Premise
patients I-Premise
also I-Premise
experienced I-Premise
greater I-Premise
rates I-Premise
of I-Premise
depression I-Premise
treatment I-Premise
( I-Premise
72 I-Premise
. I-Premise
3 I-Premise
% I-Premise
v I-Premise
10 I-Premise
. I-Premise
4 I-Premise
% I-Premise
of I-Premise
euc I-Premise
patients I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
. I-Premise
0001 I-Premise
) I-Premise
and I-Premise
significantly I-Premise
better I-Premise
quality I-Premise
- I-Premise
of I-Premise
- I-Premise
life I-Premise
outcomes I-Premise
, I-Premise
including I-Premise
social I-Premise
/ I-Premise
family I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
between I-Premise
groups I-Premise
, I-Premise
2 I-Premise
. I-Premise
7 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
1 I-Premise
. I-Premise
22 I-Premise
to I-Premise
4 I-Premise
. I-Premise
17 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
emotional I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
1 I-Premise
. I-Premise
29 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
26 I-Premise
to I-Premise
2 I-Premise
. I-Premise
22 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
01 I-Premise
) I-Premise
, I-Premise
functional I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
1 I-Premise
. I-Premise
34 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
08 I-Premise
to I-Premise
2 I-Premise
. I-Premise
59 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
04 I-Premise
) I-Premise
, I-Premise
and I-Premise
physical I-Premise
well I-Premise
- I-Premise
being I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
2 I-Premise
. I-Premise
79 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
49 I-Premise
to I-Premise
5 I-Premise
. I-Premise
1 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
adapt B-Claim
- B-Claim
c B-Claim
collaborative I-Claim
care I-Claim
is I-Claim
feasible I-Claim
and I-Claim
results I-Claim
in I-Claim
significant I-Claim
reduction I-Claim
in I-Claim
depressive I-Claim
symptoms I-Claim
, I-Claim
improvement I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
and I-Claim
lower I-Claim
pain I-Claim
levels I-Claim
compared I-Claim
with I-Claim
euc I-Claim
for I-Claim
patients I-Claim
with I-Claim
depressive I-Claim
disorders I-Claim
in I-Claim
a I-Claim
low I-Claim
- I-Claim
income I-Claim
, I-Claim
predominantly I-Claim
hispanic I-Claim
population I-Claim
in I-Claim
public I-Claim
sector I-Claim
oncology I-Claim
clinics I-Claim
. I-Claim
!LF! !LF!
depression O
is O
common O
among O
older O
cancer O
patients O
, O
but O
little O
is O
known O
about O
the O
optimal O
approach O
to O
caring O
for O
this O
population O
. O
!LF! !LF!
this O
analysis O
evaluates O
the O
effectiveness O
of O
the O
improving O
mood O
- O
promoting O
access O
to O
collaborative O
treatment O
( O
impact O
) O
program O
, O
a O
stepped O
care O
management O
program O
for O
depression O
in O
primary O
care O
patients O
who O
had O
an O
icd O
- O
9 O
cancer O
diagnosis O
. O
!LF! !LF!
two O
hundred O
fifteen O
cancer O
patients O
were O
identified O
from O
the O
1 O
, O
801 O
participants O
in O
the O
parent O
study O
. O
!LF! !LF!
subjects O
were O
60 O
years O
or O
older O
with O
major O
depression O
( O
18 O
% O
) O
, O
dysthymic O
disorder O
( O
33 O
% O
) O
, O
or O
both O
( O
49 O
% O
) O
, O
recruited O
from O
18 O
primary O
care O
clinics O
belonging O
to O
8 O
health O
- O
care O
organizations O
in O
5 O
states O
. O
!LF! !LF!
patients O
were O
randomly O
assigned O
to O
the O
impact O
intervention O
( O
n O
= O
112 O
) O
or O
usual O
care O
( O
n O
= O
103 O
) O
. O
!LF! !LF!
intervention O
patients O
had O
access O
for O
up O
to O
12 O
months O
to O
a O
depression O
care O
manager O
who O
was O
supervised O
by O
a O
psychiatrist O
and O
a O
primary O
care O
provider O
and O
who O
offered O
education O
, O
care O
management O
, O
support O
of O
antidepressant O
management O
, O
and O
brief O
, O
structured O
psychosocial O
interventions O
including O
behavioral O
activation O
and O
problem O
- O
solving O
treatment O
. O
!LF! !LF!
at B-Premise
6 I-Premise
and I-Premise
12 I-Premise
months I-Premise
, I-Premise
55 I-Premise
% I-Premise
and I-Premise
39 I-Premise
% I-Premise
of I-Premise
intervention I-Premise
patients I-Premise
had I-Premise
a I-Premise
50 I-Premise
% I-Premise
or I-Premise
greater I-Premise
reduction I-Premise
in I-Premise
depressive I-Premise
symptoms I-Premise
( I-Premise
scl I-Premise
- I-Premise
20 I-Premise
) I-Premise
from I-Premise
baseline I-Premise
compared I-Premise
to I-Premise
34 I-Premise
% I-Premise
and I-Premise
20 I-Premise
% I-Premise
of I-Premise
usual I-Premise
care I-Premise
participants I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
003 I-Premise
and I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
029 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
intervention B-Premise
patients I-Premise
also I-Premise
experienced I-Premise
greater I-Premise
remission I-Premise
rates I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
031 I-Premise
) I-Premise
, I-Premise
more I-Premise
depression I-Premise
- I-Premise
free I-Premise
days I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
less I-Premise
functional I-Premise
impairment I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
011 I-Premise
) I-Premise
, I-Premise
and I-Premise
greater I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
039 I-Premise
) I-Premise
at I-Premise
12 I-Premise
months I-Premise
than I-Premise
usual I-Premise
care I-Premise
participants I-Premise
. I-Premise
!LF! !LF!
the B-Claim
impact I-Claim
collaborative I-Claim
care I-Claim
program I-Claim
appears I-Claim
to I-Claim
be I-Claim
feasible I-Claim
and I-Claim
effective I-Claim
for I-Claim
depression I-Claim
among I-Claim
older I-Claim
cancer I-Claim
patients I-Claim
in I-Claim
diverse I-Claim
primary I-Claim
care I-Claim
settings I-Claim
. I-Claim
!LF! !LF!
sunitinib O
has O
demonstrated O
antitumor O
activity O
in O
metastatic O
renal O
cell O
carcinoma O
( O
mrcc O
) O
when O
given O
at O
50 O
mg O
/ O
d O
on O
a O
4 O
- O
weeks O
- O
on O
2 O
- O
weeks O
- O
off O
regimen O
. O
!LF! !LF!
herein O
, O
we O
report O
results O
of O
an O
open O
- O
label O
, O
multicenter O
phase O
ii O
mrcc O
study O
of O
sunitinib O
administered O
on O
a O
continuous O
once O
- O
daily O
dosing O
regimen O
. O
!LF! !LF!
eligibility O
criteria O
included O
histologically O
proven O
mrcc O
with O
measurable O
disease O
, O
failure O
of O
one O
prior O
cytokine O
regimen O
, O
and O
good O
performance O
status O
. O
!LF! !LF!
patients O
were O
randomly O
assigned O
to O
a O
sunitinib O
starting O
dose O
of O
37 O
. O
5 O
mg O
/ O
d O
in O
the O
morning O
( O
am O
) O
or O
evening O
( O
pm O
) O
. O
!LF! !LF!
recist O
- O
defined O
objective O
response O
rate O
( O
orr O
) O
was O
the O
primary O
end O
point O
. O
!LF! !LF!
secondary O
end O
points O
included O
progression O
- O
free O
survival O
( O
pfs O
) O
, O
overall O
survival O
( O
os O
) O
, O
adverse O
events O
( O
aes O
) O
, O
and O
quality O
- O
of O
- O
life O
measures O
. O
!LF! !LF!
one O
hundred O
seven O
patients O
were O
randomly O
assigned O
to O
am O
( O
n O
= O
54 O
) O
or O
pm O
( O
n O
= O
53 O
) O
dosing O
and O
on O
study O
for O
a O
median O
8 O
. O
3 O
months O
. O
!LF! !LF!
eighty O
- O
three O
patients O
discontinued O
, O
65 O
due O
to O
disease O
progression O
and O
16 O
because O
of O
aes O
"""" O
; O
"""" O
two O
patients O
withdrew O
consent O
. O
!LF! !LF!
dosing O
was O
reduced O
to O
25 O
mg O
/ O
d O
in O
46 O
patients O
( O
43 O
% O
) O
due O
to O
grade O
3 O
/ O
4 O
aes O
. O
!LF! !LF!
the B-Premise
most I-Premise
common I-Premise
grade I-Premise
3 I-Premise
treatment I-Premise
- I-Premise
related I-Premise
aes I-Premise
were I-Premise
asthenia I-Premise
/ I-Premise
fatigue I-Premise
( I-Premise
16 I-Premise
% I-Premise
) I-Premise
, I-Premise
diarrhea I-Premise
( I-Premise
11 I-Premise
% I-Premise
) I-Premise
, I-Premise
hypertension I-Premise
( I-Premise
11 I-Premise
% I-Premise
) I-Premise
, I-Premise
hand I-Premise
- I-Premise
foot I-Premise
syndrome I-Premise
( I-Premise
9 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
anorexia I-Premise
( I-Premise
8 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
orr O
was O
20 O
% O
with O
a O
7 O
. O
2 O
- O
month O
median O
response O
duration O
. O
!LF! !LF!
median B-Premise
pfs I-Premise
and I-Premise
os I-Premise
were I-Premise
8 I-Premise
. I-Premise
2 I-Premise
and I-Premise
19 I-Premise
. I-Premise
8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
at I-Premise
median I-Premise
follow I-Premise
- I-Premise
up I-Premise
of I-Premise
26 I-Premise
. I-Premise
4 I-Premise
months I-Premise
. I-Premise
!LF! !LF!
efficacy B-Premise
, I-Premise
tolerability I-Premise
, I-Premise
and I-Premise
quality I-Premise
- I-Premise
of I-Premise
- I-Premise
life I-Premise
results I-Premise
were I-Premise
similar I-Premise
between I-Premise
patients I-Premise
dosed I-Premise
in I-Premise
the I-Premise
am I-Premise
or I-Premise
pm I-Premise
. I-Premise
!LF! !LF!
sunitinib B-Claim
37 I-Claim
. I-Claim
5 I-Claim
mg I-Claim
, I-Claim
administered I-Claim
on I-Claim
a I-Claim
continuous I-Claim
once I-Claim
- I-Claim
daily I-Claim
dosing I-Claim
regimen I-Claim
, I-Claim
has I-Claim
a I-Claim
manageable I-Claim
safety I-Claim
profile I-Claim
as I-Claim
second I-Claim
- I-Claim
line I-Claim
mrcc I-Claim
therapy I-Claim
, I-Claim
providing I-Claim
flexible I-Claim
dosing I-Claim
, I-Claim
which I-Claim
can I-Claim
be I-Claim
explored I-Claim
in I-Claim
combination I-Claim
studies I-Claim
. I-Claim
!LF! !LF!
observational O
studies O
demonstrate O
an O
association O
between O
physical O
activity O
and O
improved O
outcomes O
in O
breast O
and O
colon O
cancer O
survivors O
. O
!LF! !LF!
to O
test O
these O
observations O
with O
a O
large O
, O
randomized O
clinical O
trial O
, O
an O
intervention O
that O
significantly O
impacts O
physical O
activity O
in O
these O
patients O
is O
needed O
. O
!LF! !LF!
the O
active O
after O
cancer O
trial O
( O
aact O
) O
was O
a O
multicenter O
pilot O
study O
evaluating O
the O
feasibility O
of O
a O
telephone O
- O
based O
exercise O
intervention O
in O
a O
cooperative O
group O
setting O
. O
!LF! !LF!
sedentary O
( O
engaging O
in O
< O
60 O
min O
of O
recreational O
activity O
/ O
week O
) O
breast O
and O
colorectal O
cancer O
survivors O
were O
randomized O
to O
a O
telephone O
- O
based O
exercise O
intervention O
or O
usual O
care O
control O
group O
. O
!LF! !LF!
the O
intervention O
was O
delivered O
through O
the O
university O
of O
california O
at O
san O
diego O
"""" O
; O
"""" O
participants O
received O
ten O
phone O
calls O
over O
the O
course O
of O
the O
16 O
- O
week O
intervention O
. O
!LF! !LF!
all O
participants O
underwent O
assessment O
of O
physical O
activity O
, O
fitness O
, O
physical O
functioning O
, O
fatigue O
and O
exercise O
self O
- O
efficacy O
at O
baseline O
and O
after O
the O
16 O
- O
week O
intervention O
. O
!LF! !LF!
one O
hundred O
and O
twenty O
- O
one O
patients O
were O
enrolled O
through O
ten O
cancer O
and O
leukemia O
group O
b O
( O
calgb O
) O
institutions O
"""" O
; O
"""" O
100 O
patients O
had O
breast O
cancer O
and O
21 O
had O
colorectal O
cancer O
. O
!LF! !LF!
participants B-Premise
randomized I-Premise
to I-Premise
the I-Premise
exercise I-Premise
group I-Premise
increased I-Premise
physical I-Premise
activity I-Premise
by I-Premise
more I-Premise
than I-Premise
100 I-Premise
versus I-Premise
22 I-Premise
% I-Premise
in I-Premise
controls I-Premise
( I-Premise
54 I-Premise
. I-Premise
5 I-Premise
vs I-Premise
. I-Premise
14 I-Premise
. I-Premise
6 I-Premise
min I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
13 I-Premise
) I-Premise
, I-Premise
and I-Premise
experienced I-Premise
significant I-Premise
increases I-Premise
in I-Premise
fitness I-Premise
( I-Premise
increased I-Premise
6 I-Premise
- I-Premise
min I-Premise
walk I-Premise
test I-Premise
distance I-Premise
by I-Premise
186 I-Premise
. I-Premise
9 I-Premise
vs I-Premise
. I-Premise
81 I-Premise
. I-Premise
9 I-Premise
feet I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
006 I-Premise
) I-Premise
and I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
7 I-Premise
. I-Premise
1 I-Premise
vs I-Premise
. I-Premise
2 I-Premise
. I-Premise
6 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
04 I-Premise
) I-Premise
as I-Premise
compared I-Premise
to I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise
!LF! !LF!
breast B-Claim
and I-Claim
colorectal I-Claim
cancer I-Claim
survivors I-Claim
enrolled I-Claim
in I-Claim
a I-Claim
multicenter I-Claim
, I-Claim
telephone I-Claim
- I-Claim
based I-Claim
physical I-Claim
activity I-Claim
intervention I-Claim
increased I-Claim
physical I-Claim
activity I-Claim
and I-Claim
experienced I-Claim
significant I-Claim
improvements I-Claim
in I-Claim
fitness I-Claim
and I-Claim
physical I-Claim
functioning I-Claim
. I-Claim
!LF! !LF!
lifestyle B-Claim
intervention I-Claim
research I-Claim
is I-Claim
feasible I-Claim
in I-Claim
a I-Claim
cooperative I-Claim
group I-Claim
setting I-Claim
. I-Claim
!LF! !LF!
the O
primary O
objective O
of O
this O
study O
was O
to O
compare O
the O
response O
rates O
of O
elderly O
, O
chemonaive O
patients O
with O
advanced O
non O
- O
small O
cell O
lung O
cancer O
( O
nsclc O
) O
treated O
with O
daily O
oral O
erlotinib O
versus O
oral O
vinorelbine O
. O
!LF! !LF!
chemonaive O
taiwanese O
patients O
aged O
70 O
years O
or O
older O
who O
had O
advanced O
nsclc O
were O
randomized O
to O
receive O
either O
oral O
erlotinib O
150 O
mg O
( O
e O
) O
daily O
or O
oral O
vinorelbine O
60 O
mg O
/ O
m O
( O
v O
) O
on O
days O
1 O
and O
8 O
every O
3 O
weeks O
. O
!LF! !LF!
from O
february O
2007 O
to O
july O
2008 O
, O
116 O
patients O
were O
enrolled O
and O
113 O
were O
included O
in O
the O
intent O
- O
to O
- O
treat O
population O
: O
57 O
patients O
in O
the O
e O
group O
and O
56 O
patients O
in O
the O
v O
group O
. O
!LF! !LF!
objective B-Premise
response I-Premise
rates I-Premise
were I-Premise
22 I-Premise
. I-Premise
8 I-Premise
% I-Premise
( I-Premise
13 I-Premise
of I-Premise
57 I-Premise
) I-Premise
in I-Premise
e I-Premise
and I-Premise
8 I-Premise
. I-Premise
9 I-Premise
% I-Premise
( I-Premise
5 I-Premise
of I-Premise
56 I-Premise
) I-Premise
in I-Premise
v I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0388 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
median B-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
( I-Premise
pfs I-Premise
) I-Premise
was I-Premise
4 I-Premise
. I-Premise
57 I-Premise
months I-Premise
in I-Premise
e I-Premise
and I-Premise
2 I-Premise
. I-Premise
53 I-Premise
months I-Premise
in I-Premise
v I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0287 I-Premise
) I-Premise
, I-Premise
with I-Premise
an I-Premise
80 I-Premise
. I-Premise
6 I-Premise
% I-Premise
increase I-Premise
in I-Premise
median I-Premise
pfs I-Premise
for I-Premise
e I-Premise
compared I-Premise
with I-Premise
v I-Premise
. I-Premise
median B-Premise
survival I-Premise
time I-Premise
was I-Premise
11 I-Premise
. I-Premise
67 I-Premise
months I-Premise
in I-Premise
e I-Premise
and I-Premise
9 I-Premise
. I-Premise
3 I-Premise
months I-Premise
in I-Premise
v I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
6975 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
toxicities B-Premise
were I-Premise
generally I-Premise
mild I-Premise
in I-Premise
both I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
median B-Premise
pfs I-Premise
was I-Premise
longest I-Premise
for I-Premise
epidermal I-Premise
growth I-Premise
factor I-Premise
receptor I-Premise
gene I-Premise
( I-Premise
egfr I-Premise
) I-Premise
- I-Premise
mutated I-Premise
patients I-Premise
in I-Premise
the I-Premise
e I-Premise
group I-Premise
, I-Premise
followed I-Premise
by I-Premise
egfr I-Premise
- I-Premise
mutated I-Premise
patients I-Premise
in I-Premise
v I-Premise
, I-Premise
egfr I-Premise
wild I-Premise
type I-Premise
in I-Premise
e I-Premise
, I-Premise
and I-Premise
egfr I-Premise
wild I-Premise
type I-Premise
in I-Premise
v I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0034 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
overall B-Premise
survival I-Premise
was I-Premise
longer I-Premise
for I-Premise
egfr I-Premise
- I-Premise
mutated I-Premise
patients I-Premise
than I-Premise
for I-Premise
egfr I-Premise
wild I-Premise
- I-Premise
type I-Premise
patients I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
0001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
erlotinib B-Claim
is I-Claim
highly I-Claim
effective I-Claim
compared I-Claim
with I-Claim
oral I-Claim
vinorelbine I-Claim
in I-Claim
elderly I-Claim
, I-Claim
chemonaive I-Claim
, I-Claim
taiwanese I-Claim
patients I-Claim
with I-Claim
nsclc I-Claim
. I-Claim
!LF! !LF!
egfr B-Claim
- B-Claim
mutated B-Claim
patients I-Claim
had I-Claim
better I-Claim
survival I-Claim
than I-Claim
those I-Claim
with I-Claim
egfr I-Claim
wild I-Claim
- I-Claim
type I-Claim
disease I-Claim
, I-Claim
regardless I-Claim
of I-Claim
the I-Claim
treatment I-Claim
received I-Claim
. I-Claim
!LF! !LF!
to O
prospectively O
evaluate O
and O
compare O
health O
- O
related O
quality O
- O
of O
- O
life O
( O
qol O
) O
outcomes O
in O
patients O
with O
head O
- O
neck O
squamous O
cell O
carcinoma O
randomized O
to O
either O
intensity O
- O
modulated O
radiation O
therapy O
( O
imrt O
) O
or O
three O
- O
dimensional O
conformal O
radiotherapy O
( O
3d O
- O
crt O
) O
and O
assess O
serial O
longitudinal O
change O
in O
qol O
over O
time O
. O
!LF! !LF!
qol O
outcomes O
were O
assessed O
using O
the O
european O
organization O
for O
research O
and O
treatment O
of O
cancer O
( O
eortc O
) O
qol O
questionnaire O
( O
qlq O
- O
c30 O
) O
and O
head O
- O
neck O
module O
( O
hn O
- O
35 O
) O
at O
baseline O
( O
pre O
- O
treatment O
) O
and O
subsequently O
periodically O
on O
follow O
- O
up O
. O
!LF! !LF!
mean O
scores O
of O
individual O
domains O
/ O
scales O
of O
3d O
- O
crt O
and O
imrt O
were O
compared O
using O
' O
t O
' O
test O
at O
each O
time O
point O
"""" O
; O
"""" O
while O
longitudinal O
change O
in O
mean O
scores O
of O
both O
groups O
over O
time O
was O
evaluated O
by O
repeated O
measurement O
analysis O
of O
variance O
. O
!LF! !LF!
fifty O
eight O
of O
the O
60 O
randomized O
patients O
who O
filled O
the O
qol O
questionnaire O
at O
least O
at O
one O
time O
point O
were O
included O
in O
the O
analysis O
. O
!LF! !LF!
several O
general O
( O
emotional O
functioning O
, O
role O
functioning O
, O
social O
contact O
) O
as O
well O
as O
head O
and O
neck O
cancer O
- O
specific O
( O
dry O
mouth O
, O
opening O
mouth O
, O
sticky O
saliva O
, O
pain O
, O
senses O
) O
qol O
domains O
were O
better O
preserved O
with O
imrt O
compared O
to O
3d O
- O
crt O
at O
different O
time O
points O
. O
!LF! !LF!
importantly O
, O
none O
of O
the O
qol O
domains O
were O
worse O
with O
imrt O
at O
any O
time O
point O
. O
!LF! !LF!
there B-Premise
was I-Premise
substantial I-Premise
deterioration I-Premise
in I-Premise
qol I-Premise
scores I-Premise
immediate I-Premise
post I-Premise
- I-Premise
treatment I-Premise
( I-Premise
3 I-Premise
- I-Premise
months I-Premise
) I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
however B-Premise
, I-Premise
qol I-Premise
scores I-Premise
gradually I-Premise
but I-Premise
definitely I-Premise
improved I-Premise
over I-Premise
time I-Premise
for I-Premise
most I-Premise
domains I-Premise
. I-Premise
!LF! !LF!
global B-Premise
qol I-Premise
, I-Premise
emotional I-Premise
/ I-Premise
role I-Premise
functioning I-Premise
, I-Premise
nausea I-Premise
/ I-Premise
vomiting I-Premise
, I-Premise
pain I-Premise
, I-Premise
swallowing I-Premise
, I-Premise
speech I-Premise
, I-Premise
social I-Premise
contact I-Premise
/ I-Premise
eating I-Premise
, I-Premise
insomnia I-Premise
showed I-Premise
rapid I-Premise
recovery I-Premise
( I-Premise
< I-Premise
6months I-Premise
) I-Premise
while I-Premise
physical I-Premise
/ I-Premise
cognitive I-Premise
functioning I-Premise
, I-Premise
dry I-Premise
mouth I-Premise
, I-Premise
sticky I-Premise
saliva I-Premise
, I-Premise
fatigue I-Premise
, I-Premise
senses I-Premise
showed I-Premise
delayed I-Premise
recovery I-Premise
( I-Premise
> I-Premise
6months I-Premise
) I-Premise
. I-Premise
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
loco I-Premise
- I-Premise
regional I-Premise
or I-Premise
survival I-Premise
between I-Premise
the I-Premise
two I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
there B-Claim
is I-Claim
substantial I-Claim
deterioration I-Claim
in I-Claim
qol I-Claim
after I-Claim
curative I-Claim
- I-Claim
intent I-Claim
head I-Claim
- I-Claim
neck I-Claim
irradiation I-Claim
that I-Claim
gradually I-Claim
improves I-Claim
over I-Claim
time I-Claim
. I-Claim
!LF! !LF!
imrt B-Claim
results I-Claim
in I-Claim
clinically I-Claim
meaningful I-Claim
and I-Claim
statistically I-Claim
better I-Claim
qol I-Claim
scores I-Claim
for I-Claim
some I-Claim
domains I-Claim
compared I-Claim
to I-Claim
3d I-Claim
- I-Claim
crt I-Claim
at I-Claim
several I-Claim
time I-Claim
points I-Claim
with I-Claim
comparable I-Claim
disease I-Claim
outcomes I-Claim
that I-Claim
could I-Claim
support I-Claim
its I-Claim
widespread I-Claim
adoption I-Claim
in I-Claim
routine I-Claim
clinical I-Claim
practice I-Claim
. I-Claim
!LF! !LF!
in O
lithuania O
, O
about O
400 O
cases O
of O
pancreatic O
cancer O
are O
diagnosed O
each O
year O
, O
and O
more O
than O
50 O
% O
of O
patients O
are O
diagnosed O
with O
stage O
iv O
disease O
. O
!LF! !LF!
quality B-Claim
of I-Claim
life I-Claim
is I-Claim
an I-Claim
important I-Claim
issue I-Claim
in I-Claim
pancreatic I-Claim
cancer I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
a O
prospective O
randomized O
clinical O
study O
on O
the O
treatment O
of O
patients O
with O
resectable O
and O
unresectable O
pancreatic O
cancer O
was O
conducted O
at O
the O
department O
of O
oncology O
of O
kaunas O
university O
of O
medicine O
hospital O
, O
and O
in O
this O
study O
, O
quality O
of O
life O
was O
analyzed O
. O
!LF! !LF!
the O
aim O
of O
the O
study O
was O
to O
analyze O
the O
effect O
of O
combined O
treatment O
methods O
on O
quality O
of O
life O
in O
patients O
diagnosed O
with O
pancreatic O
cancer O
. O
!LF! !LF!
during O
2000 O
- O
2005 O
, O
two O
concomitant O
chemoradiation O
treatment O
methods O
( O
radiotherapy O
with O
5 O
- O
fluorouracil O
and O
radiotherapy O
with O
gemcitabine O
) O
were O
analyzed O
in O
the O
study O
. O
!LF! !LF!
a O
total O
of O
60 O
patients O
were O
enrolled O
: O
41 O
patients O
diagnosed O
with O
resectable O
and O
19 O
patients O
diagnosed O
with O
unresectable O
pancreatic O
cancer O
. O
!LF! !LF!
quality O
of O
life O
was O
assessed O
using O
european O
organization O
for O
research O
and O
treatment O
of O
cancer O
quality O
of O
life O
core O
30 O
( O
eortc O
qlq O
- O
c30 O
) O
questionnaire O
. O
!LF! !LF!
three O
main O
quality O
of O
life O
scales O
( O
general O
health O
status O
, O
functional O
, O
and O
symptom O
scales O
) O
were O
assessed O
and O
compared O
between O
two O
treatment O
groups O
. O
!LF! !LF!
the B-Premise
analysis I-Premise
of I-Premise
quality I-Premise
of I-Premise
live I-Premise
assessment I-Premise
showed I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
after I-Premise
treatment I-Premise
in I-Premise
patients I-Premise
with I-Premise
resectable I-Premise
pancreatic I-Premise
cancer I-Premise
and I-Premise
treated I-Premise
with I-Premise
radiotherapy I-Premise
and I-Premise
gemcitabine I-Premise
. I-Premise
!LF! !LF!
decreased B-Premise
quality I-Premise
of I-Premise
life I-Premise
later I-Premise
after I-Premise
treatment I-Premise
was I-Premise
also I-Premise
observed I-Premise
in I-Premise
patients I-Premise
diagnosed I-Premise
with I-Premise
unresectable I-Premise
pancreatic I-Premise
cancer I-Premise
and I-Premise
treated I-Premise
with I-Premise
the I-Premise
same I-Premise
regimen I-Premise
. I-Premise
!LF! !LF!
treatment B-Claim
with I-Claim
radiotherapy I-Claim
and I-Claim
5 I-Claim
- I-Claim
fluorouracil I-Claim
changed I-Claim
only I-Claim
some I-Claim
aspects I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
did I-Claim
not I-Claim
have I-Claim
a I-Claim
significant I-Claim
impact I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim
!LF! !LF!
therapy B-Claim
of I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
gastric I-Claim
or I-Claim
gastroesophageal I-Claim
junction I-Claim
cancer I-Claim
should I-Claim
provide I-Claim
symptom I-Claim
relief I-Claim
and I-Claim
improve I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
qol I-Claim
) I-Claim
because I-Claim
most I-Claim
patients I-Claim
are I-Claim
symptomatic I-Claim
at I-Claim
baseline I-Claim
. I-Claim
!LF! !LF!
using O
validated O
instruments O
, O
we O
prospectively O
assessed O
qol O
( O
even O
after O
completion O
of O
protocol O
treatment O
) O
as O
one O
of O
the O
secondary O
end O
points O
of O
the O
v325 O
phase O
iii O
trial O
. O
!LF! !LF!
four O
hundred O
forty O
- O
five O
patients O
randomly O
received O
either O
docetaxel O
75 O
mg O
/ O
m O
( O
2 O
) O
and O
cisplatin O
75 O
mg O
/ O
m O
( O
2 O
) O
each O
on O
day O
1 O
plus O
fluorouracil O
750 O
mg O
/ O
m O
( O
2 O
) O
/ O
d O
continuous O
infusion O
on O
days O
1 O
to O
5 O
every O
3 O
weeks O
( O
dcf O
) O
or O
cisplatin O
100 O
mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
plus O
fluorouracil O
1 O
, O
000 O
mg O
/ O
m O
( O
2 O
) O
/ O
d O
continuous O
infusion O
on O
days O
1 O
to O
5 O
every O
4 O
weeks O
( O
cf O
) O
. O
!LF! !LF!
the O
european O
organisation O
for O
research O
and O
treatment O
of O
cancer O
quality O
of O
life O
questionnaire O
c30 O
( O
eortc O
qlq O
- O
c30 O
) O
and O
, O
where O
available O
, O
the O
euroqol O
eq O
- O
5d O
questionnaire O
were O
administered O
every O
8 O
weeks O
from O
baseline O
until O
progression O
and O
then O
every O
3 O
months O
. O
!LF! !LF!
time O
to O
definitive O
deterioration O
of O
qol O
parameters O
was O
analyzed O
. O
!LF! !LF!
the O
proportions O
of O
patients O
having O
assessable O
eortc O
qlq O
- O
c30 O
and O
eq O
- O
5d O
questionnaires O
at O
baseline O
were O
86 O
. O
0 O
% O
and O
78 O
. O
7 O
% O
with O
dcf O
, O
respectively O
, O
and O
89 O
. O
7 O
% O
and O
92 O
. O
8 O
% O
with O
cf O
, O
respectively O
. O
!LF! !LF!
time B-Premise
to I-Premise
5 I-Premise
% I-Premise
deterioration I-Premise
of I-Premise
global I-Premise
health I-Premise
status I-Premise
( I-Premise
primary I-Premise
end I-Premise
point I-Premise
) I-Premise
significantly I-Premise
favored I-Premise
dcf I-Premise
over I-Premise
cf I-Premise
( I-Premise
log I-Premise
- I-Premise
rank I-Premise
test I-Premise
, I-Premise
p I-Premise
= I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
qol B-Premise
was I-Premise
preserved I-Premise
longer I-Premise
for I-Premise
patients I-Premise
on I-Premise
dcf I-Premise
than I-Premise
those I-Premise
on I-Premise
cf I-Premise
for I-Premise
all I-Premise
time I-Premise
to I-Premise
deterioration I-Premise
analyses I-Premise
, I-Premise
demonstrating I-Premise
the I-Premise
statistical I-Premise
superiority I-Premise
of I-Premise
dcf I-Premise
compared I-Premise
with I-Premise
cf I-Premise
. I-Premise
!LF! !LF!
v325 O
represents O
the O
largest O
trial O
with O
the O
longest O
prospectively O
controlled O
evaluations O
of O
qol O
during O
protocol O
chemotherapy O
and O
follow O
- O
up O
in O
patients O
with O
advanced O
gastric O
or O
gastroesophageal O
junction O
cancer O
. O
!LF! !LF!
in B-Claim
v325 I-Claim
, I-Claim
advanced I-Claim
gastric I-Claim
or I-Claim
gastroesophageal I-Claim
junction I-Claim
cancer I-Claim
patients I-Claim
receiving I-Claim
dcf I-Claim
not I-Claim
only I-Claim
had I-Claim
statistically I-Claim
improved I-Claim
overall I-Claim
survival I-Claim
and I-Claim
time I-Claim
to I-Claim
tumor I-Claim
- I-Claim
progression I-Claim
, I-Claim
but I-Claim
they I-Claim
also I-Claim
had I-Claim
better I-Claim
preservation I-Claim
of I-Claim
qol I-Claim
compared I-Claim
with I-Claim
patients I-Claim
receiving I-Claim
cf I-Claim
. I-Claim
!LF! !LF!
many O
patients O
with O
cancer O
experience O
depression O
and O
anxiety O
, O
and O
an O
associated O
decrease O
in O
quality O
of O
life O
( O
qol O
) O
during O
radiation O
therapy O
( O
rt O
) O
. O
!LF! !LF!
the O
main O
objective O
of O
the O
study O
was O
to O
determine O
the O
benefits O
of O
psychosocial O
interventions O
for O
cancer O
patients O
who O
received O
rt O
. O
!LF! !LF!
patients O
with O
cancer O
( O
n O
= O
178 O
) O
who O
agreed O
to O
participate O
in O
the O
study O
were O
randomized O
to O
the O
intervention O
arm O
( O
n O
= O
89 O
) O
or O
the O
control O
arm O
( O
n O
= O
89 O
) O
. O
!LF! !LF!
patients O
in O
the O
intervention O
group O
received O
psychosocial O
care O
during O
rt O
, O
whereas O
the O
control O
group O
received O
rt O
only O
. O
!LF! !LF!
the O
benefits O
of O
the O
intervention O
were O
evaluated O
using O
the O
zung O
self O
- O
rating O
depression O
scale O
( O
sds O
) O
to O
measure O
depression O
, O
the O
self O
- O
rating O
anxiety O
scale O
( O
sas O
) O
to O
assess O
anxiety O
, O
and O
the O
european O
organization O
for O
research O
and O
treatment O
of O
cancer O
quality O
of O
life O
questionnaire O
- O
core O
30 O
( O
eortc O
qlq O
- O
c30 O
) O
to O
survey O
health O
- O
related O
qol O
. O
!LF! !LF!
the O
association O
between O
intervention O
and O
survival O
was O
also O
assessed O
. O
!LF! !LF!
patients B-Premise
randomly I-Premise
assigned I-Premise
to I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
showed I-Premise
significant I-Premise
improvements I-Premise
on I-Premise
symptoms I-Premise
of I-Premise
depression I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
and I-Premise
anxiety I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
, I-Premise
health I-Premise
- I-Premise
related I-Premise
qol I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
( I-Premise
i I-Premise
. I-Premise
e I-Premise
. I-Premise
better I-Premise
global I-Premise
health I-Premise
status I-Premise
, I-Premise
and I-Premise
physical I-Premise
and I-Premise
emotional I-Premise
functioning I-Premise
, I-Premise
and I-Premise
less I-Premise
insomnia I-Premise
) I-Premise
when I-Premise
compared I-Premise
with I-Premise
controls I-Premise
. I-Premise
!LF! !LF!
in B-Claim
the I-Claim
subset I-Claim
analysis I-Claim
, I-Claim
female I-Claim
patients I-Claim
, I-Claim
those I-Claim
that I-Claim
received I-Claim
high I-Claim
dose I-Claim
irradiation I-Claim
, I-Claim
and I-Claim
those I-Claim
that I-Claim
underwent I-Claim
adjuvant I-Claim
chemotherapy I-Claim
could I-Claim
benefit I-Claim
more I-Claim
from I-Claim
psychosocial I-Claim
intervention I-Claim
. I-Claim
!LF! !LF!
there B-Premise
was I-Premise
no I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
in I-Premise
disease I-Premise
- I-Premise
free I-Premise
survival I-Premise
( I-Premise
dfs I-Premise
) I-Premise
( I-Premise
2 I-Premise
- I-Premise
year I-Premise
dfs I-Premise
79 I-Premise
. I-Premise
8 I-Premise
% I-Premise
in I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
and I-Premise
76 I-Premise
. I-Premise
4 I-Premise
% I-Premise
in I-Premise
the I-Premise
control I-Premise
arm I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
527 I-Premise
) I-Premise
and I-Premise
overall I-Premise
survival I-Premise
( I-Premise
os I-Premise
) I-Premise
( I-Premise
2 I-Premise
- I-Premise
year I-Premise
os I-Premise
83 I-Premise
. I-Premise
1 I-Premise
% I-Premise
in I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
and I-Premise
84 I-Premise
. I-Premise
3 I-Premise
% I-Premise
in I-Premise
the I-Premise
control I-Premise
arm I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
925 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
psychosocial B-Claim
intervention I-Claim
is I-Claim
a I-Claim
cost I-Claim
- I-Claim
effective I-Claim
approach I-Claim
that I-Claim
can I-Claim
improve I-Claim
a I-Claim
patient I-Claim
' I-Claim
s I-Claim
mood I-Claim
and I-Claim
qol I-Claim
both I-Claim
during I-Claim
and I-Claim
after I-Claim
rt I-Claim
. I-Claim
!LF! !LF!
however B-Claim
, I-Claim
the I-Claim
intervention I-Claim
was I-Claim
not I-Claim
found I-Claim
to I-Claim
reduce I-Claim
the I-Claim
risk I-Claim
of I-Claim
cancer I-Claim
recurrence I-Claim
and I-Claim
death I-Claim
. I-Claim
!LF! !LF!
dignity O
therapy O
is O
a O
unique O
, O
individualised O
, O
short O
- O
term O
psychotherapy O
that O
was O
developed O
for O
patients O
( O
and O
their O
families O
) O
living O
with O
life O
- O
threatening O
or O
life O
- O
limiting O
illness O
. O
!LF! !LF!
we O
investigated O
whether O
dignity O
therapy O
could O
mitigate O
distress O
or O
bolster O
the O
experience O
in O
patients O
nearing O
the O
end O
of O
their O
lives O
. O
!LF! !LF!
patients O
( O
aged O
≥18 O
years O
) O
with O
a O
terminal O
prognosis O
( O
life O
expectancy O
≤6 O
months O
) O
who O
were O
receiving O
palliative O
care O
in O
a O
hospital O
or O
community O
setting O
( O
hospice O
or O
home O
) O
in O
canada O
, O
usa O
, O
and O
australia O
were O
randomly O
assigned O
to O
dignity O
therapy O
, O
client O
- O
centred O
care O
, O
or O
standard O
palliative O
care O
in O
a O
1 O
: O
1 O
: O
1 O
ratio O
. O
!LF! !LF!
randomisation O
was O
by O
use O
of O
a O
computer O
- O
generated O
table O
of O
random O
numbers O
in O
blocks O
of O
30 O
. O
!LF! !LF!
allocation O
concealment O
was O
by O
use O
of O
opaque O
sealed O
envelopes O
. O
!LF! !LF!
the O
primary O
outcomes O
- O
- O
reductions O
in O
various O
dimensions O
of O
distress O
before O
and O
after O
completion O
of O
the O
study O
- O
- O
were O
measured O
with O
the O
functional O
assessment O
of O
chronic O
illness O
therapy O
spiritual O
well O
- O
being O
scale O
, O
patient O
dignity O
inventory O
, O
hospital O
anxiety O
and O
depression O
scale O
, O
items O
from O
the O
structured O
interview O
for O
symptoms O
and O
concerns O
, O
quality O
of O
life O
scale O
, O
and O
modified O
edmonton O
symptom O
assessment O
scale O
. O
!LF! !LF!
secondary O
outcomes O
of O
self O
- O
reported O
end O
- O
of O
- O
life O
experiences O
were O
assessed O
in O
a O
survey O
that O
was O
undertaken O
after O
the O
completion O
of O
the O
study O
. O
!LF! !LF!
outcomes O
were O
assessed O
by O
research O
staff O
with O
whom O
the O
participant O
had O
no O
previous O
contact O
to O
avoid O
any O
possible O
response O
bias O
or O
contamination O
. O
!LF! !LF!
analyses O
were O
done O
on O
all O
patients O
with O
available O
data O
at O
baseline O
and O
at O
the O
end O
of O
the O
study O
intervention O
. O
!LF! !LF!
165 O
of O
441 O
patients O
were O
assigned O
to O
dignity O
therapy O
, O
140 O
standard O
palliative O
care O
, O
and O
136 O
client O
- O
centred O
care O
. O
!LF! !LF!
108 O
, O
111 O
, O
and O
107 O
patients O
, O
respectively O
, O
were O
analysed O
. O
!LF! !LF!
no B-Premise
significant I-Premise
differences I-Premise
were I-Premise
noted I-Premise
in I-Premise
the I-Premise
distress I-Premise
levels I-Premise
before I-Premise
and I-Premise
after I-Premise
completion I-Premise
of I-Premise
the I-Premise
study I-Premise
in I-Premise
the I-Premise
three I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
for B-Premise
the I-Premise
secondary I-Premise
outcomes I-Premise
, I-Premise
patients I-Premise
reported I-Premise
that I-Premise
dignity I-Premise
therapy I-Premise
was I-Premise
significantly I-Premise
more I-Premise
likely I-Premise
than I-Premise
the I-Premise
other I-Premise
two I-Premise
interventions I-Premise
to I-Premise
have I-Premise
been I-Premise
helpful I-Premise
( I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
= I-Premise
35 I-Premise
· I-Premise
50 I-Premise
, I-Premise
df I-Premise
= I-Premise
2 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
0 I-Premise
· I-Premise
0001 I-Premise
) I-Premise
, I-Premise
improve I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
= I-Premise
14 I-Premise
· I-Premise
52 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
· I-Premise
001 I-Premise
) I-Premise
, I-Premise
increase I-Premise
sense I-Premise
of I-Premise
dignity I-Premise
( I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
= I-Premise
12 I-Premise
· I-Premise
66 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
· I-Premise
002 I-Premise
) I-Premise
, I-Premise
change I-Premise
how I-Premise
their I-Premise
family I-Premise
saw I-Premise
and I-Premise
appreciated I-Premise
them I-Premise
( I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
= I-Premise
33 I-Premise
· I-Premise
81 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
0 I-Premise
· I-Premise
0001 I-Premise
) I-Premise
, I-Premise
and I-Premise
be I-Premise
helpful I-Premise
to I-Premise
their I-Premise
family I-Premise
( I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
= I-Premise
33 I-Premise
· I-Premise
86 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
0 I-Premise
· I-Premise
0001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
dignity B-Premise
therapy I-Premise
was I-Premise
significantly I-Premise
better I-Premise
than I-Premise
client I-Premise
- I-Premise
centred I-Premise
care I-Premise
in I-Premise
improving I-Premise
spiritual I-Premise
wellbeing I-Premise
( I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
= I-Premise
10 I-Premise
· I-Premise
35 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
· I-Premise
006 I-Premise
) I-Premise
, I-Premise
and I-Premise
was I-Premise
significantly I-Premise
better I-Premise
than I-Premise
standard I-Premise
palliative I-Premise
care I-Premise
in I-Premise
terms I-Premise
of I-Premise
lessening I-Premise
sadness I-Premise
or I-Premise
depression I-Premise
( I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
= I-Premise
9 I-Premise
· I-Premise
38 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
· I-Premise
009 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
significantly B-Premise
more I-Premise
patients I-Premise
who I-Premise
had I-Premise
received I-Premise
dignity I-Premise
therapy I-Premise
reported I-Premise
that I-Premise
the I-Premise
study I-Premise
group I-Premise
had I-Premise
been I-Premise
satisfactory I-Premise
, I-Premise
compared I-Premise
with I-Premise
those I-Premise
who I-Premise
received I-Premise
standard I-Premise
palliative I-Premise
care I-Premise
( I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
= I-Premise
29 I-Premise
· I-Premise
58 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
0 I-Premise
· I-Premise
0001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
although B-Claim
the I-Claim
ability I-Claim
of I-Claim
dignity I-Claim
therapy I-Claim
to I-Claim
mitigate I-Claim
outright I-Claim
distress I-Claim
, I-Claim
such I-Claim
as I-Claim
depression I-Claim
, I-Claim
desire I-Claim
for I-Claim
death I-Claim
or I-Claim
suicidality I-Claim
, I-Claim
has I-Claim
yet I-Claim
to I-Claim
be I-Claim
proven I-Claim
, I-Claim
its B-Claim
benefits I-Claim
in I-Claim
terms I-Claim
of I-Claim
self I-Claim
- I-Claim
reported I-Claim
end I-Claim
- I-Claim
of I-Claim
- I-Claim
life I-Claim
experiences I-Claim
support I-Claim
its I-Claim
clinical I-Claim
application I-Claim
for I-Claim
patients I-Claim
nearing I-Claim
death I-Claim
. I-Claim
!LF! !LF!
the O
finding O
of O
a O
decrease O
in O
contralateral O
breast O
cancer O
incidence O
following O
tamoxifen O
administration O
for O
adjuvant O
therapy O
led O
to O
the O
concept O
that O
the O
drug O
might O
play O
a O
role O
in O
breast O
cancer O
prevention O
. O
!LF! !LF!
to O
test O
this O
hypothesis O
, O
the O
national O
surgical O
adjuvant O
breast O
and O
bowel O
project O
initiated O
the O
breast O
cancer O
prevention O
trial O
( O
p O
- O
1 O
) O
in O
1992 O
. O
!LF! !LF!
women O
( O
n O
= O
13388 O
) O
at O
increased O
risk O
for O
breast O
cancer O
because O
they O
1 O
) O
were O
60 O
years O
of O
age O
or O
older O
, O
2 O
) O
were O
35 O
- O
59 O
years O
of O
age O
with O
a O
5 O
- O
year O
predicted O
risk O
for O
breast O
cancer O
of O
at O
least O
1 O
. O
66 O
% O
, O
or O
3 O
) O
had O
a O
history O
of O
lobular O
carcinoma O
in O
situ O
were O
randomly O
assigned O
to O
receive O
placebo O
( O
n O
= O
6707 O
) O
or O
20 O
mg O
/ O
day O
tamoxifen O
( O
n O
= O
6681 O
) O
for O
5 O
years O
. O
!LF! !LF!
gail O
' O
s O
algorithm O
, O
based O
on O
a O
multivariate O
logistic O
regression O
model O
using O
combinations O
of O
risk O
factors O
, O
was O
used O
to O
estimate O
the O
probability O
( O
risk O
) O
of O
occurrence O
of O
breast O
cancer O
over O
time O
. O
!LF! !LF!
tamoxifen B-Premise
reduced I-Premise
the I-Premise
risk I-Premise
of I-Premise
invasive I-Premise
breast I-Premise
cancer I-Premise
by I-Premise
49 I-Premise
% I-Premise
( I-Premise
two I-Premise
- I-Premise
sided I-Premise
p I-Premise
< I-Premise
. I-Premise
00001 I-Premise
) I-Premise
, I-Premise
with I-Premise
cumulative I-Premise
incidence I-Premise
through I-Premise
69 I-Premise
months I-Premise
of I-Premise
follow I-Premise
- I-Premise
up I-Premise
of I-Premise
43 I-Premise
. I-Premise
4 I-Premise
versus I-Premise
22 I-Premise
. I-Premise
0 I-Premise
per I-Premise
1000 I-Premise
women I-Premise
in I-Premise
the I-Premise
placebo I-Premise
and I-Premise
tamoxifen I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
the O
decreased O
risk O
occurred O
in O
women O
aged O
49 O
years O
or O
younger O
( O
44 O
% O
) O
, O
50 O
- O
59 O
years O
( O
51 O
% O
) O
, O
and O
60 O
years O
or O
older O
( O
55 O
% O
) O
"""" O
; O
"""" O
risk B-Premise
was I-Premise
also I-Premise
reduced I-Premise
in I-Premise
women I-Premise
with I-Premise
a I-Premise
history I-Premise
of I-Premise
lobular I-Premise
carcinoma I-Premise
in I-Premise
situ I-Premise
( I-Premise
56 I-Premise
% I-Premise
) I-Premise
or I-Premise
atypical I-Premise
hyperplasia I-Premise
( I-Premise
86 I-Premise
% I-Premise
) I-Premise
and I-Premise
in I-Premise
those I-Premise
with I-Premise
any I-Premise
category I-Premise
of I-Premise
predicted I-Premise
5 I-Premise
- I-Premise
year I-Premise
risk I-Premise
. I-Premise
!LF! !LF!
tamoxifen B-Premise
reduced I-Premise
the I-Premise
risk I-Premise
of I-Premise
noninvasive I-Premise
breast I-Premise
cancer I-Premise
by I-Premise
50 I-Premise
% I-Premise
( I-Premise
two I-Premise
- I-Premise
sided I-Premise
p I-Premise
< I-Premise
. I-Premise
002 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
tamoxifen B-Premise
reduced I-Premise
the I-Premise
occurrence I-Premise
of I-Premise
estrogen I-Premise
receptor I-Premise
- I-Premise
positive I-Premise
tumors I-Premise
by I-Premise
69 I-Premise
% I-Premise
, I-Premise
but I-Premise
no I-Premise
difference I-Premise
in I-Premise
the I-Premise
occurrence I-Premise
of I-Premise
estrogen I-Premise
receptor I-Premise
- I-Premise
negative I-Premise
tumors I-Premise
was I-Premise
seen I-Premise
. I-Premise
!LF! !LF!
tamoxifen B-Premise
administration I-Premise
did I-Premise
not I-Premise
alter I-Premise
the I-Premise
average I-Premise
annual I-Premise
rate I-Premise
of I-Premise
ischemic I-Premise
heart I-Premise
disease I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
however I-Premise
, I-Premise
a I-Premise
reduction I-Premise
in I-Premise
hip I-Premise
, I-Premise
radius I-Premise
( I-Premise
colles I-Premise
' I-Premise
) I-Premise
, I-Premise
and I-Premise
spine I-Premise
fractures I-Premise
was I-Premise
observed I-Premise
. I-Premise
!LF! !LF!
the B-Premise
rate I-Premise
of I-Premise
endometrial I-Premise
cancer I-Premise
was I-Premise
increased I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
( I-Premise
risk I-Premise
ratio I-Premise
= I-Premise
2 I-Premise
. I-Premise
53 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
= I-Premise
1 I-Premise
. I-Premise
35 I-Premise
- I-Premise
4 I-Premise
. I-Premise
97 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
this I-Premise
increased I-Premise
risk I-Premise
occurred I-Premise
predominantly I-Premise
in I-Premise
women I-Premise
aged I-Premise
50 I-Premise
years I-Premise
or I-Premise
older I-Premise
. I-Premise
!LF! !LF!
all O
endometrial O
cancers O
in O
the O
tamoxifen O
group O
were O
stage O
i O
( O
localized O
disease O
) O
"""" O
; O
"""" O
no B-Premise
endometrial I-Premise
cancer I-Premise
deaths I-Premise
have I-Premise
occurred I-Premise
in I-Premise
this I-Premise
group I-Premise
. I-Premise
!LF! !LF!
no B-Premise
liver I-Premise
cancers I-Premise
or I-Premise
increase I-Premise
in I-Premise
colon I-Premise
, I-Premise
rectal I-Premise
, I-Premise
ovarian I-Premise
, I-Premise
or I-Premise
other I-Premise
tumors I-Premise
was I-Premise
observed I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
. I-Premise
!LF! !LF!
the B-Premise
rates I-Premise
of I-Premise
stroke I-Premise
, I-Premise
pulmonary I-Premise
embolism I-Premise
, I-Premise
and I-Premise
deep I-Premise
- I-Premise
vein I-Premise
thrombosis I-Premise
were I-Premise
elevated I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
these I-Premise
events I-Premise
occurred I-Premise
more I-Premise
frequently I-Premise
in I-Premise
women I-Premise
aged I-Premise
50 I-Premise
years I-Premise
or I-Premise
older I-Premise
. I-Premise
!LF! !LF!
tamoxifen B-Claim
decreases I-Claim
the I-Claim
incidence I-Claim
of I-Claim
invasive I-Claim
and I-Claim
noninvasive I-Claim
breast I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
despite B-Claim
side I-Claim
effects I-Claim
resulting I-Claim
from I-Claim
administration I-Claim
of I-Claim
tamoxifen I-Claim
, I-Claim
its I-Claim
use I-Claim
as I-Claim
a I-Claim
breast I-Claim
cancer I-Claim
preventive I-Claim
agent I-Claim
is I-Claim
appropriate I-Claim
in I-Claim
many I-Claim
women I-Claim
at I-Claim
increased I-Claim
risk I-Claim
for I-Claim
the I-Claim
disease I-Claim
. I-Claim
!LF! !LF!
to O
compare O
the O
efficacy O
of O
a O
standard O
anthracycline O
- O
based O
regimen O
to O
a O
dose O
- O
intensified O
anthracycline O
regimen O
in O
locally O
advanced O
breast O
cancer O
. O
!LF! !LF!
locally O
advanced O
breast O
cancer O
patients O
were O
randomly O
assigned O
onto O
a O
study O
comparing O
cyclophosphamide O
( O
c O
"""" O
; O
"""" O
75 O
mg O
/ O
m O
( O
2 O
) O
orally O
days O
1 O
to O
14 O
) O
, O
epirubicin O
( O
e O
"""" O
; O
"""" O
60 O
mg O
/ O
m O
( O
2 O
) O
intravenously O
[ O
iv O
] O
days O
1 O
, O
8 O
) O
, O
and O
fluorouracil O
( O
f O
"""" O
; O
"""" O
500 O
mg O
/ O
m O
( O
2 O
) O
iv O
days O
1 O
, O
8 O
) O
six O
cycles O
every O
28 O
days O
versus O
e O
( O
120 O
mg O
/ O
m O
( O
2 O
) O
iv O
day O
1 O
) O
, O
c O
( O
830 O
mg O
/ O
m O
( O
2 O
) O
iv O
day O
1 O
) O
, O
and O
granulocyte O
colony O
- O
stimulating O
factor O
( O
filgrastim O
"""" O
; O
"""" O
5 O
micro O
g O
/ O
kg O
/ O
d O
subcutaneously O
days O
2 O
to O
13 O
) O
six O
cycles O
every O
14 O
days O
. O
!LF! !LF!
the O
study O
was O
designed O
to O
detect O
a O
15 O
% O
improvement O
"""" O
; O
"""" O
that O
is O
, O
from O
50 O
% O
to O
65 O
% O
in O
median O
progression O
- O
free O
survival O
( O
pfs O
) O
in O
favor O
of O
the O
dose O
- O
intensified O
regimen O
. O
!LF! !LF!
a O
total O
of O
448 O
patients O
were O
enrolled O
over O
a O
period O
of O
3 O
years O
. O
!LF! !LF!
the O
median O
dose O
intensity O
delivered O
for O
c O
and O
e O
reached O
, O
respectively O
, O
85 O
% O
and O
87 O
% O
of O
that O
planned O
in O
the O
cef O
arm O
and O
96 O
% O
and O
95 O
% O
of O
that O
planned O
in O
the O
ec O
arm O
. O
!LF! !LF!
the B-Premise
dose I-Premise
- I-Premise
intensified I-Premise
arm I-Premise
was I-Premise
slightly I-Premise
more I-Premise
emetogenic I-Premise
and I-Premise
generated I-Premise
more I-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
anemia I-Premise
but I-Premise
less I-Premise
febrile I-Premise
neutropenia I-Premise
episodes I-Premise
. I-Premise
!LF! !LF!
after O
a O
median O
follow O
- O
up O
of O
5 O
. O
5 O
years O
, O
277 O
events O
have O
been O
reported O
. O
!LF! !LF!
the B-Premise
median I-Premise
pfs I-Premise
was I-Premise
34 I-Premise
and I-Premise
33 I-Premise
. I-Premise
7 I-Premise
months I-Premise
for I-Premise
cef I-Premise
and I-Premise
ec I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
68 I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
5 I-Premise
- I-Premise
year I-Premise
survival I-Premise
rate I-Premise
was I-Premise
53 I-Premise
% I-Premise
and I-Premise
51 I-Premise
% I-Premise
for I-Premise
cef I-Premise
and I-Premise
ec I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
94 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
dose B-Claim
- B-Claim
intensified B-Claim
ec I-Claim
does I-Claim
not I-Claim
provide I-Claim
a I-Claim
measurable I-Claim
therapeutic I-Claim
benefit I-Claim
over I-Claim
cef I-Claim
as I-Claim
neoadjuvant I-Claim
chemotherapy I-Claim
for I-Claim
unselected I-Claim
locally I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
to O
compare O
dose O
- O
volume O
histogram O
variables O
for O
the O
internal O
and O
external O
urinary O
sphincters O
( O
ius O
/ O
eus O
) O
with O
urinary O
quality O
of O
life O
after O
prostate O
brachytherapy O
. O
!LF! !LF!
subjects O
were O
42 O
consecutive O
men O
from O
a O
prospective O
study O
of O
brachytherapy O
as O
monotherapy O
with O
( O
125 O
) O
i O
for O
intermediate O
- O
risk O
localized O
prostate O
cancer O
. O
!LF! !LF!
no O
patient O
received O
hormonal O
therapy O
. O
!LF! !LF!
preplanning O
constraints O
included O
prostate O
v100 O
higher O
than O
95 O
% O
, O
v150 O
lower O
than O
60 O
% O
, O
and O
v200 O
lower O
than O
20 O
% O
and O
rectal O
r100 O
less O
than O
1cm O
( O
3 O
) O
. O
!LF! !LF!
patients O
completed O
the O
expanded O
prostate O
cancer O
index O
composite O
quality O
- O
of O
- O
life O
questionnaire O
before O
and O
at O
1 O
, O
4 O
, O
8 O
, O
and O
12 O
months O
after O
implantation O
, O
and O
urinary O
domain O
scores O
were O
analyzed O
. O
!LF! !LF!
all O
structures O
including O
the O
ius O
and O
eus O
were O
contoured O
on O
t2 O
- O
weighted O
mri O
at O
day O
30 O
, O
and O
doses O
received O
were O
calculated O
from O
identification O
of O
seeds O
on O
ct O
. O
spearman O
' O
s O
( O
nonparametric O
) O
rank O
correlation O
coefficient O
( O
ρ O
) O
was O
used O
for O
statistical O
analyses O
. O
!LF! !LF!
overall O
urinary O
morbidity O
was O
worst O
at O
1 O
month O
after O
the O
implant O
. O
!LF! !LF!
urinary B-Premise
function I-Premise
declined I-Premise
when I-Premise
the I-Premise
ius I-Premise
v285 I-Premise
was I-Premise
0 I-Premise
. I-Premise
4 I-Premise
% I-Premise
( I-Premise
ρ I-Premise
= I-Premise
- I-Premise
0 I-Premise
. I-Premise
32 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
04 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
bother B-Premise
worsened I-Premise
when I-Premise
the I-Premise
ius I-Premise
v35 I-Premise
was I-Premise
99 I-Premise
% I-Premise
( I-Premise
ρ I-Premise
= I-Premise
- I-Premise
0 I-Premise
. I-Premise
31 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
or I-Premise
the I-Premise
eus I-Premise
v240 I-Premise
was I-Premise
63 I-Premise
% I-Premise
( I-Premise
ρ I-Premise
= I-Premise
- I-Premise
0 I-Premise
. I-Premise
31 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
irritation B-Premise
increased I-Premise
when I-Premise
the I-Premise
ius I-Premise
v35 I-Premise
was I-Premise
95 I-Premise
% I-Premise
( I-Premise
ρ I-Premise
= I-Premise
- I-Premise
0 I-Premise
. I-Premise
37 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
and I-Premise
the I-Premise
eus I-Premise
v265 I-Premise
was I-Premise
24 I-Premise
% I-Premise
( I-Premise
ρ I-Premise
= I-Premise
- I-Premise
0 I-Premise
. I-Premise
32 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
04 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
and O
urgency B-Premise
worsened I-Premise
when I-Premise
the I-Premise
ius I-Premise
v35 I-Premise
was I-Premise
99 I-Premise
. I-Premise
5 I-Premise
% I-Premise
( I-Premise
ρ I-Premise
= I-Premise
- I-Premise
0 I-Premise
. I-Premise
38 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
incontinence B-Premise
did I-Premise
not I-Premise
correlate I-Premise
with I-Premise
eus I-Premise
or I-Premise
ius I-Premise
dose I-Premise
. I-Premise
!LF! !LF!
doses B-Claim
to I-Claim
the I-Claim
ius I-Claim
and I-Claim
eus I-Claim
on I-Claim
mri I-Claim
/ I-Claim
ct I-Claim
predicted I-Claim
worse I-Claim
urinary I-Claim
function I-Claim
, I-Claim
with I-Claim
greater I-Claim
bother I-Claim
, I-Claim
irritative I-Claim
symptoms I-Claim
, I-Claim
and I-Claim
urgency I-Claim
. I-Claim
!LF! !LF!
incorporating B-Claim
mri I-Claim
- I-Claim
based I-Claim
dose I-Claim
- I-Claim
volume I-Claim
histogram I-Claim
analysis I-Claim
into I-Claim
the I-Claim
treatment I-Claim
planning I-Claim
process I-Claim
may I-Claim
reduce I-Claim
acute I-Claim
urinary I-Claim
morbidity I-Claim
after I-Claim
brachytherapy I-Claim
. I-Claim
!LF! !LF!
the B-Claim
incidence I-Claim
and I-Claim
development I-Claim
of I-Claim
cancer I-Claim
are I-Claim
closely I-Claim
related I-Claim
to I-Claim
dysfunction I-Claim
of I-Claim
immune I-Claim
function I-Claim
. I-Claim
!LF! !LF!
the O
immune O
system O
can O
not O
identify O
and O
remove O
malignant O
and O
mutant O
cells O
, O
which O
cause O
tumor O
cells O
to O
escape O
from O
surveillance O
and O
clearance O
of O
the O
immune O
system O
. O
!LF! !LF!
immunobiological O
cancer O
therapy O
plays O
an O
important O
role O
in O
strengthening O
body O
immunological O
surveillance O
function O
and O
killing O
remaining O
tumor O
cells O
in O
the O
body O
. O
!LF! !LF!
we O
investigated O
the O
role O
of O
dc O
/ O
cik O
( O
dendritic O
cell O
/ O
cytokine O
- O
induced O
killer O
cells O
) O
immunobiological O
cancer O
therapy O
in O
maintenance O
therapy O
of O
advanced O
non O
- O
small O
cell O
lung O
cancer O
. O
!LF! !LF!
when O
60 O
cases O
of O
non O
- O
small O
cell O
lung O
cancer O
patients O
in O
stage O
iiib O
and O
iv O
reached O
stable O
disease O
after O
treatment O
with O
4 O
cycles O
of O
a O
two O
- O
drug O
regimen O
with O
platinum O
, O
they O
were O
randomly O
divided O
into O
two O
groups O
. O
!LF! !LF!
one O
group O
was O
treated O
with O
dc O
/ O
cik O
immunobiological O
cancer O
therapy O
, O
and O
the O
other O
was O
taken O
as O
a O
control O
group O
. O
!LF! !LF!
finally O
, O
cancer O
progression O
time O
and O
toxicity O
reaction O
of O
the O
two O
groups O
were O
evaluated O
. O
!LF! !LF!
dc B-Premise
/ B-Premise
cik B-Premise
treatment I-Premise
prolongs I-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
( I-Premise
3 I-Premise
. I-Premise
20 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
2 I-Premise
. I-Premise
94 I-Premise
- I-Premise
3 I-Premise
. I-Premise
50 I-Premise
] I-Premise
vs I-Premise
2 I-Premise
. I-Premise
56 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
2 I-Premise
. I-Premise
39 I-Premise
- I-Premise
2 I-Premise
. I-Premise
73 I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
in B-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
the I-Premise
proportion I-Premise
of I-Premise
nk I-Premise
cells I-Premise
, I-Premise
t I-Premise
- I-Premise
cell I-Premise
subgroups I-Premise
cd3 I-Premise
+ I-Premise
, I-Premise
cd4 I-Premise
+ I-Premise
and I-Premise
cd8 I-Premise
+ I-Premise
had I-Premise
a I-Premise
significant I-Premise
change I-Premise
before I-Premise
and I-Premise
after I-Premise
treatment I-Premise
. I-Premise
!LF! !LF!
liver B-Premise
and I-Premise
kidney I-Premise
function I-Premise
and I-Premise
blood I-Premise
tests I-Premise
of I-Premise
the I-Premise
treatment I-Premise
group I-Premise
were I-Premise
within I-Premise
the I-Premise
normal I-Premise
range I-Premise
before I-Premise
and I-Premise
after I-Premise
treatment I-Premise
. I-Premise
!LF! !LF!
in B-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
1 I-Premise
case I-Premise
suffered I-Premise
from I-Premise
chest I-Premise
distress I-Premise
, I-Premise
3 I-Premise
cases I-Premise
suffered I-Premise
from I-Premise
acratia I-Premise
, I-Premise
and I-Premise
4 I-Premise
cases I-Premise
suffered I-Premise
from I-Premise
pyrexia I-Premise
. I-Premise
!LF! !LF!
dc B-Claim
/ B-Claim
cik B-Claim
treatment I-Claim
had I-Claim
potential I-Claim
benefit I-Claim
for I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non I-Claim
- I-Claim
small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
compared I-Claim
with I-Claim
the I-Claim
control I-Claim
group I-Claim
and I-Claim
had I-Claim
no I-Claim
obvious I-Claim
side I-Claim
effects I-Claim
. I-Claim
!LF! !LF!
dc B-Claim
/ B-Claim
cik B-Claim
treatment I-Claim
is I-Claim
a I-Claim
safe I-Claim
and I-Claim
effective I-Claim
method I-Claim
for I-Claim
maintenance I-Claim
therapy I-Claim
of I-Claim
advanced I-Claim
non I-Claim
- I-Claim
small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
many O
women O
with O
breast O
cancer O
need O
psychological O
help O
to O
cope O
more O
effectively O
after O
treatment O
. O
!LF! !LF!
cognitive O
and O
behavioural O
techniques O
are O
not O
yet O
well O
established O
in O
france O
. O
!LF! !LF!
a O
multi O
- O
site O
randomized O
study O
was O
conducted O
to O
evaluate O
the O
effects O
of O
a O
psycho O
- O
educational O
group O
intervention O
in O
this O
population O
. O
!LF! !LF!
two O
hundred O
and O
three O
patients O
, O
recruited O
after O
primary O
treatment O
, O
were O
randomly O
assigned O
either O
to O
a O
treatment O
group O
( O
psycho O
- O
educational O
intervention O
) O
or O
to O
a O
waiting O
- O
list O
control O
group O
. O
!LF! !LF!
the O
8 O
- O
week O
programme O
of O
2 O
h O
sessions O
comprised O
of O
thematic O
discussions O
, O
information O
and O
training O
in O
stress O
management O
techniques O
. O
!LF! !LF!
evaluation O
at O
baseline O
, O
after O
8 O
sessions O
, O
and O
1 O
month O
after O
programme O
completion O
, O
included O
evaluations O
using O
the O
stai O
, O
poms O
, O
mac O
, O
eortc O
qlq O
- O
c30 O
and O
eortc O
qlq O
- O
br23 O
breast O
module O
scales O
. O
!LF! !LF!
we B-Premise
observed I-Premise
a I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
anxiety I-Premise
( I-Premise
stai I-Premise
, I-Premise
poms I-Premise
) I-Premise
among I-Premise
group I-Premise
participants I-Premise
, I-Premise
a I-Premise
reduction I-Premise
in I-Premise
anger I-Premise
, I-Premise
depression I-Premise
and I-Premise
fatigue I-Premise
( I-Premise
poms I-Premise
) I-Premise
, I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
vigor I-Premise
and I-Premise
interpersonal I-Premise
relationships I-Premise
( I-Premise
poms I-Premise
) I-Premise
, I-Premise
in I-Premise
emotional I-Premise
and I-Premise
role I-Premise
functioning I-Premise
, I-Premise
in I-Premise
health I-Premise
status I-Premise
and I-Premise
fatigue I-Premise
level I-Premise
( I-Premise
eortc I-Premise
qlq I-Premise
- I-Premise
c30 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
in O
contrast O
, O
coping B-Premise
strategies I-Premise
( I-Premise
mac I-Premise
) I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
no B-Premise
group I-Premise
- I-Premise
related I-Premise
negative I-Premise
effects I-Premise
were I-Premise
observed I-Premise
and I-Premise
the I-Premise
global I-Premise
satisfaction I-Premise
levels I-Premise
were I-Premise
very I-Premise
high I-Premise
. I-Premise
!LF! !LF!
this B-Claim
study I-Claim
demonstrates I-Claim
the I-Claim
feasibility I-Claim
and I-Claim
effectiveness I-Claim
of I-Claim
a I-Claim
psycho I-Claim
- I-Claim
educational I-Claim
intervention I-Claim
, I-Claim
which I-Claim
can I-Claim
accelerate I-Claim
the I-Claim
reduction I-Claim
of I-Claim
those I-Claim
negative I-Claim
affects I-Claim
which I-Claim
are I-Claim
present I-Claim
at I-Claim
the I-Claim
end I-Claim
of I-Claim
treatment I-Claim
. I-Claim
!LF! !LF!
it B-Claim
represents I-Claim
an I-Claim
excellent I-Claim
complement I-Claim
or I-Claim
an I-Claim
alternative I-Claim
to I-Claim
individual I-Claim
psycho I-Claim
- I-Claim
oncologic I-Claim
therapeutic I-Claim
support I-Claim
, I-Claim
widely O
proposed O
in O
france O
, O
and O
should O
now O
be O
tested O
in O
groups O
with O
other O
types O
of O
cancer O
and O
at O
other O
disease O
phases O
. O
!LF! !LF!
to O
examine O
the O
effects O
of O
a O
scapula O
- O
oriented O
exercise O
on O
upper O
limb O
dysfunction O
in O
breast O
cancer O
survivors O
. O
!LF! !LF!
a O
prospective O
randomized O
, O
controlled O
pilot O
trial O
with O
historical O
control O
. O
!LF! !LF!
rehabilitation O
department O
at O
a O
university O
hospital O
. O
!LF! !LF!
thirty O
- O
two O
women O
with O
breast O
cancer O
were O
randomly O
assigned O
to O
scapula O
- O
oriented O
exercise O
group O
( O
n O
= O
16 O
) O
and O
general O
exercise O
group O
( O
n O
= O
16 O
) O
. O
!LF! !LF!
an O
historical O
control O
group O
( O
n O
= O
18 O
) O
without O
exercise O
was O
enrolled O
from O
breast O
cancer O
survivors O
. O
!LF! !LF!
the O
scapula O
- O
oriented O
exercises O
were O
designed O
focusing O
on O
scapulothoracic O
movement O
. O
!LF! !LF!
the O
general O
exercise O
group O
performed O
body O
conditioning O
exercise O
. O
!LF! !LF!
exercise O
therapies O
were O
performed O
for O
one O
session O
per O
week O
for O
eight O
weeks O
. O
!LF! !LF!
pain O
and O
physical O
disabilities O
related O
to O
upper O
limb O
dysfunction O
, O
quality O
of O
life O
and O
depression O
were O
used O
as O
subjective O
outcomes O
. O
!LF! !LF!
objective O
outcome O
measures O
included O
shoulder O
range O
of O
motion O
and O
strength O
. O
!LF! !LF!
outcomes O
were O
assessed O
at O
baseline O
and O
post O
exercise O
. O
!LF! !LF!
at O
baseline O
, O
no O
significant O
difference O
was O
observed O
among O
the O
three O
groups O
. O
!LF! !LF!
the B-Premise
scapula I-Premise
- I-Premise
oriented I-Premise
exercise I-Premise
group I-Premise
showed I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
, I-Premise
physical I-Premise
function I-Premise
, I-Premise
social I-Premise
function I-Premise
, I-Premise
and I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
compared I-Premise
with I-Premise
baseline I-Premise
, I-Premise
whereas I-Premise
the I-Premise
general I-Premise
exercise I-Premise
group I-Premise
showed I-Premise
improved I-Premise
fatigue I-Premise
and I-Premise
range I-Premise
of I-Premise
motion I-Premise
. I-Premise
!LF! !LF!
the B-Premise
change I-Premise
in I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
067 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0 I-Premise
. I-Premise
33 I-Premise
) I-Premise
and I-Premise
strength I-Premise
of I-Premise
external I-Premise
rotation I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
001 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0 I-Premise
. I-Premise
55 I-Premise
) I-Premise
were I-Premise
significantly I-Premise
greater I-Premise
in I-Premise
the I-Premise
scapula I-Premise
- I-Premise
oriented I-Premise
exercise I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
general I-Premise
exercise I-Premise
and I-Premise
control I-Premise
group I-Premise
. I-Premise
!LF! !LF!
scapula B-Claim
- B-Claim
oriented B-Claim
exercise I-Claim
had I-Claim
beneficial I-Claim
effects I-Claim
on I-Claim
pain I-Claim
, I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
aspects I-Claim
of I-Claim
strength I-Claim
. I-Claim
!LF! !LF!
the O
sample O
size O
required O
in O
a O
larger O
definitive O
study O
is O
32 O
subjects O
per O
group O
. O
!LF! !LF!
the O
aim O
of O
the O
project O
was O
to O
identify O
clinical O
and O
quality O
of O
life O
( O
ql O
) O
factors O
that O
together O
predict O
survival O
and O
response O
to O
chemotherapy O
in O
advanced O
breast O
cancer O
. O
!LF! !LF!
potential O
prognostic O
factors O
were O
studied O
in O
187 O
women O
with O
baseline O
ql O
data O
from O
a O
trial O
of O
paclitaxel O
versus O
doxorubicin O
as O
first O
- O
line O
chemotherapy O
. O
!LF! !LF!
demographic O
and O
clinical O
factors O
studied O
were O
age O
, O
performance O
status O
, O
dominant O
site O
of O
disease O
and O
preceding O
disease O
- O
free O
interval O
( O
dfi O
) O
. O
!LF! !LF!
factors O
from O
the O
eortc O
qlq O
- O
c30 O
were O
all O
function O
scales O
, O
fatigue O
, O
nausea O
/ O
vomiting O
, O
pain O
, O
dyspnoea O
, O
insomnia O
, O
loss O
of O
appetite O
and O
global O
ql O
. O
!LF! !LF!
the O
proportional O
hazards O
regression O
model O
with O
stratification O
for O
treatment O
, O
and O
the O
logistic O
regression O
model O
adjusting O
for O
treatment O
arm O
were O
used O
for O
univariate O
and O
multivariate O
analyses O
of O
survival O
and O
response O
to O
treatment O
, O
respectively O
. O
!LF! !LF!
for B-Premise
survival I-Premise
, I-Premise
multiple I-Premise
sites I-Premise
of I-Premise
visceral I-Premise
disease I-Premise
, I-Premise
pain I-Premise
, I-Premise
global I-Premise
ql I-Premise
and I-Premise
fatigue I-Premise
were I-Premise
significant I-Premise
prognostic I-Premise
factors I-Premise
in I-Premise
the I-Premise
univariate I-Premise
analysis I-Premise
. I-Premise
!LF! !LF!
the B-Premise
final I-Premise
multivariate I-Premise
model I-Premise
predicted I-Premise
poor I-Premise
survival I-Premise
with I-Premise
multiple I-Premise
sites I-Premise
of I-Premise
visceral I-Premise
disease I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
003 I-Premise
) I-Premise
, I-Premise
dfi I-Premise
< I-Premise
/ I-Premise
= I-Premise
2 I-Premise
years I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
026 I-Premise
) I-Premise
and I-Premise
pain I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
003 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
for B-Premise
response I-Premise
, I-Premise
age I-Premise
, I-Premise
dyspnoea I-Premise
, I-Premise
fatigue I-Premise
and I-Premise
global I-Premise
ql I-Premise
were I-Premise
significant I-Premise
predictive I-Premise
factors I-Premise
in I-Premise
the I-Premise
univariate I-Premise
analysis I-Premise
. I-Premise
!LF! !LF!
the B-Premise
final I-Premise
multivariate I-Premise
model I-Premise
for I-Premise
response I-Premise
selected I-Premise
dfi I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
009 I-Premise
) I-Premise
, I-Premise
multiple I-Premise
sites I-Premise
of I-Premise
visceral I-Premise
disease I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
037 I-Premise
) I-Premise
and I-Premise
dyspnoea I-Premise
( I-Premise
p I-Premise
= I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
using I-Premise
forward I-Premise
selection I-Premise
, I-Premise
but B-Premise
model I-Premise
instability I-Premise
was I-Premise
indicated I-Premise
by I-Premise
the I-Premise
inclusion I-Premise
of I-Premise
fatigue I-Premise
and I-Premise
emotional I-Premise
function I-Premise
in I-Premise
the I-Premise
final I-Premise
model I-Premise
when I-Premise
backward I-Premise
selection I-Premise
was I-Premise
used I-Premise
. I-Premise
!LF! !LF!
in O
addition O
to O
known O
clinical O
factors O
, O
patient B-Claim
- B-Claim
assessed B-Claim
ql I-Claim
variables I-Claim
appear I-Claim
to I-Claim
be I-Claim
prognostic I-Claim
for I-Claim
survival I-Claim
and I-Claim
response I-Claim
to I-Claim
chemotherapy I-Claim
in I-Claim
women I-Claim
with I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
however B-Claim
, I-Claim
identification I-Claim
of I-Claim
prognostic I-Claim
factors I-Claim
from I-Claim
responses I-Claim
to I-Claim
questionnaires I-Claim
may I-Claim
be I-Claim
unstable I-Claim
, I-Claim
and I-Claim
their I-Claim
reliability I-Claim
and I-Claim
clinical I-Claim
utility I-Claim
should I-Claim
be I-Claim
tested I-Claim
prospectively I-Claim
. I-Claim
!LF! !LF!
everolimus O
( O
eve O
) O
+ O
exemestane O
( O
exe O
"""" O
; O
"""" O
n O
= O
485 O
) O
more O
than O
doubled O
median O
progression O
- O
free O
survival O
versus O
placebo O
( O
pbo O
) O
+ O
exe O
( O
n O
= O
239 O
) O
, O
with O
a O
manageable O
safety O
profile O
and O
no O
deterioration O
in O
health O
- O
related O
quality O
- O
of O
- O
life O
( O
hrqol O
) O
in O
patients O
with O
hormone O
- O
receptor O
- O
positive O
( O
hr O
( O
+ O
) O
) O
advanced O
breast O
cancer O
( O
abc O
) O
who O
recurred O
or O
progressed O
on O
/ O
after O
nonsteroidal O
aromatase O
inhibitor O
( O
nsai O
) O
therapy O
. O
!LF! !LF!
to O
further O
evaluate O
eve O
+ O
exe O
impact O
on O
disease O
burden O
, O
we O
conducted O
additional O
post O
- O
hoc O
analyses O
of O
patient O
- O
reported O
hrqol O
. O
!LF! !LF!
hrqol O
was O
assessed O
using O
eortc O
qlq O
- O
c30 O
and O
qlq O
- O
br23 O
questionnaires O
at O
baseline O
and O
every O
6 O
weeks O
thereafter O
until O
treatment O
discontinuation O
because O
of O
disease O
progression O
, O
toxicity O
, O
or O
consent O
withdrawal O
. O
!LF! !LF!
endpoints O
included O
the O
qlq O
- O
c30 O
global O
health O
status O
( O
ql2 O
) O
scale O
, O
the O
qlq O
- O
br23 O
breast O
symptom O
( O
brbs O
) O
, O
and O
arm O
symptom O
( O
bras O
) O
scales O
. O
!LF! !LF!
between O
- O
group O
differences O
in O
change O
from O
baseline O
were O
assessed O
using O
linear O
mixed O
models O
with O
selected O
covariates O
. O
!LF! !LF!
sensitivity O
analysis O
using O
pattern O
- O
mixture O
models O
determined O
the O
effect O
of O
study O
discontinuation O
on O
/ O
before O
week O
24 O
. O
!LF! !LF!
treatment O
arms O
were O
compared O
using O
differences O
of O
least O
squares O
mean O
( O
lsm O
) O
changes O
from O
baseline O
and O
95 O
% O
confidence O
intervals O
( O
cis O
) O
at O
each O
timepoint O
and O
overall O
. O
!LF! !LF!
progression O
- O
free O
survival O
, O
survival O
, O
response O
rate O
, O
safety O
, O
and O
hrqol O
. O
!LF! !LF!
linear B-Premise
mixed I-Premise
models I-Premise
( I-Premise
primary I-Premise
model I-Premise
) I-Premise
demonstrated I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
overall I-Premise
difference I-Premise
between I-Premise
eve I-Premise
+ I-Premise
exe I-Premise
and I-Premise
pbo I-Premise
+ I-Premise
exe I-Premise
for I-Premise
ql2 I-Premise
( I-Premise
lsm I-Premise
difference I-Premise
= I-Premise
- I-Premise
1 I-Premise
. I-Premise
91 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
- I-Premise
4 I-Premise
. I-Premise
61 I-Premise
, I-Premise
0 I-Premise
. I-Premise
78 I-Premise
) I-Premise
, I-Premise
brbs I-Premise
( I-Premise
lsm I-Premise
difference I-Premise
= I-Premise
- I-Premise
0 I-Premise
. I-Premise
18 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
- I-Premise
1 I-Premise
. I-Premise
98 I-Premise
, I-Premise
1 I-Premise
. I-Premise
62 I-Premise
) I-Premise
, I-Premise
or I-Premise
bras I-Premise
( I-Premise
lsm I-Premise
difference I-Premise
= I-Premise
- I-Premise
0 I-Premise
. I-Premise
42 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
- I-Premise
2 I-Premise
. I-Premise
94 I-Premise
, I-Premise
2 I-Premise
. I-Premise
10 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
based O
on O
pattern O
- O
mixture O
models O
, O
patients O
who O
dropped O
out O
early O
had O
worse O
ql2 O
decline O
on O
both O
treatments O
. O
!LF! !LF!
in B-Premise
the I-Premise
expanded I-Premise
pattern I-Premise
- I-Premise
mixture I-Premise
model I-Premise
, I-Premise
eve I-Premise
+ I-Premise
exe I-Premise
- I-Premise
treated I-Premise
patients I-Premise
who I-Premise
did I-Premise
not I-Premise
drop I-Premise
out I-Premise
early I-Premise
had I-Premise
stable I-Premise
brbs I-Premise
and I-Premise
bras I-Premise
relative I-Premise
to I-Premise
pbo I-Premise
+ I-Premise
exe I-Premise
. I-Premise
!LF! !LF!
hrqol O
data O
were O
not O
collected O
after O
disease O
progression O
. O
!LF! !LF!
these B-Claim
analyses I-Claim
confirm I-Claim
that I-Claim
eve I-Claim
+ I-Claim
exe I-Claim
provides I-Claim
clinical I-Claim
benefit I-Claim
without I-Claim
adversely I-Claim
impacting I-Claim
hrqol I-Claim
in I-Claim
patients I-Claim
with I-Claim
hr I-Claim
( I-Claim
+ I-Claim
) I-Claim
abc I-Claim
who I-Claim
recurred I-Claim
/ I-Claim
progressed I-Claim
on I-Claim
prior I-Claim
nsais I-Claim
versus I-Claim
endocrine I-Claim
therapy I-Claim
alone I-Claim
. I-Claim
!LF! !LF!
to O
examine O
the O
effect O
of O
a O
progressive O
upper O
- O
body O
exercise O
program O
on O
lymphedema O
secondary O
to O
breast O
cancer O
treatment O
. O
!LF! !LF!
fourteen O
breast O
cancer O
survivors O
with O
unilateral O
upper O
extremity O
lymphedema O
were O
randomly O
assigned O
to O
an O
exercise O
( O
n O
= O
7 O
) O
or O
control O
group O
( O
n O
= O
7 O
) O
. O
!LF! !LF!
the O
exercise O
group O
followed O
a O
progressive O
, O
8 O
- O
week O
upper O
- O
body O
exercise O
program O
consisting O
of O
resistance O
training O
plus O
aerobic O
exercise O
using O
a O
monark O
rehab O
trainer O
arm O
ergometer O
. O
!LF! !LF!
lymphedema O
was O
assessed O
by O
arm O
circumference O
and O
measurement O
of O
arm O
volume O
by O
water O
displacement O
. O
!LF! !LF!
patients O
were O
evaluated O
on O
five O
occasions O
over O
the O
experimental O
period O
. O
!LF! !LF!
the O
medical O
outcomes O
trust O
short O
- O
form O
36 O
survey O
was O
used O
to O
measure O
quality O
of O
life O
before O
and O
after O
the O
intervention O
. O
!LF! !LF!
significance O
was O
set O
at O
alpha O
< O
or O
= O
0 O
. O
01 O
. O
!LF! !LF!
no B-Premise
changes I-Premise
were I-Premise
found I-Premise
in I-Premise
arm I-Premise
circumference I-Premise
or I-Premise
arm I-Premise
volume I-Premise
as I-Premise
a I-Premise
result I-Premise
of I-Premise
the I-Premise
exercise I-Premise
program I-Premise
. I-Premise
!LF! !LF!
three B-Premise
of I-Premise
the I-Premise
quality I-Premise
- I-Premise
of I-Premise
- I-Premise
life I-Premise
domains I-Premise
showed I-Premise
trends I-Premise
toward I-Premise
increases I-Premise
in I-Premise
the I-Premise
exercise I-Premise
group I-Premise
: I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
050 I-Premise
) I-Premise
, I-Premise
general I-Premise
health I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
048 I-Premise
) I-Premise
, I-Premise
and I-Premise
vitality I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
023 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
mental B-Premise
health I-Premise
increased I-Premise
, I-Premise
although I-Premise
not I-Premise
significantly I-Premise
, I-Premise
for I-Premise
all I-Premise
subjects I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
019 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
arm B-Premise
volume I-Premise
measured I-Premise
by I-Premise
water I-Premise
displacement I-Premise
was I-Premise
correlated I-Premise
with I-Premise
calculated I-Premise
arm I-Premise
volume I-Premise
( I-Premise
r I-Premise
= I-Premise
. I-Premise
973 I-Premise
, I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
although B-Premise
the I-Premise
exercise I-Premise
and I-Premise
control I-Premise
group I-Premise
means I-Premise
were I-Premise
significantly I-Premise
different I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
participation B-Claim
in I-Claim
an I-Claim
upper I-Claim
- I-Claim
body I-Claim
exercise I-Claim
program I-Claim
caused I-Claim
no I-Claim
changes I-Claim
in I-Claim
arm I-Claim
circumference I-Claim
or I-Claim
arm I-Claim
volume I-Claim
in I-Claim
women I-Claim
with I-Claim
lymphedema I-Claim
after I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
and I-Claim
they I-Claim
may I-Claim
have I-Claim
experienced I-Claim
an I-Claim
increase I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim
!LF! !LF!
additional B-Claim
studies I-Claim
should I-Claim
be I-Claim
done I-Claim
in I-Claim
this I-Claim
area I-Claim
to I-Claim
determine I-Claim
the I-Claim
optimum I-Claim
training I-Claim
program I-Claim
. I-Claim
!LF! !LF!
studies O
have O
shown O
that O
there O
is O
a O
high O
prevalence O
of O
depression O
in O
cancer O
patients O
. O
!LF! !LF!
women B-Claim
with I-Claim
breast I-Claim
cancer I-Claim
may I-Claim
have I-Claim
an I-Claim
even I-Claim
higher I-Claim
risk I-Claim
of I-Claim
depression I-Claim
particularly I-Claim
in I-Claim
a I-Claim
postmenopausal I-Claim
or I-Claim
estrogen I-Claim
deficiency I-Claim
state I-Claim
. I-Claim
!LF! !LF!
a O
small O
number O
of O
randomized O
controlled O
trials O
have O
examined O
the O
efficacy O
of O
antidepressants O
compared O
to O
that O
of O
a O
placebo O
in O
cancer O
patients O
, O
but O
some O
results O
have O
been O
difficult O
to O
interpret O
due O
to O
a O
heterogeneous O
patient O
group O
. O
!LF! !LF!
in O
the O
current O
investigation O
, O
we O
screened O
newly O
diagnosed O
early O
stage O
breast O
cancer O
patients O
for O
depressive O
symptoms O
prior O
to O
the O
initiation O
of O
adjuvant O
therapy O
and O
investigated O
whether O
the O
oral O
antidepressant O
fluoxetine O
affected O
depressive O
symptoms O
, O
completion O
of O
adjuvant O
treatment O
, O
and O
quality O
of O
life O
. O
!LF! !LF!
patients O
with O
newly O
diagnosed O
early O
stage O
breast O
cancer O
were O
screened O
for O
depressive O
symptoms O
prior O
to O
the O
initiation O
of O
adjuvant O
therapy O
. O
!LF! !LF!
patients O
with O
depressive O
symptoms O
were O
randomized O
to O
a O
daily O
oral O
fluoxetine O
or O
a O
placebo O
. O
!LF! !LF!
patients O
were O
then O
followed O
for O
6 O
months O
and O
evaluated O
for O
quality O
of O
life O
, O
completion O
of O
adjuvant O
treatment O
, O
and O
depressive O
symptoms O
. O
!LF! !LF!
a O
high O
percentage O
of O
patients O
with O
newly O
diagnosed O
early O
stage O
breast O
cancer O
were O
found O
to O
have O
depressive O
symptoms O
prior O
to O
the O
initiation O
of O
adjuvant O
therapy O
. O
!LF! !LF!
the B-Premise
use I-Premise
of I-Premise
fluoxetine I-Premise
for I-Premise
6 I-Premise
months I-Premise
resulted I-Premise
in I-Premise
an I-Premise
improvement I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
a I-Premise
higher I-Premise
completion I-Premise
of I-Premise
adjuvant I-Premise
treatment I-Premise
( I-Premise
chemotherapy I-Premise
, I-Premise
hormonal I-Premise
therapy I-Premise
, I-Premise
chemotherapy I-Premise
plus I-Premise
hormonal I-Premise
therapy I-Premise
) I-Premise
, I-Premise
and I-Premise
a I-Premise
reduction I-Premise
in I-Premise
depressive I-Premise
symptoms I-Premise
compared I-Premise
to I-Premise
patients I-Premise
who I-Premise
received I-Premise
placebo I-Premise
. I-Premise
!LF! !LF!
an B-Claim
antidepressant I-Claim
should I-Claim
be I-Claim
considered I-Claim
for I-Claim
early I-Claim
stage I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
depressive I-Claim
symptoms I-Claim
who I-Claim
are I-Claim
receiving I-Claim
adjuvant I-Claim
treatment I-Claim
. I-Claim
!LF! !LF!
the O
second O
international O
society O
of O
paediatric O
oncology O
( O
siop O
) O
study O
for O
rhabdomyosarcoma O
( O
mmt84 O
) O
had O
several O
goals O
. O
!LF! !LF!
the O
two O
principal O
aims O
were O
: O
( O
1 O
) O
to O
improve O
the O
survival O
of O
children O
with O
rhabdomyosarcoma O
"""" O
; O
"""" O
and O
( O
2 O
) O
to O
reduce O
the O
late O
effects O
from O
therapy O
by O
restricting O
the O
indications O
for O
surgery O
and O
/ O
or O
radiotherapy O
after O
good O
response O
to O
initial O
chemotherapy O
. O
!LF! !LF!
a O
further O
aim O
was O
to O
investigate O
the O
role O
of O
high O
- O
dose O
chemotherapy O
in O
young O
patients O
with O
parameningeal O
primary O
tumours O
. O
!LF! !LF!
186 O
previously O
untreated O
eligible O
patients O
entered O
the O
study O
. O
!LF! !LF!
patients O
with O
completely O
resected O
primary O
tumour O
received O
three O
courses O
of O
iva O
( O
ifosfamide O
, O
vincristine O
and O
actinomycin O
d O
) O
. O
!LF! !LF!
patients O
with O
incompletely O
resected O
tumour O
received O
six O
to O
10 O
courses O
of O
iva O
according O
to O
stage O
. O
!LF! !LF!
patients O
achieving O
complete O
remission O
with O
chemotherapy O
alone O
did O
not O
usually O
receive O
radiotherapy O
or O
undergo O
extensive O
surgery O
, O
but O
patients O
remaining O
in O
partial O
remission O
received O
local O
therapy O
with O
surgery O
and O
/ O
or O
radiotherapy O
. O
!LF! !LF!
only O
patients O
over O
5 O
years O
of O
age O
with O
parameningeal O
disease O
and O
patients O
over O
12 O
years O
with O
tumours O
at O
any O
site O
were O
given O
systematic O
irradiation O
. O
!LF! !LF!
complete B-Premise
remission I-Premise
was I-Premise
achieved I-Premise
in I-Premise
91 I-Premise
% I-Premise
( I-Premise
170 I-Premise
/ I-Premise
186 I-Premise
) I-Premise
of I-Premise
all I-Premise
patients I-Premise
. I-Premise
!LF! !LF!
with B-Premise
a I-Premise
median I-Premise
follow I-Premise
- I-Premise
up I-Premise
of I-Premise
8 I-Premise
years I-Premise
, I-Premise
the I-Premise
5 I-Premise
- I-Premise
year I-Premise
overall I-Premise
survival I-Premise
was I-Premise
68 I-Premise
% I-Premise
( I-Premise
+ I-Premise
/ I-Premise
- I-Premise
3 I-Premise
% I-Premise
standard I-Premise
error I-Premise
of I-Premise
the I-Premise
mean I-Premise
( I-Premise
sem I-Premise
) I-Premise
and I-Premise
the I-Premise
5 I-Premise
- I-Premise
year I-Premise
event I-Premise
- I-Premise
free I-Premise
survival I-Premise
53 I-Premise
% I-Premise
( I-Premise
+ I-Premise
/ I-Premise
- I-Premise
4 I-Premise
% I-Premise
sem I-Premise
) I-Premise
. I-Premise
!LF! !LF!
these B-Premise
results I-Premise
show I-Premise
an I-Premise
improvement I-Premise
over I-Premise
previous I-Premise
siop I-Premise
study I-Premise
( I-Premise
rms75 I-Premise
) I-Premise
in I-Premise
which I-Premise
survival I-Premise
was I-Premise
52 I-Premise
% I-Premise
and I-Premise
event I-Premise
- I-Premise
free I-Premise
survival I-Premise
was I-Premise
47 I-Premise
% I-Premise
. I-Premise
!LF! !LF!
among B-Premise
the I-Premise
54 I-Premise
patients I-Premise
who I-Premise
exhibited I-Premise
isolated I-Premise
local I-Premise
relapse I-Premise
, I-Premise
35 I-Premise
% I-Premise
( I-Premise
19 I-Premise
/ I-Premise
54 I-Premise
) I-Premise
survived I-Premise
in I-Premise
further I-Premise
remission I-Premise
longer I-Premise
than I-Premise
2 I-Premise
years I-Premise
after I-Premise
retreatment I-Premise
, I-Premise
including I-Premise
local I-Premise
therapy I-Premise
( I-Premise
surgery I-Premise
+ I-Premise
/ I-Premise
- I-Premise
radiotherapy I-Premise
) I-Premise
. I-Premise
!LF! !LF!
analysis O
of O
the O
overall O
burden O
of O
therapy O
received O
by O
all O
surviving O
children O
( O
including O
primary O
treatment O
and O
treatment O
for O
relapse O
if O
required O
) O
showed O
that O
24 O
% O
( O
28 O
/ O
116 O
) O
were O
treated O
by O
limited O
surgery O
followed O
by O
three O
courses O
of O
iva O
, O
29 O
% O
( O
34 O
/ O
116 O
) O
were O
treated O
by O
chemotherapy O
alone O
( O
after O
initial O
biopsy O
) O
and O
13 O
% O
( O
15 O
/ O
116 O
) O
received O
chemotherapy O
plus O
conservative O
local O
treatment O
( O
limited O
surgery O
or O
radiotherapy O
for O
residual O
disease O
) O
. O
!LF! !LF!
only O
34 O
% O
( O
39 O
/ O
116 O
) O
received O
intensive O
local O
therapy O
defined O
as O
radical O
wide O
field O
radiotherapy O
or O
radical O
surgery O
or O
both O
. O
!LF! !LF!
compared B-Claim
with I-Claim
the I-Claim
results I-Claim
obtained I-Claim
in I-Claim
the I-Claim
previous I-Claim
siop I-Claim
study I-Claim
, I-Claim
treatment I-Claim
in I-Claim
mmt84 I-Claim
was I-Claim
based I-Claim
on I-Claim
response I-Claim
to I-Claim
initial I-Claim
chemotherapy I-Claim
and I-Claim
, I-Claim
despite I-Claim
an I-Claim
overall I-Claim
reduction I-Claim
of I-Claim
the I-Claim
use I-Claim
of I-Claim
local I-Claim
therapy I-Claim
, I-Claim
significantly I-Claim
improved I-Claim
survival I-Claim
for I-Claim
patients I-Claim
with I-Claim
non I-Claim
- I-Claim
metastatic I-Claim
disease I-Claim
. I-Claim
!LF! !LF!
this B-Claim
trial I-Claim
, I-Claim
also I-Claim
for I-Claim
the I-Claim
first I-Claim
time I-Claim
, I-Claim
provides I-Claim
evidence I-Claim
that I-Claim
retreatment I-Claim
after I-Claim
local I-Claim
relapse I-Claim
can I-Claim
achieve I-Claim
long I-Claim
- I-Claim
term I-Claim
second I-Claim
remissions I-Claim
. I-Claim
!LF! !LF!
dppe B-Claim
( I-Claim
tesmilifene I-Claim
) I-Claim
plus I-Claim
doxorubicin I-Claim
( I-Claim
dox I-Claim
) I-Claim
demonstrated I-Claim
a I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
survival I-Claim
versus I-Claim
dox I-Claim
in I-Claim
a I-Claim
phase I-Claim
iii I-Claim
clinical I-Claim
trial I-Claim
in I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
however B-Premise
, I-Premise
dppe I-Premise
is I-Premise
associated I-Premise
with I-Premise
unusual I-Premise
toxicity I-Premise
in I-Premise
the I-Premise
form I-Premise
of I-Premise
hallucinations I-Premise
, I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
which I-Premise
were I-Premise
anticipated I-Premise
to I-Premise
impact I-Premise
on I-Premise
short I-Premise
- I-Premise
term I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
qol I-Premise
) I-Premise
. I-Premise
!LF! !LF!
standard O
national O
cancer O
institute O
of O
canada O
clinical O
trials O
group O
( O
ncic O
ctg O
) O
approaches O
were O
applied O
as O
the O
primary O
method O
to O
analyze O
the O
qol O
data O
from O
this O
trial O
. O
!LF! !LF!
this O
includes O
cross O
- O
sectional O
comparisons O
, O
together O
with O
a O
global O
test O
for O
the O
qol O
response O
rate O
. O
!LF! !LF!
sensitivity O
analyses O
were O
also O
performed O
for O
selected O
qol O
domains O
and O
items O
, O
using O
other O
types O
of O
summary O
measures O
and O
statistics O
. O
!LF! !LF!
two O
hundred O
seventy O
one O
patients O
( O
89 O
% O
of O
randomized O
) O
submitted O
the O
baseline O
qol O
questionnaires O
and O
were O
included O
in O
the O
qol O
analysis O
. O
!LF! !LF!
no B-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
in I-Premise
qol I-Premise
response I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
was I-Premise
found I-Premise
for I-Premise
any I-Premise
domain I-Premise
or I-Premise
item I-Premise
except I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
04 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
cross B-Premise
- B-Premise
sectional B-Premise
comparisons I-Premise
showed I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
for I-Premise
some I-Premise
domains I-Premise
/ I-Premise
items I-Premise
at I-Premise
specific I-Premise
assessment I-Premise
times I-Premise
with I-Premise
all I-Premise
differences I-Premise
favoring I-Premise
the I-Premise
dox I-Premise
alone I-Premise
arm I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
on I-Premise
dppe I-Premise
/ I-Premise
dox I-Premise
arm I-Premise
were I-Premise
significantly I-Premise
worse I-Premise
in I-Premise
terms I-Premise
of I-Premise
average I-Premise
and I-Premise
median I-Premise
pain I-Premise
change I-Premise
scores I-Premise
. I-Premise
!LF! !LF!
different B-Claim
analyses I-Claim
yielded I-Claim
slightly I-Claim
different I-Claim
conclusions I-Claim
but O
, O
in B-Claim
general I-Claim
, I-Claim
the I-Claim
qol I-Claim
analyses I-Claim
were I-Claim
concordant I-Claim
and I-Claim
showed I-Claim
that I-Claim
patients I-Claim
on I-Claim
dox I-Claim
alone I-Claim
had I-Claim
fewer I-Claim
disease I-Claim
and I-Claim
treatment I-Claim
related I-Claim
adverse I-Claim
events I-Claim
and I-Claim
better I-Claim
qol I-Claim
. I-Claim
!LF! !LF!
interestingly B-Claim
, I-Claim
the I-Claim
qol I-Claim
response I-Claim
analysis I-Claim
also I-Claim
showed I-Claim
that I-Claim
aggressive I-Claim
premedication I-Claim
regimens I-Claim
appear I-Claim
to I-Claim
ameliorate I-Claim
potential I-Claim
negative I-Claim
effects I-Claim
of I-Claim
dppe I-Claim
on I-Claim
emesis I-Claim
and I-Claim
nausea I-Claim
as I-Claim
measured I-Claim
by I-Claim
patient I-Claim
assessed I-Claim
qol I-Claim
. I-Claim
!LF! !LF!
numerous O
studies O
have O
examined O
the O
comorbidity O
of O
depression O
with O
cancer O
, O
and O
some O
have O
indicated O
that O
depression O
may O
be O
associated O
with O
cancer O
progression O
or O
survival O
. O
!LF! !LF!
however O
, O
few O
studies O
have O
assessed O
whether O
changes O
in O
depression O
symptoms O
are O
associated O
with O
survival O
. O
!LF! !LF!
in O
a O
secondary O
analysis O
of O
a O
randomized O
trial O
of O
supportive O
- O
expressive O
group O
therapy O
, O
125 O
women O
with O
metastatic O
breast O
cancer O
( O
mbc O
) O
completed O
a O
depression O
symptom O
measure O
( O
center O
for O
epidemiologic O
studies O
- O
depression O
scale O
[ O
ces O
- O
d O
] O
) O
at O
baseline O
and O
were O
randomly O
assigned O
to O
a O
treatment O
group O
or O
to O
a O
control O
group O
that O
received O
educational O
materials O
. O
!LF! !LF!
at O
baseline O
and O
three O
follow O
- O
up O
points O
, O
101 O
of O
125 O
women O
completed O
a O
depression O
symptom O
measure O
. O
!LF! !LF!
we O
used O
these O
data O
in O
a O
cox O
proportional O
hazards O
analysis O
to O
examine O
whether O
decreasing O
depression O
symptoms O
over O
the O
first O
year O
of O
the O
study O
( O
the O
length O
of O
the O
intervention O
) O
would O
be O
associated O
with O
longer O
survival O
. O
!LF! !LF!
median B-Premise
survival I-Premise
time I-Premise
was I-Premise
53 I-Premise
. I-Premise
6 I-Premise
months I-Premise
for I-Premise
women I-Premise
with I-Premise
decreasing I-Premise
ces I-Premise
- I-Premise
d I-Premise
scores I-Premise
over I-Premise
1 I-Premise
year I-Premise
and I-Premise
25 I-Premise
. I-Premise
1 I-Premise
months I-Premise
for I-Premise
women I-Premise
with I-Premise
increasing I-Premise
ces I-Premise
- I-Premise
d I-Premise
scores I-Premise
. I-Premise
!LF! !LF!
there B-Premise
was I-Premise
a I-Premise
significant I-Premise
effect I-Premise
of I-Premise
change I-Premise
in I-Premise
ces I-Premise
- I-Premise
d I-Premise
over I-Premise
the I-Premise
first I-Premise
year I-Premise
on I-Premise
survival I-Premise
out I-Premise
to I-Premise
14 I-Premise
years I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
007 I-Premise
) I-Premise
but B-Premise
no I-Premise
significant I-Premise
interaction I-Premise
between I-Premise
treatment I-Premise
condition I-Premise
and I-Premise
ces I-Premise
- I-Premise
d I-Premise
change I-Premise
on I-Premise
survival I-Premise
. I-Premise
!LF! !LF!
neither O
demographic O
nor O
medical O
variables O
explained O
this O
association O
. O
!LF! !LF!
decreasing B-Claim
depression I-Claim
symptoms I-Claim
over I-Claim
the I-Claim
first I-Claim
year I-Claim
were I-Claim
associated I-Claim
with I-Claim
longer I-Claim
subsequent I-Claim
survival I-Claim
for I-Claim
women I-Claim
with I-Claim
mbc I-Claim
in I-Claim
this I-Claim
sample I-Claim
. I-Claim
!LF! !LF!
further B-Claim
research I-Claim
is I-Claim
necessary I-Claim
to I-Claim
confirm I-Claim
this I-Claim
hypothesis I-Claim
in I-Claim
other I-Claim
samples I-Claim
, I-Claim
and I-Claim
causation I-Claim
can I-Claim
not I-Claim
be I-Claim
assumed I-Claim
based I-Claim
on I-Claim
this I-Claim
analysis I-Claim
. I-Claim
!LF! !LF!
we O
aimed O
to O
determine O
the O
effect O
of O
dietary O
counseling O
or O
oral O
supplements O
on O
outcome O
for O
patients O
with O
cancer O
, O
specifically O
, O
nutritional O
outcome O
, O
morbidity O
, O
and O
quality O
of O
life O
( O
qol O
) O
, O
during O
and O
3 O
months O
after O
radiotherapy O
. O
!LF! !LF!
seventy O
- O
five O
patients O
with O
head O
and O
neck O
cancer O
who O
were O
referred O
for O
radiotherapy O
( O
rt O
) O
were O
randomized O
to O
the O
following O
groups O
: O
group O
1 O
( O
n O
= O
25 O
) O
, O
patients O
who O
received O
dietary O
counseling O
with O
regular O
foods O
"""" O
; O
"""" O
group O
2 O
( O
n O
= O
25 O
) O
, O
patients O
who O
maintained O
usual O
diet O
plus O
supplements O
"""" O
; O
"""" O
and O
group O
3 O
( O
n O
= O
25 O
) O
, O
patients O
who O
maintained O
intake O
ad O
lib O
. O
!LF! !LF!
nutritional O
intake O
( O
determined O
by O
diet O
history O
) O
and O
status O
( O
determined O
by O
ottery O
' O
s O
subjective O
global O
assessment O
) O
, O
and O
qol O
( O
determined O
by O
the O
european O
organization O
for O
the O
research O
and O
treatment O
of O
cancer O
quality O
of O
life O
questionnaire O
version O
3 O
. O
0 O
[ O
eortc O
qlq O
- O
c30 O
] O
) O
were O
evaluated O
at O
baseline O
, O
at O
the O
end O
of O
rt O
, O
and O
at O
3 O
months O
. O
!LF! !LF!
energy B-Premise
intake I-Premise
after I-Premise
rt I-Premise
increased I-Premise
in I-Premise
both I-Premise
groups I-Premise
1 I-Premise
and I-Premise
2 I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
protein B-Premise
intake I-Premise
also I-Premise
increased I-Premise
in I-Premise
both I-Premise
groups I-Premise
1 I-Premise
and I-Premise
2 I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
. I-Premise
006 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
both B-Premise
energy I-Premise
and I-Premise
protein I-Premise
intake I-Premise
decreased I-Premise
significantly I-Premise
in I-Premise
group I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
at B-Premise
3 I-Premise
months I-Premise
, I-Premise
group I-Premise
1 I-Premise
maintained I-Premise
intakes I-Premise
, I-Premise
whereas I-Premise
groups I-Premise
2 I-Premise
and I-Premise
3 I-Premise
returned I-Premise
to I-Premise
or I-Premise
below I-Premise
baseline I-Premise
levels I-Premise
. I-Premise
!LF! !LF!
after B-Premise
rt I-Premise
, I-Premise
> I-Premise
90 I-Premise
% I-Premise
of I-Premise
patients I-Premise
experienced I-Premise
rt I-Premise
toxicity I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
this B-Premise
was I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
groups I-Premise
, I-Premise
with I-Premise
a I-Premise
trend I-Premise
for I-Premise
reduced I-Premise
symptomatology I-Premise
in I-Premise
group I-Premise
1 I-Premise
versus I-Premise
group I-Premise
2 I-Premise
/ I-Premise
group I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
07 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
at B-Premise
3 I-Premise
months I-Premise
, I-Premise
the I-Premise
reduction I-Premise
of I-Premise
incidence I-Premise
/ I-Premise
severity I-Premise
of I-Premise
grade I-Premise
1 I-Premise
+ I-Premise
2 I-Premise
anorexia I-Premise
, I-Premise
nausea I-Premise
/ I-Premise
vomiting I-Premise
, I-Premise
xerostomia I-Premise
, I-Premise
and I-Premise
dysgeusia I-Premise
was I-Premise
different I-Premise
: I-Premise
90 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
improved I-Premise
in I-Premise
group I-Premise
1 I-Premise
versus I-Premise
67 I-Premise
% I-Premise
in I-Premise
group I-Premise
2 I-Premise
versus I-Premise
51 I-Premise
% I-Premise
in I-Premise
group I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
0001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
after B-Premise
rt I-Premise
, I-Premise
qol I-Premise
function I-Premise
scores I-Premise
improved I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
003 I-Premise
) I-Premise
proportionally I-Premise
with I-Premise
improved I-Premise
nutritional I-Premise
intake I-Premise
and I-Premise
status I-Premise
in I-Premise
group I-Premise
1 I-Premise
/ I-Premise
group I-Premise
2 I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
05 I-Premise
) I-Premise
and I-Premise
worsened I-Premise
in I-Premise
group I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
05 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
at B-Premise
3 I-Premise
months I-Premise
, I-Premise
patients I-Premise
in I-Premise
group I-Premise
1 I-Premise
maintained I-Premise
or I-Premise
improved I-Premise
overall I-Premise
qol I-Premise
, I-Premise
whereas I-Premise
patients I-Premise
in I-Premise
groups I-Premise
2 I-Premise
and I-Premise
3 I-Premise
maintained I-Premise
or I-Premise
worsened I-Premise
overall I-Premise
qol I-Premise
. I-Premise
!LF! !LF!
during B-Claim
rt I-Claim
, I-Claim
nutritional I-Claim
interventions I-Claim
positively I-Claim
influenced I-Claim
outcomes I-Claim
, I-Claim
and I-Claim
counseling I-Claim
was I-Claim
of I-Claim
similar I-Claim
/ I-Claim
higher I-Claim
benefit I-Claim
"""" I-Claim
; I-Claim
"""" I-Claim
in B-Claim
the I-Claim
medium I-Claim
term I-Claim
, I-Claim
only I-Claim
counseling I-Claim
exerted I-Claim
a I-Claim
significant I-Claim
impact I-Claim
on I-Claim
patient I-Claim
outcomes I-Claim
. I-Claim
!LF! !LF!
pemetrexed O
maintenance O
therapy O
significantly O
improved O
overall O
survival O
and O
progression O
- O
free O
survival O
compared O
with O
placebo O
, O
and O
had O
a O
good O
safety O
profile O
in O
a O
phase O
3 O
placebo O
- O
controlled O
study O
in O
patients O
with O
advanced O
non O
- O
small O
- O
cell O
lung O
cancer O
( O
nsclc O
) O
. O
!LF! !LF!
results O
for O
quality O
of O
life O
, O
symptom O
palliation O
, O
and O
tolerability O
are O
presented O
here O
. O
!LF! !LF!
after O
four O
cycles O
of O
platinum O
- O
based O
induction O
therapy O
, O
663 O
patients O
with O
stage O
iiib O
or O
stage O
iv O
nsclc O
and O
eastern O
cooperative O
oncology O
group O
performance O
status O
of O
0 O
or O
1 O
were O
randomly O
assigned O
( O
in O
a O
2 O
: O
1 O
ratio O
) O
from O
march O
15 O
, O
2005 O
, O
to O
july O
20 O
, O
2007 O
, O
using O
the O
pocock O
and O
simon O
minimisation O
method O
to O
receive O
pemetrexed O
( O
500 O
mg O
/ O
m O
( O
2 O
) O
every O
21 O
days O
"""" O
; O
"""" O
n O
= O
441 O
) O
or O
placebo O
( O
n O
= O
222 O
) O
plus O
best O
supportive O
care O
until O
disease O
progression O
. O
!LF! !LF!
the O
primary O
efficacy O
data O
have O
been O
reported O
previously O
. O
!LF! !LF!
patients O
completed O
the O
lung O
cancer O
symptom O
scale O
( O
lcss O
) O
at O
baseline O
, O
after O
each O
cycle O
, O
and O
post O
- O
discontinuation O
. O
!LF! !LF!
worsening O
of O
symptoms O
was O
defined O
as O
an O
increase O
of O
15 O
mm O
or O
more O
from O
baseline O
on O
a O
100 O
mm O
scale O
for O
each O
lcss O
item O
. O
!LF! !LF!
the O
primary O
outcome O
for O
these O
quality O
- O
of O
- O
life O
analyses O
was O
time O
to O
worsening O
of O
symptoms O
, O
analysed O
for O
all O
randomised O
patients O
. O
!LF! !LF!
baseline O
characteristics O
, O
including O
lcss O
scores O
, O
were O
well O
balanced O
between O
groups O
. O
!LF! !LF!
baseline O
lcss O
scores O
were O
low O
, O
indicating O
low O
symptom O
burden O
for O
patients O
without O
disease O
progression O
after O
completion O
of O
first O
- O
line O
treatment O
. O
!LF! !LF!
longer B-Premise
time I-Premise
to I-Premise
worsening I-Premise
was I-Premise
recorded I-Premise
for I-Premise
pain I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
hr I-Premise
] I-Premise
0 I-Premise
· I-Premise
76 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
· I-Premise
59 I-Premise
- I-Premise
0 I-Premise
· I-Premise
99 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
· I-Premise
041 I-Premise
) I-Premise
and I-Premise
haemoptysis I-Premise
( I-Premise
hr I-Premise
0 I-Premise
· I-Premise
58 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
· I-Premise
34 I-Premise
- I-Premise
0 I-Premise
· I-Premise
97 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
· I-Premise
038 I-Premise
) I-Premise
with I-Premise
pemetrexed I-Premise
than I-Premise
with I-Premise
placebo I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
no B-Premise
other I-Premise
significant I-Premise
differences I-Premise
in I-Premise
analyses I-Premise
of I-Premise
time I-Premise
to I-Premise
worsening I-Premise
were I-Premise
noted I-Premise
. I-Premise
!LF! !LF!
additional B-Premise
longitudinal I-Premise
analyses I-Premise
showed I-Premise
a I-Premise
greater I-Premise
increase I-Premise
in I-Premise
loss I-Premise
of I-Premise
appetite I-Premise
in I-Premise
the I-Premise
pemetrexed I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
( I-Premise
4 I-Premise
· I-Premise
3 I-Premise
mm I-Premise
vs I-Premise
0 I-Premise
· I-Premise
2 I-Premise
mm I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
· I-Premise
028 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
rates B-Premise
of I-Premise
resource I-Premise
use I-Premise
were I-Premise
statistically I-Premise
higher I-Premise
for I-Premise
pemetrexed I-Premise
than I-Premise
for I-Premise
placebo I-Premise
: I-Premise
admissions I-Premise
to I-Premise
hospital I-Premise
for I-Premise
drug I-Premise
- I-Premise
related I-Premise
adverse I-Premise
events I-Premise
( I-Premise
19 I-Premise
[ I-Premise
4 I-Premise
% I-Premise
] I-Premise
vs I-Premise
none I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
· I-Premise
001 I-Premise
) I-Premise
, I-Premise
transfusions I-Premise
( I-Premise
42 I-Premise
[ I-Premise
10 I-Premise
% I-Premise
] I-Premise
vs I-Premise
seven I-Premise
[ I-Premise
3 I-Premise
% I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
· I-Premise
003 I-Premise
) I-Premise
, I-Premise
and I-Premise
erythropoiesis I-Premise
- I-Premise
stimulating I-Premise
agents I-Premise
( I-Premise
26 I-Premise
[ I-Premise
6 I-Premise
% I-Premise
] I-Premise
vs I-Premise
four I-Premise
[ I-Premise
2 I-Premise
% I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
· I-Premise
017 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
quality B-Claim
of I-Claim
life I-Claim
during I-Claim
maintenance I-Claim
therapy I-Claim
with I-Claim
pemetrexed I-Claim
is I-Claim
similar I-Claim
to I-Claim
placebo I-Claim
, I-Claim
except B-Claim
for I-Claim
a I-Claim
small I-Claim
increase I-Claim
in I-Claim
loss I-Claim
of I-Claim
appetite I-Claim
, I-Claim
and I-Claim
significantly I-Claim
delayed I-Claim
worsening I-Claim
of I-Claim
pain I-Claim
and I-Claim
haemoptysis I-Claim
. I-Claim
!LF! !LF!
in O
view O
of O
the O
improvements O
in O
overall O
and O
progression O
- O
free O
survival O
noted O
with O
pemetrexed O
maintenance O
therapy O
, O
such B-Claim
treatment I-Claim
is I-Claim
an I-Claim
option I-Claim
for I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non I-Claim
- I-Claim
squamous I-Claim
nsclc I-Claim
who I-Claim
have I-Claim
not I-Claim
progressed I-Claim
after I-Claim
platinum I-Claim
- I-Claim
based I-Claim
induction I-Claim
therapy I-Claim
. I-Claim
!LF! !LF!
the B-Claim
role I-Claim
of I-Claim
high I-Claim
- I-Claim
dose I-Claim
chemotherapy I-Claim
( I-Claim
hdct I-Claim
) I-Claim
in I-Claim
metastatic I-Claim
breast I-Claim
cancer I-Claim
remains I-Claim
controversial I-Claim
. I-Claim
!LF! !LF!
trials B-Claim
with I-Claim
late I-Claim
intensification I-Claim
hdct I-Claim
have I-Claim
failed I-Claim
to I-Claim
show I-Claim
an I-Claim
advantage I-Claim
in I-Claim
overall I-Claim
survival I-Claim
. I-Claim
!LF! !LF!
this O
study O
was O
initiated O
to O
compare O
up O
- O
front O
tandem O
hdct O
and O
standard O
combination O
therapy O
in O
patients O
with O
metastatic O
breast O
cancer O
. O
!LF! !LF!
patients O
without O
prior O
chemotherapy O
for O
metastatic O
disease O
were O
randomly O
assigned O
to O
standard O
combination O
therapy O
with O
doxorubicin O
and O
paclitaxel O
( O
at O
) O
or O
double O
hdct O
with O
cyclophosphamide O
, O
mitoxantrone O
, O
and O
etoposide O
followed O
by O
peripheral O
- O
blood O
stem O
- O
cell O
transplantation O
. O
!LF! !LF!
hdct O
was O
repeated O
after O
6 O
weeks O
. O
!LF! !LF!
patients O
were O
stratified O
by O
menopausal O
and O
hormone O
- O
receptor O
status O
. O
!LF! !LF!
the O
primary O
objective O
was O
to O
compare O
complete O
response O
( O
cr O
) O
rates O
. O
!LF! !LF!
a O
total O
of O
93 O
patients O
were O
enrolled O
onto O
the O
trial O
. O
!LF! !LF!
intent B-Premise
- B-Premise
to B-Premise
- B-Premise
treat B-Premise
cr I-Premise
rates I-Premise
for I-Premise
patients I-Premise
randomized I-Premise
to I-Premise
hdct I-Premise
and I-Premise
at I-Premise
were I-Premise
12 I-Premise
. I-Premise
5 I-Premise
% I-Premise
and I-Premise
11 I-Premise
. I-Premise
1 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
84 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
objective B-Premise
response I-Premise
rates I-Premise
were I-Premise
66 I-Premise
. I-Premise
7 I-Premise
% I-Premise
for I-Premise
patients I-Premise
in I-Premise
the I-Premise
high I-Premise
- I-Premise
dose I-Premise
group I-Premise
and I-Premise
64 I-Premise
. I-Premise
4 I-Premise
% I-Premise
for I-Premise
patients I-Premise
in I-Premise
the I-Premise
at I-Premise
arm I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
82 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
in B-Premise
an I-Premise
intent I-Premise
- I-Premise
to I-Premise
- I-Premise
treat I-Premise
analysis I-Premise
, I-Premise
there I-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
two I-Premise
treatments I-Premise
in I-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
( I-Premise
hdct I-Premise
, I-Premise
11 I-Premise
. I-Premise
1 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
at I-Premise
, I-Premise
10 I-Premise
. I-Premise
6 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
67 I-Premise
) I-Premise
, I-Premise
duration I-Premise
of I-Premise
response I-Premise
( I-Premise
hdct I-Premise
, I-Premise
13 I-Premise
. I-Premise
9 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
at I-Premise
, I-Premise
14 I-Premise
. I-Premise
3 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
98 I-Premise
) I-Premise
, I-Premise
and I-Premise
overall I-Premise
survival I-Premise
( I-Premise
hdct I-Premise
, I-Premise
26 I-Premise
. I-Premise
9 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
at I-Premise
, I-Premise
23 I-Premise
. I-Premise
4 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
60 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
hdct B-Premise
was I-Premise
associated I-Premise
with I-Premise
significantly I-Premise
more I-Premise
myelosuppression I-Premise
, I-Premise
infection I-Premise
, I-Premise
diarrhea I-Premise
, I-Premise
stomatitis I-Premise
, I-Premise
and I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
, I-Premise
whereas I-Premise
patients I-Premise
treated I-Premise
with I-Premise
at I-Premise
developed I-Premise
more I-Premise
neurotoxicity I-Premise
. I-Premise
!LF! !LF!
this B-Claim
trial I-Claim
failed I-Claim
to I-Claim
show I-Claim
a I-Claim
benefit I-Claim
for I-Claim
up I-Claim
- I-Claim
front I-Claim
tandem I-Claim
hdct I-Claim
compared I-Claim
with I-Claim
standard I-Claim
combination I-Claim
therapy I-Claim
. I-Claim
!LF! !LF!
hdct B-Claim
was I-Claim
associated I-Claim
with I-Claim
more I-Claim
acute I-Claim
adverse I-Claim
effects I-Claim
. I-Claim
!LF! !LF!
standard O
guidelines O
for O
cancer O
pain O
treatment O
routinely O
recommend O
training O
patients O
to O
reduce O
barriers O
to O
pain O
relief O
, O
use O
medications O
appropriately O
, O
and O
communicate O
their O
pain O
- O
related O
needs O
. O
!LF! !LF!
methods B-Claim
are I-Claim
needed I-Claim
to I-Claim
reduce I-Claim
professional I-Claim
time I-Claim
required I-Claim
while I-Claim
achieving I-Claim
sustained I-Claim
intervention I-Claim
effectiveness I-Claim
. I-Claim
!LF! !LF!
in O
a O
multisite O
, O
randomized O
controlled O
trial O
, O
this O
study O
tested O
a O
pain O
training O
method O
versus O
a O
nutrition O
control O
. O
!LF! !LF!
at O
six O
oncology O
clinics O
, O
physicians O
( O
n O
= O
22 O
) O
and O
nurses O
( O
n O
= O
23 O
) O
enrolled O
patients O
( O
n O
= O
93 O
) O
who O
were O
over O
18 O
years O
of O
age O
, O
with O
cancer O
diagnoses O
, O
pain O
, O
and O
a O
life O
expectancy O
of O
at O
least O
6 O
months O
. O
!LF! !LF!
pain O
training O
and O
control O
interventions O
were O
matched O
for O
materials O
and O
method O
. O
!LF! !LF!
patients O
watched O
a O
video O
followed O
by O
about O
20 O
min O
of O
manual O
- O
standardized O
training O
with O
an O
oncology O
nurse O
focused O
on O
reviewing O
the O
printed O
material O
and O
adapted O
to O
individual O
concerns O
of O
patients O
. O
!LF! !LF!
a O
follow O
- O
up O
phone O
call O
after O
72 O
h O
addressed O
individualized O
treatment O
content O
and O
pain O
communication O
. O
!LF! !LF!
assessments O
at O
baseline O
, O
one O
, O
three O
, O
and O
6 O
months O
included O
barriers O
, O
the O
brief O
pain O
inventory O
, O
opioid O
use O
, O
and O
physician O
and O
nurse O
ratings O
of O
their O
patients O
' O
pain O
. O
!LF! !LF!
trained B-Premise
versus I-Premise
control I-Premise
patients I-Premise
reported I-Premise
reduced I-Premise
barriers I-Premise
to I-Premise
pain I-Premise
relief I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
lower I-Premise
usual I-Premise
pain I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
, I-Premise
and I-Premise
greater I-Premise
opioid I-Premise
use I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
no B-Premise
pain I-Premise
training I-Premise
patients I-Premise
reported I-Premise
severe I-Premise
pain I-Premise
( I-Premise
> I-Premise
6 I-Premise
on I-Premise
a I-Premise
0 I-Premise
- I-Premise
10 I-Premise
scale I-Premise
) I-Premise
at I-Premise
1 I-Premise
- I-Premise
month I-Premise
outcomes I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
physician O
and O
nurse O
ratings O
were O
closer O
to O
patients O
' O
ratings O
of O
pain O
for O
trained O
versus O
nutrition O
groups O
( O
p O
= O
. O
04 O
and O
< O
. O
001 O
, O
respectively O
) O
. O
!LF! !LF!
training O
efficacy O
was O
not O
modified O
by O
patient O
characteristics O
. O
!LF! !LF!
using B-Claim
video I-Claim
and I-Claim
print I-Claim
materials I-Claim
, I-Claim
with I-Claim
brief I-Claim
individualized I-Claim
training I-Claim
, I-Claim
effectively I-Claim
improved I-Claim
pain I-Claim
management I-Claim
over I-Claim
time I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
of I-Claim
varying I-Claim
diagnostic I-Claim
and I-Claim
demographic I-Claim
groups I-Claim
. I-Claim
!LF! !LF!
sexual O
dysfunction O
represents O
a O
complex O
and O
multifactorial O
construct O
that O
can O
affect O
both O
men O
and O
women O
and O
has O
been O
noted O
to O
often O
deteriorate O
significantly O
after O
treatment O
for O
rectal O
and O
anal O
cancer O
. O
!LF! !LF!
despite O
this O
, O
it O
remains O
an O
understudied O
, O
underreported O
, O
and O
undertreated O
issue O
in O
the O
field O
of O
cancer O
survivorship O
. O
!LF! !LF!
this O
study O
examined O
the O
characteristics O
of O
women O
enrolled O
in O
an O
intervention O
trial O
to O
treat O
sexual O
dysfunction O
, O
and O
explored O
the O
relationship O
between O
sexual O
functioning O
and O
psychological O
well O
- O
being O
. O
!LF! !LF!
there O
were O
70 O
female O
posttreatment O
anal O
or O
rectal O
cancer O
survivors O
assessed O
as O
part O
of O
the O
current O
study O
. O
!LF! !LF!
participants O
were O
enrolled O
in O
a O
randomized O
intervention O
trial O
to O
treat O
sexual O
dysfunction O
and O
completed O
outcome O
measures O
prior O
to O
randomization O
. O
!LF! !LF!
the O
main O
outcome O
measures O
are O
quality O
of O
life O
( O
qol O
) O
( O
european O
organization O
for O
research O
and O
treatment O
of O
cancer O
core O
quality O
of O
life O
questionnaire O
[ O
eortc O
- O
qlq O
- O
c30 O
] O
and O
colorectal O
cancer O
- O
specific O
module O
[ O
qlq O
- O
cr38 O
] O
) O
, O
sexual O
functioning O
( O
female O
sexual O
functioning O
index O
) O
, O
and O
psychological O
well O
- O
being O
( O
brief O
symptom O
inventory O
depression O
/ O
anxiety O
, O
impact O
of O
events O
scale O
- O
revised O
, O
cr O
- O
38 O
body O
image O
) O
. O
!LF! !LF!
women O
enrolled O
in O
the O
study O
intervention O
were O
on O
average O
55 O
years O
old O
, O
predominantly O
caucasian O
( O
79 O
% O
) O
, O
married O
( O
57 O
% O
) O
, O
and O
a O
median O
of O
4 O
years O
postprimary O
treatment O
. O
!LF! !LF!
for O
those O
reporting O
sexual O
activity O
at O
baseline O
( O
n O
= O
41 O
) O
, O
sexual O
dysfunction O
was O
associated O
with O
a O
range O
of O
specific O
measures O
of O
psychological O
well O
- O
being O
, O
all O
in O
the O
hypothesized O
direction O
. O
!LF! !LF!
the B-Premise
sexual I-Premise
/ I-Premise
relationship I-Premise
satisfaction I-Premise
subscale I-Premise
was I-Premise
associated I-Premise
with I-Premise
all I-Premise
measures I-Premise
of I-Premise
psychological I-Premise
well I-Premise
- I-Premise
being I-Premise
( I-Premise
r I-Premise
= I-Premise
- I-Premise
0 I-Premise
. I-Premise
45 I-Premise
to I-Premise
- I-Premise
0 I-Premise
. I-Premise
70 I-Premise
, I-Premise
all I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
body B-Premise
image I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
and I-Premise
cancer I-Premise
- I-Premise
specific I-Premise
posttraumatic I-Premise
distress I-Premise
were I-Premise
notable I-Premise
in I-Premise
their I-Premise
association I-Premise
with I-Premise
subscales I-Premise
of I-Premise
sexual I-Premise
functioning I-Premise
, I-Premise
while I-Premise
a I-Premise
global I-Premise
qol I-Premise
measure I-Premise
was I-Premise
largely I-Premise
unrelated I-Premise
. I-Premise
!LF! !LF!
for B-Premise
sexually I-Premise
active I-Premise
female I-Premise
rectal I-Premise
and I-Premise
anal I-Premise
cancer I-Premise
survivors I-Premise
enrolled I-Premise
in I-Premise
a I-Premise
sexual I-Premise
health I-Premise
intervention I-Premise
, I-Premise
sexual I-Premise
dysfunction I-Premise
was I-Premise
significantly I-Premise
and I-Premise
consistently I-Premise
associated I-Premise
with I-Premise
specific I-Premise
measures I-Premise
of I-Premise
psychological I-Premise
well I-Premise
- I-Premise
being I-Premise
, I-Premise
most I-Premise
notably I-Premise
sexual I-Premise
/ I-Premise
relationship I-Premise
satisfaction I-Premise
. I-Premise
!LF! !LF!
these B-Claim
results I-Claim
suggest I-Claim
that I-Claim
sexual I-Claim
functioning I-Claim
may I-Claim
require I-Claim
focused I-Claim
assessment I-Claim
by I-Claim
providers I-Claim
, I-Claim
beyond I-Claim
broad I-Claim
qol I-Claim
assessments I-Claim
, I-Claim
and O
that O
attention B-Claim
to I-Claim
sexual I-Claim
/ I-Claim
relationship I-Claim
satisfaction I-Claim
may I-Claim
be I-Claim
critical I-Claim
in I-Claim
the I-Claim
development I-Claim
and I-Claim
implementation I-Claim
of I-Claim
interventions I-Claim
for I-Claim
this I-Claim
cohort I-Claim
of I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
we O
have O
recently O
suggested O
that O
bolus O
5 O
- O
fluorouracil O
( O
5 O
- O
fu O
) O
may O
work O
via O
a O
rna O
directed O
mechanism O
while O
continuous O
infusion O
5 O
- O
fu O
may O
kill O
cells O
via O
a O
thymidylate O
synthase O
related O
pathway O
. O
!LF! !LF!
it O
may O
thus O
be O
possible O
to O
selectively O
modulate O
each O
schedule O
biochemically O
. O
!LF! !LF!
we O
have O
compared O
an O
alternating O
regimen O
of O
bolus O
and O
continuous O
infusion O
5 O
- O
fu O
, O
selectively O
modulated O
for O
the O
schedule O
of O
administration O
, O
with O
modulated O
bolus O
5 O
- O
fu O
in O
advanced O
colorectal O
cancer O
patients O
. O
!LF! !LF!
two O
hundred O
fourteen O
patients O
from O
nineteen O
italian O
centers O
were O
randomized O
to O
the O
control O
arm O
consisting O
of O
biweekly O
cycles O
of O
mtx O
, O
200 O
mg O
/ O
m2 O
on O
day O
1 O
, O
followed O
by O
bolus O
5 O
- O
fu O
600 O
mg O
/ O
m2 O
on O
day O
2 O
and O
6 O
- O
s O
- O
leucovorin O
rescue O
, O
or O
to O
the O
experimental O
arm O
consisting O
of O
two O
biweekly O
cycles O
of O
the O
same O
regimen O
as O
in O
the O
control O
arm O
alternated O
to O
three O
weeks O
of O
continuous O
infusion O
5 O
- O
fu O
( O
200 O
mg O
/ O
m2 O
day O
) O
+ O
weekly O
bolus O
6 O
- O
s O
- O
leucovorin O
, O
20 O
mg O
/ O
m2 O
. O
!LF! !LF!
nine B-Premise
cr I-Premise
and I-Premise
twenty I-Premise
- I-Premise
seven I-Premise
pr I-Premise
were I-Premise
obtained I-Premise
on I-Premise
one I-Premise
hundred I-Premise
eleven I-Premise
evaluable I-Premise
patients I-Premise
treated I-Premise
in I-Premise
experimental I-Premise
arm I-Premise
( I-Premise
rr I-Premise
= I-Premise
32 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
) I-Premise
: I-Premise
24 I-Premise
% I-Premise
- I-Premise
42 I-Premise
% I-Premise
) I-Premise
, I-Premise
while I-Premise
two I-Premise
cr I-Premise
and I-Premise
eleven I-Premise
pr I-Premise
were I-Premise
observed I-Premise
among I-Premise
one I-Premise
hundred I-Premise
three I-Premise
evaluable I-Premise
patients I-Premise
in I-Premise
control I-Premise
arm I-Premise
( I-Premise
rr I-Premise
= I-Premise
13 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
: I-Premise
7 I-Premise
% I-Premise
- I-Premise
21 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
who B-Premise
grade I-Premise
3 I-Premise
- I-Premise
4 I-Premise
toxicity I-Premise
occurred I-Premise
in I-Premise
13 I-Premise
% I-Premise
of I-Premise
cycles I-Premise
of I-Premise
experimental I-Premise
arm I-Premise
and I-Premise
in I-Premise
8 I-Premise
% I-Premise
of I-Premise
cycles I-Premise
in I-Premise
control I-Premise
arm I-Premise
. I-Premise
!LF! !LF!
the B-Premise
pfs I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
in I-Premise
experimental I-Premise
arm I-Premise
( I-Premise
6 I-Premise
. I-Premise
2 I-Premise
vs I-Premise
. I-Premise
4 I-Premise
. I-Premise
3 I-Premise
months I-Premise
, I-Premise
odds I-Premise
ratio I-Premise
0 I-Premise
. I-Premise
66 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
003 I-Premise
) I-Premise
, I-Premise
while O
the B-Premise
overall I-Premise
survival I-Premise
was I-Premise
similar I-Premise
in I-Premise
both I-Premise
arms I-Premise
( I-Premise
14 I-Premise
. I-Premise
8 I-Premise
months I-Premise
in I-Premise
experimental I-Premise
arm I-Premise
vs I-Premise
. I-Premise
14 I-Premise
. I-Premise
1 I-Premise
months I-Premise
in I-Premise
control I-Premise
arm I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
quality B-Claim
of I-Claim
life I-Claim
was I-Claim
similar I-Claim
as I-Claim
well I-Claim
. I-Claim
!LF! !LF!
eighty B-Premise
percent I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
second I-Premise
- I-Premise
line I-Premise
chemotherapy I-Premise
in I-Premise
control I-Premise
arm I-Premise
were I-Premise
treated I-Premise
with I-Premise
continuous I-Premise
infusion I-Premise
5 I-Premise
- I-Premise
fu I-Premise
. I-Premise
!LF! !LF!
alternating O
, O
schedule B-Claim
- B-Claim
specific B-Claim
biochemical I-Claim
modulation I-Claim
of I-Claim
fu I-Claim
is I-Claim
more I-Claim
active I-Claim
than I-Claim
mtx I-Claim
- I-Claim
- I-Claim
> I-Claim
5 I-Claim
- I-Claim
fu I-Claim
as I-Claim
first I-Claim
- I-Claim
line I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
colorectal I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
however B-Claim
, I-Claim
the I-Claim
overall I-Claim
survival I-Claim
was I-Claim
similar I-Claim
suggesting I-Claim
that I-Claim
alternating I-Claim
bolus I-Claim
and I-Claim
infusional I-Claim
5 I-Claim
- I-Claim
fu I-Claim
upfront I-Claim
may I-Claim
be I-Claim
as I-Claim
effective I-Claim
as I-Claim
giving I-Claim
them I-Claim
in I-Claim
sequence I-Claim
as I-Claim
first I-Claim
- I-Claim
and I-Claim
second I-Claim
- I-Claim
line I-Claim
treatment I-Claim
. I-Claim
!LF! !LF!
gefitinib O
has O
shown O
high O
response O
rate O
and O
improved O
progression O
- O
free O
survival O
( O
pfs O
) O
in O
never O
- O
smokers O
with O
lung O
adenocarcinoma O
( O
nslas O
) O
. O
!LF! !LF!
we O
compared O
efficacy O
of O
gefitinib O
with O
gemcitabine O
and O
cisplatin O
( O
gp O
) O
chemotherapy O
in O
this O
group O
of O
patients O
as O
first O
- O
line O
therapy O
. O
!LF! !LF!
in O
this O
randomized O
phase O
iii O
trial O
, O
a O
total O
of O
313 O
korean O
never O
- O
smokers O
with O
stage O
iiib O
or O
iv O
lung O
adenocarcinoma O
, O
eastern O
cooperative O
oncology O
group O
performance O
status O
0 O
to O
2 O
, O
and O
adequate O
organ O
function O
were O
randomly O
assigned O
to O
receive O
either O
gefitinib O
( O
250 O
mg O
daily O
) O
or O
gp O
chemotherapy O
( O
gemcitabine O
1 O
, O
250 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
"""" O
; O
"""" O
cisplatin O
80 O
mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
every O
3 O
weeks O
, O
for O
up O
to O
nine O
courses O
) O
. O
!LF! !LF!
the O
primary O
objective O
was O
to O
demonstrate O
better O
overall O
survival O
( O
os O
) O
for O
gefitinib O
compared O
with O
gp O
in O
chemotherapy O
- O
naive O
nslas O
. O
!LF! !LF!
three O
hundred O
nine O
patients O
were O
analyzed O
per O
protocol O
( O
gefitinib O
arm O
, O
n O
= O
159 O
"""" O
; O
"""" O
gp O
arm O
, O
n O
= O
150 O
) O
. O
!LF! !LF!
gefitinib B-Premise
did I-Premise
not I-Premise
show I-Premise
better I-Premise
os I-Premise
compared I-Premise
with I-Premise
gp I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
hr I-Premise
] I-Premise
, I-Premise
0 I-Premise
. I-Premise
932 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
716 I-Premise
to I-Premise
1 I-Premise
. I-Premise
213 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
604 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
median I-Premise
os I-Premise
, I-Premise
22 I-Premise
. I-Premise
3 I-Premise
v I-Premise
22 I-Premise
. I-Premise
9 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
1 I-Premise
- I-Premise
year I-Premise
pfs I-Premise
rates I-Premise
were I-Premise
16 I-Premise
. I-Premise
7 I-Premise
% I-Premise
with I-Premise
gefitinib I-Premise
and I-Premise
2 I-Premise
. I-Premise
8 I-Premise
% I-Premise
with I-Premise
gp I-Premise
( I-Premise
hr I-Premise
, I-Premise
1 I-Premise
. I-Premise
198 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
944 I-Premise
to I-Premise
1 I-Premise
. I-Premise
520 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
response B-Premise
rates I-Premise
were I-Premise
55 I-Premise
% I-Premise
with I-Premise
gefitinib I-Premise
and I-Premise
46 I-Premise
% I-Premise
with I-Premise
gp I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
101 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
myelosuppression B-Premise
, I-Premise
renal I-Premise
insufficiency I-Premise
, I-Premise
and I-Premise
fatigue I-Premise
were I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
gp I-Premise
arm I-Premise
, I-Premise
but O
skin B-Premise
toxicities I-Premise
and I-Premise
liver I-Premise
dysfunction I-Premise
were I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
gefitinib I-Premise
arm I-Premise
. I-Premise
!LF! !LF!
two B-Premise
patients I-Premise
( I-Premise
1 I-Premise
. I-Premise
3 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
gefitinib I-Premise
arm I-Premise
developed I-Premise
interstitial I-Premise
lung I-Premise
disease I-Premise
and I-Premise
died I-Premise
. I-Premise
!LF! !LF!
gefitinib B-Claim
failed I-Claim
to I-Claim
demonstrate I-Claim
superior I-Claim
os I-Claim
compared I-Claim
with I-Claim
gp I-Claim
as I-Claim
first I-Claim
- I-Claim
line I-Claim
therapy I-Claim
for I-Claim
nslas I-Claim
. I-Claim
!LF! !LF!
to O
compare O
survival O
in O
patients O
with O
recurrent O
or O
metastatic O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
( O
scchn O
) O
treated O
with O
gefitinib O
250 O
or O
500 O
mg O
/ O
day O
or O
standard O
methotrexate O
. O
!LF! !LF!
four O
hundred O
eighty O
- O
six O
patients O
with O
recurrent O
scchn O
were O
randomly O
assigned O
to O
oral O
gefitinib O
250 O
mg O
/ O
day O
, O
gefitinib O
500 O
mg O
/ O
day O
, O
or O
methotrexate O
40 O
mg O
/ O
m O
( O
2 O
) O
intravenously O
weekly O
. O
!LF! !LF!
primary O
end O
point O
was O
overall O
survival O
, O
secondary O
end O
points O
were O
objective O
response O
rate O
( O
orr O
) O
, O
safety O
, O
symptom O
improvement O
, O
and O
quality O
of O
life O
( O
qol O
) O
. O
!LF! !LF!
exploratory O
end O
points O
included O
association O
of O
efficacy O
with O
epidermal O
growth O
factor O
receptor O
gene O
copy O
number O
and O
other O
biomarkers O
. O
!LF! !LF!
neither B-Premise
gefitinib I-Premise
250 I-Premise
nor I-Premise
500 I-Premise
mg I-Premise
/ I-Premise
day I-Premise
improved I-Premise
overall I-Premise
survival I-Premise
compared I-Premise
with I-Premise
methotrexate I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
hr I-Premise
] I-Premise
, I-Premise
1 I-Premise
. I-Premise
22 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
95 I-Premise
to I-Premise
1 I-Premise
. I-Premise
57 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
12 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
and I-Premise
hr I-Premise
, I-Premise
1 I-Premise
. I-Premise
12 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
87 I-Premise
to I-Premise
1 I-Premise
. I-Premise
43 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
39 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise
!LF! !LF!
in B-Premise
the I-Premise
gefitinib I-Premise
250 I-Premise
mg I-Premise
/ I-Premise
day I-Premise
, I-Premise
500 I-Premise
mg I-Premise
/ I-Premise
day I-Premise
, I-Premise
and I-Premise
methotrexate I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
, I-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
5 I-Premise
. I-Premise
6 I-Premise
, I-Premise
6 I-Premise
. I-Premise
0 I-Premise
, I-Premise
and I-Premise
6 I-Premise
. I-Premise
7 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
orrs I-Premise
( I-Premise
response I-Premise
evaluation I-Premise
criteria I-Premise
in I-Premise
solid I-Premise
tumors I-Premise
) I-Premise
were I-Premise
2 I-Premise
. I-Premise
7 I-Premise
% I-Premise
, I-Premise
7 I-Premise
. I-Premise
6 I-Premise
% I-Premise
and I-Premise
3 I-Premise
. I-Premise
9 I-Premise
% I-Premise
, I-Premise
with I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
between I-Premise
either I-Premise
gefitinib I-Premise
arm I-Premise
and I-Premise
methotrexate I-Premise
. I-Premise
!LF! !LF!
no B-Premise
unexpected I-Premise
adverse I-Premise
events I-Premise
were I-Premise
observed I-Premise
, I-Premise
except B-Premise
for I-Premise
tumor I-Premise
hemorrhage I-Premise
- I-Premise
type I-Premise
events I-Premise
with I-Premise
gefitinib I-Premise
( I-Premise
8 I-Premise
. I-Premise
9 I-Premise
% I-Premise
, I-Premise
gefitinib I-Premise
250 I-Premise
mg I-Premise
/ I-Premise
day I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
11 I-Premise
. I-Premise
4 I-Premise
% I-Premise
, I-Premise
gefitinib I-Premise
500 I-Premise
mg I-Premise
/ I-Premise
day I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
1 I-Premise
. I-Premise
9 I-Premise
% I-Premise
, I-Premise
methotrexate I-Premise
) I-Premise
. I-Premise
!LF! !LF!
qol B-Premise
improvement I-Premise
rates I-Premise
( I-Premise
functional I-Premise
assessment I-Premise
of I-Premise
cancer I-Premise
therapy I-Premise
- I-Premise
head I-Premise
& I-Premise
amp I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
neck I-Premise
total I-Premise
score I-Premise
) I-Premise
were I-Premise
13 I-Premise
. I-Premise
4 I-Premise
% I-Premise
, I-Premise
18 I-Premise
. I-Premise
0 I-Premise
% I-Premise
, I-Premise
and I-Premise
6 I-Premise
. I-Premise
0 I-Premise
% I-Premise
for I-Premise
gefitinib I-Premise
250 I-Premise
mg I-Premise
/ I-Premise
day I-Premise
, I-Premise
500 I-Premise
mg I-Premise
/ I-Premise
day I-Premise
, I-Premise
and I-Premise
methotrexate I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
in B-Claim
patients I-Claim
with I-Claim
recurrent I-Claim
or I-Claim
metastatic I-Claim
scchn I-Claim
, I-Claim
while I-Claim
responses I-Claim
with I-Claim
gefitinib I-Claim
were I-Claim
seen I-Claim
, I-Claim
neither I-Claim
gefitinib I-Claim
250 I-Claim
nor I-Claim
500 I-Claim
mg I-Claim
/ I-Claim
day I-Claim
improved I-Claim
overall I-Claim
survival I-Claim
compared I-Claim
with I-Claim
methotrexate I-Claim
. I-Claim
!LF! !LF!
with B-Claim
the I-Claim
exception I-Claim
of I-Claim
tumor I-Claim
hemorrhage I-Claim
- I-Claim
type I-Claim
events I-Claim
with I-Claim
gefitinib I-Claim
, I-Claim
the I-Claim
adverse I-Claim
event I-Claim
profiles I-Claim
were I-Claim
generally I-Claim
consistent I-Claim
with I-Claim
those I-Claim
previously I-Claim
observed I-Claim
. I-Claim
!LF! !LF!
gemcitabine O
( O
g O
) O
is O
standard O
therapy O
for O
pancreatic O
cancer O
. O
!LF! !LF!
enzastaurin O
( O
e O
) O
inhibits O
pkcβ O
and O
pi3k O
/ O
akt O
signaling O
pathways O
with O
a O
dose O
- O
dependent O
effect O
on O
growth O
of O
pancreatic O
carcinoma O
xenografts O
. O
!LF! !LF!
data B-Claim
suggest I-Claim
that I-Claim
the I-Claim
ge I-Claim
combination I-Claim
may I-Claim
improve I-Claim
clinical I-Claim
outcomes I-Claim
. I-Claim
!LF! !LF!
primary O
objective O
was O
overall O
survival O
( O
os O
) O
"""" O
; O
"""" O
secondary O
objectives O
assessed O
progression O
- O
free O
survival O
( O
pfs O
) O
, O
response O
rate O
( O
rr O
) O
, O
quality O
of O
life O
( O
qol O
) O
, O
toxicity O
, O
and O
relationships O
between O
biomarker O
expression O
and O
clinical O
outcomes O
. O
!LF! !LF!
patients O
were O
randomly O
assigned O
( O
2 O
: O
1 O
) O
to O
ge O
or O
g O
treatment O
"""" O
; O
"""" O
ge O
arm O
: O
e O
500 O
mg O
p O
. O
o O
. O
!LF! !LF!
daily O
"""" O
; O
"""" O
loading O
- O
dose O
( O
1200 O
mg O
"""" O
; O
"""" O
day O
1 O
cycle O
1 O
only O
) O
and O
g O
1000 O
mg O
/ O
m O
( O
2 O
) O
i O
. O
v O
. O
!LF! !LF!
days O
1 O
, O
8 O
, O
and O
15 O
in O
28 O
- O
day O
cycles O
"""" O
; O
"""" O
g O
arm O
: O
g O
as O
in O
ge O
. O
!LF! !LF!
biomarker O
expression O
was O
assessed O
by O
immunohistochemistry O
. O
!LF! !LF!
randomization O
totaled O
130 O
patients O
( O
ge O
= O
86 O
, O
g O
= O
44 O
) O
"""" O
; O
"""" O
121 O
patients O
were O
treated O
( O
ge O
= O
82 O
, O
g O
= O
39 O
) O
. O
!LF! !LF!
ge O
/ O
g O
median O
os O
was O
5 O
. O
6 O
/ O
5 O
. O
1 O
months O
"""" O
; O
"""" O
median O
pfs O
was O
3 O
. O
4 O
/ O
3 O
. O
0 O
months O
. O
!LF! !LF!
ge O
responses O
: O
1 O
complete O
response O
( O
cr O
, O
1 O
. O
2 O
% O
) O
, O
6 O
partial O
response O
( O
pr O
, O
7 O
. O
4 O
% O
) O
, O
and O
33 O
stable O
disease O
( O
sd O
, O
40 O
. O
7 O
% O
) O
"""" O
; O
"""" O
disease O
control O
rate O
( O
dcr O
= O
cr O
+ O
pr O
+ O
sd O
, O
49 O
. O
4 O
% O
) O
. O
!LF! !LF!
g O
responses O
: O
2 O
pr O
( O
5 O
. O
3 O
% O
) O
and O
16 O
sd O
( O
42 O
. O
1 O
% O
) O
"""" O
; O
"""" O
dcr O
( O
47 O
. O
4 O
% O
) O
. O
!LF! !LF!
no B-Premise
qol I-Premise
differences I-Premise
were I-Premise
noted I-Premise
between I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
ge B-Premise
/ B-Premise
g B-Premise
grade I-Premise
3 I-Premise
- I-Premise
4 I-Premise
toxicities I-Premise
included I-Premise
: I-Premise
neutropenia I-Premise
( I-Premise
18 I-Premise
. I-Premise
3 I-Premise
% I-Premise
/ I-Premise
28 I-Premise
. I-Premise
2 I-Premise
% I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
thrombocytopenia I-Premise
( I-Premise
14 I-Premise
. I-Premise
6 I-Premise
% I-Premise
/ I-Premise
25 I-Premise
. I-Premise
6 I-Premise
% I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
and I-Premise
fatigue I-Premise
( I-Premise
11 I-Premise
. I-Premise
0 I-Premise
% I-Premise
/ I-Premise
7 I-Premise
. I-Premise
7 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
no B-Premise
statistically I-Premise
significant I-Premise
relationships I-Premise
between I-Premise
biomarker I-Premise
expression I-Premise
and I-Premise
outcomes I-Premise
were I-Premise
observed I-Premise
. I-Premise
!LF! !LF!
however O
, O
patients B-Premise
with I-Premise
low I-Premise
expression I-Premise
of I-Premise
cytoplasmic I-Premise
pgsk I-Premise
- I-Premise
3β I-Premise
trended I-Premise
toward I-Premise
greater I-Premise
os I-Premise
with I-Premise
ge I-Premise
treatment I-Premise
. I-Premise
!LF! !LF!
os B-Premise
, I-Premise
pfs I-Premise
, I-Premise
qol I-Premise
, I-Premise
and I-Premise
rr I-Premise
were I-Premise
comparable I-Premise
between I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
adding B-Claim
e I-Claim
to I-Claim
g I-Claim
did I-Claim
not I-Claim
increase I-Claim
hematologic I-Claim
toxicities I-Claim
. I-Claim
!LF! !LF!
ge O
does O
not O
warrant O
further O
investigation O
in O
unselected O
pancreatic O
cancer O
patients O
. O
!LF! !LF!
to O
determine O
whether O
the O
impact O
of O
"""" O
laying O
on O
of O
hands O
"""" O
on O
the O
well O
- O
being O
of O
patients O
with O
advanced O
cancer O
is O
more O
efficient O
when O
performed O
by O
a O
person O
with O
self O
- O
declared O
"""" O
healing O
powers O
"""" O
as O
compared O
to O
an O
actor O
mimicking O
the O
healer O
in O
close O
detail O
. O
!LF! !LF!
a O
total O
of O
80 O
patients O
were O
registered O
to O
participate O
in O
a O
randomized O
, O
single O
- O
blind O
phase O
iii O
trial O
to O
evaluate O
the O
difference O
in O
efficacy O
of O
"""" O
laying O
on O
of O
hands O
"""" O
by O
either O
a O
"""" O
healer O
"""" O
or O
an O
actor O
. O
!LF! !LF!
each O
group O
consisted O
of O
40 O
patients O
, O
scheduled O
to O
receive O
treatment O
for O
5 O
min O
, O
three O
times O
a O
week O
. O
!LF! !LF!
the O
effect O
of O
treatment O
was O
measured O
using O
a O
"""" O
well O
- O
being O
scale O
"""" O
, O
with O
the O
difference O
of O
the O
average O
score O
of O
the O
"""" O
well O
- O
being O
scale O
"""" O
on O
day O
10 O
being O
defined O
as O
primary O
and O
that O
on O
day O
5 O
as O
secondary O
endpoint O
. O
!LF! !LF!
there B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
average I-Premise
score I-Premise
values I-Premise
between I-Premise
the I-Premise
"""" I-Premise
healer I-Premise
"""" I-Premise
and I-Premise
the I-Premise
actor I-Premise
with I-Premise
regard I-Premise
to I-Premise
the I-Premise
primary I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
34 I-Premise
) I-Premise
or I-Premise
the I-Premise
secondary I-Premise
endpoint I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
94 I-Premise
) I-Premise
, I-Premise
but B-Premise
the I-Premise
comparison I-Premise
was I-Premise
limited I-Premise
due I-Premise
to I-Premise
major I-Premise
protocol I-Premise
violations I-Premise
by I-Premise
the I-Premise
"""" I-Premise
healer I-Premise
"""" I-Premise
who I-Premise
unblinded I-Premise
his I-Premise
status I-Premise
after I-Premise
the I-Premise
first I-Premise
run I-Premise
and I-Premise
quit I-Premise
the I-Premise
study I-Premise
. I-Premise
!LF! !LF!
the O
study O
was O
completed O
by O
the O
actor O
as O
a O
descriptive O
, O
explorative O
study O
on O
the O
impact O
of O
"""" O
laying O
on O
of O
hands O
"""" O
. O
!LF! !LF!
a B-Premise
significant I-Premise
improvement I-Premise
in I-Premise
symptoms I-Premise
after I-Premise
treatment I-Premise
was I-Premise
found I-Premise
on I-Premise
day I-Premise
5 I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
and I-Premise
on I-Premise
day I-Premise
10 I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
0002 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
"""" B-Claim
laying I-Claim
on I-Claim
of I-Claim
hands I-Claim
"""" I-Claim
resulted I-Claim
in I-Claim
a I-Claim
significant I-Claim
improvement I-Claim
of I-Claim
cancer I-Claim
- I-Claim
or I-Claim
cancer I-Claim
- I-Claim
therapy I-Claim
- I-Claim
associated I-Claim
symptoms I-Claim
. I-Claim
!LF! !LF!
the B-Claim
magnitude I-Claim
of I-Claim
improvement I-Claim
obtained I-Claim
was I-Claim
similar I-Claim
whether I-Claim
on I-Claim
a I-Claim
self I-Claim
- I-Claim
declared I-Claim
- I-Claim
healer I-Claim
- I-Claim
or I-Claim
an I-Claim
actor I-Claim
- I-Claim
provided I-Claim
"""" I-Claim
treatment I-Claim
"""" I-Claim
. I-Claim
!LF! !LF!
to O
assess O
the O
effect O
of O
a O
multimodal O
group O
exercise O
intervention O
, O
as O
an O
adjunct O
to O
conventional O
care O
, O
on O
fatigue O
, O
physical O
capacity O
, O
general O
wellbeing O
, O
physical O
activity O
, O
and O
quality O
of O
life O
in O
patients O
with O
cancer O
who O
were O
undergoing O
adjuvant O
chemotherapy O
or O
treatment O
for O
advanced O
disease O
. O
!LF! !LF!
randomised O
controlled O
trial O
. O
!LF! !LF!
two O
university O
hospitals O
in O
copenhagen O
, O
denmark O
. O
!LF! !LF!
269 O
patients O
with O
cancer O
"""" O
; O
"""" O
73 O
men O
, O
196 O
women O
, O
mean O
age O
47 O
years O
( O
range O
20 O
- O
65 O
) O
representing O
21 O
diagnoses O
. O
!LF! !LF!
main O
exclusion O
criteria O
were O
brain O
or O
bone O
metastases O
. O
!LF! !LF!
235 O
patients O
completed O
follow O
- O
up O
. O
!LF! !LF!
supervised O
exercise O
comprising O
high O
intensity O
cardiovascular O
and O
resistance O
training O
, O
relaxation O
and O
body O
awareness O
training O
, O
massage O
, O
nine O
hours O
weekly O
for O
six O
weeks O
in O
addition O
to O
conventional O
care O
, O
compared O
with O
conventional O
care O
. O
!LF! !LF!
the O
general O
linear O
model O
was O
used O
for O
continuous O
outcome O
while O
analysis O
of O
associates O
between O
categorical O
outcomes O
was O
performed O
as O
analysis O
of O
marginal O
homogeneity O
in O
contingency O
tables O
. O
!LF! !LF!
adjusted B-Premise
for I-Premise
baseline I-Premise
score I-Premise
, I-Premise
disease I-Premise
, I-Premise
and I-Premise
demographic I-Premise
covariates I-Premise
, I-Premise
the I-Premise
intervention I-Premise
group I-Premise
showed I-Premise
an I-Premise
estimated I-Premise
improvement I-Premise
at I-Premise
six I-Premise
weeks I-Premise
for I-Premise
the I-Premise
primary I-Premise
outcome I-Premise
, I-Premise
fatigue I-Premise
, I-Premise
of I-Premise
- I-Premise
6 I-Premise
. I-Premise
6 I-Premise
points I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
- I-Premise
12 I-Premise
. I-Premise
3 I-Premise
to I-Premise
- I-Premise
0 I-Premise
. I-Premise
9 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
effect I-Premise
size I-Premise
= I-Premise
0 I-Premise
. I-Premise
33 I-Premise
, I-Premise
0 I-Premise
. I-Premise
04 I-Premise
to I-Premise
0 I-Premise
. I-Premise
61 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
significant B-Premise
effects I-Premise
were I-Premise
seen I-Premise
on I-Premise
vitality I-Premise
( I-Premise
effect I-Premise
size I-Premise
0 I-Premise
. I-Premise
55 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
. I-Premise
27 I-Premise
to I-Premise
0 I-Premise
. I-Premise
82 I-Premise
) I-Premise
, I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
0 I-Premise
. I-Premise
37 I-Premise
, I-Premise
0 I-Premise
. I-Premise
09 I-Premise
to I-Premise
0 I-Premise
. I-Premise
65 I-Premise
) I-Premise
, I-Premise
role I-Premise
physical I-Premise
( I-Premise
0 I-Premise
. I-Premise
37 I-Premise
, I-Premise
0 I-Premise
. I-Premise
10 I-Premise
to I-Premise
0 I-Premise
. I-Premise
64 I-Premise
) I-Premise
, I-Premise
role I-Premise
emotional I-Premise
( I-Premise
0 I-Premise
. I-Premise
32 I-Premise
, I-Premise
0 I-Premise
. I-Premise
05 I-Premise
to I-Premise
0 I-Premise
. I-Premise
59 I-Premise
) I-Premise
, I-Premise
and I-Premise
mental I-Premise
health I-Premise
( I-Premise
0 I-Premise
. I-Premise
28 I-Premise
, I-Premise
0 I-Premise
. I-Premise
02 I-Premise
to I-Premise
0 I-Premise
. I-Premise
56 I-Premise
) I-Premise
scores I-Premise
. I-Premise
!LF! !LF!
improvement B-Premise
was I-Premise
noted I-Premise
in I-Premise
physical I-Premise
capacity I-Premise
: I-Premise
estimated I-Premise
mean I-Premise
difference I-Premise
between I-Premise
groups I-Premise
for I-Premise
maximum I-Premise
oxygen I-Premise
consumption I-Premise
was I-Premise
0 I-Premise
. I-Premise
16 I-Premise
l I-Premise
/ I-Premise
min I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
. I-Premise
1 I-Premise
to I-Premise
0 I-Premise
. I-Premise
2 I-Premise
, I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
0001 I-Premise
) I-Premise
and I-Premise
for I-Premise
muscular I-Premise
strength I-Premise
( I-Premise
leg I-Premise
press I-Premise
) I-Premise
was I-Premise
29 I-Premise
. I-Premise
7 I-Premise
kg I-Premise
( I-Premise
23 I-Premise
. I-Premise
4 I-Premise
to I-Premise
34 I-Premise
. I-Premise
9 I-Premise
, I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
0001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
no B-Premise
significant I-Premise
effect I-Premise
was I-Premise
seen I-Premise
on I-Premise
global I-Premise
health I-Premise
status I-Premise
/ I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise
!LF! !LF!
a B-Claim
supervised I-Claim
multimodal I-Claim
exercise I-Claim
intervention I-Claim
including I-Claim
high I-Claim
and I-Claim
low I-Claim
intensity I-Claim
components I-Claim
was I-Claim
feasible I-Claim
and I-Claim
could I-Claim
safely I-Claim
be I-Claim
used I-Claim
in I-Claim
patients I-Claim
with I-Claim
various I-Claim
cancers I-Claim
who I-Claim
were I-Claim
receiving I-Claim
adjuvant I-Claim
chemotherapy I-Claim
or I-Claim
treatment I-Claim
for I-Claim
advanced I-Claim
disease I-Claim
. I-Claim
!LF! !LF!
the B-Claim
intervention I-Claim
reduced I-Claim
fatigue I-Claim
and I-Claim
improved I-Claim
vitality I-Claim
, I-Claim
aerobic I-Claim
capacity I-Claim
, I-Claim
muscular I-Claim
strength I-Claim
, I-Claim
and I-Claim
physical I-Claim
and I-Claim
functional I-Claim
activity I-Claim
, I-Claim
and I-Claim
emotional I-Claim
wellbeing I-Claim
, I-Claim
but B-Claim
not I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim
!LF! !LF!
to O
determine O
whether O
weekly O
epoetin O
alfa O
could O
improve O
hemoglobin O
( O
hgb O
) O
levels O
, O
reduce O
rbc O
transfusions O
, O
and O
improve O
quality O
of O
life O
( O
qol O
) O
in O
patients O
with O
advanced O
cancer O
and O
with O
anemia O
after O
receiving O
myelosuppressive O
chemotherapy O
. O
!LF! !LF!
this O
double O
- O
blind O
, O
placebo O
- O
controlled O
study O
randomly O
assigned O
patients O
to O
placebo O
or O
epoetin O
alfa O
( O
ortho O
biotech O
, O
bridgewater O
, O
nj O
) O
40 O
, O
000 O
u O
subcutaneous O
weekly O
for O
16 O
weeks O
. O
!LF! !LF!
qol O
, O
hgb O
, O
and O
rbc O
transfusions O
were O
measured O
pretreatment O
and O
monthly O
. O
!LF! !LF!
the O
study O
accrued O
344 O
patients O
"""" O
; O
"""" O
330 O
were O
assessable O
for O
efficacy O
and O
305 O
were O
assessable O
for O
qol O
. O
!LF! !LF!
placebo B-Premise
- B-Premise
treated B-Premise
patients I-Premise
had I-Premise
a I-Premise
mean I-Premise
increase I-Premise
in I-Premise
hgb I-Premise
of I-Premise
0 I-Premise
. I-Premise
9 I-Premise
g I-Premise
/ I-Premise
dl I-Premise
( I-Premise
range I-Premise
, I-Premise
- I-Premise
3 I-Premise
. I-Premise
8 I-Premise
to I-Premise
+ I-Premise
5 I-Premise
. I-Premise
3 I-Premise
) I-Premise
compared I-Premise
with I-Premise
2 I-Premise
. I-Premise
8 I-Premise
g I-Premise
/ I-Premise
dl I-Premise
( I-Premise
range I-Premise
, I-Premise
- I-Premise
2 I-Premise
. I-Premise
2 I-Premise
to I-Premise
+ I-Premise
7 I-Premise
. I-Premise
5 I-Premise
) I-Premise
for I-Premise
epoetin I-Premise
- I-Premise
treated I-Premise
patients I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
0001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
during B-Premise
the I-Premise
study I-Premise
, I-Premise
31 I-Premise
. I-Premise
7 I-Premise
% I-Premise
of I-Premise
placebo I-Premise
- I-Premise
treated I-Premise
patients I-Premise
achieved I-Premise
a I-Premise
> I-Premise
or I-Premise
= I-Premise
2 I-Premise
g I-Premise
/ I-Premise
dl I-Premise
hgb I-Premise
increase I-Premise
compared I-Premise
with I-Premise
72 I-Premise
. I-Premise
7 I-Premise
% I-Premise
of I-Premise
epoetin I-Premise
- I-Premise
treated I-Premise
patients I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
0001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
incidence I-Premise
of I-Premise
rbc I-Premise
transfusion I-Premise
for I-Premise
placebo I-Premise
and I-Premise
epoetin I-Premise
treatment I-Premise
arms I-Premise
was I-Premise
39 I-Premise
. I-Premise
6 I-Premise
% I-Premise
and I-Premise
25 I-Premise
. I-Premise
3 I-Premise
% I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
005 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
the O
placebo O
group O
received O
256 O
units O
of O
rbcs O
compared O
with O
127 O
units O
in O
the O
epoetin O
group O
( O
p O
< O
. O
0001 O
) O
. O
!LF! !LF!
the B-Premise
incidence I-Premise
of I-Premise
toxicity I-Premise
in I-Premise
the I-Premise
groups I-Premise
was I-Premise
similar I-Premise
. I-Premise
!LF! !LF!
changes B-Premise
in I-Premise
the I-Premise
average I-Premise
qol I-Premise
scores I-Premise
from I-Premise
baseline I-Premise
to I-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
study I-Premise
were I-Premise
similar I-Premise
in I-Premise
the I-Premise
two I-Premise
groups I-Premise
( I-Premise
p I-Premise
= I-Premise
not I-Premise
significant I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
hgb I-Premise
responders I-Premise
( I-Premise
irrespective I-Premise
of I-Premise
treatment I-Premise
arm I-Premise
) I-Premise
had I-Premise
a I-Premise
mean I-Premise
change I-Premise
in I-Premise
functional I-Premise
assessment I-Premise
of I-Premise
cancer I-Premise
therapy I-Premise
( I-Premise
fact I-Premise
) I-Premise
fatigue I-Premise
score I-Premise
from I-Premise
a I-Premise
baseline I-Premise
of I-Premise
+ I-Premise
5 I-Premise
. I-Premise
1 I-Premise
compared I-Premise
with I-Premise
- I-Premise
2 I-Premise
. I-Premise
1 I-Premise
for I-Premise
the I-Premise
nonresponders I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
006 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
epoetin B-Claim
alfa I-Claim
significantly I-Claim
improved I-Claim
hgb I-Claim
and I-Claim
reduced I-Claim
transfusions I-Claim
in I-Claim
this I-Claim
patient I-Claim
population I-Claim
. I-Claim
!LF! !LF!
these B-Claim
results I-Claim
support I-Claim
the I-Claim
use I-Claim
of I-Claim
weekly I-Claim
epoetin I-Claim
alfa I-Claim
as I-Claim
an I-Claim
ameliorative I-Claim
agent I-Claim
for I-Claim
cancer I-Claim
- I-Claim
related I-Claim
anemia I-Claim
. I-Claim
!LF! !LF!
temozolomide O
( O
tmz O
) O
is O
an O
alkylating O
agent O
licensed O
for O
treatment O
of O
high O
- O
grade O
glioma O
( O
hgg O
) O
. O
!LF! !LF!
no O
prospective O
comparison O
with O
nitrosourea O
- O
based O
chemotherapy O
exists O
. O
!LF! !LF!
we O
report O
, O
to O
our O
knowledge O
, O
the O
first O
randomized O
trial O
of O
procarbazine O
, O
lomustine O
, O
and O
vincristine O
( O
pcv O
) O
versus O
tmz O
in O
chemotherapy O
- O
naive O
patients O
with O
recurrent O
hgg O
. O
!LF! !LF!
four O
hundred O
forty O
- O
seven O
patients O
were O
randomly O
assigned O
to O
pcv O
( O
224 O
patients O
) O
or O
tmz O
( O
sub O
- O
random O
assignment O
: O
tmz O
- O
5 O
[ O
200 O
mg O
/ O
m O
( O
2 O
) O
for O
5 O
days O
, O
112 O
patients O
] O
or O
tmz O
- O
21 O
[ O
100 O
mg O
/ O
m O
( O
2 O
) O
for O
21 O
days O
, O
111 O
patients O
] O
) O
for O
up O
to O
9 O
months O
or O
until O
progression O
. O
!LF! !LF!
the O
primary O
outcomes O
were O
survival O
( O
pcv O
v O
tmz O
) O
and O
12 O
- O
week O
progression O
- O
free O
survival O
( O
pfs O
"""" O
; O
"""" O
tmz O
- O
5 O
v O
tmz O
- O
21 O
) O
. O
!LF! !LF!
this O
study O
is O
registered O
as O
isrctn83176944 O
. O
!LF! !LF!
percentages O
of O
patients O
completing O
9 O
months O
of O
treatment O
in O
the O
pcv O
, O
tmz O
- O
5 O
, O
and O
tmz O
- O
21 O
arms O
were O
17 O
% O
, O
26 O
% O
, O
and O
13 O
% O
, O
respectively O
. O
!LF! !LF!
major B-Premise
toxicity I-Premise
was I-Premise
similar I-Premise
across I-Premise
all I-Premise
three I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
with B-Premise
a I-Premise
median I-Premise
follow I-Premise
- I-Premise
up I-Premise
time I-Premise
of I-Premise
12 I-Premise
months I-Premise
and I-Premise
382 I-Premise
deaths I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
clear I-Premise
survival I-Premise
benefit I-Premise
when I-Premise
comparing I-Premise
pcv I-Premise
with I-Premise
tmz I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
hr I-Premise
] I-Premise
, I-Premise
0 I-Premise
. I-Premise
91 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
74 I-Premise
to I-Premise
1 I-Premise
. I-Premise
11 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
350 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
for B-Premise
tmz I-Premise
- I-Premise
5 I-Premise
versus I-Premise
tmz I-Premise
- I-Premise
21 I-Premise
, I-Premise
12 I-Premise
- I-Premise
week I-Premise
pfs I-Premise
rates I-Premise
were I-Premise
similar I-Premise
( I-Premise
63 I-Premise
. I-Premise
6 I-Premise
% I-Premise
and I-Premise
65 I-Premise
. I-Premise
7 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
745 I-Premise
) I-Premise
, I-Premise
but B-Premise
tmz I-Premise
- I-Premise
5 I-Premise
improved I-Premise
overall I-Premise
pfs I-Premise
( I-Premise
hr I-Premise
, I-Premise
1 I-Premise
. I-Premise
38 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
1 I-Premise
. I-Premise
05 I-Premise
to I-Premise
1 I-Premise
. I-Premise
82 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
023 I-Premise
) I-Premise
, I-Premise
survival I-Premise
( I-Premise
hr I-Premise
, I-Premise
1 I-Premise
. I-Premise
32 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
99 I-Premise
to I-Premise
1 I-Premise
. I-Premise
75 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
056 I-Premise
) I-Premise
, I-Premise
and I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
49 I-Premise
% I-Premise
v I-Premise
19 I-Premise
% I-Premise
improved I-Premise
> I-Premise
10 I-Premise
points I-Premise
at I-Premise
6 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
005 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
although B-Claim
tmz I-Claim
( I-Claim
both I-Claim
arms I-Claim
combined I-Claim
) I-Claim
did I-Claim
not I-Claim
show I-Claim
a I-Claim
clear I-Claim
benefit I-Claim
compared I-Claim
with I-Claim
pcv I-Claim
, I-Claim
comparison I-Claim
of I-Claim
the I-Claim
tmz I-Claim
schedules I-Claim
demonstrated I-Claim
that I-Claim
the I-Claim
21 I-Claim
- I-Claim
day I-Claim
schedule I-Claim
was I-Claim
inferior I-Claim
to I-Claim
the I-Claim
5 I-Claim
- I-Claim
day I-Claim
schedule I-Claim
in I-Claim
this I-Claim
setting I-Claim
. I-Claim
!LF! !LF!
this B-Claim
challenges I-Claim
the I-Claim
current I-Claim
understanding I-Claim
of I-Claim
increasing I-Claim
tmz I-Claim
dose I-Claim
- I-Claim
intensity I-Claim
by I-Claim
prolonged I-Claim
scheduling I-Claim
. I-Claim
!LF! !LF!
radiation O
- O
induced O
mucositis O
is O
an O
acute O
reaction O
of O
the O
mucosa O
of O
patients O
undergoing O
head O
and O
neck O
radiotherapy O
. O
!LF! !LF!
it O
can O
have O
debilitating O
and O
dose O
- O
limiting O
consequences O
. O
!LF! !LF!
there B-Claim
is I-Claim
no I-Claim
consensus I-Claim
on I-Claim
an I-Claim
accepted I-Claim
intervention I-Claim
that I-Claim
significantly I-Claim
reduces I-Claim
its I-Claim
severity I-Claim
. I-Claim
!LF! !LF!
misoprostol O
is O
a O
synthetic O
prostaglandin O
e1 O
analogue O
, O
with O
properties O
of O
a O
mucosal O
cytoprotectant O
. O
!LF! !LF!
we O
designed O
a O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
trial O
of O
misoprostol O
in O
patients O
with O
head O
and O
neck O
cancer O
. O
!LF! !LF!
the O
aim O
of O
this O
study O
was O
to O
determine O
if O
topical O
misoprostol O
was O
effective O
in O
reducing O
the O
severity O
of O
radiation O
- O
induced O
mucositis O
in O
patients O
receiving O
radical O
dose O
radiotherapy O
. O
!LF! !LF!
the O
effect O
of O
this O
intervention O
on O
a O
patient O
' O
s O
general O
well O
- O
being O
was O
also O
investigated O
. O
!LF! !LF!
the O
primary O
end O
- O
point O
of O
the O
study O
was O
the O
incidence O
of O
radiation O
therapy O
oncology O
group O
grade O
3 O
mucositis O
. O
!LF! !LF!
between O
1999 O
and O
2002 O
, O
83 O
patients O
were O
recruited O
into O
the O
study O
at O
westmead O
and O
nepean O
hospitals O
, O
sydney O
. O
!LF! !LF!
forty O
- O
two O
patients O
were O
randomized O
to O
receive O
misoprostol O
and O
41 O
to O
receive O
a O
placebo O
. O
!LF! !LF!
most O
patients O
received O
radiotherapy O
in O
the O
adjuvant O
setting O
( O
52 O
of O
the O
83 O
) O
and O
had O
either O
an O
oral O
cavity O
( O
42 O
of O
the O
83 O
) O
or O
an O
oropharyngeal O
( O
16 O
of O
the O
83 O
) O
cancer O
. O
!LF! !LF!
we B-Claim
could I-Claim
not I-Claim
identify I-Claim
any I-Claim
significant I-Claim
difference I-Claim
in I-Claim
the I-Claim
incidence I-Claim
of I-Claim
severe I-Claim
mucositis I-Claim
based I-Claim
on I-Claim
whether I-Claim
patients I-Claim
were I-Claim
allocated I-Claim
to I-Claim
receive I-Claim
misoprostol I-Claim
or I-Claim
placebo I-Claim
. I-Claim
!LF! !LF!
there B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
mean I-Premise
area I-Premise
under I-Premise
the I-Premise
mucositis I-Premise
curve I-Premise
( I-Premise
13 I-Premise
. I-Premise
2 I-Premise
vs I-Premise
16 I-Premise
. I-Premise
6 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
1 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
allocated I-Premise
to I-Premise
misoprostol I-Premise
did I-Premise
report I-Premise
slightly I-Premise
increased I-Premise
soreness I-Premise
( I-Premise
7 I-Premise
. I-Premise
6 I-Premise
vs I-Premise
6 I-Premise
. I-Premise
9 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
04 I-Premise
) I-Premise
and I-Premise
a I-Premise
greater I-Premise
use I-Premise
of I-Premise
analgesics I-Premise
. I-Premise
!LF! !LF!
however B-Premise
, I-Premise
this I-Premise
difference I-Premise
did I-Premise
not I-Premise
translate I-Premise
into I-Premise
a I-Premise
worse I-Premise
feeling I-Premise
of I-Premise
general I-Premise
well I-Premise
- I-Premise
being I-Premise
as I-Premise
measured I-Premise
by I-Premise
a I-Premise
simple I-Premise
visual I-Premise
analogue I-Premise
scale I-Premise
( I-Premise
5 I-Premise
. I-Premise
8 I-Premise
vs I-Premise
5 I-Premise
. I-Premise
2 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
3 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
in B-Claim
conclusion I-Claim
, I-Claim
we I-Claim
were I-Claim
unable I-Claim
to I-Claim
identify I-Claim
a I-Claim
reduction I-Claim
in I-Claim
radiation I-Claim
- I-Claim
induced I-Claim
mucositis I-Claim
in I-Claim
patients I-Claim
receiving I-Claim
misoprostol I-Claim
. I-Claim
!LF! !LF!
there B-Claim
is I-Claim
a I-Claim
paucity I-Claim
of I-Claim
high I-Claim
- I-Claim
level I-Claim
evidence I-Claim
on I-Claim
potentially I-Claim
useful I-Claim
interventions I-Claim
and I-Claim
a I-Claim
continued I-Claim
need I-Claim
for I-Claim
new I-Claim
and I-Claim
innovative I-Claim
research I-Claim
, I-Claim
incorporating I-Claim
quality I-Claim
- I-Claim
of I-Claim
- I-Claim
life I-Claim
measurements I-Claim
, I-Claim
in I-Claim
patients I-Claim
experiencing I-Claim
radiation I-Claim
- I-Claim
induced I-Claim
mucositis I-Claim
. I-Claim
!LF! !LF!
this O
randomized O
phase O
ii O
study O
compared O
two O
treatment O
schedules O
of O
gemcitabine O
in O
patients O
with O
non O
- O
small O
- O
cell O
lung O
cancer O
( O
nsclc O
) O
and O
impaired O
karnofsky O
performance O
status O
( O
kp O
) O
. O
!LF! !LF!
primary O
objectives O
were O
to O
record O
changes O
from O
baseline O
kp O
and O
to O
assess O
symptom O
palliation O
. O
!LF! !LF!
secondary O
objectives O
were O
overall O
survival O
, O
tumor O
response O
, O
and O
toxicity O
. O
!LF! !LF!
patients O
with O
stage O
iiib O
and O
iv O
nsclc O
and O
kp O
< O
/ O
= O
70 O
were O
randomly O
assigned O
to O
receive O
gemcitabine O
1 O
, O
000 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
, O
8 O
, O
and O
15 O
of O
each O
28 O
- O
day O
cycle O
( O
3w4 O
) O
or O
gemcitabine O
1 O
, O
500 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
of O
each O
21 O
- O
day O
cycle O
( O
2w3 O
) O
, O
both O
for O
up O
to O
six O
cycles O
. O
!LF! !LF!
kp O
, O
toxicity O
, O
and O
ss14 O
lung O
cancer O
specific O
questions O
were O
recorded O
before O
each O
cycle O
of O
treatment O
. O
!LF! !LF!
response O
was O
evaluated O
4 O
weeks O
after O
the O
last O
cycle O
. O
!LF! !LF!
one O
hundred O
seventy O
- O
four O
patients O
were O
enrolled O
. O
!LF! !LF!
there B-Premise
was I-Premise
significant I-Premise
early I-Premise
attrition I-Premise
due I-Premise
to I-Premise
disease I-Premise
progression I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
only I-Premise
61 I-Premise
. I-Premise
5 I-Premise
% I-Premise
of I-Premise
patients I-Premise
were I-Premise
alive I-Premise
at I-Premise
2 I-Premise
months I-Premise
. I-Premise
!LF! !LF!
there B-Premise
was I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
kp I-Premise
from I-Premise
baseline I-Premise
to I-Premise
pre I-Premise
- I-Premise
cycle I-Premise
3 I-Premise
in I-Premise
both I-Premise
arms I-Premise
, I-Premise
with I-Premise
a I-Premise
trend I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
3w4 I-Premise
regimen I-Premise
for I-Premise
duration I-Premise
and I-Premise
faster I-Premise
onset I-Premise
of I-Premise
improvement I-Premise
. I-Premise
!LF! !LF!
eight B-Premise
of I-Premise
the I-Premise
17 I-Premise
quality I-Premise
- I-Premise
of I-Premise
- I-Premise
life I-Premise
( I-Premise
qol I-Premise
) I-Premise
variables I-Premise
assessed I-Premise
showed I-Premise
an I-Premise
improvement I-Premise
of I-Premise
more I-Premise
than I-Premise
10 I-Premise
% I-Premise
between I-Premise
baseline I-Premise
and I-Premise
the I-Premise
start I-Premise
of I-Premise
the I-Premise
third I-Premise
cycle I-Premise
of I-Premise
treatment I-Premise
. I-Premise
!LF! !LF!
response B-Premise
rate I-Premise
, I-Premise
survival I-Premise
, I-Premise
and I-Premise
duration I-Premise
were I-Premise
similar I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
there B-Claim
was I-Claim
no I-Claim
significant I-Claim
difference I-Claim
between I-Claim
the I-Claim
two I-Claim
schedules I-Claim
examined I-Claim
in I-Claim
terms I-Claim
of I-Claim
improvement I-Claim
in I-Claim
kp I-Claim
or I-Claim
qol I-Claim
, I-Claim
but I-Claim
there I-Claim
seemed I-Claim
to I-Claim
be I-Claim
a I-Claim
trend I-Claim
in I-Claim
favor I-Claim
of I-Claim
the I-Claim
3w4 I-Claim
schedule I-Claim
. I-Claim
!LF! !LF!
behavioral O
symptoms O
are O
common O
in O
breast O
cancer O
survivors O
, O
including O
disturbances O
in O
energy O
, O
sleep O
, O
and O
mood O
, O
though O
few O
risk O
factors O
for O
these O
negative O
outcomes O
have O
been O
identified O
. O
!LF! !LF!
our O
study O
examined O
intrusive O
thoughts O
as O
a O
predictor O
of O
lingering O
symptoms O
in O
breast O
cancer O
survivors O
in O
the O
year O
following O
treatment O
. O
!LF! !LF!
data O
come O
from O
the O
moving O
beyond O
cancer O
psychoeducational O
intervention O
trial O
, O
aimed O
at O
easing O
the O
transition O
from O
patient O
to O
survivor O
. O
!LF! !LF!
women O
( O
n O
= O
558 O
) O
completed O
psychosocial O
questionnaires O
within O
4 O
weeks O
posttreatment O
and O
again O
2 O
, O
6 O
, O
and O
12 O
months O
later O
. O
!LF! !LF!
we O
examined O
intrusive O
thoughts O
about O
cancer O
at O
the O
baseline O
assessment O
as O
a O
predictor O
of O
fatigue O
, O
sleep O
problems O
, O
pain O
, O
breast O
cancer O
- O
specific O
symptoms O
, O
depressive O
symptoms O
, O
negative O
affect O
, O
and O
quality O
of O
life O
using O
growth O
curve O
modeling O
, O
controlling O
for O
study O
condition O
and O
other O
covariates O
. O
!LF! !LF!
intrusive B-Premise
thoughts I-Premise
were I-Premise
associated I-Premise
with I-Premise
higher I-Premise
levels I-Premise
of I-Premise
all I-Premise
symptoms I-Premise
at I-Premise
baseline I-Premise
and I-Premise
at I-Premise
the I-Premise
12 I-Premise
- I-Premise
month I-Premise
assessment I-Premise
. I-Premise
!LF! !LF!
intrusive B-Premise
thoughts I-Premise
also I-Premise
influenced I-Premise
the I-Premise
trajectory I-Premise
of I-Premise
pain I-Premise
, I-Premise
depressive I-Premise
symptoms I-Premise
, I-Premise
negative I-Premise
affect I-Premise
, I-Premise
and I-Premise
physical I-Premise
functioning I-Premise
over I-Premise
time I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
women B-Premise
with I-Premise
higher I-Premise
intrusions I-Premise
at I-Premise
baseline I-Premise
started I-Premise
worse I-Premise
and I-Premise
improved I-Premise
over I-Premise
time I-Premise
, I-Premise
whereas I-Premise
those I-Premise
with I-Premise
lower I-Premise
intrusions I-Premise
remained I-Premise
at I-Premise
a I-Premise
constant I-Premise
, I-Premise
lower I-Premise
level I-Premise
over I-Premise
time I-Premise
. I-Premise
!LF! !LF!
intrusions B-Premise
were I-Premise
not I-Premise
associated I-Premise
with I-Premise
the I-Premise
trajectory I-Premise
of I-Premise
fatigue I-Premise
, I-Premise
sleep I-Premise
, I-Premise
breast I-Premise
cancer I-Premise
- I-Premise
specific I-Premise
symptoms I-Premise
, I-Premise
or I-Premise
mental I-Premise
functioning I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
women B-Premise
with I-Premise
higher I-Premise
intrusions I-Premise
at I-Premise
baseline I-Premise
started I-Premise
worse I-Premise
and I-Premise
remained I-Premise
worse I-Premise
over I-Premise
time I-Premise
. I-Premise
!LF! !LF!
intrusive B-Claim
thoughts I-Claim
are I-Claim
associated I-Claim
with I-Claim
enduring I-Claim
elevations I-Claim
in I-Claim
behavioral I-Claim
symptoms I-Claim
and I-Claim
impaired I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
the I-Claim
year I-Claim
after I-Claim
breast I-Claim
cancer I-Claim
treatment I-Claim
and I-Claim
may I-Claim
be I-Claim
a I-Claim
risk I-Claim
factor I-Claim
for I-Claim
poor I-Claim
outcomes I-Claim
. I-Claim
!LF! !LF!
on O
march O
15 O
, O
2005 O
, O
the O
us O
food O
and O
drug O
administration O
approved O
temozolomide O
( O
temodar O
capsules O
, O
schering O
- O
plough O
research O
institute O
) O
for O
the O
treatment O
of O
adult O
patients O
with O
newly O
diagnosed O
glioblastoma O
multiforme O
concomitantly O
with O
radiotherapy O
and O
then O
as O
maintenance O
treatment O
. O
!LF! !LF!
five O
hundred O
seventy O
- O
three O
glioblastoma O
multiforme O
patients O
were O
randomized O
to O
receive O
either O
temozolomide O
+ O
radiotherapy O
( O
n O
= O
287 O
) O
or O
radiotherapy O
alone O
( O
n O
= O
286 O
) O
. O
!LF! !LF!
patients O
in O
the O
temozolomide O
+ O
radiotherapy O
arm O
received O
concomitant O
temozolomide O
( O
75 O
mg O
/ O
m2 O
) O
once O
daily O
for O
the O
duration O
of O
radiation O
therapy O
( O
42 O
- O
49 O
days O
) O
. O
!LF! !LF!
this O
was O
followed O
, O
4 O
weeks O
later O
, O
by O
six O
cycles O
of O
temozolomide O
, O
150 O
or O
200 O
mg O
/ O
m2 O
daily O
for O
5 O
days O
, O
every O
4 O
weeks O
. O
!LF! !LF!
patients O
in O
the O
control O
arm O
received O
radiotherapy O
only O
. O
!LF! !LF!
in O
both O
arms O
, O
radiotherapy O
was O
delivered O
as O
60 O
gy O
/ O
30 O
fractions O
to O
the O
tumor O
site O
with O
a O
2 O
to O
3 O
cm O
margin O
. O
!LF! !LF!
pneumocystis O
carinii O
pneumonia O
prophylaxis O
was O
required O
during O
temozolomide O
+ O
radiotherapy O
treatment O
and O
was O
continued O
until O
recovery O
of O
lymphocytopenia O
( O
common O
toxicity O
criteria O
grade O
< O
1 O
) O
. O
!LF! !LF!
at O
disease O
progression O
, O
temozolomide O
salvage O
treatment O
was O
given O
to O
161 O
of O
282 O
patients O
( O
57 O
% O
) O
in O
the O
radiotherapy O
alone O
arm O
, O
and O
to O
62 O
of O
277 O
patients O
( O
22 O
% O
) O
in O
the O
temozolomide O
+ O
radiotherapy O
arm O
. O
!LF! !LF!
patients B-Claim
receiving I-Claim
concomitant I-Claim
and I-Claim
maintenance I-Claim
temozolomide I-Claim
+ I-Claim
radiotherapy I-Claim
had I-Claim
significantly I-Claim
improved I-Claim
overall I-Claim
survival I-Claim
. I-Claim
!LF! !LF!
the B-Premise
hazard I-Premise
ratio I-Premise
was I-Premise
0 I-Premise
. I-Premise
63 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
, I-Premise
0 I-Premise
. I-Premise
52 I-Premise
- I-Premise
0 I-Premise
. I-Premise
75 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
log I-Premise
- I-Premise
rank I-Premise
, I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
0001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
median B-Premise
survival I-Premise
was I-Premise
14 I-Premise
. I-Premise
6 I-Premise
months I-Premise
( I-Premise
temozolomide I-Premise
+ I-Premise
radiotherapy I-Premise
) I-Premise
versus I-Premise
12 I-Premise
. I-Premise
1 I-Premise
months I-Premise
( I-Premise
radiotherapy I-Premise
alone I-Premise
) I-Premise
. I-Premise
!LF! !LF!
adverse B-Claim
events I-Claim
during I-Claim
temozolomide I-Claim
treatment I-Claim
included I-Claim
thrombocytopenia I-Claim
, I-Claim
nausea I-Claim
, I-Claim
vomiting I-Claim
, I-Claim
anorexia I-Claim
, I-Claim
constipation I-Claim
, I-Claim
alopecia I-Claim
, I-Claim
headache I-Claim
, I-Claim
fatigue I-Claim
, I-Claim
and I-Claim
convulsions I-Claim
. I-Claim
!LF! !LF!
this O
study O
examined O
the O
feasibility O
and O
acceptability O
of O
an O
individual O
internet O
intervention O
( O
iii O
) O
embedded O
and O
integrated O
into O
an O
internet O
support O
group O
( O
isg O
) O
with O
the O
ultimate O
goal O
of O
enhancing O
adherence O
and O
learning O
, O
compared O
with O
an O
individual O
internet O
invention O
alone O
. O
!LF! !LF!
thirty O
- O
one O
posttreatment O
cancer O
survivors O
were O
randomized O
in O
groups O
of O
seven O
to O
nine O
to O
either O
the O
8 O
- O
week O
iii O
+ O
isg O
intervention O
or O
the O
8 O
- O
week O
iii O
condition O
. O
!LF! !LF!
seventeen O
participants O
met O
the O
hospital O
anxiety O
and O
depression O
scale O
( O
hads O
) O
criteria O
for O
depressive O
symptoms O
( O
hads O
≥ O
8 O
) O
. O
!LF! !LF!
among O
all O
participants O
, O
the O
mean O
number O
of O
logins O
over O
8 O
weeks O
was O
20 O
. O
8 O
± O
17 O
. O
7 O
logins O
for O
the O
iii O
+ O
isg O
compared O
with O
12 O
. O
5 O
± O
12 O
. O
5 O
in O
iii O
- O
only O
( O
p O
= O
0 O
. O
15 O
) O
. O
!LF! !LF!
two O
participants O
in O
the O
iii O
+ O
isg O
dropped O
out O
, O
compared O
with O
five O
in O
iii O
( O
p O
= O
0 O
. O
39 O
) O
. O
!LF! !LF!
among B-Premise
the I-Premise
17 I-Premise
participants I-Premise
with I-Premise
depressive I-Premise
symptoms I-Premise
at I-Premise
baseline I-Premise
, I-Premise
both I-Premise
the I-Premise
onward I-Premise
and I-Premise
the I-Premise
iii I-Premise
- I-Premise
only I-Premise
condition I-Premise
showed I-Premise
large I-Premise
reductions I-Premise
in I-Premise
the I-Premise
depression I-Premise
scale I-Premise
of I-Premise
hads I-Premise
( I-Premise
d I-Premise
= I-Premise
1 I-Premise
. I-Premise
27 I-Premise
and I-Premise
0 I-Premise
. I-Premise
89 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise
!LF! !LF!
improvement B-Premise
over I-Premise
time I-Premise
and I-Premise
time I-Premise
x I-Premise
treatment I-Premise
effects I-Premise
only I-Premise
reached I-Premise
trend I-Premise
significance I-Premise
levels I-Premise
( I-Premise
ps I-Premise
= I-Premise
0 I-Premise
. I-Premise
07 I-Premise
& I-Premise
amp I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
0 I-Premise
. I-Premise
12 I-Premise
) I-Premise
as I-Premise
this I-Premise
pilot I-Premise
was I-Premise
not I-Premise
powered I-Premise
to I-Premise
detect I-Premise
these I-Premise
differences I-Premise
. I-Premise
!LF! !LF!
both B-Claim
the I-Claim
iii I-Claim
+ I-Claim
isg I-Claim
and I-Claim
iii I-Claim
- I-Claim
only I-Claim
demonstrated I-Claim
pre I-Claim
- I-Claim
post I-Claim
reductions I-Claim
in I-Claim
depressive I-Claim
symptoms I-Claim
and I-Claim
high I-Claim
rates I-Claim
of I-Claim
utilization I-Claim
compared I-Claim
with I-Claim
other I-Claim
web I-Claim
- I-Claim
based I-Claim
treatments I-Claim
for I-Claim
depression I-Claim
. I-Claim
!LF! !LF!
although B-Claim
it I-Claim
is I-Claim
premature I-Claim
to I-Claim
make I-Claim
any I-Claim
determination I-Claim
as I-Claim
to I-Claim
the I-Claim
efficacy I-Claim
of I-Claim
the I-Claim
interventions I-Claim
tested I-Claim
in I-Claim
this I-Claim
feasibility I-Claim
study I-Claim
, I-Claim
these B-Claim
results I-Claim
indicate I-Claim
that I-Claim
pursuing I-Claim
the I-Claim
iii I-Claim
+ I-Claim
isg I-Claim
model I-Claim
, I-Claim
as I-Claim
well I-Claim
as I-Claim
standard I-Claim
iiis I-Claim
, I-Claim
may I-Claim
be I-Claim
fruitful I-Claim
areas I-Claim
of I-Claim
future I-Claim
research I-Claim
. I-Claim
!LF! !LF!
the O
optimal O
duration O
over O
which O
lung O
sbrt O
should O
be O
delivered O
is O
unknown O
. O
!LF! !LF!
we O
conducted O
a O
randomized O
pilot O
study O
in O
patients O
treated O
with O
four O
fractions O
of O
lung O
sbrt O
delivered O
over O
4 O
or O
over O
11 O
days O
. O
!LF! !LF!
patients O
with O
a O
peripheral O
solitary O
lung O
tumor O
( O
nsclc O
or O
pulmonary O
metastasis O
) O
≤ O
5 O
cm O
were O
eligible O
. O
!LF! !LF!
for O
nsclc O
lung O
tumors O
≤ O
3 O
cm O
, O
a O
dose O
of O
48 O
gy O
in O
4 O
fractions O
was O
used O
, O
otherwise O
52 O
gy O
in O
4 O
fractions O
was O
delivered O
. O
!LF! !LF!
patients O
were O
randomized O
to O
receive O
treatment O
over O
4 O
consecutive O
days O
or O
over O
11 O
days O
. O
!LF! !LF!
the O
primary O
end O
- O
point O
was O
acute O
grade O
≥ O
2 O
toxicity O
. O
!LF! !LF!
secondary O
end O
- O
points O
included O
quality O
of O
life O
( O
qol O
) O
assessed O
using O
the O
eortc O
qlq O
- O
c30 O
and O
qlq O
- O
lc13 O
questionnaires O
. O
!LF! !LF!
fifty O
four O
patients O
were O
enrolled O
. O
!LF! !LF!
more O
patients O
in O
the O
11 O
day O
group O
had O
respiratory O
symptoms O
at O
baseline O
. O
!LF! !LF!
55 B-Premise
. B-Premise
6 B-Premise
% I-Premise
patients I-Premise
treated I-Premise
over I-Premise
4 I-Premise
days I-Premise
and I-Premise
33 I-Premise
. I-Premise
3 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
over I-Premise
11 I-Premise
days I-Premise
experienced I-Premise
acute I-Premise
grade I-Premise
≥ I-Premise
2 I-Premise
toxicity I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
085 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
dyspnea B-Premise
, I-Premise
fatigue I-Premise
and I-Premise
coughing I-Premise
domains I-Premise
were I-Premise
worse I-Premise
in I-Premise
the I-Premise
11 I-Premise
day I-Premise
group I-Premise
at I-Premise
baseline I-Premise
. I-Premise
!LF! !LF!
at B-Premise
1 I-Premise
and I-Premise
4 I-Premise
months I-Premise
, I-Premise
more I-Premise
patients I-Premise
in I-Premise
the I-Premise
4 I-Premise
day I-Premise
group I-Premise
experienced I-Premise
a I-Premise
clinically I-Premise
meaningful I-Premise
worsening I-Premise
in I-Premise
the I-Premise
dyspnea I-Premise
qol I-Premise
domain I-Premise
compared I-Premise
to I-Premise
the I-Premise
11 I-Premise
day I-Premise
group I-Premise
( I-Premise
44 I-Premise
. I-Premise
5 I-Premise
% I-Premise
vs I-Premise
15 I-Premise
. I-Premise
4 I-Premise
% I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
38 I-Premise
. I-Premise
5 I-Premise
% I-Premise
vs I-Premise
12 I-Premise
. I-Premise
0 I-Premise
% I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
03 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise
!LF! !LF!
however B-Premise
, I-Premise
raw I-Premise
qol I-Premise
scores I-Premise
were I-Premise
not I-Premise
different I-Premise
at I-Premise
these I-Premise
time I-Premise
- I-Premise
points I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
grade B-Claim
2 I-Claim
or I-Claim
higher I-Claim
acute I-Claim
toxicity I-Claim
was I-Claim
more I-Claim
common I-Claim
in I-Claim
the I-Claim
4 I-Claim
day I-Claim
group I-Claim
, I-Claim
approaching I-Claim
statistical I-Claim
significance I-Claim
. I-Claim
!LF! !LF!
more B-Claim
patients I-Claim
treated I-Claim
on I-Claim
4 I-Claim
consecutive I-Claim
days I-Claim
reported I-Claim
a I-Claim
clinically I-Claim
meaningful I-Claim
increase I-Claim
in I-Claim
dyspnea I-Claim
, I-Claim
although B-Claim
interpretation I-Claim
of I-Claim
these I-Claim
results I-Claim
is I-Claim
challenging I-Claim
due I-Claim
to I-Claim
baseline I-Claim
imbalance I-Claim
between I-Claim
treatment I-Claim
groups I-Claim
. I-Claim
!LF! !LF!
larger B-Claim
studies I-Claim
are I-Claim
required I-Claim
to I-Claim
validate I-Claim
these I-Claim
results I-Claim
. I-Claim
!LF! !LF!
several O
guidelines O
on O
the O
treatment O
of O
cancer O
- O
related O
fatigue O
recommend O
optimizing O
treatment O
of O
accompanying O
symptoms O
. O
!LF! !LF!
however O
, O
evidence O
for O
this O
recommendation O
from O
randomized O
clinical O
trials O
is O
lacking O
. O
!LF! !LF!
we O
investigated O
whether O
monitoring O
and O
protocolized O
treatment O
of O
physical O
symptoms O
alleviates O
fatigue O
. O
!LF! !LF!
in O
all O
, O
152 O
fatigued O
patients O
with O
advanced O
cancer O
were O
randomly O
assigned O
to O
protocolized O
patient O
- O
tailored O
treatment O
( O
ppt O
) O
of O
symptoms O
or O
care O
as O
usual O
. O
!LF! !LF!
the O
ppt O
group O
had O
four O
appointments O
with O
a O
nurse O
who O
assessed O
nine O
symptoms O
on O
a O
0 O
to O
10 O
numeric O
rating O
scale O
( O
nrs O
) O
. O
!LF! !LF!
patients O
received O
a O
nonpharmacologic O
intervention O
for O
symptoms O
with O
a O
score O
≥ O
1 O
and O
a O
medical O
intervention O
for O
symptoms O
with O
a O
score O
≥ O
4 O
. O
!LF! !LF!
fatigue O
dimensions O
, O
fatigue O
nrs O
score O
, O
interference O
of O
fatigue O
with O
daily O
life O
, O
symptom O
burden O
, O
quality O
of O
life O
, O
anxiety O
, O
and O
depression O
were O
measured O
at O
baseline O
and O
after O
1 O
, O
2 O
, O
and O
3 O
months O
. O
!LF! !LF!
differences O
between O
the O
groups O
over O
time O
were O
assessed O
by O
using O
mixed O
modeling O
. O
!LF! !LF!
seventy O
- O
six O
patients O
were O
randomly O
assigned O
to O
each O
study O
arm O
. O
!LF! !LF!
mean O
age O
was O
58 O
± O
10 O
years O
, O
57 O
% O
were O
female O
, O
and O
65 O
% O
were O
given O
palliative O
chemotherapy O
. O
!LF! !LF!
we B-Premise
found I-Premise
significant I-Premise
improvements I-Premise
over I-Premise
time I-Premise
in I-Premise
favor I-Premise
of I-Premise
ppt I-Premise
for I-Premise
the I-Premise
primary I-Premise
outcome I-Premise
general I-Premise
fatigue I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
01 I-Premise
) I-Premise
, I-Premise
with I-Premise
significant I-Premise
group I-Premise
differences I-Premise
at I-Premise
month I-Premise
1 I-Premise
( I-Premise
effect I-Premise
size I-Premise
, I-Premise
0 I-Premise
. I-Premise
26 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
007 I-Premise
) I-Premise
and I-Premise
month I-Premise
2 I-Premise
( I-Premise
effect I-Premise
size I-Premise
, I-Premise
0 I-Premise
. I-Premise
35 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
005 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
improvements B-Premise
in I-Premise
favor I-Premise
of I-Premise
ppt I-Premise
were I-Premise
also I-Premise
found I-Premise
for I-Premise
the I-Premise
following I-Premise
secondary I-Premise
outcomes I-Premise
: I-Premise
fatigue I-Premise
dimensions I-Premise
"""" I-Premise
reduced I-Premise
activity I-Premise
"""" I-Premise
and I-Premise
"""" I-Premise
reduced I-Premise
motivation I-Premise
, I-Premise
"""" I-Premise
fatigue I-Premise
nrs I-Premise
, I-Premise
symptom I-Premise
burden I-Premise
, I-Premise
interference I-Premise
of I-Premise
fatigue I-Premise
with I-Premise
daily I-Premise
life I-Premise
, I-Premise
and I-Premise
anxiety I-Premise
( I-Premise
all I-Premise
p I-Premise
≤ I-Premise
. I-Premise
03 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
in B-Claim
fatigued I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
, I-Claim
nurse I-Claim
- I-Claim
led I-Claim
monitoring I-Claim
and I-Claim
protocolized I-Claim
treatment I-Claim
of I-Claim
physical I-Claim
symptoms I-Claim
is I-Claim
effective I-Claim
in I-Claim
alleviating I-Claim
fatigue I-Claim
. I-Claim
!LF! !LF!
bevacizumab B-Claim
, I-Claim
a I-Claim
monoclonal I-Claim
antibody I-Claim
against I-Claim
vascular I-Claim
endothelial I-Claim
growth I-Claim
factor I-Claim
, I-Claim
increases I-Claim
survival I-Claim
when I-Claim
combined I-Claim
with I-Claim
irinotecan I-Claim
- I-Claim
based I-Claim
chemotherapy I-Claim
in I-Claim
first I-Claim
- I-Claim
line I-Claim
treatment I-Claim
of I-Claim
metastatic I-Claim
colorectal I-Claim
cancer I-Claim
( I-Claim
crc I-Claim
) I-Claim
. I-Claim
!LF! !LF!
this O
randomized O
, O
phase O
ii O
trial O
compared O
bevacizumab O
plus O
fluorouracil O
and O
leucovorin O
( O
fu O
/ O
lv O
) O
versus O
placebo O
plus O
fu O
/ O
lv O
as O
first O
- O
line O
therapy O
in O
patients O
considered O
nonoptimal O
candidates O
for O
first O
- O
line O
irinotecan O
. O
!LF! !LF!
patients O
had O
metastatic O
crc O
and O
one O
of O
the O
following O
characteristics O
: O
age O
> O
or O
= O
65 O
years O
, O
eastern O
cooperative O
oncology O
group O
performance O
status O
1 O
or O
2 O
, O
serum O
albumin O
< O
or O
= O
3 O
. O
5 O
g O
/ O
dl O
, O
or O
prior O
abdominal O
/ O
pelvic O
radiotherapy O
. O
!LF! !LF!
patients O
were O
randomly O
assigned O
to O
fu O
/ O
lv O
/ O
placebo O
( O
n O
= O
105 O
) O
or O
fu O
/ O
lv O
/ O
bevacizumab O
( O
n O
= O
104 O
) O
. O
!LF! !LF!
the O
primary O
end O
point O
was O
overall O
survival O
. O
!LF! !LF!
secondary O
end O
points O
were O
progression O
- O
free O
survival O
, O
response O
rate O
, O
response O
duration O
, O
and O
quality O
of O
life O
. O
!LF! !LF!
safety O
was O
also O
assessed O
. O
!LF! !LF!
median B-Premise
survival I-Premise
was I-Premise
16 I-Premise
. I-Premise
6 I-Premise
months I-Premise
for I-Premise
the I-Premise
fu I-Premise
/ I-Premise
lv I-Premise
/ I-Premise
bevacizumab I-Premise
group I-Premise
and I-Premise
12 I-Premise
. I-Premise
9 I-Premise
months I-Premise
for I-Premise
the I-Premise
fu I-Premise
/ I-Premise
lv I-Premise
/ I-Premise
placebo I-Premise
group I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0 I-Premise
. I-Premise
79 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
16 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
median B-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
was I-Premise
9 I-Premise
. I-Premise
2 I-Premise
months I-Premise
( I-Premise
fu I-Premise
/ I-Premise
lv I-Premise
/ I-Premise
bevacizumab I-Premise
) I-Premise
and I-Premise
5 I-Premise
. I-Premise
5 I-Premise
months I-Premise
( I-Premise
fu I-Premise
/ I-Premise
lv I-Premise
/ I-Premise
placebo I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hazard B-Premise
ratio I-Premise
was I-Premise
0 I-Premise
. I-Premise
50 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
0002 I-Premise
. O
!LF! !LF!
response B-Premise
rates I-Premise
were I-Premise
26 I-Premise
. I-Premise
0 I-Premise
% I-Premise
( I-Premise
fu I-Premise
/ I-Premise
lv I-Premise
/ I-Premise
bevacizumab I-Premise
) I-Premise
and I-Premise
15 I-Premise
. I-Premise
2 I-Premise
% I-Premise
( I-Premise
fu I-Premise
/ I-Premise
lv I-Premise
/ I-Premise
placebo I-Premise
) I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
055 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
duration B-Premise
of I-Premise
response I-Premise
was I-Premise
9 I-Premise
. I-Premise
2 I-Premise
months I-Premise
( I-Premise
fu I-Premise
/ I-Premise
lv I-Premise
/ I-Premise
bevacizumab I-Premise
) I-Premise
and I-Premise
6 I-Premise
. I-Premise
8 I-Premise
months I-Premise
( I-Premise
fu I-Premise
/ I-Premise
lv I-Premise
/ I-Premise
placebo I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hazard B-Premise
ratio I-Premise
was I-Premise
0 I-Premise
. I-Premise
42 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
088 I-Premise
. I-Premise
!LF! !LF!
grade B-Premise
3 I-Premise
hypertension I-Premise
was I-Premise
more I-Premise
common I-Premise
with I-Premise
bevacizumab I-Premise
treatment I-Premise
( I-Premise
16 I-Premise
% I-Premise
v I-Premise
3 I-Premise
% I-Premise
) I-Premise
but B-Premise
was I-Premise
controlled I-Premise
with I-Premise
oral I-Premise
medication I-Premise
and I-Premise
did I-Premise
not I-Premise
cause I-Premise
study I-Premise
drug I-Premise
discontinuation I-Premise
. I-Premise
!LF! !LF!
addition B-Claim
of I-Claim
bevacizumab I-Claim
to I-Claim
fu I-Claim
/ I-Claim
lv I-Claim
as I-Claim
first I-Claim
- I-Claim
line I-Claim
therapy I-Claim
in I-Claim
crc I-Claim
patients I-Claim
who I-Claim
were I-Claim
not I-Claim
considered I-Claim
optimal I-Claim
candidates I-Claim
for I-Claim
first I-Claim
- I-Claim
line I-Claim
irinotecan I-Claim
treatment I-Claim
provided I-Claim
clinically I-Claim
significant I-Claim
patient I-Claim
benefit I-Claim
, I-Claim
including I-Claim
statistically I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
progression I-Claim
- I-Claim
free I-Claim
survival I-Claim
. I-Claim
!LF! !LF!
the B-Claim
generalizability I-Claim
of I-Claim
palliative I-Claim
care I-Claim
intervention I-Claim
research I-Claim
is I-Claim
often I-Claim
limited I-Claim
by I-Claim
high I-Claim
rates I-Claim
of I-Claim
study I-Claim
attrition I-Claim
. I-Claim
!LF! !LF!
this O
study O
examined O
factors O
associated O
with O
attrition O
from O
a O
randomized O
controlled O
trial O
comparing O
meaning O
- O
centered O
group O
psychotherapy O
( O
mcgp O
) O
, O
an O
intervention O
designed O
to O
help O
advanced O
cancer O
patients O
sustain O
or O
enhance O
their O
sense O
of O
meaning O
to O
the O
supportive O
group O
psychotherapy O
( O
sgp O
) O
, O
a O
standardized O
support O
group O
. O
!LF! !LF!
patients O
with O
advanced O
solid O
tumor O
cancers O
( O
n O
= O
153 O
) O
were O
randomized O
to O
eight O
sessions O
of O
either O
the O
mcgp O
or O
sgp O
. O
!LF! !LF!
they O
completed O
assessments O
of O
psychosocial O
, O
spiritual O
, O
and O
physical O
well O
- O
being O
pretreatment O
, O
midtreatment O
, O
and O
2 O
months O
post O
- O
treatment O
. O
!LF! !LF!
attrition O
was O
assessed O
in O
terms O
of O
the O
percent O
of O
participants O
who O
failed O
to O
complete O
these O
assessments O
, O
and O
demographic O
, O
psychiatric O
, O
medical O
, O
and O
study O
- O
related O
correlates O
of O
attrition O
were O
examined O
for O
the O
participants O
in O
each O
of O
these O
categories O
. O
!LF! !LF!
the B-Premise
rates I-Premise
of I-Premise
attrition I-Premise
at I-Premise
these I-Premise
time I-Premise
points I-Premise
were I-Premise
28 I-Premise
. I-Premise
1 I-Premise
% I-Premise
, I-Premise
17 I-Premise
. I-Premise
7 I-Premise
% I-Premise
, I-Premise
and I-Premise
11 I-Premise
. I-Premise
1 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
43 I-Premise
. I-Premise
1 I-Premise
% I-Premise
of I-Premise
the I-Premise
participants I-Premise
( I-Premise
66 I-Premise
of I-Premise
153 I-Premise
) I-Premise
completed I-Premise
the I-Premise
entire I-Premise
study I-Premise
. I-Premise
!LF! !LF!
the B-Premise
most I-Premise
common I-Premise
reason I-Premise
for I-Premise
dropout I-Premise
was I-Premise
patients I-Premise
feeling I-Premise
too I-Premise
ill I-Premise
. I-Premise
!LF! !LF!
attrition B-Premise
rates I-Premise
did I-Premise
not I-Premise
vary I-Premise
significantly I-Premise
between I-Premise
study I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
the O
participants O
who O
dropped O
out O
pretreatment O
reported O
less O
financial O
concerns O
than O
post O
- O
treatment O
dropouts O
, O
and O
the O
participants O
who O
dropped O
out O
of O
the O
study O
midtreatment O
had O
poorer O
physical O
health O
than O
treatment O
completers O
. O
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
other I-Premise
significant I-Premise
associations I-Premise
between I-Premise
attrition I-Premise
and I-Premise
any I-Premise
demographic I-Premise
, I-Premise
medical I-Premise
, I-Premise
psychiatric I-Premise
, I-Premise
or I-Premise
study I-Premise
- I-Premise
related I-Premise
variables I-Premise
. I-Premise
!LF! !LF!
these B-Claim
findings I-Claim
highlight I-Claim
the I-Claim
challenge I-Claim
of I-Claim
maintaining I-Claim
advanced I-Claim
cancer I-Claim
patients I-Claim
in I-Claim
longitudinal I-Claim
research I-Claim
and I-Claim
suggest I-Claim
the I-Claim
need I-Claim
to I-Claim
consider I-Claim
alternative I-Claim
approaches I-Claim
( I-Claim
e I-Claim
. I-Claim
g I-Claim
. I-Claim
, I-Claim
telemedicine I-Claim
) I-Claim
for I-Claim
patients I-Claim
who I-Claim
might I-Claim
benefit I-Claim
from I-Claim
group I-Claim
interventions I-Claim
but I-Claim
are I-Claim
too I-Claim
ill I-Claim
to I-Claim
travel I-Claim
. I-Claim
!LF! !LF!
we O
evaluated O
the O
role O
of O
glutathione O
- O
related O
genotypes O
on O
overall O
survival O
, O
time O
to O
progression O
, O
adverse O
events O
, O
and O
quality O
of O
life O
( O
qol O
) O
in O
stage O
iiib O
/ O
iv O
non O
- O
small O
cell O
lung O
cancer O
patients O
who O
were O
stable O
or O
responding O
from O
initial O
treatment O
with O
platinum O
- O
based O
chemotherapy O
and O
subsequently O
randomized O
to O
receive O
daily O
oral O
carboxyaminoimidazole O
or O
a O
placebo O
. O
!LF! !LF!
of O
the O
186 O
total O
patients O
, O
113 O
had O
initial O
treatment O
with O
platinum O
therapy O
and O
dna O
samples O
of O
whom O
46 O
also O
had O
qol O
data O
. O
!LF! !LF!
these O
samples O
were O
analyzed O
using O
six O
polymorphic O
dna O
markers O
that O
encode O
five O
important O
enzymes O
in O
the O
glutathione O
metabolic O
pathway O
. O
!LF! !LF!
patient O
qol O
was O
assessed O
using O
the O
functional O
assessment O
of O
cancer O
therapy O
- O
lung O
and O
the O
uniscale O
qol O
questionnaires O
. O
!LF! !LF!
a O
clinically O
significant O
decline O
in O
qol O
was O
defined O
as O
a O
10 O
% O
decrease O
from O
baseline O
to O
week O
- O
8 O
. O
!LF! !LF!
multivariate O
analyses O
were O
used O
to O
evaluate O
the O
association O
of O
the O
genotypes O
on O
the O
four O
endpoints O
. O
!LF! !LF!
patients B-Premise
carrying I-Premise
a I-Premise
gclc I-Premise
77 I-Premise
genotype I-Premise
had I-Premise
a I-Premise
worse I-Premise
overall I-Premise
survival I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
( I-Premise
hr I-Premise
) I-Premise
= I-Premise
1 I-Premise
. I-Premise
5 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
carrying I-Premise
the I-Premise
gpx1 I-Premise
- I-Premise
cc I-Premise
genotype I-Premise
had I-Premise
a I-Premise
clinically I-Premise
significant I-Premise
decline I-Premise
in I-Premise
the I-Premise
uniscale I-Premise
( I-Premise
odds I-Premise
ratio I-Premise
( I-Premise
or I-Premise
) I-Premise
: I-Premise
7 I-Premise
. I-Premise
5 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
04 I-Premise
) I-Premise
, I-Premise
total I-Premise
functional I-Premise
assessment I-Premise
of I-Premise
cancer I-Premise
therapy I-Premise
- I-Premise
lung I-Premise
score I-Premise
( I-Premise
or I-Premise
: I-Premise
11 I-Premise
. I-Premise
0 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
04 I-Premise
) I-Premise
, I-Premise
physical I-Premise
( I-Premise
or I-Premise
: I-Premise
7 I-Premise
. I-Premise
1 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
03 I-Premise
) I-Premise
, I-Premise
functional I-Premise
( I-Premise
or I-Premise
: I-Premise
5 I-Premise
. I-Premise
2 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
04 I-Premise
) I-Premise
, I-Premise
and I-Premise
emotional I-Premise
well I-Premise
- I-Premise
being I-Premise
constructs I-Premise
( I-Premise
or I-Premise
: I-Premise
23 I-Premise
. I-Premise
8 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
genotypes B-Claim
of I-Claim
glutathione I-Claim
- I-Claim
related I-Claim
enzymes I-Claim
, I-Claim
especially I-Claim
gclc I-Claim
, I-Claim
may I-Claim
be I-Claim
used I-Claim
as I-Claim
host I-Claim
factors I-Claim
in I-Claim
predicting I-Claim
patients I-Claim
' I-Claim
survival I-Claim
after I-Claim
platinum I-Claim
- I-Claim
based I-Claim
chemotherapy I-Claim
. I-Claim
!LF! !LF!
gpx1 B-Claim
may I-Claim
be I-Claim
an I-Claim
inherited I-Claim
factor I-Claim
in I-Claim
predicting I-Claim
patients I-Claim
' I-Claim
qol I-Claim
. I-Claim
!LF! !LF!
further B-Claim
investigation I-Claim
to I-Claim
define I-Claim
and I-Claim
measure I-Claim
the I-Claim
effects I-Claim
of I-Claim
these I-Claim
genes I-Claim
in I-Claim
chemotherapeutic I-Claim
regimens I-Claim
, I-Claim
drug I-Claim
toxicities I-Claim
, I-Claim
disease I-Claim
progression I-Claim
, I-Claim
and I-Claim
qol I-Claim
are I-Claim
critical I-Claim
. I-Claim
!LF! !LF!
serum O
ca125 O
concentration O
often O
rises O
several O
months O
before O
clinical O
or O
symptomatic O
relapse O
in O
women O
with O
ovarian O
cancer O
. O
!LF! !LF!
in O
the O
mrc O
ov05 O
/ O
eortc O
55955 O
collaborative O
trial O
, O
we O
aimed O
to O
establish O
the O
benefits O
of O
early O
treatment O
on O
the O
basis O
of O
increased O
ca125 O
concentrations O
compared O
with O
delayed O
treatment O
on O
the O
basis O
of O
clinical O
recurrence O
. O
!LF! !LF!
women O
with O
ovarian O
cancer O
in O
complete O
remission O
after O
first O
- O
line O
platinum O
- O
based O
chemotherapy O
and O
a O
normal O
ca125 O
concentration O
were O
registered O
for O
this O
randomised O
controlled O
trial O
. O
!LF! !LF!
clinical O
examination O
and O
ca125 O
measurement O
were O
done O
every O
3 O
months O
. O
!LF! !LF!
patients O
and O
investigators O
were O
masked O
to O
ca125 O
results O
, O
which O
were O
monitored O
by O
coordinating O
centres O
. O
!LF! !LF!
if O
ca125 O
concentration O
exceeded O
twice O
the O
upper O
limit O
of O
normal O
, O
patients O
were O
randomly O
assigned O
( O
1 O
: O
1 O
) O
by O
minimisation O
to O
early O
or O
delayed O
chemotherapy O
. O
!LF! !LF!
patients O
and O
clinical O
sites O
were O
informed O
of O
allocation O
to O
early O
treatment O
, O
and O
treatment O
was O
started O
as O
soon O
as O
possible O
within O
28 O
days O
of O
the O
increased O
ca125 O
measurement O
. O
!LF! !LF!
patients O
assigned O
to O
delayed O
treatment O
continued O
masked O
ca125 O
measurements O
, O
with O
treatment O
commencing O
at O
clinical O
or O
symptomatic O
relapse O
. O
!LF! !LF!
all O
patients O
were O
treated O
according O
to O
standard O
local O
practice O
. O
!LF! !LF!
the O
primary O
outcome O
was O
overall O
survival O
. O
!LF! !LF!
analysis O
was O
by O
intention O
to O
treat O
. O
!LF! !LF!
this O
study O
is O
registered O
, O
isrctn87786644 O
. O
!LF! !LF!
1442 O
patients O
were O
registered O
for O
the O
trial O
, O
of O
whom O
529 O
were O
randomly O
assigned O
to O
treatment O
groups O
and O
were O
included O
in O
our O
analysis O
( O
265 O
early O
, O
264 O
delayed O
) O
. O
!LF! !LF!
with B-Premise
a I-Premise
median I-Premise
follow I-Premise
- I-Premise
up I-Premise
of I-Premise
56 I-Premise
· I-Premise
9 I-Premise
months I-Premise
( I-Premise
iqr I-Premise
37 I-Premise
· I-Premise
4 I-Premise
- I-Premise
81 I-Premise
· I-Premise
8 I-Premise
) I-Premise
from I-Premise
randomisation I-Premise
and I-Premise
370 I-Premise
deaths I-Premise
( I-Premise
186 I-Premise
early I-Premise
, I-Premise
184 I-Premise
delayed I-Premise
) I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
evidence I-Premise
of I-Premise
a I-Premise
difference I-Premise
in I-Premise
overall I-Premise
survival I-Premise
between I-Premise
early I-Premise
and I-Premise
delayed I-Premise
treatment I-Premise
( I-Premise
hr I-Premise
0 I-Premise
· I-Premise
98 I-Premise
, I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
· I-Premise
80 I-Premise
- I-Premise
1 I-Premise
· I-Premise
20 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
· I-Premise
85 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
median B-Premise
survival I-Premise
from I-Premise
randomisation I-Premise
was I-Premise
25 I-Premise
· I-Premise
7 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
23 I-Premise
· I-Premise
0 I-Premise
- I-Premise
27 I-Premise
· I-Premise
9 I-Premise
) I-Premise
for I-Premise
patients I-Premise
on I-Premise
early I-Premise
treatment I-Premise
and I-Premise
27 I-Premise
· I-Premise
1 I-Premise
months I-Premise
( I-Premise
22 I-Premise
· I-Premise
8 I-Premise
- I-Premise
30 I-Premise
· I-Premise
9 I-Premise
) I-Premise
for I-Premise
those I-Premise
on I-Premise
delayed I-Premise
treatment I-Premise
. I-Premise
!LF! !LF!
our B-Claim
findings I-Claim
showed I-Claim
no I-Claim
evidence I-Claim
of I-Claim
a I-Claim
survival I-Claim
benefit I-Claim
with I-Claim
early I-Claim
treatment I-Claim
of I-Claim
relapse I-Claim
on I-Claim
the I-Claim
basis I-Claim
of I-Claim
a I-Claim
raised I-Claim
ca125 I-Claim
concentration I-Claim
alone I-Claim
, I-Claim
and B-Claim
therefore I-Claim
the I-Claim
value I-Claim
of I-Claim
routine I-Claim
measurement I-Claim
of I-Claim
ca125 I-Claim
in I-Claim
the I-Claim
follow I-Claim
- I-Claim
up I-Claim
of I-Claim
patients I-Claim
with I-Claim
ovarian I-Claim
cancer I-Claim
who I-Claim
attain I-Claim
a I-Claim
complete I-Claim
response I-Claim
after I-Claim
first I-Claim
- I-Claim
line I-Claim
treatment I-Claim
is I-Claim
not I-Claim
proven I-Claim
. I-Claim
!LF! !LF!
kaposi O
' O
s O
sarcoma O
is O
currently O
the O
most O
common O
tumor O
in O
zimbabwe O
. O
!LF! !LF!
the O
purpose O
of O
our O
study O
is O
to O
compare O
the O
effectiveness O
of O
supportive O
care O
vs O
. O
3 O
intervention O
approaches O
, O
namely O
oral O
etoposide O
, O
a O
3 O
- O
drug O
combination O
, O
and O
radiotherapy O
using O
quality O
of O
life O
( O
qol O
) O
as O
the O
primary O
measure O
of O
success O
. O
!LF! !LF!
in O
addition O
, O
our O
study O
was O
to O
determine O
whether O
a O
disease O
- O
specific O
module O
has O
greater O
sensitivity O
to O
group O
differences O
than O
a O
generic O
qol O
questionnaire O
and O
to O
determine O
the O
most O
pragmatic O
approach O
to O
treating O
epidemic O
kaposi O
' O
s O
sarcoma O
( O
eks O
) O
in O
zimbabwe O
. O
!LF! !LF!
histologically O
confirmed O
hiv O
- O
positive O
patients O
with O
kaposi O
' O
s O
sarcoma O
were O
randomized O
to O
receive O
supportive O
care O
only O
or O
supportive O
care O
plus O
either O
radiotherapy O
, O
oral O
etoposide O
or O
a O
3 O
- O
drug O
combination O
consisting O
of O
actinomycin O
- O
d O
, O
vincristine O
and O
bleomycin O
. O
!LF! !LF!
no O
patient O
received O
antiretroviral O
therapy O
. O
!LF! !LF!
the O
primary O
outcome O
was O
qol O
measured O
by O
the O
functional O
living O
index O
- O
cancer O
( O
fli O
- O
c O
) O
and O
supplemented O
by O
the O
kaposi O
' O
s O
sarcoma O
module O
( O
ksm O
) O
. O
!LF! !LF!
from O
1994 O
- O
1999 O
, O
495 O
eks O
patients O
were O
accrued O
, O
and O
470 O
were O
evaluable O
. O
!LF! !LF!
of O
these O
, O
433 O
are O
known O
to O
be O
dead O
, O
26 O
are O
lost O
to O
follow O
- O
up O
and O
11 O
are O
still O
alive O
. O
!LF! !LF!
the B-Premise
group I-Premise
treated I-Premise
with I-Premise
oral I-Premise
etoposide I-Premise
had I-Premise
a I-Premise
significantly I-Premise
better I-Premise
qol I-Premise
than I-Premise
the I-Premise
radiotherapy I-Premise
group I-Premise
for I-Premise
the I-Premise
total I-Premise
fli I-Premise
- I-Premise
c I-Premise
score I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
plus I-Premise
standard I-Premise
error I-Premise
at I-Premise
3 I-Premise
- I-Premise
months I-Premise
89 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
3 I-Premise
vs I-Premise
. I-Premise
76 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
3 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
004 I-Premise
) I-Premise
and I-Premise
for I-Premise
the I-Premise
hardship I-Premise
( I-Premise
11 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
0 I-Premise
. I-Premise
4 I-Premise
vs I-Premise
. I-Premise
9 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
0 I-Premise
. I-Premise
4 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
social I-Premise
( I-Premise
10 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
0 I-Premise
. I-Premise
4 I-Premise
vs I-Premise
. I-Premise
8 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
0 I-Premise
. I-Premise
4 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
and I-Premise
nausea I-Premise
( I-Premise
9 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
0 I-Premise
. I-Premise
4 I-Premise
vs I-Premise
. I-Premise
8 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
0 I-Premise
. I-Premise
4 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
002 I-Premise
) I-Premise
subscales I-Premise
. I-Premise
!LF! !LF!
in B-Premise
addition I-Premise
, I-Premise
on I-Premise
the I-Premise
physical I-Premise
and I-Premise
psychological I-Premise
subscales I-Premise
, I-Premise
the I-Premise
etoposide I-Premise
group I-Premise
had I-Premise
a I-Premise
significantly I-Premise
better I-Premise
qol I-Premise
than I-Premise
the I-Premise
other I-Premise
3 I-Premise
treatment I-Premise
groups I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
04 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
3 I-Premise
- I-Premise
drug I-Premise
combination I-Premise
, I-Premise
supportive I-Premise
care I-Premise
and I-Premise
radiotherapy I-Premise
groups I-Premise
did I-Premise
not I-Premise
differ I-Premise
significantly I-Premise
from I-Premise
each I-Premise
other I-Premise
with I-Premise
respect I-Premise
to I-Premise
the I-Premise
total I-Premise
fli I-Premise
- I-Premise
c I-Premise
score I-Premise
or I-Premise
its I-Premise
subscales I-Premise
. I-Premise
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
group I-Premise
differences I-Premise
with I-Premise
respect I-Premise
to I-Premise
survival I-Premise
. I-Premise
!LF! !LF!
oral B-Claim
etoposide I-Claim
therapy I-Claim
resulted I-Claim
in I-Claim
better I-Claim
total I-Claim
fli I-Claim
- I-Claim
c I-Claim
qol I-Claim
score I-Claim
than I-Claim
radiotherapy I-Claim
. I-Claim
!LF! !LF!
as O
well O
, O
etoposide B-Claim
resulted I-Claim
in I-Claim
better I-Claim
physical I-Claim
and I-Claim
psychological I-Claim
subscale I-Claim
scores I-Claim
than I-Claim
radiotherapy I-Claim
, I-Claim
3 I-Claim
- I-Claim
drugs I-Claim
and I-Claim
supportive I-Claim
care I-Claim
. I-Claim
!LF! !LF!
thus B-Claim
, I-Claim
funds I-Claim
permitting I-Claim
, I-Claim
oral I-Claim
etoposide I-Claim
is I-Claim
a I-Claim
pragmatic I-Claim
approach I-Claim
to I-Claim
treating I-Claim
eks I-Claim
in I-Claim
an I-Claim
environment I-Claim
where I-Claim
antiretroviral I-Claim
drugs I-Claim
are I-Claim
not I-Claim
universally I-Claim
available I-Claim
. I-Claim
!LF! !LF!
the B-Claim
study I-Claim
underscores I-Claim
the I-Claim
value I-Claim
of I-Claim
undertaking I-Claim
studies I-Claim
in I-Claim
areas I-Claim
of I-Claim
disease I-Claim
prevalence I-Claim
and I-Claim
the I-Claim
necessity I-Claim
of I-Claim
selecting I-Claim
appropriate I-Claim
outcome I-Claim
measures I-Claim
. I-Claim
!LF! !LF!
to O
determine O
functional O
and O
psychological O
benefits O
of O
a O
12 O
week O
supervised O
group O
exercise O
programme O
during O
treatment O
for O
early O
stage O
breast O
cancer O
, O
with O
six O
month O
follow O
- O
up O
. O
!LF! !LF!
pragmatic O
randomised O
controlled O
prospective O
open O
trial O
. O
!LF! !LF!
three O
national O
health O
service O
oncology O
clinics O
in O
scotland O
and O
community O
exercise O
facilities O
. O
!LF! !LF!
203 O
women O
entered O
the O
study O
"""" O
; O
"""" O
177 O
completed O
the O
six O
month O
follow O
- O
up O
. O
!LF! !LF!
supervised O
12 O
week O
group O
exercise O
programme O
in O
addition O
to O
usual O
care O
, O
compared O
with O
usual O
care O
. O
!LF! !LF!
functional O
assessment O
of O
cancer O
therapy O
( O
fact O
) O
questionnaire O
, O
beck O
depression O
inventory O
, O
positive O
and O
negative O
affect O
scale O
, O
body O
mass O
index O
, O
seven O
day O
recall O
of O
physical O
activity O
, O
12 O
minute O
walk O
test O
, O
and O
assessment O
of O
shoulder O
mobility O
. O
!LF! !LF!
mixed B-Premise
effects I-Premise
models I-Premise
with I-Premise
adjustment I-Premise
for I-Premise
baseline I-Premise
values I-Premise
, I-Premise
study I-Premise
site I-Premise
, I-Premise
treatment I-Premise
at I-Premise
baseline I-Premise
, I-Premise
and I-Premise
age I-Premise
gave I-Premise
intervention I-Premise
effect I-Premise
estimates I-Premise
( I-Premise
intervention I-Premise
minus I-Premise
control I-Premise
) I-Premise
at I-Premise
12 I-Premise
weeks I-Premise
of I-Premise
129 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
83 I-Premise
to I-Premise
176 I-Premise
) I-Premise
for I-Premise
metres I-Premise
walked I-Premise
in I-Premise
12 I-Premise
minutes I-Premise
, I-Premise
182 I-Premise
( I-Premise
75 I-Premise
to I-Premise
289 I-Premise
) I-Premise
for I-Premise
minutes I-Premise
of I-Premise
moderate I-Premise
intensity I-Premise
activity I-Premise
reported I-Premise
in I-Premise
a I-Premise
week I-Premise
, I-Premise
2 I-Premise
. I-Premise
6 I-Premise
( I-Premise
1 I-Premise
. I-Premise
6 I-Premise
to I-Premise
3 I-Premise
. I-Premise
7 I-Premise
) I-Premise
for I-Premise
shoulder I-Premise
mobility I-Premise
, I-Premise
2 I-Premise
. I-Premise
5 I-Premise
( I-Premise
1 I-Premise
. I-Premise
0 I-Premise
to I-Premise
3 I-Premise
. I-Premise
9 I-Premise
) I-Premise
for I-Premise
breast I-Premise
cancer I-Premise
specific I-Premise
subscale I-Premise
of I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
and I-Premise
4 I-Premise
. I-Premise
0 I-Premise
( I-Premise
1 I-Premise
. I-Premise
8 I-Premise
to I-Premise
6 I-Premise
. I-Premise
3 I-Premise
) I-Premise
for I-Premise
positive I-Premise
mood I-Premise
. I-Premise
!LF! !LF!
no B-Premise
significant I-Premise
effect I-Premise
was I-Premise
seen I-Premise
for I-Premise
general I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
fact I-Premise
- I-Premise
g I-Premise
) I-Premise
, I-Premise
which I-Premise
was I-Premise
the I-Premise
primary I-Premise
outcome I-Premise
. I-Premise
!LF! !LF!
at B-Premise
the I-Premise
six I-Premise
month I-Premise
follow I-Premise
- I-Premise
up I-Premise
, I-Premise
most I-Premise
of I-Premise
these I-Premise
effects I-Premise
were I-Premise
maintained I-Premise
and I-Premise
an I-Premise
intervention I-Premise
effect I-Premise
for I-Premise
breast I-Premise
cancer I-Premise
specific I-Premise
quality I-Premise
of I-Premise
life I-Premise
emerged I-Premise
. I-Premise
!LF! !LF!
no B-Premise
adverse I-Premise
effects I-Premise
were I-Premise
noted I-Premise
. I-Premise
!LF! !LF!
supervised B-Claim
group I-Claim
exercise I-Claim
provided I-Claim
functional I-Claim
and I-Claim
psychological I-Claim
benefit I-Claim
after I-Claim
a I-Claim
12 I-Claim
week I-Claim
intervention I-Claim
and I-Claim
six I-Claim
months I-Claim
later I-Claim
. I-Claim
!LF! !LF!
clinicians B-Claim
should I-Claim
encourage I-Claim
activity I-Claim
for I-Claim
their I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
policy B-Claim
makers I-Claim
should I-Claim
consider I-Claim
the I-Claim
inclusion I-Claim
of I-Claim
exercise I-Claim
opportunities I-Claim
in I-Claim
cancer I-Claim
rehabilitation I-Claim
services I-Claim
. I-Claim
!LF! !LF!
the O
purpose O
of O
this O
study O
is O
to O
compare O
the O
treatment O
and O
retention O
effects O
between O
standard O
decongestive O
lymphatic O
therapy O
( O
dlt O
) O
combined O
with O
pneumatic O
compression O
( O
pc O
) O
and O
modified O
dlt O
, O
in O
which O
the O
use O
of O
a O
short O
- O
stretch O
bandage O
is O
replaced O
with O
the O
use O
of O
kinesio O
tape O
( O
k O
- O
tape O
) O
combined O
with O
pc O
. O
!LF! !LF!
forty O
- O
one O
patients O
with O
unilateral O
breast O
- O
cancer O
- O
related O
lymphedema O
for O
at O
least O
3 O
months O
were O
randomly O
grouped O
into O
the O
dlt O
group O
( O
bandage O
group O
, O
n O
= O
21 O
) O
or O
the O
modified O
dlt O
group O
( O
k O
- O
tape O
group O
, O
n O
= O
20 O
) O
. O
!LF! !LF!
skin O
care O
, O
30 O
- O
min O
manual O
lymphatic O
drainage O
, O
1 O
- O
h O
pneumatic O
compression O
therapy O
, O
application O
of O
a O
short O
- O
stretch O
bandage O
or O
k O
- O
tape O
for O
each O
group O
, O
and O
a O
20 O
- O
min O
physical O
therapy O
exercise O
were O
given O
during O
every O
treatment O
session O
. O
!LF! !LF!
patient O
evaluation O
items O
included O
physical O
therapy O
assessment O
, O
limb O
size O
, O
water O
composition O
of O
the O
upper O
extremity O
, O
lymphedema O
- O
related O
symptoms O
, O
quality O
of O
life O
, O
and O
patients O
' O
acceptance O
to O
the O
bandage O
or O
tape O
. O
!LF! !LF!
there B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
groups I-Premise
in I-Premise
all I-Premise
outcome I-Premise
variables I-Premise
( I-Premise
p I-Premise
> I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
through I-Premise
the I-Premise
whole I-Premise
study I-Premise
period I-Premise
. I-Premise
!LF! !LF!
excess B-Premise
limb I-Premise
size I-Premise
( I-Premise
circumference I-Premise
and I-Premise
water I-Premise
displacement I-Premise
) I-Premise
and I-Premise
excess I-Premise
water I-Premise
composition I-Premise
were I-Premise
reduced I-Premise
significantly I-Premise
in I-Premise
the I-Premise
bandage I-Premise
group I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
excess B-Premise
circumference I-Premise
and I-Premise
excess I-Premise
water I-Premise
composition I-Premise
were I-Premise
reduced I-Premise
significantly I-Premise
in I-Premise
the I-Premise
tape I-Premise
group I-Premise
. I-Premise
!LF! !LF!
the B-Premise
acceptance I-Premise
of I-Premise
k I-Premise
- I-Premise
tape I-Premise
was I-Premise
better I-Premise
than I-Premise
the I-Premise
bandage I-Premise
, I-Premise
and I-Premise
benefits I-Premise
included I-Premise
longer I-Premise
wearing I-Premise
time I-Premise
, I-Premise
less I-Premise
difficulty I-Premise
in I-Premise
usage I-Premise
, I-Premise
and I-Premise
increased I-Premise
comfort I-Premise
and I-Premise
convenience I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Claim
study I-Claim
results I-Claim
suggest I-Claim
that I-Claim
k I-Claim
- I-Claim
tape I-Claim
could I-Claim
replace I-Claim
the I-Claim
bandage I-Claim
in I-Claim
dlt I-Claim
, I-Claim
and I-Claim
it I-Claim
could I-Claim
be I-Claim
an I-Claim
alternative I-Claim
choice I-Claim
for I-Claim
the I-Claim
breast I-Claim
- I-Claim
cancer I-Claim
- I-Claim
related I-Claim
lymphedema I-Claim
patient I-Claim
with I-Claim
poor I-Claim
short I-Claim
- I-Claim
stretch I-Claim
bandage I-Claim
compliance I-Claim
after I-Claim
1 I-Claim
- I-Claim
month I-Claim
intervention I-Claim
. I-Claim
!LF! !LF!
if O
the O
intervention O
period O
was O
prolonged O
, O
we O
might O
get O
different O
conclusion O
. O
!LF! !LF!
moreover O
, O
these B-Claim
two I-Claim
treatment I-Claim
protocols I-Claim
are I-Claim
inefficient I-Claim
and I-Claim
cost I-Claim
time I-Claim
in I-Claim
application I-Claim
. I-Claim
!LF! !LF!
more B-Claim
efficient I-Claim
treatment I-Claim
protocol I-Claim
is I-Claim
needed I-Claim
for I-Claim
clinical I-Claim
practice I-Claim
. I-Claim
!LF! !LF!
to O
study O
the O
effects O
of O
fuzheng O
jianpi O
decoction O
( O
fjd O
) O
combined O
chemotherapy O
on O
the O
quality O
of O
life O
( O
qol O
) O
and O
the O
survival O
time O
of O
children O
with O
solid O
tumor O
. O
!LF! !LF!
recruited O
were O
167 O
solid O
tumor O
children O
patients O
at O
department O
of O
tumor O
, O
beijing O
children O
' O
s O
hospital O
. O
!LF! !LF!
they O
were O
randomly O
assigned O
to O
the O
treatment O
group O
( O
83 O
cases O
) O
and O
the O
control O
group O
( O
84 O
cases O
) O
according O
to O
the O
random O
digit O
table O
. O
!LF! !LF!
all O
had O
chemotherapy O
. O
!LF! !LF!
those O
in O
the O
treatment O
group O
additionally O
took O
fjd O
, O
50 O
- O
100 O
ml O
each O
time O
, O
twice O
daily O
. O
!LF! !LF!
after O
chemotherapy O
those O
in O
the O
treatment O
group O
took O
modified O
fjd O
. O
!LF! !LF!
the O
wbc O
, O
hb O
, O
and O
plt O
were O
detected O
in O
all O
patients O
before O
treatment O
, O
6 O
months O
after O
treatment O
, O
and O
1 O
year O
after O
treatment O
. O
!LF! !LF!
the O
- O
1 O
, O
- O
2 O
, O
and O
3 O
- O
year O
qol O
, O
3 O
- O
year O
survival O
rate O
, O
and O
the O
survival O
life O
of O
dead O
children O
patients O
were O
observed O
. O
!LF! !LF!
compared B-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
of I-Premise
the I-Premise
same I-Premise
period I-Premise
, I-Premise
the I-Premise
6 I-Premise
- I-Premise
month I-Premise
and I-Premise
1 I-Premise
- I-Premise
year I-Premise
wbc I-Premise
and I-Premise
hb I-Premise
increased I-Premise
, I-Premise
the I-Premise
1 I-Premise
- I-Premise
year I-Premise
plt I-Premise
increased I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
showing I-Premise
statistical I-Premise
difference I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
, I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
compared B-Premise
with I-Premise
1 I-Premise
- I-Premise
year I-Premise
treatment I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
the I-Premise
2 I-Premise
- I-Premise
and I-Premise
3 I-Premise
- I-Premise
year I-Premise
psychological I-Premise
functions I-Premise
and I-Premise
the I-Premise
general I-Premise
symptoms I-Premise
scores I-Premise
decreased I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
, I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
compared B-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
of I-Premise
the I-Premise
same I-Premise
period I-Premise
, I-Premise
the I-Premise
2 I-Premise
- I-Premise
and I-Premise
3 I-Premise
- I-Premise
year I-Premise
somatic I-Premise
functions I-Premise
, I-Premise
psychological I-Premise
functions I-Premise
, I-Premise
and I-Premise
the I-Premise
general I-Premise
symptoms I-Premise
scores I-Premise
decreased I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
the B-Premise
2 I-Premise
- I-Premise
year I-Premise
somatic I-Premise
functions I-Premise
and I-Premise
psychological I-Premise
functions I-Premise
decreased I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
the B-Premise
3 I-Premise
- I-Premise
year I-Premise
psychological I-Premise
functions I-Premise
and I-Premise
the I-Premise
general I-Premise
symptoms I-Premise
scores I-Premise
decreased I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
all I-Premise
with I-Premise
statistical I-Premise
difference I-Premise
( I-Premise
all I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
compared B-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
the I-Premise
death I-Premise
number I-Premise
decreased I-Premise
, I-Premise
the I-Premise
survival I-Premise
rate I-Premise
increased I-Premise
, I-Premise
the I-Premise
life I-Premise
span I-Premise
of I-Premise
dead I-Premise
children I-Premise
was I-Premise
prolonged I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
showing I-Premise
statistical I-Premise
difference I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
fjd B-Claim
combined I-Claim
chemotherapy I-Claim
could I-Claim
effectively I-Claim
improve I-Claim
the I-Claim
qol I-Claim
of I-Claim
solid I-Claim
tumor I-Claim
children I-Claim
patients I-Claim
, I-Claim
elevate I-Claim
their I-Claim
survival I-Claim
rate I-Claim
, I-Claim
and I-Claim
prolong I-Claim
their I-Claim
life I-Claim
spans I-Claim
. I-Claim
!LF! !LF!
this O
study O
examined O
whether O
changes O
in O
self O
- O
efficacy O
explain O
the O
effects O
of O
a O
mailed O
print O
intervention O
on O
long O
- O
term O
dietary O
practices O
of O
breast O
and O
prostate O
cancer O
survivors O
. O
!LF! !LF!
the O
relationship O
between O
change O
in O
self O
- O
efficacy O
and O
long O
- O
term O
physical O
activity O
( O
pa O
) O
also O
was O
examined O
. O
!LF! !LF!
breast O
and O
prostate O
cancer O
survivors O
( O
n O
= O
543 O
) O
from O
39 O
us O
states O
and O
two O
canadian O
provinces O
participated O
in O
the O
fresh O
start O
intervention O
trial O
. O
!LF! !LF!
participants O
were O
randomly O
assigned O
to O
receive O
a O
10 O
- O
month O
program O
of O
mailed O
print O
materials O
on O
diet O
and O
pa O
available O
in O
the O
public O
domain O
or O
a O
10 O
- O
month O
program O
of O
tailored O
materials O
designed O
to O
increase O
fruit O
and O
vegetable O
( O
f O
& O
v O
) O
intake O
, O
decrease O
fat O
intake O
, O
and O
/ O
or O
increase O
pa O
. O
changes O
in O
self O
- O
efficacy O
for O
f O
& O
v O
intake O
and O
fat O
restriction O
were O
analyzed O
as O
potential O
mediators O
of O
the O
intervention O
' O
s O
effects O
on O
diet O
at O
2 O
- O
year O
follow O
- O
up O
. O
!LF! !LF!
because O
we O
previously O
found O
that O
change O
in O
self O
- O
efficacy O
for O
pa O
did O
not O
vary O
by O
group O
assignment O
, O
the O
relationship O
between O
change O
in O
self O
- O
efficacy O
and O
pa O
at O
2 O
- O
year O
follow O
- O
up O
was O
examined O
across O
study O
conditions O
. O
!LF! !LF!
results B-Claim
suggest I-Claim
that I-Claim
change I-Claim
in I-Claim
self I-Claim
- I-Claim
efficacy I-Claim
for I-Claim
fat I-Claim
restriction I-Claim
partially I-Claim
explained I-Claim
the I-Claim
intervention I-Claim
' I-Claim
s I-Claim
effect I-Claim
on I-Claim
fat I-Claim
intake I-Claim
( I-Claim
mean I-Claim
indirect I-Claim
effect I-Claim
= I-Claim
- I-Claim
0 I-Claim
. I-Claim
28 I-Claim
) I-Claim
, I-Claim
and I-Claim
change I-Claim
in I-Claim
self I-Claim
- I-Claim
efficacy I-Claim
for I-Claim
f I-Claim
& I-Claim
v I-Claim
consumption I-Claim
partially I-Claim
explained I-Claim
the I-Claim
intervention I-Claim
' I-Claim
s I-Claim
effect I-Claim
on I-Claim
daily I-Claim
f I-Claim
& I-Claim
v I-Claim
intake I-Claim
( I-Claim
mean I-Claim
indirect I-Claim
effect I-Claim
= I-Claim
. I-Claim
11 I-Claim
) I-Claim
. I-Claim
!LF! !LF!
change B-Premise
in I-Premise
self I-Premise
- I-Premise
efficacy I-Premise
for I-Premise
fat I-Premise
restriction I-Premise
partially I-Premise
accounted I-Premise
for I-Premise
the I-Premise
intervention I-Premise
' I-Premise
s I-Premise
impact I-Premise
on I-Premise
overall I-Premise
diet I-Premise
quality I-Premise
among I-Premise
men I-Premise
only I-Premise
( I-Premise
mean I-Premise
indirect I-Premise
effect I-Premise
= I-Premise
0 I-Premise
. I-Premise
60 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
finally O
, O
change O
in O
self O
- O
efficacy O
for O
pa O
predicted O
pa O
at O
2 O
- O
year O
follow O
- O
up O
. O
!LF! !LF!
findings B-Claim
suggest I-Claim
that I-Claim
self I-Claim
- I-Claim
efficacy I-Claim
may I-Claim
influence I-Claim
long I-Claim
- I-Claim
term I-Claim
maintenance I-Claim
of I-Claim
healthy I-Claim
lifestyle I-Claim
practices I-Claim
among I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim
!LF! !LF!
patients O
experience O
reductions O
in O
quality O
of O
life O
( O
qol O
) O
while O
receiving O
cancer O
treatment O
and O
several O
approaches O
have O
been O
proposed O
to O
address O
qol O
issues O
. O
!LF! !LF!
in O
this O
project O
, O
the O
qol O
differences O
between O
older O
adult O
( O
age O
65 O
) O
and O
younger O
adult O
( O
age O
18 O
- O
64 O
) O
advanced O
cancer O
patients O
in O
response O
to O
a O
multidisciplinary O
intervention O
designed O
to O
improve O
qol O
were O
examined O
. O
!LF! !LF!
this O
study O
was O
registered O
on O
clinicaltrials O
. O
gov O
. O
!LF! !LF!
newly O
diagnosed O
advanced O
cancer O
patients O
undergoing O
radiation O
therapy O
were O
randomized O
to O
active O
qol O
intervention O
or O
control O
groups O
. O
!LF! !LF!
those O
in O
the O
intervention O
group O
received O
six O
multidisciplinary O
90 O
- O
minute O
sessions O
designed O
to O
address O
the O
five O
major O
domains O
of O
qol O
. O
!LF! !LF!
outcomes O
measured O
at O
baseline O
and O
weeks O
4 O
, O
27 O
, O
and O
52 O
included O
qol O
( O
linear O
analogue O
self O
- O
assessment O
( O
lasa O
) O
, O
functional O
assessment O
of O
cancer O
therapy O
- O
general O
( O
fact O
- O
g O
) O
) O
and O
mood O
( O
profile O
of O
mood O
states O
( O
poms O
) O
) O
. O
!LF! !LF!
kruskall O
- O
wallis O
methodology O
was O
used O
to O
compare O
scores O
between O
older O
and O
younger O
adult O
patients O
randomized O
to O
the O
intervention O
. O
!LF! !LF!
of O
131 O
patients O
in O
the O
larger O
randomized O
controlled O
study O
, O
we O
report O
data O
on O
54 O
evaluable O
patients O
( O
16 O
older O
adults O
and O
38 O
younger O
adults O
) O
randomized O
to O
the O
intervention O
. O
!LF! !LF!
older B-Premise
adult I-Premise
patients I-Premise
reported I-Premise
better I-Premise
overall I-Premise
qol I-Premise
( I-Premise
lasa I-Premise
74 I-Premise
. I-Premise
4 I-Premise
vs I-Premise
. I-Premise
62 I-Premise
. I-Premise
9 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
040 I-Premise
) I-Premise
, I-Premise
higher I-Premise
social I-Premise
well I-Premise
- I-Premise
being I-Premise
( I-Premise
fact I-Premise
- I-Premise
g I-Premise
91 I-Premise
. I-Premise
1 I-Premise
vs I-Premise
. I-Premise
83 I-Premise
. I-Premise
3 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
045 I-Premise
) I-Premise
, I-Premise
and I-Premise
fewer I-Premise
problems I-Premise
with I-Premise
anger I-Premise
( I-Premise
poms I-Premise
anger I-Premise
- I-Premise
hostility I-Premise
95 I-Premise
. I-Premise
0 I-Premise
vs I-Premise
. I-Premise
86 I-Premise
. I-Premise
4 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
028 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
long B-Premise
- B-Premise
term B-Premise
benefits I-Premise
for I-Premise
older I-Premise
patients I-Premise
were I-Premise
seen I-Premise
in I-Premise
the I-Premise
anger I-Premise
- I-Premise
hostility I-Premise
scale I-Premise
at I-Premise
week I-Premise
27 I-Premise
( I-Premise
92 I-Premise
. I-Premise
2 I-Premise
vs I-Premise
. I-Premise
84 I-Premise
. I-Premise
2 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
027 I-Premise
) I-Premise
and I-Premise
week I-Premise
52 I-Premise
( I-Premise
96 I-Premise
. I-Premise
3 I-Premise
vs I-Premise
. I-Premise
85 I-Premise
. I-Premise
9 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
005 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
older B-Claim
adult I-Claim
patients I-Claim
who I-Claim
received I-Claim
a I-Claim
multidisciplinary I-Claim
intervention I-Claim
to I-Claim
improve I-Claim
qol I-Claim
while I-Claim
undergoing I-Claim
advanced I-Claim
cancer I-Claim
treatments I-Claim
benefited I-Claim
differently I-Claim
in I-Claim
some I-Claim
qol I-Claim
domains I-Claim
, I-Claim
compared I-Claim
to I-Claim
younger I-Claim
adult I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
future O
studies O
can O
provide O
further O
insight O
on O
how O
to O
tailor O
qol O
interventions O
for O
these O
age O
groups O
. O
!LF! !LF!
the O
objective O
of O
this O
study O
is O
to O
explore O
the O
inflammatory O
modulation O
effect O
of O
glutamine O
- O
enriched O
total O
parenteral O
nutrition O
( O
tpn O
) O
by O
investigating O
the O
alterations O
of O
inflammation O
- O
related O
cytokines O
in O
gastrointestinal O
( O
gi O
) O
cancer O
patients O
postoperatively O
. O
!LF! !LF!
fifty O
gi O
cancer O
patients O
received O
postoperative O
7 O
days O
of O
isocaloric O
and O
isonitrogenous O
tpn O
after O
operation O
. O
!LF! !LF!
they O
were O
randomly O
divided O
to O
receive O
either O
glutamine O
- O
enriched O
tpn O
or O
standard O
tpn O
. O
!LF! !LF!
the O
inflammation O
- O
related O
cytokines O
including O
interleukin O
- O
6 O
, O
interleukin O
- O
10 O
, O
and O
tumor O
necrosis O
factor O
- O
α O
were O
also O
determined O
. O
!LF! !LF!
records O
of O
nutritional O
assessments O
, O
inflammatory O
status O
, O
and O
postoperative O
complications O
were O
compared O
between O
the O
two O
groups O
. O
!LF! !LF!
of O
50 O
enrolled O
patients O
, O
25 O
patients O
were O
classified O
as O
the O
intervention O
group O
, O
and O
the O
control O
group O
also O
comprised O
25 O
patients O
. O
!LF! !LF!
the O
differences O
of O
gender O
, O
age O
, O
primary O
gi O
malignancies O
, O
and O
hematological O
and O
biochemical O
data O
between O
the O
two O
compared O
groups O
were O
not O
statistically O
significant O
( O
all O
p O
> O
0 O
. O
05 O
) O
. O
!LF! !LF!
compared B-Premise
with I-Premise
standard I-Premise
tpn I-Premise
, I-Premise
a I-Premise
higher I-Premise
serum I-Premise
prealbumin I-Premise
level I-Premise
and I-Premise
better I-Premise
nitrogen I-Premise
balance I-Premise
were I-Premise
observed I-Premise
in I-Premise
glutamine I-Premise
- I-Premise
enriched I-Premise
tpn I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
039 I-Premise
and I-Premise
0 I-Premise
. I-Premise
048 I-Premise
respectively I-Premise
) I-Premise
. I-Premise
!LF! !LF!
a B-Premise
significantly I-Premise
lower I-Premise
serum I-Premise
interleukin I-Premise
- I-Premise
6 I-Premise
level I-Premise
was I-Premise
found I-Premise
in I-Premise
comparing I-Premise
glutamine I-Premise
- I-Premise
enriched I-Premise
with I-Premise
standard I-Premise
tpn I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
, I-Premise
but B-Premise
not I-Premise
in I-Premise
interleukin I-Premise
- I-Premise
10 I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
374 I-Premise
) I-Premise
and I-Premise
tumor I-Premise
necrosis I-Premise
factor I-Premise
- I-Premise
α I-Premise
levels I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
653 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
moreover O
, O
a B-Premise
significant I-Premise
lower I-Premise
serum I-Premise
c I-Premise
- I-Premise
reactive I-Premise
protein I-Premise
level I-Premise
was I-Premise
detected I-Premise
in I-Premise
glutamine I-Premise
- I-Premise
enriched I-Premise
tpn I-Premise
compared I-Premise
with I-Premise
standard I-Premise
tpn I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
013 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
indeed O
, O
four B-Premise
cases I-Premise
of I-Premise
postoperative I-Premise
infectious I-Premise
complications I-Premise
were I-Premise
noted I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
but I-Premise
no I-Premise
postoperative I-Premise
infectious I-Premise
complications I-Premise
were I-Premise
observed I-Premise
in I-Premise
the I-Premise
interventional I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
037 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
our B-Claim
present I-Claim
study I-Claim
shows I-Claim
that I-Claim
glutamine I-Claim
- I-Claim
enriched I-Claim
tpn I-Claim
may I-Claim
be I-Claim
beneficial I-Claim
in I-Claim
improving I-Claim
the I-Claim
inflammatory I-Claim
status I-Claim
and I-Claim
decreasing I-Claim
the I-Claim
infectious I-Claim
morbidity I-Claim
in I-Claim
postoperative I-Claim
gi I-Claim
cancer I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
this O
study O
was O
designed O
to O
evaluate O
the O
impact O
of O
laparoscopic O
rectal O
resection O
on O
short O
- O
term O
postoperative O
morbidity O
and O
costs O
. O
!LF! !LF!
a O
total O
of O
168 O
patients O
with O
rectal O
cancer O
were O
randomly O
assigned O
to O
laparoscopic O
( O
n O
= O
83 O
) O
or O
open O
( O
n O
= O
85 O
) O
resection O
. O
!LF! !LF!
outcome O
parameters O
were O
: O
postoperative O
morbidity O
, O
length O
of O
hospital O
stay O
, O
quality O
of O
life O
, O
long O
- O
term O
survival O
, O
and O
local O
recurrences O
. O
!LF! !LF!
the O
mean O
follow O
- O
up O
period O
was O
53 O
. O
6 O
months O
. O
!LF! !LF!
cost O
- O
benefit O
analysis O
was O
based O
on O
hospital O
costs O
. O
!LF! !LF!
operative B-Premise
time I-Premise
was I-Premise
53 I-Premise
minutes I-Premise
longer I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
group I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
0001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
postoperative B-Premise
morbidity I-Premise
rate I-Premise
was I-Premise
28 I-Premise
. I-Premise
9 I-Premise
percent I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
vs I-Premise
. I-Premise
40 I-Premise
percent I-Premise
in I-Premise
the I-Premise
open I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
18 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
mean I-Premise
length I-Premise
of I-Premise
hospital I-Premise
stay I-Premise
was I-Premise
10 I-Premise
( I-Premise
4 I-Premise
. I-Premise
9 I-Premise
) I-Premise
days I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
group I-Premise
and I-Premise
13 I-Premise
. I-Premise
6 I-Premise
( I-Premise
10 I-Premise
) I-Premise
days I-Premise
in I-Premise
the I-Premise
open I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
004 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
local B-Premise
recurrence I-Premise
rate I-Premise
and I-Premise
five I-Premise
- I-Premise
year I-Premise
survival I-Premise
were I-Premise
similar I-Premise
in I-Premise
both I-Premise
groups I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
however B-Claim
, I-Claim
the I-Claim
limited I-Claim
number I-Claim
of I-Claim
patients I-Claim
does I-Claim
not I-Claim
allow I-Claim
firm I-Claim
conclusions I-Claim
. I-Claim
!LF! !LF!
quality B-Premise
of I-Premise
life I-Premise
was I-Premise
better I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
group I-Premise
only I-Premise
in I-Premise
the I-Premise
first I-Premise
year I-Premise
after I-Premise
surgery I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
0001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
additional I-Premise
charge I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
group I-Premise
was I-Premise
$ I-Premise
1 I-Premise
, I-Premise
748 I-Premise
per I-Premise
patient I-Premise
randomized I-Premise
( I-Premise
$ I-Premise
1 I-Premise
, I-Premise
194 I-Premise
the I-Premise
result I-Premise
of I-Premise
surgical I-Premise
instruments I-Premise
and I-Premise
$ I-Premise
554 I-Premise
the I-Premise
result I-Premise
of I-Premise
longer I-Premise
operative I-Premise
time I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
saving I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
group I-Premise
was I-Premise
$ I-Premise
1 I-Premise
, I-Premise
396 I-Premise
per I-Premise
patient I-Premise
randomized I-Premise
( I-Premise
$ I-Premise
647 I-Premise
the I-Premise
result I-Premise
of I-Premise
shorter I-Premise
length I-Premise
of I-Premise
hospital I-Premise
stay I-Premise
and I-Premise
$ I-Premise
749 I-Premise
the I-Premise
result I-Premise
of I-Premise
the I-Premise
lower I-Premise
cost I-Premise
of I-Premise
postoperative I-Premise
complications I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
net I-Premise
balance I-Premise
resulted I-Premise
in I-Premise
$ I-Premise
351 I-Premise
extra I-Premise
cost I-Premise
per I-Premise
patient I-Premise
randomly I-Premise
allocated I-Premise
to I-Premise
the I-Premise
laparoscopic I-Premise
group I-Premise
. I-Premise
!LF! !LF!
short B-Claim
- B-Claim
term B-Claim
postoperative I-Claim
morbidity I-Claim
was I-Claim
similar I-Claim
in I-Claim
the I-Claim
two I-Claim
groups I-Claim
. I-Claim
!LF! !LF!
laparoscopic B-Claim
resection I-Claim
reduced I-Claim
length I-Claim
of I-Claim
hospital I-Claim
stay I-Claim
, I-Claim
improved I-Claim
first I-Claim
- I-Claim
year I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
and I-Claim
slightly I-Claim
increased I-Claim
hospital I-Claim
costs I-Claim
. I-Claim
!LF! !LF!
the O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
specialized O
supportive O
enteral O
and O
parenteral O
feeding O
have O
superior O
effects O
compared O
to O
oral O
nutrition O
on O
recovery O
during O
long O
- O
term O
postoperative O
treatment O
of O
cancer O
patients O
with O
preoperative O
weight O
loss O
and O
reduced O
maximum O
exercise O
capacity O
. O
!LF! !LF!
one O
hundred O
twenty O
- O
six O
patients O
referred O
for O
resection O
of O
the O
esophagus O
( O
n O
= O
48 O
) O
, O
stomach O
( O
n O
= O
28 O
) O
, O
or O
pancreas O
( O
n O
= O
50 O
) O
were O
considered O
to O
be O
included O
before O
operation O
. O
!LF! !LF!
included O
patients O
( O
n O
= O
80 O
) O
received O
supportive O
enteral O
or O
parenteral O
nutrition O
postoperatively O
at O
home O
corresponding O
to O
1000 O
kcal O
/ O
d O
until O
the O
patients O
did O
not O
wish O
to O
continue O
with O
artificial O
nutrition O
for O
any O
reason O
. O
!LF! !LF!
patients O
randomized O
to O
oral O
nutrition O
only O
served O
as O
control O
subjects O
. O
!LF! !LF!
caloric O
intake O
, O
body O
composition O
( O
dual O
- O
energy O
x O
- O
ray O
absorptiometry O
) O
, O
and O
respiratory O
gas O
exchanges O
at O
rest O
and O
during O
exercise O
were O
measured O
including O
health O
- O
related O
quality O
of O
life O
. O
!LF! !LF!
survival B-Premise
and I-Premise
hospital I-Premise
stay I-Premise
did I-Premise
not I-Premise
differ I-Premise
among I-Premise
the I-Premise
groups I-Premise
, I-Premise
whereas I-Premise
overall I-Premise
complications I-Premise
were I-Premise
higher I-Premise
on I-Premise
artificial I-Premise
nutrition I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
changes B-Premise
in I-Premise
resting I-Premise
energy I-Premise
expenditure I-Premise
and I-Premise
biochemical I-Premise
tests I-Premise
did I-Premise
not I-Premise
differ I-Premise
during I-Premise
follow I-Premise
- I-Premise
up I-Premise
among I-Premise
the I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
body B-Premise
weight I-Premise
and I-Premise
whole I-Premise
body I-Premise
fat I-Premise
declined I-Premise
similarly I-Premise
over I-Premise
time I-Premise
in I-Premise
all I-Premise
groups I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
005 I-Premise
) I-Premise
, I-Premise
whereas O
lean B-Premise
body I-Premise
mass I-Premise
was I-Premise
unchanged I-Premise
during I-Premise
follow I-Premise
- I-Premise
up I-Premise
compared I-Premise
to I-Premise
preoperative I-Premise
values I-Premise
. I-Premise
!LF! !LF!
maximum B-Premise
exercise I-Premise
capacity I-Premise
and I-Premise
maximum I-Premise
oxygen I-Premise
consumption I-Premise
were I-Premise
normalized I-Premise
within I-Premise
6 I-Premise
months I-Premise
postoperatively I-Premise
in I-Premise
all I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
there B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
recovery I-Premise
of I-Premise
food I-Premise
intake I-Premise
among I-Premise
the I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
parenteral B-Claim
feeding I-Claim
was I-Claim
associated I-Claim
with I-Claim
the I-Claim
highest I-Claim
rate I-Claim
of I-Claim
nutrition I-Claim
- I-Claim
related I-Claim
complications I-Claim
, I-Claim
whereas O
enteral B-Claim
feeding I-Claim
reduced I-Claim
quality I-Claim
of I-Claim
life I-Claim
most I-Claim
extensively I-Claim
. I-Claim
!LF! !LF!
after B-Claim
major I-Claim
surgery I-Claim
, I-Claim
specialized I-Claim
supportive I-Claim
enteral I-Claim
and I-Claim
parenteral I-Claim
nutrition I-Claim
are I-Claim
not I-Claim
superior I-Claim
to I-Claim
oral I-Claim
nutrition I-Claim
only I-Claim
when I-Claim
guided I-Claim
by I-Claim
a I-Claim
dietitian I-Claim
. I-Claim
!LF! !LF!
to O
analyze O
and O
compare O
radiologic O
lung O
expansion O
after O
talc O
pleurodesis O
performed O
either O
by O
videothoracoscopy O
or O
chest O
tube O
and O
correlate O
it O
with O
clinical O
outcome O
. O
!LF! !LF!
secondary O
end O
points O
evaluated O
were O
as O
follows O
: O
clinical O
efficacy O
"""" O
; O
"""" O
quality O
of O
life O
"""" O
; O
"""" O
safety O
"""" O
; O
"""" O
and O
survival O
. O
!LF! !LF!
prospective O
randomized O
study O
that O
included O
60 O
patients O
( O
45 O
women O
, O
15 O
men O
"""" O
; O
"""" O
mean O
age O
, O
55 O
. O
2 O
years O
) O
with O
recurrent O
malignant O
pleural O
effusion O
between O
january O
2005 O
and O
january O
2008 O
. O
!LF! !LF!
they O
were O
randomized O
into O
the O
following O
two O
groups O
: O
video O
- O
assisted O
thoracic O
surgery O
( O
vats O
) O
talc O
poudrage O
"""" O
; O
"""" O
and O
talc O
slurry O
( O
ts O
) O
administered O
through O
a O
chest O
tube O
. O
!LF! !LF!
lung O
expansion O
was O
evaluated O
through O
chest O
ct O
scans O
obtained O
0 O
, O
1 O
, O
3 O
and O
6 O
months O
after O
pleurodesis O
. O
!LF! !LF!
complications O
, O
drainage O
time O
, O
hospital O
stay O
, O
and O
quality O
of O
life O
( O
medical O
outcomes O
study O
36 O
- O
item O
short O
form O
and O
world O
health O
organization O
quality O
- O
of O
- O
life O
questionnaires O
) O
were O
also O
analyzed O
. O
!LF! !LF!
there O
were O
no O
significant O
differences O
in O
preprocedure O
clinical O
and O
pathologic O
variables O
between O
groups O
. O
!LF! !LF!
the O
immediate O
total O
( O
ie O
, O
> O
90 O
% O
) O
lung O
expansion O
was O
observed O
in O
27 O
patients O
( O
45 O
% O
) O
and O
was O
more O
frequent O
in O
the O
vats O
group O
( O
60 O
% O
vs O
30 O
% O
, O
respectively O
"""" O
; O
"""" O
p O
= O
0 O
. O
027 O
) O
. O
!LF! !LF!
during B-Premise
follow I-Premise
- I-Premise
up I-Premise
, I-Premise
71 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
showed I-Premise
unaltered I-Premise
or I-Premise
improved I-Premise
lung I-Premise
expansion I-Premise
and I-Premise
9 I-Premise
patients I-Premise
( I-Premise
15 I-Premise
% I-Premise
) I-Premise
needed I-Premise
new I-Premise
pleural I-Premise
procedures I-Premise
( I-Premise
vats I-Premise
group I-Premise
, I-Premise
5 I-Premise
recurrences I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
ts I-Premise
group I-Premise
, I-Premise
4 I-Premise
recurrences I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
999 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
no B-Premise
differences I-Premise
were I-Premise
found I-Premise
between I-Premise
groups I-Premise
regarding I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
complications I-Premise
, I-Premise
drainage I-Premise
time I-Premise
, I-Premise
hospital I-Premise
stay I-Premise
, I-Premise
and I-Premise
survival I-Premise
. I-Premise
!LF! !LF!
immediate B-Premise
lung I-Premise
expansion I-Premise
did I-Premise
not I-Premise
correlate I-Premise
with I-Premise
radiologic I-Premise
recurrence I-Premise
, I-Premise
clinical I-Premise
recurrence I-Premise
, I-Premise
or I-Premise
complications I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
60 I-Premise
, I-Premise
0 I-Premise
. I-Premise
15 I-Premise
, I-Premise
and I-Premise
0 I-Premise
. I-Premise
20 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise
!LF! !LF!
immediate B-Premise
partial I-Premise
lung I-Premise
expansion I-Premise
was I-Premise
a I-Premise
frequent I-Premise
finding I-Premise
and I-Premise
was I-Premise
more I-Premise
frequent I-Premise
after I-Premise
ts I-Premise
. I-Premise
!LF! !LF!
nonetheless O
, O
no B-Claim
correlation I-Claim
between I-Claim
immediate I-Claim
lung I-Claim
expansion I-Claim
and I-Claim
clinical I-Claim
outcome I-Claim
was I-Claim
found I-Claim
in I-Claim
this I-Claim
study I-Claim
. I-Claim
!LF! !LF!
psychological B-Claim
interventions I-Claim
are I-Claim
efficacious I-Claim
in I-Claim
reducing I-Claim
emotional I-Claim
distress I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
however B-Claim
, I-Claim
it I-Claim
is I-Claim
not I-Claim
clear I-Claim
whether I-Claim
psychological I-Claim
improvements I-Claim
are I-Claim
, I-Claim
in I-Claim
turn I-Claim
, I-Claim
related I-Claim
to I-Claim
improved I-Claim
health I-Claim
. I-Claim
!LF! !LF!
a O
clinical O
trial O
tests O
whether O
a O
psychological O
intervention O
for O
cancer O
patients O
can O
do O
so O
, O
and O
also O
tests O
two O
routes O
to O
achieve O
better O
health O
: O
( O
a O
) O
reducing O
patients O
' O
emotional O
distress O
, O
and O
/ O
or O
( O
b O
) O
enhancing O
their O
functional O
immunity O
. O
!LF! !LF!
post O
- O
surgery O
, O
227 O
breast O
cancer O
patients O
were O
randomized O
to O
intervention O
or O
assessment O
only O
study O
arms O
. O
!LF! !LF!
conducted O
in O
small O
groups O
, O
intervention O
sessions O
were O
offered O
weekly O
for O
4 O
months O
and O
followed O
by O
monthly O
sessions O
for O
8 O
months O
. O
!LF! !LF!
measures O
included O
psychological O
( O
distress O
) O
, O
biological O
( O
immune O
) O
, O
and O
health O
outcomes O
( O
performance O
status O
and O
evaluations O
of O
patient O
' O
s O
symptomatology O
, O
including O
toxicity O
from O
cancer O
treatment O
, O
lab O
values O
) O
collected O
at O
baseline O
, O
4 O
months O
, O
and O
12 O
months O
. O
!LF! !LF!
a B-Premise
path I-Premise
model I-Premise
revealed I-Premise
that I-Premise
intervention I-Premise
participation I-Premise
directly I-Premise
improved I-Premise
health I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
05 I-Premise
) I-Premise
at I-Premise
12 I-Premise
months I-Premise
. I-Premise
!LF! !LF!
these B-Premise
effects I-Premise
remained I-Premise
when I-Premise
statistically I-Premise
controlling I-Premise
for I-Premise
baseline I-Premise
levels I-Premise
of I-Premise
distress I-Premise
, I-Premise
immunity I-Premise
, I-Premise
and I-Premise
health I-Premise
as I-Premise
well I-Premise
as I-Premise
sociodemographic I-Premise
, I-Premise
disease I-Premise
, I-Premise
and I-Premise
cancer I-Premise
treatment I-Premise
variables I-Premise
. I-Premise
!LF! !LF!
regarding B-Premise
the I-Premise
mechanisms I-Premise
for I-Premise
achieving I-Premise
better I-Premise
health I-Premise
, I-Premise
support I-Premise
was I-Premise
found I-Premise
for I-Premise
an I-Premise
indirect I-Premise
effect I-Premise
of I-Premise
distress I-Premise
reduction I-Premise
. I-Premise
!LF! !LF!
that B-Premise
is I-Premise
, I-Premise
by I-Premise
specifically I-Premise
lowering I-Premise
intervention I-Premise
patients I-Premise
' I-Premise
distress I-Premise
at I-Premise
4 I-Premise
months I-Premise
, I-Premise
their I-Premise
health I-Premise
was I-Premise
improved I-Premise
at I-Premise
12 I-Premise
months I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
although B-Premise
the I-Premise
intervention I-Premise
simultaneously I-Premise
improved I-Premise
patients I-Premise
' I-Premise
t I-Premise
- I-Premise
cell I-Premise
blastogenesis I-Premise
in I-Premise
response I-Premise
to I-Premise
phytohemagglutinin I-Premise
( I-Premise
pha I-Premise
) I-Premise
, I-Premise
the B-Premise
latter I-Premise
increases I-Premise
were I-Premise
unrelated I-Premise
to I-Premise
improved I-Premise
health I-Premise
. I-Premise
!LF! !LF!
a B-Premise
convergence I-Premise
of I-Premise
biobehavioral I-Premise
effects I-Premise
and I-Premise
health I-Premise
improvements I-Premise
were I-Premise
observed I-Premise
. I-Premise
!LF! !LF!
behavioral B-Claim
change I-Claim
, I-Claim
rather I-Claim
than I-Claim
immunity I-Claim
change I-Claim
, I-Claim
was I-Claim
influential I-Claim
in I-Claim
achieving I-Claim
lower I-Claim
levels I-Claim
of I-Claim
symptomatology I-Claim
and I-Claim
higher I-Claim
functional I-Claim
status I-Claim
. I-Claim
!LF! !LF!
distress B-Claim
reduction I-Claim
is I-Claim
highlighted I-Claim
as I-Claim
an I-Claim
important I-Claim
mechanism I-Claim
by I-Claim
which I-Claim
health I-Claim
can I-Claim
be I-Claim
improved I-Claim
. I-Claim
!LF! !LF!
to O
compare O
directly O
the O
effect O
of O
intensity O
- O
modulated O
radiotherapy O
( O
imrt O
) O
vs O
. O
conventional O
radiotherapy O
( O
crt O
) O
on O
salivary O
flow O
and O
quality O
of O
life O
( O
qol O
) O
in O
patients O
with O
early O
- O
stage O
nasopharyngeal O
carcinoma O
( O
npc O
) O
. O
!LF! !LF!
fifty O
- O
one O
patients O
with O
t2 O
, O
n0 O
/ O
n1 O
, O
m0 O
npc O
took O
part O
in O
a O
randomized O
controlled O
clinical O
study O
and O
received O
imrt O
or O
crt O
. O
!LF! !LF!
stimulated O
whole O
( O
sws O
) O
and O
parotid O
( O
sps O
) O
saliva O
flow O
were O
measured O
and O
medical O
outcomes O
short O
form O
36 O
( O
sf O
- O
36 O
) O
, O
european O
organization O
for O
research O
and O
treatment O
of O
cancer O
( O
eortc O
) O
core O
quetionnaire O
, O
and O
eortc O
head O
- O
and O
- O
neck O
module O
( O
qlq O
- O
h O
& O
amp O
"""" O
; O
"""" O
n35 O
) O
were O
completed O
at O
baseline O
and O
2 O
, O
6 O
, O
and O
12 O
months O
after O
radiotherapy O
. O
!LF! !LF!
forty B-Premise
- B-Premise
six B-Premise
patients I-Premise
( I-Premise
88 I-Premise
% I-Premise
) I-Premise
were I-Premise
in I-Premise
disease I-Premise
remission I-Premise
12 I-Premise
months I-Premise
after I-Premise
radiotherapy I-Premise
. I-Premise
!LF! !LF!
at B-Premise
12 I-Premise
months I-Premise
postradiotherapy I-Premise
, I-Premise
12 I-Premise
( I-Premise
50 I-Premise
. I-Premise
0 I-Premise
% I-Premise
) I-Premise
and I-Premise
20 I-Premise
patients I-Premise
( I-Premise
83 I-Premise
. I-Premise
3 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
imrt I-Premise
group I-Premise
had I-Premise
recovered I-Premise
at I-Premise
least I-Premise
25 I-Premise
% I-Premise
of I-Premise
preradiotherapy I-Premise
sws I-Premise
and I-Premise
sps I-Premise
flow I-Premise
respectively I-Premise
, I-Premise
compared I-Premise
with I-Premise
1 I-Premise
( I-Premise
4 I-Premise
. I-Premise
8 I-Premise
% I-Premise
) I-Premise
and I-Premise
2 I-Premise
patients I-Premise
( I-Premise
9 I-Premise
. I-Premise
5 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
, I-Premise
in I-Premise
the I-Premise
crt I-Premise
group I-Premise
. I-Premise
!LF! !LF!
global B-Premise
health I-Premise
scores I-Premise
showed I-Premise
continuous I-Premise
improvement I-Premise
in I-Premise
qol I-Premise
after I-Premise
both I-Premise
treatments I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
however B-Premise
, I-Premise
after I-Premise
12 I-Premise
months I-Premise
subscale I-Premise
scores I-Premise
for I-Premise
role I-Premise
- I-Premise
physical I-Premise
, I-Premise
bodily I-Premise
pain I-Premise
, I-Premise
and I-Premise
physical I-Premise
function I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
imrt I-Premise
group I-Premise
, I-Premise
indicating I-Premise
a I-Premise
better I-Premise
condition I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
dry B-Premise
mouth I-Premise
and I-Premise
sticky I-Premise
saliva I-Premise
were I-Premise
problems I-Premise
in I-Premise
both I-Premise
groups I-Premise
2 I-Premise
months I-Premise
after I-Premise
treatment I-Premise
. I-Premise
!LF! !LF!
in B-Premise
the I-Premise
imrt I-Premise
group I-Premise
, I-Premise
there I-Premise
was I-Premise
consistent I-Premise
improvement I-Premise
over I-Premise
time I-Premise
with I-Premise
xerostomia I-Premise
- I-Premise
related I-Premise
symptoms I-Premise
significantly I-Premise
less I-Premise
common I-Premise
than I-Premise
in I-Premise
the I-Premise
crt I-Premise
group I-Premise
at I-Premise
12 I-Premise
months I-Premise
postradiotherapy I-Premise
. I-Premise
!LF! !LF!
imrt B-Claim
was I-Claim
significantly I-Claim
better I-Claim
than I-Claim
crt I-Claim
in I-Claim
terms I-Claim
of I-Claim
parotid I-Claim
sparing I-Claim
and I-Claim
improved I-Claim
qol I-Claim
for I-Claim
early I-Claim
- I-Claim
stage I-Claim
disease I-Claim
. I-Claim
!LF! !LF!
the B-Claim
findings I-Claim
support I-Claim
the I-Claim
case I-Claim
for I-Claim
assessment I-Claim
of I-Claim
health I-Claim
- I-Claim
related I-Claim
qol I-Claim
in I-Claim
relation I-Claim
to I-Claim
head I-Claim
- I-Claim
and I-Claim
- I-Claim
neck I-Claim
cancer I-Claim
using I-Claim
a I-Claim
site I-Claim
- I-Claim
specific I-Claim
approach I-Claim
. O
!LF! !LF!
a O
dramatic O
rise O
in O
incidence O
, O
an O
aging O
population O
, O
and O
expensive O
palliative O
treatments O
have O
led O
to O
an O
escalating O
burden O
on O
clinicians O
managing O
inoperable O
esophageal O
cancer O
with O
only O
limited O
evidence O
of O
effectiveness O
. O
!LF! !LF!
this O
study O
compares O
the O
clinical O
effectiveness O
and O
cost O
- O
effectiveness O
of O
self O
- O
expanding O
metal O
stents O
( O
semss O
) O
with O
other O
palliative O
therapies O
to O
aid O
clinicians O
in O
making O
an O
evidence O
- O
based O
treatment O
choice O
. O
!LF! !LF!
we O
conducted O
a O
prospective O
, O
multicenter O
, O
randomized O
, O
controlled O
, O
clinical O
trial O
with O
215 O
patients O
followed O
until O
death O
or O
study O
closure O
. O
!LF! !LF!
the O
primary O
outcome O
measures O
were O
dysphagia O
, O
quality O
of O
life O
( O
ql O
) O
6 O
weeks O
following O
treatment O
, O
and O
total O
cost O
of O
treatment O
. O
!LF! !LF!
secondary O
outcome O
measures O
included O
treatment O
- O
associated O
morbidity O
, O
mortality O
, O
survival O
, O
and O
cost O
- O
effectiveness O
. O
!LF! !LF!
an O
intention O
- O
to O
- O
treat O
analysis O
was O
carried O
out O
. O
!LF! !LF!
there B-Premise
was I-Premise
a I-Premise
significant I-Premise
difference I-Premise
in I-Premise
mean I-Premise
dysphagia I-Premise
grade I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
6 I-Premise
weeks I-Premise
following I-Premise
treatment I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
046 I-Premise
) I-Premise
, I-Premise
with I-Premise
worse I-Premise
swallowing I-Premise
reported I-Premise
by I-Premise
rigid I-Premise
stent I-Premise
- I-Premise
treated I-Premise
patients I-Premise
( I-Premise
mean I-Premise
dysphagia I-Premise
score I-Premise
difference I-Premise
= I-Premise
- I-Premise
0 I-Premise
. I-Premise
49 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
ci I-Premise
) I-Premise
- I-Premise
0 I-Premise
. I-Premise
10 I-Premise
to I-Premise
- I-Premise
0 I-Premise
. I-Premise
89 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
014 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
global B-Premise
ql I-Premise
scores I-Premise
were I-Premise
lower I-Premise
at I-Premise
both I-Premise
1 I-Premise
and I-Premise
6 I-Premise
weeks I-Premise
following I-Premise
treatment I-Premise
for I-Premise
patients I-Premise
treated I-Premise
by I-Premise
semss I-Premise
( I-Premise
mean I-Premise
difference I-Premise
ql I-Premise
index I-Premise
week I-Premise
1 I-Premise
= I-Premise
- I-Premise
0 I-Premise
. I-Premise
66 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
: I-Premise
- I-Premise
0 I-Premise
. I-Premise
02 I-Premise
to I-Premise
- I-Premise
1 I-Premise
. I-Premise
30 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
04 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
mean I-Premise
difference I-Premise
ql I-Premise
index I-Premise
week I-Premise
6 I-Premise
= I-Premise
- I-Premise
1 I-Premise
. I-Premise
01 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
- I-Premise
0 I-Premise
. I-Premise
30 I-Premise
to I-Premise
- I-Premise
1 I-Premise
. I-Premise
72 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
006 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
these B-Premise
findings I-Premise
were I-Premise
associated I-Premise
with I-Premise
higher I-Premise
post I-Premise
- I-Premise
procedure I-Premise
pain I-Premise
scores I-Premise
in I-Premise
the I-Premise
sems I-Premise
patient I-Premise
group I-Premise
( I-Premise
mean I-Premise
difference I-Premise
of I-Premise
the I-Premise
european I-Premise
organisation I-Premise
for I-Premise
research I-Premise
and I-Premise
treatment I-Premise
of I-Premise
cancer I-Premise
qlq I-Premise
c I-Premise
- I-Premise
30 I-Premise
pain I-Premise
symptom I-Premise
score I-Premise
at I-Premise
week I-Premise
1 I-Premise
= I-Premise
11 I-Premise
. I-Premise
13 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
: I-Premise
2 I-Premise
. I-Premise
89 I-Premise
- I-Premise
19 I-Premise
. I-Premise
4 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
although B-Premise
mean I-Premise
eq I-Premise
- I-Premise
5d I-Premise
ql I-Premise
values I-Premise
differed I-Premise
between I-Premise
the I-Premise
treatments I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
this I-Premise
difference I-Premise
dissipated I-Premise
following I-Premise
generation I-Premise
of I-Premise
quality I-Premise
- I-Premise
adjusted I-Premise
life I-Premise
year I-Premise
values I-Premise
. I-Premise
!LF! !LF!
total O
costs O
varied O
between O
treatment O
arms O
but O
these O
findings O
canceled O
out O
when O
semss O
were O
compared O
with O
non O
- O
sems O
therapies O
( O
95 O
% O
ci O
- O
845 O
. O
15 O
- O
1 O
, O
332 O
. O
62 O
) O
. O
!LF! !LF!
these O
results O
were O
robust O
to O
sensitivity O
analysis O
. O
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
in I-Premise
- I-Premise
hospital I-Premise
mortality I-Premise
or I-Premise
early I-Premise
complication I-Premise
rates I-Premise
, I-Premise
but B-Premise
late I-Premise
complications I-Premise
were I-Premise
more I-Premise
frequent I-Premise
after I-Premise
rigid I-Premise
stenting I-Premise
( I-Premise
risk I-Premise
ratio I-Premise
= I-Premise
2 I-Premise
. I-Premise
47 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
1 I-Premise
. I-Premise
88 I-Premise
- I-Premise
3 I-Premise
. I-Premise
04 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
there B-Premise
was I-Premise
a I-Premise
survival I-Premise
advantage I-Premise
for I-Premise
non I-Premise
- I-Premise
stent I-Premise
- I-Premise
treated I-Premise
patients I-Premise
( I-Premise
log I-Premise
- I-Premise
rank I-Premise
statistic I-Premise
= I-Premise
4 I-Premise
. I-Premise
21 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
04 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Claim
treatment I-Claim
choice I-Claim
for I-Claim
patients I-Claim
with I-Claim
inoperable I-Claim
esophageal I-Claim
cancer I-Claim
should I-Claim
be I-Claim
between I-Claim
a I-Claim
sems I-Claim
or I-Claim
a I-Claim
non I-Claim
- I-Claim
stent I-Claim
treatment I-Claim
after I-Claim
consideration I-Claim
has I-Claim
been I-Claim
given I-Claim
to I-Claim
both I-Claim
patient I-Claim
and I-Claim
tumor I-Claim
characteristics I-Claim
and I-Claim
clinician I-Claim
and I-Claim
patient I-Claim
preferences I-Claim
. I-Claim
!LF! !LF!
the B-Claim
efficacy I-Claim
and I-Claim
safety I-Claim
of I-Claim
uterine I-Claim
- I-Claim
artery I-Claim
embolization I-Claim
, I-Claim
as I-Claim
compared I-Claim
with I-Claim
standard I-Claim
surgical I-Claim
methods I-Claim
, I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
symptomatic I-Claim
uterine I-Claim
fibroids I-Claim
remain I-Claim
uncertain I-Claim
. I-Claim
!LF! !LF!
we O
conducted O
a O
randomized O
trial O
comparing O
uterine O
- O
artery O
embolization O
and O
surgery O
in O
women O
with O
symptomatic O
uterine O
fibroids O
. O
!LF! !LF!
the O
primary O
outcome O
was O
quality O
of O
life O
at O
1 O
year O
of O
follow O
- O
up O
, O
as O
measured O
by O
the O
medical O
outcomes O
study O
36 O
- O
item O
short O
- O
form O
general O
health O
survey O
( O
sf O
- O
36 O
) O
. O
!LF! !LF!
patients O
were O
randomly O
assigned O
in O
a O
2 O
: O
1 O
ratio O
to O
undergo O
either O
uterine O
- O
artery O
embolization O
or O
surgery O
, O
with O
106 O
patients O
undergoing O
embolization O
and O
51 O
undergoing O
surgery O
( O
43 O
hysterectomies O
and O
8 O
myomectomies O
) O
. O
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
groups I-Premise
in I-Premise
any I-Premise
of I-Premise
the I-Premise
eight I-Premise
components I-Premise
of I-Premise
the I-Premise
sf I-Premise
- I-Premise
36 I-Premise
scores I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise
!LF! !LF!
the B-Premise
embolization I-Premise
group I-Premise
had I-Premise
a I-Premise
shorter I-Premise
median I-Premise
duration I-Premise
of I-Premise
hospitalization I-Premise
than I-Premise
the I-Premise
surgical I-Premise
group I-Premise
( I-Premise
1 I-Premise
day I-Premise
vs I-Premise
. I-Premise
5 I-Premise
days I-Premise
, I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
and I-Premise
a I-Premise
shorter I-Premise
time I-Premise
before I-Premise
returning I-Premise
to I-Premise
work I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
at B-Premise
1 I-Premise
year I-Premise
, I-Premise
symptom I-Premise
scores I-Premise
were I-Premise
better I-Premise
in I-Premise
the I-Premise
surgical I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
03 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
during B-Premise
the I-Premise
first I-Premise
year I-Premise
of I-Premise
follow I-Premise
- I-Premise
up I-Premise
, I-Premise
there I-Premise
were I-Premise
13 I-Premise
major I-Premise
adverse I-Premise
events I-Premise
in I-Premise
the I-Premise
embolization I-Premise
group I-Premise
( I-Premise
12 I-Premise
% I-Premise
) I-Premise
and I-Premise
10 I-Premise
in I-Premise
the I-Premise
surgical I-Premise
group I-Premise
( I-Premise
20 I-Premise
% I-Premise
) I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
22 I-Premise
) I-Premise
, I-Premise
mostly I-Premise
related I-Premise
to I-Premise
the I-Premise
intervention I-Premise
. I-Premise
!LF! !LF!
ten B-Premise
patients I-Premise
in I-Premise
the I-Premise
embolization I-Premise
group I-Premise
( I-Premise
9 I-Premise
% I-Premise
) I-Premise
required I-Premise
repeated I-Premise
embolization I-Premise
or I-Premise
hysterectomy I-Premise
for I-Premise
inadequate I-Premise
symptom I-Premise
control I-Premise
. I-Premise
!LF! !LF!
after B-Premise
the I-Premise
first I-Premise
year I-Premise
of I-Premise
follow I-Premise
- I-Premise
up I-Premise
, I-Premise
14 I-Premise
women I-Premise
in I-Premise
the I-Premise
embolization I-Premise
group I-Premise
( I-Premise
13 I-Premise
% I-Premise
) I-Premise
required I-Premise
hospitalization I-Premise
, I-Premise
3 I-Premise
of I-Premise
them I-Premise
for I-Premise
major I-Premise
adverse I-Premise
events I-Premise
and I-Premise
11 I-Premise
for I-Premise
reintervention I-Premise
for I-Premise
treatment I-Premise
failure I-Premise
. I-Premise
!LF! !LF!
in B-Claim
women I-Claim
with I-Claim
symptomatic I-Claim
fibroids I-Claim
, I-Claim
the I-Claim
faster I-Claim
recovery I-Claim
after I-Claim
embolization I-Claim
must I-Claim
be I-Claim
weighed I-Claim
against I-Claim
the I-Claim
need I-Claim
for I-Claim
further I-Claim
treatment I-Claim
in I-Claim
a I-Claim
minority I-Claim
of I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
pain O
is O
1 O
of O
the O
most O
common O
symptoms O
that O
a O
cancer O
patient O
would O
experience O
. O
!LF! !LF!
a O
significant O
barrier O
to O
positive O
pain O
management O
is O
patients O
' O
misconceptions O
regarding O
analgesics O
and O
inadequate O
use O
of O
nonpharmacological O
strategies O
as O
pain O
relief O
. O
!LF! !LF!
the O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
effectiveness O
of O
a O
pain O
management O
program O
( O
pmp O
) O
on O
pain O
intensity O
, O
use O
of O
prn O
drugs O
and O
nonpharmacological O
strategies O
as O
pain O
relief O
, O
and O
barriers O
to O
managing O
pain O
in O
cancer O
patients O
. O
!LF! !LF!
the O
study O
was O
conducted O
in O
the O
palliative O
care O
and O
hospice O
ward O
of O
a O
public O
hospital O
in O
hong O
kong O
. O
!LF! !LF!
patients O
were O
randomized O
to O
either O
an O
experimental O
group O
( O
receiving O
the O
pmp O
) O
or O
a O
control O
group O
( O
routine O
care O
) O
. O
!LF! !LF!
there O
were O
38 O
hospitalized O
patients O
, O
with O
20 O
( O
13 O
males O
and O
7 O
females O
) O
in O
the O
experimental O
group O
and O
18 O
( O
11 O
males O
and O
7 O
females O
) O
in O
the O
control O
group O
"""" O
; O
"""" O
mean O
age O
was O
61 O
. O
95 O
years O
( O
experimental O
group O
) O
to O
63 O
. O
94 O
years O
( O
control O
group O
) O
. O
!LF! !LF!
upon B-Premise
the I-Premise
completion I-Premise
of I-Premise
pmp I-Premise
, I-Premise
pain I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
reduced I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
yet B-Premise
patients I-Premise
in I-Premise
the I-Premise
experimental I-Premise
group I-Premise
showed I-Premise
a I-Premise
significant I-Premise
increase I-Premise
in I-Premise
the I-Premise
use I-Premise
of I-Premise
prn I-Premise
analgesics I-Premise
and I-Premise
nonpharmacological I-Premise
strategies I-Premise
to I-Premise
relieve I-Premise
pain I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
05 I-Premise
) I-Premise
and I-Premise
significantly I-Premise
reduce I-Premise
barriers I-Premise
to I-Premise
managing I-Premise
their I-Premise
cancer I-Premise
pain I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
05 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise
!LF! !LF!
cancer B-Claim
patients I-Claim
should I-Claim
be I-Claim
empowered I-Claim
with I-Claim
pain I-Claim
management I-Claim
education I-Claim
to I-Claim
gain I-Claim
knowledge I-Claim
and I-Claim
correct I-Claim
misconceptions I-Claim
in I-Claim
managing I-Claim
their I-Claim
cancer I-Claim
pain I-Claim
. I-Claim
!LF! !LF!
integration B-Claim
of I-Claim
the I-Claim
pmp I-Claim
into I-Claim
routine I-Claim
clinical I-Claim
work I-Claim
may I-Claim
help I-Claim
to I-Claim
improve I-Claim
the I-Claim
standard I-Claim
of I-Claim
care I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
it O
is O
recommended O
to O
provide O
pain O
management O
education O
to O
all O
cancer O
patients O
. O
!LF! !LF!
this O
phase O
iii O
trial O
was O
conducted O
to O
test O
whether O
the O
novel O
vascular O
disrupting O
agent O
asa404 O
( O
vadimezan O
) O
, O
when O
combined O
with O
first O
- O
line O
platinum O
- O
based O
chemotherapy O
, O
improves O
survival O
in O
patients O
with O
advanced O
non O
- O
small O
- O
cell O
lung O
cancer O
( O
nsclc O
) O
versus O
chemotherapy O
alone O
. O
!LF! !LF!
patients O
with O
advanced O
stage O
iiib O
or O
iv O
nsclc O
, O
stratified O
by O
sex O
and O
tumor O
histology O
, O
were O
randomly O
assigned O
1 O
: O
1 O
to O
paclitaxel O
( O
200 O
mg O
/ O
m O
( O
2 O
) O
) O
and O
carboplatin O
( O
area O
under O
the O
curve O
, O
6 O
. O
0 O
) O
with O
or O
without O
asa404 O
( O
1 O
, O
800 O
mg O
m O
( O
2 O
) O
) O
, O
given O
intravenously O
once O
every O
3 O
weeks O
for O
six O
cycles O
followed O
by O
maintenance O
asa404 O
or O
placebo O
. O
!LF! !LF!
primary O
end O
point O
was O
overall O
survival O
( O
os O
) O
"""" O
; O
"""" O
secondary O
end O
points O
included O
overall O
response O
rate O
( O
orr O
) O
and O
progression O
- O
free O
survival O
( O
pfs O
) O
. O
!LF! !LF!
one O
thousand O
two O
hundred O
ninety O
- O
nine O
patients O
were O
randomly O
assigned O
. O
!LF! !LF!
the O
trial O
was O
stopped O
for O
futility O
at O
interim O
analysis O
. O
!LF! !LF!
at O
final O
analysis O
, O
there B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
os I-Premise
seen I-Premise
between I-Premise
asa404 I-Premise
( I-Premise
n I-Premise
= I-Premise
649 I-Premise
) I-Premise
and I-Premise
placebo I-Premise
( I-Premise
n I-Premise
= I-Premise
650 I-Premise
) I-Premise
arms I-Premise
: I-Premise
median I-Premise
os I-Premise
was I-Premise
13 I-Premise
. I-Premise
4 I-Premise
and I-Premise
12 I-Premise
. I-Premise
7 I-Premise
months I-Premise
respectively I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
hr I-Premise
] I-Premise
, I-Premise
1 I-Premise
. I-Premise
01 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
85 I-Premise
to I-Premise
1 I-Premise
. I-Premise
19 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
535 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
similarly O
, O
no B-Premise
os I-Premise
difference I-Premise
was I-Premise
seen I-Premise
in I-Premise
the I-Premise
histologic I-Premise
( I-Premise
squamous I-Premise
or I-Premise
nonsquamous I-Premise
) I-Premise
and I-Premise
sex I-Premise
( I-Premise
male I-Premise
or I-Premise
female I-Premise
) I-Premise
strata I-Premise
. I-Premise
!LF! !LF!
median B-Premise
pfs I-Premise
was I-Premise
5 I-Premise
. I-Premise
5 I-Premise
months I-Premise
in I-Premise
both I-Premise
arms I-Premise
( I-Premise
hr I-Premise
, I-Premise
1 I-Premise
. I-Premise
04 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
727 I-Premise
) I-Premise
, I-Premise
while I-Premise
orr I-Premise
was I-Premise
25 I-Premise
% I-Premise
in I-Premise
both I-Premise
arms I-Premise
( I-Premise
p I-Premise
= I-Premise
1 I-Premise
. I-Premise
0 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
overall B-Premise
rate I-Premise
of I-Premise
adverse I-Premise
events I-Premise
( I-Premise
aes I-Premise
) I-Premise
was I-Premise
comparable I-Premise
between I-Premise
the I-Premise
asa404 I-Premise
and I-Premise
placebo I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
grade B-Premise
4 I-Premise
neutropenia I-Premise
( I-Premise
27 I-Premise
% I-Premise
v I-Premise
19 I-Premise
% I-Premise
) I-Premise
and I-Premise
infusion I-Premise
site I-Premise
pain I-Premise
( I-Premise
10 I-Premise
% I-Premise
v I-Premise
0 I-Premise
. I-Premise
5 I-Premise
% I-Premise
) I-Premise
were I-Premise
reported I-Premise
more I-Premise
frequently I-Premise
in I-Premise
the I-Premise
asa404 I-Premise
arm I-Premise
. I-Premise
!LF! !LF!
the B-Claim
addition I-Claim
of I-Claim
asa404 I-Claim
to I-Claim
carboplatin I-Claim
and I-Claim
paclitaxel I-Claim
, I-Claim
although I-Claim
generally I-Claim
well I-Claim
tolerated I-Claim
, I-Claim
failed I-Claim
to I-Claim
improve I-Claim
frontline I-Claim
efficacy I-Claim
in I-Claim
advanced I-Claim
nsclc I-Claim
. I-Claim
!LF! !LF!
the B-Claim
postoperative I-Claim
clinical I-Claim
superiority I-Claim
of I-Claim
the I-Claim
interposition I-Claim
of I-Claim
jejunum I-Claim
reconstruction I-Claim
( I-Claim
int I-Claim
) I-Claim
to I-Claim
roux I-Claim
- I-Claim
en I-Claim
- I-Claim
y I-Claim
reconstruction I-Claim
( I-Claim
ry I-Claim
) I-Claim
after I-Claim
total I-Claim
gastrectomy I-Claim
has I-Claim
not I-Claim
been I-Claim
clarified I-Claim
. I-Claim
!LF! !LF!
postoperative O
quality O
of O
life O
( O
qol O
) O
was O
evaluated O
between O
the O
2 O
methods O
by O
a O
multi O
- O
institutional O
prospective O
randomized O
trial O
. O
!LF! !LF!
a O
total O
of O
103 O
patients O
with O
gastric O
cancer O
were O
prospectively O
randomly O
divided O
into O
groups O
for O
ry O
( O
n O
= O
51 O
) O
or O
int O
reconstruction O
( O
n O
= O
52 O
) O
after O
total O
gastrectomy O
. O
!LF! !LF!
they O
were O
stratified O
by O
sex O
, O
age O
, O
institute O
, O
histology O
, O
and O
degree O
of O
lymph O
node O
dissection O
. O
!LF! !LF!
postoperatively O
, O
body O
mass O
index O
( O
bmi O
) O
and O
nutritional O
conditions O
were O
measured O
serially O
, O
and O
qol O
and O
postoperative O
squalor O
scores O
were O
evaluated O
at O
3 O
, O
12 O
, O
and O
60 O
months O
and O
compared O
between O
the O
2 O
groups O
. O
!LF! !LF!
after O
removing O
patients O
who O
did O
not O
complete O
the O
follow O
- O
up O
survey O
or O
censured O
cases O
, O
24 O
patients O
in O
the O
ry O
group O
and O
18 O
patients O
in O
the O
int O
group O
were O
clinically O
available O
and O
their O
postoperative O
status O
was O
assessed O
. O
!LF! !LF!
qol B-Premise
scores I-Premise
were I-Premise
increased I-Premise
and I-Premise
complication I-Premise
scores I-Premise
were I-Premise
improved I-Premise
in I-Premise
the I-Premise
postoperative I-Premise
periods I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
postoperative B-Premise
bmi I-Premise
significantly I-Premise
deteriorated I-Premise
compared I-Premise
with I-Premise
preoperative I-Premise
bmi I-Premise
in I-Premise
each I-Premise
group I-Premise
. I-Premise
!LF! !LF!
the B-Premise
postoperative I-Premise
qol I-Premise
and I-Premise
complication I-Premise
scores I-Premise
at I-Premise
60 I-Premise
months I-Premise
after I-Premise
surgery I-Premise
were I-Premise
significantly I-Premise
better I-Premise
than I-Premise
those I-Premise
at I-Premise
3 I-Premise
months I-Premise
after I-Premise
surgery I-Premise
in I-Premise
each I-Premise
group I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
however O
, O
there B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
of I-Premise
qol I-Premise
scores I-Premise
and I-Premise
postoperative I-Premise
complication I-Premise
scores I-Premise
between I-Premise
the I-Premise
2 I-Premise
reconstruction I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
the B-Premise
nutritional I-Premise
condition I-Premise
in I-Premise
the I-Premise
int I-Premise
group I-Premise
was I-Premise
nearly I-Premise
the I-Premise
same I-Premise
as I-Premise
that I-Premise
in I-Premise
the I-Premise
ry I-Premise
group I-Premise
. I-Premise
!LF! !LF!
although B-Premise
our I-Premise
patient I-Premise
sample I-Premise
was I-Premise
small I-Premise
and I-Premise
patients I-Premise
who I-Premise
did I-Premise
not I-Premise
complete I-Premise
the I-Premise
follow I-Premise
- I-Premise
up I-Premise
survey I-Premise
were I-Premise
present I-Premise
, I-Premise
we B-Claim
could I-Claim
not I-Claim
identify I-Claim
any I-Claim
clinical I-Claim
difference I-Claim
between I-Claim
int I-Claim
and I-Claim
ry I-Claim
after I-Claim
total I-Claim
gastrectomy I-Claim
60 I-Claim
months I-Claim
after I-Claim
surgery I-Claim
. I-Claim
!LF! !LF!
the B-Claim
safer I-Claim
and I-Claim
simpler I-Claim
ry I-Claim
method I-Claim
may I-Claim
be I-Claim
a I-Claim
more I-Claim
suitable I-Claim
reconstruction I-Claim
method I-Claim
than I-Claim
int I-Claim
after I-Claim
total I-Claim
gastrectomy I-Claim
. I-Claim
!LF! !LF!
approximately O
30 O
% O
of O
lung O
cancer O
cases O
are O
diagnosed O
in O
patients O
> O
70 O
years O
of O
age O
. O
!LF! !LF!
standard B-Claim
chemotherapy I-Claim
regimens I-Claim
are I-Claim
generally I-Claim
considered I-Claim
too I-Claim
toxic I-Claim
for I-Claim
elderly I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
we O
conducted O
a O
multicenter O
phase O
ii O
trial O
to O
determine O
the O
efficacy O
and O
safety O
of O
carboplatin O
combined O
with O
vinorelbine O
every O
4 O
weeks O
as O
first O
- O
line O
treatment O
for O
advanced O
non O
- O
small O
- O
cell O
lung O
cancer O
( O
nsclc O
) O
in O
elderly O
patients O
. O
!LF! !LF!
patients O
were O
eligible O
if O
they O
were O
aged O
> O
or O
= O
70 O
years O
, O
had O
stage O
iiib O
( O
with O
pleural O
effusion O
) O
or O
stage O
iv O
nsclc O
, O
had O
a O
performance O
status O
of O
0 O
/ O
1 O
, O
had O
not O
previously O
received O
chemotherapy O
, O
and O
had O
normal O
organ O
function O
. O
!LF! !LF!
forty O
patients O
( O
31 O
men O
and O
9 O
women O
) O
were O
enrolled O
and O
received O
3 O
- O
5 O
courses O
of O
treatment O
. O
!LF! !LF!
median O
age O
was O
72 O
years O
( O
range O
, O
70 O
- O
82 O
years O
) O
. O
!LF! !LF!
eighty O
percent O
of O
patients O
had O
stage O
iv O
nsclc O
, O
with O
squamous O
cell O
( O
n O
= O
21 O
) O
, O
adenocarcinoma O
( O
n O
= O
12 O
) O
, O
and O
undifferentiated O
( O
n O
= O
7 O
) O
histologies O
. O
!LF! !LF!
forty O
patients O
were O
assessable O
for O
toxicity O
and O
32 O
for O
treatment O
response O
. O
!LF! !LF!
among B-Premise
these I-Premise
32 I-Premise
patients I-Premise
, I-Premise
8 I-Premise
had I-Premise
a I-Premise
partial I-Premise
response I-Premise
( I-Premise
intent I-Premise
- I-Premise
to I-Premise
- I-Premise
treat I-Premise
response I-Premise
rate I-Premise
, I-Premise
20 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
10 I-Premise
( I-Premise
25 I-Premise
% I-Premise
) I-Premise
had I-Premise
stable I-Premise
disease I-Premise
. I-Premise
!LF! !LF!
the B-Premise
median I-Premise
survival I-Premise
was I-Premise
7 I-Premise
. I-Premise
8 I-Premise
months I-Premise
( I-Premise
range I-Premise
, I-Premise
4 I-Premise
- I-Premise
11 I-Premise
. I-Premise
6 I-Premise
months I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
- I-Premise
1 I-Premise
and I-Premise
2 I-Premise
- I-Premise
year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
25 I-Premise
% I-Premise
and I-Premise
7 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
median B-Premise
time I-Premise
to I-Premise
progression I-Premise
was I-Premise
4 I-Premise
. I-Premise
3 I-Premise
months I-Premise
( I-Premise
range I-Premise
, I-Premise
0 I-Premise
. I-Premise
2 I-Premise
- I-Premise
13 I-Premise
. I-Premise
8 I-Premise
months I-Premise
) I-Premise
. I-Premise
!LF! !LF!
grade B-Premise
3 I-Premise
/ I-Premise
4 I-Premise
neutropenia I-Premise
was I-Premise
seen I-Premise
in I-Premise
27 I-Premise
patients I-Premise
( I-Premise
68 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
grade I-Premise
3 I-Premise
/ I-Premise
4 I-Premise
anemia I-Premise
was I-Premise
seen I-Premise
in I-Premise
5 I-Premise
patients I-Premise
( I-Premise
13 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
one B-Premise
patient I-Premise
died I-Premise
of I-Premise
febrile I-Premise
neutropenia I-Premise
during I-Premise
treatment I-Premise
. I-Premise
!LF! !LF!
the B-Premise
main I-Premise
nonhematologic I-Premise
adverse I-Premise
effect I-Premise
was I-Premise
fatigue I-Premise
( I-Premise
grade I-Premise
3 I-Premise
/ I-Premise
4 I-Premise
in I-Premise
18 I-Premise
% I-Premise
of I-Premise
patients I-Premise
) I-Premise
. I-Premise
!LF! !LF!
carboplatin B-Claim
/ B-Claim
vinorelbine B-Claim
is I-Claim
well I-Claim
tolerated I-Claim
by I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
extensive I-Claim
- I-Claim
stage I-Claim
nsclc I-Claim
. I-Claim
!LF! !LF!
efficacy B-Claim
is I-Claim
low I-Claim
but I-Claim
similar I-Claim
to I-Claim
that I-Claim
of I-Claim
other I-Claim
treatments I-Claim
used I-Claim
in I-Claim
this I-Claim
setting I-Claim
. I-Claim
!LF! !LF!
the O
purpose O
of O
this O
pilot O
study O
was O
to O
examine O
the O
effects O
of O
a O
combined O
cardiorespiratory O
and O
resistance O
exercise O
training O
program O
of O
short O
duration O
on O
the O
cardiorespiratory O
fitness O
, O
strength O
endurance O
, O
task O
specific O
functional O
muscle O
capacity O
, O
body O
composition O
and O
quality O
of O
life O
( O
qol O
) O
in O
women O
breast O
cancer O
survivors O
. O
!LF! !LF!
sixteen O
subjects O
were O
randomly O
assigned O
to O
either O
a O
training O
( O
n O
= O
8 O
"""" O
; O
"""" O
age O
: O
50 O
+ O
/ O
- O
5 O
yrs O
) O
or O
control O
non O
- O
exercising O
group O
( O
n O
= O
8 O
"""" O
; O
"""" O
age O
: O
51 O
+ O
/ O
- O
10 O
yrs O
) O
. O
!LF! !LF!
the O
training O
group O
followed O
an O
8 O
- O
week O
exercise O
program O
consisting O
of O
3 O
weekly O
sessions O
of O
90 O
- O
min O
duration O
, O
supervised O
by O
an O
experienced O
investigator O
and O
divided O
into O
resistance O
exercises O
and O
aerobic O
training O
. O
!LF! !LF!
before O
and O
after O
the O
intervention O
period O
, O
all O
of O
the O
subjects O
performed O
a O
cardiorespiratory O
test O
to O
measure O
peak O
oxygen O
uptake O
( O
vo2peak O
) O
, O
a O
dynamic O
strength O
endurance O
test O
( O
maximum O
number O
of O
repetitions O
for O
chest O
and O
leg O
press O
exercise O
at O
30 O
- O
35 O
% O
and O
100 O
- O
110 O
% O
of O
body O
mass O
, O
respectively O
) O
and O
a O
sit O
- O
stand O
test O
. O
!LF! !LF!
quality O
of O
life O
was O
assessed O
using O
the O
european O
organization O
for O
research O
and O
treatment O
of O
cancer O
qlq O
- O
c30 O
( O
eortc O
- O
c30 O
) O
questionnaire O
. O
!LF! !LF!
in B-Premise
response I-Premise
to I-Premise
training I-Premise
, I-Premise
qol I-Premise
, I-Premise
vo2peak I-Premise
( I-Premise
mean I-Premise
3 I-Premise
. I-Premise
9 I-Premise
ml I-Premise
/ I-Premise
kg I-Premise
/ I-Premise
min I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
93 I-Premise
, I-Premise
6 I-Premise
. I-Premise
90 I-Premise
) I-Premise
performance I-Premise
in I-Premise
leg I-Premise
press I-Premise
( I-Premise
17 I-Premise
. I-Premise
9 I-Premise
kg I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
12 I-Premise
. I-Premise
8 I-Premise
, I-Premise
22 I-Premise
. I-Premise
4 I-Premise
) I-Premise
and I-Premise
sit I-Premise
- I-Premise
stand I-Premise
test I-Premise
( I-Premise
- I-Premise
0 I-Premise
. I-Premise
67 I-Premise
s I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
- I-Premise
0 I-Premise
. I-Premise
52 I-Premise
, I-Premise
- I-Premise
1 I-Premise
. I-Premise
2 I-Premise
) I-Premise
improved I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
we B-Premise
observed I-Premise
no I-Premise
significant I-Premise
changes I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise
!LF! !LF!
combined B-Claim
cardiorespiratory I-Claim
and I-Claim
resistance I-Claim
training I-Claim
, I-Claim
even I-Claim
of I-Claim
very I-Claim
brief I-Claim
duration I-Claim
, I-Claim
improves I-Claim
the I-Claim
qol I-Claim
and I-Claim
the I-Claim
overall I-Claim
physical I-Claim
fitness I-Claim
of I-Claim
women I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim
!LF! !LF!
phase O
iii O
egf104900 O
data O
demonstrated O
that O
lapatinib O
plus O
trastuzumab O
significantly O
improved O
progression O
- O
free O
survival O
( O
pfs O
) O
and O
clinical O
benefit O
rate O
versus O
lapatinib O
monotherapy O
, O
offering O
a O
chemotherapy O
- O
free O
option O
for O
patients O
with O
heavily O
pretreated O
human O
epidermal O
growth O
factor O
receptor O
2 O
( O
her2 O
) O
- O
positive O
metastatic O
breast O
cancer O
( O
mbc O
) O
. O
!LF! !LF!
final O
planned O
overall O
survival O
( O
os O
) O
analysis O
from O
egf104900 O
is O
reported O
here O
. O
!LF! !LF!
patients O
with O
her2 O
- O
positive O
mbc O
whose O
disease O
progressed O
during O
prior O
trastuzumab O
- O
based O
therapies O
were O
randomly O
assigned O
to O
receive O
lapatinib O
monotherapy O
or O
lapatinib O
in O
combination O
with O
trastuzumab O
. O
!LF! !LF!
os O
and O
updated O
pfs O
data O
are O
presented O
using O
kaplan O
- O
meier O
curves O
and O
log O
- O
rank O
tests O
stratified O
for O
hormone O
receptor O
and O
visceral O
disease O
status O
. O
!LF! !LF!
subgroup O
analyses O
were O
conducted O
to O
identify O
characteristics O
of O
patients O
deriving O
the O
greatest O
clinical O
benefit O
. O
!LF! !LF!
in B-Premise
this I-Premise
updated I-Premise
final I-Premise
analysis I-Premise
of I-Premise
all I-Premise
patients I-Premise
randomly I-Premise
assigned I-Premise
with I-Premise
strata I-Premise
( I-Premise
n I-Premise
= I-Premise
291 I-Premise
) I-Premise
, I-Premise
lapatinib I-Premise
plus I-Premise
trastuzumab I-Premise
continued I-Premise
to I-Premise
show I-Premise
superiority I-Premise
to I-Premise
lapatinib I-Premise
monotherapy I-Premise
in I-Premise
pfs I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
hr I-Premise
] I-Premise
, I-Premise
0 I-Premise
. I-Premise
74 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
58 I-Premise
to I-Premise
0 I-Premise
. I-Premise
94 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
011 I-Premise
) I-Premise
and I-Premise
offered I-Premise
significant I-Premise
os I-Premise
benefit I-Premise
( I-Premise
hr I-Premise
, I-Premise
0 I-Premise
. I-Premise
74 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
57 I-Premise
to I-Premise
0 I-Premise
. I-Premise
97 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
026 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
improvements B-Premise
in I-Premise
absolute I-Premise
os I-Premise
rates I-Premise
were I-Premise
10 I-Premise
% I-Premise
at I-Premise
6 I-Premise
months I-Premise
and I-Premise
15 I-Premise
% I-Premise
at I-Premise
12 I-Premise
months I-Premise
in I-Premise
the I-Premise
combination I-Premise
arm I-Premise
compared I-Premise
with I-Premise
the I-Premise
monotherapy I-Premise
arm I-Premise
. I-Premise
!LF! !LF!
multiple B-Premise
baseline I-Premise
factors I-Premise
, I-Premise
including I-Premise
eastern I-Premise
cooperative I-Premise
oncology I-Premise
group I-Premise
performance I-Premise
status I-Premise
of I-Premise
0 I-Premise
, I-Premise
nonvisceral I-Premise
disease I-Premise
, I-Premise
< I-Premise
three I-Premise
metastatic I-Premise
sites I-Premise
, I-Premise
and I-Premise
less I-Premise
time I-Premise
from I-Premise
initial I-Premise
diagnosis I-Premise
until I-Premise
random I-Premise
assignment I-Premise
, I-Premise
were I-Premise
associated I-Premise
with I-Premise
improved I-Premise
os I-Premise
. I-Premise
!LF! !LF!
incidence B-Premise
of I-Premise
adverse I-Premise
events I-Premise
was I-Premise
consistent I-Premise
with I-Premise
previously I-Premise
reported I-Premise
rates I-Premise
. I-Premise
!LF! !LF!
these B-Claim
data I-Claim
demonstrated I-Claim
a I-Claim
significant I-Claim
4 I-Claim
. I-Claim
5 I-Claim
- I-Claim
month I-Claim
median I-Claim
os I-Claim
advantage I-Claim
with I-Claim
the I-Claim
lapatinib I-Claim
and I-Claim
trastuzumab I-Claim
combination I-Claim
and I-Claim
support I-Claim
dual I-Claim
her2 I-Claim
blockade I-Claim
in I-Claim
patients I-Claim
with I-Claim
heavily I-Claim
pretreated I-Claim
her2 I-Claim
- I-Claim
positive I-Claim
mbc I-Claim
. I-Claim
!LF! !LF!
the O
aim O
of O
the O
present O
trial O
was O
to O
evaluate O
the O
effects O
of O
chemotherapy O
on O
the O
quality O
of O
life O
and O
survival O
of O
patients O
with O
advanced O
non O
- O
small O
cell O
lung O
cancer O
( O
nsclc O
) O
( O
stage O
iiib O
or O
iv O
) O
. O
!LF! !LF!
in O
a O
controlled O
multicentre O
trial O
, O
patients O
were O
randomised O
to O
receive O
supportive O
care O
only O
or O
supportive O
care O
plus O
chemotherapy O
. O
!LF! !LF!
chemotherapy O
consisted O
of O
intravenous O
( O
i O
. O
v O
. O
) O
!LF! !LF!
carboplatin O
300 O
mg O
/ O
m2 O
on O
day O
1 O
and O
etoposide O
120 O
mg O
/ O
m2 O
orally O
on O
days O
1 O
- O
5 O
every O
4 O
weeks O
for O
a O
maximum O
of O
eight O
courses O
. O
!LF! !LF!
quality O
of O
life O
was O
measured O
at O
randomisation O
and O
prior O
to O
each O
treatment O
course O
and O
at O
corresponding O
4 O
- O
week O
intervals O
in O
the O
control O
arm O
, O
using O
the O
eortc O
qlq O
- O
c30 O
+ O
lc13 O
questionnaire O
. O
!LF! !LF!
48 O
patients O
were O
randomised O
( O
supportive O
care O
26 O
, O
chemotherapy O
22 O
) O
, O
being O
eligible O
for O
comparative O
analyses O
. O
!LF! !LF!
another O
102 O
patients O
, O
97 O
of O
which O
received O
chemotherapy O
, O
were O
subsequently O
included O
in O
the O
study O
on O
an O
individual O
treatment O
preference O
basis O
. O
!LF! !LF!
data O
from O
these O
patients O
were O
used O
for O
confirmative O
purposes O
. O
!LF! !LF!
patients B-Premise
in I-Premise
the I-Premise
chemotherapy I-Premise
group I-Premise
reported I-Premise
better I-Premise
overall I-Premise
physical I-Premise
functioning I-Premise
and I-Premise
symptom I-Premise
control I-Premise
compared I-Premise
with I-Premise
the I-Premise
supportive I-Premise
care I-Premise
group I-Premise
. I-Premise
!LF! !LF!
group B-Premise
differences I-Premise
were I-Premise
smaller I-Premise
within I-Premise
the I-Premise
psychosocial I-Premise
domain I-Premise
, I-Premise
although B-Premise
trends I-Premise
were I-Premise
seen I-Premise
in I-Premise
favour I-Premise
of I-Premise
the I-Premise
chemotherapy I-Premise
group I-Premise
. I-Premise
!LF! !LF!
no B-Premise
significant I-Premise
differences I-Premise
were I-Premise
seen I-Premise
in I-Premise
favour I-Premise
of I-Premise
the I-Premise
supportive I-Premise
care I-Premise
group I-Premise
, I-Premise
except B-Premise
for I-Premise
hair I-Premise
loss I-Premise
. I-Premise
!LF! !LF!
median B-Premise
survival I-Premise
times I-Premise
were I-Premise
29 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
chemotherapy I-Premise
group I-Premise
versus I-Premise
11 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
supportive I-Premise
care I-Premise
group I-Premise
, I-Premise
and I-Premise
1 I-Premise
- I-Premise
year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
28 I-Premise
% I-Premise
versus I-Premise
8 I-Premise
% I-Premise
. I-Premise
!LF! !LF!
quality B-Premise
of I-Premise
life I-Premise
and I-Premise
survival I-Premise
outcomes I-Premise
were I-Premise
similar I-Premise
in I-Premise
the I-Premise
randomised I-Premise
and I-Premise
non I-Premise
- I-Premise
randomised I-Premise
patients I-Premise
receiving I-Premise
chemotherapy I-Premise
. I-Premise
!LF! !LF!
no B-Premise
treatment I-Premise
- I-Premise
related I-Premise
deaths I-Premise
occurred I-Premise
. I-Premise
!LF! !LF!
in B-Claim
conclusion I-Claim
, I-Claim
treatment I-Claim
with I-Claim
carboplatin I-Claim
and I-Claim
etoposide I-Claim
can I-Claim
improve I-Claim
both I-Claim
the I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
the I-Claim
survival I-Claim
of I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
nsclc I-Claim
. I-Claim
!LF! !LF!
to O
assess O
the O
efficacy O
of O
prophylactic O
swallowing O
exercises O
on O
swallowing O
function O
in O
patients O
undergoing O
chemoradiation O
therapy O
( O
crt O
) O
for O
head O
and O
neck O
cancer O
. O
!LF! !LF!
randomized O
controlled O
trial O
. O
!LF! !LF!
tertiary O
care O
, O
academic O
medical O
center O
. O
!LF! !LF!
twenty O
- O
six O
patients O
with O
head O
and O
neck O
cancer O
receiving O
crt O
. O
!LF! !LF!
patients O
performed O
5 O
targeted O
swallowing O
exercises O
throughout O
their O
crt O
and O
participated O
in O
weekly O
swallowing O
therapy O
sessions O
to O
promote O
adherence O
and O
accurate O
technique O
. O
!LF! !LF!
controls O
had O
no O
prophylactic O
exercises O
and O
were O
referred O
for O
swallowing O
treatment O
after O
completion O
of O
crt O
if O
indicated O
. O
!LF! !LF!
swallowing O
function O
was O
assessed O
with O
the O
functional O
oral O
intake O
scale O
( O
fois O
) O
and O
the O
performance O
status O
scale O
for O
head O
and O
neck O
cancer O
patients O
( O
pss O
- O
h O
& O
n O
) O
at O
baseline O
, O
immediately O
after O
crt O
, O
and O
at O
3 O
, O
6 O
, O
9 O
, O
and O
12 O
months O
after O
crt O
. O
!LF! !LF!
there B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
fois I-Premise
scores I-Premise
between I-Premise
intervention I-Premise
and I-Premise
control I-Premise
patients I-Premise
immediately I-Premise
after I-Premise
crt I-Premise
( I-Premise
immediately I-Premise
after I-Premise
crt I-Premise
: I-Premise
intervention I-Premise
group I-Premise
median I-Premise
score I-Premise
, I-Premise
3 I-Premise
[ I-Premise
range I-Premise
, I-Premise
1 I-Premise
- I-Premise
7 I-Premise
] I-Premise
, I-Premise
vs I-Premise
median I-Premise
control I-Premise
score I-Premise
, I-Premise
4 I-Premise
[ I-Premise
range I-Premise
, I-Premise
1 I-Premise
- I-Premise
6 I-Premise
] I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
88 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
however O
, O
intervention B-Premise
patients I-Premise
had I-Premise
significantly I-Premise
better I-Premise
scores I-Premise
at I-Premise
months I-Premise
3 I-Premise
and I-Premise
6 I-Premise
( I-Premise
median I-Premise
3 I-Premise
- I-Premise
month I-Premise
intervention I-Premise
score I-Premise
, I-Premise
7 I-Premise
[ I-Premise
range I-Premise
, I-Premise
5 I-Premise
- I-Premise
7 I-Premise
] I-Premise
, I-Premise
vs I-Premise
median I-Premise
control I-Premise
score I-Premise
, I-Premise
5 I-Premise
[ I-Premise
range I-Premise
, I-Premise
3 I-Premise
- I-Premise
7 I-Premise
] I-Premise
[ I-Premise
p I-Premise
= I-Premise
. I-Premise
03 I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
median I-Premise
6 I-Premise
- I-Premise
month I-Premise
intervention I-Premise
score I-Premise
, I-Premise
7 I-Premise
[ I-Premise
range I-Premise
, I-Premise
6 I-Premise
- I-Premise
7 I-Premise
] I-Premise
, I-Premise
vs I-Premise
median I-Premise
control I-Premise
score I-Premise
, I-Premise
6 I-Premise
[ I-Premise
range I-Premise
, I-Premise
3 I-Premise
- I-Premise
7 I-Premise
] I-Premise
[ I-Premise
p I-Premise
= I-Premise
. I-Premise
009 I-Premise
] I-Premise
) I-Premise
. I-Premise
!LF! !LF!
there B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
scores I-Premise
at I-Premise
months I-Premise
9 I-Premise
and I-Premise
12 I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
24 I-Premise
and I-Premise
p I-Premise
= I-Premise
. I-Premise
93 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
same I-Premise
pattern I-Premise
between I-Premise
intervention I-Premise
and I-Premise
control I-Premise
patients I-Premise
was I-Premise
observed I-Premise
for I-Premise
scores I-Premise
on I-Premise
the I-Premise
pss I-Premise
- I-Premise
h I-Premise
& I-Premise
n I-Premise
. I-Premise
!LF! !LF!
patients B-Claim
who I-Claim
performed I-Claim
prophylactic I-Claim
swallowing I-Claim
exercises I-Claim
had I-Claim
improved I-Claim
swallowing I-Claim
function I-Claim
at I-Claim
3 I-Claim
and I-Claim
6 I-Claim
months I-Claim
after I-Claim
crt I-Claim
but I-Claim
not I-Claim
immediately I-Claim
after I-Claim
crt I-Claim
or I-Claim
at I-Claim
9 I-Claim
and I-Claim
12 I-Claim
months I-Claim
after I-Claim
crt I-Claim
. I-Claim
!LF! !LF!
the B-Claim
small I-Claim
sample I-Claim
size I-Claim
may I-Claim
have I-Claim
limited I-Claim
our I-Claim
ability I-Claim
to I-Claim
detect I-Claim
significant I-Claim
differences I-Claim
beyond I-Claim
6 I-Claim
months I-Claim
of I-Claim
observation I-Claim
as I-Claim
well I-Claim
as I-Claim
additional I-Claim
significant I-Claim
differences I-Claim
in I-Claim
our I-Claim
study I-Claim
. I-Claim
!LF! !LF!
to O
prospectively O
evaluate O
health O
- O
related O
quality O
of O
life O
( O
hrqol O
) O
outcomes O
for O
uterine O
artery O
embolization O
( O
uae O
) O
and O
hysterectomy O
up O
to O
24 O
months O
after O
the O
intervention O
in O
terms O
of O
mental O
and O
physical O
health O
, O
urinary O
and O
defecatory O
function O
, O
and O
overall O
patient O
satisfaction O
. O
!LF! !LF!
ethics O
committee O
approval O
and O
informed O
consent O
were O
obtained O
for O
the O
embolisation O
versus O
hysterectomy O
trial O
. O
!LF! !LF!
women O
( O
n O
= O
177 O
) O
with O
uterine O
fibroids O
and O
heavy O
menstrual O
bleeding O
who O
were O
scheduled O
to O
undergo O
hysterectomy O
were O
randomly O
assigned O
to O
undergo O
uae O
( O
n O
= O
88 O
) O
or O
hysterectomy O
( O
n O
= O
89 O
) O
. O
!LF! !LF!
hrqol O
was O
measured O
six O
times O
during O
a O
24 O
- O
month O
follow O
- O
up O
period O
with O
the O
following O
validated O
questionnaires O
: O
medical O
outcome O
study O
short O
form O
36 O
( O
sf O
- O
36 O
) O
mental O
component O
summary O
( O
mcs O
) O
and O
physical O
component O
summary O
( O
pcs O
) O
, O
health O
utilities O
index O
mark O
3 O
, O
euroqol O
5d O
, O
urogenital O
distress O
inventory O
( O
udi O
) O
, O
incontinence O
impact O
questionnaire O
, O
and O
defecation O
distress O
inventory O
( O
ddi O
) O
. O
!LF! !LF!
satisfaction O
was O
assessed O
with O
a O
seven O
- O
point O
likert O
scale O
. O
!LF! !LF!
repeated O
measurement O
analysis O
was O
performed O
for O
between O
- O
group O
analysis O
. O
!LF! !LF!
paired O
t O
tests O
were O
performed O
for O
within O
- O
group O
analysis O
. O
!LF! !LF!
satisfaction O
was O
analyzed O
with O
the O
fisher O
exact O
test O
. O
!LF! !LF!
the B-Premise
sf I-Premise
- I-Premise
36 I-Premise
mcs I-Premise
and I-Premise
pcs I-Premise
, I-Premise
health I-Premise
utilities I-Premise
index I-Premise
mark I-Premise
3 I-Premise
, I-Premise
euroqol I-Premise
5d I-Premise
, I-Premise
and I-Premise
udi I-Premise
scores I-Premise
were I-Premise
improved I-Premise
significantly I-Premise
in I-Premise
both I-Premise
groups I-Premise
at I-Premise
6 I-Premise
months I-Premise
and I-Premise
afterward I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the O
ddi O
score O
was O
improved O
significantly O
in O
only O
the O
uae O
group O
at O
6 O
months O
and O
afterward O
( O
p O
< O
. O
05 O
) O
. O
!LF! !LF!
no O
differences O
between O
groups O
were O
observed O
, O
with O
the O
exception O
of O
pcs O
scores O
at O
6 O
- O
week O
follow O
- O
up O
: O
patients O
in O
the O
uae O
group O
had O
significantly O
better O
scores O
than O
did O
patients O
in O
the O
hysterectomy O
group O
( O
p O
< O
. O
001 O
) O
. O
!LF! !LF!
improvement O
in O
pcs O
score O
at O
24 O
- O
month O
follow O
- O
up O
was O
significantly O
higher O
for O
patients O
who O
were O
employed O
at O
baseline O
( O
p O
= O
. O
035 O
) O
. O
!LF! !LF!
at B-Premise
24 I-Premise
- I-Premise
month I-Premise
follow I-Premise
- I-Premise
up I-Premise
, I-Premise
patients I-Premise
in I-Premise
the I-Premise
hysterectomy I-Premise
group I-Premise
were I-Premise
significantly I-Premise
more I-Premise
satisfied I-Premise
than I-Premise
those I-Premise
in I-Premise
the I-Premise
uae I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
both B-Claim
uae I-Claim
and I-Claim
hysterectomy I-Claim
improved I-Claim
hrqol I-Claim
. I-Claim
!LF! !LF!
no B-Claim
differences I-Claim
were I-Claim
observed I-Claim
between I-Claim
groups I-Claim
regarding I-Claim
hrqol I-Claim
at I-Claim
24 I-Claim
- I-Claim
month I-Claim
follow I-Claim
- I-Claim
up I-Claim
. I-Claim
!LF! !LF!
on B-Claim
the I-Claim
basis I-Claim
of I-Claim
hrqol I-Claim
results I-Claim
, I-Claim
the I-Claim
authors I-Claim
determined I-Claim
that I-Claim
uae I-Claim
is I-Claim
a I-Claim
good I-Claim
alternative I-Claim
to I-Claim
hysterectomy I-Claim
. I-Claim
!LF! !LF!
there O
are O
no O
known O
effective O
treatments O
for O
painful O
chemotherapy O
- O
induced O
peripheral O
neuropathy O
. O
!LF! !LF!
to O
determine O
the O
effect O
of O
duloxetine O
, O
60 O
mg O
daily O
, O
on O
average O
pain O
severity O
. O
!LF! !LF!
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
crossover O
trial O
at O
8 O
national O
cancer O
institute O
( O
nci O
) O
- O
funded O
cooperative O
research O
networks O
that O
enrolled O
231 O
patients O
who O
were O
25 O
years O
or O
older O
being O
treated O
at O
community O
and O
academic O
settings O
between O
april O
2008 O
and O
march O
2011 O
. O
!LF! !LF!
study O
follow O
- O
up O
was O
completed O
july O
2012 O
. O
!LF! !LF!
stratified O
by O
chemotherapeutic O
drug O
and O
comorbid O
pain O
risk O
, O
patients O
were O
randomized O
to O
receive O
either O
duloxetine O
followed O
by O
placebo O
or O
placebo O
followed O
by O
duloxetine O
. O
!LF! !LF!
eligibility O
required O
that O
patients O
have O
grade O
1 O
or O
higher O
sensory O
neuropathy O
according O
to O
the O
nci O
common O
terminology O
criteria O
for O
adverse O
events O
and O
at O
least O
4 O
on O
a O
scale O
of O
0 O
to O
10 O
, O
representing O
average O
chemotherapy O
- O
induced O
pain O
, O
after O
paclitaxel O
, O
other O
taxane O
, O
or O
oxaliplatin O
treatment O
. O
!LF! !LF!
the O
initial O
treatment O
consisted O
of O
taking O
1 O
capsule O
daily O
of O
either O
30 O
mg O
of O
duloxetine O
or O
placebo O
for O
the O
first O
week O
and O
2 O
capsules O
of O
either O
30 O
mg O
of O
duloxetine O
or O
placebo O
daily O
for O
4 O
additional O
weeks O
. O
!LF! !LF!
the O
primary O
hypothesis O
was O
that O
duloxetine O
would O
be O
more O
effective O
than O
placebo O
in O
decreasing O
chemotherapy O
- O
induced O
peripheral O
neuropathic O
pain O
. O
!LF! !LF!
pain O
severity O
was O
assessed O
using O
the O
brief O
pain O
inventory O
- O
short O
form O
"""" O
average O
pain O
"""" O
item O
with O
0 O
representing O
no O
pain O
and O
10 O
representing O
as O
bad O
as O
can O
be O
imagined O
. O
!LF! !LF!
individuals B-Premise
receiving I-Premise
duloxetine I-Premise
as I-Premise
their I-Premise
initial I-Premise
5 I-Premise
- I-Premise
week I-Premise
treatment I-Premise
reported I-Premise
a I-Premise
mean I-Premise
decrease I-Premise
in I-Premise
average I-Premise
pain I-Premise
of I-Premise
1 I-Premise
. I-Premise
06 I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
72 I-Premise
- I-Premise
1 I-Premise
. I-Premise
40 I-Premise
) I-Premise
vs I-Premise
0 I-Premise
. I-Premise
34 I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
01 I-Premise
- I-Premise
0 I-Premise
. I-Premise
66 I-Premise
) I-Premise
among I-Premise
those I-Premise
who I-Premise
received I-Premise
placebo I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
003 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0 I-Premise
. I-Premise
513 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
observed I-Premise
mean I-Premise
difference I-Premise
in I-Premise
the I-Premise
average I-Premise
pain I-Premise
score I-Premise
between I-Premise
duloxetine I-Premise
and I-Premise
placebo I-Premise
was I-Premise
0 I-Premise
. I-Premise
73 I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
26 I-Premise
- I-Premise
1 I-Premise
. I-Premise
20 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
fifty B-Premise
- B-Premise
nine B-Premise
percent I-Premise
of I-Premise
those I-Premise
initially I-Premise
receiving I-Premise
duloxetine I-Premise
vs I-Premise
38 I-Premise
% I-Premise
of I-Premise
those I-Premise
initially I-Premise
receiving I-Premise
placebo I-Premise
reported I-Premise
decreased I-Premise
pain I-Premise
of I-Premise
any I-Premise
amount I-Premise
. I-Premise
!LF! !LF!
among B-Claim
patients I-Claim
with I-Claim
painful I-Claim
chemotherapy I-Claim
- I-Claim
induced I-Claim
peripheral I-Claim
neuropathy I-Claim
, I-Claim
the I-Claim
use I-Claim
of I-Claim
duloxetine I-Claim
compared I-Claim
with I-Claim
placebo I-Claim
for I-Claim
5 I-Claim
weeks I-Claim
resulted I-Claim
in I-Claim
a I-Claim
greater I-Claim
reduction I-Claim
in I-Claim
pain I-Claim
. I-Claim
!LF! !LF!
the O
majority O
of O
prostate O
carcinoma O
survivors O
experience O
enduring O
sexual O
difficulties O
and O
associated O
distress O
in O
the O
years O
after O
definitive O
treatment O
. O
!LF! !LF!
a O
counseling O
intervention O
aimed O
at O
improving O
levels O
of O
sexual O
satisfaction O
and O
increasing O
successful O
utilization O
of O
medical O
treatment O
for O
erectile O
dysfunction O
( O
ed O
) O
was O
developed O
and O
pilot O
- O
tested O
for O
both O
the O
survivor O
of O
prostate O
carcinoma O
and O
his O
partner O
. O
!LF! !LF!
all O
male O
participants O
were O
3 O
- O
month O
to O
5 O
- O
year O
survivors O
of O
localized O
prostate O
carcinoma O
who O
had O
been O
treated O
with O
radical O
prostatectomy O
or O
radiation O
therapy O
, O
and O
were O
married O
or O
in O
a O
committed O
relationship O
. O
!LF! !LF!
couples O
were O
randomized O
to O
attend O
four O
sessions O
of O
counseling O
together O
or O
to O
have O
the O
man O
attend O
alone O
. O
!LF! !LF!
in O
both O
groups O
, O
partners O
completed O
behavioral O
homework O
. O
!LF! !LF!
the O
sessions O
included O
education O
on O
prostate O
carcinoma O
and O
sexual O
function O
and O
options O
to O
treat O
ed O
as O
well O
as O
sexual O
communication O
and O
stimulation O
skills O
. O
!LF! !LF!
standardized O
questionnaires O
at O
baseline O
, O
posttreatment O
, O
and O
at O
3 O
- O
month O
and O
6 O
- O
month O
follow O
- O
up O
assessed O
sexual O
function O
, O
marital O
adjustment O
, O
psychologic O
distress O
, O
and O
utilization O
of O
treatments O
for O
ed O
. O
!LF! !LF!
fifty O
- O
one O
of O
84 O
couples O
randomized O
to O
treatment O
completed O
the O
intervention O
( O
61 O
% O
) O
. O
!LF! !LF!
attendance O
by O
the O
partner O
did O
not O
affect O
outcomes O
. O
!LF! !LF!
participants B-Premise
completing I-Premise
the I-Premise
intervention I-Premise
demonstrated I-Premise
improvement I-Premise
in I-Premise
male I-Premise
overall I-Premise
distress I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
, I-Premise
male I-Premise
global I-Premise
sexual I-Premise
function I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
0001 I-Premise
) I-Premise
, I-Premise
and I-Premise
female I-Premise
global I-Premise
sexual I-Premise
function I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
at I-Premise
3 I-Premise
- I-Premise
month I-Premise
follow I-Premise
- I-Premise
up I-Premise
, I-Premise
but B-Premise
regression I-Premise
toward I-Premise
baseline I-Premise
was I-Premise
noted I-Premise
at I-Premise
6 I-Premise
- I-Premise
month I-Premise
follow I-Premise
- I-Premise
up I-Premise
. I-Premise
!LF! !LF!
however B-Premise
, I-Premise
utilization I-Premise
of I-Premise
ed I-Premise
treatments I-Premise
increased I-Premise
from I-Premise
31 I-Premise
% I-Premise
at I-Premise
the I-Premise
time I-Premise
of I-Premise
study I-Premise
entry I-Premise
to I-Premise
49 I-Premise
% I-Premise
at I-Premise
the I-Premise
6 I-Premise
- I-Premise
month I-Premise
follow I-Premise
- I-Premise
up I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
003 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Claim
results I-Claim
of I-Claim
this I-Claim
brief I-Claim
pilot I-Claim
counseling I-Claim
intervention I-Claim
demonstrated I-Claim
significant I-Claim
gains I-Claim
in I-Claim
sexual I-Claim
function I-Claim
and I-Claim
satisfaction I-Claim
and I-Claim
increased I-Claim
utilization I-Claim
of I-Claim
treatments I-Claim
for I-Claim
ed I-Claim
. I-Claim
!LF! !LF!
however B-Claim
, I-Claim
modifications I-Claim
are I-Claim
needed I-Claim
in I-Claim
future I-Claim
randomized I-Claim
trials I-Claim
to I-Claim
reduce I-Claim
the I-Claim
rate I-Claim
of I-Claim
premature I-Claim
termination I-Claim
and I-Claim
to I-Claim
improve I-Claim
long I-Claim
- I-Claim
term I-Claim
maintenance I-Claim
of I-Claim
gains I-Claim
. I-Claim
!LF! !LF!
the O
aim O
of O
this O
prospective O
controlled O
study O
was O
to O
assess O
the O
efficacy O
of O
two O
different O
combination O
treatment O
modalities O
of O
lymphedema O
( O
le O
) O
. O
!LF! !LF!
manual O
lymphatic O
drainage O
( O
mld O
) O
and O
compression O
bandage O
combination O
( O
complex O
decongestive O
therapy O
) O
have O
been O
compared O
with O
intermittent O
pneumatic O
compression O
( O
ipc O
) O
plus O
self O
- O
lymphatic O
drainage O
( O
sld O
) O
. O
!LF! !LF!
both O
mld O
with O
compression O
bandage O
( O
complex O
decongestive O
therapy O
) O
group O
( O
group O
i O
, O
n O
= O
15 O
) O
and O
ipc O
with O
sld O
group O
( O
group O
ii O
, O
n O
= O
15 O
) O
received O
treatment O
for O
le O
3 O
days O
in O
a O
week O
and O
every O
other O
day O
for O
6 O
weeks O
. O
!LF! !LF!
arm O
circumferences O
were O
measured O
before O
and O
the O
1st O
, O
3rd O
, O
and O
6th O
weeks O
of O
the O
treatment O
. O
!LF! !LF!
eortc O
- O
qlq O
and O
ases O
- O
tests O
were O
performed O
to O
assess O
the O
quality O
of O
life O
before O
and O
after O
6 O
week O
- O
treatment O
. O
!LF! !LF!
patients O
in O
both O
groups O
had O
similar O
demographic O
and O
clinical O
characteristics O
. O
!LF! !LF!
even O
though O
both B-Premise
treatment I-Premise
modalities I-Premise
resulted I-Premise
in I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
the I-Premise
total I-Premise
arm I-Premise
volume I-Premise
( I-Premise
12 I-Premise
. I-Premise
2 I-Premise
% I-Premise
decrease I-Premise
in I-Premise
group I-Premise
ii I-Premise
and I-Premise
14 I-Premise
. I-Premise
9 I-Premise
% I-Premise
decrease I-Premise
in I-Premise
group I-Premise
i I-Premise
) I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
no B-Premise
significant I-Premise
difference I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
582 I-Premise
) I-Premise
was I-Premise
found I-Premise
between I-Premise
those I-Premise
two I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
similarly B-Premise
, I-Premise
ases I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
improved I-Premise
in I-Premise
both I-Premise
group I-Premise
i I-Premise
and I-Premise
ii I-Premise
without I-Premise
any I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
while B-Premise
emotional I-Premise
functioning I-Premise
, I-Premise
fatigue I-Premise
, I-Premise
and I-Premise
pain I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
improved I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
global I-Premise
health I-Premise
status I-Premise
, I-Premise
functional I-Premise
and I-Premise
cognitive I-Premise
functioning I-Premise
scores I-Premise
appeared I-Premise
to I-Premise
be I-Premise
improved I-Premise
only I-Premise
in I-Premise
patients I-Premise
of I-Premise
group I-Premise
i I-Premise
. I-Premise
!LF! !LF!
different B-Claim
treatment I-Claim
modalities I-Claim
consisting I-Claim
of I-Claim
mld I-Claim
and I-Claim
compression I-Claim
bandage I-Claim
( I-Claim
complex I-Claim
decongestive I-Claim
therapy I-Claim
) I-Claim
or I-Claim
ipc I-Claim
and I-Claim
sld I-Claim
appear I-Claim
to I-Claim
be I-Claim
effective I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
le I-Claim
with I-Claim
similar I-Claim
therapeutic I-Claim
efficacy I-Claim
in I-Claim
patients I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
however B-Claim
, I-Claim
combination I-Claim
modalities I-Claim
including I-Claim
ipc I-Claim
and I-Claim
sld I-Claim
may I-Claim
be I-Claim
the I-Claim
preferred I-Claim
choices I-Claim
for I-Claim
their I-Claim
applicability I-Claim
at I-Claim
home I-Claim
. I-Claim
!LF! !LF!
this O
randomized O
, O
multicenter O
, O
phase O
iii O
study O
compared O
doxorubicin O
and O
docetaxel O
( O
at O
) O
with O
doxorubicin O
and O
cyclophosphamide O
( O
ac O
) O
as O
first O
- O
line O
chemotherapy O
( O
ct O
) O
in O
metastatic O
breast O
cancer O
( O
mbc O
) O
. O
!LF! !LF!
patients O
( O
n O
= O
429 O
) O
were O
randomly O
assigned O
to O
receive O
doxorubicin O
50 O
mg O
/ O
m O
( O
2 O
) O
plus O
docetaxel O
75 O
mg O
/ O
m O
( O
2 O
) O
( O
n O
= O
214 O
) O
or O
doxorubicin O
60 O
mg O
/ O
m O
( O
2 O
) O
plus O
cyclophosphamide O
600 O
mg O
/ O
m O
( O
2 O
) O
( O
n O
= O
215 O
) O
on O
day O
1 O
, O
every O
3 O
weeks O
for O
up O
to O
eight O
cycles O
. O
!LF! !LF!
time B-Premise
to I-Premise
progression I-Premise
( I-Premise
ttp I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
primary I-Premise
end I-Premise
point I-Premise
) I-Premise
and I-Premise
time I-Premise
to I-Premise
treatment I-Premise
failure I-Premise
( I-Premise
ttf I-Premise
) I-Premise
were I-Premise
significantly I-Premise
longer I-Premise
with I-Premise
at I-Premise
than I-Premise
ac I-Premise
( I-Premise
median I-Premise
ttp I-Premise
, I-Premise
37 I-Premise
. I-Premise
3 I-Premise
v I-Premise
31 I-Premise
. I-Premise
9 I-Premise
weeks I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
log I-Premise
- I-Premise
rank I-Premise
p I-Premise
= I-Premise
. I-Premise
014 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
median I-Premise
ttf I-Premise
, I-Premise
25 I-Premise
. I-Premise
6 I-Premise
v I-Premise
23 I-Premise
. I-Premise
7 I-Premise
weeks I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
log I-Premise
- I-Premise
rank I-Premise
p I-Premise
= I-Premise
. I-Premise
048 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
overall I-Premise
response I-Premise
rate I-Premise
( I-Premise
orr I-Premise
) I-Premise
was I-Premise
significantly I-Premise
greater I-Premise
for I-Premise
patients I-Premise
taking I-Premise
at I-Premise
( I-Premise
59 I-Premise
% I-Premise
, I-Premise
with I-Premise
10 I-Premise
% I-Premise
complete I-Premise
response I-Premise
[ I-Premise
cr I-Premise
] I-Premise
, I-Premise
49 I-Premise
% I-Premise
partial I-Premise
response I-Premise
[ I-Premise
pr I-Premise
] I-Premise
) I-Premise
than I-Premise
for I-Premise
those I-Premise
taking I-Premise
ac I-Premise
( I-Premise
47 I-Premise
% I-Premise
, I-Premise
with I-Premise
7 I-Premise
% I-Premise
cr I-Premise
, I-Premise
39 I-Premise
% I-Premise
pr I-Premise
) I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
009 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
orr I-Premise
was I-Premise
also I-Premise
higher I-Premise
with I-Premise
at I-Premise
in I-Premise
patients I-Premise
with I-Premise
visceral I-Premise
involvement I-Premise
( I-Premise
58 I-Premise
% I-Premise
v I-Premise
41 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
liver I-Premise
, I-Premise
62 I-Premise
% I-Premise
v I-Premise
42 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
lung I-Premise
, I-Premise
58 I-Premise
% I-Premise
v I-Premise
35 I-Premise
% I-Premise
) I-Premise
, I-Premise
three I-Premise
or I-Premise
more I-Premise
organs I-Premise
involved I-Premise
( I-Premise
59 I-Premise
% I-Premise
v I-Premise
40 I-Premise
% I-Premise
) I-Premise
, I-Premise
or I-Premise
prior I-Premise
adjuvant I-Premise
ct I-Premise
( I-Premise
53 I-Premise
% I-Premise
v I-Premise
41 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
overall B-Premise
survival I-Premise
( I-Premise
os I-Premise
) I-Premise
was I-Premise
comparable I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
grade B-Premise
3 I-Premise
/ I-Premise
4 I-Premise
neutropenia I-Premise
was I-Premise
frequent I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
although B-Premise
febrile I-Premise
neutropenia I-Premise
and I-Premise
infections I-Premise
were I-Premise
more I-Premise
frequent I-Premise
for I-Premise
patients I-Premise
taking I-Premise
at I-Premise
( I-Premise
respectively I-Premise
, I-Premise
33 I-Premise
% I-Premise
v I-Premise
10 I-Premise
% I-Premise
, I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
8 I-Premise
% I-Premise
v I-Premise
2 I-Premise
% I-Premise
, I-Premise
p I-Premise
= I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
severe B-Premise
nonhematologic I-Premise
toxicity I-Premise
was I-Premise
infrequent I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
including I-Premise
grade I-Premise
3 I-Premise
/ I-Premise
4 I-Premise
cardiac I-Premise
events I-Premise
( I-Premise
at I-Premise
, I-Premise
3 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
ac I-Premise
, I-Premise
4 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
at B-Claim
significantly I-Claim
improves I-Claim
ttp I-Claim
and I-Claim
orr I-Claim
compared I-Claim
with I-Claim
ac I-Claim
in I-Claim
patients I-Claim
with I-Claim
mbc I-Claim
, I-Claim
but B-Claim
there I-Claim
is I-Claim
no I-Claim
difference I-Claim
in I-Claim
os I-Claim
. I-Claim
!LF! !LF!
at B-Claim
represents I-Claim
a I-Claim
valid I-Claim
option I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
mbc I-Claim
. I-Claim
!LF! !LF!
few O
intervention O
studies O
have O
been O
conducted O
to O
help O
couples O
manage O
the O
effects O
of O
prostate O
cancer O
and O
maintain O
their O
quality O
of O
life O
. O
!LF! !LF!
the O
objective O
of O
this O
study O
was O
to O
determine O
whether O
a O
family O
- O
based O
intervention O
could O
improve O
appraisal O
variables O
( O
appraisal O
of O
illness O
or O
caregiving O
, O
uncertainty O
, O
hopelessness O
) O
, O
coping O
resources O
( O
coping O
strategies O
, O
self O
- O
efficacy O
, O
communication O
) O
, O
symptom O
distress O
, O
and O
quality O
of O
life O
in O
men O
with O
prostate O
cancer O
and O
their O
spouses O
. O
!LF! !LF!
for O
this O
clinical O
trial O
, O
263 O
patient O
- O
spouse O
dyads O
were O
stratified O
by O
research O
site O
, O
phase O
of O
illness O
, O
and O
treatment O
"""" O
; O
"""" O
then O
, O
they O
were O
randomized O
to O
the O
control O
group O
( O
standard O
care O
) O
or O
the O
experimental O
group O
( O
standard O
care O
plus O
a O
5 O
- O
session O
family O
intervention O
) O
. O
!LF! !LF!
the O
intervention O
targeted O
couples O
' O
communication O
, O
hope O
, O
coping O
, O
uncertainty O
, O
and O
symptom O
management O
. O
!LF! !LF!
the O
final O
sample O
consisted O
of O
235 O
couples O
: O
123 O
couples O
in O
the O
control O
group O
and O
112 O
couples O
in O
the O
experimental O
group O
. O
!LF! !LF!
data O
collection O
occurred O
at O
baseline O
before O
randomization O
and O
at O
4 O
months O
, O
8 O
months O
, O
and O
12 O
months O
. O
!LF! !LF!
at B-Premise
4 I-Premise
- I-Premise
month I-Premise
follow I-Premise
- I-Premise
up I-Premise
, I-Premise
intervention I-Premise
patients I-Premise
reported I-Premise
less I-Premise
uncertainty I-Premise
and I-Premise
better I-Premise
communication I-Premise
with I-Premise
spouses I-Premise
than I-Premise
control I-Premise
patients I-Premise
, I-Premise
but B-Premise
they I-Premise
reported I-Premise
no I-Premise
other I-Premise
effects I-Premise
. I-Premise
!LF! !LF!
intervention B-Premise
spouses I-Premise
reported I-Premise
higher I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
more I-Premise
self I-Premise
- I-Premise
efficacy I-Premise
, I-Premise
better I-Premise
communication I-Premise
, I-Premise
and I-Premise
less I-Premise
negative I-Premise
appraisal I-Premise
of I-Premise
caregiving I-Premise
, I-Premise
uncertainty I-Premise
, I-Premise
hopelessness I-Premise
, I-Premise
and I-Premise
symptom I-Premise
distress I-Premise
at I-Premise
4 I-Premise
months I-Premise
compared I-Premise
with I-Premise
controls I-Premise
, I-Premise
and I-Premise
some I-Premise
effects I-Premise
were I-Premise
sustained I-Premise
to I-Premise
8 I-Premise
months I-Premise
and I-Premise
12 I-Premise
months I-Premise
. I-Premise
!LF! !LF!
men B-Premise
with I-Premise
prostate I-Premise
cancer I-Premise
and I-Premise
their I-Premise
spouses I-Premise
reported I-Premise
positive I-Premise
outcomes I-Premise
from I-Premise
a I-Premise
family I-Premise
intervention I-Premise
that I-Premise
offered I-Premise
them I-Premise
information I-Premise
and I-Premise
support I-Premise
. I-Premise
!LF! !LF!
programs B-Claim
of I-Claim
care I-Claim
need I-Claim
to I-Claim
be I-Claim
extended I-Claim
to I-Claim
spouses I-Claim
who I-Claim
likely I-Claim
will I-Claim
experience I-Claim
multiple I-Claim
benefits I-Claim
from I-Claim
intervention I-Claim
. I-Claim
!LF! !LF!
exercise O
training O
improves O
supportive O
care O
outcomes O
in O
patients O
with O
breast O
cancer O
who O
are O
receiving O
adjuvant O
therapy O
, O
but O
the O
responses O
are O
heterogeneous O
. O
!LF! !LF!
in O
this O
study O
, O
the O
authors O
examined O
personal O
and O
clinical O
factors O
that O
may O
predict O
exercise O
training O
responses O
. O
!LF! !LF!
breast O
cancer O
patients O
who O
were O
initiating O
adjuvant O
chemotherapy O
( O
n O
= O
242 O
) O
were O
assigned O
randomly O
to O
receive O
usual O
care O
( O
uc O
) O
( O
n O
= O
82 O
) O
, O
resistance O
exercise O
training O
( O
ret O
) O
( O
n O
= O
82 O
) O
, O
or O
aerobic O
exercise O
training O
( O
aet O
) O
( O
n O
= O
78 O
) O
for O
the O
duration O
of O
chemotherapy O
. O
!LF! !LF!
endpoints O
were O
quality O
of O
life O
( O
qol O
) O
, O
aerobic O
fitness O
, O
muscular O
strength O
, O
lean O
body O
mass O
, O
and O
body O
fat O
. O
!LF! !LF!
moderators O
were O
patient O
preference O
for O
group O
assignment O
, O
marital O
status O
, O
age O
, O
disease O
stage O
, O
and O
chemotherapy O
regimen O
. O
!LF! !LF!
adjusted O
linear O
mixed O
- O
model O
analyses O
demonstrated O
that O
patient O
preference O
moderated O
qol O
response O
( O
p O
= O
. O
005 O
) O
. O
!LF! !LF!
patients B-Premise
who I-Premise
preferred I-Premise
ret I-Premise
improved I-Premise
qol I-Premise
when I-Premise
they I-Premise
were I-Premise
assigned I-Premise
to I-Premise
receive I-Premise
ret I-Premise
compared I-Premise
with I-Premise
uc I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
16 I-Premise
. I-Premise
5 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
95 I-Premise
% I-Premise
ci I-Premise
] I-Premise
, I-Premise
4 I-Premise
. I-Premise
3 I-Premise
- I-Premise
28 I-Premise
. I-Premise
7 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
008 I-Premise
) I-Premise
or I-Premise
aet I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
11 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
- I-Premise
1 I-Premise
. I-Premise
1 I-Premise
- I-Premise
23 I-Premise
. I-Premise
4 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
076 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
who I-Premise
had I-Premise
no I-Premise
preference I-Premise
had I-Premise
improved I-Premise
qol I-Premise
when I-Premise
they I-Premise
were I-Premise
assigned I-Premise
to I-Premise
receive I-Premise
aet I-Premise
compared I-Premise
with I-Premise
ret I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
23 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
4 I-Premise
. I-Premise
9 I-Premise
- I-Premise
41 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
014 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
marital B-Premise
status I-Premise
also I-Premise
moderated I-Premise
qol I-Premise
response I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
026 I-Premise
) I-Premise
, I-Premise
age I-Premise
moderated I-Premise
aerobic I-Premise
fitness I-Premise
response I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
029 I-Premise
) I-Premise
, I-Premise
chemotherapy I-Premise
regimen I-Premise
moderated I-Premise
strength I-Premise
gain I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
009 I-Premise
) I-Premise
, I-Premise
and I-Premise
disease I-Premise
stage I-Premise
moderated I-Premise
both I-Premise
lean I-Premise
body I-Premise
mass I-Premise
gain I-Premise
( I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
and I-Premise
fat I-Premise
loss I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
059 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
unmarried B-Premise
, I-Premise
younger I-Premise
patients I-Premise
who I-Premise
were I-Premise
receiving I-Premise
nontaxane I-Premise
- I-Premise
based I-Premise
therapies I-Premise
and I-Premise
had I-Premise
more I-Premise
advanced I-Premise
disease I-Premise
stage I-Premise
experienced I-Premise
better I-Premise
outcomes I-Premise
. I-Premise
!LF! !LF!
the O
findings O
were O
not O
explained O
by O
differences O
in O
adherence O
. O
!LF! !LF!
patient B-Claim
preference I-Claim
, I-Claim
demographic I-Claim
variables I-Claim
, I-Claim
and I-Claim
medical I-Claim
variables I-Claim
moderated I-Claim
the I-Claim
effects I-Claim
of I-Claim
exercise I-Claim
training I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
who I-Claim
were I-Claim
receiving I-Claim
chemotherapy I-Claim
. I-Claim
!LF! !LF!
if O
replicated O
, O
these O
results O
may O
inform O
clinical O
practice O
. O
!LF! !LF!
to O
compare O
short O
- O
and O
long O
- O
term O
effects O
of O
adjuvant O
treatment O
versus O
observation O
after O
surgery O
on O
health O
- O
related O
quality O
of O
life O
( O
hrql O
) O
of O
prostate O
cancer O
patients O
. O
!LF! !LF!
the O
southwest O
oncology O
group O
( O
swog O
) O
intergroup O
trial O
compared O
radical O
prostatectomy O
( O
rp O
) O
plus O
observation O
versus O
rp O
plus O
adjuvant O
radiation O
therapy O
( O
rt O
) O
. O
!LF! !LF!
two O
- O
hundred O
seventeen O
of O
425 O
therapeutic O
trial O
patients O
were O
eligible O
and O
registered O
to O
the O
hrql O
study O
. O
!LF! !LF!
patients O
completed O
the O
swog O
quality O
of O
life O
questionnaire O
( O
emotional O
, O
physical O
, O
social O
, O
and O
role O
function O
"""" O
; O
"""" O
general O
symptom O
status O
"""" O
; O
"""" O
treatment O
/ O
disease O
- O
specific O
symptoms O
"""" O
; O
"""" O
and O
global O
hrql O
[ O
ghrql O
] O
) O
at O
baseline O
, O
6 O
weeks O
, O
6 O
months O
, O
and O
annually O
for O
5 O
years O
. O
!LF! !LF!
prespecified O
outcomes O
were O
three O
genitourinary O
symptoms O
( O
bowel O
function O
tenderness O
, O
frequent O
urination O
, O
and O
erectile O
dysfunction O
[ O
ed O
] O
) O
and O
measures O
of O
physical O
and O
emotional O
function O
. O
!LF! !LF!
adjustments O
were O
made O
for O
the O
baseline O
score O
. O
!LF! !LF!
patients O
receiving O
adjuvant O
rt O
reported O
worse O
bowel O
function O
( O
through O
approximately O
2 O
years O
) O
and O
worse O
urinary O
function O
. O
!LF! !LF!
there O
were O
no O
statistically O
significant O
differences O
for O
ed O
. O
!LF! !LF!
ghrql B-Premise
was I-Premise
initially I-Premise
worse I-Premise
for I-Premise
the I-Premise
rp I-Premise
+ I-Premise
rt I-Premise
arm I-Premise
but I-Premise
improved I-Premise
over I-Premise
time I-Premise
and I-Premise
was I-Premise
better I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
period I-Premise
than I-Premise
the I-Premise
ghrql I-Premise
reported I-Premise
for I-Premise
rp I-Premise
alone I-Premise
( I-Premise
treatment I-Premise
arm I-Premise
x I-Premise
time I-Premise
interaction I-Premise
, I-Premise
p I-Premise
= I-Premise
. I-Premise
0004 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
symptom B-Premise
distress I-Premise
was I-Premise
significantly I-Premise
worse I-Premise
for I-Premise
the I-Premise
rp I-Premise
+ I-Premise
rt I-Premise
arm I-Premise
compared I-Premise
with I-Premise
the I-Premise
rp I-Premise
alone I-Premise
arm I-Premise
, O
but B-Premise
the I-Premise
treatment I-Premise
arms I-Premise
did I-Premise
not I-Premise
differ I-Premise
with I-Premise
respect I-Premise
to I-Premise
other I-Premise
general I-Premise
measures I-Premise
of I-Premise
hrql I-Premise
. I-Premise
!LF! !LF!
the B-Premise
addition I-Premise
of I-Premise
rt I-Premise
to I-Premise
surgery I-Premise
resulted I-Premise
in I-Premise
more I-Premise
frequent I-Premise
urination I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
early I-Premise
report I-Premise
of I-Premise
more I-Premise
bowel I-Premise
dysfunction I-Premise
, O
although B-Premise
bowel I-Premise
function I-Premise
differences I-Premise
disappeared I-Premise
over I-Premise
the I-Premise
5 I-Premise
- I-Premise
year I-Premise
period I-Premise
. I-Premise
!LF! !LF!
the B-Claim
addition I-Claim
of I-Claim
rt I-Claim
did I-Claim
not I-Claim
negatively I-Claim
impact I-Claim
ed I-Claim
. I-Claim
!LF! !LF!
evidence B-Claim
suggests I-Claim
that I-Claim
the I-Claim
re I-Claim
- I-Claim
entry I-Claim
phase I-Claim
( I-Claim
ie I-Claim
, I-Claim
early I-Claim
period I-Claim
after I-Claim
medical I-Claim
treatment I-Claim
completion I-Claim
) I-Claim
presents I-Claim
distinct I-Claim
challenges I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
to O
facilitate O
the O
transition O
to O
recovery O
, O
we O
conducted O
the O
moving O
beyond O
cancer O
( O
mbc O
) O
trial O
, O
a O
multisite O
, O
randomized O
, O
controlled O
trial O
of O
psychoeducational O
interventions O
for O
breast O
cancer O
patients O
. O
!LF! !LF!
breast O
cancer O
patients O
were O
registered O
within O
6 O
weeks O
after O
surgery O
. O
!LF! !LF!
after O
medical O
treatment O
, O
they O
completed O
baseline O
measures O
and O
were O
randomly O
assigned O
to O
standard O
national O
cancer O
institute O
print O
material O
( O
ctl O
) O
"""" O
; O
"""" O
standard O
print O
material O
and O
peer O
- O
modeling O
videotape O
( O
vid O
) O
"""" O
; O
"""" O
or O
standard O
print O
material O
, O
videotape O
, O
two O
sessions O
with O
a O
trained O
cancer O
educator O
, O
and O
informational O
workbook O
( O
edu O
) O
. O
!LF! !LF!
two O
primary O
end O
points O
were O
examined O
: O
energy O
/ O
fatigue O
and O
cancer O
- O
specific O
distress O
. O
!LF! !LF!
secondary O
end O
points O
were O
depressive O
symptoms O
and O
post O
- O
traumatic O
growth O
. O
!LF! !LF!
perceived O
preparedness O
for O
re O
- O
entry O
was O
analyzed O
as O
a O
moderator O
of O
effects O
. O
!LF! !LF!
of O
558 O
women O
randomly O
assigned O
to O
treatment O
, O
418 O
completed O
the O
6 O
- O
month O
assessment O
and O
399 O
completed O
the O
12 O
- O
month O
assessment O
. O
!LF! !LF!
in B-Premise
analyses I-Premise
controlling I-Premise
for I-Premise
study I-Premise
site I-Premise
and I-Premise
baseline I-Premise
depressive I-Premise
symptoms I-Premise
, I-Premise
vid I-Premise
produced I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
energy I-Premise
/ I-Premise
fatigue I-Premise
at I-Premise
6 I-Premise
months I-Premise
relative I-Premise
to I-Premise
ctl I-Premise
, I-Premise
particularly I-Premise
among I-Premise
women I-Premise
who I-Premise
felt I-Premise
less I-Premise
prepared I-Premise
for I-Premise
re I-Premise
- I-Premise
entry I-Premise
at I-Premise
baseline I-Premise
. I-Premise
!LF! !LF!
no B-Premise
significant I-Premise
main I-Premise
effect I-Premise
of I-Premise
the I-Premise
interventions I-Premise
emerged I-Premise
on I-Premise
cancer I-Premise
- I-Premise
specific I-Premise
distress I-Premise
, I-Premise
but B-Premise
edu I-Premise
prompted I-Premise
greater I-Premise
reduction I-Premise
in I-Premise
this I-Premise
outcome I-Premise
relative I-Premise
to I-Premise
ctl I-Premise
at I-Premise
6 I-Premise
months I-Premise
for I-Premise
patients I-Premise
who I-Premise
felt I-Premise
more I-Premise
prepared I-Premise
for I-Premise
re I-Premise
- I-Premise
entry I-Premise
. I-Premise
!LF! !LF!
between B-Premise
- B-Premise
group B-Premise
differences I-Premise
in I-Premise
the I-Premise
primary I-Premise
outcomes I-Premise
were I-Premise
not I-Premise
significant I-Premise
at I-Premise
12 I-Premise
months I-Premise
, I-Premise
and B-Premise
no I-Premise
significant I-Premise
effects I-Premise
emerged I-Premise
on I-Premise
the I-Premise
secondary I-Premise
end I-Premise
points I-Premise
. I-Premise
!LF! !LF!
a B-Claim
peer I-Claim
- I-Claim
modeling I-Claim
videotape I-Claim
can I-Claim
accelerate I-Claim
the I-Claim
recovery I-Claim
of I-Claim
energy I-Claim
during I-Claim
the I-Claim
re I-Claim
- I-Claim
entry I-Claim
phase I-Claim
in I-Claim
women I-Claim
treated I-Claim
for I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
particularly I-Claim
among I-Claim
those I-Claim
who I-Claim
feel I-Claim
less I-Claim
prepared I-Claim
for I-Claim
re I-Claim
- I-Claim
entry I-Claim
. I-Claim
!LF! !LF!
sentinel B-Claim
lymph I-Claim
node I-Claim
biopsy I-Claim
in I-Claim
women I-Claim
with I-Claim
operable I-Claim
breast I-Claim
cancer I-Claim
is I-Claim
routinely I-Claim
used I-Claim
in I-Claim
some I-Claim
countries I-Claim
for I-Claim
staging I-Claim
the I-Claim
axilla I-Claim
despite I-Claim
limited I-Claim
data I-Claim
from I-Claim
randomized I-Claim
trials I-Claim
on I-Claim
morbidity I-Claim
and I-Claim
mortality I-Claim
outcomes I-Claim
. I-Claim
!LF! !LF!
we O
conducted O
a O
multicenter O
randomized O
trial O
to O
compare O
quality O
- O
of O
- O
life O
outcomes O
between O
patients O
with O
clinically O
node O
- O
negative O
invasive O
breast O
cancer O
who O
received O
sentinel O
lymph O
node O
biopsy O
and O
patients O
who O
received O
standard O
axillary O
treatment O
. O
!LF! !LF!
the O
primary O
outcome O
measures O
were O
arm O
and O
shoulder O
morbidity O
and O
quality O
of O
life O
. O
!LF! !LF!
from O
november O
1999 O
to O
october O
2003 O
, O
1031 O
patients O
were O
randomly O
assigned O
to O
undergo O
sentinel O
lymph O
node O
biopsy O
( O
n O
= O
515 O
) O
or O
standard O
axillary O
surgery O
( O
n O
= O
516 O
) O
. O
!LF! !LF!
patients O
with O
sentinel O
lymph O
node O
metastases O
proceeded O
to O
delayed O
axillary O
clearance O
or O
received O
axillary O
radiotherapy O
( O
depending O
on O
the O
protocol O
at O
the O
treating O
institution O
) O
. O
!LF! !LF!
intention O
- O
to O
- O
treat O
analyses O
of O
data O
at O
1 O
, O
3 O
, O
6 O
, O
and O
12 O
months O
after O
surgery O
are O
presented O
. O
!LF! !LF!
all O
statistical O
tests O
were O
two O
- O
sided O
. O
!LF! !LF!
the B-Premise
relative I-Premise
risks I-Premise
of I-Premise
any I-Premise
lymphedema I-Premise
and I-Premise
sensory I-Premise
loss I-Premise
for I-Premise
the I-Premise
sentinel I-Premise
lymph I-Premise
node I-Premise
biopsy I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
standard I-Premise
axillary I-Premise
treatment I-Premise
group I-Premise
at I-Premise
12 I-Premise
months I-Premise
were I-Premise
0 I-Premise
. I-Premise
37 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
ci I-Premise
] I-Premise
= I-Premise
0 I-Premise
. I-Premise
23 I-Premise
to I-Premise
0 I-Premise
. I-Premise
60 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
absolute I-Premise
rates I-Premise
: I-Premise
5 I-Premise
% I-Premise
versus I-Premise
13 I-Premise
% I-Premise
) I-Premise
and I-Premise
0 I-Premise
. I-Premise
37 I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
= I-Premise
0 I-Premise
. I-Premise
27 I-Premise
to I-Premise
0 I-Premise
. I-Premise
50 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
absolute I-Premise
rates I-Premise
: I-Premise
11 I-Premise
% I-Premise
versus I-Premise
31 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
drain B-Premise
usage I-Premise
, I-Premise
length I-Premise
of I-Premise
hospital I-Premise
stay I-Premise
, I-Premise
and I-Premise
time I-Premise
to I-Premise
resumption I-Premise
of I-Premise
normal I-Premise
day I-Premise
- I-Premise
to I-Premise
- I-Premise
day I-Premise
activities I-Premise
after I-Premise
surgery I-Premise
were I-Premise
statistically I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
the I-Premise
sentinel I-Premise
lymph I-Premise
node I-Premise
biopsy I-Premise
group I-Premise
( I-Premise
all I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
and I-Premise
axillary I-Premise
operative I-Premise
time I-Premise
was I-Premise
reduced I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
055 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
overall B-Premise
patient I-Premise
- I-Premise
recorded I-Premise
quality I-Premise
of I-Premise
life I-Premise
and I-Premise
arm I-Premise
functioning I-Premise
scores I-Premise
were I-Premise
statistically I-Premise
significantly I-Premise
better I-Premise
in I-Premise
the I-Premise
sentinel I-Premise
lymph I-Premise
node I-Premise
biopsy I-Premise
group I-Premise
throughout I-Premise
( I-Premise
all I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
. I-Premise
003 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
these B-Premise
benefits I-Premise
were I-Premise
seen I-Premise
with I-Premise
no I-Premise
increase I-Premise
in I-Premise
anxiety I-Premise
levels I-Premise
in I-Premise
the I-Premise
sentinel I-Premise
lymph I-Premise
node I-Premise
biopsy I-Premise
group I-Premise
( I-Premise
p I-Premise
> I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
sentinel B-Claim
lymph I-Claim
node I-Claim
biopsy I-Claim
is I-Claim
associated I-Claim
with I-Claim
reduced I-Claim
arm I-Claim
morbidity I-Claim
and I-Claim
better I-Claim
quality I-Claim
of I-Claim
life I-Claim
than I-Claim
standard I-Claim
axillary I-Claim
treatment I-Claim
and I-Claim
should I-Claim
be I-Claim
the I-Claim
treatment I-Claim
of I-Claim
choice I-Claim
for I-Claim
patients I-Claim
who I-Claim
have I-Claim
early I-Claim
- I-Claim
stage I-Claim
breast I-Claim
cancer I-Claim
with I-Claim
clinically I-Claim
negative I-Claim
nodes I-Claim
. I-Claim
!LF! !LF!
to O
determine O
the O
immediate O
and O
long O
- O
term O
effects O
of O
true O
acupuncture O
versus O
sham O
acupuncture O
on O
hot O
flash O
frequency O
in O
women O
with O
breast O
cancer O
. O
!LF! !LF!
seventy O
- O
two O
women O
with O
breast O
cancer O
experiencing O
three O
or O
more O
hot O
flashes O
per O
day O
were O
randomly O
assigned O
to O
receive O
either O
true O
or O
sham O
acupuncture O
. O
!LF! !LF!
interventions O
were O
given O
twice O
weekly O
for O
4 O
consecutive O
weeks O
. O
!LF! !LF!
hot O
flash O
frequency O
was O
evaluated O
at O
baseline O
, O
at O
6 O
weeks O
, O
and O
at O
6 O
months O
after O
initiation O
of O
treatment O
. O
!LF! !LF!
patients O
initially O
randomly O
assigned O
to O
the O
sham O
group O
were O
crossed O
over O
to O
true O
acupuncture O
starting O
at O
week O
7 O
. O
!LF! !LF!
the O
mean O
number O
of O
hot O
flashes O
per O
day O
was O
reduced O
from O
8 O
. O
7 O
( O
standard O
deviation O
[ O
sd O
] O
, O
3 O
. O
9 O
) O
to O
6 O
. O
2 O
( O
sd O
, O
4 O
. O
2 O
) O
in O
the O
true O
acupuncture O
group O
and O
from O
10 O
. O
0 O
( O
sd O
, O
6 O
. O
1 O
) O
to O
7 O
. O
6 O
( O
sd O
, O
5 O
. O
7 O
) O
in O
the O
sham O
group O
. O
!LF! !LF!
true B-Premise
acupuncture I-Premise
was I-Premise
associated I-Premise
with I-Premise
0 I-Premise
. I-Premise
8 I-Premise
fewer I-Premise
hot I-Premise
flashes I-Premise
per I-Premise
day I-Premise
than I-Premise
sham I-Premise
at I-Premise
6 I-Premise
weeks I-Premise
, O
but B-Premise
the I-Premise
difference I-Premise
did I-Premise
not I-Premise
reach I-Premise
statistical I-Premise
significance I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
- I-Premise
0 I-Premise
. I-Premise
7 I-Premise
to I-Premise
2 I-Premise
. I-Premise
4 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
3 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
when B-Premise
participants I-Premise
in I-Premise
the I-Premise
sham I-Premise
acupuncture I-Premise
group I-Premise
were I-Premise
crossed I-Premise
over I-Premise
to I-Premise
true I-Premise
acupuncture I-Premise
, I-Premise
a I-Premise
further I-Premise
reduction I-Premise
in I-Premise
the I-Premise
frequency I-Premise
of I-Premise
hot I-Premise
flashes I-Premise
was I-Premise
seen I-Premise
. I-Premise
!LF! !LF!
this O
reduction O
in O
hot O
flash O
frequency O
persisted O
for O
up O
to O
6 O
months O
after O
the O
completion O
of O
treatment O
. O
!LF! !LF!
hot B-Claim
flash I-Claim
frequency I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
was I-Claim
reduced I-Claim
following I-Claim
acupuncture I-Claim
. I-Claim
!LF! !LF!
however O
, O
when B-Premise
compared I-Premise
with I-Premise
sham I-Premise
acupuncture I-Premise
, I-Premise
the I-Premise
reduction I-Premise
by I-Premise
the I-Premise
acupuncture I-Premise
regimen I-Premise
as I-Premise
provided I-Premise
in I-Premise
the I-Premise
current I-Premise
study I-Premise
did I-Premise
not I-Premise
reach I-Premise
statistical I-Premise
significance I-Premise
. I-Premise
!LF! !LF!
we B-Claim
can I-Claim
not I-Claim
exclude I-Claim
the I-Claim
possibility I-Claim
that I-Claim
a I-Claim
longer I-Claim
and I-Claim
more I-Claim
intense I-Claim
acupuncture I-Claim
intervention I-Claim
could I-Claim
produce I-Claim
a I-Claim
larger I-Claim
reduction I-Claim
of I-Claim
these I-Claim
symptoms I-Claim
. I-Claim
!LF! !LF!
single O
- O
agent O
therapy O
with O
bicalutamide O
, O
a O
nonsteroidal O
antiandrogen O
, O
was O
compared O
with O
castration O
, O
either O
surgical O
or O
medical O
, O
in O
patients O
with O
untreated O
stage O
d2 O
prostate O
cancer O
. O
!LF! !LF!
in O
an O
open O
, O
randomized O
, O
multicenter O
trial O
, O
patients O
were O
randomized O
to O
treatment O
with O
50 O
mg O
bicalutamide O
( O
n O
= O
243 O
) O
once O
daily O
or O
to O
castration O
( O
n O
= O
243 O
) O
, O
either O
orchiectomy O
or O
depot O
injection O
of O
goserelin O
acetate O
every O
28 O
days O
. O
!LF! !LF!
primary O
efficacy O
endpoints O
were O
times O
to O
treatment O
failure O
and O
objective O
disease O
progression O
and O
survival O
. O
!LF! !LF!
assessments O
included O
review O
of O
measurable O
metastases O
, O
prostate O
dimensions O
, O
eastern O
cooperative O
oncology O
group O
performance O
status O
, O
pain O
, O
analgesic O
requirements O
, O
and O
quality O
of O
life O
responses O
. O
!LF! !LF!
the O
median O
duration O
of O
therapy O
was O
39 O
weeks O
for O
bicalutamide O
- O
treated O
patients O
and O
42 O
weeks O
for O
castrated O
patients O
"""" O
; O
"""" O
treatment O
failure O
occurred O
in O
53 O
% O
and O
42 O
% O
and O
disease O
progression O
in O
43 O
% O
and O
33 O
% O
, O
respectively O
. O
!LF! !LF!
treatment B-Premise
effects I-Premise
favored I-Premise
castration I-Premise
for I-Premise
both I-Premise
endpoints I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
0 I-Premise
. I-Premise
002 I-Premise
) I-Premise
, I-Premise
with I-Premise
hazard I-Premise
ratios I-Premise
( I-Premise
bicalutamide I-Premise
: I-Premise
castration I-Premise
) I-Premise
of I-Premise
1 I-Premise
. I-Premise
54 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
ci I-Premise
] I-Premise
, I-Premise
1 I-Premise
. I-Premise
18 I-Premise
to I-Premise
2 I-Premise
. I-Premise
00 I-Premise
) I-Premise
for I-Premise
time I-Premise
to I-Premise
treatment I-Premise
failure I-Premise
and I-Premise
1 I-Premise
. I-Premise
6 I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
1 I-Premise
. I-Premise
19 I-Premise
to I-Premise
2 I-Premise
. I-Premise
15 I-Premise
) I-Premise
for I-Premise
time I-Premise
to I-Premise
disease I-Premise
progression I-Premise
. I-Premise
!LF! !LF!
from B-Premise
the I-Premise
1 I-Premise
- I-Premise
year I-Premise
survival I-Premise
analysis I-Premise
, I-Premise
the I-Premise
hazard I-Premise
ratio I-Premise
for I-Premise
probability I-Premise
of I-Premise
death I-Premise
was I-Premise
1 I-Premise
. I-Premise
29 I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
, I-Premise
0 I-Premise
. I-Premise
96 I-Premise
to I-Premise
1 I-Premise
. I-Premise
72 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
thus B-Premise
far I-Premise
, I-Premise
with I-Premise
a I-Premise
median I-Premise
follow I-Premise
- I-Premise
up I-Premise
of I-Premise
86 I-Premise
weeks I-Premise
, I-Premise
median I-Premise
survival I-Premise
has I-Premise
not I-Premise
been I-Premise
reached I-Premise
in I-Premise
either I-Premise
group I-Premise
. I-Premise
!LF! !LF!
changes B-Premise
from I-Premise
baseline I-Premise
in I-Premise
several I-Premise
quality I-Premise
of I-Premise
life I-Premise
variables I-Premise
were I-Premise
significantly I-Premise
different I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
periodically I-Premise
from I-Premise
months I-Premise
1 I-Premise
to I-Premise
6 I-Premise
, I-Premise
and I-Premise
all I-Premise
favored I-Premise
bicalutamide I-Premise
. I-Premise
!LF! !LF!
overall B-Premise
, I-Premise
the I-Premise
antiandrogen I-Premise
was I-Premise
well I-Premise
tolerated I-Premise
compared I-Premise
with I-Premise
castration I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
with B-Premise
bicalutamide I-Premise
, I-Premise
hot I-Premise
flushes I-Premise
occurred I-Premise
less I-Premise
often I-Premise
and I-Premise
breast I-Premise
tenderness I-Premise
and I-Premise
gynecomastia I-Premise
more I-Premise
often I-Premise
. I-Premise
!LF! !LF!
although B-Premise
a I-Premise
dosage I-Premise
of I-Premise
50 I-Premise
mg I-Premise
of I-Premise
bicalutamide I-Premise
once I-Premise
daily I-Premise
was I-Premise
not I-Premise
as I-Premise
effective I-Premise
as I-Premise
castration I-Premise
, I-Premise
the B-Claim
favorable I-Claim
quality I-Claim
of I-Claim
life I-Claim
outcomes I-Claim
and I-Claim
the I-Claim
low I-Claim
incidence I-Claim
of I-Claim
nonhormonal I-Claim
adverse I-Claim
events I-Claim
provide I-Claim
reasons I-Claim
to I-Claim
evaluate I-Claim
bicalutamide I-Claim
, I-Claim
as I-Claim
a I-Claim
single I-Claim
therapeutic I-Claim
agent I-Claim
, I-Claim
at I-Claim
higher I-Claim
doses I-Claim
. I-Claim
!LF! !LF!
to O
test O
the O
equivalence O
of O
three O
versus O
four O
cycles O
of O
bleomycin O
, O
etoposide O
, O
and O
cisplatin O
( O
bep O
) O
and O
of O
the O
5 O
- O
day O
schedule O
versus O
3 O
days O
per O
cycle O
in O
good O
- O
prognosis O
germ O
cell O
cancer O
. O
!LF! !LF!
the O
study O
was O
designed O
as O
a O
2 O
x O
2 O
factorial O
trial O
. O
!LF! !LF!
the O
aim O
was O
to O
rule O
out O
a O
5 O
% O
decrease O
in O
the O
2 O
- O
year O
progression O
- O
free O
survival O
( O
pfs O
) O
rate O
. O
!LF! !LF!
the O
study O
included O
the O
assessment O
of O
patient O
quality O
of O
life O
. O
!LF! !LF!
a O
cycle O
of O
bep O
consisted O
of O
etoposide O
500 O
mg O
/ O
m O
( O
2 O
) O
, O
administered O
at O
either O
100 O
mg O
/ O
m O
( O
2 O
) O
days O
1 O
through O
5 O
or O
165 O
mg O
/ O
m O
( O
2 O
) O
days O
1 O
through O
3 O
, O
cisplatin O
100 O
mg O
/ O
m O
( O
2 O
) O
, O
administered O
at O
either O
20 O
mg O
/ O
m O
( O
2 O
) O
days O
1 O
through O
5 O
or O
50 O
mg O
/ O
m O
( O
2 O
) O
days O
1 O
and O
2 O
. O
!LF! !LF!
bleomycin O
30 O
mg O
was O
administered O
on O
days O
1 O
, O
8 O
, O
and O
15 O
during O
cycles O
1 O
through O
3 O
. O
!LF! !LF!
the O
randomization O
procedure O
allowed O
some O
investigators O
to O
participate O
only O
in O
the O
comparison O
of O
three O
versus O
four O
cycles O
. O
!LF! !LF!
from O
march O
1995 O
until O
april O
1998 O
, O
812 O
patients O
were O
randomly O
assigned O
to O
receive O
three O
or O
four O
cycles O
: O
of O
these O
, O
681 O
were O
also O
randomly O
assigned O
to O
the O
5 O
- O
day O
or O
the O
3 O
- O
day O
schedule O
. O
!LF! !LF!
histology O
, O
marker O
values O
, O
and O
disease O
extent O
are O
well O
balanced O
in O
the O
treatment O
arms O
of O
the O
two O
comparisons O
. O
!LF! !LF!
the B-Premise
projected I-Premise
2 I-Premise
- I-Premise
year I-Premise
pfs I-Premise
is I-Premise
90 I-Premise
. I-Premise
4 I-Premise
% I-Premise
on I-Premise
three I-Premise
cycles I-Premise
and I-Premise
89 I-Premise
. I-Premise
4 I-Premise
% I-Premise
on I-Premise
four I-Premise
cycles I-Premise
. I-Premise
!LF! !LF!
the B-Premise
difference I-Premise
in I-Premise
pfs I-Premise
between I-Premise
three I-Premise
and I-Premise
four I-Premise
cycles I-Premise
is I-Premise
- I-Premise
1 I-Premise
. I-Premise
0 I-Premise
% I-Premise
( I-Premise
80 I-Premise
% I-Premise
confidence I-Premise
limit I-Premise
[ I-Premise
cl I-Premise
] I-Premise
, I-Premise
- I-Premise
3 I-Premise
. I-Premise
8 I-Premise
% I-Premise
, I-Premise
+ I-Premise
1 I-Premise
. I-Premise
8 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
equivalence B-Claim
for I-Claim
three I-Claim
versus I-Claim
four I-Claim
cycles I-Claim
is I-Claim
claimed I-Claim
because I-Claim
both I-Claim
the I-Claim
upper I-Claim
and I-Claim
lower I-Claim
bounds I-Claim
of I-Claim
the I-Claim
80 I-Claim
% I-Claim
cl I-Claim
are I-Claim
less I-Claim
than I-Claim
5 I-Claim
% I-Claim
. I-Claim
!LF! !LF!
in B-Premise
the I-Premise
- I-Premise
5 I-Premise
versus I-Premise
3 I-Premise
- I-Premise
day I-Premise
comparison I-Premise
, I-Premise
the I-Premise
projected I-Premise
2 I-Premise
- I-Premise
year I-Premise
pfs I-Premise
is I-Premise
88 I-Premise
. I-Premise
8 I-Premise
% I-Premise
and I-Premise
89 I-Premise
. I-Premise
7 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
difference I-Premise
, I-Premise
- I-Premise
0 I-Premise
. I-Premise
9 I-Premise
% I-Premise
, I-Premise
( I-Premise
80 I-Premise
% I-Premise
cl I-Premise
, I-Premise
- I-Premise
4 I-Premise
. I-Premise
1 I-Premise
% I-Premise
, I-Premise
+ I-Premise
2 I-Premise
. I-Premise
2 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
hence O
, O
equivalence B-Claim
is I-Claim
claimed I-Claim
in I-Claim
this I-Claim
comparison I-Claim
also I-Claim
. I-Claim
!LF! !LF!
frequencies B-Premise
of I-Premise
hematologic I-Premise
and I-Premise
nonhematologic I-Premise
toxicities I-Premise
were I-Premise
essentially I-Premise
similar I-Premise
. I-Premise
!LF! !LF!
quality B-Premise
of I-Premise
life I-Premise
was I-Premise
maintained I-Premise
better I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
three I-Premise
cycles I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
no B-Premise
differences I-Premise
were I-Premise
detected I-Premise
between I-Premise
3 I-Premise
and I-Premise
5 I-Premise
days I-Premise
of I-Premise
treatment I-Premise
. I-Premise
!LF! !LF!
we O
conclude O
that O
three B-Claim
cycles I-Claim
of I-Claim
bep I-Claim
, I-Claim
with I-Claim
etoposide I-Claim
at I-Claim
500 I-Claim
mg I-Claim
/ I-Claim
m I-Claim
( I-Claim
2 I-Claim
) I-Claim
, I-Claim
is I-Claim
sufficient I-Claim
therapy I-Claim
in I-Claim
good I-Claim
- I-Claim
prognosis I-Claim
germ I-Claim
cell I-Claim
cancer I-Claim
and O
that O
the B-Claim
administration I-Claim
of I-Claim
the I-Claim
chemotherapy I-Claim
in I-Claim
3 I-Claim
days I-Claim
has I-Claim
no I-Claim
detrimental I-Claim
effect I-Claim
on I-Claim
the I-Claim
effectiveness I-Claim
of I-Claim
the I-Claim
bep I-Claim
regimen I-Claim
. I-Claim
!LF! !LF!
the O
effectiveness O
of O
a O
pain O
education O
program O
in O
cancer O
patients O
with O
chronic O
pain O
offered O
by O
nurses O
was O
investigated O
in O
a O
randomized O
controlled O
clinical O
trial O
. O
!LF! !LF!
a O
multi O
- O
method O
approach O
was O
used O
in O
which O
verbal O
instruction O
, O
written O
material O
, O
an O
audio O
cassette O
tape O
, O
and O
the O
use O
of O
a O
pain O
diary O
were O
combined O
to O
inform O
and O
instruct O
patients O
about O
pain O
and O
pain O
management O
. O
!LF! !LF!
the O
pain O
education O
program O
was O
tailored O
to O
the O
needs O
of O
the O
individual O
patient O
and O
consisted O
of O
three O
elements O
: O
( O
1 O
) O
educating O
patients O
about O
the O
basic O
principles O
regarding O
pain O
and O
pain O
management O
"""" O
; O
"""" O
( O
2 O
) O
instructing O
patients O
how O
to O
report O
their O
pain O
in O
a O
pain O
diary O
"""" O
; O
"""" O
and O
( O
3 O
) O
instructing O
patients O
how O
to O
communicate O
about O
pain O
and O
how O
to O
contact O
health O
care O
providers O
. O
!LF! !LF!
following O
pretesting O
in O
313 O
patients O
, O
patients O
who O
needed O
district O
nursing O
and O
who O
did O
not O
need O
district O
nursing O
at O
home O
were O
randomly O
assigned O
to O
a O
control O
or O
intervention O
group O
. O
!LF! !LF!
intervention O
group O
patients O
received O
the O
pain O
education O
program O
in O
the O
hospital O
, O
and O
3 O
and O
7 O
days O
postdischarge O
by O
telephone O
"""" O
; O
"""" O
this O
was O
done O
by O
nurses O
who O
were O
specially O
trained O
as O
pain O
counselors O
. O
!LF! !LF!
follow O
- O
up O
assessments O
were O
at O
2 O
, O
4 O
and O
8 O
weeks O
postdischarge O
. O
!LF! !LF!
results O
of O
the O
pretest O
showed O
that O
many O
patients O
lacked O
knowledge O
about O
pain O
and O
pain O
management O
. O
!LF! !LF!
the O
majority O
of O
pain O
topics O
had O
to O
be O
discussed O
. O
!LF! !LF!
the B-Claim
pain I-Claim
education I-Claim
program I-Claim
proved I-Claim
to I-Claim
be I-Claim
feasible I-Claim
: I-Claim
75 B-Premise
. B-Premise
0 B-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
had I-Premise
read I-Premise
the I-Premise
entire I-Premise
pain I-Premise
brochure I-Premise
, I-Premise
55 I-Premise
. I-Premise
7 I-Premise
% I-Premise
had I-Premise
listened I-Premise
to I-Premise
the I-Premise
audio I-Premise
cassette I-Premise
, I-Premise
and I-Premise
85 I-Premise
. I-Premise
6 I-Premise
% I-Premise
of I-Premise
pain I-Premise
scores I-Premise
were I-Premise
completed I-Premise
in I-Premise
the I-Premise
pain I-Premise
diary I-Premise
. I-Premise
!LF! !LF!
results B-Claim
showed I-Claim
a I-Claim
significant I-Claim
increase I-Claim
in I-Claim
pain I-Claim
knowledge I-Claim
in I-Claim
patients I-Claim
who I-Claim
received I-Claim
the I-Claim
pain I-Claim
education I-Claim
program I-Claim
and I-Claim
a I-Claim
significant I-Claim
decrease I-Claim
in I-Claim
pain I-Claim
intensity I-Claim
. I-Claim
!LF! !LF!
however B-Premise
, I-Premise
pain I-Premise
relief I-Premise
was I-Premise
mainly I-Premise
found I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
patients I-Premise
without I-Premise
district I-Premise
nursing I-Premise
. I-Premise
!LF! !LF!
it B-Claim
can I-Claim
be I-Claim
concluded I-Claim
that I-Claim
the I-Claim
tailored I-Claim
pain I-Claim
education I-Claim
program I-Claim
is I-Claim
effective I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
in I-Claim
chronic I-Claim
pain I-Claim
. I-Claim
!LF! !LF!
the B-Claim
use I-Claim
of I-Claim
the I-Claim
pain I-Claim
education I-Claim
program I-Claim
by I-Claim
nurses I-Claim
should I-Claim
be I-Claim
seriously I-Claim
considered I-Claim
on I-Claim
oncology I-Claim
units I-Claim
. I-Claim
!LF! !LF!
proinflammatory O
cytokines O
, O
especially O
tumour O
necrosis O
factor O
alpha O
( O
tnf O
- O
alpha O
) O
, O
play O
a O
prominent O
role O
in O
the O
pathogenesis O
of O
cancer O
cachexia O
. O
!LF! !LF!
thalidomide B-Claim
, I-Claim
which I-Claim
is I-Claim
an I-Claim
inhibitor I-Claim
of I-Claim
tnf I-Claim
- I-Claim
alpha I-Claim
synthesis I-Claim
, I-Claim
may I-Claim
represent I-Claim
a I-Claim
novel I-Claim
and I-Claim
rational I-Claim
approach I-Claim
to I-Claim
the I-Claim
treatment I-Claim
of I-Claim
cancer I-Claim
cachexia I-Claim
. I-Claim
!LF! !LF!
to O
assess O
the O
safety O
and O
efficacy O
of O
thalidomide O
in O
attenuating O
weight O
loss O
in O
patients O
with O
cachexia O
secondary O
to O
advanced O
pancreatic O
cancer O
. O
!LF! !LF!
fifty O
patients O
with O
advanced O
pancreatic O
cancer O
who O
had O
lost O
at O
least O
10 O
% O
of O
their O
body O
weight O
were O
randomised O
to O
receive O
thalidomide O
200 O
mg O
daily O
or O
placebo O
for O
24 O
weeks O
in O
a O
single O
centre O
, O
double O
blind O
, O
randomised O
controlled O
trial O
. O
!LF! !LF!
the O
primary O
outcome O
was O
change O
in O
weight O
and O
nutritional O
status O
. O
!LF! !LF!
thirty O
three O
patients O
( O
16 O
control O
, O
17 O
thalidomide O
) O
were O
evaluated O
at O
four O
weeks O
, O
and O
20 O
patients O
( O
eight O
control O
, O
12 O
thalidomide O
) O
at O
eight O
weeks O
. O
!LF! !LF!
at B-Premise
four I-Premise
weeks I-Premise
, I-Premise
patients I-Premise
who I-Premise
received I-Premise
thalidomide I-Premise
had I-Premise
gained I-Premise
on I-Premise
average I-Premise
0 I-Premise
. I-Premise
37 I-Premise
kg I-Premise
in I-Premise
weight I-Premise
and I-Premise
1 I-Premise
. I-Premise
0 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
in I-Premise
arm I-Premise
muscle I-Premise
mass I-Premise
( I-Premise
ama I-Premise
) I-Premise
compared I-Premise
with I-Premise
a I-Premise
loss I-Premise
of I-Premise
2 I-Premise
. I-Premise
21 I-Premise
kg I-Premise
( I-Premise
absolute I-Premise
difference I-Premise
- I-Premise
2 I-Premise
. I-Premise
59 I-Premise
kg I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
ci I-Premise
) I-Premise
- I-Premise
4 I-Premise
. I-Premise
3 I-Premise
to I-Premise
- I-Premise
0 I-Premise
. I-Premise
8 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
005 I-Premise
) I-Premise
and I-Premise
4 I-Premise
. I-Premise
46 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
( I-Premise
absolute I-Premise
difference I-Premise
- I-Premise
5 I-Premise
. I-Premise
6 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
- I-Premise
8 I-Premise
. I-Premise
9 I-Premise
to I-Premise
- I-Premise
2 I-Premise
. I-Premise
2 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
002 I-Premise
) I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise
!LF! !LF!
at B-Premise
eight I-Premise
weeks I-Premise
, I-Premise
patients I-Premise
in I-Premise
the I-Premise
thalidomide I-Premise
group I-Premise
had I-Premise
lost I-Premise
0 I-Premise
. I-Premise
06 I-Premise
kg I-Premise
in I-Premise
weight I-Premise
and I-Premise
0 I-Premise
. I-Premise
5 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
in I-Premise
ama I-Premise
compared I-Premise
with I-Premise
a I-Premise
loss I-Premise
of I-Premise
3 I-Premise
. I-Premise
62 I-Premise
kg I-Premise
( I-Premise
absolute I-Premise
difference I-Premise
- I-Premise
3 I-Premise
. I-Premise
57 I-Premise
kg I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
- I-Premise
6 I-Premise
. I-Premise
8 I-Premise
to I-Premise
- I-Premise
0 I-Premise
. I-Premise
3 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
034 I-Premise
) I-Premise
and I-Premise
8 I-Premise
. I-Premise
4 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
( I-Premise
absolute I-Premise
difference I-Premise
- I-Premise
7 I-Premise
. I-Premise
9 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
( I-Premise
95 I-Premise
% I-Premise
ci I-Premise
- I-Premise
14 I-Premise
. I-Premise
0 I-Premise
to I-Premise
- I-Premise
1 I-Premise
. I-Premise
8 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
014 I-Premise
) I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise
!LF! !LF!
improvement B-Premise
in I-Premise
physical I-Premise
functioning I-Premise
correlated I-Premise
positively I-Premise
with I-Premise
weight I-Premise
gain I-Premise
( I-Premise
r I-Premise
= I-Premise
0 I-Premise
. I-Premise
56 I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
thalidomide B-Claim
was I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
effective I-Claim
at I-Claim
attenuating I-Claim
loss I-Claim
of I-Claim
weight I-Claim
and I-Claim
lean I-Claim
body I-Claim
mass I-Claim
in I-Claim
patients I-Claim
with I-Claim
cachexia I-Claim
due I-Claim
to I-Claim
advanced I-Claim
pancreatic I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
the O
purpose O
of O
our O
study O
was O
to O
evaluate O
the O
effect O
of O
cognitive O
behavioral O
therapy O
( O
cbt O
) O
, O
physical O
exercise O
( O
pe O
) O
, O
and O
of O
these O
two O
interventions O
combined O
( O
cbt O
/ O
pe O
) O
on O
menopausal O
symptoms O
( O
primary O
outcome O
) O
, O
body O
image O
, O
sexual O
functioning O
, O
psychological O
well O
- O
being O
, O
and O
health O
- O
related O
quality O
of O
life O
( O
secondary O
outcomes O
) O
in O
patients O
with O
breast O
cancer O
experiencing O
treatment O
- O
induced O
menopause O
. O
!LF! !LF!
patients O
with O
breast O
cancer O
reporting O
treatment O
- O
induced O
menopausal O
symptoms O
( O
n O
= O
422 O
) O
were O
randomly O
assigned O
to O
cbt O
( O
n O
= O
109 O
) O
, O
pe O
( O
n O
= O
104 O
) O
, O
cbt O
/ O
pe O
( O
n O
= O
106 O
) O
, O
or O
to O
a O
waiting O
list O
control O
group O
( O
n O
= O
103 O
) O
. O
!LF! !LF!
self O
- O
report O
questionnaires O
were O
completed O
at O
baseline O
, O
12 O
weeks O
, O
and O
6 O
months O
. O
!LF! !LF!
multilevel O
procedures O
were O
used O
to O
compare O
the O
intervention O
groups O
with O
the O
control O
group O
over O
time O
. O
!LF! !LF!
compared B-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
the I-Premise
intervention I-Premise
groups I-Premise
had I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
levels I-Premise
of I-Premise
endocrine I-Premise
symptoms I-Premise
( I-Premise
functional I-Premise
assessment I-Premise
of I-Premise
cancer I-Premise
therapy I-Premise
- I-Premise
endocrine I-Premise
symptoms I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0 I-Premise
. I-Premise
31 I-Premise
- I-Premise
0 I-Premise
. I-Premise
52 I-Premise
) I-Premise
and I-Premise
urinary I-Premise
symptoms I-Premise
( I-Premise
bristol I-Premise
female I-Premise
lower I-Premise
urinary I-Premise
tract I-Premise
symptoms I-Premise
questionnaire I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
002 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0 I-Premise
. I-Premise
29 I-Premise
- I-Premise
0 I-Premise
. I-Premise
33 I-Premise
) I-Premise
, I-Premise
and I-Premise
they I-Premise
showed I-Premise
an I-Premise
improvement I-Premise
in I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
36 I-Premise
- I-Premise
item I-Premise
short I-Premise
form I-Premise
health I-Premise
survey I-Premise
physical I-Premise
functioning I-Premise
subscale I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
002 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0 I-Premise
. I-Premise
37 I-Premise
- I-Premise
0 I-Premise
. I-Premise
46 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Premise
groups I-Premise
that I-Premise
included I-Premise
cbt I-Premise
also I-Premise
showed I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
the I-Premise
perceived I-Premise
burden I-Premise
of I-Premise
hot I-Premise
flashes I-Premise
and I-Premise
night I-Premise
sweats I-Premise
( I-Premise
problem I-Premise
rating I-Premise
scale I-Premise
of I-Premise
the I-Premise
hot I-Premise
flush I-Premise
rating I-Premise
scale I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
. I-Premise
001 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0 I-Premise
. I-Premise
39 I-Premise
- I-Premise
0 I-Premise
. I-Premise
56 I-Premise
) I-Premise
and I-Premise
an I-Premise
increase I-Premise
in I-Premise
sexual I-Premise
activity I-Premise
( I-Premise
sexual I-Premise
activity I-Premise
questionnaire I-Premise
habit I-Premise
subscale I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
027 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0 I-Premise
. I-Premise
65 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
most O
of O
these O
effects O
were O
observed O
at O
both O
the O
12 O
- O
week O
and O
6 O
- O
month O
follow O
- O
ups O
. O
!LF! !LF!
cbt B-Claim
and I-Claim
pe I-Claim
can I-Claim
have I-Claim
salutary I-Claim
effects I-Claim
on I-Claim
endocrine I-Claim
symptoms I-Claim
and I-Claim
, I-Claim
to I-Claim
a I-Claim
lesser I-Claim
degree I-Claim
, I-Claim
on I-Claim
sexuality I-Claim
and I-Claim
physical I-Claim
functioning I-Claim
of I-Claim
patients I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
experiencing I-Claim
treatment I-Claim
- I-Claim
induced I-Claim
menopause I-Claim
. I-Claim
!LF! !LF!
future B-Claim
work I-Claim
is I-Claim
needed I-Claim
to I-Claim
improve I-Claim
the I-Claim
design I-Claim
and I-Claim
the I-Claim
planning I-Claim
of I-Claim
these I-Claim
interventions I-Claim
to I-Claim
improve I-Claim
program I-Claim
adherence I-Claim
. I-Claim
!LF! !LF!
randomized B-Claim
trials I-Claim
in I-Claim
fluorouracil I-Claim
( I-Claim
fu I-Claim
) I-Claim
- I-Claim
refractory I-Claim
colorectal I-Claim
cancer I-Claim
demonstrate I-Claim
significant I-Claim
survival I-Claim
advantages I-Claim
for I-Claim
patients I-Claim
receiving I-Claim
irinotecan I-Claim
. I-Claim
!LF! !LF!
we O
prospectively O
compared O
the O
efficacy O
and O
tolerability O
of O
two O
irinotecan O
regimens O
( O
once O
a O
week O
for O
4 O
weeks O
followed O
by O
a O
2 O
- O
week O
rest O
period O
[ O
weekly O
] O
v O
once O
every O
3 O
weeks O
) O
in O
such O
patients O
. O
!LF! !LF!
this O
multicenter O
, O
open O
- O
label O
, O
phase O
iii O
study O
randomly O
assigned O
patients O
in O
a O
1 O
: O
2 O
ratio O
to O
irinotecan O
given O
either O
weekly O
( O
125 O
mg O
/ O
m O
( O
2 O
) O
) O
or O
once O
every O
3 O
weeks O
( O
350 O
mg O
/ O
m O
( O
2 O
) O
, O
or O
300 O
mg O
/ O
m O
( O
2 O
) O
in O
patients O
who O
were O
> O
/ O
= O
70 O
years O
of O
age O
, O
who O
had O
eastern O
cooperative O
oncology O
group O
performance O
status O
equal O
to O
2 O
, O
or O
who O
had O
prior O
pelvic O
irradiation O
) O
. O
!LF! !LF!
with B-Premise
median I-Premise
follow I-Premise
- I-Premise
up I-Premise
of I-Premise
15 I-Premise
. I-Premise
8 I-Premise
months I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
1 I-Premise
- I-Premise
year I-Premise
survival I-Premise
( I-Premise
46 I-Premise
% I-Premise
v I-Premise
41 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
42 I-Premise
) I-Premise
, I-Premise
median I-Premise
survival I-Premise
( I-Premise
9 I-Premise
. I-Premise
9 I-Premise
v I-Premise
9 I-Premise
. I-Premise
9 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
43 I-Premise
) I-Premise
, I-Premise
or I-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
( I-Premise
4 I-Premise
. I-Premise
0 I-Premise
v I-Premise
3 I-Premise
. I-Premise
0 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
. I-Premise
54 I-Premise
) I-Premise
between I-Premise
the I-Premise
two I-Premise
regimens I-Premise
. I-Premise
!LF! !LF!
grade B-Premise
3 I-Premise
/ I-Premise
4 I-Premise
diarrhea I-Premise
occurred I-Premise
in I-Premise
36 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
weekly I-Premise
and I-Premise
in I-Premise
19 I-Premise
% I-Premise
of I-Premise
those I-Premise
treated I-Premise
once I-Premise
every I-Premise
3 I-Premise
weeks I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
002 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
grade B-Premise
3 I-Premise
/ I-Premise
4 I-Premise
neutropenia I-Premise
occurred I-Premise
in I-Premise
29 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
weekly I-Premise
and I-Premise
34 I-Premise
% I-Premise
of I-Premise
those I-Premise
treated I-Premise
once I-Premise
every I-Premise
3 I-Premise
weeks I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
35 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
treatment B-Premise
- B-Premise
related B-Premise
mortality I-Premise
occurred I-Premise
in I-Premise
five I-Premise
patients I-Premise
( I-Premise
5 I-Premise
. I-Premise
3 I-Premise
% I-Premise
) I-Premise
receiving I-Premise
irinotecan I-Premise
weekly I-Premise
and I-Premise
three I-Premise
patients I-Premise
( I-Premise
1 I-Premise
. I-Premise
6 I-Premise
% I-Premise
) I-Premise
given I-Premise
therapy I-Premise
once I-Premise
every I-Premise
3 I-Premise
weeks I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
12 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
global B-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
not I-Premise
statistically I-Premise
different I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
irinotecan B-Claim
schedules I-Claim
of I-Claim
weekly I-Claim
and I-Claim
of I-Claim
once I-Claim
every I-Claim
3 I-Claim
weeks I-Claim
demonstrated I-Claim
similar I-Claim
efficacy I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
patients I-Claim
with I-Claim
fu I-Claim
- I-Claim
refractory I-Claim
, I-Claim
metastatic I-Claim
colorectal I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
the B-Claim
regimen I-Claim
of I-Claim
once I-Claim
every I-Claim
3 I-Claim
weeks I-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
significantly I-Claim
lower I-Claim
incidence I-Claim
of I-Claim
severe I-Claim
diarrhea I-Claim
. I-Claim
!LF! !LF!
gefitinib O
and O
pemetrexed O
are O
drugs O
used O
as O
second O
- O
line O
therapy O
for O
advanced O
non O
- O
small O
cell O
lung O
cancer O
( O
nsclc O
) O
, O
although O
studies O
comparing O
the O
two O
drugs O
are O
limited O
. O
!LF! !LF!
the O
aim O
of O
this O
study O
is O
to O
explore O
the O
effects O
, O
safety O
, O
and O
quality O
of O
life O
( O
qol O
) O
of O
gefitinib O
and O
pemetrexed O
on O
patients O
with O
advanced O
non O
- O
squamous O
nsclc O
. O
!LF! !LF!
forty O
- O
six O
advanced O
non O
- O
squamous O
nsclc O
patients O
who O
failed O
to O
first O
- O
line O
therapy O
were O
randomly O
divided O
into O
two O
groups O
with O
23 O
patients O
each O
, O
one O
using O
oral O
gefitinib O
( O
gefitinib O
group O
) O
and O
the O
other O
using O
intravenous O
injection O
pemetrexed O
( O
pemetrexed O
group O
) O
. O
!LF! !LF!
the O
effects O
, O
safety O
, O
and O
qol O
were O
determined O
and O
analyzed O
. O
!LF! !LF!
for B-Premise
the I-Premise
pemetrexed I-Premise
group I-Premise
, I-Premise
objective I-Premise
response I-Premise
rate I-Premise
( I-Premise
orr I-Premise
) I-Premise
was I-Premise
13 I-Premise
. I-Premise
0 I-Premise
% I-Premise
( I-Premise
3 I-Premise
/ I-Premise
23 I-Premise
) I-Premise
, I-Premise
disease I-Premise
control I-Premise
rate I-Premise
( I-Premise
dcr I-Premise
) I-Premise
was I-Premise
30 I-Premise
. I-Premise
4 I-Premise
% I-Premise
( I-Premise
7 I-Premise
/ I-Premise
23 I-Premise
) I-Premise
, I-Premise
and I-Premise
median I-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
( I-Premise
mpfs I-Premise
) I-Premise
was I-Premise
3 I-Premise
. I-Premise
1 I-Premise
months I-Premise
. I-Premise
!LF! !LF!
in B-Premise
the I-Premise
gefitinib I-Premise
group I-Premise
, I-Premise
orr I-Premise
was I-Premise
17 I-Premise
. I-Premise
3 I-Premise
% I-Premise
( I-Premise
4 I-Premise
/ I-Premise
23 I-Premise
) I-Premise
, I-Premise
dcr I-Premise
was I-Premise
39 I-Premise
. I-Premise
1 I-Premise
% I-Premise
( I-Premise
9 I-Premise
/ I-Premise
23 I-Premise
) I-Premise
, I-Premise
and I-Premise
mpfs I-Premise
was I-Premise
4 I-Premise
. I-Premise
4 I-Premise
months I-Premise
. I-Premise
!LF! !LF!
compared B-Premise
with I-Premise
the I-Premise
pemetrexed I-Premise
group I-Premise
, I-Premise
the I-Premise
orr I-Premise
, I-Premise
dcr I-Premise
, I-Premise
and I-Premise
mpfs I-Premise
in I-Premise
the I-Premise
gefitinib I-Premise
group I-Premise
exhibited I-Premise
no I-Premise
statistical I-Premise
significance I-Premise
( I-Premise
p I-Premise
> I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
furthermore O
, O
the B-Premise
most I-Premise
common I-Premise
toxicities I-Premise
in I-Premise
the I-Premise
pemetrexed I-Premise
group I-Premise
were I-Premise
neutropenia I-Premise
( I-Premise
n I-Premise
= I-Premise
9 I-Premise
, I-Premise
39 I-Premise
. I-Premise
13 I-Premise
% I-Premise
) I-Premise
and I-Premise
fatigue I-Premise
( I-Premise
n I-Premise
= I-Premise
8 I-Premise
, I-Premise
34 I-Premise
. I-Premise
78 I-Premise
% I-Premise
) I-Premise
, I-Premise
whereas I-Premise
those I-Premise
in I-Premise
the I-Premise
in I-Premise
gefitinib I-Premise
group I-Premise
were I-Premise
skin I-Premise
rash I-Premise
( I-Premise
n I-Premise
= I-Premise
8 I-Premise
, I-Premise
34 I-Premise
. I-Premise
78 I-Premise
% I-Premise
) I-Premise
and I-Premise
diarrhea I-Premise
( I-Premise
n I-Premise
= I-Premise
4 I-Premise
, I-Premise
17 I-Premise
. I-Premise
39 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
compared B-Premise
with I-Premise
baseline I-Premise
, I-Premise
the I-Premise
qol I-Premise
improved I-Premise
in I-Premise
both I-Premise
groups I-Premise
but I-Premise
to I-Premise
different I-Premise
degrees I-Premise
. I-Premise
!LF! !LF!
likewise O
, O
emotional B-Premise
, I-Premise
functional I-Premise
well I-Premise
- I-Premise
being I-Premise
, I-Premise
and I-Premise
qol I-Premise
aspects I-Premise
specifically I-Premise
related I-Premise
to I-Premise
lung I-Premise
cancer I-Premise
were I-Premise
better I-Premise
improved I-Premise
in I-Premise
the I-Premise
gefitinib I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
pemetrexed I-Premise
group I-Premise
( I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Claim
effects I-Claim
of I-Claim
pemetrexed I-Claim
and I-Claim
gefitinib I-Claim
as I-Claim
second I-Claim
line I-Claim
therapy I-Claim
were I-Claim
similar I-Claim
, I-Claim
although B-Premise
with I-Premise
different I-Premise
aes I-Premise
. I-Premise
!LF! !LF!
both B-Claim
drugs I-Claim
could I-Claim
improve I-Claim
the I-Claim
qol I-Claim
, I-Claim
but O
gefitinib B-Claim
showed I-Claim
better I-Claim
overall I-Claim
results I-Claim
than I-Claim
pemetrexed I-Claim
. I-Claim
!LF! !LF!
patients B-Claim
with I-Claim
advanced I-Claim
non I-Claim
- I-Claim
small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
nsclc I-Claim
) I-Claim
do I-Claim
not I-Claim
have I-Claim
curative I-Claim
treatment I-Claim
options I-Claim
"""" I-Claim
; I-Claim
"""" I-Claim
therefore O
, O
treatments O
should O
prolong O
survival O
and O
improve O
quality O
of O
life O
( O
qol O
) O
. O
!LF! !LF!
we O
compared O
the O
effect O
on O
qol O
of O
two O
docetaxel O
- O
platinum O
regimens O
with O
vinorelbine O
- O
cisplatin O
. O
!LF! !LF!
qol O
was O
assessed O
by O
the O
lung O
cancer O
symptom O
scale O
( O
lcss O
) O
and O
the O
general O
euroqol O
five O
- O
dimensional O
questionnaire O
( O
eq O
- O
5d O
) O
in O
926 O
chemotherapy O
- O
naive O
patients O
with O
stages O
iiib O
to O
iv O
nsclc O
. O
!LF! !LF!
patients O
were O
randomly O
assigned O
to O
receive O
: O
docetaxel O
75 O
mg O
/ O
m2 O
plus O
cisplatin O
75 O
mg O
/ O
m2 O
, O
every O
3 O
weeks O
( O
dc O
) O
"""" O
; O
"""" O
docetaxel O
75 O
mg O
/ O
m2 O
and O
carboplatin O
6 O
mg O
/ O
ml O
min O
, O
every O
3 O
weeks O
( O
dcb O
) O
"""" O
; O
"""" O
or O
vinorelbine O
25 O
mg O
/ O
m2 O
/ O
week O
plus O
cisplatin O
100 O
mg O
/ O
m2 O
, O
every O
4 O
weeks O
( O
vc O
) O
. O
!LF! !LF!
overall B-Premise
, I-Premise
patients I-Premise
treated I-Premise
with I-Premise
either I-Premise
docetaxel I-Premise
- I-Premise
containing I-Premise
regimen I-Premise
had I-Premise
better I-Premise
qol I-Premise
than I-Premise
vc I-Premise
- I-Premise
treated I-Premise
patients I-Premise
( I-Premise
lcss I-Premise
global I-Premise
item I-Premise
"""" I-Premise
qol I-Premise
today I-Premise
"""" I-Premise
: I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
064 I-Premise
for I-Premise
dc I-Premise
and I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
016 I-Premise
for I-Premise
dcb I-Premise
versus I-Premise
vc I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
eq I-Premise
- I-Premise
5d I-Premise
global I-Premise
item I-Premise
"""" I-Premise
health I-Premise
state I-Premise
today I-Premise
"""" I-Premise
: I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
016 I-Premise
for I-Premise
dc I-Premise
and I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
for I-Premise
dcb I-Premise
versus I-Premise
vc I-Premise
) I-Premise
. I-Premise
!LF! !LF!
dc B-Premise
- B-Premise
treated B-Premise
patients I-Premise
experienced I-Premise
improved I-Premise
pain I-Premise
relief I-Premise
compared I-Premise
with I-Premise
vc I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
033 I-Premise
) I-Premise
, I-Premise
whereas O
pain B-Premise
relief I-Premise
with I-Premise
dcb I-Premise
and I-Premise
vc I-Premise
was I-Premise
similar I-Premise
. I-Premise
!LF! !LF!
patients B-Premise
treated I-Premise
with I-Premise
either I-Premise
docetaxel I-Premise
regimen I-Premise
had I-Premise
more I-Premise
favorable I-Premise
changes I-Premise
in I-Premise
performance I-Premise
status I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
065 I-Premise
for I-Premise
dc I-Premise
and I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
for I-Premise
dcb I-Premise
versus I-Premise
vc I-Premise
) I-Premise
and I-Premise
mean I-Premise
weight I-Premise
loss I-Premise
( I-Premise
0 I-Premise
. I-Premise
06 I-Premise
kg I-Premise
, I-Premise
gain I-Premise
of I-Premise
0 I-Premise
. I-Premise
08 I-Premise
kg I-Premise
, I-Premise
and I-Premise
2 I-Premise
. I-Premise
27 I-Premise
kg I-Premise
for I-Premise
dc I-Premise
, I-Premise
dcb I-Premise
, I-Premise
and I-Premise
vc I-Premise
, I-Premise
respectively I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
for I-Premise
both I-Premise
dc I-Premise
versus I-Premise
vc I-Premise
and I-Premise
dcb I-Premise
versus I-Premise
vc I-Premise
) I-Premise
. I-Premise
!LF! !LF!
the B-Claim
tax I-Claim
326 I-Claim
study I-Claim
shows I-Claim
that I-Claim
docetaxel I-Claim
- I-Claim
platinum I-Claim
regimens I-Claim
relieve I-Claim
symptoms I-Claim
and I-Claim
improve I-Claim
qol I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
nsclc I-Claim
. I-Claim
!LF! !LF!
dcb B-Claim
and I-Claim
dc I-Claim
were I-Claim
superior I-Claim
to I-Claim
vc I-Claim
in I-Claim
all I-Claim
qol I-Claim
outcomes I-Claim
assessed I-Claim
except I-Claim
for I-Claim
the I-Claim
difference I-Claim
between I-Claim
dc I-Claim
and I-Claim
vc I-Claim
in I-Claim
lcss I-Claim
"""" I-Claim
qol I-Claim
today I-Claim
"""" I-Claim
, I-Claim
which I-Claim
was I-Claim
not I-Claim
significant I-Claim
. I-Claim
!LF! !LF!
relapse B-Claim
after I-Claim
completing I-Claim
adjuvant I-Claim
tamoxifen I-Claim
therapy I-Claim
is I-Claim
a I-Claim
persistent I-Claim
threat I-Claim
for I-Claim
women I-Claim
with I-Claim
hormone I-Claim
- I-Claim
responsive I-Claim
breast I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
third O
- O
generation O
aromatase O
inhibitors O
, O
such O
as O
letrozole O
, O
provide O
a O
new O
option O
for O
extended O
adjuvant O
hormonal O
therapy O
after O
5 O
years O
of O
tamoxifen O
. O
!LF! !LF!
ma O
. O
17 O
was O
conducted O
to O
determine O
whether O
letrozole O
improves O
outcome O
after O
discontinuation O
of O
tamoxifen O
. O
!LF! !LF!
postmenopausal O
women O
with O
hormone O
receptor O
- O
positive O
breast O
cancer O
( O
n O
= O
5 O
, O
187 O
) O
were O
randomized O
to O
letrozole O
2 O
. O
5 O
mg O
or O
placebo O
once O
daily O
for O
5 O
years O
. O
!LF! !LF!
at B-Premise
a I-Premise
median I-Premise
follow I-Premise
- I-Premise
up I-Premise
of I-Premise
30 I-Premise
months I-Premise
, I-Premise
letrozole I-Premise
significantly I-Premise
improved I-Premise
disease I-Premise
- I-Premise
free I-Premise
survival I-Premise
( I-Premise
dfs I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
the I-Premise
primary I-Premise
end I-Premise
point I-Premise
, I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
hr I-Premise
] I-Premise
for I-Premise
recurrence I-Premise
or I-Premise
contralateral I-Premise
breast I-Premise
cancer I-Premise
0 I-Premise
. I-Premise
58 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
ci I-Premise
] I-Premise
0 I-Premise
. I-Premise
45 I-Premise
, I-Premise
0 I-Premise
. I-Premise
76 I-Premise
] I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
furthermore B-Premise
, I-Premise
letrozole I-Premise
significantly I-Premise
improved I-Premise
distant I-Premise
dfs I-Premise
( I-Premise
hr I-Premise
= I-Premise
0 I-Premise
. I-Premise
60 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
. I-Premise
43 I-Premise
, I-Premise
0 I-Premise
. I-Premise
84 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
002 I-Premise
) I-Premise
and I-Premise
, I-Premise
in I-Premise
women I-Premise
with I-Premise
node I-Premise
- I-Premise
positive I-Premise
tumors I-Premise
, I-Premise
overall I-Premise
survival I-Premise
( I-Premise
hr I-Premise
= I-Premise
0 I-Premise
. I-Premise
61 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
ci I-Premise
0 I-Premise
. I-Premise
38 I-Premise
, I-Premise
0 I-Premise
. I-Premise
98 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
04 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
clinical B-Premise
benefits I-Premise
, I-Premise
including I-Premise
an I-Premise
overall I-Premise
survival I-Premise
advantage I-Premise
, I-Premise
were I-Premise
also I-Premise
seen I-Premise
in I-Premise
women I-Premise
who I-Premise
crossed I-Premise
over I-Premise
from I-Premise
placebo I-Premise
to I-Premise
letrozole I-Premise
after I-Premise
unblinding I-Premise
, I-Premise
indicating I-Premise
that I-Premise
tumors I-Premise
remain I-Premise
sensitive I-Premise
to I-Premise
hormone I-Premise
therapy I-Premise
despite I-Premise
a I-Premise
prolonged I-Premise
period I-Premise
since I-Premise
discontinuation I-Premise
of I-Premise
tamoxifen I-Premise
. I-Premise
!LF! !LF!
the O
efficacy O
and O
safety O
of O
letrozole O
therapy O
beyond O
5 O
years O
is O
being O
assessed O
in O
a O
re O
- O
randomization O
study O
, O
following O
the O
emergence O
of O
new O
data O
suggesting O
that O
clinical O
benefit O
correlates O
with O
the O
duration O
of O
letrozole O
. O
!LF! !LF!
ma B-Claim
. B-Claim
17 B-Claim
showed I-Claim
that I-Claim
letrozole I-Claim
is I-Claim
extremely I-Claim
well I-Claim
- I-Claim
tolerated I-Claim
relative I-Claim
to I-Claim
placebo I-Claim
. I-Claim
!LF! !LF!
letrozole B-Claim
should I-Claim
be I-Claim
considered I-Claim
for I-Claim
all I-Claim
women I-Claim
completing I-Claim
tamoxifen I-Claim
"""" I-Claim
; I-Claim
"""" I-Claim
new B-Claim
results I-Claim
from I-Claim
the I-Claim
post I-Claim
- I-Claim
unblinding I-Claim
analysis I-Claim
suggest I-Claim
that I-Claim
letrozole I-Claim
treatment I-Claim
should I-Claim
also I-Claim
be I-Claim
considered I-Claim
for I-Claim
all I-Claim
disease I-Claim
- I-Claim
free I-Claim
women I-Claim
for I-Claim
periods I-Claim
up I-Claim
to I-Claim
5 I-Claim
years I-Claim
following I-Claim
completion I-Claim
of I-Claim
adjuvant I-Claim
tamoxifen I-Claim
. I-Claim
!LF! !LF!
lung O
cancer O
is O
one O
of O
the O
most O
common O
cancers O
in O
the O
united O
states O
and O
is O
associated O
with O
high O
levels O
of O
symptoms O
, O
including O
pain O
, O
fatigue O
, O
shortness O
of O
breath O
, O
and O
psychological O
distress O
. O
!LF! !LF!
caregivers O
and O
patients O
are O
adversely O
affected O
. O
!LF! !LF!
however O
, O
previous O
studies O
of O
coping O
skills O
training O
( O
cst O
) O
interventions O
have O
not O
been O
tested O
in O
patients O
with O
lung O
cancer O
nor O
have O
systematically O
included O
caregivers O
. O
!LF! !LF!
this O
study O
tested O
the O
efficacy O
of O
a O
caregiver O
- O
assisted O
cst O
protocol O
in O
a O
sample O
of O
patients O
with O
lung O
cancer O
. O
!LF! !LF!
two O
hundred O
thirty O
- O
three O
lung O
cancer O
patients O
and O
their O
caregivers O
were O
randomly O
assigned O
to O
receive O
14 O
telephone O
- O
based O
sessions O
of O
either O
caregiver O
- O
assisted O
cst O
or O
education O
/ O
support O
involving O
the O
caregiver O
. O
!LF! !LF!
patients O
completed O
measures O
assessing O
pain O
, O
psychological O
distress O
, O
quality O
of O
life O
( O
qol O
) O
, O
and O
self O
- O
efficacy O
for O
symptom O
management O
"""" O
; O
"""" O
caregivers O
completed O
measures O
assessing O
psychological O
distress O
, O
caregiver O
strain O
, O
and O
self O
- O
efficacy O
for O
helping O
the O
patient O
manage O
symptoms O
. O
!LF! !LF!
patients B-Premise
in I-Premise
both I-Premise
treatment I-Premise
conditions I-Premise
showed I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
, I-Premise
depression I-Premise
, I-Premise
qol I-Premise
, I-Premise
and I-Premise
self I-Premise
- I-Premise
efficacy I-Premise
, I-Premise
and I-Premise
caregivers I-Premise
in I-Premise
both I-Premise
conditions I-Premise
showed I-Premise
improvements I-Premise
in I-Premise
anxiety I-Premise
and I-Premise
self I-Premise
- I-Premise
efficacy I-Premise
from I-Premise
baseline I-Premise
to I-Premise
four I-Premise
- I-Premise
month I-Premise
follow I-Premise
- I-Premise
up I-Premise
. I-Premise
!LF! !LF!
results B-Premise
of I-Premise
exploratory I-Premise
analyses I-Premise
suggested I-Premise
that I-Premise
the I-Premise
cst I-Premise
intervention I-Premise
was I-Premise
more I-Premise
beneficial I-Premise
to I-Premise
patients I-Premise
/ I-Premise
caregivers I-Premise
with I-Premise
stage I-Premise
ii I-Premise
and I-Premise
iii I-Premise
cancers I-Premise
, I-Premise
whereas O
the B-Premise
education I-Premise
/ I-Premise
support I-Premise
intervention I-Premise
was I-Premise
more I-Premise
beneficial I-Premise
to I-Premise
patients I-Premise
/ I-Premise
caregivers I-Premise
with I-Premise
stage I-Premise
i I-Premise
cancer I-Premise
. I-Premise
!LF! !LF!
taken B-Premise
together I-Premise
with I-Premise
the I-Premise
broader I-Premise
literature I-Premise
in I-Premise
this I-Premise
area I-Premise
, I-Premise
results B-Claim
from I-Claim
this I-Claim
study I-Claim
suggest I-Claim
that I-Claim
psychosocial I-Claim
interventions I-Claim
can I-Claim
lead I-Claim
to I-Claim
improvements I-Claim
in I-Claim
a I-Claim
range I-Claim
of I-Claim
outcomes I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
suggestions O
for O
future O
studies O
include O
the O
use O
of O
three O
- O
group O
designs O
( O
e O
. O
g O
. O
, O
comparing O
two O
active O
interventions O
with O
a O
standard O
- O
care O
control O
) O
and O
examining O
mechanisms O
of O
change O
. O
!LF! !LF!
